<SEC-DOCUMENT>0001759138-26-000011.txt : 20260323
<SEC-HEADER>0001759138-26-000011.hdr.sgml : 20260323
<ACCEPTANCE-DATETIME>20260323073612
ACCESSION NUMBER:		0001759138-26-000011
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260323
DATE AS OF CHANGE:		20260323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cabaletta Bio, Inc.
		CENTRAL INDEX KEY:			0001759138
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39103
		FILM NUMBER:		26779910

	BUSINESS ADDRESS:	
		STREET 1:		2929 ARCH STREET
		STREET 2:		SUITE 600
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(267) 759-3100

	MAIL ADDRESS:	
		STREET 1:		2929 ARCH STREET
		STREET 2:		SUITE 600
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>caba-20251231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-03-22T19:37:20.9839+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:caba="http://www.cabalettabio.com/20251231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_e2d8e1c8-abad-4975-8fb0-29afbef25850" name="dei:EntityCentralIndexKey" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62">0001759138</ix:nonNumeric><ix:nonNumeric id="F_debbdddf-3755-4212-a1ba-5a5e8c0c061f" name="dei:AmendmentFlag" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62">false</ix:nonNumeric><ix:nonNumeric id="F_167f4452-39b1-4651-9793-471cc2862419" name="dei:DocumentFiscalPeriodFocus" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62">FY</ix:nonNumeric><ix:nonFraction id="F_437f05d5-bc3e-4917-9472-758eed38a299" name="us-gaap:CommitmentsAndContingencies" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_8ac70644-54ad-4b79-9c48-216491e81014" name="us-gaap:CommitmentsAndContingencies" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_6b79aa44-243a-42b1-94f6-81fb189f1245" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_cfcf9106-b91e-443d-b454-eae693a2da98">http://www.cabalettabio.com/20251231#PropertyPlantAndEquipmentEstimatedUsefulLives1</ix:nonNumeric><ix:nonFraction id="F_11331fa4-2d51-42cc-aee7-5b9ce9481ad0" name="us-gaap:NumberOfOperatingSegments" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" unitRef="U_Segment" decimals="0" format="ixt:num-dot-decimal">1</ix:nonFraction><ix:nonNumeric id="F_d6a034d6-bb46-42f3-a934-8529b7b3bdda" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_c5e572df-716d-4de5-9c9d-63027d072da4" format="ixt-sec:duryear">3</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="caba-20251231.xsd"/></ix:references><ix:resources><xbrli:context id="C_80a04733-0f39-46fd-b536-fb1363c8d09a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81d87e23-aacc-4a1f-bb17-8d1d063bc827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8260baff-a8b4-45a6-baff-5209fef975bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_848456ab-d285-4d96-bbb7-61690adf497f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_861b1b33-e760-4f7d-921f-9f81e9699673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8624a3cf-a78d-4c1b-b918-bf5987be2150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86c00fdd-0440-4c28-9ac0-005ffb97dc98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88a0af93-4579-4bef-b89d-e83437cf1886"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a513f9d-25e1-4123-992e-02e1600e5c57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8aef1329-81e5-4652-81c2-c852b8d7cbfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8afc398a-f701-4181-b888-7da00743bdd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b9c77dd-2189-4362-bddb-fa1398cd7baf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d6d69e2-dda1-4ea0-94e8-32274096c469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-21</xbrli:startDate><xbrli:endDate>2019-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8fdeb9c1-e391-4554-b8f2-1372cdb91313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90e4ec5b-1296-4608-ba2a-60bd4683d74f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9110b0c0-85f9-4944-8142-2673163f54ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9448925f-7edb-4e94-9f16-2bf8d36d4bb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95690f42-b502-4305-81ac-58e03c9072fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95be2256-2ce7-4d09-8e55-757a475e082c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b692d20-2d25-4b0c-9112-df05af5b8f14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-21</xbrli:startDate><xbrli:endDate>2019-10-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2620028-ec6f-4274-a235-71be3c62c04d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a37aa587-2f96-418b-936d-2a9c780d2b31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a412af93-e740-4e39-b6e6-1cea95e44cc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:SponsoredResearchAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a5873561-482d-4211-8d1a-100b3d8724c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5bfe75d-e5fd-47a2-9113-a7d3d374a0e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a76bf89e-0076-44be-bb89-64f8a0be9373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7cf1e88-d94b-419a-946f-6fef5bc3a6d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8062a63-67f4-417e-aa58-0c10ea3f25d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa89a8f6-fbbc-4204-881f-c09f6fd89717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_abd6b14f-1396-44f4-b7be-b17c6ae488c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:June2025FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac256694-f886-4361-a4f9-4104adc42ab6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:WuxiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad2a1234-93ce-48dc-96ba-3cf1de4b7bff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b10e6031-e107-4203-ad40-05b14067806e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2015ae2-7987-46fd-9f1a-14a53e158ee2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4761317-427b-4343-a89f-5a138a161168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7652f53-0a7b-4044-a278-9b0b094b3818"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:MasterTranslationalResearchServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7f6bbbb-6c89-48bc-8dc4-f9feb90a3989"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:NanjingIasoBiotherapeuticsCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8a71800-f4b2-48f9-bccb-e404ed69141b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b91d5295-ad40-4ba7-93e0-4f6e19c9bd4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bbae0f84-acad-4f21-9dc4-943f64e17a13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbf56b13-a2f8-466a-a449-916231816cd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf882905-b0ee-4b75-99c2-4fea38e7170e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1c27316-e3fc-40d0-af16-e93b32732100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5e572df-716d-4de5-9c9d-63027d072da4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c776a8c2-6701-42d5-9906-29329e10a253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:NanjingIasoBiotherapeuticsCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8b36cac-3990-46a9-8114-ac5487ea54a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca4270cc-f26d-45c8-b902-287451c596e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ccb31ebd-a7c1-4540-8895-81d30d0fcefb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd82e612-a082-48f2-92a1-6e1196a216e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:LonzaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce57e4a4-13e3-4eba-acdf-d75280f60ad4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce88c5ac-13e2-456a-a311-22121b1635b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">caba:StockOptionRepricingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-19</xbrli:startDate><xbrli:endDate>2025-05-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfcf9106-b91e-443d-b454-eae693a2da98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5ccabe0-42f9-4792-b82a-3e639809d25d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8e43c4b-0fae-4bc3-81be-0f50e637fc37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_daa2ae1c-8456-4d82-aeee-31d8df8ec889"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd8bc73d-ffbf-455c-a0b5-28fd1d7b9c00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">caba:StockOptionRepricingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-19</xbrli:startDate><xbrli:endDate>2025-05-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e26415e9-74b5-445d-8fc5-da0f16985c3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4c08503-897b-4429-95f6-4ae813ed7f89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e53823f2-5fac-496e-8cc6-671906c1651f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6e85024-5586-4627-9417-cf890b8d4e9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7b46819-cb47-4a65-abeb-52c116bdf1ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e89f40c1-a23f-40a4-8bee-23bda33abf3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:AutolusHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec1351eb-6c75-4b2b-a584-b9e9880ef824"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">caba:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed842e09-7bf5-4486-9ae9-cadd5f4e3ba9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:WuxiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-24</xbrli:startDate><xbrli:endDate>2024-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0f07fb5-2799-4c77-8564-71079e67edae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f31f321e-4cd2-4185-92e3-2690e8409af5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4a1bbdb-8974-49d9-84ce-4c03b4cc5207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6fec174-bee9-4e5c-b065-1b69e2425c7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f731d894-5793-46d0-97d4-8c8276db0097"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7fa1328-feb2-4be1-8511-2b7650cd1cce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f804a965-6bd2-440f-a975-8966b026c5f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9e49f68-10ed-47f9-abad-85f88ab41fed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe0a6b1e-4837-4292-aa3f-e02510edce97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff686e3b-b5f7-498f-866d-a3514dd25fe3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:MasterTranslationalResearchServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fff8e9a1-e956-45e4-b598-b1977fa3c367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:NanjingIasoBiotherapeuticsCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_024369a9-8747-4977-86bc-392c39212422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_079cb61a-3d40-45c2-80a6-92ffcd32eec0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_086e189e-9e52-4c9c-bd06-f74bb4383472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08dd7fa2-382e-4330-ac22-084c92a87490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09c552e5-3642-480f-b739-e2c13490ca62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0aa15530-7fe2-4778-84a1-34356a306f70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">caba:OrphanDrugCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bea9175-88d0-41db-856a-9e2da9edda2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:June2025FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c2ad5d4-742d-4a38-be11-a6e3ac78b64f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:NanjingIasoBiotherapeuticsCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0cc46475-ebfa-4cb1-8610-3a9fac50cfa5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0dc245ae-95a8-4120-80e6-fdc0fc50dc5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1246f5d0-6b41-48ca-8d69-6d21472a4329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1308d5b8-718f-4b53-9940-2c08e1043f52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_141635e9-25cf-411e-813a-935f24e93c8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1535e593-36e6-42c7-88b6-f44cc18d20a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16102a2e-2a9b-4c06-88d6-cd190d09c7a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenAndTwoThousandNinteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-19</xbrli:startDate><xbrli:endDate>2025-05-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_188e5d31-bb66-43a0-923f-07b3e3e5e7ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_206c187b-7d49-476f-aa68-2c6889189b8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22909102-0e37-4650-b154-28e36d4712cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_230d7c39-9555-4903-a435-0134ba444e94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_257b7837-c492-46b4-8e4c-f8c32fc79674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:AutolusHoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26ba7aad-e65f-4202-9148-f8d56de48c1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">caba:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26cba5b6-ff41-4da4-a18a-c184d569c17f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27282b93-17b5-4ddf-b071-79f5ec3755de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27b86f31-4de3-446f-a21a-b648b1caf82f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27ee9d75-5f66-482b-86f1-88d8cb0a5d9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_281e3d4d-125e-4a9b-80b5-a01331ef864c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-07</xbrli:startDate><xbrli:endDate>2025-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28aa1ca1-487f-4ec6-a7ce-bf5b8437c05e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a18d8f9-5332-4a23-b605-cb3d2126221d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_344e5b09-4b43-4e4c-aece-b1dccaea79db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_344f4aad-150b-49f4-ab92-dffefb18753f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">caba:UnvestedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34daf3e1-57d3-4a11-a83e-a499f1e0f442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:June2025FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36c99cf7-ca6d-4bef-8c7d-d86f756b67a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_380f4971-911e-418e-9b42-9f671cdeed55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_383948ef-273f-45f3-8285-76bb7b9800da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39d08eb8-8fae-43b4-8fb0-2080c3f9bfa0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:AutolusHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a126bb1-aa0b-4ca4-9d54-2b0f17069a24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">caba:Rese-CelAndMuSK-CAARTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a1c09a0-02a7-4e33-a36d-e454e4730213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a5e1afc-a743-4a56-b440-dbd774e83bda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b4d07dc-82b8-43f1-b613-4a8e7b71d9a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d0986e1-7018-41a1-8dff-d52329443bdd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ffe9587-1afc-4c50-9fc3-01d795f0f236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandTwentyFiveSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_44bcec1f-529b-4c9d-949c-c36ef0fc03f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47fea706-96f6-4208-96a0-a6f66f6cd4b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4cd483e2-d5ac-481f-a4e4-14e2c5f3b0c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4df289a5-f84c-498b-9dea-19951da65c82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e7202fb-fc1c-4811-8134-37c7e8ba4ea8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_522cbfa4-2c21-424d-9038-128e92ccffdf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52dc384d-c584-4bd9-9b46-8ad7c00c3f6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53241714-a77e-447f-a6cb-6e14c8221a31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53f6eed2-717f-409c-9e2e-aeb5ff23e199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:June2025FinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5622934b-004c-469d-b5bd-42fbf445d82b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandTwentyFiveInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56867ab7-d91f-49f7-8e38-359323e03001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57a2c95e-1173-4087-adbb-3d92d6dbeea3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5923d687-6b09-4b10-ab7a-35a81dfd434d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_598dae7f-b88a-453f-bb9e-2b82884748a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c1cb0e3-26dc-41c6-a7e9-aa32d0639495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f4640a1-b6f6-4783-b105-897dd65c4d00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62c46a84-f119-4e55-9084-2d63a76277e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63066961-ec40-4822-b55c-b127b3bbe2fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66b45ca8-e68d-4849-8c5f-5bbff16e963f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">caba:VestedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68400128-05f8-412b-8bce-a9b588eb4efa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d087c0e-36a2-45cb-b85c-7485d4eed9e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">caba:StockOptionRepricingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ebe76ca-6547-40a0-a4fb-a46ca3d1dafe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f0d1f48-cee2-4ab8-ae48-a9a04ad2fe08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:AutolusHoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70a0fab7-be2b-4ccd-99f2-f48e769150b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7100f48a-8add-4128-a465-4164ef21fd92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72fa9a9d-1938-4032-8385-aa9b1119676b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77952c23-092c-4512-8995-d28a63420b8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77e60dc1-c4d2-45f5-a2f2-00307e31ec35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_792e0634-91e5-4b0d-aabc-c71a1e755f4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b8638c5-f1ef-4620-8819-259d96ac947a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LonzaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e3f7626-666d-4e8c-8445-9541d4f207e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e7085e6-b579-40fa-abdc-6e0040e9e363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e883d39-427a-4782-a11e-f726f65e38ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001759138</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_Segment"><xbrli:measure>caba:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_a817dc11-a357-48c9-937a-02cf05c1a9c1" fromRefs="F_d92528eb-7b2c-4ba7-8060-2a7ca155f441 F_ea99062d-d4be-49eb-bbc9-f6883b27d25f"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_81b3b034-bf57-4e0a-a22f-af0f469cef56" fromRefs="F_dd88b983-a9d1-402b-abf4-72008a80eafd F_24b538e9-4d41-4e26-9cb5-05ac1e543de0 F_84809593-766c-4e4f-921c-01b456a76dd6 F_3e127737-dbcb-4e43-8404-99aeae424e1d F_9761809e-1865-40ba-8285-293bc8977423 F_e9e68f48-16ac-48e9-a196-ca01bc017555 F_f7ca623a-0882-47ef-85cf-be529169c529 F_ddbbaca2-d4f5-499b-a90f-cbf5c904658c F_2fc57670-68c2-40ed-aa05-239005c777b4 F_e53e7da2-e18c-4919-92a9-0a8e1378d3ec"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_7b1988d3-18b3-4e45-95d7-cf5f32b934e9" fromRefs="F_ff4b9c29-de45-4861-b7a3-e7d6162129c9 F_4bcd57e1-e3fd-44e0-b5d3-f0238dc5238e F_b7161c44-d327-4a04-b67c-59b4ab1359a9 F_baeb6475-4eeb-4dc6-8b63-3cb09f80023e"/></ix:resources></ix:header></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:0.6in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:180pt;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:2.5in;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee1217d9-029c-47b8-ad17-a22489920a62" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:180pt;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:2.5in;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:5%;box-sizing:content-box;"/>
      <td style="width:95%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_8b36a69f-cd01-4509-9af3-66da1d2ac22a" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_faa8d701-882d-4c84-981a-3d3b5aede45e" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c06fc779-6843-4f10-b814-30983b86b531" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ceaba6b7-e873-4ab3-a671-656dd15ff93a" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:5%;box-sizing:content-box;"/>
      <td style="width:95%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_1070a541-7c5f-4b4d-ad82-ba78c89d0e2f" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">                     </span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ccbc2d84-a59f-4a96-9e0c-02255ea8d7f6" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-39103</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:180pt;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:2.5in;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f2c29154-45cf-441b-b85a-c3e51685dda9" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CABALETTA BIO, INC.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:180pt;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:2.5in;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:50%;box-sizing:content-box;"/>
      <td style="width:50%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_93830fa7-2a86-42e0-bc0d-4bad71afceb1" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_d9aba0dc-3382-4887-97fb-6fc614c74530" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">82-1685768</span></ix:nonNumeric></span></p></td>
     </tr>
     <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
     </tr>
     <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_cc6978f0-1c0d-4ba4-92b4-a63d6f22b0cc" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2929 Arch Street</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;"><ix:nonNumeric id="F_2eb6b669-a29d-4455-8347-5446bad82558" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 600</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_92936e26-f21a-4516-93ea-02e60f26d442" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Philadelphia</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;"><ix:nonNumeric id="F_c690595f-e88a-4c36-9cba-c897180ae5b7" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PA</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_43d996c9-a729-44c7-8996-a7258e64c94a" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">19104</span></ix:nonNumeric></span></p></td>
     </tr>
     <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f1d258f-b848-425a-b812-ed7c112aab5c" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">267</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a78b995-6ce2-4954-9f7c-b667c1f47a49" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">759-3100</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:180pt;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:2.5in;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:39.988%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:18.004%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:40.008%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
     </tr>
     <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_2ec5f6e6-4c71-411f-be00-0610bb45b884" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.00001 per share</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_84fa459e-2c99-49ba-919a-7060400793ee" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CABA</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_9fce271b-3f35-4a76-8e8d-e305a5393e7e" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bdc4e508-8036-4586-bbd8-18860df1ed82" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a1dfbc0-fc61-4fd8-84f4-123de75db998" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a86f853-d637-4083-ac4b-32523d34b11c" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb5b3368-95a3-425d-896b-d88d7ffae299" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:18.9%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:55.84%;box-sizing:content-box;"/>
      <td style="width:1.06%;box-sizing:content-box;"/>
      <td style="width:20.08%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:2.12%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     </tr>
     <tr style="height:3pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_c2f8791c-aa11-4e93-a833-c4b63619ba13" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_70556f90-29f9-425a-b99c-a515fe3966d9" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_ce1c237a-8b70-4c3b-a969-f5f378a76516" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_b4d1a710-8863-47c9-bd38-a32c36b9854a" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_41f0aefd-94eb-46d9-9966-54896a7bc2ca" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes </span><span style="font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_a96331f0-2d36-4f68-ab53-99da13853bf8" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of June 30, 2025 (the last business day of the registrant's most recently completed second fiscal quarter), the aggregate market value of the registrant's common stock held by non-affiliates was approximately $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_986ee9d4-98e1-4318-a1a2-f4d20ad367ca" contextRef="C_27ee9d75-5f66-482b-86f1-88d8cb0a5d9e" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">137</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million based on the last reported sale price of the registrant's common stock on the Nasdaq Global Select Market on June 30, 2025.</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of shares of registrant&#8217;s Common Stock outstanding as of March 19, 2026 was </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2b4cecb-5d4b-44bd-bd64-4e775f2df757" contextRef="C_7e7085e6-b579-40fa-abdc-6e0040e9e363" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">111,322,671</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.6in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:10%;box-sizing:content-box;"/>
      <td style="width:81.02%;box-sizing:content-box;"/>
      <td style="width:8.98%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_1"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors_1_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Reserved</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_market_risk"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Financial Statements and Supplementary Data</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Part III</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_governance"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_exec_comp"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_beneficial_ownership"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_transactions"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits, Consolidated Financial Statement Schedules</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
     </tr>
     <tr style="height:2.15pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10_k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138</span></p></td>
     </tr>
     <tr style="height:2.15pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Signatures</span></a></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of the Material and Other Risks Associated with Our Business</span></p><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.1664861117129615%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage company with a limited operating history, have incurred significant losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.1664861117129615%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent on our relationships with Minaris Advanced Therapies, LLC, or Minaris (f/k/a WuXi Advanced Therapies, Inc) and/or Lonza Houston Inc., or Lonza, and/or Cellares Corporation, or Cellares, for our current manufacturing needs for our Phase 1/2 RESET, or Restoring Self-Tolerance, clinical trials for resecabtagene autoleucel, or rese-cel (formerly referred to as CABA-201), and if manufacturing capacity at any of these manufacturing partners is reduced or otherwise delayed or limited, including due to legislative action, or if we, Minaris, Lonza, Cellares or any third-party manufacturers encounter difficulties in manufacturing our product candidates, this could adversely impact the supply of product candidates for and enrollment in our trials.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.1664861117129615%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are reliant on intellectual property licensed to us by Nanjing IASO Biotherapeutics Co., Ltd., or IASO, and termination of this license agreement would result in the loss of significant rights, which would have a material adverse effect on our business.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.1664861117129615%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection for our current product candidates and technologies or any future product candidates, we may not be able to compete effectively in our markets.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.1664861117129615%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need to raise substantial additional funding before we can expect to complete development of any of our product candidates or generate any revenues from product sales.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.1664861117129615%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.1664861117129615%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to successfully develop our current programs into a portfolio of product candidates, or experience significant delays in doing so, we may not realize the full commercial potential of our current and future product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.1664861117129615%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we encounter difficulties enrolling patients in our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials for rese-cel or future clinical trials, these clinical development activities could be delayed or otherwise adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.1664861117129615%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.1664861117129615%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of earlier studies may not be predictive of future study or trial results, and we may fail to establish an adequate safety and efficacy profile to conduct clinical trials or obtain regulatory approval for our product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.1664861117129615%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If serious adverse events, undesirable side effects or unexpected characteristics are identified during the development of any of our product candidates, we may need to delay, abandon or limit our further clinical development of those product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.1664861117129615%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing and administering our product candidates is complex and we may encounter difficulties in technology transfer to a contract manufacturing organization.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.1664861117129615%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to reach agreement with the FDA or comparable foreign regulatory authorities on the methodologies for, and assessment of, comparability of different versions of a product candidate used in non-pivotal studies, pivotal studies and for intended commercial use or may be unable to establish such comparability.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.1664861117129615%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.1664861117129615%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may establish our own manufacturing facility and infrastructure in addition to or in lieu of relying on third parties for the manufacture of our product candidates, which will be costly and time-consuming, and which may not be successful.</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.1664861117129615%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future success depends in part upon our ability to retain our key employees, consultants and advisors and to attract, retain and motivate other qualified personnel. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.5in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.1664861117129615%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have identified conditions that raise substantial doubt about our ability to continue as a going concern. If we are unable to secure additional funding beyond our current cash position that enables our operations into the fourth quarter of 2026, we may be forced to delay, reduce or discontinue our product development programs efforts or other operations.</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K, including the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; contains express or implied forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this Annual Report on Form 10-K include, but are not limited to, statements about:</span></p><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success, cost and timing and conduct of our clinical trial programs, including our Phase 1/2 RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials for rese-cel, and any other product candidates, including statements regarding the timing of initiation, enrollment and completion of the clinical trials and the period during which the results of the clinical trials will become available;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expected timing and significance around the announcement of safety, biologic activity and/or any additional clinical data from our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials for rese-cel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of and our ability to obtain and maintain regulatory approval of our product candidates, including rese-cel, and any other product candidates, in any of the indications for which we plan to develop them, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations for the tolerability and clinical activity of rese-cel and ability to advance this product candidate through our license agreement with IASO;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential benefits of our Orphan Drug, Rare Pediatric Disease and Fast Track designations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expected use of proceeds from sales of our common stock in "at-the-market" offerings and other offerings, and the period over which such proceeds, together with existing cash, will be sufficient to extend our current cash runway beyond our current expectations into the fourth quarter of 2026 and meet our operating needs, including our ability to continue as a going concern;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans to pursue research and development of other product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential advantages of our proprietary Cabaletta Approach for B cell Ablation platform, called our CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform, and our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which our scientific approach and CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform may potentially address a broad range of diseases;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential benefits and success of our arrangements with IASO, Oxford, Minaris, Lonza and Cellares;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully leverage our research and translational insights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the results observed with the similarly-designed construct employed in recent academic publications, including the dosing regimen, and the implications on rese-cel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully commercialize our product candidates, including rese-cel and any other product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential receipt of revenue from future sales of rese-cel and any other product candidates, if approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rate and degree of market acceptance and clinical utility of rese-cel and any other product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates regarding the potential market opportunity for rese-cel and any other product candidates, and our ability to serve those markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our sales, marketing and distribution capabilities and strategy, whether alone or with potential future collaborators;</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain arrangements or a facility for manufacture of rese-cel and any other product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain funding for our operations, including funding necessary to initiate and complete our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials of rese-cel and any ongoing preclinical studies of other product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations for the efficiency of the trial design for our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials for rese-cel and the potential success and therapeutic benefits of rese-cel, including our belief that rese-cel may enable an &#8220;immune system reset&#8221; and provide deep and durable responses in patients across an increasing number of autoimmune diseases;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential achievement of milestones and receipt of payments under our collaborations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to enter into additional collaborations with existing collaborators or other third parties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and our ability to operate our business without infringing on the intellectual property rights of others;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding international expansion and results of our efforts to do so; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of competing therapies that are or become available, and our competitive position;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of government laws and regulations in the United States and foreign countries, including any newly introduced legislation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of any geopolitical conflicts or new or increased international tariffs, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to any preclinical studies or research and development efforts, ongoing clinical trials and future clinical trials; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.6701388888888888in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;font-kerning:none;min-width:4.288103467499163%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to attract and retain key scientific or management personnel.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this Annual Report on Form 10-K. The forward-looking statements contained in this Annual Report on Form 10-K are made as of the date of this Annual Report on Form 10-K, and we undertake no obligations to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="part_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Business.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a late clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Our proprietary CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or Cabaletta Approach to B cell Ablation platform, focuses on the CARTA approach. CARTA refers to Chimeric Antigen Receptor T cells for Autoimmunity and is designed to potentially reset the immune system. Based on clinical data reported to date, we believe our CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform has the potential to safely enable complete and durable responses for a broad range of autoimmune diseases and that it has potential applicability across dozens of autoimmune diseases that we have identified, evaluated and prioritized.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Resecabtagene autoleucel, or rese-cel (formerly referred to as CABA-201), is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a broad range of autoimmune diseases and our lead product candidate within the CARTA strategy. Rese-cel is designed to achieve transient and deep depletion of all B cells following a single, weight-based infusion of T cells that are engineered to express an antibody fragment that recognizes a B cell receptor expressed on the surface of all B cells. The construct is designed to allow for the deep elimination of all B cells, including all B cells that contribute to disease, with subsequent repopulation by healthy transitional, na&#239;ve B cells. This approach has demonstrated the potential to reset the immune system and result in meaningful clinical responses without chronic therapy requirements in patients. The efficacy and safety of rese-cel was recently reviewed along with all other commercial and academic constructs in development in a February 2026 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature Biotechnology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> publication.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, we initiated a registrational trial with rese-cel for patients with dermatomyositis or anti-synthetase syndrome. In addition, we have ongoing Phase 1/2 trials evaluating rese-cel with a standard preconditioning regimen, fludarabine and cyclophosphamide, in systemic lupus erythematosus, or SLE, in patients with active lupus nephritis, or LN, or active SLE without renal involvement, systemic sclerosis, or SSc, and generalized myasthenia gravis, or gMG. In addition to our core development program across multiple indications using standard preconditioning regimens and standard manufacturing processes with partnered Contract and Development Manufacturing Organizations, or CDMOs, based on early data from a phase 1/2 trial evaluating rese-cel without preconditioning in pemphigus vulgaris patients, we are evaluating rese-cel without preconditioning in non-renal SLE and LN patients.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in January 2026 we announced INDa clearance for rese-cel to be manufactured using an automated manufacturing platform &#8211; the Cell Shuttle</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from Cellares - offering the potential for scalability to produce rese-cel for thousands of patients per year with minimal capital investment by the Company. The first clinical experience from these patients is expected to be presented in the first half of 2026.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Durability data from the no preconditioning SLE, LN and PV patients as well as the patients treated with rese-cel manufactured by the Cellares Cell Shuttle</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is expected to be presented in the second half of 2026.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The three adult myositis subtypes, dermatomyositis, or DM, anti-synthetase syndrome, or ASyS, and immune-mediated necrotizing myopathy, or IMNM, being evaluated in the RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trial of rese-cel affect approximately 80,000 patients in the U.S. Myositis typically affects middle-aged individuals, particularly women, and disease is often refractory, despite existing therapies. In the United States, we believe approximately 20% to 25% of the prevalent population, or 16,000 to 20,000 people, would be potentially eligible patients for rese-cel.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trial is designed to treat at least six patients with DM, or ASyS, at least six patients with IMNM, as well as at least six patients with juvenile idiopathic inflammatory myopathy, or JIIM, all in separate parallel cohorts, with a single weight-based dose of 1.0 x 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells/kg. We announced the FDA granted Fast Track Designation for rese-cel for the treatment of patients with dermatomyositis and Orphan Drug Designation for rese-cel for the treatment of myositis in January and February 2024, respectively. In March 2024, we announced the FDA granted Rare Pediatric Disease designation for rese-cel for juvenile dermatomyositis. In May 2025, we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announced the FDA granted Regenerative Medicine Advanced Therapy, or RMAT, designation to rese-cel for the treatment of myositis.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on clinical data presented in October 2025 at the American College of Rheumatology, or the ACR, Convergence 2025, we have initiated a DM/ASyS registrational cohort within the RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial. There are approximately 60,000 patients with DM in the U.S. who have IVIg as their only FDA-approved treatment option and approximately 15,000 patients with ASyS in the U.S. who have no FDA-approved treatment options. Our registrational trial design includes a 16-week primary endpoint of moderate or major TIS response while off immunomodulators and on no or low-dose steroids. Based on the safety data from the phase 1/2 cohort, the protocol permits outpatient administration. In addition, we are planning for a pediatric submission in juvenile idiopathic inflammatory myopathy, or JIIM, based on data available at the time of adult submission from the ongoing Ph 1/2 cohort to support a pediatric label claim.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The planned size of 17 patients for the registrational cohort is based on the assumed treatment effect of rese-cel in DM/ASyS patients and an estimated background rate. The estimated background rate will be determined from a retrospective analysis of an external myositis patient registry and will include patients with similar inclusion criteria as those in the registrational DM/ASyS cohort. Based on comprehensive literature review to estimate the background rate, we estimate the likelihood of an active, refractory myositis patient achieving moderate or major TIS response within 16 weeks and concurrently discontinuing all immunomodulators to be less than 10%. Changes in the assumed background rate would result in a change in the number of rese-cel treated patients who would need to achieve the primary endpoint in the 17-patient registrational cohort.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrational cohorts will evaluate the same single, weight-based infusion of rese-cel at 1 x 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells/kg as used in the Phase 1/2 myositis cohorts with similar enrollment criteria. As presented at ACR Convergence 2025, all myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no immunomodulators. Based on discussions with the FDA, we plan to use pooled rese-cel safety data from across the entire RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trial program to supplement myositis specific safety data for the Biologics License Application, or BLA, submission in myositis, and the required safety database is expected to be approximately 100 autoimmune disease patients treated with the same single weight-based dose. We initiated enrollment in the registrational DM/ASyS cohort in December 2025 and anticipate BLA submission in 2027.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SLE is a chronic, potentially severe, autoimmune disease, most commonly impacting young women between the ages of 15 and 40 with higher frequency and more severity in people of color, where the immune system attacks healthy tissue throughout the body. SLE affects an estimated up to 320,000 patients in the U.S., with LN as the most common end-organ manifestation, affecting approximately 30-40% of SLE patients.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trial is designed to treat six SLE patients with active LN, and in a separate parallel cohort, six patients with active SLE without renal involvement, with a single weight-based dose of 1.0 x 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells/kg. In May 2023, we announced the FDA granted Fast Track Designation for rese-cel in patients with SLE and LN. In November 2025, we announced the FDA granted RMAT designation to rese-cel for treatment of SLE and LN. In January 2026, Cabaletta announced registrational cohort designs in RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to evaluate the current rese-cel weight-based dose of 1 million cells/kg in a single infusion with preconditioning, including two independent, single-arm cohorts, one consisting of patients with non-renal SLE and one consisting of patients with LN each evaluating approximately 25 patients with unique endpoints in each cohort. Complete Phase 1/2 data from both cohorts is anticipated in the first half of 2026. Cabaletta will provide an update on next steps for these cohorts in 2026, subject to dose-ranging data evaluating rese-cel without preconditioning in lupus patients.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RESET-SSc</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SSc is a rare and potentially fatal chronic autoimmune disease characterized by progressive skin and internal organ fibrosis that can be life-threatening, including interstitial lung disease, pulmonary hypertension, and scleroderma renal crisis. SSc affects approximately 90,000 patients in the U.S., typically middle-aged individuals, particularly women.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RESET-SSc</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trial of rese-cel is designed to treat six patients with severe skin manifestations and six patients with severe organ involvement associated with SSc, each in separate parallel cohorts, with a single weight-based dose of 1.0 x 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells/kg. We announced the FDA granted Fast Track Designation for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rese-cel for the treatment of patients with SSc to improve associated organ dysfunction and Orphan Drug Designation for rese-cel for the treatment of SSc in January and March 2024, respectively. In January 2026, Cabaletta announced the FDA granted RMAT designation to rese-cel for treatment of SSc. Complete Phase 1/2 data from both cohorts is anticipated in the first half of 2026, and we anticipate announcing the registrational cohort design for SSc in the first half of 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RESET-MG</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MG is a rare autoimmune disease characterized by autoantibodies that interfere with signaling at the neuromuscular junction, leading to potentially life-threatening muscle weakness. The majority of patients with MG have autoantibodies known to be pathogenic based on their interference with proteins in the NMJ, of which the majority target AChR. gMG affects approximately 100,000 patients in the U.S. Symptoms of gMG include profound muscle weakness throughout the body, disabling fatigue, and potential shortness of breath due to respiratory muscle weakness, with risk for episodes of respiratory failure.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RESET-MG</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trial of rese-cel is designed to treat six patients with AChR-positive gMG and six patients with AChR-negative gMG, each in separate parallel cohorts, with a single weight-based dose of 1.0 x 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells/kg.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, we announced that rese-cel was generally well tolerated across two AChR-positive and two AChR-negative patients (both seronegative; no anti-MuSK or anti-LRP4 antibodies). No CRS (cytokine release syndrome) occurred in three of four patients, and grade 2 CRS occurred in AChR-pos-2 that resolved with no sequelae. As of the September 11, 2025 data cut-off, two evaluable patients (AChR-neg-1 and AChR-neg-2) remained off immunomodulatory medication and achieved significant improvements in MG-ADL (with AChR-neg-1 achieving Minimal Symptom Expression). AChR-pos-1 is not evaluable due to use of a prohibited cytotoxic medication that may have inhibited CAR T activity and AChR-pos-2 has insufficient follow-up.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Both cohorts have been fully enrolled. Complete Phase 1/2 data from both cohorts is anticipated in the first half of 2026, and we anticipate announcing the registrational cohort design for studies in MG in mid-2026.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pemphigus vulgaris, or PV, is an autoimmune disease that occurs when the immune system produces antibodies that attack a protein called desmoglein, or DSG. DSG normally enables skin cells and the cells lining the inside of your mouth, nose, throat, eyelids, etc. to bind tightly together. Disruption by the antibodies directed to DSG causes the painful blisters and erosions characteristic of PV. Approximately 15,000 patients in the U.S. are affected by PV.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ongoing RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial is designed to evaluate rese-cel as a monotherapy without preconditioning in patients with mucosal pemphigus vulgaris, or mPV, and mucocutaneous pemphigus vulgaris, or mcPV.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, we announced that rese-cel exhibited similar CAR T cell expansion and contraction kinetics relative to translational data reported from other RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials with preconditioning. All three patients experienced substantial depletion of B cells within the first month post-infusion, with patients 2 and 3 achieving complete peripheral B cell depletion. In these two patients, rapid reduction in autoantibodies to desmoglein was observed and the increase in peak B cell activating factor, or BAFF, was at the low end of the range of patients dosed with rese-cel plus preconditioning from pre-infusion through the latest follow-up, suggestive of potential deep B cell depletion in the tissue. Additional follow up will be required to determine if the initial clinical effects are durable and to determine if the findings can be replicated in other autoimmune diseases. Rese-cel was generally well tolerated with no immune effector cell-associated neurotoxicity syndrome, or ICANS, reported as of the data cutoff. After infusion, patient 1 experienced transient fever (grade 1 cytokine release syndrome). Patient 2 required a course of steroids for a disease flare in the first two weeks following infusion after discontinuing immunomodulators.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PDAI activity scores have formed the basis for recent regulatory approvals in PV, and total PDAI scores in these patients were also reported to be consistent with the PDAI activity scores in the late breaking clinical trial session.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PDAI improvements were most significant in the two patients who seemed to experience complete peripheral B cell depletion.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our History and Team</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our scientific co-founders, Aimee Payne, M.D., Ph.D., and Michael Milone, M.D., Ph.D., began partnering at Penn in 2013 to combine Dr. Payne&#8217;s expertise in B cell-mediated autoimmune diseases with Dr. Milone&#8217;s deep and experienced insights into the design and implementation of CAR T products. Dr. Payne is a worldwide leader in characterizing B cell-mediated autoantibody repertoires in PV and other autoimmune diseases. Dr. Milone is a renowned scientist in CAR T therapy and was a co-inventor of and a key driver in the preclinical discovery and development efforts that yielded Kymriah&#174;, the first FDA-approved CAR T therapy for the treatment of B cell cancers. Their research attracted the attention of a colleague Steven Nichtberger, M.D., a professor of practice in the Vagelos LSM program and adjunct professor at the Wharton School at the University of Pennsylvania, and in 2017, based on over a year of interaction and discussions regarding the optimal strategy to advance the scientific opportunity into a commercially developed product portfolio that could offer potentially curative treatment options to patients, Drs. Payne, Milone and Nichtberger decided to launch Cabaletta Bio. The longstanding and highly productive partnership between our co-founders has been complemented by additional management experience that brings a successful history of translating academic cellular therapy research from Penn and elsewhere into commercially sponsored clinical trials and the establishment of a GMP manufacturing facility and organization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gwendolyn Binder, Ph.D., our President, Science and Technology, was an early member of the Translational Research Program Operations team at Penn for over five years and participated in the submission and acceptance of multiple INDs for novel engineered T cell therapy products. As part of the cell therapy organization at Penn, Dr. Binder partnered with Dr. Milone and others to drive the IND-enabling translational studies that facilitated the initial CAR T clinical trial in B cell cancers at Penn. Dr. Binder also built and led a clinical stage biotechnology company&#8217;s manufacturing operations and quality teams, including creation of a fully functioning commercial grade GMP facility. Dr. Binder also built the translational research program and ultimately led the company&#8217;s research organization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Medical Officer, David Chang, M.D. was the late-stage clinical development leader of the only two drugs approved for SLE in the United States in over 60 years, belimumab, or Benlysta, and anifrolumab, or Saphnelo, through his roles at GlaxoSmithKline plc and AstraZeneca Pharmaceuticals LP prior to joining the team at Cabaletta Bio. Dr. Chang completed his fellowship in Rheumatology and was a faculty member in the Division of Rheumatology at the Perelman School of Medicine at the University of Pennsylvania prior to his transition to the biopharmaceutical industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Commercial Officer, Steve Gavel, joined Cabaletta in October 2025 and was previously Senior Vice President, Global Cell Therapy Commercial Development at Legend Biotech from 2018 to 2025, reporting to the CEO, where he created and scaled its commercial organization and implementation of all CAR T logistics and management of the leading CAR T centers in the U.S., in partnership with Johnson &amp; Johnson, to successfully launch and grow Carvykti</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a treatment for patients with multiple myeloma. Earlier, Mr. Gavel led U.S. commercial strategy at Celgene.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cabaletta was founded with the purpose of developing targeted, potential curative engineered cell therapies for patients with autoimmune disease. After three years developing a legacy form of cell therapy, we were encouraged by results from an initial case report published in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New England Journal of Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in August 2021 and a follow-up academic clinical study published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in September 2022, showing the potential for CD19-CAR T cell therapy to transform the course of SLE. In five patients with SLE, one-time treatment with a 4-1BB-containing CD19-CAR T cell therapy induced deep and durable clinical responses in all five patients within three months after treatment, with favorable tolerability. Healthy B cells repopulated in all patients within five months of treatment, and responses remained durable off SLE-associated medications for up to 4 years of follow-up, as of September 2025. These findings demonstrate the potential for CD19-CAR T cell therapy to &#8220;reset the immune system,&#8221; eliminating the cause of autoimmune disease with restoration of the healthy immune system.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Building on these results, we announced in October 2022 the development of rese-cel, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases. Prompted by the initial case report in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New England Journal of Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we conducted a global search to identify the optimally designed product candidate for patients with autoimmune diseases to be highly similar to the construct used by Dr. Georg Schett in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> paper. We are employing a clinically-evaluated fully human CD19 binder that has high</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">similarity, including identical epitopes and similar binding activity, to the construct employed in the academic reports. Our exclusive translational research partnership with Dr. Schett involves our robust translational research laboratory combined with confidential sharing of his unpublished clinical data to generate early and actionable insights from his trials that are informing our clinical development strategy and plans. As a result of the collaboration, in September 2023, Cabaletta scientists published &#8220;Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy&#8221; in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Molecular Therapy: Methods and Clinical Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, highlighting studies performed on serum samples from the first six SLE patients treated with CD19-CAR T cell therapy by Dr. Schett&#8217;s team. The publication reports that in the three months following infusion, cytokine markers of systemic inflammation resolved, autoantibody titers declined, and humoral immunity was maintained.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since announcing rese-cel in October 2022, Cabaletta has had five IND applications cleared within the routine 30-day period for the RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trials in SLE, myositis, SSc, gMG and MS, in addition to the RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial that is evaluating rese-cel without preconditioning. Accelerated by the emerging clinical data with rese-cel, our team&#8217;s deep expertise in cell therapy in autoimmunity, demonstrated track record of strong clinical execution, positive regulatory interaction since 2018, and our successful cell therapy manufacturing, we are uniquely positioned to advance CD19-targeting cell therapy candidates to further our mission to develop therapies that deliver deep, durable and potentially curative responses for patients in a broad range of autoimmune diseases.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our goal is to build upon our deep expertise in engineered T cell therapies for autoimmune diseases to accelerate the discovery, development and commercialization of our product candidates. We believe achieving this goal could result in potentially curative therapies for patients with unmet medical needs who suffer from a broad range of autoimmune diseases with B cell involvement. To achieve this goal, key elements of our strategy include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.444391288973938%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Achieving compelling clinical responses and a favorable safety profile for our lead product candidate, rese-cel, and demonstrating its ability to be administered in the outpatient setting. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, we announced that all 4 DM/ASyS patients who met the key inclusion criteria for the myositis registrational cohort with sufficient follow-up achieved immunomodulatory-free TIS responses of moderate or major improvement at week 16, which formed the foundation to initiate the registrational cohort in DM and ASyS.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, we initiated enrollment in the DM/ASyS registrational trial and we announced that in the first 40 patients dosed with rese-cel with preconditioning across 4 RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials, 95% of patients had either no CRS or Grade 1 CRS (transient fever) and 95% of patients experienced no ICANS. Outpatient administration of rese-cel is permitted within the myositis registrational trial, and, if ultimately approved, for outpatient administration. If successful, we believe outpatient administration can reduce hospital resource utilization and improve the reimbursement framework for the 30% of autoimmune patients who are Medicare-insured.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.444391288973938%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leveraging our cellular therapy knowledge and manufacturing experience to manufacture rese-cel with the ability to achieve scalability to meet commercial demand with minimal capital investment. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our team has a successful track record of manufacturing novel cell therapy product candidates with academic and industry partners. We plan to launch utilizing multiple suppliers to ensure supply capacity and redundancy, while eliminating capital expenditure associated with a manufacturing facility. In addition, since 2023, we have partnered with Cellares Corporation, or Cellares, to incorporate automated manufacturing for rese-cel, which can enable scalability to produce rese-cel for thousands of patients per year with minimal capital investment, provide scheduling flexibility for rese-cel after commercialization and permit rapid expansion to support global expansion. Cellares is currently a manufacturer of rese-cel for the RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical program and we anticipate initial clinical experience with Cellares in the first half of 2026 with full clinical and durability data in the second half of 2026.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.444391288973938%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Develop differentiated innovations for rese-cel, including rese-cel without preconditioning, which could enable market expansion, improve patient and provider experience and accelerate outpatient adoption in the commercial setting. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, we announced initial clinical and translational data from the initial dose cohort in the RESET-PV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial evaluating rese-cel without preconditioning. All three patients experienced substantial depletion of B cells within the first month post-infusion, with patients 2 and 3 achieving complete peripheral B cell depletion. Meaningful early clinical responses were observed in all three patients starting in the first month post-infusion based on Pemphigus Disease Area Index, or PDAI, score for skin, scalp and mucosal surfaces. Based on the safety and early efficacy data, multiple patients have now been enrolled at a higher dose cohort within the RESET-PV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> study, and the no preconditioning approach was expanded in the RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial. We believe this innovation can potentially provide a simpler and more patient-focused alternative for lupus patients, many of whom are women of child-bearing potential, who may desire rese-cel without preconditioning. Based on evaluation of clinical durability data, the no-preconditioning strategy may be incorporated into each of our clinical trials.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.444391288973938%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Advancing the RESET</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trials to address significant unmet patient need while continuing to commit to optimize the patient experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We are focused on developing the first potentially curative targeted cellular therapies for patients with autoimmune diseases. We plan to continue development of rese-cel across a broad range of autoimmune diseases where the biologic opportunity for cure or treatment may be possible, addressing significant unmet patient need across multiple indications for rese-cel, with the goal of realizing the potential of rese-cel. While potentially serving a broad range of patients, we are committed to advancing to optimize the patient experience through minimizing the requirement for inpatient stay, optimizing the preconditioning regimen, reducing the burden of apheresis, and/or innovating manufacturing to address scale in autoimmune disease.</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">B Cells in Autoimmune Diseases: Overview and Current Treatment Paradigm</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The body&#8217;s immune system, which is designed to protect the body from infection and cancer, includes B cells and T cells. In addition to producing antibodies against antigens that the body perceives as foreign, B cells are responsible for producing inflammatory cytokines, co-stimulating other immune cells, and presenting antigen to T cells to enable cell-mediated immunity. Autoimmune disease occurs when the immune response becomes mistakenly targeted to healthy tissues and cells, and B cells can contribute to the incitement and/or maintenance of these processes through their varied immune mechanisms. In the case of many autoimmune diseases, B cells are responsible for driving disease through production of autoantibodies, or antibodies against the &#8216;self,&#8217; that lead to disease, as well as through costimulation of T cells and through cytokine production.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><img src="img117331299_0.jpg" alt="img117331299_0.jpg" style="width:558px;height:267px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Thomas G. Forsthuber, et al. &#8220;B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.&#8221; Therapeutic Advances in Neurological Disorders (2018): Vol 11: 1-13</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Key markers of B cell lineage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> CD19 serves as a B cell marker from the pro B cell phase until differentiation to plasma cells, while CD20 is a surface marker expressed in a narrower range of the B cell maturation process. Rese-cel is directed to the CD19 B cell marker. CAAR T product candidates are designed to eliminate antigen specific B cells in each targeted disease, preventing their further development to antibody secreting plasma cells. IgM: immunoglobulin M; IgD: immunoglobulin D; IgA: immunoglobulin A; sIg: surface immunoglobulin, representing the autoantibody on the B cell surface.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is currently no cure for autoimmune diseases. Current treatment options for autoimmune diseases involve generalized immune suppression, achieved through corticosteroids, immunosuppressive medications and biologics. Most commonly, corticosteroids are used on both a chronic and acute basis to control disease and act via a variety of mechanisms to control or downregulate multiple inflammatory pathways. In many cases, systemic immunosuppressive medications often used in chemotherapy such as mycophenolate, azathioprine and methotrexate, are added in an effort to minimize symptoms and manage the expected recurrences in patients. Biologic therapies have emerged as a new class of therapies and have a variety of targets including cytokines, B cells, and co-stimulation molecules. All of these current treatment options impair or destroy healthy B cells and/or other immune cells as well as pathogenic ones, weakening the patient&#8217;s overall immune function, potentially putting them at risk for infection and impairing their response to vaccines. In general, these drugs require chronic administration and may have life-threatening side effects. We believe the ideal therapy in autoimmune diseases with B cell involvement would completely and specifically eliminate the pathogenic B cells with restoration of the normal immune system, enabling an &#8220;immune reset,&#8221; restoring the body&#8217;s immune system to its normal function of fighting foreign invaders, not healthy tissues.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Pipeline and Product Candidates</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">autoimmune diseases. Our CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform focuses on the CARTA approach. Our current product candidate pipeline is illustrated below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><img src="img117331299_1.gif" alt="img117331299_1.gif" style="width:624px;height:215px;"/></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Myositis patients can also be treated by neurologists or dermatologists; lupus nephritis patients can also be treated by nephrologists.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> &#8211; REstoring SElf-Tolerance; Ab &#8211; Antibody; AChR &#8211; Acetylcholine receptor; gMG &#8211; Generalized myasthenia gravis; PV &#8211; Pemphigus vulgaris; SLE &#8211; Systemic lupus erythematosus; SSc &#8211; Systemic sclerosis. FDA Fast Track Designation received in dermatomyositis, SLE and lupus nephritis, systemic sclerosis, generalized myasthenia gravis and multiple sclerosis. FDA RMAT received in myositis, SLE, LN and systemic sclerosis.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rese-cel for multiple autoimmune indications</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rese-cel is designed to achieve transient but deep depletion of all B cells following a single infusion, allowing for the elimination disease-causing B cells with subsequent repopulation by translational na&#239;ve healthy B cells. This strategy may be able to reset the immune system, providing potentially meaningful clinical responses to patients off immunosuppressive therapies. Cabaletta is advancing five RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trials in SLE, myositis, SSc, gMG and PV, with potential application in a broad range of other autoimmune diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rese-cel is comprised of a fully human anti-CD19 binder, which is the extracellular targeting domain. In addition, it contains a 4-1BB costimulatory domain and a CD3-zeta signaling domain, as shown in the figure below:</span></p><p style="text-indent:27pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><img src="img117331299_2.jpg" alt="img117331299_2.jpg" style="width:399px;height:330px;"/></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Image showing the design of rese-cel, with a fully human anti-CD19 binder, the 4-1BB costimulatory domain and the CD3-Zeta signaling domain. The costimulatory and signaling domain are identical to the construct used in the academic clinical studies published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nature Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lancet Rheumatology </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">that were evaluated in SLE and myositis, respectively.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our exclusively licensed fully human CD19 binder has been clinically evaluated in a dual-CD19xCD22 CAR T candidate under development for B cell leukemia and lymphoma in an investigator-initiated trial in China in approximately 20 patients, where IASO has reported a tolerability profile that we believe is favorable for development in autoimmune diseases. Compared to FMC63-CART, rese-cel exhibits comparable biologic activity in vitro and in vivo (Peng, et al).</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the clinical and translational data that we have presented to date and given rese-cel&#8217;s structural and functional similarity to the CD19-CAR T construct employed in the academic clinical study published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including incorporation of a 4-1BB co-stimulatory domain, we believe rese-cel may have the potential to reset the immune system and transform treatment of a broad range of autoimmune diseases with high unmet need.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disease Backgrounds</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Systemic lupus erythematosus is a chronic autoimmune disease, most common in young women between the ages of 15 and 40, with higher frequency and greater severity in people of color. In SLE, the immune system attacks healthy tissue throughout the body. It is results in a range of clinical manifestations, including end organ damage and an increased risk of death. SLE affects an estimated up to 320,000 patients in the U.S. Lupus nephritis is the most common end-organ manifestation of SLE, affecting approximately 30-40% of SLE patients. Among these patients, the risk of end-stage renal disease is approximately 17% and the risk of death is approximately 12%, each within 10 years of diagnosis.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Myositis refers to a group of autoimmune diseases characterized by severe inflammation and muscle weakness. It commonly impacts women of middle age, and in some cases, myositis may also affect other organs and systems in the body, such as the lungs, heart, or skin. Myositis is classified into several subtypes based on the underlying immune mechanisms and clinical characteristics. Although the pathogenesis of myositis is not well understood, there are several subtypes thought to be driven by B cells, including DM, ASyS and IMNM. All three subtypes can lead to severe functional impairment and may be life-threatening. Including juvenile myositis, or JIIM, patients, approximately 80,000 patients are affected by these subtypes in the U.S. Current standard of care typically involves medications to suppress the immune system and/or chronic intensive therapies such as intravenous immunoglobulin, or IVIg. Despite these therapies, many myositis patients have disease that remains refractory to existing medications.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Systemic sclerosis is a rare and potentially fatal chronic autoimmune disease characterized by progressive fibrosis and scarring of the skin and internal organs that can lead to life-threatening conditions, including interstitial lung disease, pulmonary hypertension, and scleroderma renal crisis. Although the etiology of SSc is not well understood, the pathogenic role of autoantibodies and B cells in SSc provides a rationale for studying CAR T therapy in this population. Approximately 90,000 patients in the U.S. are affected by SSc, commonly middle-aged women. Current treatments, which have modest effects, include generalized immunosuppression or drugs targeted to specific symptomatic manifestations. In some cases, autologous hematopoietic stem cell transplant may provide some benefits in organ involvement, but is associated with significant risks, including mortality, infertility, and secondary autoimmune disease, limiting its potential to be applied broadly. The risk of mortality in SSc remains high due to the lack of adequate treatments, with an average survival of approximately 12 years following initial diagnosis.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Myasthenia gravis is a rare autoimmune disease characterized by autoantibodies that interfere with signaling at the neuromuscular junction, or NMJ, leading to potentially life-threatening muscle weakness. The majority of patients with MG have autoantibodies known to be pathogenic based on their interference with proteins in the NMJ, of which the majority target AChR. Generalized MG affects approximately 100,000 patients in the U.S. Symptoms of gMG include profound muscle weakness throughout the body, disabling fatigue, shortness of breath due to respiratory muscle weakness and risk for episodes of respiratory failure. Standard of care therapies include cholinesterase inhibitors, steroids, immunomodulators, and biologics, which often require chronic administration, increasing the risk of serious long-term side effects.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pemphigus vulgaris is an autoimmune disease that occurs when the immune system produces antibodies that attack a protein called DSG. DSG normally enables skin cells and the cells lining the inside of your mouth, nose, throat, and eyelids to bind tightly together. Disruption by the antibodies directed to DSG can cause extensive, painful blistering and life-threatening wounds characteristic of PV. Approximately 15,000 patients in the U.S. and approximately 20,000 patients in Europe are affected by PV. Current therapies do not adequately control the underlying autoimmune process, and PV management often involves long-term immunosuppression, with high-dose steroids used in initial treatment and for relapses. The risk of mortality among patients with PV has been reported to be 2- to 3-fold higher than in the general population.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development Plan</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cabaletta is advancing RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trials in SLE, myositis, SSc, gMG and PV, with potential application in a broad range of other autoimmune diseases. These five RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trials are comprised of independent cohorts with specific objectively defined disease sub-types, which can enroll and dose patients in parallel, and each cohort is expected to be comprised of 6 patients. The trials are initiating at a weight-based dose, which is equivalent to the dose of the 4-1BB CD19-CAR T used in the academic publications (1.0 x 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells/kg) with the same preconditioning regimen of fludarabine and cyclophosphamide, with the exception of the RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials, which contain cohorts that are evaluating rese-cel without preconditioning. Our clinical strategy enables broad investigation of rese-cel across cohorts with well-defined patient populations in our Phase 1/2 clinical trials with the same dose and similar design. We have also received FDA Fast Track Designation for rese-cel in SLE, lupus nephritis, dermatomyositis, systemic sclerosis and multiple sclerosis.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing supply is comprised of three primary components: plasmid (for lentiviral vector production), lentiviral vector (for gene transfer in the cellular product) and cellular product (the final drug product). Our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing strategy utilizes proven external suppliers, with a philosophy of maintaining redundant supply capability for cellular products while leveraging inventory build for plasmid and lentiviral vector, to mitigate potential supply interruption risk.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We established and implemented a phase-appropriate manufacturing supply strategy that optimized financial resources and speed for early clinical phase, or the Process A, and which was designed to enable a transition to a partially automated and commercially scalable process prior to the initiation of our first pivotal study in 2026, or the Process B. In addition, we are pursuing an automated version of Process B, or the Process C, capable of providing flexible and cost efficient supply at a scale that is estimated to be greater than what is achievable with the same footprint with Process B at existing CDMOs.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To support this manufacturing lifecycle plan, we designed and implemented a comparability strategy, which in alignment with our discussions with the FDA, supports the use of clinical safety data across Process A, B and C. Accordingly, Process A is undergoing a planned obsolescence in 2026. Process B is intended for initial commercial launch and is undergoing process validation activities in 2026 and 2027 to support BLA submission. Initial clinical manufacturing data using Process C is expected in 2026. If supportive, the process will be further refined and then put through process validation activities to support commercial application post BLA approval, in time to meet expanded commercial demand.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contract and Development Manufacturing Organizations (CDMOs)</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2021, we entered into the License and Supply agreement, or the LSA, with Oxford Biomedica (UK) Limited, or Oxford, to supply lentiviral vector for the clinical and commercial development of a legacy product candidate. In May 2023, we amended the LSA with Oxford to expand the license to include our rese-cel program. In August 2023, we entered into a vector supply agreement with Oxford, and a related second amendment to the LSA, for rese-cel. In February 2024, we and Oxford entered into a third amendment to the LSA to update the patent schedule. In June 2024, we and Oxford entered into a fourth amendment to the LSA eliminating royalties on net sales of products that incorporate the Oxford technology if Oxford manufactures the vector. Starting in December 2024, we and Oxford entered into work orders for certain process validation activities as part of commercial readiness activities.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For early phase cellular product supply, in January 2021 and as amended in August 2022, we entered into an agreement with Minaris to serve as a cell processing manufacturing partner for a legacy program and have since completed enabling engineering and patient production runs. In August 2023, as amended in August 2024, we entered into an agreement with Minaris to serve as our manufacturing partner for the global clinical development of rese-cel in multiple indications using Process A. Minaris serves as a second CMDO for Process A, in addition to the Cell and Vaccine Production Facility, or CVPF, at the University of Pennsylvania, which has been phased out of clinical production supply as of 2026.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to expand our clinical supply to address the increasing pace of enrollment in our clinical trials, as well as to implement Process B and prepare for registrational trial(s) across the RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical development program, we entered into a clinical supply agreement with Lonza to serve as a clinical supplier of rese-cel using Process B. This clinical supply agreement supports the global clinical development of rese-cel, including potential late-stage clinical trials and preparations for commercial readiness. Our manufacturing process at Lonza will be used for registrational trial enrollment and plans are underway for commercial launch and supply.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In conjunction with our efforts to expand scalable commercial supply for rese-cel through full automation of production, in November 2023, we partnered with Cellares to evaluate Cellares&#8217; automated manufacturing platform, the Cell Shuttle</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, through Cellares&#8217; Technology Adoption Program. As part of the collaboration, we and Cellares agreed on a proof-of-concept technology transfer process for the manufacture of rese-cel. In March 2025, we and Cellares announced the successful conclusion of the Technology Adoption Program on Cellares&#8217; automated cell therapy manufacturing Cell Shuttle</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In June 2025 and January 2026, we expanded our partnership with Cellares to introduce the Cellares manufacturing platform to support the RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical program. In January 2026, we and Cellares entered into a clinical supply agreement with Cellares to service as a clinical supplier of rese-cel using Process C. This clinical supply agreement supports the clinical development of rese-cel. Engineering runs in Cellares&#8217; GMP facility were completed, and our IND amendment has been cleared. Initial clinical runs are ongoing in 2026 providing additional manufacturing and drug product quality data. Based on the outcome of clinical manufacturing performance and comparability data, the Cell Shuttle</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> may be integrated into our future commercial manufacturing strategy for rese-cel.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our aim is to become a fully integrated cellular therapy company focused on improving the lives of patients with autoimmune diseases. The product candidates from our CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform are designed to address autoimmune indications where there is a compelling opportunity to improve clinical outcomes in comparison with the current standard of care.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rese-cel is under development for autoimmune diseases with serious unmet medical need. Based on the differentiated expertise of Cabaletta&#8217;s team members and our years of experience in conducting cell therapy clinical trials in autoimmunity, we are focused on launching an autologous CAR T product for patients with autoimmune diseases, while continuing to innovate on next-generation approaches and differentiation strategies to deliver an optimal product candidate profile.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We aim to launch rese-cel through expanding our CDMO relationships, including advancing a fully automated approach, offering the potential for scalability to produce rese-cel for thousands of patients per year with minimal capital investment. Our development and commercialization efforts will focus initially on the United States, with expansion to the European Union and Asia-Pacific geographies, potentially with the support of strategic partners.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong focus on intellectual property. We face competition from many different players, including large and specialty pharmaceutical and biotechnology companies, academic research organizations and governmental agencies. Any therapeutic candidates we successfully develop and commercialize will compete with the existing standard of care as well as any novel therapies that may gain regulatory approval in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are multiple companies with marketed CAR T therapies for the treatment of hematologic cancers, including Novartis Pharmaceuticals Corporation, Gilead Sciences, Inc., Bristol Myers Squibb, Johnson and Johnson, Inc., Legend Biotech Corporation and Autolus. A subset of these companies along with other biopharmaceutical companies have announced CD19-targeting therapies and other methods of engineering T cells in development for the treatment of autoimmune diseases with B cell involvement, including SLE, myositis, SSc and MG, among others. There are also a number of companies with leading autoimmune franchises but without disclosed cell therapy platforms who may become competitors.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within the CAR T field, we recognize that a subset of companies with an investment and expertise in CAR T cell development for oncology indications have announced they intend to leverage their technology in autoimmune disease-affected populations. We are aware of other pharmaceutical and biotechnology companies that are exploring CD19-CAR T as well as other methods of engineering T cells, natural killer, or NK, cells or bispecific antibodies for the treatment of autoimmune conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property and Barriers to Entry</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We strive to protect the proprietary technologies that we believe are important to our business, including pursuing and maintaining patent protection intended to cover our product candidates and their use, as well as other inventions that are important to our business. In addition to patent protection, we also rely on know-how, confidentiality agreements, invention assignment agreements and trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection, to develop and maintain our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">proprietary position. The confidentiality agreements are designed to protect our proprietary information and the invention assignment agreements are designed to grant us ownership of technologies that are developed for us by our employees, consultants or certain other third parties. We seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in our agreements and security measures, either may be breached, and we may not have adequate remedies. In addition, our trade secrets may otherwise become known or independently discovered by competitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part upon our ability to obtain and maintain patent and other proprietary protection for commercially important technologies, inventions and trade secrets related to our business, defend and enforce our intellectual property rights, particularly our patent rights, preserve the confidentiality of our trade secrets and operate without infringing valid and enforceable intellectual property rights of others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent positions for biotechnology companies like us are generally uncertain and can involve complex legal, scientific and factual issues. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 1, 2026, our in-licensed patent estate included eight granted U.S. patents, ten granted foreign patents, six pending U.S. patent applications, and 28 pending foreign patent applications. See &#8220;Our Material Agreements - IASO Agreement&#8221; and &#8220;Our Material Agreements - Amended and Restated License Agreement with the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia.&#8221; As of March 1, 2026, our Cabaletta-owned patent estate included three pending international patent applications, two pending U.S. patent applications, and nine pending foreign applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With regard to our rese-cel product candidate, under the IASO Agreement, we have in-licensed one patent family which is directed to a CD19-specific chimeric antigen receptor and a CD19-specific antibody and contains granted patents in the United States, China, Japan, and Canada, which are scheduled to expire in 2040, without taking patent term adjustment or patent term extension into account. The family also contains one pending U.S. patent application and counterpart patent applications pending in Australia, China, Europe, and Hong Kong, which, if issued, would be expected to expire in 2040. This patent family is owned by IASO and is exclusively licensed to us in the field of the license. We also own two patent families containing two pending U.S. patent applications and nine pending foreign patent applications drawn to methods of treating autoimmune diseases with a chimeric antigen receptor, including a CD19-specific chimeric antigen receptor, including certain treatment methods that have different preconditioning regimens. Any granted patents in these two families would be expected to expire in 2044. We also own one international patent application drawn to other dosing regimens for treating autoimmune diseases with a chimeric antigen receptor, including a CD19-specific chimeric antigen receptor; one international patent application drawn to CD19-binding antibodies and CD19-specific chimeric antigen receptors; and one international patent application drawn to methods of manufacturing cell-therapy compositions. Any granted patents claiming priority to these applications would be expected to expire in 2045.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, the term of a patent covering an FDA-approved drug may be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years beyond the expiration of the patent but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension may be extended, and a given patent may only be extended once. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that issued U.S. patents covering each of our product candidates may be entitled to patent term extensions. If our product candidates receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved product candidates. We also intend to seek patent term extensions in any jurisdictions where they are available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to patent protection, we also rely on know-how and trade secret protection for our proprietary information that is not amenable to, or that we do not consider appropriate for, patent protection, to develop and maintain our proprietary position. However, trade secrets can be difficult to protect. Although we take steps to protect our proprietary information, including restricting access to our premises and our confidential information, as well as entering into agreements with our employees, consultants, advisors and potential collaborators, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our know-how, trade secrets, and other proprietary information. In addition, we plan to rely on regulatory protection based on orphan drug exclusivities, data exclusivities, and market exclusivities. See &#8220;Government Regulation&#8221; for additional information.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Material Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IASO Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 7, 2022, we entered into an Exclusive License Agreement, or the IASO Agreement, with IASO. Pursuant to the IASO Agreement, we received an exclusive, worldwide license under certain IASO intellectual property to use a novel clinical-stage anti-CD19 binder to develop, manufacture, commercialize and otherwise exploit T cell products directed to CD19 for the purpose of diagnosis, prevention or treatment of any autoimmune or alloimmune indications in humans. IASO has the right of first negotiation if we desire to grant a third party an exclusive license to develop, manufacture, commercialize or otherwise exploit the licensed products in the Greater China region. Pursuant to the IASO Agreement, we and IASO have agreed, subject to certain exceptions, to refrain from engaging in certain competitive activities with respect to certain programs. As partial consideration for the exclusive license, IASO received an upfront payment of $2.5 million. IASO is also eligible to receive up to mid double digit millions in milestone payments based upon the achievement of specified pre-clinical, development and regulatory milestones, and up to an additional low triple digit millions in milestone payments based upon achievement of specified sales milestones, for a total consideration, inclusive of the upfront payment, of up to $162 million, along with tiered mid-single digit royalties on future net sales for licensed products that may result from the IASO Agreement. We also may sublicense through multiple tiers the rights granted to it by IASO under the IASO Agreement at any time, however, we must pay IASO a low double-digit percentage of any revenue obtained from sublicenses or options to third parties, subject to certain customary exclusions. The IASO Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the IASO Agreement, unless earlier terminated. We and IASO may terminate the IASO Agreement for a material, uncured breach or insolvency of the other party. We may also terminate the IASO Agreement at will upon advance written notice and in the event IASO rejects the IASO Agreement due to bankruptcy-related matters. IASO may also terminate the IASO Agreement if we fail to achieve certain specified diligence milestones in a timely manner and/or if we commence any patent challenges with respect to the patents and patent applications relating to the licensed sequence, in each case upon advance written notice. A milestone payment of $1.5 million was paid to IASO in the first quarter of 2024 after the first patient in a rese-cel trial was dosed.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Oxford Biomedica</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2021, we entered into the LSA with Oxford wherein the LSA grants us a non-exclusive license to Oxford&#8217;s LentiVector&#174; platform for its application in our DSG3-CAART program and puts in place a multi-year vector supply agreement. Under the terms of the agreement, we were required to pay Oxford an upfront fee, as well as costs associated with initial vector manufacturing activities. Oxford, is eligible to receive regulatory and sales milestones in the low tens of millions and royalties in the low single digits on net sales of products that incorporate the Oxford technology. We can terminate the agreement at will upon advance written notice and subject to certain manufacturing slot cancellation fees. In May 2023, we amended the LSA with Oxford to expand the license to include our rese-cel program for an upfront fee of $0.5 million and in August 2023, we entered into a vector supply agreement with Oxford, and a related second amendment to the LSA, for rese-cel with a total cost of up to approximately $5.0 million under the vector supply agreement. In February 2024, we and Oxford entered into a third amendment to the LSA to update the patent schedule. In June 2024, we and Oxford entered into a fourth amendment to the LSA eliminating royalties on net sales of products that incorporate the Oxford technology if Oxford manufactures the vector. Starting in December 2024, we and Oxford entered into work orders for certain process characterization and process performance qualification activities as part of commercial readiness activities. We can terminate the LSA or any work order under the LSA at will upon advance written notice and subject to certain cancellation fees.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Minaris Manufacturing Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2021, we entered into a Development and Manufacturing Services Agreement, or the Minaris Agreement, with Minaris to serve as an additional cell processing manufacturing partner for the MuSK-CAART Phase 1 clinical trial, or MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial. The Minaris Agreement is scheduled to expire upon completion of Minaris' services related to MuSK-CAART and rese-cel. In August 2023, as amended in August 2024, we entered into an agreement with Minaris to serve as one of our manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and commercial readiness activities for rese-cel. Under the August 2023 work orders, Minaris converted our non-dedicated suite to a dedicated suite for GMP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing for our rese-cel and MuSK-CAART programs, or the Dedicated Suite, for an initial term of 18 months with two 18 month extensions at our sole option on six months' notice prior to the end of the term. In August 2024, we notified Minaris that we would extend the initial term by 18 months through August 2026. In addition, we agreed to certain monthly minimum runs. In August 2024, the 2023 work order related to GMP manufacturing was amended to reduce the minimum monthly runs through the end of 2024. In lieu of the original $1.5 million termination fee under the terms of the Minaris Agreement, we would incur up to a $1.08 million termination fee if we terminate both the rese-cel and MuSK-CAART work orders for any reason. We may terminate for convenience the Minaris Agreement or any work order with six months' prior written notice, however, we may not terminate the Dedicated Suite without terminating both the MuSK-CAART and rese-cel GMP run work orders. Minaris may terminate the Minaris Agreement or any work order for convenience on 18 months' prior written notice, but such notice may not be effective prior to February 2028. In February 2026, we notified Minaris that we intend to permit the term to expire in August 2026.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lonza Manufacturing Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we entered into a Development and Manufacturing Services Agreement, or the Lonza Agreement, with Lonza to serve as one of our manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and preparations for commercial readiness. The Lonza Agreement has a term of five years and can be extended for an additional three year term upon notice to Lonza at least 18 months prior to the expiration of the Lonza Agreement. We can terminate the Lonza Agreement at will upon nine months advance written notice to Lonza subject to the terms of the Lonza Agreement. Lonza can terminate the Lonza Agreement at will upon 24 months advance written notice to us subject to the terms of the Lonza Agreement. Under the initial work order, Lonza will perform cell therapy manufacturing activities for our CAR-T cell therapy product, rese-cel, for an initial term of 12 months with the ability to extend the manufacturing period on a rolling basis subject to the terms of the Lonza Agreement.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cellares Agreement</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2026, we entered into a Development and Clinical Manufacturing Services Agreement, or the Cellares Agreement, with Cellares to serve as one of our manufacturing partners for the clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and preparations for commercial readiness. The Cellares Agreement has a term of five years. We can terminate the Cellares Agreement at will by providing a certain advance written notice to Cellares subject to the terms of the Cellares Agreement. Cellares can terminate the Cellares Agreement at will by providing a certain advance written notice to us subject to the terms of the Cellares Agreement. Under the initial work order, Cellares will perform clinical cell therapy manufacturing activities for our CAR-T cell therapy product, rese-cel.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated License Agreement with the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2018, we entered into a license agreement with Penn, which was amended and restated in July 2019 to include CHOP, collectively, the Institutions, and collectively with such amendment, as amended in May 2020 and October 2021, the License Agreement, pursuant to which we obtained (a) a non-exclusive, non-sublicensable, worldwide research license to make, have made and use products in two subfields of use, (b) effective as of October 2018, an exclusive, worldwide, royalty-bearing license, with the right to sublicense, under certain of the Institutions&#8217; intellectual property to make, use, sell, offer for sale and import products in the same two subfields of use, and (c) effective as of October 2018, a non-exclusive, worldwide, royalty-bearing license, with limited rights to sublicense, under certain of Penn&#8217;s know-how to make, have made, use, sell, offer for sale, import and have imported products in the same two subfields of use. Our rights are subject to the rights of the U.S. government and certain rights retained by the Institutions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless earlier terminated, the License Agreement expires on the expiration or abandonment or other termination of the last valid claim in Penn&#8217;s intellectual property licensed by us. We may terminate the License Agreement at any time for convenience upon 60 days' written notice. In the event of an uncured, material breach, Penn may terminate the License Agreement upon 60 days' written notice.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a biopharmaceutical company that operates in the United States, we are subject to extensive regulation. Our cell products will be regulated as biologics. With this classification, commercial production of our products will need to occur in registered facilities in compliance with cGMP for biologics. The FDA categorizes human cell- or tissue-based products as either minimally manipulated or more than minimally manipulated and has determined that more than minimally manipulated products require clinical trials to demonstrate product safety and efficacy and the submission of a BLA for marketing authorization. Our products are considered more than minimally manipulated and will require evaluation in clinical trials and the submission and approval of a BLA before we can market them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities in the United States (at the federal, state and local level) and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products such as those we are developing. Our product candidates must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way, but country-specific regulation remains essential in many respects. The process for obtaining regulatory marketing approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Biological Product Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act, or FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations. Biologics are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may result in delays to the conduct of a study, regulatory review and approval or subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, license suspension or revocation, refusal to allow an applicant to proceed with clinical trials, imposition of a clinical hold, issuance of untitled or warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations or penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our drug product candidates must be approved by the FDA through the BLA process before they may be legally marketed in the United States. The process required by the FDA before a biologic may be marketed in the United States generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of extensive nonclinical, sometimes referred to as preclinical, laboratory tests, animal studies and formulation studies in accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practice, or GLP, regulations and standards; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an IND which must become effective before human clinical trials may begin; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated; </span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practices, or GCPs, and other clinical trial-related regulations to establish the safety and efficacy of the proposed drug product candidate for its proposed indication; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of a BLA, which includes not only the results of the clinical trials, but also, detailed information on the chemistry, manufacture and quality controls for the product candidate and proposed labeling; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the product is produced to assess compliance with the FDA&#8217;s current good manufacturing practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality, purity and potency; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential FDA audit of the preclinical trial sites and/or clinical trial sites that generated the data in support of the BLA; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval of the BLA prior to any commercial marketing or sale of the product in the United States. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The data required to support a BLA is generated in two distinct development stages: preclinical and clinical. The preclinical development stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The conduct of the preclinical studies must comply with federal regulations, including GLPs. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, as well as other information, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug product candidate at any time before or during clinical trials due to safety concerns, non-compliance, or other issues affecting the integrity of the trial. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United States, certain human clinical trials involving recombinant or synthetic nucleic acid molecules are subject to oversight of institutional biosafety committees, or IBCs, as set forth in the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, or NIH Guidelines. Under the NIH Guidelines, recombinant and synthetic nucleic acids are defined as: (i) molecules that are constructed by joining nucleic acid molecules and that can replicate in a living cell (i.e., recombinant nucleic acids); (ii) nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules (i.e., synthetic nucleic acids); or (iii) molecules that result from the replication of those described in (i) or (ii). Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The clinical stage of development involves the administration of the drug product candidate to healthy volunteers and patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products, including biologics, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials are generally conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3, and may overlap. Phase 1 clinical trials generally involve a small number of healthy volunteers who are initially exposed to a single dose and then multiple doses of the drug product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action tolerability, adverse effects, and safety of the drug product candidate and, if possible, to gain early evidence on effectiveness. Phase 2 clinical trials typically involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, as well as identification of possible adverse effects and safety risks and preliminary evaluation of efficacy. Phase 3 clinical trials generally involve large numbers of patients at multiple sites, in multiple countries, and are designed to provide the data necessary to demonstrate the efficacy of the product for its intended use, its safety in use, and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. Phase 3 clinical trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. Generally, two adequate and well-controlled Phase 3 clinical trials have been required by the FDA for approval of a BLA, although there are known exceptions, particularly for rare diseases. FDA leadership announced in February 2026 that the FDA will, going forward, adopt the default position that one adequate and well-controlled trial, combined with confirmatory evidence, can serve as the basis of approval for novel products. In certain instances, FDA may condition approval of a BLA on the sponsor&#8217;s agreement to conduct additional clinical trials to further assess the biologic&#8217;s safety and effectiveness after BLA approval. Such post-approval trials are sometimes referred to as Phase 4 clinical trials. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and further document clinical benefit in the case of drugs approved under Accelerated Approval regulations. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the biologic, findings from animal or in vitro testing that suggest a significant risk for human subjects, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated intervals based on access to certain data from the trial and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as interim data suggesting a lack of efficacy. We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate. Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">drug product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug product candidate and, among other things, must develop methods for testing the identity, strength, quality, potency and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">BLA and FDA Review Process</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following trial completion, trial data are analyzed to assess safety and efficacy. The results of preclinical studies and clinical trials are then submitted to the FDA as part of a BLA, along with proposed labeling for the product and information about the manufacturing process and facilities that will be used to ensure product quality, results of analytical testing conducted on the chemistry of the drug product candidate, and other relevant information. The BLA is a request for approval to market the biologic for one or more specified indications and must contain proof of safety, purity, potency and efficacy, which is demonstrated by extensive preclinical and clinical testing. The application may include both negative or ambiguous results of preclinical and clinical trials as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic may be marketed in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee, which is adjusted on an annual basis. PDUFA also imposes an annual prescription drug product program fee. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once a BLA has been accepted for filing, which occurs, if at all, sixty days after the BLA&#8217;s submission, the FDA&#8217;s goal is to review BLAs within 10 months of the filing date for standard review or six months of the filing date for priority review, if the application is for a product intended for a serious or life-threatening condition and the product, if approved, would provide a significant improvement in safety or effectiveness. The FDA has substantial discretion in the approval process and may refuse to accept any application or decide that the data is insufficient for approval, and may require additional preclinical, clinical or other studies before it accepts the filing. Additionally, the review process is often significantly extended by FDA requests for additional information or clarification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the BLA submission is accepted for filing, the FDA reviews the BLA to determine, among other things, whether the proposed drug product candidate is safe and effective for its intended use, and whether the drug product candidate is being manufactured in accordance with cGMP to assure and preserve the drug product candidate&#8217;s identity, strength, quality, purity and potency. The FDA may refer applications for novel drug product candidates or drug product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA will likely re-analyze the clinical trial data, which could result in extensive discussions between the FDA and us during the review process. The review and evaluation of a BLA by the FDA is extensive and time consuming and may take longer than originally planned to complete, and we may not receive a timely approval, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving a BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether the facilities comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. In addition, before approving a BLA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the BLA identified by the FDA. The Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, withdraw the application or request a hearing. Even if such data and information is submitted, the FDA may ultimately decide that the BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive, and the FDA may interpret data differently than we interpret the same data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no assurance that the FDA will ultimately approve a product for marketing in the United States, and we may encounter significant difficulties or costs during the review process. If a product receives marketing approval, the approval may be significantly limited to specific populations, severities of allergies, and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the BLA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post-market testing or clinical trials and surveillance to monitor the effects of approved products. For example, the FDA may require Phase 4 testing which involves clinical trials designed to further assess the product&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve the BLA without an approved REMS, if required. a REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or based on the results of post-market studies or surveillance programs. Additionally, post-approval, many types of changes to the approved product, such as adding new indications, changing manufacturing processes and adding labeling claims, are subject to further testing requirements and FDA review and approval. Such post-approval requirements can be costly and time-consuming and can affect the potential market and profitability of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Designation and Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval for the use or indication for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug or biologic for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity on the basis of greater effectiveness or safety or providing a major contribution to patient care or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication but that could be used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if our product is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If we pursue marketing approval for an indication broader than the orphan drug designation we have received, we may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for Fast Track Designation if they are intended to treat a serious or life-threatening condition and nonclinical or clinical data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstrate the potential to address unmet medical needs for the condition. Fast Track Designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biologic may request the FDA to designate the drug or biologic as a Fast Track product concurrently with, or at any time after, submission of an IND, and the FDA must determine if the product qualifies for Fast Track Designation within 60 days of receipt of the sponsor&#8217;s request. Under the Fast Track Designation, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review, or review within a six-month timeframe from the date a complete BLA is accepted for filing, if it has the potential to provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for priority review in an effort to facilitate the review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, a product may be eligible for accelerated approval. An investigational drug may obtain accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials and, under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast Track Designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Breakthrough Designation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product can be designated as a breakthrough therapy if it is intended to treat a serious or life-threatening condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. A sponsor may request that a drug product candidate be designated as a breakthrough therapy concurrently with, or at any time after, the submission of an IND, and the FDA must determine if the drug product candidate qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#8217;s request. If so designated, the FDA shall act to expedite the development and review of the product&#8217;s marketing application, including by meeting with the sponsor throughout the product&#8217;s development, providing timely advice to the sponsor to ensure that the development program to gather preclinical and clinical data is as efficient as practicable, involving senior managers and experienced review staff in a cross-disciplinary review, assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor, and taking steps to ensure that the design of the clinical trials is as efficient as practicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accelerated Approval for Regenerative Medicine Advanced Therapies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA&#8217;s regenerative medicine advanced therapy, or RMAT, program is intended to facilitate efficient development and expedite review of regenerative medicine advanced therapies, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition. A drug sponsor may request that FDA designate a drug as an RMAT concurrently with or at any time after submission of an IND. FDA has 60 calendar days to determine whether the drug meets the criteria, including whether there is preliminary clinical evidence indicating that the drug has the potential to address unmet medical needs for a serious or life-threatening disease or condition. A BLA for an RMAT may be eligible for priority review or accelerated approval through (1) surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit or (2) reliance upon data obtained from a meaningful number of sites. Benefits of such designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. An RMAT that is granted accelerated approval and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is subject to post approval requirements may fulfill such requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post approval monitoring of all patients treated with such therapy prior to its approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and efficacy of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDCA requires that a sponsor who is planning to submit a marketing application for a drug or biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within sixty days of an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from nonclinical studies, early phase clinical trials, and/or other clinical development programs. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of data or full or partial waivers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Marketing Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following approval of a new product, a manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated safety and efficacy information, product sampling, distribution, and tracking and tracing requirements, and complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may prescribe legally available drugs and biologics for off-label uses, manufacturers may not market or promote such off-label uses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Modifications or enhancements to the product or its labeling or changes of the site of manufacture are often subject to the approval of the FDA and other regulators, which may or may not be received or may result in a lengthy review process. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, once a product is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMPs. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. cGMP regulations require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These regulations also impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. BLA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such facilities or the ability to distribute products manufactured, processed or tested by them. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA also may require post-approval testing, sometimes referred to as Phase 4 testing, REMS and post-marketing surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, untitled or warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Regulatory Matters</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the United States, the Centers for Medicare &amp; Medicaid Services, or CMS, other divisions of the Department of Health and Human Services, or HHS (e.g., the Office of Inspector General, or OIG, and Office for Civil Rights), the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency and state and local governments. In the United States, sales, marketing and scientific/educational programs must also comply with federal and state fraud and abuse laws, data privacy and security laws, transparency laws, and pricing and reimbursement requirements in connection with governmental payor programs, among others. The handling of any controlled substances must comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also potentially subject to federal and state consumer protection and unfair competition laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure to comply with regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. In addition, even if a firm complies with FDA and other requirements, new information regarding the safety or efficacy of a product could lead the FDA to modify or withdraw product approval. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, legislation is drafted, introduced, passed in Congress and signed into law that could significantly change the statutory provisions governing the approval, manufacturing, and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations, guidances, and policies are often revised or reinterpreted by the agency in ways that may significantly affect the manner in which pharmaceutical products are regulated and marketed. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Patent Term Restoration and Marketing Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and specifics of the FDA approval of our drug product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patent. The U.S. PTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product was created by the Biologics Price Competition and Innovation Act of 2009, or BPCI Act, which was part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA. This amendment to the PHSA attempts to minimize duplicative testing. Biosimilarity, which requires that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times, that the product and the reference product may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product. However, complexities associated with the larger, and often more complex, structure of biological products as compared to small molecule drugs, as well as the processes by which such products are manufactured, pose significant hurdles to implementation that are still being worked out by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reference biological product is granted twelve years of exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after first licensure. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. This does not include a supplement for the biological product or a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device, or strength, unless that change is a modification to the structure of the biological product and such modification changes its safety, purity, or potency. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a case-by-case basis with data submitted by the sponsor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods. This six-month exclusivity, which attaches to the twelve-year exclusivity period for reference biologics, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial, provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pricing and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">United States</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of our products will depend, in part, on the extent to which our products, once approved, will be covered and reimbursed by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly reducing reimbursements for medical products and services. The process for determining whether a third-party payor will provide coverage for a drug product, including a biologic, typically is separate from the process for setting the price of a drug product or for establishing the reimbursement rate that a payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the approved drugs for a particular indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to secure coverage and reimbursement for any drug product candidate that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the drug product candidate, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Whether or not we conduct such studies, our drug product candidates may not be considered medically necessary or cost-effective. A third-party payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on our investment in product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development. In the United States, the principal decisions about reimbursement for new drug products are typically made by CMS, an agency within HHS. CMS decides whether and to what extent a new drug product will be covered and reimbursed under Medicare, and private payors tend to follow CMS to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists among third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor. Additionally, one third-party payor&#8217;s decision to cover a particular product or service does not ensure that other payors will also provide coverage for the product or service, and the level of coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage determination process will often require us to provide scientific and clinical support for the use of our products to each payor separately and can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Factors payors consider in determining reimbursement are based on whether the product is:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a covered benefit under its health plan; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safe, effective and medically necessary; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">appropriate for the specific patient; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cost-effective; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">neither experimental nor investigational. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The containment of healthcare costs has become a priority of federal and state governments, and the prices of drugs, including biologics, have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. In many countries, the prices of drug products are subject to varying price control mechanisms as part of national health systems. In general, the prices of drug products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for drug products but monitor and control company profits. Accordingly, in markets outside the United States, the reimbursement for drug products may be reduced compared with the United States. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our drug product candidate or a decision by a third-party payor to not cover our drug product candidate could reduce physician usage of the drug product candidate and have a material adverse effect on our sales, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside of the United States, the pricing of pharmaceutical products is subject to governmental control in many countries. For example, in the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been approved. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular therapy to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products but monitor and control product volumes and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical products will likely continue as countries attempt to manage healthcare expenditures. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Healthcare Laws and Compliance Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers, physicians, and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our business operations in the United States and our current and future arrangements with clinical investigators, healthcare providers, consultants, third-party payors and patients may expose us to broadly applicable federal and state fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include: the federal Anti-Kickback Statute, the False Claims Act, and HIPAA.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration, directly or indirectly, in cash or in kind, that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by imprisonment, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we would not submit claims directly to payors, drug manufacturers can be held liable under the federal civil False Claims Act, which imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities (including manufacturers) for, among other things, knowingly presenting, or causing to be presented to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. Penalties for a False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties for each separate false claim, the potential for exclusion from participation in federal healthcare programs and, although the federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. The government may deem manufacturers to have &#8220;caused&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off- label. Claims which include items or services resulting from a violation of the federal Anti-Kickback Statute are false or fraudulent claims for purposes of the False Claims Act. The federal False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery. Our future marketing and activities relating to the reporting of wholesaler or estimated retail prices for our products, if approved, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state and third-party reimbursement for our products, and the sale and marketing of our product candidates, are subject to scrutiny under this law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we may be subject to data privacy and security regulations by both the federal government and states in which we conduct our business. For example, HIPAA created new federal criminal statutes that prohibit among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or the HITECH, and its implementing regulations, mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common healthcare transactions, as well as standards relating to the privacy and security of individually identifiable health information, which require the adoption of administrative, physical and technical safeguards to protect such information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business associates, defined as independent contractors or agents of covered entities, which include certain health care providers, health plans, and healthcare clearinghouses, that create, receive or obtain protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, certain state laws govern the privacy and security of health information and other personal data in certain circumstances, some of which are more stringent or otherwise different than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and criminal penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the federal Physician Payments Sunshine Act, or the Sunshine Act, within the ACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other licensed health care practitioners and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. In addition, many states also govern the reporting of payments or other transfers of value, many of which differ from each other in significant ways, are often not pre-empted, and may have a more prohibitive effect than the Sunshine Act, thus further complicating compliance efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may become subject to federal government price reporting laws, which would require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs, as well as federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar federal, state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services. Such laws are generally broad and are enforced by various state agencies and private actions. Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant federal government compliance guidance, and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, individual imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource- consuming and can divert a company&#8217;s attention from the business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Current and Future Legislation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, in 2010, the ACA was enacted in the United States. The ACA includes measures that have significantly changed, and are expected to continue to significantly change, the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA of greatest importance to the pharmaceutical industry are that the ACA:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217; rebate liability by raising the minimum basic Medicaid rebate on average manufacturer price, or AMP, on most branded prescription drugs and adding a new rebate calculation for &#8220;line extensions&#8221; (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposed a requirement on manufacturers of branded drugs to provide a 70% point-of-sale discount as a condition for a manufacturer&#8217;s outpatient drugs being covered under Medicare Part D; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extended a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expanded the entities eligible for discounts under the 340B Drug Discount Program; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs, apportioned among these entities according to their market share in certain government healthcare programs, and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">established a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. The research conducted by the Patient-Centered Outcomes Research Institute may affect the market for certain pharmaceutical products. The ACA established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Budget Control Act of 2011 and subsequence legislation, among other things, created measures for spending reductions by Congress that include aggregate reductions of Medicare payments to providers of 2% per fiscal year, which remain in effect through 2031. Due to the Statutory Pay-As-You-Go Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent legislation, Medicare payments to providers were further reduced starting on January 1, 2025; however, legislation has been introduced in the U.S. Congress that would, if enacted, reverse these payment reductions.&#8239;In addition to provider payment cuts under Medicare, the American Rescue Plan Act of 2021 also eliminated the statutory Medicaid drug rebate cap, previously set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024. These laws and regulations may result in additional reductions in Medicare and other healthcare funding available for healthcare providers and may otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to request access to certain IND products that have completed a Phase I clinical trial and that are undergoing investigation for FDA approval. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2017, CMS published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On&#8239;May 23, 2019, CMS published a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient assistance programs, and reform government program reimbursement methodologies for drugs. At a federal level, President Trump reversed some of President Biden&#8217;s executive orders including rescinding Executive Order 14087 entitled &#8220;Lowering Prescription Drug Costs for Americans." President Trump may issue new executive orders designed to impact drug pricing. A number of these and other proposed measures may require authorization through additional legislation to become effective. Congress and the Trump administration have indicated that they will continue to seek new legislative measures to control drug costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Inflation Reduction Act of 2022, or IRA includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket spending cap for Medicare Part D beneficiaries from $7,050 to $2,000 which became effective in 2025, thereby effectively eliminating the coverage gap; impose new manufacturer financial liability on certain drugs under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January 1, 2032 the implementation of the HSS rebate rule that would have limited the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition. Under the One Big Beautiful Bill Act of 2025, or OBBBA, this restriction was eliminated; and effective for the 2028 initial price applicability year, all orphan drugs, regardless of the number of orphan drug designations or indications, are exempt from the Medicare drug price negotiation program. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Certain states are also pursuing cost containment efforts through Prescription Drug Affordability Boards, or PDABs, and similar entities. While many PDABs have been granted authority to promote drug price transparency and reporting, some states have granted PDABs more expansive authority, including to set Upper Payment Limits, or UPLs, on select, high price drugs. The adoption and implementation of UPLs may put downward pressure on drug prices and impact our company&#8217;s future revenues. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict what healthcare reform initiatives may be adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Such reforms could have an adverse effect on anticipated revenues from product candidates and may affect our overall financial condition and ability to develop product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Foreign Corrupt Practices Act</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FCPA prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional Regulation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Europe / Rest of World Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to regulations in the United States, we may be subject to a variety of regulations in other jurisdictions that we may in the future select governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval of a product, we would need to obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial authorization application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial application must be submitted through the centralized EU platform (CTIS) for coordinated assessment by the competent authorities of the concerned Member States together with review by an ethics committee in accordance with national law, much like the FDA and IRB, respectively. Once the clinical trial authorization application is approved in accordance with the applicable Member State requirements under the EU Clinical Trials Regulation, the clinical trial may proceed in the relevant Member State(s).</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain regulatory approval of a medicinal product in the EU, we must submit a marketing authorization application, or MAA. The application used to file the BLA in the United States is similar to that required in the EU, with the exception of, among other things, country-specific document requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States. A medicinal product can be designated as an orphan if its sponsor can establish that: (1) the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition, (2) either (i) such condition affects no more than five in ten thousand persons in the EU when the application is made, or (ii) without the benefits derived from orphan status, it is unlikely that the marketing of the product in the EU would generate sufficient return to justify the necessary investment in its development; (3) there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the product would be of significant benefit to those affected by that condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An orphan designation provides a number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized EU marketing authorization. Upon grant of a marketing authorization, orphan medicinal products are entitled to a ten-year period of market exclusivity, which means that the EMA and the competent authorities of the EU member states cannot accept another MAA, or grant a marketing authorization, or accept an application to extend a marketing authorization for a similar medicinal product for the same indication for a period of ten years. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed pediatric investigation plan. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The orphan exclusivity period may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for which it received orphan destination, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity or where the prevalence of the condition has increased above the threshold. Additionally, a marketing authorization may be granted to a similar medicinal product for the same indication as an authorized orphan product at any time if (i) a second applicant can</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish that its product, although similar to the authorized orphan product, is safer, more effective or otherwise clinically superior; (ii) the marketing authorization holder for the authorized orphan product consents to a second medicinal product application; or (iii) the marketing authorization holder for the authorized product cannot supply enough orphan medicinal product.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The PRIority MEdicines (&#8220;PRIME&#8221;), scheme is intended to encourage product development in areas of unmet medical need. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if there is, the new medicine will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of therapeutic candidates with PRIME designation, including but not limited to early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated EMA contact and rapporteur from the Committee for Medicinal Products for Human Use are appointed early in the PRIME scheme facilitating increased understanding of the product at the EMA&#8217;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. Where, during the course of development, a medicine no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission introduced legislative proposals in April 2023 that, if implemented, will replace the current regulatory framework in the European Union for all medicines (including those for rare diseases and for children). In April 2024, the European Parliament adopted its position on the legislative proposals and, in June 2025, the Council of the European Union adopted its position. A common position on the text was agreed upon on December 11, 2025, in the context of subsequent inter-institutional trilogue negotiations. The proposed revisions remain to be adopted into EU law, and are not expected to become applicable before 2028.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">European Union General Data Protection Regulation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to EU regulations related to the approval and commercialization of our products, we may be subject to the EU&#8217;s General Data Protection Regulation, or GDPR. The GDPR imposes stringent requirements for controllers and processors of personal data of persons in the EU, including, for example, ensuring an appropriate legal basis or condition applies to the processing of personal data, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of data, such as health data, and additional obligations when we contract with third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other third countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, further to the UK&#8217;s exit from the EU, the GDPR ceased to apply in the UK at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the UK&#8217;s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the UK&#8217;s data protection regime, which is independent from but aligned to the EU&#8217;s data protection regime.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The GDPR and UK GDPR apply extraterritorially, and we may be subject to the GDPR and UK GDPR because of our data processing activities that involve the personal data of individuals located in the European Union or United Kingdom, such as in connection with our EU and UK clinical trials. Failure to comply with the requirements of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GDPR or UK GDPR and the applicable national data protection laws of the EU member states and UK may result in fines of up to &#8364;20,000,000 (or &#163;17.5 million for the UK) or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. GDPR and UK GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital Resources</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had 156 employees, 154 of whom were full-time and 2 whom were part-time. Of those, 139 were engaged in research and development activities. Two full-time employees are located in Switzerland and two full-time employees are located in Germany. We do not have any employees that are represented by a labor union or covered under a collective bargaining agreement. We consider our relationship with our employees to be good.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future success depends on our ability to attract, develop and retain key personnel, maintain our culture, and ensure diversity and inclusion in our board, management and broader workforce. Our human resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards. As these areas directly impact our ability to compete and innovate, they are key focus areas for our board of directors and senior executives. A testament to our strong culture is the strong results from our annual employee survey.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate History and Trademarks</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated under the laws of the State of Delaware in April 2017 under the name Tycho Therapeutics, Inc. In August 2018, our corporate name was changed to Cabaletta Bio, Inc. We have two subsidiaries, Cabaletta Bio GmbH, incorporated in Switzerland and Cabaletta Bio (Germany) GmbH, incorporated in Germany. Our principal executive offices are located at 2929 Arch Street, Suite 600, Philadelphia, PA 19104, and we have limited corporate and research operations in Germany and Switzerland. Our telephone number is (267) 759-3100, and our website address is www.cabalettabio.com. We do not incorporate the information on or accessible through our website into this Annual Report on Form 10-K, and you should not consider any information on, or that can be accessed through, our website to be part of this Annual Report on Form 10-K. We have included our website address in this Annual Report on Form 10-K solely as an inactive textual reference.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We view our operations and measure our business as one reportable segment. All of the Company's tangible assets are held in the United States. Refer to Note 8, Segment Information, to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K for additional information.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own or have rights to various trademarks, service marks and trade names that we use in connection with the operation of our business. This Annual Report on Form 10-K may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties&#8217; trademarks, service marks, trade names or products in this Annual Report on Form 10-K is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this Annual Report on Form 10-K may appear without the &#174;, &#153; or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service marks and trade names.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, and any amendments to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge on our website located at www.cabalettabio.com as soon as reasonably practicable after they are filed with or furnished to the SEC. These reports are also available at the SEC&#8217;s Internet website at www.sec.gov.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investors and others should note that we announce material information to our investors using our investor relations website (https:// https://www.cabalettabio.com/investors), SEC filings, press releases, public conference calls and webcasts. We use these channels as well as social media, including LinkedIn and X (formerly Twitter) (@CabalettaBio), to communicate with the public about our company, our business, our product candidates and other matters. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the social media channels listed on our investor relations website. Information that is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contained in and can be accessed through our website or our social media posts are not incorporated into, and does not form a part of, this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A copy of our Corporate Governance Guidelines, Code of Conduct and Business Ethics and the charters of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee are posted on our website, www.cabalettabio.com, under the heading &#8220;Investors &amp; Media.&#8221;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;" id="item_1a_risk_factors_1_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Risk Factors.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business involves material and other risks, some of which are summarized and described below. You should carefully consider the risks and uncertainties described below, together with all of the other information contained in this Annual Report on Form 10-K, including "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the consolidated financial statements and the related notes. If any of the following risks actually occur, it could harm our business, prospects, operating results and financial condition and future prospects. In such event, the market price of our common stock could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Annual Report.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business, Technology and Industry</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Clinical Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are early in our development efforts. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are early in our development efforts and we have not yet completed any clinical trials. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Even if we are able to develop and commercialize a marketable product, we may face challenges generating revenue from product sales. The success of our product candidates will depend on several factors, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful completion of preclinical studies resulting in data that is supportive of advancing to an investigational new drug, or IND, or clinical trial application, or CTA submission; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful submission and acceptance of INDs, CTAs or comparable applications; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful initiation of clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstration of adequate safety to progress to a therapeutic dose level; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful patient enrollment in and completion of clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt and related terms of regulatory and marketing approvals and licensures from applicable regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers for clinical supply and commercial manufacturing of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">making arrangements with various medical divisions across hospitals for administration of our product candidates, including with cancer treatment centers to conduct leukapheresis and with the relevant hospital divisions to perform infusion; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing sales, marketing and distribution and patient administration capabilities and launching commercial sales of our products, if and when licensed, whether alone or in collaboration with others; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of our products, if and when licensed, by patients, the medical community and third-party payors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effectively competing with established and emerging therapies targeting the same indications as our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining third-party coverage and adequate reimbursement; and </span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining a continued acceptable safety profile of our products following licensure. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or be unable to successfully commercialize our product candidates, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cellular therapies, including our engineered chimeric antigen receptor T cell, or CAR T, chimeric autoantibody receptor T cell, or CAAR T, product candidates, represent a novel approach to the treatment of autoimmune diseases, which creates significant challenges for us. Negative perception or increased regulatory scrutiny of any product candidates that we develop could adversely affect our ability to conduct our business or obtain regulatory approvals for such product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cellular therapies are a novel approach to the treatment of autoimmune diseases, and negative perception or increased regulatory scrutiny of any product candidates that we develop could adversely affect our ability to conduct our business or obtain regulatory approvals for such product candidates. There are no cellular immunotherapies licensed to date in the United States or the European Union to treat autoimmune diseases or alloimmune responses. CAR T or CAAR T cell therapies for autoimmune or alloimmune diseases may not gain the acceptance of the public or the medical community. For example, CAR Ts and other cellular therapies have in some cases caused severe side effects, including death, and their broader use may therefore be limited. In the future, in the event such severe side effects are observed with other CAR T therapies (including those with a CD19 binder), it may increase negative perception of, and regulatory scrutiny on, our product candidates. For example, in November 2023, the FDA announced that it would be conducting an investigation into reports of T cell malignancies following treatment with BCMA-directed or CD19-directed autologous CAR T cell immunotherapies. The FDA also stated that patients and clinical trial participants receiving treatment with such approved products should be monitored life-long for new malignancies. In January 2024, the FDA determined that new safety information related to T cell malignancies should be included in the labeling with boxed warning language on these malignancies for all BCMA- and CD19-directed genetically modified autologous T cell immunotherapies. Public perception may be influenced by claims that gene therapy, including the insertion of a transgene, is unsafe, and products incorporating gene therapy may not gain the acceptance of the public or the medical community. The patient populations targeted by our product candidates are also typically not at risk of near-term death, even if they may suffer life-threatening symptoms, so patients will need to deem the benefits of cell therapy to be worth the risk of unknown potential adverse side effects. Our success will depend upon physicians who specialize in the treatment of autoimmune diseases targeted by our product candidates prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are more familiar and for which greater clinical data may be available. Adverse events in clinical trials of our product candidates, in clinical trials of others developing similar products or in the post-approval setting and the resulting publicity, as well as any other adverse events in the field of cellular therapies, could result in a decrease in demand for any product that we may develop.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are developing a pipeline of CAR T and CAAR T product candidates that are intended for use in treating individuals with autoimmune diseases. Advancing these novel product candidates creates significant challenges for us, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing our product candidates to our specifications and in a timely manner to support our clinical trials, and, if licensed, commercialization; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sourcing clinical and, if licensed, commercial supplies for the materials used to manufacture our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">understanding and addressing variability in the quality and quantity of a subject&#8217;s T cells, which could ultimately affect our ability to manufacture clinical supply and, if licensed, commercial supply of our product candidates in a reliable and consistent manner; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">educating medical personnel regarding the potential side effect profile of our product candidates, if licensed, such as the potential adverse side effects related to worsening of systemic lupus erythematosus, or SLE, idiopathic inflammatory myopathy (IIM), or myositis, systemic sclerosis, or SSc, muscle-specific kinase myasthenia gravis, or MuSK MG, generalized myasthenia gravis, or gMG, pemphigus vulgaris, or PV, multiple sclerosis, or MS, adverse effects related to infusion of activated T cells or medication taper, including cytokine release syndrome, or CRS, immune effector cell-associated neurotoxicity syndrome, </span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or ICANS, or other unexpected adverse effects of therapy with our product candidates or potential class-wide side effects, such as those related to CD19-directed autologous CAR T cell immunotherapies;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">facilitating patient access to the limited number of facilities able to administer our product candidates, if licensed; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">using medicines to manage adverse side effects of our product candidates that may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">utilizing preconditioning agents in patients to enhance engraftment in advance of administering our product candidates, which may increase the risk of adverse side effects and potentially reduce the population eligible for therapy; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining regulatory approval for our product candidates, as the FDA and other regulatory authorities have limited or no experience with development of engineered T cell therapies for the treatment of autoimmune diseases where B cells may play a role in initiating or maintaining disease; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of a novel therapy; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">managing costs of inputs and other supplies while scaling production. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, preclinical murine and other animal models may not exist or be adequate for some or all of the autoimmune diseases where B cells may play a role in initiating or maintaining disease we choose to pursue in our programs, and because we are early in the clinical development process, we are unable to predict whether there may be short-term or long-term effects from treatment with any product candidates that we develop. In developing our product candidates, we have not exhaustively explored different options in the method for manufacturing CAR T or CAAR T cells. We may find our existing manufacturing process may be substantially improved with future design or process changes, necessitating further clinical testing, delaying commercial launch of our first products, and causing us to incur additional expenses. For example, while we have used a lentiviral vector in our manufacturing process, we may in the future find that another viral vector or non-viral vector-based process offers advantages. Switching from one lentiviral vector to another or switching from lentiviral to another delivery system would necessitate additional process development and clinical testing, and this may delay the development of existing product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, for certain RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials, we do not know the doses to be evaluated in pivotal trials or, if licensed, commercially. Finding a suitable dose may delay our anticipated clinical development timelines, and we may elect to pause clinical trials to find a suitable dose or make assessments ahead of continuing a trial. Our expectations with regard to our scalability and costs of manufacturing may vary significantly as we develop our product candidates and understand these critical factors. We may experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical studies or commercializing our product candidates on a timely or profitable basis, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, our product candidates may not perform successfully in clinical trials or may be associated with adverse events that distinguish them from the CAR T therapies that have previously been licensed. For instance, subjects in our CAAR T clinical trials have been infused with our proposed therapies, and may possess strongly activating soluble antibodies, which are not present in oncology patients, and when they interact with our infused product candidates, could result in potential adverse side effects, such as CRS or ICANS, which have been observed in our clinical trials. Additionally, adverse side effects caused by even one of our CAR T or CAAR T product candidates could negatively affect our ability to develop future product candidates based on our CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform. Unexpected side effects or clinical outcomes from any of our products candidates would significantly impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the clinical study requirements of the FDA, the European Medicines Agency, or EMA, and other regulatory agencies and the criteria they use to determine the safety, potency and purity of a product candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours is less clear, and can be more complex and consequently have higher development risk, be more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. Approvals by the FDA for existing cell therapies treating B cell-mediated diseases, such as Kymriah (Novartis Pharmaceuticals Corporation) and Yescarta</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Gilead Sciences, Inc.) in oncology indications, may not be indicative of what the FDA may require for approval of our therapies in autoimmune indications. Approvals by any regulatory agency may not be indicative of what any other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory agency may require for approval or what such regulatory agencies may require for approval in connection with new product candidates. As we advance our product candidates, we will be required to consult with these regulatory agencies and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of such product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. More restrictive statutory regimes, government regulations or negative public opinion would have an adverse effect on our business, financial condition, results of operations and prospects and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, responses by agencies at the federal and state level to negative public perception or ethical concerns may result in new legislation or regulations that could limit our ability to develop or commercialize any product candidates, obtain or maintain regulatory approval or otherwise achieve profitability. The FDA has expressed interest in further regulating biotechnology products, such as cellular therapies. Agencies at both the federal and state level in the United States, as well as the U.S. Congressional committees and other government entities or governing agencies have also expressed interest in further regulating the biotechnology industry. Such action may delay or prevent commercialization of some or all of our product candidates. Adverse developments in clinical trials of cellular therapy products conducted by others or in the post-approval setting may cause the FDA or other oversight bodies to change the requirements for approval of any of our product candidates. These regulatory review agencies and committees and the new requirements or guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patients receiving T cell-based immunotherapies, such as our product candidates, have in the past and may in the future experience serious adverse events, including ICANS, CRS and killing of cells other than the intended B cells that express the autoantibodies. If our product candidates are revealed to have high and unacceptable severity and/or prevalence of side effects or unexpected characteristics, their clinical development, regulatory approval, and commercial potential will be negatively impacted, which will significantly harm our business, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates are CAR T or CAAR T cell-based immunotherapies. In our clinical trials and clinical trials of other similarly designed cellular immunotherapies to treat cancer, there have been life threatening events related to ICANS and/or CRS requiring intense medical intervention, such as intubation or medications to support blood pressure, and in several cases in clinical trials of other similarly situated clinical trials and of other similarly designed immunotherapies to treat cancer resulted in death. We have observed events of CRS and ICANS in our ongoing rese-cel REstoring SElf-Tolerance, or RESET, trial. ICANS is a condition that is currently defined clinically by cerebral edema, confusion, drowsiness, speech impairment, tremors, seizures or other central nervous system side effects, when such side effects are serious enough to lead to intensive care. CRS is a condition that is currently defined clinically by certain symptoms related to the release of cytokines, which can include fever, chills and low blood pressure, when such side effects are serious enough to lead to intensive care with mechanical ventilation or significant medications to support blood pressure. There is a possibility that our product candidates could have similarly life threatening serious adverse side effects, such as ICANS and CRS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates may have serious and potentially fatal consequences due to the targeting of cells within the body due to unexpected protein interactions with the CAR or CAAR. Although we have completed multiple preclinical studies designed to screen for toxicity caused by unintended off-target recognition by the cell binding domain of the DSG3 CAAR, MuSK CAAR and rese-cel and intend to screen future CAR candidates not yet tested in patients through preclinical studies, our product candidates may still recognize and react with one or more proteins unrelated to the intended surface immunoglobin target protein to which it is designed to link. If unexpected binding occurs in normal tissue, our product candidates may target and kill the normal tissue in a patient, leading to serious and potentially fatal adverse events, undesirable side effects, toxicities or unexpected characteristics. Detection of any unexpected targeting may halt or delay any ongoing clinical trials for our product candidates and prevent or delay regulatory approval. While we have developed a preclinical screening process to identify cross-reactivity of our product candidates, we cannot be certain that this process will identify all potential tissue that our product candidates may target. For example, a membrane protein array with DSG3-CAART yielded one weak signal against a protein that is designed to bind to glycoproteins and which was detected in both the test and control conditions. Further analysis of this protein in confirmatory cell-based assays repeatedly demonstrated that DSG3-CAART does not</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recognize nor activate against this protein. We performed similar preclinical studies for rese-cel and did not observe any confirmed off target activity for rese-cel. However, this further analysis may prove to be inaccurate. Any unexpected targeting that impacts patient safety could materially impact our ability to advance our product candidates into clinical trials or to proceed to marketing approval and commercialization. Furthermore, in the event subjects are re-treated, they may respond differently than other subjects given the same dose, and may not tolerate the dose or develop safety concerns.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of our studies could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory agencies. Our clinical trials of rese-cel represent the first evaluation of this product candidate in patients and rese-cel is directed against all B cells expressing CD19; therefore, there is a risk for prolonged B cell aplasia and/or hypogammaglobulinemia, which may predispose patients to infections. Given that the autoimmune and alloimmune diseases we are seeking to treat are, in some cases, less serious than the later stage cancers being treated with other immunotherapy products, we believe the FDA and other regulatory authorities likely will apply a different benefit-risk assessment thresholds such that even if our product candidate demonstrated a similar safety profile as current CAR T therapies, the FDA may ultimately determine that the harmful side effects outweigh the benefits and require us to cease clinical trials or deny approval of our product candidates. We believe tolerance for adverse events in the patient population being pursued with our CAAR T and CAR T cell therapies in autoimmune and alloimmune indications will be lower than it is in oncology, and the risks of negative impact from these toxicities may therefore be higher for us than for CAR T programs in oncology.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the studies or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from T cell-based immunotherapies are not normally encountered in routine medical care. Medical personnel may need additional training regarding T cell-based immunotherapy product candidates to understand their side effects. Inadequate training in recognizing or failure to effectively manage the potential side effects of T cell-based immunotherapy product candidates could result in patient deaths. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition to side effects caused by our product candidates, any preconditioning, administration process or related procedures, which we evaluate from time to time as part of our process improvement and optimization efforts, may also cause adverse side effects. For example, prolonged or persistent cytopenias and ICANS have been noted to be associated with the use of certain lymphodepleting regimens and CAR T therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preconditioning regimens, as currently implemented in several of our clinical trials, may increase the risk of adverse side effects and impact our ability to accurately assess the efficacy of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In oncology patients receiving CAR T cell therapy, a lymphodepleting preconditioning regimen is typically used to condition the patient prior to CAR T cell infusion in order to improve tumor immunogenicity and to promote the expansion of the infused CAR T cells. Together, these effects have been shown to enhance the clinical activity of CAR T cells in oncology patients. These regimens often include cyclophosphamide and fludarabine and are usually administered within the week prior to infusion of CAR T cells. We implemented a preconditioning regimen in the DesCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial where certain subjects were pre-treated with IVIg and cyclophosphamide, and other patients were pre-treated with IVIg, cyclophosphamide, and fludarabine prior to DSG3-CAART infusion, have included planned dosing cohorts in the MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial where subjects were pre-treated with fludarabine and cyclophosphamide prior to MuSK-CAART infusion, and we have incorporated a lymphodepleting preconditioning regimen of fludarabine and cyclophosphamide in our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials. We are evaluating rese-cel without preconditioning in our RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial in patients with mPV and mcPV, as well as in a subset of patients enrolled in our RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial. Serious adverse events have been observed in some patients following CAR T cell infusion, and these include infection, cytokine release syndrome and ICANS. The lymphodepleting and immunomodulatory preconditioning regimen may contribute to the occurrence and severity of these adverse events due to its role in inducing leukopenia, or low levels of white blood cells in the blood, including lymphopenia, or low levels of lymphocytes in the blood, and regulating the activation and effector functions of other immune cells and antibodies, and enhanced CAR T cell activity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, a lymphodepleting regimen may eliminate pathogenic B cells targeted by our CAAR T cell product candidates. As a result, any lymphodepleting regimen for preconditioning that we use may delay or otherwise</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adversely affect our ability to use DSG3 or MuSK autoantibody titers, a standard clinical assay, to assess the activity of DSG3-CAART and MuSK-CAART, respectively. An inability to use DSG3 or MuSK autoantibody levels to demonstrate the specific activity of our CAAR T cell product candidates may require us to rely on the subjective measurement of blister formation in patients in the DesCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial or muscle weakness in the MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, which can be a less sensitive and accurate measurement of CAAR T cell activity. This therefore could delay a signal of potential biologic activity attributable to CAAR and therefore may slow clinical development. We are not actively enrolling patients in the MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial at this time.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to lymphodepleting preconditioning, other preconditioning regimens with immunomodulatory effects may be considered to prepare the body for CAR T or CAAR T infusion. For example, if autoantibody is found to reduce or inhibit function of CAAR T in the body, then pretreatment of patients with antibody reducing therapies, such as FcRN inhibitors, IVIg, plasmapheresis, or treatment of post rituximab patients may be considered. Some of these types of preconditioning are standard of care for this autoimmune population and therefore are already considered to have a beneficial risk profile in this patient population. These other preconditioning regimens may cause serious adverse events, including hypotension, thromboembolism, and opportunistic infections.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subjects in our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials, except for our RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial and a subset of patients enrolled in our RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial, will be treated with a standard preconditioning regimen consisting of fludarabine and cyclophosphamide prior to rese-cel infusion. In addition, the lymphodepleting regimen may eliminate some of the pathogenic B cells targeted by rese-cel. As a result, the lymphodepleting regimen may contribute to the initial clinical response that may be observed after rese-cel, which may make interpretation of early efficacy difficult to assess and may also delay our ability to characterize the activity of rese-cel independent of the effects of fludarabine and cyclophosphamide. We intend to evaluate this potential impact of preconditioning in our CAAR and rese-cel studies, through the comparison to non-lymphodepletion arms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our clinical patients may experience increased or more severe adverse effects specifically related to the preconditioning regimens, such as severe allergic reactions, difficulty breathing, severe headaches, fevers and chills, serious infections, low blood counts, inflammation of the colon with bleeding, bladder irritation, blood clots, development of certain cancers, damage to the heart, lung or kidneys, and even death. These undesirable side effects, whether associated with the preconditioning regimen alone or in combination with our CAR T cell product candidates or CAAR T cell product candidates, could cause delays in patient enrollment in our clinical trials, could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a change to our clinical trial design, a more restrictive label or the delay or denial of regulatory approval by the FDA. Any of the foregoing may increase the duration and expense of the clinical development of our product candidates or limit market acceptance of such product candidates, if approved, any of which could have a material adverse effect on our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business is highly dependent on the success of our initial product candidates targeting autoimmune diseases where B cells may play a role in initiating or maintaining disease. All of our product candidates will require significant additional preclinical and/or clinical development before we can seek regulatory approval for and launch a product commercially.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business and future success depend on our ability to obtain regulatory approval of, and then successfully launch and commercialize our initial product candidates targeting autoimmune diseases where B cells may play a role in initiating or maintaining disease. There is no guarantee that we will be able to advance our product candidates through clinical development or obtain marketing approval for any of our product candidates. The process for obtaining marketing approval for any product candidate is very long and risky and there will be significant challenges for us to address in order to obtain marketing approval as planned, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The initial clinical results we have observed may not be predictive of results of subsequent cohorts in this clinical trial, or of any future clinical trials. Because rese-cel is the first CAR T product candidate that we are testing in the clinic, we may experience preliminary complications surrounding trial design, protocol establishment and execution, establishing trial protocols, patient recruitment and enrollment, quality and supply of clinical doses, or safety issues.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, a failure of our rese-cel RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trial could influence physicians&#8217; and regulators&#8217; opinions with regard to the viability of our CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform more broadly, particularly if treatment-related side effects are observed. The occurrence of any of these risks could significantly harm our development plans and business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prospects. If treatment-related side effects are observed with the administration of rese-cel, or if they are viewed as less safe, potent or pure than other therapies, our ability to develop other CAR T cell therapies may be significantly harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have never successfully completed any clinical trials, and we may be unable to do so for any product candidates we develop.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not yet demonstrated our ability to successfully complete any clinical trials, including large-scale, pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Although our key employees have significant experience in leading clinical development programs, our experience conducting clinical trials with our product candidates is limited. We may not be able to file INDs or CTAs for any of our other product candidates on the timelines we expect, if at all. For example, we cannot be certain that the IND-enabling or CTA-enabling studies for our future product candidates will be completed in a timely manner or be successful or that the manufacturing process will be validated in a timely manner. Even if we submit an IND or CTA for a future product candidate, the FDA, the EMA, or other foreign regulatory authorities may not clear the IND or CTA and allow us to begin clinical trials in a timely manner or at all. The timing of submissions on future product candidates will be dependent on further preclinical and manufacturing success. Moreover, we cannot be sure that submission of an IND or a CTA will result in the FDA or other foreign regulatory authorities allowing further clinical trials to begin, or that, once begun, issues will not arise that require us to suspend or terminate clinical trials. Commencing each of these clinical trials is subject to finalizing the trial design based on discussions with the FDA and other foreign regulatory authorities. Any guidance we receive from the FDA or other foreign regulatory authorities is subject to change. These regulatory authorities could change their position, including, on the acceptability of our trial designs or selection of comparator or clinical endpoints, which may require us to complete additional clinical trials or impose stricter approval conditions than we currently expect. If the FDA disagrees with, or subsequently revises or withdraws its prior feedback regarding our clinical endpoints or how to measure clinically meaningful significance, then even if we meet clinical endpoints we may be prevented or delayed in obtaining marketing approval for such product candidates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not obtain marketing approval at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to post-marketing testing requirements; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have the product removed from the market after obtaining marketing approval. </span></div></div><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our registrational trials may rely on a single-arm design and an external control; if regulatory authorities determine that the external control is unsuitable, we may be unable to obtain approval on our anticipated timelines, or at all.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to conduct registrational trials using an open-label, single-arm design with an external comparator(s) rather than a blinded, randomized controlled trial. As a result, data generated from these studies may be subject to heightened FDA scrutiny regarding potential bias, confounding variables, and the overall reliability of treatment-effect estimates. In externally controlled trials, outcomes for patients who receive the investigational therapy according to the trial protocol are compared with outcomes from individuals who did not receive the investigational therapy and who are external to the trial. External controls may be historical (from an earlier time period) or concurrent (collected during the same time period in a different setting), and may be derived from real&#8209;world data sources such as patient registries, electronic health records, or medical claims. For example, in our RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> program for rese-cel, we intend to conduct a single-arm registrational trial in patients with dermatomyositis or antisynthetase syndrome evaluating a 16-week primary endpoint&#8212;defined as achievement of a moderate or major Total Improvement Score</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">while off immunomodulators and on no or low&#8209;dose steroids&#8212;and we intend to rely on a retrospective analysis of a myositis patient registry to estimate control response rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of a registry dataset introduces risks, including whether the dataset is sufficiently comparable to our trial population and whether key clinical and demographic variables are assessed consistently. If the FDA disagrees with, or subsequently revises or withdraws its prior feedback regarding the suitability of our trial design, analytical methods, or the external control dataset, the FDA may require additional data, extended follow-up, alternative endpoints, or a randomized controlled trial. Any of these outcomes could substantially delay or prevent regulatory approval. The FDA has highlighted multiple risks associated with the use of external controls, including the potential for confounding and bias arising from, among other factors: temporal changes in standard of care; geographic differences in treatment practices or access to care; heterogeneity in diagnostic criteria; differences in prognostic indicators; variations in background therapies; differing clinical characteristics and responses to standard of care among patients with different disease subtypes; differing assessment schedules or endpoint definitions; missing data; and selection bias in the external dataset. The FDA also generally expects patient-level access to external datasets and robust, pre-specified statistical analysis plans. Even with such plans, as well as propensity methods and sensitivity analyses, these approaches may insufficiently mitigate confounding and bias in the view of the FDA.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our external control dataset, its pre-specification, or our planned analyses are viewed as inadequate, the FDA may determine that our single-arm registrational trial does not constitute an &#8220;adequate and well&#8209;controlled&#8221; investigation under applicable regulations, and may make such determination even where we believe that we have previously aligned with the FDA on the design of the registrational trial. The FDA may also determine that any patient registry we use&#8212;including the myositis registry supporting our RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cohort&#8212;is unsuitable as an external control. In March 2026, FDA noted that concerns with the use of a registry include potential differences between the enrolled study population and registry population for the RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cohort (e.g. diagnosis classification and refractory definition) and missing data as well as other criteria established by FDA guidance for industry, and that such details are needed in order to assess suitability of the proposed registry as an external control. In addition, FDA has recently issued Complete Response Letters or changed its feedback to sponsors in pre-BLA meetings citing concerns with external controls such as potential bias and design flaws, including eligibility criteria, endpoints, and timing of assessments not being closely aligned between trial population and the external dataset. If the FDA reaches similar conclusions in our case, it could reject our comparative analyses, request confirmatory data, or require a randomized trial, resulting in significant delays, increased costs, or failure to obtain approval.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if our clinical data and statistical analyses comparing our data to an external control&#8212;such as a myositis registry&#8212;demonstrate favorable evidence of the investigational candidate&#8217;s effectiveness, the FDA may still determine that such evidence is insufficient to support approval. This could occur for a variety of reasons, including unfavorable interpretation of comparative analyses, perceived differences between the clinical and external datasets, questions regarding the adequacy of our sensitivity analyses, or concerns about the absence of additional control sources.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to bring our product candidates to the market; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiation of investigations by regulators; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs to defend the related litigation; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a diversion of management&#8217;s time and our resources; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exhaustion of any available insurance and our capital resources; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize any product candidate; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a decline in our share price. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since we have not yet commenced marketing of any products, we do not yet hold product liability insurance for commercialization of our product candidates. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. Assuming we obtained clinical trial insurance for our clinical trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Industry</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Undesirable or unacceptable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other foreign regulatory authorities. Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the drug. Undesirable side effects could also result in an expansion in the size of our clinical trials, increasing the expected costs and timeline of our clinical trials. Additionally, results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensed CAR T cell therapies and those under development have shown frequent rates of CRS and ICANS, and adverse events have resulted in the death of patients. Similar adverse events have occurred and could occur during treatment with our current or future CAR T or CAAR T cell product candidates. For example, activation of CAAR T cells by patient autoantibodies or alloantibodies could stimulate CRS. When CAAR T cells are infused and the CAAR binds to soluble antibodies in the blood or tissues of treated patients, these soluble antibodies may cause the CAAR T cells to proliferate, resulting in an activation of the immune system that is too high, leading to CRS. Further, it is possible that patients will exhibit acute rejection of the CAAR T cells because of preexisting immunity to the antigen within the CAAR. This could render our product candidates ineffective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If unacceptable toxicities or health risks, including risks inferred from other unrelated immunotherapy trials, arise in the development of our product candidates, we could suspend or terminate our trials or the FDA, the Safety Monitoring Boards for our trials (e.g. Data Safety Monitoring Board, or DSMB, or Independent Data Safety Monitoring Committee, or IDMC), or local regulatory authorities such as institutional review boards, or IRBs, or independent ethics commits, or IECs, as applicable, could recommend or order us to cease clinical trials. Regulatory authorities, such as the FDA, could also deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from T cell therapy are not normally encountered in the general patient population and by medical personnel. We expect to have to train medical personnel using CAR T or CAAR T cell product candidates to understand the side effect profile of our product candidates for both our preclinical studies and clinical trials and upon any commercialization of any of our product candidates, if licensed. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient deaths. Any of these occurrences may harm our business, financial condition and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our preclinical studies and clinical trials may fail to demonstrate the safety, potency and purity of any of our product candidates, which would prevent or delay regulatory approval and commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe, potent and pure for use in each target indication. Clinical trials are expensive and can take many years to complete, and their outcomes are inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, including in any post-approval studies of our product candidates. In addition, initial success in any clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety, potency and purity profile despite having progressed through preclinical studies and initial clinical trials. Similarly, while we believe rese-cel has a similar overall design to the construct used for the patients in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature Medicine,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lancet, Annals of Rheumatic Diseases, and Rheumatology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> publications, those studies involved a small number of patients, and a different product candidate, and the initial clinical results observed in those studies may not be predictive of clinical trial results with rese-cel or any of our other product candidates. Additionally, because those studies are not our own, we may not have access to accurate follow-up information or peer-reviewed results.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of potency or efficacy, insufficient durability of potency or efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical and other nonclinical findings made while clinical trials were underway, or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or European Commission approval. Most product candidates that commence clinical trials are never approved as products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any preclinical studies or clinical trials that we may conduct may not demonstrate the safety, potency and purity necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future preclinical studies and clinical trials are inconclusive with respect to evaluations of efficacy, the safety, potency and purity of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significance, or if there are safety concerns associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for such product candidates. In some instances, there can be significant variability in evaluations of efficacy, safety, potency or purity results between different preclinical studies and clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. For example, because our CAAR T cell product candidates only target approximately 0.01% to 1% of the B cells in a patient, they may not engage enough of the target to achieve adequate engraftment necessary for elimination of all pathogenic B cells. Insufficient safety or potency in clinical trials may delay product development to enable time to modify the product candidate for next generation approaches or make manufacturing changes or may lead us to discontinue development of the product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, our ongoing clinical trials utilize, and our planned trials may utilize, an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an active drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we cannot guarantee that the FDA or other foreign regulatory authorities will interpret the results of any of our ongoing or planned clinical trials as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or other foreign regulatory authorities to support a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant must obtain the necessary approvals by the comparable foreign regulatory authorities before commencing clinical trials or marketing of the product in those countries or jurisdictions. For example, the process governing approval of medicinal products in the European Union generally follows the same lines as in the United States but can differ in significant ways. It entails the satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission of a marketing authorization application to the EMA (for products within the scope of the centralized marketing authorization procedure) and the granting of a marketing authorization by the European Commission before the product can be marketed and sold in the European Union.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim, topline or preliminary data from any preclinical studies or clinical trials that we conduct may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials in SLE, myositis, SSc, gMG, MS and PV are designed as open-label trials. From time to time, we may publicly disclose interim, preliminary or topline data from our preclinical studies and clinical trials, including safety data and evaluations of efficacy, which will be based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following our receipt of additional data or a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from planned interim analyses in our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or our competitors, or by patients or caregivers who are aware that a patient is receiving investigational product, due to the open-label design of the trial, could result in volatility in the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory agencies, including the FDA or other foreign regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the interim, topline or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The increasing use of social media platforms presents new risks and challenges.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Social media is increasingly being used to communicate about our clinical development programs and the diseases our product candidates are being developed to treat. We intend to utilize appropriate social media in connection with communicating about our development programs. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to report an alleged adverse event during a clinical trial, or public news outlets and opinion pieces relating to our industry or CAR T therapies more generally may be published and/or disseminated. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations, or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our investigational products and/or the industry in which we operate. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website, or a risk that a post on a social networking website by any of our employees may be construed as inappropriate promotion. If any of these events were to occur or we otherwise fail to comply with any applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business such as reputational damage.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may encounter substantial delays in our clinical trials or may not be able to conduct our trials on the timelines we expect or at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical testing is expensive, time consuming and subject to uncertainty. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. Even if these trials begin as planned, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our ongoing and future clinical trials may not be successful. Events that may prevent successful or timely completion of clinical development include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in developing suitable assays for screening patients for eligibility for clinical trials with respect to certain product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching a consensus with the FDA and other regulatory agencies on trial design; </span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective CMOs, CROs and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CMOs, CROs and clinical trial sites; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in obtaining required institutional review board, or IRB, approval at each clinical trial site; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND submission or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical study operations or study sites; developments on trials conducted by competitors for related technology or by those that rely on a similar construct, design and/or third-party research that raise FDA or other foreign regulatory authorities concerns about risk to patients of the technology or construct broadly, and/or negative public perception of the same; or if FDA or other foreign regulatory authorities find that the investigational protocol or plan is clearly deficient to meet its stated objectives; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in recruiting eligible patients to participate in our clinical trials, including pediatric patients who need parental consent; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in treating one or more patients, once enrolled, due to a patient&#8217;s inability to accommodate parts of the complex study procedures schedule; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulty collaborating with patient groups and investigators; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure by our CROs, other third parties or us to adhere to clinical trial requirements and the potential termination of ongoing agreements with our CROs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to perform in accordance with the FDA&#8217;s Good Clinical Practice, or GCP, requirements or applicable regulatory guidelines in other countries; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">transfer of manufacturing processes to any new CMO or our own manufacturing facilities or any other development or commercialization partner for the manufacture of product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in having patients complete participation in a trial or return for post-treatment follow-up; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patients dropping out of a trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of clinical trials of our product candidates being greater than we anticipate; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon product development programs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or failure to secure supply agreements with suitable raw material suppliers, or any failures by suppliers to meet our quantity or quality requirements for necessary raw materials; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in manufacturing or inability to manufacture sufficient clinical supply (for example, due to capacity constraints, supply interruption, or the need to engineer the process to meet higher dose requirements), testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. If we make manufacturing or formulation changes to our product candidates, we may be required to, or we may elect to, conduct additional trials to bridge our modified product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">candidates to earlier versions. Clinical trial delays could also shorten any periods during which our product candidates and products, if licensed, have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended or terminated by us, the FDA or other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delays in the initiation, conduct or completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. In the event we identify any additional product candidates to pursue, we cannot be sure that submission of an IND or comparable foreign regulatory submission will result in the FDA or other foreign regulatory authorities allowing clinical trials to begin in a timely manner, if at all.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, from time to time, we may publicly announce the expected timing of various scientific, clinical, regulatory, manufacturing and other product development milestones. These milestones may include the commencement, completion or development of data from our preclinical studies and clinical trials or the submission of regulatory filings, such as an IND or a CTA. All of these milestones are, and will be, based on a variety of assumptions. If any of the foregoing events impact our ability to meet the publicly announced timing of our milestones, we may experience adverse effects on our business, financial condition and prospects and the price of our common stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Monitoring safety of patients receiving our product candidates will be challenging, which could adversely affect our ability to obtain regulatory approval and commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and other planned clinical trials, we expect to continue to contract with academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials. In the future, we may also contract with non-academic medical centers and hospitals with similar capabilities. Nonetheless, these centers and hospitals may have difficulty observing patients, including due to failure by patients to comply with post-clinical trial follow-up programs, and treating toxicities, which may be more challenging due to personnel changes, inexperience, inadequate institutional safety procedures, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA delaying, suspending or terminating one or more of our clinical trials, and which could jeopardize regulatory approval. We also expect the centers using rese-cel and our other product candidates, if licensed, on a commercial basis could have similar difficulty in managing adverse events. Medicines used at centers to help manage adverse side effects of rese-cel, DSG3-CAART, MuSK-CAART and our other product candidates may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. The enrollment of patients depends on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and nature of the patient population; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patient eligibility criteria defined in the protocol; </span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recruiting an adequate number of suitable patients to participate in a clinical trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining IRB and other required reviewing body approval at each clinical trial site; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity of patients to trial sites; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the trial and whether the FDA or other foreign regulatory authorities agree to the design and implementation of the trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to identify clinical trial sites and recruit clinical trial investigators with the appropriate capabilities, competencies and experience; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinicians&#8217;, patients&#8217; and parents' (for juvenile patients) perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating, or with CAR T cell therapies broadly following the FDA&#8217;s investigation into reports of T cell malignancies for approved BCMA- and CD19-directed CAR T cell immunotherapies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the occurrence of dose-limiting toxicity in the clinical trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efforts to facilitate timely enrollment in clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patient referral practices of physicians; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain patient consents; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before the infusion of our product candidates or trial completion; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of patients to meet the complex follow-up requirements of the clinical trial. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, some of our clinical trial sites may also be used by some of our competitors, which may reduce the number of patients who are available for our clinical trials in that clinical trial site.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, because our product candidates represent a departure from more commonly used methods for autoimmune diseases where B cells may play a role in initiating or maintaining disease treatment, potential patients and their doctors may be inclined to use conventional therapies, such as corticosteroids or systemic immunosuppressive medications, rather than enroll patients in our clinical trial. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing and planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials in SLE, myositis, SSc, gMG, PV and MS and any additional expected clinical trials for each of our product candidates will enroll a limited number of patients. The activity and toxicity data from these clinical trials of our product candidates may differ from future results of subsequent clinical trials that enroll a larger number of patients. Since the number of patients that we plan to dose in our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials in SLE, myositis, SSc, gMG, PV and MS is small, and the number of patients in clinical trials for any future product candidates may be small, the results from such clinical trials, once completed, may be less reliable than results achieved in larger clinical trials, which may hinder our efforts to obtain regulatory approval for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In a subset of our RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial, our RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial and our RESET-MS</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial, we plan to evaluate the toxicity profile of our product candidates and establish the recommended dose for the next clinical trial. The preliminary results of clinical trials with smaller sample sizes, such as our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials, as well as any clinical trials for future product candidates, can be disproportionately influenced by various biases associated with the conduct of small clinical trials, such as the potential failure of the smaller sample size to accurately depict the features of the broader patient population, which limits the ability to generalize the results across a broader community, thus making the clinical trial results less reliable than clinical trials with a larger number of patients. As a result, there may be less certainty that such product candidates would achieve a statistically significant effect in any future clinical trials. If we conduct any future clinical trials of rese-cel, we may not achieve a statistically significant result or the same level of statistical significance, if any, that we might have anticipated based on the results observed in our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Sales, Marketing and Competition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our projections of both the number of people who have autoimmune diseases where B cells may play a role in initiating or maintaining disease we are targeting, as well as the subset of people with these diseases in a position to receive second or later lines of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these autoimmune diseases where B cells may play a role in initiating or maintaining disease. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biopharmaceutical and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong focus on intellectual property. We face competition from many different players, including large and specialty pharmaceutical and biotechnology companies, academic research organizations and governmental agencies. Any therapeutic candidates we successfully develop and commercialize will compete with the existing standard of care as well as novel therapies that may gain regulatory approval in the future. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. We are one of several companies developing CAR T drug candidates for the treatment of autoimmune diseases where B cells may play a role in initiating or maintaining disease. Additionally, despite the significant differences in discovery, development and target</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">populations between oncology and autoimmune targets, we recognize that companies with an investment and expertise in CAR T cell development for oncology indications could also attempt to leverage their expertise into autoimmune diseases where B cells may play a role in initiating or maintaining disease affected populations. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware of several other biopharmaceutical companies developing therapies for SLE, myositis, SSc, gMG and PV. Some product candidates may be directly competitive to our product candidates, such that even if we obtain regulatory approval of our product candidates, the availability and price of these other products, whether directly competitive or not, could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval of our product candidates, the products may not gain the market acceptance among physicians, patients, hospitals, treatment centers and others in the medical community necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The use of engineered T cells as a potential treatment for B cell-mediated autoimmune diseases is a recent development and may not become broadly accepted by physicians, patients, hospitals, treatment centers and others in the medical community. We expect physicians to be particularly influential and we may not be able to convince them to use our product candidates for many reasons. Additional factors will influence whether our product candidates are accepted in the market, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical indications for which our product candidates are licensed; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">physicians, hospitals, treatment centers and patients considering our product candidates as a safe and effective treatment; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential and perceived advantages of our product candidates over alternative treatments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any side effects; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product labeling or product insert requirements of the FDA or other regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations or warnings contained in the labeling approved by the FDA or other regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of market introduction of our product candidates as well as competitive products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of treatment in relation to alternative treatments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of coverage and adequate reimbursement and pricing by third-party payors and government authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our sales and marketing efforts. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The product candidates we plan to develop and commercialize are premised on offering a potential cure for autoimmune diseases where B cells may play a role in initiating or maintaining disease, which may result in a high degree of uncertainty related to pricing and long-term demand for our product. Our target patient populations are relatively small. Because of this pricing and demand for our product candidates, if licensed, may not be adequate to support an extended period of commercial viability, which could adversely affect our continued ability to successfully produce and market our product or any follow-on products.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if our product candidates are licensed but fail to achieve market acceptance among physicians, patients, hospitals, treatment centers or others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Business Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, which may prove to be wrong and may adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we intend to explore other therapeutic opportunities, in addition to the product candidates that we are currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional potential product candidates, our business could be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research programs to pursue the development of our existing and planned product candidates for additional indications and to identify new product candidates and disease targets require substantial technical, financial and human resources whether or not they are ultimately successful. Our research programs may initially show promise in identifying potential indications and/or product candidates, yet fail to yield results for clinical development for a number of reasons, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the research methodology used may not be successful in identifying potential indications and/or product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential product candidates may be identified but may not be able to be expressed on T cells in a manner that enables product activity;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential product candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective drugs; or </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have limited financial and human resources, we intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to develop additional product candidates, our commercial opportunity will be limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of our core strategies is to pursue clinical development of additional product candidates beyond rese-cel. Developing, obtaining regulatory approval and commercializing additional product candidates will require substantial additional funding and is prone to the risks of failure inherent in medical product development. We cannot provide you any assurance that we will be able to successfully advance any of these additional product candidates through the development process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we receive FDA or other foreign regulatory authority approval to market additional product candidates for the treatment of autoimmune diseases where B cells may play a role in initiating or maintaining disease, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. If we are unable to successfully develop and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commercialize additional product candidates, our commercial opportunity will be limited. Moreover, a failure in obtaining regulatory approval of additional product candidates may have a negative effect on the approval process of any other, or result in losing approval of any approved, product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific, and medical personnel, including our Chief Executive Officer and President, our Scientific Advisory Board members, our President, Science and Technology, our Chief Medical Officer, our Chief Financial Officer and our Chief Commercial Officer. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect to grow the size of our organization, and we may experience difficulties in managing this growth.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had 154 full-time employees and two part-time employees. As our development and commercialization plans and strategies develop, and as we continue to broaden our operational capabilities, we expect to expand our employee base and continue to add managerial, operational, sales, research and development, marketing, financial and other personnel. Current and future growth imposes significant added responsibilities on members of management, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identifying, recruiting, integrating, retaining and motivating additional employees in an increasingly competitive, inflationary market; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">managing our internal development efforts effectively, including the clinical and FDA or other regulatory authority review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">improving our operational, financial and management controls, reporting systems and procedures. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage our growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including certain research and development as well as general and administrative support, pursuant to agreements which expire after a certain period of time. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, or if we are not able to raise sufficient funds in the future to support our hiring efforts beyond our research and development personnel, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business disruptions, including due to natural disasters, global conflicts or political unrest, could seriously impact our operations, research and trials and harm our future revenue and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations, Minaris Advanced Therapies, LLC, or Minaris', operations, Lonza Houston Inc., or Lonza's, operations, Cellares Corporation, or Cellares, and those of any CMOs, CROs and other contractors and consultants that we may engage could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. Further, global conflicts or political unrest, such as the ongoing military conflict between Russia and Ukraine, the Israel-Hamas war, and the conflict in the Middle East may disrupt our global clinical trials and increase the likelihood of supply interruptions. Additionally, the effect of global financial and economic conditions and geopolitical events, including the consequences of the current administration in the United States, events or changes related thereto, including reductions in force at administrative agencies and tariffs, or political unrest or otherwise, or similar events, may have an impact on our business. Sanctions imposed by the U.S. and other countries in response to geopolitical events and conflicts may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. The occurrence of any of these business disruptions could seriously harm our research, clinical trials, operations and financial condition and increase our costs and expenses. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are also geopolitical tensions with China. For example, in December, 2025, the National Defense Authorization Act for Fiscal Year 2026, or the NDAA, was enacted, which includes Section 851, commonly referred to as the &#8220;BIOSECURE Act.&#8221; The BIOSECURE Act restricts U.S. government agencies from procuring biotechnology equipment or services from, or entering into contracts with, entities that use biotechnology equipment or services from, designated &#8220;biotechnology companies of concern&#8221;, or BCCs, and from expending federal loan or grant funds for such equipment or services. If our current or future vendors with which we work are designated as BCCs in the future, or if our collaborators, customers, investors, or future commercial partners become subject to BIOSECURE-related restrictions as a result of their relationships with such vendors, we could be required to terminate or restructure existing arrangements, transition manufacturing or other services to alternative suppliers, or delay or suspend development activities, subject to a grace period of 5 years during which time a company could continue to work with such restricted vendor. Any such transition could involve significant cost, operational complexity, regulatory risk, and delays, and alternative suppliers may not be available on acceptable terms or at all.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the increased prevalence of personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business operations. Further, this could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and other important agencies and contractors.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Condition and Capital Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Past Financial Condition</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses over the next several years, and may never achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products licensed for commercial sale, and we will continue to incur significant research and development and other expenses related to our ongoing operations. Our net losses may fluctuate significantly from quarter to quarter and year to year. We have to date financed our operations primarily through private placements of our preferred stock, the sale of common stock in our initial and secondary public offerings and sales of our common stock from time to time in &#8220;at-the-market&#8221; offerings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, we are not profitable and have incurred net losses in each period since our inception. For the years ended December 31, 2025 and 2024, we recorded net losses of $167.9 million and $115.9 million, respectively. As of December 31, 2025, we had an accumulated deficit of $517.0 million. We expect to incur significant losses for the foreseeable future, and we expect these losses to increase substantially if, and as, we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue our research and development efforts and submit additional INDs and/or CTAs for our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conduct preclinical studies and clinical trials for our current and future product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further develop our product candidate platform; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to discover and develop additional product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hire additional clinical, scientific manufacturing and commercial personnel; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval, whether through a CMO or through a manufacturing facility that we establish; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquire or in-license other product candidates and technologies, including advanced manufacturing and translational capabilities that we will need for the further development and possible commercialization of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek marketing approvals for any product candidates that successfully complete clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to support the sales and marketing of any product candidates for which we may obtain marketing approvals; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts, as well as to support our operations as a public company. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To become and remain profitable, we must succeed in developing, and eventually commercializing, a product or products that generate significant revenue. The ability to achieve this success will require us to be effective in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, discovering additional product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities and have not yet demonstrated our ability to successfully develop any product candidate, obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. We may never be able to develop, manufacture or commercialize a marketable product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we are able to succeed in these activities, we may never generate revenues that are significant enough to achieve profitability. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Our expenses will increase if, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there are any delays in completing our clinical trials or the development of any of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are required by the FDA or other regulatory authorities to perform trials or studies in addition to, or different than, those expected; or </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there are any third-party challenges to our intellectual property or we need to defend against any intellectual property-related claim. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop, seek regulatory approval for and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a limited operating history, which may make it difficult to evaluate the success of our business to date and to assess our future viability, and we may face significant challenges and expense as we test our product candidates and build our capabilities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated in 2017 and initially acquired rights to license certain patent rights from Penn in August 2018, and acquired rights to license certain patent rights from Nanjing IASO Biotherapeutics Co., Ltd., or IASO, in October 2022. All of our product candidates are still in the preclinical development or clinical stage. We have not yet demonstrated our ability to successfully complete any clinical trials, including large-scale, pivotal clinical trials, obtain marketing approvals, manufacture clinical and commercial scale therapeutics, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Our ability to generate product revenue or profits, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates, which may never occur. We may never be able to develop or commercialize a marketable product.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our limited operating history, particularly in light of the rapidly evolving cell therapy field, may make it difficult to evaluate our current business and predict our future performance. Our relatively short history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by clinical-stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer. Similarly, we expect that our financial condition and operating results will continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. As a result, our shareholders should not rely upon the results of any quarterly or annual period as an indicator of future operating performance.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently do not have in-house resources sufficient to enable the development of our product candidates, including our CAR T and CAAR T cell platforms. We are reliant on Minaris manufacturing services for rese-cel in multiple indications through a Development, Manufacturing and Testing Services Agreement, or the Minaris Agreement. Our ability to rely on services from Minaris is limited to a specified period of time, to specific capabilities, and is subject to Minaris' right to terminate these services with or without cause. We are also reliant on Lonza manufacturing services for rese-cel in multiple indications through a Development and Manufacturing Services Agreement, or the Lonza Agreement. Our ability to rely on services from Lonza is limited to a specified period of time, to specific capabilities, and is subject to Lonza&#8217;s right to terminate these services with or without cause. If we are unable to establish necessary relationships with third party partners and/or build our own capabilities, our operating and financial results could differ materially from our expectations, and our business could suffer. As we build our own capabilities, and enter into agreements with third parties, we expect to encounter risks and uncertainties frequently experienced by growing companies in new and rapidly evolving fields, including the risks and uncertainties described herein.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our programs require additional preclinical research and development, clinical development, regulatory approval in multiple jurisdictions, obtaining manufacturing supply, capacity and expertise, building of a commercial organization, substantial investment and significant marketing efforts before we generate any revenue from product sales. Other programs of ours require additional discovery research and then preclinical and clinical development. In addition, our product candidates must be licensed for marketing by the FDA or other foreign regulatory authorities before we may commercialize any product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have not generated any revenue from our product candidates and our ability to generate revenue from product sales and become profitable depends significantly on our success in a number of areas.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To become and remain profitable, we or any potential future collaborator must develop and eventually commercialize products with significant market potential at an adequate profit margin after cost of goods sold and other expenses. All of our product candidates are in the early stages of development and we will require additional preclinical studies, clinical development, regulatory review and approval, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. Our ability to generate revenue depends on a number of factors, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timely completion of our preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party academic and commercial contractors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to complete IND-enabling studies and successfully submit INDs or comparable applications; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether we are required by the FDA or other foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned to support the licensure and commercialization of our product candidates or any future product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to demonstrate to the satisfaction of the FDA or other foreign regulatory authorities, the safety, potency, purity and acceptable risk to benefit profile of our product candidates or any future product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future product candidates, if any; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing and processing our product candidates being greater than we anticipate; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timely receipt of necessary marketing approvals from the FDA or other foreign regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product candidates or future product candidates to treat autoimmune diseases where B cells may play a role in initiating or maintaining disease; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability and the ability of third parties with whom we contract to manufacture adequate clinical and commercial supplies of our product candidates or any future product candidates, remain in good standing with regulatory authorities and develop, validate and maintain commercially viable manufacturing processes that are compliant with FDA&#8217;s current Good Manufacturing Practices, or cGMP; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully develop a commercial and competitive strategy and thereafter commercialize our product candidates or any future product candidates in the United States or other countries, if licensed for marketing, reimbursement, sale and distribution, whether alone or in collaboration with others; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient demand for our product candidates and any future product candidates, if licensed; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates. </span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of the factors listed above are beyond our control and could cause us to experience significant delays or prevent us from obtaining regulatory approvals or commercialize our product candidates. Even if we are able to commercialize our product candidates, we may not achieve profitability soon after generating product sales, if ever. If we are unable to generate sufficient revenue through the sale of our product candidates or any future product candidates, we may be unable to continue operations without continued funding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Additionally, even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to research, develop and market additional product candidates. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Future Financial Condition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will require substantial additional financing to develop and commercialize our product candidates and implement our operating plans. We have also identified conditions that raise substantial doubt about our ability to continue as a going concern. If we fail to obtain additional financing or cannot obtain financing at the levels we require, we may be forced to delay, reduce or discontinue our plans and operations or unable to complete the development and commercialization of our product candidates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to continue the preclinical and clinical development of our product candidates, including our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials, and our research and development, preclinical studies and clinical trials for any future product candidates, to seek regulatory approvals for our product candidates, to enable commercial production of our products, if licensed, and to initiate and complete registration trials for multiple products. As of December 31, 2025, we had $133.6 million of cash, cash equivalents and investments. Since our initial public offering and through December 31, 2025, we have generated cash from public offerings of our common stock and pre-funded warrants to purchase our common stock resulting in aggregate net proceeds of approximately $384.0 million. While we currently expect our existing cash, cash equivalents and investments to be sufficient to fund our operations into the fourth quarter of 2026, which includes our plans to complete the Phase 1/2 RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, RESET-SSc</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and RESET-MG</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials and generate clinical data from the RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> dose escalation trial and RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> without preconditioning, we expect to require significant additional financing to complete these clinical trials and any future clinical trials of these and our other product candidates. Further, if marketing approval is received, we will require significant additional amounts of cash to launch and commercialize our product candidates. However, we have based this estimate on assumptions that may prove to be wrong. Additionally, changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may require substantial additional capital for the further development and commercialization of our product candidates, including funding our internal manufacturing capabilities, and may need to raise additional funds sooner if we choose to expand more rapidly than we presently anticipate. Because the length of time and activities associated with development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. Our future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, progress, timing, costs and results of preclinical studies and clinical trials for our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical development plans we establish for these product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and characteristics of product candidates that we may develop or in-license; </span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms of any collaboration agreements we may choose to conclude; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcome, timing and cost of meeting regulatory requirements established by the FDA or other foreign regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effect of competing technological and market developments; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of establishing and maintaining a supply chain for the development and manufacture of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing of establishing, expanding and scaling manufacturing capabilities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of maintaining the amount patient data for which we would be responsible following commercialization of one or more of our product candidates; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be certain that additional funding will be available on acceptable terms, or at all. As widely reported, global credit and financial markets have experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, inflation, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Until we are able to generate sufficient revenue to finance our cash requirements, we will need to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue our research and development initiatives and clinical development plans. We could be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our current operating plan, we believe there is substantial doubt about our ability to continue as a going concern for at least twelve months following the filing of this Annual Report on Form 10-K, and we will need to obtain additional funding. We may be forced to delay or reduce the scope of our product development programs, reduce our research and development costs and/or limit or cease our operations if we are unable to obtain additional funding to support our current operating plan. Our cash forecast contains estimates and assumptions based on the success of our ongoing clinical trials, and management cannot predict the amount or timing of all expenditures with certainty. Nevertheless, our financial statements do not include any adjustments that might result from the outcome of this uncertainty. We will need to raise additional capital to fund our future operations and remain as a going concern. However, we cannot guarantee that we will be able to obtain any or sufficient additional funding or that such funding, if available, will be obtainable on terms satisfactory to us.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequently, we issued (i) 39,200,000 shares of our common stock and accompanying warrants to purchase an aggregate of 39,200,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to 10,800,000 shares of our common stock and accompanying warrants to purchase an aggregate of 10,800,000 shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $0.00001 per pre-funded warrant, or the 2025 Offering. The combined offering price of each share of common stock and accompanying common stock warrant was $2.00. The combined offering price of each pre-funded warrant and accompanying common stock warrant was $1.99999. The accompanying warrant has an exercise price of $2.50 per share, is immediately exercisable from the date of issuance and will expire on September 12, 2026, fifteen months from the date of issuance. Aggregate net proceeds were $93.6 million after deducting underwriting discounts and commissions and offering expenses. As a result of this offering, our stockholders experienced significant dilution. Sales of common stock, debt securities or other equity securities by us may represent a significant percentage of our common stock currently outstanding. If we sell, or the market perceives that we intend to sell, substantial number of additional shares of our common stock under the 2025 Registration Statement or otherwise, the market price of our common stock could decline significantly.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 7, 2025, we filed the 2025 Registration Statement (File No. 333-289339) with SEC, which was declared effective on August 15, 2025, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into the 2025 Sales Agreement with TD Cowen to provide for the offering, issuance and sale of up to an aggregate amount of $150.0 million of our common stock from time to time in &#8220;at-the-market&#8221; offerings, or 2025 ATM Program, under the 2025 Shelf Registration Statement and subject to the limitations thereof. During the year ended December 31, 2025, we sold 4,160,176 shares pursuant to the 2025 ATM Program for net proceeds of $10.2 million. Subsequent to December 31, 2025, we sold 8,055,260 shares of common stock pursuant to the 2025 ATM Program for net proceeds of $22.6 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as of December 31, 2025, we had outstanding 53,090,190 common stock warrants and pre-funded warrants to purchase 6,000,000 shares of our common stock. If some or all of these warrants are exercised, our stockholders could experience substantial dilution and may cause the market price of our stock to decline.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also filed registration statements on Form S-8 to register shares issued or reserved for issuance under our equity compensation plans and will file additional registration statements on Form S-8 to register additional shares pursuant to the &#8220;evergreen&#8221; provisions under our equity compensation plans, the Plan Amendment and any subsequent amendments to our equity compensation plans. Shares registered under these registration statements on Form S-8 can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates and the lock-up agreements described above. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to our equity incentive plans, our management is authorized to grant stock options to our employees, directors and consultants. Additionally, the number of shares of our common stock reserved for issuance under the 2019 Stock Option and Incentive Plan, or the 2019 Plan, automatically increased on January 1, 2026 and will automatically increase each January 1 thereafter through and including January 1, 2029, by 4% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall. In addition, on April 7, 2023, our board of directors adopted, and at our 2023 annual meeting our stockholders approved, an amendment to the 2019 Plan, or the Plan Amendment, to increase the aggregate number of shares authorized for issuance under the 2019 Plan by 3,000,000 shares, subject to adjustment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, certain of our employees, executive officers, and directors may enter into Rule 10b5-1 trading plans providing for sales of shares of our common stock from time to time. Under a Rule 10b5-1 trading plan, a broker executes trades pursuant to parameters established by the employee, director, or officer when entering into the plan, without further direction from the employee, officer, or director. A Rule 10b5-1 trading plan may be amended or terminated in some circumstances. Our employees, executive officers, and directors also may buy or sell additional shares outside of a Rule 10b5-1 trading plan when they are not in possession of material, nonpublic information.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future issuances of our common stock or other equity securities, or the perception that sales of this nature may occur, could adversely affect the trading price of our common stock, and impair our ability to raise capital through future offerings of shares or equity securities. No prediction can be made as to the effect, if any, that future sales of common stock or the availability of common stock for future sales will have on the trading price of our common stock.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our outstanding common stock warrants may not be exercised, and we may not receive any additional funds upon the exercise of such warrants.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had outstanding 53,090,190 common stock warrants. If all common stock warrants were exercised for cash, we would receive approximately an additional $132 million in gross proceeds from the 2025 Offering. However, the warrant holders are not obligated to exercise these warrants, so we may receive little to no additional proceeds. Our common stock warrants have an exercise price of $2.50 per share and are exercisable at any time after the date of issuance. The common stock warrants expire on September 12, 2026, fifteen months from the date of issuance. Warrant holders are unlikely to exercise their warrants voluntarily unless our stock price is above the exercise price. We cannot provide any assurance that our stock price will meaningfully exceed the exercise price before the warrants expire. If our stock price remains at or below the exercise price, the warrants will likely expire unexercised, and we will not receive any additional funds from these warrants to support our clinical trials and operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the common stock warrants may be exercised on a cashless basis if there is no effective registration statement registering the shares underlying such warrants, in which case we would not receive any additional proceeds. Though we intend to maintain an effective registration statement for the underlying shares, we may not be able to do so. If the common stock warrants are not exercised for cash, or only a portion of the common stock warrants are exercised for cash, we would not receive anticipated warrant exercise proceeds which could materially and adversely affect our financial condition and ability to execute our business strategy.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will not receive any meaningful amount of additional funds upon the exercise of the pre-funded warrants; however, any exercise would increase the number of shares of our common stock eligible for future resale in the public market and result in dilution to our stockholders.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the 2025 Offering, we issued and sold pre-funded warrants to purchase up to 10,800,000 shares of our common stock. As of December 31, 2025, 4,800,000 pre-funded warrants had been exercised and 6,000,000 remain outstanding. Each pre-funded warrant is exercisable until it is fully exercised and by means of payment of the nominal cash purchase price upon exercise or by means of a &#8220;cashless exercise&#8221; according to a formula set forth in the pre-funded warrant. Accordingly, we will not receive any meaningful additional funds upon the exercise of the pre-funded warrants. To the extent such pre-funded warrants are exercised, additional shares of common stock will be issued for nominal or no additional consideration, which will result in dilution to the then existing holders of our common stock and will increase the number of shares eligible for resale in the public market.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely heavily on certain in-licensed patent and other intellectual property rights in connection with our development of our product candidate and, if we fail to comply with our obligations under our existing and any future intellectual property licenses with third parties, we could lose license rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to develop and commercialize our product candidate is heavily dependent on in-licenses to patent rights and other intellectual property granted to us by third parties. For example, we depend on our Exclusive License Agreement with IASO, which was entered into in October 2022, pursuant to which we obtained a worldwide, exclusive license under certain intellectual property to develop, manufacture, commercialize and otherwise exploit T cell products directed to CD19 for the purpose of diagnosis, prevention or treatment of an autoimmune or alloimmune indication in humans, or the IASO Agreement. We may enter into additional license agreements in the future. Our license agreement with IASO imposes, and we expect that future license agreements will impose, various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with our obligations under these licenses, our licensors, including IASO may have the right to terminate these license agreements, in which event we might not be able to market our product candidate. Termination of any of our license agreements or reduction or elimination of our licensed rights may also result in our having to negotiate new or reinstated licenses with less favorable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may need to obtain additional licenses from third parties to advance our research or allow commercialization of our product candidate, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidate, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current product candidate or future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, in many cases, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we in-license from third parties. For example, pursuant to our IASO Agreement, IASO controls such activities for the patent rights licensed to us under such agreement. Therefore, although we provide input to IASO on these activities, we cannot be certain that these patents will be prosecuted, maintained and enforced in a manner consistent with the best interests of our business. If our current or future licensors or collaboration partners fail to obtain, maintain or protect any patents or patent applications licensed to us, our rights to such patents and patent applications may be reduced or eliminated and our right to develop and commercialize any of our product candidate that are the subject of such licensed rights could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disputes may arise between us and our current and future licensors regarding intellectual property subject to a license agreement, including those related to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted under the IASO Agreement and other interpretation-related issues; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether we have breached the IASO Agreement and whether any such breach is subject to a cure period; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidate, and what activities satisfy those diligence obligations; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, disputes may arise between us and our current or future licensors regarding the ownership of intellectual property developed by us, such that we may be required to assign or otherwise transfer such intellectual property to such licensor. In the event that the assigned or transferred intellectual property is covered by an existing license agreement with such licensor we may be required to make additional royalty or milestone payments, or both,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to such licensor. If the assigned or transferred intellectual property is not covered by an existing license agreement, then we may be required to enter into an additional license agreement to advance our research or allow commercialization of our product candidate, which may not be available on commercially reasonable terms or at all.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If disputes over intellectual property that we have licensed, or license in the future, prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our efforts to protect the proprietary nature of the intellectual property related to our current and any future product candidates are not adequate, we may not be able to compete effectively in our market.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain intellectual property protection in the United States and other countries with respect to our product candidates. If we do not adequately protect or enforce our intellectual property rights, competitors may be able to erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. To protect our proprietary position, we have filed and in-licensed patent rights in the United States and abroad relating to the product candidates that are important to our business. The patent application and approval process is expensive, complex and time-consuming. We or our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination of patent rights with respect to biological and pharmaceutical products commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Assuming the other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent. However, prior to March 16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in the patents or pending patent applications, or that we and our licensors were the first to file for patent protection of such inventions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, the patents or pending patent applications that we own or in-license may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third party preissuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in post-grant review procedures, derivation proceedings, reexaminations, or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review in the United States, or oppositions and other comparable proceedings in foreign jurisdictions, challenging our patent rights or the patent rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of the patents we in-license or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent or in the same manner as the laws of the United States. For example, European patent law is more restrictive than U.S. patent law in connection with the patentability of methods of treatment of the human body and Chinese bankruptcy law may not provide a licensee the same protections as U.S. bankruptcy law. This could impact our in-license under the IASO Agreement with IASO, a China-based company, if IASO declared bankruptcy, and could have a material adverse effect on the development of rese-cel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A European Unified Patent Court, or the UPC, came into force during 2023. The UPC is a common patent court to hear patent infringement and revocation proceedings effective for member states of the European Union. This could enable third parties to seek revocation of our European patents in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated. Any such revocation and loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect our ability to enforce or defend the validity of our European patents. Although we have decided, and may continue to decide, to opt out certain of our European patents and patent applications from the UPC, if certain formalities and requirements are not met, then our European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. Thus, we cannot be certain that our European patents and patent applications will avoid falling under the jurisdiction of the UPC.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict whether the patent applications that we own or in-license will issue as patents, whether the claims of any patent that has or may issue will provide us with a competitive advantage or prevent competitors from designing around the claims to develop competing technologies in a non-infringing manner, or whether we or our licensors will be able to successfully pursue patent applications in the future relating to our current product candidates or future products and product candidates. Moreover, the patent application and approval process is expensive and time-consuming. We or our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Furthermore, we, or any future partners, collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to seek additional patent protection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that defects of form in the preparation or filing of patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If there are material defects in the form, preparation, prosecution or enforcement of the patents or patent applications we in-license, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if the patent applications we own or in-license issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patent rights by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may also seek approval to market their own products similar to or otherwise competitive with our product candidates. Alternatively, our competitors may seek to market generic versions of any approved products by submitting abbreviated BLAs to the FDA during which process they may claim that our owned or in-licensed patents are invalid, unenforceable or not infringed. In these circumstances, we may need to defend or assert our intellectual property rights, or both, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find the patents we own or in-license invalid or unenforceable, or that our competitors are competing in a non-infringing manner. Thus, even if we own or in-license valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the future, we likely will need to expand our patent portfolio to pursue patent coverage for new product candidates that we wish to develop. The patent prosecution process is competitive, and other companies, some which may have greater resources than we do in this area, may also be pursuing intellectual property rights that we may consider necessary or attractive in order to develop and commercialize future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting, maintaining, defending and enforcing patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. Although our IASO Agreement grants us worldwide rights, there can be no assurance that we will obtain or maintain patent rights in or outside the United States under any future license agreements. In addition, the laws of some foreign countries do not protect intellectual property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rights to the same extent as federal and state laws in the United States even in jurisdictions where we and our licensors pursue patent protection. Consequently, we and our licensors may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in jurisdictions where we and our licensors pursue patent protection, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we and our licensors have not pursued and obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates and the patents we in-license or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of the patents we in-license or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights, even if obtained, in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put the patents we in-license at risk of being invalidated or interpreted narrowly and the patent applications we own or in-license at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We or our licensors may be subject to claims challenging the inventorship or ownership of the patents and other intellectual property that we own or license.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an ownership interest in the patents and intellectual property that we own or in-license or that we may own or in-license in the future. While it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own or such assignments may not be self-executing or may be breached. Our licensors may face similar obstacles. We or our licensors could be subject to ownership disputes arising, for example, from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against any claims challenging inventorship or ownership. If we or our licensors fail in defending any such claims, we may have to pay monetary damages and may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property, which could adversely impact our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Some intellectual property which we have in-licensed was discovered through government funded programs and thus is subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. industry. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of the intellectual property rights we have licensed were generated through the use of U.S. government funding and may therefore be subject to certain federal laws and regulations. As a result, the U.S. government has certain rights to intellectual property embodied in our DSG3-CAART product candidate and may have rights in future product candidates pursuant to the Bayh-Dole Act of 1980. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations, also referred to as &#8220;march-in rights&#8221;. The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. Intellectual property generated under a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for product candidates covered by such intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patent rights or other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe, misappropriate or otherwise violate patents, trademarks, copyrights or other intellectual property that we own or in-license. To counter infringement, misappropriation or other unauthorized use, we may be required to file claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived violators could provoke these parties to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property, in addition to counterclaims asserting that the patents we in-license are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent we own or in-license is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. In the U.S., grounds for a validity challenge in a court proceeding could be an alleged failure to meet one or more statutory requirements for patentability, including, for example, lack of novelty, obviousness, lack of written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Additionally, third parties are able to challenge the validity of issued patents through administrative proceedings in the patent offices of certain countries, including the USPTO and the European Patent Office.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if the validity of a patent is upheld during a court proceeding, there is a risk that the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that the patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving the patents we own or in-license could limit our ability to assert the patent against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we establish infringement, misappropriation or another violation of our intellectual property rights, the court may decide not to grant an injunction against the offender and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our shares. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. Any of the foregoing may have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in either the patent laws or the interpretation of the patent laws in the United States or other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. When implemented, the Leahy-Smith Act included several significant changes to U.S. patent law that impacted how patent rights could be prosecuted, enforced and defended. In particular, the Leahy-Smith Act also</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">included provisions that switched the United States from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system, allowed third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO developed new regulations and procedures governing the administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, became effective on March 16, 2013. It remains unclear what impact, if any, the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of the patent applications we in-license and the enforcement or defense of the issued patents we in-license, all of which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent positions of companies engaged in the development and commercialization of biologics are particularly uncertain. For example, the Supreme Court of the United States issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., or Myriad, a case involving patent claims held by Myriad Genetics, Inc. relating to the breast cancer susceptibility genes BRCA1 and BRCA2. Myriad held that an isolated segment of naturally occurring DNA, such as the DNA constituting the BRCA1 and BRCA2 genes, is not patent-eligible subject matter, but that complementary DNA, which is an artificial construct that may be created from RNA transcripts of genes, may be patent-eligible. Thereafter, the USPTO issued a guidance memorandum instructing USPTO examiners on the ramifications of the Prometheus and Myriad rulings and apply the Myriad ruling to natural products and principles including all naturally occurring nucleic acids. Certain claims of our owned and in-licensed patent applications contain, and any future patents we may obtain may contain, claims that relate to specific recombinant DNA sequences that are naturally occurring at least in part and, therefore, could be the subject of future challenges made by third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure you that our efforts to seek patent protection for one or more of our product candidates will not be negatively impacted by this Supreme Court decision, rulings in other cases or changes in guidance or procedures issued by the USPTO. We cannot fully predict what impact the Supreme Court&#8217;s decisions in Myriad may have on the ability of life science companies to obtain or enforce patents relating to their products in the future. These decisions, the guidance issued by the USPTO and rulings in other cases or changes in USPTO guidance or procedures could have a material adverse effect on our existing patent rights and our ability to protect and enforce our intellectual property in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect certain proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect and some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our trade secrets may otherwise become known or be independently discovered by competitors. Competitors and other third parties could infringe, misappropriate or otherwise violate our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If our trade secrets are not adequately protected or sufficient to provide an advantage over our competitors, our competitive position could be adversely affected, as could our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent term may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during the period of extension). However, a patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of the product&#8217;s approval by the FDA, only one patent applicable to an approved drug is eligible for the extension, and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. In the future, if and when our product candidates receive FDA approval, we plan to apply for patent term extensions on patents covering those product candidates in any jurisdiction where these are available. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to the patents we own or in-license, or may grant more limited extensions than we request. Moreover, we may not receive an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. Our licensors may face similar risks, which could have an adverse impact on intellectual property that is licensed to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become subject to claims that we are infringing certain third-party patents or other third-party intellectual property rights, any of which may prevent or delay our development and commercialization efforts and have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part on avoiding infringing, misappropriating and otherwise violating the patents and other intellectual property and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, and administrative proceedings such as interferences,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review and post grant review proceedings before the USPTO and opposition proceedings before foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned or controlled by third parties, including our competitors, exist in the fields in which we are pursuing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may assert that we or our licensors are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, methods of manufacture or methods for treatment relating to our product candidates and, because patent applications can take many years to issue, there may be currently pending third party patent applications which may later result in issued</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patents, in each case that our product candidates, their manufacture or use may infringe or be alleged to infringe. We may fail to identify potentially relevant patents or patent applications, incorrectly conclude that a patent is invalid or does not cover our activities, or incorrectly conclude that a patent application is unlikely to issue in a form of relevance to our activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties making patent infringement claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, including demonstrating non-infringement, invalidity or unenforceability of the respective patent rights in question, regardless of their merit, is time-consuming, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. For example, in order to successfully challenge the validity of any U.S. patent in federal court, we would need to overcome a presumption of validity. This is a high burden requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, and we can provide no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. We may not have sufficient resources to bring these actions to a successful conclusion. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that a holder of any such patents seeks to enforce its patent rights against us with respect to one or more of our product candidates, and our defenses against the infringement of such patent rights are unsuccessful, we may be precluded from commercializing our product candidates, even if approved, without first obtaining a license to some or all of these patents, which may not be available on commercially reasonable terms or at all. Moreover, we may be required to pay significant fees and royalties to secure a license to the applicable patents. Such a license may only be non-exclusive, in which case our ability to stop others from using or commercializing technology and products similar or identical to ours may be limited. Furthermore, we could be liable for damages to the holder of these patents, which may be significant and could include treble damages if we are found to have willfully infringed such patents. In the event that a challenge to these patents were to be unsuccessful or we were to become subject to litigation or unable to obtain a license on commercially reasonable terms with respect to these patents, it could harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are aware of third-party U.S. patents relating to the lentiviral vectors which may be used in the manufacture or use of our product candidates. We are also aware of a patent family that includes granted U.S. and European patent rights directed to methods using, and compositions containing, genetically engineered T cells that may be relevant to our rese-cel product candidate. If these patent rights were enforced against us, we believe that we have defenses against any such action, including that these patents would not be infringed by our product candidates and/or that these patents are not valid. However, if these patents were enforced against us and defenses to such enforcement were unsuccessful, unless we obtain a license to these patents, which may not be available on commercially reasonable terms, or at all, we could be liable for damages and precluded from commercializing any product candidates that were ultimately held to infringe these patents, which could have a material adverse effect on our business, financial condition, results of operations and prospects. Furthermore, even if our arguments are successful, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could significantly harm our business and operating results.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even in the absence of a finding of infringement, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, or at all. In that event, we would be unable to further develop and commercialize our product candidates. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. Any of the foregoing could materially adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make products that are similar to our product candidates or utilize similar cell therapy technology but that are not covered by the claims of our current or future patent portfolio; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our current or future licensors or collaborators, might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or license now or that we may own in the future; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or our current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our current or future owned or licensed patent applications will not lead to issued patents; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may harm our business; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party patents may issue with claims covering our activities; we may have infringement liability exposure arising from such patents. </span></div></div><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently, and will likely continue to, rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We depend and will continue to depend upon third parties, including independent investigators and collaborators, such as universities, medical institutions, CROs and strategic partners, to conduct our preclinical studies and clinical trials under agreements with us. Specifically, we depend on clinical trial sites to enroll patients and conduct the RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials in a timely and appropriate manner. If our clinical trial sites do not conduct the trials on the timeline we expect or otherwise fail to support the trials, our clinical trial results could be significantly delayed, thereby adversely impacting our leadership position in the autoimmune cell therapy space and our ability to progress additional product candidates. As we open additional clinical trial sites, we expect to have to negotiate budgets and contracts with CROs and study sites, which may result in delays to our development timelines and increased costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will rely heavily on these third parties to conduct our manufacturing, and as a result, will have limited control over pace at which these activities are carried out. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with FDA&#8217;s GCPs which are regulations and guidelines enforced by the FDA for product candidates in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our marketing applications. We cannot provide assurance that, upon inspection, such regulatory authorities will not determine that some or all of our clinical trials do not fully comply with the GCP requirements. For any violations of laws and regulations during the conduct of our clinical trials, we could be subject to untitled and warning letters or enforcement action that may include civil penalties up to and including criminal prosecution. In addition, our clinical trials must be conducted with biologic product produced under cGMPs and will require a large number of test patients. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As widely reported, global credit and financial markets have experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. Regional or single-source dependencies may in some cases accentuate these risks. For example, the pharmaceutical industry in general, and in some instances we or our collaborators or other third parties on which we or they rely, depend on China-based suppliers or service providers for certain raw materials, products and services, or other activities, Our ability or the ability of our collaborators or such other third parties to continue to engage these China-based suppliers or service providers for certain preclinical research programs and clinical development programs could be restricted due to geopolitical developments between the United Sates and China.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been, and may continue to be, significant changes to U.S. trade policies, sanctions, legislation, treaties and tariffs, including, but not limited to, trade policies and tariffs affecting products from outside of the U.S. The extent and duration of increased tariffs and the resulting impact on general economic conditions and on our business are uncertain and depend on various factors, such as negotiations between the U.S. and affected countries, the responses of other countries or regions, exemptions or exclusions that may be granted, availability and cost of alternative sources of supply and demand in affected markets. Supply chain disruptions and delays as a result of any new tariff policies or trade restrictions could negatively impact our cost of materials processes. If we or our current or future service providers, manufacturers and other partners are unable to obtain materials in sufficient quantity and in a timely manner due to disruptions in the global supply chain caused by macroeconomic events and conditions, the development, testing and our clinical trials and any future product candidates may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, in the event that one or more of our current or future service providers, manufacturers and other partners do not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, due to the economic downturn, the enactment of legislative proposals or for any other reasons, then we may not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines. Our failure or the failure of these third parties to comply with applicable regulatory requirements or our stated protocols could also subject us to enforcement action. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any third parties conducting our clinical trials will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical and clinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of our relationships with trial sites, or any CRO that we may use in the future, terminates, we may not be able to enter into arrangements with alternative trial sites or CROs or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is often a natural transition period when a new third party commences work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, producing additional losses and depriving us of potential product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We intend to rely on third parties to manufacture our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if licensed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we may eventually secure our own clinical manufacturing facility for any late phase clinical development that we undertake, we currently rely on third parties to manufacture our product candidates, and we intend in the future to continue to rely on CMOs. In the case of any manufacturing performed for us by third parties, the services performed for us risk being delayed because of the competing priorities that such parties have for utilization of their manufacturing resources and any capacity issues that thereby arise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not yet have sufficient information to reliably estimate the cost of the manufacturing and processing of our product candidates in clinical quantity or commercial quantity, and the actual cost to manufacture and process our product candidates could ultimately materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our anticipated reliance on a limited number of third-party manufacturers exposes us to the following risks:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of FDA questions, if any. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract manufacturers may not be able to execute our manufacturing procedures appropriately. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any contract manufacturers that we engage may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our product candidates. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our third-party manufacturers could breach or terminate their agreement with us. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, all of our contract manufacturers are engaged with other companies to supply and/or manufacture materials or products for such companies, which exposes our manufacturers to regulatory risks related to the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may affect the regulatory clearance of our contract manufacturers&#8217; facilities generally. If the FDA does not approve these facilities for the manufacture of our product candidates or if any agency withdraws</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">its approval in the future, we may need to find alternative manufacturing facilities, which would negatively impact our ability to develop, obtain regulatory approval for or market our product candidates, if licensed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contract manufacturers would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above. Each of these risks could delay our clinical trials, the approval, if any of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. In addition, we will rely on third parties to perform release tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For more information, see &#8220;Risk Factors&#8212;Risks Related to Manufacturing and Supply&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety, potency and purity. Any delays in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue or specific net income that justifies such transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not realize the benefits of acquired assets or other strategic transactions, including any transactions whereby we acquire or license manufacturing and other advanced technologies.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2022, we entered into the IASO Agreement, pursuant to which we were granted worldwide license under certain intellectual property to develop, manufacture, commercialize and otherwise exploit T cell products directed to CD19 for the purpose of diagnosis, prevention or treatment of an autoimmune or alloimmune indication in humans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We actively evaluate various strategic transactions on an ongoing basis. We may acquire other businesses, products or technologies as well as pursue joint ventures or investments in complementary businesses. The success of our strategic transactions, including the License Agreement, and any future strategic transactions depends on the risks and uncertainties involved including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated liabilities related to acquired companies or joint ventures; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties integrating acquired personnel, technologies and operations into our existing business; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">retention of key employees; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diversion of management time and focus from operating our business to management of strategic alliances or joint ventures or acquisition integration challenges; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increases in our expenses and reductions in our cash available for operations and other uses; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruption in our relationships with collaborators or suppliers as a result of such a transaction; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">possible write-offs or impairment charges relating to acquired businesses or joint ventures. </span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of these risks or uncertainties occur, we may not realize the anticipated benefit of any acquisition or strategic transaction. Additionally, foreign acquisitions and joint ventures are subject to additional risks, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations and the particular economic, political, legal and regulatory risks associated with specific countries. For example, IASO is based in China and we may not receive the same protections under Chinese law, including with respect to applicable bankruptcy, insolvency, liquidation, arrangement, moratorium or similar laws relating to or affecting our rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Manufacturing and Supply</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are reliant on Minaris and Lonza for our current manufacturing activities and termination would disrupt normal business operations, and we intend to continue to rely on other third parties for our future manufacturing needs prior to establishing our own manufacturing facility.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are reliant on Minaris and Lonza for our current manufacturing activities for our preclinical and clinical research. If Minaris were to fail to perform their obligations in accordance with the terms of the Minaris Agreement or terminate the Minaris Agreement, or if Lonza were to fail to perform their obligations in accordance with the terms of the Lonza Agreement or terminate the Lonza Agreement, we may have difficulty continuing our normal business operations and our business prospects, financial condition and results of operations could be harmed. We continue to expand our agreements for manufacturing operations within the industry, including Cellares.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are also current geopolitical tensions with China. These tensions and the related risks are described in the Risk Factor in this Report titled, &#8220;Risks Related to Business Development &#8211; Business disruptions, including due to natural disasters, global conflicts or political unrest, could seriously impact our operations, research and trials and harm our future revenue and financial condition.&#8221;</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CARTA Services Agreement is scheduled to expire on the later of February 9, 2026 or completion of all research and development projects, and unless the CARTA Services Agreement is amended, Penn will not be obligated to provide any further services under the CARTA Services Agreement after that time. In addition, Penn has the right to terminate the CARTA Services Agreement in whole at any time with 180 days&#8217; notice. From time to time, we may enter into further addenda to the CARTA Services Agreement that provide Penn with the right to terminate such addenda with limited notice periods. If we do not have adequate personnel and capabilities at the time that we assume responsibilities for such services, we may not be successful in effectively or efficiently transitioning these services from Penn, which could disrupt our business and have a material adverse effect on our financial condition and results of operations. Even if we are able to successfully transition these services, they may be more expensive or less efficient than the services we are receiving from Penn during the transition period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Minaris Agreement is scheduled to expire upon completion of Minaris' services related to MuSK-CAART and rese-cel. In August 2023, as amended in August 2024, we entered into new work orders under the Minaris Agreement for Minaris to serve as one of our cell processing manufacturing partners for the planned global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and commercial readiness activities for rese-cel. Under the August 2023 work orders, Minaris converted our non-dedicated suite to a dedicated suite for GMP manufacturing for our rese-cel and MuSK-CAART programs, or the Dedicated Suite, for an initial term of 18 months with two 18 month extensions at our sole option on six months notice prior to the end of the term. In August 2024, we notified Minaris that we would extend the initial term by 18 months through August 2026. We may terminate for convenience with six months prior written notice, however, we may not terminate the Dedicated Suite without terminating both the MuSK-CAART and rese-cel GMP run work orders. In lieu of the existing 18 month termination right for convenience under the Minaris Agreement, Minaris may not terminate prior to February 2028. If Minaris were to fail to perform their obligations in accordance with the terms of the Minaris Agreement or terminate the Minaris Agreement, our clinical trials and commercial readiness may be adversely impacted which could in turn</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> materially and adversely affect our business, results of operations and prospects.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Lonza Agreement has an initial five year term with the ability to extend subject to the terms. Under the Lonza Agreement, Lonza will serve as one of our manufacturing partners for the global clinical development of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rese-cel in multiple indications, including potential late-stage clinical trials and preparations for commercial readiness. Lonza has the right to terminate the Lonza Agreement in whole at any time with written notice including a three month ramp down period. If Lonza were to fail to perform their obligations in accordance with the terms of the Lonza Agreement or terminate the Lonza Agreement, our clinical trials and commercial readiness may be adversely impacted which could in turn materially and adversely affect our business, results of operations and prospects.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we may not be able to achieve clinical manufacturing and cell processing through our CMOs or on our own on a timely basis. While our current manufacturing process is similar to the well-established process developed at Penn for CD19 CAR-T, or CART19, which was later commercialized, we have limited experience as an organization in managing the CAR-T engineering process at commercial scale. Finally, because clinical manufacturing and cell processing is highly complex and patient donor material is inherently variable, we cannot yet be sure that our manufacturing process, will consistently result in product that meets specifications for release. Success in manufacturing in smaller early phase clinical trials may not predict the frequency of success at larger late phase clinical trials, or success at the commercial phase production until process qualification and validation is completed and submitted for BLA filing.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in manufacturers or manufacturing processes for rese&#8209;cel, including process optimization and scale&#8209;up for commercial production, present significant risks. If we cannot establish comparability, validate our processes and methods (including for critical materials such as lentiviral vector), and/or if our CMO(s) fails pre-approval inspection, the initiation or completion of pivotal studies, regulatory approval and commercialization could be delayed or prevented.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cell therapy products like rese-cel are complex and sensitive to changes in materials, equipment, sites, and processes. The physical and chemical properties of cell therapies such rese-cel generally cannot be fully characterized, and regulators expect robust process controls and phase-appropriate but maturing analytical methods to assure identity, quality, purity, and strength. As a result, assays of the finished product may not be sufficient to ensure that the product will perform in the intended manner. Accordingly, we employ multiple steps to control our manufacturing process to assure that the product candidate is made strictly and consistently in compliance with the applicable quality standards. We may encounter problems achieving adequate quantities and quality of clinical materials that meet FDA, or other applicable foreign standards or specifications. Manufacturing deviations or seemingly minor process changes can alter critical quality attributes, leading to lot failures, supply interruptions, or additional investigations, any of which can delay clinical timelines or regulatory submissions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Challenges complying with cGMP requirements and other quality issues could arise during efforts to increase manufacturing capacity, optimize manufacturing and scale up production. In addition, in order to obtain regulatory approval of our product candidates (and in order to release our products for commercial use), our manufacturing processes and analytical methods, including with respect to certain raw materials used in the manufacturing of our product candidates, such as lentiviral vector, must be validated in accordance with regulatory guidelines. Failure to successfully validate, or maintain validated state of our manufacturing processes and analytical methods for the product candidates or certain raw materials used in the manufacturing of our product candidates, such as lentiviral vector, in a timely or cost-effective manner, or at all, may undermine our clinical development timelines or delay, or prevent, our ability to obtain regulatory approval of our product candidates. Any process performance qualification (PPQ) campaign for rese-cel must show that the commercial process can consistently produce product meeting predefined specifications under normal variability, including variability of critical materials such as lentiviral vector (LVV). Regulators may question PPQ approaches that rely on limited or single lots of critical inputs to establish consistency, and may expect a risk assessment, process characterization, and evidence that input material specifications are representative of intended commercial supply. If our PPQ design or results are deemed insufficient, we could be required to perform additional PPQ runs, repeat validation activities, adjust specifications, or conduct further studies, which could be costly and delay our BLA or other regulatory approval.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lentiviral vector, or LVV, is a critical manufacturing input for CAR T-cell products. FDA guidance highlights expectations for vector manufacturing and testing, including identity, purity, functional (e.g., potency-related) characteristics, and safety testing. Regulators also emphasize having an appropriately qualified potency strategy in place as development progresses, and they may expect potency-relevant assays for critical components used to support pivotal study supplies, or, if not available at the time of manufacture, a risk-based justification with follow-up testing. Challenges in qualifying or validating vector-related assays, securing vector supply, or meeting evolving specifications could delay batch release, clinical milestones, or approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transferring processes, methods, and know-how to a new manufacturers or manufacturing site is complex and time-consuming, may necessitate method bridging/transfer, and can introduce site-specific changes in equipment, raw materials, or procedures. As is customary, we have been, and may continue, optimizing and scaling manufacturing for later-stage development and potential commercialization, and we have transferred, and may in the future transfer, manufacturing to one or more contract manufacturers or additional manufacturing sites. Regulators expect sponsors to demonstrate comparability&#8212;analytically, and when needed via nonclinical or clinical bridging&#8212;between products made before and after process changes and across manufacturing sites. If our manufacturers fail to demonstrate adequate comparability on the expected timelines and at the required quality, and/or if FDA or other applicable foreign regulators do not agree with our proposed plans for demonstrating the comparability of the two processes, it may require us to incur additional costs or delay initiation or completion of clinical trials, complete additional pre-clinical studies and/or clinical trials, develop additional assays, or modify release specifications, and/or could delay or prohibit regulatory approval, including regulatory approval of certain manufacturing sites or processes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reliance on third parties for manufacture of our product candidates and raw materials utilized in manufacturing our product candidates entails certain risks, including reliance on the third party for regulatory compliance and quality assurance, the possibility that the third-party manufacturer does not maintain the financial, personnel or other resources to meet its obligations, the possibility that the third party fails to manufacture such components, or our product candidates or any products we may eventually commercialize, in accordance with our specifications, misappropriation of our proprietary information, including our trade secrets and know-how, and the possibility of termination of our manufacturing relationship by the third party, based on its own business priorities, at a time that is costly or damaging to us. In addition, the FDA and other regulatory authorities require that our product candidates and any products that we may eventually commercialize be manufactured according to cGMP and similar jurisdictional standards. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. The FDA or similar foreign regulatory agencies may also implement new standards at any time, or change their interpretations and enforcement of existing standards for manufacture, packaging or testing of products. We have little control over our manufacturers&#8217; compliance with these regulations and standards.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, the technical skills required to manufacture our product candidates may be unique or proprietary to a particular CMO, and we may have difficulty, or there may be contractual restrictions prohibiting us from transferring such skills to a back-up or alternate supplier if needed, or we may be unable to transfer such skills at all.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates are uniquely manufactured. If we or any of our third-party manufacturers encounter difficulties in manufacturing our product candidates, our ability to provide supply of our product candidates for clinical trials or, if licensed, for commercial sale, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacturing process used to produce our product candidates is complex and novel, and it has not yet been validated for commercial production. The manufacture of our product candidates includes harvesting white blood cells from each patient, stimulating certain T cells from the white blood cells and thereby causing them to activate and proliferate, combining patient T cells with lentiviral delivery vector through a process known as transduction, expanding the transduced T cells to obtain the desired dose, formulating and freezing the cell product, and ultimately infusing the modified T cells back into the patient&#8217;s body. Because of the bespoke nature of this product for patients, the cost to manufacture our product candidates is higher than traditional small molecule chemical compounds and monoclonal antibodies. Furthermore, our manufacturing process development and scale-up is at an early stage, and evaluation of cost at large scale has not yet been finalized. The actual cost to manufacture and process our product candidates could be greater than we expect and could materially and adversely affect the commercial viability of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our manufacturing process may be susceptible to technical and logistics delays or failures due to the fact that each patient is an independent manufacturing lot, and also due to unique supply chain requirements. These include the collection of white blood cells from patients&#8217; blood, variability in the quality of white blood cells collected from patients&#8217; blood, cryopreservation of the white blood cells collected, packaging and shipment of frozen white blood cells to the manufacturing site in order to enable multi-site studies, procurement of lentiviral vectors that meet potency and purity requirements and shipment to the product candidate manufacturing site, shipment of the final product to clinical centers, manufacturing issues associated with interruptions in the manufacturing process, scheduling constraints for cell manufacturing slots, process contamination, equipment or reagent failure or supply shortage(s)/interruption(s), improper installation or operation of equipment, vendor or operator error, and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inconsistency in cell growth. Even minor deviations from normal manufacturing processes could result in reduced production yields, lot failures, product defects, product recalls, product liability claims and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, production at such manufacturing facilities may be interrupted for an extended period of time to investigate and remedy the contamination. Further, as product candidates are developed through preclinical studies to late-stage clinical trials toward approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes may result in the need to enroll additional patients or to conduct additional clinical studies to evaluate the impact of changes on product safety and efficacy. Penn has informed us that it will be unable provide clinical supply for any late-phase or non-U.S. clinical trials of our product candidates that we may conduct. Therefore, we will need maintain and/or add new agreements with additional CMOs to produce clinical supply of our product candidates for late-phase clinical trials and at the necessary scale. We cannot guarantee that we will be able to enter into such agreements on commercially acceptable terms, if at all. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of ongoing and planned clinical trials or other future clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we continue to optimize our manufacturing process for our product candidates, doing so is a difficult and uncertain task, and there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, lot consistency and timely availability of reagents and/or raw materials. If we are unable to adequately scale-up the manufacturing process for our product candidates with Minaris and Lonza, we may need to transfer to another manufacturer and/or our own facility, which can be lengthy. If we are able to adequately establish and scale-up the manufacturing process for our product candidates with an alternative manufacturer, we will still need to negotiate with such manufacturer an agreement for commercial supply and it is not certain we will be able to come to agreement on terms acceptable to us. This may impact our cost of goods and thus commercial viability and/or competitiveness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, many of the components which are required to support our cell manufacturing process, such as equipment, media, growth factors and disposables, are highly specialized and it is possible that the supply chain for these materials may be interrupted. If we are unable to promptly remedy such interruption, then there may be delays to our clinical development efforts.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The manufacturing process for any products that we may develop is subject to the FDA approval process, and we will need to contract with manufacturers who can meet all applicable FDA requirements on an ongoing basis.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacturing process for any products that we may develop is subject to the FDA approval process, and we will need to contract with manufacturers who can meet all applicable FDA requirements on an ongoing basis. If we or our CMOs are unable to reliably produce products to specifications acceptable to the FDA, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CMOs will be able to manufacture the approved product in accordance with requirements from the FDA, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, suspension of production or recalls of the product candidates or marketed biologics, operating restriction and criminal prosecutions, delay approval of our product candidates, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations and growth prospects. Our future success depends on our ability to manufacture our products, if licensed, on a timely basis with acceptable manufacturing costs, while at the same time maintaining good quality control and complying with applicable regulatory requirements, and an inability to do so could have a material adverse effect on our business, financial condition, and results of operations. In addition, we could incur higher manufacturing costs if manufacturing processes or standards change, and we could need to replace, modify, design, or build and install equipment, all of which would require additional capital expenditures. Specifically, because our product candidates may have a higher cost of goods than conventional therapies, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The manufacture of viral vectors is complex and variable, and there are a limited number of manufacturers able to supply us with viral vectors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our rese-cel product candidates utilize a lentiviral delivery vector and some or all of our other product candidates may require a lentiviral delivery vector, a key drug substance that delivers the CAR to the target T cells. We do not have the capability to manufacture lentiviral vector and plan to obtain the vector we require from third parties. The manufacturing process for lentiviral vector is variable and still evolving. It is not uncommon for manufacturing runs to fail, whether due to contamination, supplier error, or equipment failure, or to be delayed. To the extent our product candidates use a lentiviral delivery vector, a lack of vector supply will cause us to be unable to manufacture our CAR T cells as well as a delay in patient enrollment, which may have a negative impact on our ability to successfully develop our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, there are a limited number of manufacturers capable of producing lentiviral vectors. It can be challenging to secure a relationship with any of these manufacturers, and the manufacturing and release process can take a significant amount of time. We have secured a supply of lentiviral vector from CAROT and Oxford for the patients we plan to enroll in our RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trials. In December 2021, as amended in May 2023, February 2024 and May 2024, we secured a license and supply agreement with Oxford to establish a process and supply lentiviral vector for the clinical and commercial development of our rese-cel candidate. There is no assurance that we will be able to continue to secure adequate and timely supply of lentiviral vector. Moreover, we cannot be certain that our CAR T cell product candidates produced with lentiviral vector from different manufacturers will be comparable or that results of clinical trials will be consistent if conducted with lentiviral vector from different manufacturers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vector production also requires the production of high-quality DNA plasmids, for which there is also a limited number of suppliers. Although we have established relationships with suppliers for lentiviral vector and plasmids, we do not yet have our own clinical-scale manufacturing facility established, and are therefore highly dependent on the ability of these suppliers to manufacture necessary materials and to deliver these materials to us on a timely and reliable basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are to operate our own manufacturing facility, significant resources will be required and we may fail to successfully operate our facility, which could adversely affect our clinical trials and the commercial viability of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we establish our own manufacturing facility, our operations will be subject to review and oversight by the FDA and the FDA could object to our use of our manufacturing facility. We must first receive approval from the FDA prior to licensure to manufacture our product candidates, which we may never obtain. Even if licensed, we would be subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMPs and other government regulations. Our license to manufacture product candidates will be subject to continued regulatory review. Our cost of goods development is at an early stage. The actual cost to manufacture and process our product candidates at a manufacturing facility of our own could be greater than we expect and could materially and adversely affect the commercial viability of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The manufacture of biopharmaceutical products is complex and requires significant expertise, and can be impacted by resource constraints, labor disputes and workforce limitations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacture of biopharmaceutical products is complex and requires significant expertise, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production and ensuring the absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of product candidates or in the manufacturing facilities upon which we currently or will rely, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability or other issues relating to the manufacture of our product candidates, whether by Minaris, Lonza, or other third-party CMOs, or at any manufacturing facility that we may establish, will not occur in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Minaris, Lonza, or other third-party CMOs that we engage, or we may fail to manage the logistics of storing and shipping our product candidates. Storage failures and shipment delays and problems caused by us, our vendors or other factors not in our control, such as weather, could result in loss of usable product or prevent or delay the delivery of product candidates to patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Minaris, Lonza, or other third-party CMOs that we engage, or we may also experience manufacturing difficulties due to resource constraints, labor disputes or workforce limitations arising from the expanding need for manufacturing in the cell therapy field and the limited number of training programs for technical staff. If we were to encounter any of these difficulties, our ability to provide our product candidates to patients would be jeopardized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are dependent upon the availability of specialty raw materials and the production capabilities of small manufacturers to source the components of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates require many specialty raw materials, some of which are manufactured by small companies with limited resources and experience to support a commercial product, and the suppliers may not be able to deliver raw materials to our specifications. In addition, those suppliers generally do not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms. The suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also do not have contracts with many of these suppliers, and we may not be able to contract with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key raw materials to support clinical or commercial manufacturing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on commercially reasonable terms, which could have a material adverse impact on our business. We are also unable to predict how changing global economic conditions or global health concerns will affect our third-party suppliers and manufacturers. Regional or single-source dependencies may in some cases accentuate these risks. For example, the pharmaceutical industry generally, and in some instances our Company or our collaborators or other third parties on which we rely, depend on China-based suppliers or service providers for certain raw materials, products and services, or other activities. Our ability or the ability of our collaborators or such other third parties to continue to engage these China-based suppliers or service providers for certain preclinical research programs and clinical development programs could be restricted due to geopolitical developments between the United States and China, including as a result of the escalation of tariffs or other trade restrictions or due to the enactment of the NDAA, which includes Section 851, commonly referred to as the &#8220;BIOSECURE Act.&#8221;. Any negative impact of such matters on our third-party suppliers and manufacturers may also have an adverse impact on our results of operations or financial condition.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may encounter difficulties in production, particularly with respect to process development or scaling up of our manufacturing capabilities. If we encounter such difficulties, our ability to provide supply of our CAR T cells for clinical trials or for commercial purposes could be delayed or stopped.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Establishing clinical and commercial manufacturing and supply is a difficult and uncertain task, and there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among others, increased costs, potential problems with process scale-out, process reproducibility, stability issues, lot consistency, and timely availability of reagents or raw materials. For example, we may find it difficult to establish a manufacturing process that is consistent. If this occurs, we may need to complete more than one manufacturing run for each treated patient, which would impact the availability of adequate coverage and reimbursement from third-party payors. Competitors that have developed CAR T cell therapies have had difficulty reliably producing engineered T cell therapies in the commercial setting. If we experience similar challenges manufacturing product candidates to approved specifications, this may limit our product candidates&#8217; utilization and our ability to receive payment for these product candidates once licensed. Alternatively, these challenges may require changes to our manufacturing processes, which could require us to perform additional clinical studies, incurring significant expense. We may ultimately be unable to reduce the expenses associated with our product candidates to levels that will allow us to achieve a profitable return on investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials. We and our suppliers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that we and our suppliers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we and our suppliers cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in product candidate manufacturing or formulation may result in additional costs or delay, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As product candidates are developed through preclinical studies to later-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods or formulation, are altered along the way in an effort to optimize processes and results. Any of these changes could cause our product candidates to perform differently and affect the results of ongoing and planned clinical trials or other future clinical trials conducted with the altered materials or with materials made with the altered methods. Such changes may also require additional testing, or notification to, or approval by the FDA or other regulatory authorities. This could delay completion of clinical trials, require the conduct of bridging clinical trials or studies, require the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and/or jeopardize our ability to commence product sales and generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug products, including biologics, are subject to extensive regulation by the FDA and other regulatory authorities in the United States and comparable authorities in other jurisdictions, such as the EMA in Europe. We are not permitted to market any biological drug product in the United States until we receive approval of a Biologics License Application, or BLA, from the FDA. We have not previously submitted a BLA to the FDA, or similar licensure filings to comparable foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidate&#8217;s safety, potency and purity for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing and controls for the product, including with respect to chain of identity and chain of custody of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, to our knowledge, the FDA has not previously reviewed regulatory applications for marketing authorization of CAR T cells for treatment of autoimmune disease or CAAR T cells for treatment of pemphigus, and there is no cell therapy currently approved by the FDA for the treatment of mPV, MuSK myasthenia gravis, SLE, myositis, SSc, gMG or MS. Because of this, we have little guidance as to which endpoints will be accepted, how many clinical trials we may expect to conduct, and whether open-label clinical trials will be deemed acceptable, among other things. We may also request regulatory approval of future CAR T or CAAR T cell-based product candidates by target, regardless of disease type or origin, which the FDA may have difficulty accepting if our clinical trials only involved diseases of certain origins. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety, potency and purity data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee&#8217;s recommendations. Further, given the rapidly evolving landscape of cell therapy, we could encounter a significant change in the regulatory environment for our product candidates once we have already begun one or more lengthy and expensive clinical trials for our product candidates. For example, the U.S. Supreme Court&#8217;s July 2024 decision to overturn prior established case law giving deference to regulatory agencies&#8217; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which FDA&#8217;s regulations, policies, and decisions may become subject to increasing legal challenges, delays, and/or changes. Moreover, the incoming U.S. administration may propose policy changes that create additional uncertainty for our business and may result in increased regulatory uncertainty, judicial interpretations overturing precedent and other impacts to the agency rulemaking process. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also experience delays in completing ongoing and planned clinical trials for a variety of reasons, including delays related to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining regulatory authorization to begin a trial, if applicable; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of financial resources to commence and complete the planned trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining approval at each clinical trial site by an independent IRB; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recruiting suitable patients to participate in a trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial before the product candidate is manufactured and returned to the site, or return for post-treatment follow-up; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trial sites deviating from trial protocol or dropping out of a trial; </span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">addressing any patient safety concerns that arise during a trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adding new clinical trial sites; or </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing sufficient quantities of qualified materials under cGMPs and applying them on a patient by patient basis for use in clinical trials. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. If we experience delays in the completion of, any future clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to a licensed biologic. Under the BPCIA, an application for a biosimilar product cannot be licensed by the FDA until 12 years after the reference product was licensed under a BLA. The law is complex and is still being interpreted and implemented by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that any of the product candidates we develop that is licensed in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></p><p style="text-indent:27.75pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the European Union, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product. For such products, the results of appropriate preclinical or clinical trials must be provided in support of an application for market authorization. Guidelines from the EMA detail the type and quantity of supplementary data to be provided for different types of biological product.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established cell therapies and other therapies for autoimmune diseases where B cells may play a role in initiating or maintaining disease are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we are developing novel CAR T and CAAR T cell product candidates that are unique biological entities, the regulatory requirements that we will be subject to are not entirely clear. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA established the Office of Tissues and Advanced Therapies, or OTAT, in 2016, within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. In September 2022, the FDA announced retitling of OTAT to the Office of Therapeutic Products, or OTP, and elevation of OTP to a &#8220;Super Office&#8221; to meet its growing cell and gene therapy workload. In addition, under guidelines</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued by the National Institutes of Health, or NIH, gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. Before a clinical trial can begin at any institution, that institution&#8217;s institutional review board, or IRB, and its IBC assesses the safety of the research and identifies any potential risk to public health or the environment. While the NIH guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. Although the FDA decides whether individual gene therapy protocols may proceed, review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if the FDA has reviewed the study and approved its initiation. Conversely, the FDA can place an IND application on clinical hold even if such other entities have provided a favorable review. Furthermore, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which a clinical trial will be conducted. In addition, adverse developments in clinical trials of gene therapy products conducted by others or in the post-approval context may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates. For example, after the FDA&#8217;s November 2023 announcement of its investigation into reports of T cell malignancies for BCMA- and CD19-directed CAR T cell immunotherapies, the FDA informed us that, based on those reports, patients receiving rese-cel in our clinical trials will require life-long monitoring for new malignancies.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the European Union, a special committee called the Committee for Advanced Therapies was established within the EMA in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products, or ATMPs, to assess and provide an opinion on the quality, safety and efficacy of ATMPs which are the subject of a marketing authorization application, and to follow scientific developments in the field. ATMPs include gene therapy products as well as somatic cell therapy products and tissue engineered products. These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Because the regulatory landscape for our CAR T and CAAR T cell product candidates is new, we may face even more cumbersome and complex regulations than those emerging for gene therapy products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn because of changes in regulations or the interpretation of regulations by applicable regulatory agencies. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States. Before we can commercialize any of our product candidates, we must obtain marketing approval. We have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction and it is possible that none of our product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. We, as a company, have no experience in filing and supporting the applications necessary to gain regulatory approvals and expect to rely on third-party CROs and/or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the drug candidate&#8217;s safety, potency and purity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process of obtaining regulatory approvals is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted IND, BLA or comparable application types in other countries, may cause delays in the approval or rejection of an application. The FDA and foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or other foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA that a drug candidate is safe, potent and pure for its proposed indication or a related companion diagnostic is suitable to identify appropriate patient populations; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA or other foreign regulatory authorities for approval; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or other foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an BLA, or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or other foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities that we may establish or of third-party manufacturers with which we may contract for clinical and commercial supplies; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval policies or regulations of the FDA or other foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of the large number of drugs in development, only a small percentage successfully complete the FDA approval process and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects. Although we have discussed the designs of our trials for rese-cel with the FDA to align on the key aspects of the studies, the FDA may not ultimately agree that the data from such trials supports regulatory approval. For example, in March 2026, the FDA noted that details are needed in order for the FDA to assess suitability of the proposed registry as an external control, including information on potential baseline differences between the enrolled study population and registry population (e.g., diagnosis classification and refractory definition) and the risk of missing or unavailable data, as well as other criteria established by FDA guidance for industry.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. As a result, our ability to develop product candidates and obtain regulatory approval may be significantly impacted. For example, the general approach for FDA approval of a new biologic or drug is for sponsors to seek licensure or approval based on dispositive data from well-controlled, Phase 3 clinical trials of the relevant product candidate in the relevant patient population. Phase 3 clinical trials typically involve hundreds of patients, have significant costs and take years to complete. We believe that we may be able to utilize the FDA&#8217;s Regenerative Medicine Advanced Therapy designation for our product candidates given the limited alternatives for treatments for certain rare diseases and autoimmune diseases where B cells may play a role in initiating or maintaining disease, but the FDA may not agree with our plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, approval of genetic or biomarker diagnostic tests may be necessary to advance some of our product candidates to clinical trials or potential commercialization. In the future, regulatory agencies may require the development and approval of such tests. Accordingly, the regulatory approval pathway for such product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, if licensed, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even though we may apply for orphan drug designation for our product candidates, we may not be able to obtain orphan drug marketing exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population of 200,000 or more in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. In order to obtain orphan drug designation, the request must be made before submitting a BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval of that particular product for the use or indication for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic (meaning, a product with the same principal molecular structural features) for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other biologics that do not have the same principal molecular structural features for use in the same indication or the same biologic for a different indication during the exclusivity period. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product or if a subsequent applicant demonstrates clinical superiority over our product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have obtained from the FDA orphan drug designation for DSG3-CAART for the treatment of pemphigus vulgaris, for MuSK-CAART for the treatment of MuSK MG and for rese-cel for the treatment of idiopathic inflammatory myopathies (IIM, or myositis) and systemic sclerosis. We may seek orphan drug designation for certain other of our product candidates, but may be unable to obtain orphan drug designation for some or all of our product candidates in specific orphan indications in which we believe there is a medically plausible basis for the use of these products. Even if we obtain orphan drug designation, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition, or if a subsequent applicant demonstrates clinical superiority over our products, if licensed. Although we may seek orphan drug designation for other product candidates, we may never receive such designations. In addition, the FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The FDA has granted rare pediatric disease designation to rese-cel for the treatment of juvenile dermatomyositis. However, a marketing application for rese-cel or any other product candidate, if approved, may not meet the eligibility criteria for a priority review voucher.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has granted rare pediatric disease designation to rese-cel for the treatment of juvenile dermatomyositis. Designation of a drug as a drug for a rare pediatric disease does not guarantee that an NDA or BLA for such drug will meet the eligibility criteria for a rare pediatric disease priority review voucher at the time the application is approved. Under the FDCA, we will need to request a rare pediatric disease priority review voucher in our original BLA for rese-cel. The FDA may determine that a BLA for rese-cel, if approved, does not meet the eligibility criteria for a priority review voucher, including for the following reasons:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">juvenile dermatomyositis no longer meets the definition of a rare pediatric disease; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the BLA contains an active ingredient that has been previously approved by the FDA; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the BLA does not rely on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population (that is, if the BLA does not contain sufficient clinical data to allow for adequate labeling for use by the full range of affected pediatric patients); or </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the BLA is approved for a different adult indication than the rare pediatric disease for which rese-cel is designated. </span></div></div><p style="text-indent:24.45pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA&#8217;s rare pediatric disease priority voucher program began to sunset on December 20, 2024, on failure to pass a continuing resolution package that included its reauthorization. Under the amended statutory sunset provisions, after December 20, 2024, the FDA may award a priority review voucher for an approved rare pediatric disease product application only if the sponsor has rare pediatric disease designation for the drug and if that designation was granted by December 20, 2024. After September 30, 2026, the FDA may not award any rare pediatric disease priority review vouchers. Congress may vote to reauthorize this program, and legislative proposals to do so remain pending in Congress, but its future remains unknown at this time unless any such proposal is passed and enacted into law. Absent any such reauthorization, if a BLA for rese-cel is not approved prior to September 30, 2026 for any reason, regardless of whether it meets the criteria for a rare pediatric disease priority review voucher, it will not be eligible for a priority review voucher.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A fast track designation by the FDA, even if granted, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our current product candidate and any future product candidates will receive marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA fast track designation for a particular indication. Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious or life-threatening conditions and address an unmet medical need. We have received fast track designation for DSG3-CAART for improving healing of mucosal blisters in patients with mPV, for MuSK-CAART for improving activities of daily living and muscle strength in patients with MuSK antibody-positive myasthenia gravis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and for rese-cel, designed to deplete CD19-positive B cells and improve disease activity in patients with SLE, LN and the myositis subtype of dermatomyositis, for the treatment of patients with systemic sclerosis to improve associated organ dysfunction and for the treatment of relapsing and progressive forms of MS. We may also apply for fast track designation for certain of our other product candidates, but there is no assurance that the FDA will grant this status to any of our other current or future product candidates. Marketing applications filed by sponsors of products in fast track development may qualify for priority review under the policies and procedures offered by the FDA, but the fast track designation does not assure any such qualification or ultimate marketing approval by the FDA. The FDA has broad discretion whether or not to grant fast track designation, so even if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even though we have received fast track designation for certain of our product candidates, we may not experience a faster development process, regulatory review or approval for these product candidates as compared to conventional FDA procedures, and receiving a fast track designation does not provide assurance of ultimate FDA approval. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. In addition, the FDA may withdraw any fast track designation at any time.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Although we may pursue expedited regulatory approval pathways for a product candidate, it may not qualify for expedited development or, if it does qualify for expedited development, it may not actually lead to a faster development or regulatory review or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we believe there may be an opportunity to accelerate the development of certain of our product candidates through one or more of the FDA&#8217;s expedited programs, such as fast track, breakthrough therapy, Regenerative Medicine Advanced Therapy, accelerated approval or priority review, we cannot be assured that any of our product candidates will qualify for such programs.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, we may seek a Regenerative Medicine Advanced Therapy, or RMAT, designation for some of our product candidates. We have received RMAT designation for our myositis and systemic sclerosis programs. An RMAT is defined as cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products. Gene therapies, including genetically modified cells that lead to a durable modification of cells or tissues may meet the definition of a Regenerative Medicine Therapy. The RMAT program is intended to facilitate efficient development and expedite review of RMATs, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition. A new drug application or a BLA for an RMAT may be eligible for priority review or accelerated approval through (1) surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit or (2) reliance upon data obtained from a meaningful number of sites. Benefits of such designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A Regenerative Medicine Therapy that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its approval. Although RMAT designation or access to any other expedited program may expedite the development or approval process, it does not change the standards for approval. If we apply for RMAT designation or any other expedited program for our product candidates, the FDA may determine that our proposed target indication or other aspects of our clinical development plans do not qualify for such expedited program. Even if we are successful in obtaining a RMAT designation or access to any other expedited program, we may not experience faster development timelines or achieve faster review or approval compared to conventional FDA procedures. Access to an expedited program may also be withdrawn by the FDA if it believes that the designation is no longer supported by data from our clinical development program. Additionally, qualification for any expedited review procedure does not ensure that we will ultimately obtain regulatory approval for such product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions at the FDA, the USPTO, the SEC and other government agencies, including from government shutdowns, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial changes in leadership and shifting policy priorities as a result of changes in the presidential administration and its appointees tasked to oversee the agency, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA, patent offices in the United States and abroad and other agencies &#8211; including as a result of reductions in force, significant organizational changes, substantial leadership departures, and policy changes &#8211; may also slow the time necessary for new drugs or biologics to be reviewed or for patent applications to be examined and granted, which would adversely affect our business. Changes and cuts in FDA staffing have also been reported by some within the pharmaceutical industry as creating instances of in delays in the FDA&#8217;s responsiveness or in its ability to review IND submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion. In addition, over the past decade, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. Specifically, in October 2025, the U.S. federal government entered a shutdown suspending services deemed non-essential as a result of the failure by Congress to enact regular appropriations for the 2026 fiscal year. In addition, the U.S. government has issued certain policies and executive orders directed towards reducing the employee headcount and costs associated with U.S. administrative agencies, including the FDA, and it remains unclear the degree to which these efforts may limit or otherwise adversely affect the FDA&#8217;s ability to conduct routine activities. If a prolonged government shutdown, such as the one that occurred in October 2025, or if funding shortages or staffing limitations hinder or prevent the FDA, the SEC or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, including formal and informal interactions with product developers, it could significantly affect the ability of the FDA or other such regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns or other substantial disruptions at other government agencies, such as the SEC, may also impact our business by delaying review of our public filings, which in turn could delay or frustrate our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate beyond the United States and, if approved, we may sell our products in countries throughout the world. Significant political, trade, or regulatory developments in the jurisdictions in which we may sell our products, such as those stemming from the change in U.S. federal administration, are difficult to predict and may have a material adverse effect on us. Similarly, changes in U.S. federal policy that affect the geopolitical landscape could give rise to circumstances outside our control that could have negative impacts on our business operations. For example, certain governments (including the United States and other countries) have imposed or may impose tariffs on a wide range of products, raw materials, and intermediate goods. Additional tariffs, or retaliatory measures by other countries in response, may be implemented at any time. Historically, tariffs have led to increased trade and political tensions, between not only the U.S. and China, but also between the U.S. and other countries in the international community. In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. Any changes in political, trade, regulatory, and economic conditions, including U.S. trade policies, could have a material adverse effect on our financial condition or results of operations. Until we know what policy changes are made, whether those policy changes are challenged and subsequently upheld by the court system and how those changes impact our business and the business of our competitors over the long term, we will not know if, overall, we will benefit from them or be negatively affected by them.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Ongoing Regulatory Obligations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety, potency and purity of the product candidate. We believe it is likely that the FDA will require a Risk Evaluation and Mitigation Strategy, or REMS, in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional observations. Additionally, manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA, and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations and applicable product tracking and tracing requirements. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker information. Additionally, under the Food and Drug Omnibus Reform Act of 2022, or FDORA, sponsors of approved drugs and biologics must provide six months&#8217; notice to the FDA of any changes in marketing status, such as the withdrawal of a drug, and failure to do so could result in a letter citing such failure to comply and public posting of such letter and redacted company response, which could damage the company&#8217;s reputation.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, we will be required to comply with FDA promotion and advertising rules, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved uses (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet and social media. Later discovery of previously unknown problems with our product candidates through follow-up programs with our clinical trial patients, including adverse events of unanticipated severity or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning letters or holds on clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of our product candidates; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action. If these executive actions impose restrictions on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development activities involve the use of biological and hazardous materials and produce hazardous</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological waste or hazardous waste insurance coverage, workers compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to comply with the laws of the FDA, provide true, complete and accurate information to the FDA, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws, or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">	</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Healthcare</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if licensed, profitably.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successful commercialization of our product candidates, if licensed, will depend in part on the extent to which reimbursement for those drug products will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drug products they will pay for and establish reimbursement levels. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford a drug product. Sales of drug products depend substantially, both domestically and abroad, on the extent to which the costs of drugs products are paid for by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. Any product candidate for which we seek regulatory approval and reimbursement will need to meet or surpass our target product profile, or TPP, to be deemed a viable alternative to currently approved therapies. In addition, because our product candidates represent new approaches to the treatment of autoimmune diseases where B cells may play a role in initiating or maintaining disease, we cannot accurately estimate the potential revenue from our product candidates. For more information, see</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the section titled &#8220;Business&#8212;Government regulation&#8212;Pricing and Reimbursement&#8221; included in this Annual Report on Form 10-K.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide the payor with supporting scientific, clinical and cost-effectiveness data for the use of our products, if licensed. In the United States, the principal decisions about reimbursement for new drug products are typically made by the Centers for Medicare and Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new drug product will be covered and reimbursed under Medicare, and private payors tend to follow CMS to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists among third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, CMS revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payors rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payors, and reduce the willingness of physicians to use our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain regulatory approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products. For more information, see the section titled &#8220;Business&#8212;Government regulation&#8212;Current and Future Legislation&#8221; included in this annual report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. For instance, multiple executive actions in the first half of 2025 signal the federal government&#8217;s increasing focus on lowering prescription drug prices, adding to the uncertainty surrounding future drug pricing and reimbursement frameworks. For example:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 12, 2025, President Trump signed the executive order titled &#8220;Delivering Most-Favored-Nation Prescription Drug Pricing,&#8221; which directs the Secretary of Health and Human Services (HHS) to identify and communicate most-favored-nation (MFN) price targets for prescription drugs and to propose a rulemaking plan to impose such pricing if &#8220;significant progress&#8221; is not made. The order also directs the federal government to explore regulatory pathways that would facilitate direct-to-patient sales for manufacturers that meet these price targets. Additionally, it signals potential further action against manufacturers that fail to offer MFN pricing, including evaluating whether to modify or rescind marketing approvals or allow individual drug importation waivers. Notably, a similar rule promulgated during </span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">President Trump&#8217;s first term would have tied Medicare Part B reimbursement rates to the lowest price available for a drug in certain foreign countries. That rule was subject to litigation and ultimately rescinded by the Biden Administration in August 2021. In a related development, FDA Commissioner Makary announced in July 2025 that the agency is considering a new fast-track priority review voucher program for manufacturers that commit to pricing drugs in line with those in economically comparable countries. The implementation timeline and commercial implications of these proposals remain uncertain.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 15, 2025, President Trump issued the executive order &#8220;Lowering Drug Prices by Once Again Putting Americans First,&#8221; which contains a broad set of directives aimed at reducing drug costs. Among other actions, the order directs HHS to revise guidance under the Inflation Reduction Act (IRA) to eliminate the so-called &#8220;pill penalty,&#8221; which currently subjects small molecule drugs to Medicare price negotiation four years earlier than biologics. The order also calls for a comprehensive evaluation of the role played by pharmacy benefit managers, or PBMs, in drug pricing and market access.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the Medicare Drug Price Negotiation Program, administered by CMS as part of the Inflation Reduction Act of 2022, commonly referred to as the IRA, may apply to our products if they are selected for negotiation, which could materially reduce the amount of revenue we can generate from our products if they are approved. Prior to the enactment of the One Big Beautiful Bill Act of 2025, or the OBBBA, orphan drugs were exempt from Medicare price negotiation under the IRA only if they had received a single orphan designation and were approved solely for the corresponding rare disease or condition. The OBBBA amended this exemption to apply more broadly: now, any orphan-designated drug is exempt from price negotiation, regardless of the number of orphan designations it has received, provided the drug&#8217;s approved indications are exclusively for those rare diseases. The OBBBA also included significant reforms to Medicaid, including an estimated $1 trillion in reduced federal Medicaid spending from 2025 through 2034, the imposition of work requirements for certain adult enrollees, more frequent eligibility redeterminations, and increased cost-sharing for beneficiaries. These changes are expected to reduce overall Medicaid enrollment and access to care. Although the effect on our future product candidates or business is unknown, any decrease in the number of insured patients or reimbursement levels for our products could adversely affect our potential for revenue and our commercial prospects.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 19, 2025, CMS released two proposed rules that would incorporate MFN pricing principles into federal reimbursement for prescription drugs. The first proposal, the Global Benchmark for Efficient Drug Pricing Model, or GLOBE, for Medicare Part B, would require manufacturers of specified single source drugs and sole source biologics to pay incremental rebates based on international benchmark prices, with participation triggered for products meeting CMS&#8217;s spending and eligibility criteria. The second proposal, the Guarding U.S. Medicare Against Rising Drug Costs, or GUARD, model for Medicare Part D, would similarly mandate manufacturer rebates for qualifying sole source drugs where the Medicare net price exceeds an MFN benchmark derived from international reference pricing methodologies. As proposed, GLOBE would begin a five year performance period on October 1, 2026 and GUARD would begin its performance period in 2027. These proposals will likely be subject to legal challenges that could delay their implementation or modify their impact on manufacturer pricing and revenue. Additionally, in November 2025, CMS introduced the GENErating cost Reductions for U.S. Medicaid Model, or GENEROUS Model, a voluntary MFN framework for manufacturers participating in the Medicaid Drug Rebate Program. Although it is voluntary, the GENEROUS Model could also impact the drug pricing landscape for manufacturers.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the demand for our product candidates, if we obtain regulatory approval; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to set a price that we believe is fair for our products, if licensed; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of taxes that we are required to pay; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of capital.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that the healthcare reform measures that have been adopted and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our relationships with customers, healthcare providers, physicians, and third-party payors will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These laws may impact, among other things, our clinical research program, as well as our proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services is subject to extensive laws and regulations designed to prevent fraud, kickbacks, self-dealing and other abusive practices, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which such companies sell, market and distribute pharmaceutical products. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. We may also be subject to federal, state and foreign laws governing the privacy and security of individual identifiable health information and other personally identifiable information. For more information, see the section titled &#8220;Business&#8212;Government regulation&#8212;Other Healthcare Laws and Compliance Requirements&#8221; included in this Annual Report on Form 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The failure to comply with any of these laws or regulatory requirements subjects entities to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Any action for violation of these laws, even if successfully defended, could cause a pharmaceutical manufacturer to incur significant legal expenses and divert management&#8217;s attention from the operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities, or our arrangements with physicians, some of whom receive stock options as compensation, could be subject to challenge under one or more of such laws. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we may be subject to investigations, enforcement actions and/or significant penalties. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct or business noncompliance, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Data Privacy and Security</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to stringent privacy and data protection requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and these requirements may become more complex as we grow our business and begin to operate in other jurisdictions. For example, the collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the European Economic Area, or the EEA, including personal health data, is subject to the EU General Data Protection Regulation, or the EU GDPR, and similarly, processing of personal data regarding individuals in the UK is subject to the UK General Data Protection Regulation and the UK Data Protection Act 2018, or the UK GDPR, and together with the EU GDPR, or the GDPR. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to having a legal basis or condition for processing personal data, stricter requirements relating to the processing of sensitive data (such as health data), where required by the GDPR obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, requiring data protection impact assessments for high risk processing and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA/UK, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million (&#163;17.5 million under UK GDPR) or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers of personal data to countries outside the EEA/UK that are not considered by the European Commission and UK government as providing &#8220;adequate&#8221; protection to personal data, or third countries, including the United States. The GDPR may increase our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Compliance with the GDPR is rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To enable the transfer of personal data outside of the EEA or the UK, adequate safeguards (for example, the European Commission approved Standard Contractual Clauses, or SCCs and the UK International Data Transfer Agreement/Addendum, or UK IDTA) must be implemented in compliance with European and UK data protection laws. In addition, transfers made pursuant to the SCCs (and other similar appropriate transfer safeguards) need to be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular regarding applicable surveillance laws and relevant rights of individuals with respect to the transferred personal data, to ensure an &#8220;essentially equivalent&#8221; level of protection to that guaranteed in the EEA in the jurisdiction where the data importer is based, or the Transfer Impact Assessment. Further, the EU and United States have adopted its adequacy decision for the EU-U.S. Data Privacy Framework, or the Framework, which entered into force on July 11, 2023. This Framework provides that the protection of personal data transferred between the EU and the United States is comparable to that offered in the EU. This provides a further avenue to ensuring transfers to the United States are carried out in line with GDPR. There has been an extension to the Framework to cover UK transfers to the United States. The Framework could be challenged like its predecessor frameworks. We are required to implement these safeguards and carry out Transfer Impact Assessments when conducting restricted data transfers under the GDPR and doing so will require significant effort and cost, and may result in us needing to make strategic considerations around where EEA or UK personal data is stored and transferred, and which service providers we can utilize for the processing of EEA/UK personal data. Although the UK is regarded as a third country under the EU GDPR, the European Commission has issued a decision recognizing the UK as providing adequate protection under the EU GDPR, or the Adequacy Decision, and, therefore, transfers of personal data originating in the EEA to the UK remain unrestricted. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite Brexit, the UK and EEA data protection regimes remain largely aligned. However, going forward, there is increasing risk for divergence in application, interpretation and enforcement of the data protection laws as between the UK and EEA, creating additional regulatory uncertainty. For example, the UK Data (Use and Access) Act 2025 (&#8220;UK Act&#8221;), now in force, further differentiates the UK&#8217;s data protection regime. In December 2025, the European Commission adopted a decision determining that the UK continues to provide a level of data protection that is &#8220;essentially equivalent&#8221; to the EU standards and extended the validity of the UK adequacy decision for six years, through December 2031. While this renewal reduces immediate adequacy concerns, uncertainty remains regarding how UK data protection laws will evolve in the medium to longer term. The lack of clarity on future UK laws and regulations and their interaction with EU laws and regulations may affect our efforts to maintain a harmonized approach to processing European personal data and expose us to two parallel regimes where the UK GDPR and EU GDPR both apply with differing interpretation and enforcement approaches. This could increase our legal risk, uncertainty, complexity and compliance cost associated with the handling of European personal data, and may require us to adapt our privacy and data security compliance programs to account for legal and regulatory divergence between the UK and EEA.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EEA, the NIS 2 Directive (&#8220;NIS 2&#8221;) is replacing the cybersecurity legal framework under the current NIS framework, aiming to ensure a high level of cybersecurity in the region. NIS 2 brings new medium and large organisations providing services in the EEA within scope of the legal framework. It extends to additional sectors and expands the list of in-scope healthcare organisations, including to certain providers engaged in research and development of medicinal products. The new regime imposes direct obligations on management in respect of an in-scope organization's compliance with NIS 2, requires covered organisations to put in place certain cyber risk management measures, strengthens incident reporting requirements and provides supervisory authorities with a greater oversight. The majority of obligations will come into force when national legislation implementing NIS 2 becomes effective in the relevant EU Member State. EU Member States had until 17 October 2024 to transpose NIS 2 into national legislation, although many countries have still not completed the transposition. As such, the cybersecurity regulatory landscape in the EU is currently fragmented and uncertain. Although we are not currently subject to NIS 2, we have evaluated its requirements and have already implemented various cybersecurity measures that align with NIS 2 obligations. To the extent that we become subject to NIS 2 in the future, we will continue working closely with our Data Protection Officer to ensure that our compliance programs are fully aligned with NIS 2 and national implementing legislation where applicable. Under NIS 2 companies may be subject to administrative fines of up to the higher amount of &#8364;10 million or 2% of worldwide turnover.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, there has been a flurry of legislative activity related to privacy at the state level. In California, for example, the California Consumer Privacy Act, or CCPA, broadly defines personal information, creates comprehensive individual privacy rights and protections for California consumers (as defined in the law), places increased privacy and security obligations on entities handling personal data of consumers or households, and provides for civil penalties for violations and a private right of action for data breaches. The CCPA requires covered companies to provide certain disclosures to consumers about their data collection, use and sharing practices, and to provide affected California residents with ways to opt-out of certain sales or transfers of personal information. The California Privacy Rights Act, or CPRA, effective January 1, 2023, significantly modified the CCPA, including by expanding</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consumers' rights with respect to certain sensitive personal information. The CPRA also created a state agency vested with authority to implement and enforce the CCPA. While there is an exception for protected health information that is subject to HIPAA and clinical trial regulations, the effects of the CCPA, as amended by the CPRA are potentially significant and may require us to modify our data collection or processing practices and policies and to incur substantial costs and expenses in an effort to comply and decrease our potential exposure to regulatory enforcement and/or litigation.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous other states have enacted similarly comprehensive privacy laws, adding additional complexity, variation in requirements, restrictions and potential legal risk, requiring additional investment of resources in compliance programs. These laws impact our strategies, the availability of previously useful data and could result in increased compliance costs and/or changes to our business practices and policies. The existence of comprehensive privacy laws in different states in the country make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance. There are also states that are specifically regulating health information. For example, Washington state passed a health privacy law that regulates the collection and sharing of health information, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data. In addition, other states have proposed and/or passed legislation that regulates the privacy and/or security of certain specific types of information. For example, a small number of states have passed laws that regulate genetic data and biometric data specifically. These various privacy and security laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products. State laws are changing rapidly and there is discussion in the U.S. Congress of comprehensive federal data privacy laws to which we may could become subject, if enacted.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the federal level, failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act (&#8220;FTC Act&#8221;). The FTC&#8217;s current guidance for appropriately securing consumers&#8217; personal information is similar to what is required by the HIPAA security regulations, but this guidance may change in the future, resulting in increased complexity and the need to expend additional resources to ensure we are complying with the FTC Act. Moreover, regulators and legislators are increasingly scrutinizing and restricting certain personal data transfers and transactions involving foreign countries. For example, the Department of Justice&#8217;s January 8, 2025, rule on &#8220;Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons,&#8221; prohibits data brokerage transactions involving certain sensitive personal data categories, including health data, genetic data, and biospecimens, to countries of concern, including China. The regulations also restrict certain investment agreements, employment agreements and vendor agreements involving such data and countries of concern, absent specified cybersecurity controls. Similar state laws regulating health and genetic data and public procurement may also restrict transfers of data to, or partnerships with entities, outside the U.S. Actual or alleged violations of these regulations may be punishable by criminal and/or civil sanctions and may result in exclusion from participation in federal and state programs.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of these evolving compliance and operational requirements impose significant costs, such as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants and legal advisors, which are likely to increase over time. Further, various other jurisdictions around the world continue to propose new and/or amended laws that regulate the privacy and/or security of certain types of personal data. Complying with these laws, if enacted, would require significant resources and leave us vulnerable to possible fines and penalties if we are unable to comply. The regulatory framework governing the collection, processing, storage, use and sharing of certain information is rapidly evolving and is likely to continue to be subject to uncertainty and varying interpretations. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our existing data management practices or the features of our services and platform capabilities. Compliance with the above and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules, modify our data processing practices and policies, utilize management&#8217;s time and/or divert resources from other initiatives and projects. Any failure or perceived failure by us, or any third parties with which we do business, to comply with our posted privacy policies, evolving laws, rules and regulations, industry standards, or contractual obligations to which we or such third parties are or may become subject, may result in actions or other claims against us by governmental entities or private actors, the expenditure of substantial costs, time and other resources or the incurrence of significant fines, penalties or other liabilities. In</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">addition, any such action, particularly to the extent we were found to be guilty of violations or otherwise liable for damages, would damage our reputation and adversely affect our business, financial condition and results of operations.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our security measures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">or those of our contractors, consultants or other service providers are breached or unauthorized access to confidential and/or proprietary information or other sensitive information, including individually identifiable health information or other personally identifiable information, is otherwise obtained, our reputation may be harmed, and we may incur significant liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and the third parties upon which we rely face a variety of evolving threats, which could cause cybersecurity incidents or data breaches, which, could result in unauthorized access to systems and data, loss of data, and compromise, misuse, or corruption of such data and information. The systems of any CMOs that we may engage now or in the future, and present and future CROs, contractors, consultants and other service providers also could experience breaches or cybersecurity incidents leading to the exposure of confidential and sensitive information. Despite the implementation of security measures, our internal computer systems and information technology systems and infrastructure and those of our third party CROs, vendors, and other contractors and consultants upon which our business relies are vulnerable to breakdown or damage or interruption from, among other things, natural disasters, terrorism, war, telecommunication and electrical failures, and sophisticated cyber attacks, including the theft, fraud, and subsequent misuse of employee credentials, wrongful conduct by insider employees or vendors, denial-of-service attacks, ransomware attacks, business email compromises, computer malware, malicious codes, viruses, breakdown, wrongful intrusions, data breaches, and social engineering (including phishing attacks). Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources. Because the techniques used by computer programmers who may attempt to penetrate and sabotage our information technology systems and infrastructure, network security or our website change frequently and may not be recognized until launched against a target, we may be unable to anticipate these techniques or to adequately prevent or address them. Attempts to disrupt or gain unauthorized access to our and our third-party vendors&#8217; information systems from malicious third parties or insider threats may be enhanced or facilitated by evolving technologies, including artificial intelligence.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is also possible that unauthorized access to our confidential and/or proprietary information or other sensitive information, including customer or employee information, may be obtained through inadequate use of security controls by customers, suppliers or other vendors. We rely on such third parties to implement effective security measures and identify and correct for any failures, deficiencies, compromises or breaches.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of a cybersecurity incident or data breach, our company could be required to provide legal notifications and disclosures, and could suffer loss of business, severe reputational damage adversely affecting investor confidence, regulatory inquiries, investigations and orders, litigation, indemnity obligations, damages for contract breach, penalties and fines for violation of applicable laws or regulations, significant costs for remediation and other liabilities. For example, the loss of preclinical study or clinical trial data from completed or future preclinical studies or clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security compromise or breach were to result in a loss or misappropriation of, or damage to, our data, systems, or applications, or inappropriate disclosure of confidential or proprietary information or other sensitive information, we could incur liability and the further development and commercialization of our product candidates could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred and expect to incur significant expenses to prevent cybersecurity incidents and data breaches, including costs related to deploying additional personnel and protection technologies, training employees, and engaging third-party solution providers and consultants. Although we expend significant resources to create security protections that are designed to shield our confidential and/or proprietary information or other sensitive information, including customer data, against potential theft and security compromises or breaches, such measures cannot provide absolute security. Moreover, as we outsource more of our information systems to vendors and rely more on cloud-based information systems, the related security risks will increase, and we will need to expend additional resources to protect our technology and information systems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Like other companies in our industry, we, and our third party vendors, have experienced and will continue to experience threats and cybersecurity incidents relating to our information technology systems and infrastructure. We remain at risk for future cybersecurity incidents and data breaches, including, without limitation, those that may occur as a result of third-party action, or wrongful conduct by insider employees or vendors or malfeasance and other causes. If, in the future, we experience a data breach or security incident, we could experience harm to our reputation, financial performance, and customer and vendor relationships. Further, we could experience possible legal notifications and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disclosures, as well as litigation or regulatory investigations or actions by state and federal governmental authorities and non-U.S. authorities, including fines, penalties, and other legal and financial exposure and liabilities. Additionally, actual, potential or anticipated attacks or compromises may cause us to incur increasing costs, including costs to deploy additional personnel and protection technologies, train employees, conduct security incident investigation or remediation and engage third-party experts and consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our privacy and data security obligations. Further, although we maintain cyber liability insurance, this insurance may not provide adequate coverage against potential liabilities related to any experienced cybersecurity incident or breach.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interruptions in the availability of server systems or communications with internet or cloud-based services, or failure to maintain the security, confidentiality, accessibility or integrity of data stored on such systems, could harm our business.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely upon a variety of internet service providers, third-party web hosting facilities and cloud computing platform providers to support our business. Failure to maintain the security, confidentiality, accessibility or integrity of data stored on or processed by such systems could result in interruptions in our operations, damage our reputation in the market, increase our service costs, cause us to incur substantial costs, subject us to liability for damages and/or fines, and divert our resources from other tasks, any one of which could materially adversely affect our business, financial condition, results of operations and prospects. If our security measures or those of our third-party data center hosting facilities, cloud computing platform providers, or third-party service partners, are breached, and unauthorized access is obtained to or there is misuse of our data or our information technology systems, we may incur significant legal and financial exposure and liabilities.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also do not have control over the operations of the facilities of our cloud service providers and our third-party web hosting providers, and they also may be vulnerable to damage, security compromise or interruption from natural disasters, cybersecurity attacks, terrorist attacks, power outages and similar events or acts of misconduct. In addition, any changes in these providers&#8217; service levels may adversely affect our ability to meet our requirements and operate our business.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our use of new and evolving technologies, such as artificial intelligence, may present risks and challenges that can impact our business, including by posing cybersecurity and other risks to our confidential and/or proprietary information, including personal information, and as a result we may be exposed to reputational harm and liability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may use and integrate artificial intelligence (AI) into our business processes both in our own development and implementation of AI and through the adoption of commercially available tools. Use of this technology could pose cybersecurity, data privacy, IT, intellectual property, regulatory, legal, operational, competitive, reputational and other risks and challenges that could affect our business. Specifically, risks related to accuracy, bias, AI hallucinations, discrimination, harmful content, misinformation, fraud, scams, targeted attacks (including model poisoning or data poisoning), surveillance, data leakage, inequality, environmental harms, and other harms may flow from our development, use, or deployment of AI technologies.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rapid evolution of AI will require the application of significant resources to design, develop, test and maintain such systems to help ensure that AI is implemented in accordance with applicable law and regulation and in a socially responsible manner and to minimize any real or perceived unintended harmful impacts. If we enable or offer solutions that draw controversy due to perceived or actual negative societal impact, we may experience brand or reputational harm, competitive harm or legal liability. Additionally, the use of certain AI technology can give rise to intellectual property risks, including by disclosing or otherwise compromising our confidential or proprietary intellectual property and intellectual property infringement, or by undermining our ability to assert or defend ownership rights in intellectual property created with the assistance of AI tools.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, a growing number of legislators and regulators are adopting laws and regulations and have focused enforcement efforts on the adoption of AI and use of such technologies in compliance with ethical standards and societal expectations. These developments may increase our compliance burden and costs in connection with use of AI and lead to legal liability if we fail to meet evolving legal standards or if use of such technologies results in harms or other causes of action we did not predict. For example, the EU began implementing the Artificial Intelligence Act, or AI Act, on August 1, 2024, with a significant part of the law scheduled to come into effect in August 2026. As</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">currently enacted, the AI Act, which may be amended as part of the EU&#8217;s Digital Omnibus, imposes significant obligations on providers and deployers of high-risk AI systems, and encourages providers and deployers of AI systems to account for EU ethical principles in their development and use of these systems. The scope of requirements depends on judicial interpretations and forthcoming legislative amendments, and non-compliance can lead to significant fines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., the AI regulatory environment is complex and uncertain. Over the past year, states have advanced, and in some cases passed, dozens of laws focusing on AI governance and regulation, including on deployment of AI in healthcare settings. At the federal level, the FDA has advanced guidance and proposed frameworks for regulating AI in drug discovery, marketing submissions, and medical device development. At the same time, the Trump Administration has endorsed a federal moratorium on the enforcement of state AI laws, including through a December 11, 2025, executive order on &#8220;Ensuring a National Policy Framework for Artificial Intelligence.&#8221; So far, these efforts have not been successful at curtailing state action on AI regulation, contributing to a complicated legislative patchwork, which may be litigated in state and federal courts. If we develop or use AI systems that are governed by the these laws or regulations, we will need to meet higher standards of data quality, transparency, and human oversight, and we would need to adhere to specific and potentially burdensome and costly ethical, accountability, and administrative requirements. We may also be subject to significant enforcement or litigation in the event of any perceived non-compliance.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rapid evolution of AI will require the application of significant resources to design, develop, test and maintain our products and services to help ensure that AI is implemented in accordance with applicable law and regulation and in a socially responsible manner and to minimize any real or perceived unintended harmful impacts. Our vendors may in turn incorporate AI tools into their offerings, and the providers of these AI tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business. Bad actors around the world also use increasingly sophisticated methods, including the use of AI, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. In addition, the use of generative AI models in our internal or third-party systems may create new attack surfaces or methods for adversaries, which could impact us and our vendors. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Ownership of Our Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Ownership Generally</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our principal stockholders and management own a large percentage of our stock and could be able to exert significant control over matters subject to stockholder approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, our executive officers, directors, and 5% stockholders beneficially owned, in the aggregate, approximately 40% of our common stock. Accordingly, these stockholders could have the ability to influence us through this ownership position and may be able to determine the outcome of certain matters requiring stockholder approval. For example, these stockholders may be able to control the outcome of elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. The Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and, beginning with our second annual report following our initial public offering, provide a management report on internal control over financial reporting. However, while we remain a smaller reporting company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. In compliance with Section 404 of the Sarbanes-Oxley Act, we will continue to dedicate internal resources, continue to engage outside consultants, and maintain a detailed work plan to assess and document the adequacy of internal control over financial reporting. Additionally, we will enhance control processes as needed, validate their effectiveness through testing, and implement a continuous monitoring and improvement process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes, and take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and harm our business. In addition, investors&#8217; perceptions that our internal controls are inadequate or that we are unable to produce accurate financial statements on a timely basis may harm our stock price and make it more difficult for us to effectively market and sell our service to new and existing customers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The dual class structure of our common stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The dual class structure of our common stock may limit your ability to influence corporate matters. Holders of our common stock are entitled to one vote per share, while holders of our non-voting common stock are not entitled to any votes. Nonetheless, each share of our non-voting common stock may be converted at any time into one share of our common stock at the option of its holder by providing written notice to us, subject to the limitations provided for in our amended and restated certificate of incorporation. Additionally, stockholders who hold, in the aggregate, more than 10% of our common stock and non-voting common stock, but 10% or less of our common stock, and are not otherwise a company insider, may not be required to report changes in their ownership due to transactions in our non-voting common stock pursuant to Section 16(a) of the Exchange Act, and may not be subject to the short-swing profit provisions of Section 16(b) of the Exchange Act. No shares of non-voting common stock are currently outstanding.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Certain holders of our common stock have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Charter and Bylaws</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws, as amended, or the amended and restated bylaws, contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer, or by a majority of the total number of authorized directors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance notice requirements for stockholder proposals and nominations for election to our board of directors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of not less than 75% of the votes that all our stockholders would be entitled to cast in an annual election of directors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a requirement of approval of not less than 75% of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our amended and restated certificate of incorporation; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our amended and restated bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to our amended and restated bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for state law claims for: (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders; (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated certificate of incorporation or amended and restated bylaws (including the interpretation, application or validity thereof); or (iv) any action asserting a claim governed by the internal affairs doctrine (the Delaware Forum Provision). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act of 1933, as amended (the Securities Act) or the Securities Exchange Act of 1934. Our amended and restated bylaws further provide that, unless</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America are the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the rules and regulations promulgated thereunder, or the Federal Forum Provision. In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, these forum selection clauses may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. While the Delaware Supreme Court and other states have upheld the validity of federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on us and/or our stockholders who assert that the provision is invalid or unenforceable. The Court of Chancery of the State of Delaware or the federal district courts of the United States of America may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Tax</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax laws could adversely affect our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. For example, the OBBBA was signed into law on July 4, 2025 and made significant changes to U.S. federal tax law. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. Prospective investors in our common stock should consult with their legal and tax advisors with respect to potential changes in tax laws and the tax consequences of investing in or holding our common stock.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had U.S. federal, state and local net operating loss, or NOL, carryforwards of $319.9 million, $255.1 million and $257.6 million, respectively. $0.3 million of the federal amounts expire in 2037. The state NOLs begin to expire in 2037 and the local NOLs begin to expire in 2042. Approximately $319.6 million of the federal NOLs can be carried forward indefinitely. Certain NOL carryforwards could expire unused and be unavailable to offset future taxable income. In addition, in general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change NOL carryforwards or tax credits to offset future taxable income or taxes. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders who own at least 5% of a corporation&#8217;s stock increases its ownership by more than 50 percentage points (by value) over its lowest ownership percentage within a specified testing period. Our existing NOLs or tax credits may be subject to limitations arising from previous ownership changes. In addition, future changes in our stock ownership, many of which are outside of our control, could result in an ownership change under Sections 382 and 383 of the Code and further limit our ability to utilize NOLs or tax credits. Our NOLs or tax credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs or tax credits. Furthermore, our ability to utilize our NOLs or tax credits is conditioned upon our attaining profitability and generating U.S. federal and state taxable income. As described above under &#8220;&#8212;Risks Related to Our Financial Condition and Capital Requirements&#8221;, we have incurred significant net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future; and therefore, we do not know whether or when we will generate the U.S. federal or state taxable income necessary to utilize our NOLs or tax credits. Under current law, U.S. federal NOL carryforwards generated in taxable years beginning after December 31, 2017 will not be subject</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to expiration. However, any such NOL carryforwards may only offset 80% of our annual taxable income in taxable years beginning after December 31, 2020.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse developments that affect financial institutions, such as events involving liquidity that are rumored or actual, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver. Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that us, the financial institutions with which we have credit agreements or arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. While it is not possible at this time to predict the extent of the impact that high market volatility and instability of the financial services industry could have on economic activity and our business in particular, the failure of other banks and financial institutions and the measures taken by governments, businesses and other organizations in response to these events could adversely impact our business, financial condition and results of operations.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Public health crises, such as a pandemic, epidemic or outbreak of other highly infectious or contagious diseases, could seriously harm our research, development and potential future commercialization efforts, increase our costs and expenses and have a material adverse effect on our business, financial condition and results of operations.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Public health crises, such as a pandemic, epidemic or outbreak of other highly infectious or contagious diseases, could adversely impact our business, the business operations of third parties on whom we rely and our ongoing or planned research and development activities. Additionally, timely enrollment in our ongoing and planned clinical trials is dependent upon clinical trial sites which may be adversely affected by global health concerns. Public health crises could result in increased adverse events and deaths in our clinical trials. Some factors from public health crises that could delay or otherwise adversely affect enrollment in the clinical trials of our product candidates, as well as our business generally, include:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential diversion of healthcare resources away from the conduct of clinical trials to focus on public health crises, including the attention of physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our prospective clinical trials and the need for drugs, such as tocilizumab, and other supplies that clinical trial sites must have on hand to conduct our clinical trials to be used to address such public health crises;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations on travel that could interrupt key trial and business activities, such as clinical trial site initiations and monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed travel restrictions or quarantines that will impact the ability or willingness of patients, employees or contractors to travel to our clinical trial sites or secure visas or entry permissions, a loss of face-to-face meetings and other interactions with potential partners, any of which could delay or adversely impact the conduct or progress of our prospective clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruption in global shipping affecting the transport of clinical trial materials, such as patient samples, investigational drug product and conditioning drugs and other supplies used in our prospective clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interruptions in operations at our third-party manufacturers, which could result in delays or disruptions in the supply of our current product candidates and any future product candidates; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees working from home, disruptions to or delays in ongoing laboratory experiments and operations, product manufacturing and supply, staffing shortages, travel limitations or mass transit </span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruptions, any of which could adversely impact our business operations or delay necessary interactions with local regulators, ethics committees and other important agencies and contractors.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these factors, and other factors related to any such disruptions that are unforeseen, could have a material adverse effect on our business and our results of operations and financial condition. Further, uncertainty around these and related issues could lead to adverse effects on the economy of the United States and other economies, which could impact our ability to raise the necessary capital needed to develop and commercialize our product candidates.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The price of our stock may be volatile, and you could lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading price of our common stock has been, and is likely to be in the future, highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section, these factors include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the commencement, enrollment or results of our planned preclinical studies or clinical trials of our product candidates or any preclinical studies or future clinical trials we may conduct, or changes in the development status of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our decision to initiate a preclinical study or clinical trial, not to initiate a preclinical study or clinical trial or to terminate an existing preclinical study or clinical trial; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse results or delays in preclinical studies or clinical trials of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including, without limitation, the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our failure to commercialize our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in laws or regulations applicable to our product candidates, including, but not limited to, clinical trial requirements for approvals; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse developments concerning our manufacturers or suppliers; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to obtain adequate product supply for any licensed product or inability to do so at acceptable prices; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to establish collaborations, if needed; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additions or departures of key scientific or management personnel; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated serious safety concerns related to the use of our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">introduction of new products or services offered by us or our competitors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to effectively manage our growth; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and growth of our initial target markets; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully treat additional types of autoimmune diseases where B cells may play a role in initiating or maintaining disease; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated variations in annual or quarterly operating results; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our cash position; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; </span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publication of news reports about us or our industry;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the market valuations of similar companies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overall performance of the equity markets; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of our common stock by us or our stockholders in the future; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading volume of our common stock; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in accounting practices; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ineffectiveness of our internal controls; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general political and economic conditions, including inflation and tariffs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">global health concerns; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other events or factors, many of which are beyond our control. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the stock market in general, and The Nasdaq Global Select Market and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations in recent years that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. Securities class action litigation has often been instituted against companies, particularly in the biopharmaceutical and life sciences industries, following periods of volatility in the market price of a company&#8217;s securities. We have been subject to such a securities class action lawsuit filed in February 2022 and voluntarily dismissed by the plaintiff in October 2022, against certain of our officers and certain of our current and former directors, and may become subject to additional securities class action lawsuits in the future. This type of litigation could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business is affected by macroeconomic conditions, including rising inflation, interest rates and supply chain constraints.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes in inflation, interest rates, the risk of economic slowdown or recession in the United States, instability in the banking system, and overall economic conditions and uncertainties such as those resulting from the current and future conditions in the global financial markets, including the presidential transition in the United States. Recent supply chain constraints have led to higher inflation, which if sustained could have a negative impact on our product development and operations. If inflation or other factors were to significantly increase our business costs, our ability to develop our current pipeline and new therapeutic products may be negatively affected. Interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect the operation of our business and our ability to raise capital on favorable terms, or at all, in order to fund our operations. Similarly, these macroeconomic factors could affect the ability of our third-party suppliers and manufacturers to manufacture clinical trial materials for our product candidates.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are a &#8220;smaller reporting company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are considered a &#8220;smaller reporting company&#8221; under Rule 12b-2 of the Exchange Act. We are therefore entitled to rely on certain reduced disclosure requirements, such as an exemption from providing selected financial data and executive compensation information. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company also mean our auditors are not required to review our internal control over financial reporting and may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our common stock prices may be more volatile. We will remain a smaller reporting company for as long as (i) the market value of our common stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is less than $700.0 million as of the prior June 30.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates or grant licenses on terms unfavorable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We could be subject to significant legal proceedings which may adversely affect our results of operations or financial condition.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the risk of litigation, derivative claims, securities class actions, regulatory and governmental investigations and other proceedings, including proceedings arising from investor dissatisfaction with us or our performance or claims brought by employees, government agencies or supplies. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. In addition, if any individuals acting on our behalf fails to satisfy his or her relevant legal or contractual duties, we could have liability to third parties, including the government or investors. If any claims were brought against us and resulted in a finding of substantial legal liability, the finding could materially adversely affect our business, financial condition or results of operations or cause significant reputational harm to us, which could seriously adversely impact our business. Allegations of improper conduct by private litigants or regulators, regardless of veracity, also may harm our reputation and adversely impact our ability to grow our business. Even if the allegations against us in future legal matters are unfounded or we ultimately are not held liable, the costs to defend ourselves may be significant and the litigation may subject us to substantial settlements, fines, penalties or judgments against us and may consume management&#8217;s bandwidth and attention, some or all of which may negatively impact our financial condition and results of operations. Litigation also may generate negative publicity, regardless of whether the allegations are valid, or we ultimately are liable, which could damage our reputation, and adversely impact our sales and our relationship with our employees, customers, and partners. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. In the event that one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The U.S. Congress or the current administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the start of the current administration in 2025, there have been significant changes to U.S. trade, healthcare, immigration and government regulatory policy and additional changes are likely. For example, the U.S. government has imposed substantial tariffs on most countries throughout the world and has further threatened to continue to broadly impose tariffs, which could lead to corresponding punitive actions by the countries with which the U.S. trades. Changes to U.S. policy implemented by the U.S. Congress, the current administration or any new future administration have impacted and may in the future impact, among other things, the U.S. and global economy, international trade relations, unemployment, immigration, healthcare, taxation, the U.S. regulatory environment, inflation and other areas. Although we cannot predict the impact, if any, of these changes to our business, they could adversely affect our business. Until we know what policy changes are made, whether those policy changes are challenged and subsequently upheld by the court system and how those changes impact our business and the business of our competitors over the long term, we will not know if, overall, we will benefit from them or be negatively affected by them.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B. Unresolve</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d Staff Comments.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5ee7f1f-8e7b-4286-becb-3d819f285855" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cyber Risk Management and Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_27f71d03-effc-4301-8e60-d9bc79d19c11" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, under the oversight of the audit committee of our board of directors, have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_acf1f37a-1362-4aec-a191-d50a96c7cf89" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implemented</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and maintain a cybersecurity risk management program that is designed to identify, assess, and mitigate risks from cybersecurity threats. Our risk management is supported by various tools and technologies, including third-party security solutions, monitoring, and alerting tools, designed to monitor, identify, and address risks from cybersecurity threats.</span></p></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_42da5cd5-225c-4480-af7c-56e787742cbe" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with other third-party providers and consultants to support our cyber risk management efforts, including through periodic security testing and assessments. We have a process to assess certain major </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99f19f0f-a213-4db8-89ba-20b500d6beb7" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party vendors and service providers</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including through a review of responses to compliance questionnaires and contractual requirements, as appropriate.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, like other companies in our industry, face a number of risks from cybersecurity threats in connection with our business. Although such risks have not </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_96e4a2cc-418a-408f-819e-34ba4163eeec" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">materially affected</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and we do not believe they are reasonably likely to materially affect, us, including our business strategy, results of operations or financial condition, to date, we have, from time to time, experienced threats to and security incidents related to our data and systems. For more information about the risks from cybersecurity threats we face, please see Item 1A- Risk Factors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance Related to Cybersecurity Risks</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_376ad518-1d1f-4d9c-956a-37edf4050db9" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors, as a whole and through its committees, has responsibility for the periodic review and oversight of information technology risks, including risks from cybersecurity threats.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_573268d9-3b42-4c63-bfdc-42bcfba00bc4" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee is responsible for oversight of our cyber risk management program</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71f0520f-e15a-4a43-bbe0-7f030333517d" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The day-to-day management of the cyber program is directed by the Director of IT under the direction of the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8ff9b025-d7b8-4092-bebd-a711f64f9638" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Currently,</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb66aa25-0ce5-460c-babf-8d27c62afc33" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.</span></ix:nonNumeric></span></ix:nonNumeric></span></p><div><ix:nonNumeric id="F_a43d36be-293f-41e7-995c-df67ca36a20a" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Director of IT meets with the Chief Financial Officer periodically to discuss and review our cybersecurity risk management processes and to address matters related to potential cybersecurity and information technology risks, with input from the Company&#8217;s third-party technology providers, as appropriate. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91b218f2-2719-46e0-b67e-1500ff70d099" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#8217;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19936983-bcaa-461e-881e-1ae321668e70" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee periodically reports</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on cybersecurity risk management to the full board of directors.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Pro</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate headquarters are located in Philadelphia, PA, where we lease 7,672 square feet of office space subject to a lease agreement that is in effect through June 30, 2026. We also have a lease consisting of approximately 13,179 square feet of laboratory space in Philadelphia, PA subject to a lease agreement that is in effect through November 15, 2026. We believe our facilities are currently adequate for us to conduct our business.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Legal </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceedings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be involved in lawsuits, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters which arise in the ordinary course of business. While the outcome of any such proceedings cannot be predicted with certainty, as of December 31, 2025, we were not party to any legal proceedings that we would expect to have a material adverse impact on our financial position, results of operations or cash flow.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine Saf</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ety Disclosures.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T II</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stoc</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">kholder Matters and Issuer Purchases of Equity Securities.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock trades on The Nasdaq Global Select Market under the symbol &#8220;CABA&#8221;. Trading of our common stock commenced on October 25, 2019, in connection with our initial public offering, or IPO. Prior to that time, there was no established public trading market for our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 19, 2026, we had approximately 86 holders of record of our common stock. The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. The number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend Policy</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and growth of our business. We do not expect to pay any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, then applicable contractual restrictions and any other factors deemed relevant by our board of directors. Investors should not purchase our common stock with the expectation of receiving cash dividends.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Compensation Plan</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We did not purchase any of our equity securities during the period covered by this Annual Report on Form 10-K.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">eserved.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_7_managements_discussion_analysis_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and Analysis of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Financial Condition and Results of Operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K, or this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section entitled &#8220;Risk Factors,&#8221; our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should carefully read the section entitled &#8220;Risk Factors&#8221; to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a late clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Our proprietary CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or Cabaletta Approach to B cell Ablation platform, focuses on the CARTA approach. CARTA refers to Chimeric Antigen Receptor T cells for Autoimmunity and is designed to potentially reset the immune system. Based on clinical data reported to date, we believe our CABA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> platform has the potential to safely enable complete and durable responses for a broad range of autoimmune diseases and that it has potential applicability across dozens of autoimmune diseases that we have identified, evaluated and prioritized.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Resecabtagene autoleucel, or rese-cel (formerly referred to as CABA-201), is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a broad range of autoimmune diseases and our lead product candidate within the CARTA strategy. Rese-cel is designed to achieve transient and deep depletion of all B cells following a single, weight-based infusion of T cells that are engineered to express an antibody fragment that recognizes a B cell receptor expressed on the surface of all B cells. The construct is designed to allow for the deep elimination of all B cells, including all B cells that contribute to disease, with subsequent repopulation by healthy transitional, na&#239;ve B cells. This approach has demonstrated the potential to reset the immune system and result in meaningful clinical responses without chronic therapy requirements in patients. The efficacy and safety of rese-cel was recently reviewed along with all other commercial and academic constructs in development in a February 2026 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nature Biotechnology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> publication.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, we initiated a registrational trial with rese-cel for patients with dermatomyositis or anti-synthetase syndrome. In addition, we have ongoing Phase 1/2 trials evaluating rese-cel with a standard preconditioning regimen, fludarabine and cyclophosphamide, in systemic lupus erythematosus, or SLE, in patients with active lupus nephritis, or LN, or active SLE without renal involvement, systemic sclerosis, or SSc, and generalized myasthenia gravis, or gMG. In addition to our core development program across multiple indications using standard preconditioning regimens and standard manufacturing processes with partnered Contract and Development Manufacturing Organizations, or CDMOs, based on early data from a phase 1/2 trial evaluating rese-cel without preconditioning in pemphigus vulgaris patients, we are evaluating rese-cel without preconditioning in non-renal SLE and LN patients.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in January 2026 we announced INDa clearance for rese-cel to be manufactured using an automated manufacturing platform &#8211; the Cell Shuttle</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from Cellares - offering the potential for scalability to produce rese-cel</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for thousands of patients per year with minimal capital investment by the Company. The first clinical experience from these patients is expected to be presented in the first half of 2026.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Durability data from the no-preconditioning SLE, LN and PV patients as well as the patients treated with rese-cel manufactured by the Cellares Cell Shuttle</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is expected to be presented in the second half of 2026.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The three adult myositis subtypes, dermatomyositis, or DM, anti-synthetase syndrome, or ASyS, and immune-mediated necrotizing myopathy, or IMNM, being evaluated in the RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trial of rese-cel affect approximately 80,000 patients in the U.S. Myositis typically affects middle-aged individuals, particularly women, and disease is often refractory, despite existing therapies. In the United States, we believe approximately 20% to 25% of the prevalent population, or 16,000 to 20,000 people, would be potentially eligible patients for rese-cel.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trial is designed to treat at least six patients with DM, or ASyS, at least six patients with IMNM, as well as at least six patients with juvenile idiopathic inflammatory myopathy, or JIIM, all in separate parallel cohorts, with a single weight-based dose of 1.0 x 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells/kg. We announced the FDA granted Fast Track Designation for rese-cel for the treatment of patients with dermatomyositis and Orphan Drug Designation for rese-cel for the treatment of myositis in January and February 2024, respectively. In March 2024, we announced the FDA granted Rare Pediatric Disease designation for rese-cel for juvenile dermatomyositis. In May 2025, we announced the FDA granted Regenerative Medicine Advanced Therapy, or RMAT, designation to rese-cel for the treatment of myositis.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on clinical data presented in October 2025 at the American College of Rheumatology, or the ACR, Convergence 2025, we have initiated a DM/ASyS registrational cohort within the RESET-Myositis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial. There are approximately 60,000 patients with DM in the U.S. who have IVIg as their only FDA-approved treatment option and approximately 15,000 patients with ASyS in the U.S. who have no FDA-approved treatment options. Our registrational trial design includes a 16-week primary endpoint of moderate or major TIS response while off immunomodulators and on no or low-dose steroids. Based on the safety data from the phase 1/2 cohort, the protocol permits outpatient administration. In addition, we are planning for a pediatric submission in juvenile idiopathic inflammatory myopathy, or JIIM, based on data available at the time of adult submission from the ongoing Ph 1/2 cohort to support a pediatric label claim.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The planned size of 17 patients for the registrational cohort is based on the assumed treatment effect of rese-cel in DM/ASyS patients and an estimated background rate. The estimated background rate will be determined from a retrospective analysis of an external myositis patient registry and will include patients with similar inclusion criteria as those in the registrational DM/ASyS cohort. Based on comprehensive literature review to estimate the background rate, we estimate the likelihood of an active, refractory myositis patient achieving moderate or major TIS response within 16 weeks and concurrently discontinuing all immunomodulators to be less than 10%. Changes in the assumed background rate would result in a change in the number of rese-cel treated patients who would need to achieve the primary endpoint in the 17-patient registrational cohort.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrational cohorts will evaluate the same single, weight-based infusion of rese-cel at 1 x 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells/kg as used in the Phase 1/2 myositis cohorts with similar enrollment criteria. As presented at ACR Convergence 2025, all myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no immunomodulators. Based on discussions with the FDA, we plan to use pooled rese-cel safety data from across the entire RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> clinical trial program to supplement myositis specific safety data for the Biologics License Application, or BLA, submission in myositis, and the required safety database is expected to be approximately 100 autoimmune disease patients treated with the same single weight-based dose. We initiated enrollment in the registrational DM/ASyS cohort in December 2025 and anticipate BLA submission in 2027.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SLE is a chronic, potentially severe, autoimmune disease, most commonly impacting young women between the ages of 15 and 40 with higher frequency and more severity in people of color, where the immune system attacks healthy tissue throughout the body. SLE affects an estimated up to 320,000 patients in the U.S., with LN as the most common end-organ manifestation, affecting approximately 30-40% of SLE patients.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trial is designed to treat six SLE patients with active LN, and in a separate parallel cohort, six patients with active SLE without renal involvement, with a single weight-based dose of 1.0 x</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells/kg. In May 2023, we announced the FDA granted Fast Track Designation for rese-cel in patients with SLE and LN. In November 2025, we announced the FDA granted RMAT designation to rese-cel for treatment of SLE and LN. In January 2026, Cabaletta announced registrational cohort designs in RESET-SLE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to evaluate the current rese-cel weight-based dose of 1 million cells/kg in a single infusion with preconditioning, including two independent, single-arm cohorts, one consisting of patients with non-renal SLE and one consisting of patients with LN each evaluating approximately 25 patients with unique endpoints in each cohort. Complete Phase 1/2 data from both cohorts is anticipated in the first half of 2026. Cabaletta will provide an update on next steps for these cohorts in 2026, subject to dose-ranging data evaluating rese-cel without preconditioning in lupus patients.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RESET-SSc</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SSc is a rare and potentially fatal chronic autoimmune disease characterized by progressive skin and internal organ fibrosis that can be life-threatening, including interstitial lung disease, pulmonary hypertension, and scleroderma renal crisis. SSc affects approximately 90,000 patients in the U.S., typically middle-aged individuals, particularly women.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RESET-SSc</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trial of rese-cel is designed to treat six patients with severe skin manifestations and six patients with severe organ involvement associated with SSc, each in separate parallel cohorts, with a single weight-based dose of 1.0 x 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells/kg. We announced the FDA granted Fast Track Designation for rese-cel for the treatment of patients with SSc to improve associated organ dysfunction and Orphan Drug Designation for rese-cel for the treatment of SSc in January and March 2024, respectively. In January 2026, Cabaletta announced the FDA granted RMAT designation to rese-cel for treatment of SSc. Complete Phase 1/2 data from both cohorts is anticipated in the first half of 2026, and we anticipate announcing the registrational cohort design for SSc in the first half of 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RESET-MG</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MG is a rare autoimmune disease characterized by autoantibodies that interfere with signaling at the neuromuscular junction, leading to potentially life-threatening muscle weakness. The majority of patients with MG have autoantibodies known to be pathogenic based on their interference with proteins in the NMJ, of which the majority target AChR. gMG affects approximately 100,000 patients in the U.S. Symptoms of gMG include profound muscle weakness throughout the body, disabling fatigue, and potential shortness of breath due to respiratory muscle weakness, with risk for episodes of respiratory failure.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RESET-MG</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 1/2 clinical trial of rese-cel is designed to treat six patients with AChR-positive gMG and six patients with AChR-negative gMG, each in separate parallel cohorts, with a single weight-based dose of 1.0 x 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cells/kg.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, we announced that rese-cel was generally well tolerated across two AChR-positive and two AChR-negative patients (both seronegative; no anti-MuSK or anti-LRP4 antibodies). No CRS (cytokine release syndrome) occurred in three of four patients, and grade 2 CRS occurred in AChR-pos-2 that resolved with no sequelae. As of the September 11, 2025 data cut-off, two evaluable patients (AChR-neg-1 and AChR-neg-2) remained off immunomodulatory medication and achieved significant improvements in MG-ADL (with AChR-neg-1 achieving Minimal Symptom Expression). AChR-pos-1 is not evaluable due to use of a prohibited cytotoxic medication that may have inhibited CAR T activity and AChR-pos-2 has insufficient follow-up.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Both cohorts have been fully enrolled. Complete Phase 1/2 data from both cohorts is anticipated in the first half of 2026, and we anticipate announcing the registrational cohort design for studies in MG in mid-2026.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pemphigus vulgaris, or PV, is an autoimmune disease that occurs when the immune system produces antibodies that attack a protein called desmoglein, or DSG. DSG normally enables skin cells and the cells lining the inside of your mouth, nose, throat, eyelids, etc. to bind tightly together. Disruption by the antibodies directed to DSG causes the painful blisters and erosions characteristic of PV. Approximately 15,000 patients in the U.S. are affected by PV.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ongoing RESET-PV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial is designed to evaluate rese-cel as a monotherapy without preconditioning in patients with mucosal pemphigus vulgaris, or mPV, and mucocutaneous pemphigus vulgaris, or mcPV.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, we announced that rese-cel exhibited similar CAR T cell expansion and contraction kinetics relative to translational data reported from other RESET</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trials with preconditioning. All three patients experienced substantial depletion of B cells within the first month post-infusion, with patients 2 and 3 achieving complete</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">peripheral B cell depletion. In these two patients, rapid reduction in autoantibodies to desmoglein was observed and the increase in peak B cell activating factor, or BAFF, was at the low end of the range of patients dosed with rese-cel plus preconditioning from pre-infusion through the latest follow-up, suggestive of potential deep B cell depletion in the tissue. Additional follow up will be required to determine if the initial clinical effects are durable and to determine if the findings can be replicated in other autoimmune diseases. Rese-cel was generally well tolerated with no immune effector cell-associated neurotoxicity syndrome, or ICANS, reported as of the data cutoff. After infusion, patient 1 experienced transient fever (grade 1 cytokine release syndrome). Patient 2 required a course of steroids for a disease flare in the first two weeks following infusion after discontinuing immunomodulators.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PDAI activity scores have formed the basis for recent regulatory approvals in PV, and total PDAI scores in these patients were also reported to be consistent with the PDAI activity scores in the late breaking clinical trial session. PDAI improvements were most significant in the two patients who seemed to experience complete peripheral B cell depletion.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated in April 2017 and started principal operations in August 2018. Our operations to date have been financed primarily by proceeds from the sale of convertible notes and convertible preferred stock prior to our initial public offering, or IPO, and proceeds from the sale of our common stock in public equity offerings, including our IPO, &#8220;at-the-market&#8221; offerings and follow-on offerings of shares of our common stock and pre-funded warrants. As of December 31, 2025, we had $133.6 million in cash, cash equivalents and investments.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Agreements</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refer to section titled &#8220;Business &#8211; Our Material Agreements&#8221; included in this Annual Report on Form 10-K for a discussion of our material agreements.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Operating Results</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sales of products for several years, if at all. If our development efforts for our current or future product candidates are successful and result in marketing approval, we may generate revenue in the future from product sales. We cannot predict if, when or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also in the future enter into license or collaboration agreements for our product candidates or intellectual property, and we may generate revenue in the future from payments as a result of such license or collaboration agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.45pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our research and development expenses include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">personnel costs, which include salaries, benefits and stock-based compensation expense; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred under agreements with consultants and third-party contract organizations that conduct research and development activities on our behalf; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs related to sponsored research service agreements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs related to production of preclinical and clinical materials, including fees paid to contract manufacturers; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">licensing fees for intellectual property and know-how;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laboratory and vendor expenses related to the execution of preclinical studies and ongoing and planned clinical trials; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laboratory supplies and equipment used for internal research and development activities and related depreciation expense. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not reported program costs since inception because historically we have not tracked or recorded our research and development expenses on a pre-clinical program-by-program basis. We use our personnel and infrastructure resources across the breadth of our research and development activities, which are directed toward identifying and developing product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and third-party service providers.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, including investments in manufacturing, as our programs advance and we conduct clinical trials. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with product development, we cannot determine with certainty the duration and completion costs of the current or future preclinical studies and clinical trials or if, when, or to what extent we will generate revenues from the commercialization and sale of our product candidates. We may never succeed in achieving regulatory approval for our product candidates. The duration, costs and timing of preclinical studies and clinical trials and development of our product candidates will depend on a variety of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful completion of preclinical studies and IND and/or CTA-enabling studies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development of chemistry, manufacturing and controls, or CMC, processes and procedures for purposes of IND and/or CTA applications; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful patient enrollment in, and the initiation and completion of, clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of any business interruptions to our operations, including the timing and enrollment of patients in our ongoing and planned clinical trials, or to those of our clinical sites, manufacturers, suppliers, or other vendors resulting from public health crises; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt of regulatory approvals from applicable regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing commercial manufacturing capabilities or arrangements with third-party manufacturers; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining patent and trade secret protection and non-patent exclusivity; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">effectively competing with other therapies and treatment options; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a continued acceptable safety and efficacy profile following approval; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enforcing and defending intellectual property and proprietary rights and claims; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">achieving desirable medicinal properties for the intended indications. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our preclinical studies and clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. A change in the outcome of any of these factors could mean a significant change in the costs and timing associated with the development of our current and future preclinical and clinical product candidates. For example, if the FDA or another regulatory authority, were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development, or if we experience significant delays in execution of or enrollment in any of our preclinical studies or clinical trials, we could be required to expend significant additional financial resources and time on the completion of preclinical and clinical development. We expect our research and development expenses to increase for the foreseeable future as we continue the development of product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our general and administrative expenses consist primarily of personnel costs, costs related to maintenance and filing of intellectual property, depreciation expense and other expenses for outside professional services, including legal, human resources, information technology, audit and accounting services. Personnel costs consist of salaries, benefits and stock-based compensation expense. We expect our general and administrative expenses to increase over the next several years to support our continued research and development activities, manufacturing activities, increased costs of operating as a public company and the potential commercialization of our product candidates. We anticipate our general and administrative costs will increase with respect to the hiring of additional personnel, developing commercial infrastructure, fees to outside consultants, lawyers and accountants, and increased costs associated with being a public company such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and the Securities and Exchange Commission, or the SEC, requirements, insurance and investor relations costs.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income consists of interest earned on our cash, cash equivalents and short-term investments and amortization of bond discount or premium.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense consists primarily of interest expense associated with finance lease arrangements.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income, net</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income, net primarily consists of foreign currency gains and losses and proceeds received from the sale of our Pennsylvania research and development tax credits.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations for the years ended December 31, 2025 and 2024</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following sets forth our results of operations:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:32.847%;box-sizing:content-box;"/>
      <td style="width:2.2%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:18.183999999999997%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:2.2%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:18.183999999999997%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:2.2%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:18.183999999999997%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Statements of Operations Data:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,674</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,203</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,471</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,567</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,938</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,629</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">172,241</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,141</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,100</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(172,241</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(125,141</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(47,100</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense):</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,031</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,025</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,994</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,004</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(748</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,256</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">358</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">358</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(167,856</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(115,864</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(51,992</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses were $142.7 million for the year ended December 31, 2025 as compared to $97.2 million for the year ended December 31, 2024. The table below summarizes our research and development expenses:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:41.548%;box-sizing:content-box;"/>
      <td style="width:1.92%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:15.563%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.92%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:15.563%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.92%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:15.563%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trials</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,581</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,286</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,295</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Manufacturing of preclinical and clinical supplies</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,240</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,523</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,717</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,934</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,239</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,695</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development services</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,350</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,417</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,067</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License of intellectual property</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,523</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,523</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,569</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,215</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">354</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,674</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,203</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,471</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specific changes in our research and development expenses year over year include a:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$22.7 million increase in manufacturing costs primarily due to expanded cell processing capabilities, increase in patient enrollment and related activities, including those for commercial readiness;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$17.3 million increase in clinical trial costs primarily due to higher enrollment and clinical trial sites across multiple clinical studies for rese-cel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$7.7 million increase in personnel costs primarily driven by an increase in headcount to support overall growth related to our rese-cel program, including an increase of $1.3 million in stock-based compensation expense; partially offset by a</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$1.5 million decrease in license of intellectual property costs due to a $1.5 million milestone payment to IASO in the first quarter of 2024 for the first patient dosed in the rese-cel trial; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$1.1 million decrease in development services due to lower spend on laboratory consumables and external research activities.</span></div></div><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses were $29.5 million for the year ended December 31, 2025 as compared to $27.9 million for the year ended December 31, 2024. The increase of $1.6 million in our general and administrative expenses year over year includes:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$1.6 million increase in personnel costs, primarily driven by higher personnel-related expenses, including a $0.2 million increase in stock-based compensation expense.</span></div></div><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Income</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income decreased by $4.0 million for the year ended December 31, 2025 as compared to the year ended December 31, 2024, primarily due to lower cash, cash equivalents and investment balances earning interest during 2025 as prior financing proceeds were utilized to fund operating activities, as well as reductions in interest rates on government securities.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense increased $1.3 million for the year ended December 31, 2025 as compared to the year ended December 31, 2024, primarily as a result of finance lease arrangements from embedded leases within our manufacturing agreements with Minaris and Lonza.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity, Capital Resources and Going Concern</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From our inception in April 2017 to the time of our initial public offering, or IPO, our operations were financed by proceeds of $86.4 million from the sale of convertible notes and our convertible preferred stock and proceeds of $71.0 million from the sale of common stock in our IPO. Since our IPO and through December 31, 2025, we have generated cash from public offerings of our common stock and pre-funded warrants to purchase our common stock resulting in aggregate net proceeds of approximately $384.0 million. As of December 31, 2025, we had $133.6 million in cash and cash equivalents which should enable us to fund our operations and capital expenditures into the fourth quarter of 2026. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred losses since our inception and, as of December 31, 2025, we had an accumulated deficit of $517.0 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding prepaid expenses and other current assets, accounts payable and accrued expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and administrative expenses, and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and development services, costs relating to the build-out of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies, clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. Based on our current operating plan, we believe there is substantial doubt about our ability to continue as a going concern for at least twelve months following the filing of this Annual Report on Form 10-K, and we will need to obtain additional funding. Our cash forecast contains estimates and assumptions based on success of ongoing clinical trials, and we cannot predict the amount or timing of all expenditures with certainty. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise capital, we will need to delay, reduce or terminate certain planned activities to reduce costs.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-The-Market Offering Sales Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 31, 2025, we converted the Form S-3ASR to a Form S-3 (File No. 333-278126) by post-effective amendments. This Form S-3 was declared effective on March 31, 2025. We had a Sales Agreement with TD Securities (USA) LLC, as successor to Cowen and Company, LLC, or TD Cowen, to provide for the offering, issuance and sale of up to an aggregate amount of $200.0 million of common stock from time to time in &#8220;at-the-market&#8221; offerings, or the 2024 ATM Program, pursuant to its S-3, and subject to the limitations thereof. On June 11, 2025, the 2024 ATM Program with TD Cowen was terminated. Prior to termination, we sold an aggregate of 2,609,865 shares pursuant to the 2024 ATM Program for total net proceeds of $7.7 million, consisting of $5.1 million in 2024 and $2.6 million in 2025.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 7, 2025, we filed a Registration Statement (File No. 333-289339) with the SEC, which was declared effective on August 15, 2025, or the 2025 Shelf Registration Statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Sales Agreement with TD Cowen to provide for the offering, issuance and sale of up to an aggregate amount of $150.0 million of our common stock from time to time in &#8220;at-the-market&#8221; offerings, or the 2025 ATM Program, under the 2025 Shelf Registration Statement and subject to the limitations thereof, or the 2025 Sales Agreement. During the year ended December 31, 2025, we sold 4,160,176 shares pursuant to the 2025 ATM Program for net proceeds of $10.2 million. Subsequent to December 31, 2025, we sold 8,055,260 shares of common stock pursuant to the 2025 ATM Program for net proceeds of $22.6 million.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">June 2025 Financing</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2025, we issued (i) 39,200,000 shares of our common stock and accompanying warrants to purchase an aggregate of 39,200,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to 10,800,000 shares of our common stock and accompanying warrants to purchase an aggregate of 10,800,000 shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $0.00001 per pre-funded warrant. The combined offering price of each share of common stock and accompanying common stock warrant was $2.00. The combined offering price of each pre-funded warrant and accompanying common stock warrant was $1.99999. The pre-funded warrants were</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exercisable immediately. The common stock and pre-funded warrants were sold in combination with an accompanying common stock warrant to purchase one share of common stock (or a pre-funded warrant in lieu thereof) for each share of common stock or pre-funded warrant sold. Each common stock warrant has an exercise price per share of $2.50. The common stock warrants are immediately exercisable from the date of issuance and will expire on September 12, 2026, fifteen months from the date of issuance. Aggregate net proceeds were $93.6 million after deducting underwriting discounts and commissions and offering expenses. As of December 31, 2025, 4,800,000 pre-funded warrants had been exercised and 6,000,000 remain outstanding. As of December 31, 2025, no common stock warrants had been exercised and 53,090,190 remain outstanding. Subsequent to December 31, 2025, 2,775,100 common stock warrants were exercised for proceeds of $6.9 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, results and costs of researching, developing and manufacturing our lead product candidates or any future product candidates, and conducting preclinical studies and clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of, and the costs involved in, obtaining regulatory approvals or clearances for our lead product candidates or any future product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of any business interruptions to our operations or to those of our clinical sites, manufacturers, suppliers, or other vendors resulting from public health crises; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and characteristics of any additional product candidates we develop or acquire; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of any cash milestone payments if we successfully achieve certain predetermined milestones; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing our lead product candidate or any future product candidates and any products we successfully commercialize, including costs associated with building-out our manufacturing capabilities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of any such agreements that we may enter into; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expenses needed to attract and retain skilled personnel; </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with being a public company; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.524191420883238%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, receipt and amount of sales of any future approved or cleared products, if any. </span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, our operating plans may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development activities. We currently have no credit facility or committed sources of capital. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our cash flows for the periods indicated:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:66.993%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.62%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.883000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in):</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating activities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(131,080</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(88,222</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(50,266</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,289</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,347</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,677</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(20</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(80,980</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(29,276</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, cash used in operating activities of $131.1 million was attributable to our net loss of $167.9 million, partially offset by non-cash charges of $37.2 million for stock-based compensation charges, amortization of finance lease, non-cash operating lease expense, depreciation, accretion of operating lease liabilities and foreign currency exchange rates and a net change of $0.4 million in our net operating assets and liabilities.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, cash used in operating activities of $88.2 million was attributable to our net loss of $115.9 million, partially offset by non-cash charges of $26.0 million for stock-based compensation charges, amortization of finance lease, non-cash operating lease expense, depreciation, amortization of premium on investments, accretion of operating lease liabilities and foreign currency exchange rates and a net change of $1.7 million in our net operating assets and liabilities.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, cash used in investing activities of $50.2 million was attributable to $99.0 million of purchases of investments and $1.2 million of purchases of property and equipment partially offset by $50.0 million from the maturity of short-term investments.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, cash provided by investing activities of $47.3 million was attributable to $49.5 million from the maturity of short-term investments, partially offset by purchases of $2.2 million of property and equipment.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, cash provided by financing activities of $100.3 million was attributable to $93.6 million in sales of common stock, warrants and pre-funded warrants to purchase common stock, net of issuance costs paid, $12.7 million in sales of common stock under our 2024 ATM Program and 2025 ATM Program, net of sales agent commission and fees and $0.3 million from the purchases of shares under our 2019 Employee Stock Purchase Plan, or 2019 ESPP, offset by $6.3 million in principal payments on finance leases.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, cash provided by financing activities of $11.7 million was from $10.9 million in sales of common stock under our 2024 ATM Program, net of issuance costs paid, $1.7 million from the exercise of employee stock and purchases of shares under our 2019 ESPP, offset by $0.9 million in principal payments on finance leases.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual Obligations and Commitments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We lease our headquarters office space and laboratory space under non-cancelable operating lease agreements. The lease term of our office space commenced in May 2019 and was amended in October 2024 for an additional 12 months through June 30, 2026. The lease term for our laboratory space was amended in September 2024 through August 2026 and further extended in October 2025 through November 2026. We also have embedded manufacturing leases with Minaris and Lonza, our cell processing manufacturing partners. Minaris' lease term is through August 2026 and Lonza's is for an initial 12 months with the ability to extend the manufacturing period on a rolling basis. Total undiscounted aggregate future finance and operating lease obligations under all of our leases as of December 31, 2025 are $28.8 million. See Note 9 of the consolidated financial statements for additional detail on our leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no material contractual obligations not fully recorded on our balance sheets or fully disclosed in the notes to the consolidated financial statements. Our commitments include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IASO Exclusive License Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As partial consideration for the exclusive license, IASO received an upfront payment of $2.5 million. IASO is also eligible to receive up to mid double digit millions in milestone payments based upon the achievement of specified pre-clinical, development and regulatory milestones, and up to an additional low triple digit millions in milestone payments based upon achievement of specified sales milestones, for a total consideration, inclusive of the upfront payment, of up to $162 million, along with tiered mid-single digit royalties on future net sales for licensed products </span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that may result from the IASO Agreement. We also may sublicense through multiple tiers the rights granted to it by IASO under the IASO Agreement at any time, however, we must pay IASO a low double-digit percentage of any revenue obtained from sublicenses or options to third parties, subject to certain customary exclusions. The IASO Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the IASO Agreement, unless earlier terminated. A milestone payment of $1.5 million was paid to IASO in the first quarter of 2024 after the first patient in a rese-cel trial was dosed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Oxford Licence and Supply Agreement. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the agreement, we were required to pay Oxford an upfront fee, as well as costs associated with initial vector manufacturing activities for our DSG3-CAART program. In May 2023, we amended the LSA with Oxford to expand the license to include our rese-cel program for an upfront fee of $0.5 million and in August 2023, we entered into a vector supply agreement with Oxford, and a related second amendment to the LSA, for rese-cel with a total cost of up to approximately $5.0 million under the vector supply agreement. In February 2024, we and Oxford entered into a third amendment to the LSA to update the patent schedule. In June 2024, we and Oxford entered into a fourth amendment to the LSA eliminating royalties on net sales of products that incorporate the Oxford technology if Oxford manufactures the vector. Starting in December 2024, we and Oxford entered into work orders for certain process characterization and process performance qualification activities as part of commercial readiness activities. We can terminate the LSA or any work order under the LSA at will upon advance written notice and subject to certain cancellation fees.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Autolus Option and License Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In January 2023, we entered into an Option and License Agreement, or the Autolus Agreement, with Autolus Holdings (UK) Limited (Autolus), wherein the Autolus Agreement grants us a non-exclusive license to access Autolus' RQR8 technology in our CD19-CAR T cell therapy program, and subject to additional nominal option exercise fees, up to four additional targets. In January 2025, the Company and Autolus agreed to novate the Autolus Agreement with both Autolus and Autolus Limited jointly assuming the rights, obligations and liabilities of Autolus under the Autolus Agreement. Under the terms of the Autolus Agreement, we were required to pay Autolus an upfront license fee of $1.2 million, of which $1.1 million was paid in 2023 and $0.1 million was paid in January 2024. Autolus is also eligible to receive regulatory milestones of up to $12 million for each licensed target, sales milestones of up to a total of $15 million and royalties in the low single digits on net sales of all products that incorporate the RQR8 technology. The Autolus Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the Autolus Agreement, unless earlier terminated. We can terminate the Autolus Agreement at will upon advance written notice. Each of Autolus and us may terminate the Agreement for a material, uncured breach or insolvency of the other party.</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">129</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Penn License Agreement. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the License Agreement, we are required to make milestone payments upon successful completion of certain development, regulatory and sales milestones on a product-by-product and geographical basis. The payment obligations under the License Agreement are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and we will be required to make development milestone payments and royalty payments in connection with the sale of products developed under the License Agreement. As of December 31, 2025, we are unable to estimate the timing or likelihood of achieving the milestones or making future product sales. </span></div></div><div class="item-list-element-wrapper" style="margin-left:0.75in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.347629490628745%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the License Agreement, we must use commercially reasonable efforts to develop and commercialize a product in each subfield. During the term of the License Agreement until the first commercial sale of the first product, we are obligated to pay Penn a non-refundable, non-creditable annual license maintenance fee of $10,000. We are required to pay certain milestone payments upon the achievement of specified clinical and commercial milestones. Milestone payments are reduced by a certain percentage for the second product that achieves a milestone, by an additional percentage for the third product that achieves a milestone, and so on, for each subsequent product that achieves a milestone. In the event that we are able to successfully develop and launch multiple products under the License Agreement, total milestone payments could be approximately $21.0 million. Penn is also eligible to receive tiered royalties at percentage rates in the low single-digits, subject to an annual minimum royalty, on annual worldwide net sales of any products that are commercialized by us or our sublicensees that contain or incorporate, or are covered by, the intellectual property licensed by us. To the extent we sublicense our license rights under the License Agreement, Penn would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits. We have also entered into a subscription and technology transfer agreement with Penn, pursuant to which we owed Penn an upfront subscription fee, which was paid in 2019, and a nominal non-refundable royalty on net sales of products, a portion of which will be credited toward milestone payments and royalties under this License Agreement. Technology transfer activities would be at our cost and subject to agreement as to the technology to be transferred.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Minaris Manufacturing agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In January 2021, we entered into the Development and Manufacturing Services Agreement, or the Minaris Agreement, to serve as an additional cell processing manufacturing partner for the MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trial. In August 2023, we entered into new work orders under the Minaris Agreement for Minaris to serve as one of our cell processing manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and commercial readiness activities for rese-cel. Under the August 2023 work orders, Minaris will convert our non-dedicated suite to a dedicated suite for GMP manufacturing for our rese-cel and MuSK-CAART programs for an initial term of 18 months with two 18 month extensions at our sole option on six months' notice prior to the end of the term. In addition, we agreed to certain monthly minimum runs. We would incur up to a $1.08 million termination fee if we terminate both the rese-cel and MuSK-CAART work orders for any reason. We may terminate for convenience the Minaris Agreement or any work order with six months' prior written notice, however, we may not terminate the Dedicated Suite without terminating both the MuSK-CAART and rese-cel GMP run work orders. In February 2026, we notified Minaris that we intend to permit the term to expire in August 2026.</span></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">130</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div class="item-list-element-wrapper" style="margin-left:0.35in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5329493209322%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lonza Manufacturing agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In December 2024, we entered into a Development and Manufacturing Services Agreement, or the Lonza Agreement, with Lonza to serve as one of our manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and preparations for commercial readiness. The Lonza Agreement has a term of five years and can be extended for an additional three year term upon notice to Lonza at least 18 months prior to the expiration of the Lonza Agreement. We can terminate the Lonza Agreement at will upon nine months advance written notice to Lonza subject to the terms of the Lonza Agreement. Lonza can terminate the Lonza Agreement at will upon 24 months advance written notice to us subject to the terms of the Lonza Agreement. Under the initial work order, Lonza will perform cell therapy manufacturing activities for our CAR-T cell therapy product, rese-cel, for an initial term of 12 months with the ability to extend the manufacturing period on a rolling basis subject to the terms of the Lonza Agreement.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.35in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5329493209322%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cellares Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In January 2026, we entered into a Development and Clinical Manufacturing Services Agreement, or the Cellares Agreement, with Cellares to serve as one of our manufacturing partners for the clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and preparations for commercial readiness. The Cellares Agreement has a term of five years. We can terminate the Cellares Agreement at will by providing a certain advance written notice to Cellares subject to the terms of the Cellares Agreement. Cellares can terminate the Cellares Agreement at will by providing a certain advance written notice to us subject to the terms of the Cellares Agreement. Under the initial work order, Cellares will perform clinical cell therapy manufacturing activities for our CAR-T cell therapy product, rese-cel.</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Purchase Commitments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In the normal course of business, we enter into various purchase commitments with third-party contract manufacturers for the manufacture and processing of our product candidates and related raw materials, contracts with contract research organizations for clinical trials and agreements with vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation other than for costs already incurred.</span></div></div><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles, or GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We estimate costs of research and development activities conducted by service providers, which include the conduct of preclinical studies, contract manufacturing activities and clinical trial activities. We record the estimated costs of research and development activities based upon the estimated amount of services provided and include these costs in the accrued and other current liabilities on the balance sheets and within research and development expense on the statements of operations. Non-refundable advance payments made for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are received or the related services are rendered.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">131</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We estimate these costs based on factors such as estimates of the work completed and budget provided and in accordance with agreements established with our collaboration partners and third-party service providers. We make significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, we adjust our accrued liabilities. We have not experienced any material differences between accrued costs and actual costs incurred since our inception.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Smaller Reporting Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a &#8220;smaller reporting company,&#8221; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended. We would cease to be a smaller reporting company if we have a public float in excess of $250 million, or have annual revenues in excess of $100 million and a public float in excess of $700 million, determined on an annual basis. This status allows us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a discussion of recently adopted accounting pronouncements please read Note 2, Summary of Significant Accounting Policies, to our consolidated financial statements included in this report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a discussion of recently issued accounting pronouncements please read Note 2, Summary of Significant Accounting Policies, to our consolidated financial statements included in this report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">132</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_7a_market_risk"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. We held cash and cash equivalents and investments of $133.6 million as of December 31, 2025. We generally hold our cash in interest-bearing money market treasury fund accounts and our investments are available-for-sale debt securities, which are invested in U.S. treasury securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents. Declines in interest rates, however, would reduce future investment income.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any foreign currency or derivative financial instruments. Inflation generally affects us by increasing our cost of labor and program costs. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience some effect in the near future (especially if inflation rates continue to rise) due to an impact on the costs to conduct clinical trials, labor costs we incur to attract and retain qualified personnel, and other operational costs. Inflationary costs could adversely affect our business, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8. Consolidated Financial Statement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s and Supplementary Data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements required to be filed pursuant to this Item 8 are appended to this Annual Report. An index of those consolidated financial statements is found in Item 15.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There has been no change of accountants nor any disagreements with accountants on any matter of accounting principles or practices of financial disclosure required to be reported under this Item.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">133</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9A. Controls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Procedures.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has established disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Securities Exchange Act of 1934, as amended, or Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and is accumulated and communicated to management, including the principal executive officer (our Chief Executive Officer) and principal financial officer (our Chief Financial Officer), to allow timely decisions regarding required disclosure. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of December 31, 2025, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective at the reasonable assurance level as of December 31, 2025.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance of the reliability of financial reporting and of the preparation of consolidated financial statements for external reporting purposes, in accordance with U.S. generally accepted accounting principles.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Internal control over financial reporting includes policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and disposition of assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with the authorization of its management and directors; and (3) provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on its consolidated financial statements.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures included in such controls may deteriorate.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2025. In making this assessment, management used the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). These criteria are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring. Management&#8217;s assessment included extensive documentation, evaluating and testing the design and operating effectiveness of its internal controls over financial reporting.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on management&#8217;s processes and assessment, as described above, management has concluded that, as of December 31, 2025, our internal control over financial reporting was effective.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attestation Report of the Registered Public Accounting Firm</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">134</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a non-accelerated filer, we are not required to provide an attestation report of our independent registered public accounting firm on the effectiveness of our internal control over financial reporting.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">135</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the fiscal quarter ended December 31, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B. Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Information.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plans</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the fiscal quarter ended on December 31, 2025, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc0b6ea2-f6aa-4e0a-8d47-f6e2f4c981fb" contextRef="C_72fa9a9d-1938-4032-8385-aa9b1119676b" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_85208bd5-ee43-4aa0-b6a7-c9351127403f" contextRef="C_72fa9a9d-1938-4032-8385-aa9b1119676b" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6823e826-92d8-43f7-a059-24bc53e32aa3" contextRef="C_72fa9a9d-1938-4032-8385-aa9b1119676b" name="caba:Rule10B51ArrModifiedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_3ba7aaee-b607-40b7-99ec-d28bf79ad2a5" contextRef="C_72fa9a9d-1938-4032-8385-aa9b1119676b" name="caba:NonRule10B51ArrModifiedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">modified </span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a159a35c-7e8e-486e-b29d-2dce34011eda" contextRef="C_72fa9a9d-1938-4032-8385-aa9b1119676b" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_b7f856e9-e2d5-42b3-8c92-c7f888d31514" contextRef="C_72fa9a9d-1938-4032-8385-aa9b1119676b" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated </span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as those terms are defined in Item 408(a) of Regulation S-K.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_9c_disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9C.</span><span id="notes_to_financial_statements"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">136</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART III</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_10_governance"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, Executive Officers and Corporate Governance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth below, the information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2026 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2025.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers and employees, including our principal executive officer and principal financial officer. The Code of Business Conduct and Ethics is posted on our website at </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">http://investors.cabalettabio.com/corporate-governance/governance-highlights</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of this Code of Business Conduct and Ethics by posting such information on our website, at the address and location specified above and, to the extent required by the listing standards of The Nasdaq Global Select Market, by filing a Current Report on Form 8-K with the SEC, disclosing such information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_11_exec_comp"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Executive Compensation.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 11 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2026 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2025 and is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_12_beneficial_ownership"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 12 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2026 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2025 and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_13_transactions"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 13 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2026 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2025 and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_14_principal_accounting"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14. Principal Accounting Fees and Services.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item 14 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2026 Annual Meeting of Stockholders within 120 days after the end of the fiscal year ended December 31, 2025 and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our independent public accounting firm is Ernst &amp; Young, Philadelphia, PA, PCAOB Auditor ID </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09d6e2f9-4122-45b4-84b0-737067bcbdff" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">137</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IV</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15. Exhibits, Consolidated Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ial Statement Schedules.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) The following documents are filed as part of this Annual Report on Form 10-K:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Consolidated Financial Statements:</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:92%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:7%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#audit_opinion"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2025 and 2024</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2025 and 2024</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#statements_convertible_preferred_stock_s"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2025 and 2024</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2025 and 2024</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#notes_to_consolidated_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
     </tr>
    </table><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) Consolidated Financial Statement Schedules:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All consolidated financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the consolidated financial statements or the notes thereto.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) Exhibits. The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Annual Report on Form 10-K are listed in the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K. The exhibits listed in the Exhibit Index are incorporated by reference herein.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="item_16_form_10_k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16. Form 10-K Summary</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">138</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
      <td style="width:92%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:7%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#audit_opinion"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2025 and 2024</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2025 and 2024</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_convertible_preferred_stock_s"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2025 and 2024</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2025 and 2024</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0.1in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:center;" id="audit_opinion"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and the Board of Directors of Cabaletta Bio, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1cdbfc0a-be8d-4425-bb0e-843002b8c2b5" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Cabaletta Bio, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's Ability to Continue as a Going Concern</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management's evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Audit Matters</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:14.16%;box-sizing:content-box;"/>
      <td style="width:2.64%;box-sizing:content-box;"/>
      <td style="width:83.2%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:0.04861111111111111in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting for Accrued Clinical Trial Expenses</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Description of the Matter</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:0.04861111111111111in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">As disclosed in Note 2 to the consolidated financial statements, the Company expenses research and development costs as incurred, which include costs relating to clinical trial activities. The Company&#8217;s accrued clinical trial expenses are based on factors such as estimates of the work completed in accordance with agreements established with a contract research organization. As disclosed in Note 5 to the consolidated financial statements, the Company&#8217;s total accrued expenses and other current liabilities related to clinical trial research and development services were $5.3 million at December 31, 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Auditing the Company&#8217;s accrued clinical trial expenses required subjective auditor judgement due to the estimation required by management in determining the services provided but not yet invoiced. Specifically, the amount of accrued clinical trial expenses recognized is sensitive to the availability of information to make the estimate, including the estimate of the period over which services will be performed, the associated cost of such services, and the level of services performed and progress in the period for which the Company has not yet received an invoice</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:0.04861111111111111in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">To test the accrued clinical trial expenses our audit procedures included, among others, reviewing a sample of agreements with the service providers to corroborate key financial and contractual terms, and testing the accuracy and completeness of the underlying data used in the accrual expense computations. We also evaluated management&#8217;s estimates of the progress of a sample of clinical trial activities by making inquiries of the Company&#8217;s operations personnel that oversee the clinical trials and confirming information directly with the contract research organization. To evaluate the completeness of the accruals, we also examined subsequent invoices from the service providers and cash disbursements to the service providers, to the extent such invoices were received, or payments were made prior to the date that the consolidated financial statements were issued.</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:14.16%;box-sizing:content-box;"/>
      <td style="width:2.64%;box-sizing:content-box;"/>
      <td style="width:83.2%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:0.04861111111111111in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Accounting for Common Stock Warrants</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Description of the Matter</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:0.04861111111111111in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:0.04861111111111111in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">As discussed in Note 10 to the consolidated financial statements, in June 2025, concurrent with the issuance of common stock and pre-funded warrants, the Company issued a total of 53,090,190 common stock warrants. The common stock warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in capital.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Auditing management&#8217;s evaluation of whether the common stock warrants required classification as a liability or equity is especially challenging and required significant audit effort and judgment due to the complex assessment of provisions within the warrants under authoritative guidance.</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;margin-right:0.04861111111111111in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">To test the classification of the common stock warrants, our audit procedures included, among others, reviewing terms and conditions of the common stock warrant agreements, evaluating management's application of authoritative accounting guidance and related judgments, and testing the accuracy of underlying data supporting management&#8217;s assertions. We involved our</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
    </table></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;">
    <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:14.16%;box-sizing:content-box;"/>
      <td style="width:2.64%;box-sizing:content-box;"/>
      <td style="width:83.2%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">internal accounting subject matter resources to assist in evaluating the Company&#8217;s assessment and judgments applied in its evaluation of the classification for the warrants.</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> /s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9cf2c99-8b3e-45ca-b3a6-bdfbe311f1c6" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2018.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d378c85d-b0b9-4345-b46e-47738087047e" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Philadelphia, Pennsylvania</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 23, 2026</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CABALETTA BIO, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Balance </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sheets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:65.813%;box-sizing:content-box;"/>
      <td style="width:1.46%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:15.003%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:12.723%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f8e7a26-b267-409d-97b3-edf77837ebaf" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,982</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f78f9ab8-4fa8-4885-92bd-2d427f6d1a2a" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,962</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_550fc29e-c230-4061-8748-0b716bf56fca" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,617</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52134146-b85f-4290-b1c4-cb7d261c2eeb" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e11ae7c-3eb5-4e66-be83-099791b511c5" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,272</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38c6a7d6-3034-4d72-8138-e58e0690b407" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,713</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d5cbf41-5029-43b2-8c6f-6c65b3b6d97c" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,871</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ab0b0c9-2a29-47de-91d4-965c3ee2eac0" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166,675</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82bf70ec-d138-48c7-ad92-efc2c8ea6c31" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,922</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bd0a6ac-43dd-4d52-94e6-cb813ff518c6" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,743</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance lease right-of-use assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4285c0cd-5a2a-40d8-9f69-43180807d3c2" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,700</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0961d633-6b7e-4cc3-bc97-38b148fe90fa" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:FinanceLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,020</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51a0252c-a123-43a0-9c1c-5f3664f8398b" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,431</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b61f6c8f-fc38-494d-92dc-b612d148a31f" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,315</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d67312a-27e5-4625-b4e9-2820bb875885" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,159</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccbcd729-845a-4be8-9865-48e5585ce5d3" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,293</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_197c34a7-4eca-462e-807b-e1460e45def6" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165,083</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85d708a2-aaac-4175-aaf6-46e1b5e83cd4" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,046</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and stockholders&#8217; equity</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48374643-47b0-47f1-9d5b-2ffc4a15240e" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,636</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43cb3a28-4350-471c-a031-d262d23cf5d1" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,923</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued and other current liabilities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1589bd51-2dc0-4dc8-a773-19af6fbd0989" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,298</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efe2b1d6-f007-494b-9ceb-c379c8d5ed5a" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,188</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance lease liabilities, current portion</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a50da081-ebc9-4669-8cf7-290eea15a3e4" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,758</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a40acd1c-5019-4eba-b960-468265253413" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,989</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current portion</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4f4a0ae-6b3c-42f6-95bd-45082b1234af" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,461</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af6aeb8c-d808-46d5-bee6-5482df4e961d" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,986</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_620b834f-d5fd-4aae-965f-c98172765192" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,153</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2830f73-dcdb-4ca6-b34e-89c60302637b" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,086</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance lease liabilities, net of current portion</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eda64ecf-80af-4413-9f39-b078fd394a00" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,879</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f043c7f0-e9ce-4830-98a8-e307040b8fa6" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:FinanceLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,241</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, net of current portion</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9c785a8-877c-474b-8eca-13900c2c666e" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d1ad65b-78ca-4c44-b90e-6af57a049031" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,384</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ab0a480-a758-4970-8459-bf0e89265dd4" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,032</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aeaca352-ff0d-465d-8ba4-2ab1de0777ee" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,711</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_437f05d5-bc3e-4917-9472-758eed38a299;"><span style="-sec-ix-hidden:F_8ac70644-54ad-4b79-9c48-216491e81014;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (see Notes 6 and 7)</span></span></span></span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_659b8981-a914-4e18-8a9b-3ca74cbe6fec" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1a3c13e9-27a5-4682-bea6-cd89dbf2c242" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.00001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value: </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c79ce3f6-48d0-449a-bbbe-459be37977af" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2a97f776-6224-4023-984b-382901794ff8" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized as of<br/>&#160;&#160;&#160;December 31, 2025 and December 31, 2024; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9087ad02-416a-414f-acf5-7104a6295117" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e277851d-1ee1-46c6-8eb5-b2966b461e41" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_35828212-92c4-4978-af4a-4057068df3b5" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_266a5a8e-419e-4f55-b99c-ff3d6a8872e9" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued or<br/>&#160;&#160;&#160;outstanding at December 31, 2025 and December 31, 2024</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad2b6a7a-c4ba-42d6-8983-e032705070c5" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50d58533-2a54-451c-8b8d-2b3cc8f1fd0f" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Voting and non-voting common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64ea3c2c-dd5e-48e6-9f31-4f22a596cf76" contextRef="C_522cbfa4-2c21-424d-9038-128e92ccffdf" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_94c9c5e6-0433-467e-aa10-d7be8e953acb" contextRef="C_848456ab-d285-4d96-bbb7-61690adf497f" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5b4e11cc-8efc-43af-8fef-1065976ed0dd" contextRef="C_3b4d07dc-82b8-43f1-b613-4a8e7b71d9a0" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_615dcdf9-4aaa-4245-bd18-5c98461423c1" contextRef="C_27b86f31-4de3-446f-a21a-b648b1caf82f" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.00001</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value: </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ced2a442-26b0-4982-9d41-5ffce9432967" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>&#160;&#160;&#160;(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_500995a2-87ed-46f4-9975-5d877395f340" contextRef="C_522cbfa4-2c21-424d-9038-128e92ccffdf" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">293,590,481</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;voting and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61bd4854-7869-4142-9f02-da93dcdba3df" contextRef="C_3b4d07dc-82b8-43f1-b613-4a8e7b71d9a0" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,409,519</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;non-voting) shares <br/>&#160;&#160;&#160;authorized as of December 31, 2025 and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1d63e2d-3629-4f91-bd0a-c31bd499788d" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">150,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>&#160;&#160;&#160;(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a58e32e5-d252-49e7-9f3f-3f25181b7760" contextRef="C_848456ab-d285-4d96-bbb7-61690adf497f" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">143,590,481</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;voting and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c2aa31d-0e5d-492c-a29f-a64b007c52d6" contextRef="C_27b86f31-4de3-446f-a21a-b648b1caf82f" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,409,519</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;non-voting) shares authorized<br/>&#160;&#160;&#160;as of December 31, 2024; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00ac8bac-1b50-4a87-ac3e-1e566b4b243b" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ec3ba541-72d9-49ab-a1bd-2a151380e67c" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">100,479,323</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;voting shares issued<br/>&#160;&#160;&#160;and outstanding as of December 31, 2025 and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0ae1fcd-3cc9-4cc6-80e4-49be6a94bead" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d08f9ea2-eefb-4a26-8aad-245239369d98" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,743,101</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>&#160;&#160;voting shares issued and outstanding as of December 31, 2024</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e45fcaff-2091-45bb-b039-0f51170b411f" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62194617-fabf-4ca4-8bdf-b3dca4712176" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ec5ba68-247d-421b-b46a-f4681c3e1e5c" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">628,982</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c138a7e3-0d9e-4173-aefb-f3d54511f95e" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">501,435</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f64c8c86-a1a2-48c5-8c45-c49e355f6c2b" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a290193-f740-43c9-bccd-69bbb130b892" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35e27410-2aeb-4d83-85ae-edfee3a14ad8" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">516,957</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b352ce51-6092-4f3a-8ab2-bcb0afd1530a" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">349,101</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e73c1259-07c8-4975-ac3e-c44515c71723" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,051</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58333bd3-a532-472c-9a67-30bc8cd174ed" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,335</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42318b62-0a8b-4081-967b-8c072d393b0f" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165,083</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55741dc2-fb8b-4c60-bee8-b4a49cd43266" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,046</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CABALETTA BIO, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Operations and Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:62.727%;box-sizing:content-box;"/>
      <td style="width:1.84%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:14.797%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.84%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:14.797%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d306c02c-a2ec-43fb-a03c-2ce7c7e508dd" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,674</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c47121bf-3f91-483e-a799-6dfbcba3edf9" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,203</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a1c0805-e016-407f-a7e8-f4aeac0ff19c" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,567</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0b9879e-da9c-498b-8acb-79df405fe6f6" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,938</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5dd706a2-3cc0-4a0e-9c2a-c348b69b5b01" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172,241</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7494f70-8be1-4e63-9ea6-9affefd35dc4" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,141</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c25ed65-52c2-47bc-a73f-f07639df4e9c" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">172,241</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d540766-4953-4373-87a6-9c6030d32904" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">125,141</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense):</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adb0c1c9-d57f-4ebe-902b-c3833333a7b6" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,031</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a8f5e84-1fe8-4122-ab62-ba84d37eccdf" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,025</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b18fc903-fd66-461c-90e3-8455876e47f8" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,004</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8e8ef8b-5666-4228-a6da-66dd15d527be" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">748</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_862504c7-588b-450c-9523-4a100a7f3966" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">358</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9137afc-7998-4758-8e5c-6f4cea0d0124" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f198c91e-99d8-4b62-9e5d-0885e185ab04" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">167,856</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e54d6890-3967-4994-8166-09b2e1e4c546" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,864</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized gain (loss) on available-for-sale investments, net of tax</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65a1880e-2a4b-4ccc-ac2c-4f019f499b03" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c0b81ae-bbfd-49db-8ea8-49f087d990ab" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net comprehensive loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a38e80d5-7f4a-46ac-8e17-3b19852ad5a6" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">167,831</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77e32d69-adbb-4592-ba75-7ace4d07fb57" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,903</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share of voting and non-voting common stock, basic and diluted</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09840fd9-827d-4efb-a13a-6087b96febfd" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_64de83a0-5c06-43a0-89ab-3a160cb5fce3" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.10</ix:nonFraction></ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc74a907-2158-4a1a-a0bb-af2423e5494c" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a619d248-352a-42d1-b59d-b1ba87019c2d" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.34</ix:nonFraction></ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:9in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:9in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CABALETTA BIO, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_convertible_preferred_stock_s"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share amounts)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:35.208%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:8.068000000000001%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.041%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:7.587999999999999%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.041%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:7.587999999999999%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.041%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:9.168999999999999%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.041%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:7.587999999999999%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.041%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:7.587999999999999%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional<br/>Paid-in Capital</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Other Comprehensive Income (Loss)</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Deficit</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>Stockholders&#8217; Equity</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance&#8212;December 31, 2023</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34cbfa23-83e0-46be-907e-8ef5f6daab64" contextRef="C_a5873561-482d-4211-8d1a-100b3d8724c2" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">47,823,232</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd503319-18c5-406a-b19c-2e705392714d" contextRef="C_a5873561-482d-4211-8d1a-100b3d8724c2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7663efa-cf45-44b2-9106-adae51e43e09" contextRef="C_9448925f-7edb-4e94-9f16-2bf8d36d4bb9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">469,396</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_637ee382-318d-4f72-ba17-38faef91ac88" contextRef="C_56867ab7-d91f-49f7-8e38-359323e03001" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb6c62e6-1256-4604-a0cd-5e7f953c7e23" contextRef="C_36c99cf7-ca6d-4bef-8c7d-d86f756b67a3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">233,237</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3a6d019-8ac8-4426-8610-bff42059893f" contextRef="C_8afc398a-f701-4181-b888-7da00743bdd1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236,198</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock, net of issuance costs of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4851507-cd69-4ded-95d6-296a6ce49d98" contextRef="C_792e0634-91e5-4b0d-aabc-c71a1e755f4a" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65ffabdb-3384-49b7-bc4e-afbad27db7e5" contextRef="C_a8062a63-67f4-417e-aa58-0c10ea3f25d7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,483,070</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2810d5fc-5600-4a5a-a070-33d3bb32f808" contextRef="C_a8062a63-67f4-417e-aa58-0c10ea3f25d7" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_073fb50c-ad14-476d-9226-829010fe5df9" contextRef="C_3d0986e1-7018-41a1-8dff-d52329443bdd" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,875</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b7d65eb-aa4a-496c-b4c2-b87c51d3e3a3" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,876</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock in connection with exercise of stock options</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2d4b8ed-535e-4cf5-af48-c6615f390bbf" contextRef="C_a8062a63-67f4-417e-aa58-0c10ea3f25d7" name="caba:StockIssuedDuringPeriodShareStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">210,695</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c0929d0-b984-43c7-8a19-6df5b591f0af" contextRef="C_3d0986e1-7018-41a1-8dff-d52329443bdd" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,430</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_383169b9-4e7e-482d-bad2-17e4248e6625" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,430</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acd46bd8-9f26-455a-b4b7-6bd057c6c8a3" contextRef="C_a8062a63-67f4-417e-aa58-0c10ea3f25d7" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">58,056</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3aae3a5-e2ff-4cbd-a735-6a3048f3562c" contextRef="C_3d0986e1-7018-41a1-8dff-d52329443bdd" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">269</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66e4b514-766c-4fa7-8dcf-517655d514bf" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">269</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of pre-funded warrants</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0dd0ead-01e6-4292-a20f-6ea278ca6cc4" contextRef="C_a8062a63-67f4-417e-aa58-0c10ea3f25d7" name="caba:IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,168,048</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c73041a3-51d1-4171-b4bb-ee4588ed302f" contextRef="C_3d0986e1-7018-41a1-8dff-d52329443bdd" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,465</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b55b946a-6212-43a6-ad1a-48d55fa2bd53" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,465</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized losses on available-for-sale securities</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de639036-6ad4-429b-81ab-2ef41b46f080" contextRef="C_4df289a5-f84c-498b-9dea-19951da65c82" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53856b55-2a9f-46f2-9195-3051d5b75191" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bca21f3-1fce-499f-b02e-c80b95699bfe" contextRef="C_5c1cb0e3-26dc-41c6-a7e9-aa32d0639495" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,864</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b04f371-5d55-41a2-a5af-efaaff456548" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,864</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance&#8212;December 31, 2024</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8a9f62e-f48d-44d8-963b-07423e17d84d" contextRef="C_188e5d31-bb66-43a0-923f-07b3e3e5e7ce" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">50,743,101</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37653100-8c11-40e1-bc4c-cf9fa8f4e953" contextRef="C_188e5d31-bb66-43a0-923f-07b3e3e5e7ce" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34f34023-7966-429e-b131-755684f12052" contextRef="C_f6fec174-bee9-4e5c-b065-1b69e2425c7e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">501,435</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83d80b34-3d1a-442c-8ca4-27825d698eeb" contextRef="C_77e60dc1-c4d2-45f5-a2f2-00307e31ec35" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d96b067e-4e74-4c5b-a3b6-d1d86444a460" contextRef="C_ce57e4a4-13e3-4eba-acdf-d75280f60ad4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">349,101</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a7de615-f93a-414d-80a0-2608e8a53351" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,335</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock, warrants and pre-funded warrants, net of issuance costs of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_891f5225-9d18-4a7b-94a0-b9c8de58adb4" contextRef="C_26ba7aad-e65f-4202-9148-f8d56de48c1d" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,442</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e567cc8-8a97-485a-ad19-b2819a0f7a7e" contextRef="C_ca4270cc-f26d-45c8-b902-287451c596e5" name="caba:IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">39,200,000</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_850450de-4f7d-48bc-b9e1-0d15f1afca8d" contextRef="C_f31f321e-4cd2-4185-92e3-2690e8409af5" name="caba:IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,558</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fbd6931-150a-4610-a684-5e4b47715039" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,558</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock from ATM offering, net of sales agent commission and fees</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c88fb4f5-0112-4c79-b7e0-3a1a3b522026" contextRef="C_ca4270cc-f26d-45c8-b902-287451c596e5" name="caba:IssuanceOfCommonStockFromATMOffering" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,545,041</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_744a14b2-30ed-4e1c-909f-5e3017c15755" contextRef="C_f31f321e-4cd2-4185-92e3-2690e8409af5" name="caba:IssuanceOfCommonStockFromATMOfferingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,745</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d26905e-4141-441e-bdf5-466478d2a5b4" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:IssuanceOfCommonStockFromATMOfferingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,745</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock upon exercise of pre-funded warrants</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e97bc2d-093b-4633-9aa7-4da1dc2fcffb" contextRef="C_ca4270cc-f26d-45c8-b902-287451c596e5" name="caba:IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,799,971</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86f3a8fc-1286-48ba-b9a8-9ca65fc2d666" contextRef="C_ca4270cc-f26d-45c8-b902-287451c596e5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">177,876</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35a0f6fd-44af-43d6-a2f6-e8ac88cbde58" contextRef="C_f31f321e-4cd2-4185-92e3-2690e8409af5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">291</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c920189-98f6-40a8-b9d1-2d0574e3d668" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">291</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock in connection with exercise of stock options</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2997a1f8-8a4a-44f4-84df-180abfc270e5" contextRef="C_ca4270cc-f26d-45c8-b902-287451c596e5" name="caba:StockIssuedDuringPeriodShareStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,334</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eef8d855-baae-41fe-849a-aadb1b8b58bc" contextRef="C_f31f321e-4cd2-4185-92e3-2690e8409af5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31256f51-dad7-41e3-bf5f-5c7774d1ed17" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c98afbf-2d9d-45cb-aa6b-2a30b5cb31d3" contextRef="C_f31f321e-4cd2-4185-92e3-2690e8409af5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,939</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddc50e56-a75e-4ad0-92ec-17366dafcf8b" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,939</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized gains on available-for-sale securities</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7557ae0-5bab-430b-a29d-b2fdc93265ab" contextRef="C_e6e85024-5586-4627-9417-cf890b8d4e9a" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5fdb854-961e-47d0-a891-1f599e664041" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_069e17a2-25a7-4760-a62f-ecfcc6b54998" contextRef="C_383948ef-273f-45f3-8285-76bb7b9800da" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">167,856</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65fa3bfd-57c1-4a3e-80a8-8b25c9964b3b" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">167,856</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance&#8212;December 31, 2025</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19cf5b63-b004-412b-be3a-4e46741ebe45" contextRef="C_6ebe76ca-6547-40a0-a4fb-a46ca3d1dafe" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">100,479,323</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38d8d03a-337f-41bd-84a3-319f4cf4f70b" contextRef="C_6ebe76ca-6547-40a0-a4fb-a46ca3d1dafe" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfb3b90e-0bce-4e81-90a2-b3964e60c281" contextRef="C_08dd7fa2-382e-4330-ac22-084c92a87490" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">628,982</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7763c5c4-4abf-466f-a7a2-7831b81a2d65" contextRef="C_b10e6031-e107-4203-ad40-05b14067806e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed5dd864-0fa1-4922-bdaf-ed9e94240f73" contextRef="C_d5ccabe0-42f9-4792-b82a-3e639809d25d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">516,957</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a93bb60f-2d4b-4b65-aff9-bc8cd373f098" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,051</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:9in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:11in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CABALETTA BIO, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:65.379%;box-sizing:content-box;"/>
      <td style="width:1.69%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:13.771%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:1.69%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:13.469999999999999%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bdfc344-76a5-46a7-88bb-49d4fa796d10" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">167,856</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f7b73b1-2152-45f1-ae04-ab7a6a7d4c0e" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,864</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4e0fb01-ee62-4b79-bd74-c1eae0f1ff38" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,939</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01ff2726-cf27-4663-9b5c-75398d6d88a1" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,465</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc7bb283-8084-4a8b-aff5-716990a7622e" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,646</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43575656-ff4b-4327-b250-3370730a0ab8" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,711</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash finance lease expense</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39e6ebb2-dd81-40ff-9249-e1f35f1d7349" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:NonCashFinanceLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,697</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff38928b-38ac-4b70-9ff6-67b3c0cb7c10" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="caba:NonCashFinanceLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,102</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash operating lease expense</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89fbf1c3-d57a-4012-baca-b2e991864a04" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:NonCashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,671</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba8002bd-8f6c-4a69-9701-1473beb0e3ef" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="caba:NonCashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,838</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of operating lease liabilities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64ce1ca5-0cf9-4cb1-9160-0bfd71cdf463" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:AccretionExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">532</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdc68fce-083f-4bc1-93f9-15bc29a58f31" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:AccretionExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">405</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of discount on investments</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32bc8974-0da0-4acd-a5a2-204a805ef14c" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,555</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdb3152b-5e0d-4133-8e69-451172c4505c" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,528</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss on foreign currency exchange rates</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da3e7700-a6cb-4f89-8430-c2b44aae0fc3" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab28945f-eb98-403c-82d7-d13f3baf494e" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b82cf237-a0dc-4bc9-aca2-6034fcdc8c47" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,559</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd74671f-e8b4-4683-aac9-f45a9e921318" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">528</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c1ef0ea-7353-49e7-bd83-e1fa58de954a" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,866</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7be861bc-2575-417c-8a91-deef00d2f18f" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">584</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c79d5a0d-483b-4785-9cb1-6ceeb11d3013" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,550</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_caf59ccd-44eb-4db5-9060-aa5d65235fb5" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,011</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued and other current liabilities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ef9b133-feeb-4db4-b880-b9df39d861f5" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,432</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e0dfacc-b28e-402b-859a-811add5d7ea0" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,947</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95199238-9e53-4ac0-babd-f7fa980e70ce" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,227</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41ff91ee-04bf-47fe-b1f8-31a730fab637" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,291</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued interest payable under finance lease</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_409cd2f1-b392-4fa4-818d-a9c8d485e6ca" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:IncreaseDecreaseInInterestPayableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">291</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2221969-1776-496c-880b-4d132e93606e" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:IncreaseDecreaseInInterestPayableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:40pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9f376f1-cbce-44ad-acfd-67bca31d6360" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">131,080</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1aa07c9-0327-479b-9ebb-144510e24ff3" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">88,222</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa77acc6-d6cd-4977-8f99-5400b88b7efd" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,229</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba6a03df-7e7a-4498-bd76-ad3962f0c252" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,211</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of investments</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc52c2a6-b251-448c-85b9-7b4d2ace5cba" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,037</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fccb7108-ed6f-4b79-8205-b204218ac74d" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from maturities of investments</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56743e5f-e7b9-43ab-8f17-09482f421400" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acdb552a-b67a-46cf-b197-c90b24039f53" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,500</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:40pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d9f1122-21f2-4631-b786-09b53a2bc63c" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">50,266</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_222a45c6-95c2-4109-9ae6-3af9aa840795" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,289</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from the issuance of common stock, warrants and pre-funded warrants, net of issuance costs</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afad77e2-842e-46f4-809d-02bc73145baf" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,558</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6acbacd4-9d5c-4250-ba74-b233eda0f8e1" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock from ATM offering, net of sales agent commission and fees</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbb160b5-e8f5-4b2e-ab29-e94ddddc7fed" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,745</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3025f14d-03cd-4c84-b774-0bc4f45ee581" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="caba:IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,875</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock under employee stock purchase plan</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc12a56d-7795-4998-8661-9bd8dc30e419" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">291</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d83b216-987d-4cb9-a089-a060140cb6c1" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">269</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock in connection with the<br/>exercise of stock options</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea256a18-3374-491d-94f5-2fa86945cfbd" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09e8bcdc-9ff2-49bb-b9dc-d63dd4baa61e" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,430</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Principal payments on finance leases</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f4c9889-e041-4f86-98d0-e0bbb21ea299" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,261</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_615ed76b-cd75-4f2e-a146-972ffce585c7" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">897</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;text-indent:40pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff548daf-f56b-47cb-a876-492eac217fc5" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,347</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83d6fbff-79e3-4f43-b277-e75445160865" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,677</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5ba3046-f5e5-48f8-9a9e-b482f6340b03" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06120ef5-6ab6-457f-a3a6-e3da7313b9a2" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c491197-2e8c-432d-ad5e-7fb4afa5d40f" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,980</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bc0f8d4-29c9-4188-a2a4-b775e00c4c2d" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29,276</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents&#8212;beginning of period</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e17728b3-33b4-48ad-8e7a-3b2b6eb8a3c7" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,962</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3994007a-4722-4787-ac36-8140b473cbc6" contextRef="C_8afc398a-f701-4181-b888-7da00743bdd1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,238</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents&#8212;end of period</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f211700-c213-4122-a50a-abd950ccbc43" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,982</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_837a15ac-ec2f-443e-b4f2-5ff6318cd6b7" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,962</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosures</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for interest</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09911eae-1d78-4d43-9f62-f9c55da276e9" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,713</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2ac43c9-678f-45c0-a59c-435084fbc04f" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">748</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment purchases included in accounts payable and accrued expenses</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e72e542c-81ba-42ca-8556-1662f62b3398" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e8301a2-a257-42f9-aad7-df31e86a6b22" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">404</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets obtained in exchange for finance lease obligations</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d3a498a-0757-4b18-adec-0b0095440a74" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,071</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3df95b7e-ace3-4325-8415-d687cacd47e2" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,963</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets obtained in exchange for operating lease obligations</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59838a3c-2f12-435b-b9ec-b7846599ee35" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">787</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
      <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7943d1d4-980f-4889-8a71-99fa8777bdce" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,242</ix:nonFraction></span></p></td>
      <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CABALETTA BIO, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to the Consolidated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_cefc8b67-affc-4a11-ad05-23f2b53c7b14" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true" continuedAt="F_cefc8b67-affc-4a11-ad05-23f2b53c7b14_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cabaletta Bio, Inc. (the Company or Cabaletta) was incorporated in April 2017 in the State of Delaware as Tycho Therapeutics, Inc. and, in August 2018, changed its name to Cabaletta Bio, Inc. The consolidated financial statements include the accounts of Cabaletta and its wholly owned subsidiaries: Cabaletta Bio GmbH and Cabaletta Bio (Germany) GmbH.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is headquartered in Philadelphia, Pennsylvania. Cabaletta is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Principal operations commenced in April 2018.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not expect to generate revenue from sales of engineered T cell therapies for autoimmune diseases or any other revenue unless and until the Company completes preclinical and clinical development and obtains regulatory approval for one or more product candidates. If the Company seeks to obtain regulatory approval for any of its product candidates, the Company expects to incur significant commercialization expenses.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. As a result, the Company is unable to predict the timing or amount of increased expenses or when or if the Company will be able to achieve or maintain profitability. Further, the Company is dependent on third parties for certain research and development activities, including manufacturing services (Note 6 and Note 7). Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. Even if the Company is able to generate revenues from the sale of its product candidates, if approved, it may not become profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then it may be unable to continue its operations at planned levels and be forced to reduce its operations.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, Going Concern, ("ASC 205-40") the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company has sustained annual operating losses since inception and expects to continue to generate operating losses for the foreseeable future. As of December 31, 2025, the Company has incurred an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5090b568-8470-453a-a307-bdfb9b447a2b" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">516,957</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and has cash, cash equivalents and investments of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ba23519-4180-4f99-a0f8-fbfe4665b58e" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,599</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company&#8217;s ultimate success depends on the outcome of its research and development activities. Management expects to incur additional losses in the future as it continues its research and development and will need to raise additional capital to fully implement its business plan and to fund its operations. The Company intends to raise such additional capital through a combination of equity offerings, debt financings, government funding arrangements, strategic alliances or other sources. However, if such financing is not available at adequate levels and on a timely basis, or such agreements are not available on favorable terms, or at all, as and when needed, the Company will need to reevaluate its operating plan and may be required to delay or discontinue the development of one or more of its product candidates or operational initiatives. Based on the Company&#8217;s current operating plan, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for at least twelve months from the issuance date of this Annual Report on Form 10-K, and the Company will need to obtain additional funding. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company's cash forecast contains estimates and assumptions based on success of ongoing clinical trials, and management cannot predict the amount or timing of all expenditures with certainty. Accordingly, the Company has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. The accompanying financial statements have been</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_cefc8b67-affc-4a11-ad05-23f2b53c7b14_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prepared </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_1cb34cf1-fb2f-476b-87e5-03f3ffeafc3f" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_1cb34cf1-fb2f-476b-87e5-03f3ffeafc3f_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_03df1f58-c4e8-42e1-a64c-cf8c87ce852f" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) and under the rules and regulations of the U.S. Securities and Exchange Commission (SEC). All intercompany balances and transactions have been eliminated in consolidation.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d48347b-3dbb-4638-98b1-b4a32f8e35e3" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:UseOfEstimates" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to advance payments and accruals related to the Company&#8217;s research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df623267-f9a9-4103-bc2a-b58ce00ee88c" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Off-Balance Sheet Risk and Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist of cash and cash equivalents, which are invested in U.S. treasury-based money market funds, and available-for-sale debt securities, which are invested in U.S. treasury securities. A portion of the Company&#8217;s cash is maintained at federally insured financial institutions, and account balances may at times exceed federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk. The Company has no off&#8209;balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and U.S. treasury securities.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a64c1888-61ff-4048-be0f-0519b978d93e" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments are available-for-sale and carried at estimated fair value. The Company&#8217;s valuations of available-for-sale debt securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than, twelve months from the balance sheet date are classified as current.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors including the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or if more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments as well as amortization of discount or premium is included in interest income.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div><ix:continuation id="F_1cb34cf1-fb2f-476b-87e5-03f3ffeafc3f_1" continuedAt="F_1cb34cf1-fb2f-476b-87e5-03f3ffeafc3f_2"><div><ix:nonNumeric id="F_0a36fa20-bc44-4d54-910d-06b245cbaf29" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property, Plant and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying statements of operations. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0458b50-0d62-4392-99d9-c4cfc921e62e" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" escape="true" continuedAt="F_c0458b50-0d62-4392-99d9-c4cfc921e62e_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimated useful lives for property and equipment are as follows:</span></p>
          <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
           <tr style="visibility:collapse;">
            <td style="width:49.17%;box-sizing:content-box;"/>
            <td style="width:1.66%;box-sizing:content-box;"/>
            <td style="width:49.17%;box-sizing:content-box;"/>
           </tr>
           <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated useful life</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_f3171ae7-6dcf-466a-a644-40c8ef88b0e8" contextRef="C_ec1351eb-6c75-4b2b-a584-b9e9880ef824" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Three years</span></ix:nonNumeric></span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_f3ad56f2-b0c0-4d7b-85da-43404400f759" contextRef="C_b91d5295-ad40-4ba7-93e0-4f6e19c9bd4e" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Three years</span></ix:nonNumeric></span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_476bd066-38dd-4e11-8daa-f028cd52693f" contextRef="C_62c46a84-f119-4e55-9084-2d63a76277e0" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Three years</span></ix:nonNumeric></span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_6b79aa44-243a-42b1-94f6-81fb189f1245;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lesser of estimated useful life or remaining lease term</span></span></span></p></td>
           </tr>
          </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_c0458b50-0d62-4392-99d9-c4cfc921e62e_1"></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9c97b39-2d0a-486c-8260-0e38e8387433" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_f8776c33-73d7-4a8d-bbef-2c63ca5c6706" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" continuedAt="F_f8776c33-73d7-4a8d-bbef-2c63ca5c6706_1"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has leases related to its facilities used for offices and laboratory space, which are classified as operating leases as well as leases related to its manufacturing arrangements, which are classified as finance leases.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease and its classification based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. Subsequent to the initial measurement, the Company will continue to account for:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the lease liability at the net present value using the incremental borrowing rate that was in effect as of the lease commencement, lease modification, or transition date, and;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the finance lease and operating lease expense on a straight line basis.</span></div></div></ix:nonNumeric></div></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div><ix:continuation id="F_1cb34cf1-fb2f-476b-87e5-03f3ffeafc3f_2" continuedAt="F_1cb34cf1-fb2f-476b-87e5-03f3ffeafc3f_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_f8776c33-73d7-4a8d-bbef-2c63ca5c6706_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases with terms of 12 months or less are considered short-term leases and right-of-use assets and lease obligations are not recognized. Payments associated with short-term leases are expensed on a straight-line basis over the lease term.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to aggregate all lease and non-lease components for each class of underlying assets into a single lease component for real-estate leases and embedded manufacturing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the guidance in ASC 842-10-55-2 to assist in determining lease classification across its leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0220077-85f2-49e8-918e-b6fa25a8c56a" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs include costs incurred for internal and external research and development activities and are expensed as incurred in the accompanying statements of operations. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to entities that conduct certain research and development and clinical trial activities on the Company&#8217;s behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers, which include preclinical studies, contract manufacturing activities and clinical trial activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided and in accordance with agreements established with service providers and includes these costs in accrued and other current liabilities in the accompanying balance sheets and within research and development expense in the accompanying statements of operations. Non-refundable advance payments made for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are received or the related services are rendered. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid expenses in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities and prepaid expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0cbf6195-81ef-4e6f-88bd-e9e136af2cff" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures its stock-based awards granted to employees and non-employees based on the estimated fair values of the awards on the respective grant dates. The Company uses the Black-Scholes option-pricing model (Black-Scholes) to estimate the fair value of its stock-based awards. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company accounts for forfeitures of stock option awards as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_e69e799f-4ee0-4499-802d-004b37e4da85" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_e69e799f-4ee0-4499-802d-004b37e4da85_1"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base, as well as for net operating loss carryforwards and research and development credits, and are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div><ix:continuation id="F_1cb34cf1-fb2f-476b-87e5-03f3ffeafc3f_3" continuedAt="F_1cb34cf1-fb2f-476b-87e5-03f3ffeafc3f_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e69e799f-4ee0-4499-802d-004b37e4da85_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03565315-7203-48ad-95d1-350f274496e1" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> interest or penalties related to uncertain income tax benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d97cf6a0-da61-4ec8-98b6-b19e1c096e03" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company calculates basic and diluted net loss per share in conformity with the two-class method required for participating securities because the Company had both voting and non-voting common stock outstanding for a portion of 2024. The rights, including the liquidation and dividend rights, of the holders of the voting and non-voting common stock are identical, except with respect to voting. Each share of non-voting common stock may be converted at any time into one share of voting common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. As of December 31, 2024, no shares of non-voting common stock remain outstanding.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted average number of shares of common stock, including any pre-funded warrants to purchase shares of common stock that may be outstanding. The undistributed loss for each year is allocated to common stockholders based on the contractual participation rights of the voting and non-voting common stock as if the losses for the year had been distributed. As the liquidation and dividend rights are identical, the undistributed losses are allocated on a proportionate basis. Diluted net loss per share attributable to common stockholders is computed under the if-converted method and assumes that all non-voting common stock has been converted to common stock. Since the Company was in a loss position for all periods presented, the effects of the other potentially dilutive securities are antidilutive.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a375f181-9513-4033-987e-b6cc862efd2f" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer (CEO). The Company has determined it operates in a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_11331fa4-2d51-42cc-aee7-5b9ce9481ad0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cdebfd8-e46b-4f24-a6ff-6982ab163d81" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:NumberOfReportingUnits" unitRef="U_Segment" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refer to Note 8 &#8211; Segment Reporting for further information related to our segment.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_83b38a72-2c8e-4b21-9aec-68d1f89c7d5e" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:DeferredChargesPolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of stockholders&#8217; equity as a reduction of additional paid-in capital or equity generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.</span></p></ix:nonNumeric></div></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div><ix:continuation id="F_1cb34cf1-fb2f-476b-87e5-03f3ffeafc3f_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_377b946d-223e-4b8f-b468-59c9b016b30b" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ASU 2023-09 enhances the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The Company adopted this ASU for the annual period ended December 31, 2025 and the amendments have been applied retrospectively to all prior periods presented in the financial statements. Refer to Note 11 &#8211; Income Taxes for further information.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement (Subtopic 220-40): Reporting Comprehensive Income-Expense Disaggregation Disclosures. ASU 2024-03 requires enhanced disclosures about components of expense captions on the face of the income statement. This standard will be effective for fiscal years beginning after December 15, 2026. Early adoption is permitted. ASU 2024-03 applies on a prospective basis for periods beginning after the effective date. However, retrospective application to any or all prior periods presented is permitted. The Company is currently planning to adopt this guidance when effective and is assessing the impact of the adoption on the Company&#8217;s consolidated financial statements and accompanying footnotes.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no other new accounting pronouncements or changes to accounting pronouncements that, if adopted, would have or may have a material impact on the Company&#8217;s consolidated statements or disclosures.</span></p></ix:nonNumeric></div></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div><ix:nonNumeric id="F_8ae0a55e-7427-4b18-8049-5fae6f9b1473" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, the Company&#8217;s financial instruments included cash and cash equivalents, available-for-sale debt securities, accounts payable and accrued expenses. The carrying amounts for cash and cash equivalents, accounts payable and accrued expenses reported in the Company&#8217;s consolidated financial statements for these instruments approximate their respective fair values because of the short-term nature of these instruments.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d567607c-9362-4232-87f0-66697bd735b1" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:36.174%;box-sizing:content-box;"/>
          <td style="width:1.561%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.365%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.561%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.485000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.561%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.365%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.561%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.365%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active Markets<br/>for Identical Assets <br/>(Level 1)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4222028-ab9d-48ca-9328-3251c5918f30" contextRef="C_57a2c95e-1173-4087-adbb-3d92d6dbeea3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,470</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73daa6f1-5a41-449d-a387-eddb93383ddd" contextRef="C_70a0fab7-be2b-4ccd-99f2-f48e769150b3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,470</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8d9ba62-206f-477d-aaaf-7c4f2f3348a2" contextRef="C_e26415e9-74b5-445d-8fc5-da0f16985c3a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c33b6daf-7c14-4716-95e5-01a24fc56b49" contextRef="C_c8b36cac-3990-46a9-8114-ac5487ea54a4" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2b2c9f5-1a87-4a7c-a082-4d94756ec477" contextRef="C_c1c27316-e3fc-40d0-af16-e93b32732100" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,617</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_193cac77-7fe6-4d82-bee6-128a5858cefd" contextRef="C_4cd483e2-d5ac-481f-a4e4-14e2c5f3b0c8" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93e270cb-ce47-4791-8546-e639b3461d58" contextRef="C_7e883d39-427a-4782-a11e-f726f65e38ec" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,617</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d50262a2-7e58-4597-ac9d-dea53fd92de6" contextRef="C_7100f48a-8add-4128-a465-4164ef21fd92" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc4ed9ad-9f4c-4b02-a548-ce96371852ca" contextRef="C_d8e43c4b-0fae-4bc3-81be-0f50e637fc37" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,087</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f11aa1a7-58c7-4056-9a97-6c33d8dd1ab0" contextRef="C_8624a3cf-a78d-4c1b-b918-bf5987be2150" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,470</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02e4f556-11e7-4f32-a8cc-5b60df18ec06" contextRef="C_230d7c39-9555-4903-a435-0134ba444e94" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,617</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73d69d51-09fc-4b50-8bbf-a7d0b8a20ce4" contextRef="C_206c187b-7d49-476f-aa68-2c6889189b8f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:35.42%;box-sizing:content-box;"/>
          <td style="width:1.52%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.020000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.52%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:14.440000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.52%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.020000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.52%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.020000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active Markets<br/>for Identical Assets<br/>(Level 1)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3870089b-e610-4452-a68e-82296e3a4b0c" contextRef="C_8aef1329-81e5-4652-81c2-c852b8d7cbfa" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,634</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb6cbd9b-e377-4945-951f-77e37b99a45e" contextRef="C_47fea706-96f6-4208-96a0-a6f66f6cd4b4" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,634</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d10dcf35-30b2-4fb6-829f-d92233d44053" contextRef="C_b4761317-427b-4343-a89f-5a138a161168" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_154b9651-fd7a-4a97-a8c9-5870a0030027" contextRef="C_8260baff-a8b4-45a6-baff-5209fef975bd" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7a0d805-30a4-4250-93b8-2a7b745f835c" contextRef="C_52dc384d-c584-4bd9-9b46-8ad7c00c3f6d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,634</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71678396-c6c4-4f68-9d36-b9c88e2ccc92" contextRef="C_a7cf1e88-d94b-419a-946f-6fef5bc3a6d5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,634</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04fbbcab-1fac-4651-9264-3e1b97d44f18" contextRef="C_8fdeb9c1-e391-4554-b8f2-1372cdb91313" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4d29b7f-8405-46ca-b5fc-3acbd9256f5c" contextRef="C_bf882905-b0ee-4b75-99c2-4fea38e7170e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level 1 inputs. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For debt securities classified as available-for-sale investments,</span><span><ix:nonNumeric id="F_0fb78e6d-f2d0-413e-a89d-dabc163151fb" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true" continuedAt="F_0fb78e6d-f2d0-413e-a89d-dabc163151fb_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Company records unrealized gains or losses resulting from changes in fair value between measurement dates as a component of other comprehensive income. The Company did not hold any available-for-sale securities as of December 31, 2024.</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0fb78e6d-f2d0-413e-a89d-dabc163151fb_1" continuedAt="F_0fb78e6d-f2d0-413e-a89d-dabc163151fb_2">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.17%;box-sizing:content-box;"/>
          <td style="width:1.66%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.283000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.66%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.283000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.66%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.283000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2af4e0cd-4a47-4cb5-9ca8-733c2b37d8f6" contextRef="C_44bcec1f-529b-4c9d-949c-c36ef0fc03f1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,512</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32c5dcbe-fc46-46ba-9722-4806983f5699" contextRef="C_44bcec1f-529b-4c9d-949c-c36ef0fc03f1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a750e98e-277e-44a6-8e60-813e27ce7aa5" contextRef="C_44bcec1f-529b-4c9d-949c-c36ef0fc03f1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,512</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb425be2-7b8e-4585-a52b-9feb34549674" contextRef="C_e4c08503-897b-4429-95f6-4ae813ed7f89" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,470</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43e6d4d4-f0f3-4d79-8570-7595d4597fa5" contextRef="C_e4c08503-897b-4429-95f6-4ae813ed7f89" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12d8c408-f984-40c1-8081-6aec59b2ea44" contextRef="C_e4c08503-897b-4429-95f6-4ae813ed7f89" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,470</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16c8695f-8ac0-482f-a655-221cacaa6b47" contextRef="C_95690f42-b502-4305-81ac-58e03c9072fa" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,982</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fc5ce7b-35f4-4f21-92cd-e3ba86002e1b" contextRef="C_95690f42-b502-4305-81ac-58e03c9072fa" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95b6453d-a4fd-4337-9646-e808f3ed1326" contextRef="C_95690f42-b502-4305-81ac-58e03c9072fa" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,982</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities - due in one year or less</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Included in short-term investments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acaac770-40dd-4510-b866-4f02298a9d36" contextRef="C_77952c23-092c-4512-8995-d28a63420b8a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,592</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8419a0b9-c8a9-41ef-8120-b78fc3114fa9" contextRef="C_77952c23-092c-4512-8995-d28a63420b8a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b00e883-2e9d-4a05-8934-556fadb671ba" contextRef="C_77952c23-092c-4512-8995-d28a63420b8a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,617</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_575e3285-55c6-43aa-87ed-8d1f64f6650d" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,574</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_976204a2-bcfa-429c-935b-456d43545c0a" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_664d9914-b834-4f01-afa4-441ee457c534" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,599</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:nonNumeric></div><div><ix:continuation id="F_0fb78e6d-f2d0-413e-a89d-dabc163151fb_2"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8abf6481-87af-442b-8de5-59f0f0f9c4a3" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Property, Plant and Equipment</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f84f2a08-2c1c-4252-bce6-1fc4ea85040e" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment consists of the following:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6865cd1-157e-47ec-b207-43c176e6d431" contextRef="C_079cb61a-3d40-45c2-80a6-92ffcd32eec0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,488</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2943582-2b0c-43c4-bd92-e00043e4792f" contextRef="C_7e3f7626-666d-4e8c-8445-9541d4f207e3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,663</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_996825bb-4c88-4594-b55e-1a74f2473d17" contextRef="C_b91d5295-ad40-4ba7-93e0-4f6e19c9bd4e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3600135a-17c0-4ecd-9ec6-850abf0ccb0a" contextRef="C_086e189e-9e52-4c9c-bd06-f74bb4383472" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3b7a53e-02f6-4843-b9df-ae95763d2151" contextRef="C_62c46a84-f119-4e55-9084-2d63a76277e0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">196</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebc18a1c-5344-4d12-b8ee-aea5f7bb5b76" contextRef="C_5923d687-6b09-4b10-ab7a-35a81dfd434d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">196</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47850371-bb20-4577-a166-4202ce8fb1f7" contextRef="C_cfcf9106-b91e-443d-b454-eae693a2da98" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2acbc5c4-4e83-4776-8f43-1987bd3973e2" contextRef="C_86c00fdd-0440-4c28-9ac0-005ffb97dc98" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property, plant and equipment</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fa4bd0a-a645-40e1-a091-743d87dc10ab" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,074</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c4f00e2-aa83-4688-8ed1-dc27d14f580a" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,249</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea36faa4-e8d3-4d56-a8de-d5fb3c4080f5" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,152</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_519fc079-0dc8-4c80-8152-a2d73460ec27" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,506</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property, plant and equipment, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcdbdcdd-b3a7-46c4-a88d-1cb2058ddb83" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,922</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dd54461-2a8f-4e86-8893-82de6d340424" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,743</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97afa9d4-f23c-4edf-a0f2-bad9653ad49c" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,646</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c7ff21e-8108-4d19-aaef-63fd313baae5" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,711</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_4b12ccac-47bf-4985-b52f-55f2c3f4614d" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Accrued and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e5c06651-2055-4a67-80c6-63bf59343514" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" escape="true" continuedAt="F_e5c06651-2055-4a67-80c6-63bf59343514_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued and other current liabilities consist of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.272%;box-sizing:content-box;"/>
          <td style="width:2%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:16.363%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:2%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:16.363%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e5827dc-0bf1-4d4c-a67f-035558b655b9" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,716</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9c3c0b2-15f8-449c-a056-8bfdcf068fb7" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,315</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trial research and development services</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9263f0f-f124-4c42-be66-f589aa82d77b" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="caba:ClinicalTrialResearchAndDevelopmentServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,335</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd2c00a9-07de-46b7-b116-e4c1dffaa10a" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="caba:ClinicalTrialResearchAndDevelopmentServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,236</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Manufacturing and other research and development services</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e665d1c7-430e-4c7c-b743-f44a7d19e7a0" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="caba:ManufacturingAndOtherResearchAndDevelopmentServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,774</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9cb739e-b94b-4966-8b68-73a0eddc89f1" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="caba:ManufacturingAndOtherResearchAndDevelopmentServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,255</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative services</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a537980-75ca-44ab-ad39-ca7863c3641c" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="caba:AccruedGeneralAndAdministrativeServicesCurrent" unitRef="U_USD" scale="3" decimals="-3">393</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11f58680-6862-4943-b35e-55696f400d1e" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="caba:AccruedGeneralAndAdministrativeServicesCurrent" unitRef="U_USD" scale="3" decimals="-3">342</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2ce2952-0467-4e9b-b5f4-d06698a26fda" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">80</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ace0bcb6-9981-4777-88d2-7ee426ba9c96" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">40</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a9f1d11-7775-49d4-b42c-caa5ce697c61" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,298</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce1329e6-81cb-4569-bb84-e1618782ad81" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,188</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_e5c06651-2055-4a67-80c6-63bf59343514_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_f84c25a1-0d29-4a7a-8237-72ec5b04485e" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" escape="true" continuedAt="F_f84c25a1-0d29-4a7a-8237-72ec5b04485e_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Collaborations, Licensing Agreements and Other Agreements</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated License Agreement with the Trustees of the University of Pennsylvania and Children&#8217;s Hospital of Philadelphia</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2018, the Company entered into a license agreement with the University of Pennsylvania (Penn), as amended and restated in July 2019 to include the Children&#8217;s Hospital of Philadelphia (CHOP) as a party, and as amended in May 2020 and October 2021 (the License Agreement) pursuant to which the Company obtained (a) a non-exclusive, non-sublicensable worldwide license to certain of Penn&#8217;s intellectual property to conduct research, product development, clinical trials, cell manufacturing and other activities, and (b) an exclusive, worldwide, royalty-bearing right and license, with a right to sublicense, on a target-by-target basis, under certain of Penn&#8217;s intellectual property to make, use, sell, offer for sale, import, and otherwise commercialize products for the treatment of autoimmune and alloimmune diseases. Unless earlier terminated, the License Agreement expires on the expiration or abandonment or other termination of the last valid claim in Penn&#8217;s intellectual property licensed by the Company. The Company may terminate the License Agreement at any time for convenience upon 60 days' written notice. In the event of an uncured, material breach, Penn may terminate the License Agreement upon 60 days' written notice. Under the terms of the License Agreement, the Company was obligated to pay $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9deff189-2904-49d6-894c-aa7725d281e6" contextRef="C_2a18d8f9-5332-4a23-b605-cb3d2126221d" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> annually for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_530bd16c-e4ac-4c05-9e15-681494f1fcb0" contextRef="C_26cba5b6-ff41-4da4-a18a-c184d569c17f" name="caba:PaymentOfObligationTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> beginning August 2018 for funding to the laboratories of each of Drs. Milone and Payne. This was satisfied through completed sponsored research agreements with a total cost of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_635a760d-2c74-4762-8eba-c1269677808a" contextRef="C_a412af93-e740-4e39-b6e6-1cea95e44cc4" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,560</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. During the term of the License Agreement until the first commercial sale of the first product, the Company is obligated to pay Penn a non-refundable, non-creditable annual license maintenance fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e39b83a-9dc5-4ffc-b412-53d8f7dcda33" contextRef="C_26cba5b6-ff41-4da4-a18a-c184d569c17f" name="caba:LicenseMaintenanceFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In May 2020, the Company paid Penn an additional, non-refundable, non-creditable license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f20b5ab3-4459-4a78-b987-982dc6835b59" contextRef="C_1246f5d0-6b41-48ca-8d69-6d21472a4329" name="caba:LicenseMaintenanceFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> under the amended License Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div><ix:continuation id="F_f84c25a1-0d29-4a7a-8237-72ec5b04485e_1" continuedAt="F_f84c25a1-0d29-4a7a-8237-72ec5b04485e_2"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to pay certain milestone payments upon the achievement of specified clinical and commercial milestones. Milestone payments are reduced by a certain percentage for the second product that achieves a milestone, by an additional percentage for the third product that achieves a milestone, and so on, for each subsequent product that achieves a milestone. In the event that the Company is able to successfully develop and launch multiple products under the License Agreement, total milestone payments could be approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c961d10-ab74-4113-a7b3-2c7945c09b3e" contextRef="C_26cba5b6-ff41-4da4-a18a-c184d569c17f" name="caba:MilestonePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Penn is also eligible to receive tiered royalties at percentage rates in the low single-digits, subject to an annual minimum royalty, on annual worldwide net sales of any products that are commercialized by the Company or its sublicensees that contain or incorporate, or are covered by, the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the License Agreement, Penn would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12174316-244e-4188-a7b1-25c92d7719d1" contextRef="C_2a18d8f9-5332-4a23-b605-cb3d2126221d" name="caba:CollaborativeAgreementPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amounts due under the License Agreement as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Master Translational Research Services Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2018 and February 2023, the Company entered into services agreements (the CAART and CARTA Services Agreements) with Penn for research, development and manufacturing services from various laboratories within Penn. The activities are detailed in separately executed Penn organization-specific addenda. In May 2020, the Company amended its Addendum with the Center for Advanced Retinal and Ocular Therapeutics (CAROT) to expand access to vector manufacturing.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expense recognized under executed addenda to the master translational research services agreements with Penn was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc8c38f6-9fa7-44a9-96c2-2418d5ad83cd" contextRef="C_ff686e3b-b5f7-498f-866d-a3514dd25fe3" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,062</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18863ca1-3705-4690-923e-37775d269194" contextRef="C_b7652f53-0a7b-4044-a278-9b0b094b3818" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,250</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively. As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0831f95b-1733-47e0-8199-86f93f4dd180" contextRef="C_ff686e3b-b5f7-498f-866d-a3514dd25fe3" name="caba:RemainingResearchAndDevelopmentExpenseToBeIncurred" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> remaining commitments under the CARTA Services Agreement.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exclusive License Agreement with IASO Biotherapeutics</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 7, 2022, the Company entered into an Exclusive License Agreement (the IASO Agreement) with Nanjing IASO Biotherapeutics Co., Ltd. (IASO). Pursuant to the IASO Agreement, the Company received an exclusive, worldwide license under certain IASO intellectual property to use a novel clinical-stage anti-CD19 binder to develop, manufacture, commercialize and otherwise exploit T cell products directed to CD19 for the purpose of diagnosis, prevention or treatment of any autoimmune or alloimmune indications in humans. As partial consideration for the exclusive license, IASO received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e61bede0-b95d-46e2-9c57-ebd235043e6c" contextRef="C_c776a8c2-6701-42d5-9906-29329e10a253" name="caba:UpfrontPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. IASO is also eligible to receive up to mid double digit millions in milestone payments based upon the achievement of specified pre-clinical, development and regulatory milestones, and up to an additional low triple digit millions in milestone payments based upon achievement of specified sales milestones, for a total consideration, inclusive of the upfront payment, of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3baa4ff1-b71c-4381-8346-3203600fb2a9" contextRef="C_0c2ad5d4-742d-4a38-be11-a6e3ac78b64f" name="caba:UpfrontPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, along with tiered mid-single digit royalties on future net sales for licensed products that may result from the IASO Agreement. Upon the U.S. Food and Drug Association&#8217;s clearance of the rese-cel Investigational New Drug application for the treatment of systemic lupus erythematosus in March 2023, a milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc76cc45-4b4a-47f1-9b72-3f12cda59ae1" contextRef="C_fff8e9a1-e956-45e4-b598-b1977fa3c367" name="caba:MilestonePayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was recognized in the accompanying statements of operations. A milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_376df2b7-9801-42bd-8e74-cd52a9595c29" contextRef="C_b7f6bbbb-6c89-48bc-8dc4-f9feb90a3989" name="caba:MilestonePayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was paid to IASO in the first quarter of 2024 after the first patient in a rese-cel trial was dosed.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IASO has the right of first negotiation if the Company desires to grant a third party an exclusive license to develop, manufacture, commercialize or otherwise exploit the licensed products in the Greater China region. Pursuant to the IASO Agreement, each of IASO and the Company have agreed, subject to certain exceptions, to refrain from engaging in certain competitive activities with respect to certain programs. The Company also may sublicense through multiple tiers the rights granted to it by IASO under the IASO Agreement at any time, however, it must pay IASO a low double-digit percentage of any revenue obtained from sublicenses or options to third parties, subject to certain customary exclusions. The IASO Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the IASO Agreement, unless earlier terminated. Each of the Company and IASO may terminate the Agreement for a material, uncured breach or insolvency of the other party. The Company may also terminate the Agreement at will upon advance written notice and in the event IASO rejects the Agreement due to bankruptcy-related matters. IASO may also terminate the Agreement if the Company fails to achieve certain specified diligence milestones in a timely manner and/or if the Company commences any patent challenges with respect to the patents and patent applications relating to the licensed sequence, in each case upon advance written notice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licence and Supply Agreement with Oxford Biomedica</span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_f84c25a1-0d29-4a7a-8237-72ec5b04485e_2"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2021, the Company entered into a Licence and Supply agreement (LSA) with Oxford Biomedica (UK) Limited (Oxford), wherein the LSA grants the Company a non-exclusive license to Oxford&#8217;s LentiVector&#174; platform for its application in the Company&#8217;s DSG3-CAART program and put in place a multi-year vector supply agreement. Oxford is eligible to receive regulatory and sales milestones in the low tens of millions and royalties in the low single digits on net sales of products that incorporate the Oxford technology. In May 2023, the Company amended the LSA with Oxford to expand the license to include the Company's rese-cel program for an upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c353442a-4933-469f-ad3e-55a7e4d6a070" contextRef="C_8a513f9d-25e1-4123-992e-02e1600e5c57" name="caba:UpfrontPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In August 2023, the Company and Oxford entered into a vector supply agreement for rese-cel, and a related second amendment to the LSA, with a total cost under the vector supply agreement of up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecec3570-0431-4157-acbd-93b3d0821b5b" contextRef="C_598dae7f-b88a-453f-bb9e-2b82884748a9" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which has been fully expensed as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024. In February 2024, the Company and Oxford entered into a third amendment to the LSA to update the patent schedule. In June 2024, the Company and Oxford entered into a fourth amendment to the LSA eliminating royalties on net sales of products that incorporate the Oxford technology if Oxford manufactures the vector. Starting in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2024, the Company and Oxford entered into work orders with a cost of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_410bfa13-d8cd-4ea2-a1dd-4fc4cd3be164" contextRef="C_daa2ae1c-8456-4d82-aeee-31d8df8ec889" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for certain process characterization and process performance qualification activities as part of commercial readiness activities. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has recognized project to date expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18ad6865-98bf-4c29-a53f-09664f3d6883" contextRef="C_daa2ae1c-8456-4d82-aeee-31d8df8ec889" name="us-gaap:OtherExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,673</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> related to these activities. The Company can terminate the LSA or any work order under the LSA at will upon advance written notice and subject to certain cancellation fees.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option and License Agreement with Autolus</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2023, the Company entered into an Option and License Agreement (Autolus Agreement) with Autolus Holdings (UK) Limited (Autolus), wherein the Autolus Agreement granted the Company a non-exclusive license to access Autolus' RQR8 technology in its CD19-CAR T cell therapy program, and subject to additional nominal option exercise fees, up to four additional t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">argets. In January 2025, the Company and Autolus agreed to novate the Autolus Agreement with both Autolus and Autolus Limited jointly assuming the rights, obligations and liabilities of Autolus, under the Autolus Agreement. Under the terms of the Autolus Agreement, the Company was required to pay Autolus an upfront license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6d2f075-f916-4387-beca-58f03df0ac2e" contextRef="C_257b7837-c492-46b4-8e4c-f8c32fc79674" name="caba:UpfrontPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that was recognized as expense in the first quarter of 2023 in the accompanying statements of operations, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_554237f9-ee21-43fa-9c05-c2ece619e90b" contextRef="C_8afc398a-f701-4181-b888-7da00743bdd1" name="caba:UpfrontPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was paid in 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b6950be-4598-4f0d-9bdb-101190abc33f" contextRef="C_e89f40c1-a23f-40a4-8bee-23bda33abf3d" name="caba:UpfrontPayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was paid in January 2024. Autolus is also eligible to receive regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_301476d6-0902-46dd-b745-5dd999966404" contextRef="C_39d08eb8-8fae-43b4-8fb0-2080c3f9bfa0" name="caba:MilestonePayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for each licensed target, sales milestones of up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c4bc1d2-572f-47d8-8de9-dbcd53200c61" contextRef="C_6f0d1f48-cee2-4ab8-ae48-a9a04ad2fe08" name="caba:MilestonePayment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and royalties in the low single digits on net sales of all products that incorporate the RQR8 technology. The Autolus Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the Autolus Agreement, unless earlier terminated. The Company can terminate the Autolus Agreement at will upon advance written notice. Each of the Company and Autolus may terminate the Agreement for a material, uncured breach or insolvency of the other party.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_28bfd0c5-92d5-4018-b852-98b0fe4f0b36" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_28bfd0c5-92d5-4018-b852-98b0fe4f0b36_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing Agreements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2021, the Company entered into a Development and Manufacturing Services Agreement (Minaris Agreement) with Minaris Advanced Therapies, LLC, or Minaris (f/k/a WuXi Advanced Therapies, Inc.) to serve as an additional cell processing manufacturing partner for the MuSK-CAART Phase 1 clinical trial, or MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial. The Minaris Agreement is scheduled to expire upon completion of Minaris' services related to MuSK-CAART and rese-cel. In August 2023, and as extended in August 2024, the Company entered into an agreement with Minaris to serve as one of the Company's manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and commercial readiness activities for rese-cel. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b8699db-1202-40fe-b1e4-7eacab256d24" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:InitialTermsOfAgreementDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the August 2023 work orders, Minaris converted the Company&#8217;s non-dedicated suite to a dedicated suite for GMP manufacturing for the Company&#8217;s rese-cel and MuSK-CAART programs, or the Dedicated Suite, for an initial term of 18 months with two 18-month extensions at the Company&#8217;s sole option on six months' notice prior to the end of the term. In August 2024, the Company sent a notice to Minaris to extend the initial term of the Minaris Agreement by 18 months through August 2026.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, the Company agreed to certain monthly minimum runs. In August 2024, the 2023 work order related to GMP manufacturing was amended to reduce the minimum monthly runs through the end of 2024. In lieu of the original $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2262e021-d71a-49d3-a1df-9f8f4c979223" contextRef="C_4e7202fb-fc1c-4811-8134-37c7e8ba4ea8" name="us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> termination fee under the terms of the Minaris Agreement, the Company would incur up to a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82aedeb9-3f06-4511-adfc-511b6233634b" contextRef="C_3a126bb1-aa0b-4ca4-9d54-2b0f17069a24" name="us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,080</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> termination </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fee if it terminates both the rese-cel and MuSK-CAART work orders for any reason. The Company may terminate for convenience the Minaris Agreement or any work order with six months' prior written notice. However, the Company may not terminate the Dedicated Suite without terminating</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_28bfd0c5-92d5-4018-b852-98b0fe4f0b36_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">both </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the MuSK-CAART and rese-cel GMP run work orders. Minaris may terminate for convenience the Minaris </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement or any work order on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_86dea01e-6700-4920-b7fa-97aedeb42783" contextRef="C_3a5e1afc-a743-4a56-b440-dbd774e83bda" name="caba:LeaseExpirationMonth" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">months' prior written notice, but such notice may not be effective prior to February 202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. In February 2026, the Company notified Minaris that it intended to permit the term to expire in August 2026.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the Company entered into a Development and Manufacturing Services Agreement (the Lonza Agreement) with Lonza Houston Inc. (Lonza) to serve as one of the Company's manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and preparations for commercial readiness. The Lonza Agreement has a term of five years and can be extended for an additional three year term upon notice to Lonza at least </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09119637-ddbe-406b-aadb-b342f45cd979" contextRef="C_7b8638c5-f1ef-4620-8819-259d96ac947a" name="caba:LeaseExpirationMonth" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">months prior to the expiration of the Lonza Agreement. The Company can terminate the Lonza Agreement at will upon nine months advance written notice to Lonza subject to the terms of the Lonza Agreement. Lonza can terminate the Lonza Agreement at will upon 24 months advance written notice to Cabaletta subject to the terms of the Lonza Agreement. Under the initial work order, Lonza will perform cell therapy manufacturing activities for Cabaletta&#8217;s CAR-T cell therapy product, rese-cel, for an initial term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a2b98cd-3dac-4342-946a-0527e371ace0" contextRef="C_7b8638c5-f1ef-4620-8819-259d96ac947a" name="caba:PaymentOfObligationTerm" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">months with the ability to extend the manufacturing period on a rolling basis subject to the terms of the Lonza Agreement.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Purchase Commitments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the normal course of business, the Company enters into various purchase commitments with third-party contract manufacturers for the manufacture and processing of its product candidates and related raw materials, contracts with contract research organizations for clinical trials and agreements with vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into certain types of contracts that contingently require the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i) the Company&#8217;s Amended and Restated Bylaws, as amended, (bylaws) under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship, (ii) contracts under which the Company must indemnify directors and certain officers and consultants for liabilities arising out of their relationship, (iii) contracts under which the Company may be required to indemnify partners against certain claims, including claims from third parties asserting, among other things, infringement of their intellectual property rights, and (iv) procurement, consulting, or license agreements under which the Company may be required to indemnify vendors, consultants or licensors for certain claims, including claims that may be brought against them arising from the Company&#8217;s acts or omissions with respect to the supplied products, technology or services. From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In addition, under these contracts, the Company may have to modify the accused infringing intellectual property and/or refund amounts received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may have a material adverse effect on the Company&#8217;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount under these contracts due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Litigation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may become involved in litigation or legal proceedings. While the outcome of any such proceedings cannot be predicted with certainty, as of December 31, 2025, the Company is not involved in any material litigation or legal proceedings that it would expect to have a material adverse impact on its financial position, results of operations, or cash flows.</span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div><ix:nonNumeric id="F_44168fb3-fe3d-491a-9736-057ab96f960a" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Segment Information</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the CODM in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is the CEO. The Company has determined it operates in a single operating segment and has one reportable segment. The segment consists of the development of clinical and preclinical product candidates for the discovery and development of innovative engineered T cell therapies and related administrative activities. The CODM assesses performance and allocates resources based on the Company&#8217;s consolidated statement of operations, which is reported on the income statement as consolidated net loss and considers forecast-to-actuals variances on a quarterly basis for expenses that are deemed significant. Further, the CODM reviews the segment&#8217;s assets based on the consolidated balance sheet to assess liquidity and funding capacity. The majority of the Company's assets are located in the United States.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s CODM views specific categories within expenses as significant given the direct correlation between cash burn and profitability as a pre-revenue company. Significant segment expenses, as provided to the CODM, are presented below. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_60655a41-2814-4071-b009-37f32178f1b2" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" escape="true" continuedAt="F_60655a41-2814-4071-b009-37f32178f1b2_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional information on the year over year change of segment expenses refer to Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_60655a41-2814-4071-b009-37f32178f1b2_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:57.12%;box-sizing:content-box;"/>
          <td style="width:2.1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:17.34%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:2.1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:17.34%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99783da7-5586-4880-ad89-55ec4a642833" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:PersonnelExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,934</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36d884e3-38a9-4394-af7d-0399ff2edb0c" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="caba:PersonnelExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,239</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trials</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1379d3a-ac41-48da-b060-78942b1d616a" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:ClinicalTrials" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,581</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31d50464-d5fd-4016-962c-53a8d5404c5e" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="caba:ClinicalTrials" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,286</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Manufacturing of preclinical and clinical supplies</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af200196-9993-44fb-becd-defad0322e59" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:ManufacturingOfPreclinicalAndClinicalSupplies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,240</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b7357ae-dd61-439f-a06a-7c951f6d33e8" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="caba:ManufacturingOfPreclinicalAndClinicalSupplies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,523</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development services</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_548280e2-624e-43b5-84df-52759aabaf96" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:DevelopmentServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,350</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_300add9f-e067-4594-94c4-97da800a4e81" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="caba:DevelopmentServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,417</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License of intellectual property</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0700414e-ba41-4329-b244-b59809f934fc" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:LicenseOfIntellectualProperty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ef6ea52-e0c6-4538-9b7a-400006921686" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="caba:LicenseOfIntellectualProperty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,523</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development costs </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d92528eb-7b2c-4ba7-8060-2a7ca155f441" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,569</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea99062d-d4be-49eb-bbc9-f6883b27d25f" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,215</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administration expenses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e22eb4e-ed4d-485d-968b-35d0b672f7d4" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,567</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8868e6c-2db9-44d7-ba4b-beed8d4b399e" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,938</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73c4df2d-0913-4542-8af3-fed2994e517a" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,031</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb4549b7-e1ea-4fed-baa6-2be63918af04" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,025</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baca9cdc-aaf7-4147-ba0f-9881d75a6637" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,004</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a27f2ae7-5a6e-4c12-86a2-60335724d98d" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">748</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7bb3598-7665-48ff-8ded-bc7c18b90f6f" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">358</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b6eed00-521d-46d1-830b-54e27676cd29" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2527d65c-b994-4258-8290-baaf8f86e594" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">167,856</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a19d82db-3832-4fa0-8eee-07cdfddaba00" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,864</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><ix:footnote id="FNT_a817dc11-a357-48c9-937a-02cf05c1a9c1" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.</span></ix:footnote></p></ix:continuation></div></ix:nonNumeric></div><div><ix:nonNumeric id="F_1bb3060e-498b-47c7-b5f8-6e71fa0467c8" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true" continuedAt="F_1bb3060e-498b-47c7-b5f8-6e71fa0467c8_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases office and laboratory space and has two manufacturing agreements that have been determined to include embedded leases.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating lease commitments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases office and laboratory space which include rent escalations and are subject to additional variable charges, including common area maintenance, property taxes and property insurance. Given the variable nature of such costs, they are recognized as expense as incurred. Additionally, some of the Company&#8217;s leases are subject to certain fixed fees which the Company has determined to be non-lease components. The Company has elected the practical expedient to account for lease and non-lease components as a single-lease component and has included fixed payments related to non-lease components in calculating the operating lease liability. The lease term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div><ix:continuation id="F_1bb3060e-498b-47c7-b5f8-6e71fa0467c8_1" continuedAt="F_1bb3060e-498b-47c7-b5f8-6e71fa0467c8_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for our laboratory space was extended in October 2025 through November 2026 resulting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in an increase of the right-of-use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8abadef-6987-4911-9b80-a1471dad5d29" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:IncreaseInTheLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">787</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Finance lease commitments - Embedded leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described further in Note 7, in August 2023, the Company entered into new work orders under the Minaris Agreement for Minaris to serve as one of the Company&#8217;s cell processing manufacturing partners for the global clinical development of rese-cel. Minaris converted the Company&#8217;s non-dedicated suite to a Dedicated Suite for GMP manufacturing for the Company&#8217;s rese-cel and MuSK-CAART programs, for an initial term of 18 months. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a6d8cca1-0618-4cb7-b561-7ed19d135eaf" contextRef="C_ed842e09-7bf5-4486-9ae9-cadd5f4e3ba9" name="caba:WorkOrdersTerm"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The terms of the August 2023 work orders included both fixed costs and contingent variable costs. The lease commenced October 1, 2023. In 2024, the Company remeasured the lease following the resolution of the contingency related to variable costs and an amendment to the 2023 work order, which extended the term of the agreement by an additional 18 months through August 2026. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may terminate the Dedicated Suite lease for convenience with six months&#8217; prior written notice and up to a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79e7e981-21bb-4dad-adb7-49eaa72118ae" contextRef="C_ed842e09-7bf5-4486-9ae9-cadd5f4e3ba9" name="caba:TerminationFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,080</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> termination fee if both the rese-cel and MuSK-CAART work orders are terminated</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2026, the Company notified Minaris that it intended to permit the term to expire in August 2026.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described further in Note 7, in December 2024, the Company entered into the Lonza Agreement with Lonza to serve as one of the Company's cell processing manufacturing partners. Under the initial work order, Lonza will perform cell therapy manufacturing activities for the CAR-T cell therapy product rese-cel for a term of 12 months with the ability to extend the manufacturing period subject to the terms of the Lonza Agreement. The Lonza Agreement was evaluated under ASC 842 and determined to contain an embedded finance lease commencing in March 2025, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">resulting in the recognition of a right-of-use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fd4bfa1-ffa3-4c43-9760-453b3d21a6aa" contextRef="C_ac256694-f886-4361-a4f9-4104adc42ab6" name="caba:IncreaseInTheLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,934</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2025, the Company extended the lease term in accordance with the Lonza Agreement resulting in an increase of the right-of-use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_394bc474-39f8-42c2-9466-cb0edf5d4d6f" contextRef="C_cd82e612-a082-48f2-92a1-6e1196a216e6" name="caba:IncreaseInTheLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,137</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of leases under ASC 842</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f32e4aa-8051-49ab-8a36-1f22d03c8a9c" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table contains information pertaining to the Company&#8217;s operating and finance leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2025 and 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.224%;box-sizing:content-box;"/>
          <td style="width:2.001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:16.387%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:2.001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:16.387%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance leases</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_854a8055-7028-4f7b-93d2-597e6a40853f" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,004</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5de6c51-2309-4ea2-8259-16173b53d01a" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:FinanceLeaseInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">748</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c2de715-32a5-48c9-bfe4-9fc197f4aea6" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:AmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,391</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9166b4e-2668-420b-a4c5-ba33df370d4b" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="caba:AmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,102</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fixed finance lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b333ce1d-54ae-47dc-8ed4-fe6ec650823a" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:TotalFixedFinanceLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,395</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8dc6cfb-faac-4fae-add2-61f225021954" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="caba:TotalFixedFinanceLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,850</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7068e2c-9496-430a-ad56-7b0c32d04c8b" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:VariableLeaseCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,508</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53ff1429-22cf-4245-95b4-110532f929e0" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="caba:VariableLeaseCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">930</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_373fc392-8c05-4de2-90b7-42c683241907" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:TotalFinanceLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,903</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a7e7833-cbed-4dd7-aa9a-01fce356f75d" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="caba:TotalFinanceLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,780</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating leases</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b432d8f-76b4-494e-8668-3c244cdec9bc" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:FixedLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,211</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2293155c-2489-4c11-a604-482af1f1090d" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="caba:FixedLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,247</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fixed operating lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb8dde73-5188-49cd-84fb-ad8a61823cf9" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,211</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_467ca1b4-9dcf-4e28-b388-4cb1618b0f19" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,247</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f99e93fe-10f0-43da-a889-4a70b03382bd" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">171</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ca2f902-b9e0-4d95-9db7-01f7f89858ef" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0fd8f7a-670a-4a1d-963c-70da60a69e44" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b060c207-1d2b-4166-8769-5480204a6e7b" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">750</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59fc16aa-8b45-4572-ab83-b689bd62430c" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,416</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_963e514b-f7bd-4f4f-8703-5007f25cecb1" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,293</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash paid in the measurement of lease liabilities</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows used for operating leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9326f8f-8791-40ed-8a25-d84b9bb4faa6" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:OperatingCashFlowsUsedForOperatingLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,227</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a39f2b90-ead1-4cbb-814b-c47adac0d34a" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="caba:OperatingCashFlowsUsedForOperatingLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,291</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows used for finance leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c9342b7-09bf-4d99-a0c1-7adfc1a06a25" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:OperatingCashFlowsUsedForFinanceLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,713</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c13918a-db93-44db-8051-2031b7dccd2b" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="caba:OperatingCashFlowsUsedForFinanceLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">748</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing cash flows for finance leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08ae1b11-c7d6-4f9f-b3fc-555ece156486" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:FinancingCashFlowsUsedForFinanceLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,261</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_397fbb12-0b00-4b2e-9089-2c187d0cd9df" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="caba:FinancingCashFlowsUsedForFinanceLeases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">897</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other information</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average remaining lease term - finance leases (in years)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_38f2601f-46c4-458a-b51e-2c7a3fdf30f7" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></ix:nonNumeric></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_21bf3441-3d5c-49d6-a0c7-f971c284b23e" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></ix:nonNumeric></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate - finance leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef7f8064-fdc7-4b4b-872d-b094e0c4885f" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">10.7</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d353294-0eb2-4eb9-9c4e-358c9065e48d" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.5</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average remaining lease term - operating leases (in years)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_6de51dca-456f-49e6-b75a-d3549281a010" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span></ix:nonNumeric></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_3fed4c2e-e587-42f3-9061-7641c599004d" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></ix:nonNumeric></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate - operating leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_707a6853-ba95-4379-847c-b6a49621484c" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">10.3</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d52503c4-f580-43e1-b071-24da1856dccb" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div><ix:continuation id="F_1bb3060e-498b-47c7-b5f8-6e71fa0467c8_2"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For finance leases embedded in CDMO arrangements, interest expense is recognized using the effective interest method, applying the Company's incremental borrowing rate as required by ASC 842, and amortization expense is recognized on a straight-line basis over the shorter of the life of the asset or the term of the lease.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d57d0fe-c8cd-46cb-90ad-9b93f64fba20" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true" continuedAt="F_8d57d0fe-c8cd-46cb-90ad-9b93f64fba20_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future lease payments under the non-cancelable leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 are as follows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:
<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance Leases</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating Leases</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93747e79-b533-4ea7-9b74-c1ad3e9d150d" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,914</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8be4089e-a2ba-4ddc-bcaf-cfb1eb3e70e1" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,633</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_561bb511-e92a-4ab8-9d76-ae7afc229f95" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,280</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_faf3a651-5e1b-4de2-ba40-ece4abadf4f8" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total undiscounted lease payments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98bf4a03-a695-4140-ad26-8e8023d369fd" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="caba:FinanceLesseeUndiscountedLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,194</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_091ab1bc-4b99-47a1-a99c-bc734d35a271" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="caba:LesseeUndiscountedLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,633</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less imputed interest</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2eb3dd14-3d0a-40f5-bcc7-8aa5f342a625" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,557</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22173212-5039-4e3a-9e6f-9a0723c1d776" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total lease liability</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eed694f6-b8b6-4aea-8830-1216752fc6c6" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,637</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebdaf7f0-684a-4db2-ac70-9153d2431787" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,461</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:continuation></div><div><ix:continuation id="F_8d57d0fe-c8cd-46cb-90ad-9b93f64fba20_1"></ix:continuation></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_24faf7e8-5b2f-4e3c-a3fc-477f704e437a" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" escape="true" continuedAt="F_24faf7e8-5b2f-4e3c-a3fc-477f704e437a_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Company&#8217;s Third Amended and Restated Certificate of Incorporation, as amended, the Company is authorized to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87b2f489-cf05-4982-a31d-27af14821d52" contextRef="C_522cbfa4-2c21-424d-9038-128e92ccffdf" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">293,590,481</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of voting common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc68b551-fda4-4ed1-b286-33c7c51a5d05" contextRef="C_3b4d07dc-82b8-43f1-b613-4a8e7b71d9a0" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,409,519</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of non-voting common stock. In May 2024, the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_798bc61a-7822-45ff-873b-e1974e552a50" contextRef="C_5f4640a1-b6f6-4783-b105-897dd65c4d00" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,444,295</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of non-voting common stock were converted to voting common stock and no shares of non-voting common stock are outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">June 2025 Financing</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2025, the Company issued (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_669c497e-a0cc-4c29-8658-22010f0edc0a" contextRef="C_abd6b14f-1396-44f4-b7be-b17c6ae488c3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">39,200,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock and accompanying warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ea07131-b184-43eb-8ec6-c48ba30a605a" contextRef="C_34daf3e1-57d3-4a11-a83e-a499f1e0f442" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">39,200,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7964875a-8a75-47ce-a49c-943634807a7f" contextRef="C_e7b46819-cb47-4a65-abeb-52c116bdf1ac" name="caba:PreFundedWarrantsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">10,800,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock and accompanying warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d55cdeb-e7b7-4166-8021-2d6eadc9824d" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:PreFundedWarrantsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">10,800,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59a369e5-d7d7-4bc1-9efc-f3e5a510fd62" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="5" format="ixt:num-dot-decimal">0.00001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant. An additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b213839-c9a6-4091-94f7-33dce0104cca" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,090,190</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common stock warrants were issued in the financing for shares purchased by the underwriters in the market to cover overallotment demand. The combined offering price of each share of common stock and accompanying common stock warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb8bc065-3e74-419e-b815-dab3b1dd1454" contextRef="C_0bea9175-88d0-41db-856a-9e2da9edda2e" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The combined offering price of each pre-funded warrant and accompanying common stock warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ce028a0-8491-4916-8691-0a544d99e891" contextRef="C_53f6eed2-717f-409c-9e2e-aeb5ff23e199" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="5" format="ixt:num-dot-decimal">1.99999</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The pre-funded warrants are exercisable immediately. The common stock and pre-funded warrants were sold in combination with an accompanying common stock warrant to purchase one share of common stock (or a pre-funded warrant in lieu thereof) for each share of common stock or pre-funded warrant sold. Each common stock warrant has an exercise price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ece243c0-ec13-40fb-86ec-485843de019f" contextRef="C_34daf3e1-57d3-4a11-a83e-a499f1e0f442" name="us-gaap:WarrantExercisePriceDecrease" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The common stock warrants are immediately exercisable from the date of issuance and will expire on September 12, 2026, fifteen months from the date of issuance. Aggregate net proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_700f1eda-349f-4405-8ef6-ae0d5321b7d2" contextRef="C_34daf3e1-57d3-4a11-a83e-a499f1e0f442" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">93,558</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after deducting underwriting discounts and commissions and offering expenses. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c13b0b73-7357-4092-bff0-a9de6e61a37f" contextRef="C_34daf3e1-57d3-4a11-a83e-a499f1e0f442" name="caba:PreFundedWarrantsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,800,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants had been exercised and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43821615-ebf6-45d7-b52e-306d5e4a8419" contextRef="C_53f6eed2-717f-409c-9e2e-aeb5ff23e199" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> remain outstanding. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, no common stock warrants had been exercised and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1480babe-658a-4886-9fd1-e2e78bc42128" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">53,090,190</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> remain outstanding. Subsequent to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9aebb9e-7811-4d58-a5a2-2b1ef0fd301a" contextRef="C_abd6b14f-1396-44f4-b7be-b17c6ae488c3" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,775,100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common stock warrants were exercised for proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b67efd7b-1f5a-4d07-a30c-2e29491dbe6b" contextRef="C_abd6b14f-1396-44f4-b7be-b17c6ae488c3" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">6,938</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded warrants and common stock warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants and common stock warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria. In addition, such pre-funded warrants and common stock warrants do not provide any guarantee of value or return.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-the-Market Offering</span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div><ix:continuation id="F_24faf7e8-5b2f-4e3c-a3fc-477f704e437a_1" continuedAt="F_24faf7e8-5b2f-4e3c-a3fc-477f704e437a_2"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 31, 2025, the Company converted the Form S-3ASR to a Form S-3 (File No. 333-278126) by post-effective amendments. This Form S-3 was declared effective on March 31, 2025. The Company had a Sales Agreement with TD Securities (USA) LLC (as successor to Cowen and Company, LLC) (TD Cowen) to provide for the offering, issuance and sale of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36030fdd-73c8-474e-a1b1-eec2768c9631" contextRef="C_a37aa587-2f96-418b-936d-2a9c780d2b31" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of common stock from time to time in &#8220;at-the-market&#8221; offerings (2024 ATM Program) pursuant to its S-3, and subject to the limitations thereof. On June 11, 2025, the 2024 ATM Program with TD Cowen was terminated. Prior to termination, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8c99599-b1de-42b1-a2e7-75256dc37194" contextRef="C_95be2256-2ce7-4d09-8e55-757a475e082c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,609,865</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares pursuant to the 2024 ATM Program for total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_377fd149-106a-4271-86dc-b6e318b6b305" contextRef="C_95be2256-2ce7-4d09-8e55-757a475e082c" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,724</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, consisting of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79219b52-2c4a-4c9f-b8f2-f52be50d449b" contextRef="C_f4a1bbdb-8974-49d9-84ce-4c03b4cc5207" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,129</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in 202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30e9a2ec-217e-4f13-918f-796ccefc21b7" contextRef="C_1535e593-36e6-42c7-88b6-f44cc18d20a0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,595</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in 2025.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 7, 2025, the Company filed a Registration Statement (File No. 333-289339) with the Securities and Exchange Commission (SEC), which was declared effective on August 15, 2025 (2025 Shelf Registration Statement), in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, the Company&#8217;s common stock, debt securities or other equity securities in one or more offerings. The Company also simultaneously entered into a Sales Agreement with TD Cowen to provide for the offering, issuance and sale of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5c01a0f-8bc5-440f-8f99-2eb7034142f1" contextRef="C_281e3d4d-125e-4a9b-80b5-a01331ef864c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the Company's common stock from time to time in &#8220;at-the-market&#8221; offerings (the 2025 ATM Program) under the 2025 Shelf Registration Statement and subject to the limitations thereof (the 2025 Sales Agreement). During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbddf141-5375-47ce-910f-feed5ae5d297" contextRef="C_53241714-a77e-447f-a6cb-6e14c8221a31" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,160,176</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares pursuant to the 2025 ATM Program for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd37d6ea-0557-4a93-8d3b-98e7a3a52d15" contextRef="C_53241714-a77e-447f-a6cb-6e14c8221a31" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,151</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subsequent to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f55d032f-afad-490c-868d-0110d5b53260" contextRef="C_3ffe9587-1afc-4c50-9fc3-01d795f0f236" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,055,260</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional shares, for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_074acb03-504f-4b58-aff4-689b957b082f" contextRef="C_3ffe9587-1afc-4c50-9fc3-01d795f0f236" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,568</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2018 Stock Option and Grant Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2018, the Company adopted the 2018 Stock Option and Grant Plan (the 2018 Plan), which provided for the Company to sell or issue common stock, or other stock-based awards, to employees, members of the board of directors and consultants of the Company. The Company generally granted stock-based awards with service conditions only (service-based awards), although there was one grant with performance conditions. As of December 31, 2020, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f33b4ce7-3264-4fab-b961-d8c2b763358c" contextRef="C_861b1b33-e760-4f7d-921f-9f81e9699673" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unvested options with performance conditions. Stock options granted under the 2018 Plan generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d6a034d6-bb46-42f3-a934-8529b7b3bdda;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a82376ac-9919-40eb-9ce2-78409f33e2d0" contextRef="C_aa89a8f6-fbbc-4204-881f-c09f6fd89717" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b71f145b-0274-4ab1-8b02-376a6c673584" contextRef="C_28aa1ca1-487f-4ec6-a7ce-bf5b8437c05e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,959,411</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> options were granted under the 2018 Plan prior to the Company&#8217;s IPO in October 2019. No further grants may be made under the 2018 Plan subsequent to the IPO.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 Stock Option and Incentive Plan</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2019 Stock Option and Incentive Plan (2019 Plan) was approved by the Company&#8217;s board of directors on October 14, 2019, and became effective on October 23, 2019. The 2019 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#8217;s officers, employees, directors and consultants. The number of shares initially reserved for issuance under the 2019 Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98e990f4-be0d-4c4c-9d37-01a788dd89d9" contextRef="C_f7fa1328-feb2-4be1-8511-2b7650cd1cce" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,342,288</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which will be increased each January 1 thereafter by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bec31805-08b6-4d11-9011-8e2570400b33" contextRef="C_9b692d20-2d25-4b0c-9112-df05af5b8f14" name="caba:IncreaseInShareReservedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&#8217;s board of directors or compensation committee of the board of directors. On June 1, 2023, at the 2023 Annual Meeting of Stockholders of the Company, the stockholders of the Company approved Amendment No. 1 to the 2019 Plan, increasing the number of shares of common stock reserved for issuance under the 2019 Plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5177e6b-9b76-43ac-828b-322a5cadd590" contextRef="C_a5bfe75d-e5fd-47a2-9113-a7d3d374a0e7" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. On January 1, 2026, the total number of shares under the 2019 Plan was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1d55460-0d18-48f0-86b4-4717fc7120f9" contextRef="C_1308d5b8-718f-4b53-9940-2c08e1043f52" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,019,172</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares pursuant to the 2019 Plan Evergreen Provision. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b08c8298-c3f2-4f2a-8e5b-b9d771825114" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="caba:SharesRemainingAvailableForIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,066,471</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remaining available for issuance under the 2019 Plan.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2025 Inducement Plan</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, the Company adopted the 2025 Inducement Plan (Inducement Plan). The Inducement Plan was adopted by the Compensation Committee of the Company&#8217;s board of directors without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4). In accordance with Rule 5635(c)(4), awards made under the Inducement Plan, including stock options and restricted stock units, may only be granted to newly hired employees as a material inducement to accept employment with the Company. Stock options granted under the Inducement Plan expire no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div><ix:continuation id="F_24faf7e8-5b2f-4e3c-a3fc-477f704e437a_2" continuedAt="F_24faf7e8-5b2f-4e3c-a3fc-477f704e437a_3"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">later than ten years from the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The number of shares reserved for issuance under the Inducement Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42ba35c4-d2e8-417e-a9cc-68c3fdaa23cd" contextRef="C_5622934b-004c-469d-b5bd-42fbf445d82b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">275,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, there were no shares available for issuance under the Inducement Plan.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Repricing</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 19, 2025, the Company&#8217;s Board of Directors approved the repricing of certain outstanding vested and unvested stock options. Pursuant to the repricing, all options granted under the 2018 Plan and 2019 Plan held by current employees, non-employee directors and certain consultants were repriced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b893ede-1910-493e-8b33-89078a56d37d" contextRef="C_16102a2e-2a9b-4c06-88d6-cd190d09c7a0" name="us-gaap:StockOptionExercisePriceIncrease" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.92</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the closing price of the Company&#8217;s common stock on May 19, 2025, to the extent such options had an exercise price in excess of 1.5x the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_313dfe9a-eb2f-4cb4-b8c7-8cf65a2090e3" contextRef="C_16102a2e-2a9b-4c06-88d6-cd190d09c7a0" name="us-gaap:StockOptionExercisePriceIncrease" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.92</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> closing price per share. To exercise the repriced options at the reduced exercise price, eligible participants must remain employed with the Company through a retention period of 12 months that begins on May 19, 2025.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the repricing, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6600a1e8-26fe-45f7-82d9-6bc961549827" contextRef="C_6d087c0e-36a2-45cb-b85c-7485d4eed9e0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,900,096</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vested and unvested stock options outstanding as of May 19, 2025, with original exercise prices ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f39bc7a2-cf50-48a4-b43b-a0e245b0b60d" contextRef="C_dd8bc73d-ffbf-455c-a0b5-28fd1d7b9c00" name="us-gaap:StockOptionExercisePriceDecrease" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.88</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_309fddac-3328-4a8c-bab0-bcdfd333d548" contextRef="C_ce88c5ac-13e2-456a-a311-22121b1635b4" name="us-gaap:StockOptionExercisePriceDecrease" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">23.97</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, were repriced. The repricing resulted in incremental stock-based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87c25c75-dce8-4a7f-945a-5db139d4976f" contextRef="C_f804a965-6bd2-440f-a975-8966b026c5f8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">3,021</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93fd81a2-5072-4cc8-952e-87d1bb857a1b" contextRef="C_66b45ca8-e68d-4849-8c5f-5bbff16e963f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,813</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> related to vested stock option awards and is being amortized over the retention period, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_263772e6-710a-47fa-8bd2-22f6114536be" contextRef="C_344f4aad-150b-49f4-ab92-dffefb18753f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,208</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> related to unvested stock option awards and is being amortized on a straight-line basis over the remaining vesting period of those awards.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Activity</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0894dc2d-c269-4979-b1d2-937f2a62243b" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of stock option activity is presented below:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:33.84%;box-sizing:content-box;"/>
          <td style="width:1.18%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.6%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.66%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.120000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.18%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.64%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.66%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:13.120000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (years)</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of January 1, 2025</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28f881cc-8d17-4d81-8cde-0f06e00a029e" contextRef="C_f9e49f68-10ed-47f9-abad-85f88ab41fed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,231,148</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9e68f48-16ac-48e9-a196-ca01bc017555" contextRef="C_f9e49f68-10ed-47f9-abad-85f88ab41fed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.63</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_3762cc34-96fa-4d3d-93a3-a12b8ee69c03" contextRef="C_344e5b09-4b43-4e4c-aece-b1dccaea79db" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></ix:nonNumeric></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84809593-766c-4e4f-921c-01b456a76dd6" contextRef="C_f9e49f68-10ed-47f9-abad-85f88ab41fed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">989</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adb428e1-3e80-4340-9d39-b41e6b3261e7" contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,469,050</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd88b983-a9d1-402b-abf4-72008a80eafd" contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.78</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_742dea64-0c0f-4787-a5af-9b3107630115" contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,334</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e127737-dbcb-4e43-8404-99aeae424e1d" contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.01</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddbbaca2-d4f5-499b-a90f-cbf5c904658c" contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_428c27b9-d651-457f-9999-c7f4adb49bec" contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">851,492</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fc57670-68c2-40ed-aa05-239005c777b4" contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.29</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_125142a9-05d7-4292-b1bc-84d64f91a484" contextRef="C_27282b93-17b5-4ddf-b071-79f5ec3755de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,835,372</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e53e7da2-e18c-4919-92a9-0a8e1378d3ec" contextRef="C_27282b93-17b5-4ddf-b071-79f5ec3755de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.57</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_76c435a1-72b8-4a26-ab91-8647c569896c" contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.1</span></ix:nonNumeric></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24b538e9-4d41-4e26-9cb5-05ac1e543de0" contextRef="C_27282b93-17b5-4ddf-b071-79f5ec3755de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,371</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options Exercisable at December 31, 2025</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df429972-fbfa-4028-9af2-ba0226d1bcb2" contextRef="C_27282b93-17b5-4ddf-b071-79f5ec3755de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">7,860,610</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9761809e-1865-40ba-8285-293bc8977423" contextRef="C_27282b93-17b5-4ddf-b071-79f5ec3755de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.45</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8d9bcdc3-3b1a-4602-aa78-c568e5f12bdf" contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.8</span></ix:nonNumeric></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7ca623a-0882-47ef-85cf-be529169c529" contextRef="C_27282b93-17b5-4ddf-b071-79f5ec3755de" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">899</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><ix:footnote id="FNT_81b3b034-bf57-4e0a-a22f-af0f469cef56" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average exercise prices and aggregate intrinsic values in this table will not reflect the impact of the May 2025 repricing until the retention period is complete in May 2026.</span></ix:footnote></p></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock. The weighted average grant-date fair value of stock options granted during the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_397e69a9-a6c2-45c5-bab0-b1afdc4afce8" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.52</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbc8e038-9b68-4135-a338-ec7211752a48" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.44</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_305beabf-0ef4-487a-a051-bfd332fcf710" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each award is estimated using Black-Scholes based on the following assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:53.049%;box-sizing:content-box;"/>
          <td style="width:1.8%;box-sizing:content-box;"/>
          <td style="width:21.676%;box-sizing:content-box;"/>
          <td style="width:1.8%;box-sizing:content-box;"/>
          <td style="width:21.676%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6de4eb7e-87b8-4167-b589-d6f9f1c2fe77" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.72</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0823b432-8e3c-4cf4-8d18-d35a29935b93" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.46</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b716806-15a2-4d73-92cb-91cc546147da" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.43</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c8d6d69-9683-4d59-a1a4-ad9df9f8f1e8" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_a771ca15-1b0a-403f-832e-5930e72af6af" contextRef="C_0dc245ae-95a8-4120-80e6-fdc0fc50dc5b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years&#8212;</span><span><ix:nonNumeric id="F_96829827-e0c1-4bc7-acd7-c080514f672d" contextRef="C_68400128-05f8-412b-8bce-a9b588eb4efa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_7e611fb2-2c44-4fe3-8329-f6a2258faee5" contextRef="C_90e4ec5b-1296-4608-ba2a-60bd4683d74f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years&#8212;</span><span><ix:nonNumeric id="F_6348024d-3b03-4da6-aba2-97ee3867a0b1" contextRef="C_9110b0c0-85f9-4944-8142-2673163f54ec" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a234c06b-4ca4-4fb9-987f-82eda4210f62" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">112</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69857f92-feec-4ec6-b2cf-58a250d4a3e9" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">118</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd02d351-97a0-4a47-bdb2-227a411dbf38" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">106</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_418a6345-d04d-4de5-ae3c-cd0f09fc1fa3" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">111</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b5e1c50-1223-4b70-a499-94bc6fa5a542" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8991adaa-c078-4407-a30f-b8f8cbeb070f" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method, which is the midpoint between the vesting period and the contractual term of the option.</span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_24faf7e8-5b2f-4e3c-a3fc-477f704e437a_3"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Expected volatility is estimated using the Company's stock price since its IPO in October 2019.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of a stock-based award.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected dividend</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0c7bb0b-34f9-43a4-8dcd-e211fdeaa76c" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has recorded stock-based compensation in the accompanying statements of operations as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fe8cc25-b293-453b-aab0-ff6f7cebd34a" contextRef="C_bbae0f84-acad-4f21-9dc4-943f64e17a13" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">11,470</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15bf36e8-f384-4679-8c72-ab829ec34d59" contextRef="C_8b9c77dd-2189-4362-bddb-fa1398cd7baf" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">10,163</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3976aef-fbb0-4fca-8610-723067272186" contextRef="C_81d87e23-aacc-4a1f-bb17-8d1d063bc827" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">9,469</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cccf6ab5-bbf3-4de1-835b-055c278a90ec" contextRef="C_141635e9-25cf-411e-813a-935f24e93c8e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">9,302</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94b151de-fa48-4b29-8b3e-c7aa6706d51c" contextRef="C_3a1c09a0-02a7-4e33-a36d-e454e4730213" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">20,939</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5199d807-616f-4eb3-b850-cd5947ff3d29" contextRef="C_80a04733-0f39-46fd-b536-fb1363c8d09a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">19,465</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39e32d22-755e-4e06-97df-98ee990ca5c4" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">35,159</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of unrecognized compensation cost related to unvested option awards and vested option awards subject to the twelve month retention period, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d956b69-3881-4468-adbc-5c2762cf8c8d" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 Employee Stock Purchase Plan</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2019 Employee Stock Purchase Plan (2019 ESPP) was approved by the Company&#8217;s board of directors on October 14, 2019, and became effective on October 23, 2019. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_355b6116-dcc3-4fe9-b048-8c6cff15b3c1" contextRef="C_a76bf89e-0076-44be-bb89-64f8a0be9373" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">234,229</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were initially reserved for issuance under the 2019 ESPP, and such number of shares will be increased each January 1 thereafter through January 1, 2029 by the least of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b43dc70c-ea66-4570-b99f-08f85bafacc6" contextRef="C_ccb31ebd-a7c1-4540-8895-81d30d0fcefb" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">234,229</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a15d49ba-30f2-4a41-8268-6d1e8c06551d" contextRef="C_8d6d69e2-dda1-4ea0-94e8-32274096c469" name="caba:IncreaseInShareReservedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31 or (iii) such lesser number of shares determined by the 2019 ESPP&#8217;s administrator. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 1, 2026, the total number of shares available under the 2019 ESPP was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e56f0c2e-2f68-4543-99be-0a66e9f79021" contextRef="C_024369a9-8747-4977-86bc-392c39212422" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">234,229</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares pursuant to the 2019 Plan Evergreen Provision. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03951777-a386-49dc-b405-e6402c945a1e" contextRef="C_22909102-0e37-4650-b154-28e36d4712cc" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">136,383</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remaining available for issuance under the 2019 ESPP.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee contributions are made through payroll deductions of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b426a4c-d67b-47d8-a4a0-5a1c30652f83" contextRef="C_63066961-ec40-4822-b55c-b127b3bbe2fc" name="caba:PercentageOfPayrollDeductionOnEligibleCompensation" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of eligible compensation over the offering period. A participant may not accrue rights to purchase more than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44bf8795-5db4-469e-a6ff-702ff73f4cb0" contextRef="C_63066961-ec40-4822-b55c-b127b3bbe2fc" name="caba:EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding. At the end of each offering period, shares of the Company&#8217;s common stock may be purchased at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28084e2f-f1ed-47b5-8309-1d4228911278" contextRef="C_63066961-ec40-4822-b55c-b127b3bbe2fc" name="caba:PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lesser of the Company&#8217;s common stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period. Each offering period will be six months in duration and will commence on each December 1 and June 1.</span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div><ix:nonNumeric id="F_c7e29131-212f-477c-b7b1-dfc7ccce31c2" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_c7e29131-212f-477c-b7b1-dfc7ccce31c2_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e4ea1660-34d3-4023-bb68-0e0351098dd6" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reconciliation of federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:51.379%;box-sizing:content-box;"/>
          <td style="width:1.679%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.035%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:6.977%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.679%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:9.036000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:7.216%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Statutory Tax Rate</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ed2dbc6-ca7c-49cc-915f-1c32d67ab8e1" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,304</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e972b140-9343-421b-8c56-77e4d17595d8" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e5ce6e8-190b-4e3e-932c-6386c80bbac3" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">24,331</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1602532f-b5da-4027-ad11-da5d6ad2baa9" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and Local Income Taxes, Net of Federal Income Tax Effect </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff4b9c29-de45-4861-b7a3-e7d6162129c9" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bcd57e1-e3fd-44e0-b5d3-f0238dc5238e" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7161c44-d327-4a04-b67c-59b4ab1359a9" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baeb6475-4eeb-4dc6-8b63-3cb09f80023e" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign Tax Effects</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a778a45-1ff8-49a0-b0c7-b57da6ae2760" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee07fbe4-a5d7-402e-9d5e-df87ca273d25" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1eb6c5e0-15be-4272-8efd-3bb6d297de01" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bee05e2-6a3b-4d76-8472-71df3fba103e" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of Cross-Border Tax Laws</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_735fa2ae-70a7-4bca-b67a-b1946356f745" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f361c478-428e-4368-83b1-3608d806c9fb" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35379415-995b-4710-aa5b-04f4d5ead147" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef224295-2408-475d-964e-a937ef863660" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Credits</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdc5fb1c-a879-4c27-9514-cb2fbc2bfe0b" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,489</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f03756f-c91f-4b52-83d6-73b76c79fb35" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">5.6</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67864d40-6293-4647-b911-8c064299c7df" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,769</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86ee114b-1a0a-4f48-9a69-e97ad023b94f" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in Valuation Allowances (Domestic)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f15ba88-677f-4cc8-9ec4-2a5329ad3344" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:IncomeTaxReconciliationTaxContingenciesDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,489</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a146cb86-ded9-4a44-8acc-4542bc14746d" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">25.9</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd8b1729-02e5-4a53-ba81-a2973cc03f3f" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:IncomeTaxReconciliationTaxContingenciesDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,176</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f937f475-f566-4493-aede-9961179a50d5" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">25.2</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or Nondeductible Items</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59eb30a5-4811-42a4-bd4d-d627d277bbc5" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">983</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b84e29e-f7cc-4a0e-be33-cd159466fff8" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0b89267-23fd-4ff4-ba46-c03e8f25f298" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">951</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae92f9dd-4cb5-43cb-8e09-3cf3359984c4" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other Adjustments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7ea2e88-3838-4c00-ae0d-535ac1352b47" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">203</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc6f4b63-b9cd-4a00-b9f4-19cb8085d5da" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a51b821-7b28-47dd-b029-d4d75de95750" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20f7ac60-4a97-4013-aaae-628c7ae0a35c" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Actual income tax benefit effective tax rate</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce9cccbe-4ea7-40c9-b81f-1cfd5d4382ec" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0e17926-5820-4311-87cb-59d1450d2e06" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b2804d7-1d30-494e-8956-252f430c1dc0" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8df79e82-fc0e-45fd-8f63-cbf7448a9816" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><ix:footnote id="FNT_7b1988d3-18b3-4e45-95d7-cf5f32b934e9" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within the State Income Tax category, Pennsylvania and Philadelphia accounted for the majority, representing over 50% of the total reconciling impact.</span></ix:footnote></p></ix:nonNumeric></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consistent with the Company&#8217;s cumulative loss position and absence of taxable income in federal, state, and local jurisdictions, the Company made no income tax payments and received no income tax refunds in the current fiscal year.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span><ix:nonNumeric id="F_94237748-569c-4c17-bb95-641bdee37c60" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_94237748-569c-4c17-bb95-641bdee37c60_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal components of the Company&#8217;s deferred tax assets and liabilities consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_94237748-569c-4c17-bb95-641bdee37c60_1">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:56.257%;box-sizing:content-box;"/>
          <td style="width:2.159%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:17.712999999999997%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:2.159%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:17.712999999999997%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal, state and local net operating loss carryforwards</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3600340b-45af-4da4-9a85-ea11c0024494" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,014</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ef6af83-0cd7-46bf-998d-44861b5c1c5b" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,369</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development costs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0eb3cc28-0c59-4b8a-bc46-bd7e1b2d985d" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="caba:CapitalizedRDCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,333</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7be5d29a-d460-4b18-b025-c91f4db0c518" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="caba:CapitalizedRDCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,646</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc185ee3-4f39-4d9e-b5a3-4765b977cc0f" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,050</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83795f5c-15f8-46ce-b2b4-1dcf4b62c03d" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,296</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation deductions</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92301624-ddf4-44cc-bb2a-fb098a491d65" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,299</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f45cdc71-cf79-4739-9875-08f6b1869edc" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,919</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License fee deductions</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_209a0d10-bee1-442d-bc05-378b119fc282" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="caba:DeferredTaxAssetsLicenseFeesDeductions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">186</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9832d3ae-4d38-4900-9b4e-92a672d2246d" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="caba:DeferredTaxAssetsLicenseFeesDeductions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">221</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d0e3026-ef9b-4135-b392-24812b13f188" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="caba:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,357</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89277a1a-4e56-4a14-8268-c86e522e8e34" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="caba:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,607</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51ecac8a-07cf-4a56-9e30-df24d2fa6d55" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,805</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_848bf0a8-e3d9-40a9-b894-0ed573df3e7e" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,603</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax assets</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efb4c9fa-fb92-43e3-9e3d-9381ef12befc" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,044</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d997f921-7beb-4b1f-9eab-677e1f8b3013" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,661</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a0acd04-86a0-4ba2-a4b8-7393a7431ccc" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,850</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab1df6fa-53d5-448c-871e-bede4e9926bb" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,723</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d29a4ad-1eb2-4cd3-a738-ff13f9f70bdf" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,194</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f298182-7c75-429c-a66f-98504346526b" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,938</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcec5997-d438-4bd8-ae63-522e34000dfa" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="caba:OperatingLeaseAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,194</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2e7e4b9-10dd-4d24-a51d-4b11632f1040" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="caba:OperatingLeaseAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,938</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efc067d8-8755-49eb-93b2-3edb4a5151d6" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4c024de-d943-45b1-8eb1-4d2d65361368" contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company increased its valuation allowance by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e3d88a5-ee94-4ece-926d-da05cbd20ac8" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,127</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the year ended December 31, 2025 in order to maintain a full valuation allowance against its deferred tax assets. Based on the Company&#8217;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December 31, 2025. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal, state and local net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db573bb5-9802-4e78-9949-fc9e97c355bc" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">319,886</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1bbb5dc-20b2-465b-8e13-9705e055be7a" contextRef="C_b2015ae2-7987-46fd-9f1a-14a53e158ee2" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">255,101</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2465898-cd50-48db-9257-e27d8e4c3159" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257,607</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_835550a9-6649-48fe-8c75-870dc32719dc" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">319,636</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the federal net operating losses do not expire, and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2de8b241-f70e-4a6c-bd55-b4b0077f0a6f" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">250</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b1470ce0-a832-4040-8d52-6bec43177e59" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:OperatingLossCarryforwardsStateCommencementOfExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The state net operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d06a8c9-9b75-4914-a3eb-a4888a7c5ff7" contextRef="C_ad2a1234-93ce-48dc-96ba-3cf1de4b7bff" name="caba:DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The local net operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8c8a6bb7-1a6c-466e-ad76-efd3fa88c3c6" contextRef="C_a2620028-ec6f-4274-a235-71be3c62c04d" name="caba:DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2042</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal and state research and development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06389d5a-d3f3-4bb2-be15-8a2b49b3f2ad" contextRef="C_88a0af93-4579-4bef-b89d-e83437cf1886" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,044</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93ea6c2e-ace2-4c6e-ab5f-1fe9c17719a0" contextRef="C_b2015ae2-7987-46fd-9f1a-14a53e158ee2" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. The research and development credits begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a4e288b-dc1e-4cd3-bf51-1ff9bf877e9b" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2038</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s federal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_c7e29131-212f-477c-b7b1-dfc7ccce31c2_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">research </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">credits consist of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09d4139d-10d6-49f5-a5c9-e8d299d52fd3" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="caba:ResearchAndDevelopmentCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,821</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Research and Development credits and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_142dc645-6f00-4374-9708-63fb6f28289b" contextRef="C_0aa15530-7fe2-4778-84a1-34356a306f70" name="caba:ResearchAndDevelopmentCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,223</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Orphan Drug credits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the provisions of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, these net operating losses, credit carryforwards and other tax attributes may be subject to limitation based on previous significant changes in ownership and upon future significant changes in ownership of the Company, as defined by the Code.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files income tax returns in the U.S. federal jurisdiction and in multiple state and local jurisdictions; however, Pennsylvania and Philadelphia constitute the Company&#8217;s most significant tax jurisdictions due to the concentration of its operational footprint and the resulting apportionment profile. The tax years 2024, 2023 and 2022 remain open to examination by the jurisdictions where the Company is subject to tax.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_021fdf16-cfe9-46a3-b328-713a6469b1a3" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="caba:PercentageOfEligibleTaxPositionsForRecognition" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15603d93-ba3f-431b-a253-10a8d3dbf681" contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized.</span></p></ix:continuation></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div><ix:nonNumeric id="F_8fd290ef-d623-4d71-9667-9bfc2a15777f" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:EarningsPerShareTextBlock" escape="true" continuedAt="F_8fd290ef-d623-4d71-9667-9bfc2a15777f_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he Company calculates basic and diluted net loss per share in conformity with the two-class method required for participating securities. In May 2024, the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b411676-cf1c-4c23-86f9-23dd0204f318" contextRef="C_5f4640a1-b6f6-4783-b105-897dd65c4d00" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,444,295</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of non-voting common stock were converted to voting common stock and no shares of non-voting common stock remain outstanding. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the rights of the voting and non-voting common stock are identical, except with respect to voting, the undistributed losses of the Company have been allocated on a proportionate basis to the two classes. Basic net loss per share of common stock is computed by dividing the net loss per share of common stock by the weighted average number of shares of common stock outstanding for the period. The weighted-average shares of common stock outstanding as of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> included outstanding pre-funded warrants to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23efd6d8-b176-470e-8820-4cc09291646b" contextRef="C_f731d894-5793-46d0-97d4-8c8276db0097" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_214f96df-2900-4f19-9cc0-5c908eb68695" contextRef="C_e53823f2-5fac-496e-8cc6-671906c1651f" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants were outstanding as of December 31, 2024.</span></p><div><ix:nonNumeric id="F_c64d00a3-1b7c-4486-92c1-206407d70400" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true" continuedAt="F_c64d00a3-1b7c-4486-92c1-206407d70400_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net loss per share is calculated using the if-converted method as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, which assumes conversion of all non-voting common stock to voting common stock.</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.02%;box-sizing:content-box;"/>
          <td style="width:3.12%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:27.86%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Voting common stock</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3fac89e-935a-41e3-9a54-ea45e3c28d6e" contextRef="C_380f4971-911e-418e-9b42-9f671cdeed55" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">167,856</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbef18e3-7fda-403d-a709-972bb750cb7c" contextRef="C_380f4971-911e-418e-9b42-9f671cdeed55" name="caba:WeightedAverageNumberOfSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">79,903,224</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ef2c1b4-1f4e-43df-a2b9-f1179b916fdb" contextRef="C_380f4971-911e-418e-9b42-9f671cdeed55" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fe3bc1ba-2d74-4974-b4b9-abd62091788e" contextRef="C_380f4971-911e-418e-9b42-9f671cdeed55" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.10</ix:nonFraction></ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div><ix:continuation id="F_8fd290ef-d623-4d71-9667-9bfc2a15777f_1"><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:continuation id="F_c64d00a3-1b7c-4486-92c1-206407d70400_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.4%;box-sizing:content-box;"/>
          <td style="width:1.92%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.88%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.92%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.88%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31, 2024</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Voting common stock</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-voting common stock</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic net loss per share:</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddfdb086-ae95-4527-9dc9-2d63d404d0a9" contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae" name="us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">114,728</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a519f07-e0d2-4c28-b1c6-5f98fd4be1ac" contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178" name="us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,136</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27d739f7-b98a-47e0-893d-51b21b335e33" contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">49,038,726</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfde7ffa-224c-4688-858e-42d328119c6c" contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">485,378</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b634d0ed-88f4-4572-9c2b-d47be903d282" contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.34</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ff5c644-043f-4a12-b6d8-aa542dbd44bd" contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.34</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted net loss per share:</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses for basic computation</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5bb5e10-c1c0-4ff0-814f-8750f79f2f11" contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">114,728</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9f38c04-2835-4caf-bb64-3e8e3b64d5e9" contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,136</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reallocation of undistributed losses as a result of conversion of<br/>&#160;&#160;&#160;&#160;&#160;non-voting to voting common shares</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_083b2507-17d6-46e3-bf3a-71b008b1dbbf" contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,136</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04d4349a-4d68-4203-9922-5d3b9046a81b" contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178" name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_012d23db-c2f5-4a52-a5ea-9f43e0541e19" contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">115,864</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20691cf8-6555-4c7c-9fa5-ca5eb450d414" contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,136</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9a8acde-a698-4292-9b43-a8e57340d3e3" contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">49,038,726</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baa2ce55-4e5f-423b-b528-23ea3598a218" contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">485,378</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: conversion of non-voting to voting common shares outstanding</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b654116-9318-41a4-9b2b-383d54ddfb05" contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">485,378</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c148d89-1ddf-4edc-9b1f-5f62a698ba01" contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in diluted per share computation</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2501529e-1d2d-4d58-b86c-1c6ade5f0c93" contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">49,524,104</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45bf5e1a-c5b3-436b-a13c-90cd29e80a16" contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">485,378</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, diluted</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0c7f37a-a0d2-4d71-8074-f64ddef9ea55" contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.34</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_448a20db-26db-4bc9-8a3d-49732d6e5d36" contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.34</ix:nonFraction></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2526544-0177-4e44-827c-80f23c7f3955" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_c2526544-0177-4e44-827c-80f23c7f3955_1"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:46.491%;box-sizing:content-box;"/>
          <td style="width:2.16%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:22.595%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:2.16%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:22.595%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ec0917f-bcc3-4f51-83e1-3cfa458f7309" contextRef="C_0cc46475-ebfa-4cb1-8610-3a9fac50cfa5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,835,372</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce1e38f4-4ece-4386-8c0f-7fc9925b046c" contextRef="C_bbf56b13-a2f8-466a-a449-916231816cd2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,231,148</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26dea99f-122a-4f65-89a1-d8890cfd6ff4" contextRef="C_b8a71800-f4b2-48f9-bccb-e404ed69141b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">53,090,190</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14b62989-b587-485e-9df5-308c97b557b4" contextRef="C_fe0a6b1e-4837-4292-aa3f-e02510edce97" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca3571ad-efb1-47b0-a0c9-2dc34ab3ffed" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">66,925,562</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9585cbe-3082-4268-9a06-f5435d080da9" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,231,148</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:continuation></div><div><ix:continuation id="F_c2526544-0177-4e44-827c-80f23c7f3955_1"></ix:continuation></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78d14481-46ef-4790-ad6e-1a5a2da4f43a" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. 401(k) Savings Plan</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company maintains a defined-contribution savings plan under Section 401(k) of the IRC, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. Effective January 1, 2020, the Plan provided for matching contributions on a portion of participant contributions pursuant to the 401(k) Savings Plan&#8217;s matching formula, up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5260a620-3a59-44c7-a004-dc7be6f10178" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of eligible compensation. All matching contributions and participant contributions vest immediately. Contributions totaled $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1fa6d3c-e6ed-49f4-85f9-0b7b744ed492" contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,063</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85dab938-0473-4514-9928-8366e7289cdf" contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">894</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and have been recorded in the statements of operations.</span></p></ix:nonNumeric></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT INDEX</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:9.84%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:89.16%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
     </tr>
     <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519278927/d759120dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-39103) filed on October 30, 2019)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312525137954/d46354dex31.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s current report on Form 8-K (File No. 001-39103) filed with the SEC on June 10, 2025)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519278927/d759120dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.2 of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-39103) filed on October 30, 2019)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000156459022019677/caba-ex33_49.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to the Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39103) filed with the SEC on May 12, 2022)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519268040/d686907dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-234017) filed on October 16, 2019</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2*</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="caba-ex4_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Securities</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312522302822/d397326dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Registrant's Current Report on Form 8-K (File No. 001-39103) filed with the SEC on December 12, 2022</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312525139517/d828604dex41.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s current report on Form 8-K (File No. 001-39103) filed with the SEC on June 12, 2025)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312525139517/d828604dex42.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Stock Warrant (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s current report on Form 8-K (File No. 001-39103) filed with the SEC on June 12, 2025)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1#</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519258869/d686907dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2018 Stock Option and Grant Plan, as amended, and form of award agreements thereunder (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-234017) filed on September 30, 2019)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2#</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519268040/d686907dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2019 Stock Option and Incentive Plan, and form of award agreements thereunder. (incorporated by reference to Exhibit 10.2 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-234017) filed on October 16, 2019)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3#</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312523158936/d516711dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 1, 2023)</span></a></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4#</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519268040/d686907dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2019 Employee Stock Purchase Plan. (incorporated by reference to Exhibit 10.3 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-234017) filed on October 16, 2019)</span></a></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5#</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000156459019045375/caba-ex104_188.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Senior Executive Cash Incentive Bonus Plan (incorporated by reference to Exhibit 10.4 of the Registrant&#8217;s Quarterly Report on Form 10-Q filed on December 5, 2019)</span></a></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6#</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519258869/d686907dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and each of its directors (incorporated by reference to Exhibit 10.5 of the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">135</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:9.84%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:89.16%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7#</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519258869/d686907dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and each of its executive officers (incorporated by reference to Exhibit 10.4 of the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8#*</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="caba-ex10_8.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cabaletta Bio, Inc. 2025 Inducement Plan</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/0001759138/000119312519258869/d686907dex106.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated License Agreement, dated as of July 23, 2019, among the Registrant, the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex109.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Master Translational Research Services Agreement, dated as of October 2018, between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit 10.9 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1011.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">CVPF Master Services Addendum to Master Translational Research Services Agreement, dated as of October 22, 2018, between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit 10.11 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1013.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease, dated as of February 11, 2019, between the Registrant and Brandywine Cira, L.P. (incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13#</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1016.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement between the Registrant and Steven Nichtberger (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14#</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1017.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement between the Registrant and Anup Marda (incorporated by reference to Exhibit 10.17 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15#</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1018.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement between the Registrant and Gwendolyn Binder (incorporated by reference to Exhibit 10.18 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16#</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312519258869/d686907dex1019.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement between the Registrant and David Chang (incorporated by reference to Exhibit 10.19 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on September 30, 2019)</span></a></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17#</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017025047201/caba-ex10_17.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Fourth Amended and Restated Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.17 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-39103) filed on March 31, 2025)</span></a></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000119312520153792/d933839dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment, dated May 27, 2020, to the Amended and Restated License Agreement, dated July 23, 2019, among the Registrant, the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-39103) filed on May 28, 2020)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000156459021053043/caba-ex102_47.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment, dated October 19, 2021, to the First Amended and Restated License Agreement, dated May 27, 2020, among the Registrant, the Trustees of the University of Pennsylvania and the Children&#8217;s Hospital of Philadelphia (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39103) filed on November 1, 2021)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000156459022010726/caba-ex1026_216.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment, dated February 15, 2022, to the Lease, dated as of February 11, 2019, between the Registrant and Brandywine Cira, L.P. (incorporated by reference to Exhibit 10.26 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-39103) filed on March 17, 2022)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">136</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:9.84%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:89.16%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21#</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000156459022010726/caba-ex1028_217.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Employment Agreement (incorporated by reference to Exhibit 10.28 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-39103) filed on March 17, 2022)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000156459022010726/caba-ex1030_56.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Option Agreement, dated December 23, 2021, by and between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit 10.30 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-39103) filed on March 17, 2022)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000156459022010726/caba-ex1031_59.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Licence and Supply Agreement, dated December 30, 2021, by and between the Registrant and Oxford Biomedica (UK) Limited (incorporated by reference to Exhibit 10.31 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-39103) filed on March 17, 2022)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017023040966/caba-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to the Licence and Supply Agreement, dated as of May 2, 2023, between the Registrant and Oxford Biomedica (UK) Limited (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39103) filed on August 10, 2023)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017023061528/caba-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment to the Licence and Supply Agreement, dated as of August 18, 2023, between the Registrant and Oxford Biomedica (UK) Limited (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39103) filed on November 9, 2023)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.26+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017022024168/caba-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exclusive License Agreement, dated October 7, 2022, by and between the Registrant and Nanjing IASO Biotherapeutics Co., LTD.(incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-39103) filed on November 10, 2022</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017023008298/caba-ex10_34.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Development, Manufacturing, and Testing Services Agreement, dated January 11, 2021, between the Registrant and WuXi Advanced Therapies Inc. (incorporated by reference to Exhibit 10.34 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-39103) filed on March 16, 2023)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.28+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017023020849/caba-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Master Translational Research Services Agreement, dated as of February 9, 2023, between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39103) filed on May 11, 2023)</span></a></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.29+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017024060045/caba-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third Amendment to the Licence and Supply Agreement, dated as of February 21, 2024, between the Registrant and Oxford Biomedica (UK) Limited (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39103) filed on May 15, 2024)</span></a></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.30+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017024093325/caba-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Fourth Amendment to the Licence and Supply Agreement, dated as of June 24, 2024, between the Registrant and Oxford Biomedica (UK) Limited (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39103) filed on August 8, 2024)</span></a></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.31+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017024126733/caba-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Services Agreement, dated as of February 1, 2019, between the Registrant and CIC Innovation Communities, LLC (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39103) filed on November 14, 2024)</span></a></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017024126733/caba-ex10_2.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to the Services Agreement, dated as of December 1, 2021, between the Registrant and CIC Innovation Communities, LLC (incorporated by reference to Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39103) filed on November 14, 2024)</span></a></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.33+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017024126733/caba-ex10_3.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to the Services Agreement, dated as of September 30, 2024, between the Registrant and CIC Innovation Communities, LLC (incorporated by reference to Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39103) filed on November 14, 2024)</span></a></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.34+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017024126733/caba-ex10_4.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment, dated September 24, 2024, to the Lease, dated as of February 11, 2019, between the Registrant and Brandywine Cira, L.P., as amended. (incorporated by reference to Exhibit 10.4 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39103) filed on November 14, 2024)</span></a></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">137</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:9.84%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:89.16%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.35+</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017025104573/caba-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Development and Manufacturing Services Agreement, dated as of December 19, 2024, between the Registrant and Lonza Houston Inc. (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39103) filed on August 7, 2025)</span></a></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.38+*</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="caba-ex10_38.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Development and Manufacturing Services Agreement, dated as of January 11, 2026, between the Registrant and Cellares Corporation</span></a></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017025047201/caba-ex19_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Policy (incorporated by reference to Exhibit 19.1 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-39103) filed on March 31, 2025)</span></a></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:12.95pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1*</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="caba-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">List of Subsidiaries of the Registrant</span></a></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1*</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="caba-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Ernst &amp; Young, independent registered public accounting firm</span></a></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1*</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="caba-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended</span></a></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2*</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="caba-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended</span></a></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1**</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="caba-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2**</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="caba-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.7</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1759138/000095017024034422/caba-ex99_7.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cabaletta Bio, Inc.'s Compensation Recovery Policy (incorporated by reference to Exhibit 99.7 to the Registrant's Annual Report on Form 10-K (File No. 001-39103) filed on March 21, 2024)</span></a></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS*</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH*</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.CAL*</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.DEF*</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.LAB*</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.PRE*</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:right;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104*</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101*)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
    </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:5.5in;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Management Contract or compensatory plan or arrangement.</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10) of Regulation S-K.</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Filed herewith.</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** The certifications furnished in Exhibit 32.1 and 32.2 hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">138</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:51.46%;box-sizing:content-box;"/>
      <td style="width:4%;box-sizing:content-box;"/>
      <td style="width:44.54%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cabaletta Bio, Inc.</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 23, 2026</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Steven Nichtberger</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer and President</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:34%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:44%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:20%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
     </tr>
     <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Steven Nichtberger</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Director, Chief Executive Officer and President</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 23, 2026</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Anup Marda</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 23, 2026</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Anup Marda</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Catherine Bollard</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Director</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 23, 2026</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Catherine Bollard, M.D.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Scott Brun</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Director</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 23, 2026</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Scott Brun, M.D.</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Richard Henriques</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Director</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 23, 2026</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Richard Henriques</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Mark Simon</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Director</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;March 23, 2026</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Mark Simon</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Shawn Tomasello</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:6pt;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Director</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 23, 2026</span></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shawn Tomasello</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">139</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>caba-ex4_2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-22T19:37:19.9117+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-4.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;min-height:0.5in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 4.2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Description of the Registrant&#x2019;s Securities Registered Pursuant to</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12 of the Securities Exchange Act of 1934, as amended</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following summary of the general terms and provisions of the registered capital stock of Cabaletta Bio, Inc. (&#x201c;Cabaletta&#x201d;, &#x201c;we&#x201d;, &#x201c;our&#x201d;) does not purport to be complete and is subject to, and qualified in its entirety by, reference to our Third Amended and Restated Certificate of Incorporation, or certificate of incorporation, our Amended and Restated Bylaws, or bylaws, each of which is incorporated by reference as an exhibit to our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, and applicable provisions of the Delaware General Corporation Law, or the DGCL. Our common stock, par value $0.00001 per share is registered pursuant to Section 12(b) of the Securities and Exchange Act of 1934 and trades on the Nasdaq Global Select Market under the symbol CABA. The summaries below do not purport to be complete statements of the relevant provisions of the certificate of incorporation, the bylaws or the DGCL.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our authorized capital stock consists of three hundred and ten million (310,000,000) shares, of which (i) two hundred and ninety three million five hundred and ninety thousand four hundred and eighty-one (293,590,481) shares are designated as voting common stock, par value $0.00001 per share, or the common stock, (ii) six million four hundred and nine thousand five hundred and nineteen (6,409,519) shares are designated as non-voting common stock, par value $0.00001 per share, or the non-voting common stock, and (iii) ten million (10,000,000) shares are designated as undesignated preferred stock, par value $0.00001 per share, or the preferred stock.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock and Non-Voting Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holders of our common stock and non-voting common stock have identical rights, provided that, (i) except as otherwise expressly provided in our certificate of incorporation or as required by applicable law, on any matter that is submitted to a vote by our stockholders, holders of our common stock are entitled to one vote per share of common stock, and holders of our non-voting common stock are not entitled to any votes per share of non-voting common stock, including for the election of directors, and (ii) holders of our common stock have no conversion rights, while holders of our non-voting common stock shall have the right to convert each share of our non-voting common stock into one share of common stock at such holder&#x2019;s election, provided that as a result of such conversion, such holder, together with its affiliates and any members of a Schedule 13(d) group with such holder, would not beneficially own in excess of 4.99% of our common stock immediately prior to and following such conversion, unless otherwise as expressly provided for in our certificate of incorporation. However, this ownership limitation may be increased or decreased to any other percentage designated by such holder of non-voting common stock upon 61 days&#x2019; notice to us.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of our common stock and non-voting common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock and non-voting common stock have no preemptive rights or other subscription rights or redemption or sinking fund provisions.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event of our liquidation, dissolution or winding up, holders of our common stock and non-voting common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock is listed on the Nasdaq Global Select Market under the trading symbol &#x201c;CABA.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transfer agent and registrar for our</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common stock is </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equiniti Trust Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, LLC.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preferred Stock</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors will have the authority, from time to time, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock and non-voting common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders and holders of our non-voting common stock will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-funded Warrants and Warrants</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;min-height:0.5in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2025, we issued (i) 39,200,000 shares of our common stock and accompanying warrants to purchase an aggregate of 39,200,000 shares of common stock (or pre-funded warrants in lieu thereof) at a combined price of $2.00 and (ii) to certain investors in lieu of common stock, pre-funded warrants to purchase 10,800,000 shares of our common stock and accompanying warrants to purchase an aggregate of 10,800,000 shares of common stock (or pre-funded warrants in lieu thereof) at a combined price of $1.99999 per pre-funded warrant. The accompanying warrant has an exercise price of $2.50 per share, is immediately exercisable from the date of issuance and will expire fifteen months from the date of issuance. As of December 31, 2025, all pre-funded warrants and warrants remain outstanding.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A holder of the pre-funded warrants will not be entitled to exercise any portion of any pre-funded warrant, (i) if immediately prior to exercise the holder (together with its affiliates) beneficially owns an aggregate number of shares of our common stock greater than 4.5%, 4.99% or 9.99%, as applicable, of the number of shares of our common stock outstanding immediately before giving effect to the exercise of any pre-funded warrant or (ii) to the extent that immediately following exercise, the holder (together with its affiliates) would beneficially own in excess of 4.5%, 4.99% or 9.99%, as applicable, of the number of shares of common stock outstanding immediately after giving effect to the issuance of such shares of common stock, and without taking account any other pre-funded warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 19.99% upon at least 61 days&#x2019; prior notice from the holder to us.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exercise price per whole share of our common stock purchasable upon the exercise of the pre-funded warrants is $0.00001 per share of common stock. The exercise price of the pre-funded warrants and the number of shares of our common stock issuable upon exercise of the pre-funded warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock. The exercise price will not be adjusted below the par value of our common stock. The pre-funded warrants will not expire.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except by virtue of such holder&#x2019;s ownership of shares of our common stock, the holder of a pre-funded warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until such holder exercises the pre-funded warrant.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A holder of the common stock warrants will not be entitled to exercise any portion of any common stock warrant, (i) if immediately prior to exercise the holder (together with its affiliates) beneficially owns an aggregate number of shares of our common stock greater than 4.5%, 4.99% or 9.99%, as applicable, of the number of shares of our common stock outstanding immediately before giving effect to the exercise of any common stock warrant or (ii) to the extent that immediately following exercise, the holder (together with its affiliates) would beneficially own in excess of 4.5%, 4.99% or 9.99%, as applicable, of the number of shares of common stock outstanding immediately after giving effect to the issuance of such shares of common stock. However, any holder may increase or decrease such percentage to any other percentage not in excess of 19.99% upon at least 61 days&#x2019; prior notice from the holder to us. If the holder is not permitted to exercise a common stock warrant due to the foregoing limitation, then the holder may exercise such warrant for an equivalent number of pre-funded warrants with an exercise price of $0.00001 in substantially the same form of pre-funded warrant to purchase shares of common stock described above.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The initial exercise price per whole share of our common stock purchasable upon the exercise of the common stock warrants is $2.50 per share of common stock (or, if the purchaser elects, $0.00001 per pre-funded warrant). The exercise price of the common stock warrants and the number of shares of our common stock (or, if the purchaser elects, pre-funded warrants) issuable upon exercise of the common stock warrants is subject to appropriate adjustment in the event of certain stock dividends, subdivisions, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting our common stock. The common warrants will expire on September 12, 2026.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except by virtue of such holder&#x2019;s ownership of shares of our common stock, the holder of a common stock warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the common stock warrant to receive shares of our common stock.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-Takeover Effects of our Certificate of Incorporation and Bylaws and Delaware Law</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our certificate of incorporation and bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board Composition and Filling Vacancies</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our certificate of incorporation provides for the division of our board of directors into three classes serving staggered three-year terms, with one class being elected each year. Our certificate of incorporation provides that directors may be removed only for cause and then only by the affirmative vote of the holders of 75% or more of the outstanding shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;min-height:0.5in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">No Written Consent of Stockholders</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of directors by our stockholders without holding a meeting of stockholders.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Meetings of Stockholders</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our certificate of incorporation and bylaws provide that only a majority of the members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Advance Notice Requirements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form and content of all stockholders&#x2019; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amendment to Certificate of Incorporation and Bylaws</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and, if required by law, our certificate of incorporation must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, limitation of liability and the amendment of our bylaws and certificate of incorporation must be approved by not less than 75% of the outstanding shares entitled to vote on the amendment, and not less than 75% of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of at least 75% of the outstanding shares entitled to vote on the amendment, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Undesignated Preferred Stock</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our certificate of incorporation authorizes 10,000,000 shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Choice of forum</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claim for: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders; (3) any action asserting a claim arising pursuant to any provision of the DGCL or our certificate of incorporation or bylaws (including the interpretation, application or validity thereof); or (4) any action asserting a claim governed by the internal affairs doctrine, or the Delaware Forum Provision. The choice of forum provision does not apply to any actions arising under the Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;min-height:0.5in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Act or the Exchange Act. Our bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America are the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the rules and regulations promulgated thereunder, or the Federal Forum Provision. In addition, our bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, these forum selection clauses may limit our stockholders&#x2019; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. While the Delaware Supreme Court and other states have upheld the validity of federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on us and/or our stockholders who assert that the provision is invalid or unenforceable. The Court of Chancery of the State of Delaware or the federal district courts of the United States of America may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 203 of the DGCL</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#x201c;business combination&#x201d; with an &#x201c;interested stockholder&#x201d; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	&#149;	before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;\</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	&#149;	upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#149;	outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	&#149;	at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 203 defines a business combination to include:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	&#149;	any merger or consolidation involving the corporation and the interested stockholder;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	&#149;	any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	&#149;	subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	&#149;	subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	&#149;	the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>3
<FILENAME>caba-ex10_8.htm
<DESCRIPTION>EX-10.8
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-22T19:37:19.9642+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.8</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.8</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CABALETTA BIO, INC.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025 INDUCEMENT PLAN</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 1. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GENERAL PURPOSE OF THE PLAN; DEFINITIONS</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The name of the plan is the Cabaletta Bio, Inc. 2025 Inducement Plan (the &#x201c;Plan&#x201d;). The purpose of the Plan is to enable Cabaletta Bio, Inc. (the &#x201c;Company&#x201d;) to grant equity awards to induce highly qualified prospective officers and employees who are not currently employed by the Company and its Affiliates to accept employment and provide them with a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company&#x2019;s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company&#x2019;s behalf and strengthening their desire to remain with the Company. The Company intends that the Plan be reserved for persons to whom the Company may issue securities without stockholder approval as an inducement pursuant to Rule 5635(c)(4) of the Marketplace Rules of the NASDAQ Stock Market, Inc.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following terms shall be defined as set forth below:</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Act&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means the Securities Act of 1933, as amended, and the rules and regulations thereunder.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Administrator&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means either the Board or the compensation committee of the Board or a similar committee performing the functions of the compensation committee and which is comprised of not less than two Non-Employee Directors who are independent.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, at the time of determination, any &#x201c;parent&#x201d; or &#x201c;subsidiary&#x201d; of the Company as such terms are defined in Rule 405 of the Act. The Board will have the authority to determine the time or times at which &#x201c;parent&#x201d; or &#x201c;subsidiary&#x201d; status is determined within the foregoing definition.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Award&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Awards,&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> except where referring to a particular category of grant under the Plan, shall include Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Units, Restricted Stock Awards, Unrestricted Stock Awards, and Dividend Equivalent Rights.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Award Certificate&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means a written or electronic document setting forth the terms and provisions applicable to an Award granted under the Plan. Each Award Certificate is subject to the terms and conditions of the Plan.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Board&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means the Board of Directors of the Company.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Code&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means the Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Consultant&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means a consultant or adviser who provides </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">bona fide</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> services to the Company or an Affiliate as an independent contractor and who qualifies as a consultant or advisor under Instruction A.1.(a)(1) of Form S-8 under the Act.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Dividend Equivalent Right&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Effective Date&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means the date on which the Plan is approved by the Board as set forth in Section 19.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Exchange Act&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Fair Market Value&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Stock on any given date means the fair market value of the Stock determined in good faith by the Administrator; provided, however, that if the Stock is listed on the National Association of Securities Dealers Automated Quotation System (&#x201c;Nasdaq&#x201d;), Nasdaq Global Market, The New York Stock Exchange or another national securities exchange or traded on any established market, the determination shall be made by reference to market quotations. If there are no market quotations for such date, the determination shall be made by reference to the last date preceding such date for which there are market quotations.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NASDAQ Inducement Exception</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Rule 5635(c)(4) of the Marketplace Rules of the NASDAQ Stock Market, Inc., or any successor rule, and related guidance thereunder.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Non-Employee Director&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means a member of the Board who is not also an employee of the Company or any Subsidiary.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Non-Qualified Stock Option&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means any Stock Option that is not an &#x201c;incentive stock option&#x201d; as defined in Section 422 of the Code.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Option&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Stock Option&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means any option to purchase shares of Stock granted pursuant to Section 5.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Restricted Shares&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means the shares of Stock underlying a Restricted Stock Award that remain subject to a risk of forfeiture or the Company&#x2019;s right of repurchase.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Restricted Stock Award&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means an Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Restricted Stock Units&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means an Award of stock units subject to such restrictions and conditions as the Administrator may determine at the time of grant.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Sale Event&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall mean (i) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii) a merger, reorganization or consolidation pursuant to which the holders of the Company&#x2019;s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii) the sale of all of the Stock of the Company to an unrelated person, entity or group thereof acting in concert, or (iv) any other transaction in which the owners of the Company&#x2019;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sale Price</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the value as determined by the Administrator of the consideration payable, or otherwise to be received by stockholders, per share of Stock pursuant to a Sale Event.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Section 409A&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means Section 409A of the Code and the regulations and other guidance promulgated thereunder.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Service Relationship&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means any relationship as an employee, director or Consultant of the Company or any Affiliate (e.g., a Service Relationship shall be deemed to continue without interruption in the event an individual&#x2019;s status changes from full-time employee to part-time employee or Consultant).</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Stock&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means the Common Stock, par value $0.00001 per share, of the Company, subject to adjustments pursuant to Section 3.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Stock Appreciation Right&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Subsidiary&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means any corporation or other entity (other than the Company) in which the Company has at least a 50 percent interest, either directly or indirectly.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201c;Unrestricted Stock Award&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> means an Award of shares of Stock free of any restrictions.</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 2. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administration of Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Plan shall be administered by the Administrator.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Powers of Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrator shall have the power and authority to grant Awards consistent with the terms of the Plan, including the power and authority:</font></p><p style="text-indent:55.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)    to select the individuals to whom Awards may from time to time be granted;</font></p><p style="text-indent:55.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)    to determine the time or times of grant, and the extent, if any, of Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Units, Unrestricted Stock Awards, Cash-Based Awards, and Dividend Equivalent Rights, or any combination of the foregoing, granted to any one or more grantees;</font></p><p style="text-indent:55.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)    to determine the number of shares of Stock to be covered by any Award;</font></p><p style="text-indent:55.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)    to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the forms of Award Certificates;</font></p><p style="text-indent:55.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)    to accelerate at any time the exercisability or vesting of all or any portion of any Award;</font></p><p style="text-indent:55.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vi)    subject to the provisions of Section 5(c), to extend at any time the period in which Stock Options may be exercised; and</font></p><p style="text-indent:55.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vii)    at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Plan grantees.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delegation of Authority to Grant Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to applicable law and the NASDAQ Inducement Exception, the Administrator, in its discretion, may delegate to a committee consisting of one or more officers of the Company including the Chief Executive Officer of the Company all or part of the Administrator&#x2019;s authority and duties with respect to the granting of Awards to individuals who are (i) not subject to the reporting and other provisions of Section 16 of the Exchange Act and (ii) not members of the delegated committee. Any such delegation by the Administrator shall include a limitation as to the amount of Stock underlying Awards that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting criteria. The Administrator may revoke or amend the terms of a delegation at any time but such action shall not invalidate any prior actions of the Administrator&#x2019;s delegate or delegates that were consistent with the terms of the Plan.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Awards under the Plan shall be evidenced by Award Certificates that set forth the terms, conditions and limitations for each Award which may include, without limitation, the term of an Award and the provisions applicable in the event employment or service terminates.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys&#x2019; fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company&#x2019;s articles or bylaws or any directors&#x2019; and officers&#x2019; liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign Award Recipients</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other countries in which the Company and its Subsidiaries operate or have employees or other individuals eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to: (i) determine which Subsidiaries shall be covered by the Plan; (ii) determine which individuals outside the United States are eligible to participate in the Plan; (iii) modify the terms and conditions of any Award granted to individuals outside the United States to comply with applicable foreign laws; (iv) establish subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such subplans and/or modifications shall be attached to this Plan as appendices); provided, however, that no such subplans and/or modifications shall increase the share limitations contained in Section 3(a) hereof; and (v) take any action, before or after</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an Award is made, that the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Administrator may not take any actions hereunder, and no Awards shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law.</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 3. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Issuable</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 275,000 shares, subject to adjustment as provided in Section 3(b). For purposes of this limitation, the shares of Stock underlying any awards under the Plan that are forfeited, canceled, held back upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) shall be added back to the shares of Stock available for issuance under the Plan. In the event the Company repurchases shares of Stock on the open market, such shares shall not be added to the shares of Stock available for issuance under the Plan. Subject to such overall limitations, shares of Stock may be issued up to such maximum number pursuant to any type or types of Award. The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to Section 3(c) hereof, if, as a result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Company&#x2019;s capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a different number or kind of shares or other securities of the Company, or additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Stock or other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i) the maximum number of shares reserved for issuance under the Plan, (ii) the number and kind of shares or other securities subject to any then outstanding Awards under the Plan, (iii) the repurchase price, if any, per share subject to each outstanding Restricted Stock Award, and (iv) the exercise price for each share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of shares subject to Stock Options and Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights remain exercisable. The Administrator shall also make equitable or proportionate adjustments in the number of shares subject to outstanding Awards and the exercise price and the terms of outstanding Awards to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event. The adjustment by the Administrator shall be final, binding and conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional shares.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mergers and Other Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the case of and subject to the consummation of a Sale Event, the parties thereto may cause the assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree. To the extent the parties to such Sale Event do not provide for the assumption, continuation or substitution of Awards, upon the effective time of the Sale Event, the Plan and all outstanding Awards granted hereunder shall terminate. In such case, except as may be otherwise provided in the relevant Award Certificate, all Options and Stock Appreciation Rights with time-based vesting conditions or restrictions that are not vested and/or exercisable immediately prior to the effective time of the Sale Event shall become fully vested and exercisable as of the effective time of the Sale Event, all other Awards with time-based vesting, conditions or restrictions shall become fully vested and nonforfeitable as of the effective time of the Sale Event, and all Awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with a Sale Event in the Administrator&#x2019;s discretion or to the extent specified in the relevant Award Certificate. In the event of such termination, (i) the Company shall have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A) the Sale Price multiplied by the number of shares of Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable at prices not in excess of the Sale Price) and (B) the aggregate exercise price of all such outstanding Options and Stock Appreciation Rights (provided that, in the case of an Option or Stock Appreciation Right with an exercise price equal to or greater than the Sale Price, such Option or Stock Appreciation Right shall be cancelled for no consideration); or (ii) each grantee shall be permitted, within a specified period of time prior to the consummation of the Sale Event as determined by the Administrator, to exercise all outstanding Options and Stock Appreciation Rights (to the extent then exercisable) held by such grantee. The Company shall also have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding other Awards in an amount equal to the Sale Price multiplied by the number of vested shares of Stock under such Awards.</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 4. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ELIGIBILITY</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grantees under the Plan will be such individuals to whom the Company may issue securities without stockholder approval in accordance with the NASDAQ Inducement Exception, as are selected from time to time by the Administrator in its sole discretion; provided that Awards may not be granted to employees who are providing services to any &#x201c;parent&#x201d; of the Company, as such term is defined in Rule 405 of the Act, unless (i) the Stock underlying the Awards is treated as &#x201c;service recipient stock&#x201d; under Section 409A or (ii) the Company has determined that such Awards are exempt from or otherwise comply with Section 409A.</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 5. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STOCK OPTIONS</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award of Stock Options</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrator may grant Stock Options under the Plan. Any Stock Option granted under the Plan shall be a Non-Qualified Stock Option, and shall be in such form as the Administrator may from time to time approve.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Options granted pursuant to this Section 5 shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The exercise price per share for the Stock covered by a Stock Option granted pursuant to this Section 5 shall be determined by the Administrator at the time of grant but shall not be less than 100 percent of the Fair Market Value on the date of grant. Notwithstanding the foregoing, Stock Options may be granted with an exercise price per share that is less than 100 percent of the Fair Market Value on the date of grant (i)  to individuals who are not subject to U.S. income tax on the date of grant, or (ii) if the Stock Option is otherwise compliant with Section 409A.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Option Term</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than ten years after the date the Stock Option is granted.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercisability; Rights of a Stockholder</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Stock Options shall become exercisable at such time or times, whether or not in installments, as shall be determined by the Administrator at or after the grant date. The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Option. An optionee shall have the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Method of Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Stock Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company, specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods except to the extent otherwise provided in the Option Award Certificate:</font></p><p style="text-indent:55.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)    In cash, by certified or bank check or other instrument acceptable to the Administrator;</font></p><p style="text-indent:55.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)    Through the delivery (or attestation to the ownership following such procedures as the Company may prescribe) of shares of Stock that are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date;</font></p><p style="text-indent:55.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)    By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Company shall prescribe as a condition of such payment procedure; or</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:55.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)    By a &#x201c;net exercise&#x201d; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment instruments will be received subject to collection. The transfer to the optionee on the records of the Company or of the transfer agent of the shares of Stock to be purchased pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance with the provisions of the Stock Option) by the Company of the full purchase price for such shares and the fulfillment of any other requirements contained in the Option Award Certificate or applicable provisions of laws (including the satisfaction of any withholding taxes that the Company is obligated to withhold with respect to the optionee). In the event an optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock Option shall be net of the number of attested shares. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet website or interactive voice response, then the paperless exercise of Stock Options may be permitted through the use of such an automated system.</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 6. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STOCK APPRECIATION RIGHTS</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award of Stock Appreciation Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrator may grant Stock Appreciation Rights under the Plan. A Stock Appreciation Right is an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of a share of Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise Price of Stock Appreciation Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The exercise price of a Stock Appreciation Right shall not be less than 100 percent of the Fair Market Value of the Stock on the date of grant.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant and Exercise of Stock Appreciation Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Stock Appreciation Rights may be granted by the Administrator independently of any Stock Option granted pursuant to Section 5 of the Plan.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Terms and Conditions of Stock Appreciation Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Stock Appreciation Rights shall be subject to such terms and conditions as shall be determined on the date of grant by the Administrator. The term of a Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appreciation Right may not exceed ten years. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees.</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 7. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RESTRICTED STOCK AWARDS</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nature of Restricted Stock Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrator may grant Restricted Stock Awards under the Plan. A Restricted Stock Award is any Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of pre-established performance goals and objectives.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rights as a Stockholder</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon the grant of the Restricted Stock Award and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting of the Restricted Shares and receipt of dividends; provided that if the lapse of restrictions with respect to the Restricted Stock Award is tied to the attainment of performance goals, any dividends paid by the Company during the performance period shall accrue and shall not be paid to the grantee until and to the extent the performance goals are met with respect to the Restricted Stock Award. Unless the Administrator shall otherwise determine, (i) uncertificated Restricted Shares shall be accompanied by a notation on the records of the Company or the transfer agent to the effect that they are subject to forfeiture until such Restricted Shares are vested as provided in Section 7(d) below, and (ii) certificated Restricted Shares shall remain in the possession of the Company until such Restricted Shares are vested as provided in Section 7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Restricted Shares may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically provided herein or in the Restricted Stock Award Certificate. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 16 below, in writing after the Award is issued, if a grantee&#x2019;s employment (or other Service Relationship) with the Company and its Subsidiaries terminates for any reason, any Restricted Shares that have not vested at the time of termination shall automatically and without any requirement of notice to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at its original purchase price (if any) from such grantee or such grantee&#x2019;s legal representative simultaneously with such termination of employment (or other Service Relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of Restricted Shares that are represented by physical certificates, a grantee shall surrender such certificates to the Company upon request without consideration.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting of Restricted Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrator at the time of grant shall specify the date or dates and/or the attainment of pre-established performance goals, objectives and other conditions on which the non-transferability of the Restricted Shares and the Company&#x2019;s right of repurchase or forfeiture shall lapse. Subsequent to such date or dates and/or the attainment of such pre-established performance goals, objectives and other conditions, the shares on which all restrictions have lapsed shall no longer be Restricted Shares and shall be deemed &#x201c;vested.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 8. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RESTRICTED STOCK UNITS</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nature of Restricted Stock Units</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrator may grant Restricted Stock Units under the Plan. A Restricted Stock Unit is an Award of stock units that may be settled in shares of Stock (or cash, to the extent explicitly provided for in the Award Certificate) upon the satisfaction of such restrictions and conditions at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of pre-established performance goals and objectives. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. Except in the case of Restricted Stock Units with a deferred settlement date that complies with Section 409A, at the end of the vesting period, the Restricted Stock Units, to the extent vested, shall be settled in the form of shares of Stock. Restricted Stock Units with deferred settlement dates are subject to Section 409A and shall contain such additional terms and conditions as the Administrator shall determine in its sole discretion in order to comply with the requirements of Section 409A.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rights as a Stockholder</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A grantee shall have the rights as a stockholder only as to shares of Stock acquired by the grantee upon settlement of Restricted Stock Units; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the stock units underlying his Restricted Stock Units, subject to the provisions of Section 11 and such terms and conditions as the Administrator may determine.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 16 below, in writing after the Award is issued, a grantee&#x2019;s right in all Restricted Stock Units that have not vested shall automatically terminate upon the grantee&#x2019;s termination of employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 9. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNRESTRICTED STOCK AWARDS</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant or Sale of Unrestricted Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrator may grant (or sell at par value or such higher purchase price determined by the Administrator) an Unrestricted Stock Award under the Plan. An Unrestricted Stock Award is an Award pursuant to which the grantee may receive shares of Stock free of any restrictions under the Plan. Unrestricted Stock Awards may be granted in respect of past services or other valid consideration, or in lieu of cash compensation due to such grantee.</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 10. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RESERVED</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 11. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DIVIDEND EQUIVALENT RIGHTS</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend Equivalent Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrator may grant Dividend Equivalent Rights under the Plan. A Dividend Equivalent Right is an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other Award to which it relates) if such shares had been issued to the grantee. A Dividend Equivalent Right may be granted hereunder to any grantee as a component of an award of Restricted Stock Units or as a freestanding award. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Certificate. Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue additional equivalents. Any such reinvestment shall be at Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any. Dividend Equivalent Rights may be settled in cash or shares of Stock or a combination thereof, in a single installment or installments. A Dividend Equivalent Right granted as a component of an Award of Restricted Stock Units shall provide that such Dividend Equivalent Right shall be settled only upon settlement or payment of, or lapse of restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 16 below, in writing after the Award is issued, a grantee&#x2019;s rights in all Dividend Equivalent Rights shall automatically terminate upon the grantee&#x2019;s termination of employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 12. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TRANSFERABILITY OF AWARDS</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transferability</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as provided in Section 12(b) below, during a grantee&#x2019;s lifetime, his or her Awards shall be exercisable only by the grantee, or by the grantee&#x2019;s legal representative or guardian in the event of the grantee&#x2019;s incapacity. No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution or pursuant to a domestic relations order. No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be null and void.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administrator Action</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Notwithstanding Section 12(a), the Administrator, in its discretion, may provide either in the Award Certificate regarding a given Award or by subsequent written approval that the grantee (who is an employee or director) may transfer his or her Non-Qualified Stock Options to his or her immediate family members, to trusts for the benefit of such family members, or to partnerships in which such family members are the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award. In no event may an Award be transferred by a grantee for value.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Family Member</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For purposes of Section 12(b), &#x201c;family member&#x201d; shall mean a grantee&#x2019;s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the grantee&#x2019;s household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than 50 percent of the beneficial interest, a foundation in which these persons (or the grantee) control the management of assets, and any other entity in which these persons (or the grantee) own more than 50 percent of the voting interests.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designation of Beneficiary</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. To the extent permitted by the Company, each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee&#x2019;s death. Any such designation shall be on a form provided for that purpose by the Administrator and shall not be effective until received by the Administrator. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee&#x2019;s estate.</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 13. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TAX WITHHOLDING</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment by Grantee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other amounts received thereunder first becomes includable in the gross income of the grantee for income tax purposes, pay to the Company, or make arrangements satisfactory to the Administrator regarding payment of, any Federal, state, or local taxes of any kind required by law to be withheld by the Company with respect to such income. The Company and its Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee. The Company&#x2019;s obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment in Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrator may require the Company&#x2019;s tax withholding obligation to be satisfied, in whole or in part, by the Company withholding from shares of Stock to be issued pursuant to any Award a number of shares with an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the withholding amount due; provided, however, that the amount withheld does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid liability accounting treatment. For purposes of share withholding, the Fair Market Value of withheld shares shall be determined in the same manner as the value of Stock includible in income of the Participants. The Administrator may also require the Company&#x2019;s tax withholding obligation to be satisfied, in whole or in part, by an arrangement whereby a certain number of shares of Stock issued pursuant to any Award are immediately sold and proceeds from such sale are remitted to the Company in an amount that would satisfy the withholding amount due.</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 14. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 409A AWARDS</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Awards are intended to be exempt from Section 409A to the greatest extent possible and to otherwise comply with Section 409A. The Plan and all Awards shall be interpreted in accordance with such intent. To the extent that any Award is determined to constitute &#x201c;nonqualified deferred compensation&#x201d; within the meaning of Section 409A (a &#x201c;409A Award&#x201d;), the Award shall be subject to such additional rules and requirements as specified by the Administrator from time to time in order to comply with Section 409A. In this regard, if any amount under a 409A Award is payable upon a &#x201c;separation from service&#x201d; (within the meaning of Section 409A) to a grantee who is then considered a &#x201c;specified employee&#x201d; (within the meaning of Section 409A), then no such payment shall be made prior to the date that is the earlier of (i) six months and one day after the grantee&#x2019;s separation from service, or (ii) the grantee&#x2019;s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section 409A. Further, the settlement of any 409A Award may not be accelerated except to the extent permitted by Section 409A.</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 15. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TERMINATION OF SERVICE RELATIONSHIP, TRANSFER, LEAVE OF ABSENCE, ETC.</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination of Service Relationship</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the grantee&#x2019;s Service Relationship is with an Affiliate and such Affiliate ceases to be an Affiliate, the grantee shall be deemed to have terminated his or her Service Relationship for purposes of the Plan.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)    For purposes of the Plan, the following events shall not be deemed a termination of a Service Relationship:</font></p><p style="text-indent:55.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)    a transfer to the employment of the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another; or</font></p><p style="text-indent:55.1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)    an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the employee&#x2019;s right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 16. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AMENDMENTS AND TERMINATION</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall materially and adversely affect rights under any outstanding Award without the holder&#x2019;s consent. Except as provided in Section 3(b) or 3(c), without prior stockholder approval, in no event may the Administrator exercise its discretion to reduce the exercise price of outstanding Stock Options or Stock Appreciation Rights or effect the repricing of such Awards through cancellation and re-grants or cancel such Awards in exchange for cash or other Awards. Nothing in this Section 16 shall limit the Administrator&#x2019;s authority to take any action permitted pursuant to Section 3(b) or 3(c).</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 17. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STATUS OF PLAN</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator may authorize the creation of trusts or other arrangements to meet the Company&#x2019;s obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the existence of such trusts or other arrangements is consistent with the foregoing sentence.</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 18. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GENERAL PROVISIONS</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Distribution</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the Company in writing that such person is acquiring the shares without a view to distribution thereof.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuance of Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. To the extent certificated, stock certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee, at the grantee&#x2019;s last known address on file with the Company. Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail (with proof of receipt) or by United States mail, addressed to the grantee, at the grantee&#x2019;s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic &#x201c;book entry&#x201d; records). Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any evidence of book entry or certificates evidencing shares of Stock pursuant to the exercise or settlement of any Award, unless and until the Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the shares of Stock are listed, quoted or traded. Any Stock issued pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with federal, state or foreign jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded. The Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may place legends on any Stock certificate or notations on any book entry to reference restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and representations as the Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations, or requirements. The Administrator shall have the right to require any individual to comply with any timing or other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Administrator.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholder Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Until Stock is deemed delivered in accordance with Section 18(b), no right to vote or receive dividends or any other rights of a stockholder will exist with respect to shares of Stock to be issued in connection with an Award, notwithstanding the exercise of a Stock Option or any other action by the grantee with respect to an Award.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Compensation Arrangements; No Employment Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases. The adoption of this Plan and the grant of Awards do not confer upon any employee any right to continued employment with the Company or any Subsidiary.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading Policy Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Option exercises and other Awards under the Plan shall be subject to the Company&#x2019;s insider trading policies and procedures, as in effect from time to time.</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)    </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clawback Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Awards under the Plan shall be subject to the Company&#x2019;s clawback policy, as in effect from time to time.</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 19. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EFFECTIVE DATE OF PLAN</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Plan shall become effective immediately upon approval by the Board.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 20. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GOVERNING LAW</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with the General Corporation Law of the State of Delaware, applied without regard to conflict of law principles.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DATE APPROVED BY BOARD OF DIRECTORS: October 1, 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.38
<SEQUENCE>4
<FILENAME>caba-ex10_38.htm
<DESCRIPTION>EX-10.38
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-22T19:37:20.1099+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.38</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:9.85pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.38</font></p><p style="font-size:10pt;margin-top:9.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-size:10pt;margin-top:9.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:154.05pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img267305973_0.jpg" alt="img267305973_0.jpg" style="width:246px;height:44px;"></p><h1 style="margin-left:0.1pt;font-size:10pt;margin-top:2.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.24791666666666667in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cabaletta Bio</font></h1><p style="font-size:10pt;margin-top:5.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.24791666666666667in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">DEVELOPMENT AND CLINICAL MANUFACTURING SERVICES AGREEMENT</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.2465277777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This Development and Manufacturing Services Agreement (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) is entered into as of the date of the last signature below (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;), by and between Cellares Corporation, a Delaware corporation, with offices located at 345 Allerton Avenue, South San Francisco, CA 94080 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Cellares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;), and Cabaletta Bio, Inc., a Delaware corporation, with offices located at 2929 Arch St Suite 600, Philadelphia, PA 19104 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Partner</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;). Cellares and Partner are sometimes referred to herein, individually, as a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Party</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; and, together, as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;.</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:6.897%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Background.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The Parties entered into that certain Technology Transfer Agreement, dated as of November 3, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">TTA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;), pursuant to which Cellares will perform certain technology transfer, validation and other services with respect to the manufacture of Partner&#x2019;s cell therapy product.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Partner desires to engage Cellares to perform certain Services (as defined below) relating to the further development and manufacture of the Product (as defined below) as described in this Agreement, and Cellares is prepared to perform such Services for Partner upon the terms and conditions set forth herein.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.2597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">As of the Effective Date, Statement of Work No. 4 under the TTA (&#x201c;SOW No. 4&#x201d;), shall be governed under this Agreement rather than the TTA. In the event of a conflict between defined terms in SOW No. 4 and this Agreement the definition ascribed in this Agreement shall govern.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:6.897%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Definitions.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to either Party, any corporation, company, partnership or other business entity that, directly or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with such Party. For the purpose of this definition, &#x201c;control&#x201d; (including, with correlative meanings, &#x201c;controlled by&#x201d; and &#x201c;under common control with&#x201d;) means the possession, directly or indirectly, of (a) the power to direct or cause the direction of management or policies of such Party (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise) or (b) at least fifty percent (50%) of the issued share capital (partnership or ownership capital &#x2013; whether directly or pursuant to any option, warrant or other similar arrangement &#x2013; or otherwise) of such Party.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Applicable Law</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means all relevant federal, state and local government laws, statutes, rules and regulations in the United States and any other jurisdictions which are applicable to the Services, including all relevant laws, statutes, rules and regulations in all countries in which Partner commercializes the Products, which countries are expressly set forth in the applicable SOW or otherwise mutually agreed in writing by the Parties, whether in effect as of the Effective Date or adopted thereafter, including the applicable regulations and guidelines of any applicable Regulatory Authority and all applicable cGMP, in each case together with </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">all amendments thereto.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Batch</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means the Product produced from a single run of the Manufacturing Process.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Batch Records</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means the executed version of a given Master Batch Record containing the production record or, as applicable, relevant portions thereof, pertaining to a given Batch.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Calendar Quarter</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Calendar Year</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means each twelve (12)-month period commencing on January 1, except that the first &#x201c;Calendar Year&#x201d; of the Term shall be the period commencing on the Effective Date and ending on December 31 of the year during which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and ends on the last day of the Term.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">cGMP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means current Good Manufacturing Practices applicable in the United States (and any other countries specified in an applicable SOW) relating to the manufacture of medicinal products for human use, as specified in applicable International Council for Harmonisation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">ICH</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) guidelines and the FD&amp;C Act at 21 CFR (Chapters 210, 211, and applicable parts of 600, 610 and 820).</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.55pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.8</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">cGMP Batch</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means a Batch of Product that is required under the applicable SOW to meet cGMP.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.9</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Cell Bank</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a Cell Line, the cell stock of such Cell Line.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:11.8pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.10</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Cell Bank Storage</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means the storage of the Cell Bank in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 4.7</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.2597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.11</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Cell Line</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means the cell line that is provided by Partner or developed under this Agreement by Cellares to produce Product.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.12</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Cell Shuttle</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means Cellares&#x2019; automated cell therapy manufacturing platform.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.13</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Cellares Operating Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means the corporate standards, standard operating procedures, standard manufacturing procedures, drug master file, Cellares-customized manufacturing procedures, electronic programs and files, raw material specifications, protocols, validation documentation, and supporting documentation used by Cellares, including with respect to, without limitation, environmental monitoring, for operation and maintenance of the Facility and Cellares equipment used in the process of producing the Product. Cellares Operating Documents shall be deemed Cellares&#x2019; Confidential Information. For the avoidance of doubt, the Cellares Operating Documents shall not include any information within the Partner Manufacturing Process information.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.14</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Certificate of Analysis</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">CoA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means a certificate of analysis prepared by or for Cellares listing the Specifications of a Product, tests performed on such Product, and the results of such testing, in a form agreed to by the Parties.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.15</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Certificate of Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">CoC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means a document prepared by Cellares: (i) listing the manufacturing date, unique Batch number and dose level of Product in such Batch; and (ii) certifying that such Batch was manufactured in accordance with processing instructions, the Specifications, the Master Batch Record and Applicable Law (including cGMP, if applicable).</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.16</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Deliver</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">,&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Delivered</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Delivery</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">,&#x201d; shall have the meaning ascribed in Section 8.3.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:4.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.17</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Development Batch</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means a Batch of Product which is expressly designated in the applicable SOW as a development or pilot Batch and which shall not be required to comply with cGMP nor meet the </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:4.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">applicable Specifications.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.18</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">EMA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means the European Medicines Agency, or any successor agency thereto.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.19</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;Engineering Batch&#x201d; or &#x201c;Engineering Run</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means a cGMP Batch that is intended to demonstrate the reproducible performance of the Manufacturing Process within analytic limits and while performed under cGMP conditions.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.20</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Facility</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means Cellares&#x2019; facility as set forth in the relevant SOW.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.21</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">FD&amp;C Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Food, Drug, and Cosmetic Act, as amended, and any regulations promulgated thereunder.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.22</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">FDA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Food and Drug Administration, or any successor agency thereto.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.23</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing Process</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means the production process for the manufacture of Product as such process may be improved or modified from time to time.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.24</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Master Batch Record</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means the set of documents, proposed by Cellares and approved by Partner, which defines the manufacturing methods, test methods and other procedures, directions and controls associated with the manufacture and testing of Product which are designed to ensure that the Products have the identity, strength, quality and purity they purport or are represented to possess, and is used to ensure uniformity from Batch to Batch and compliance with cGMPs.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.25</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Partner Manufacturing Process</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means Partner&#x2019;s proprietary process for manufacturing the Product as disclosed by Partner to Cellares in writing pursuant to the TTA. Notwithstanding anything herein to the contrary, the Partner Manufacturing Process information is Confidential Information of Partner and not Cellares.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.26</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Partner Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning ascribed in Section 3.5(b).</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.27</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Product</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means the product identified in the applicable SOW and manufactured by Cellares under this Agreement.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.28</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Quality Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means the quality agreement, including any amendments thereto, executed by the Parties pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 5.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, setting out the responsibilities of the Parties in relation to quality as required for compliance with cGMP. Upon signature by both Parties, the Quality Agreement is incorporated into and shall be an integral part of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.55pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.29</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Raw Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means all materials required to perform the Manufacturing Process or Services set forth in the applicable SOW (other than Starting Materials), including without limitation ingredients, reagents, primary packaging materials, consumables (including cartridges for Cell Shuttle), sterile liquid transfer devices and other components of the Product.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.30</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means the FDA, EMA and any other similar applicable regulatory authorities.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.31</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Services</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means all or any part of the services to be performed by Cellares under this Agreement, as set out in the relevant SOW, and which may include, to the extent specified in an SOW, process and analytical method transfer, process development and automation, process optimization, validation, clinical manufacturing of Batches, as well as quality control and quality assurance activities.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:4.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.32</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Starting Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means all materials required to perform the Manufacturing Process or Services set forth in the applicable SOW (other than Raw Materials), which may include human biologic materials, including apheresis or peripheral blood mononuclear cells (PBMCs), and lentiviral vectors.</font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.33</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Statement of Work</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">SOW</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means a statement of work describing the Services to be performed by Cellares under this Agreement, including any amendments to such statement of work, in each case in writing and as executed by the Parties pursuant to this Agreement.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.2597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.34</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Specifications</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means the written specifications for the Product as set forth in the applicable SOW.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.35</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Third Party</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; means any person or entity other than the Parties or their respective Affiliates.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:6.897%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Services.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Scope of Agreement; SOWs. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">As a master agreement, this Agreement allows the Parties to contract for Services through the issuance of multiple SOWs that reference this Agreement, which shall be separately specified in writing on terms acceptable to the Parties. Each SOW shall upon execution thereof by both Parties become part of this Agreement and incorporated herein. Each SOW shall set forth the specific Services to be performed by Cellares, the Product to be manufactured, the Specifications, the protocol for the applicable Manufacturing Process, the timeline and schedule for the performance of such Services, and the compensation to be paid by Partner to Cellares for the provision of such Services (including fees and reimbursable expenses), as well as any other relevant terms and conditions. If the Services include development of specific deliverables, such deliverables and the specifications thereof shall be set forth on the relevant SOW.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Amendments to SOWs</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Each SOW may be amended from time to time upon the mutual written agreement of the Parties. If a Party becomes aware of any unforeseen or unusual events or assumptions, factors, or criteria not previously taken into consideration that would affect the outcome of the budget, timeline, or other aspects of the Services set forth in the applicable SOW, or would require additional or different services not originally contemplated, such Party shall promptly notify the other Party and the Parties shall confer in good faith to address such matter. Cellares shall not be required to perform any additional or different work until the Parties execute an applicable amendment. Notwithstanding the foregoing, no change in the Services or Quality Agreement shall be implemented by Cellares without the prior written consent of Partner in each instance.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Conduct of Services</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Cellares will conduct the Services in accordance with the terms of this Agreement (including the applicable SOW) and Applicable Law, and in a professional and workmanlike manner. Cellares does not guarantee any particular outcome or results with respect to developmental services. Cellares shall use </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> to conduct the Services in accordance with the time frames and budget set forth in the applicable SOW. Cellares shall adhere to the Specifications agreed to by both parties in an applicable SOW. Cellares shall retain appropriately qualified and trained personnel with the requisite knowledge and experience to perform the Services in accordance with this Agreement. Cellares may delegate or subcontract any part of the Services to an Affiliate or subcontractor </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">provided that (i) such work is performed in accordance with this Agreement and the applicable SOW and (ii) Cellares shall remain fully responsible to Partner for the acts or omissions of such subcontractor in connection with the performance of such work; provided further that, in the event the subcontractor is required by Partner, Cellares shall not be responsible for any liability to the extent resulting from the performance of services by such subcontractor.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:4.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Governance.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Project Manager</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. With respect to each SOW, each Party will appoint a project manager (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Project Manager</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) who will be responsible for overseeing the performance of such SOW on behalf of such Party.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Joint </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #2d96d2;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Project </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. The Parties shall appoint a joint project committee composed of an equal number of senior representatives from each Party such as Manufacturing, Quality, Process and Analytical Development, and Business Development (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Joint Project Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;). The Joint Project Committee shall meet in person or by teleconference based on the needs of the project(s) as determined by the Project Managers or Joint Project Committee. Cellares shall be responsible for coordinating meetings </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">and meeting minutes and circulating to Joint Project Committee members as soon as reasonably practicable for comments and approval of the meeting minutes. The Joint Project Committee shall function as an information sharing body only and shall not have any decision-making authority. In the event of a dispute under this Agreement, the Parties shall first work in good faith for a period of up to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> to resolve such dispute through the Joint Project Committee. For avoidance of doubt, the Joint Project Committee shall not have the authority to amend or modify this Agreement or any SOW.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Partner Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">To the extent not already provided by Partner to Cellares under the TTA, Partner will provide to Cellares, at Partner&#x2019;s sole cost and expense, all information regarding Partner&#x2019;s current cell therapy manufacturing process as required by Cellares to perform the Services, including process flow diagrams, an equipment list for each piece of equipment used in the current cell therapy manufacturing process, and process-associated documents, such as documents related to analytical methods and Specifications, or comparable documents.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Each applicable SOW will specify necessary amounts of all Cell Lines (including any Cell Lines intended for use in a Cell Bank or for Cell Bank Storage pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 4.7(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">), Raw Materials, Starting Materials and other materials of any nature to be provided by Partner (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Partner Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;), and Partner at its sole cost shall provide such Partner Materials meeting the relevant specifications as necessary for Cellares to perform the applicable Services. Each applicable SOW will also provide an estimated cost for any Raw Materials to be procured by Cellares on behalf of Partner.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Unless otherwise specified in the applicable SOW, Partner shall be solely responsible for all testing, quality control, defects and regulatory compliance with respect to Partner Materials prior to delivery of such Partner Materials to Cellares, and Cellares shall be solely responsible for all testing, quality control, defects and regulatory compliance with respect to Raw Materials other than Partner Materials.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Prior to delivery of any Partner Materials, Partner shall provide to Cellares all relevant environmental, health and safety information related to such Partner Materials in Partner&#x2019;s possession and reasonably necessary to perform the Services, including details of any hazards relating to the Partner Materials of which Partner is aware. Such documentation shall include all applicable safety data sheets, toxicology reports issued by authoritative third parties, internal toxicology evaluation reports and other supporting documents with respect to environmental, health and safety matters concerning such Partner Materials. If Partner becomes aware of any changes to the aforesaid information or hazards during the performance of the Services, Partner shall promptly and accurately inform Cellares of such changes and provide relevant information and supporting documentation thereof. Any cell samples that are intended to be transferred to Cellares by Partner as part of this Agreement must include an original vendor Certificate of Analysis. If any cell sample has been adulterated or otherwise modified from its original vendor composition or format, then, Partner shall provide Cellares with three aliquots of such samples for safety and pathogen analysis and other quality assurance testing.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Partner shall deliver to Cellares all Partner Materials Delivery Duty Paid (DDP) Facility (Incoterms 2020). For the avoidance of doubt, DDP (Facility) means Partner is responsible for delivery to the Facility and pays all shipping costs including import duties and taxes. Partner is responsible for regulatory release and inspection of Partner Materials prior to delivery to Cellares. All costs associated with procuring, shipping, inspecting, handling and disposal of the Partner Materials prior to delivery to Cellares shall be the responsibility of Partner. Following delivery to Cellares, Cellares shall be responsible for all applicable visual inspecting and review of CoA, releasing, storage, handling and disposal of the Partner Materials.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Partner shall be solely responsible for procuring, at Partner&#x2019;s cost, all licenses or other rights to all Partner Materials as necessary for Cellares to perform the applicable Services under this Agreement. Cellares shall not be responsible for any delays resulting from Partner&#x2019;s failure to provide such Partner Materials.</font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">All Partner Materials shall remain the sole property of Partner and are the Confidential Information of Partner. Partner shall be solely responsible for and shall bear the risk of loss of any Partner Materials while in Cellares&#x2019; possession or control, except for any loss of Partner Materials due to Cellares&#x2019; </font><font style="color:#623177;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">gross </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">negligence or willful misconduct. Cellares will use </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> to protect the Partner Materials from loss, damage and theft while in Cellares&#x2019; possession and control. Cellares shall use the Partner Materials solely to perform its obligations under this Agreement and shall not transfer the Partner Materials to any Third Party (except to an Affiliate or subcontractor of Cellares performing Services hereunder to the extent permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 3.3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">) without Partner&#x2019;s prior written consent. Cellares shall only use any data arising from its use of the Partner Materials to conduct the Services and for Cellares&#x2019; internal research and development purposes, subject to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 11.2(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(h)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cellares shall, at Partner&#x2019;s option and expense, destroy, return to Partner or otherwise dispose of unused Partner Materials promptly after the earlier of (a) completion of the Services for which the Partner Materials were provided (unless such Partner Materials are anticipated to be used for future Services), or (b) termination of the applicable SOW. Notwithstanding the foregoing, if Partner provides no response to Cellares&#x2019; written notice of such unused Partner Materials, then Cellares may dispose of them at its sole discretion after </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> of such written notice to Partner. Partner is responsible for return shipping of Partner Materials. Cellares is responsible for disposing of Partner Materials at Partner&#x2019;s expense.</font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="display:flex;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:6.897%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Manufacturing.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Specifications; Manufacturing Process</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Cellares shall, in accordance with the terms of this Agreement and the Quality Agreement, manufacture each Product in accordance with the applicable Specifications and Manufacturing Process, Applicable Law, and, to the extent set forth in the applicable SOW, cGMP.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.3in;display:flex;margin-top:11.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;min-width:0.2in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:3.3618053101658356%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">i.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">If a Batch of Product fails to comply with the applicable Specifications, Manufacturing Process or cGMP, and Cellares is responsible for such failure as provided in this Section 4.1, then </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.2597222222222222in;display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;min-width:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.01089258698941%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">ii.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Without limiting the generality of the foregoing, Cellares shall not be responsible for the failure of any Product or the manufacture thereof to comply with the applicable Specifications, Manufacturing Process or cGMP to the extent due to (a) the Partner Manufacturing Process, (b) any specimens, samples, Partner Materials, information, instructions or intellectual property provided by Partner, or</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.5in;display:flex;margin-top:0.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.22013888888888888in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:3.828016643550624%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">the inherent properties of such Product.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.229861111111111in;display:flex;margin-top:4.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;min-width:0.2701388888888889in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.487210366587986%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">iii.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Any change or modification to the Specifications or Manufacturing Process must be agreed in writing in advance by the Parties and will be made in accordance with the provisions of the Quality Agreement (if applicable) and this Agreement; provided that deviations from the Manufacturing Process may be made by Cellares for technical, safety, regulatory or emergency reasons upon written notification to Partner only to the extent explicitly permitted under the Quality Agreement, and provided that the applicable Product meets the applicable Specifications and is manufactured in accordance with cGMP, as applicable.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.2201388888888889in;display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;min-width:0.2798611111111111in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.641096549236503%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">iv.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Partner shall be responsible for any costs or expenses incurred by Cellares in connection with implementing any change to the Specifications or Manufacturing Process.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.2597222222222222in;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;min-width:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.01089258698941%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">v.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">If Cellares makes any Cellares-requested change without Partner&#x2019;s consent (except as such change is otherwise permitted under this Agreement) and such change results in a Non-Conformance, then in addition to the remedies in Article 9, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Development Batches; Engineering Batches.</font></div></div><div class="item-list-element-wrapper" style="text-indent:102.25pt;font-size:0;margin-top:11.85pt;justify-content:flex-start;margin-bottom:0;margin-right:0.25in;min-width:1.4201388888888888in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Arial;justify-content:flex-start;min-width:3.86%;">i.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Development Batches</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Cellares shall manufacture each Development Batch in accordance with the applicable SOW, but for clarity, unless otherwise set forth in the SOW, Cellares shall have no obligation to manufacture each Development Batch to meet Specifications nor comply with cGMP. At Partner&#x2019;s option, Cellares shall deliver such Development Batches to Partner or dispose of such Development Batches, in each case at Partner&#x2019;s sole cost and expense. Partner shall use Development Batches only in accordance with the applicable SOW and with Applicable Law and shall not use any Development Batch in humans.</font></div></div><div class="item-list-element-wrapper" style="text-indent:100.1pt;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:0.25in;min-width:1.3902777777777777in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Arial;justify-content:flex-start;min-width:4.272%;">ii.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Engineering Batches. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Engineering Batches may be used for analytical characterization and comparability studies. The Parties shall jointly define the objectives, success criteria, and reporting requirements for each Engineering Batch. The number, scope, and timing of Engineering Batches shall be set forth in a mutually agreed Statement of Work.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Process Assumptions; Finalization of Process and Specifications</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Prior to commencement of cGMP manufacturing, the Parties shall review the technical, process and other assumptions underlying the Specifications and Manufacturing Process. If there is a material difference in such assumptions as compared with the Specifications or process results demonstrated during the manufacture of the </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">applicable Development Batches, the Parties shall meet to discuss in good faith the consequences of such differences and any necessary changes to the Manufacturing Process or Specifications. Any agreed changes will be reflected in an amendment to the Manufacturing Process or Specifications. The final Manufacturing Process and Specifications shall be subject to each Party&#x2019;s review and approval prior to commencement of manufacturing of cGMP Batches.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">cGMP Batches</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Cellares shall manufacture cGMP Batches in accordance with this Agreement (including the applicable Quality Agreement and SOW), cGMP, Applicable Law, the approved manufacturing Batch Records, and the applicable Specifications. Cellares shall deliver to Partner a Certificate of Analysis and Certificate of Compliance with respect to each cGMP Batch.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Raw Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Cellares shall procure all required Raw Materials </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Partner will be asked to approve the type, quantity and pricing of such Raw Materials in writing prior to purchase. Partner and Cellares will develop specifications for Raw Materials based on assessed risk.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Hazardous Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Cellares shall be responsible, at Cellares&#x2019; sole cost and expense (without reimbursement), for the generation, collection, storage, handling, transport, and release of hazardous materials and waste generated by or on behalf of Cellares in connection with any SOW unless otherwise specified in this Agreement or an SOW.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.55pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cell Bank and Product Storage</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><p style="font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">If Cell Bank Storage services are included within the Services under an SOW, Cellares shall perform such Cell Bank Storage of the applicable Cell Banks at no charge for up to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> and shall notify Partner of the start date of such </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> storage period as soon as possible prior to such date. Cellares shall store finished Product made available to Partner pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 8.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> (and any unused Partner Materials that are not going to be used in subsequent Services) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> after Release and shall notify Partner of the start date of such </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> storage period as soon as possible prior to such date. After such </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> period, if Partner wishes Cellares to continue Cell Bank Storage or storage of finished Product (or other Partner Materials), such storage shall be subject to availability and, if storage is available, a mutually agreed storage fee will be charged to Partner.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cellares shall store any stored Cell Banks and finished Product (or other Partner Materials) in a safe and environmentally controlled manner in accordance with Partner&#x2019;s instructions and the requirements of the applicable SOW and Applicable Law. Cellares shall not transfer the Cell Bank or such finished Product (or other Partner Materials) to a Third Party or Affiliate of Cellares without Partner&#x2019;s prior written consent. Upon Partner&#x2019;s prior written consent, Cellares may perform such testing of the Cell Bank or Product as mutually agreed by the Parties in accordance with the Quality Agreement for quality assurance, regulatory or safety purposes. Cellares shall disclose the results of such testing within a reasonable time following Partner&#x2019;s request. Upon expiration of the storage period set forth in Section 4.7(a), Cellares shall have the right, upon prior written notice to Partner, to dispose of any such Cell Banks, finished Product or unused Partner Materials.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Without limiting </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 3.5(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> with respect to the Cell Bank, Cellares&#x2019; liability for loss, theft or damage of any Cell Bank or finished Product stored by or on behalf of Cellares hereunder shall not exceed </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> with respect to such Cell Bank or Product storage pursuant to Section 4.7(a). Further, for any loss, theft or damage of any finished Product stored by or on behalf of Cellares during the first </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> storage period, Cellares also agrees to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Cellares will at all times label (or otherwise designate) the Product and Partner Materials as the property of Partner. Cellares shall keep the Product and Partner Materials free and clear of all claims, encumbrances, and liens. Cellares bears all risk of loss for Partner Materials (including Product) while in Cellares&#x2019; or its contractors&#x2019; possession or control.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The price for and other terms applicable to Cell Bank Storage or storage of finished Product following the expiration of the free storage period described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 4.7(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> shall be as mutually agreed </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">by the Parties pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 4.7(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Any changes to such Cell Bank Storage or finished Product storage Services shall be made via an amendment to the applicable SOW as set forth in Section 3.2. If Partner does not timely pay all fees due for such storage, Partner shall within </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> of Cellares&#x2019; written notice arrange collection and shipping of the applicable Cell Bank or finished Product at Partner&#x2019;s sole cost and Cellares shall not be obliged to continue such storage at the end of such </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> period.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Upon expiration or termination of this Agreement or the SOW(s) pursuant to which Cellares provides Cell Bank Storage or storage of finished Product as described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 4.7(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> (or completion of such storage Services), Cellares shall destroy, return to Partner or otherwise dispose of the Cell Bank or such finished Product pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 3.5(</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #b5082d;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">h</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">) at Partner&#x2019;s expense.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:11.6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:6.897%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Quality; Regulatory</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Quality Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. The Parties shall enter into the Quality Agreement within </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> of the Effective Date. Responsibility for quality assurance and quality control of Product shall be allocated between Partner and Cellares as set forth in the Quality Agreement and in Cellares&#x2019; standard operating procedures. If there is a conflict between the terms and conditions of this Agreement and the Quality Agreement, the terms and conditions of this Agreement shall prevail with the exception that the Quality Agreement shall control for matters relating to the quality and disposition of the Product. If the Quality Agreement is not in place within </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> of the Effective Date, Cellares and Partner commit to enter into the Quality Agreement in a timely manner, but in no event later than the commencement of cGMP manufacturing.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Regulatory Inspections and Audits</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. The Parties&#x2019; responsibilities regarding inspections by Regulatory Authorities and audits shall be set out in the Quality Agreement (but in no case shall the Quality Agreement reduce the scope of any audit rights provided herein or impose any fee on Partner).</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Partner Inspections</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. During the Term and subject to reasonable prior written notice by Partner to Cellares, Partner or Partner&#x2019;s representatives shall be granted access to (i) each portion of the Facility where Cellares performs Services, (ii) relevant personnel involved in performing Services and (iii) relevant records pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 5.4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, in each case solely for the purpose of observing process performance and verifying that Cellares is performing Services in accordance with cGMP (as applicable) and all other Applicable Laws, the applicable SOW, the Quality Agreement and the Master Batch Records, as applicable with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">prior written notification. Audits shall be designed to minimize disruption of operations at the Facility. Such inspections shall be limited to no more than </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> (other than for cause), conducted by </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> representatives of Partner and over the course of no more than </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> per inspection. Partner will pay Cellares a </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> fee, as set forth in the relevant SOW, to cover Partner audits exceeding </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> Partner audit per year; provided that, Cellares shall permit a for-cause audit by Partner and/or its representatives </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> given reasonable timely notification as agreed by the Parties in the Quality Agreement. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Recordkeeping</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Cellares will maintain complete and accurate records of the production of each Batch of Product (including without limitation Batch Records) in electronic form accessible to Partner and as required by Applicable Laws, including without limitation cGMP, and in accordance with the Quality Agreement. Cellares will retain possession of the Master Batch Record and Batch Records and will make copies of the Master Batch Record and Batch Records available to Partner. Cellares Operating Documents will remain Cellares&#x2019; Confidential Information. Cellares will make the Cellares Operating Documents available during site visits by Partner but Partner will not be permitted to make copies of and/or remove Cellares Operating Documents from the Facility. In connection with a filing or correspondence with a Regulatory Authority in connection with a Product, Cellares will provide Partner with the documents necessary or reasonably useful for Partner to address an inquiry from a Regulatory Authority. If any Confidential Information of Cellares is necessary for Partner to include in a filing for regulatory approval of the Product or to address an inquiry from a Regulatory Authority, Cellares shall provide the Confidential Information to Partner for the specific purpose of disclosure to the applicable Regulatory Authority, provided that Cellares shall have the right to provide such information only to such </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Regulatory Authority to extent permitted by Applicable Law. Cellares will promptly provide to Partner such regulatory support, including data and documentation, as reasonably requested by Partner in connection with regulatory filings relating to the Facility or equipment to the extent used to manufacture Product hereunder.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Facility Approvals</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Cellares shall maintain all manufacturing licenses and other regulatory and governmental permits, licenses and approvals for the Facility that may be necessary to manufacture and supply Products under this Agreement.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Product Approvals</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Partner shall be solely responsible for obtaining and maintaining regulatory approval of the Product. Prior to Partner&#x2019;s submission of any applicable substantive information to any Regulatory Authority related in any way to Cellares that has not previously been reviewed or provided by Cellares, the Manufacturing Process or the Services provided under this Agreement (including information related to a Regulatory Authority&#x2019;s request for additional information or an inspection, and Partner&#x2019;s answer or other response thereto), Partner shall provide to Cellares, for Cellares&#x2019; review , otherwise relevant copies of what is intended to be submitted, provided that such copies may be redacted with respect to information not pertinent to Cellares&#x2019; potential rights and obligations under this Agreement. Partner shall consider in good faith any comments provided by Cellares. Subject to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 5.4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, Cellares will promptly provide to Partner such support, including data and documentation, as reasonably requested by Partner in connection with regulatory filings relating to the Product or the manufacture thereof. Cellares shall timely respond to any requests received by Cellares from a Regulatory Authority that relate to this Agreement, including the Cellares Operating Documents, the Manufacturing Process, the Product or the Services provided under this Agreement, and shall timely provide all documents and information requested by the applicable Regulatory Authority in any such request, in each case in a timely manner sufficient to meet any applicable statutory deadlines or deadlines requested by the applicable Regulatory Authority.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:6.897%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Orders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Forecasts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Partner shall provide Cellares with a rolling </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> forecast of its requirements for manufacturing of all Products (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Rolling Forecast</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) at least </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> prior to the beginning of each month during the Term representing Partner&#x2019;s good-faith estimate of the type and quantity of such Products that Partner expects to place a Purchase Order for manufacturing of such Products on a monthly basis within each of the following </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Except as specified in an applicable SOW, the initial Rolling Forecast will be provided at least </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> prior to the manufacturing of Product hereunder, or at such other date as the Parties mutually agree in an applicable SOW. With respect to any Calendar Quarter for which Partner at any time does not provide a Rolling Forecast pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 6.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, or provides a Rolling Forecast that is otherwise not compliant with this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Article 6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> or is not accompanied by a Purchase Order for the Commitment Amount in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 6.3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, then (a) Cellares shall have no obligation to accept any Purchase Order during such Calendar Quarter and the lead time pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 6.5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> for fulfillment by Cellares of any Purchase Orders it elects to accept shall be at Cellares&#x2019; sole discretion, provided that Partner may cancel any Purchase Order if Cellares&#x2019; proposed lead time for such Purchase Order is not reasonably acceptable to Partner in light of the timing required for administration of such Product to a patient, and in which case Partner shall notify Cellares of the same and the Parties shall discuss the matter in good faith.</font></div></div><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.2597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Upon progression of the Product to the next clinical phase of development or commercialization, to the extent a material change in demand is reasonably anticipated, at the request of either Party, the Parties will renegotiate the Forecast structure in good faith.</font></div></div><p style="font-size:10pt;margin-top:11.9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> Binding Forecast.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.55pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">With respect to each Rolling Forecast, the first </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> of such Rolling Forecast (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Binding </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.55pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Forecast</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) shall be a binding commitment on Partner to purchase the Products described in such Rolling Forecast; provided that the quantity of Products projected to be purchased during the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> may only be adjusted by Partner in subsequent Rolling Forecasts </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Collar</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;). Partner shall be required to issue a Purchase Order for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> of the quantities of such Products described in the Binding Forecast (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Commitment Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;); and the quantities of Products described in the remaining </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> in the Rolling Forecast shall be non-binding and for planning purposes only (subject to the Collar).</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:10.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Upon progression of the Product to the next clinical phase of development or commercialization, to the extent a material change in demand is reasonably anticipated, at the request of either Party, the Parties will renegotiate the Binding Forecast structure in good faith.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Within </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> of receipt of a Rolling Forecast, Cellares shall notify Partner if Cellares has a </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> belief that Cellares&#x2019; manufacturing capacity will be insufficient to meet the forecasted quantities reflected in the non-binding portion of such Rolling Forecast. and shall use good faith efforts to accept such Rolling Forecast. Once accepted, the Binding Forecast will be a binding commitment on Cellares to manufacture the Products and a binding commitment by Partner to issue a Purchase Order(s) to purchase such Products. Notwithstanding anything to the contrary, Cellares will accept any Rolling Forecast that falls within the applicable Minimum Capacity and the Commitment Amount and otherwise is compliant with this Article 6.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Purchase Orders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. From time to time, Partner may issue purchase orders for manufacturing of volumes of Product (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Purchase Order</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) consistent with the Rolling Forecast. For each month, Partner shall submit Purchase Orders for at least the Commitment Amount corresponding to the first month of the most recent Binding Forecast for delivery in such month concurrently with the Rolling Forecast (i.e., at least </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> prior to the beginning of each month). Partner may submit additional Purchase Orders from time to time. Each such Purchase Order shall specify: (i) the quantity of each Product desired, (ii) the destination of Delivery, and (iii) the requested Initiation Date (defined below) (to the extent known by Partner and subject to change by the Partner within the same Calendar Quarter for the Products under such Purchase Order (which shall comply with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 6.5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">). Once a Purchase Order is accepted by Cellares, the Purchase Order is non-cancelable by Partner or Cellares and no changes may be made to the Purchase Order by either Party without written consent by the other Party.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Acceptance of Purchase Orders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">No later than </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> after receipt of a Purchase Order, Cellares shall confirm in writing its receipt of the Purchase Order, provided that (1) if (i) the type and quantity of Products described in a Purchase Order are consistent with the most recent Binding Forecast, (ii) the quantities of such Products described in such Purchase Order are no more than (when aggregated with all other Purchase Orders for the applicable Calendar Quarter) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> of the Commitment Amount</font><font style="color:#2d96d2;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(iii) the requested Initiation Dates of such Products complies with the lead-time requirements described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 6.5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, and (iv) the Purchase Order otherwise complies with the terms of this Agreement, then Cellares shall accept such Purchase Order by sending an acknowledgement to Partner (any such accepted or deemed accepted Purchase Order, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Confirmed Order</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) and (2) Cellares may reject the portion of any Purchase Order covering any Calendar Quarter outside the Binding Forecast or in excess of (when aggregated with all other Purchase Orders for the applicable Calendar Quarter) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> of the quantity set forth in the Binding Forecast. Any Purchase Order that is compliant with (i) - (iv) above but not accepted in writing by Cellares within </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> after its receipt thereof shall be deemed accepted. Any Purchase Order that is not compliant with (i) - (iv) above but not accepted in writing by Cellares within </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> after its receipt thereof shall be deemed rejected.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Subject to the foregoing, Cellares shall use commercially reasonable efforts (but shall otherwise have no obligation) to accommodate Purchase Orders for quantities of Products that in the aggregate with all other Purchase Orders for the applicable Calendar Quarter exceed </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> but are no more than </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> of the Commitment Amount for the applicable Calendar Quarter. Cellares shall notify Partner whether or not Cellares will agree to supply the additional amount of Products requested in any such Purchase Order, the estimated Delivery Dates for such excess Product, and if the remainder of such </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Purchase Order is acceptable in accordance with this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 6.4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, then upon such written notice, such additional amount of Products accepted by Cellares shall be included in the Confirmed Order. Cellares shall not be considered to have accepted any Purchase Order for such additional Product quantities without written confirmation. Cellares shall have no obligation to accommodate any Purchase Orders for quantities of Products that in the aggregate exceed </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> of the Commitment Amount.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Lead Time; Delivery Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Partner will issue Purchase Orders that specify requested date(s) of initiation of manufacturing (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Initiation Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;), and Cellares&#x2019; written confirmation of Purchase Orders (if any) shall set forth a delivery date for each Product ordered (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Delivery Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;). For each Product, the time between the Initiation Date and the Delivery Date shall be not less than the lead time as specified in the applicable SOW, unless otherwise agreed by Cellares. Cellares shall use </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> to comply with any maximum turnaround time specified in the applicable SOW. The Initiation Date and Delivery Date for each Product shall be binding on Cellares once such Purchase Order is accepted by Cellares unless otherwise mutually agreed; provided that, in the event Cellares reasonably anticipates that it will be unable to meet any Initiation Date or Delivery Date for any accepted Purchase Order due to circumstances outside of Cellares&#x2019; control, Cellares shall promptly notify Partner and the Parties shall work together in good faith to find a mutually agreeable alternative Initiation Date or Delivery Date to the extent feasible based on bona fide patient needs.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Failure to Comply with Binding Forecast</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Unless otherwise set forth in an applicable SOW, if Partner does not purchase the full quantity of Products in the Commitment Amount during a given Calendar Quarter as set forth in the Binding Forecast, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">No Other Terms and Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. If a sales acknowledgment, invoice, Purchase Order, or other document submitted by either Party contains terms or conditions conflicting with or additional to the terms and conditions of this Agreement, the Parties hereby reject such terms and conditions, and the terms and conditions of this Agreement shall prevail unless otherwise expressly agreed to in writing by both Parties.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:11.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.8</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Supply Shortfall; Minimum Capacity Guarantee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.75in;display:flex;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:3.8458535497183646%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Supply Shortfall</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. In the event Cellares&#x2019; reasonably believes its manufacturing capacity will be insufficient to supply the Commitment Amount of Product, Cellares shall have the right to allocate its manufacturing capacity (including raw materials) between Partner and Cellares&#x2019; other customers </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.75in;display:flex;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:3.8458535497183646%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Minimum Capacity Guarantee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Notwithstanding anything herein to the contrary, provided that Partner complies with the forecasting structure set forth above (as may be amended from time to time in writing), Cellares shall provide Partner with manufacturing capacity, [***]: (i) [***], or (ii) [***].</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:6.897%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Pricing; Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Service Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Partner will pay Cellares the fees and other costs for all Services properly performed (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Service Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) and Product Delivered hereunder (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Product Price</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) (comprised of a Batch fee and Raw Materials pass-through costs as set forth on the applicable SOW) following receipt by Partner of Cellares&#x2019; invoices for such Product pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 7.3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> or as otherwise set forth in the applicable SOW. Unless otherwise expressly set forth in the applicable SOW, all Service Fees are non-refundable. The initial Batch fee is set forth on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">hereto.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Price Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:1.2902777777777779in;display:flex;margin-top:11.85pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;min-width:0.20972222222222223in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:3.5193362772648196%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">i.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Following the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, or (b) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. No later than </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, Cellares shall notify Partner of any such changes with respect to the next Calendar Year.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Invoicing</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Cellares shall invoice Partner on a monthly basis for the total Product Price of all </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Products Delivered to Partner in the prior month and, except as otherwise set forth in the applicable SOW, for all other Service Fees incurred or otherwise due in such prior month. Each invoice issued by Cellares hereunder shall specify: </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Partner may withhold disputed amounts subject to a good faith dispute. In the event of a payment dispute, Partner shall nevertheless pay the undisputed portion of the applicable invoice and the parties will work reasonably and in good faith to resolve the dispute as quickly as possible. All undisputed amounts not paid by Partner when due shall accrue interest from the applicable due date until paid, at the rate of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> (or, if less, the maximum rate allowed under the law). Additionally, Cellares may stop performing the applicable Services and withhold Products and other deliverables until payment of all undisputed invoices is made.</font></div></div><p style="font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
    <table style="margin-left:0.006944444444444444in;border-spacing:0;table-layout:auto;width:97.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:42.84%;box-sizing:content-box;"></td>
      <td style="width:57.16%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:25.2pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
      <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-indent:5.5pt;border-left:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:5.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Cellares shall submit all invoices to:</font></p></td>
      <td style="border-top:0.5pt solid #000000;padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:5.25pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Partner shall remit payment in US dollars (USD) via wire transfer or ACH:</font></p></td>
     </tr>
     <tr style="height:12.95pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
      <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.5pt;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:5.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Cabaletta Bio, Inc.</font></p></td>
      <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:5.25pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Cellares Corporation</font></p></td>
     </tr>
     <tr style="height:12.95pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
      <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.5pt;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:5.5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
      <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:5.25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
     </tr>
     <tr style="height:12.95pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
      <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.5pt;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:5.5pt;text-indent:0;font-size:10.5pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Trebuchet MS',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:5.25pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:12.95pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
      <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.5pt;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:5.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.25pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:5.25pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
      <td style="padding-top:0in;border-right:0.5pt solid #000000;text-indent:5.5pt;border-left:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="margin-left:5.5pt;text-indent:0;font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
    </table><p style="margin-left:5.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:4.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Unless otherwise agreed by the Parties in an applicable SOW, all fees are exclusive of all sales, use, services, Value Added Taxes (VAT) or similar taxes which shall be charged to Partner at the prevailing rate. The fees also exclude the cost of import, export, insurance and transportation of Partner Materials and other samples or specimens (including the return thereof) which shall be the sole responsibility of Partner.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Equipment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Any capital or other equipment required for the performance of the Services, including without limitation to a Cell Shuttle and associated cartridges shall be solely the expense of Cellares unless otherwise agreed by the Parties in an applicable SOW, such as equipment that is specific to Partner's Process.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:6.897%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Release and Delivery</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Quality Release</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Cellares shall provide to Partner the applicable Batch Records, CoA, CoC and such other documentation for Product as is reasonably required to meet all applicable regulatory requirements of the Regulatory Authorities and completion of other release activities completed per the Quality Agreement upon Delivery (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Delivery Without Batch Documentation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Upon Partner&#x2019;s request, Cellares shall Deliver restricted Product prior to Release, provided that such request must be accompanied by Partner&#x2019;s written acknowledgement that (a) the Product has been Delivered without a CoA or CoC or other applicable documentation, (b) accordingly, the Product cannot be administered to humans until transmittal of such certificates and documentation, and (c) Partner nevertheless accepts full risk of loss, title and ownership of the Product. Cellares shall have no liability or responsibility for any such Product or the use thereof by or on behalf of Partner provided without the applicable documentation. Cellares shall deliver the CoA, CoC and such other documentation as required pursuant to Applicable Law and the applicable SOW as soon as such documentation is available.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Delivery</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. All Products shall be delivered EXW (Facility) (Incoterms 2020) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Deliver</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">,&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Delivered</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">,&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Delivery</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">,&#x201d; as appropriate), in each case no later than the Delivery Date specified on Cellares&#x2019; written confirmation of the applicable Purchase Order (or, if no such Delivery Date is specified, the Delivery Date shall be consistent with the turnaround time set forth in the applicable SOW and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 6.5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">) (unless the Delivery Date is changed by written agreement of the Parties or a Force Majeure occurs). Partner shall be responsible for all loading, transit, export and import from the Facility, including the selection of a carrier and management thereof. Title and risk of loss for the Products shall pass from Cellares to Partner upon Delivery. Partner shall be solely responsible, in its discretion and at its expense, for procuring any insurance it desires for shipping and transportation after Release. In the event Cellares stores any </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Product pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 4.7</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> as a result of Partner&#x2019;s failure to take Delivery of such Product within </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, then Cellares shall have a right to invoice Partner for such storage at mutually agreed rates for any storage beyond </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> and up to a maximum of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, and Partner shall pay each such invoice within </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> following receipt thereof. Except as specified in the applicable SOW, Cellares shall have no obligation to store or retain any Product for more than </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">[***] </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">of such Product.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Packaging and Labeling</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Cellares will package and label Product for Delivery in accordance with Cellares Operating Documents and the applicable Specifications.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Samples</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Cellares shall retain quality control samples of each Batch of Product Delivered hereunder in accordance with the Quality Agreement and Applicable Law.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Manufacturing Issues</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Cellares shall not be responsible or liable for any carrier or other delays or factors adversely impacting its performance hereunder due to Force Majeure.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:6.897%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Acceptance/Rejection of Product</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Acceptance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Following Delivery of each shipment of Product pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 8.3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, Partner shall have the right to inspect and test Product to determine compliance with this Agreement, including the Product Warranty (defined below). If Partner believes that any Product in any shipment does not conform to the Product Warranty (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Conformance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;), </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">). The mere failure of a Product to have a particular therapeutic or other effect in and of itself shall not be grounds for deeming such Product to have a Non-Conformance. If Partner fails to notify Cellares of a Non-Conformance within the timelines set forth above in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">9.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, such Product shall be deemed accepted by Partner.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Rejection and Remedy for Non-Conformance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Rejection for Non-Conformance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Upon timely receipt of a Deficiency Notice pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 9.1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, if Cellares believes in good faith that (i) rejected Product complies with the Product Warranty or (ii) such Non-Conformance is attributable to the Partner Manufacturing Process, any specimens, samples, Partner Materials, information, instructions or intellectual property provided by Partner or the inherent properties of such Product (this clause (ii), &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Partner Fault</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;), the Parties shall initiate an investigation of such Non-Conformance which will be conducted, upon mutual agreement of the Parties, by either Party, the Parties jointly, or a Third Party independent laboratory agreed by the Parties, provided that Cellares notifies Partner of its belief that rejected Product complies with the Product Warranty within </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> after receipt of the Deficiency Notice, after which time Cellares shall have waived its right to challenge the rejection. Partner shall provide Cellares with reasonable assistance in such investigation, including the return of all such Non-Conforming Product at Cellares&#x2019; expense. If the investigation determines that (i) such Non-Conformance does exist, then the applicable Products shall be deemed to be properly rejected or (ii) such Non-Conformance does not exist or is the result of any Partner Fault or cannot be definitively established, then Partner shall be deemed to have accepted Delivery of such Products (and Partner shall be obligated to pay for such Products as set forth in this Agreement and Partner shall reimburse expenses paid by Cellares pursuant to the immediately preceding sentence). The costs of the investigation related to such Deficiency Notice shall be borne by Partner, unless it is determined by the Parties that a Non-Conformance not resulting from any Partner Fault exists, in which case Cellares shall pay such costs. If the foregoing investigation is conducted by a Third Party independent laboratory as set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 9.2(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, the determination by such independent laboratory shall be binding on the Parties, absent manifest error.</font></div></div><p style="font-size:10pt;margin-top:0.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Disagreement Regarding Non-Conformance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. In the event Partner provides a timely Deficiency Notice and Cellares timely challenges such Deficiency Notice, and following an investigation by either Party or the Parties jointly under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Subsection 9.2(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> either Party in good faith disagrees with the determination that the Product was or was not Non-Conforming or whether any Non-Conformance was the result of any Partner Fault, then the Party that disagrees with such determination may cause an independent third-party laboratory agreeable to both Parties to perform comparative tests and/or </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">analyses on samples of the alleged Non-Conforming Product to determine whether such Product is Non-Conforming and if so, whether such Non-Conformance was the result of any Partner Fault, in which case such laboratory&#x2019;s results shall be in writing and shall be final and binding on the Parties absent manifest error on the face of its report. Unless otherwise agreed to by the Parties in writing, the costs associated with such third-party testing and review shall be borne by the Party against whom the independent third-party laboratory rules or, if the laboratory does not rule in favor of either Party, then the Parties shall share equally the expenses of the laboratory.</font></div></div><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Remedy for Non-Conformance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***].</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.24791666666666667in;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Delivery of Non-Conforming Product</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Notwithstanding the foregoing, Partner may upon its request take delivery of Non-Conforming Product, or any Product that otherwise does not meet the applicable Specifications or cGMP (including any Development Batch), at Partner&#x2019;s sole risk and cost. Cellares shall have no liability or responsibility for any such Product or the use thereof by or on behalf of Partner.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:6.897%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Confidentiality.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Each Party (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Disclosing Party</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) may disclose or otherwise make available, directly or indirectly, to the other Party (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Receiving Party</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) confidential information of the Disclosing Party (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) during the term of this Agreement, whether disclosed or otherwise made available hereunder or under the Quality Agreement, whether written, graphic, oral, visual, tangible or intangible, in any form or format. The existence and terms of this Agreement are deemed to be the Confidential Information of both Parties. The Receiving Party shall (a) maintain all Confidential Information in confidence and employ commercially reasonable procedures to prevent its unauthorized publication or disclosure, (b) only disclose Confidential Information to those of its officers, directors, employees, consultants and advisors who have a need to know such Confidential Information for purposes permitted under this Agreement and who are subject to written obligations of confidentiality and non-use at least as protective as those set forth therein (except that each Party may disclose the terms of this Agreement to bona fide actual or prospective underwriters, investors (which are not competitors of Partner), lenders or other financing sources or to potential acquirers of the business to which this Agreement relates, and who in each case have a specific need to know such Confidential Information and who are bound by an obligation of confidentiality and restrictions on use that are at least as protective of the Disclosing Party as those in this Article 10, and (c) Confidential Information of Cellares to Regulatory Authorities solely as contemplated and permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Article 5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">); provided that the Receiving Party shall be liable for any failure to comply with the Receiving Party&#x2019;s obligations hereunder and use the Confidential Information only for any purposes permitted under this Agreement and the Quality Agreement. Subject to the requirements of the preceding sentence, Partner also may disclose Confidential   Information   of   Cellares   to   third   parties   (each,   a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration Partner</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) with whom Partner has (or is negotiating) a marketing and/or development collaboration agreement (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;), provided that (i) the specific Collaboration Partner and scope of necessary disclosure is identified to Cellares in advance, and (ii) notwithstanding clause (c) of the preceding sentence, the Collaboration Partner&#x2019;s use of the Cellares Confidential Information is solely to evaluate and (if executed) to perform the Collaboration Agreement. In addition, if Cellares identifies a Collaboration Partner as a competitor to or customer of Cellares, then the parties will discuss specific ways to mitigate Cellares&#x2019; concerns with respect to the disclosure of Cellares Confidential Information in such context. The Receiving Party&#x2019;s obligations under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Article 10</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> will survive termination or expiration of this Agreement for a period of </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">; provided that with respect to any trade secret of the Disclosing Party, such obligations shall survive and continue for as long as such Confidential Information qualifies as a trade secret of the Disclosing Party under Applicable Law. Confidential Information shall include any &#x201c;Confidential Information&#x201d; as defined under the TTA. For clarity, Partner Background IP, Partner Materials, Partner Arising IP, and the Partner Manufacturing Process are the Confidential Information of Partner, and Cellares Background IP, Cellares Technology and Cellares Inventions are the Confidential information of Cellares.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The Receiving Party&#x2019;s obligations under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Article 10</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> shall not apply to any Confidential </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Information that, as demonstrated by contemporaneous written evidence, (a) is known to the Receiving Party without obligation of confidentiality at the time it was obtained from the Disclosing Party; (b) is acquired without obligation of confidentiality by the Receiving Party from a third party having a right to so disclose such Confidential Information; (c) is or becomes published or otherwise in the public domain other than by violation of this Agreement by the Receiving Party; or (d) is independently developed by the Receiving Party without reference to or reliance upon the Confidential Information disclosed by the Disclosing Party. The Receiving Party may disclose Confidential Information that it is required to disclose under Applicable Law or an order by a court or other regulatory body having competent jurisdiction (including the rules of any securities exchange); provided that except where not legally permitted, the Receiving Party shall give the Disclosing Party reasonable advance notice of such disclosure requirement and shall cooperate with the Disclosing Party to oppose, limit or secure confidential treatment for such required disclosure. In the event of any such required disclosure, the Receiving Party shall disclose only that portion of the Confidential Information that the Receiving Party is legally required to disclose, and any such Confidential Information required to be disclosed shall remain subject to the obligations of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Article 10</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> in all other respects.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cellares will provide Partner with access to an encrypted data storage platform for the transfer, storage, use, or processing of personal data in connection with the applicable SOW. The Receiving Party shall immediately notify the Disclosing Party of any unauthorized disclosure or use Confidential Information and reasonably cooperate with the Disclosing Party in the response thereto. In the event of a conflict between the terms of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Article 10</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> and the terms of the TTA, the terms of this Agreement shall control.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Each Party expressly agrees that any breach or threatened breach by a Receiving Party of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Article 10</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> may cause irreparable harm to the Disclosing Party and that money damages may not provide a sufficient remedy to the Disclosing Party for any breach or threatened breach. In the event of any such breach and/or threatened breach, then, in addition to all other remedies available at law or in equity, the Disclosing Party shall be entitled to seek injunctive relief and any other relief deemed appropriate by the Disclosing Party.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:6.897%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Background IP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Each Party shall retain ownership of all technology or intellectual property rights owned or controlled by a Party as of the Effective Date or developed by or on behalf of such Party independent of this Agreement (such Party&#x2019;s &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Background IP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;), and the other Party shall have no rights in such Party&#x2019;s Background IP except as expressly provided in this Agreement.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:4.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Any Partner Materials and/or Confidential Information of Partner provided to Cellares by or on behalf of Partner in connection with this Agreement, in any form whatsoever, shall remain the sole and exclusive property of Partner (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Partner Property</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;). Cellares shall not acquire any right, title or interest in the Partner Property as a result of its performance of the Services.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.55pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">All data, documentation, information, know-how, procedures, discoveries, inventions and/or techniques (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) developed by or on behalf of Cellares, solely or jointly with others, in the course of performing the Services that do not rely on and/or are not specifically related to the Product or Partner Property (for clarity, Inventions are not specifically related to the Product or Partner Property where they: (i) are generally applicable to the development or manufacture of chemical or biological products or products components, (ii) relate to or improve Cellares&#x2019; Confidential Information or Background IP, including the Manufacturing Process (other than the Partner Manufacturing Process) or</font></div></div><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.2513888888888889in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(iii) relate to the conduct of Cellares&#x2019; business, Cellares&#x2019; products or services or the use of materials in connection therewith) shall be collectively referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Cellares Inventions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; (together with Cellares&#x2019; Background IP, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Cellares Technology</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;), are and shall remain solely owned by Cellares.</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Any Inventions developed by or on behalf of Cellares, solely or jointly with others, in the course of </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">performing the Services, and which rely on and/or are specifically related to the Product or Partner Property (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Partner Arising IP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) shall be solely owned by Partner, and Cellares hereby assigns to Partner all of Cellares&#x2019; right, title and interest in such Partner Arising IP; provided that Cellares shall retain the right to use such Partner Arising IP to the extent necessary to conduct the Services and for Cellares&#x2019; internal research and development purposes, subject in each case to the obligations of Cellares under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #b5082d;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Article 10</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Cellares shall, at Partner&#x2019;s request and expense, use reasonable efforts to assist Partner to obtain, maintain and enforce the patents and other intellectual property covering the Partner Arising IP. Cellares shall ensure that its personnel, Affiliates, subcontractors or agents involved in the performance of the Services assign to Cellares all Partner Arising IP to enable Cellares&#x2019; assignment to Partner as described above.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Partner hereby grants to Cellares a limited, non-exclusive, non-sublicensable, royalty-free, fully paid-up license under Partner&#x2019;s Background IP (to the extent actually disclosed to Cellares hereunder by or on behalf of Partner) and Partner Arising IP solely to the extent necessary to perform the Services.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">To the extent any Cellares Technology is incorporated into any Product, Cellares hereby grants to Partner a limited, non-exclusive, worldwide, royalty-free, fully paid-up, sublicensable (solely with Cellares&#x2019; prior written consent) and non-transferrable (except as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 15.4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">) license, during the term of this Agreement, under such Cellares Technology solely as necessary for Partner to sell, have sold, offer for sale, import, and otherwise commercialize such Product. For clarity, Partner shall have no license or right to use or authorize the use of any Cellares Technology to make or have made any Product or product or perform or perform or authorize the performance of any services.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Patent Filings</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Each Party shall have the right to file and prosecute patents covering inventions to be owned by such Party pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 11.2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, and the other Party shall reasonably cooperate with the filing Party at the filing Party&#x2019;s expense. Notwithstanding the foregoing, neither Party shall have the right to disclose any Confidential Information of the other Party in any patent filing without the other Party&#x2019;s prior consent</font><font style="color:#b5082d;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Notice of Infringement; Infringement Claims.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.75in;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:3.8458535497183646%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">	Each Party shall promptly notify the other Party of any claims that any Product, the practice of the Manufacturing Process of the performance of the Services infringes, misappropriates or otherwise violates the valid intellectual property rights of any Third Party. In the event that either Party notifies the other Party of its reasonable belief that the Services infringe, misappropriate or otherwise violate the valid intellectual property rights of any Third Party, then the Parties shall meet to discuss in good faith (x) the existence of such infringement or misappropriation, (y) the risk of a third-party claim based on such potential infringement or misappropriation, and (z) any steps that can be taken (including modifications to the manner of performance of the Services) to mitigate the risk of such a claim.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.75in;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;margin-right:0.24027777777777778in;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:3.8458535497183646%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">If a Third Party claim is initiated against Cellares in a court of competent jurisdiction alleging the Product infringes, misappropriates or otherwise violates the valid intellectual property rights of such Third Party (such claim a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Product Infringement Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">,&#x201d; the applicable country over which the court has jurisdiction, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Applicable Product Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;), then Cellares may suspend the infringing Services for the Applicable Product Jurisdiction by providing Partner with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> written notice; provided that Cellares: (i) may shorten such notice to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> in the event that Partner fails to fulfill its obligations under Section 13.2 to defend, indemnify and hold harmless Cellares Indemnitees from and against such Product Infringement Claim and fails to cure within such notice period, and (ii) shall continue performance of the Services for the balance of the Term if the risk of such Product Infringement Claim has been reasonably mitigated (e.g. dismissal, </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="margin-left:0.75in;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;margin-right:0.24027777777777778in;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:3.8458535497183646%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">abandonment or release).</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.75in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:3.8458535497183646%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">If a Third Party claim is initiated against Cellares in a court of competent jurisdiction alleging the Services (not the Product) infringes, misappropriates or otherwise violates the valid intellectual property rights of such Third Party (such claim a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Services Infringement Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">,&#x201d; the applicable country over which the court has jurisdiction, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Applicable Services Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;), then subject to the following, Cellares shall use reasonable commercial efforts to revise the Services to render them non-infringing (without materially changing the Services), and/or to secure rights, at Cellares&#x2019; cost, to the Third Party claimant&#x2019;s intellectual property to allow performance to continue. If after using reasonable commercial efforts, Cellares decides in good faith, and based on advice of competent counsel, that it cannot secure either of the foregoing solutions in a reasonably timely manner and/or on commercially reasonable terms, then Cellares may suspend the infringing Services for the Applicable Services Jurisdiction by providing Partner with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> written notice; provided that Cellares shall continue performance of the Services for the balance of the Term if the risk of such Services Infringement Claim has been reasonably mitigated (e.g. dismissal, abandonment or release).</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:6.897%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Warranties; Disclaimer.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Mutual</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Each Party represents and warrants that:</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(i) it validly exists under the laws of the jurisdiction in which it was organized, (ii) it has the full power, right and authority to execute and deliver this Agreement and to perform its obligations under this Agreement, (iii) this Agreement once executed will constitute a legal, valid and binding agreement enforceable against it, and (iv) its performance of this Agreement will not conflict with any obligations it may have to any other person; and</font></div></div><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.24722222222222223in;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(i) it will not employ, contract with, or retain any person directly or indirectly in connection with the performance of the Services if, to such Party&#x2019;s knowledge, such person is presently debarred by the FDA pursuant to the Generic Drug Enforcement Act of 1992, as amended (21 U.S.C. &#167; 301, et seq.), or are ineligible to participate in any federal and/or state healthcare programs or federal procurement or non-procurement programs (as defined in 42 U.S.C. &#167; 1320a-7b(f)), or is disqualified by any other governmental or Regulatory Authority or pursuant to foreign equivalents thereof; and (ii) it has not knowingly engaged in any conduct or activity that could lead to any debarment actions. If during the Term, such Party or, to such Party&#x2019;s knowledge, any person employed or retained by it in connection with the performance of the Services (x) is debarred or becomes subject of an investigation for debarment, or (y) engages in any conduct or activity that would result in debarment, such Party shall, to the extent that it is legally able to do so, promptly notify the other Party of the same.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">By Partner. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Partner represents, warrants and (as applicable) covenants that:</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">it will perform its obligations under this Agreement and use all Products and other results of the Services in compliance with Applicable Law; and</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.2597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Partner has the right to supply the Partner Materials and Partner&#x2019;s Confidential Information to Cellares and the necessary rights to grant to Cellares the license to use the same as granted hereunder;</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">to Partner&#x2019;s actual knowledge, all Partner Materials supplied by Partner shall (i) be manufactured in accordance with cGMP (if applicable), (ii) meet other testing requirements and/or specifications as set forth in the applicable SOW or as otherwise agreed in writing by the Parties, and (iii) not be adulterated or misbranded within the meaning of the FD&amp;C Act or similar provisions of any Applicable Laws; and</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Partner has the right to supply the Partner Materials to Cellares and the necessary rights to license or permit Cellares to use the same for the purpose of the Services.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:11.65pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">By Cellares. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cellares represents, warrants and (as applicable) covenants that:</font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">the Services shall be performed in a professional manner, with due care, and in compliance with all Applicable Laws and the terms of this Agreement, and shall not be performed in violation of any agreement, judgment, order or decree to which Cellares is a party;</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.95pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">except as otherwise provided in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 4.4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, all cGMP Batches delivered by Cellares hereunder shall, upon Delivery: (i) conform to the applicable Specifications; (ii) be manufactured, stored, tested, labelled, packed and delivered in accordance with the Quality Agreement, cGMP, all relevant Applicable Laws, and the Manufacturing Process described in the Master Batch Record; (iii) not be adulterated or misbranded within the meaning of the FD&amp;C Act or similar provisions of any Applicable Laws in any country where the Product is manufactured or distributed; and (iv) be free of any lien or encumbrance granted by Cellares to any Third Party (this clause (b), the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Product Warranty</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;);</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">all of Cellares&#x2019; and its Affiliates&#x2019; employees and subcontractors that perform Services hereunder are under an obligation to assign to Cellares all right, title and interest in and to any and all Partner Arising IP and to protect Confidential Information in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Article 10</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> (and, for clarity, any such rights in Partner Arising IP shall be assigned to Partner through Cellares hereunder in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Article 11</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">);</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">to Cellares&#x2019; knowledge, Cellares&#x2019; use of Cellares&#x2019; Background IP in the performance of the Services does not and will not infringe or misappropriate any third-party intellectual property or other rights; and</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.2597222222222222in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">the CoA, CoC, and Batch Records (as applicable) provided by Cellares with respect to each Batch will (i) reflect the results of the tests conducted on the Batch to which they relate,</font></div></div><p style="font-size:10pt;margin-top:0.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.25277777777777777in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(ii) be accurate and true, and (iii) accurately reflect the processes and procedures followed by Cellares in manufacturing the applicable Batch</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:4.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">as of the Effective Date, it is not a party to any litigation, inspection, warning letter, arbitration or mediation involving the research, development, or commercialization of pharmaceutical products or medical devices that could have an adverse impact on its performance of this Agreement, and Cellares will promptly notify Partner in the event Cellares becomes a party to any such litigation, inspection, warning letter, arbitration or mediation </font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:4.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">it will implement industry standard physical and technological measures to prevent Confidential Information of Partner from being disclosed to or accessed by Third Parties, and it will use commercially reasonable technical measures to detect and eliminate computer viruses and other destructive code introduced to any computer systems used in connection with the Services and to correct any reproducible error in any computer systems used in connection with the Services reported to Cellares by Partner during the Term; and</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(h)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">it or its Affiliates hold all necessary permits, approvals, consents and licenses to enable it to perform the Services at the Facility.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY DISCLAIMS ALL WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, TITLE, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR COURSE OF PERFORMANCE OR COURSE OF DEALING. CELLARES DISCLAIMS ALL WARRANTIES, EXPRESS, IMPLIED OR STATUTORY REGARDING ACCEPTANCE OR APPROVAL OF ANY APPLICATIONS, PRODUCTS, PROCESSES OR TREATMENTS BY A REGULATORY OR GOVERNMENTAL AGENCY, OR THAT THE RESULTS OF ANY SERVICES WILL ENABLE PARTNER TO FURTHER DEVELOP OR COMMERCIALIZE THE MANUFACTURING PROCESS OR THE PRODUCTS, OR ANY OTHER PROCESS, PRODUCT OR SERVICE. CELLARES SHALL NOT BE RESPONSIBLE FOR ANY DELAYS OR OTHER ADVERSE IMPACTS TO PARTNER&#x2019;S DEVELOPMENT (INCLUDING CLINICAL) OR COMMERCIAL PROGRAMS ARISING FROM THIS AGREEMENT. IN ADDITION, ANY EXPRESS WARRANTIES OF </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">CELLARES HEREUNDER ARE LIMITED OR DISCLAIMER TO THE EXTENT THAT SUCH WARRANTIES ARE NOT MET DUE TO ALL PARTNER MATERIALS NOT (I) NOT BEING MANUFACTURED IN ACCORDANCE WITH CGMP, (II) NOT MEETING OTHER TESTING REQUIREMENTS AND/OR SPECIFICATIONS AS SET FORTH IN THE APPLICABLE SOW OR AS OTHERWISE AGREED IN WRITING BY THE PARTIES, OR (III) BEING ADULTERATED OR MISBRANDED WITHIN THE MEANING OF THE FD&amp;C ACT OR SIMILAR PROVISIONS OF ANY APPLICABLE LAWS.</font></div></div><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:3.571132653906703%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Indemnities; Insurance.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">By Cellares</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Subject to the limitations of liability contained in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 13.5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, Cellares will defend, indemnify and hold harmless Partner and its Affiliates and their respective directors, officers, employees and agents (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Partner Indemnitees</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) from and against any losses, damages, fines and liabilities, including reasonable attorney fees (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Losses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) arising from Third Party claims, demands, suits, actions or causes of action (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) which may be asserted against such Partner Indemnitees by Third Parties to the extent arising out of: (a) the gross negligence, willful misconduct or violation of Applicable Law of or by any Cellares Indemnitee during the Term; or (b) any claims alleging that the use of the Cellares Background IP in the performance of the Services (for avoidance of doubt excluding use by any Cellares Indemnitees of any Partner Property in accordance with Partner&#x2019;s instructions) infringes any intellectual property rights of a Third Party; except, in each case of (a) through (b), to the extent such Claim is subject to indemnification by Partner pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 13.2.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">By Partner. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Partner will defend, indemnify and hold harmless Cellares and its Affiliates and their respective directors, officers, employees and agents (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Cellares Indemnitees</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) from and against any Losses arising from Claims which may be asserted against such Cellares Indemnitees by Third Parties to the extent arising out of: (a) the research, development, use, sales or distribution by or on behalf of Partner, or any distributor, collaborator, customer, patient, licensee, representative or agent of Partner, of any Product or product containing the Product, (b) any claims alleging that the use of the Partner Property in accordance with Partner&#x2019;s instructions infringes any intellectual property rights of Third Parties, (c) the gross negligence or willful misconduct of any Partner Indemnitee during the Term, or (d) any injuries suffered by Partner&#x2019;s employee or representative while at the Facility or elsewhere; except to the extent such Claim is subject to indemnification by Cellares pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 13.1.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> Procedure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Each indemnified party shall give the indemnifying Party prompt notice of any Claim for which indemnification is sought hereunder. The indemnifying Party shall have the right to control the defense and settlement of a Claim, at its sole expense, provided the indemnified party shall reasonably cooperate in the investigation, defense and settlement of such Claim at the indemnifying Party&#x2019;s expense. Neither Party will enter into any settlement agreement that attributes fault or negligence to the other Party, requires any payment by the other Party, or restricts the future actions or activities of the other Party, without the other Party&#x2019;s prior written consent, which shall not be unreasonably withheld. Any indemnified party shall have the right to participate in the defense and settlement of a Claim and to employ separate legal counsel of its own choice at the indemnified party&#x2019;s own expense. The costs and expenses, including reasonable fees and disbursements of counsel, incurred by any indemnified party in connection with any Claim shall be reimbursed on a monthly basis by the indemnifying Party subject to refund in the event the indemnifying Party is ultimately held not to be obligated to indemnify the indemnified party.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Insurance</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Each Party shall carry insurance sufficient to cover its interest or potential liabilities hereunder including, but not limited to worker&#x2019;s compensation, if applicable, and comprehensive general liability.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Limitation of Liability.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">EXCEPT WITH RESPECT TO (i) ANY FRAUD, GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, (ii) ANY BREACH OF SECTION 10 (CONFIDENTIALITY) OR SECTION 11 (INTELLECTUAL PROPERTY), OR (iii) LIABILITY FOR DEATH OR PERSONAL INJURY, IN NO EVENT WILL EITHER PARTY BE LIABLE UNDER THIS AGREEMENT FOR ANY CONSEQUENTIAL, </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">INDIRECT, EXEMPLARY, SPECIAL, PUNITIVE, OR INCIDENTAL DAMAGES OR LOST PROFITS ARISING FROM OR RELATING TO THIS AGREEMENT, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR IF SUCH DAMAGES ARE FORESEEABLE, WHETHER IN CONTRACT OR TORT OR OTHERWISE. FOR THE AVOIDANCE OF DOUBT, THE AMOUNTS PAID AS LOSSES TO THIRD PARTY CLAIMANTS UNDER THE PARTIES&#x2019; INDEMNIFICATION OBLIGATIONS ARE NOT PRECLUDED BY THIS 13.5(a).</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">EXCEPT WITH RESPECT TO (i) ANY FRAUD, GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, (ii) ANY BREACH OF SECTION 10 (CONFIDENTIALITY) OR SECTION 11 (INTELLECTUAL PROPERTY), (iii) INDEMNIFICATION OBLIGATIONS UNDER SECTION 12, OR (iv) LIABILITY FOR DEATH OR PERSONAL INJURY, CELLARES&#x2019; TOTAL CUMULATIVE LIABILITY IN CONNECTION WITH THIS AGREEMENT, WHETHER IN CONTRACT OR TORT OR OTHERWISE, WILL NOT EXCEED THE AGGREGATE AMOUNT OF FEES PAID BY PARTNER TO CELLARES IN THE </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> PRECEDING THE CLAIM UNDER THE APPLICABLE SOW FOR THE SERVICES GIVING RISE TO THE LIABILITY.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:6.897%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Term; Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. This Agreement shall commence upon the Effective Date and continue until the later of (a) the fifth (5</font><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">) anniversary of the Effective Date, or (b) completion of all Services set forth in all SOWs entered into prior to expiration of the Term, unless earlier terminated in accordance with this Article 14 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:13.793%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:1.479861111111111in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:20.412%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Either Party may terminate this Agreement or any SOW at any time upon ninety</font></div></div><p style="font-size:10pt;margin-top:4.15pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> (</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> for non-payment) prior written notice to the other Party for material breach of this Agreement by the other Party if such breach is not cured to the non-breaching Party&#x2019;s reasonable satisfaction within the applicable notice period; provided, however, that such </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> period shall be extended an additional </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> as agreed by the Parties in writing if the identified breach is incapable of cure within </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> and if the breaching Party provides a plan and timeline to cure the breach, promptly commences efforts to cure the breach and diligently prosecutes such cure (it being understood that this extended period shall be unavailable for any breach regarding non-payment).</font></p><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Partner may terminate this Agreement or any SOW for any reason or no reason upon </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> prior written notice to Cellares.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cellares may terminate this Agreement or any SOW for any reason or no reason upon </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> prior written notice to Partner.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Either Party may terminate this Agreement if the other Party enters into administration, becomes insolvent, is dissolved or liquidated, makes a general assignment for the benefit of its creditors, or files or has filed against it, a petition in bankruptcy or has an administrator or receiver appointed for a substantial part of its assets, except in the event such petition, appointment or action is withdrawn within </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Effect of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Upon expiration or termination of this Agreement or any SOW, the following shall apply:</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.24027777777777778in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Partner shall promptly pay Cellares (i) any Service Fees due in connection with Services properly rendered through the effective date of expiration or termination, and (ii) all non-cancellable commitments, such as time and materials and pass through costs, made prior to the date of notice of such termination or expiration, in each case solely to the extent such costs are expressly authorized in the SOW; provided, however, that Partner shall have no payment obligations under the foregoing (ii) in the event of termination by Partner for Cellares&#x2019; material breach pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">14.2(a), unless to the extent the non-cancellable commitments are specific to the Product;</font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cellares shall deliver, and Partner shall pay for, all finished but undelivered Product;</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cellares will, at Partner&#x2019;s election and expense, dispose of or deliver to Partner (i) all Partner Material (including Cell Lines and Cell Banks) in accordance with Section 3.5(f), and (ii) any retained samples (except for samples Cellares is required to retain pursuant to Applicable Law), and any records, reports and other deliverables required to be provided to Partner under the applicable SOW;</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">neither Party shall be relieved of any obligation accruing prior to such expiration or termination; and</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 3.5(e) and (f)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 4.6(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Article 5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Article 7</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> (with respect to any amounts payable prior to or in connection with expiration or termination), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Article 9</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Article 10</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Article 11</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 12.4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Article 13</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Section 14.3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Article 15</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> shall survive such expiration or termination.</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.5in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:6.897%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Miscellaneous</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.1</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Force Majeure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Except for the payment of monies due hereunder, neither Party shall be considered in default of the performance of any obligation hereunder to the extent that the performance of such obligation is prevented or delayed by fire, flood, earthquake, explosion, acts of terrorism, disease, war, insurrection, embargo, changes in Applicable Law that materially impacts that Party&#x2019;s performance of this Agreement, civil or military authority, act of God, or any other event, occurrence or condition which is not caused, in whole or in part, by that Party, and which is beyond the reasonable control of that Party (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Force Majeure</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;). A Party that is prevented from performing any of its obligations due to Force Majeure will promptly give notice to the other Party of the event and the obligations as to which performance is prevented or delayed, and shall use commercially reasonable efforts to mitigate such Force Majeure. If a Force Majeure continues for more than [***], the Parties will discuss an appropriate resolution that may include an amendment or termination of the affected SOW or this Agreement.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.2</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. All notices from one Party to the other will be in writing sent to the Party&#x2019;s address set forth in the preamble above. For Partner, notices must be sent Attention: General Counsel, with a cc to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Notices must be sent by overnight courier, certified mail, return receipt requested, or by other means of delivery requiring a written acknowledged receipt. All notices will be effective upon receipt.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.15pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.3</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Independent Contractor</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. The business relationship of Cellares to Partner is that of an independent contractor and not of a partner, joint venturer, employer, employee or any other kind of relationship. Neither Party shall at any time enter into, incur, or hold itself out to Third Parties as having authority to enter into or incur, on behalf of the other Party, any commitment, expense, or liability whatsoever.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:11.9pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.4</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. This Agreement, and the rights and obligations hereunder, may not be assigned or transferred by either Party without the prior written consent of the other Party, except that either Party may assign or transfer this Agreement to an Affiliate of such Party or to a purchaser of all or substantially all of its business or assets to which this Agreement relates, whether by way of sale of assets or stock of such Party or merger, acquisition, reorganization or otherwise. Any assignment not in compliance with this Section 15.5 is null and void.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.5</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Publicity. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Neither Party shall use the other Party&#x2019;s name, symbol or trademarks in any publicity releases, advertising, sales or promotional material, including customer lists or in any publication without the other Party&#x2019;s prior written consent in each case, unless required by Applicable Law. For clarity, the foregoing does not apply with respect to any filings by Partner or its Affiliates to any Regulatory Authority.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.6</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Entire Agreement; Waiver; Severability. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This Agreement, including each SOW and the Exhibits attached hereto, sets forth the entire agreement and understanding between the Parties, superseding any and all previous statements, negotiations, documents agreements and understandings, whether oral or written, as to the subject matter of this Agreement. No modification, amendment, or waiver of the </font></div></div></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">provisions of this Agreement shall be valid or binding on either Party unless in writing and signed by both Parties. No waiver of any term, right or condition under this Agreement on any one occasion shall be construed or deemed to be a waiver or continuing waiver of any such term, right or condition on any subsequent occasion or a waiver of any other term, right or condition hereunder. In the event that any one or more of the provisions contained in this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, that invalidity, illegality or unenforceability will not affect any other provisions of this Agreement, and all other provisions will remain in full force and effect. In the event of conflict between the terms of this Agreement and the terms of any SOW, the terms of this Agreement will control.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.7</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Applicable Law. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This Agreement and any claim, controversy or dispute arising under or related to this Agreement, the relationship of the parties under this Agreement, or the enforcement of the rights and obligations of the parties under this Agreement will be governed by the laws of the State of Delaware and shall be construed and governed under and in accordance with the laws of that State without regard to the provisions governing conflict of laws.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.8</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Counterparts. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This Agreement may be executed in counterparts, each of which, when executed, shall be deemed to be an original and all of which, together with this writing, shall be deemed one and the same instrument. This Agreement may be executed by facsimile, PDF or electronic signatures, which signatures shall have the same force and effect as original signatures.</font></div></div><div class="item-list-element-wrapper" style="font-size:0;margin-top:12.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:4.69%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.9</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Further Actions. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font></div></div><p style="margin-left:0.4pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.24791666666666667in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Signature page follows.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">]</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.61in;min-height:0.79in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:9.6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.58125in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, the Parties have by duly authorized persons executed this Agreement as of the Effective Date.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><h1 style="margin-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Cellares Corporation					Cabaletta Bio, Inc.</font></h1><p style="margin-left:18pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:18pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:18pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">By: 	/s/ </font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Fabian Gerlinghaus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">				By:	/s/ </font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Steven Nichtberger</font></p><p style="margin-left:18pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Name: 	</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Fabian Gerlinghaus				</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Name: </font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.<br></font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:18pt;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Title:	</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Co-Founder &amp; CEO</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">				Title: 	</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Chairman and CEO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;"><br> 		11 January 2026 | 3:28:59 PM PST</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">				</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">11 January 2026 | 3:28:59 PM PST</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.14in;z-index:2;min-height:0.68in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><p style="font-size:10pt;margin-top:8.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.24791666666666667in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Exhibit A</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:0.3pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.24791666666666667in;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Initial Batch Fee = </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.75in;width:7.25in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>caba-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-22T19:37:19.8629+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 21.1</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cabaletta Bio, Inc.</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a list of subsidiaries of Cabaletta Bio, Inc. as of December 31, 2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:50%;box-sizing:content-box;"></td>
      <td style="width:50%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">SUBSIDIARY</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION</font></p></td>
     </tr>
     <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cabaletta Bio, Inc.</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cabaletta Bio GmbH</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Switzerland</font></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cabaletta Bio (Germany) GmbH</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Germany</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>caba-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-22T19:37:19.8429+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#333333;white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-234367) pertaining to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan, the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, and the Cabaletta Bio, Inc. 2019 Employee Stock Purchase Plan, </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-237484) pertaining to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan and the Cabaletta Bio, Inc. 2019 Employee Stock Purchase Plan, </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-254342) pertaining to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan and the Cabaletta Bio, Inc. 2019 Employee Stock Purchase Plan,</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-263637) pertaining to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan,</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-270595) pertaining to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan,</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-273863) pertaining to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan,</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-278124) pertaining to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan,</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-286246) pertaining to the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan, </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(9)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-3 No. 333-278126) of Cabaletta Bio, Inc., and</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.25in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Calibri;font-kerning:none;min-width:3.9998336002662396%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(10)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-3 No. 333-289339) of Cabaletta Bio, Inc.;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">of our report dated March 23, 2026, with respect to the consolidated financial statements of Cabaletta Bio, Inc. included in this Annual Report (Form 10-K) of Cabaletta Bio, Inc. for the year ended December 31, 2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Philadelphia, Pennsylvania</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">March 23, 2026</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>caba-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-22T19:37:19.8552+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.27in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.27in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Steven Nichtberger, certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2025 of Cabaletta Bio, Inc. (the &#x201c;registrant&#x201d;);</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;  	</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:45.34%;box-sizing:content-box;"></td>
      <td style="width:4.94%;box-sizing:content-box;"></td>
      <td style="width:3.36%;box-sizing:content-box;"></td>
      <td style="width:46.36%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 23, 2026</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Steven Nichtberger</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer and President</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.27in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.27in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>caba-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-22T19:37:19.8770+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.27in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;min-height:1in;position:relative;"></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.27in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Anup Marda, certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2025 of Cabaletta Bio, Inc. (the &#34;registrant&#34;);</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.427%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:45.34%;box-sizing:content-box;"></td>
      <td style="width:4.94%;box-sizing:content-box;"></td>
      <td style="width:3.36%;box-sizing:content-box;"></td>
      <td style="width:46.36%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 23, 2026</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Anup Marda</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Anup Marda</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.27in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.27in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>caba-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-22T19:37:19.8682+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Cabaletta Bio, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the fiscal year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></p><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:45.389%;box-sizing:content-box;"></td>
      <td style="width:4.961%;box-sizing:content-box;"></td>
      <td style="width:3.241%;box-sizing:content-box;"></td>
      <td style="width:46.409%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 23, 2026</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Steven Nichtberger</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Steven Nichtberger, M.D.</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>caba-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-22T19:37:19.8531+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Cabaletta Bio, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the fiscal year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p><p style="margin-left:24.5pt;text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></p><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:45.389%;box-sizing:content-box;"></td>
      <td style="width:4.961%;box-sizing:content-box;"></td>
      <td style="width:3.241%;box-sizing:content-box;"></td>
      <td style="width:46.409%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 23, 2026</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Anup Marda</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Anup Marda</font></p></td>
     </tr>
     <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
      <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Principal Accounting and Financial Officer)</font></p></td>
     </tr>
    </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img117331299_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img117331299_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &6 U(# 2(  A$! Q$!_\0
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M!UP?;OG'/3- $E%(&!/'/&<CD'DC&>F1CD?_ %\+0 44UG5<DGH<'@DY(R.
M">1TP/;K3/.C&<D@#'S%6P?7!QV_BSC ()XYH EHJ%;B%@"KA@S;5V@G<?\
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M67V?5+Z>:5T:CXH_\$^?VQ_VW[7_ (*"_&3XB_#SX3_LO>-?VHOV:_A%\#_
MOPDM/'.C^/=1O/$OPI^).G>/-5\:^/O&/AC3M.T:\M_$,%A%HNA172W%_;1J
MZW_^BJ4E[?QY^R/\<$\9? C]L37_ -@[X$_M+^/_ !)^S?IWP#^-G[,_Q$\=
M?#>\/P\\0^$XO#EGX0^('AKQQXQ\+:WX9U*SFTWPO?VNMV>BV6F:@(=8L+>1
M[R&UDDA%_P -MMIKY;V[?@.]VW+?=[ZOLG\]WIIU>C]-\7?\%1/VK?CC%^S;
M9_L'_!/P9X[O?V@OV2KS]HZ_UGXA>)8=&T3X8S:+K6EV.J+K,\<%Y+KNEZG+
M>OH>BKI,"O-J=Q:7$KVMF\]Q%S/P$_X*^?M2_$3X[_L4M\2_V48_A7^S5^VM
MKFJ?"KP'?W_C/0]<^(>E_$;PMX6FUR]\<:K8:3&UE;_#WQ3=S65MX8L5F;6+
M>**Z?5OL<[) ?M;X<?LX_%'0OVCOA;\2M2\&_#'P3X=T;]@SQ'\&-=T?X;WV
MDZ=X4\/?$?6/'OA[Q''X:\.:-:V.EH=!M+.U>-;^"QL;226T@DC@97+)\?>&
MOV%/VB--T7_@CM9:CHGA5;W]DCXT>(O&?QG4^*M)G&B:#?>#(-+AN-'>"(QZ
MO=O>1SQ,ELELP$C7(D$C[&=MNM^FOK^O3_(7K^?]7_X?N?HW^W[^UQXE_9K\
M)_#?P-\(M$TKQ7^TU^TGX]L/A-^SUX=\222V7@^3Q??W5J=2\2^,;V*-Y4\+
M^#]'NI-;U>* "[N;:!X+)&N'(/Y__M;?\%(/VFOV*/V7OA'IO[2^N?LN_!W]
MKGXL?$WQ3X4L_&GBK7]>3]G*P\'>&HKWQ"GBV1M.T75/$;7FMZ3!8>';'1WM
M!<0:Q<R:A<SK9Q+%+]?_ /!2/]G'XG?& _LV_'OX 1>&/$?QG_8]^,NF?%[P
MEX$\0:Y#H%O\2M),^GV7C/P+;>)KA+S3O#FH>(_#L5[96&KZCI]W:6]W-"[^
M2(Q.GRY^TE\)/VD_VDO"'[./[3_Q+_8J^"GQ%^+'P=^(WQ-3Q%^QCX_^(?@+
MQ9I.K?#'QSX=U'P9HT\7Q'USPU>>"5\6:%JBZ?XO65M*$L>F?:=.M[L374BA
M;=G\MMM[K^MNX]//K?\ 1?YOSVTU\E^!W[8]E^WC\6_^".'Q\6+P^-;O?B'^
MW5X&\5W?A6\34/"NI>)?AY\)[OPSKNM^#M3EM[/4-0\(Z_=VUIJ^@R2V=E)'
M:21I>PVLZ_99?U(_X)?QF/\ 8T^&S9&R36_B@Z1A OE9^*_C<N,J</O<M+N(
MW_.?,9G+8^6OAO\ LW_&&Y^)?_!.'XCWWP/^#7P T?X->+_VIO%?Q)^%?PJU
MGPW%X:^'&E?%GP!)H?@C2;9?#^E>'M$\1>(1.(XO$U[I&EO"-0FEEANYX%GN
M;G[J_86^&7BSX.?LV^"_AQXYM[&T\4:#J?CF?4+;3M0AU.VBCUKQ]XFURPQ=
MVX\EI'T[4K222-26B>0HW0$G7KM;UM;R^[YI;,+Z+T;MHOM2>J6V_76S/KZB
M@$'H0<'!QV/I]:*!!3'#%<(0#D<G/3.3C'<]*?37;:,XSR!CH.3CD] /<\4
M?SL_\%==<_8)T;]LO]C2#_@HWK?@O1_@#=_ ;]J:2U@\<ZCXKLM$O/'46L?!
MM=(:UC\+31W,VM0V$NJQZ<[*"C7<HAR[ KY5\-OVQ/VO/V>_V>?V!?@G\!OA
M4/BKJW[5&N_&7PM\ +KXFZ]+9S>"?@IX;G\.:A\$_&OCC4]65]7OM$LO"&MI
M+J-M<^9XBO;![!(Y&FC*O^JO[1_[)GAO]H3]M;]FOXA_%+X7?#3XH_!KX:?!
M3]H'PYK^F?$G1/#GB>RL/&WC'7OA9/X3N[+PWXBLM0628VGA[74.JV\0:U4F
M)9"MP^:/[2G[/7C/QI^UK_P3V^)'PSTGP[:?#3]GG5/BS_PG,,6I:9HZZ%HN
MOZ+X*TWP[::+HVY!);(-#NX!:6$*B"!(5 5!M9Z=/Q_KO^'>^@?-W[3O[:G[
M=_@SXD_%?4/V=_@S\-_'GP0_8P\+>#=5_:POM=\02:9XR\=>)=1\*Z;\0?''
MA/X)6K6;QQ7'A'P+J%MJTESK4J6^H7=[;:?9MYXFV?J3X#_:>^!'Q G\&:/X
M>^)7A$>*O'7A[3?$_A[P->:W86?C&ZTG5;,W]K<#P[-,FI[7M5DG5OLV)(T,
MBY4YK\C_ -JKX/\ [>^F_$W]L/X8?LX>"_A[XQ^$/[?6C^$HD^,6L_$O2O#<
M_P"S3XB_X0"P^%?Q%U77O"%_I%[JWCBSU?PMHUEJ&@Q^'[Q5AOCY$T5FZO<2
M?H3\.?V"_P!D?P#XU^''QAA^%?@J_P#CK\-_">B^$]$^+ES'>-XJ@L-$T630
M;98G?4GM (]/FGM8GDMI9!;R;=V=I5?U^>RM_2MVU>EMG>[_ $M\EK^CNC^8
M7]F/QM^R1#^U#^PS8? ZU\8?#3]LS5OVY_CI8_M&_%368?B)X9\'?$SP5%K_
M ,<8]5\"7'BG695\$_$2\UQ8?#-OX>\-Z2D\HN],$L+"+3VNW_H@_;=_:3_:
M:\/_ !)^%O[,?[$&@_##Q%^T=XZ\->,OBCX@O?C#J%[8_#_PC\*? <VA:9>W
M=^^F0S:A<Z[XC\1>*M#TO0X+2%[==M[=7LT440W?FGX;_9A_;(^).B_!O]E+
MQ;^S#\,/@Q\/O@U^U1K'QNU+]KB3XL>$O%/BCQ%X2T3XK^./'NGP^#O!VAZ/
M#XU\/>*?%6G^(M.T626YUZ"WT^P_M*WNI7M62W;] _VP/ G[0?PZ_:+^!W[8
MO[,?PM\.?'WQ)X2^&'Q%^!?Q)^%.H?$;2/AEJ.O^&O&EUX6\0^'_ !7IGB;Q
M#:ZEHT?_  C'B'PA&E]ILEO#J%[;:FC17;QQO"X[?EMHNGF_FWYMVU2'O_GY
M[6VT[+IHCX,_X*%?\%E?B/\ L@>(OA9\)_\ A*/V8/AG\9_#_P %="^+GQ^\
M)?&GQAK%BGB/6;^6]LKKX7_!V[T'P_K<$NNW-YH&LSVVNZRL&CQ)?Z/  7DN
MOLU_XJ_%S0OC_J7[>_QIT"PEM-$^)?\ P1=^$7C*RT[4%87=I;^(M2^/^K&P
MNO+5(I?):[DM))(9=KO:B147*;>U_:)_9D^.,?QTTK]I2;]A7]F?]LWQ#\;?
M@!X*\&_$?P#\0O%?PVL#\#OBSX7U'5M5EU_1O$'Q"\)ZU;^(_"M[;>)GT:]A
MT&'2;J\?P]%<O8R)+!Y/L_Q!_9,^,^O7_P"UM=V'A;X>:2/BS_P31^'G[.WA
M;1_".L:7I'ABW^+6@W?Q:N-6\.Z1IYM-/BTKPQ8_\)?I4.FZ@;.TM)8(Y"L$
M.TA6GOKZ:6ZKK>_3M;M>]R6M%:VZT]&O/I^)^P'P]##P'X*#$$_\(GX<QM!
M &C60 Z^V3@ 9)P!785S?@VVFL?"?AG3[EHFN=.T#1K"Z,,R7$8NK/3;6"Y5
M)D)20+,CKO4D-C/>NDI#"BBB@".0J,9 .01@YZ<$G(5B,8![>O88_E[_ &B?
M%O[64/Q._P""BG[47@[]LKXL^ ?#O[$'CSX-2^"_V?Y)=$N_A'XWL)? ?@SQ
M7KGA;6]);11?ZC/XXN-8N-(TX0WP^S:E>6CY<1R1C^H*;(\LXR V",@=0>"3
M_"1D$<CD$CC(_ _X$?L/_!#]HK]N#_@H'\2/C=X*\8>(+OP?\>?@1<^%M)U+
MQ=\0-!^&OB)- ^#'@S6],O=:\ 6&KZ=X*\:KI/B&$2)-K&EZL%FL+6&<B*-8
M*/TLUVNFK=;[[6];JP?UW_,^PI_^"F/PRB_:6O?V4[?X8?&C6?B/X0TGP5XH
M^*^MZ)X6@G\!_"CP1XQ\$+XWC\8^-?%5YJ=E#8Z'ID/FZ??+#%<:JMS#(T6F
MRVZ^:+GP=_X*2>!?C'\9=#^%]M\%?CWX)\&_$2[\5:;\#OC]X[\(66E_!SXW
M:GX/M-0U/4[?P+K$>L7&K*;G1M(UG6=';Q#HNCIJVG:3=SVC2*8ED\4\/_##
M5O'7[1?_  6,\-:'IC:7XF^(W@/X3>"/"'BB6P-F[SZS^R\^B6*6FMF$226=
MAK-\DCQ6[M%:7 FW(97<)^1O_!.6R_8L\5>-/A;^R?!X1_;<\!?\% _A?X?^
M*7@3Q5XTU?7/CUJ/PT^$'BOP[H7BCPOXD^*_A'4?$OB-OA9:V^N6%Y(?"+Z!
M90WD,7B:UMK>*W5)&C/\_P /\]_Z6K5K?/6_IHUY=U:^FFZ/U*_X+M?&OXK?
M!C]ECX.:A\)OC9K_ .S[J/CS]KOX ?#+Q9\4?#EY8:=>Z)X$\9:_=Z?XG9KW
M4[>YM;:W%INDENE0?9Y8896*H'(O_P#!*SQ[\7+SXD?M??"/Q#^T_J/[:?P9
M^%OBOP0_PQ_:!U7^Q]4U"W\0:_:^(&\:_"J_\1Z);6NF^(]1\(VFF^&M5N+Z
M"/RX&U\KYBB4QC\SO^"P/[*^L?LU_L->!8?CC\</CO\ MD_#^[_;A_9G\4^.
M;'XBP>)/B#JFD_#G0-6\2S^,-/L=(TJ?5=0N+34-)OI(KB&S:Q$T]M9JC)+Y
M*U]6?\$@/$7P!^(/[5?[2_CK]@+X6>/?@K^PHWPB^'NC:KX5\3^$/%WPX\-^
M*/VGY?&?B'4]?\8>&_!/C$M?VM_%X FTS3/$VK11P1:F\NE>;"[0B64_IKOM
M;R\^NW>US2WKUTT>ETTN9N^T7=+JW9-'Z.>)?^"B7@C3OVD/^&?O WP;^-_Q
MALM!UWPEX5^*_P 9OAEX8T_7?A1\&/$_C.XEBTG0?B!K4NLVNJP:C! MM?:M
M%I&CZFNEVEU ;J19/-C'">'O^"L/P&\6?&3PW\/_  _\/OC7J/PK\7?$N3X(
M>'_VJ1X'V?L_W_QGM]1DT:7X=1>)I]1BUDZG_P )$H\,KJ T(:'+K_F:?'J1
MDAF*?G5^S'^T=X6_X)V?M5?M0?L9?'KPM\6?$_Q>_:\_:\OOC1\#_%/@SX?:
M]XR\'^*/!OQN73]*T"+7/&D43Z9X3;X?WNEW\.I6.K7,45G:(ES8!?/E5/@K
M_@GKI'['_P &?C/\/OV2_P!J'X"_MA7?[;_A?]L;Q)XA\(65IJ?QQU3X"ZM'
MJ/Q.UGXC^ ?C0(X?$%O\)M,T?1=,U&/4=6AGL$OY[RRN&EM[M[I(B=?ZV^YZ
M]^VFF]RW2VOF][K1K5>JZ/3I:_ZTIX^^(">(?V=;>3QOXQ5-5_X+._'CP-J,
M)U[4XQJ/@G3]#^,9TWPA?H;B7[9X4LVL-/FM=)D_T +:VLJ0QA!7[X*"  <
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M#X UKQ[#\9D\0:UX"\1V6FZ?'JOA:[NDTV>&TMV18;@#;_5KYW!(7.-V1GD
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MXU^$,^JP?&31=>TC4]=T[P_I\_PSET34H_$-P?$4EK-*(%TN>_:YA!M?'?\
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MW@MWN)KBXF\(:JL4,,"*[3O)(T48C5&+%R-K8VG\O_\ @CU^P]\#?AQ^RO\
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MXYAU"]D^(/BK43J5HVDZ1X8T_2M1OM:M);8ZT;>RN6TW3;TVY(E^!7_!8O\
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MOB;X>?"VZNMEG]FTN]T^6P6"QLM/TJZTNQL+K3HVD\Y4^M_BK\?- _X)<_\
M!6W]L3]I;]I?P;\4?$_PB_;2^#OP=\-_ [7OA=\.]>^)EU%XP^$>E6-AXG\
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M7_X)LC<!\-OB: PP0/VD_P!HH97(8!O^+J?, RHV.!E0< X(_9; ]!^0]O\
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MZ8LL&I>.?$?B34;2$65K;Q?9+:ZAMLQ!_*+\CZGP/0=,=!TP!CZ8 'T ]*
M,X &>N!C/U]:+_U9   &<#&22?J>II:** "D90P*L,@]1ZTM% 'YY?M,?\$P
M/V/_ -KCX@0_$WXV^$?&.N>+K?3(=)AOM!^,7Q=\$6B6<$K2Q)_9'@KQSX?T
MHRHS,1<?9!,3MW,P!W?.H_X(+_\ !-E2&7X;?$U64@JP_:3_ &B@0PP001\5
M 0002"#D9&#QS^RV!C&!CTP,<YSQ[Y/YFC ]!^0]_P#$_F?4T[VVM]R]>JZ@
M?C2/^"#'_!-L;<_#CXF_*I08_:3_ &C!A6+[U7_BZIVJP=@5Y!+.3G<13?\
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MP=XR^$&G:UIFFW>E1:_X3N9$CTJX\11I=3//IMI!H=U<6=S'IKS16[-70?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN;62XU 26D?F^5^#/^%__$GQI^QQ^QK^U'<?$'0/AYXL\:?&#5]>T+5KC3M
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M)J3BI'Z?T445^,G["%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHI ,?YS^II:2::NG?S^?R&%%%%, HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "D.<<=>/U(%+37.!^(_P ?Z4K7<;6O=6OM;FC?\-/F-;KU
M7YGYZ_M7^-O$GA?]H[]C[2M*\0ZAI.BZYXI\6OXAT^WO[BTL=5M],LM->(:F
M(IPDRVRWTCVRWD+V1E=K69XI+VTECPM(_P""@</C/QUX7\!Z!\'O&<=GX^\1
M^(/#WA;Q=?:EI5GIUY:Z!$MS?:Y%"(KB66TALI[:X!L)+P>7.9FNH!$GG/\
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M@LUH+%Y?55?#2E.$:L8U8QDX.*T]HE?>^BTV=FFD^BBBO./0(I7* -DX&<@
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MP3X^\+7-IX@0::J;M>TV.80W6DRN\4S!#&LMT!'$\DDD*V[?NIG!_(SX*?\
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MM^5[:LGNX8KN"YM)T$EO<0&"93T=)5(DC/)^5XBR.K=1P1M:OCOP9^PI\"_
MWQ"T_P"(FAVOB5)]'U9M<T+PM>^(;^[\'Z'K+).%O])T29VCM'ADE\^WC200
M07$:31(KI&T?AZ?\%5OV?8]/OK[4= ^)VF)HGB=?"7C&"X\(QK-X+O\ >\*R
M^)636&&G6<MW%>V4%SB1&GL;KS!%'&&;[NU;XQ_#K0/A=??%VX\4:7/X TW0
M[C7FU^SN(I+&?3K:.5V:SD\QDGEE:&2WMXQ(?-N5\E6)-?3/ \8<.4Y4E0S3
M+Z><M8/V48U80QW,H15&T$U*<H5%R)>].#ER73DCYWZ[PQG51U)U,OQM;*V\
M2ZCJ0G+"J#MS\\962@XWYI>ZK*:T<6_42.,_+M]3QD<<Y/8_7OQQBA""1A1[
M$$]><\=/3N>O:OSG\)_\%*?@CXRF\!66A:)\1[K7?BAXB&A>"- ;PO -6UFT
M+W,4FOO:+J\HM-%62RG_ -+F9/W%M,R12/#+&OZ(VTC2K%*\;Q-+%&XA<!7A
M+1JS)*!P)5)9&"DC(..AKR,RR;-LGG3AFN#Q&!G64I4X5KP=2,)*$Y1B_BBI
MWA)K1RC*.Z:/2R[,\!F<*E3+\73Q%*E/DFZ4XU(PDU&48RL_=<HM-76JU6S+
ME%%%><>B%%%% !1110 4444 & >HS4<@_=MC .W /IZ=UX'^\OU'6I*9)]QL
M=<<8Z_S'\Q]1UH_'\12^&5]K/\C^77X.A3XX^#A4M&!^V+\:G12R;]BIXD4Q
MLP: NDGFQRR8B;,EM;NK0 2F;^G36M*L=<TC4]%U.%+C3=7TZ\TV_@D&4FL[
MV"6VN8VP00'AE<94JPX(((!'\Q7P=)?QO\%GRKK+^V+\8?+F MR9=UGXJ>V1
M7D"W(@BMS*3+"RVY9X/FE25)$_J'ZX'3MS]2:_8O%B3CC\DJ1DTU0QM2,UNF
ML6G&5UIS)K=.[DKNTW)+\P\-*<9X/-8587INO3A*,U>-G3J1:M+9.[M%Z*]H
M7@HR?\I7QI_9,\5?!KP]\>-/U:;Q%I^B_!+XAZ%X]^"FKZA]FEMM:T74$U:T
M>5;X1BS*RW&EZ;'=6[I'<V#:?'-)%%;3P05]"?M&>$?%?Q:_:#^+WQ)AN[V_
M\6?!+]G+X?2^ -&L[**Z-[XE\=^&+J."?R26?S$O[F[$9V"XN;JZMX8XYO+C
MC;]'?^"HD<2?LD>.9V YEMTF8[@SP>3?EXR\>)&C FD4('&Q781A=S9\X_9M
MC2?]MCXP02Q+/&?@G\"I&1_*95D7PI?G<8&+D_*HC6Y.Q8A--!N+3QL/?P7%
MV/QN11XDK1A+,,NPF=4H<\;QDJ#X6I5H23W6*;J5*_+9P]O[KU4EX6-X;PV&
MSJ60T9.EA,=B,LJ2@DTJ<JTLYJ4Y6YDW*E'EC3O)<_)9MRNG]'?L)_LUP_LR
M? +P]X,O(9!XMU2:ZU_QE<3F-YO[:OGQ]EA:)F\FSL[9(XX(M[. [R.8W=HD
M^T8QA%'H,>O^?R_"HU "@@'/.<X^[R3G'.,DGD@Y+8[8E7[H_'^9K\+S+,<5
MF^/Q>98V7/B\;B*V(K3LTG*I-RM&\I-0BG&,%?2,;=#]AP&"H9=@\-@</'EH
MX6C"A2M:TJ<(0CS2T7ON2U:277J.HHHKB.PBE!.UADX+97 *G*GELYX7'&.I
M('>OS,_;)_9GL-5\6>,?VG+.Y>TO/#G[,WQA\$:_8A$-OJ4>H:#<RZ+?%MZR
MF[MF:X@54CS"F<RB"[NUE_3<Y[#L><XP3TX[Y.*\#_:C;/[-WQV!Z_\ "I_'
M8R"0<'P[J&3E>P&"0<*0"'*IN8>QP]C,7@LXP<L+4</K.(HX*LXNSEAL54IT
MJM-VZ23E>]FM&M+,\G.L+1Q66XF->',J$)XNF[)J-7#TY3ANFDVUHFGLVC^=
M;]G/0+GQ5\7?V+O#MC,]M<Z_^RQ\4-,L&_=RBWGNM6^(MI:7=M%*Q;S%DN;=
MGA>X98I+<R(&7S[N;^BW]G7X-:9\"/A!X6^&^F[Y7TJ"]O=2NW$7FW^M:Q?3
MZSJ]P1$BJD;ZA>7"0HHSY2HS%I'=C^!/[&*D?M*_\$_L;N/V>/&,8Y0QY7Q-
MXS,OEE)BLB.Z.^Z1YG+1/+!;QQ!9(/Z:D)VJ, ,%!(RS $ # ) )&.^!G.<
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M<^ZQM=0>-;B:R8QI(A?(8[G('FA5^Q%C(QN<L0>I !P ,9QU.<DGWQQBO9X
MX8P.39?#,H?O<3FF$R^LZTDG5ITW@<+4G!2Y8M>VQ2J5IQC[K;@WK&YKA*48
M+GU]^$;6WUC&7YZ[M7MVN2#@ >E%%%?H!TA1110 4444 %>.?&WXT:#\"O!%
M[X^\4:3X@U70=.D?^TF\.V4=_<Z=;10SW$M]=0-/%(+.**VF,DL22F/;ND"1
MAI%]CKG/$OAG1O%V@ZSX;\06%KJVBZ[I][I6IV%[;I<6]S:7T$UM/'+$^0ZM
M#,4&2I7 *%3@CDQU/%5,+7A@JD*&*E1JK#UZE)5HT:_+^ZFZ;:4DI;INU[7N
MM',^;E?)O;1VO;5*]KJ]KWM^;LG\A>$?V^?@9XR^('@+X>6$WB6TU#XF:=I^
MH^#M6OM'*:#JIU#[4HT]=0CN9!'J%K+;K!>0O&$@EE1M[1,KU[;\>/C_ . ?
MV=/ DWQ ^(EU>V^CQZCIVE06VG0?;=1O+W4I62"*UM5=6DVI%//,5):*W@FF
M".L3BOP"U_\ 8[^(GPET7XRK+XBBL/$G[,>IZ/\ %[X6>)K!94_M#PYJ$MWJ
M-Q;J9ID>S2*;1(+ZY'G74>FZI#)+<74=E=,]]WW[:6H_$C]H;Q9I=G<ZN]MX
M>^%_P!?XKWVD01Q7-GJWB%Y)1I[W>G70_L^=;G5+NPT^1[NWN52S,T#!Q=!H
M/QRAQSQ1A,KS6CFF6?\ "]"<(Y7&EAZ<:$N;$5\'4=2"JM26'KX><M)MSA.G
M.2=)JI/@5>K&,N:+56ZY+;6YN5W5VFDXZ;:>33/U5^!?[=GPH_:$\??\*Z\"
MZ'X\CUN/0V\17[:SH!LK32M+,5E)#)J=P+F2*WDG^WVHA2-IA(TP\MGCCDE7
MZT\5:MJ.E>'M2U/1]*FUK4;*QNKNQTR*5+=[^:VADF%J)9Y8(8S,(S&CR2[?
M,9% .\9^(/\ @G3^SV?@Y\!M%UCQ1IT'_"Q_'TMYXL\2:A.B3ZI##K4EO/8Z
M;<7_ )UR]R\=E;6<MTXF\J2Z:5T5MTDT_P!_M;A]P)!5@00RA\AOOKAL@!AD
M<=,\=,5^D<+5,[Q>0X3%9Y5IO,,7'ZTHTJ*H+"TJT(RHTG"R;G"#3ES)R4VX
MRNHW._!U&I4ZM:*J).,Y0E*48RBI+]VE'57C\5FDUI=/5?BZ?^"R'POMM*\/
MZIJ/P[\6:2TOC*#P)X_L+NUL4NO!6L74]];V$E^@UIU>QF72=4G6[M#J%NT-
ME-")ENHX[>7]%/CS^T[\,/@#\'+CXS^+-7>;PU<:=;76@BSMGO)]>GO+,WUC
M:V<$;(I>ZB(&YGCCB>2-)&$D@#_E[\=_V O!VC?M(?$G6QI]M=?"[]HKX:_%
M+6M:T'[.%L_#GQ,T&TTK4]+UVQA9C;P7 ?4-:U*VNXGM?*E6[@N46&XA>?\
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M\8QBFW*4J-112MU;DMVEYH_GC_8RVG]I?_@G^P P?V?O'"1MY3*P\KQ+XZB
M,C/*"ODP.D;^=(DD B6(3*J7D/\ 36OWO^ C^2U^.'[/G[!GQC^%WQ?_ &7/
M'WB+5/"$VE_!CX7>(_!GC"+3=4O;V6[U/5=5\1:E%)I'VFSBFFLXUU>UR9Q
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M[S4=4U"YE:2XUC7M3N7N]7U>[=(X5DN+VZD=R1!$H5541H,!?PU_8F7&J?\
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MMTU"%TUONWY?B=%13(V5U!#!O7G/<CU/I3Z]DO\ 'S6S] HHHH **** "D.
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M.&C!+GH.6R.>QQ_WU\M<DWQ5TH$JJ!L;AN,ZA6(^ZP(^8*00#\I.0YQ@+O\
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MWVM_[(TEHP;=50S7-QO;?O#G#0(P*HH(4!@SQG:<'E7\%V,PR=0U0,Q+8^U
MA6(.>44!C]P,=X) 7<<[ /2(-.B!#9)#$]6'SDG+%MN,,6.21M_@7;M48O\
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M$8F"-]ED\U9@J)Y0BRZ($"G[Q\$^,;?6;&W)N(I,KDF,<CY1M!4X=0QY&[H
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M 9/)550MQO=V0# )49P'<A5[&\F,%K)*@)*J<#!))(*@8"NQPQ!PJDG& "2
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M>',@4%F;(VGSO3OVW?CY9X>\?PEJT1E5FAN?#J6J6\2E"Z0RV4D+2, 0@:=
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M.Y^?:L[=OZ?_  #V&K?<FO1KKY]]_5CJ***0CSSXC7LECX5U62-BK-93B-@
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M9[KRH+#5H+>^GTV^$,A\AIB,18!C:X7&P2[%C2SXCT4H9(V))5'/RJ,#YFZ
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MD5KY0_+KKKYO<T:***X3I/*OBO>/:>%=1",PDG2*W5EV[P\]P(QM&"<NBF+
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M+LC^64JNYV:,%=IVD8VR,  )FW>=_#.:'R@F_!$MJ^6W_P#+,['^9V"A8Y2
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M23:M;F6SLX[=>M_*R3:OK^H2_=7Z#^7X_P Z9* 8V![J1^8(_K^=2 8&!T'
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M[+J[DDIA%=857]ZD;-Q?C;PPXBED6 H51_-5%)9 5E+S%4VJ(H_FD+.Y\N9
M(]C ,OT/X)O+2TMYC<&,AD(;<0""KS @L.5)1HP&/.#&B@LT9K@?B%<6;_;G
MC\EOW$^1L+C<5D()#(PWN@DD"[4R9#_I*+*I@_.Z&,JO&N'+I=6E[R;E[K=[
M^[;6RLM%;75HXHRM*]];N_GJE\F[:ZZ_RK1O\X_'&E+$SX23[@!!7!(9V!3
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M Y[]AS7UCXL02^'M67O]DN''7@(F]CPK\[00HVG+$#(.#7R3X?YLHE/!\N4
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MCC)./O;XH2Q>2V"N3;1X8%@I_P!8^\.H"L^TI@'S0H2*1")%6&7X>\7\O=H
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M'W1R,KEFV/"B@O&YW1@-YD@^6/AD\2_9<$C]R4888D&21\%@HVD[0 CL%5B
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MS(B)NCCD4(-P9T!)4*,YWCV\M)I)Y;<QF-;>7YP9 "Q1P 2R;N56-$+A)74
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MQ1S6]U$(YXI$5EEB(99(9>26CE#2K,,_,'*GH!6U\8XOL7B7P]>,6$=W!/:
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M;,IW.3&(V &Y@&^E_P!F;X?3Z%H^J>.M:T_[/JOB(K;:0DZ@W=KHT"SH[^6
M%0WLDT_E-YAD:$(66+>ZG!^&/[/NK:EJ>F>+?B!##:Z-;W(NH_#DTHFOM3@,
M1EMY9Y[60101F5H"(096E"E'1(R0WU_<ND:)$L44444:1I;I&D<<*(FQ(T2,
M&(*J[0H5%\M%^3!R*QSG-*<L/++\)-2C)0]M7@^:-DXRY(26C3:7.UIHHI/W
MCS\?C$H*%-\T7:^BNU9>[?I>Z=]M&FU9HSKHKAAN;:Q!#2 EL*>%(PQX.U"6
M&%&"1N(0_#?Q@\0ZAXK^*]MX!B=6\/>&[.SU"^C"L6N-8O;<&#S,<2"W1F2W
M255\D22N"Q8QG[7O)T\J3!VM'&\CLS%$"JDA!\S.[(PW\6%+MG.01\5> +3_
M (2CXL>)_$#QF5-2UG4XK8OMD*6]@6M;7RG8*XQ'$"L:!@I.$<."1\QBINGA
M8\LGJU>SM+972T;TLFVWK:R:<KGD8.*JUI3:34;KO9WBW;6_PIJ^SZ7L?H9\
M"O#JZ-I*S"$1--I]LIY.6^9B<Y9@?FW$LORDG )"U] 5S'A.Q6RT2QC5%C;[
M/"&VKM)V@'D# P0>,$C!XXQ73U\W4O+57VN[VOLO3\CVC"UV,2Z/J*E=P^RR
M!@"02I4A@"O(..XP1C(93S7Q_HY$320 _P"IO+NW/&S;FX>10,$=5=<$;2N0
M.64EOM"\C#6MPC997B=&7&<AA@>O0G)X/&>_-?&=S;KIWB/7;$NS^7J$EW"S
M *)()]LJLNTN&W;D5F&Y2VTL0053V,HG":Q$4W>2BXJW6-FV^JLOD_DCS<Q3
M^KQ;7PSWT;5WIYV>[Z+=HS/B3X#L_B3X'NO#%[(R/]I&HZ5(96C2UU6V3_1Y
MD,:N!YD>Z"54C020E0SQ@DI^>&EK>:)JDVDWZ20:AIEQ):7MM*"ACEMYFCW2
M@["J'RU=4QD@)G[H>OU"M)B1RS!2F<9#!7";MX!4D\*<@J5+#H^[Y/*OBE\%
M[#QY;+JVAK8Z9XP^T!KN^=?)BU.,[8RUPJ 1K*(4P6B0M/(4>:0%>?L,HS-8
M6*PU=-8:<E>3LXTY77OV5]&U%.S?O)-*[<EME>,C3@J=222;7*MU;1OLE);W
MOK?K=6\\\$>*5LI-XG(WB-V!#X88!'FL/*;:2T8.]MA$;.Q##(]X;QQ:FV_U
MMR,J5,+[5 )1<HS(7?RR/D5A&R!@1A Q)^(;A/$7@.]?3/$VFWEG<V[^09<+
M):W9W^4\MI/&S@*2V1YXA92Z-D&3Y]=_'-L(0GG3 HBJ\32M(.L2J% +PLR;
M-S8^5%<[<LKL.ZOEE/%2C4HM3IO:5.2<6DDK>[VZ[.+=FT>VZ<)^]%II6LTX
MZ>M]G_PW0]1\<>*!>174HER%AC!8!0#M#AE"E1&<F)I/,5R/+4#)QD_+-Q9:
MEXHUNVT31+::^UC5;B.VL;2(Y:3(>:YE0$8C$<2F7<X6.,X$C$ M7>V:>(O'
MNIV^A^'K:6_GO&V1.2L=H@RA>XNYC$J101)-EHD9GW%3%SD-]??"7X,Z?\.H
M7UC6#9ZIXT=9U35;=)3'I-O,D9>UT]YPGFR QNYOUCCF;S7B#"-2HWGB</D^
M'G'26*<+4J*U3YE&/-.UE&*<;.]I634=[O*OB*>'I27,G/E:BD[WTCO;R:=W
MKJ[:-M]QX"\*P^ ? _AWPDH5Y],LMNI,A,D<^H73?:-1N$D?$DC27<LJEF<K
MM48(%3ZM?1:=87E].?W.G6MQ>3DE1^YMH'G9LL57E$ ^9A@D!B%R1KW$BH3&
M!@*<D$LQ#,<XW'DGG)+ $;]A3<I:O$_C;X@70_AWXB=I&AN-2M6TFVD0N6#Z
MC#-'"Q\MD?"-&P.UQ@,';Y0P'Q?/.I.K6JOFG.<YSFW=RE-IMV6]W=NU]]+:
MGRM>I[>HDG=S:E+=;VDVF[:WZOS;1\V?!BWUKQ]XIU'Q3KL\M_/J&J^=;K.P
M86UE+>>;!ID*J/+2U@^T+Y*<?O<LR9 !_7SPEIRZ9HMG:I'Y:!97VY!YDD)4
MG'5B@#,>F20N !GX(_9C\*>1:V[.(T=&LB?DP$VA,!2C'Y@P(ZE  41MA93^
MBT*&(+&,!%0; !QM4 <$\CJ,#)(QR>A/SU64Y/WTK][J7GH_FF_/9M'T$%&,
M++=VLDDM-'?33KJM]$]66*8_0?7^AI](PW#&<<YK)NVI,DVFE_6IY/\ %RU-
MQX6F( Q#%=2YR1M9(PV3VQA=H/J0"<5X?ILNY6P-N2C GIAL$=1@DK@Y7<%;
M(RVWGZ5\=67V[PYJ5LVX;K6Y6,QJ9'+/;O@E ,X#YY4Y4 MSBOE/3+I5MXIB
M2!(J+(%;E& 56)'+!EVG"$NR [0=H 'N94HRPU:+W=12M?=/5;Z;W5O)OS/+
MS%-*D]M+)Z_$FFUH]K.U[66JO=V/$_VCOAK=>*K"T\<Z-NDU7PI8WBZO#&Y-
MQ>Z0@6Y (*2F86<T)D$9;?ME<*2X91\T^"M5C6>*6.5669B(I,\^60$WI@$S
M1':44JS+A@0&CWD?IC&L,RR12PQLDJE7MY462&1&C\F9)8VW1S)+N9F65"CA
M@H4J,#Y?^)'P N%OI_%/PWMK.STZ.'S[WPZDCK+')&-]R^FL^0RE?,N)86.T
M[56*-I'&W[#*LUBJ2P>+DH4VK4Y2VCJM&[MI2F[1BHV2<N9QLN;T<NQD.14I
MRU7NNZMO;5:WW;NDO.T;:]EX*\7M:VT"R2AHPX212=[*1\_F0#S=RNZ!V#?,
M92<L42,-7>:OXWM1; QS2>8F&+. X"YRQ!:25#(25B,:[=R*=H$AC=_BFU\3
M3Z--_9^J07=C>1;BUK<%DF5@W#!D'EG*#)*RF577)V2!R-:]\;(84+33AI0W
MDEMCH3DE_+;=*QQC9E5!"KO(W(<ZU,I56JJD&I0E*ZY&G&2TZQNI1:WOI:S?
M-8]-THRES)Q:O:Z:M?1_EJ^NMUY[WCC7?,AED,VTL\K",-\RK("&WLH;;O?)
M8L6=#\F_9N+>:_#OX=:E\4_&-II8'E:#H]Y9ZOXHD#E83IGF^6EDCP[@MY?P
MG="JE5559LLBDQ];X9^'WC;XIWB_V7"+/38R]Q=ZSJ+_ &>V2'S2A6VC!\Z[
MGQ&[@1J,ILCWMOB\[[?\#^!]&^'7A\:+HB0^?<&.?5M56#;/JMTBHANIB\DT
MHCQM2*W68I;H[>0J@L#KC,QI99AI8;#U(SQC2CRQU5)-I-N:?*II7<8OWKN\
MDD[G/BL93P]-QA).=ULFXI:7U5K+H];K71;KI[AE6(PQJD<2A4CCC0(B11(%
MB1%55"@ $;/NY56&"37S_P#'SQ7?>$OASJU[I3F/5=2FM=#L) %\RVEU)_+E
MO%+,FTV]NDS(5;=YQBXQS7N-S)NR!UQ@<CIQU. #NSR02.>"RX)^2/VB]1.H
M:SX-\&*JF2:\_MZYPYV+':I-;1IMP-P,LTCI(#^[EAAPOSE9/BI-QH2EL^1V
M:T;;6C]6W9?*R9\U%*KBZ:2<E"2YKZ]59/5?/IKKY=/^S-X.:X&GW=U'YT]S
M;/)<RR<F2YD*N9YR!M=I)-[;OGD?Y6,C1C<?TUMU"00H.B1HGM\@"\>V1Q[5
M\S?L^Z#%9Z-8R[8P5L5QM097<P;EL*V,8"J1@@;@ -H7Z<C!"C/N"/0@D'N<
M\YYS] .E>!-RE)N:][2_?9*[;U=^_9GOI148*.J2Z=/P2V2V3U\MGT445('!
M_$6'[1X,\0IL#;].D*[@ #B)FV\@9)QR 6W#"=< _,'AR0G3;!'WATM52;;N
M9F<!5=HR2?F0H$4GC<Q(P!N/U[XAMA=Z)?6^.);1U+8&<;#@8)P"P) ).%)Y
M/-?'M@4M)I]/8_O=/N[VWE&,$QF<['&XL<!&VIC( 5L,=U>OE;<E6IVNFE)+
MNUIM]U^_R/-S*#E3IM)NU2VC\G;JK>O:_P N*^-7PO?XE>%8$TF*(>)](NA?
MZ5*7,/GP11LMSIQF6,Y$\)"!"X#NQ9'Q& _Q!X6OUMY8HSB)X=L$\2@^9#<Q
MNJS1W*Y8":)P R\_> ^X3C]0[255"%&)7"D'YE/]\8/52#C:03MVD$D\5X%\
M4?@1'XENUU_P'!I>DZI(99]5TN1I+2'6KF0M.]TDX#Q0W<CDAD9$BD67<\JK
M%BOL<GS6-*,L#C&XTIZT:DG[M)VO-2;3LINVR48R;;T<CIRO&QC35"I)<L4D
MF[MQ:NW?=65TDEHK=+7<'@CQ4+%D+S.%F> [@"6 8J\J)NQM?!^5Q*2Q*HI;
M"X]8OO'5N]NV'>1<2LC-MCVD8P[#:VT@[F19 $"$ ,JLRQ_#\6HZOX6N'T_7
M;6ZTN=)CNM[A%)(W;0L;@R1R1;RRQLVUBDD;H2GEK6Y/XZ@D@D_>ON$;.?,N
M"0 2C!$(=GP70R.C#*J%0#*QYZZ^41JU%4@E*,K6E!IQ:=E=6TUN_M:JZOK8
M]=TX3M*+332::<=M+/7;HM/P9W7C;Q)%<"ZF:X?R^&/R$$%0[;QN^? 1D#$.
M,2MO8,,[OGG3/"FM_$CQ+!X9T%)7O+XS7-Q*'6&.TLD)>XN)) /]1(KE P"[
MV<*KHWE@]_HVA^*OBAJ4>B>&[.X(N6\ZXU*X06]E9VBCS);J1V&) BKY@CM4
M8[S&#G(<?9WPR^%_A[X:Z0@ACCNO%%U$;?6-=B$BK.L4@E2TLXIPQMH(BJJX
MC6-)0H+"1@3)I7QM'*:'LJ<H2Q4XQ48)M\BE&T*DW'E45=:+F4I)6C%)N2RQ
M.)AAJ?+"474:T2Z))6U36FJZK2[.VTS1['PUHNE^']+3R=,T2QM=+T^( *JV
M]I#' &8  R22/&9))& 9GR<D@!>'^(6OS>&?!/BOQ#;X-WI&BWMY9+(@>,W4
M<3"V5XCL\P-*Z$HS(ORXDD109!W<\QW,6.1N.P<C&,]\DG/&2<GN!U%?-O[0
MVO6UEX1M/#S,YN/%6IV^EQHBMB2&WFAN+L2$8VHJ!%*[OWOF^7T)9?CN:3A.
M=1OVG--ZKF<I.UMG=N4MVM9-WU=[?,591KXB"3OS24JEE9)1LWIK]F]M[:>;
M.%_9R\,76L7D&JZ@)KR^U.]AU"_O'=I)9KZ_#3W8+.''V>&1Y$B7Y\(QC4#)
M6OU@TFR%CI]G; !?(CP!UQD$;<X&.H)&.",8P!7Q]^SIX96VM+:XDC1=RVLQ
M(3+9\@E6<GY2[GD%=A D?*,1N;[4&,<=.U?.U)RD[2M=-[:V3LTN;Y[7MVNC
MWE%QC&ZW5[][:-_>@HHHK,!K$8(/3:Q([D#&<'(]?QSU&*^7?BTC0>,=+F(4
M1W-A=H<8R<2JRJQSCG<7 &0<,Q9 "#]1, >"2,JRC_@6,_CP,=NM?.GQKLG%
MYX=U10HBM+B3SB, "*13 VYB5'RF0/MP<E1@D*V.S+VEBX-WVDEIHVXO;ILV
MG=6V]'CB$W1FN\6U=-I\NKV[?@<?9?-"J3%9"RM#+@9W0-O#H P (E5MK[EV
MNA(!SR/@OXU?#:?P-XPFU_2+%++P=XDOXC9JC*;>SU>6!V;3@K /;QL]O));
M1AMFQ@F[<56ON;3I-C;&8@9W(&QEC][:W S\Y8L"<L"5R" 1<UGP_P"'_%FF
M76B^)=.CU+3KLQDP2NZB%HRA62 H1Y4Z.&99T9)%5FBW^6S _5X#'3RW$QJW
M<J<VX5J<4[2A=6:2]WFTNGK9I[)L\S+<6Z%1*_[N6KC=IZM7O%Z)K5+L])7:
ML?"O@76 A55.UXE&-S?)_&NT@!1(/FE3)P57YP<J)*^L_#WC>WCMU2:ZG+K&
MA"*0LI$6-PD5)$+#)8+N<855$8)="?F?Q?\ "+Q7\.+B75K0KK/AV1IVAN;!
MV-Y:0J"R1W=C(V043]WYD4LI;#<9V,<*Q\:H@:*>YDW0.'F5U$<D3KNRS1.X
M<E-NTF( H.A9F4O]%BL-ALRBJV'G&K3D]T[2BVTN5JW-%WT2TUVT9]/>G7M*
M$KZVT:33LKK7>_XVNNY]1>*_&4<UNZ;RJ?,/E+'S7V^6Q+*N6$B[49S$2=PE
MDF=B%7Y&\<ZH)IMD4CR;_,>0J"2%4%GF$8.2$1&=I5P56-WVA 16EJ?C'[3B
M"V^T223 -$(@\TK*TC,J+'&K,9/,E"L"4#2F-1YS. ?1_A[\!M<\5WVG^*O&
ML::=X8CN#(=-N'D_M+5H(D.^!5MW"P6[2>5#-EEFD1GPF&WNL/3PV4TG5K24
M+:1A[KJ2D[-1C!>])ZW?DKO392E"A"4FTI+17LVV[;I:[:V5G9-V:+7[,WPL
M4W4_Q5UR$1MLN=+\*"0R%PDY%M>:H(5B"?N_WEK;R.Q?+-(D3K^^'US=.R[L
MGYAP<M@ALDAB21SD!V!_V@V1DFUY-A8VL5EIUK%:V-O&L-M9PJ5M[>$'Y8DC
MY!QMW>;)ND+$L7+MN./<R CDD$E01G'4AL;F4."2%7&X$X&1GBOE\3BZN88R
M6*F[-J-.G3?-RPA!W26B3OUDG=R;:23LOFL9B'5=ZMDY25FE>RV4=+I6L[W?
M72]E;XW_ &AM;OM8\6>&/A[:S.=,96UG684VAI)[?[.-+MPTBY=09'F*G<FU
MH6*DIA_MW]GGPP=*TY+GR!$HT^WB)))8M]YADKG!XSN8MC;SU)^"8-OBWXX>
M+]0B4S6UM>V^EV^]DV(-,M8[:Y:+@B-8[BWF W*6F6.-@ Q.W]7/ .GC3]#M
M8RH5C;6Y;"A=WR'DX)_BW8].@)7!/SN-J-U:D)/WHRLEUM:-];[6MY;M/5GH
M8:"A2A;3W5V?JWYMW;U];V.YP!GW.3]< ?R I,<D^H _(D_UI:*X3H/F;XRV
MY3Q'HUVV/+,3P-R3D&.YE"D?*H4[-I!)W.064(K,><TV0&)-Y)9%56(Z9P%/
M (SD@  *"S%2J*>%]%^-%KFRM-1P +&]L)';&<Q[KA'#,JETXF !)9>-F/G
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MGJ>_6O!KU/:3<K;N][WO?7[M=&VY=]SVX1Y(I=DELE;1*VFG3IH/I&.!^/\
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M+<@%0PR5(&5(*ON&Y?+(.\$KQG(^(Y;*71]8U73Y&*0I=_:K=,*%>UD>6,;
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MD@E=W(.,9P,\XQR!V'M7/7_B/0].9UN]<TFTEB.PPS:C:PNL@(Q&\!W2 D(
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M5JF^5V6FOEKH[=2Q49))SETO:ZZKLKV;7STOIOJR3R$Y<[6R!\K;BH^7: V
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M#OA2VTJ",%65@J8!P>% QR#C/+8XXR<"NP6)%"J%&U<X]3G(YX]#DG<#N (
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M]C46E[:WK*2I^SSQ.VY6*E1&9!-N&U@592WR9'RG(]H\1?"'3-061DBG(90
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MTI8(!CJP8@8;DD)O@\3_  "LY LR6-P\L/S0N+H QL""62:,;R265W)X1HP
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M4M+BU*ZBT:XTV:-KFZB,DL/YV?LF_L]:OJ/[$NE^"_!/[ WQ _9-@\=?MN_
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MG_H'ET_Y>_X?[OK^O4_=_P#M32?^@EIX_P"WRT_^.$\>_P"M']J:3_T$]/\
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M;V;347KK&S?1AVZU2"KQCAX.<8U)VY_9Q;BI32C:4N5-R4='I:^YT#:QI;$
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MK\+_ /A3OB?C_B;^,,<\_P!GKP00,$;]W.200"N 22!C)_PIWQ/D@ZOXP'.
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MNP)&"#@GG !.Y<O_ %R\5/\ HT_:_P#QE&6]>7_J%]=5Y=T'^IGA?_T==?\
MB+9GY?\ 3_T_'S/W1_M?2?\ H*Z?_P"!MI_\<KR#Q%\)?A'XG^,OP^^/>KPV
MEW\3OA?X2\<>#/!6N?VZ\<&E:#\0GT63Q5:MIBW(TZYFU$Z#I:I=7$#W%O'!
M(D,B)+(&_([_ (4[XGSC^V/&'I_R#ACMWW8_B'/3K_=;!_PIWQ/D@ZOXP'.
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MIP3C@E7*\;AD@D<-R0I(4?!WQ.<?\3CQASC'_$N'?)&?FX/'(."#@'!(R_\
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M['L/R'H*#X3\.'_F#V.?7[/%GZ_=_P Y/MCH:* N^_\ 7])'/?\ "*>'NO\
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M%C]?L\7MC^'L!@?_ *J/^$4\.'G^Q['U_P"/>/GG/]W_ #]>:W/-'M_WT/\
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MWT/\* OY2_\  9?Y>:^\P_\ A%/#W_0)LN?^G>+W_P!GW/YGUH_X13P]_P!
MFR[_ /+O%WS_ +/N?S/K6YYH]O\ OH?X4>:/;_OH?X4!?RE_X#+_ "\U]YA_
M\(IX>_Z!-E_X#Q^^?X>^3GZGUH_X13P[_P! FR_\!XO?_8]S^9]36YYH]O\
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M/YGU-'_"*>'O^@39?^ \7O\ [/N?S/J:W/-'M_WT/\*/-'M_WT/\* OY2_\
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MH_-?K;\#G_\ A%/#O_0(L>1C_CWCZ#H/N]!QCZ"C_A%/#O\ T"+'H1_Q[Q\
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M]Y<G_";ZI_S^WAR"1AI3D#.2,2\CCJ,YRN/O+D7 O"NG_"?A.G_,ORSKR_\
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M=.7_ *>>7Y^5_P!Y_P#A<WB+_HX3XK?^%0__ ,G4?\+F\1?]'"?%;_PJ'_\
MDZOP8_X3?5/^?V\.02,-*<@9R1B7D<=1G.5Q]Y<G_";ZI_S^WAR"1AI3D#.2
M,2\CCJ,YRN/O+D7 O"NG_"?A.G_,ORSKR_\ 4+_>8+..(M/^%K-^G_,RQG3E
M_P"GGE^?E?\ >?\ X7-XB_Z.$^*W_A4/_P#)U'_"YO$7_1PGQ6_\*A__ ).K
M\&/^$WU3_G]O#D$C#2G(&<D8EY''49SE<?>7)_PF^J?\_MX<@D8:4Y SDC$O
M(XZC.<KC[RY%P+PKI_PGX3I_S+\LZ\O_ %"_WF"SCB+3_A:S?I_S,L9TY?\
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M/RO^\_\ PN7Q%_T<)\5O_"ID_P#D[C\*/^%S>(O^CA/BM_X5#_\ R=7X,?\
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ML9TY?^GGE^?E?]Y_^%R^(O\ HX3XK]<_\C3)Z8_Y_P#I[=,\]>:/^%S>(O\
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M %"_WF"SCB+3_A:S?I_S,L9TY?\ IYY?GY7_ 'G_ .%S>(O^CA/BM_X5#_\
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M+H3SC-7%XW"J2GF6+E%WK4ERRC[2-T]+J]G;7W7K_HL>'M134M*L[U0Q$MO
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M<C(S$,#(QAL-STX;'A/_  FEI_T,&E#IUO(>,XZX/;=SC^XV,Y3<?\)I:?\
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ML=_T#U?_  5+R_N]-?N/=CJI&?NG! ^^.0<\C,0P !DAL, 0<=<!U4\\*<'
M^;KP3D9B&!@=&PW(XZX\*/C:UY/_  D&E9(Y N[?_8) &0 <DC@@?*P!P5WG
M_":VO/\ Q4&E#^'/VN#H"H##'(R.<X#$*^1E@&?^M.7?]!N&_P#"BEY?W_7[
MO,/]7L=_T#U=O^?,M]/+IU_!]_=?[5/.-IY&,..0<_,,Q# X'#88Y&!P<']J
MGG&TX.!AQR.1N&8AQP,9P3D8!YQX5_PFMJ?^9@TH=!_Q]P\<*.<>F>2,DE'/
M)*[C_A-K4@G_ (2#2AGG'VNWR#\_ P<#H. 0OS+GH=A_K5EW_0;AO_"BC_\
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M)#&\)\A);95L?)E;ZJ_:)\9^(T_:X_X)QZ0NLWZ:6G@GX>W%OI\#-]FAGO\
M3O QGN)(Y)FN'::'47$4Q\ZZ@$R7,DOV>)I(OPL_:K_X*:_'7]KS2M,\+_$K
MQ5X,T[P3HVH'5]/\'>%K2STS2CJQ@BA.I7LLD\UY>72;;EK<>?!##]LN04<O
MN',^.?\ @H/\7/B'\1?@U\4O$GB'P+<>*?@9IVBZ7X&\K3K2.RCM]".DFUFU
M1/MC3W=Y-_9%F;FXAN+?>ZS,B0&:4S>K2R?%8BN\;F$LBIU<37XMS"K@L/B8
MU<-@ZF=97@\MP5'#2E0AS3IO!QJU'+DM[65E)7.&ICZ%*E]5P:S5TZ5#A_!P
MQ-6E*E6Q$<LQU7&XFIB%3G+FC-8ATXJ/-[U*+YEKS>]_M[W8L_VPOV@X8BC?
M\7/\7%F!4!U7Q%JT9E^4,<R(B%'9L*$QA@RL/D=M6))XR=S9)=02,C!/RGDG
M.1V/\39XX?XJ_'_6OC'\1/%OQ1\8Z]X;3Q-XSUB^UK5AI)M;*Q%YJ%Y->SQ6
MMH;B=X8/M%W*Z+)*YY*+*P147@/^$VMB.=?TL8[?:[<$X7CD,<_="\XPS ]"
MY'[!P]GF#RW(\IP&(QV%^L8/+L%AZW+B*?(ZE+#PA)P3E%I7CJFHV=]+WO\
MG.<91B,;FN88NAA:ZHXG&8FM2YJ4G-4ZE7F7.W'5V?1MO1WLU;W8ZJ>?NG!P
M/G'(Y^89B'''?!.00#@X#JIY^Z<''WP,CGD9B' QR#AN1QUQX4?&MKP/^$AT
MKCC(NX>Y/S'D$@8W'JVUE4#((5/^$UM/^A@TOOQ]L@XX!P3GJ<[!C(W DD+@
MGV/]:LN_Z#<-_P"%%+_Y-?AZ=[>;_J]CO^@>KT_Y=2\O[OF_N\SW8ZJ1G[IP
M<#YP,CDY&8A@8 .&PW(XX. ZJ1G[IP<#YP,CDY&8A@8 .&PW(XX./"?^$TM/
M^A@TH]>EY#SC/3)[[>,_WUSC#[3_ (32T_Z&'2N_2[AYQGIDCKMXSC[ZYQA]
MK_UJR[_H-PW_ (44OTGZ_P!/0_U>QW_0/5_\%2\O+U^[<]V.JGG[IP<#YQR.
M>1F(8''1L-STX;!_:IY^Z<' PXY'(R,Q# R,8;#<].&QX3_PFMIC/_"0:7ZX
M^V09[<<D#/.,YQ\C'G*[C_A-+3_H8-*/7I>0\XSTR>^WC/\ ?7.,/M/]:LN_
MZ#<-_P"%%'_Y/U_IZ'^KV._Z!ZO3_EU+RO\ 9\W]WF>['53S]TX.!AQR.1D9
MB&!D8PV&R1A>&P'53S]TX.!AQR,D9&8AP"!D'##(XZX\*_X36UR3_P )!I1Z
M]+N#!^]T'09Q\O V[TZ;6VG_  FUKT_X2#2L;@,BZMQPO ;KD @] "Q()89Q
ME?ZU9=_T&X;_ ,**7S^W;\=?OL?ZO8[_ *!ZN_\ SYEY>7=_<CW7^U3S]TX.
M!AQR.1D9B&!D8PV&YZ<-@_M4\_=.#@8<<CD9&8A@9&,-AN>G#8\*_P"$VM>3
M_P )!I6<=/M=OCE22 ,X!!^7H "1M)'SJ?\ ":VHSCQ!I1ZC_C[A[%B,9Z9V
MKSP<, < OM?^M.7?]!N&Z?\ ,12^?V^@?ZO8[_H'JK_N#+R\O7[MF>ZG53S]
MTX.!\XY'/(S$,#CHV&YZ<-@.JGG[IP<#YQR.>1F(8''1L-STX;'A7_":6G_0
MPZ7WZ7D/.-W3)'7"X)Z;@2/O!4'C2TX_XJ#2AT_Y?(>,[<]">F6SC/W3C/R[
MU_K5EW_0;A__  HI?_)^OX=]#_5['?\ 0/5_\%2\O[OF_N\SW8ZJ1G[IP<#Y
MP,CDY&8A@8 .&PW(XX. ZJ1G[IP<#YP,CDY&8A@8 .&PW(XX./"1XTM./^*@
MTH=/^7R'C.W/0GIELXS]TXS\N\'C2TX_XJ#2AT_Y?(>,[<]">F6SC/W3C/R[
MW_K5EW_0;AO_  HH_P#R?K_3T/\ 5['?] ]7S_=2\O[OK]Q[L=5//W3@X'SC
MD>HS$,#IPV&^8<=<']JGG[IP<##CD<C(S$,#(QAL-STX;'A(\:6G'_%0:4.G
M_+Y#QG;GH3TRV<9^Z<9^7>H\:VO_ $,&E<X!S=P\<H3ZXQDY(YPK 9!7>?ZU
M9=_T&X;_ ,**/_R?K_3T/]7L=_T#U?\ P3+ROT]?NZGNO]JGG[IP<##CD<C(
MS$,#(QAL-STX; =5/.-IP1C#=0<\C,0]N#AOF'R]<>%#QK:XQ_PD&E<X)_TN
M'(^[WY/&YL@<':>N$W \;6O _P"$@TH<'K=V_!8[2#@D\###&0 "5(<XI?ZU
M9=_T&X;_ ,**7_R?]:?(_P!7L=_T#U?_  3+3:_3S?;;8]U.JGG[IP0!AQ\P
M.?F&8AQTZX)R,#AL']JGG[IP<##CD<C(S$,#(QAL-STX;'A7_";6N/\ D8-*
MZ8P;NWSU)Z@GDE<9R>'49VAL!\:VO_0P:4<9'%W",\L?;.<<$\@.@. K;3_6
MK+O^@W#?^%%+_P"3#_5['?\ 0/5Z?\N9:;7Z>O;;8]U.JGG[IP<#YQR.>1F(
M8''1L-STX; =5//W3@X'SCD<\C,0P..C8;GIPV/"?^$TM,X_X2'2OK]KAQUV
M^N?]OI]WC[YV@_X36T_Z&#2^A/\ Q]P<< @'YNY.W(XW YPN'+_UJR[_ *#L
M-_X/I?\ R?KY/374/]7L=_T#5?\ P5+R[1\W]WF>['52,_=.#@?.!D<G(S$,
M# !PV&Y''!P'52,\*<''#=0<\C,0]N#AOF'R]<>$GQI:<_\ %0:4>O\ R^0\
MXW8ZD=<+C./O#./FV._X3:U'_,P:2<8(_P!*@YVA@.OKA<@X#%E+<[MB_P!:
MLN_Z#<-_X44O_D_7^GH?ZO8[_H'J_P#@F7EY>O?:_D_=#JIY^Z<$ 8<?,#GY
MAF(<=.N"<C X;!_:IYQM/(QAQR#GYAF(8' X;#'(P.#CPG_A-;7!'_"0:7V/
M_'W!D_*3@')Q@Y4C."Q4Y*KN"_\ ":VN,?\ "0:4<9/%W#D]>_7G:, \#>O3
MY\'^M67:?[;AO_"BE_\ )_AI_D?ZO8[_ *!ZO_@F6FU^FO77RZ]?=?[5/.-I
MY&,..0<_,,Q# X'#88Y&!P<!U4\_=.#QAQR/49B''3@X;YAA>N/"CXUM?^A@
MTHX]+N 9P"/;KL&,]W!.#YA"?\)I:?\ 0PZ5UQG[7#CJ1GJ#@8W' +890!G=
MM/\ 6K+NN-PW_A12?_M_]==-4?ZO8[_H'J_^"I>7]WU^X]V.JD9^Z<' ^<#(
MY.1F(8& #AL-R..#@.JD9X4X./O]1@_,/W0QC@X;#<CY2 V/"CXVM>?^*@TK
MG)/^EVXP0N0.HQDG;A?EW*<X7:U'_":VHSCQ!I1^MW <X+$?>]=J^F0P!P"X
M4_UJR[_H-PW_ (44O_D_7^GH?ZO8[_H'J^?[F6^GEMJ^^Q[JNK'Y@=I('RG[
MI)&"<KA\9YY^95X5B,-)7,ZMK!CU'1Y"J#&K:4 K-*3+(NI6_DQ!88YKEI)I
MFCACC@LYG=RD44,LQ19/,/\ A.+<D?\ $^TH#_KXL\=003CYL#'(&<C((.0!
M%%XFLKC5=%%MJL%W=2:WH$,"6EZINS+)J]A'&\8BBOY93 S"9H5LKM;@(\,M
MM=12.LGF9SQ'@<1E68THXW#2E+ XM0A]8BU4D\/44(/DE*3NVDTDY._NQ<DD
M=^5Y)BZ&8X&K+#UU&.+PSE+V4DX15:FY22E%+1)O5J-U:32NW_IM?#T,GA+1
M4?.Y;"V7Y@02!!'MP"2-NS;L"?($VA0H&T=H._N?Z"N'^'Q*^$-"RNPII]J@
M1E9<!8(QN0-C,;D,R,N5<$N-A;R8NW3."3W)-?YCZRG*IS*2E?5:7DFDVDM$
MK)67W:6/[L2LDEL[V[I*VC^;:^6HZBBBJ&%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5E:M:F]T[4+;"XN()8"'R%97C9""0 =KA]IZX&<$C K
M5H_S^72FFTTUHT[I]F@_'UU7S74_!/XG_P#!(C]GOQIX\\1^++GX-^$+B\UN
M^-_>S/>:HAFNY HE8I%>*B(%7R8X[<1I'$J;>0Q?SX_\$7_V=L$GX+^#V/)!
M-[J8'3Y0?]-9R<D9^084$<D@K_1,;>(Y(4 LVXG S[@<<#&>G?DYIWD0_P!P
M?K]?7UYKT?[8S;E45F6/44TU%8NLDK)+1<UDK+965]=[M\+RS+Y2<Y8'"2D[
MN4G0IW;;NVWRMMWUU=[G\ZW_  Y>_9TS_P D6\'[0>?]+U7.,_=_X^< @ _-
MR"3]P;?F/^'+_P"SKW^"W@_CCB[U7DG.#S=#: >J_,2%)# MA?Z*?(A_YYK^
MO^/L/RH\B'_GFOZ_X^P_*DLXS5?\S+']/^8JKTM_>\OQ\D+^R\N_Z <)_P""
M8>7]WR_!=V?SK?\ #E[]G7_HB_@_C@_Z7JHY).#_ ,?1Q@8^4Y+$$;ESE3_A
MR]^SKS_Q9?P>. !FZU7AN,D_Z7R#AL+P1D9)P<_T4^1#_P \U_7_ !]A^5'D
M0_\ /-?U_P ?8?E1_:^:_P#0RQ_3_F*JK^7^]Y?CY LKR[_H PG_ ()I^7]W
MR_!?+^=;_AR_^SK_ -$6\'CH.;O5>".IXNN02#A?E(!!+$J0P?\ @B]^SKDX
M^"_@\#/&;O520.>"/M0R3ZY7&#\IW?+_ $4^1#_SS7]?\?8?E1Y$/_/-?U_Q
M]A^5']KYKI_PI8_3_J+K?W?[WE_74_LO+O\ H PG_@BGY?W/+\%\OYUO^'+W
M[.O/_%E_!XYXS=:J=HYX;%WRW3D8'!X.>#_AR_\ LZ\_\66\'XSG!O-5! Y^
M4D7)&3_? PN#\C9^7^BGR(?^>:_K_C[#\J/(A_YYK^O^-"S?-5_S,L?T_P"8
MNMTY?[W]T/[+R[_H PG_ ((I^7]SR_!?+^=;_AR]^SK_ -$7\'<97_C]U++/
M@D8'VW( !4L&'*Y;<%(*N_X<N?L\=3\%/"&WY03]MU(\G!/S+>./F ;:#C''
M+;3G^B-HXE)&Q0,<\9XX)YP3C//?GGK7SY^U7\:4_9S_ &?/BM\;UT$>(Y/A
MQX2O_$::(L[6K:C]DV(UM]LCM[F2URKEO/\ )98V4-*\,6^:/.KGF9T(3JU<
MSQT:=&C5JU7]9K:1II34E:;>D8W:49-]$K6?5@.'\/F.-P>783+,)4QF/QF%
MP6%IN%&"G5Q-6E1IISG%1BY3JTTFVE%+FD]7R_B]_P .7/V>_P#HB/A#DX_X
M_-4/3/(_TL;F..4^4)EL2/L'F'_#EO\ 9\_Z(AX0_P# W5!G'09^T' ;JQP3
M$?E59P=X]0\*?\%5_B7XT\.:+XJT'X.^"[C1]>L(=1L)9?&\\<OD3#F.9%T&
M2-)HGW0RK'++$9(W,,TT065NA_X>7_&+_HB_@?\ \+N?_P"9ZOD'XKY5%N+X
MAS)-.S5LPT:<5;X.Z7X;]?Z C]$/Q7DHR7!^36DE)7SG(HNSY6O=>(33\FDT
M[)ZGAW_#ES]GL9_XLCX0X&>;S5%S[-_I;;%X^^/,)R?W8V#>?\.6_P!GOC/P
M1\(GYL_\?FJ#*?+N_P"7H[7'S8^^IRF2F6Q[C_P\O^,7_1%_ _\ X7<__P S
MU'_#R_XQ?]$7\#_^%W/_ /,]2_XBSE7_ $469=.F/_N_]._+\5V0U]$'Q7T_
MXP_)>G_,[R+^[_U$^6GR[L\.'_!%O]GS'/P1\(Y[XO-4/OG'VH9.?EV[@-O[
MSS,_N:/^'+?[/?4_!'P@.Y_TW5,#UY^T#(7JK$#S3\K+ !O/N/\ P\O^,7_1
M%_ __A=S_P#S/4?\/+_C%_T1?P/_ .%W/_\ ,]1_Q%G*O^BAS+ITS#^[_<\E
M]ZMYG_$H7BOI_P 8?DO3_F=9%_=_ZB?Z]T\._P"'+?[/>>?@CX1 ((&+S5"=
MV1@X-TH(*ABPR"C8 ,J@N0?\$7/V>^/^+(^$/N\XO-4.'!4-MS=KN3.\9.QE
M)3(;YL>X_P##R_XQ?]$7\#_^%W/_ /,]1_P\O^,7_1%_ _\ X7<__P SU'_$
M6,J_Z*',NG3,/[O]SR7WKYG_ !*%XK_]$?DO3_F=9#_=_P"HG[O^W3P[_ARW
M^SWW^"/A'[HSB\U0X?Y>1FZ7<AP^"?+8?+PWS83_ (<N?L]]_@EX0'R\XO-3
M.'&W<1F[7<GW^3Y;+E,AOFQ[E_P\O^,7_1%_ _\ X7<__P SU'_#R_XQ?]$7
M\#_^%W/_ /,]1_Q%C*O^BAS+ITS#^[_<\E]Z^9_Q*%XK_P#1'Y+T_P"9UD/]
MW_J)^[_MT\._X<N?L]\9^"/A#JP;%YJGHQ0K_I?WL;"Z' QO*R'"Y!_P1;_9
M[X_XLCX1_B#8O-4_VMI7_2NH^3>AP!A]LAPN?<?^'E_QB_Z(OX'_ /"[G_\
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MK-@^4?E59Q\X]Q_X>7_&+_HB_@?_ ,+N?_YGJ/\ AY?\8O\ HB_@?_PNY_\
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MU#PI1PH4Y)9-V&5E]R_X>7_&(C!^"_@?'_8]S]_^Y>H_X>7_ !B_Z(OX'_\
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M)2H8BI5F^:2O&%.32C*3M&+FOD3_ (<O_LZ\8^"_@\\<_P"EZJ.<G!'^E'
M(^4YW$$;EW J?\.7_P!G7_HBW@_@<YN]5&<]&'^E'  (^4\L01N4,"/Z)Q%"
MW_+,?=5L\_Q;NV3CH>YZ_F[R(?\ GFOZ^_O[G\S7U2SC-?\ H98[I_S%5?+S
M\OR[(_#_ .R\N_Z <)T_Y<P\O[OE^'FS^=;_ (<O?L[?]$6\'<#_ )^]5&<]
M&_X^C@#(^7G=C[Z[OE/^'+W[.HQ_Q9?P><#+ 76J@GGL3=X7(P!G(SST.!_1
M3Y$/_/-?U]_?W/YFCR(?^>:_K[^_N?S-/^V,U_Z&6/Z?\Q57R\_+^K(/[+R[
M_H!PG3_ES#R_N^7X>;/YUO\ AR]^SKW^"_@_@'_E[U7DD<'_ (^N "1D?-D#
M(8;L*?\ #E_]G7_HBW@_IU^UZKCKG<1]J&!CY=H).<-NP2H_HI\B'_GFOZ^_
MO[G\S1Y$/_/-?U]_?W/YFE_;&:_]#+']/^8JKTM_>\OQ\D/^R\N_Z <)_P""
M8>7]WR_!=W;^=;_AR_\ LZ_]$6\'YY./MFJ\ XQS]I&=IY)P-_  3.:/^'+W
M[.O/_%E_!XX&,W6J\'C)/^E\J><#@C(R3@Y_HI\B'_GFOZ^_O[G\S1Y$/_/-
M?U]_?W/YFC^U\U_Z&6/TM_S%5NG+_>\OQ\@_LO+O^@#"?^":?E_<\OP7R_G6
M_P"'+_[.O_1%O!_8_P#'YJH&!U!/VG(+Y!!VD(,@[^"3_AR_^SK@_P#%EO!^
M0.,7>J\G(.<&Z& 1\H&>N&W8.T?T4^1#_P \U_7W]_<_F:/(A_N#]?\ 'W/Y
MT?VOFO\ T,L?T_YBJW3E_O>7X^0?V7EW_0!A/_!-/R_N>6GHOE_.Q_PY?_9R
MS_R13PAC_L(:GG'S=O-]AQGN>>!NVO#?_!&S]G33-?T74E^"WA -IVI6=\CB
M[U-V26TFCFBD6,W)5VCGC655?=&=JQR)(C,3_0;Y$7]P?K_C2>1#_<7VXSC\
M#D?F"#W!H>;9FTT\PQS3333Q=:2::5[IORMZ?@UEF7IIK X1---/V%/1JUOL
M=+?@OEA^&M*.CZ/::=DD6\9"AMF$#9Q&BQA46-#E5 4 %3C/WCT"J5S[XH55
M7.T8SC/7MT_SW[TZO.6FBVM;T2[([EIIY6]$W?\ ,**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M C(RQ/H5Q^)'^?\ (K\Y_P#@K!,8O^"?G[4V"0J_"_4YL+L#;H[VR^92R, 0
M..05R<L&!(/Z,Y&6Y[I_2OS>_P""M3[/^">O[5;A=S#X4ZRR#Y_G9+BV;9^[
M61VR,?+'%*YR&",0H/%F*OE^8)J_^RXF*]/JZ]-+WZV6_2Q]-P5R_P"MW"LI
M.RCQ+DTK]G'-,(T]+ZI+3T['\7WPE^+?B;PCX7T[3+6_OI=.73[8PV?VK"6T
MC0@;K=9$E6!&<RNT2X#NL4CKM++)ZLO[1?B3+?+<-DYQ]M/R# 3:,(#C<CGY
MBS;BPW84*/B/PSJ)&E6ZKEHQ;Q*A+-L8=04 'S*6^8A<A]T;*^"I/0'4P,G8
M=F!\A)!WC<,YQ@CA\91"N2N2!N?^2JM*2J5;)V4Y+JOM/3R:V>S['_0'E^:0
ME@L%)QBV\/2DY2Y7JJ=-:MIN47:ZNI)ZMZR][Z]_X:-\0GHLQSC'^G-SG;C^
M'OO7'KN7U&3_ (:-\0GHLQSC'^G-SG;C^'OO7'KN7U&?D#^U$_YY'_OOZ_['
ML/S'O@_M1/\ GD>O]\],CG[@/0\\=CUXSG[*?\LOO?\ F=O]JT^U#_P5#R_Z
M=_U\F?7_ /PT;XAQG;-CU^W-C[N_KM_N_-_N_-TYH_X:-\0C.5F&,Y_TYN,;
MLY^7ML;/IM;T./D#^U$_YY'_ +[^G^Q[G\C[9/[57&/+.!D@%S@$[<_P'';)
M /W>_P N3V4_Y9?>_P#,/[5I=J'_ (*AY?\ 3OU_I,^O_P#AHWQ",Y688SG_
M $YN,;LY^7ML;/IM;T.#_AHWQ",Y688SG_3FXQNSGY>VQL^FUO0X^0/[53_G
MD?\ OOZ<?<//)QVR#D@8)/[43_GD?^^_K_L>P_,>^#V4_P"67WO_ ##^U:?:
MAT_Y=1\O^G?_  W79GU__P -&^(@<%)\YQC[<V<_+QC;U^9?^^E]1D_X:-\0
MGHLQSC'^G-SG;C^'OO7'KN7U&?D#^U$_YY'_ +[^O^Q[#\Q[X/[43_GEZ]'/
MU'6,=>AZ8/J/FH]E/^67WO\ S#^U:7:A_P""X>7_ $[_ *^3/K__ (:-\0GH
MLQSC'^G-SG;C^'OO7'KN7U&0?M&^(CC"3G)P,7S')*[@!\O)*_-_N\]*^0/[
M43_GD<?[Y]<?W.F.1U.,Y . 3^U$_P">1_[[^G^Q[G\C[9/93_EE][_S#^U:
M?:A_X*AY?]._Z^3/K_\ X:-\0GHLQSC'^G-SG;C^'OO7'KN7U&3_ (:-\0GH
MLQSC'^G-SG;C^'OO7'KN7U&?D#^U4_YY'_OOZ<?<//)QVR#D@8)/[43_ )Y'
MK_?/3)&1\GT/;@^O%'LI_P LOO?^8?VK3[4.G_+J/E_T[_X;KLSZ_P#^&C?$
M/7;-C&<_;FZ$$@_=Z$*QSTPI/0&C_AHWQ$#@I/G.,?;FSGY>,;>OS+_WTOJ,
M_(']J)_SR/\ WW]/]CW/Y'VR?VHG_/(_]]_3_8]S^1]LGLI_RR^]_P"8?VK2
M[4.G_+N'E_T[_P"&^3/K_P#X:-\0GHLQSC'^G-SG;C^'OO7'KN7U&3_AHWQ#
MUVS8P3G[<W0 $G[O0!E)/3# ]"*^0/[53_GD?^^^>F?[F/0=>OMR3^U$_P">
M1_[[^O\ L>P_,>^#V4_Y9?>_\P_M6GVH?^"HKM_T[_KY,^O_ /AHWQ%_<GX#
M$_Z<W13AC]WHIX;T/!Q1_P -&^(1G*S#&<_Z<W&-V<_+VV-GTVMZ''R!_:B?
M\\C_ -]_7_8]A^8]\']J)_SR/7^^>F2,CY/H>W!]>*/93_EE][_S#^U:?:A_
MX*AY?]._Z^3/L ?M&>(CD!)R1U OF..2.?E]5(^H(Z@U]H?L3>"_%_[6WQ"U
MW1-2\4S^ _ ?A#P[=^)?%GB^9FEBLH8+F&&'3;>XN(8-.AGD>^M3</<WK3Q6
M1B:* R327EO^. U/>0@/EJ2.IW#L6!W&-,,50$EEQM)R3M*_MO\ L8W,\/\
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MLJ<U3DO;UY4^1TW_ #1Z%\;_ (@^*+LV'AKP[XD\0W^ XL=!L]5UJ[:$D@7
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M<XQ_IS<YVX_A[[UQZ[E]1GY _M1/^>1Q_OGUQ_<Z8Y/0XQ@$Y /[53_GD?\
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M,XC/(PV'."!@X_U8S\P&,@#(R<8&3V4_Y9?>_P#,/[5I]J'_ (*AY?\ 3O\
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M, GN>< ' 3_A)KG;CRX]V,;L';NQUV[<[<_P[L]MW>OVL_X<:^)?^BH_$?\
M\)S1/_E?1_PXU\2_]%1^(_\ X3NB?_*__P#7WH_XAWF':E_X/]-=O339WU6H
M?\3@<&?\_L8M5_S"U]%[MU_#]?/>S5S\5#XFN><)&.,+D$X;GDX49!X^4;3P
M?FY^4_X2>YR?W:8P,#OG)R<[,$$8P,#&#DG.!^U?_#C7Q+_T5'XC_P#A.:)_
M\KZ/^'&OB7_HJ/Q'_P#"<T3_ .5]+_B'>8=J?3_F(]--NNGGYZNXOI@<&:?O
ML;M_T"XCRU?[O=:^7EJK?BH/$]SWC0\GIQP2<#E#R!C)[G) &< 'B:YXRD9X
MPV 1EN.1E3@#G*G<>1\W'S?M7_PXU\2_]%1^(_\ X3FB?_*^C_AQKXE_Z*C\
M1_\ PG-$_P#E?3_XAWF':E_X/WV\O3:V_F@_XG X,_Y^XS_PEKZ;?].^GXV\
MW?\ %0>)KGC*1G ^; (RW'(RIVCKP=QY'S#!R#Q-<]XXSR>G'&3CJAY P">Y
MYP <#]J_^'&OB7_HJ/Q'_P#"<T3_ .5]'_#C7Q+_ -%1^(__ (3FB?\ ROH_
MXAWF':E_X/\ 2W3S7K?6Z8?\3@<&?\_<8MO^86OY7_Y=^J?H[6;N?BI_PDUS
MS\D8Y!&0>%XR#\O)/S888 R/E;!W'_"37//R1CD$9!X7C(/R\D_-AA@#(^5L
M'=^U?_#C7Q+_ -%1^(__ (3FB?\ ROH_X<:^)?\ HJ/Q'_\ "<T3_P"5]+_B
M'>8=J?\ X4>GEZ?TW<7TP.#-/WV-VU_V7$:[:NU/=:[67EJK?BI_PD]SQB-
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M:_6#^" HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&V_[Y8^F?XN0>21T8@%LD\'_  C>D_\ /E;_ /?+Y[<YW9SC(SUP ,X) **
M#_A&])_Y\;;_ +Y;VZ?-T7DJ. I (P2<'_"-Z3_SXVW_ 'RQ],_Q<@\DCHQ
M+9)X** #_A&])_Y\K?\ [Y?/;G.[.<9&>N !G!(!_P (WI/_ #XVW_?+>W3Y
MNB\E1P%(!&"3@HH /^$;TG_GQMO^^6/IG^+D'DD=&(!;)/!_PC>D_P#/E;_]
M\OGMSG=G.,C/7  S@D HH /^$;TG_GQMO^^6]NGS=%Y*C@*0",$G!_PC>D_\
M^-M_WRQ],_Q<@\DCHQ +9)X** #_ (1O2?\ GRM_^^7SVYSNSG&1GK@ 9P2
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61110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img117331299_1.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img117331299_1.gif
M1TE&.#EA/ \]!?<  /___P  ,P  9@  F0  S   _P S   S,P S9@ SF0 S
MS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9_P#,  #,
M,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3,
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MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
M,\P 9LP F<P S,P _\PS ,PS,\PS9LPSF<PSS,PS_\QF ,QF,\QF9LQFF<QF
MS,QF_\R9 ,R9,\R99LR9F<R9S,R9_\S, ,S,,\S,9LS,F<S,S,S,_\S_ ,S_
M,\S_9LS_F<S_S,S___\  /\ ,_\ 9O\ F?\ S/\ __\S /\S,_\S9O\SF?\S
MS/\S__]F /]F,_]F9O]FF?]FS/]F__^9 /^9,_^99O^9F?^9S/^9___, /_,
M,__,9O_,F?_,S/_,____ /__,___9O__F?__S/___P    8&!@P,#!,3$QD9
M&2 @("8F)BPL+#,S,SDY.4! 0$9&1DQ,3%-34UE966!@8&9F9FQL;'-S<WEY
M>8" @(:&AHR,C).3DYF9F:"@H*:FIJRLK+.SL[FYN<# P,;&QLS,S-/3T]G9
MV>#@X.;FYNSL[//S\_GY^2'Y! $     +      \#ST%1PC_  $('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&/*G$FSILV;.'/JW,FSI\^?0(,*'4JTJ-&C2),J7<JTJ=.G4*-*G4JUJM6K
M3&>QD$%.QM:N7[UR%0MV;-BS9M.674NV+5JV;]VJE0MW;MR[=O/6W4NW+UZ^
M?_WJ%0QX<.##AA,77DRX,6+&CQTKE@QY<N3+EC/O1300$>;*H"F+_CQ:<^G0
MI%.;5HUZM>O6L$_+9CW[=>W8M'/;UHU[M^_>P&\+YRV[WD!]Z]9U6==.>7+G
MS9<G7Q[].77GTYECA[[]NG3NW[U;_]<>GOSXZMG1@S_?W7SZ]NK%OR\?W_WZ
M^>SIP]^OOW_^__@%>-^ \A%H7X$('JA@?0SR!Z"!#?HG8((1/DBA@Q,NB"&$
M&UXH(8<?>FBAAB&2.&*%&:((XHD=FIABBRJ*^&)Y]QRWXHPLEABCBS?V**./
M//XH9)!$[F@DC$CJF&2.3.+H))!'*BEEDU N^>2045*)I9553GEED5QNZ667
M6BYHG$#]B%EFEE^R26:;88(YIIIPSBGGFG&Z2>>;?.[IYYUUXFFGGH#V6>B?
MA"::YZ*#(LF90EK]-IRDQ%5*Z:7!69HIII-NZFFGH&H:*J>//0J 9Z2F^JFH
MK*HZZJJNMO\*ZZROUBJKK;'F2NNMO.J*ZZZ3G0D <H8JVNBQ@B8;Z++%,JIL
ML\@RBZBSTAYJK;'/3ALMM-E>2RVWU6);;8T"(:=MM^*"J^ZYX7[+[KK>;OON
MO/&BZVZ][<J++[SITMOOOOX*FR; !/]K\+T'ZYNPO0HC['##$#,L<;X3\_MP
MQ?Y>3/'&W)F*4*3 AOSKR+V*7#+)OIZL<LHLFZR8J:BZ+#/*,Z]<<\LTYVRS
MSCCO['//0-\L-,^A"4MLQA%SC#3&!6ML<=)/,[VPTDU#O3354T>-M=-7&TKN
ML%J'W?7854O-==E;6XVVV&N3G;7;9[_=]MQRMR,PW&K7'??>>?/_;7;?@/\M
M>-J#LZUWX(0G;OA^'A\$,M&0_SRTY)$'7?GDEE-N,\R:9^XYYJ!?+GKGH9,^
M^N>GEXZZZ:(:K3C>A</^.MU^SWYX[+0COKCNLN^.^^U4?VUN[K_7[KOMQO>N
M//'(\\[\\= O#WST!=_]O/3)7Z_]]-@[S_WVV7\O?OCD>U\^>XT;]#CKJ[</
MUD;]M*/Z_*G7SS[]FW=VO_WN\X]__ZP2R:00,C.$[.^  $S@_Q;8%]=1;WSF
MBV#QY+61633G@>5#R'\TN#B$2'!9&NS>!$?8/!(:2'@8_& *32C"0'VD'@$*
M(?A4V#MZ+&1*_2B(/,;S-8KPXWPE#.(*_X6()>M!D(4S1&*,0M(/(#;+@X+C
M8 LY!$4!0?&(1-10%8?(Q2EF+'T%69\"_1<YA%B&'P?A!P,1N,8QLI&,;^&<
M&^?8QCK"D8Z"(> =/V5 /+[QCWX,)*T<Z,4D9A&+7=1@C-!H$'X@$F\<[*(A
MP27#1TZRD);\%PHQZ41.TO"2YI&BBRJ)'83@ R*S()$_)N*/"/4P(AU:)40&
M)BV$T*,Y6[S0+'28)W<<1!^?S&0G02D^(PY3F,'LI")A)(]??FB7$/%'A_+Q
MD/C)\#VYU X8&]+*]DB$/AJ$ID'FD1Y91L0?!9*(>JZX'QM*9!;PB) &YP$1
M")DSFA?*)C*5>/],AVUS(&*T(R!W9<;%_%-^=(E(.M*B#X3$K"VO/$Y=Z.FX
MMZ@CAPGIBT+!<LIQUH6:!M&'7Q*"3K1@%"'O8,L]!\(/0>[Q-G(4J$L'^E*:
MLD^/B(F(.M""4[-TM"#S^.@O-7H0F\[TJ#)-JF@(2<Q^)O.IL5NFA"(ZD';4
M1Z'?4<=*!9*/^+BS(-TLSSL0(H_R?+4@Z>A/),4C2O0HI*O=^6E!AH?-@ZCU
M(.3L&$+2\1XPTB,_#6UD# \BR7T>TJG=VF13H7I8QJZP(_R0$%DI=$T?I8,>
MC#0(?3)[D'[48TM^M=!!_GHP?7JS(&)J!TD]R4_'LA9KQG3M8EL;U8W_\.,=
M$!(60<H*(%\:A+?1 6E!8&@@N1)D/]D\:6?OX0XUM14^"*'EF]*!".42I$&F
M_0X[I=/,D(HHL$ %#T+RBB"I-HFZUJTJ<NU*V\:VUV+_%$A :XK4X;R3'_S
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MZ%J0I*0DX4E?]4K,V5"6PYG#U:2&-?EF;;[WM6]^Z[M?^O87O_S]KW_U*V
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MXAP>VI&*EK')-][P?6L'U!GO>+T=3NE\[WWAEL9T +[C=W9_"N'K5CC%+PV
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M 9Q \6(.1)B($,P^>;@_-J ')LRYB>BN*+R_=4"$N).'&F0.G . !20(>+#
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M ,J)4"\ J$J%0,OO4,LPK FWY(^?-(F]Q,J#F$OM.(BK!(!#C! 7]$2,($P
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M3TK+4E)]3U!EX/&DM&@'54M=#QR,%O8X-2U)#U/14E,_SVK+\OBR=BQQ#P'
M(4M9P$N=EFPS#TQ9;VS?TOSTTO2B5@;_[!1JW9;ZXM3TK)91Y79O-R]+Q9)I
ML=0M@<])$:!4@795275G'7=6'_=5)5=6)[=Q(?=R*Y=Q-7=Q+W,S$^Y6F:K$
M=-4TZ35T_/ ZUD)<$>,MEG5 =!5G5&)%XI4Z8A>X4.R/X"RM2$)8;85_F'5W
MNZ,OZ"E9:E<YNE&NP%$YQ3%@F;<B6" !$. !$N !6D!Z'P !$, ;;@Q[K7=Z
MJS=ZL==(N'=ZO?=ZKQ<!VD40O. *O* +UK=]W]=]V5=^O0 +X9=]O< +:'0@
M_.%^\]<+0-0A!A8>"[8=/3 ='$EC/9!A0U#I_($>*=83'E8]6Y!CU=."Y]$$
M/_:N0E9F8_9E_STXA$%XA&>VA#_8A$48A4GXA)FB9C]S2#/'2#'7\GHV7WY6
M<;>/3<//:7TO3A,7]@27',34]*BV]<#6;D$O3K^A\X36+<WT\<ZR4%7/AP\7
M+<V4'Z;T3IVX;3L5]O*4^9SVB:=TB*$8<$^/3@=7](IX]-Y4AZ$OBN-432.7
M<NG8<C.7<W%XCNVXCC<WCV=XCP&YC_58D/]8]#RW $'WMHA*>%FFN* +.-A*
M---#NDC#D?MC7I]@1,"UCR[$)<Y5,")9/S"Y#<+G/4)Y5)[K56""=Z_#?4K9
M,))U)$K /7J5-5897LF58]CJDZTEE(R3XI#3XI0WXYJ7@LIW>A_@ ?\< GM9
M@'JM-YFG]P 0XIFMMP66! &0N9H?@ 44 IN=.9NA5R' V9FM1)N1V4FB=YQ;
M 'T3(IV_.9D?@!O:F9J]EYT1PIVK-YOE65T2 9H?H'X1(A_@^9^OP'JO@']G
MH'I;8'V=>09"-"$NEH(-6&$GNJ(E^J([-H/=T0;[JH-7.(59&*1%^J-)6H5-
M.J1+&J5/>J3SQ(6WD4@W1X;ON(;UY88'&8]OVH_O6*?Y>'$%=8B3KVY9@"T#
M&:<+V:AW.J>5^JAYNJB;FI"3FJF7.JJIFO<.V3NH$1OY3EE!9W9=(SBI@@U>
MV3-LLRMX^5):,RK*YJOM@@T&B$+:=3O2VKC_.B:6P0(U;GE]1((R-GE:*R1>
M3:66N>-X]568^75YBWF"CAF>)8)\X7EZ[;D@Z)EZKUF=)QM[ ^ B++N<%UN9
MF\2=_3F?'QMZI;DB0-N<1QL!2MLBFCFT)UNTH3FR'Z*?K1>@#T*@X1F@"]JU
M6R 1!**@J]>A$YM>+LH4#">C"KN@>OFE;[:Y8?BY;1:Z7SBZJ;N56 JFJYNY
MI5N[LUNKE4BF>YJF_<6FI;J\J]JII[JGGQJIU3N]T=N\VQN^W_N\H3J^Z9N]
MY]N^]3N_!;!6.1/6/).[IWO !;S O9N0?-F0CE.!..G%#'2X_::S4=NUL[F9
M5?LA7CO#+1N<)X(;_Q+ L6%[PJU7M@EBPQ_[G2G\Q"MBPJ^$>U/\Q:67Q!?"
MQ45<PL/9(% \QIUD%M17?4N4(/K!"WJ\%69.R(4\(WM<R!\:PM5K(PC'N#_H
M@Y([KDR(P _\RJTRR[';RK7<N;O[6:[;R[E\RPV\R[<;RW4%O/F[OM<<O]G\
MS=T\SM=[SMT;SNE<ONV\SN5<S^_\OOM\O_,<SSO7OS\7P'&US,D<S<4<T1<]
M= B[XAJ\KAZ<R?=&PAOBQ$4[ 1CBM9,DQZ>WL3'=LPUBLZN$Q1G"Q%V;(*(W
MQ&5\(3A=U7.\U17BU0G"TV6=TO6LN(\[H9!W<4"IRAG]S,W\RQ-]V,>\T?^-
MW<#"7-B+O=F1W=F9?='5/-#]G,^M7=#_O,VSG=H!?<^Q_=JK_=O%/=S)O=NW
MW=O+/1>OFCRR.MD5/=KAG=B??: 27+F3&[PD'=<#Q](CXK2]5]-Q'-5KW-/)
M>9IAW,9SG)O%.=0%'N'S62),W4E:>^!#O+-O72 FWN$U/)DO'@"\@>%!WI]7
M6]_+RZ-7.J596J55/N59'N5=_N1A?N5?_H,[R]UM/LUS%MW-'=QW?MQ[/MVY
M7=MY7NA]GNB!7N>-_N>5/NF9/NCS?-W1H]VA7=[C_=BK/MB!_3/L'=+QG0))
M_NO!/NS%OB%,7N9CON7/?N;1WNS9?NW=7NWA/NW_):;FI][J(V/:D=[I\W[O
MS[WOAU[O_;[H ?_O^9[P __H#W_I!U_P!_U!;-700Y?J)=_N*1_K*]\S'CV8
M(]WKQ[[S/?_SF;SLWU[NVS[N2Y_T1__T53_U6=_T6Y\FZ'[>K]XV\#[QF[[P
M&=_V%Q_Q#;_W<]_W>?_WA3_XB5_Q<;_X^]OQ_[MH(O_R;U[V)]_RI1_SZSU?
MN=[%\AWTM7_[N=\<17],@ [(,]0FVH%"<S(F"E$@:-)'OY,@_*'N:F(='M3K
M  4/E1 2#?'U5]_U^1_U^W__ :+-$S9/!!(T6'!@PH,*$3IL")&AQ(44'TZT
M6#%BQHL:,7KL")*CR(TD_S^.-%DR9,J3*C&N:Z5O5CZ8K6;&M%D3IDR:-G?J
MRWF3ITZ</8D.%1KT9U&D/H$V7:KT:-2D3HU2A5J5J=6G^.[EPS>KWRQ^8\N*
M)8LV;-FT9]>J34L6WX,6#Q(\N&N7KEV\<^O>]:OW;UZ_?.E>,>N6;%NVB=^Z
M78P8KF/&DB$K;FQY<N3'F#M7]LSYL^C0I"F7WFPZ->K5ET>K;GT:]FO-LEG3
MOITY-^C9NEW;[AT;]^[?PVL;%^[[.'#>Q9$'7TX\N7/FTJ$K;VY]>O3GV+M7
M]\[]N_CPY*F7)XZO:[ZM[&'J2^\5@'P /Z<^E9K5?GO]6OOS_Y]?@%@-B!^!
M5_\5B."!"MZWX'X")LA@A X:**%_#S9H(8430K@AA@!JF"&'(7IX884?BG@B
MAC-9E=.*.>%3TWLOM@+C/33F<P\BIK1RCS_S_0ADD$(.26211AZ)9))*+LED
MDTX^"6644DY)99567HEEEEINR6677GX)9IABCGGD+/2DIP=*:K8TT"Q!RK-2
MG/W\V,Y$^?S83SH5 :FG0T"ZXR:2[L1I4:#RX<,F2Q?ATV0[(/DX'R)(]B.2
MI$RN0Q(_/[[#J)/RK*DHH8F*&BJHI)YJ:JJCJEKJJJZV"BNJK\H:*ZNTWFIK
MKK/J6NNNOO8*+*Z_"ALLK\0>:VRRPRI;[++.-DO02R3_@IBBB25V:"VUUXZ8
M;8'J@95=N(W)%5AAA %V[F![H;ON8(==-YYY:8$C POUSF(O.?>FQD*^,L2[
MG;P!#]P: OK:*R[ \)ZWL, -$ZS=PQ)'3''"#%<,GL,8*[SQQ19K_#'$(4\\
M<L<@9RPRRB2K;'+*')<,\RSPK<>M3>^I]V-]VU:+;<\U_\PST#L/K6W1*!)]
MM-'3)LWTTDYW^[3/04^-=-1"*PWU3BY.U6+7,.8CXTPPUGACCCOV2&;::J_-
M=MMNOPUWW'+/37?==M]-MYEH,DLL/9 "^0Y(G<J'R)UXKJ3/C_1$E/A\^:@$
M3\Z] HEL0_3\^+B:0-KYXSTC_VDZWSL262J?/HD"^= ]/\YB4A>=/ULYM+'/
MSG?ML-LN.^ZTW\Y[[KWO[GOPP ^O>_&_&R\\\L0?SWSRQ[MC-=582UUUUM1/
MS].W+4],;KI]M?N]8.&;"[YA+GN<& L'(\!6O3*0PP)L!\O05CCN@P/:_(NY
M3P[[G/G[C;>HSWWCZ(R_"I@;!/CK,@ 4H/XZ\XWWW4LL_F(!;O@G@P"VY8%P
M&:"]3O8REL4LA"1$7PE!:,(4HG"%YV/ARD[8PAB^4(4RW)X-1TC#&;KPAMV9
MF=1N%I_YZ Q[TFN:]:YFQ.LE$8G1JYX2FTA$)S+QB$6$XA*K2$4I8M%G6P-*
MUUSTM?^PT6B,-L('CG3$H[_A;8UL;*,;WPC'.,IQCG2LHQV%I#=\I(EYAI,/
MZT8%NM)-9!Z*FT@Z^%010CHND3E+B3M6QRM#R:=.<6H'D/I1D4 " %$?T20
M],00>?R('Q^YG! +A3F5S.E'?5)(Y.;##Y:LDC[+<YXM:XE+Y>FR>;GDY2YO
M^<M> M.7Q!RF,86)S& JLYC)O!WTLAC%:%Y1B]2,IO9P.)ONE<][Y6*7^+KI
MKAI^3($2%,T!YA= ?^'O+!*T8,(\R(+,C(. 9B&GOI3#/]O8+U]EH9>]+,C
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MKNRLRP) /DB@]13M?1+@I :KR-IJU2;FH9;LJUZMR5JM# :M_Y6FK=1?M@)
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MCSJW;WNZL[NY:WNYCWN\K[N[JSN\0[>J*WNU4SNT\_NT([N_YWN_2[NO/GC
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M#RQ2!+-63E-,\()"5"<0<<A.'?80GC^,9Q#=.<1YMO.>[Y3G/NF93WOR$Y\
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M;FHPWZ;BY&+1<*#QD*3_$:($L&P>K,'"YA?-,6S0L<,,;-:HXN3*Z!G;J"J
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MB^I\*FS0SR]-CX;\;XP<R9V(RH/MR?4,TX:0*OB(_')QLQ'[U6/=LV%=O_2
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M^\./;IOK*Y=N<$%+^%.,'V[BYEH#[A19%M5-D/348RV?=P8I_E3EN4&>=F/
M6=2/:_C5"'[>U_<EOO.1M0/1+"B^7[7W1,G3V1.W4WR\::JK&.M<]Q38,<0G
MO1O([W23P,28:!W@HM_DS$;!"5HP21<\4@8KB,$.:M"#'/R@"$-(P@V:$(0G
M'&$*2XC!);DI6:&*2:YNI2M<V;"&.*2A#F?(PQONT(<]S&$0?RA$(!JQB$@D
MHA*'R,0CH@E4HB((J9;HQ"8FT8I4O&(5MZC%+F;QBUCL(:^JY"LZC=%8PTJ6
ML9*%+&69@EE9BR/6YK@UST6MCG+$(QWSM<>&Z?'_CWP$R0$ AH $!.T!_$)
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M,E04W)8EU9<J%A1+DX[<9+C2YT@+7NI7E'RDI[A'OV@Q<B:AE!8H9]6P=3V
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MW3##E,"')Y@'H/ '^YL-+W0+?M -I3L)?B@/G5B'+5,ZE- '^&!$?W#$!C1
M!^3$3?1$303%!?S_1%$,Q4XLQ5%<,PC<P ]<11!<KWLCP5:4Q5BD15:L15?$
MQ<X1P5D\+QX$D=&3#1ATB"YCO3"K/0,A1L'I+PJ)/?7 00'QQ0ST0122B LS
MK%A#ND"Z0BU\PF[,0BFLPG#<1G <1RN$0G/T1F[\1G1<1W'<0LJPC#O;JYWP
MA]"0!YB@!\Q8!Z= C7FD"4/,C:Y0C7?@B7J8#8*TB7ILCW; +7^XA]1PAZT
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MO"HR95>>Y5>VY5K&97V8W"/M8PHY6AR1.0CAW/H0QH/X7!K16=E@W3R#VNU
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M/&::K;9IUH_?P.;!;@7%GA 7_.7^@.8:B6PI&6;PP+T[?@C2S<$\QA'.;:%
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M?7:#D"(MZ\AS"O-$G"1GB41YN1+!LD*8_-$W9'LB7)*#<:*,+2YWV\G-\>,
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M<U_4>4>5<PPF>[%'>PU8>K/W>A/(>@]H@13H>A6(@1*H@1V8@1_()XJ4 PY
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M'__N)W_P-W_Q+W_U/__U3W_V?W_WCW_<1P32/\;V1W_\OW_]A__\Y__]EW^
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MKOR-[ZX#2  $:"$^:\\J9X:2=_(N)FEAB-%F\CJRR<2>#,&FQ_(Y'7ZJQ)M
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M@_O\XAZ_^=>/_O:KG_SC)WBE+G4IZRH\X9_*HW8_Q=V0_[_D1$X  7#D"G
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M'_3@ D<(0H@$T#T#U(A^2"C"$KJPA3 ,H0Q9.,,7UC"&-,RA#76(PQWZL(=
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M1 Z TFDG!-KX:"AU$@IFDH('NP8%,T&9=0]L72>?TMZ'MK"][8""-[S8->8
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M!X#FO15DQTR94GCNO$,&S9[99^30  @\H'CO84:%6+P4F<=]UE&J'ALY5NN
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MOETSW.:VMKC!C>YS;WO<[.ZVNML=;WBGN][OYO:1".UG0:^YWWSF][_W+7!
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M!&"74CM(!%Y/BZ>A@[/T@T3D\[*LPVMC!8KW-<+P-D/(=E5<!#[(@XA6A#I
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M>#E7N+A!='M7^(-$R,-@J/M 1#M6.#9:V#.0KX4^[ 2](_=R*[=Q$[S %_S
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MP 45;#! !/EST, '&:10P@0MS'#"#3'D,$(-.PSQ0P\%%+'$$3M<KSU\)@+
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MD5+XTM1,%W%-U[2RG#(R293-"L[-J!+[-I%#-W1//=%6&#  Q=+FTB]0Y<\
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M$&!5N('DS'<BMMBYPOB%QMCBQG96O#<_Y[=N=_%NKSA_^7>/L_A=$).*K4^
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MY$V>Y$0.Q$7^Y$S^JZX*Y4@NY5D>Y5N.Y5RNY$ZNY5V.M4*,WV"UVB9BVO]
MB=KN(1,&8;CHX6Z6W2)F;" LHB )3IC,K!$B,]MH;B$A,]L<0^??S)AL3)06
MRMO,[=LF_N(K[N@J#NDN_NB2'NE^'.. [+F##.)#&=W[U]YE7M[8G=^C+NJE
M'NJGGM[J<<FDCNJ?OM^FGNJM;M^L'NNUKJ3O_>JR#NJV/NNP[NJT_NN^WNL\
MU=]A7D45_AEZOA!0M'(<CA;321C*G$,XP>!EL9RAD4*[X<T:4AS4+AG:;. 8
M+K\ZE.'VZ^$CB^@F.^*M6.*3WNB5[N[Q#N_S3NGUGCN7+L<,;+*+>^,1G.-7
M_N53#N9>#O %3^7&;O #S\-''O (?_ $__!BWO#_$*_P$R_Q"2\<T1?Q%L_Q
M&._P%>_Q%"_P(__Q0?S8ZL?K6M7G!#/HG,TOF*+&^C#:(B7G&^+9:!S:'9($
MX^;RLBTM#S/HW-XTF$T0K!TA>$XT@:XR2C^(AJ[;(0Y:TPHDORWO]E[U[V[U
M]([U6R_O*3JO]@KV\5JO8A_V7T_V9V_V:3_V:E_V:^_V;0_W(>()*9_K= _L
MPV[W3$HUPK[KP:[K=>_W>?_W=]_W>+\BQ2[R,[;S1U'MBT%8,*&]:7'%+5&_
MK>#@NE'@!I(6TH[YW@X7W.OF1O3X!]%CB_]7733Z,M<7IN\0D2\<Y=X<&S[.
M.?[A^1NG)\ONC'[UNZ_U_[R?];_/];V?E38KM4U[M$H+M<A?_%%K_$M[_$ZK
M_,V?_-!/_<]O_<Z/_=-__=J?_<N_-W-_\1L?\N$/\N(O'3-,\HFO_N2?_NQ?
M\N^__AUO_JE*YH!_59.-,HL_42R_\C@_2/,!$&R>R'DBD*#!@@,3'E2(T&%#
MA?I:2:2H#PE$AFPF3M1'<6-'CQ4E"GQ($ G'D"@_J@S9T1M#F MEEI29$F0K
MDAAGZD0H<N7-EA1W'F3YL>//HSEA>O,9%*G-HTX]YMM(56(^?52MMM*:E:L^
M?/FPAL77JBQ9?&COS0( P%];MW#?MIT;EZY<O'?UVN5;UV_>OH#_[AT<F+!@
MQ/^'%1MF7-AQXL:0'R^>')FR9,R7-5OF7-ESYLZ@/V\>'9JT:-2G59MF7=IU
MZM:P7Z^>'9NV;-RW%\_+AT\/3> \A<<,3GSX4.3%DQ]7WISY<^/1ETMW3AWZ
M=.S5LU_7WIW[=^OAMXOW3A[\>/3ETY]7WY[]>_/QU\MW3Q_^?/SU\]_7WY__
M?_L"W$] _P@$<$ $]?/D*0:E,@HJ"!M\4,*F)G2P0@R+RA H"SO<,"H/-121
MPP\CO'!$$$ND$$430R21Q15?E#%%&$^<L445G1+KGMYHO#%&'X/$L487A01R
MR!]M-%))))<LLDDHCY22R2F?K#)'*ZG4,DLNL?22R"__D^P23#+%#-/),Z/<
M,LTKRT33337'-).E?'A,"RX KJ(1JY3X7,G/J?84M,]!_RPT4$)#>BFAG) X
MM"H0+\IH)Z420H(;/1-E%"*!,C4TT8\XK6FCARK-J51*1T5THE0% A124*?:
M]*%5:X5U(TEG%1555#U%=--)43WI55]OE?74ACY55JA@GW T5F.C+=;3K:KE
MZEJMONHJK+%ZZ\VL.M/J#1%3V++MW-K2S0W===75C=UWW85W7GGK;??>>/&E
M5U][\_5WWW_[!7A@@0OF=UW>?$.V689U;7AAAR.&>&)@):Z88E,OUCACCEO=
M]>.'-_8XY(YY!=GBDD_&>&24_UE>V6227189YI9I?EGEF7%..6:;<^999YEW
MKAGHGH6^^6>DAT[Z:*6;9OIIGYV.&FJCI[:Z:JR#UKKHK8GV>NFKNP8[:Z[+
M_EIJH1>T==JOH&6;V+:7E3;NM>F>&VZ\'WU;;[OW=KMOP//^6W"Y_2X\<+X)
MKUOQNQ-W?/#'_ZSS6\,7C]QRR#,_G/'*&]<<\\TO]SSTST<'_7334^]\=<1+
M9YWSUDF7'?771:_=]=AISUWUW6^?G7?8@[>]=^*#G_Q.N.)D<TTXVP0*N>7E
M?'-.ZJ>W7OGFF:\>^^V=O]Y[[JW/U2'PV[16SVROTO8K;L'Z]JS>Q$UKK8 /
MKO]^@O_MSQ]_@_G7O__]!1"  _Q? ?UW0 $:,($()" # 9.PWQRH0 F28 4-
M=$$*8G""&[1@!CW(00UV$(0?%&$)0WA"$J)PA"LT80I=R$(5MA"&+Y1A#6-X
M0QJ*1VW2"U\/RZ>][P'1AT+\(0^+&#TD9L^(1"3BCGHTQ"5&,8G=8Z(4E3C%
M(%J1BEK,(A:AZ,4C7E&,6P1C%<O(Q2^.L8MJ3",9V3B1X^$#3[[3G?!P9T=#
MD>!BOZ,C\(:'QSK^49!W'"0?BU?(0!(R5I3"U"$5>2WUJ2];D_1*M[I%%G#=
M0W[D,E<#%_A)3X92@:)T8"E!.4I4FI*4IU1E*EGYRE7&4H'_$*2:V-!FRUJ:
M;6RX#)LN;^G+7)XMF+L$9B^%:4QB'I-LRN3E,I/YS%\RLYC.C"8TAUE-;%Y3
MF\C,)C>W2<UO-E.<TQRG-,UI36^F$YP5VV$?W>E(0P+2CX],9#P1.4][TA.?
M]>3G/H%W/'^^4YX"O2=!]6G0?":TGPA=*#P;.E"'!C2B#)4H1"U:T(EF]*('
MU2A&-[JY.,XQC&XDZ1IEM)-GC=2D*VTC2U7:4IB^5*9F!-.BR%=2[)UO?=;"
MRK;$XKZS@"LM:NFD*V792J3"TJA+3>I1E=I4ICY5JDZE:E2K"M75T-*&!7%'
M/U@SC^>XPR[]*(\\ZJ*/K<Y0/^XH_^IEZ)%#N*JU@NO@1VGX 0\<EL2LR4NK
M"!$! '[(-:]]'6QAXTK8PQI6L(EE[&(=B]C'*A:R!VKG&VF*TYFBL4IB"8N=
MCO=9SX;66Z+M[&A-6UK4@O:TJDTM:5G[6M?&=K6R;>UL;5M;W,+VMKK-+6UY
M^UO?!G>WPNWM<(U;7.0"][C*32YQF?M<YT9WN=)M[G2M6UWL0O>ZVLTN=;G[
M7>^&=[OB[>YXS5M>](+WO.I-+WE_JZ:0)J^C'/WH0FV:$(KF=[X*K:A'_4O?
M__)7OUA!5DH?&CF=3A);.W7?)=\7+K)P$JM3M6J%)WQ5"E_8PAGF,(8]O.$/
M:UC$ ]/J.O]3!@^^W+5AZVBK/R:FCKOXHYLF+B<ZA29'O?C#'1I+1UWQLF-R
M!OF<,RYG/?HR"WE(S!W\X L^U.FQ==C%Q4,.9\]B3&0AV[C&6*;RD[/,92U_
MN<I=IK&8O4SF+8\YS&@V<YG9_.:D5;:^_05PG06,.,[6:1;\Z <_]OQG/OM9
MT'ON,Z )/6A!%QK1B@8THQ.-Z$,;.M"2=G2D%PWI25^:TIBN=*8;S6E0;UK4
MFB;UIT=MZE(_^M2J3K6E4?UJ5L/:U;&F]:QM[>E:X_K6G>9UJ%NM:V#W>M6[
M]K6L@UWL7 O[U\HV-K.3C6QB#_O8TG9VM)<-[6E?F]K8KG:VF\W_;7!O6]S:
M)O>WQVWN<C_[W.I.]ZWYX=G7Q;<M,;VL2^M-;\W>.[-GY+=E\_WO?F-6WR=*
M<"6KPN#V81)^0XT?_3H,8HB/.,0/EWC$*7[QB6?<XAJO>,<9H]7!ZF4\ZO +
M3_ B68+,HQ]O\<<L[J&.$99<A?302SZ\(]:ZH ,\O&E+/\ *DW;4PZMNZ<?+
MU8,.1.C#'W/QAS[JD8X!U4,?<.%'/J!>GW;X91;R>8=<MIX<=="#SU37!SRV
M(W*#\,9<3H^/.E3NU;=4_1W\H4<^W#*+M[*AJ%>?+,H;V_>_^SVR@2?\X T/
M^,,+'O&+QV%E!0YP?P?<WEP9[2SZH>A"_U]>U9J/-.<G[?G,8][/H!^]Z"UO
M>M*??O.H9_WJ7=_YUL/^]9^//>UG'_K;ES[WJI=][VWO>]P#7_?"Y_WOC1_\
MXP\_^<5'?O.5[WSF/U_ZT:=^ZJU?>^A??_?:)S[WE^_][&-_^N ?O_BK;W[R
MGW_[Z&?_^MW?_?;#__W?CS_]YQ_^^Y<__^J7?__M[__L>S=O@2\[P;%YVZ\#
ML[,$O+,Y&[  6T (I#,&?$ )C$ 'C"1(6C %ZRGV^2FR>#!-BK!R\3B.P[B-
M.T$21$$33$$67$$7+$$85,&Z*+$T Y:5\[HDNR8FHPMWF!0#;#F^.XB]FY6B
MZJK/ +(ADSDB&_\ZMZ '9R(YN.B'71FZMW"'?"B,=7B">S -?*@+?N"4=WB-
M>H@8)O0'>& RS\ KJ4'#ML '-7L"(U.-=N"5HC*RROC"C-E"U^A!A_&QMG"'
MJ8L-LVNS&G2S-3M$,$O$-US$,T-$1C1$16S$2(3$1RQ$2R1$3(2SB)$S"KS
M"53 QLFSM? V=D,W4RQ%5+2V4U3%5"1%5GQ%5XS%;IO%<&LW6:S%5;S%=8-%
M6MQ%7;3%7@1&7&S%8,S%8B3&8>3%9/Q%8US&8U1&7WQ&9D3&:'1&:ZQ&;$0T
M 0R+>"M D1HXR'L\R<.W<=RWR#M'<43'R2M'<&3'@\- #N2I2FHPH#+_"Z&2
M'WQPN!ALP7U\01G\1WX$2'\,2(GK!VC0!VC@AX-,R(542(1T2(9\R(:<2(FL
MR(B\2(C,2(K$2(K<P8&\.)!+K"Y$#'R .>CP0P"8.X+X07J0CD!T"S7L";Q
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M)$_T-,_9P(=.\(3VW 7WC,_WE,_XA,_VO$]/L$_ZU$_\Y,_ZI,_YQ,\ W4\
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MD-%0AT8((A"-*#(F8@R*-+,B?"#"%"]"U:EJ:*H;EBJ'-,3A#G4(I18\ (A
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M$1]SCCN@ZD8W-===F CK&Z+Z5@:%)#(1BEK8&/\5N6B4/"0E@0=L8 $CN)1
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M8 O*X O.8 S2X W:8 Z>Q;U1G[[QFZ,E&J,)880HW! BVO'01L' BW.%U[F
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M/1!5_TI0^]1<TFG(TAWC"8G(?D5=BKB0B51=(?9B+O+B8S+F#941$4W) 2"
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M>AOV>DLFX,XP&R6 #*>=Y^+FXZZ8.0]N&8&NVV5N<+*=$-%U7X_I,_]W9[*
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MNFP,RRP;65>'Y?%A@/XS'0F]5UJ*\B[A0"0+Q ))!"Q&L(3_#,=?(OU82,H
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MLS>!\S=Y<SCM,0*Y<""H[DCXH><>*,+ 8R,W0@118NE*DB(0# <G CM/HJ'
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M<9<[W.@FMU6I:M]UUU>J6]9J_;[LR#!W)*QCI?.=]ZWO?MO9WWCF][\''G"
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MP5J#K"/3_X6ND06]!\&4!1U=1(80F<Q>=*P.@I71 \&]L>2]A/S))BM:(@L
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MFN1*IIY(EJ1+HB1,>J1,JN1,OJ1-YB1+WF1-[J1.QF1+TF10XN3F_6&)X<8
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MD<F9)A0%L/GFD?S6XZL-)V]P[!DM*@#P<0L$\(>DKQ;YKC\H+R&],1E):HB
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M<L0P^0I)'PUS%:(49),?,1@;D9:Q0YYR((I<""/[P;..:85E;-F*Q@BRR<5
MK))[;*,E/=/+7_HR-,1$Y3&%6<QA+E.9S40F'I\93&@F,YK M*8QJ9G-:6Y3
MFMV\)DT0AYH=+NXVN2D6LLZIK'0R:YW.0N>SVGDL=<*3GN^TYSSOR<YZMB=Z
M!VH@G:H7)^Q1B("VR=#_])?0_@&0H0I%Z$(=VE"(3O2A%96H12.:48I>E*,:
MQ>A&/3HC 9*3303%!P*M!U &.I"E"LJG._$94WV^5)XSE2E,;9I3G.ZTIO\\
M;59/@?I3H<9SJ/O4:5")FE2C^G11L)+54I$*U:+2=*HWC2I5E8I5J6;5JE4]
MJE>9NM5-18LVA<N;60F"1G>-"ZU^2]<;URK'P+F5'_DZ@.$0EJ^&7*QDN#0(
MQQBB,TPNI%KX^L9, L:T P#LL X)VL%N6;A\?0-=@/57M0!KLK8ZQ+!PV8HW
MOM99D-SKE3 ;;"9I*1'0GJRSVRH93PZ2V(LM-F"-Q4A+#M9:BND56R4#V4,^
M6R_="NZL>"7N<>F:W+DNUV[*;2YS ?=<Z4:7NIN=KG6K:USG9K>XW44N=+$;
M7NV"]W"U(6*GR-FX+EH1C%X,XWO=&U_VPG>^\L7_(GWO:]_UYK>^_>5O"_LY
MO>DA** 02A-!M1>A[GTOI T&Z8,_&N&.0GC"$G:PA2E\X0IO6,,=SO"',6S1
MD=;&0O<PX)NL)R'JK5C #VQI>_V[7QEK$;\SYB*-]8OC&.OXOS:&<8]Y[.,:
M!YG(-S;RCX6<XR,/><FO&^*.FPQE)!=YRE$&LI63+&4F5YG+6_:RDKL,9LV1
ME8S>W*-:X<B,:CH&KG"4JS,W@Q)#<C,M*^M920[S%("YA&/?4!I3PI$6/0M,
M!H;<2F-3>9-1(B0F47D+:>?\EY(-);!F9O1" FU*IB!%+@QC)&+O[)+($G+3
M>"'MOF99ET$/S- D071=_U%=E$;WQ8Z*QA=/P@(QI*AZUMJT-)SIC,U@,W/-
MQ/;U-X']ZV(G&]G+=O:QA:UL:!M[V,R.=K,A$TXB*C&]YA2K5L'=5:Y^==QA
M#3>YORWN=*/[W.;.DXM9C*<5H[1-)MT>AA@,8@[KV\,AWK>_^_UO@0><X/PV
M., //O"$%UQ((RYHO5$LT#BIM,4MU=-5U=UNC+,[XQWG^,?=#?*-AYSD(S<Y
M6$]>[I2ON^0H'ZI35ZYQEZM\YBR/N<=;3G.=V[SF,M_Y/<DL7N_. LWNXN[>
MVORN[UYWO$P?.GF?[O2E'WV[0I^ZU:O>=*I#_>I:QSK7LQ[UK4L][%T7^]?)
M#O]VM:>=[6-W.]K?[G6YGWWNV-*VXLRK7BI_6<MB]GO? 7_E, <^RX+GN^'_
MCGC6!7BE#"2P@0T\4-ILKWOKR,;E,9\-;60>\YOGO.8_#_K/>Y[SI,^\Z3L?
M>M1??O6B+[WJ83_ZV+]>]K6G_>U//_O<VW[WN$\][W_O>];K/OB]-W[QD3]\
MX"M?^*X_/O.?[_SD2Q_ZTV_]]8E??>U3G_O87W[WLP_^[WN_^>2/OOFM'W[T
M;W_]XB^_^N$__OB_7_[UI__]SS___-M___A//___S__83_\"L/\,L  1<  !
M4 $%T/T.D $?T $34 (A< +;[P()L (UD (Y$ ,7L /_,Q $/] #&Y $(] $
M+3 $47 #5U $2U %87 $8_ %9; &:? &3W &<] &=Q '4Y '_^\;QFC:BJGH
MU.@9] $)E3 )F7 )G; )H7 )DRZ.L*W:GLT*B? *I0T+N7 +O; *O_#:Q)#:
MPI ,P? ,Q]#:S# -M1 -U_ -U3 .VY -L[ .N] -Y= .I2F<Z $$R:$VZD'O
M?([G?@[G;D[D>LX0$Q$1"Y$1"5%8&._Q\F3>4JS>#.C>#DKA$&X3-;$3&<X3
M%RX4.?$325$407$43;$4_\?A;*.D#(C>YJWQ+,[%!K$6%;$1<^X1;=$1=S$7
M>_$0??$6=5$8?W$1@Y&=8,X8_X%Q&96Q&7&1&9_1&8>1%XFQ&JDQZ.K.:HQP
MK;@QS;RQ&\&1"LMN'-<N[NCN',TN'<FQ[>"N';.Q'-T1'=?1'-41'M^1'>^1
M'N<Q'NL1'^71'O_1'_M1'P%2<.XN4Q8G'_0.R_8N\0KO(1N2\")2\2@2(AGR
M(@>O(AN2\01,I>A-\A+L-!8,%4GR%$U2%4\R%56R)%&R)5<R)5GR)5U21EBQ
MQ$[LI%)L@21QI>!-(S'R\"PR(X,2*"=R*!VR*)'R)X]2*262*7U2*),2*IT2
M-J0%6J3R*HER*J,R*[%R*;NR*;_R*;ER++THZ.Z0+;;Q&]4R'-G2&]]L#N$0
M+O/P+/_C4@_Q4"[QTB[ID"[GL@S[\B[ULB[Y,B\',S#_<B_]DC 3TS 5$S +
MDQ\.DMORSMN*,1HM<QJ/,3.A$3,WLS(YLUDB\9]TLA(IY!(K)!-G$B95,S59
M4R9=,R9A<S5?4S9CLS5K,S=JTA4/J!)CL2/?C:4\,SBM43.E43BI\3B)\S*-
M,SD_4SF'LS.?TSZ2T3F1$SJKLSBCDSJ9<SFM<SNS<ZR&,!_Y<1_%LSP#DB %
MDCS/<SP+4CT'DCW3LSWE,S[I$SWM$S[OTSS?4S_=LS_G,S_7DS^YY2#1:S)Q
MPRC!DBP3U"L55"P9]$$7-$(==$$Y4A8I4>) DO*\YS8YE#;_/=0V/W0V071$
M1;1$.Y1$3_1$!"@'_,$!7/1%':!%8=1%971&:Q1&;_1%<Y1&9Y1'>W1'8[1'
M@_1'A11(C;1(D91(E=1&DY1)EQ1'FQ1*GU1'HY1*I]1'G31+I51+K91+L71+
MP;1+P_1+Q;1,R?1,A]1+TW1,U]1,VQ1-C_1*WW1.XU1-ZY1-[]1-\Q1.JY1/
MY71/Z;1/ _5/!150#;50$950%=5.$Y51%Q5/&Q52'U5/(Y52)]5/'353)553
M+953,7530;530_53*;4+)O14$115H](L%_,Q6_55'1-6$3-6:756;54P9157
M:U57;_4P>?57?358&[-7AQ58BU58_QDS65VU"B,3@Q)2$+^3.['S.K6S.ZUU
M6KV36EDN-"WN0B-O0DSS0E#31$,T1<VU7-$51=.57-6U7=GU7:5D14=U4#V5
M7N?U4"_57D5U7TFU7_757_&U7@/V7BL58 OV7Q%V8/DU80]680TV7QV682&V
M82EV8BU68"L68R^68#=V82/V8S.68S5V9$6V9#TV9$^V8Q\68TU56Z6U6A,1
M&P-T9O>39OVS/O$S9P449W<60&OV9V_69X-69VWV/XD6:(VV9X]V:)6V:8L6
M'PF44Y[5V[2R:L,R5;%V*R%45:VV0;.V:T>H0COR\3X2XD*2>S9T7<_57=<6
M7M7V;=D6;O_=-F[I5M]6%&155F))-F7W=F5-UF_Y]F_U5G#QMF\'-W 1%W 5
M]W 7MW )%V4;%W(9=W(=-W$I5W(K-W+S-G,O=W,Q]W,]-W0-EW./M&6U5D*_
M]FJUB%5W%5F7E5B5-5==5W:/M79CMW5M]W6-]79A5W=G%W=Y=W=]-W=I-WA_
MMW?KHEDC:&H/M#F=]V6?-UJEUV6G-UNMMZ>X-7J\]7K M4).,]_:-GSE5GSK
MEGSG]GS--WW'=WVK1%XMEW1!=W3C]W%%EW[EMW[?=W[S%W\U]W[]UWX!>'__
M5X #N'\+N','V( )>($5N($1^(#AEW\?F(&#U'2O%68Q&#RE96G_D_9IA;:#
MD99G/9B#13B$/[B$F7:$G=:$2?B$7;B%87B%4YB%91B$M25J0X5Y'0=L4?=T
MN59U>?B'O=:'4W>(E5)L&X]L2=-L-11\V1=]GUA]RS>*J7B*K1B*KUC"[E9_
M'3B"$WB"NYB+P7B,O1B"Q;B,*1B-PUB"U9B,S_B-V1B.O[B-Z5B.S3B.\7B.
M[3A_33>(BWAK4Y?,QFB0!ZB0$]*\$)F0#UF1$]F0&WF1'9F1)3F2*1F2+?F1
M,7F2+UF3,[F2.WF3/9F313F421F43?F347F43UF54[F46WF579F593F6:1F6
M;?F5<7F6;UF7<[F6>WF7?9F7A3F8B1F8_XWYEY%YF(]9F9.YF)MYF<4)BG0X
M@Z&WFJOW@J.7>K7Y>K$U>R=1B3&T>PL*WZ08B\VYG-&YBL_Y0Q& !1X  1Z@
M!1[ G5G@ +)8G=-9?]QWC?4XC^^XGP'ZGP4ZC?>8GP?:H G:GQ,ZH!?ZH-U8
MH1$ZHA^:H26ZCB%ZHAT:9"T86['9FK>YHZ^9HT4Z.F:C-D8ZF[F9FD-:I3_Z
MI#TZI5$:I%N:I6&Z0"]D(8$XIXU8IP&9B'W:CW^:IWM8@I!XP!IDB1&LB?-Y
MG>_9P>3YJ1\@ >)YJN59JJ%:GN$9 1# &YADJJV:JJ,:K*M:K,/ZJ8&DG;V:
MK+^:!1# 2<;ZJO_+&JR_&JKG^@%&A*[5.J_ANJ[%!*_WFJRS>JMO!)[ANJV]
MQ)WKNJT]1*NGFJUCY #<&:L-NZF9NK(;[C18](R?!#;HP1TJNJ ?^$1*5K0;
MNK0_^Z)U!+3IF$54N[51V[4I&J--6[9/.[8MVK9A.Z-S>[8/M8^%6HA[&JB%
M^[?_>*BK3$U,K+B!V[AWNKF#F[B#VKF9^[FE>[FM6[FQ.[HGJ-N:]Z5ENJ97
M.J9=.KR]>[Q9Q9OE#9R_U=Z^=ZG=&Y\G#*[EFZSG&ZI9@$CH.[_K6ZQA1+_]
M&ZY]9+\%W+_O^K\-?+[[^L 5_ !H! $0G$SH>[(;.S?V.P'L.3<B^P'_*/N]
M-WQ(]OFA[6<6:ENW\[4?0J0=(M;$103%=WO$>3MC51Q%VH'$ 3K&/63&7_RU
M=1RW=YS&?3S'>3S(?]S%B9RVC;R.-YJFOWO)S1N\9UJ\&:6D::/)F5S)J?S*
MK3S+H7S+RUO+NYS+HY6[=QBZA[NZL[O,J3O-IWO-K[N'BMKQCAI#F5C!TK;#
M[=RRU^>OH\0!_'J>622MS1JA #V>)_M%"!O0$6!'WGJJ 4ZM-ZK/E^30%YVK
M142N";U)''S02X2P$STWK!I%#N#05233[YO#\?S.<6.+\9<?:$0>_/0=6D3(
M@5Q2^V%%X$'6B_RVA_Q-:QU$;EW79SW8<[W%_X^<V(%]V'M<V(L]V9$=UY?=
MV4NWS=&<S<^<S*W=S'\:N:7]VM5\V[%]VKV]VZO]V[F=VK7;W,'=(L7<R\F[
MW9_\R^'=W9T\,]';3M2;>]E;7)T8U>&;WY?DP;6$OO]<OB$JOQ\*X#-,X"UJ
MO@.>X$<DPZ':L(U$TJ=:L3'\TBD\GDF$L;&ZP3O>U$&^WW$3LR&8U6>$'OH4
M'U8$']9TWV%$Y8O4Y$L$'UQ>1-2AG(RD17?T'E;$Q(ND']2!3!521?3!YV]$
M'\ITZ#ND'K!T'6I^1EQ=Z3>$Z=-4'T)D'L!4YG,#Y7VTUZ-D'O"5YT&$ZLU4
MY<>^ZJ\^ZT>$ZX-4ZO])A.RI=!VL).I#!.[]P>K'!.F%GD;J@=57A.E;U.W]
M >YI].EUA.N/_=EW/?$9W]@=G]D57]D;'_(G']H1-<G!_-WEO<HS?]ZQ6<IC
MA=TU?_0]'\L[G_/CG?11?_--/_5]<=W//=S1O=QEO_;'7=QCWRC?W-[C//+F
M7"3K_-2%/^2W1,^QQ-+EF=)I9-!;8*(06Z_!VK'-9-'EN='W^M$U_4@._:LE
M?M2I_P&X84BX ; 'WL]QX]-59,)Q(\/]??CA6]7]EQY"A.6M]!W<H1Y4OD;Z
MP49;G4P#444 (I\#!_X&.K@'(*&_A #Z&2PX<*%"A@XC&M3'4"(^@P0=T /_
M(!$D 'H<.Q(,N7 C1W^()DYT5[)@/Y$*$94DV)(F@'HQ=?J;99'C.I\,>9;4
MAW*DR9(?7>*#.'"62P K.<+SQP\?(G?JJMZ$RA&CRW=@#:++F/$F4K0DRPYL
M2O,IQYPA[STT.-,E6*A#IRZT"_$>/7WZ^/$#L"[F0*)?\_D%^<[K0+H,[09E
MK-C!NW[]\-WC^O7F4LFD[X8^G3EUZ:"J3;=FO7JTZ]AN9<.>C?NV;MN\:_L6
M_1LU;>#$A>?N7?PU<N.[@RMW/ISY\N?)HU.7#OUX]N;5M7?GCOW[=.ODO8?O
MTDI?JWR$T[MGKS[^^O;RX;M7;[\^_??[\?>?+Y]__P$">!^!^@V8'W\(_I>@
M@ 4V:*""#S)(X8(63GCA@1ANJ&&'$GKH((@1AOAAB22>.&**$*Y8(8?OY7,/
MC":JV**(+&8XXXTNHJBCC37F^"./0=*(HY!%$KDCDCX>V2.03 [9I)%)1JFD
MDU-"B>636EZYY9)<?NEEF%:**269598Y9IIHKGFFBC#F@P\^# $P(&%U_F=G
M@7D&B&>?=_ZIIY^! LHGH?<)6NB@BB;*Z*&&QH>HHXM*VBBDCZ87J:63:EHI
MII?N26FHG(KJZ::E=@KJJ*J>2FJJK*[J:JR9ODJKJ_F\Q]^MM^(WGZ[ZX),/
M>\#BTPJQP\8)IV=2$?58L__,/IN4L]%"BY:TU5)K;;;8;CMMM]=ZJRVXW'Y+
M;K@ M/  NNJFR^ZZ[K8++[K2QDOON_:VRRT"]^Y+K[7\_EOO ^)V6V^YXSH+
M<,+Q(@!NO015J^_"X"*  +LL(-#L 2Q8C/'!'@]L,,CFCOQQR":3+'+)*)^\
M[3QPYE >>!S5D_*T_<AS$UPUHU42S=7:=D]2#KGE\T3ZC ;/5"KU]C-4\U2[
MU\Q3"<3:TR[QPY$\4#L7[=%W.8:245[-DQ35#S4%KCXXAR?<LB%5!79&-BD6
MMT)BFT8V6F8/9#5-_)2E-4I (><7UHJM4P\^G'%KE-/7HG-<WQ+]?5/>TO*#
M\W;_XYEW7><Q;R[SYYJ/+A[I;'O.N>BEKWZZZJVG#GOHL8-.N^FHRXY[[:S?
MKOOKN=ON.N_ DR'KI[,6;RKRJ![/O/'.)]\\],\O/WVKT5,O??;8;V]]]9H&
M&^,]UW>O/?G<PSH^^M[7FC[[ZRMO?OSJES__^>[3?[_]\-<O?_[][^\__@DP
M@ 0$H ';=\#W(7"!"FP@_A+X0/J\*4YS8A.5+I@E,*FI31CLT@8[J$$+9M!,
M("3A"#]X0A%Z4(4AY& *7<BK&*YGAKJBH3Y\!2QAP0E.Q8(1LK1B"K>Q;&<K
M*Z+*CDA$) YQB49,HA/)]:X$T$N*47P  @Y0,W91,5U,_U2B0B@&KRVN:XL=
M(PJZQ/B )G;1'U-<(\O&.,4XNHMA+-O8N\JXD(JA$65@M*,5K8A%-ZIQD%XL
MY!,)>4A#"K)E+P.>=]SAD\$%+Y'^\%I!DB:XT 0N(Y*\"R8Y>9.S7"TX3T'+
MTC23%*S5!I(NZ8=;R((653[D9ZL)6BQ'<QB=D.0VGU3(X'[CCGSDA5KI$!XK
M0^*U=B3%'UV932Y#LDO9]!(DOQP(+"=BN+OXI3J424@V?^(L?NBC'O-PAUA"
M<K>!R".5R[FF2+*Y&W,N1%R0\UWOA+>[X.ES=H[\73[Y^4]_VK.?]]RG0/$Y
MT( 6%* );2A"'VK0A1XTH@2%#O\92HC"%<*PA1AEH0DUVM&-?I2C+PRI24N*
M4@2]Z1X9)2E(4^K2F(YTIBVEJ4=KBM.;ZE2D.>7I3D_ZTJ#*M*= '>I/86I3
MGRJUJ$D%7[(J&$$'ZH^!4:WJ5*7Z/ZI>U:I9Q>H (;C5L':5JU]MWZYFZ)\:
M\HH]. S6KWAHK&0=ZQY"1.0B*7G7O-IUKXKDZQ/OY2QN!*P%W"J87^\:L,<
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MZ_5Z]-2M+O>\WUWO54^DK$D\3(D$=^ #4<<\%K>0?NAC'N1V3> 3,OBE/!X
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MT 5=\*FG&JJGFJI=T ^F>JJP^JJG2JJG.JNQ:JNP6JNNJJNRVJNY2JN^&JS
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MXB=NXBF.XBNNXBW.XB_NXC$.XS,NXS5.XS=NXSF.XSNNT2+MXQ^]S>/  N-
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M6IQ%6W2AX;.S6MS%6^Q%7OQ%7PQ&8!Q&8<2]1*NH1<O "ZQ "E1& '1&#(S
M9I3&981&9JQ&:GS&;(0UA6L_"]3&;XS&<+Q&<)S&<;1&=-Q&<A1'<VQ';)Q
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M!&54-A+KM&);^H-([1&P[<Y<LHZJX27XG-)&U(]4^N7J!&5&PE&O_>6Q(20
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MJF5J,F5>9B=O\DTJ)D%^[>S(+ 4?445VA3Q@42B+SBCC7GKT9=&BCE3*K#Q
M4=2BG>^X\F%6)B=_LB?[<C ?4%$),S#W\C$;<S(/I"M?$2]SVTHFZT(D$V*&
M)#XY1 CY#CK4!@J]SL#.V>S@\B#)I%0*QH)%A?^(L5NRL#(7\R^[<SO#<^B
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MXY11B953J957N952"3751E4E"#B"DX+?YE7@ECB+PW)K>7(MEW)L^99MF3H
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MC>1O[$M:?.E8]%,Y'K>81Z@^!/0? /PYVL$:FPD YHJ%X3H[_RMQS6HYZ_$
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MIE*5JV1E*UWY2EC&4I:SI&4M;6FNXECP8 ZX92]]^4M@!E.8PR1F,4=I0HE
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MV[M%=$2TF\1(A$2[D\1*?$1-I,1+M$2\\\1&!$5,[,1-S$1._$2,*;;)8Z_
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MP0>3LI2;PZ5*=KII%#Q^B)Y24,J-N<G'0=0H1'>D29!S;),B 4#(2<'#B//
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MW[8/S"%YCSM6!SK<'$XBWQ4//6:RYK]N1')[2^QX3(D2.]:5)[8D3YL5@G$
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M(0!4(D+4')UU1,U=E>VX3$WDSH#X ]7M#2%R!/&M!QR91"D"0"&J!./D##_
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M@@@-/_G,$BH_^.@#8JKXH*I/JO>\>F4^L.9S#SSJ(+I30[R^U*M*O^[JZ[#
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M7?GFF1_^>>G_HZ?>^>JAMSY[["<MJ5EIM9\>_.O#WYY\\\='7WSPJ0JV_:^
M[>I8M<@R"ZU[Y&GKN^[VU[__\/P'3P#Y]S\""A"  S1@ 1&XP ,V4($.3& $
M&?A "E)G.?L23F[2\19U:(<XV.G'2J C&X;9!CFYT0X*B9/!$UHP.YYX& 4E
M",$%^N,>Y2%3#M<4IRWU,$PZ;),/RQ3$'^Y0B$"$TQ&-6$0B#C&)3'RB$WD(
MQ2E*48E-1&(5LWC%*&Z1BES4XA*M^$4RCM&,7CRC&-&X1C6V$8MN["(<182[
M])6OCN=3GQWSB$<]VF0LBKIC(/<HR#[RT9"$/.0@%5E(1#9RD8D\_U6STB(M
M2%;2D8Q\Y"4MF4E.%G(K5@'65:PR%K&$957S4Y;]X $MNDBKE7EQ9;5>R9=8
M4FN6?:GEM&ZY2UGVTI:^U"4P<SE,6!:3EL;$)3)Y^4MF!K.9Q#QF-),IS64Z
MTYK0G&8VJXG-;2I3F-Y\)CBO*4YN?I.:YM0F.KMYSG"R<YS'M%<\&S9/>=:3
MGO>T)V]BZ,YRMC.=_ESG/ZTYL7Q43&]VDUO>YH;0O=W-H0GM&T0?VE")5I2B
M%V5H1@^ZT85R5*$?C2A&/1I2C7;4I""=:$E1:E&5DG2D*7TI2V,JTI.&]'4W
MC1U.9Z?3VO%T=;9KG4^#FE.B[K2H/3WJ3_^%RCJF K6I2W5J5*$ZU:1^C(Z=
MW"0FM9I5KFHRD&<Y7E>QZM6QEG6K9#VK6<6:5K:NU:V0ZMY)OM=6M+Y5K77%
MZUWUZBOV];586-$*_(@%EE*>I7[+4F7^9#C!&2Z6AH]U;&0;.UG&9H8%#F#!
M V2@V0=<]K+?J"QD*2M: "  LYS=[&99@ #0CE:RH=7++. A"'F08;;R\,)M
M;4O;W-)V%G"IAQ<$,5Q$P ,1< &,/A Q7$'8U@LD(LUS4NC"#$I78=,=X0NM
MNUWM=G<[L'5M> TS'AR"T;QE9.,;U1O']8:QO>=-XWO1*T?XII>]]W4O?NM+
MW_G*-[[Z[2^ _YO_7P+OU[_V+7" $SQ@ PL8P0U>\(/_<U6Z[M6N%<;PA2^<
M*+3D-<,>UC"(16SA$7^8Q"<V<88E&:T0H[C%*7YQC$O<5?>%DEC&*FRRT#*_
MDSPK6A$#<I"%/&1VH9:SF4WMD8VL6M0Z !S;2C*2C2SE*"^YLYSE%I6OG&0F
M1YE;2N;REJ=L92I3:\QAUG*7SZS9=*59S%56[9?AO"XWUYG,5KY6/F:P9C@_
M8 :(2$D79A#F>53K"H,V,CV^)0Q\-CJ?CH;TH^6Y3R)7VEL$-:A,:PK336MZ
MI33]=$LY'>J9BMK3+NTTJ%%-ZE2;6M6C7G6L83WK4]/ZU;7&]:UU[6I>_^N-
MJD8%-E*#K=2J/K784CWVKX6];&(/>ZC.-C:TD2UM9=\.QC/&MHNS?6U<%2^L
MVY:QML7-;7*'N]S@1O>X-QG7:*D[W>=V=[SA?11$E,$+]][!O;V0;WSK.]]D
M0$1@[^C73\)/L/)CEF'5<C_%BI>T#W\MQ!WNV#?[N>)[UC+&IUR9)&N\XQ<'
M>68G@X#,9CSD2]8,9SVN\I-_',E^,?+*-RMSBYO\Y09$P,Q;SG(ILR R,>]L
M96D^])UO=C'\N$(7E)[T+HB9Z5U@.C_@TO2,_S8NB*!YOTB3C.Q6U[LHO&[8
MN>MULH-][&!_!GC5+G&[V!"'_&6P@B$\=[G7/?_N=Y<PWN&>=[[OW>\'_KN#
M Q_AP=-=[X!'O. 33_C%&[[OC;?[XQ4_^3G.V]R7?S?FY?W'#LM;\Y;/?.@]
M+WK0C][TY99D<U3R>=:3OO6GI[$@\CW[?=>>]K>WO>T%8<B"B_*OHS0E*4^9
M</NMA97J1#Y D_].@?:3^0&%_O*=/WURPA+,?+Y^GS?[Y%O:&<UW#C,OM>Q]
M['-?EN#'OIJ]/*V*JS_[[X^S\JE%?NU?'[31;'_SQ5E_]_=?S,[WAQS8,QF8
M =_(I:8+LQGP KP(P#Y3-'Y*"7V0M$BCP FTP(8Q0.J#P W4/PZ,OKFH!XKI
MM58KM1(DP1-DM124M5S_&T$5M+467,%=,T$79,$9C$$8?$$;S$$4O$$=K$$>
MW$$:E$$@_$$AQ,$B[$$B'$(C],$E-!L*>[W2D\(HI$+T :M5F4+7TT+8V\(L
MY,(O],(PW!1VFZLJ!$,S%,,N1!5$^ )_<\-^@\/:BT-^L[U[<)Z^FHK?"ZQC
MD9_"*@M42BRWF+A!7+N(,T1"7(TS\PR2XS,$0 SW>SA&1+/#R+GL<T3%R#]$
MK(OOD[A*'#_'D$0P0X#'R+[*XL1#;+L<T#E], P$]#,OV+,]8\64F ?.N@)!
MT#A%\XY^8#3L\D6Q^SKJ,KM@[+IAS"!A""%49#NV(R\..PGB0Q;A&ZS!"J5J
M_\3#JCA#-=3&;.3&-.Q&- 1'N.*P</S&;?3&<R1'=#3'=(0D9US'=RS'>%1'
M>61'>)S'2UDQ2K+'>J3'?<R\W,.]@ 3(@13(?!.?&ANEA,RQP^(Q9X$62X/(
MB)1(B20S<%DS:^FS=RG%;;E(:]G((7.S>%'$;7$ -'. :QG)-L.S( O  2S
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M.18P]L 8;(W#Y)*W\K7V<L@""!8/9 Q\,..!0!D(_ %HR-!A0P<)"QZ4T1#
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M1"-]-,]-&RUTT4E'S?332CLM]=)09VUUU5-K?3756(/]===;>\VUV&6//30
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MAW?HAWT(B'PHB'@88"P&2(.H.+FW*CDF8X($>KR"!"I )\"S>9QDB50F!]^
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MDI(=)Y,>B5@#]SE941(I.$@2R#P0R$I448JRA)*/Q()<]77$EG+64UDZJ%[
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M[_$A;_(C?_(EC_(KK_(M3_(OG_(PS_(R[_(Q;_,S?_,UC_,[K_,]3_,_G_-
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MX/BI-\$';H25<?0'%?NZP!B@XLB'*VD' PR2;]PW'NFX'I''@PP3=QB>+3G
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M[0  /X*!7J"\8VHK_R'(.]+[$H+XER5,$:]W"0S> I,7P=K=6E2F J$)62A
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MP%S4T%W3B2;3D69HEF;=G>9HFN9JHB9KJF9KPN9KRF9JTJ;A<.+L8,[L( \
MT(-16 Z H:+8S84L=L+454X]L$T]I 3;U0[5%87<Q69M1F?:_ [>W1[SH5[N
M92=VQAYWPMYWSLMP%HX\;&=Y=J=Y@N?LH>?KL:=ZGN=[IN=UKJ=[QJ=VPF=[
MRN=]TB=^VF=]>B=__N=^"FA^^N=\$JB^N",]PB-A,JAD-J@^%)]4R. '+M^
M&D\D32@,=I+XO1(F>0.=A8D _RK4.&1*0DD@'UE?BM9)(16:+:W3,QE*(+7?
M07$*2EX2 R*3JRW3-_D?'Y'H)V%?3684_?U1H75HHJTH124IDH9)0<&?.X4H
M-]'2]L53F'C##LY@AM(@#F8IENH@EWYI#FJHF&XIF6KIF7KIF'8IF*IIF*ZI
MF:9IF;[IG'Y4#][##S+-03CHGHX,'M)AAU3A$#I!8,'(7]6A9/P,6QV&R(W(
M7ZC N/ 5&%+E8O%IB#3&-U396IT(63$J/S0&N'SJ3FEJN-&+5CCF@X+55_1E
M'XJ+$>8ASBB6I/JA8Q0,(5K6R5669FE6S/&JS(76=P&K@05K@AU8L0[K@A'K
ML6;7LO^.%[(Z*[,J&+0:J[!2:[)6Z[,VJ[0J:[9R:[1VZ[1::[ABJ[=^#2?R
M1"H"Q3T 9U$T)SWX43!T#RBBXDUTSBRND+W*8H MQ;:2*[B.J[^:38/IXCJ2
M(S<2[#>RH\&F8X+, SZ0AI[J0RD@;,'N8\4FK,52[,5J;,9R[,1Z[#A^[,&"
M[,B*;,DN;,B>+,FFK,DJ;,MB+,*R08(^J(+2[,S:K$YMF8\8I9Z &<HR1C\B
M):Z@$Y\<0)U\0Y[06J Q9*8%9$NBDZJ%R=$:"2_QR4="K:<DR8\V;3D=6I*$
M)$%:J:,<9)*PY)=0&BLQVJIHK9@$R=>NY)H%RINT&=KN;-#_VJU2WFU2ZFW=
MXFW?[FW>\NW?^FW@$B[@.LFT4<L</>6VU&REQDR]E)M=WBQB_N5.Q5ZG4B[@
MA>%/4>:"<DA9G4OO3<S%@"X;A N^Q,N-6%S'R9MA3NYD*IQ?;LRW:.5@LDA<
M,>98OB/"F.Z+7";0F!S*J9PANEQFO9PB>I9 4)!K2N=L,N_S3F?T.J_T-F_U
M0N_T8J_U4N_UTB;4^:9Q+N=+K,/4O$/4;=U+H,;I\,/ED-U_ 0 ZM-U-?%@_
MV([;$:=OO@1T9B_WSMW=Y8/PZ.>!6FB "G !]R> &N@!#W "$[ "&W #0S #
M2W  .W %1S %7W"!8O $:W '(_ &_X.P!R]P"'^P"!//[GEN"C>N"K\N3D7H
M\;6I2E4H"9^,\]$I#/[9D,ID/8F*!1I@*Y$#+K42F2K*H-S3VG;2C[H?*<6D
M$=.3FK'M'K5?$!\4B [:'CV3^?G2*>73B>Y1$Y,#*@WQ0J$?BHZQ/N&H+A&I
M%1^:G+KI&\>P&\<QFK*I'-LQ'<-I'>/Q#=]QG.XQ'/>Q'OOQ( MR(>>Q(-DI
MGD*E03AN(^N#GX;A7]GN[E*JMR3,@X6,N$A5A1VFE3G&&3HH7IUJ'+%A6,EE
M8F"NI:IAP>F%$#[6) <?7ITEC!B6S<A+DL%RN,V55J2RBPSB+T.#(08S(KJ<
M9RVB0+#6+?\J\S(S<S,[\S-#<S1+<R6:Z^6@JU)T#RG&(DNL1DU8,TP,A;RF
M5V[D0RCFZRRF1"U.,R1"12ZZ[,;Z[,NJ[#MW[#S+,\O>\\KJ,SW',SS;LS_C
M,T#O<S[S\S_7<T ?]$ +=$$C=#\G-#W+K".O\$2WL$3KD3T6;I'HXT++ = .
MKI-DL:NHI)7TWZ'PF=<^VIX\4Z-,;9B8I)4\TYF0K4QN24EKR40"B:QM21/+
MM$OVM).4)-+J]"R$-)%\Y*'4R3B@M-GJB9&R=)<4VCC$M.%^=%4+[E5G-%93
MM59;=59[]59_=5>#-2%1FU-26U1:-%;.S.9"YD1W+KC8)>%%YEO_UIX0"DPC
M2VZWY>XHOQO"N!'/( $W9&5B DPOU^&_-*Y=;NX;^G7 L=YB<YOK1I;)8>;]
M$ WQPMSQ)F^&\._V>O;^?K;VCLT#R !I/\ ,/  +F'9IH[9JES9KI[8#L  "
M$ YLN[9IM_9JGW9JZW9NES;>? -N\_9K[[9JLX #>(/A%'=O#[=PW[9MK[;6
M.#=S/_=R$[=OD_;2(<!M8S=TS_;N;/=T7S=O?W=GOTT.H'9Z[[9ZL_=I3XT^
MM/<,=,':^$-\SP "[<UMXN_F['?]^K=S_O?G\/> TR)H&WAM5N?_CK )6S '
ME_"#+SB$/["#1WB%3S@-7SB#9["$-SB&_W>XAE-XAG/XAEOXAX]XB)MXB9,X
M]$0T"Z>UB\/X"K_P'_]3A8KXN6 H(><@H5PI1O5P.:1M($%*0Y6?)*VMB!I2
M$9<#I EYDU;20?JP)!&I0-'2E=Z2.NU1.U$23VN:'PD:H+PHIYT?+>W?(?&X
M)!DID@^2-UVQCU9D)BFQC<*YH8$)C0?R(?.QG>NYCN<YGP/RGAMRGP?ZG_OY
M'!?ZG0LZGA,Z"O8@/BAR3=%7C L?)%L+I9>(N_P'SGQRQ^058BVJ7P(B6L(%
M9(-J$LZL).>47%7RNJ#ZNCS6=91J503B9 +(B;#J@\ZABEDR68PROI7%HT[T
M*^.,K596KK;<KO\BK\PA<[_R*\!^:[-#^[5JJ[0_.[4W-W%7=VEG^[4[ '<1
MM[;K-KA_^[6;MFH3%P*(NVYO^VVS0'6I>[B3>[IC>W:/%KRON[WCNPR(J]<$
MM[R7>[X_ ++V>[P3_&W_:[07!'JO][O'=T',PKR7]G"@!1F@-KC/0 XL;W!5
ML[YR/#I[?,>#O,>K\[3O>[67/+/CHH,9M$.S_,J[?$._O$(_-$'3/$?;_,S?
M?,O#_,[+O,[W?,PS],_S?- 3?<WC_-%#2,Q*^HM3--.W<,[>X][VK,M[-%8;
M*:T@<=:V)*(,-:IM[=8+"3-5))HIR=AFB=:N"9D<I)/P&=/2WZ:94Y7_K.W7
M@U^19+V9N;W1JGW>XS29+!-7 WY8!_Y8BW7A#[[A"W[B$_[A,_ZN(6Y3*NY9
M&T336R%X:DCNYI!?W8O!L&7"7$Q@ELOMXHM.N4NI5M7H>V[E\J'+:+KG<R[/
MV'+IDF5<AT^YJ3X\/G:EF\L:ODOJVNRXV<M<6V;)"8WP7C;+&:]G)OMG9?R!
MF[=H0__S]\Z_C_N]5_]J=[O<6/^[7_^XHTWW<W_XM_O> #S$AS^V2_?VF__Z
ME_O.E3_U<[\#W,W[^[NXR[_TM\T]X+87G$VB3?<5  0 ?P (ZGLPXX&,A EG
M]!-(\"'!@1*3=?(4[&)&BQ@Y>MJ8$>/'CB(U_X(LV3&DR90H/:ILR?(CM(@S
M)]*$6!/G39T2=]KD^=-GT)Q A]KT5^]>/CU/Y,R1\X2-4Z92HSYM^K3J5*Q2
MKT+E2O7K5JM@QXK5ZK4LVK-9N[(ENS:LVK9QW9J=F[:NW+=WX>*E^]=OX+Z#
M^1;>>]@N8KV)&2]VG!<R8,**(PLVW+CR9,R2+S_F3/GS9LN@1XO6[+DTZM.9
M.[,FO3JTZM:Q79N>G;JV[->W8>.F_=MW\-[#>1???=PV<MW)F2]WGIN-/'W]
M\O&;7OVZ=>K:L6_/_MU[^.[CN9<'3_Z\>?'JT:]/_]Y]_/;SV=>'CYU?4GSY
M]/GC-ZL_?OP)$$#_!O_TKT !"0SPP/\8U"<?X8RS2P\%$7SP0@,7U#!#"QWD
MT$$9R)&AG'$^]##! \,A4<0&621GG T59+$<<E#L;\5R:!211!M37)!''864
M0< 1=02'PW%8#*?!!&F,$<191AP1R1/]47)((T6,,4AP/M12R"CU&0?,%V5@
MTDI]GKS1GQQW--)'##_$\DURU!32RR89I%-'-OW44\Q _Y01T$$[+!110A4]
M=-$T&7W4T4A_A'122>6L%--+-14T44HW-=123AO-5%1/2PT55%)3_;135%M5
M]5561Y75U%5/A7766VEUM3\(]9.OOOV2N@<B .P#]KYCZ4OO*CF:8L-9IZ+_
MA;;99Z-%PCHGJ)76VJM42/8Z)ZQ% EEMIU6VO&[%$U=:)Y -;ULYT&666R>6
M=8^I:.7]SMQGYPT/"7WE</=>[/J= UMPWPVX68*UVS;>:>4@MSMGKW)"X?&T
MDH,-\::*N%MNYP Y/H:=PAA8)/)M*N%W"S9O983_Q:^ZFOFI#AH(^<FY.GST
M\1EH??03.A]A\ZFIV*257IKIIIU^&NJHI9Z:ZJJMOAKKK(M=2"$6N%[(:X7$
M?B#LK\N6H>FNOU9[;+;-_KIILM=." %PBCV !0?:EENAI_E^>^^SP5Y;Z<$#
MGUMPM\76&@#%P4:@V&\02%QN%IYVO&O((9*<<J\M_V<<]*3OF4&A&;QH>I:Q
MKY@!(1D0*?8=N5<O/0>'HO:'I=Q=TIWWW7WO'?C?70J=^.*-EZB>_?(0.&2+
M1V;^^6JC%QGDZ9VO'GOHLY=^>^JU_YY[\+T/G_SQS;]>?/3+5_]\B==WO_WF
MX6>?_OGMEQ]_Z^_7/__NZ^\_??OSGP #",#W&3!^_%/@ !'XOP46\($'C& "
M&3A!!U80@Q#,H 0W2$$-?I"#(/1@"$DX0A->4(0H+*$*3TC %;JPA0V$(0MI
M.$,;RK!YTG'9S'B8L1[NT(=!!.(07R9$_@@+'__A1S^4R,19++&)47RB$Z$X
M12E"41\=K&&W*D1%+U[QB_]6%&,5R1C&,H(1C6,TXQK3>$8UMI&-;Y2C&^D8
MQSK"$8]SM.,>\WA'/;J)''K4TCCTV$<^%A*1?E3D(1=I2$<FDI&1?&0C(3E)
M2582DY34Y"4W:4E/9I*3H?QD)T$Y2E&6$I6D_)FP?H@/5^:#6! AX@^+.$OP
ML(66/3P+"90%%HK-:RTPRPHO,R8NM-BR'TCXBA"5:94GG(<I7OEEQJ*9E5KF
MHYH(0^9XC&G-7&9'9=[TH1/40AXVG*66N$S/.:OBC9>=LRO7G-DR=YB/[=@,
MG_Q(8L]T%K2AW>-G1 .H[832DZ(<U* ))8I""[I0AS84H@A]J$0CRE"*7M2B
M&97_R-<0\KF*EJVC"7% 44KW-XQ.M"=>"VG7+(J L874<@<]R-_0AE*;5I0@
M@D/(27$:D86L=*0,_09'R::YH?R4;T%]Z%!?6M2;\A2J.KF'W$QW4'Z$5!Z(
M0 CK;)>ZF>:#=0QQ"$:A<1*3D&0E9W4)6E^B5IBL%:YO[8@P--K3J#ZUKG<M
MJ#_ND912M$,/@5U'8 /K"<(>]K"&1:P>#-M8PBJ6L8^-;&(G*UG(%K:RF+UL
M9#?K6,IV-K.<1:QG+3O:T))6LZ8%[6I5V]K/NK:TKY5M;&F;VMG:MK:BO:UN
M<XM:WN(6N+\5KF^)>UKCLG:WQ45N;X\+V^ JU[G#;6YR_Z?+W.4^M[K8O:YT
MMPM=ZG8WN]R-KG>M.][PDE>[HVV')]P!6?2*][OF!>]\Y5O?^-ZWO/A-KW[A
MFU__[O>__07P@ 4,7QW*TXC?W*:"$;S@!#_8/?DI&G]T5>$;1>@YP%E+A7!5
MJUA9^,.V$G&(29RK$9NXQ!Y&\8I5G"$M16H<.AI1H\S$8EZU^,8Y[K".=[5C
M'_<8R""V\8^%C&,BG]C(048RCXO,Y"4?.<5.CC*4AZSD*5MY0[XJVBR-AH]B
M,1C,$.:FNAI<2Y,-+%G-=):]_N4\9X''9&Q V3M%5F;K0$5?WE!8,Z.W'C4_
MQ<S,<T++7O9G-L/'S?6IRKG$S/\==E'K&X6.&1O,<S!"HZM;D:[T]?YUYHDY
M>#U.B-ZAZWDS4T/CU*?^F3Y7O1^?_1.6L1X(TGI2+%H#Q=9+N_5,<JVT7?]:
MU\'VM;"3!NQA'[O8Q.YULI&];&?7&MJX)@A-$\+K: O$I6\;]N&:?6U@<YO9
M2:-<39D-N' _6]KIMK;CU&WL<]\$<<HFR.3F]NMX=QL ]-Z;N]%M[783>ZJE
M.QVSO:H0> "@=0^8AT"ZL-73Y8!V!.4W )XAO.!=W.(9QWCOA&&[B?\;W_X6
M^<='+F^0"R1YL,3'L(I&M* E$6BLQIG.;(9J>Y+GYF$&M9T;W?.=ZYSG/_=Y
MT(D.=*/_#_WH0E=ZT9'>]*4GG>E/=WK4J0[F?*@<'U+7>M6G#G6O=QWL6_^Z
MV,/.=;*?W>QII^7/5&Y*1^ICBQ:\7Q?=GLI3DA+O=]=[W?/.][TC$DSC\,84
MP;&C<GC)BB;JAS=V!(Z_]]WN?I=\Y"D/><L_'O.3O[SF,U_YSF_>\YP7?>A)
M3TIHO/(>K41]L= ^=NR<Y=)=9Z=3- T?MLR9/4X@YUPZ1IZRN-,^WT!"-[D"
M9KO@'LYA(75W;I\>)'AC^/!\2^S?U?R4K47/R=267) /ZJQ$Y9ST(2=;GND=
M;[2E_&:F2OJY$TV6 =$;UH_Z][N/\WO><V<WFX7-?,9/F <4_Z!>K>583N+R
MR@#Q"@'MZ@ 5, 'UR@$7\ &)PG"J+0$IIR@L$ (9:MPR<*+NC0$_<&S*)@(;
MBMH48@2/"@,;,*_HK7.*Z@$#[B"\P*K&1A  8!Y^"@#R@:IFP1_"2@8:X@-/
MD .#< B%4 6/D A1ZBCT(]8 ZI\"*N;Z3^;T*=5PYF;NKV9:K^Q<CPNWT NU
M$ S5[@O%, R[L S'T S)4 W3D TAS-5@J0W/4 [7$ WK< [CD [OT [SD ^_
M3L+VH\J$#,,F),.LHD*NK,FH+,D2$<L6\<D:4<H"\1%/Q4R&1,98)$W>I$4B
MT1$1<1(_T1-#41)%L1-'T11+$14Y4?\5%7$5(9$57]$58Y$19Q$43U'+LDZ>
MC":6" (/D^[,V _LOB'1[N/14FC-T.,;M&A:ZH^6BI&$EL_1<(A_GH#Z"L89
M789=+@@8A4Y<;FADNL_3IFF'_NP)R$.9J*4<>>@<KP7HLI%C;,G4\HEG=J:?
MH!  !W#"DF+7CH<?^]$?_Q$@ Q( S*UJ](:F'(!IV*T?/0=QG(IX2E @EP;<
M_M$@.\<!["9T*A)Q+O)X6O!P9  AKV9T! YUQN;@  #B#H(,NF A3C(E9Z!V
M(E(F9Y(F:Q)KCF(_H"$?\1%H6DX*I3"?\$D/A[(/][ 7C1(IB?(HE3(IBY(I
MG](IHW(I:R;_'TX/%Z<2*YLR*Z%R*Z52*[^2*\$R[=CN'I*H]-@HBXQ1&JF%
M[LYR]$ /+C]/+M]R+DLI'%9$2ZB$C1JO+N.2+O_2+0/3+P6S+PL3, <3,0V3
M, ]3,1-S\E8)#H7(E82%];SRY\0"&J?.F-YO68C#E^2#^(2C&ADL_G2##8#O
M/3P3*ZC1P6!O9K:/+]C@6\A.&'<C^\;C_-"B]HCH*\21_HQ(!3"3Z=1B--,C
MYX+2U/9I"OUI .]QH(H0.I'0").0.J?3.J-3((C*HS *I/@& 4AJID00.W'"
M 58*J1+' ;X! L.3:\:SKG3J :X3*%2*VLPS<_2*/N%3<%C@.Q?0_QO8LZGT
MDVZB:JI42@8-ZJKD1AX$0JNHBB%F+0=:!PCELSK=4SHMM$(O]$+YB@F?4 #_
M[_]ZI@KC,?^R(^?$LBM3%$57-"Q;U#)?5$5=-$9AE$6=\@U3KT9G5$=SE$=E
MM$=IU$>#=%G^D,)JT5/Z@1[NH13N(4F7M$F95$FAU$FC]$FKE$JOM!3,4A:-
MM!5ID12[E$MAT4M/$4R_5$S#=$O--$W)]$S5=$Q3L4W9=$WA=$[+5$[?U$[I
M%$_C-$-ND<MBS<L@8D>%=%!I=-#<\9R>[T<+M1G';QF18#>!5%*MCD1M+O]F
M#D3UB2<%2M9*+N1(#E1-SE/?[>3Z+50_5?]43Y541]54"\<C 0=6QP8CD^TC
M8W4"Q\;=RN950Y!N6G4@>;56@=5L4C5I%%)5?=4@,:<$*V=5)R)9E[4%/:K=
MLHU7I54@GE5MO*%9(0(&3>?8"NX!%I0@KF!P9N!U".(E8[)4O8U84=5=M_5=
M?15>YU5>ZY5=D<T?Z&$>Z*$4YF%?^_5?_95?!19@!S9@#]9@$[9@%Y9@&Q9A
M&?9A'59A)19B)S9B+]9B,[9B-Y9B.Q9C.?9C/59C119D1S9D3]9D4[9D5Y9D
M6Q9E6?9E759E919F9S9F;]9F<[9F=Y9F>Q9G>?9G?59GA19HAS9HC]9HD[9H
MEY9HFQ9IF?9IG5;_::46:J<V:J_6:K.V:K>6:KL6:[GV:[U69>D!B1C3;!<3
M;1TS;1N3;<]6;=^V;=?6;>,6;N?6;N46;^LV;^F6;^]6;:T2EH1V%59/EB9U
M40^74!'7<!.7<=7N./'/YO8O.>L11(7F'@4P*0I00S.4<RG4<S'T<Y_J5D=7
M6755 QLR6$?WIG05=6%U.PVJ=855=JM-KX0U="/B67?5<)2JH7(W=G=7HJ@M
MIE)J;L@-H[KU0(F"'\9FX08"'[[F"FZBX<2J<T'7>C?W=K,W _.U7TMA8+VW
M>[]7?,.7?.<!?,UW?-&W?,^7?=.W?=?7?>,7?N=7?>OW?>U7?O&7?N^7_W_S
MMW_WUW\#&( '6'\+^'\-6( 1F( /F($3N($7V($C&((G6($K^($M6((QF((O
MF(,SN(,WV(-#&(1'6(-+^(--6(11F(1/F(53N(57V(5C&(9G6(5K^(5M6(9Q
MF(9OF(=SN(=WV(?]%RDF[$[1=$_KE$_S5(F3F(F1V(F/&(J-6(K==(J+F(JO
MV(JS6$^K>(NQN(NU>(F?F(O#N%2TC$DIF!Z:\,L4EU'9V(T;MXWA^(V'%#GG
M<1Y?[G)=KE-MDH_[V(__V&]FMW3G1CVA9I!3UVT*\I!=UVF@]7<5)VLF<B99
M%Y&3BFHHV5;9)B25!I.ME1_K8:9FH M09ZO"M?]8IA<A=A$E68>K -F57QF6
MLR9?D8(>ZB%):_F6ZX&6=9E)>3E):?D>@%F8H728?YF8\<&8?QF9@_F8DSF8
MEUF8H;F9F5F9G3EYK%F:JYF:GQF;NWF;K_F;LYF;P]F;H[F<I]F<R5F=TYF=
MT=F=M;F=X?F=QSF>Z7F>P;F>\?F>Q5F?Y=F?[?F?^QF@!UJ@"YJ?#_J< QJA
MUWF?$YJ@%SJ?(;JA&5JA'=J@+5JB*YJB'QJC.WJC+_JC,YJC0SJ9=5FD03JB
M/3JE29JE5]JE)_JE-3JF1WJF41JF;UJF<9JF==JF<]JG=_JG>QJHAUJHB_JD
MCUJE=;IL]]9O^Y:IGUK_;Z/:J:6ZJ:L:JJ<:JZV:JJ]:J[.:J[]ZJP<3,OOJ
MI9.',@LWCA=7K=.:K>>XK>6XGO /.97S)_,X  5J.JZW>K%7K[67K_]:*+13
ML /T ;25ITI*/ &;HKR!6@'T/!="INRSKXFWJ?S:)_3ML0D;;>X*LQ%[L&V"
ML!5[LD6;M/?:M"T;M3.*0W?RU2Z7U4*4"JU0'LOC1.%ZK=T:MVW[K6];MW.;
MMW\[CF]TMX?;MXF[MX\;N(N[YXA4C+V8C,>XB:/8N:,;NIL;C*E[NJW[B[?[
MN;-;NJ];N[L;O+^;N[%[O*N;O#_$3W,14-<8N8T[N=];N>6;OE]FMF6;'C/5
M_]5<CE/UD57OE5X!W%[7E<#_N\"/5< 3_,!-#B)OS0&B=5LE><'CM=98L"&M
M=2((4L$-?-VH#>0RF6\"'"B^02,#1W,&?"9(O'1/'")24,0Y',$G_,5C',;;
M=<9M',5I7,=M'"=5CN4^% I?>PKGL>:NT/[B&\GA6\GG.\F9?,GK^\F;_)ZP
M#LJ=W,JK',NE7,N[DBS-,JR]^LN[6LS!&LS+?,S#G,S/W,S3G,W1W,W7_,W5
M_), %T>':#)AJ3*C7,^O?,OY?,]E]'&+/!\DEY_\[[4M%\@)<+1/>]%3N[0=
M/3LAV:$:FU=7M]X:O:[V9G$D,' PG2!LUZ(>F6PL=/]9Y;/4=<)8/9W1'UW5
M(=W56QWE.A26^/NNH[ >112_;0X+C?S/^SS+>QW8_5S8?WW8XUNXBSW8B5W9
M?9W9DQW!F+N\P]N\HSV]IUV\J1V]L]V[M?V\M]W;NQW<L?W;Q3W<K]W<K1W=
MI;T1UYN'=-&]FQW9XWW9G9W>E[N.=>:.[3'1=W(?8]G?_QW@I4;#F^;!$8?%
M$]+#CT=8/1EJ(')I'+XF)9QI'+EMM@98#SYJ%!(B  ?C#3GABT58"SG@1Y[D
M2][D;2WE=+++^'N_ZQHYA1+>YUW>8Y[FZUWF;[[F4?3JK!+G;3[G>W[F?;Y0
MNUS.VQS.C[[HX]SHDQ[IE][_Z94>ZIL^ZIF>ZI^^+L=:]<Z:((">ZW_>ZX4^
MZ(^31/EO<OV/UITSKUE=[5>=[5]][?U!.S6J/D?]H3S;!-VS.\.F/V_J/\WS
M=3=*LM^^Q8G*<Y\UI-3SI++-/,F3L!%?HQ3?I'0B[T<=H3IJ<A! Y-V^[6%=
M\#M_\U5PM5?^KO5#R']R1(O<1+L>[%4_Z%N?]5__ZWOTV&%_]6.?]EW?]L40
MVKF=W'O_W-6]VH&?]W\_^(M_^-/=^,>=^(]?^)4?^9D_^<O]^1&1W7VHR]Z]
M]K,?][7_]I7ROB\UOTM_4UG.OW><PF4\QW%\P\W_QL^_QO&MP>6-(?<MV"1>
MQR^\_UDIG5E[;>#?/\!3'2  "!SH;Z#!@@8%(DS(XH$,AQ!9.$@(8*'!A@\S
M/F"!@")&B \E4K0X\*-&CB-!1CPP4J"#DPXG$J18D29)A39SMMR9\&9-G@=U
M]A0:%.A,HSB1_ARJU*=3HD>92BTZ-:J_>OCRW<-W3VL^?/JZ@AW+CRS8?/R@
MZ4/+-BV_?/W0ZHO[ENY<N7;SXMW+[VY?O7_Y^AT,F+#@PH@/*P[,V'#CQ(\7
M.YX,F;+DRI@O:X[,V7+GS)\W>QX-FK3HTJA/JP[-VG3KU*]7NYX-F[;LVKAO
MZX[-VW$^K?CPY>X]W#;QW<:3%U^.G/GQY\J;2X?N/#KUZ?_6LU=/K"_K5GZS
M^/4#+Y[\^/#GRZ,WSWZ]>_7PT\MO'Y_^_/?WZ^.WSW^_?_T YB=@?P$2..!_
M!Q:(H($,+NB@@A F*&&#$5(XX8,75HBAA1QNZ*&&(&8H8H<ADCCBAR>6B**)
M+*[HHHHPIBACBS'2...+%T(3G%;$!>>=0=MA%^1U1&HGY)%%#FEDDD@NZ:22
M4#8)&%QLT846-&_-TM999777)5CW=!?65V-VU8]5:":UU$)LIKFFFVVJ&>>;
M<L)I9YUXTJGGG'S>N:>??>;I3T0@ 8I 2"K)H*=)A&J$J*,;);I15) ^Z@!*
M-7V#P$>,RN  GY)V&BFDHC8D**7_C3X0Z)^G C"J2@UQ] U!""#P4JHAT?DJ
M3++2:BM,)]&Y::A1B:IHJZPFN^JR@#:+++//.JNLM-!.&^VUUM9T55=Z/"''
M''(\P0:XWI([;KC?AGMNN>J2FZZX[IH;;[OHRELOO>S">Z^^^:[[KK_V]CLO
MO_\.##"^!>][,,$!)RRPP@9'#/'$#U?L\,4-9XRPQ@QO['''("\LLL06<SPR
MQ1A_?'+)*I.<<L@NFQQSRRC+7#/-+,-\L\XYK_RRSS;W/#///P\--,Y%[WPT
MT4$G+;321D<-]=1/5^WTU4UGC;363&_M===@+^T)DV0_*>7995?&CUCYZ.,/
M>&[SXT_<_[/$/??;=;]]-]QZTVVWWWWC_;?@@?,M-^"'$YZXX7OGO;CCC0_.
M..*1%PXYY9@K7OGCDE^N>>:3?RYZZ*1[7GKGJ%N>.N>JM\[ZZYO'#KKIM*\N
M^^BUNW[[Z;K/;KOOO>/^N_#!\PX[\,<3G[SQN^>^O//-#\\\\M$7#SWUV"M?
M_?/27Z]]]M-_+W[XY'L?^EIBP>:=5@:EC;;9[L</__Q1RE\__>_?KW_^LKWE
M?UMJN=):OB0F,)&);5WQ"4T6R, &.O"!$(R@!"=(P0I:\((8E""L'$)!;^#J
M ;.BR*,V2*I0)6J!ES)A"5<(P@;NZH,C!)9**EC"#$8P5BHD(?\).\) '+)0
MAL#B(0-?&,,/VO"(2$RB$I?(Q"8ZT8E7R4H>Y) N*LZ!#5:DXK>P6,4M9M&*
M7 07&+_HQ2Y>D8QG-&,8M9A&,9;1C6UDXQK'J$8TSO&-<K2C'NO(1SC>,8YT
M].,>!=G'/!8RD(8DI"(3R4A$.A*/CP0D)"<IR4K^\9*#;"0E,7G(368RDIQ<
M)"@_Z<E.6I*4IS1E*#692E&6TI6M9.4J1ZE*5,[RE;*TI2YKR4M8WC*6M/3E
M+H79RUP6,YC&)*8RD\E,9#H3E\\$)C2G.8>QX<]^_,.F-BW3'>#8Z)LX F>-
MPDG.<9KS1N<4)SK7J<YVEI.=[W1G.N/_2<]YVA.>]Y0G/O>ISW[6DY__]&<^
M UJW'=VC1P8%4C:OR=#];=.A#5TH1"<JT8H^=#54^I]&T8(/_W%I+&,"DYBZ
M$J8S8:M:**662D^ZTFREE*4P=2E!5#*#26&K(34U"0\7\I"<TO2%/M5(4#F(
MIQ0*%:A(90&<'C#4GB;UIXRZZ4]?*E,$//6HC)((LZS*J*8R]85:M1-7H4K6
M65'UK"U%:TS5*M.UIO6M;HVKMN[!K;!)S6I<6YI>[XJUK^V5:GVU*V#SRE?"
M#M:OA47L806+5\4VEK&!_>MC)1O9Q$+6L).U+&4Q6]G%;M:QG<VL9S5+VM&:
M5K2H#:UJ.<M:_]"V]@G6I.A%9QO1(JWM*VVS7O=VJ]O><L^WVPLN^,Q'7-[^
M]KC"'5]Q@3M<XR:W?,YM+G.5&UWJ3A>ZUUTN<J6[7>MV%[O?U>YSQ<O=\587
MO.;-[GG)Z]WTAM=MZ/N*^KR"C_;5]KZRQ:]%]4O;_/IWO__M[V+:<B7_84F
M'37+ 1=,TGP4Y"E-@8J:J$+AJ%1XPA;.,(8WO)0+=UC#'^8PA*LB8@F'.,1$
M/#&$;S5"I>+DAS DXJA(#(!2F1!3)785$&-LXX=XF"1%S#&-1SR08<$X) X
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M?[_\MVTEO',TW!PMMT@-6-*" _S__A> !#>  4>  &B  EB "GB "YB #/B
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MK=C*K=_JK=HJKN ZKN%J</505SM)#U2%#R[SG#5Q#WA5#S^!#Q(J,O/ 4O(
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M,B</:@(-,^,/;*(.*$D//\$/%PM:[X 3^F"Q$*N^_$NQ]UNQ&3O &%O _DO
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MG-?YI%5T3B_U3@?UH-_T4"?U4?=YHR?ZHR_ZI5?ZID_ZIQ=ZH!_ZJ/_YJF=
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M-S_WQ[_][Z\?_>P/?_OC#__YJY_^Y9=__?-_?_N?'__[UW__\5_Z_1\!!B
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MQ9;;;+\U=:$)(320PHKN\0@ !N%]L,%T_^F=U]YXZ\7W7GGU[9???_,%>-^
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M,\PECUPSSC>W;+/,.[^LL\]"T_QSSCP'3?30/2?-]-).([TP9]9.6]516 $
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MO/1=;WW5BU_YLO>]_(UO?^=KWP#G][_[]:^! 3S@ Q<8P?J];X,%_. $,YC
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MF<N[N(N''HNS+\N_^^N_+ON_-PO  RS !3RS-GO .:O _4O "<S !ERS"QS
MD[6SC-&S2MF[&8R_]\O!N^O!O4NF=T-]Z*8WQEMY7WFG*:S"*\S"+>S"+PS#
M,2S#VE4/J+.^-TR_\_N^.+S#.2R_/\S#[BO$[4O$\1O$1:S#0VS$/GS$X<NI
M':S!,MJYK*NZK4O%KVO%65S%6XS%7'S%7ZS%72S&8%Q%N-J&NPI'&_S!:AS%
M:PS%;#R5QNJ'R H:@8A][CE='8>]U+O'UBN]?LS'?]S'@RS(A1S(APS(LT%+
MX3JQ%ONPC2RQ"UNQD7RQCHRQD@S)DZS)F<S)F.S_R95,R8_\R:(,RIL\RI=<
MRIV<RJ=LR:T<RJA,RK$,R[/LR/;KQK><?/J+P!'\P X\P;S\R[LLS!+<P,!<
MS,/<R\8,P<@<S,2\S,[LR\5<P8MQP;*#RW#\QME\S=K<QG&$M,J5E<3+E7><
M&BB\M><\MG++M>J,SFC+SND\M^M<F C  @Z0)/7, @C0SFO[SNX<S_N<8-Y
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MAR<>$?J0 S@  %R0 UPP\B%_\B9/\B)/\BJ/\BU_\BQ?\C$_\@_A#WF@!W,
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M-+O_:#W"TBL[Y9AO,#1'\P:  =0ZU1; &A?+LJQB.2-P6);)0B1[*8S"B"P
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MJR.0;?.Y%]-#T;S#9 N-^>#Z0.@Z&ZNQ&2O[%WN/ANN,O_A,/V@/KP>-D .
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MOO_IAW[JL_[JNS[JO[[JP_[LRWZ$E#4%:TR[VC< D'SOGSSG [_O=SX0SK6
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M(+N NJFS$;R),;S5ZZFD-PO12S6-50Z@%PZ=);VV9UKK6ZNT"JO[:ZO\J[\
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MN7G_WAW<M_#>Q8$/1VZ<^''ER9D_7Q[=N?3FU:%/QVX=+S1\=.G]1-<]'ST
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MI94^VNFHC1:::J:?EKKJIJV&6FNLN<[ZZJFW)OOKLL<V.VVT9X24U$A[- \
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M),9C',9D%,9E-$9E;$9F1$9H=,9H?,9JI,9KG,9LE,9MM,;5>\-.S,02@3\
M-, "-$=R/$<"1,=U5,=V+$=V?$=W3,=XI,=Y/,<VXR,%!"'S ,=-E,!_#$>
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M[#)IY$(&<_W6DAPN<[V.HAY.<_T6D\GVX3)GYRYQY,!^-(!^9$*+\W1.$P0
MATLF\W&NZ"9I\#WOX4 Q=#.O[!X>]$6O9\8>:"699\ZF_W0NA\%/EM8&PY)[
MP#=^R!)_*&[DGK@X:Q).!^Y01_53WS92#Y)[$&Y1A_54S^57E_7?GO7DOO7C
MKG5:5_5<OU]>CG(H/_+KBK)A#_9C-_9DE_)EIQ%+Y&YF1W9H5_;BR5DRVM[M
M[4MQ^EEO_FB/[FAN__9P%O>XH6^^ W1,;FAU$NAP7G>6:N]Y\N=NKR@'WV9\
M+JGV3G?S>'>5VO<)?X#',? *=_1Q#W=Y)WB-+OB$QZ@.G\:"2@?>0Q+72P=Z
M8!$'>X=:I =T*1)H> ?+FWB-3Q*.CSYX@(8.+)=YV#UW4H?+DX>2OT37+L9Y
MX&, @(9Y"%L]H(?U>!SUJ >3QO]QX4.GE:>]4@ 2(8$&>C@_BO?T*?D4FQ^_
M=.!C?D!YY$N'>JAXIC_ZA^?Q'<_QK??ZK@?[G^=ZL<]-'X]V89?V;F%JND#[
MMC_[MY]VN/=BJ_Y4MX_[NT_[;!H5#*,L& )K[C7O']'R+O=L2U??N;X3R-82
MQ5]S=(;O.2EW.O_G1^MK/8?K01ES<JX2^J9D+BGT?&YH(_'A*%GHQV\2'ZYT
MPD]]$ 3M$9T'(N&'>UN'+.D'8M/T-L$'<2./*-&'!ECZ+LE]"GA],JD'9(.'
M+.$'>9@3>.BV>I 2:'" ?%@3?W"'YG_^9$,'DW^2>N"T\%02?. U?' 2?,"V
MX6?Z8@/_^3R9AR 4[2;I^'7;$JWW-/$?$O+7-O,WDMB7->?'$NA?MG0 "'_^
M ! <6) @ 'H.'. S"& @/@H-'#206.\@QH<(!_*32-&C XGW,N)SP$_CP706
M,T);Z+%B WT9'=(D2&\B3)<X0;[DN7-BR)\Z/P+M651H4*)#<R9E:G2I3Z5-
MHSI%^G3J4:E7MUKMJM5KU:]BPY*E:C9K6;1GH:IMR_8M5KA<QZZ-:W=N6KE@
MZ^+EN]?MW;]ZZ0+N6UAP8,*#\R9F;'BQ7[I<^.GKEX^R9<R7*V_.S%DSZ,^B
M/9/N;#IT:=2G1Z].S5HU[->R7=-N;3MV;=RW9^_.S5LW\-_"_WT3[VT\>''D
M^?+ARW</W_#CT953GVX]^77IV+=K[UZ=^W?OV<.3'V\>_'GQZ->K;U^>_7OW
MZ>/3GV\?_GWYJ9O?<XX00'WX":@?@0$6F)^!"2*XX( *-LC@@0]*N!L_EUE8
M(3_0Z'.9AI=!]Z$^T/4G(G/.Y>/0?RFJN"*++;KX(HPQRC@CC37:>"...>HH
MXP,R]/@ "SW>Z&.0/OK((I$_'KDCBT$6J2203*H())0R2&FCD3\&>66+6BI9
M8Y)9KHA F#]^ R.41:KH )'__?A?EMZD6*0#7-IY)YYYZKFGGO[4TQP7% 0E
MJ$2$5C0HHH4F>FBA_:CXSJ*&"NK.BO\W&>JHC9 J6BB*-5HS8RF2A@1-COEL
M>FBG-;9SJJ"IOK.I'C6FL^*KC#:PHAZB<OHHHC+=Z$\ZD0I+02DJZF.KJ/"H
MV,^IN.I:D:N(INH.J[/2&*N*U 9%#X[SL%KGLBOZH^BTI_IJHS_J(#OLNM^Z
MVRZ\S\K+[KSOUALOO?G:JR^^^_K;+\#W"LSOP/\6'##!"1NL,,(+.]PPQ =+
MS/#$#U<<,<496ZPQQAMO.AF$#D8XLL@EAWSRA":GC/*!^D"#3W,DLZRRS"O;
M7#/.-.L\,\\W[^QSSSD'_;/00!M=M'HP\_??T40[/33434>-]--26TWUU!5F
M=B'7_."#(73_'H:HSXADC]W?/95MM/9,;*/T=DUMRPVWVW'3/;?=>=>]-]Y\
MW_VWWGT+#KC?@1,^>-Y0SA EX@3]N#B==OL(^8^&6^[V-P]0GB7E+#C P@&-
MSZ0YE486?KKH #PY^0.7IV[0XZ4?CA*9I#]I=Y";,_[WZJ3+B=$!12( ^Y8H
M?=[C\ 0%C[SKLS?_/.K.1P_]Z]-;7SWVTO?MSSW]!7J88G;-4U-'8-&#Z=L*
M!35/1OV\X]0Z;J\CU?AN\Z,N2'_S(Q7=^AC53MOD891\S&0>4WG'W@2X$P!F
M1'T]02!&_'&4B\"M'TY!AT'B9L&A7(0FQZ**/,C'$U)A!!Y(60?Z_PPR"\2\
MA&YEX19&CL5!N'T0+2%<6_E< D&42% J]8A;#W.2CEGDC1\YP4<%L<(^N$%E
MAW'3Q_P:X(ZB.+$@0B$@333U$W4XBB;^:$QD',/",8;O,6 $GQC+2,8TLC&,
M;D3C&R$#QSG*L8YGM*,9\[C&.-ZQCWI4(R#;2$<_[G&0?Q0D'@L)F2Y4#6M7
M:R0DLR;)1T[2."%R#G0HJ4E'<C*2F_1D)RL)RE&*LI2?-&4H3_E)_C#G/Z14
M92IC^4I9HG*6MJQER+H&#0SMDD,A\MHOFT,B$J'M1&_[3ZJ.Z39DBJN9*DHF
M-)V9HF@^4YK,K"8VIVG-97(S(]?49C:_*?_.;BK3F^1,5>F^1,T#? ,!3JJ2
MD*J9I3)EJ7?TK)PS:W?/?0() >%D6YK@:<]TUG.;YKRG.1-:SH7Z0Z &59U
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M-KB$/_B$@W:%._AS&6].4SB'6WB'JZCSKI<O#;+7-"8Q&77X"G"*(["*%_
M*S"+QSB,IR,H.V/[)ICW#03![3A5R\XXA6;_EDDV2F-78[7#E6,TNCA#Z>^,
MP^*)O>F+&[&,2WF31[F5KWB58SF52_E:&W9B[]9.SNR7)^O:F-UC-4 [O"U&
M3#%B>[E@BPL^_WR= [A#*:2*/^#P8>?YF+MYF_>YGO/YG_OYG@LZH ]Z;,D
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MV3(NW5(NX7(N[;(N\?(J];(K]W(L^S(M__(M Y,N!_,N"S,O^7(K-7$"@:\
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9N(5[N(F[N(W[N)$[N95[N9F[N0DU(   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img117331299_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img117331299_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" I&#&(# 2(  A$! Q$!_\0
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M?L6FV5GI]I]IN9/L]C:6UI#L@@BC2'471/YZ?YFJH/[4DO37_+]3^ROXM?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"X_XF^G?;[#1O!^[1O$=CXCL/^$[UWPM_P )!HD5[/X8_MNZM_L;_@C^U/\
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M]%/ECV_,3JS?VG]R7Y(_%C_AQ/\ LC_]%%_:-_\ "N^&?_SH:/\ AQ/^R/\
M]%%_:-_\*[X9_P#SH:_:>BCECV7]?\-^?=B]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
MF9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M
M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_ (5WPS_^=#1_PXG_ &1_
M^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\ F9^+'_#B?]D?_HHO[1O_
M (5WPS_^=#1_PXG_ &1_^BB_M&_^%=\,_P#YT-?M/11RQ[+^O^&_/NP]I/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >??$CX2_"KXR:':>&/B_P##/X??%7PU8:M!KUCX>^)'@SPYXYT.SURU
ML[[3[;6;32?$^FZI86^K6]AJFIV,&HPVZ7D-GJ-];1S+#=W"2>)_\,'_ +#O
M_1FG[*7_ (CO\(?_ )CZ^K:*UA7K4URPK581O?EA4G%7>[LFE=F<J5*;O*G3
MD^\H1;^]IL_/SXG?\$J?^"=WQ<_L/_A*OV2_A1I/_"/_ -I?8/\ A6.GZG\$
MOM']K?V?]J_MS_A3.J> ?^$F\K^S;;^S?^$D_M;^Q?,U#^Q_L']K:I]L\2U[
M_@AG_P $R]8T/6M)T_X ZMX5O]4TG4=.L?$^@_&+XT7&N>'+R]LYK:VU[1K?
MQ/X_\1^&I]6T>:5-0TZ'Q#X>U[0Y;RWA35M&U2P:XL9_UPHKHAF684THPQV,
MA&+NHQQ-916MW[O/RV;;;5K.[O>YE+!X.;;EA<-)O>3H4W)Z6WY;Z+1:Z=#^
M>+7O^#;;]CFXT/6K?PQ\9?VE]'\2SZ3J,/A[5M>U_P"%OB/0]+UR6SF32=1U
MKP]I_P *O"M_KVDV5^UO<ZCHUCXG\.7FJ6<4UC;:]H\TZ:A;_'OCC_@V8\<V
M'A?5+OX;_M=>%/%GC2+[%_8V@>./@_J_P^\+W_F:C:1:C_:GB_0?B#\3=6TC
M[+I+WU[9?9/ ^M_;]1MK32Y_[-MKV;5[#^M^BNVGQ#G%)Z8R4U=-JI3HU$[=
M+RIN23V:C*+ZIIZG-/)\NFM<-&+LTG"=2#5^MHS46UNN9->5M#^#+XD?\$$?
M^"CO@;7+32?#'P]^'WQDL+C28-1F\3_#?XK>#]+T.PO)KR^MI-!N[?XOWGPJ
M\2OJUK#:6^H3S6/AZ\T-K/5+%+;6;B_CU.QT[\T/B1^S3^T;\&]#M/$_Q?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC:W_ *>_A7\(?AA\$/"-GX$^$O@;PYX \*67V>3^RO#FG0V7]H7UOIFG:/\
MVUKM]A]2\2>([O3=)TVVU3Q-X@O-3\0ZQ]B@FU74[V=/-/HU%;**7KW.6<Y3
M>NW1+;_@_,****9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/_>^U_5I7\I?_!L9_P WN?\ =MG_ +WVOZM*\/B3_D=8W_N6_P#42@>IDO\
MR+,-_P!QO_4BJ%%%%>&>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?^19AO\ N-_ZD50HHHKPSU HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHKXL_;N_;!\/?L<?!#5O&_G>'-4^)VO;M%^$O@37;V^B_P"$
MJ\0FXL8=2U.>STJ*34I_#G@K3;__ (2+Q')Y^BV-YY6E^$_^$FT'7/%OA^YD
M&[:L:3;26[=CX]_X*K?\%!M(^ O@?7?V?_A)XJU*#]H7QCIMC%JNM^%-0M;:
MZ^#GA74)+2]NK[4M2:VO);'QKXNT%I=/\,:5I;:?XE\/Z1K ^(BZSX;N(/ S
M^*?Y+*[7XC?$;QQ\6_''B7XD?$CQ+J7B[QOXNU)]5\0>(-5>-KJ]NFCCMX8H
MH;>."RT_3=/LH+;3-'T;3+:STC0](L['1]'L;'2[&TM(>*K"3N_+H=D(*$;=
M=V_/\-.P5^A'[ ?[ ?CC]M'QP]W=OJ7A'X&>$=2@A^(?Q#A@C6ZO+I8X+P^!
M/ AO()[+4/&NH6<]O->7DUO>:1X'TB\MO$'B"VOKJ^\+>%O%WD_['W['WQ/_
M &R/B?#X$\"0_P!D>'-(^Q:A\1OB-J%E-=>'O /AZZFE2.YN8TEM?[7\1ZO]
MEO+;PEX2MKRUOO$-]:W<TUWI'AS2/$OB70?[@_AS\.? _P )/ _AKX;_  W\
M-:;X1\$>$=-32O#_ (?TI)%M;*U622XFEEFN))[W4-2U"]GN=3UG6=3N;S5]
M<U>\OM8UB^OM4OKN[FJ,;ZO;\_Z_KRFK4Y=%\3_\EVW7GT^\/AS\.? _PD\#
M^&OAO\-_#6F^$?!'A'34TKP_X?TI)%M;*U622XFEEFN))[W4-2U"]GN=3UG6
M=3N;S5]<U>\OM8UB^OM4OKN[F[6BBM3D"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%%;['&VV[O5L****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MY@_;&_:/TC]E3]GGX@_&"]DTV;7M,TTZ-\/M$U)K62/Q+\1==62R\)Z4=-FU
MSP[>ZQIMI>E_$7BNQT34X]=@\#Z%XHU?38II=,*5]/U_'Q_P6!_::_X7I^T[
M=_#K0KGS? ?[.W]L_#_3OW/E_;OB#<7=K_PM/5O],T#2-9M?LNLZ1I?@3[!/
M?:WHDW_"!?\ "3^'+U;7Q3<>;,G9>?3^O(NG'FDET6K]%T^>WXGY8:SK.K^(
MM7U7Q!X@U74M=U[7=2OM9UO6]9OKK4]7UC5]3NI;W4M5U74KV6>]U#4M0O9Y
MKN^OKN::ZN[J:6XN)9)9'<YM%>C?"'X5^+OC?\3_  -\)? EG]M\5^/_ !'I
MWAS2O,M]3N+'3_MLP^W:[K7]C:=JVI6GASPWIJ7GB#Q-JEMIM[_8_A[3-3U6
M:!X+*7&)V[>1^L/_  1U_8O_ .%S_$\?M(>.[#S?AC\%O$=M_P (?';>(?[/
MOM;^-^@S>'/$VA_:],L(9-2G\.>"M-O[/Q)J'VF_T&WU/Q#=^$K"'_A*-#B\
M;:+;_P!8-><_"'X5^$?@A\,/ WPE\"6?V+PIX \.:=X<TKS+?3+>^U#[%"/M
MVNZU_8VG:3IMWXC\2:D]YX@\3:I;:;9?VQXAU/4]5F@2>]ESZ-6\596^_P!3
MBG)SDWTZ+LOZW"BBBF0%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS/.\DKN"N[]%MZBK2LE%;O5^G_!?Y,Z.BBBM3E"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDV4%OIMK[W6\59)??ZG#.7-)OIT]%HO\PHHHIDA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML_:YBKM>6OW&U1VA)]=OOT_(_<JBBBMCB"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% 'YR_\%7/BU_PJ;]B'XL?8O$']@>(_B7_8OPE\-_\
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M +D__=H^7XD_Y@O^YG_W ?U:?\&QG_-[G_=MG_O?:_JTK^4O_@V,_P";W/\
MNVS_ -[[7]6E>'Q)_P CK&_]RW_J)0/4R7_D68;_ +C?^I%4****\,]0****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?Q8_\%:O^4@OQ_P#^Z5?^J3^&]?G+7[3_ /!=C_D[CX=?]FY>$?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% '^<O1117.>@?U@_P#!"?\ Y-'^(O\ V<;XN_\ 59_"&OVG
MK\6/^"$__)H_Q%_[.-\7?^JS^$-?M/6\=EZ+\CBJ?'+U"BBBF0%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_)]
M_P %V/\ D[CX=?\ 9N7A'_U9GQ>K\6*_:?\ X+L?\G<?#K_LW+PC_P"K,^+U
M?BQ6,_B?R_)';3^"/H?HU_P25_Y2"_ #_NJO_JD_B17]IU?Q8_\ !)7_ )2"
M_ #_ +JK_P"J3^)%?VG5<-GZ_HC"O\:_PK\V%%%%68A1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_E+U_JT
M5_E+U]QP9_S,O^Y/_P!VCY?B3_F"_P"YG_W ?U:?\&QG_-[G_=MG_O?:_JTK
M^4O_ (-C/^;W/^[;/_>^U_5I7A\2?\CK&_\ <M_ZB4#U,E_Y%F&_[C?^I%4*
M***\,]0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1%UK369F8X5547)+,Q(  !))P!F@5GV_K^FOO.AHHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#^3[_ (+L?\G<?#K_ +-R\(_^K,^+
MU?BQ7[3_ /!=C_D[CX=?]FY>$?\ U9GQ>K\6*QG\3^7Y([:?P1]#]&O^"2O_
M "D%^ '_ '57_P!4G\2*_M.K^+'_ ()*_P#*07X ?]U5_P#5)_$BO[3JN&S]
M?T1A7^-?X5^;"BBBK,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *_REZ_U:*_REZ^XX,_YF7_<G_P"[1\OQ
M)_S!?]S/_N _JT_X-C/^;W/^[;/_ 'OM?U:5_*7_ ,&QG_-[G_=MG_O?:_JT
MKP^)/^1UC?\ N6_]1*!ZF2_\BS#?]QO_ %(JA1117AGJ!1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEW=[K%M_:UWI\&AZGQ7_ !"#?]9"_P#S4S_\I>OBW_B% _X*)?\ 19OV+?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(2%!9B%502S$@
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ME8@(P((?.TCH: /0:*^2+S]O7]C"QE,,W[37P<=QG+6?C72=0BX.#BXL)KF
M\],2'(Y&00:[+PO^UM^RWXTN(K+PM^T3\%-9OYVVPZ;:_$SP>-4F;_IEI<VK
MQ:A(,\92V(SQG-*Z[K^O^'7WCY9?RO[F?0M%1Q2Q3Q1SP21S0S1I+#-$ZR12
MQ2*'CDCD0E'C="&1U)5E(9200:DIB"BBB@ HHI&954LQ"JH+,S$!54#)))X
M Y)/ ')H _G[_P""Z_QZ_LGP=\+OV<='O=E[XMOY/B7XUABDVR+X>T*2YTCP
ME97" GS+35]??6=1*L%*77A2S<$@D5_,Y7UQ^W3\>6_:._:E^+'Q+M;PW?AJ
M37Y/#/@<JY: >"O"8_L/0;FV7)$2:S#:2>(KB(,RK?:Q=D,0V:^1ZPD[MO[O
MZ_$[:<>6"77=^K_JWR"OTE_X)X_L R?MN:I\2+C6_&&J> O!OP_L-%A;7-,T
M:VU>XU/Q-KUQ<O9Z5!%>W=E!Y-KI6FZA>:C)'))-;O/I*LBI>!C^;5?VR?\
M!,3X"_\ "@OV0/AOINH67V/Q9\0X'^*OC /'Y=PNH^,;>TGT6QN$8>;#/I/A
M&V\.Z9=VTAS#J%M?-LC:5T#BDWKVN*K-QCIHV[+\WO\ =\SX$_X<'?#K_HXK
MQK_X0NA?_+RC_AP=\.O^CBO&O_A"Z%_\O*_?^BM.2/;\7_F<_M:G\WX1_P C
M\ /^'!WPZ_Z.*\:_^$+H7_R\H_X<'?#K_HXKQK_X0NA?_+ROW_HHY(]OQ?\
MF'M:G\WX1_R/P _X<'?#K_HXKQK_ .$+H7_R\H_X<'?#K_HXKQK_ .$+H7_R
M\K]_Z*.2/;\7_F'M:G\WX1_R/P _X<'?#K_HXKQK_P"$+H7_ ,O*_<[X>>!M
M!^&/@/P9\.O"UO\ 9?#G@;PQH?A/182%\P:;H.FV^FVKSL@427,T5LLUU,1O
MGN9)9I"SR,Q[&BFHI;(F4Y2MS.]MM$OR2"BBBF2%%%% !1110 4444 %%%%
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M6KKXCZQK6L>';JX\-P0:#\;/!_AW2IK'0-<30+RXM->M/$_X3_M-_P#!K?\
MM\?">^N[[]G?Q%\,/VK_  E)K6CZ5H]KI6N:;\&/BF;&[\.R:CK/B3Q)X/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !117G7Q:^*O@CX(_#KQ7\4_B+J\>
MB>#_  =I<NJ:K>,!)/+\Z06>FZ=;ET-[JVK7TUMIFDV*,LEYJ%U;6ZE3)N &
M^QJ>/OB%X(^%GA/5_'7Q%\4Z-X-\(Z#;FYU77M>O8K*QMD)VQ1*SGS+F\NI"
MMO8Z?:1SWU_=216EE;W%S+'$_P#/=^T__P %Q]1DNM1\+?LI^#K:VL8FEMA\
M4_B'8O<7EW@E/M?AGP.)8H+&+<HFL[[Q5<7TMQ#+LO?"NGS(5K\J_P!M']MO
MXG_MD>/YM9\275SH'PZT6\N!\/\ X:VEV[Z1X>LB7BCU'4@GEQ:SXKO;<YU3
M7)XMRF22QTR.RTM(K1?BVLI3>RV[]?\ @?F=4**2O)7?;HO\WWZ?F_>?BS^U
M#^T/\<[BXF^*_P 8O'OC*WN69WT:^UZZM/#$1<Y?['X2TMK#PQ8*W&Y;'2+=
M6"J&!"*!X-4MO;SW<\-K:P37-S<2QP6]O;QO-//-*P2*&&*-6DEED=E2.-%9
MW8A5!) KZ,T#]CK]K#Q1:QWVA?LV_'"_L9D$D%\/ACXPM[*XC."'MKR[TB"V
MN%(((,$LF>W0XC5]W^)KHNR^Y'S=17L_CG]G+]H'X96DVH_$/X(_%CP5IEN&
M,NK>)OA]XJT?1U5#AG&KWNE0Z:Z ]72Z9.1\V",^,4#NGL[G<^ OB=\1OA9K
M">(/AKX[\7> M:C>-O[2\(^(=5\/W4HB;<D5S)IEU;?:[<G*R6UT)K>5&>.6
M)XW=3^Z_[%7_  6?\36FM:/\.OVNI+36= OYH-/L/C-IFG0:?K&A32,(H7\<
MZ+I4$.G:MHX)C6;6]%L+'5-/1'N;^RUTS2W-K_/?133:V?RZ$RA&2U7SZKY_
MTC_1?LKVSU*SM-1TZ[MK_3]0M;>]L+ZRGBNK.]L[J))[6[M+F!Y(;FVN8)$F
M@GA=XIHG22-V1@39K\+/^")'[3NJ_$'X:^+_ -G7Q=J4NH:O\(H;+7? =Q=R
MM-=2?#S6+E[.[T0.[-(]KX1UTVZ6;2-B#3O$>GZ7;+'::9!&G[IULG=7_I''
M*+C)Q?3KW71A117 ?%'XH^ _@QX%\0_$GXE^(['PKX-\,69O-5U:_9B!EA';
M6=E;1+)=:CJ>H7#1VFFZ98PSWVH7DT5K:P2S2*I9.^QW4TT-M#-<7$T5O;V\
M4DT\\TB10PPQ(9)9II9"J1Q1HK/)([*B(I9B ":_'O\ :I_X+(? ?X+7&I>$
MO@Y:+\=O'EFTMK-?Z3J*V'PTT>[3*,+CQ7'%=2^)98&*2?9O"]K=:9<J)+=_
M$EA<HRK^,/[=/_!3?XI?M7:CJG@KP;/JGPV^ \<\MO;>$K.[-OKOC:U20B+4
M/B#?6<I6Z2<*L\7A2TF?0=/9HUNFUN^M(=5K\OJSE/\ E^__ "_X)T0H]9_^
M K]7^B^\^\_CA_P4L_;$^.T]W#K7Q8U;P/X<N3*%\(?"Q[CP+HL5O*3OM+B]
MTRY/B?6+5U(1X-?\0:K&RC 0!F!^$KFYN;RXFN[RXGNKJXD>:XN;F62>XGFD
M8M)+--*S22R.Q+.[LS,Q)))-0T5G=O=FZ26B27H%%2212PL%FCDB9D60+(C(
MQ1U#(X# $HZD,K#AE(()!J.@9](_ G]KK]HG]F_4K6]^$OQ1\2:#IT$R2W'A
M*[O)-9\$:F@?=)%J'A+5&N=%<S(7B-[;6MMJENDLC65_:S$2K_4S^P)_P4J\
M#?M@VP\"^*["P^'_ ,=M,T][RZ\+PW,K^'_&=E9Q![_6? ]Q>2/=![50USJ7
MAB^FN=4TRSS=VU[K5A;7]]9_QJUTW@SQCXF^'OBSP[XY\&:Q>:!XK\)ZQ8Z]
MH&LV+^7=:?J>G3I<VLZ9#)(@= D]O,DEO=0-);7,4L$LD;5&37IU1G.G&:[/
MH_\ /O\ U8_T0J*^=?V3OCYIO[37[/OPV^,MC%!:7?BG1/+\2:7;L3'H_B[1
MKB;1_%&FQJSO,EK#K5C=RZ8;@B:?29["[88N%)^BJVW.-JS:>ZT85\%?\%+/
MCU_PS]^R%\3=?T^]^Q>+/&UHOPO\%NDGE7"ZWXT@NK.^O;20'='=:+X7@\0Z
M[:RJK;;O3+=3MWAA]ZU_*]_P7%^/7_"8_&_P7\!M(O?,T;X0^'QKOB6&*3Y'
M\<^.(+6]CM[E%)61M(\(P:)-9R,0\+^(M4@V+EB\R=DRZ<>::71:OY?\'0_#
MBBBBL3M/JO\ 8D^!#_M'_M/_  F^%L]J]SX>O_$4.N>-<*3%'X)\+HVO>)8Y
MI!\L!U/3[%]$M)G!4:CJEE'M=I%1O[NT1(D2.-%CCC54CC10B(B *B(J@*JJ
MH"JJ@!0   !7\]__  0F^ O]G^'/BI^TAK%EMNO$-W'\+O!$\L>V1=&TI[/7
M/&5[ S ^9:ZEJ[>'M.CF0KLN?#NI0'?DA?Z$JU@K+U_(Y*TKSMTBK?/=_HOD
M%%%%69!1110 4444 %?Q7?M]?%WXP^&/VROVB-#T7XK?$K1M)L?B-J?]GZ7I
M?CKQ1I^GV-K<V]I>16]G96FJPVUM;H+C]W%!$D:@_*H%?VHU_$-_P4WM?LG[
M=O[1<6-N_P 5Z-=8_P"OWP7X9O<_\"^T;O?-1/9>O]?D;4/B?^'\FK'S3_PO
MSXZ?]%I^+/\ X<;QA_\ +FC_ (7Y\=/^BT_%G_PXWC#_ .7->345E=]W_7_#
M+[CJLNR_K_AE]Q_H?^!GED\%>#Y)Y))II/"WA]YI97:2665M)M&DDDD<L[R.
MY+.[$LS$LQ))-=37-^#4\OPAX5C_ +GAO0T_[YTRU7^E=)70>>%%%5[N[M;"
MUN;Z^N;>RLK*WFN[R\NYH[:UM+6VC::XN;FXF9(8+>"%'EFFE=(XHT9W954D
M 'E_QP^-'@7]GSX7^+?BU\1M3&F^&/">G/=RI&8VO]7U"4B'2M T:WD>,7>L
MZU?O!I^GVY=(_.F$US-;V<-Q<P_Q3?'?]MC]H+XY_%3Q9\2KOXC^-_!]OKU^
MQT?PCX4\9>(='T#PQH-L/(TC1+"TTZ^LK>5K.S6,7NHM;1W&JZ@]WJ=RJSW;
MJOT3_P %-_VZ;K]K+XH_\(CX(U"X3X$_#74;NV\(PHTD,7C37D$EGJ'Q O[=
MMC-'<1F6Q\*P7*^=8:$\MT8K.^UW5+5/R_K*4KNR>B[=?^&Z'72I\JNU[S_!
M=%Z]SUG_ (7Y\=/^BT_%G_PXWC#_ .7-;_A7XI?M+>./$NA>#O"/Q1^,_B#Q
M/XGU6QT/0=$TWX@>,9[[5-5U*X2ULK.VB&L@&2:>1%W.RQQJ3)*Z1H[KX/7]
M4O\ P20_8#_X5!X:L?VEOBYHOE?%+QEI1;X>^']2M\7/P_\ !NJV^&U>Y@F7
M=:>+/%ME+AD*+=Z)X<F73Y'@O-8UJPMDDV[)_P# V_X'X%3DH1O97Z+N]/RL
MON]#]!/V*/V;]>_9M^#>F^'O'?C?Q'\0_BCXB^S:Y\0_$FO^)-9\1V\.L-!M
MA\.>')-7N[EK;P_X>CDDM+>6-89-6O7O]8N(X!>PV-E]?T45ML<;;;;?4***
M*!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[WVOZM*\/B3_ )'6-_[EO_42@>IDO_(LPW_<;_U(JA1117AGJ!1110 4444
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MO;RX<1P6MI!+<W,[D$A(8(5>65R 2%1&. 3CBOI#P3^QE^UA\1/)?PC^SO\
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MH4444R HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M88@0HSLS@9JX1O=O;]3.K-PLEN]?DO\ ,_FW_P"'!WQ$_P"CB_!?_A":Y_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '^<O1117.>@?U@_P#!"?\ Y-'^(O\ V<;XN_\ 59_"&OVGK\6/^"$__)H_
MQ%_[.-\7?^JS^$-?M/6\=EZ+\CBJ?'+U"BBBF0%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>+?M&?'SX=?LM?
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M._<J1DY3JX;FC0Q7-/F4*\H5X?QU_P#!"'_@N]_PI;_A#?V)/VW/&7_%EO\
M0/#'P#^/GB>__P"2+?ZNST;X7?%'6;R3_DBW^IL/!/C:_F_XLM_H_AWQ%<?\
M*6_LW4O@M_=C7^6)_P %,_\ @D1^TO\ \$QO$6AW?Q'ET7XD_!/QWK6M:1\.
M_CGX$M=7C\.WE]97VKRZ5X0^(&D:E:K<?#KXGZKX2TV'Q@OA-]1\1^'=0L9-
M:M? _CSQV_@KQK/H/Z0_\$@/^#A+XB_LG_\ "K/V7?VNIO\ A/\ ]DS1?/\
M">A?$_[#KFM?&'X$:'=_V1;>$[7S;6^N_P#A/_@MX ^R:C:_\(7'X?N_B+X8
M\+ZUY'@+7=:T#P!X+^#6I>%DN?5LMJ?V3G:J4G2<84:U5>]13LHTZTKM2H<K
M3IUDVH1T;=+E=/\ 1>/?#? \58;_ %T\/YX;&K%JKB,=@,(TJ>-E#F=7$X&G
MRQ=/,/:1E#%X"483KUFYPA#%^TAB?]!JBL7PWXD\.^,_#N@>,/!^OZ+XK\)>
M*]%TKQ)X7\4>&]5L==\.^)/#NNV,&J:)K^@:WI<]UIFL:+K&F75KJ.E:KIUU
M<V.H6-S!=VD\UO-'(VU7WZ::33335TUJFGLT^J9_-,HRC)QDG&46XRC)-2C)
M.S33U33T:>J>C"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2/4D\.ZY?:.M_&BLZHEXMF+A5#,%60 ,P&3QE9G3N%?WF?L7?$'5/BE^RA\
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M_9*<J=*FPHHHKUSXH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,
M/C1\%_A9^T1\+/&_P3^-G@C1?B+\+?B+HLN@>,/!^OQ3-8ZG8M-#=VL\%S:3
M6NIZ/K6CZG:V.N>&_$FAWVF^(O"WB+3=*\2>&]5TK7M*T[4;;_-(_P""N_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGQ'K.E:!H]DADO-5UO4;32M-M(P"3)<WU]-!:P( "2\LJ* "2< U^,/[;?\
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M#%;:?8)++!I.EV]GIT$DJV[3S?15;15EYO?_ "..I/GEY+1?J_G^5@K^5O\
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M@YOE4$,ZBKM?>_0=27+!OKLO5_U?Y'[ZT445N<04444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ?YR]%%%<YZ!_6#_P0G_Y-'^(O_9QOB[_ -5G\(:_:>OQ8_X(3_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _D^_X+L?\G<?
M#K_LW+PC_P"K,^+U?BQ7[3_\%V/^3N/AU_V;EX1_]69\7J_%BL9_$_E^2.VG
M\$?0_1K_ ()*_P#*07X ?]U5_P#5)_$BO[3J_BQ_X)*_\I!?@!_W57_U2?Q(
MK^TZKAL_7]$85_C7^%?FPHHHJS$**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "O\ *7K_ %:*_P I>ON.#/\
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M/7]5G+,$40Z?I5M=W<F78*-D+98@#D@5^I_[._\ P1N_:A^+=S8ZI\3K>Q^
MW@N5XY+BX\5A-5\<75JV"W]F>"-.NEEM;C.8WB\5:IX:EAYE2WN@%CD_K8\/
M>%?#'A&Q72_"?AS0?#&F+MVZ=X>T?3]%L5V@A=MIIMO;6XV@D+B/@$@8S6]5
M*"ZMO\"95Y/X4EYO5_Y?@SY"_98_8@^ 7[(NC-;_  S\-->^+KZT6U\0?$CQ
M,T&J>-=;3*M+;B_$$%MHFDR2)&YT70+73=/E,-O-?17M[%]L?Z]HHJTK:(Q;
M;=V[M]6%<MXX\41^"?!GBWQE+IFIZU'X5\-ZWXB;1M$L[G4=9U?^QM-N=072
M])T^SAN+N]U/46MQ9V%I;033W%U-%%%$[N%/4T4"/X,/B#\(_P!JCXE^._&7
MQ$\4? KXU77B+QQXGUSQ9K<X^%GCLH^IZ_J5SJ=VL(;0V,=O'-<M%;1 [88$
MCB0!$4#D/^&;/VB_^B!?&K_PUGCG_P"45?W_ %%9^S7=_P!?T_Z6N_MW_*OO
M]/+U_#MK_ ;I_P"R]^TEJ=_8Z;:_ /XR"YU"\MK&W-Q\,_&=I;B>[F2WA\^Z
MN=%BMK:'S)%\VXN)8X(4W22R)&K,/[D?V?OA'I/P&^"GPR^#^C>4]IX!\(:3
MH5Q=0IY::GK"0_:?$.M%"%VR:YK]QJ6KS#:N)KV3Y5Z#V&BJC%1\R)U'.RM9
M+7U?]7^\****HS"BBB@ HHHH **** "BBB@ K^?+_@N7\+/B+\0-3_9HO? '
M@#QKXX_L^Q^+EKJQ\'^%==\3?V9YEQ\-Y; :C_8MA>_8OMG^FFT^T^5]I^RW
M7D[_ ")MG]!M%)JZM_6Y4)<LE*U[7T]58_@!_P"&;/VB_P#H@7QJ_P##6>.?
M_E%1_P ,V?M%_P#1 OC5_P"&L\<__**O[_J*CV:[O^OZ?]+7;V[_ )5]_P#P
M/7^EK^07_!*S]@9/V;/ R?&/XH:.J?'/XAZ3'Y.G7T(^T_#3P=>B.YA\/)'(
MN^V\3:RJP7GBN4A)[%4M?#L:0FSU634_U]HHJTDE9&$I.3;>[_JP4444Q!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHH **** "BBB@ HHHH _/G_@H_\ \$X/@5_P4J^!5Q\)_BQ;_P#".^-?#O\
M:>L?!?XT:/IEO?>,?A%XQOK>WBFO;*&6XL?^$B\%>(OL.FV7Q#^'E[J5CI?C
M'2['3[FVU#P[XU\.^"/&_A+_ #$OVP/V/_CK^PS\=?%7[/?[0GA7_A'?&OAW
MR]0TK5=/DN+[P=\0/!U]<7<&@?$/X>:_/:6/_"1>"O$7V&\2RO7L['5-*U2Q
MUCPIXKT?P[XU\.^)/#>C_P"OG7Y(?\%?O^"5O@[_ (*A? K1M @\1_\ "!?'
M_P"#O_"4ZY\ ?'>H7>J/X.@U3Q3;Z(OBCP-\0]%L4O/M'@KQ[_PBWAJ"]\3:
M5I5YXQ\":IHVC^)- AUW2;?Q3\/_ !W\MQ'D$,RI2Q6&@EF%**M:T5BH1M^[
MFW9>TC&_LIOLJ4WR.,J?[#X6>)-;A3&TLHS:O*?#6,JRYG)2J2RC$5+M8K#I
M7E]5J5+?7</%-)2EBZ,77C4IXKY'_P""(O\ P6Z\._M\^'=,_9T_:+U/1?"G
M[:/A319GM+M(;'0O#O[2OAW0K&2ZU'QEX-TZUCM=,T?XGZ/IEK/JGQ+^&FEP
M6UC<6-M?_$CX;V$/@R'QAX/^$G]$]?X['Q#^'GQU_9$^.NL> _'FC^-?@?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#^3[_@NQ_R=Q\.O^S<O"/_ *LSXO5^+%?M/_P78_Y.X^'7_9N7
MA'_U9GQ>K\6*QG\3^7Y([:?P1]#]&O\ @DK_ ,I!?@!_W57_ -4G\2*_M.K^
M+'_@DK_RD%^ '_=5?_5)_$BO[3JN&S]?T1A7^-?X5^;"BBBK,0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M_P I>O\ 5HK_ "EZ^XX,_P"9E_W)_P#NT?+\2?\ ,%_W,_\ N _JT_X-C/\
MF]S_ +ML_P#>^U_5I7\I?_!L9_S>Y_W;9_[WVOZM*\/B3_D=8W_N6_\ 42@>
MIDO_ "+,-_W&_P#4BJ%%%%>&>H%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% '^<O1117.>@?U@_\ !"?_ )-'^(O_ &<;XN_]5G\(:_:>OQ8_X(3_ /)H
M_P 1?^SC?%W_ *K/X0U^T];QV7HOR.*I\<O4****9 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X@_\'#7[3=]^S7_ ,$P
MOB]::#=ZUIOBW]HW6O#_ .S)X=U32M'\.ZS8VEC\1;36];^)MIXDC\1R,FGZ
M+XD^"?@SXG^#X-8T;3M5\1:7XB\1:!=:/'I%PI\4:!_!G_P2S_8_U3]N']NK
MX ? O_A%?^$J\ 2>-=)\<_'*"ZD\8Z?H=G\"O FHV6O_ !,AUWQ)X'M+C6O"
M7_"6Z+;_ /"N?">N?;- MY?B+XU\%Z#_ ,)-X>N];M-5MOVE_P"#L#X^?\)K
M^UU^S_\ L\:;J7@K5=%^ _P6U'QIJO\ 8=Y]N\8^'OB+\<O$O_$_\)^.?(UF
M[M-)\CP!\,/A/XO\,Z%<Z)H^N1Z7XVF\07MUJ^B^)/#?]G_3O_!I'^SQ_P G
M<_M8:WX0_P"A(_9X^&?C[_A(/^NWQ)^.7A#_ (1:TUO_ +-XUK_A(/$'AS_J
M'>$-;_Y'BPK\XS!?VSQ71P;O+#X64:4UJX.%",L1B.96:BYU.:@VT^9J";5T
ME_5'#,GP'X,X[/8-4\SSBG5QE"2M"M&OF-6GEF6>SFYPJ5%A\,J>8J,))TU+
M$3IPE:4I_P!I%%%%?HY_*X4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!^!G_!=;_@D1??\%'OA9X9^)WP3ET72
MOVK/@3HOB&V\'Z;J%KX=TFQ^.'@G4IK;5;KX3^(O&MW:VNIZ/K6CZG:WVL?!
MW4M<UY? &A>(O$WC31O$EEH=C\1=1^(G@G_/_P#V>/CO\=?V _VIO"'QH\#:
M7_PA7QT_9_\ &OB#3[WPG\2?"5PWV#5([/6_ ?Q#^'GC[PAK":9K6F?VGHNI
M^)O!'BFRAF\/>,= ^W7\NAZQX9\5:?I^KZ=_KYU_(-_P<!_\$1?#OC?P[\4?
M^"A?[*>F:+X4\>>%-%\2?$S]J7X5I-8Z%X=^(OAW0K&[\0>-/CAX-:XDM=,T
M?XGZ/IEK?^(/B7X>,EM8_%FQMK_Q=I A^,,.K6/QG^*XFR2I.7]KY>I1Q=%Q
MJUXTY-2FJ*3A7I+=5J2BG)1:YXQ3BG4C:?[]X3>(.'P]-\$\3SI5<EQ\:N$R
MZIB*:G2HRQLI0K9;C)-\KP&,=::A*I"2HU:LH59K"U$\/^^?_!.#_@H_\"O^
M"E7P*M_BQ\)[C_A'?&OAW^S-'^-'P7UC4[>^\8_"+QC?6]Q+#97LT5O8_P#"
M1>"O$7V'4KWX>?$.RTVQTOQCI=CJ%M<Z?X=\:^'?&_@CPE^@U?Y.O_!.#_@H
M_P#'7_@FK\=;?XL?">X_X2+P5XB_LS1_C1\%]8U.XL?!WQ=\'6-Q<2PV5[-%
M;WW_  COC7P[]NU*]^'GQ#LM-OM4\':I?:A;7.G^(O!7B+QOX(\6_P"I#^SG
M\?/AU^U+\"OA5^T/\)]2_M/P!\7?!6B^-- \Z\T.\U31_P"T[<?VKX3\3?\
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M?X5^;"BBBK,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6SMWLPHHHK(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBO9E%%%??'\V!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\2U&6MOM4TY2W;THJRWTNU_)!75^"/'GCGX9>*-+\<?#?QGXK^'WC31/MO\
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MK345-6\I(WAC<73MR8K$12=[*K/EOYQ<N5^=T[G] _\ Q$A_MQ?]$K_92_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _D^_X+L?\G<?#K_LW+PC_P"K,^+U?BQ7[3_\%V/^3N/A
MU_V;EX1_]69\7J_%BL9_$_E^2.VG\$?0_1K_ ()*_P#*07X ?]U5_P#5)_$B
MO[3J_BQ_X)*_\I!?@!_W57_U2?Q(K^TZKAL_7]$85_C7^%?FPHHHJS$****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_.7HHHKG/0/ZP?\
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MXL?^"2O_ "D%^ '_ '57_P!4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K_*7K_5HK_*7K[C@S_F9?]R?_NT?+\2?\P7_ ',_^X#^K3_@V,_YO<_[
MML_][[7]6E?RE_\ !L9_S>Y_W;9_[WVOZM*\/B3_ )'6-_[EO_42@>IDO_(L
MPW_<;_U(JA1117AGJ!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXHU6]UWQ'XCU2^UO7=9U*=[F_P!4U;4[F2[O[^\G<EI;BZN99)9&.!N8A0%
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M;V\$:10000HL<,,,485(HHHU5(XT541%"J  !4M%%;G"%%%% !1110!\4?\
M!0WX\_\ #._[)?Q5\:V-[]B\5:WI)\ >!G23R[D>*_&B3:5;7MBV0/M>@:6V
MK>*(U.0RZ%("K_<;^&ZO]!CXI_!7X4?&[2=-T'XM^ O#OQ!T;2-1.KZ9I?B:
MR&H65GJ9MIK/[?#;NPC%TMI<7%NDQ4ND,\R(5660-X=_P[^_8K_Z-G^$W_A,
M6_\ \542BY6U_K^OR\S:G4C!6:;;=W:WE;KZ_P!;?Q]_L7? J3]H[]IOX2_"
MF6V>XT+5_$L&K>,BH;9%X)\-(^O^*5DE'RV[WVDZ?/I-G,YV_P!I:A91!7>5
M(W_O"BBC@CCAAC2&&%$BBBB18XXHXU"1QQQH J(B@*B* JJ    !7@_PP_9;
M_9V^"_B&X\6?"GX.>!/ 7B6ZTJXT2XUOPYHEO8ZC)I-W<V=W=6!N5W.MM/<Z
M?932HI7>UM'N) P?>Z<8\J)J3YVK*R2Z]WO_ %Y?)%%%%49A1110 4444 %%
M%% !1110 4444 %%%% 'YX?\%1OCU_PH?]C[XAW.G7OV3Q9\3(T^%'A,QR>7
M<+<>+K:[C\0WT#(?.ADTWP?:^(;JVNX@#;ZF-.'F1R2Q-7\4U?M;_P %NOCU
M_P )[^T)X9^"FD7OFZ#\%/#HFUF**3,4GCOQQ!8ZOJ*R;"8Y_P"S/#,'AFVA
M+EI+.\N]9ML1NTZM^*58S=WZ:?YG92C:"[RU_P OPU^9]L?\$\O@+_PT1^UI
M\*_!5]9?;?"NAZL/B!XY1X_-M3X4\%R0ZK<V5ZN"?LGB#5%TGPO(1@AM<0AD
M^^O]R%?@U_P0O^ O_"-_"SXB?M"ZQ9;-2^).LKX)\(3S1XD3P?X/G9];O;.4
M#FVUOQ9,^GW2$G%QX-B8!1R_[RUI!67KK_E_7F85I7G;I'3Y]?\ +Y!1115&
M04444 %%%% !1110 4444 %%%% !1110!^!W_!=/X]_V!\.?AO\ LZZ/>[-1
M\?ZJWC_QE!%)B5/"?A:=[3PY97<>?FM-;\4R7&HPL%)6Z\&?>49#_P Q%?VR
M?M2?L)_LC?&#7O%'Q^_:%@\1"70/"D;ZYKS^.]=T30] \*>%+">Y?R;*RG2V
MM+2WC^VZA.D*-)<7MU=3!7FN-I_C,^(%WX0U3QWXMO/AUHE[X?\  MWXDU9_
M!>A7]Y<:GJ>G>&FOYET*TU&^N)9Y[S4QIPMOM\WF,DEZTQA5(?+C7*:=[OKM
M\CKHM<MDGINWU;^?R]%J?KM_P1(^ O\ PG_[1/B+XSZO9>=H'P1\.M_94LL>
MZ&3QYXVAOM'TG8)!Y4W]F^'(?%%[)LW2V5])HUS^[=X'/]1_Q%\=:#\,/ /C
M3XC^*)_LWAWP+X7USQ9K,H*B3^SM!TVXU*YC@#$"2ZGCMS!:PC+SW,D4,:L\
MBJ?CS_@FY^S7-^S'^RSX+\,:Y8?8?'WC1I/B+\0XI8]EU9^(/$=M:?8]"N P
MWQR^&O#UIH^BWEN'>!=6M-4N8"%NVS]2_&;X0>#?CS\-_$?PH^(,>K3^#?%B
M6$.NVFBZO>:'>WEMIVIV>KPVO]I6#QW<5M+>6%M]KBBD1;NW62TGWVTTT3W%
M67GO\_ZT,)R4IW^S=*_DMVOQ:/X(/B;\0->^*WQ%\<?$SQ/+YWB#Q[XJUWQ9
MJQ#,T<5YKNHW&H26MONY2SL_/%I90@*D%I###&J1QJHYK1-%U3Q)K6D>'=#L
MIM1UK7M4T_1=(T^W7=<7^J:I=PV.GV4"D@--=7<\,$2Y&7D49&:_6+_@J;^S
M_P#LC?LO:MX$^%?P*T+6(/B??K+XJ\<W>H>,=9\0Q>'O"\D$MIH&CRV5[=36
MT&I>(;M[C5F$B+>V>FZ58S!1:ZW"\D__  1N_9GN/B_^T?'\7-<T]I? GP%2
MW\0K-/%FUU'XB:@L\/@S3HBR@22Z,T=[XMDD@=GLKO1M&2X41ZE#ORMK;SMI
MK_5NIT\ZY.=:*VE_PT]=/^ ?U!_LZ_!_2_@#\#OA?\'=)\EX/ ?A'2]'O;J!
M=D6I:\T9OO$VLA-J[6UKQ%=ZIJSJ5!#WK CBO:***WV.)N[;>[U84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% '^<O1117.>@?U@_P#!"?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?^19AO\ N-_ZD50HHHKPSU HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML[ -&NK^+I]<@NXU!29/#NF3;VPH3A_^'!WPZ_Z.*\:_^$+H7_R\K]OOA/\
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MO;'5-/DF@M[@VEY"+FVMK@2P1^6U&J[K\#6T9):)IK33IY']\G[+?[1/A/\
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M.V4FH^(/%6N:3X<T+3XO];?:QK=_;Z9IEG'_ +=S>W4$*?[3BL.OUQ_X(T?
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MGQJLU>TU>6ZN9;CP1\/+I05:W\17%C<0W>O>)(2-LOAK3KRT^P.7.MZK97<
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M %_3"I4YK)*T5LO\^FG1= HHHJC,**** "BBB@ HHHH **** "BBB@ HHHH
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M[/W=;I+]#J***^//>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OF/]H#XNW'A6W3PAX6OX8O$&H0R-K-[;3.;_P_
M82)$UM% 43R[;4]5CEDDBG\\7NFV4:W<-M%-J&F:C;]E\:?BG;_#[0);33;V
M$>,M6A T:U,"7ALK=IA%<ZS>0O(L<,,,:W$>FM<+.EWJB1I]BO;.UU,6_P";
M]S<W%Y<3W=W/-=7=U-+<W5U<RO/<7-Q.[2S3SS2LTDTTTC-)++(S/([,[L6)
M)^;SS-?81E@\/+]].*]K4C+6C%_8BT[JI-;WLX0DFO>DG']5\/N#?[1J4\]S
M.FG@*%27U/"U:;MC:T$K5ZBDE&>$HS?NI.4:]>G*%3]U3G"M#1117Q9^]A11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >R?!
MWXJ:A\/-<AM;FX\WPEJU[ FN6<YG>*Q\QHX'UZQ6"*XFCO;*$*]S#!!)_:MG
M +.6,W$>G75C^DUM<V]Y;P7=I/#=6EU#%<VMU;2I/;W-O.BRPSP31,T<T,T;
M+)%+&S)(C*Z,5()_'6OI;X _%O\ X174%\)^)]4\GPI?[_[,GNEWP:'J\TZ.
M-]TTJ?8-&O\ ?<&\W1S6MMJ#P7[?8()M8O)/H\DS7V$HX/$2_<SE:E4E+2C)
M_9;;LJ4GY^Y)MVM)M?E?B#P;_:5*IG>64U]?H4[XS#4Z;<L?2@DE4@H)N6*H
MQ35G%NO22@I*=*G&I]]4445]J?@84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!_)]_P78_Y.X^'7_9N7A'_P!69\7J_%BOVG_X
M+L?\G<?#K_LW+PC_ .K,^+U?BQ6,_B?R_)';3^"/H?HU_P $E?\ E(+\ /\
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M$\6:MJEO9:"+\V6F:7-X?\;>%X+2P>?4KFZO(WMKB6[N%MFEG*6EM'%]I?\
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M "BBB@ HHHH **** "BBB@#_ #EZ***YST#^L'_@A/\ \FC_ !%_[.-\7?\
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MQX&\4:M?7^7QCS%TWQIHB%,_<16 Y8U^%]93^)_+\D=5-WA'T2^[1G]%/_!
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M^"A,K&YEEN?$T,4<=MX<U"Y_H]JX)VN[^2\OZ_K4QK.+=HI:;M):^5UVZ_\
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M$/\ :$UBRWZ9\-=&7P5X0GECS&_C#QA [ZW>6<N#BXT7PG#)I]TA*_N/&,+
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M'@_1/A[X,\)> O#5N;3P[X*\-:'X3T*U)#-!I'A[3+72=.B=@%#R):6D0D?
M+N&<C+&OP&_X(F?LA7.FV^K?M;^.M+>"74[74?"?P<M;R$K)_9TKM9^+?&\*
MN-RK>M%+X5T6=2K26B^)V:-[:\L9W_H@9E16=V5$52S,Q"JJJ,LS,< * "22
M0 !D\5<%97[_ )?U^AE6ES2Y5M&_S?7[MOO/Y]O^"['QZ_LOPI\+?V<-'O=E
MYXHO9/B=XV@BDVR+H.BR76C>#[*X4$^9::KKC:[J+(P79=>%[&12V<#^:&OK
M3]N3X\-^T=^U'\6?B;;7;7?AN?Q#+X<\#D.6A7P3X54:%X>GMTR1"NKVUFWB
M"YB4LJW^KWC!FWEC\EUG)W;?W?U^)O3CRQ2Z[OU>_P!VWR/W4_X(:_ 7_A*_
MC'X[^/VL66_2?A5H7_"+^%9Y8_D?QKXV@G@O[NTD((:71O",.I6=Y'\I5?%=
MC(&/(K^I2OA?_@G!\!?^&>OV1?A=X7OK+['XK\5Z>?B5XW1X_*N1XC\:PVVH
M1V5XF 5O-!\/1Z#X;N02P\[1G8,0PK[HK6*LE][.6I+FFWT6B]%_F[OYGXM_
M\%MOCU_PK[]G3P_\&=)O?)\0?&_Q$J:I'%)MFC\">"9K'6M8+&,^9#_:/B&;
MPO8*'*1WM@-9MOWB).@_D[K]&/\ @J=\>O\ A>W[8/C\Z=>_:O"?PL*?"?PM
MY<F^W<>%;F['B>^BVGR91?>,;O7V@O(MWVK2X=,_>21Q1$?G/6<G=O[D=-*/
M+!=WJ_G_ )*Q^M7_  1N^ 0^+?[5EMX_U:R^T^%?@1I!\;3M+'YEK+XSU)YM
M)\"V<AP=EQ;W7]J^*;)\KMN/"JY)!VM_7]7Y7_\ !(#X"_\ "G?V1]"\6:I9
M?9_%7QPU&3XCZB\D>VYC\,RQ+IW@6R+X&^TET*#_ (26U!!*/XHNE+'@+^J%
M:15DO/4YZLN:;[+1?+?\0K^;C_@NW\>OM.J?"C]F[1[W,.FPR_%;QO!%)E&O
MKQ;[P]X)LIMA 2:TLE\4:C<6TNXM%JNCW01 (G?^CR_O[/2[&]U/4;J"RT_3
MK2YO[^]N9%BMK2SM(7N+JZN)7(2*"W@C>661B%2-&9B #7\$?[5'QKO/VB/V
MA?BO\8;IYS:^,/%E]-X?@N-PEL?".F"/1O"&GR(QPDMEX:T_2X+D*J*]TD\V
MQ6D84INRMW_0JC&\K](K\7M^I\_5_0G_ ,$)O@+_ &AXC^*O[2&L66ZV\/VD
M7PM\$SRQ[HSK.JI9Z[XSO8"P'EW6FZ0OAW3HID+%[;Q%J4!VX8/_ #W(CR.D
M<:-))(RHB(I9W=B%5$5069F8@*H!))  )-?W<_L1? A/V<?V7_A-\+KBU6U\
M0V/AR'7O&HV@2OXV\4,VO>)89I!@S_V7?WS:':2L QT[2[--J! BS!7?I^9K
M6E:%NLG;Y;O]%\SZMK^#;]M/XC3_ !7_ &L?V@?',MPUU!J7Q0\3Z;I,S-N+
M>'?"]\WA3PR,\@!/#VB:8@4$J@7:I8 $_P!Y!) ) R0"0/4@=/QZ5_G1ZA=W
M&H7][?W;,UU?7=S=W+-G<UQ<S/-,S;OFW&1V)SSDG/-.IT^?Z&=!:R?9)???
M_(J5_>C^QK\.[;X5?LJ? #P+;P+;RZ5\+?"=[JD:*%4^(?$6FQ>)?$\H  .)
M_$6L:I/EAO;S,N2Y)K^"ZO[ZOV5_B7H/Q?\ V<_@Q\0O#MW!=V.N_#SPP+I8
M)%D_L_7-,TNWTGQ'HT^TD+=Z+KUEJ.EW2=!-:.5+(59E#=][?U^A5>]H]KN_
MKT_4]^HHKXN_;:_;1^'W[''PQO/$6M75CK'Q'URSN[;X:_#T7(_M#Q%JX4Q1
MZEJ$$+BYL?">D3LD^N:LWE(40:98R2:M>6<#ZMVU9SI-M):MZ(_&_P#X+F?M
M)6VN>*/ 7[,'AR_$UOX,:/XA_$=8)0T:^)=5T^6T\&Z).%(9+K2O#M]J>MW4
M3AXI8?%&CR*5FMG _GXKJO'/C;Q/\2?&7B?Q]XTU:XUSQ7XPUO4/$&OZK=$>
M;>ZGJ=R]S<R!% C@@5W\JUM8%CMK.VCAM;:**WACC7EE5G9412S,0JJH+,S,
M<!5 R222   22<"L&[MON=L8\L5'MOZ]3^@G_@A/\!?[4\6?%+]H[6++?9^%
MK*/X8^"9Y8]T;:_K<=KK/C"]MV('EW>E:&FA:<LBLP>U\47T3 $9/]+U?)?[
M#7P'7]G']ESX3?#.YM!:>)(/#\7B3QP"@6=O&WBMCKOB&WN'P#,VCW-XOAZV
ME959K#1[-2J[<#ZPEC$T4D3%@LL;QDJ2& =2I*D<A@#D$<@\UM%62_'U.2I+
MFFWTO9>BT7W[G^>U\5_&,_Q$^*7Q)\?W4K37/CCQ[XO\73RMG,DGB/Q!J&L.
MW)) )O.%)^487H*X_2M-O-9U/3M'TZ(SZAJU_9Z;8P X,UY?7$=K:Q G@&2>
M5$!/3=4NN:/>^'M;UC0-2C,.HZ'JNH:/?PL"K17NF7<UE=1LK ,I2>"12& (
M(P0#6KX&\0IX1\;>#O%<L!NH_#'BGP_XADMEQNN$T75K34G@7<0N95MC&-Q
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M7PA82(W"36GAK3M+AN0JHKW:W$VQ6E85\^JK.RHBEF8A55069F8X"J!DDDD
M  DDX%92=VV=4(\L4NO7U>K_ ,C]\/\ @AG^SLGB3X@>/?VE-?L1+IOP\M7\
M!^!)9HPT;>,?$=BL_B;4K5ROR76A>%+BVTQANP\'C.0@%X@R_P!.]?)7[#/P
M&7]G#]ESX3_#.YM!:>)(?#\7B3QP"@6=O&WBL_VYX@M[A\ RMH]Q=IX>MI2J
MLUAH]FI4%<5]:UK%62^]^IR5)<TF^FR]%M]^_P PHHHJB HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
MSEZ***YST#^L'_@A/_R:/\1?^SC?%W_JL_A#7[3U^+'_  0G_P"31_B+_P!G
M&^+O_59_"&OVGK>.R]%^1Q5/CEZA1113("BBB@ HHHH **** "BBB@ HHHH
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MWVINW._.S7*O1OJ%%%%>X>:%%%% !1110 4444 %%%% !1110 4444 %%%%
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M-:%&KB:U'#T(2JU\15IT:-./Q5*M6:ITX1O9<TYR45JM6CY[_:0^)J:3I;>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^3[_@NQ_R=Q\.O^S<O"/\
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M'X__ /#K_P#;R_Z-V\1_^%)X!_\ FLH<7?9OSLQQG&2O=+6R3:3Z=/F?5/\
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M2?"^D7NCZ7IGA#4+IU\)J(+_ %/5[J>74]'AM]?%S)>N6M]8MX2 8"S?Q_\
M[/W[&'QY^-GQ/\!>$?\ A4OQ2TGPEK_BW1=+\4^-KKP'XGLO#_ACP]+?PKKV
MK7VMW>DQZ5:/8:8MW-;Q7-RC7-VD-I$&FF13_<=!96/@_P +0Z=X>T5VTWPM
MH$=EH?AW25A21K'1-.$&F:+IB7$L,".8+6"QLEGGBA5O+$LJ(&<:0OUV6B7W
M?I;[_4YZW(K<J5VVVU_77]#^6_\ X+@?'K_A-_CWX2^!VD7OFZ)\&?#PU#7H
MHI/W;^._',%EJ<\4RH3',=*\*P>'!;.Q,EK<ZMK%MMC9I?,_$:OTT^*7[ 7_
M  4/^+?Q(\=?$_Q/^SWXCDU_Q]XKUWQ7J@'B?P&\4%SK>HSWQLK8MXL!6SL$
MF2RLH@%2"TMX(8T1(U4<+'_P2\_;QDDCC_X9Y\01^8Z)YDGB;P"L:;F"[Y&'
MBLE47.YR 2%!.#TJ&FVW9_<S:+C&*7-'1;W7J_Q?XH_7_P#X(6? 7_A'_AO\
M2?VB-8LMFH_$#5E\ ^#IY8\2+X3\*S+=^(KVTDQ\UIK?BF6#3IU+$K=>#.%4
M<O\ O?7D7P#^$ND? CX,?#3X0:)Y3V7@#PCI&@2W4*>6NIZK# )M>UIDPNV;
M7-<GU'6+@;5_?WTA"KT'KM:Q5DE]_J<DY<TF_/3TZ?@%%%%,D**** "BBB@#
M\]O^"EO[*-Y^U;^SAJNC>%;-+KXG?#V^/CKX>1#8DVKWMG:3VVM>$UE<JJ?\
M)+I$LT-DCO' ^OV6A/<RQ6T4LB_Q47=I=V%W<V%_;7%E?65Q-:7EG=PR6UW:
M7=M(T-Q;7-O,J307$$R/%-#*B212(R.JLI _T8*_)3]N7_@E+\.?VH=2U/XF
M_#;5+'X5?&B]#3ZM>/923>"?'EV%PMQXIT^Q0W>E:U*0HF\4:/#=3W"^9)JV
MC:S=/%<V\2C?5;_F;4JBC[LMF]'V?GY?E\S^0*NZ\"?%#XE?"W4I-8^&GQ!\
M:_#[59E1)]1\%>*=;\+WES'&6*17-QHM]927,(WN##.TD3*[JR%78'ZG^+/_
M  3A_;.^#UY=0ZY\#/%WBC3+=W\KQ#\-;-_B)HUU;H2/MF/"ZW^K:;;':21K
MNE:3<QKAYK>-64M\IW_PV^(NEW/V/4_ /C73KO>8_LM_X6UVTN?,!4&/R+BP
MCEW@N@*;=P+KD?,,Y:KNCI3C+9II^C/6?$W[8/[5?C'3Y=)\2_M&?&K5M+G1
MHKG39OB1XKBT^[C<$-'>V=MJD-M>(02-EU',H!( &37SF[O([22,SN[,[N[%
MG=V)9F9F)+,Q)+,22222<FO8_"_[.G[0/C:>.W\(? _XN>)I96*K_8GPZ\7:
MC&N#AFEGM=(D@AC3_EI+-(D<8!,CJ 37WS\&/^"-_P"V#\3;BTN?&FC>'O@K
MX<E:)YM1\<:Q:ZAKKVC$>8]AX3\,3:M?_;(^<67B"Y\-!R#FY0%2SLWT;Z";
MC'2\8^6B_ _*)59V5$4LS$*JJ"S,S' 50,DDD@  $DG K]ZO^"=W_!)C7?&]
M]H?QJ_:E\/W>@^!+9[?5/"GPEU>&6SU[QI(A2:TU'QK8R".YT3PID+)'H-RL
M.K^(<?Z=#8:(476_U:_90_X)=_LX?LO7&G>*I-/F^+'Q2L3'-#X\\<6=J]OH
MUZA!^T^#_"<9N-)\.RHZK);ZA<RZUXBM'\Q;;7HX97AK](ZN,.K^[_,QG6O=
M0_\  NOR[>OW:D-M;6]G;P6EI!#:VEK#%;6UM;1)!;VUO BQ0P00Q*L<,,,:
MK'%%&JI&BJB*%  Y'XD>/-!^%OP_\:_$CQ1/]G\/>!/"VN^+-8D#*LAL-!TV
MXU*>& ,0)+JY2W^SVD(R\]U+%#&K22*I[2OS7_X*E^$/V@?BA^S@OPA_9]\
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M\1_^%)X!_P#FLK.=W9)/OM_7F=%&RO)M)O1)M+M?[VT?!%?W(?\ !/+X"_\
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MSX6TZSU/QQXCN39RP&UU?7]/NYAX>T+2[-;6Z-NJ";7]6@C+!69OQR_X=?\
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MQ5J=K;:IXBL+Q8H;2U\.Z$?M%G&PNM%O9(7D@GC8_E1_PZ__ &\O^C=O$?\
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M,+C0?#MEK-]K&KZ-<)'X:TG^W;VVTK2=/M/#EH/%8>SMQJ!U&61VDUK?3O\
MY?KZD*5.+Y8\J;W:M;YO\DKZ]MS^>VOOC_@FA\!?^&@/VOOAGH=_9?;/"G@:
M[;XH^,U>/S+<Z-X+N+6[TZRND(V2VNL^*I_#VB7<3,N^SU&Y8;MA4I_PZ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'*\']=QE.DU^[C^]K?\ 7N#5U_V_)QAY<U^AR8VO]7P\YKXW[E/_ !R3L_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#^3[_@NQ_R=Q\.O^S<O"/_ *LSXO5^+%?M/_P78_Y.X^'7_9N7
MA'_U9GQ>K\6*QG\3^7Y([:?P1]#]&O\ @DK_ ,I!?@!_W57_ -4G\2*_M.K^
M+'_@DK_RD%^ '_=5?_5)_$BO[3JN&S]?T1A7^-?X5^;"BBBK,0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M_P I>O\ 5HK_ "EZ^XX,_P"9E_W)_P#NT?+\2?\ ,%_W,_\ N _JT_X-C/\
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M29OCLLFY26%KRC2J25G5P\TJF'JM62YIT9PE-1O&,W**;2NRBBBNH\@****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% '^<O1117.>@?U@_P#!"?\ Y-'^(O\ V<;XN_\
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M=H-N%WJ^6_F?6X*M[?#4IMWDER3[\T-&W_B5I:::V"BBBO/.L**** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?YR]%%%<YZ!_
M6#_P0G_Y-'^(O_9QOB[_ -5G\(:_:>OQ8_X(3_\ )H_Q%_[.-\7?^JS^$-?M
M/6\=EZ+\CBJ?'+U"BBBF0%%%% !1110 4444 %?G1^WSXUB6S\#_  YMY+:2
M::YN/&NK1/;W@O+6*WBN]"\/2079*6#6U^]UXG6[MU6XO$ETZRE8V4,B"_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5]A?LI>)7%QXG\'RO,T<D,/B73T6&W%O
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M****LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K_*7K_5HK_*7K[C@S_F9?]R?_NT?+\2?\P7_ ',_^X#^
MK3_@V,_YO<_[ML_][[7]6E?RE_\ !L9_S>Y_W;9_[WVOZM*\/B3_ )'6-_[E
MO_42@>IDO_(LPW_<;_U(JA1117AGJ!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!_G+T445SGH']8/_!"?_DT?XB_]G&^+O\ U6?PAK]IZ_%C_@A/_P F
MC_$7_LXWQ=_ZK/X0U^T];QV7HOR.*I\<O4****9 4444 %%%% !1110!B>)=
M>L_"OASQ!XGU".YFL/#>B:KKU]#9)%)>2V>CV$^H7,=I'/-;PR7,D-NZP)-<
M01-*462:)"77^>.]O;S4;R[U#4+NYO[^_N9[V^OKV>6ZO+V\NI7GN;N[N9WD
MFN+FXF=YIYYG>6:5WDD=G8D_LK^V'XK_ .$9^!NO6L4VI6U[XMU+2/"EE<:;
M)Y.S[3<-J^J0W\JW-O*NFZAH&BZOI=U'$MS]K^W1V5Q;-97-U+%^,-?9\-4>
M7#XBNUK5JJFG_=I1O==DY5))]W'79'S^<5+U:5)/X(.3]9O9^:44_1Z=0HHH
MKZ4\<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "OU6_8.\5_VE\/_%GA&:;4I[GPMXDA
MU*#[5)YNG6FC^)[+_1+#2]]S));[=6T37M0O;5+:WM5GU-;N.2XN;R]\K\J:
M^QOV(?%?]B?&&7P]--J1MO&GAO5--@L[63_B7-K&D"/Q#:7^J6[W,4;?9-)T
MW7K.RND@NKJWGU1K>..*VO;V>/RLZH^VR[$)*\J:5:/E[*2E-_\ @OG_ *T.
MW+ZGL\72[3;IO_M]6C_Y-R_D?KU1117YX?5A1110 4444 %%%% !1110 444
M4 %%%9FM:K;Z%HVK:W=I-)::-IE_JMU';*CW$EOI]K+=S) DLD,;3-'"RQ+)
M+$C.5#R(I+!-J*<F[**;;[)*[?R1=.$ZLX4Z<7*=2<80BMY3FU&,5YMM)>I^
M<'QT\2OXE^)GB%P\QM-#F'AJQBGAMXG@31GDAOT4VY8S0S:TVJ7=M-<2/<-;
MW,2N(%1+6#R&IKFYN+RXGN[N>:ZN[J:6YNKJYE>>XN;B=VEFGGFE9I)III&:
M2661F>1V9W8L23#7Y;B*LJ]>K6DVW5J3F[].:3:7DHJR26B226B/[ RW!4\N
MR_!8"FHJ&#PM##IQ5E)TJ<82F]%>522<Y2:YI2DY2]YMA11161VA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% 'ZL?#7Q*_B_P)X8\03/-)=WNF1Q:A-/#;
MV[W&J:?))IFJ7*PVA-O'#<ZC9W4]LL2Q#[/)$3!;L3!'W%?+O[*^O?;?">O>
M'Y)+V6;0]9CO(O/??9V^GZW;?N+6QW3.\6V_TS5;NY@6&& 2WHN$>6:YN?+^
MHJ_3,OK_ %G!8:LWS2G2BIN]VZD/<J-MZW<XRO>[\WN?R9Q-EZRO/\VP,8J%
M.CC*LJ$$DE##U[8C#125DDJ%6FE9)=4DM$4445V'A!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"19AO^XW_J15"BBBO#/4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /Y/O\ @NQ_R=Q\.O\ LW+PC_ZLSXO5
M^+%?M/\ \%V/^3N/AU_V;EX1_P#5F?%ZOQ8K&?Q/Y?DCMI_!'T/T:_X)*_\
M*07X ?\ =5?_ %2?Q(K^TZOXL?\ @DK_ ,I!?@!_W57_ -4G\2*_M.JX;/U_
M1&%?XU_A7YL****LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K_*7K_5HK_*7K[C@S_F9?]R?_ +M'R_$G
M_,%_W,_^X#^K3_@V,_YO<_[ML_\ >^U_5I7\I?\ P;&?\WN?]VV?^]]K^K2O
M#XD_Y'6-_P"Y;_U$H'J9+_R+,-_W&_\ 4BJ%%%%>&>H%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '^<O1117.>@?U@_\$)_^31_B+_V<;XN_]5G\(:_:
M>OQ8_P""$_\ R:/\1?\ LXWQ=_ZK/X0U^T];QV7HOR.*I\<O4****9 4444
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MH^OZ!J%SI>KZ9=:;XB\^ROK20Q3P2-%H\D3[74E)89)(94*RPR21.KM](5^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y/O\ @NQ_R=Q\.O\
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M]VV?^]]K^K2O#XD_Y'6-_P"Y;_U$H'J9+_R+,-_W&_\ 4BJ%%%%>&>H%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1%3I*:UY;27^&5K_ */T1PX>7+5Y7IS7B_5:K\5;YG[15_/_ /\ !3OXF?\
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M2Q_%G_LIGCS_ -2G5:_7'_@DY_R)/Q@_[&GPS_Z:=0KHK?[NO2'Z'-0_C?\
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MI']*>#7_ "067?\ 87F?_J;6"BBBOAC]3"BBB@ HHHH **** "BBB@ HHHH
M*^]/V5KFW;P-KMHL\+7<'BRYN9K594-Q#;W6CZ-%:SRPAC)'#<R6=W'!*ZA)
MGM;E(V9H)0OP77V%^R7<VZW'CNT:>%;N>'PY<PVK2H+B:WM7UN*ZGBA+"22&
MVDO+2.>5%*0O=6R2,K3Q!O8R&?)F=%:6J1JP;;M;]U*:MYMP4;>?<^&\1J'M
MN$LPG>5\/5P5=**OS?[91HR3ZJ,85I3;6W+KI<^SJ***_0#^: HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXL?^"2O_ "D%^ '_ '57_P!4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K_*7K_5HK_*7K[C@S_F9?]R?_NT?+\2?\P7_ ',_^X#^K3_@V,_YO<_[
MML_][[7]6E?RE_\ !L9_S>Y_W;9_[WVOZM*\/B3_ )'6-_[EO_42@>IDO_(L
MPW_<;_U(JA1117AGJ!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWJMWJ?V/[7_PL*U^U?9?M7D?:/LUOYVSS/(BW>6O,_\ #I'_ *N!_P#,4_\
MXR:[U5HN$8RDGI&Z<9;JWEW//]C7C)RC%IW=FI1Z_,\5_P"'IW[0_P#T*OP?
M_P#"=\8?_-[1_P /3OVA_P#H5?@__P"$[XP_^;VO:O\ ATC_ -7 _P#F*?\
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M%C_P25_Y2"_ #_NJO_JD_B17]IU7#9^OZ(PK_&O\*_-A1115F(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?Y2]?ZM%?Y2]?<<&?\S+_N3_ /=H^7XD_P"8+_N9_P#<!_5I_P &QG_-[G_=
MMG_O?:_JTK^4O_@V,_YO<_[ML_\ >^U_5I7A\2?\CK&_]RW_ *B4#U,E_P"1
M9AO^XW_J15"BBBO#/4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M K^;^OZ0*^3XH_Y@?^YG_P!USW,F_P"8G_N#_P"Y0HHHKY,]P**** "BBB@
MHHHH **** /C?]K7_FG_ /W-?_NMU\;U]D?M:_\ -/\ _N:__=;KXWK\]SS_
M )&F*_[@?^HU$_ISP\_Y(_)_^ZA_ZM,:%%%%>2?:!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA[_D8Q_Z\U?RB>=FG^Z2_P =/_TH^)Z***^\/F HHHH **** "BBB@ HHHH
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M +JK_P"J3^)%?VG5<-GZ_HC"O\:_PK\V%%%%68A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_E+U_JT5_E+
MU]QP9_S,O^Y/_P!VCY?B3_F"_P"YG_W ?U:?\&QG_-[G_=MG_O?:_JTK^4O_
M (-C/^;W/^[;/_>^U_5I7A\2?\CK&_\ <M_ZB4#U,E_Y%F&_[C?^I%4****\
M,]0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_)]_P78_Y.X^
M'7_9N7A'_P!69\7J_%BOVG_X+L?\G<?#K_LW+PC_ .K,^+U?BQ6,_B?R_)';
M3^"/H?HU_P $E?\ E(+\ /\ NJO_ *I/XD5_:=7\6/\ P25_Y2"_ #_NJO\
MZI/XD5_:=5PV?K^B,*_QK_"OS844459B%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^4O7^K17^4O7W'!G_
M #,O^Y/_ -VCY?B3_F"_[F?_ ' ?U:?\&QG_ #>Y_P!VV?\ O?:_JTK^4O\
MX-C/^;W/^[;/_>^U_5I7A\2?\CK&_P#<M_ZB4#U,E_Y%F&_[C?\ J15"BBBO
M#/4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_.7HHHKG/0/ZP?^"$__
M ":/\1?^SC?%W_JL_A#7[3U^+'_!"?\ Y-'^(O\ V<;XN_\ 59_"&OVGK>.R
M]%^1Q5/CEZA1113("BBB@ HHHH *^ _V^_#WVGPAX \5_;-G]B^)-3\/?8/L
M^[[3_P )-I:ZE]L^U>>OD_8?^$2\G[/]FE^T_P!H>9Y]O]D\NY^_*^.?VX](
MU'4O@O:WME;^=;>'_&VAZOJ\GFP1_9-.FT_6]!BN-DLL<EQNU;6]+M/*M4FG
M7[5Y[1"VAN)HO1RF;AF6$DFHWJJ%W;:I&5-K72\E+E76[5M;')CX\V$KJS=H
M<UE?[,E*^G16N^EEKH?D+1117Z.?)!1110 4444 %%%% !1110 4444 %%%%
M 'P-_P %#OA?X^^+GPF\#>%/ASX8U#Q5KQ^*NDWTMG8>1&EI81^$_&5M)?ZA
M>WDUM8:=8QW%U;0/>7US;VZS7$$1D\R:-6\#_9X_X)DZ=HMS8>*OC_J5GK]W
M 8[FW^'FA3S-HL4RD/&/$FMCR)M5$9P)M*TN.WL&EC"S:IJEE));/^NM%:1J
MSC#DB[*[=U\6OGT^6OF9.C"4^>2N]-'\.BMMU^>GD?S7?\%"+.TT[]J3QG8:
M?:VUC8V6@^ K2RLK."*VM+2UM_!6APV]M:VT"I#;V\$2)%##$B1Q1JJ(JJH
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M_?\ PGK1ED6/H7DYTLUJ5&G>T:=;"81047MK.E5;2V>OV@HHHKYT_40HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?J)\6%%%% !1110 4444 %%%% !1110 4444 %%%% '\V_\ P44_Y.O\>_\
M8)\$?^H=HM>__P#!)_\ Y*+\5_\ L2M'_P#3Z*\ _P""BG_)U_CW_L$^"/\
MU#M%KW__ ()/_P#)1?BO_P!B5H__ *?17?4_W5?X*?YQ//C_ +R_^OD_SD?N
M3117PU_P4"U7XI>%_@:GC7X6>*_$'A:\\+^)M,E\43>'[R2RN)_#&JQ7.E22
M/+"IN!]DUNYT5]T3Q^5!+=32.$C)'%&/-)1NE=VN]M3NE+EBY6;LKV6]EO\
MAJ='\>?V(?@I\>=0N/$>I6-_X/\ &MR,W7BKPD]K:3:K(HVQR:]IEU;7.FZK
M(H^5[T0VFK2HL<4FIF&&*-/E/2_^"3?@Z'44EUKXQ^)=0TD2 R6.F>%=+TC4
M'BSDHNJ76JZU;HY7CS#I#@'YO+[5^97@K]ISXQ^&_B%X/\<Z]\1/'_C*+PSX
MATW6+K1?$'C3Q#J5EJMC;7*-?Z9)%?W]U;QI?61N+57\AUMVE658R8PM?NQ:
M?M^_LL7/AA/$LGQ&^QR&T$\OARZT#7_^$FAN2@8Z:VGP:=/!-=+(?(^T6UY/
MI9?]X-1-L#..B4:])1C&4I)K3E5[/MJFUY;7UMU.:,J%5N4HQBT_M2Y;^;LT
MGY[GYU?\%"OAW\-?@=X/^"GPF^&NB0:1;2W7B_Q7KLKR-=ZSJUQ##H6DZ;JF
MMZC-FYOI[@RZO' &,=K9I!);V%M;6VV%/DC]C_PY+XI_:;^"VFPQM(UIXXTS
MQ&X7^&'PBLWBN9V]%2+1F8YZXQU(%0?M1_'R]_:+^+&I^.FLY]*T&TL[?P_X
M1TBY='NK#P[I\US/ U\86>#^T=1O+R]U.]2%Y8[>6[%C%<7,%I%/)]W?\$MO
M@O?7/B#Q1\<]8LGBTK3+"Y\'>#I)XRJWVK7[P2^(=3M"R@M'I=A%%I(G0M#-
M+JVH6X)FL9ECVUIT&Y/WFG>[N^:5^O=7U]'KU,4E4KKD7N\T;65K1C97\M%I
M?K;2^A^V%%%%>>>B%%%% !1110 4444 %%%% !1110 4444 ?=7[!.D:C-\1
M_&.O16^[2=-\$MI%[=^; ODZCK>NZ1>Z7;^0THN9/M5MX?U>3S8H9((?LFRX
MEBDN+5)OU6K\^OV =!O+?PY\1O$[R6QL-8UO0=!MH4>4WD=YX;L+_4+Z2>,P
MK"MM+#XJT];1X[B6626&]6:&!(X'N/T%K\^SV?/F>(2LU!4H)J_2E!ROYJ3D
MM+*R7J_J<MAR8.G>]YN<W?SFTK>3BD^N_P D4445Y!WA1110 4444 %%%% !
M1110!C>(](_M_P /:[H/VC[)_;>C:II'VKRO/^S?VE8SV?VCR/-A\[R?.\SR
MO.B\S;L\V/=N'Y$5^R%?DKXTT^STGQCXLTK3X?L]AIGB;7M/L8/,EE\BSLM4
MNK:VA\V=Y)I/+AC1/,FDDE?;ND=W)8_*<3T],'55KWK4Y:N[O[.4;+:RM.[T
M>JW6W[-X1XI\V=X)N33C@L537+'EBXO$4JS<M)\TU*ARQ]Z*4)/W6WS\S111
M7R1^U!1110 4444 %%%% !1110 4444 %%%% !1110 5_&)^VG_R=G^T/_V5
MGQE_Z=IZ_L[K^,3]M/\ Y.S_ &A_^RL^,O\ T[3U^J>%/_(US/\ [%\/_4FF
M?@WCY_R(<C_[&]3_ -0JQ]^?\$6/^2V_%O\ [)9!_P"I;HE?T?U_.!_P18_Y
M+;\6_P#LED'_ *ENB5_1_7B^(W_)58S_ +!\%_ZC0/I?!G_D@\O_ .PS,O\
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MB,*_QK_"OS844459B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7^4O7^K17^4O7W'!G_,R_[D__ ':/E^)/
M^8+_ +F?_<!_5I_P;&?\WN?]VV?^]]K^K2OY2_\ @V,_YO<_[ML_][[7]6E>
M'Q)_R.L;_P!RW_J)0/4R7_D68;_N-_ZD50HHHKPSU HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M06TL-N681 U\Q_L7_P#!/_P#^RG ?%6J7L/CSXOZA9/:7OBZ6S-OIGAVTN4
MN])\'6$QDFM(IU_<7VM7;'5=3A5HUCTNQN)]-;]!:_.>.^+:6?UJ.!R]R>6X
M.I*K[647!XO$N+@JJA)*4:5*$IPI<RC.3J5)2BER)?LGA3X?8CA/#8G-,WC"
M.=9E2A1^KPE&I_9^"4HU70G4@W">(KU8PGB.24Z<%1HPA-R51LHHHK\]/V *
M*** "BBB@ HHHH **** "BBB@ HHHH *_63P)HS^'_!?A719K*'3KO3M TJ#
M4+2 6X2+5!9Q/JC,UHS6\TTVHM=3W-S$\@NKB26Y,LK2F1ORT\.:1_;_ (AT
M+0?M'V3^V]9TO2/M7E>?]F_M*^@L_M'D>;#YWD^=YGE>=%YFW9YL>[</UWKZ
MOABEKBZS3T5*E%W5G=RG-6^*ZM3L]$[O=K3\9\7,7:&2X&,E[TL9BZL;3NN1
M4*-"2=U!J7/B4U:4TXIW@G[Y1117UI^*A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?R??\%V/^3N/AU_V;EX1_]69\7J_%BOVG_P""['_)W'PZ_P"S<O"/
M_JS/B]7XL5C/XG\OR1VT_@CZ'Z-?\$E?^4@OP _[JK_ZI/XD5_:=7\6/_!)7
M_E(+\ /^ZJ_^J3^)%?VG5<-GZ_HC"O\ &O\ "OS844459B%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^4O
M7^K17^4O7W'!G_,R_P"Y/_W:/E^)/^8+_N9_]P']6G_!L9_S>Y_W;9_[WVOZ
MM*_E+_X-C/\ F]S_ +ML_P#>^U_5I7A\2?\ (ZQO_<M_ZB4#U,E_Y%F&_P"X
MW_J15"BBBO#/4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110![O^SAI5QJ'Q2TR[A>%8M"TS6=5NUE9U>2WFL9-
M$5+8)&ZO,+O6;61EE:%!;QSN)#(L<4OZ,U\B?LHZ#LT_Q9XGECLG^U7MEH-E
M-LW:A;_88#J&IQ^8T(\FRO/[1TAMD5PWVB>QW7$*?9;9W^NZ^^R"BZ674Y/1
MUZE2M;LFU3C]\:<9*W1][G\V>)..6,XIQ%.+3C@,-AL#&2M9N,98JHO6%7%5
M*;OK>#6R04445[1\$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_)]_P78_
MY.X^'7_9N7A'_P!69\7J_%BOVG_X+L?\G<?#K_LW+PC_ .K,^+U?BQ6,_B?R
M_)';3^"/H?HU_P $E?\ E(+\ /\ NJO_ *I/XD5_:=7\6/\ P25_Y2"_ #_N
MJO\ ZI/XD5_:=5PV?K^B,*_QK_"OS844459B%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^4O7^K17^4O7W
M'!G_ #,O^Y/_ -VCY?B3_F"_[F?_ ' ?U:?\&QG_ #>Y_P!VV?\ O?:_JTK^
M4O\ X-C/^;W/^[;/_>^U_5I7A\2?\CK&_P#<M_ZB4#U,E_Y%F&_[C?\ J15"
MBBBO#/4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_.7HHHKG/0/ZP?^
M"$__ ":/\1?^SC?%W_JL_A#7[3U^+'_!"?\ Y-'^(O\ V<;XN_\ 59_"&OVG
MK>.R]%^1Q5/CEZA1113("BBB@ HHHH **** .)^)/A3_ (3GX?\ C/PBD.FS
M7/B#PWJ^FZ=_:\?F:=;ZQ-92_P!BW]QBVNY(O[-U9;+4(KJ"VFNK.>UBN[2,
MW,,5?SZU_2!7X,_'?PI_PA7QA^(?AY(=-M;:'Q)>:EIUGI$?DZ=8Z/X@$?B'
M1;"WMQ;6D=M]ATG5+*SEM8(!:VL\,MO:236T<4\GU?#-;WL5AV]U"M%>CY)O
MY\U/TMYGB9Q3THU5T<J;?JN:/Y3_ .!U\EHHHKZT\(**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "OTI_8!\-RI9_$;Q=<:9;&&XN=!\-Z3K#K9R7BRV45_J?B'3(&#-?
MVMLZ7_ABZNU9(;._ECLBK7$VG.+7\UJ_<+]E_P *?\(E\#? =K+#IJ7NM::_
MBN]N--CV_;O^$FN)=7TN:_E:VMI;G4K;0+G2-+NI)5E\G^SX[*WN;BRM+65O
M#XAK^RR]TU\6(J0I^:C%^UDUY>Y&+WTGMV]+*J?/BE-[4H2GY7?N)?\ DS:V
MU6_1^_4445\&?3!1110 4444 %%%% !1110 4444 %%%% 'Y7?%/0?\ A&OB
M'XNTA8[*"&/6;B\L[?3T\NSM=/U8)J^FVL,0A@2'[+87UM;R011"""6-XH'D
MA2.5^ KZU_:MT"XCUGPQXI4S26EWIDV@3!;5_L]G<:?=3ZC:F6]#M'YVI1ZG
M=^1:O'$X32KF:-YU,JVWR57YIF5#ZMCL32LU%5'*%_Y*G[R&S=[1DE?NG=)W
M2_K#A7,5FO#V58QR4JDL)"C7:;;^L8:^'KMWC%IRJ4I3LTTE)<LIQY9R****
MXCZ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK?\*Z!<>*O$FA^';4S++K&I
MVEBTT%J]Z]I;S2J+N_:UC>-I8=/M!-?7.9842WMY9)9H8U>5*C&4Y1A%7E.2
MC%::RDTDM=-6TM=#.M5IT*56O6DH4J-.=6K-W:A3IQ<YR:2;:C%-NR;TT39^
MC7P0T'_A'_AAX5@>.R6YU*R;7KF:S3;]I_MN:34+&2ZD,,,DU[#I4VGV,[R"
M3R_LBVT,TMM! Y]7HHK]1H4HT*-*C'6-*G"FG:UU"*C=J[U=KO5ZO=[G\?9A
MC*F88[&8^JK5,9BJ^)G&_,HRKU95'!.RO&'-RQT244DDE9(HHHK4Y HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /Y/O^"['_)W'PZ_[-R\(_P#JS/B]7XL5
M^T__  78_P"3N/AU_P!FY>$?_5F?%ZOQ8K&?Q/Y?DCMI_!'T/T:_X)*_\I!?
M@!_W57_U2?Q(K^TZOXL?^"2O_*07X ?]U5_]4G\2*_M.JX;/U_1&%?XU_A7Y
ML****LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBO/OB1\6OA5\&]#M/$_Q?\ B9\/OA5X:O\ 5H-!L?$/Q(\9
M^'/ VAWFN75G?:A;:-::MXGU+2["XU:XL-+U.^@TZ&X>\FL].OKF.%H;2X>-
MQC*348Q<I-V48IMM]DE=M^@FU%-R:BENVTDO5O1'H-?Y2]?VP_M/?\'"W[)_
MP_\ "_B+3/V:+3Q7\>/B5=>%$N_!6O7O@[6O!OP>TSQ1?:C<Z<++QQ-XPN?!
MOQ*NO^$>LH!XFN]+\,^#9-.\2P3Z7X:M/&_AZ]U#5M:\+?Q/5^A<*8'%X2&-
MJ8FA.@J[PZIQJKDF_9*LYMP=I12]I%+F2N[I;,^1S_%8?$2PT:%6%5TE6<W!
M\T5S^RY4IJ\6WR2NDW;2^Z/ZM/\ @V,_YO<_[ML_][[7]6E?RE_\&QG_ #>Y
M_P!VV?\ O?:_JTKYCB3_ )'6-_[EO_42@>WDO_(LPW_<;_U(JA1117AGJ!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ=1\S4N6)1117OGYL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?R?
M?\%V/^3N/AU_V;EX1_\ 5F?%ZOQ8K]I_^"['_)W'PZ_[-R\(_P#JS/B]7XL5
MC/XG\OR1VT_@CZ'Z-?\ !)7_ )2"_ #_ +JK_P"J3^)%?VG5_%C_ ,$E?^4@
MOP _[JK_ .J3^)%?VG5<-GZ_HC"O\:_PK\V%%%%68A1110 4444 %%%% !11
M10 4444 %%%% !1110 5_-%\>/\ @W:_X7;\<?C-\9O^&P?^$9_X6Y\5_B)\
M3O\ A&_^&?O[:_X1_P#X3[Q?K'BK^P_[8_X7;I/]K?V3_:WV#^TO[+TW[?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '^<O
M1117.>@?U@_\$)_^31_B+_V<;XN_]5G\(:_:>OQ8_P""$_\ R:/\1?\ LXWQ
M=_ZK/X0U^T];QV7HOR.*I\<O4****9 4444 %%%% !1110 4444 >2_'+X>P
M?$WX7^+/"_V'[=JS:;<:IX82,Z=%=1^*-+ADN]%6UO=3C>VL/M]RG]CW]UYE
MH[:/J6I6OVVTCN9)T_!FOZ0*_%C]K#X;7G@#XN:YJ 6YFT/QY<WGC#2;Z82R
M*;S4[N2?Q#ICW(L+*S-SIVL33S1V5L]Y+9Z'J&@R7UU)=7;D_5<-XNTJV#D]
M)_OJ5V_B22J12VUCRRTM;ED];Z>)F]"\:>(BOA_=S?D]8-^CNNNZ6A\S4445
M]<>$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5^AW[!WP]@O-1\6?$S4;'S?[(\GPMX8NY3ITT$6HW
MD'VWQ+/% \<NI6>I6>FRZ+9V]_$]G!+IVO:O8@WOFW*6?Y]65E>:C>6FGZ?:
M7-_?W]S!96-C902W5Y>WEU*D%M:6EM DDUQ<W$SI#!!"CRS2ND<:,[ '][_A
M#X#_ .%9?#;PCX'>Y^UW.B::W]HW"S?:()-8U*[N=7UK[%*;.PD?34U:_O4T
MOS[2*Z73EM5N_,N5EE?P>(,7[#!^PB_WF*ER;V:I1M*I+YOEIM/1QG+JCT\K
MH>TQ'M&O=HKF\G-Z17R7-+39Q7<](HHHKX4^E"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH _.S]HGP1_P (MXXDUFT3;I7C#[3J\/S9\K5TDC_M
MZW_>7=Q<OON;B#5?->*UM5_M;[#9Q&.Q?;X%7Z9?'#P9<>-?A_J-I8":35-&
MFC\0Z9:PAW-]<:?!=13V7DPVMW<7,USIUW?1V%M;K$\VJ&Q1YT@,P;\S:_/\
M[PBPN-FX1M2Q'[Z'92;_ 'D5Z3O)))*,9125DC^F/#_.WG'#]"%::GC,M:P-
M=MWG.G3BGA:TT];SH<M.4VY.I5HU9MW;2****\<^X"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "KNG:?>:MJ%AI6GP_:+_4[VUT^Q@\R*+S[R]G2VMH?-G>.&/S)I$3S)I(XD
MW;I'1 6%*OIS]F/P9<:IXKN/&4PFBT[PQ#/;6DBAXTO-9U2TFM&@#O:R07$-
MEI=Q=37L45U;W5M<7>C2%9+>>16Z<'AI8O%4</&_[R:4FMXTUK4EKI[L$VKZ
M-V74\G/<UIY+E..S.IRMX6A.5*$VU&KB)>YAJ+:]ZU6O*G"3CK&+<MHL^S_!
MWABS\&^&-%\,V+>9#I-DL#S[94^UWDCO<ZA?>5-<73P?;K^:YO/LPN)(K;S_
M +/ 1#'&HZ6BBOTV$(TX0IP2C"$8PA%;1C%*,4O)))(_DJO6JXFM6Q%><JM?
M$5:E:M4E\52K5FZE2<K67-.<G)Z+5L****HR"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /Y/O^"['_)W'PZ_[-R\(_P#JS/B]7XL5^T__  78_P"3
MN/AU_P!FY>$?_5F?%ZOQ8K&?Q/Y?DCMI_!'T/T:_X)*_\I!?@!_W57_U2?Q(
MK^TZOXL?^"2O_*07X ?]U5_]4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _S
MEZ***YST#^L'_@A/_P FC_$7_LXWQ=_ZK/X0U^T]?BQ_P0G_ .31_B+_ -G&
M^+O_ %6?PAK]IZWCLO1?D<53XY>H4444R HHHH **** "BBB@ HHHH *^;_V
MI/A5_P +0^%^H_V;9_:?%GA+S?$?AOR;?SKZ\^S0G^V-!M_(T[4-2N/[:TU9
M/LFEV'V;^T?$-CX>^U3K;VS5](45M0K3P]:E7INTZ4U-=G;>+\I*\7W39G5I
MQJTYTY?#.+B_*^S7FG9KS1_-_17TA^U)\*O^%7_%#4?[-L_LWA/Q;YOB/PWY
M-OY-C9_:9C_;&@V_D:=I^FV_]BZDTGV32[#[3_9WAZ^\/?:IVN+EJ^;Z_3:%
M:&(HTJ]-WA5@IKNK[Q?G%WB^S3/CJM.5*I.G+XH2<7YVV:\FK->3"BBBM2 H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHJS965YJ-Y::?I]I<W]_?W,%E8V-E!+=7E[>74J06UI:6T"237%S<3.D
M,$$*/+-*Z1QHSL 1M)-MV2U;>R7=AOL?9_[%/PJ_X2OQS<_$'5[/S= \";/[
M+^TV^^UO_%]Y&WV+R_M6G7-E=?\ ".V1EU>;[/>V>J:3K$_A2_BW12M7ZT5Y
M=\&OAM9_"CX=>'O!T"VSW]K;?;?$-];")EU/Q'?A9]6NQ<I8:=->6T,Q&G:3
M/?6JW\>AV&EV=R[O:@UZC7YQFF,>-QE2JG>E#]W173V<6[2_[?;<W_B2Z'UN
M"P_U>A"#7OR]^I_BET_[=5H_*_4****\XZPHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "OS9^.GP\?P+XPGNK2"&'PYXEFN]1T-87MU%LZFWDU7
M3/LD$%JMG#I]W>*+"*.%K==+GL8DNI[J&\2#])J\T^+?@C_A/O ^J:- F_5;
M7;J^@_-MSJ]C'+Y-O\]W9VP_M&VFNM*\V\E:UM/MWVYXGDM8\>7F^!^NX2<8
MJ]:C>K1MNY)>]3\_:17*E=+GY&W9-/[#@GB!\/YW1J59J. QKAA,?S-J-.G.
M2]GB;WLGA:C4Y2:D_8.O",>::DORZHJ:YMKBSN)[2[@FM;NUFEMKJUN8G@N+
M:X@=HIH)X9562&:&16CEBD57C=61U# @0U^=M--IJS6C3W3[,_I]-22E%IQ:
M3333335TTUHTUJFM&@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!=T[3[S5M0L-*T^'[1?ZG>V
MNGV,'F11>?>7LZ6UM#YL[QPQ^9-(B>9-)'$F[=(Z("P_4OX<^#+?P%X/TCP[
M$(6NX(?M.KW4(0B]UFZ EU"?SEM;.2YACD(L["6Z@%TFEVMC;S,S09KY<_9C
M\ 7%QJEQ\0-3M)HK*PAGL?#<DJ/&E[?W0FM-3O[9UN8VEAT^T$^FMYUI<65Q
M<:C.(9DO=(E6/[;K[/A[ ^RHRQE2+52LG&DFMJ*:]Y)JZ=22=N\(QDM)'X+X
MG\0_6\=#(L-44L-@'&KC)0=U4QTHR2I-IN,HX6E-*26L:]2K3FE.BK%%%%?2
MGY2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\GW_!=C_D[C
MX=?]FY>$?_5F?%ZOQ8K]I_\ @NQ_R=Q\.O\ LW+PC_ZLSXO5^+%8S^)_+\D=
MM/X(^A^C7_!)7_E(+\ /^ZJ_^J3^)%?VG5_%C_P25_Y2"_ #_NJO_JD_B17]
MIU7#9^OZ(PK_ !K_  K\V%%%%68A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 ?YR]%%%<YZ!_6#_P $)_\ DT?XB_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?R??\%V/^3N/AU_V;EX1_\ 5F?%ZOQ8K]I_^"['
M_)W'PZ_[-R\(_P#JS/B]7XL5C/XG\OR1VT_@CZ'Z-?\ !)7_ )2"_ #_ +JK
M_P"J3^)%?VG5_%C_ ,$E?^4@OP _[JK_ .J3^)%?VG5<-GZ_HC"O\:_PK\V%
M%%%68A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ?YR]%%%<YZ!_6#_P0G_Y-'^(O_9QOB[_ -5G\(:_:>OQ8_X(3_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5]E&Q1117D'<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTXSA*=.<)R****P/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI2K46[*M2;>B2J0NWVW/I>BBBL#4**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU,/-PJ1MORR5^6:[Q?7=76Z>C284445U& 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&J6\.HP6.IZC9PWB31VU]=PJEQ)_I^5_/Q_Q#>?L._\ 15/VK?\ PN/A#_\
M.,KZ3AW,L'EL\74Q3J*56-&%+D@YJR=1U.9*UG?V=OF>+G."Q.-CAXX=0:A*
MI*?-)1U:@H6OOISW^1_$]17]L/\ Q#>?L._]%4_:M_\ "X^$/_SC*/\ B&\_
M8=_Z*I^U;_X7'PA_^<97U/\ K3E/\]?_ ,$2_P SPO[!S#^6E_X-7^1_$]17
M]D'Q(_X-JOV<M4T.TM_A!^T/\;/ WB5-6@FOM6^)&E^!/BKH=QH:V=\ESIUI
MX>\,:-\&[^SU::_DTRY@UF;Q/?V=O9VE]8R:#=3:C;ZAI?B?_$,9_P!7N?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '\GW_!=C_D[CX=?]FY>$?_5F?%ZOQ8K]I_\ @NQ_R=Q\.O\ LW+PC_ZL
MSXO5^+%8S^)_+\D=M/X(^A^C7_!)7_E(+\ /^ZJ_^J3^)%?VG5_%C_P25_Y2
M"_ #_NJO_JD_B17]IU7#9^OZ(PK_ !K_  K\V%%%%68A1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'B?Q(_9I_9R^,
MFN6GB?XO_ #X)_%7Q+8:3!H-CXA^)'PJ\">.=<L]#M;R^U"VT:TU;Q/H.J7]
MOI-O?ZIJ=]!IT-PEG#>:C?7,<*S7=P\GYH?$C_@@C_P3B\<Z'::3X8^'OQ!^
M#=_;ZM!J,WB?X;_%;QAJFN7]G#9WUM)H-W;_ !?O/BKX:32;J:[M]0GFL?#U
MGKBWFEV*6VLV]A)J=CJ/[-T5UT,=C<-;V&+Q%)*WNPK3C!\M[)P4N225W9--
M*[TU.>KA<-7O[6A1J-W]Z5.+EK:]I6YDW97::>A_$]^T]_P;R_M,_!SPOXB\
M<_!/XB^%/VCM \*^%$U_4?"UEX9U[P)\8=:U&WU&Y36=(\$> H;GQWH'BK^S
M- 6UUVTB7X@:;XH\1SKJGASPYX0U/7X=!LO$W\_%?ZM%?Y2]??\ #>:XO,H8
MJ.+E"<L.Z'+4C",)25554U*,$H:.DFG&,?B:>B5OD\ZP&'P4L/+#J4%657F@
MY.44Z?L[.+E>6O.[WD]E:VM_ZW_^#9CQOXHO_ W[77PWN]4\WP7X3\5_!_QO
MH&C?8M.C^P>*/B#I'Q!T'Q?JG]HQ6B:M=?VOI/PR\$6GV*]OKG3K#^Q//TNT
MLKG4M7FO_P"HFOY2_P#@V,_YO<_[ML_][[7]6E?(<1I+.<:DDE>@[))*\L+0
ME)Z=7)MM[MMMZL^AR9MY;AFVV[55J[Z*O527HDDDNB22T"BBBO$/3"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXL?^"2O_ "D%^ '_ '57_P!4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K_*7K_5HK_*7K[C@S_F9?]R?_NT?+\2?\P7_ ',_^X#^K3_@V,_YO<_[
MML_][[7]6E?RE_\ !L9_S>Y_W;9_[WVOZM*\/B3_ )'6-_[EO_42@>IDO_(L
MPW_<;_U(JA1117AGJ!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_G+T4
M45SGH']8/_!"?_DT?XB_]G&^+O\ U6?PAK]IZ_%C_@A/_P FC_$7_LXWQ=_Z
MK/X0U^T];QV7HOR.*I\<O4****9 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '^<
MO1117.>@?U@_\$)_^31_B+_V<;XN_P#59_"&OVGK\6/^"$__ ":/\1?^SC?%
MW_JL_A#7[3UO'9>B_(XJGQR]0HHHID!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\\_P!O_P#8 \#_ +:G@=+N
MT?3?"'QU\(:;/#\._B)-!(MK>6JR3W@\!^/#9P3WNH^"=1O9[B>SO(;>\U?P
M/J]Y<^(/#]M?6M]XI\+>+_XR?B/\./''PB\<>)?AM\2?#6I>$/''A#4GTKQ!
MX?U5(UNK*Z6..X@EBFMY)[+4=-U&RGMM3T;6=,N;S2-<TB\L=8T>^OM+OK2[
MF_T0J_//]O\ _8 \#_MJ>!TN[1]-\(?'7PAIL\/P[^(DT$BVMY:K)/>#P'X\
M-G!/>ZCX)U&]GN)[.\AM[S5_ ^KWESX@\/VU]:WWBGPMXO\ C.)^&(YE&6.P
M,8PS"$;S@K1CC(Q22C)MJ,:\8JU.H[*:2IU';DG3_AOZ5GT4\+XHX7%<>\!8
M7#X/Q&P>'Y\?@(>SP^%XUPN'IJ,:%>4G"E0XAH4H1IY?F%24:>,IQIY=F-2-
M*.#QF7_Q_?L^_M!_%#]F/XH:'\6OA+KG]D>)-(WVE]8W:377A[Q9X>NIK>75
M?"/B[2HKBU_M?PWJ_P!EMVN;9;BUOK&^M=/UW0M0TCQ)I&C:SI_]MG[(/[5?
M@?\ ;$^#&E_%SP58:EH4L>I7'A;QIX4U42377A#QQI=AI>HZOH,6KBUM++Q%
MIHLM9TK5-&\0:?##'J.D:I8MJ.GZ%K\>L>'-'_A>^(_PX\<?"+QQXE^&WQ)\
M-:EX0\<>$-2?2O$'A_54C6ZLKI8X[B"6*:WDGLM1TW4;*>VU/1M9TRYO-(US
M2+RQUC1[Z^TN^M+N;WW]CS]L/XH?L:?%"'QYX#F_M?PWJ_V+3_B/\.-0O9K7
MP]X_\/6LTKQVUS(D5U_9'B32/M5Y<^$?%UM9W5]X=OKJ[AFM-7\-ZOXE\-:_
M\7PYGU7),5+#XKVGU&I4<<11E%\^&JIJ+K1@USQE!QY:U-).44_=E4A!'\.?
M1E^D-G'@-Q;7X9XN>:+@+,<?6PG$F25\/6EC.&,XIS6&J9UA<OJQCBL/BL)5
MH_5<\R^E&%;%86$F\-B,PP&!I+^\6BO%/V??V@_A?^TY\+]#^+7PEUS^U_#>
MK[[2^L;M(;7Q#X3\0VL-O+JOA'Q=I45Q=?V1XDTC[5;M<VRW%U8WUC=:?KNA
M:AJ_AO5]&UG4/:Z_9*56G6IPJTIQJ4JD8SIU(-2C.$E>,HM:--.Z9_MQE>:9
M;G>6X'.,GQV%S/*LSPM'&Y?F&"K4\1A,9A,13C5H8C#UZ4I4ZM*K3DI1E%M-
M/O=!1115G>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 ?R??\ !=C_ ).X^'7_ &;EX1_]69\7J_%BOVG_ ."['_)W'PZ_[-R\
M(_\ JS/B]7XL5C/XG\OR1VT_@CZ'Z-?\$E?^4@OP _[JK_ZI/XD5_:=7\6/_
M  25_P"4@OP _P"ZJ_\ JD_B17]IU7#9^OZ(PK_&O\*_-A1115F(4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %?Y2]?ZM%?Y2]?<<&?\S+_N3_\ =H^7XD_Y@O\ N9_]P']6G_!L9_S>Y_W;
M9_[WVOZM*_E+_P"#8S_F]S_NVS_WOM?U:5X?$G_(ZQO_ '+?^HE ]3)?^19A
MO^XW_J15"BBBO#/4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_.7HHH
MKG/0/ZP?^"$__)H_Q%_[.-\7?^JS^$-?M/7XL?\ !"?_ )-'^(O_ &<;XN_]
M5G\(:_:>MX[+T7Y'%4^.7J%%%%,@**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#\S_\ @I;^PGI'[7?PFO?$'@OPWILG[1W@'38W
M^&^N-J=KX>D\2Z1#J2WNL?#CQ%J5S:3V6HZ;J-E/J]WX,CUB?2[70/'-Q:W
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M(,]Q$J?!&.Q>(3639]7FG'A]2KS2AEN?5)3674:4FZ.?3IX>AAJKSJM6PO\
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M8;_N-_ZD50HHHKPSU HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _SEZ*
M**YST#^L'_@A/_R:/\1?^SC?%W_JL_A#7[3U^+'_  0G_P"31_B+_P!G&^+O
M_59_"&OVGK>.R]%^1Q5/CEZA1113("BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;P]G-<09/RX7'5IQ3E37]H4UA\VIJG*450S"E&4:52-2A2****]D_;@HHHH
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M 4444 %%%% !1110 4444 %%%% !1110 4444 ?YR]%%%<YZ!_6#_P $)_\
MDT?XB_\ 9QOB[_U6?PAK]IZ_%C_@A/\ \FC_ !%_[.-\7?\ JL_A#7[3UO'9
M>B_(XJGQR]0HHHID!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXURC^QY.K2ISQ%7'8+,\/C<#&-1.5>%3!1J8Z=&ARUD\NIXAS]A0KPG\=_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT,/2>74*E.I7ISP^48'"X/+?:4:T\/B\5A\7F-"-*..=.)1117NG] !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3Q%XCT;^V=/DG_DT_;3_ ."F7QQ_;"^W^$<?\*M^!]U_PCT__"I-#U&WU?\
MM74]"\Z[_M3QEXT_L30]9\4^=K-Q_:%KH/V;2O"%A_9'A6[_ .$<NO%&@?\
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M:GBG2D\+@*6"P\\9+,"BBBOK3^Q@HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!_G+T445SGH']8/_!"?_DT?XB_]G&^+O_59_"&OVGK\6/\
M@A/_ ,FC_$7_ +.-\7?^JS^$-?M/6\=EZ+\CBJ?'+U"BBBF0%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.<9DJ=.MCJM)XBM'#PDHX;!TJDJ&"H8;#VI(HHHKT#]&"BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#^3[_@NQ_R=Q\.O^S<O"/\ ZLSXO5^+%?M/_P %V/\ D[CX=?\
M9N7A'_U9GQ>K\6*QG\3^7Y([:?P1]#]&O^"2O_*07X ?]U5_]4G\2*_M.K^+
M'_@DK_RD%^ '_=5?_5)_$BO[3JN&S]?T1A7^-?X5^;"BBBK,0HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_
MREZ_U:*_S+OVO/V6_B)^QS\??'GP+^(NG:M%-X<U:^G\&^)]1TF+1[/XD_#N
M?4[^V\'_ !(T&WM=5UZP72?%5A9-/-8V>O:Q+X:UR#6O!VM7<7B7PYK=C:?:
M\&U(*ICZ3DE4G'#3A!O64:;KJ;7=1=2%_P#$O,^9XDA-PPE11;A"5:,I=(RF
MJ3BGVYN25O1G] __  ;):]H=OKG[9?ABXUG28/$NL:3\!=>TGP]-J-G%KFJ:
M'X<O/B_I_B'6=.TEYEO[W2=!O_%7ABQUK4;:WEL]+O/$>@VU]-!-K&GI<?UE
M5_EA>"/'GCGX9>*-+\<?#?QGXK^'WC31/MO]C>+_  1XBU?PGXHTC^TM.N](
MU'^R]?T&\L-6L/M^DW]]I=[]DNXOM6G7MW93^9;7,T3_ +#?LZ_\%[/VZ?@M
M_9&C?$'6?"G[1O@NP_X0O2Y;'XG:,EAXYM/"_ACS+35[30_B1X0.B:M>^*_%
MFDR1PZEXW^*>G?%C45U>PT_7I[*_N9M?@U_HSOAW%XW%UL;A:E*;JJGS4:C=
M.:=.G"E:$K2A)-04O?=.UVM;*^.5YQ0PV'IX6O"<5!SM5BE.-ISE4]Z-U)6<
MFO=4MD[:NW]V]%?S;_#?_@Y5_9RU30[NX^+_ .SQ\;/ WB5-6GAL=)^&^J>!
M/BKH=QH:V=B]MJ-WXA\3ZS\&[^SU::_DU.VGT:'PQ?V=O9VEC?1Z]=3:C<:?
MI?Z,^"/^"Q/_  37^(/BC2_"&@_M4>%+#5M7^V_9+OQQX3^)GPR\+Q?8-.N]
M4G_M3QO\2/!/A/P7HGF6UE-%9?VUK]A_:6HO::1IWVK5K^QLKGY2MD^:8>_M
M,#B+)2;E3INM!**3;<Z/M()).]VTG9V>CM[]/,<#5MR8JC=VLIS5.3<M$E&I
MR2;OT2NM+K5'Z7T5XG\-_P!I;]G+XR:Y=^&/A!\?_@G\5?$MAI,^O7WA[X;_
M !5\">.=<L]#M;RQT^YUF[TGPQKVJ7]OI-O?ZIIEC/J,UNEG#>:C8VTDRS7=
MNDGME>?.$Z;Y9PE"6_+.+B[/9V:3U.N,HS5X2C);7BU)7[73:"BBBI*"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH _SEZ***YST#^L'_@A/_P FC_$7_LXWQ=_ZK/X0
MU^T]?BQ_P0G_ .31_B+_ -G&^+O_ %6?PAK]IZWCLO1?D<53XY>H4444R HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M****LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGA&\M;'Q#-X*\3O WAKQSI.G37^G.=>\'ZMKFAW-GJFDZA9ZC<6&JZ?<W/\
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MVBY*,*:^:IJ*?J[LVCF./@FEBZ[OK[U24W\G-R:]%H?T#_\ $2'^W%_T2O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M '57_P!4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@ HHHH **** "BBB@
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MJ%S<^_FG$>'RZM/"QH5*^(IJ#FN94Z47.,9Q3FU.4GR24FHT^751Y[\W+Y.
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M\3^&/V3?V:/#GB7PYJVG:]X>\0Z#\"/A;H^N:#KFCWD.H:3K.C:MI_A6WO\
M2]6TN_M[>^T[4;&X@O+*\@AN;::*:)'7Z7HHKGG4J5&G4J3J-:)SG*32[+F;
MM\C:,(034(1@GJU&*BF^[LD%%%%04%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML?\ )W'PZ_[-R\(_^K,^+U?BQ6,_B?R_)';3^"/H?HU_P25_Y2"_ #_NJO\
MZI/XD5_:=7\6/_!)7_E(+\ /^ZJ_^J3^)%?VG5<-GZ_HC"O\:_PK\V%%%%68
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5_E+U_JT5_E+U]QP9_S,O^Y/\ ]VCY?B3_ )@O^YG_ -P']6G_
M  ;&?\WN?]VV?^]]K^K2OY2_^#8S_F]S_NVS_P![[7]6E>'Q)_R.L;_W+?\
MJ)0/4R7_ )%F&_[C?^I%4****\,]0**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCGKRU4>VK]7M]VOWA1116A@%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_G+T445SGH
M']8/_!"?_DT?XB_]G&^+O_59_"&OVGK\6/\ @A/_ ,FC_$7_ +.-\7?^JS^$
M-?M/6\=EZ+\CBJ?'+U"BBBF0%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&EZ'I-I\.-=U^34O$&H_"_[8?_!*;X__ +*]C-XST&7_ (7C\*8?MLE]XO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH _SEZ***YST#^L'_@A/_R:/\1?^SC?%W_JL_A#7[3U^+'_  0G
M_P"31_B+_P!G&^+O_59_"&OVGK>.R]%^1Q5/CEZA1113("BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@#^3[_@NQ_R=Q\.O^S<O"/\ ZLSXO5^+%?M/_P %V/\
MD[CX=?\ 9N7A'_U9GQ>K\6*QG\3^7Y([:?P1]#]&O^"2O_*07X ?]U5_]4G\
M2*_M.K^+'_@DK_RD%^ '_=5?_5)_$BO[3JN&S]?T1A7^-?X5^;"BBBK,0HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *_REZ_U:*_REZ^XX,_YF7_ ')_^[1\OQ)_S!?]S/\ [@/ZM/\ @V,_
MYO<_[ML_][[7]6E?RE_\&QG_ #>Y_P!VV?\ O?:_JTKP^)/^1UC?^Y;_ -1*
M!ZF2_P#(LPW_ '&_]2*H4445X9Z@4444 %%%% !1110 4444 %%%% !1110
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MLXJDN:;:VV7HO\W=_,****H@**** "BBB@ I&945G=@JJ"S,Q"JJJ,EF)P
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M,6@>*=/9ES\FH^'-4U2R8E6"^?OV,5 K^]NMH.ZUW7]:G)5@HRTT36W9K?\
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M:?:XT8?8?"F@:MJFH6?AS1K=I)-GEF?5M09O-U74;E([*UL?H^BO/_BE\4O
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M$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!_G+T445SGH']8/_!"?_DT?XB_]G&^+O\ U6?PAK]I
MZ_%C_@A/_P FC_$7_LXWQ=_ZK/X0U^T];QV7HOR.*I\<O4****9 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M98B<L/0IY7B'@L%C?WCHHHK[L_T'"BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-G9P06L$,*4I<JLMWU[?\'R\_5&4H<\[R^&.R[O=_+H_33N>H_M%_M+?%O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH^)-7UG_ (23^V6\ V%YHUWHW@7P[XD_H8K_ #AZ_M:_X)F_MI_\-A? X_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!_)]_P78_Y.X^'7_9N7A'_P!69\7J
M_%BOVG_X+L?\G<?#K_LW+PC_ .K,^+U?BQ6,_B?R_)';3^"/H?HU_P $E?\
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MU\#>#YY8\QOXN\70&;7KRTDP=MSHGA2$:?<J2H-MXR0@.<E/P6K^Y7_@GO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _P Y>BBBN<]
M_K!_X(3_ /)H_P 1?^SC?%W_ *K/X0U^T]?BQ_P0G_Y-'^(O_9QOB[_U6?PA
MK]IZWCLO1?D<53XY>H4444R HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!QO_4BJ%%%%>&>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !117BG[1OQO\/?LW_ [XE?&[Q/!]MTWX?^&Y
M]3MM*\V^MO[?\0WMQ;Z-X1\,?;M/TG79]*_X2CQ7J6B^'O[:DTF]L=$_M/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y/O\ @NQ_R=Q\.O\
MLW+PC_ZLSXO5^+%?M/\ \%V/^3N/AU_V;EX1_P#5F?%ZOQ8K&?Q/Y?DCMI_!
M'T/T:_X)*_\ *07X ?\ =5?_ %2?Q(K^TZOXL?\ @DK_ ,I!?@!_W57_ -4G
M\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K_*7K_5HK_*7K[C@S_F9?
M]R?_ +M'R_$G_,%_W,_^X#^K3_@V,_YO<_[ML_\ >^U_5I7\I?\ P;&?\WN?
M]VV?^]]K^K2O#XD_Y'6-_P"Y;_U$H'J9+_R+,-_W&_\ 4BJ%%%%>&>H%%%%
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M6[\6_L[^ /BMIUJ]S-\(O'DEKK#HA/V+PO\ $.UM=)N[UW .$'B?1_!]CM.
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M99_P21^ O_"EOV0O"FNZG9?9O%GQHNY/BCK321XN(]%U6"&T\#V7F$*YM?\
MA%K6QUR.)E'D7GB#4%&=Q9B*NUY:A5ERP?=Z??O^!^GE%%%;'&%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!_G+T445SGH']8/_  0G_P"31_B+_P!G
M&^+O_59_"&OVGK\6/^"$_P#R:/\ $7_LXWQ=_P"JS^$-?M/6\=EZ+\CBJ?'+
MU"BBBF0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW\O^":1K<J2459+O][VZZ_?Y:_YW?_"&^+_^A5\2?^"/5/\ Y%K^O[_@D7\
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M_:9^+/Q6C\.^*+C0]8\2SZ7X.5]$U8)#X)\-HF@^%=D+6N+=[W2-/M]4O84
M7^TK^]E)>25W;^Z.BIE'FZV^1<)\C;M>ZMO;KKT/\[O_ (0WQ?\ ]"KXD_\
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M>62T^)/P^L;S7-&%BI9DG\1:7;1S:UX1FCB\L7?]LVB:2ERYM]/UK5$43O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"M/B_P"/'_"<_!#X 2?\(I\!=2\K0=4\;?9=3TWXA?%'3(/[0AUZ#?/=0?\
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MXO5^+%8S^)_+\D=M/X(^A^C7_!)7_E(+\ /^ZJ_^J3^)%?VG5_%C_P $E?\
ME(+\ /\ NJO_ *I/XD5_:=5PV?K^B,*_QK_"OS844459B%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7^4O7
M^K17^4O7W'!G_,R_[D__ ':/E^)/^8+_ +F?_<!_5I_P;&?\WN?]VV?^]]K^
MK2OY2_\ @V,_YO<_[ML_][[7]6E>'Q)_R.L;_P!RW_J)0/4R7_D68;_N-_ZD
M50HHHKPSU HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _SEZ***YST#^L
M'_@A/_R:/\1?^SC?%W_JL_A#7[3U^+'_  0G_P"31_B+_P!G&^+O_59_"&OV
MGK>.R]%^1Q5/CEZA1113("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M480A"*48PC%*,8Q244DDDD%%%%,L**** "BBB@ HHHH **** "BBB@ HHHH
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O\
M*7K_ $#OVGO^"R_["W[.WA?Q%-H/QA\*?'CXE6OA1-?\&_#GX.ZN_C+3O%FH
MWVHW.CZ9I&H_%/PSI_B'X:^#?(O;6;4?$L6LZ])XHT7PO ^LZ=X0\0WNH>&M
M$\0_Y^-??\(X7$4(8ZI6HU*4*SPRI.I!P<_9JNYN*DE)Q7M(>];E;;2;<9)?
M)<0UZ-66%A3JPJ2IJLYJ$E+EY_9<JDU=)ODEI>Z2NTDU?^K3_@V,_P";W/\
MNVS_ -[[7]6E?RE_\&QG_-[G_=MG_O?:_JTKYSB3_D=8W_N6_P#42@>SDO\
MR+,-_P!QO_4BJ%%%%>&>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '^
M<O1117.>@?U@_P#!"?\ Y-'^(O\ V<;XN_\ 59_"&OVGK\6/^"$__)H_Q%_[
M.-\7?^JS^$-?M/6\=EZ+\CBJ?'+U"BBBF0%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5X%^T/^TW\&/V7/ ]]XY^,'C'3="BCT
MW4[[P_X5AO+";QQX\NM+DTZVGT;P'X8N+VTO?$6I"]UG1[6\EA:'2- CU2VU
M;Q3JNA:!'=ZM;?E7^V'_ ,%JOA[\+KZ;P1^RWIOAOXT^*X/ML&L_$'6IM;B^
M%_AK4],\0Q6$NEZ996*:-J7Q-_M#3;'698]>\.>)=$\(6L-_X8UO0_$?C:"X
MU72+#^9_XJ_%_P"*'QP\7WGCSXN>.O$GQ \5WOVB/^U?$>HS7O\ 9]C<:GJ.
ML_V+H-CE--\-^&[34M6U*YTOPQX?L],\/:/]MGATG3+*!_*'Q>=<8X/ J>'R
M]PQN*2:=1.^%HRTMS3BU[>23^&E+D33C*HI)Q/X6\=?IM\&<!PQW#OAO/!<<
M<7PA4H3S*C4E5X3R/$V@U*MC:,H1S_$4XSO]5RBO+!PJQG1Q694<11K81_=/
M[=G_  4M^+/[7>K^)/!?A^]U+P#^SC)J6F-H?PW2/38=7\2Q^'KJ[N=-\1?$
M?6+)9[W4=2U&]G@UB3P9::O<>!] NM+\-"WM==\1^&D\;ZM^9]:6C:-J_B+5
M]*\/^']*U+7=?UW4K'1M#T/1K&ZU35]9U?5+J*RTW2M*TVRBGO=1U+4;V>"T
ML;&T@FNKNZFBM[>*261$/])W[!W_  1HL= _LGXK?MCZ5]K\5Z5XD74/#GP+
MM]4\/:[X0BL=)^W6\%S\5;W2_P"VM-\7?VIJ1L=<T[PCX?UM/#T6F:;9VOC2
M[\40>)->\%:!\!AL)F_$V.G.\Z\VU[;%5;JAAX-MJ-TN6$5>3I4*2NUS.$+*
M37^=7#'!WC)]*GC[&8[VV/S_ #"M5B\[XISB=>GP[PS@:U>M6HX1UXTYX;+\
M+3E5Q$LJX?RRDZU2*Q$L#@71HXNM2_)G]CS_ ()S_'_]L*^AU70=-_X5Y\*8
M?L5S??%KQMI6LV_A[5;%O$,NA:K:?#JWBLU_X6'XDTO^SO$$LVGZ??:=X>L+
M[0WT;Q3XN\+7^J:,M_\ UN_LJ_L@_!C]COP/?^"OA'I>I22Z[J1U7Q7XT\4W
M%AJGCCQ?=0R70TB+7M7T[2]&LCIOAVRNYM/\/Z-I>E:7I&G1S:AJ*V,FOZ[X
MCUC6/H_1M&TCP[I&E>'_  _I6FZ%H&A:;8Z-H>AZ-8VNEZ1HVD:7:Q66FZ5I
M6FV44%EIVFZ=9006EC8VD$-K:6L,5O;Q1Q1H@TJ_4<DX;P631C4BOK&-<;3Q
M51:QNK2C0AJJ4&FTVFZDE=2FXOE7^M'@3]%_@/P2H4,SH4_]8^.9X5T<;Q9F
M%&*GAW5A.&)H9!@G*K3R?"U:=2="I.%2MF&)H.=+$XV="?U>!1117T1_2P44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^R_VY_PN:^^+GV?^Q?L=S_9O_"-_\(_YO]K:A_;']K>7I?\ 9OYH?&;]J_\
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MP0G_ .31_B+_ -G&^+O_ %6?PAK]IZWCLO1?D<53XY>H4444R HHHH ****
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M6?"&GWSZU:_L5^Q'_P $6M(\(76B?$[]KR33?%'B;3M2T37O#_P8T+4+75_
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M3>.6X"+NL)0;V]Z"FONGS+YVN?GY\,?^"5/_  3N^$?]N?\ "*_LE_"C5O\
MA(/[-^W_ /"SM/U/XV_9_P"R?[0^R_V'_P +FU3Q]_PC/F_VE<_VE_PC?]D_
MVUY>G_VQ]O\ [)TO[']6_#'X#_ [X)?VY_PIGX,_"CX1_P#"3?V;_P ))_PK
M'X=^$/ /_"0?V+_:']C_ -N?\(KH^D_VM_9/]K:I_9OV_P"T?8/[2U#[+Y7V
MRY\SU:BN.KBL36YO;8BO5YK<WM:U2IS<MK<W-)WM96OM96V1T0H4*5O9T:5/
MEOR\E.$+7O>W*E:]W>V]WW"BBBL#4**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH _SEZ***YST#^L'_@A/_R:/\1?
M^SC?%W_JL_A#7[3U^+'_  0G_P"31_B+_P!G&^+O_59_"&OVGK>.R]%^1Q5/
MCEZA1113("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO;?VE*IM;3EMN[WTMX$>(,=&]UAYWM\5.2MOMR5(;];WVTMK?_0._P"'W?\
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MV:^9VIJ23BTT]4TTTUW36C"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /\ .7HHHKG/0/ZP?^"$_P#R:/\ $7_LXWQ=_P"JS^$-?M/7XL?\$)_^
M31_B+_V<;XN_]5G\(:_:>MX[+T7Y'%4^.7J%%%%,@**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#^3[_ (+L?\G<?#K_ +-R\(_^K,^+U?BQ7[3_ /!=C_D[CX=?]FY>$?\
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MTN9U*-&LDJU*G547=*I3C-)O1M*2:3MU1^4O_#D3_@E__P!&Q_\ F:/VA/\
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M 4444 ?YR]%%%<YZ!_6#_P $)_\ DT?XB_\ 9QOB[_U6?PAK]IZ_%C_@A/\
M\FC_ !%_[.-\7?\ JL_A#7[3UO'9>B_(XJGQR]0HHHID!1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@#_.7HHHKG/0/ZP?^"$__ ":/\1?^SC?%W_JL_A#7[3U^+'_!"?\
MY-'^(O\ V<;XN_\ 59_"&OVGK>.R]%^1Q5/CEZA1113("BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO
M+_C)\2+/X4_#OQ#XPG:V>_M;;['X>L;DQ,NI>([\-!I-J;9[[3IKRVAF)U'5
MH+&Z6^CT.PU2[MD=[4B@#XJ_;>^+\5Q+9_![0[JY5["YM=8\<E8[RUB>5[.V
MOO#FB+.+J&'4;80W@UW4H);&ZLTO$\.2VE\M_8:A;6_\R7_!5/\ X*"?\,9?
M"FR\,_#/5_#%Q^T7\2LVWA32M1;^TK_P%X-EAU2WU/XMW7A\V%]IE]]AU.QB
M\/\ @[3?%%QI^E:WXDN;S58[+Q?H_@7Q?X9N/T\^(7C[1_!GACQQ\4?B#KES
M:Z!X3T'Q+X^\<>)+R+5-:O+?1]"T^]\0^)=<NX;&#4=:U:YBLK6]OYXK.UOM
M4OY5=+>"ZNY4C?\ SY_VOOVH?&7[87QZ\8?'#QC:?V)_;?V'2O"O@ZWUG5=;
MTKP+X-T2V6ST/PSI5UJLG_7UKOB"XTZQT32M:\9:WXF\2V?A_1/[;DTZW_6/
M"7@F'%6>2QF8T/:Y)DWLZV*C-+V6,QDVWA,#*,K^UI2Y)U\5%*4?8TXT:O*L
M53YOC>,\^ED^7JAAJG)C\=S4Z,HWYZ%"*2K8A-?!-<T:=%MJ7/-U(7=&5OF6
MBBBO[0/PD**** "BBB@ HHHH **** "BBB@ HHHH ]-^#'Q;\9? ;XK> /C'
M\/KW[#XO^'?B?3/$VD>9<ZK;6&H_89A]O\/ZY_8FI:/J=YX8\3Z8][X<\5:5
M;:I8_P!M>&]4U72)KA+>^ES_ '^?LL?M)> OVL/@AX*^,_@'4-,DAU_3+.'Q
M;X<L-4DU6Z^'WCV'3K&X\5?#[6Y[G3=$OFU/PU?7BPQ7MUHNE1^(=&FTCQ9I
M%M)X>U_1[RZ_SMJ_:?\ X(M?MI7_ ,!/CU9_L^^*IOM'PJ_:,\3Z)H=K+=WW
MB2?_ (0GXK2VUWI'@[5-!T33H=4TQ_\ A8FIW.A^ ?%LDFDZ?-+M\%>(-4\5
M:9H'@6\L-3_'_&#@M<19'+.,%1<\YR.C4K04+<^+RZ+=7%X9QWJ5*,5/%8:*
MO-SC5HTHRGB4C[;@C/7EF81P->:C@<PG&$N;X:.*=H4:M_LQF[4:K=HJ+A4F
MU&E<_P!,']E3XPS_ !4\ -8:R^_Q7X'_ +-T35YVFU"[GU?3Y+(IHOB*]NKY
M)-^I:K]AU&WU-!J%]/+J&FW.J2K90:K9V<7U!7X+_!OXD7GPI^(GA[QA UR]
MA:W/V/Q#8VQE9M2\.7Y6#5K46R7VG0WES#"1J.DP7UTMC'KEAI=W<HZ6H%?N
M_9WEGJ-G:ZAI]U;7]A?VT%Y8WUG/%=6=Y9W42SVUU:W,#O#<6UQ"Z303PN\4
MT3K)&[(P)_C<_<BS1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% '\GW_  78_P"3N/AU_P!FY>$?_5F?%ZOQ8K]I_P#@NQ_R=Q\.
MO^S<O"/_ *LSXO5^+%8S^)_+\D=M/X(^A^C7_!)7_E(+\ /^ZJ_^J3^)%?VG
M5_%C_P $E?\ E(+\ /\ NJO_ *I/XD5_:=5PV?K^B,*_QK_"OS844459B%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5_$]_P '(?\ R?%\*_\ LU+P/_ZM[XYU_;#7\3W_  <A_P#)
M\7PK_P"S4O __JWOCG7T?"O_ "-H?]>*_P#Z2CQL^_Y%\O\ K[2_-GY2_L'_
M /)\7[&?_9UO[.__ *M[P?7^EW7^:)^P?_R?%^QG_P!G6_L[_P#JWO!]?Z7=
M=W&/^\X/_KQ4_P#3B.7AS^!B?^OL/_2 HHHKXX^C"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /\Y>BBBN<] _K!_X(3_\FC_$7_LXWQ=_ZK/X0U^T]?BQ_P $
M)_\ DT?XB_\ 9QOB[_U6?PAK]IZWCLO1?D<53XY>H4444R HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@?N+1117Y^?2!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/X&)_P"OL/\ T@****^./HPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_ #EZ
M***YST#^L'_@A/\ \FC_ !%_[.-\7?\ JL_A#7[3U^+'_!"?_DT?XB_]G&^+
MO_59_"&OVGK>.R]%^1Q5/CEZA1113("BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /Y/O^"['_)W'PZ_[-R\(_\ JS/B]7XL5^T_
M_!=C_D[CX=?]FY>$?_5F?%ZOQ8K&?Q/Y?DCMI_!'T/T:_P""2O\ RD%^ '_=
M5?\ U2?Q(K^TZOXL?^"2O_*07X ?]U5_]4G\2*_M.JX;/U_1&%?XU_A7YL**
M**LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *_B>_X.0_^3XOA7_V:EX'_P#5O?'.O[8:_B>_X.0_
M^3XOA7_V:EX'_P#5O?'.OH^%?^1M#_KQ7_\ 24>-GW_(OE_U]I?FS\I?V#_^
M3XOV,_\ LZW]G?\ ]6]X/K_2[K_-$_8/_P"3XOV,_P#LZW]G?_U;W@^O]+NN
M[C'_ 'G!_P#7BI_Z<1R\.?P,3_U]A_Z0%%%%?''T84444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!_G+T445SGH']8/_  0G_P"31_B+_P!G&^+O_59_"&OVGK\6
M/^"$_P#R:/\ $7_LXWQ=_P"JS^$-?M/6\=EZ+\CBJ?'+U"BBBF0%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ*_,_P#B+7B%_P!%%4_\-V4?_.\^L_U+X9_Z%<?_  JQW_S2?Q6?\0;OP_\
M^C^/&/\ XCSHG_SWJ/\ B#=^'_\ T?QXQ_\ $>=$_P#GO5_:G11_Q%KQ"_Z*
M*I_X;LH_^=X?ZE\,_P#0KC_X58[_ .:3^*S_ (@W?A__ -'\>,?_ !'G1/\
MY[U'_$&[\/\ _H_CQC_XCSHG_P ]ZO[4Z*/^(M>(7_115/\ PW91_P#.\/\
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M.U#^S]-\3?;?".I?Z)]K^V_VS;M_8FG_ "6US/;?:?%=MX?_ -+M_L_D[/\
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M<-GZ_HC"O\:_PK\V%%%%68A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?Q/?\ !R'_ ,GQ?"O_ +-2
M\#_^K>^.=?VPU_$]_P '(?\ R?%\*_\ LU+P/_ZM[XYU]'PK_P C:'_7BO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_.7HHHKG/0/ZP?^"$__)H_
MQ%_[.-\7?^JS^$-?M/7XL?\ !"?_ )-'^(O_ &<;XN_]5G\(:_:>MX[+T7Y'
M%4^.7J%%%%,@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSR*C3Q>%Q4FK*-'$RH8I+>UJ=2CBH*^R]W7S3/Y*OV@O^"4/_!R1\-OMVH?
M[_@IK\1?VD=&A\S[#IFG_M*?$KX4^/[T)DKYNA>/]5B\#69E7:$'_"T+G$A9
M'VHJRO\ AS^T#\7/^#B;]E@WLWQ^^*'_  4C^'&D:>7%SXLU/QO\6-3\ @QY
M\P0?$/P_JFK^!KSRP-[_ &3Q#/MC9)&PCHS?ZEU! (((!!&"#R"#U!'<&OJ<
MJ\6L7A.6&:<+\+YO35N::RO#9?BY][U:%&IA5?\ NX)6>NJT/(QG!E&M>6#S
M?-\%)[1>+JXFC'M:%2<:KM9;UWHEUU/\@7_A[;_P4^_Z/\_:T_\ #Y>/_P#Y
M=T?\/;?^"GW_ $?Y^UI_X?+Q_P#_ "[K_3__ &@?^"67_!.[]J/[=/\ &[]C
M_P""/BC6=2\PWWB[2/"-OX!\?732Y+-/\0?AW)X4\;2E6+/'YFOL(Y&=XPK.
MY;\.?V@O^#1S]B'Q[]NU#]GWXU?&[]GW6+GS#:Z5K;:)\9O 5AG)B2WT?65\
M)^.752=LC7OQ*O6= FT(ZNTGZ7E/BOX;XSEAF?#=/)ZCMS3GE&!QV$C?M5PM
M)XF5M;_[$M-5=Z+Y3&<&\4T+RPF:2QL5\,5C<1AZSV^Q6FJ*V5O]H>WDC^,;
M_A[;_P %/O\ H_S]K3_P^7C_ /\ EW7C7QQ_;D_;'_:9\)Z?X#_:%_:>^./Q
MJ\%Z3XBM/%VF>%OB7\2/$_C#0K#Q18:;J^C67B"TTS6M1N[6#5[72=>UO3H+
MZ.-;B*SU6_MT<1W4JM^['[07_!I]_P %&/AE]NU#X*^)_@E^TIHT/F&QT_0?
M%DOPR\>721Y(-SH/Q)@TKP9:/(NWRT@^)6H$OO1R@"-+^%'[2'[#G[8'[(4T
M"_M+_LX?%SX-V%[J@T33/$GC'P=JEKX*UK66MKN\72M \>6L5WX+U_439V%[
M>"ST77K^X-I:W%UY?D1/(/T_(\TX"S6K2JY%7X<K8I-2HPPU+!4,?"5M)1P\
MJ=+&4W:^OLXO==&?)9AA.(\'"<,QIYI3HM<LY59UZF&DM/==52G0DM%ISOIY
M'RK1117V9X04444 %%%% '^B[^R_XQ\2?$3]FC]G?X@^,=1_MCQ?XZ^!?PD\
M8^*M7^QV&G_VIXD\3^ ?#^MZYJ/V#2[6QTRQ^W:G?75S]CTZRL["V\WR;.UM
M[=(XD_I)_9]UZS\1_!3X9ZA8QW,4-OX3TS076[2))3>>%HSX8U"15AFG0VTU
M_I%S-9N7662S>"2>&WF:2WB_CB_X(RZWHVJ_\$[?@?8Z7J^F:E?>&M3^*^B>
M([.PO[6\NM UF?XN^./$<&D:W;V\LDVE:G-X>U_0=>BL+](+J31M;TC5$B:Q
MU*SGF_K._8M\0?VS\#[#3?LGV;_A$O$GB'P_YWVCSO[0^TW$/BK[7Y?DQ?9-
MG_"3?8/L_F7.[[%]J\Y?M/V>W_SQXDP4<MXBSW+XI*&"SC,L+3Y:2HQ=.AC*
MU.G*%)-JG"5.,90A%N,8.*BW&S?],Y57>*RS+L3)MRKX'"5I7G[27/4H4Y34
MINSE)2;4I-)N2;:3NCZQHHHKQ3O"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#^3[_@NQ_P G<?#K_LW+PC_ZLSXO5^+%?M/_ ,%V/^3N/AU_
MV;EX1_\ 5F?%ZOQ8K&?Q/Y?DCMI_!'T/T:_X)*_\I!?@!_W57_U2?Q(K^TZO
MXL?^"2O_ "D%^ '_ '57_P!4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '^<O1117.>@?U@_\$)_^31_B+_V<;XN_P#59_"&OVGK\6/^"$__
M ":/\1?^SC?%W_JL_A#7[3UO'9>B_(XJGQR]0HHHID!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?D5^W!J^GZ
ME\9K6SLKCSKGP_X*T/2-7C\J>/[)J$U_K6O16^^6*..?=I6MZ9=>;;/- OVG
MR&E%S#<0Q?KK7XJ_M;?\G!_$#_N5/_4)\-T ?PW_ /!P)_R>3\-/^S9?!O\
MZM/XSU^&-?L#_P %Q_B-_P )O^WGX@\,_P!C?V9_PI[X9?#CX<_;?[0^V_\
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M)_+\D=M/X(^A^C7_  25_P"4@OP _P"ZJ_\ JD_B17]IU?Q8_P#!)7_E(+\
M/^ZJ_P#JD_B17]IU7#9^OZ(PK_&O\*_-A1115F(4444 %%%% !1110 4444
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MJ5[/78^[Q->O1C_L^"JXN=O=C3JX:C!/HI2KUJ<HKSA3GZ'Z;?&3]I']GO\
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M.X^'7_9N7A'_ -69\7J_%BL9_$_E^2.VG\$?0_1K_@DK_P I!?@!_P!U5_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 ?YR]%%%<YZ!_6#_P0G_Y-'^(O_9QOB[_U6?PA
MK]IZ_%C_ ((3_P#)H_Q%_P"SC?%W_JL_A#7[3UO'9>B_(XJGQR]0HHHID!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#AY#_P40_Z/U_;0_\ $I/CC_\ -S1_P\A_X*(?]'Z_MH?^)2?''_YN:/\
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M $E'C9]_R+Y?]?:7YL_*7]@__D^+]C/_ +.M_9W_ /5O>#Z_TNZ_S1/V#_\
MD^+]C/\ [.M_9W_]6]X/K_2[KNXQ_P!YP?\ UXJ?^G$<O#G\#$_]?8?^D!11
M17QQ]&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 ?YR]%%%<YZ!_6#_P $)_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,)4U&37+LVEKOIKYN;\!X7+<LQF/AF%>K+"T74C3E1IQC-J459M2;2UW2/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH _D^_X+L?\G<?#K_LW+PC_P"K
M,^+U?BQ7[3_\%V/^3N/AU_V;EX1_]69\7J_%BL9_$_E^2.VG\$?0_1K_ ()*
M_P#*07X ?]U5_P#5)_$BO[3J_BQ_X)*_\I!?@!_W57_U2?Q(K^TZKAL_7]$8
M5_C7^%?FPHHHJS$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K^)[_@Y#_Y/B^%?_9J7@?_ -6]\<Z_
MMAK^)[_@Y#_Y/B^%?_9J7@?_ -6]\<Z^CX5_Y&T/^O%?_P!)1XV??\B^7_7V
ME^;/RE_8/_Y/B_8S_P"SK?V=_P#U;W@^O]+NO\T3]@__ )/B_8S_ .SK?V=_
M_5O>#Z_TNZ[N,?\ ><'_ ->*G_IQ'+PY_ Q/_7V'_I 4445\<?1A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% '^<O1117.>@?U@_\ !"?_ )-'^(O_ &<;XN_]
M5G\(:_:>OQ8_X(3_ /)H_P 1?^SC?%W_ *K/X0U^T];QV7HOR.*I\<O4****
M9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ18P:?;27<D$-O"]R\-NC3O#;P1-*7:.&)"$7;K^8S]9"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH _D^_X+L?\G<?#K_LW+PC_ .K,
M^+U?BQ7[3_\ !=C_ ).X^'7_ &;EX1_]69\7J_%BL9_$_E^2.VG\$?0_1K_@
MDK_RD%^ '_=5?_5)_$BO[3J_BQ_X)*_\I!?@!_W57_U2?Q(K^TZKAL_7]$85
M_C7^%?FPHHHJS$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K^)[_@Y#_Y/B^%?_9J7@?\ ]6]\<Z_M
MAK^)[_@Y#_Y/B^%?_9J7@?\ ]6]\<Z^CX5_Y&T/^O%?_ -)1XV??\B^7_7VE
M^;/RE_8/_P"3XOV,_P#LZW]G?_U;W@^O]+NO\T3]@_\ Y/B_8S_[.M_9W_\
M5O>#Z_TNZ[N,?]YP?_7BI_Z<1R\.?P,3_P!?8?\ I 4445\<?1A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% '^<O1117.>@?U@_P#!"?\ Y-'^(O\ V<;XN_\
M59_"&OVGK\6/^"$__)H_Q%_[.-\7?^JS^$-?M/6\=EZ+\CBJ?'+U"BBBF0%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %?A!\</A]/\,_B?XK\,?8?L.E+J4^I^&%C.H2VLGA?5)I+K15M
M;S4XTN;_ .P6S_V/?W/F72+J^FZC:_;;N2VDG?\ =^OBK]M/X5_\)7X'MOB!
MI%GYNO>!=_\ :?V>WWW5_P"$;R1?MOF?9M.N;VZ_X1Z],6KP_:+VSTS2=(G\
M57\NZ65: /\ --_X+2_LK?\ "@/VK+SXF>'[7R?A[^TK_;?Q&TW]_P"9_9_Q
M'MKRT_X6WHW^F^(M9UNZ^U:WK.E?$#^T+BPT'08/^%A?\(IX9L6M/"=SY7X_
M5_?3_P %&?V5O^&O?V4_'OPSTJU^T_$+0?*^(WPD_?\ D[_B/X3L]1_LW1O]
M)\1>&=$7_A--$U'Q!\/_ .T/$U_-H/AS_A+/^$KN+&YN]!LMG\"U?VKX1<5?
MZR<+4<-B*G/F>0^RRW%\TKU*N&4'_9V+ENW[7#TY8><YR<ZN)P>)JRLIH_!N
M-<G_ ++S>=6E#EPF8\^*H65HPJN2^M45LER59*I&,4HPI5Z4%\+L4445^IGR
M!_2)_P &K'_*5G2?^S??C)_Z#X9K_3$K_'%_8-_;J^,O_!.WX]V_[1GP)TOP
M%J_CRV\(^)/!<=G\2-$UG7_#1TCQ0+(:C(^GZ%XC\+7YOH_L$'V28:JL41,G
MF6\VX;?VS_XBU_\ @IQ_T(/[('_AK/B;_P#/NK^>O$[PUXFXLXECFN4QP+PJ
MRW"X5O$XOV-3VM&IB)3]SV<_=M5C9WUUTT5_TOA+BK*LFRJ6#QKQ"K/%5JW[
MJC[2/).%)1][F6MX.ZMH?FO_ ,%Q?^4L_P"W1_V6FZ_]1SP_7Y35[W^U#^T7
MX\_:W_: ^*?[2/Q/L_#6G^/OB]XFD\5^*+/P?I]_I7AFWU*2SM+%H]&T[4]5
MUR_M+00V4)$5UJU]+YA=C.0P5?!*_<LEPE7 9-E.!Q'*J^"RS 82LH2YH>UP
M^%I4:G+*RYH\\)<LK*ZL['Y_CZT,1CL;B*=_9U\7B:U/F5I<E6M.<;KH^62N
MNCT"BBBO3.0**** "BBB@ HHHH ***]S_9G^!'B3]IOX]?"_X$^%9_L.I_$3
MQ/!I=UJ_E6%S_P ([X;L;:YUOQCXJ^P:CK&@6^K_ /"*>$-+USQ)_8<>L6-_
MKO\ 9?\ 8^ER/J=]9Q288K$T,%AL1C,55C0PN$H5<3B:TW:%&A0IRJUJLVDV
MHTZ<)3DTGHGH:4:52O5I4*,'4K5JD*5*G'XIU*DE"$(WLKRE)15WNS^D+_@@
M?^RM_P (G\./&G[6WB:UVZW\5?M_PY^&7[_/V;X<>&=>C_X336?^)?XBN;2;
M_A+/B%H-OHG]G^(/#>G:]H/_  K'^TM*OKC1/&C^=_8%^PU\/I]7\<:Q\0[V
MQW:5X2TV?3-(O)3J$&?%&MQK!*UB\4::??\ V#PZ^IP:K;7-S(]E_;VC7*V3
MR3V]W:_GU\/? .C^#/#'@?X7?#[0[FUT#PGH/AKP#X'\-V<NJ:U>6^CZ%I]E
MX>\-:':S7T^HZUJUS%96ME802WEU?:I?RJKW$]U=RO(_] WP;^&]G\*?AWX>
M\'P+;/?VMM]L\0WUL(F74O$=^%GU:Z%RECITUY;0S$:=I,]]:K?1Z'8:7:7+
MN]J#7\ \6<0U^*>(,RSNNI0CBZ[6%HR=WAL%12I8/#Z-PYJ="$/;2A:-2NZM
M:RE49_2&3993RC+<+@*?*W1IIUJD5_%Q$_?KU=4I-2J.7(I7<*:A"]HH]0HH
MHKYP]0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^3[
M_@NQ_P G<?#K_LW+PC_ZLSXO5^+%?M/_ ,%V/^3N/AU_V;EX1_\ 5F?%ZOQ8
MK&?Q/Y?DCMI_!'T/T:_X)*_\I!?@!_W57_U2?Q(K^TZOXL?^"2O_ "D%^ '_
M '57_P!4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH _D^_P""['_)W'PZ_P"S<O"/_JS/B]7XL5^T_P#P78_Y.X^'7_9N
M7A'_ -69\7J_%BL9_$_E^2.VG\$?0_1K_@DK_P I!?@!_P!U5_\ 5)_$BO[3
MJ_BQ_P""2O\ RD%^ '_=5?\ U2?Q(K^TZKAL_7]$85_C7^%?FPHHHJS$****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?YR]%%%<YZ!_6#_P0G_Y-'^(O_9QOB[_U6?PAK]IZ_%C_
M ((3_P#)H_Q%_P"SC?%W_JL_A#7[3UO'9>B_(XJGQR]0HHHID!1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /Y/O^"['_)W'PZ_[-R\(_\ JS/B]7XL5^T__!=C_D[CX=?]FY>$?_5F
M?%ZOQ8K&?Q/Y?DCMI_!'T/T:_P""2O\ RD%^ '_=5?\ U2?Q(K^TZOXL?^"2
MO_*07X ?]U5_]4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M_B>_X.0_^3XOA7_V:EX'_P#5O?'.O[8:_B>_X.0_^3XOA7_V:EX'_P#5O?'.
MOH^%?^1M#_KQ7_\ 24>-GW_(OE_U]I?FS\I?V#_^3XOV,_\ LZW]G?\ ]6]X
M/K_2[K_-$_8/_P"3XOV,_P#LZW]G?_U;W@^O]+NN[C'_ 'G!_P#7BI_Z<1R\
M.?P,3_U]A_Z0%%%%?''T84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_G+T445
MSGH']8/_  0G_P"31_B+_P!G&^+O_59_"&OVGK\6/^"$_P#R:/\ $7_LXWQ=
M_P"JS^$-?M/6\=EZ+\CBJ?'+U"BBBF0%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!_G+T445SGH']8/_!"?_DT?
MXB_]G&^+O_59_"&OVGK\6/\ @A/_ ,FC_$7_ +.-\7?^JS^$-?M/6\=EZ+\C
MBJ?'+U"BBBF0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(^"VL?VCJ5OBTMY-GA_2K6\WW%VOV'RXK*7^&G_A#/$O_0-_\G+#_P"2J/\
MA#/$O_0-_P#)RP_^2J/]?<=_+E7W5O\ YL#_ (ENX>_GXS_\"P/_ ,XC^RS5
M_P#@JM_P3UTW4+BRL_VEM-\06T/E>7J^D?";]H*'3[OS((I7^SQ:]\(]$U5?
M(DD>VE^UZ9;;IX96@\ZV,-Q+F_\ #V3_ ()_?]%]_P#,5_&K_P"=Q7\<O_"&
M>)?^@;_Y.6'_ ,E4?\(9XE_Z!O\ Y.6'_P E4?Z^X[^7*ONK?_-@?\2W</?S
M\9_^!8'_ .<1_9]X?_X*D?\ !.O6?M?]H_M7>&_"7V;[/Y/_  D'PB_:9N?[
M0\[SO,^R?\(K\#O$VS[)Y4?VC[?]BW?:8?LOVG;<?9_?/"O_  4C_P"",D7D
MS>-_V_-2OO,TV/[1IOA7]F[]I?2OL>KO]G>7R=;U?X+:Q_:.FV^+NWCW^']*
MNKS?;W;?8?+ELI?X1?\ A#/$O_0-_P#)RP_^2J/^$,\2_P#0-_\ )RP_^2J/
M]?<=_+E7W5O_ )L#_B6[A[^?C/\ \"P/_P XC_1K^'W_  6J_P""%GPS@L?^
M$8_:2TU=5L<R)XGU/]GG]IO5/%$EU+I\>F7ETNM77P0>YL/M]LDGVJPT?^S=
M(5[J]^RZ=;1W<\;^L_\ $0U_P1[_ .CO?_, _M0__.4K_,[_ .$,\2_] W_R
M<L/_ )*H_P"$,\2_] W_ ,G+#_Y*H_U]QW\N5?=6_P#FP/\ B6[A[^?C/_P+
M _\ SB/],3_B(:_X(]_]'>_^8!_:A_\ G*4?\1#7_!'O_H[W_P P#^U#_P#.
M4K_,[_X0SQ+_ - W_P G+#_Y*H_X0SQ+_P! W_R<L/\ Y*H_U]QW\N5?=6_^
M; _XENX>_GXS_P# L#_\XC_3$_XB&O\ @CW_ -'>_P#F ?VH?_G*4?\ $0U_
MP1[_ .CO?_, _M0__.4K_,[_ .$,\2_] W_R<L/_ )*H_P"$,\2_] W_ ,G+
M#_Y*H_U]QW\N5?=6_P#FP/\ B6[A[^?C/_P+ _\ SB/]/GX>?\%W?^"2_P 3
M_&.C^!O#?[9G@K3-:US^T/L5[\0_!7Q<^$7@Z#^S-+O=8N?[8^(?Q8^'O@KP
M!X>\RTT^>'3_ .W_ !-IG]K:I)9:'I7VS6M3TW3[O]._AY\2?AU\7?!VC_$/
MX3^/O!7Q/\ >(?[0_L#QS\//%.A^-?!VN?V3JE[H>J_V/XF\-W^IZ+J?]F:U
MIFI:/J'V*]G^QZII][I]SY=W:3PQ_P"-S=:#K5F91<:9>JL"&265('FMT0()
M&<W, DMRB(<R,)2(R&5RK*P'J?P#_:,^.O[+7Q%TWXL?L\?%7QK\(O'^F?8X
M?[?\%ZU<:9_;&EV>NZ-XE_X1GQ9I69-%\:^"M0UKP]HE[KO@;Q?INN>#O$?]
MF6MMX@T/4[2/R#W83CFLY+ZUA*%6FWK/"3G3E&+Y6FHU)UHS=N9VYZ:E>.L;
M/F^>SKZ.^!A3DLGSG,L'B8Q]VCG5"CB*=2<>=2C*KA:&!J4(MNFN98?$.GR3
MO"?M(JE_L3T5_'9_P3#_ .#G'_A8?C'P'\ _^"A6B>"O!5WK_P!G\-:5^UEX
M;N/^$5\'-KD>E^&]+T!OC?X'GBN-%\)?\);K5OXGU+Q7\6_"6L^'OAUX8U36
M_#MG=_"SP)X T_Q)XZT'^OGPWXD\.^,_#N@>,/!^OZ+XK\)>*]%TKQ)X7\4>
M&]5L==\.^)/#NNV,&J:)K^@:WI<]UIFL:+K&F75KJ.E:KIUU<V.H6-S!=VD\
MUO-'(WV^7YG@\SI>UPE53Y7:=.2Y*M-V3M.#U2UTE'FA)W49.SM_/7$W"6>\
M(XQ8/.L&Z#J)RP^)I25;!XJ";7-A\1%<LFN5N5&:IXBFG%U:4%.+EM4445Z!
M\T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\GW_  78_P"3
MN/AU_P!FY>$?_5F?%ZOQ8K]I_P#@NQ_R=Q\.O^S<O"/_ *LSXO5^+%8S^)_+
M\D=M/X(^A^C7_!)7_E(+\ /^ZJ_^J3^)%?VG5_%C_P $E?\ E(+\ /\ NJO_
M *I/XD5_:=5PV?K^B,*_QK_"OS844459B%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_$]_P '(?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /\Y>BBBN<] _
MK!_X(3_\FC_$7_LXWQ=_ZK/X0U^T]?BQ_P $)_\ DT?XB_\ 9QOB[_U6?PAK
M]IZWCLO1?D<53XY>H4444R HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWV@NAGV3VLSNL%W"&V$@MMBF5AF"X:-1+Y>YT8;Q%--Y4I3^E;_@WM_X*_\
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M_P"K>\'U_I=U_FB?L'_\GQ?L9_\ 9UO[._\ ZM[P?7^EW7=QC_O.#_Z\5/\
MTXCEX<_@8G_K[#_T@****^./HPHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-XO_ +&\2_M)?&G2O[=\)_\ "/\ ]H_\)G\'O@[ITOC3Q9_Q/;K1+ZP\._\
M"._%J^^ >I?Z'K.A>*-7\W['IO\ :?AI/&EJG].U?Q;_ /!WS_SCT_[NS_\
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M1M/,,BP&+Q+M!<U:&(QV C*\8Q<K8?!4(WJ.<_=LI*"A"!1117UA^+!1110
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MJ%%%%,@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "OXM_P#@[Y_YQZ?]W9_^^SU_:17\6_\ P=\_\X]/^[L__?9Z^?XI
M_P"1#C_^Y7_U,PY^F>#O_)QN'?\ NK_^J+,S^0?X;?\ ,:_[AW_M_7J%>7_#
M;_F-?]P[_P!OZ]0K\!QO^\U?^W/_ $W _P!,N'O^1/@_^YC_ -2JX4445RGM
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R_C/_
M )%K4O\ MS_]+[6NHKE_&?\ R+6I?]N?_I?:UK0_CT?^OM/_ -+B<69?\B['
M_P#8%BO_ $Q4/TL_X-Y?^4PG[(7_ '7[_P!9>^-=?Z=E?YB?_!O+_P IA/V0
MO^Z_?^LO?&NO].ROW/@G_D58C_L85?\ U&PA_G-X_P#_ "666?\ 9,X/_P!6
MN<A1117V!^&A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\GW_  78
M_P"3N/AU_P!FY>$?_5F?%ZOQ8K]I_P#@NQ_R=Q\.O^S<O"/_ *LSXO5^+%8S
M^)_+\D=M/X(^A^C7_!)7_E(+\ /^ZJ_^J3^)%?VG5_%C_P $E?\ E(+\ /\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /\Y>BBBN
M<] _K!_X(3_\FC_$7_LXWQ=_ZK/X0U^T]?BQ_P $)_\ DT?XB_\ 9QOB[_U6
M?PAK]IZWCLO1?D<53XY>H4444R HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *_BW_P"#OG_G'I_W=G_[[/7]I%?Q;_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_=?O_67OC77^G97^8G_ ,&\O_*83]D+_NOW_K+WQKK_ $[*_<^"?^15B/\
ML85?_4;"'^<WC_\ \EEEG_9,X/\ ]6N<A1117V!^&A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '\GW_!=C_D[CX=?]FY>$?\ U9GQ>K\6*_:?_@NQ
M_P G<?#K_LW+PC_ZLSXO5^+%8S^)_+\D=M/X(^A^C7_!)7_E(+\ /^ZJ_P#J
MD_B17]IU?Q8_\$E?^4@OP _[JK_ZI/XD5_:=5PV?K^B,*_QK_"OS844459B%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5_$]_P<A_\GQ?"O_LU+P/_ .K>^.=?VPU_$]_P<A_\GQ?"
MO_LU+P/_ .K>^.=?1\*_\C:'_7BO_P"DH\;/O^1?+_K[2_-GY2_L'_\ )\7[
M&?\ V=;^SO\ ^K>\'U_I=U_FB?L'_P#)\7[&?_9UO[.__JWO!]?Z7==W&/\
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MLNG<_J<LH)+6SM+6:[GOYK:V@@EOKH0+=7LD,21O=W*VT-O;">X93-,+>""
M2.PBACCVHMFBBMCC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X?XF_
M$#0?A3\._''Q,\42^3X?\!>%==\6:L0ZI)+9Z%IUQJ$EK;[LA[R\\@6EE" S
MSW<T,,:/)(JG^.74_P#@J]^WG?:EJ%[:_'6ZTJUO+Z[NK;2[/P-\,Y;33;>X
MGDEAL+62\\%W%W);V<;K;P/=7$]P\4:M/-+*6=OVA_X+>?'K_A!/V?O"_P $
MM(O?*UWXT^(EN=;BBDQ+'X$\#SV6K7R2A")(/[4\3S^&H8&<B.\M+'6;;;*J
MS!/Y2*SG)WLKJV^ITT8)Q<FD[O2Z3LEZ]W^1^A'_  ]4_;[_ .CA-2_\(/X5
M_P#S"U^LW_!)?]H_]L7]J3XJ>/=;^+GQ>U3Q/\*?AQX6@CO-)D\)^ ](M]6\
M9^*;EX/#]L]_HGA32]0,.GZ7IFOZG<QVM\A2ZBTE;E&M[HI)_,C7]IW_  2O
M^ O_  HK]C[P#_:-E]D\6_%3S/BOXH\R/9<)_P )3;6O_"+V,N\":+[#X.M-
M!\^SDV_9=4N-3_=I)++N46V]6]-=V.JHQAI&-V[+1:=V?HU1116IRA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '^<O1117.>@?U@_\$)_^31_B+_V<;XN_P#59_"&OVGK\6/^"$__ ":/
M\1?^SC?%W_JL_A#7[3UO'9>B_(XJGQR]0HHHID!1110 4444 %%%% !1110
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MPJ_^HV$/\YO'_P#Y+++/^R9P?_JUSD****^P/PT**** "BBB@ HHHH ****
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MPC_Z*E\.?_"W\,__ "SHNN_]?TU]X[/L_P"O^'7WGHU%<GH7CWP+XHO)-/\
M#/C3PGXBOXK=[R6QT+Q'H^KWD=I')%#)=26VGWEQ,EO'+/!$\[((EDFB1F#2
M(&ZR@045X]\4/V@_@=\%(1+\6/BSX!\ 2/";BWT_Q+XFTNPUF]A'5].T)[@Z
MSJ8'7&GV%RV.<8KXQUO_ (*\?L&:/<2V\'Q<U777AP&DT3X<_$*6!GW;62*X
MU#PUIT$VT?.9(G>!E!\N5VPI5UW7WC49/9-^B9^E]%? ?@#_ (*@_L-?$2_M
M])TOX[Z)H.I7,BQQP>.M%\3^!;0,YPGF:[XGT;3?#<>X\ /K((. P7<N[[SL
MKVSU*SM=0TZ[MK^PO8(KJROK*>*ZL[NUG198+FUN8'DAN()HV62*:)WCD1E=
M&*D&G=/9W!IK=->J:_,LT444""BBB@ HHKYO^(O[8/[+?PFGGL_B!\>_A?H&
MIVK,MSHG_"5Z;JOB&W9"0PG\.Z)-J6N1<@J/,T]=S*RKEE( -)O9-^FI](45
M^9^L?\%>?V"M+D>*W^+NK:XT9(8Z/\-OB.8RRE05274_"^F12#DD/&[1,$8J
MYRF^C8?\%A?V#KQU2X^)WB32E+[3)?\ PT\>R(HP#YC#2]!U*39D[<+&SY!^
M3;@E77=?>A\D_P"67W/_ "/T^HKY%^'W[>W[''Q0N8++P?\ M$?#>:_NV2.T
MT[Q#JTO@C4KR63&R"TT[QO:^';VZN6SQ;6\$DYP?W?RMCZWBECGCCFAD2:&9
M$EBEB=9(Y8Y%#QR1R(2KHZD,CJ2K*002"#3NGL[B::W37JK#Z***!!114%S<
MVUE;7%Y>7$%I9VD$MS=75S+'!;6UM!&TL]Q<3RLD4,$,2/)++(RQQQJSNRJI
M( )Z*\Y_X7#\(_\ HJ7PY_\ "W\,_P#RSH_X7#\(_P#HJ7PY_P#"W\,__+.E
M==U_7_#K[QV?9_U_PZ^\]&HK%T+Q)X=\4VDFH>&=?T7Q%80W#V<M[H6JV.KV
MD5W''%,]K)<Z?/<0I<)#/!*\#.)5CFB<J%D0F[J.I:=H]C=ZIJU_9:7IEA ]
MS?:CJ-U!96-G;1#=)<7=W<R16]O!&O+RS2)&@Y9@*8B[17PE\0/^"F/[#OPX
MNI[#6OV@/"VLW\#;#;>!;+Q!\08GD!(9%U3P9I&MZ(K)AM_FZG$%*["?,*HW
MFFE_\%@/V#=1NQ:S_%/7M'0R"-+S5/AMX_\ LC$DJKEM-\/:C/'&3@EYK>((
M"&DV ,55UW7WHKDG_++_ ,!?^1^G%%>3?"CX[_!OXYZ5-K/PA^)?@_X@V5J(
MS?KX;UJTO;_2S-_JDUG2-Z:MHTLH&8X=5L;.5U^94((->LTR0HHKD?&GQ \"
M?#?1I/$7Q"\:>%? N@0DK)K7B_Q!I7AS2U<#=Y?V[5[NSMFE(^[$LAD<D!5)
M(! .NHK\Z_%O_!5S]A#PC<S64OQNA\07D!8/%X2\'>.?$-LQ4<>3J]GX<_L*
MX#GY5:#5)%SRQ5?FJAX7_P""M?[!_B>\AL#\8KGP[<7#!(6\4>!?'6EV9<MM
M FU1/#UUI=FN/G,M]>VT*J?FD#94*Z[K[T5R3_EE_P" O_(_2.BN7\'>-_!O
MQ#\/V7BOP%XJ\.^,_#.I*6L=?\+ZSI^NZ1=;<;TAU#3+BYM6EB+!9HO,\V%_
MDE1'!4=13)"BBB@ HHHH **Y+QCX^\"_#O2FUWQ_XT\*>!]%0L&U?Q?XBTCP
MWI@* ,R_;M9O+*UW*""5$N[D<<C/Q=XM_P""HW["/@Z:6UO_ (_Z'JUU$2!%
MX3\.>-?%\,K+G(BU+PYX;U+1V!QP[:BL;9&'.:3:6[2]1I-[)OT3?Y'W]17Y
M=1?\%B_V$I+GR'^(GBN"+<5^V2_#;QH;; . ^V'29KO:1R!]EWXZH#Q7T5\,
M/V]?V/?C%>6VF^!/C]X#NM6O'2*ST;Q#=WO@;6;V=R MM8:5XYL?#E_J%R2<
M""Q@N)6 +*K("U%UW7WH;C):N,DN]G8^NZ*.O2BF2%%%% !117G)^,/PD!(/
MQ2^'((X(/C?PSD'T/_$SH ]&HKSG_A</PC_Z*E\.?_"W\,__ "SKI= \7>%/
M%:W3^%O$_A[Q*EDT27KZ!K6FZRMH\XD,"W3:=<W(MVF$4IB64H9!'(4#!&P7
M7?\ K^F@L^W]?TU]YT-%1S30V\,MQ<2QP6\$<DT\\TBQ0PPQ*7EEEE<JD<<:
M*SR2.P5%!9B ":^+?B1_P46_8J^%5S<6'BC]H+P5=ZE;%XYM.\&'5?B'<QW$
M9*O:3MX$TWQ%;6=TC@QRPWUQ:F!P5G,15L%TMV-)O9-^BN?:U%?F%:?\%A?V
M#KF\%M-\3O$=A"6"_P!H7?PT\?/9@'^,I8Z#>W^T=_\ 0=WHIK[*^#W[3'P"
M^/\ !-+\'?BQX-\=SVT(N;O2=*U1(?$=C;$JHN=0\+ZDECXCT^V9F"+<7NEP
M0M(&C5RZ,H5T]FG\QN,EJXM+NT['N=%%%,D**P?$OBKPQX,T>Z\0^,/$>@^%
M- L@&O=<\2ZQI^A:/:*02&NM3U2XM;*W!"L099T!"D]C7PUXT_X*D_L*>![F
M6QO?CSI&O7L+E##X+\/>+_&-L^TD,T6M>'] OO#\B CAEU8[P0T>]<D)M+=I
M>HTF]DWZ)O\ (_0.BOS/T'_@KQ^P=K=W':3?%G5O#[S2"*.;7OAYX]@M2QV[
M3)=6'A[48+:-B2#+=/!$FUFE>-,,?O3X=_%'X<?%SP_%XJ^&'CGPMX^\.ROY
M7]K>%-;L-:M(;C:&:TO&L9Y7L;Z-2/.L;U(+N$_++ C9%%T]FG\P<9+=->J:
M.\HHHIB"BBOES]M'XZQ_LX?LR_%GXK17*6^NZ1X:GTKP:&*EY?&WB5TT'PL8
MX3\UPECJVH6^JWL*?-_9NGWLI*)$\B&PTKM);MI?>?RC?\%0_CU_POK]L'XB
MWFGWOVOPG\-I4^%'A(I)OMVM/"%Q=Q:_?0,I\F:/4_&%UXAO+:[C'[_39-/7
M?(D4;G\\Z?++)/))--(\TTSO+++*[222R2,7DDDD<EG=V)9W8EF8DDDDFF5S
MMW;?<[DK)+LDCZ8_8Z^!D_[1W[2GPG^$A@EET?7_ !/;WOBV2/>OV?P5X?23
M7O%DAF7 MY9M#T^\LK*5V56U*[LH5)DFC1O[RX((+6"&UM88K>VMHHX+>W@C
M2*&""%%CBAAB0*D<44:JD<:*J(BA5   K^=S_@A)\!?)L_BO^TEK%GA[N2+X
M4>!YI8\,+:W-AXB\;WT(D!W1SW!\+:;;7<(&V2RUJS,C9FC7]V?B9\:_A#\&
MM/35/BM\2_!'P]LYD:2T/BSQ)I>C7.H!&*LNEV%Y<QW^J2A@08=.MKJ7Y6^3
M"MC6&D;O2_Y=/Z\SFK/FGRK[*M\WJ_T^X]/HK\U=?_X*Y_L&:%<2VL7Q?U#7
MY825D;0/AY\0KFWWAU4K%>7OAK3[.Y&"9!+:W$\#(K!92^$.[X._X*J_L)>,
M[R+3K;XY67A^]G95C3QCX5\:>%K,;@/FEUO5?#\/A^V52=K&YU6'!!(!3#&K
MKNOO1GR3_EE]S_R/T-HK$\.^)?#GB_1[+Q%X2U_1/%'A_4HO.T[7?#NJV.M:
M/?PY(\VRU/39[FRNH\@C?!/(N01G-;=,D**** "BBO/IOBW\*;::6WN/B;\/
M8+B"62&>";QIX;BFAFB<I+%+$^I*\<L;JR21NJLCJ58 @B@#T&BO.?\ A</P
MC_Z*E\.?_"W\,_\ RSKHM \9>$/%C72^%O%?AOQ*UB(6O5T#7-+UEK-;DRBW
M-T-.NKDVXG,$PA,VP2F&4)N\M\%UW_K^F@L^W]?TU]YTE%(2%!9B%502S$@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\GW_!=C_D[C
MX=?]FY>$?_5F?%ZOQ8K]I_\ @NQ_R=Q\.O\ LW+PC_ZLSXO5^+%8S^)_+\D=
MM/X(^A^C7_!)7_E(+\ /^ZJ_^J3^)%?VG5_%C_P25_Y2"_ #_NJO_JD_B17]
MIU7#9^OZ(PK_ !K_  K\V%%%%68A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?Q/?\'(?_ "?%\*_^
MS4O _P#ZM[XYU_;#7\3W_!R'_P GQ?"O_LU+P/\ ^K>^.=?1\*_\C:'_ %XK
M_P#I*/&S[_D7R_Z^TOS9^4O[!_\ R?%^QG_V=;^SO_ZM[P?7^EW7^:)^P?\
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MC3M+MY':&PLVOKR\OY;>U2*.:_O;R^E5[J[N)I/L;]G;_@GE^U5^TU:6NN>
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M/5-2OIGN+R^OKRX>2>YN;B9WDEED=F9F))J)2MHM_P O^";4J?-[TOA[=_\
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MTX/=)O?JW?OU_0_$.BOJG]IK]C#]H#]DO5+*T^+WA%+;1-7GDM=!\;^'KO\
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M?5^OS/QZHISH\3O'(C1R1LR21NI1T="5='5@&5E8%65@"I!! (IM26?T0_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX;/U_1&%?XU_A7YL****LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCLJ(B*6=B%4$D"HZ_=?_ ((O_L=6'Q)\::K^TY\0-)2]\*?#'5H](^&VGWT
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MQW\1Z<Z2:?X@^,OQ0UNQDC(,;V>J^-]<O[5XR"04:"X1E()!4@@D5G4Z?/\
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M6Z1V]K:6MO''!;V\$<<,$*)'&BHJJ+C&^KVZ>9C5J<ONQ^+J^W;3JW^!\J_
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MJVJ:AJ;1Y!\MK^[FNF3( !V&4KD  XX K.IT^?Z'30O:7:Z^_6_Z&77]2?\
MP0:UFYN/@)\:= =V-II?Q=M=6MT))5)]<\':):714=MZ:!;%L<$@'KFOY;*_
MJK_X(2^&YK#]FGXH^)YHS&OB/XSWMA:E@09K7P]X-\*?OT/1H_MFKWEN"/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI#8Z?90+D[8;6T@A@B7)PD:C/%:,DB0QR2RNJ1Q(TDCL<*B(I9W8]E5023V
MK=*R2['!)N3;>[?]+Y'\8W_!6CXPS?%C]M/XAV$%V;C0?A1;:7\*]#C#GRX9
MO#T3WOBH&,'8+@>,]5\0VLD@!DD@M+1)&Q"B1_FG79?$7Q;=>/\ X@^.O'=\
M[R7OC7QCXG\6WCR$F1[KQ'K=]K%PSD\EVEO'+9[DUQM8-W;?<[HJT4NR2"BO
MMC]CG]A/XK?MK3?$!/AMX@\$>&X/AS'X:;6KSQO>:]9V]S+XJ;71IMMIQT+P
M_KTDTR)X>OY;KSX[=(D,&UW:4*/N'_AQ%^U#_P!%3^ G_@Y^(?\ \[JFHM[+
M^OZ_K1B<XIV<DFNA^(U%?MS_ ,.(OVH?^BI_ 3_P<_$/_P"=U1_PXB_:A_Z*
MG\!/_!S\0_\ YW5'++L_Z_X?\^S%[2'\R/Q&HK]N?^'$7[4/_14_@)_X.?B'
M_P#.ZH_X<1?M0_\ 14_@)_X.?B'_ /.ZHY9=G_7_  _Y]F'M(?S(_$:OZ1?^
M""?PREATGX^_&2[MV$-_J'A;X:Z%<E,#?IEO<^)_%4(D(^?(U7P>VU" A0E]
MQ9-OSG_PXB_:A_Z*G\!/_!S\0_\ YW5?T!?L4_LW+^RE^SIX'^#UU>:9JOB/
M3#JNL^,M;TC[2=.UCQ5KVHSWU_<V;WEM974MG96S6.BV$US96EQ+I^EVCSV\
M4S.M5&+O=K;\_P"OQ,ZM2+@U%W;MMVW?^1]6U_&U_P %=/CU_P +G_:\\3^'
MM,O?M/A3X*64?PQTA8Y-UO)KVGSRWOCF]\L%E6[7Q-<W6@3R*?WUMX<L6(4K
MM']5W[3OQHT_]GKX!?%3XQ7[0&3P3X2U"]T:WN"!#J'BF]V:3X2TN3)!\O4_
M$U_I5C*5#,D5P\@5MA!_@<U/4K_6=2U#6-5NY[_5-6OKO4M2O[ES+<WM_?7$
MEU>7=Q(>9)[FXEDFE<\O([,>33F]EWW_ *_K8FA'5R[:+U>_W:?>4:]N_9N^
M#6J?M!_'7X7_  <TKSDD\=>+-/TS4;NW4-+IGAVW+ZEXIUA%*LK'1O#=EJNJ
M!6&US:!#C=7B-?T&_P#!"?X"_P!I>*?BG^T?K%ENM/#5G'\,/!,\L>Z-M=UB
M.TUOQC>V[$#R[O2]%30-.21"P>U\3ZA$P7',15VE]_H;SERQ;ZVT]7L?TC:%
MHFE>&=$T?PYH5C!IFA^']*T_1-&TVV79;:?I6E6D-AIUC;H22L%I9V\,$2DG
M;'&HR<5JT45N<)RWCCQCH?P\\&>+/'OB>Z%EX<\%^&];\5:[=G;FWTG0--N=
M4U"10S*'D6UM9?*CW R2;47YF%?P"?%SXDZ[\8OBAX_^*?B5RVM^/_%FN>*;
MZ/S&ECM&U>_FNH--MV8 BSTNV>'3K&,!5BL[6")554"C^I3_ (+5_'K_ (5M
M^S-IOPFTF]\CQ)\=/$*:5=1QR;+B/P+X1DLM<\33*RGS$%YJLGAC194(6.ZT
M_4]3A+E4DC?^2>LIO6W;?^OZW.FA&R<N[LO1?\'\@K]:_P#@CI^SI'\9?VH(
MOB)KM@+OP;\!+&U\:3^=&'M;GQU?S3VG@&RDR.);.[MM4\5V[JPV7/A:W1PR
M3%6_)2O[,/\ @DI\!1\%/V0?".M:E9?9O%GQFN9/BEKC21[;A-(U>"&V\$V/
MF,%D-LOA2UT_64@=5%O?:]J04'>SNHJ[7EJ75ERP=MWHOGO^!^G%%%%;'&?
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M11VJX1:;;TTM^O\ 7_ ,:TU))1=]6W;RV_/\"[1116A@%%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!_)]_P78_Y.X^'7_9N7A'_U9GQ>K\6*_:?_ (+L
M?\G<?#K_ +-R\(_^K,^+U?BQ6,_B?R_)';3^"/H?HU_P25_Y2"_ #_NJO_JD
M_B17]IU?Q8_\$E?^4@OP _[JK_ZI/XD5_:=5PV?K^B,*_P :_P *_-A1115F
M(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7\3W_!R'_P GQ?"O_LU+P/\ ^K>^.=?VPU_$]_P<A_\
M)\7PK_[-2\#_ /JWOCG7T?"O_(VA_P!>*_\ Z2CQL^_Y%\O^OM+\V?E+^P?_
M ,GQ?L9_]G6_L[_^K>\'U_I=U_FB?L'_ /)\7[&?_9UO[.__ *M[P?7^EW7=
MQC_O.#_Z\5/_ $XCEX<_@8G_ *^P_P#2 HHHKXX^C"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "OP"_X+K?'K^Q? WPQ_9ST>]V7_ (TU
M%_B/XTABDVR+X9\.RSZ9X6LKE,_O+36?$<FIZBOR@I=^$(&#8)4_OX2 "20
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M=1)Y:ZEJ5M;+)K>LNF!MGUS6I=0UBY&U0;B^E(50<#UFBBM]C@;NVWN]6(2
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MUKE+_6I6MDN+W3M'TJY;]*Y)$B1Y972..-&DDDD8(D:("SN[L0JHJ@LS,0%
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MB_\ 9QOB[_U6?PAK]IZWCLO1?D<53XY>H4444R HHHH **** "BBB@ HHHH
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M+%?^F*A^EG_!O+_RF$_9"_[K]_ZR]\:Z_P!.RO\ ,3_X-Y?^4PG[(7_=?O\
MUE[XUU_IV5^Y\$_\BK$?]C"K_P"HV$/\YO'_ /Y+++/^R9P?_JUSD****^P/
MPT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _D^_X+L?\ )W'PZ_[-
MR\(_^K,^+U?BQ7[3_P#!=C_D[CX=?]FY>$?_ %9GQ>K\6*QG\3^7Y([:?P1]
M#]&O^"2O_*07X ?]U5_]4G\2*_M.K^+'_@DK_P I!?@!_P!U5_\ 5)_$BO[3
MJN&S]?T1A7^-?X5^;"BBBK,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "OXGO^#D/_ )/B^%?_ &:E
MX'_]6]\<Z_MAK^)[_@Y#_P"3XOA7_P!FI>!__5O?'.OH^%?^1M#_ *\5_P#T
ME'C9]_R+Y?\ 7VE^;/RE_8/_ .3XOV,_^SK?V=__ %;W@^O]+NO\T3]@_P#Y
M/B_8S_[.M_9W_P#5O>#Z_P!+NN[C'_><'_UXJ?\ IQ'+PY_ Q/\ U]A_Z0%%
M%%?''T84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\(_\
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M!7AY(]!\**L+8%O)<Z+I]IJ%[$@"G4KV]F.Z25W;^T?]JSPC\5?B!^SW\4_
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M%>%!_8>@7%LI)$*:S!:2>(;B)2RK?ZQ=L&.[)^2*_83_ (<A?ME_]!3X*_\
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MA?ME_P#04^"O_A<:_P#_ #%5CRR[/^O^'_/LSLYX?S1^]>7^?]69Z7_P0W^
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MQ5/CEZA1113("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K^+?\ X.^?^<>G_=V?_OL]?VD5_%O_ ,'?/_./3_N[/_WV
M>OG^*?\ D0X__N5_]3,.?IG@[_R<;AW_ +J__JBS,_D'^&W_ #&O^X=_[?UZ
MA7E_PV_YC7_<._\ ;^O4*_ <;_O-7_MS_P!-P/\ 3+A[_D3X/_N8_P#4JN%%
M%%<I[04444 %%%% !7UM^SK^W;^UM^R9H/B'PQ^SK\;/$GPMT'Q5J\&O>(=-
MT33_  U>0ZGJ]M9II\%],^N:'JLR2QV<:0!8)8HBJ@F,OEC\DT5K1KU\-457
M#UJM"K%-1J4:DZ51)JS2G!QDDUH[/5:,X\?EV7YKAIX+-,#@\RP=24)5,)C\
M+0QF&G*G)3IRG0Q$*E*4H32G!R@W&24HV:3/T^_X?/?\%/O^CO/'W_@C^'__
M ,Q]'_#Y[_@I]_T=YX^_\$?P_P#_ )CZ_,&BNS^V,W_Z&N9?^%V*_P#EODON
M/ _U#X'_ .B,X4_\1W*/_F,_3[_A\]_P4^_Z.\\??^"/X?\ _P Q]'_#Y[_@
MI]_T=YX^_P#!'\/_ /YCZ_,&BC^V,W_Z&N9?^%V*_P#EODON#_4/@?\ Z(SA
M3_Q'<H_^8S]/O^'SW_!3[_H[SQ]_X(_A_P#_ #'T?\/GO^"GW_1WGC[_ ,$?
MP_\ _F/K\Z?!G@CQI\1_$NE^#/A[X1\3>.O%^N3_ &71O"W@_0M4\2^(M6N<
M%O(T[1=&M;S4;V4*"Q2WMI&5 S$!02/U0\&?\$)?^"HWC328=:@_9KD\.6=S
M%YMM#XS^)/PK\,:M(-H8)-H.H^-$US3Y3G;Y>JZ=8N&R&"@$CLPN)XEQO-]3
MQ&>8KDTF\-6Q]90>C2DZ<I*/2UVNENAX><95X1\/^S_MW*_#O)G55Z4<TP'#
M>!G52=FZ4,31I2J)/1N"DE9WV.%_X?/?\%/O^CO/'W_@C^'_ /\ ,?1_P^>_
MX*??]'>>/O\ P1_#_P#^8^O./C[_ ,$O?V^OV9=)O?$7Q?\ V9/B%I'A;38Y
M+C4O%WAA-'^(_A32[./DWVM>(?AQJOBO2]!LR,8GURYTU59EB?9,1'7P165?
M'\082?LL5C<XPU2U_9U\3C:,[::\E2<96VZ=CLRSAKPQSK#K&9/P_P "9KA&
M^58G+<JX?QV'YK7Y?;8;#U:?-;5QYKKL>[_M"_M-_'?]JWQIIGQ$_:%^(^K_
M !/\::-X7LO!>F:_K5IH]G=6?A?3M6UO7++1XXM$TW2[1K>WU;Q'K5ZDDEN]
MP9-0E5YFC6)(_"***\JI5J5IRJUJDZM2;O.I4G*<YOO*<FY2?FVV?9X3"83
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_$]_P<A_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7^?]>I56:MR1MV=NEMDNGKVV[D]%%%:'.%%%% !1110 4444 %%%% !1110
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MII'Q!L(=-UFVOV$)FOUM+/\ M*/1%FF":0?$'B%[15;6+PR>/G7!66YFZ%?
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MX;/U_1&%?XU_A7YL****LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCA/"?AVK2A&%3,*^=8W%2BDG5K?VSCL'"<VE>4EA<)AJ5W=J-.,;V21^H_\
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M@_\ U:YR%%%%?8'X:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8^CF>74\QCBJ='+,5B*47B<WS#&4N6M3BX3O0Q%*3Y7[LFXO5,_D\_X)T_\
M)_\ ^Q'_ -G9?L]?^K7\*5_J35_/;\#_ /@W-_96^!/QF^$WQM\-_&S]H'5_
M$/PA^)'@GXF:'I6MWGPY?1M2U?P-XCT[Q+IUAJRV'@.ROFTZ[N]-B@O5L[RU
MN3;22""XAEVR+_0E7T_!F2X_)<+C:6/A3A.OB*=2FJ=6-5.,:?*VW!M)WZ,_
M(?'WQ X;\0,YR#&\-XC$XBAE^68C"XF6)PE;"2C6J8IU8J,:R3FG#5RCHGIN
M?PD_\'/G_)_'PC]_V0? .?\ P\_Q^K^<6OZ.O^#GS_D_CX1?]F@^ ?\ U<_Q
M_K^<6ORKBK_DHLV_["G_ .D0/[0\&_\ DU_!7_8EH_\ IVL%%%%?/GZ8%%%%
M !7+^,_^1:U+_MS_ /2^UKJ*Y?QG_P BUJ7_ &Y_^E]K6M#^/1_Z^T__ $N)
MQ9E_R+L?_P!@6*_],5#]+/\ @WE_Y3"?LA?]U^_]9>^-=?Z=E?YB?_!O+_RF
M$_9"_P"Z_?\ K+WQKK_3LK]SX)_Y%6(_[&%7_P!1L(?YS>/_ /R666?]DS@_
M_5KG(4445]@?AH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF^'EJ0ES>EF[_(]LHHHK U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /\Y>BBBN<] _K!_P""$_\
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M (?/?\%/O^CO/'W_ ((_A_\ _,?7Z1_Q$?*/^@+,O_ ,+_\ -/K_ $]/Y/\
M^)4N./\ H?\ "G_@_-__ )T'^EE17^:;_P /GO\ @I]_T=YX^_\ !'\/_P#Y
MCZ/^'SW_  4^_P"CO/'W_@C^'_\ \Q]'_$1\H_Z LR_\ PO_ ,T^O]/0_P")
M4N./^A_PI_X/S?\ ^=!_I945_FF_\/GO^"GW_1WGC[_P1_#_ /\ F/H_X?/?
M\%/O^CO/'W_@C^'_ /\ ,?1_Q$?*/^@+,O\ P#"__-/K_3T/^)4N./\ H?\
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M=*$KW]T****\P^N"BBB@ KE_&?\ R+6I?]N?_I?:UU%<OXS_ .1:U+_MS_\
M2^UK6A_'H_\ 7VG_ .EQ.+,O^1=C_P#L"Q7_ *8J'Z6?\&\O_*83]D+_ +K]
M_P"LO?&NO].RO\Q/_@WE_P"4PG[(7_=?O_67OC77^G97[GP3_P BK$?]C"K_
M .HV$/\ .;Q__P"2RRS_ +)G!_\ JUSD****^P/PT**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFA7T%X(_9+_:J^)OA?2_''PW_9F_:"^(/@O6_MO]C>+_  1\&?B-XL\+ZO\
MV;J-WI&H_P!EZ_H/AN_TF_\ L&K6%]I=[]DNY?LNHV5W93^7<VTT2<U;"Y?R
MKZQA\'R<RM[:C0Y>:SM;GC;FMS6MK:_2YO3KXOF?L:V)YK._LZE7FY;J]^5W
MM>U^E[>1]L?\/N_^"H'_ $<Y_P"87_9[_P#G3T?\/N_^"H'_ $<Y_P"87_9[
M_P#G3U\I?\,'_MQ?]&:?M6_^([_%[_YCZ/\ A@_]N+_HS3]JW_Q'?XO?_,?7
M-]5R3_H'RK_P3A/_ )$V]OFG_/['_P#@S$?YGU;_ ,/N_P#@J!_T<Y_YA?\
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M$/\ %[_Y^=?*7_#D3_@J!_T;'_YFC]GO_P">Q1_PY$_X*@?]&Q_^9H_9[_\
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ML!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDJ\YU6U_@I^RY>UN>7>_0]REPY22_?XFI)]J48P2?^*?M+^O+'T1_&_\-_\
M@VJ_:-U37+NW^+_[0_P3\#>&DTF>:QU;X;Z7X[^*NN7&N+>6*6VG7?A[Q/HW
MP;L+/29K"34[F?68?$]_>6]Y:6-C'H-U#J-QJ&E_5OPW_P"#9[X5:7KEW<?%
M_P#:I^(/CGPT^DSPV.D_#?X<>'/A5KEOKC7EB]MJ-WXA\3^(_C)87FDPV$>I
MVT^C0^&+"\N+R[L;Z/7K6'3KC3]4_ISHKR:G$F<5+KZTJ<6K<M.C1C;S4G3E
M43?6T_2R.^&2Y="W[AS:=[SJ5'\G%34&O6+\[GXG_#'_ (( ?\$[O /]N?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI.7?;T"BBBF2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT445L<84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9_\ OL]?VD5_%O\ \'?/_./3_N[/_P!]GKY_BG_D0X__ +E?_4S#GZ9X._\
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M *.0^ O_ (>#X>__ #14?\-4_LP?]'(? 7_P\'P]_P#FBK#ZAP__ - >3?\
MA/@O_D/)?<=_^L?B7_T/N.O_  Z9_P#_ "_R7W'R#_PYH_X)B_\ 1H/P[_\
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M_P"QA5_]1L(?YS>/_P#R666?]DS@_P#U:YR%%%%?8'X:%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ?R??\%V/^3N/AU_V;EX1_P#5F?%ZOQ8K]I_^
M"['_ "=Q\.O^S<O"/_JS/B]7XL5C/XG\OR1VT_@CZ'Z-?\$E?^4@OP _[JK_
M .J3^)%?VG5_%C_P25_Y2"_ #_NJO_JD_B17]IU7#9^OZ(PK_&O\*_-A1115
MF(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY<C0[1F7<&:?PE?#.TJJA65_QEHHYI=W]X.$']F/R5ORL?VN_LA_\%*?V?\
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M]7O(-/TG1]/O-5U2_N7$=M8Z=I]M)=WMY<2'A(+:VAEFE<\+&C-VK^:?6?\
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M_;_B>&*3Y'\<>.+>UO+>VNHU)5WT?PC!HUQ9R,0\3>)=2AVC)9OPTKT;XO\
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M#OVG=8TOX?\ BG3[CX-_%?57CM=)T#7M3@U/PMXJOY,JECX7\6K;Z<K:K<.
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M@VNEZ=96T80K;1Q7#1L#>3 _"E%%9MWW.A)1225DN@5^W7PY_P""V'CWX7>
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MN P( KZ(^'7_  6M_;'\)7-O_P )F_PZ^*NGAE%W'XB\(6_AS5)8@<N;._\
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MC);7?%#V^W[#9S2(D_\ PCOAN*232] @=85:+[7JTMM!J&L:@'<>9O=V6_\
ME^&OS[ZJI&G!:17,]M7IY[]-/5_,^S****T.<**** "BBB@ KXD_:;_X*#_L
MS?LJFYTGQ[XR;7_'D4/F1_#7P+%!XA\7J60/$-6C^U6ND>&5D5XY8_\ A)=5
MTJXN;=_/L+:]52*_+/\ X*1?\%7]1T75/$'P"_99UY;2]TZ6ZT;Q_P#&/2YE
MDN+6]C9[;4/#?P[NDW)!<6CA[;4O&4+/-#<B6#PTT$UO%KC?SC7EY=ZA=W5_
M?W5S?7U[<37=[>WD\MS=W=W<R--<7-U<S,\UQ<3RN\LTTKO)+([.[,S$F'.V
MVOGT_P"";PHW2<KI=NK]>W];'[M_%;_@N[\8=8N+JU^#?PB\#>!],+R1P:GX
MVO-6\<>('A&1'=1P:=/X5T73[E\!VMKBVUZ"')B$]Q@3'XUU_P#X*Q_M[:].
M\@^.!T2W+%H['0/ /PWL((<D$A+A_"5QJ<B\# N;^? R!C<^[\YJ*SYI=W^7
MY&RIP6T5\]?SN?>-I_P4Y_;NLI/-A_:*\4NVY6Q=Z'X)OX\H21^YOO"]Q%M)
M/S+LVN,*X8  >[> ?^"T7[:OA*Y@?Q1K'P_^*%FK*+BW\6>!M-T>>6'(WB&[
M\ /X.6"?9D132VUU$CX>6VG *-^3%%',^[^\;A!_9C]R/[ /V0O^"N/P1_:/
MUK2OA]X\TN;X*_$_5Y8;+1['6-4AU7P5XIU*8^7#I^A^*S;:<]CJUY(,6ND:
M_IVGK<336VFZ7JNLZC-' _ZT5_G,*S(RNC%64AE925964Y#*1@@@@$$$$$9%
M?V/_ /!)O]JK7?VD_P!G6;1?'6I3:O\ $?X-:G9>#=?U>ZE:?4/$'AV\L6NO
M!GB+4YW)DFU.XM+34]$O[F9I+G4;OP]+JUW-)=:C,1I&5]'O^9SU::BN:.W5
M=NUO+U?8_4BBBBK,2*>>"U@FN;F:*WMK:*2>XN)Y%BA@@A1I)9II7*I'%%&K
M/)([!412S$ $U_-;XQ_X+Q>-['Q;XHL?!OP3\$:OX1LO$.LVGA?5M4\0>(;?
M4M4\/6VHW$.C:EJ%M!"(;:\O]/2WNKFWB!C@FE>%68(&/Z??\%3_ (]?\*)_
M8^\?G3KW[)XL^*?E_"?POY<FRX0^*K:['B>^BV$31&Q\'6FOF"\BV_9=4GTS
M]XDDL6[^+"LYR::2?K^AO2@I)RDKZV7RU;_3[S][O^']GQ<_Z('\.?\ PIO$
MW_QJOTD_X)U?MZ_%?]MKQ!\1SXB^%GA/P1X)^'VCZ.)M;T75=:O[R_\ %'B"
M]F_LS2HDU%4MC;Q:5I>LWFH/&7GMY#I2L$2\!;^.VOT1^''[??BW]G?]F.R^
M G[.MH_@WQ;XKU;6_%GQ9^+US';R>(I]6U=H]-L-"\!P-Y\>C6>D^%]-T>SG
M\17GFZF=6DU2?0;/172'5[Y*33U;MV[[?\/_ ,.:2I1M:,5=Z7;>GGOY>>_J
M?U,?M+_MT?LW_LI6TD/Q/\;QW'BYK<7%C\./"<<7B#QW?))'YL#RZ1%<P6VA
MVURF7M=0\3ZAHFG705UMKN:5?+/X;?&+_@NQ\8-=N;JQ^"'PL\'> -()DBAU
MGQM->^-O%$J _NKR"ULYM \/:5,PYDLKJT\2Q(?E6[D^_7X7:IJFIZYJ-]K&
MM:C?ZOJ^IW4]]J6J:I>7&H:CJ%[<R-+<WE]?7<DUS=W5Q*S23W%Q+)-+(S/(
M[,230I.;>VGY_?\ \,$:,4M5S/SV^2_SN?H+K?\ P5/_ &\]=N)9I_C]JNGI
M)@+;:)X0^'NC00H&WJD7]G^$H)S@C!DEFEG=<I)*ZDBNS\ ?\%>_VY?!-_;W
M&J?$C1/B+IL4BM)H7CKP3X8EM+A0?G234_#&G^&/$B[QP"FN (0"J\L&_,>B
MES/N_O+Y(?RQ^Y']HW["G_!2#X;?ME6]SX4N]+'P[^,NCV#:AJ/@>ZU!;_3O
M$&G6^Q+O6_!FJO%;2ZA;6S.DFHZ/=V\6JZ2DJN#J=C%+J=?I%7^>[\(?B?XF
M^"WQ.\#?%7P==R6GB/P)XDTWQ#I[)(\270LYU-[I=V4YDT[6+!KK2=3MR"ES
MI][<V\BM'*RG_0+\/:W8^)M T/Q)IC,^F^(-'TS6]/=P SV.JV4%_:,P4LH9
MK>XC)"LPR3@D<UK&5T[[HYJL%!JVSOIVM;_,UZ***HR"OA/]J?\ X**?LV_L
MH&YT3Q=XDF\7_$:*+?%\,_ HM=7\26[R1[X&\17,ES;Z/X5@??#*4UJ^@U66
MTE%WIND:E&-I_-;_ (*2_P#!5R[\,7^O_ ']EO7HX]=LI+G1_B#\8-,E28Z-
M=(6@O_#/P^N4+Q?VM;.)+75O%L>_^RYUEM?#Y74XAJ]A_-K>7EWJ-W=7^H75
MS?7]]<37=[>WD\MS=WEW<R--<75U<SL\UQ<3S.\LTTKO)+([.[,S$F)3MHM7
M^1O"C=)RNEVZOU[?UL?M/\6O^"X_[27BNZNK?X3^#? /PGT5F<6EQ>6D_C[Q
M9&I)"--J>L?8?#3?+M<Q+X/RDF09Y4P#\C:E_P %0/V\=5N#<W/[1'B.%RS-
MLTWPYX#T>W&_&0+;2O"EG;A1M 4&,A>=N"S%O@BBL^:7=_>;J$%M%?==_>]3
M]0O /_!87]N3P7>P3:QX_P##?Q)T^)T9M'\<^!?#2V\J!LO&VH^#[+PEKQ+@
MD!WU:0H<%1M!4_N1^Q;_ ,%7OA%^U!JVF?#GQQI:_"#XOZD4MM)TB_U-=0\'
M^,[TC:MKX7\0S0V<MMK-RX+6_AO6;:&YF:2&STC4]>NS(J_QZU+;W$]K/#=6
MLTMM<VTL=Q;W%O(\,\$\+K)#-#-&RR12Q2*KQR(RNCJK*P8 TU-KS]?\R94H
M2Z6?=:?ALS^^+]JGXV6?[.W[/7Q6^,-T\ NO!_A.^F\/P7&TQ7WB[4S'HWA#
M3Y$;)>*]\2ZAI<%SM5VCM7GFV,L;"OX([^_O-4OKW4]1NI[W4-1N[F_O[VYD
M:6YN[R[F>XNKJXE<EY9[B>1Y99&)9Y'9F))-?I=^U!_P40\6?M*_LE? [X)^
M))[V7QSX8\2:G>_%K79 T:>,(O"VGVVG?#O5VE3*W-QJMKK6L7/B:"1E#>(]
M"M]56".*\M(X/S&HE*[TV7ZBI0<4[[M_@MOU"OZ&?^"$OP%^VZY\5OVD-8LM
MUOHEM%\+/!$\L>Y#JFHI9:_XTO8"P'EW%AIB^&M.AGCW%[?7-4MR4 =7_GIC
MCDFD2*)'EEE=8XXXU9Y))'8*B(B@L[NQ"JJ@LS$  DU_=]^Q3\"8_P!G#]F/
MX3?"N:U2VU_3/#<&L^-, >9)XV\3.VO>*$EE'S7"Z?J=_-H]G,^&_LW3;*,*
MB1JBN"N_3\PK2M"W63M\MW^B^9]3T445J<@4444 %%%% !1110 4444 %%%%
M !1110 4444 ?YR]%%%<YZ!_6#_P0G_Y-'^(O_9QOB[_ -5G\(:_:>OQ8_X(
M3_\ )H_Q%_[.-\7?^JS^$-?M/6\=EZ+\CBJ?'+U"BBBF0%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\6__  =\_P#.
M/3_N[/\ ]]GK^TBOXM_^#OG_ )QZ?]W9_P#OL]?/\4_\B''_ /<K_P"IF'/T
MSP=_Y.-P[_W5_P#U19F?R#_#;_F-?]P[_P!OZ]0KR_X;?\QK_N'?^W]>H5^
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M>69[BYD9F/4DGO43>B7??Y6-Z"O)OLM/G?\ 1/[S K[=_8%_9"N?VR?CG!X
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MX2MI PV[[:S7Q)X@MI V^"_T*Q<*=P9?ZY*T@M&^_P"7]?D85Y7:CV5WZO\
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M2KFVU_QG:2 63*HFT_PI*$\[?XBU"SM?W6IJ(D:+'&JHB*J(B*%1$4!5554
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M69B0%4 DD@ 9-?Z%?PM\/W7A/X9?#KPM? K>^&O GA'P_>*W+"ZT;P_I^G7
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MZ^CX5_Y&T/\ KQ7_ /24>-GW_(OE_P!?:7YL_*7]@_\ Y/B_8S_[.M_9W_\
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M+?.X5_6U_P $7_V<H?A;^SE<_&36].6+QG\=;_\ M2TGGB"W=C\.]!GN-/\
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M&9+?Q9XT"LP(65X_^$)2-X]KK$UU&QV3X/\ 1U6L%97[_D<U:5Y<O2/YO?\
MR^\****LQ"OYHO\ @O9\1(;SQI^S_P#"FVN$,WA_PUXN\?:O;JV6QXJU/3M
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MNMSZGJ:R&SDTZWL_T(K:,;+S?X>7]?H<M6?,[+X5MYOO_E_P0HHHJC(****
M"BBB@ KY[^.?[5?[/G[-U@MY\9?BAX<\(74\!N+'P^TT^K>+=3B^8)+IWA/1
M(-1\0W5L\B^2;]=.&G0RLHN;R!3N'YG?\%-?^"G,W[/]Q?\ P&^ E[97/QBE
MM(_^$R\9M';W]G\,K:^@2>VTW3K2=)K._P#&UY:31W;?;(YK#P]9RV\D]K>Z
ME=K%IG\L_B/Q+XB\8:YJ?B?Q9KNK^)O$>M74E]J^O:]J-WJVL:G>2X\RYO\
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M@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5*A6E"C7Q*IU8N&(I5J7+--0;E"Z;2339YS_ ,0LOP2_Z.Q^*?\ X;_PE_\
M+:C_ (A9?@E_T=C\4_\ PW_A+_Y;5_5+17ZW_J=PW_T*Z7_@[%?_ "_R_/NS
M^(?^(Z^+'_18XS_P@R?_ .=WE^?=G\K7_$++\$O^CL?BG_X;_P )?_+:C_B%
ME^"7_1V/Q3_\-_X2_P#EM7]4M%'^IW#?_0KI?^#L5_\ +_+\^[#_ (CKXL?]
M%CC/_"#)_P#YW>7Y]V?RM?\ $++\$O\ H['XI_\ AO\ PE_\MJ_IX\ ^$X/
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M\3W_  <A_P#)\7PK_P"S4O __JWOCG7T?"O_ "-H?]>*_P#Z2CQL^_Y%\O\
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M?LI=2U[Q-K.E^']$T^$9FO\ 5]9OH-.TVSB'>2ZO+F&! >-SBL6OUJ_X(V_
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M8%O+-H>G6=[>Q(JJVI7=[,VZ29W;YFHHK#<[TK))=%;[C]%?^"6GP%_X7O\
MM@_#Z/4;+[7X3^%[2?%CQ5YD>^W>/PG<VC>&K&4./)F6_P#&-WX?BN+.0G[3
MID>IGRY(X90/[4Z_%?\ X(C_  %_X0#]G?Q%\:-7LO)U_P"-OB)AI,LL>V:/
MP)X)GOM'TK9Y@$D/]I>(YO$]Y)L"Q7MC%HUS^\1(7'[45M!67KJ<E65YOM'3
M_/\ '3Y'R3^W'^T2/V7?V9_B-\5+.2 >*H;"+PUX!MYUCD6X\<>)7.G:),8)
M08KJ'10]UXEOK1]HNM.T2\@#!G6OX6]3U/4=:U+4-8U>^NM3U;5KZ[U/4]2O
MIY+J]U#4;^>2ZO;Z\N9F>6XNKNYEEGN)Y7:26:1Y'9F8D_TB?\%\/'5U;>&/
MV=?AG;S.++6==\=>.=5@#$(;GPWI^A:!H,K)]UV$7BGQ&JL>8QN SYIQ_-;4
M3>MNQM15H7ZR;_!V7Z_>%?O1_P $[O\ @DQHWQE\&:!\=_VD9M8M_!'B2--3
M\"_#32+J;1[[Q1H;,1;>(O%6LVY34]-T+5D#3:-INBRV.IZC8M;:P=8M+*>W
MM[S\%Z_T.?AZ_AF3P#X'?P5):R^#7\(>&F\)2V10V<GADZ-9'0GM/+)C^S-I
M?V4P;"4\HKM.,402;=^G]?H*M)Q22TO?7T\^ESD_A=\!/@K\%-/CTWX3_"WP
M/X!A2(0R7'ASP]IUEJMX@&W=JFMB%M9U:8K\K7.J7]W<.H"O*P  ];HKYT_:
M7_:D^$?[*?P^O/'OQ3U^"T=H;E/#/A.SF@E\5>--5A12FE>'=+>1);@^9)"M
M]J4HBTO2(9DN=3N[:)D+ZZ+R1S:R?5M_-L_,#_@MY^T?#X*^#GAG]G70=05?
M$WQ<O[?Q#XM@AE GLOAWX7OTN;6*X52LD(\2^+;6R2TD!:.XM/#.NVDJ%)1G
M^6&O<?VCOC[XT_::^,7C#XQ>.I$35?$UZHL-(MY9)=.\->'K%/LVA^&]+\P*
M?L>E6*1Q-,8XY-0O6O-4NE-[?7+OX=6$G=M_<=D(\D4NN[]7O_E\@K^YO_@G
M]\!!^SE^RC\*_ 5Y9?8_%.I:0OCCQVKQ^7<_\)AXQ2+5M0L[P  -<:!9R:=X
M6W@?-!H4!RQR[?R;?\$]O@@OQ_\ VN?A!X)OK07GAK3->7QUXQCD026K>&?!
M"?\ "075E>K@G[+KM]::=X:<@9WZU'\R#,B?W+5<%N_E_7X&5>6T5ZO]/U_
M*I:EJ-CI&G7^K:I=0V.FZ7976HZC?7+B.WL[&R@DN;NZN)&XCAM[>*2:5SPD
M:,QX%7:_-;_@K'\;6^#7[&GCVUT^[-KXC^+5S9?"71"CXE%KXFBN[GQ;)L4B
M3RF\%Z9X@L?.4JL%WJ%EN;<Z1R6W9-]C"*YFDNKL?R<?M/?&>_\ VA?C]\5?
MC%?-/Y7C7Q;J%[HMO<D^=8>%K'9I/A'2Y 20)-,\,V&E6,I4*KRP22!5WE1X
M/116!WI65ELM$?IY_P $D/@,/C1^U_X4US4[+[3X4^#%G+\4M9:2/-N^LZ3<
M06G@BS,A!1;H>*KNPUR*%E8SVF@:@H "LZ_V65^+7_!#WX3:;X3_ &9/%'Q4
M*PRZ]\6_'E_%)<(!YD'AKP$)="T?3I206$D>MW7BJ_;!"O#J%J-FZ/<W[2UM
M%62\]3CJRO-]EI_G^(5^1W_!:[7KC2/V*9M/A<K'XI^*_@+0;M0<"2WMX=>\
M3JC#(R!=^'+:3'/S(IQQD?KC7Y2_\%F_"=UXD_8@\2:I;1-*O@;X@> /%ET$
M4LR6LVI7'@YY<#)VQR>+8FD;&$CW.V%4D$OA?]>OX$P^.-_YE^>GXG\>-%%%
M8G<?U\_\$4[.QM?V*+:>T"?:-1^*OCV\U/;C<;Z--#T^,R8.=_\ 9MAIX&<'
MRQ'QC!/ZWU_-)_P1#_:J\->%+WQA^RYXUU:VTB7QGX@'C?X775_,D-KJ7B:?
M3;+2/$OA-9Y6"QZCJ5CI&C:EH%IE8[V>SUJWC)U&ZLK>\_I;K:+NEZ6^XXZJ
M:G*_75>C_JWJ%%%? /[;_P#P4"^%7['?A6\LI+S3_&/QHU.P9O"7PRL[Q7N8
M9)X_]%U[QF]LYE\/^&H2RS*)C#J>O;&M-%B=%O=1TVF[:LA)R=DKO^OZN?._
M_!77]LZS^!?P?NO@=X*U9!\6OC)I%UI]]]CN,7G@[X;WGFV6N:U.8R9+6_\
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M&;364\,V0FC\RUU'_A)Y(9'M]10U\=53=TET27WV_0B$>5R;WE)OY7T_X/\
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MRO'Y=P-=\9V]K=V5C=(1OCNM#\,0^']!NHF9@MWIEPZ[?,*C[TI  H"J JJ
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MO[07B1%07^J^/_"6B7+@#>UGH'AV^O[)6.,[%F\2WY09P&=\#DY_?6OY=?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQQ^&/$M]-IU]<M!!H/B6_P!1U"#0;;^ASKTK_(/K]\O^";'_  7>^.?['_\
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MQ&#P]:JU',JZBG4J4Y3:BDDDWHDDM$=Y\0_BI\3_ (O:U:^)?BQ\1_'GQ/\
M$5CI<&AV6O\ Q#\8>(?&NM6>BVUW>W]MH]KJOB74=3OK?2[>^U/4KV#3XITM
M(KO4+VYCA6:[G>3@Z**^*E*4Y.4Y2E)N[E)N4F^[;NV_4_H&E1I8>G"C0I4Z
M-&FN6G2I0C3IPC_+"$%&,5Y1204444C0**** "N7\9_\BUJ7_;G_ .E]K745
MR_C/_D6M2_[<_P#TOM:UH?QZ/_7VG_Z7$XLR_P"1=C_^P+%?^F*A^EG_  ;R
M_P#*83]D+_NOW_K+WQKK_3LK_,3_ .#>7_E,)^R%_P!U^_\ 67OC77^G97[G
MP3_R*L1_V,*O_J-A#_.;Q_\ ^2RRS_LF<'_ZM<Y"BBBOL#\-"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /Y/O^"['_)W'PZ_[-R\(_P#JS/B]7XL5
M^T__  78_P"3N/AU_P!FY>$?_5F?%ZOQ8K&?Q/Y?DCMI_!'T/T:_X)*_\I!?
M@!_W57_U2?Q(K^TZOXL?^"2O_*07X ?]U5_]4G\2*_M.JX;/U_1&%?XU_A7Y
ML****LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *_B>_X.0_^3XOA7_V:EX'_ /5O?'.O[8:_B>_X
M.0_^3XOA7_V:EX'_ /5O?'.OH^%?^1M#_KQ7_P#24>-GW_(OE_U]I?FS\I?V
M#_\ D^+]C/\ [.M_9W_]6]X/K_2[K_-$_8/_ .3XOV,_^SK?V=__ %;W@^O]
M+NN[C'_><'_UXJ?^G$<O#G\#$_\ 7V'_ *0%%%%?''T84444 %%%% !1110
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MB"WMV\3:YM*2R6-@L>^'PYX<%PBRP:#ICE7\JVEU>]UF_MDOS]FUI&-M7O\
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MRL#D,I&""" 00<@\BOJS]IG]B[X__LHZ]<Z=\3_!EXWAHW;6^B_$;0(+K5/
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M*X>YU#P/>6SN#B6PN/AEX+:Q:-CD.D=N$@RI(1X7B.&C91^>M?TQ_P#!9_\
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M?$\OE:!X"\*Z[XLU4AU226TT/3KB_>TM]V0]Y>M MG91 ,\]W/##&CO(JG^
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M6"KM:GPM:WVA2RJP\B\\0Z>QW;@K:MV3?8Y(KF:2ZNQ_*?\ M0_&F^_:&_:
M^*OQBO6G\GQIXMO[O0[>XW>=8>%+ 1Z1X1TR0$D"73O#.GZ59S;0JO/#+($3
M>5'@E%%8'>E966RT1^G'_!)3X"_\+K_:_P#".LZG9?:?"?P9M9?BGK;21[K>
M35M'N(+7P39>8P,8N3XLN].UE('5C<6.A:DH ",Z?V85^/7_  1;^ O_  K'
M]F"[^*6JV7V?Q-\=M??7HWDC\NXC\#^&'O-#\)6TBL-VRZO7\2>(+>0,$N+#
M7+!P@VAF_86MH*R]=3CJRYIOLM/NW_$***\F^._Q8T?X%_!OXE?%[7?+:P\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '\GW_!=C_D[CX=?]FY>$?\
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M\2^ /$.ID*H*HTVI2L,[G,A&#WG@#_@C;^Q'X)NH+S5?#'CCXE36Y#QIX_\
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MCQ;\0-1MH'(.0)%\%6W@YV7.,KY@5@,,"I8'[T^%7[.GP)^!T'D_"7X2^!/
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M_P"SK 731!6G%G;B0L(D ]8HH$FUJG9]T?)__#"7[&G_ $;'\%?_  @= _\
MD2C_ (82_8T_Z-C^"O\ X0.@?_(E?6%%*R[+^O\ AE]Q7-+^:7WO^NB^XR=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?Q;_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?Q;_P#!WS_SCT_[NS_]]GK^TBOXM_\ @[Y_YQZ?
M]W9_^^SU\_Q3_P B''_]RO\ ZF8<_3/!W_DXW#O_ '5__5%F9_(/\-O^8U_W
M#O\ V_KU"O+_ (;?\QK_ +AW_M_7J%?@.-_WFK_VY_Z;@?Z9</?\B?!_]S'_
M *E5PHHHKE/:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFN^HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\6__  =\_P#./3_N[/\ ]]GKY_BG_D0X_P#[E?\ U,PY^F>#O_)QN'?^ZO\
M^J+,S^0?X;?\QK_N'?\ M_7J%>7_  V_YC7_ '#O_;^O4*_ <;_O-7_MS_TW
M _TRX>_Y$^#_ .YC_P!2JX4445RGM!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5R_C/_D6M2_[<_P#TOM:ZBN7\9_\ (M:E_P!N
M?_I?:UK0_CT?^OM/_P!+B<69?\B['_\ 8%BO_3%0_2S_ (-Y?^4PG[(7_=?O
M_67OC77^G97^8G_P;R_\IA/V0O\ NOW_ *R]\:Z_T[*_<^"?^15B/^QA5_\
M4;"'^<WC_P#\EEEG_9,X/_U:YR%%%%?8'X:%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#_ #EZ***YST#^L'_@A/\ \FC_ !%_[.-\7?\ JL_A#7[3U^+'_!"?
M_DT?XB_]G&^+O_59_"&OVGK>.R]%^1Q5/CEZA1113("BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^+?_@[Y_P"<>G_=
MV?\ [[/7]I%?Q;_\'?/_ #CT_P"[L_\ WV>OG^*?^1#C_P#N5_\ 4S#GZ9X.
M_P#)QN'?^ZO_ .J+,S^0?X;?\QK_ +AW_M_7J%>7_#;_ )C7_<._]OZ]0K\!
MQO\ O-7_ +<_]-P/],N'O^1/@_\ N8_]2JX4445RGM!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5R_C/_D6M2_[<_\ TOM:ZBN7
M\9_\BUJ7_;G_ .E]K6M#^/1_Z^T__2XG%F7_ "+L?_V!8K_TQ4/TL_X-Y?\
ME,)^R%_W7[_UE[XUU_IV5_F)_P#!O+_RF$_9"_[K]_ZR]\:Z_P!.ROW/@G_D
M58C_ +&%7_U&PA_G-X__ /)999_V3.#_ /5KG(4445]@?AH4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXKUN<:S\1=C:EK^I7.IW:PJWP[8QV\<URT5M"#MAMTCA0!$4#C_^'$7[4/\
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M^#L#X!_\)K^R+^S_ /M#Z;IOC75=:^ _QIU'P7JO]AV?V[P=X>^'7QR\-?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNLYQ#I45ZS*&DCWQ@O7\*%'3I2YWV7X_YENA&VCE?N[/\++]#_1HH) !)(
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MN(+2":ZNIX;:VMXGFN+BXD2&""&)2\DLTLC+'%%&@+/([*J*"S$ $U\D^/\
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MKX:\2:%>PZCHVO:'?W.F:MI=];MNANK&_LY(KFVF0Y >*125+(V59@?[/_\
M@FM^U_??M=_ -=8\7/;#XI_#S4XO"'Q":VBBMHM9F-FEWH7B^&SMU6"SC\1V
M'G)>6\*0VZ:[I>MBRMK73_L<*5&5]+6?Y_U\S*I2<%=.\?Q7^9^AM%%%69!1
M6?JVK:5H&EZCKFN:E8:-HVD65SJ6JZMJEW!8:;INGV4+W%Y?7]]=216UI9VL
M$<DUQ<W$L<,,2-)(ZJI(_G=_;)_X+5W%M>ZM\/\ ]D.TM'CMGGL;[XT^(]-6
M[2>524:7P!X7U&/[,\$;C]UKWBNTN8;L>:MOX:$(M=4G3:6Y482F[)>K>R]?
MZN?T(^)_%WA3P3I,VO>,_$_A[PCH=M_Q\:SXGUK3= TFW^5F_?:CJMS:6<7R
MJS?O)E^56/0$U\9^+_\ @II^PMX)GEMM5_:(\):E/$Q3;X0TWQ5X[@D<9XBO
M_!>@:[ISJ<<2_;! >/WN"#7\8?Q&^*WQ+^+VOS>*/BAX[\5>/=>F:0C4O%.M
MW^L2VZ2MO:WL([N:2#3;)2 (K#3XK:R@14C@@CC1%' 5FZCZ)?/7_(W5!=9-
M^EE^=S^R.3_@L9^PDDZQ+\0_%DL;%0;F/X;>,Q FXX)99=*BN2$'S-LMW)!^
M0,V5'>>%O^"J7[!WBR>.TM?CSIVCW<C*HB\4^$O'OAF!-Y 4R:KK'A>UT5%R
M2&)U+Y I:3:F&/\ %!11SOLOQ_S'["'>7WK_ "/]#CP3\0_ /Q*T=/$/P[\;
M>$_'>A.P1=8\'^(M(\2:9YA!/E->Z/=WENDP .Z%Y%E0JRL@*D#L*_SV?AE\
M6/B5\&?%-EXU^%?C;Q#X%\3V+QM%JGA[4)K)YXDD60V6I6P+66KZ9,R@76E:
MK;7FFWD>8KJUFB9D/]=O_!-S_@H!9_MC>#=2\+^-8-.T3XY> K"VN?$]AIZ_
M9M,\7: \L5E#XUT*S9W>TVWDD-CXDTN-I+?3-1N[&>U>.RU>TLK*HSOIL_P_
MK^KF4Z3@KIW772UNQ^G-%%%69!7+Z]XW\%^%9H+;Q1XO\+^&[BZB:>U@U[7]
M)T>:YA1_+::"+4;NW>:)7^1I(U9%?Y20>*ZBOXG?^"GOQZ_X7Y^V!\1]1T^]
M^U^$_AU,GPJ\(%)/,MVL/!UQ=P:W>V[J?*FAU7Q=<^(M1M;F,8FT^XL1OD6)
M',RERK^OF73ASNU[)*[=OP/['/\ A</PC_Z*E\.?_"W\,_\ RSH_X7#\(_\
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MQ;2?$WQ):PG;F_G^&GCUK1=V,Y2UT&YOODR2VVR.=K;-QV[OL?X.?M._L_\
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M/[;/_0^_LL_^%3\6O_G5T?ZH\0_]"VM]\?\ Y+^K/RN?\1R\+_\ HJL%_P"
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M76B_ .R\6+JNF:UIG]IZ+J<WBSXAZSX(M=6USPUX.LM/T*74OA_XA^)_P_\
M&EI]A_\ !*__ (-P/C!\=?$7P\^._P"W!::?\-?V;6\OQ,OP=L/%?F?&;XLV
MZ6/A_5=!T/7_ /A%9+FW^$?@K5[C4]4T?Q]#J?B;2/CKX?O_  EX@\#'P-X!
MUG6M-^(GAG^Z;X+_  7^%G[._P +/!'P3^"?@C1?AU\+?AUHL6@>#_!^@13+
M8Z98K--=W4\]S=S76IZQK6L:G=7VN>)/$FN7VI>(O%/B+4M5\2>)-5U77M5U
M'4;G[/ASA.I*5+$XZC['"4Y<\<-5BU6Q,E9Q=6$DN6BWK+G]Z:CR*"IR4E^!
M^*?C1AZ=+&97P]CUF&=8JG[&KFV$J0E@LKI2<XU(82M3DU5QL8KEI>P7LL/*
MK[=UY8FG*D_3Z***_3S^0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH _D^_X+L?\G<?#K_LW+PC_ .K,^+U?BQ7[3_\ !=C_ ).X^'7_ &;E
MX1_]69\7J_%BL9_$_E^2.VG\$?0_1K_@DK_RD%^ '_=5?_5)_$BO[3J_BQ_X
M)*_\I!?@!_W57_U2?Q(K^TZKAL_7]$85_C7^%?FPHHHJS$**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K^)[_@Y#_Y/B^%?_9J7@?\ ]6]\<Z_MAK^)[_@Y#_Y/B^%?_9J7@?\ ]6]\
M<Z^CX5_Y&T/^O%?_ -)1XV??\B^7_7VE^;/RE_8/_P"3XOV,_P#LZW]G?_U;
MW@^O]+NO\T3]@_\ Y/B_8S_[.M_9W_\ 5O>#Z_TNZ[N,?]YP?_7BI_Z<1R\.
M?P,3_P!?8?\ I 4445\<?1A1110 4444 %%%% !1110 4444 <SXS\8>'/A]
MX1\2^.O%^J0:+X6\(:'J?B/Q!JMR6\FPTG2+26^OKAE0-)*Z00OY4$*//<2E
M(((Y)I$1OXA?VV/VQ?'7[8OQ9O\ Q?K<][I7@+1+B\T_X9^!&GS9>&/#[2A5
MNKJ&)C;W/B?6TAAO/$.J?O));CRM/MI5TG3=-MK?]_/^"X'Q?O\ P1^S1X2^
M&&E74EK=?&3QS';:QY;E#=>$? ]O#KVIV?RX;$OB.Z\(/(=VU[>*>WD1TG./
MY.ZRF];=M_/^OZV.FC%6YGN[I>2Z_>_R]0K[#_9:_86_:%_:[N;R;X6^&[*R
M\):7="QU?XA>,+R?0_!=A?%4D;3XKZ&SU#4=9U***2.:YL- TO5;BQBFMI=1
M2SBN[62;X\K^\O\ 8NM_AQ:_LI_ 2'X3R:;-X*7X9>%FLYM-:$B;5I--AD\4
M3:EY/W?$$GB9]7?Q'',$N8M=;4(KF..='15%7>OJ74FX)66K[[+^O7[S\0-'
M_P""!?C6>U1]?_:4\+Z9?%%,EOH_PVU;7+57(^94O+WQ=X>FD0'A7:PC+#DQ
MITKQ_P"*O_!#G]I3PAIEUJOPU\;?#_XM"TB>0Z%')?>"/$]Z54L(].MM;^U^
M')7(!&V\\5:>Q8JL:REB%_J\HK3DCV_%F'MI]T_)I?I9_B?YW/BWPAXI\!>)
M-8\'>-?#^K^%?%7A^\?3]:\/Z]87&F:MIEY&%<PW=G=1QS1%XWCFA<KY<\$D
M5Q"\D,L<C<[7]>?_  4Q_P""=/B']L+5?AKXT^$D_@?PW\1M#>_\.^,-:\6W
MNIZ38ZSX-EA^V:.]U/HNA:_>WM_X?U..Z@T^,609[37+I)KCR;2V2+XJ\$_\
M$#M=E\F;XC?M&:38;=IN--\$^ ;S5_,R/F6'6]=\0Z)Y.T_==_#\^\<F-.E9
MN#OIKY_TS958-)MV?5:O\D?A7\'/BCXC^"GQ4\ _%CPG<26^O> O%&E>(K,1
MRM$M[%97"G4-)N63!:PUK37N](U*$Y6XT^^N8'!21@?] ?0-;T_Q-H.B>)-)
ME\_2O$&D:;K>F3D &;3]5LX;^SE(5F4>9;7$;X#,.>&(YK\BO!/_  1"_9"\
M.>3-XIUGXM?$*X789X-7\5:9H6DR,OWA#:^%= T?5((W_B5]<N)!_!*M?KAX
M7\-Z/X-\->'?"'AVU>Q\/^%="TGPWH5E)=7=Z]GH^AV%OIFF6KWM_/<WUV]O
M96L$375[<W%W<%#+<3RS.\C7%-7O^?\ 7](QJSC.UKZ7O=?\'].IN5\ _P#!
M37X]?\*!_9 ^)6KZ?>_8_%GCZV3X6>#623R[A=5\9V]W;:K>VTBGS(KG1_"=
MOXBUBTG128[ZQM%W(9%=?OZOY5O^"X7QZ_X37X[>#_@7I%[YNB_!SP\-5\0P
MQ2?NW\=>.8+347@N%0E)FTGPG!X?:UD8^9;3:WJUOLC+2&1R=DR:<>::71:O
MT7^;LOF?B!1174^!O!NN_$3QIX2\ ^&+4WOB/QKXDT3PKH5H-V)]6U_4K;2[
M"-RJL4B-S=1^;)M(CB#R-\JFL3M/Z>O^"'7P%_X0WX'>,_COJ]EY>L_%_P 0
M'1/#<TL?SIX&\#3W5BUQ;.P#1KJ_BV?78;N-04GC\/Z7-O;"A/W%KSSX2_#?
M0O@]\,/ /PL\-(%T/P!X3T/PK82>6L<EVFCV$%I+J-RJD@WFIW$<VHWTA9FE
MO+J>5V9G+'M-5U33M#TS4M:UB^M=,TC1["\U35=2O9DM[+3].T^WDN[Z^N[B
M0K'!:VEM#+/<32,J111N[D*I-;I6278X92YI.7=_ALOP/F?]K[]J[P'^R#\(
M=3^)7C KJ>L7+OI/@3P9!<I;ZEXR\420M);Z? Y65K/2[)!]NU_5VAEBTS3H
MV,<5UJ-SINGWW\47QX^/7Q,_:0^(^M?%#XJZ_-K?B+5I#';6Z>9#HWAW2(Y)
M'L?#OAS33))'I>B:<LC+;VR,\T\SSW^H7%[J=Y>WMQ[I^WM^UMK7[7OQXUSQ
MFEQ>0?#GPU)=>&OA5H$YDBCT_P *V]P<ZS<6C86'7/%D\2ZUK#,K7$"O8:,T
M\]KHMDR_$]92E=^2V_S.JG!05W\36ODNW^?F%=[\-?A;\1/C%XLL/ WPN\&Z
M_P".?%FI9:VT7P_82WMPL",B37MY(H6VTW3;8R(;S5-1GM=.LD827=U#'\U=
M7^S[\!_'O[2GQ7\+?"+X<V*W.O>)+HFYO[A9!I7AS0[7;)K'B77)XT=K;2=(
MM29IBJM/=3M;:;8Q7&HWMG:S_P!L?[*O[)GPH_9'^'5IX&^'&E12ZI<PVTWC
M+QS?6T(\3^-]9BC(DO\ 5;I=[P6$,CS#1]"MY?[-T:VD=($ENY[Z^O",;^G5
MA4J*"[M[+]7Y?F?SK>"_^"&W[56OZ1%J7BOQC\(O 5Y/#YBZ!?:WKVOZM:RE
M-P@U&;P]X>O-"B(<A&DT[6M50 ,R[P%#_(?[4G_!._\ :4_9+L!XD\?^']*\
M1^ 6N8K0_$+P#?W6N^&;*YN9!%:V^MI>:?I6N>'Y+F1XH(+C5]'M-,NKR:.R
ML=0N[IA&?[@JP_$_AGP_XS\.ZWX2\5Z18Z_X:\2:7>Z+KNB:G MSI^J:5J-N
M]K>V5W _$D,\$CHV,,N0R,KJK"^1>9BJTKZI-=K?E_P3_.SKZ^^/7[7GC?X\
M?!']F[X-^(Y;N2U^!'AS7-*O=2GGWMXGO[C43I_AF[N$WNTK>&O VG:-H5O<
MW#"XENIM9G<$7(>3C?VM_@A_PSC^T=\6?@U%+/<:;X.\3N/#US='?=7'A37+
M&S\1^%)+J0 +->?\([J^FI?2H%1[U+@JJ#Y%^<ZRU5U\G]__  #IT=G\T_5?
MY,*^D_V0?@=<?M&_M(_";X1K#+)I7B3Q3:W'BJ2+>IMO!>A))KOBZ?SDP()6
MT#3K^VLI'9%;4;BS@#>9,BM\V5_1O_P0C^ V$^+'[26L67+F+X3^!YIH^=J_
M8/$?CB^@$@Y#,?"FFVUY".J:W9^9_KXPXJ[2^_T%.7+%ORLO5Z+_ #/Z*[:W
MM[.W@M+2"*VM;6&*WMK:"-(8+>W@18H8(8HPJ1111JL<<:*J(BJJ@* *FHJE
MJ6I6&C:=J&KZI=P6&F:5976I:C?7+B.VLK"Q@DNKR[N)#Q'!;V\4DTKGA8T9
MCP*W.$_F[_X+M?'K[=KWPJ_9OT>]W6^AVTOQ3\;P12;D.K:DEYH/@NRG"D>7
M<Z?I:^)-1F@D#;[?7M+N %PA?^>BO>?VG_C1?_M#?'_XJ_&*^:<1>-?%M_>:
M+;W!/G6'A:Q\O2?"6F2 D@2:;X9L-*LI2H57F@DD"J7('@U8-W;9W0CRQ2ZV
MU]7N%:VL:]K7B&XMKO7=5U#5[FSTS3-%LYM1NY[M[/1]%LH=-T?2;0S.XM=-
MTK3K:WL=.L8!':V5I#%;V\4<2*HCT;1M6\1:OI>@:#IM]K.N:WJ%GI6CZ1IE
MK->ZCJ>IZA<1VMC86%G;I)/=7EW<RQ06]O"CRS2R)&BLS 5_5S^P!_P2D\$?
M W3-#^*?[0.CZ3XZ^-5Q';ZGI_AF_2WU;P?\,9&59K>W@M6$UAXB\86C%7O-
M=N%N=-TF^18O#<9DLE\0:B)-O\WV"<U!7?79=6?AK^S[_P $R?VN/VBM/LO$
M/A_P);^!O!FHI'-8^,OBC>S^$]*O[>4!HKK3-+2QU+Q9JME-&?,M]2T[P[<Z
M7<+CR[X[AGZ=\>?\$//VJ/"_ANZUSPMXM^%7Q#U*QM'N9?"NCZKKVC:W?O&C
M,UKHDWB#0;#1;R=L 1KJ6JZ,)"=JDN51OZRJ*TY%Y_U_7XG.ZT[Z))=K'^=-
MJFEZEH>IZCHNLV%YI6L:1?7>EZKI>HVTMGJ&FZE87$EI?6%]:3I'/:WEG=12
MV]S;S(DL$T;QR(KJ0*%?;/\ P4=OO#VH_MP_M(7'A@6XTU/B!+97'V4*(CX@
MTS1]*TWQ:S;.#</XJM-9:[;[S71F9R7+&OB:LGN^ITIW2>UTG;U.@\)ZQJ/A
M[Q5X:U_2))(M6T/Q!HVL:9+$2LL>HZ9J-M>V4D;*0RR)<P1,A4@A@""#S7^B
M17\$_P"R!\+KKXS_ +3_ ,#?AQ;P-/!K_P 1?#TVL(JEV3PSH-V/$?BN<*."
M;;PWI.JSJ&(0M& S*I)'][%:0V;_ *_K4YZ]KQ76S^YVM^3"O@K_ (*!_MK:
M'^QK\(CJ]DMCK'Q8\;?;M'^&/AB[8O U[!%'_:/BK6H4996\/>&%N;6:YA1H
MY-4U&YTW2(Y;:.\N;^Q^]:_&K]M+_@E5XR_:\^,.J?%R^_:630T;3=,T'POX
M(O\ X8S:EI?A30-,@)73K+68/']I+,UYJDVH:S?SMHT;7%_J=RRK%!%;P);O
M;3?^NYE#EYES.R6NS=_+1/Y^1_*OXY\<^+OB7XNU_P >>//$&H^*/%_BC49]
M5UW7=5G,][?WLY&68@+'#!#&L=O9V=M'#9V-G#!964$%I!#"G*5^ZNN?\$&O
MCY;[_P#A&OC3\(-6P&\O^W+?QGX>W$?<#_8-!\3^6&XW%?,*=@_=/@[_ ,$1
M/CI;?%_P2GQMU;X=77PAM-82_P#&USX(\6:Q>:KJ.E6$,MXNB6%OJ/AS0;V+
M^W;N&VTBYOD,,VG65Y<W\!:XMX8WRY97V^?]>OY]F=?M(6^):+;_ "7Z'YY_
MLV_L$_M-?M4V_P#;/PP\"B#P:MQ):2_$#Q??)X:\'?:87,<\-C>W$<^H:]);
M2!HKQ/#>EZRUC*/+O1;N55OT!C_X(._M&'3S)+\7_@HFJ["5LXYO'4NGE]H(
M4ZFWA"*Y5"^5+C26(4!_+))0?U$:!H&B>%=$TGPUX:TG3]!\/Z#I]II.BZ+I
M-I#8Z9I>F6,*6]G8V-G;I'!;6MM!&D4,,2*B(H %:]7R+S?]?U]Y@ZTV]+)=
MM_Q/X0_VG_V,/CU^R+J^F6'Q=\-VD>CZ])/#X=\:>&K\ZWX/UV>U4/<6MIJ1
MM[.[LK^*,^=_9FMZ=I.IR6ZM=0V<EJK3#Y3K^PS_ (+.ZCX8LOV'_$=KKT=M
M)JVK_$'X>V/@HS!#-!XDAU>35+R>SW LL_\ PA^G>*K=WCPWV6XN$)V.P/\
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MNPB7QS\2[FT4WMQ+($EGT#POYZ&?1/"=K.JK':Q>5=ZS)#%J.M-+,EG;:?\
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MFL/"&C:_I4+E#ND@N->@NH&(BGMXY1*D?[(_\$S_ /@GPG[)'A?6O&GQ0L-
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MVU/_ +\VO_R;1_PL#1O^?;4_^_-K_P#)M>044<\O+[OZ_IORL>QAY_>>O_\
M"P-&_P"?;4_^_-K_ /)M'_"P-&_Y]M3_ ._-K_\ )M>044<\O+[OZ_IORL>Q
MAY_>>O\ _"P-&_Y]M3_[\VO_ ,FT?\+ T;_GVU/_ +\VO_R;7D%%'/+R^[^O
MZ;\K'L8>?WGK_P#PL#1O^?;4_P#OS:__ ";1_P + T;_ )]M3_[\VO\ \FUY
M!11SR\ON_K^F_*Q[&'G]YZ__ ,+ T;_GVU/_ +\VO_R;1_PL#1O^?;4_^_-K
M_P#)M>044<\O+[OZ_IORL>QAY_>>O_\ "P-&_P"?;4_^_-K_ /)M'_"P-&_Y
M]M3_ ._-K_\ )M>044<\O+[OZ_IORL>QAY_>>O\ _"P-&_Y]M3_[\VO_ ,FT
M?\+ T;_GVU/_ +\VO_R;7D%%'/+R^[^OZ;\K'L8>?WGL*>/M%=T5H=1B5F56
MD>" I&&(!=Q'=22%4!W,(XW<@'8C-A3MVWB;0;K?Y6J6J^7MW?:6:SSNW8V?
M:U@\S&T[O+W;,KOV[ESX'134WY,3HPZ-KYW/LCP;X_\ &?P_OWU'P=XAU#0K
MB;;]ICMGCFL+[RX;J"'^T=*NX[C3-2^S)>W36?V^SN?L<TS7-KY-P%E7](/@
MG^U%H/Q ^R^'O&C:?X9\;W6H"RTZ*VCO(]!\0?:?.DLTT^>YDO/[-U!/+6P?
M3]3O_P#B87DEE_9%S=W.HMI6G_A[H?BF_P!%VP_\?=@/-/V.1@FQY,-O@G\N
M1X<.-QCP\+;YCY0ED\Y?9-.U&TU6TCO+.3?$_#*<"2&0 %X9D!.R5,C(R592
MLD;/$Z.UJ2EZ]C"=.4/-='_GV_JQ_0=17R?^R]\;/^%@:"O@OQ#=:A=^-_#.
MGR7,NHWI^T_\)!H,=Y';0:@]Y'#'LU#3/MEAIFH)?M)>:A_HVK_;=1N;O55T
M_P"L*H@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXT#X5"R^$N@QARR0/X4\]_%(*@[!-_PF^H>)8V=1O:"&VC=CY2A=)NR]=/\
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M6DZ#IL1 EU#6M1L]+L8R<D"2[OIH+="0"0&D&<'TKYV\1_MK_LA^%'EBUO\
M:5^"D-Q!N$]I8_$7PSK5]"RY)CEL=%U#4+N.7 R(GA$I!!"'<N?X7?%?C;QG
MX\U236_''B[Q/XSUF4LTNK^*]>U7Q%J<A<@N9+_5[N\NG+$ L6E.X@$YKF*G
MVCZ+^OP-E0763^2/[6_$/_!5?]@OPZ)%F^/-EJMP@)6V\/>"_B)K9E(_A2[L
M/"4NF@^AEOHE/9J^<_&/_!<7]DO0DFC\+>%_C!XYNUW>0]IX;T+0-)D(Z>=>
M:[XFMM3@5OX2FA7#8SN12 #_ "844N>7D-48+>[^>GX)/\3]&_V_O^"A.O\
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M'7?$L,4GR-XW\=0VM[%;74:DK(^D^$;;0[FTD8AXCXCU&$*N6+_AO7HWQ?\
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M4TCR2/\ *I)8EF)+$DDDDDDG)))Y))Y)/)-0ZG9?>;*AWE]R_5_Y']RFO?\
M!1;]B'PYYG]H?M)_#BX\K[W]@WU_XJS_ -<_^$8T_6/._P"V6^O#/$__  6,
M_84T!93IGQ \6^,WC!Q%X8^'/BZ!I6'5(I/%NG>%K=CG@.TRQ-U60J0Q_C=H
MI<[[+\?\RO80[R^]?Y']-GQ(_P""]'PVM+2\A^$?P,\;Z_J#Q2QV6H?$+6]"
M\)6-O.598KJ?3?#LOC.XOH(WVR&S74M-DN$&PW=JQW+_ #6>(_$.L>+?$.O>
M*O$-]-J>O^)M9U3Q!KFI7!!GU#6-9OI]1U.^F( !EN[VYGGD( &^1L #BL:B
MI;;W-(PC#X5ON]_Z^05_1M_P0@^!LB_\+@_:,U6T*I(EK\)/!L\B?? ?3_%'
MC>XCWC[H=/!UG;W,((+#5;4N"DJ5_.?;6UQ>7-O9VD$UU=W<\5M:VUO&\T]Q
M<3R+%#!!%&&>6:61UCCC16=W954$D"O[SOV/_@;;_LX_LW?"?X1B&&/5O#GA
MBVN?%<L.UA=>-->DDUWQ;-YRY-Q"FO:C?6ME([,RZ=;6<"D1PQHM05W?M^9%
M:5HV_F=ODM7^B^9]*52U/4K#1M-U#5]5NX+#2]*LKO4M2OKEQ';65A8P275Y
M=W$AXC@MK>*2:5SPD:,QX%7:_+[_ (*Y?'K_ (4Q^R'XH\/Z9>_9O%GQJO(_
MAAHZQ2;;B/0M2@EO/'-[Y8*LUHWABUN] FD5@8;KQ'8,0P;:=&[)OL<L5S-)
M=78_E0_:>^-%_P#M#?'[XJ_&*^:?R_&OBV_O-%M[C/G:?X6L?+TGPCI<@)($
MFF>&;#2K&4J%5YH)) BERH\'HHK [TK*RV6B/TZ_X))? 7_A=7[7WA/6]3LO
MM/A/X,6LOQ2UMI(]UO)K&DSPVG@FR\Q@4%R?%5WI^M1PLK?:++0-14 ;2Z?V
M75^/G_!%SX"_\*P_9>N?BAJME]G\3?';7W\0(\D?EW$?@CPR]YH?A&VD!&[9
M<W;>(_$%M(&"3V&O63A1M#-^P=;15DO/4XZLN:;[+3[M_P 0K^1C_@M#\>O^
M%H?M16_PPTJ]^T>&?@3H">'62.3S+:3QOXE2TUSQ?=1D';YEM:KX<\/7,97=
M#?:!>*6(;"_U-?&CXH:)\%?A-\1/BQXB*G2/A_X1UOQ-/;F01/J$^FV4LMAI
M,#MP+O6=1^RZ59 _?N[R!/XJ_@&\7^*M;\=>+/$_C;Q+>-J'B+Q?X@UGQ/KU
M\^0UYK&O:C<:IJ5R02Q'GWEU-(%W':&"@X%*;TMWW_K^MBZ$;MRZ+1>K_P E
M^9SM;OA?PUKGC/Q+X?\ "'AC3I]7\1^*=:TOP]H.E6JAKG4=8UF]@T[3;& $
M@>;=7EQ#"A8A0S@LP4$C"K]K_P#@B9^SHGQ$^._B'XZ:_8"?PW\$M,2'P^9X
MMUO=?$3Q7;W=GI\L8D!BN#X>\/1ZS?RJH,MCJ=_X=O5:-Q$6S2NTNYO*7+%R
M[+\=E^)_0I^QW^S!X4_9+^!WA?X7:!%:7.NB"+6?B!XFABV3^*_&][;P_P!L
M:F\C*LQT^V9$TO0;:3YK/1;*RADWW1N9Y_J6BBM]CB;;=WJV%?@=_P %UOCH
MNA?#?X8_L]Z3>!=1\>:U+\0/%L$4F)8_"WA0R6'A^TNXR?FM-:\2W=S?P,%)
M%UX//S*!MD_?&OX:?^"@_P >O^&BOVLOBKXYL;W[;X6TG5SX$\#.DGF6I\)>
M#&ETBSO;)LDBU\0:A'J?BA5)RLFNRC:GW%B;LK=_Z_X'S-*,;SOTCK\^G^?R
M/BVBBOM?_@GG\!?^&B?VM/A5X*OK+[;X5T35AX_\<H\?F6I\*>"WAU6YLKU<
M$_9/$&J+I/A>0@ AM<0ADP77):M+N=3:2;>R5S^L7_@G]\#&_9[_ &2_A%X$
MOK/['XFOM!7QKXTCDC\NZ7Q7XT8:]?V5Z,#-SH-M=6/AHL!@Q:+$,OC>WV91
M170M$EV.%MMMO=NY^4'_  6@T#4]9_8BUV_T^.62W\+?$;P!K^L>6"PCTR6]
MO?#BR2@=(EU3Q!I@)((5BI.,;A_'M7^A?\3/AWX6^+?P^\8_#+QK8G4?"OCG
MP]J?AO6[9&6.?[%J=L\!N+.9DD^S:A92-'>Z=>*C/9W]O;W48\R%37\1O[7O
M[&/Q:_9 \?W_ (=\9Z1>ZGX(O;^X7P+\2[*QF_X1KQ;IA+RVJ&Z020:5XD@M
M@!K'AR[F%[9SQR36IOM)EL=3O,IK6_1[^1T4)*SCUO=>G7[OU\CY"KU+X3_&
MWXM_ OQ#_P )5\(?B#XG\ :VXB2ZN/#VI2VUMJ<$+,\5IK>EOYNE:[8QR.TB
MV.LV5]9B0^9Y&\!J\MHJ#=I/1JZ[,_=/X+?\%T?C7X86TTSXW_#CPI\4K"/R
MXIO$/AJ=O /BQEP!+=W=O#;:MX5U&9?OI:6&C>&H7.4-Q$"'3]<O@?\ \%7/
MV-OC4]GILOC^?X4^);LQQKH'Q:M(?"T+3-A2L'BJ&[U+P6R-,1';I<^(;.^N
M-R%;%&+1I_%U15*;7G_7<SE2@^EGY?Y;?=8_T8+2[M+^UM[ZPNK>]LKR&*YM
M+RTFCN;6ZMYD$D-Q;W$+/%/#+&RO%+$[1R(P96*D&K%?PE?LV_MM_M%_LKZG
M;3?"_P >7S>%TN!/J'PY\2O<:[X!U56<O.DF@SW"?V3<7)P9M5\.7.C:PVU5
M:_:+=&W];W[$G[;GP]_;1^'MSK^@6W_"+^/O#'V.U^('P^N[Q;N[T*ZNTD^R
M:II=YY<#:MX9U5H+@:=J/V>WGBGM[BQO[:"XA1KC2,D_)_UL<\Z<H:[KNOU7
M3\5YGVO1115&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!_G+T445SGH']8/_  0G_P"31_B+_P!G&^+O_59_"&OVGK\6/^"$_P#R:/\
M$7_LXWQ=_P"JS^$-?M/6\=EZ+\CBJ?'+U"BBBF0%%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '\GW_!=C_D[CX=?]FY>$?\
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MODV[(W99C\2_KT_$NK_#E;R_-7_ _IJHHHK8XPK\I_\ @KM^TW!\"_V9-4\
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MU;V-C9VT;37-W>7<R6]M;6\2 O+///(D44:@L\CJJ@D@55K],_\ @DQ\!?\
MA=G[8'@[5=2LOM/A/X.6\GQ4UUI(]UO)J>AW%O;^"[(NP,?VA_%MWI>JBW<,
M;FPT74E"[4=TS2NTNYTR?*FWT5S^K/\ 95^"=G^SM^SU\*/@];1P+=^$/"=C
M%XAGM]IBOO%VJ&36?%^H(ZY+Q7GB74-4FMBS.T=HT$(=EB4U]!445OL<#=VV
M]WJS^(+_ (*7^/Y/B+^W!^T!JAG,UKX?\7)X L8]VZ.UB^'VEV'A"\@B&3M#
MZOI&I7<JY_X^;F=L#=@?"E>K?'?4YM;^.'QEUFY9GN-6^*WQ$U.=F)+--?\
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MU\,LZRVQ\;^)71[/4/'5Y:2".2*T-N9-.\*6MW&+NSTF6]OYTL[O7KW3K/\
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M-GI=C9Z9IUK!9:?IUI;V-C9VT:Q6UI9VD*6]K:V\2 )%!!!&D44:@*D:*J@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?A_\ %G_DJGQ+_P"R@>,O_4CU*OCS77>36M6:1V=AJ-X@9V+$
M)%.\<: L20L<:)&B]$1550%4 ?8?Q9_Y*I\2_P#LH'C+_P!2/4J^.M:_Y#.K
M?]A._P#_ $JEK.IT^?Z&]#>7I^IF4445F=(4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'L/@%W?19E=V98M1G2-68L(T,%K
M(40$D(IDDDD*K@%W=L;F8G]=_P!BG_DE>O\ _90-5_\ 4<\*5^0WP_\ ^0-<
M_P#83F_]);*OUY_8I_Y)7K__ &4#5?\ U'/"E;QV7HOR.*I\<O4^P****9 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!_)]_P78_Y.X^'7_9N7A'_
M -69\7J_%BOVG_X+L?\ )W'PZ_[-R\(_^K,^+U?BQ6,_B?R_)';3^"/H?HU_
MP25_Y2"_ #_NJO\ ZI/XD5_:=7\6/_!)7_E(+\ /^ZJ_^J3^)%?VG5<-GZ_H
MC"O\:_PK\V%%%%68A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %?Q/?\'(?_)\7PK_[-2\#_P#JWOCG
M7]L-?Q/?\'(?_)\7PK_[-2\#_P#JWOCG7T?"O_(VA_UXK_\ I*/&S[_D7R_Z
M^TOS9^4O[!__ "?%^QG_ -G6_L[_ /JWO!]?Z7=?YHG[!_\ R?%^QG_V=;^S
MO_ZM[P?7^EW7=QC_ +S@_P#KQ4_].(Y>'/X&)_Z^P_\ 2 HHHKXX^C"BBB@
MHHHH **** "BBB@#^=+_ (+T?"2]F@^!GQSL+5Y+&S.N_"WQ-=*A(MI+IO\
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MJ,^E:[H.KVSVNH:=?6[8>*:)LAT=2DUM<PM);7EK+#=VDTUM-%*^,U9WZ/\
M,ZZ4N:*76.GRZ/\ 3Y',5_0M_P $]_\ @KGX6^'_ ('\._ _]J.?5[73/"EG
M;:)X)^+-C87FNI;>'K1%@TW0?&VE:?'<ZRPT6V2.PTO7='LM3EGT^.TM-3TZ
M*6SEU>]_GIHI)M.Z+E%35G]_5>A_=5!^W[^Q9<:>-3C_ &F/A&MLT0F$4_BN
MRMM0V%2V&TBY,6JK+@',#60G#84QAF4'X8_:-_X+6?L^_#[2[_2_@)9ZA\:_
M&S12PV.ISZ?JOACX=Z7=;607&I7^K6^G^(=;6VE*2K8Z)I45GJ<221Q^)=/W
M1W!_D\HJG-^2,U1BM6V_+2WST_4]<^-_QT^)W[1/Q!U;XF?%GQ-=>)?$^J8A
MC+@6^F:+I<4DCV>A>'],C/V72-%L/-D^S65LHWRR3WMW)=:A=W=W<>1T5]0?
MLP?L@_&S]K7Q>GAKX6>&Y7TBTN88_%'CS5TGLO!?A&WDVL9=7U=891-?-$WF
M6FAZ;'>ZU?*&DM[$VT5S<P1J_-FK:BM;)+Y)'G_P)^!GQ%_:,^)OAWX4_##1
M9-7\2:_/F69Q)'I6@:1"\8U+Q'X@O4CE73M#TF*19;NY9'EED:"QL8+O4KRR
ML[C^W?\ 92_9D\"_LF_!S0/A1X)07<MMG5/%WBB:W2WU'QCXNO(84U77[Y$:
M0PQOY,5EI5AYLRZ7H]I8:>)[F2"2ZGY+]CS]C#X5_L;^ #X8\$P'6O%VM1VT
MWCSXBZG:PQ:]XMU"!6*1*B-,-(\/6$DDPT;P];3RP62.\]W<:CJMQ>ZG=?7U
M:QC;5[O\#EJ5.?1:17XON_T^_P D5_*O_P %POCU_P )I\=?!_P*TB]\W1?@
M[X>&K>(H8I/W;^.O',%IJ#07"*2DK:3X3@\/O:R,?,MYM<U:#:A:3?\ T^>/
M?&FA?#CP1XO^(/BBY%GX<\$>&M;\5ZY<_+NBTK0--N=4O3&K,H>8V]LZP1 [
MI9F2),LZ@_P!_%?XC:[\7OB9X]^*/B:0OKOC[Q9KOBO45$C21VTVLZA/>I86
MS, 5L].AECL+&(*J0V=M!"B(B*H)O2W?]+#H1O)R[+\7_P "YY_74>!_!VN_
M$/QGX3\!>&+4WOB/QIXDT3PKH5H-P%QJVOZE;:7I\;LJL4C:ZNHO-DVD1Q[I
M",*:Y>OV0_X(J? 7_A9/[3.I?%G5K+S_  W\"_#SZK:R2Q[[>3QUXNCO=#\,
MP,K#RW-GI4?BC6HG!:2TU#3-,F"!G21,TKM+NSID^6+?9?CT7S9_4I\(_AMH
M7P=^%_@#X6>&D"Z)X \):'X5L9/+6*2\72+"&UGU*Y520;S5+E)M1OGRQEO+
MJ>5F9G)/HE%%;G!N1S30V\,MQ<2QP001R33SS.L<4,,2EY)99'*I''&BL[NY
M"HH+,0 37\'/[9?QTE_:._:7^+/Q82XDGT76_$UQIW@]7W*L/@GPZD>@^% L
M+8%O)=:-I]KJ5[$@"G4KZ]F;=)*[M_5Q_P %2/CS_P *(_8^^(4^G7OV3Q9\
M3DC^%'A3RY-EPLWBVWNT\1WT)0^="^G>#K7Q!/;W<8'V;4SIH\R.2:(G^*FL
MYO9?-_U_6YTT(Z.7?1?F_P!/N"OT(_X)@? 7_A??[8'PYL-0LOM?A/X<3/\
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M2OZ\?#7AO0/!WA_1?"GA72+#0/#?AS3++1M"T32[>.TT[2]+TZ!+:RL;.WB
M2*"W@C2-% S@98LQ+&XQZOY?Y_U^6^=6I9."W>_DNWJ_R-NBBBM#F"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /\ .7HHHKG/0/ZP?^"$
M_P#R:/\ $7_LXWQ=_P"JS^$-?M/7XL?\$)_^31_B+_V<;XN_]5G\(:_:>MX[
M+T7Y'%4^.7J%%%%,@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M '57_P!4G\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_B>_X.
M0_\ D^+X5_\ 9J7@?_U;WQSK^V&OXGO^#D/_ )/B^%?_ &:EX'_]6]\<Z^CX
M5_Y&T/\ KQ7_ /24>-GW_(OE_P!?:7YL_*7]@_\ Y/B_8S_[.M_9W_\ 5O>#
MZ_TNZ_S1/V#_ /D^+]C/_LZW]G?_ -6]X/K_ $NZ[N,?]YP?_7BI_P"G$<O#
MG\#$_P#7V'_I 4445\<?1A1110 4444 %%%% !1110 5\_?M$?LO_!;]J7P>
M/!OQB\(V^NV]J9Y=!UZT<:=XK\*WEPJ+)>^&]>A1KJP>4Q0M=64JW.DZE]G@
MCU73KZ&%(A] T4#3:=UHT?R]?&[_ ((5_%G0;N\U'X!_$KPQX_T/=)+:^'?'
M7F^#_%\$98^591:E:6^H^&-;G5<>9?W4OA*)R3LL8]N&_/SQ9_P3;_;B\&32
MPZI^SGX[U#RF8"7PF-&\<0RJ,D/$_@[5=<+*ZX905609"NB290?W$45#@O-&
MJK36CL_7?\-/P/X)9/V._P!KB*0Q/^RY^T2'\QHAM^"GQ)=7= Q81/'X:9)1
MM1W#1,ZLBEU)0;JZOPY^P/\ MH>*98H=,_9E^,-J\K^6A\1^#=3\'Q!NF99O
M%L>B0PI_TTFDCC[[\5_=?12]FN[_ *_I_P!+5^WE_*OQ/Y(OA/\ \$2_VLO&
MMQ:S?$B_\"?!O1W93>C5=<@\:>)H8F(^:ST7P=-?:)=2@?,8;OQ=I>/NF0-E
M1^W/[*__  2W_9I_9CN].\5-I=S\5_B;I[0W%OXX\?6]G<6^C7\)#"[\)>%(
M4?1]!E254GM+^[;6_$%A*I-IKT:,R'])**I12\_4B56<NMEV6G_!_$****HS
M/G#]KCP7\6/B1^SM\4?AU\%)]"L_B!X\\/2>$;'4/$>JW6CZ7IVC:]/#I_BF
MY:]LM/U*Z2[;PS-JMIIWD6V]+^YMI_-C6%B?YJO^'(7[9?\ T%/@K_X7&O\
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MQW?QT_X(17LNIWNK?LY?%S3(-,N)))K;P9\6(+^*3303O^SVWC7PUI^I27\
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M;2MH*R]=?\OZ\SEJRYI63TCHO7K_ )?(*_)+_@J'^R-^TK^V%#\+O!WPCO/
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MA_PY"_;+_P"@I\%?_"XU_P#^8JOZY**'%-W8HU)05E:U[ZKT\_+\7Y'\C?\
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M%DR3PZ[\28K.[T&PNT((GT;P/;1#0(=CJDUO+KJ^)-1LKA?.L]1@; 7\H?\
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M['Q%HL<K%AI>M6US]E22Y.D76DW-U+='[/HH&FT[IM/R/Y*/C/\ \$3/VIO
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M7@^:WMKP:'86=QJ<-M+) =6N+^999FE::3YO_P"'(7[9?_04^"O_ (7&O_\
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M?2M-TK6]8M7TVWUJXOK:SOYH6T5+J35K94M)O/NK."W9565G7U6BJ,C^1O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X?_ !9_Y*I\
M2_\ LH'C+_U(]2KXZUK_ )#.K?\ 83O_ /TJEK[%^+/_ "53XE_]E \9?^I'
MJ5?'6M?\AG5O^PG?_P#I5+6=3I\_T-Z&\O1?F9E%%%9G2%%%% !1110 5O\
MAKPKXE\9:F-&\)Z#JWB/5F@ENETW1;"YU&]-O!M\Z<6UK'+*8HMZ>8^W:FY=
MQ&16!7VM^P)_R<!;_P#8G^)?Y6--:M+NT3)\L6^RN?/NH_ SXRZ187NJZI\+
M?'NGZ;IUK/>W]]=^%M8@M;.SMHVFN+JYFDM!'#!!$CRS2NRI'&K.[!5)'E=?
MU*R1QS1R12QI+%*C1RQ2*KQR1NI5XY$8%71U)5E8%64D$$$BOPO_ &NOV<KC
MX-^+'\2>&[.1OAOXJO)9-+:)&:/PWJLN^>X\.7+C/EP "2XT.60@S6*R6I:6
M?3KB:6I0LKWOW,X5>9V:2?3S\O7M\SXZHHHJ#8**** "BBOJC]EK]G&Z^//B
M>[GU:>ZTSP'X::W?Q!J%J%2[U"ZGR]KH.ERR(\<=U<1H\]Y=&.8:?:!6:/S[
MNS#B5W;N)M13;V1\KT5_2KX.^$OPT\ 6$.G>$?!'AS1H845#/!IEM-J-QM 4
M27NJW23ZG?S$  S7EW/*0 -V  #Q=\)?AGX[LY;+Q;X%\,ZU%*C)Y]QI5K%J
M$.X8+V>JVR0:G8RXX$UG=P2@<!Q6GLWWU_KK_P  Q]NK_"[=[Z_=_P $_FJH
MK[I_:D_9 N?A#;3>._ D]YK'P^:XC34K*[/GZMX3DNI5BMS<7"(HO]%EG=+:
M"^=$NK266WMKW[0TBWTOPM4--.S-HR4E=.Z_K1A1112&%%%% 'K_ ,/_ /D#
M7/\ V$YO_26RK]>?V*?^25Z__P!E U7_ -1SPI7Y#?#_ /Y US_V$YO_ $EL
MJ_7G]BG_ ))7K_\ V4#5?_4<\*5O'9>B_(XJGQR]3[ HHHID!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% '\GW_!=C_D[CX=?]FY>$?_5F?%ZOQ8K]
MI_\ @NQ_R=Q\.O\ LW+PC_ZLSXO5^+%8S^)_+\D=M/X(^A^C7_!)7_E(+\ /
M^ZJ_^J3^)%?VG5_%C_P25_Y2"_ #_NJO_JD_B17]IU7#9^OZ(PK_ !K_  K\
MV%%%%68A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %?Q/?\'(?_ "?%\*_^S4O _P#ZM[XYU_;#7\3W
M_!R'_P GQ?"O_LU+P/\ ^K>^.=?1\*_\C:'_ %XK_P#I*/&S[_D7R_Z^TOS9
M^4O[!_\ R?%^QG_V=;^SO_ZM[P?7^EW7^:)^P?\ \GQ?L9_]G6_L[_\ JWO!
M]?Z7==W&/^\X/_KQ4_\ 3B.7AS^!B?\ K[#_ -("BBBOCCZ,**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^?7_ (+Z:'?7
M'@C]FSQ+'&YTS2?%7Q'T.[E /EI?>(=(\)W^G1NW0/);^&-4:,$Y98I2.%./
MZ"J^3OVU_P!F33OVM?V?/%WPEFNK;3/$3O:^)O 6MWBNUMHWC?0EN&TB>Z,:
M2R)I^I6]SJ'A_5IHH9Y[?2=9OI[:&6ZBA0J2NFD73?+.+>U_ST_4_A(HKOOB
M=\+O'_P:\:ZU\//B;X6U7P?XOT"Y>WU#2-6MS%(4#NL-]8SJ6M=3TJ]5#/IV
MK:?-<Z=J-L4N;*YGA=7/ U@=N^Q^JW_!.3_@I%+^QHGB#X?>._#&I^,/@]XL
MUP>)9D\/26B^*?"/B.2RL],OM6TBUU&XL]/UFRU73].TVWU#2+O4-,:.6PMK
M^QOXW%Y::C^Y%G_P6/\ V%;JS2ZG\>>,-.G>/>VG7GPW\6O>1-MW>2[Z?87V
MGF3/R9COY(MW/F[/FK^.&BJ4VE;3YF<J49.[NGUL]_P_*Q_4I\8_^"Z?P2T#
M3;RT^"7PX\:_$'Q&8G2SU+QA'9>"_"$$KKB*ZD6&]U?Q+J20-\\VGG2]#-PJ
MB*/5+<N9HOYU/CY^T#\4OVEOB+J?Q.^+7B%]=\0WZ):6=M#&;31/#NCP/(]G
MH'AS2A))%I>CV9EE=(5>6XNKF6XU#4KJ^U.\O+VX\6HI.3>_W#C3C#9:[7;U
M_P @K[._85_9)\0_M?\ QST3P/!!>6O@#0)+7Q#\4_$L"O''H_A*"Y7S-.MK
MO:T<>O\ B>2-]'T&'$DJ2R76K-;RV&CZ@T47[)O[#/QT_:\\16]KX$T";1?
M=O>+#XD^*7B&TN;;P?HD,;J+N&RN"L;>)->CC8"'P_HSS70EDMVU.;2=/DDU
M&'^Q']EW]E[X9?LF?"_3_AI\-K%V4NNH^*?%.H)$?$'C/Q$\*17.MZS/$H50
M%06^FZ;!BRTFQ2.UME9S<7%PXQOJ]OS)J5%%633E]]O7S[+]#WK1-%TGPWHN
MD>'=!T^UTG0M TNPT71=*LHQ#9Z;I.EVD5CIVGVD*_+%;6=G!#;P1CA(HT4<
M"M2BBMCD"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#_ #EZ***YST#^L'_@A/\ \FC_ !%_[.-\7?\ JL_A#7[3U^+'_!"?
M_DT?XB_]G&^+O_59_"&OVGK>.R]%^1Q5/CEZA1113("BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _#_ .+/_)5/
MB7_V4#QE_P"I'J5?'6M?\AG5O^PG?_\ I5+7V+\6?^2J?$O_ +*!XR_]2/4J
M^.M:_P"0SJW_ &$[_P#]*I:SJ=/G^AO0WEZ+\S,HHHK,Z0HHHH **** "OM;
M]@3_ ). M_\ L3_$O\K&OBFOM;]@3_DX"W_[$_Q+_*QIQW7JOS(J?!+T/W"K
MFO%_A'P[X\\-ZKX3\5:;!JV@ZU:M:WUG,#AE)#Q3P2KB2WN[698[FSNX62>V
MN8HIX761%8=+7Y@?!?\ :P7P7\6?'_PK^)6HD>$9_B/XRM_"OB2\D)7PO/-X
MGU(+I.IS.3M\/3RM_HMTYVZ),Y28C2I/,TS9M*R?7[OF<D8R=W&]XV>F_JO-
M'QM^T1^SAXI^!'B%O,2XUCP-J=RX\.>*4A_=L&WR)I.L^6OE66M6\2ME2$M]
M1BC:\L>%N;:S^;Z_I]U_P_H'B_1+[0?$6EV&NZ#JUOY-[I]]#'=6=U ^'1MI
MR Z,$FM[B)EF@F2.>WDCE1'7\H_CC^P+X@T66\\0_!F9_$>C$O/)X.U"YC3Q
M!IRDEVCTF^G:*VUJUB7<(H+F2VU946.%#J]R[2'.4+:K7RZK_,WIU4U:3L^_
M1^O9]^A^;U%:.JZ1JNA:A<Z3K>F7^CZI92&*[T[5+.XL+ZUE'6.XM+J.*>%\
M<[9(U.""."*SJ@W"OZ"OV3? T'@/X#> [-85BOO$.F1^,=7DVA99[WQ,D>HV
MYG&!B6TTE],T[!&Y4LD5OF!)_ [P[H.I>*=?T7PWH\#W.JZ]JECI&GP(K,TE
MWJ%S':P A02%$DH9VQA$#.V%4D?TWZ3IL&CZ5IFD6HQ:Z5I]EIML,8Q!8VT=
MM", D#$<2\ G'3-:06K?R_K^NIA7>D5W;;^6WY_@5_$'B#1?"NBZEXB\1:E:
MZ/HFD6KWFI:E>R>7;6MO'@%W(!9F=V6*&&-7FGF>."&.2:1$;@OAM\;OA;\7
M&U"/X?>+;/7KG2E62^L3::EI>HP0,XC2[&GZS9:?>RV32,D?VR&"2V262.&2
M5)G6,_-?_!0?7)M,^!VGZ7!*4_X2/QUHFGW488CSK&RT_6=:8,/XE2_TW3GP
M<@.$;J!7YI_LO_$S0OA+\8="\8>)[K4;7P_#8:UIVJ-IMJU[-)%J.FSP6RRV
MRRQO);17_P!DNI?+$LBFW1HX9'4 -RM)+[_G_5S.-/F@Y:WULNCM_GLMC^@#
M7=$TSQ)HNK>'M9M4O=)UO3KS2M2M)!E+BRO[>2VN8CW4O%(P5Q\R-AU(901_
M-)XW\,7/@KQCXJ\(7C%[GPQXAUC0I967;YYTN_GLUN%7ILN4A6>,C*LDBLI(
M(-?T(^"_C[\&OB#Y*>%?B)X:OKN?;Y6EW=Z-&UEV;^%-'UI-/U.0J2%8Q6KJ
M&(^;#*3^+G[85A'IO[2/Q/MXE"K)J&B7Y"C ,FJ^%="U29OJTMX[,?[Q-*>J
M3OUM]ZO_ %ZE4;J4HM-:7L]-G;]3YIHHHK,Z0HHHH ]?^'__ "!KG_L)S?\
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M.X^'7_9N7A'_ -69\7J_%BL9_$_E^2.VG\$?0_1K_@DK_P I!?@!_P!U5_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!_G+T445SGH']8/_!"?_DT?XB_]G&^
M+O\ U6?PAK]IZ_%C_@A/_P FC_$7_LXWQ=_ZK/X0U^T];QV7HOR.*I\<O4**
M**9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%C_P25_Y2"_ #_NJO_JD_B17]IU7#9^OZ(PK_&O\*_-A1115F(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7\3W_!R'_R?%\*_^S4O _\ ZM[XYU_;#7\3W_!R'_R?%\*_^S4O _\
MZM[XYU]'PK_R-H?]>*__ *2CQL^_Y%\O^OM+\V?E+^P?_P GQ?L9_P#9UO[.
M_P#ZM[P?7^EW7^:)^P?_ ,GQ?L9_]G6_L[_^K>\'U_I=UW<8_P"\X/\ Z\5/
M_3B.7AS^!B?^OL/_ $@****^./HPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _#_P"+/_)5/B7_ -E
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_G+T44
M5SGH']8/_!"?_DT?XB_]G&^+O_59_"&OVGK\6/\ @A/_ ,FC_$7_ +.-\7?^
MJS^$-?M/6\=EZ+\CBJ?'+U"BBBF0%%%% !1110 4444 %%%% !1110 4444
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MBO[3JN&S]?T1A7^-?X5^;"BBBK,0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OXGO^#D/_ )/B^%?_
M &:EX'_]6]\<Z_MAK^)[_@Y#_P"3XOA7_P!FI>!__5O?'.OH^%?^1M#_ *\5
M_P#TE'C9]_R+Y?\ 7VE^;/RE_8/_ .3XOV,_^SK?V=__ %;W@^O]+NO\T3]@
M_P#Y/B_8S_[.M_9W_P#5O>#Z_P!+NN[C'_><'_UXJ?\ IQ'+PY_ Q/\ U]A_
MZ0%%%%?''T84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUO[._P#ZM[P?7^EW7^:)^P?_ ,GQ?L9_]G6_L[_^K>\'U_I=UW<8_P"\X/\
MZ\5/_3B.7AS^!B?^OL/_ $@****^./HPHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*S,S%F)9F)9F8DLS$Y))/))/))Y)Y-)114FH4444 %%%% !1110!Z_\ #_\
MY US_P!A.;_TELJ_7G]BG_DE>O\ _90-5_\ 4<\*5^0WP_\ ^0-<_P#83F_]
M);*OUY_8I_Y)7K__ &4#5?\ U'/"E;QV7HOR.*I\<O4^P****9 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]>A:%XN\)^*$,GAGQ/X>\11JN]GT+6M-U=%0G <MI]S<*%)(&XG&>]&C[/\
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M/[%/_)*]?_[*!JO_ *CGA2MX[+T7Y'%4^.7J?8%%%%,@**** "BBB@ HHHH
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MX(3_ /)H_P 1?^SC?%W_ *K/X0U^T];QV7HOR.*I\<O4****9 4444 %%%%
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MUW8M,EW]M^R026Y_7ROY:59D971F1U8,K*2K*RG*LK#!# @$$$$$9'-?TU>
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MFI>!_P#U;WQSK^V&OXGO^#D/_D^+X5_]FI>!_P#U;WQSKZ/A7_D;0_Z\5_\
MTE'C9]_R+Y?]?:7YL_*7]@__ )/B_8S_ .SK?V=__5O>#Z_TNZ_S1/V#_P#D
M^+]C/_LZW]G?_P!6]X/K_2[KNXQ_WG!_]>*G_IQ'+PY_ Q/_ %]A_P"D!111
M7QQ]&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?YR]%%%<YZ!_6#_ ,$)_P#D
MT?XB_P#9QOB[_P!5G\(:_:>OQ8_X(3_\FC_$7_LXWQ=_ZK/X0U^T];QV7HOR
M.*I\<O4****9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'X?\ Q9_Y*I\2_P#LH'C+_P!2/4J^.M:_Y#.K?]A.
M_P#_ $JEK[%^+/\ R53XE_\ 90/&7_J1ZE7QUK7_ "&=6_["=_\ ^E4M9U.G
MS_0WH;R]%^9F4445F=(4444 %%%% !7VM^P)_P G 6__ &)_B7^5C7Q37VM^
MP)_R<!;_ /8G^)?Y6-..Z]5^9%3X)>A^X5?SU?M5N7_:&^*K-R1XD"?A'IUC
M&OY*H%?T*U^3?QP_8O\ C'\0?BQXY\::!)X1&C>(=9:_T\7^N7-M=B VUO"/
M/@32YEC??$WRB5QC!SS@:S3:T[_YG/1DHR;;LN5K\4?F717V_P#\._?CW_ST
M\#?^%%=__*:C_AW[\>_^>G@;_P **[_^4U9<LNS_ *_X?\^S.CVD/YD?$%%?
M;_\ P[]^/?\ ST\#?^%%=_\ RFH_X=^_'O\ YZ>!O_"BN_\ Y34<LNS_ *_X
M?\^S#VD/YD?$%?TE_!0D_!KX2$\D_#+P$2?<^%=*)K\D_P#AW[\>_P#GIX&_
M\**[_P#E-7["_#?0;[PK\._ 7A?5# =3\-^"_"V@ZB;:0S6QOM'T.QT^[-O*
MR1M+ ;BWD\J1HXR\>UBBD[1<$T[M6T_R,:THR4;-/5GQU_P46_Y(EX6_[*GH
MG_J)>-Z_&"OV?_X*+?\ )$O"W_94]$_]1+QO7XP5,_B?R_)&E'X%ZL****DU
M"BBB@ HHHH ]?^'_ /R!KG_L)S?^DME7Z\_L4_\ )*]?_P"R@:K_ .HYX4K\
MAOA__P @:Y_["<W_ *2V5?KS^Q3_ ,DKU_\ [*!JO_J.>%*WCLO1?D<53XY>
MI]@4444R HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^3[_@NQ_P G
M<?#K_LW+PC_ZLSXO5^+%?M/_ ,%V/^3N/AU_V;EX1_\ 5F?%ZOQ8K&?Q/Y?D
MCMI_!'T/T:_X)*_\I!?@!_W57_U2?Q(K^TZOXL?^"2O_ "D%^ '_ '57_P!4
MG\2*_M.JX;/U_1&%?XU_A7YL****LQ"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_B>_X.0_\ D^+X
M5_\ 9J7@?_U;WQSK^V&OXGO^#D/_ )/B^%?_ &:EX'_]6]\<Z^CX5_Y&T/\
MKQ7_ /24>-GW_(OE_P!?:7YL_*7]@_\ Y/B_8S_[.M_9W_\ 5O>#Z_TNZ_S1
M/V#_ /D^+]C/_LZW]G?_ -6]X/K_ $NZ[N,?]YP?_7BI_P"G$<O#G\#$_P#7
MV'_I 4445\<?1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '^<O1117.>@?U@_
M\$)_^31_B+_V<;XN_P#59_"&OVGK\6/^"$__ ":/\1?^SC?%W_JL_A#7[3UO
M'9>B_(XJGQR]0HHHID!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M -1SPI6\=EZ+\CBJ?'+U/L"BBBF0%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ?R??\%V/^3N/AU_V;EX1_P#5F?%ZOQ8K]I_^"['_ "=Q\.O^S<O"
M/_JS/B]7XL5C/XG\OR1VT_@CZ'Z-?\$E?^4@OP _[JK_ .J3^)%?VG5_%C_P
M25_Y2"_ #_NJO_JD_B17]IU7#9^OZ(PK_&O\*_-A1115F(4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7\3W_!R'_R?%\*_^S4O _\ ZM[XYU_;#7\3W_!R'_R?%\*_^S4O _\ ZM[X
MYU]'PK_R-H?]>*__ *2CQL^_Y%\O^OM+\V?E+^P?_P GQ?L9_P#9UO[._P#Z
MM[P?7^EW7^:)^P?_ ,GQ?L9_]G6_L[_^K>\'U_I=UW<8_P"\X/\ Z\5/_3B.
M7AS^!B?^OL/_ $@****^./HPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_.7H
MKUCX]>!-(^%OQS^-'PR\/W.I7F@_#KXL?$7P)HEWK,UK<:O=:1X1\8:QX?TV
MYU6XLK/3[*?4I[+3X9;Z:TL+&UENFE>WL[:)DA3R>N<]!:I/N?U@_P#!"?\
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MB("TVG7L5M>QJ#*L4ELT=Q(W%K?[R85(ST3L^SW^7<\9HHHI%A1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH _@V_;8T;5]"_;"_:ALM;TK4M'O9_CW\5M9AM-5L;K3[J;2/$7C76?$'A
M_58K>[BAEDTW7=!U/3=;T>^1#:ZGI&H6.I64L]E=V\TGS!7Z6?\ !7?1M7TS
M]OOXSWNI:5J6GV7B+3?A?K/A^[OK&ZM+77=(@^%7@SP_-JNC7%Q%'%J>FPZ]
MH6MZ)+?63SVL>KZ/JNFO*+W3[N&'\TZP>C:[-G='6,7_ '5^1_1I_P $ /\
MF[3_ +H/_P"]FK^C2OY+/^"&NLZ1IG[87BRRU+5=-T^]\1? 3QGHWA^TOKZU
MM+K7=7@\:_#;Q!-I6C6]Q+'+J>I0Z#H6MZW+8V23W4>D:/JNI/$++3[N:'^M
M.M(/W?1V_7]3FK+]X_-)_A;] HHHJS(**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OXGO^#D/_ )/B^%?_ &:EX'_]6]\<Z_MAK^)[_@Y#_P"3XOA7
M_P!FI>!__5O?'.OH^%?^1M#_ *\5_P#TE'C9]_R+Y?\ 7VE^;/RE_8/_ .3X
MOV,_^SK?V=__ %;W@^O]+NO\T3]@_P#Y/B_8S_[.M_9W_P#5O>#Z_P!+NN[C
M'_><'_UXJ?\ IQ'+PY_ Q/\ U]A_Z0%%%%?''T84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK_P__P"0-<_]A.;_ -);*OUY_8I_Y)7K_P#V4#5?_4<\*5^0WP__ .0-<_\
M83F_]);*OUY_8I_Y)7K_ /V4#5?_ %'/"E;QV7HOR.*I\<O4^P****9 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&4FEW:BG9$RG"%N><87VYI*-_2[5SZ7HKY2_X;P_8=_Z/+_92_\ $B/A#_\
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M55M<WVN6+<=+1;NN"KQ'5=U1PT(;I2J3E4ZZ-QBJ=G;IS-)]6E9_U:?M(_\
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MFM+R:5U%291117AGJ!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLK8 4%F.U%5% 55 S:*EMO=FL81C\*MW?5_/]-@HHHI%!1110 4444 %%%%
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M^S-X3^P7WQO^-/Q7^,>K:=XKM=7_ +.\*V.@_"+P-K?A>T_LN;_A$/$FC?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5FZSHVD>(
MM(U7P_X@TK3==T'7=-OM&UO1-9L;74](UC2-3M9;+4M*U73;V*>RU#3=0LIY
MK2^L;N&:UN[6:6WN(I(I'0Z5% '\"7[4GP7NOV>/VAOB]\&9H-2@LO WC75+
M'PV^LZAI&J:O?^!]09-;\ :SJM[H20Z7)J6N^"-3\/ZS?16]II\EK=7\MI=Z
M5I-[!<:;:^"5_2O_ ,%V?V?K[5_#WPI_:5\/:']J_P"$2^V?"_XF:K;/XAO+
MZU\/:O??VQ\-[Z[L8;>Z\.:1X<TCQ'=>,M(U#7KJ;2+ZZ\0^.O"6B,VM?:M.
MBTC^:BL)*S:^X[:<N:*?79^J_J_S/V$_X(M_M V/PG_:=U+X8^)-<_LGPI\?
M/#D/AFRBG3P];:9-\3_#=V^J_#^35-8U:XLM2LOMNFWOC;PAH6F:)<7<WB'Q
M=XQ\.:7+HM].]A?:1_7)7^=3H^LZOX=U?2O$'A_5=2T+7M"U*QUG1-;T>^NM
M,U?1]7TRZBO=-U72M2LI8+W3]2T^]@AN[&^M)H;JTNH8KBWECEC1Q_=O^QS^
MT?I'[5?[//P^^,%E)IL.O:GIHT;X@Z)IK6L<?AKXBZ$L=EXLTH:;#KGB*]T?
M3;N]">(O"ECK>IR:[/X'UWPOJ^I10RZF$JX/=?/^OZZF->.JDNNC\K;??^A]
M/T445H8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!^6_[9'A"31/B9:>*8TN#8^-='MIGGFGM'C_ +9\/Q6^CW]I:6\0
M2Z@MX-)3P]<LUVLBS7=_<FWN76-[:S_/GQ_IMPTMKJL:M) D M+C:@(MRLSR
M0R.P8MMG:=XP?+"1O&BM(7GC6OWN^.OPY_X6?\.-9T"VC\S6[/;KOAGY]F=>
MTV*?[/:_O+[3[0?VM:3WNB>?J$SV=A_:?]I/#)+9PX_&#5=*='OM'UBQF@F@
MFGL=1TZ^@EMKFVN;:5HI[:Y@E6.>UNK6>-D='6.>VN(_^6<L?RIJZ:*A+DDG
M]_H]_GV\SYFHK8UK1;O1+LV]P-\3[FMKE5(CN(P1D@9.R5,J)H2Q:)B""\3Q
M2R8]8-6T9VIII-:IZH****!A1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !4]M;7%Y<16MK$TT\S;(XT RQP2222%554%W=RJ1HK.[*BLP@
MKUKP?X:DT_&J7Z[+N6(I;6SHI>UCDQNEE+*6CNI%&P1H5:&%Y(YBTDKQ0.*N
M_+J1.:@K]>B[_P##=3M;*V^QV=I:;_,^RVMO;>9MV>9Y$21;]FYMN[;NV[FV
MYQN.,G]P?A!X0D\!_#/P;X6N$N(K[3M'CFU2"YGM+J2UUG599M8UJT6XL0+6
M6WM-6U"\MK1H6F7[)%"#<W;!KF7\[_V4OA==^,O'MIXNU"QN/^$6\%7"ZD+Q
MHY$M;[Q1;&";1=+AN([RTF-Q832P^(+DP)?6\4=A:6.JVZ0:W:F7]6*WV.+<
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K-UG6=(\.Z1JOB#Q!JNFZ%H.A
M:;?:SK>MZS?6NF:1H^D:9:RWNI:KJNI7LL%EI^FZ?9037=]?7<T-K:6L,MQ<
M2QQ1NXTJ_%C_ (+2?M3_ /"JO@AIO[/_ (2UC[+X\^.GG?\ "3?V=J'DZGH7
MPCTBX3^VOM']F>(=.UG2_P#A86LK;>$K/^T-&U?PSXL\(V/Q4T&[\JZM8\)N
MR;[%1CS22[O7R75_(_G+_:Y^.W_#2_[2'Q9^-L6G?V3IOC7Q''_PCVGR6?V"
M^M_"/AO2M.\)>#?[:M%UC7H(O$<OA30=&G\3?8=6N],D\0R:G)I7D::]K;0_
M.5%%8;G:E9)+9)+[C]A/^"+?[/UC\6/VG=2^)WB30_[6\*? /PY#XFLI9W\/
M7.F0_$_Q)=OI7P_CU31]6M[W4KW[%IMEXV\7Z%J>B6]I-X>\7>#O#FJ2ZU8S
MI86.K_UR5\$?\$T/V?K[]G3]D'X;^&/$6A_V!X\\9?VA\4/B%8R/XACOHO$/
MC)H9=(L=:TKQ';V-UX>\1^'O =CX-\*>)M!M=-L+'3_$.@:F%6_NI+O6=3^]
MZVBK+UU9QU)<TFULM%\NOSW"BBBJ("BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\,N@:)8V/B'3O%OA?1DU2P\++K-_][ULG=7[G"TXMI[H****8@HHHH ****
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M_E;2]FN[_K^G_2U/;O\ E7WL^.O[%UG_ *!.I_\ @!=?_&J/[%UG_H$ZG_X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]NUW6O[&T[5M2M/#GAO34O/$'B;5+;3;W^Q_#VF:GJLT#P64N,3LV\C]/O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'SE^U=^S9X1_:Q^"'BSX,^+
M;K^QO[9^Q:IX9\6P:1IFLZGX*\7:-<"[T7Q'I=MJ<?\ U\Z+KL&GWNC:GK'A
M'6?$?AVTUW1O[9DU"#^([]H']G[XG_LR_$_7/A/\6-#_ +(\1Z1LN[&^M'FN
MO#WBOP]=37$6E>+?"6JRV]K_ &OX<U?[+<+;7+6]K?6-]:ZAH6NZ?I'B/2-9
MT;3_ ._ZOAK]OS]C'2/VTO@RG@^WU/3?#'Q)\':E/XG^&7B[4-.M;FUM]7>P
MGL[_ ,*:_?)I]YKUCX*\71-:+KQ\/R)=6FKZ/X7\33:;XD7PQ%X;U2)1OJMU
M^)K3J<CL_A;^YNVO_ /X?*[7X<_$;QQ\)/''AKXD?#?Q+J7A'QOX1U)-5\/^
M(-*>-;JRNECDMYHI8;B.>RU#3=0LI[G3-9T;4[:\TC7-(O+[1]8L;[2[Z[M)
MCXC?#GQQ\)/''B7X;_$CPUJ7A'QOX1U)]*\0>']52-;JRNECCN(98IK>2>RU
M#3=0LI[;4]'UG3+F\TC7-(O+'6-'OK[2[ZTNYN*K+;R.O1KNG]S1_;!^P'^W
MYX'_ &T? [VEVFF^$?CGX1TV";XA_#R&>1;6\M5D@LSX[\""\GGO=0\%:A>3
MV\-Y9S7%YJ_@?5[RV\/^(+F^M;[PMXI\7?H17^>9\.?B-XX^$GCCPU\2/AOX
MEU+PCXW\(ZDFJ^'_ !!I3QK=65TL<EO-%+#<1SV6H:;J%E/<Z9K.C:G;7FD:
MYI%Y?:/K%C?:7?7=I-_8/^PM_P %*?A/^UQI'ASP7X@O=-\!?M&2:;J;:W\.
M'CU*'2/$LGAZUM;G4O$/PYUB]6>RU#3=0LIYM7C\&W>KW'CC0+73/$HN+77?
M#OAI_&VJZQE?1[_G_P 'R.6I2Y?>C\/;M^K7GTZGZ644459B%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;F-);7^U_$>K_9;RV\)>$K:\M;[Q#?6MW--=Z1X<TCQ+XET'^V#X&?!?P/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N<\6^,?"/@#P]J'BWQWXJ\.>"O"FD_9/[5\3>+=<TSPWX>TS[??6V
MF6/]H:UK-U9:;9?;=2O;/3[3[3<Q_:+Z[MK2'?//%&_S!^UY^VS\&?V/? ^I
MZWXUUK3==^(,FFV]SX+^#VE:U80^./%UUJ<FIVND7DMB?M=[X=\%&]T?5$UG
MQWJ&FS:1IT>F7UEIT.N^*)-(\,:O_);^V#^W=\;_ -L?Q#-_PF^K?V#\,=+\
M1WNN^!/A+HK6X\/>%?-L8M*LY]3U*&QL-2\:^(X--CG\SQ'XB\W['?:UXF_X
M1/2_"6AZ]<^'XYE)+S?8TA3E/7:/?_)?/T\S[3_X* _\%9/%WQV_X3CX)? *
M3_A%/@/J7E:%JGC7[+J>F_$'XH:9!]OAUV#?/<P?\(I\./%?GVD'_".-I,'B
M[6M$TWR_%.J:;I7BOQ'\.[/\6***R;;=V=<8J*LO^'?=^85]8?L??L??$_\
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M_#.WCR7SO^)=\0-9M+CX?7WE_P!OWG_$I^*GV72-&M?LNC:18SW_ /PG>E^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[/8VES=S;(()9$]JJC.S6ZL%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"=O7YRT4[ON_O$XQ>\8OU2/T:_X>T_\%!?^B__ /F*O@G_ /.WH_X>T_\
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M.2'\L?\ P%?Y'Z-?\/:?^"@O_1?_ /S%7P3_ /G;T?\ #VG_ (*"_P#1?_\
MS%7P3_\ G;U^<M%%WW?WL.2'\L?_  %?Y'Z-?\/:?^"@O_1?_P#S%7P3_P#G
M;T?\/:?^"@O_ $7_ /\ ,5?!/_YV]?G+11=]W][#DA_+'_P%?Y'Z-?\ #VG_
M (*"_P#1?_\ S%7P3_\ G;T?\/:?^"@O_1?_ /S%7P3_ /G;U^<M%%WW?WL.
M2'\L?_ 5_D?HU_P]I_X*"_\ 1?\ _P Q5\$__G;T?\/:?^"@O_1?_P#S%7P3
M_P#G;U^<M%%WW?WL.2'\L?\ P%?Y'Z-?\/:?^"@O_1?_ /S%7P3_ /G;T?\
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M^"@O_1?_ /S%7P3_ /G;U^<M%%WW?WL.2'\L?_ 5_D?HU_P]I_X*"_\ 1?\
M_P Q5\$__G;T?\/:?^"@O_1?_P#S%7P3_P#G;U^<M%%WW?WL.2'\L?\ P%?Y
M'Z-?\/:?^"@O_1?_ /S%7P3_ /G;T?\ #VG_ (*"_P#1?_\ S%7P3_\ G;U^
M<M%%WW?WL.2'\L?_  %?Y'Z-?\/:?^"@O_1?_P#S%7P3_P#G;T?\/:?^"@O_
M $7_ /\ ,5?!/_YV]?G+11=]W][#DA_+'_P%?Y'Z-?\ #VG_ (*"_P#1?_\
MS%7P3_\ G;T?\/:?^"@O_1?_ /S%7P3_ /G;U^<M%%WW?WL.2'\L?_ 5_D?H
MU_P]I_X*"_\ 1?\ _P Q5\$__G;T?\/:?^"@O_1?_P#S%7P3_P#G;U^<M%%W
MW?WL.2'\L?\ P%?Y'Z-?\/:?^"@O_1?_ /S%7P3_ /G;T?\ #VG_ (*"_P#1
M?_\ S%7P3_\ G;U^<M%%WW?WL.2'\L?_  %?Y'Z-?\/:?^"@O_1?_P#S%7P3
M_P#G;T?\/:?^"@O_ $7_ /\ ,5?!/_YV]?G+11=]W][#DA_+'_P%?Y'Z-?\
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M\/:?^"@O_1?_ /S%7P3_ /G;U^<M%%WW?WL.2'\L?_ 5_D?HU_P]I_X*"_\
M1?\ _P Q5\$__G;T?\/:?^"@O_1?_P#S%7P3_P#G;U^<M%%WW?WL.2'\L?\
MP%?Y'Z-?\/:?^"@O_1?_ /S%7P3_ /G;T?\ #VG_ (*"_P#1?_\ S%7P3_\
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ML.2'\L?_  %?Y'Z-?\/:?^"@O_1?_P#S%7P3_P#G;T?\/:?^"@O_ $7_ /\
M,5?!/_YV]?G+11=]W][#DA_+'_P%?Y'Z-?\ #VG_ (*"_P#1?_\ S%7P3_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M .=#1_PXG_:X_P"BB_LY?^%=\3/_ )T-%%"2TT[?^V?YL.>7?\%_D'_#B?\
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ML.>7?\%_D'_#B?\ :X_Z*+^SE_X5WQ,_^=#1_P .)_VN/^BB_LY?^%=\3/\
MYT-%%"2TT[?^V?YL.>7?\%_D'_#B?]KC_HHO[.7_ (5WQ,_^=#1_PXG_ &N/
M^BB_LY?^%=\3/_G0T44)+33M_P"V?YL.>7?\%_D'_#B?]KC_ **+^SE_X5WQ
M,_\ G0T?\.)_VN/^BB_LY?\ A7?$S_YT-%%"2TT[?^V?YL.>7?\ !?Y!_P .
M)_VN/^BB_LY?^%=\3/\ YT-'_#B?]KC_ **+^SE_X5WQ,_\ G0T44)+33M_[
M9_FPYY=_P7^0?\.)_P!KC_HHO[.7_A7?$S_YT-'_  XG_:X_Z*+^SE_X5WQ,
M_P#G0T44)+33M_[9_FPYY=_P7^0?\.)_VN/^BB_LY?\ A7?$S_YT-'_#B?\
M:X_Z*+^SE_X5WQ,_^=#110DM-.W_ +9_FPYY=_P7^0?\.)_VN/\ HHO[.7_A
M7?$S_P"=#1_PXG_:X_Z*+^SE_P"%=\3/_G0T44)+33M_[9_FPYY=_P %_D'_
M  XG_:X_Z*+^SE_X5WQ,_P#G0T?\.)_VN/\ HHO[.7_A7?$S_P"=#110DM-.
MW_MG^;#GEW_!?Y!_PXG_ &N/^BB_LY?^%=\3/_G0T?\ #B?]KC_HHO[.7_A7
M?$S_ .=#110DM-.W_MG^;#GEW_!?Y!_PXG_:X_Z*+^SE_P"%=\3/_G0T?\.)
M_P!KC_HHO[.7_A7?$S_YT-%%"2TT[?\ MG^;#GEW_!?Y!_PXG_:X_P"BB_LY
M?^%=\3/_ )T-'_#B?]KC_HHO[.7_ (5WQ,_^=#110DM-.W_MG^;#GEW_  7^
M0?\ #B?]KC_HHO[.7_A7?$S_ .=#1_PXG_:X_P"BB_LY?^%=\3/_ )T-%%"2
MTT[?^V?YL.>7?\%_D'_#B?\ :X_Z*+^SE_X5WQ,_^=#1_P .)_VN/^BB_LY?
M^%=\3/\ YT-%%"2TT[?^V?YL.>7?\%_D'_#B?]KC_HHO[.7_ (5WQ,_^=#1_
MPXG_ &N/^BB_LY?^%=\3/_G0T44)+33M_P"V?YL.>7?\%_D'_#B?]KC_ **+
M^SE_X5WQ,_\ G0T?\.)_VN/^BB_LY?\ A7?$S_YT-%%"2TT[?^V?YL.>7?\
M!?Y!_P .)_VN/^BB_LY?^%=\3/\ YT-'_#B?]KC_ **+^SE_X5WQ,_\ G0T4
M4)+33M_[9_FPYY=_P7^0?\.)_P!KC_HHO[.7_A7?$S_YT-'_  XG_:X_Z*+^
MSE_X5WQ,_P#G0T44)+33M_[9_FPYY=_P7^0?\.)_VN/^BB_LY?\ A7?$S_YT
M-'_#B?\ :X_Z*+^SE_X5WQ,_^=#110DM-.W_ +9_FPYY=_P7^0?\.)_VN/\
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.BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img267305973_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img267305973_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  L /8# 2(  A$! Q$!_\0
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M&*;;>R1@_P#"3>(_^A@UO_P:W_\ \D4?\)-XC_Z&#6__  :W_P#\D5^ENM^
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M^#6__P#DBC_A)O$?_0P:W_X-;_\ ^2*Q**\$]$V_^$F\1_\ 0P:W_P"#6_\
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M= VL]Q\3;.:2/R[A 6DMH6WAAMP 3OD' F(SW)*W$%3B'AG(<MI9J\F53/\
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MJPI1<GG$VHJ5244Y63=D[V3=M#X8KV?]GOX:O\6OC'X$\#M$TNG:CK4-YKY
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M&BVI:1K&*VF_TF41@O)MT/5;TW,3NOG7'AK6[74+EHHM/V#\Y?!W_(W>%O\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>caba-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-03-22T19:37:21.7983+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.cabalettabio.com/20251231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:caba="http://www.cabalettabio.com/20251231" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" namespace="http://xbrl.sec.gov/ecd/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" namespace="http://xbrl.sec.gov/country/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" namespace="http://xbrl.sec.gov/cyd/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>75000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>75010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>75020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>75030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>75040 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>75050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>75060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>995457 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureBasisOfPresentation" id="Role_DisclosureBasisOfPresentation">
        <link:definition>995467 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995477 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>995487 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment" id="Role_DisclosurePropertyPlantAndEquipment">
        <link:definition>995497 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities" id="Role_DisclosureAccruedAndOtherCurrentLiabilities">
        <link:definition>995507 - Disclosure - Accrued and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements" id="Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements">
        <link:definition>995517 - Disclosure - Collaborations, Licensing Agreements and other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995527 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995537 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995547 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>995557 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995567 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>995577 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_Disclosure401KSavingsPlan" id="Role_Disclosure401KSavingsPlan">
        <link:definition>995587 - Disclosure - 401(k) Savings Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequentEvent" id="DisclosureSubsequentEvent">
        <link:definition>995597 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995607 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995617 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>995627 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables" id="Role_DisclosurePropertyPlantAndEquipmentTables">
        <link:definition>995637 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables">
        <link:definition>995647 - Disclosure - Accrued and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>995657 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>995667 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>995677 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>995687 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995697 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>995707 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureBasisOfPresentationAdditionalInformationDetails">
        <link:definition>995717 - Disclosure - Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995727 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails">
        <link:definition>995737 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives for Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>995747 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>995757 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails">
        <link:definition>995767 - Disclosure - Fair Value Measurements - Schedule of Debt Securities Classified as Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" id="Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails">
        <link:definition>995777 - Disclosure - Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails">
        <link:definition>995787 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails">
        <link:definition>995797 - Disclosure - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails" id="Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails">
        <link:definition>995807 - Disclosure - Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>995817 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails">
        <link:definition>995827 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" id="DisclosureSegmentInformationAdditionalInformationDetails">
        <link:definition>995837 - Disclosure - Segment Information (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails" id="DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails">
        <link:definition>995847 - Disclosure - Segment Information - Schedule of Profit and Loss from Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>995857 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails" id="DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails">
        <link:definition>995867 - Disclosure - Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails2" id="DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails2">
        <link:definition>995877 - Disclosure - Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails3" id="DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails3">
        <link:definition>995887 - Disclosure - Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details) 3</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails4" id="DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails4">
        <link:definition>995897 - Disclosure - Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details) 4</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails" id="DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails">
        <link:definition>995907 - Disclosure - Leases - Schedule of Company's operating and finance leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2" id="DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2">
        <link:definition>995917 - Disclosure - Leases - Schedule of Company's operating and finance leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" id="Role_DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>995927 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails" id="Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails">
        <link:definition>995937 - Disclosure - Common Stock - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" id="Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails">
        <link:definition>995947 - Disclosure - Common Stock - Schedule of Assumptions Used to Estimate Fair Value of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails" id="Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails">
        <link:definition>995957 - Disclosure - Common Stock - Summary of Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" id="Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails">
        <link:definition>995967 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanysEffectiveIncomeTaxRateDetails2" id="DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanysEffectiveIncomeTaxRateDetails2">
        <link:definition>995977 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails">
        <link:definition>995987 - Disclosure - Income Taxes - Summary of Principal Components of Company's Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>995997 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>996007 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails">
        <link:definition>996017 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>996027 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" id="DisclosureNetLossPerShareAdditionalInformationDetails">
        <link:definition>996037 - Disclosure - Net Loss Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_Disclosure401KSavingsPlanAdditionalInformationDetails" id="Role_Disclosure401KSavingsPlanAdditionalInformationDetails">
        <link:definition>996047 - Disclosure - 401 (k) Savings Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails" id="DisclosureSubsequenteventsAdditionalInformationDetails">
        <link:definition>996057 - Disclosure - SubsequentEvents - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="caba-20251231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanysEffectiveIncomeTaxRateDetails2" xlink:href="caba-20251231.xsd#DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanysEffectiveIncomeTaxRateDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2" xlink:href="caba-20251231.xsd#DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails2" xlink:href="caba-20251231.xsd#DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails3" xlink:href="caba-20251231.xsd#DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="caba-20251231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails4" xlink:href="caba-20251231.xsd#DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails4" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="caba-20251231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails" xlink:href="caba-20251231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="caba-20251231.xsd#Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:href="caba-20251231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails" xlink:href="caba-20251231.xsd#DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails" xlink:href="caba-20251231.xsd#DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" xlink:href="caba-20251231.xsd#Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails" xlink:href="caba-20251231.xsd#Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:href="caba-20251231.xsd#Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="caba-20251231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="caba-20251231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="caba-20251231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="caba-20251231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="caba-20251231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureBasisOfPresentation" xlink:href="caba-20251231.xsd#Role_DisclosureBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="caba-20251231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="caba-20251231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment" xlink:href="caba-20251231.xsd#Role_DisclosurePropertyPlantAndEquipment" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities" xlink:href="caba-20251231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements" xlink:href="caba-20251231.xsd#Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformation" xlink:href="caba-20251231.xsd#DisclosureSegmentInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="caba-20251231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeases" xlink:href="caba-20251231.xsd#DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStock" xlink:href="caba-20251231.xsd#Role_DisclosureCommonStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="caba-20251231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="caba-20251231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_Disclosure401KSavingsPlan" xlink:href="caba-20251231.xsd#Role_Disclosure401KSavingsPlan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequentEvent" xlink:href="caba-20251231.xsd#DisclosureSubsequentEvent" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="caba-20251231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="caba-20251231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="caba-20251231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables" xlink:href="caba-20251231.xsd#Role_DisclosurePropertyPlantAndEquipmentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" xlink:href="caba-20251231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="caba-20251231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationTables" xlink:href="caba-20251231.xsd#DisclosureSegmentInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesTables" xlink:href="caba-20251231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:href="caba-20251231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="caba-20251231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="caba-20251231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails" xlink:href="caba-20251231.xsd#Role_DisclosureBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="caba-20251231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" xlink:href="caba-20251231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="caba-20251231.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="caba-20251231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" xlink:href="caba-20251231.xsd#Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails" xlink:href="caba-20251231.xsd#Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="caba-20251231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails" xlink:href="caba-20251231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:href="caba-20251231.xsd#DisclosureSegmentInformationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails" xlink:href="caba-20251231.xsd#DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="caba-20251231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:href="caba-20251231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails" xlink:href="caba-20251231.xsd#Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" xlink:href="caba-20251231.xsd#Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails" xlink:href="caba-20251231.xsd#Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="caba-20251231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" xlink:href="caba-20251231.xsd#DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="caba-20251231.xsd#Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:href="caba-20251231.xsd#DisclosureNetLossPerShareAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/Role_Disclosure401KSavingsPlanAdditionalInformationDetails" xlink:href="caba-20251231.xsd#Role_Disclosure401KSavingsPlanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails" xlink:href="caba-20251231.xsd#DisclosureSubsequenteventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" xlink:label="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_December2022FinancingMember" xlink:label="caba_December2022FinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PreFundedWarrantsExercised" xlink:label="caba_PreFundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingLeasesAbtract" xlink:label="caba_OperatingLeasesAbtract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate" xlink:label="caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:label="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_FundingTermEndingDate" xlink:label="caba_FundingTermEndingDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ManufacturingAndOtherResearchAndDevelopmentServices" xlink:label="caba_ManufacturingAndOtherResearchAndDevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityAbstract" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportingUnits" xlink:label="us-gaap_NumberOfReportingUnits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" xlink:label="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockFromATMOffering" xlink:label="caba_IssuanceOfCommonStockFromATMOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember" xlink:label="caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ResearchAndDevelopmentCredits" xlink:label="caba_ResearchAndDevelopmentCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_MayTwoThousandTwentyThreeFinancingMember" xlink:label="caba_MayTwoThousandTwentyThreeFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AnnualIncreasePercentageOfBaseRent" xlink:label="caba_AnnualIncreasePercentageOfBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ArunDasOneMember" xlink:label="caba_ArunDasOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ObligationToBePaidCommencementDate" xlink:label="caba_ObligationToBePaidCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue" xlink:label="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IncreaseInShareReservedPercentage" xlink:label="caba_IncreaseInShareReservedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_WorkOrdersTerm" xlink:label="caba_WorkOrdersTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TerminationFees" xlink:label="caba_TerminationFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CellaresAgreementMember" xlink:label="caba_CellaresAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CommonStockAndWarrantsMember" xlink:label="caba_CommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_NonCashFinanceLeaseExpense" xlink:label="caba_NonCashFinanceLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" xlink:label="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="us-gaap_PaymentsForUnderwritingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_WuXiAdvancedTherapiesMember" xlink:label="caba_WuXiAdvancedTherapiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_FinancingCashFlowsUsedForFinanceLeases" xlink:label="caba_FinancingCashFlowsUsedForFinanceLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_StockOptionRepricingMember" xlink:label="caba_StockOptionRepricingMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember" xlink:label="caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_GwendolynBinderOneMember" xlink:label="caba_GwendolynBinderOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_DE" xlink:label="country_DE"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_MilestonePayments" xlink:label="caba_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_DevelopmentAndManufacturingServicesAgreementMember" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ArunDasMember" xlink:label="caba_ArunDasMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OxfordBiomedicaMember" xlink:label="caba_OxfordBiomedicaMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ManufacturingOfPreclinicalAndClinicalSupplies" xlink:label="caba_ManufacturingOfPreclinicalAndClinicalSupplies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ContractualCostIncurred" xlink:label="caba_ContractualCostIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AutolusHoldingsMember" xlink:label="caba_AutolusHoldingsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AnupMardaOneMember" xlink:label="caba_AnupMardaOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AmortizationExpense" xlink:label="caba_AmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_GwendolynBinderMember" xlink:label="caba_GwendolynBinderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_VariableLeaseCosts" xlink:label="caba_VariableLeaseCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_FixedLeaseCost" xlink:label="caba_FixedLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantPurchaseCommitmentDescription" xlink:label="us-gaap_SignificantPurchaseCommitmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EarningsPerShareBasicAndDilutedTable" xlink:label="caba_EarningsPerShareBasicAndDilutedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PreFundedWarrantsMember" xlink:label="caba_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_SubscriptionAndTechnologyTransferAgreementMember" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_NumberOfFaculty" xlink:label="caba_NumberOfFaculty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_VestedStockOptionMember" xlink:label="caba_VestedStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OrphanDrugCreditsMember" xlink:label="caba_OrphanDrugCreditsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LeaseAmendmentPeriod" xlink:label="caba_LeaseAmendmentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingLeaseAgreementMember" xlink:label="caba_OperatingLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_VotingCommonStockMember" xlink:label="caba_VotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ClinicalTrialResearchAndDevelopmentServices" xlink:label="caba_ClinicalTrialResearchAndDevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="us-gaap_StockOptionExercisePriceIncrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_Rese-CelAndMuSK-CAARTMember" xlink:label="caba_Rese-CelAndMuSK-CAARTMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_NonCashLeaseExpense" xlink:label="caba_NonCashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_FinanceLeasesAbstract" xlink:label="caba_FinanceLeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_Rule10B51ArrModifiedFlag" xlink:label="caba_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AdvancePayments" xlink:label="caba_AdvancePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ChildrenSHospitalOfPhiladelphiaMember" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LeaseExpirationMonth" xlink:label="caba_LeaseExpirationMonth"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceDecrease" xlink:label="us-gaap_StockOptionExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandTwentyFiveSalesAgreementMember" xlink:label="caba_TwoThousandTwentyFiveSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_StevenNichtbergerMember" xlink:label="caba_StevenNichtbergerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingCashFlowsUsedForFinanceLeases" xlink:label="caba_OperatingCashFlowsUsedForFinanceLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AtTheMarketOfferingSalesAgreementMember" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IncreaseInTheRouAsset" xlink:label="caba_IncreaseInTheRouAsset"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_WeightedAverageNumberOfSharesOutstanding" xlink:label="caba_WeightedAverageNumberOfSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:label="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LeaseExpirationMonthAndYear" xlink:label="caba_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsShares" xlink:label="us-gaap_CommonStockDividendsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_WuxiAgreementMember" xlink:label="caba_WuxiAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_StevenNichtbergerOneMember" xlink:label="caba_StevenNichtbergerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_NanjingIasoBiotherapeuticsCoLtdMember" xlink:label="caba_NanjingIasoBiotherapeuticsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandTwentyFiveInducementPlanMember" xlink:label="caba_TwoThousandTwentyFiveInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ExpectedCostIncurredForPurchaseOfPlasmids" xlink:label="caba_ExpectedCostIncurredForPurchaseOfPlasmids"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_InitialTermsOfAgreementDescription" xlink:label="caba_InitialTermsOfAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PaymentOfObligationTerm" xlink:label="caba_PaymentOfObligationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ClinicalTrials" xlink:label="caba_ClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ContractualExpenses" xlink:label="caba_ContractualExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CapitalizedRDCosts" xlink:label="caba_CapitalizedRDCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_MilestonePayment" xlink:label="caba_MilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_NonVestedCommonStockMember" xlink:label="caba_NonVestedCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingLeaseAssets" xlink:label="caba_OperatingLeaseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PercentageOfEligibleTaxPositionsForRecognition" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember" xlink:label="caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PersonnelExpenses" xlink:label="caba_PersonnelExpenses"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:label="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ResearchServiceAgreementMember" xlink:label="caba_ResearchServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OtherInformationAbstract" xlink:label="caba_OtherInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_UpfrontPayment" xlink:label="caba_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AgreementWithContractManufacturingOrganizationMember" xlink:label="caba_AgreementWithContractManufacturingOrganizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_DevelopmentServices" xlink:label="caba_DevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_FinanceLesseeUndiscountedLeasePayments" xlink:label="caba_FinanceLesseeUndiscountedLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares" xlink:label="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LesseeUndiscountedLeasePayments" xlink:label="caba_LesseeUndiscountedLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IncomeTaxDisclosureTable" xlink:label="caba_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_Caba201AndMuskCaartMember" xlink:label="caba_Caba201AndMuskCaartMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="caba_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LeaseCommencementMonthAndYear" xlink:label="caba_LeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LonzaAgreementMember" xlink:label="caba_LonzaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="caba_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockFromATMOfferingAmount" xlink:label="caba_IssuanceOfCommonStockFromATMOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IncomeTaxDisclosureLineItems" xlink:label="caba_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="us-gaap_CommonStockConversionFeatures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LicenseMaintenanceFee" xlink:label="caba_LicenseMaintenanceFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LaboratoryEquipmentMember" xlink:label="caba_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EarningPerShareBasicAndDilutedLineItems" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CommitmentsAndContingenciesDisclosureTable" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AdditionalOptionsToBePurchasedByUnderwriters" xlink:label="caba_AdditionalOptionsToBePurchasedByUnderwriters"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedResearchAndDevelopmentServicesCurrent" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TotalFixedFinanceLeaseCost" xlink:label="caba_TotalFixedFinanceLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingCashFlowsUsedForOperatingLeases" xlink:label="caba_OperatingCashFlowsUsedForOperatingLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_DeferredTaxAssetsLicenseFeesDeductions" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TotalFinanceLeaseCost" xlink:label="caba_TotalFinanceLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CollaborativeAgreementPaymentsDue" xlink:label="caba_CollaborativeAgreementPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_NonRule10B51ArrModifiedFlag" xlink:label="caba_NonRule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_SharesRemainingAvailableForIssuance" xlink:label="caba_SharesRemainingAvailableForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_MasterTranslationalResearchServicesAgreementMember" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PercentageOfPayrollDeductionOnEligibleCompensation" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees" xlink:label="caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_UnvestedStockOptionMember" xlink:label="caba_UnvestedStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LicenseAgreementMember" xlink:label="caba_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_June2025FinancingMember" xlink:label="caba_June2025FinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_RentExpense" xlink:label="caba_RentExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedGeneralAndAdministrativeServicesCurrent" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_SponsoredResearchAgreementsMember" xlink:label="caba_SponsoredResearchAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LicenseOfIntellectualProperty" xlink:label="caba_LicenseOfIntellectualProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IncreaseInTheLeaseLiability" xlink:label="caba_IncreaseInTheLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_RemainingResearchAndDevelopmentExpenseToBeIncurred" xlink:label="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_RegentsOfUniversityOfCaliforniaMember" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AnupMardaMember" xlink:label="caba_AnupMardaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in Unrecognized Tax Benefits amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Changes in Unrecognized Tax Benefits Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation Changes in Unrecognized Tax Benefits Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest payable under finance lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Interest Payable, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_December2022FinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">December 2022 Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_December2022FinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">December Two Thousand Twenty Two Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_December2022FinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">December 2022 Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PreFundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeasesAbtract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases [Abtract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeasesAbtract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Leases [Abtract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeasesAbtract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. Treasury securities - due in one year or less</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal and State Research and Development Tax Credit Carryforwards Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal and State Research and Development Tax Credit Carryforwards Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state research and development tax credit carryforwards expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs (Level 2)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborations licensing agreements and other agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborations Licensing Agreements And Other Agreements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid In The Measurement Of Lease Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash Paid In The Measurement Of Lease Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid in the measurement of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, authorized shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FundingTermEndingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding term ending date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FundingTermEndingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Term Ending Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FundingTermEndingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding term end date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ManufacturingAndOtherResearchAndDevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing and Other Research and Development Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ManufacturingAndOtherResearchAndDevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing and Other Research and Development Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ManufacturingAndOtherResearchAndDevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing and other research and development services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic net loss per share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity of Counterparty, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity of Counterparty, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Obligation to be paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contractual Obligation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">liability related to agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportingUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reporting Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportingUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, issued shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of use assets obtained in exchange for lease obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant-date fair value of stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Valuation Allowances (Domestic) percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Contingency, Domestic, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses and Other Current Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock and pre-funded warrants for the purchase of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock and pre-funded warrants for the purchase of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of pre-funded warrants, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Statutory Tax Rate Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Service [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and Service [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Actual income tax benefit effective tax rate percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, operating loss carryforwards, not subject to expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Profit and Loss From Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockFromATMOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock from ATM offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockFromATMOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Of Common Stock from ATM offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockFromATMOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from ATM offering, net of sales agent commission and fees, share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Five At The Market Offering Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Five At The Market Offering Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 At-The-Market Offering Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Earnings Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ResearchAndDevelopmentCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ResearchAndDevelopmentCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ResearchAndDevelopmentCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and Development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share of voting and non-voting common stock, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period share stock options exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Share Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with exercise of stock options, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MayTwoThousandTwentyThreeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">May 2023 Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MayTwoThousandTwentyThreeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">May Two Thousand Twenty Three Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MayTwoThousandTwentyThreeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">May Two Thousand Twenty Three Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AnnualIncreasePercentageOfBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual increase percentage of base rent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AnnualIncreasePercentageOfBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Increase Percentage Of Base Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AnnualIncreasePercentageOfBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual increase of base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards local commencement of expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Local Commencement Of Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards local commencement of expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options outstanding aggregate intrinsic value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation deductions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accretion of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ArunDasOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arun Das One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ArunDasOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Arun Das One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of Cross-Border Tax Laws amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards federal commencement of expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Federal Commencement Of Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards federal commencement of expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, operating loss carryforwards, subject to expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Forfeited/Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ObligationToBePaidCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Obligation to be paid, commencement date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ObligationToBePaidCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Obligation To Be Paid Commencement Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ObligationToBePaidCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment commencement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, warrants and pre-funded warrants, net of issuance costs, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock, Warrants and Pre Funded Warrants, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Common Stock, Warrants and Pre Funded Warrants, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInShareReservedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in share reserved percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInShareReservedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Share Reserved Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInShareReservedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in share reserved percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Add: Conversion of non-voting to voting common shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Adjustment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Statutory Tax Rate Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WorkOrdersTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work orders terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WorkOrdersTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Work Orders Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WorkOrdersTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Work Orders Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional common stock warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TerminationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TerminationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Termination Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TerminationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CellaresAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cellares Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CellaresAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cellares Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CellaresAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cellares Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Operating Income (Expense), Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock and Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock and Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock and Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonCashFinanceLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash finance lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonCashFinanceLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Finance Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonCashFinanceLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Cash Finance Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after rolling year three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Rolling Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions Used to Estimate Fair Value of Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForUnderwritingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions and offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForUnderwritingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Underwriting Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized gain (loss) on available-for-sale investments, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WuXiAdvancedTherapiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">WuXi Advanced Therapies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WuXiAdvancedTherapiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wu Xi Advanced Therapies [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WuXiAdvancedTherapiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WuXi Advanced Therapies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Debt Securities Classified as Available-for-Sale Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on foreign currency exchange rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinancingCashFlowsUsedForFinanceLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Cash Flows Used For Finance Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinancingCashFlowsUsedForFinanceLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financing Cash Flows Used For Finance Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinancingCashFlowsUsedForFinanceLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing cash flows for finance leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive shares have been excluded from calculation of diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StockOptionRepricingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option Repricing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StockOptionRepricingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Option Repricing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 and 2019 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen and Two Thousand Ninteen Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Eighteen and Two Thousand Ninteen Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (years), Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Rolling Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_GwendolynBinderOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gwendolyn Binder One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_GwendolynBinderOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gwendolyn Binder One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_DE_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GERMANY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_DE_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Germany</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax credit carryforwards commencement of expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Commencement Of Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets tax credit carryforwards commencement of expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and manufacturing services agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development And Manufacturing Services Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Wuxi Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborations licensing agreements and other agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborations Licensing Agreements And Other Agreements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations, Licensing Agreements and other Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ArunDasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arun Das [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ArunDasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Arun Das [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value By Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, outstanding shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OxfordBiomedicaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Oxford Biomedica.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OxfordBiomedicaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Oxford Biomedica [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OxfordBiomedicaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Oxford Biomedica</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ManufacturingOfPreclinicalAndClinicalSupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing of Preclinical and Clinical Supplies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ManufacturingOfPreclinicalAndClinicalSupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing of Preclinical and Clinical Supplies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ManufacturingOfPreclinicalAndClinicalSupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing of preclinical and clinical supplies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and Local Income Taxes, Net of Federal Income Tax Effect Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nontaxable or Nondeductible Items amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with exercise of stock options, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Principal Components of Company's Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ContractualCostIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual cost incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ContractualCostIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Cost Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ContractualCostIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AutolusHoldingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Autolus Holdings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AutolusHoldingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Autolus Holdings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AutolusHoldingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Autolus Holdings Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AnupMardaOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Anup Marda One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AnupMardaOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Anup Marda One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense, Minimum Rentals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial annual base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant, Exercise Price, Decrease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in exercise price of Warrents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.00001 par value: 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; no shares issued or outstanding at December 31, 2025 and December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_GwendolynBinderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gwendolyn Binder [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_GwendolynBinderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gwendolyn Binder [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_VariableLeaseCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_VariableLeaseCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Variable Lease Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_VariableLeaseCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs (Level 3)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Sale Products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued liabilities and other liabilities current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (see Notes 6 and 7)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FixedLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fixed Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FixedLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fixed Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FixedLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantPurchaseCommitmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Commitment, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantPurchaseCommitmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and clinical manufacturing services agreement, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liabilities, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate - finance leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-voting Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvoting Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-voting Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EarningsPerShareBasicAndDilutedTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Earnings per share basic and diluted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EarningsPerShareBasicAndDilutedTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EarningsPerShareBasicAndDilutedTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Basic And Diluted [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Compensation amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of shares used in basic per share computation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subscription and technology transfer agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subscription And Technology Transfer Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subscription and Technology Transfer Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Compensation percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NumberOfFaculty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of faculty.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NumberOfFaculty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Faculty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NumberOfFaculty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of faculty member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credits percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Allocation of undistributed losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_VestedStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vested Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_VestedStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vested Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OrphanDrugCreditsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Orphan Drug credits [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OrphanDrugCreditsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Orphan Drug credits [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OrphanDrugCreditsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Orphan Drug Credits [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateNoteSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. Treasury securities - original maturity less than three months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateNoteSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Note Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateNoteSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Note Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseAmendmentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease amendment period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseAmendmentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Amendment Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseAmendmentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Amendment Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reallocation of undistributed losses as a result of conversion of non-voting to voting common shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Lease Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_VotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Voting Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_VotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Voting common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_VotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Voting Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_VotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voting Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ClinicalTrialResearchAndDevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trial Research and Development Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ClinicalTrialResearchAndDevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical Trial Research and Development Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ClinicalTrialResearchAndDevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical trial research and development services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option, Exercise Price, Increase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_Rese-CelAndMuSK-CAARTMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rese-Cel and MuSK-CAART [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_Rese-CelAndMuSK-CAARTMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rese-Cel and MuSK-CAART [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_Rese-CelAndMuSK-CAARTMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rese-Cel and MuSK-CAART [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non cash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonCashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-cash operating lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Operating and Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Operating and Nonoperating, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinanceLeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinanceLeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinanceLeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Leases:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen stock option and incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Stock Option And Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule 10b51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rule 10b51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rule 10b5-1 Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AdvancePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AdvancePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advance Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AdvancePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplyCommitmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supply Commitment Arrangement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplyCommitmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Commitment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Adjustments amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Children S Hospital Of Philadelphia [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Children's Hospital of Philadelphia</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Children&#8217;s Hospital of Philadelphia.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Committed payment obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitment, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Adjustments percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized losses on available-for-sale securities, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation unvested number of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseExpirationMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration month</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseExpirationMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseExpirationMonth_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease Expiration Month</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Tax Effects Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionExercisePriceDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option, Exercise Price, Decrease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandTwentyFiveSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Five Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandTwentyFiveSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Five Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandTwentyFiveSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, contribution amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Options Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StevenNichtbergerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Steven Nichtberger [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StevenNichtbergerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Steven Nichtberger [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingCashFlowsUsedForFinanceLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Cash Flows Used For Finance Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingCashFlowsUsedForFinanceLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Cash Flows Used For Finance Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingCashFlowsUsedForFinanceLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows used for finance leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation and Employee Benefit Plans [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) Savings Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market offering sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-The-Market Offering Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInTheRouAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in the ROU asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInTheRouAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in the ROU asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInTheRouAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in the ROU asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WeightedAverageNumberOfSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average number of shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WeightedAverageNumberOfSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average number of shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WeightedAverageNumberOfSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of Changes in Tax Laws or Rates Enacted in the Current Period Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in Unrecognized Tax Benefits percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Changes in Unrecognized Tax Benefits Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation Changes in Unrecognized Tax Benefits Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock dividends, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Dividends, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Tax Effects Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of finance lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted average number of shares used in diluted per share computation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WuxiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">WuXi Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_WuxiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">WuXi Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StevenNichtbergerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Steven Nichtberger One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_StevenNichtbergerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Steven Nichtberger One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administration expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of Changes in Tax Laws or Rates Enacted in the Current Period Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Monthly fee included in minimum lease payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan maximum annual rights to purchase common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Maximum Annual Rights To Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan maximum annual rights to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NanjingIasoBiotherapeuticsCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nanjing IASO Biotherapeutics Co., Ltd. member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NanjingIasoBiotherapeuticsCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nanjing IASO Biotherapeutics Co., Ltd. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NanjingIasoBiotherapeuticsCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IASO Biotherapeutics</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Recently Issued Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Payments for Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandTwentyFiveInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 Inducement Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandTwentyFiveInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Five Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandTwentyFiveInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Five Inducement Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards state commencement of expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards State Commencement Of Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards state commencement of expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nontaxable or Nondeductible Items percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ExpectedCostIncurredForPurchaseOfPlasmids_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected cost incurred for purchase of plasmids.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ExpectedCostIncurredForPurchaseOfPlasmids_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Cost Incurred For Purchase Of Plasmids</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ExpectedCostIncurredForPurchaseOfPlasmids_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, outstanding shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Off-Balance Sheet Risk and Concentrations of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_InitialTermsOfAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Terms agreement description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_InitialTermsOfAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Terms of Agreement, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_InitialTermsOfAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial Terms of Agreement, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PaymentOfObligationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of obligation, term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PaymentOfObligationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Obligation Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PaymentOfObligationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PaymentOfObligationTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payment term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal, state and local net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical Trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical trials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, net of issuance costs, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized income tax benefits that would affect effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ContractualExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ContractualExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ContractualExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense related to agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fixed operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total fixed operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CapitalizedRDCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized R&amp;D costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CapitalizedRDCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized R&amp;D costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CapitalizedRDCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonVestedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-vested Founder Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonVestedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-vested common stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonVestedCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Vested Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingLeaseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of eligible tax positions for recognition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Eligible Tax Positions For Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of eligible tax positions for recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Four At The Market Offering Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Four At The Market Offering Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 At-The-Market Offering Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in connection with the exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credits amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax Credits amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PersonnelExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Personnel Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PersonnelExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Personnel Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PersonnelExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lesser of estimated useful life or remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property Plant And Equipment Estimated Useful Lives 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ResearchServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Service Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ResearchServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Service Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ResearchServiceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research service agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other inforamation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to unvested stock-based awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AgreementWithContractManufacturingOrganizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement with contract manufacturing organization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AgreementWithContractManufacturingOrganizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement With Contract Manufacturing Organization [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AgreementWithContractManufacturingOrganizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement with Contract Manufacturing Organization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, to be Paid, Next Rolling 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DevelopmentServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock under employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinanceLesseeUndiscountedLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lessee Undiscounted Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinanceLesseeUndiscountedLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance Lessee Undiscounted Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinanceLesseeUndiscountedLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_FinanceLesseeUndiscountedLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term - finance leases (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allocation of undistributed losses for basic computation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited/Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock, Warrants and Pre Funded Warrants, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Common Stock, Warrants and Pre Funded Warrants, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, warrants and pre-funded warrants, net of issuance costs, share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LesseeUndiscountedLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee Undiscounted Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LesseeUndiscountedLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Undiscounted Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LesseeUndiscountedLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LesseeUndiscountedLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_Caba201AndMuskCaartMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CABA-201 and MuSK-CAART [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_Caba201AndMuskCaartMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CABA-201 and MuSK-CAART [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company status.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement month and year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Month And Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LeaseCommencementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Contingency, Domestic, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Valuation Allowances (Domestic) amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lessee, Operating Lease, Liability, to be Paid, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LonzaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lonza Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LonzaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lonza Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LonzaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lonza Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LonzaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lonza Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional in fixed undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets, Operating Lease Liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockFromATMOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from ATM offering, net of sales agent commission and fees, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockFromATMOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock from ATM Offering Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockFromATMOfferingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Of Common Stock from ATM Offering Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of estimated useful lives of property and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Estimated Useful Lives Of Property And Equipment Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Lives for Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-voting common stock, terms of conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Terms of Conversion, Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Terms of Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseMaintenanceFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License maintenance fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseMaintenanceFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Maintenance Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseMaintenanceFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License maintenance fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets, Operating Loss Carryforwards, Local</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Earning per share basic and diluted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earning Per Share Basic And Diluted [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earning Per Share Basic And Diluted [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voting and non-voting common stock, $0.00001 par value: 300,000,000 (293,590,481 voting and 6,409,519 non-voting) shares authorized as of December 31, 2025 and 150,000,000 (143,590,481 voting and 6,409,519 non-voting) shares authorized as of December 31, 2024; 100,479,323 voting shares issuedand outstanding as of December 31, 2025 and 50,743,101voting shares issued and outstanding as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Principal Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Principal payments on finance leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Termination fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Subject to Compromise, Early Contract Termination Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early termination fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Equity, Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity Type of Counterparty [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity Type of Counterparty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive income:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and Local Income Taxes, Net of Federal Income Tax Effect Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplyCommitmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supply Commitment [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplyCommitmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Commitment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, authorized shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of Cross-Border Tax Laws Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties related to uncertain income tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AdditionalOptionsToBePurchasedByUnderwriters_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional options to be purchased by underwriters</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AdditionalOptionsToBePurchasedByUnderwriters_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Options to be purchased by underwriters</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AdditionalOptionsToBePurchasedByUnderwriters_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Options to be purchased by underwriters</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborations licensing agreements and other agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborations Licensing Agreements And Other Agreements [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations Licensing Agreements And Other Agreements [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Actual income tax benefit effective tax rate amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock, warrants and pre-funded warrants, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development services current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Services Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of shares purchased at fair market value of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Shares Purchased At Fair Market Value Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares to be purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TotalFixedFinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Fixed Finance Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TotalFixedFinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total Fixed Finance Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TotalFixedFinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Fixed Finance Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TotalFixedFinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Fixed Finance Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (years), Options Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingCashFlowsUsedForOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Cash Flows Used For Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingCashFlowsUsedForOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Cash Flows Used For Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_OperatingCashFlowsUsedForOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows used for operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets license fees deductions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets License Fees Deductions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fee deductions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TotalFinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Finance Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TotalFinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of lease cost recognized by lessee for lease contract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TotalFinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total finance lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TotalFinanceLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total finance lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, net of issuance costs, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborativeAgreementPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative agreement payments due.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborativeAgreementPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Agreement Payments Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborativeAgreementPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts due to agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted net loss per share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share of voting and non-voting common stock, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Rule 10b51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Rule 10b51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Rule 10b5-1 Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lesser of estimated useful life or remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SharesRemainingAvailableForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SharesRemainingAvailableForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">shares remaining available for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SharesRemainingAvailableForIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">shares remaining available for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen stock option and grant plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Stock Option And Grant Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) from Litigation Settlement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss related to litigation settlement accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Master translational research services agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Master Translational Research Services Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Master Translational Research Services Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term - operating leases (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, plant and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for operating lease obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents&#8212;end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents&#8212;beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issuance commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of payroll deduction on eligible compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Payroll Deduction On Eligible Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll deduction percentage of eligible compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from ATM offering, net of sales agent commission and fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock from ATM offering, net of sales agent commission and fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock from ATM offering, net of sales agent commission and fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_UnvestedStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_UnvestedStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate - operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Company's Operating and Finance Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets, Operating Loss Carryforwards, Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_June2025FinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">June 2025 Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_June2025FinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">June 2025 Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_June2025FinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">June 2025 Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rent expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rent Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued general and administrative services current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued General And Administrative Services Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Amortization of discount on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of (discount) premium on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued And Other Current Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SponsoredResearchAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sponsored Research Agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SponsoredResearchAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sponsored Research Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_SponsoredResearchAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sponsored Research Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal research and development net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement with Federal Government, Costs Incurred, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseOfIntellectualProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License of Intellectual Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseOfIntellectualProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License of Intellectual Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_LicenseOfIntellectualProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License of intellectual property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Allocation of undistributed losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Undistributed Earnings (Loss) Available to Common Shareholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allocation of undistributed losses attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Undistributed Earnings (Loss) Available to Common Shareholders, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInTheLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in the lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInTheLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in the lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_IncreaseInTheLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in the lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining research and development expense to be incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Research And Development Expense To Be Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining research and development expense to be incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborations licensing agreements and other agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborations Licensing Agreements And Other Agreements [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations, Licensing Agreements And Other Agreements [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Included in Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regents of the university of California.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regents Of University Of California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Penn</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, number of shares available for grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost, weighted average period for recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AnupMardaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Anup Marda [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="caba_AnupMardaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Anup Marda [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" xlink:to="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_December2022FinancingMember" xlink:to="caba_December2022FinancingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PreFundedWarrantsExercised" xlink:to="caba_PreFundedWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingLeasesAbtract" xlink:to="caba_OperatingLeasesAbtract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate" xlink:to="caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_FundingTermEndingDate" xlink:to="caba_FundingTermEndingDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ManufacturingAndOtherResearchAndDevelopmentServices" xlink:to="caba_ManufacturingAndOtherResearchAndDevelopmentServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportingUnits" xlink:to="us-gaap_NumberOfReportingUnits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" xlink:to="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IssuanceOfCommonStockFromATMOffering" xlink:to="caba_IssuanceOfCommonStockFromATMOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember" xlink:to="caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ResearchAndDevelopmentCredits" xlink:to="caba_ResearchAndDevelopmentCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:to="caba_StockIssuedDuringPeriodShareStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_MayTwoThousandTwentyThreeFinancingMember" xlink:to="caba_MayTwoThousandTwentyThreeFinancingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AnnualIncreasePercentageOfBaseRent" xlink:to="caba_AnnualIncreasePercentageOfBaseRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" xlink:to="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="us-gaap_AccretionExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ArunDasOneMember" xlink:to="caba_ArunDasOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" xlink:to="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ObligationToBePaidCommencementDate" xlink:to="caba_ObligationToBePaidCommencementDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue" xlink:to="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IncreaseInShareReservedPercentage" xlink:to="caba_IncreaseInShareReservedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_WorkOrdersTerm" xlink:to="caba_WorkOrdersTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TerminationFees" xlink:to="caba_TerminationFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CellaresAgreementMember" xlink:to="caba_CellaresAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CommonStockAndWarrantsMember" xlink:to="caba_CommonStockAndWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_NonCashFinanceLeaseExpense" xlink:to="caba_NonCashFinanceLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" xlink:to="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForUnderwritingExpense" xlink:to="us-gaap_PaymentsForUnderwritingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_WuXiAdvancedTherapiesMember" xlink:to="caba_WuXiAdvancedTherapiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_FinancingCashFlowsUsedForFinanceLeases" xlink:to="caba_FinancingCashFlowsUsedForFinanceLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_StockOptionRepricingMember" xlink:to="caba_StockOptionRepricingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember" xlink:to="caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_GwendolynBinderOneMember" xlink:to="caba_GwendolynBinderOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DE" xlink:to="country_DE_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" xlink:to="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_MilestonePayments" xlink:to="caba_MilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DevelopmentAndManufacturingServicesAgreementMember" xlink:to="caba_DevelopmentAndManufacturingServicesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ArunDasMember" xlink:to="caba_ArunDasMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OxfordBiomedicaMember" xlink:to="caba_OxfordBiomedicaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ManufacturingOfPreclinicalAndClinicalSupplies" xlink:to="caba_ManufacturingOfPreclinicalAndClinicalSupplies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ContractualCostIncurred" xlink:to="caba_ContractualCostIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AutolusHoldingsMember" xlink:to="caba_AutolusHoldingsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AnupMardaOneMember" xlink:to="caba_AnupMardaOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AmortizationExpense" xlink:to="caba_AmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_GwendolynBinderMember" xlink:to="caba_GwendolynBinderMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_VariableLeaseCosts" xlink:to="caba_VariableLeaseCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_FixedLeaseCost" xlink:to="caba_FixedLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantPurchaseCommitmentDescription" xlink:to="us-gaap_SignificantPurchaseCommitmentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvotingCommonStockMember" xlink:to="us-gaap_NonvotingCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="caba_EarningsPerShareBasicAndDilutedTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PreFundedWarrantsMember" xlink:to="caba_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_SubscriptionAndTechnologyTransferAgreementMember" xlink:to="caba_SubscriptionAndTechnologyTransferAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_NumberOfFaculty" xlink:to="caba_NumberOfFaculty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_VestedStockOptionMember" xlink:to="caba_VestedStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OrphanDrugCreditsMember" xlink:to="caba_OrphanDrugCreditsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateNoteSecuritiesMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LeaseAmendmentPeriod" xlink:to="caba_LeaseAmendmentPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingLeaseAgreementMember" xlink:to="caba_OperatingLeaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_VotingCommonStockMember" xlink:to="caba_VotingCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ClinicalTrialResearchAndDevelopmentServices" xlink:to="caba_ClinicalTrialResearchAndDevelopmentServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_Rese-CelAndMuSK-CAARTMember" xlink:to="caba_Rese-CelAndMuSK-CAARTMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_NonCashLeaseExpense" xlink:to="caba_NonCashLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_FinanceLeasesAbstract" xlink:to="caba_FinanceLeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:to="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_Rule10B51ArrModifiedFlag" xlink:to="caba_Rule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AdvancePayments" xlink:to="caba_AdvancePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="us-gaap_SupplyCommitmentArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ChildrenSHospitalOfPhiladelphiaMember" xlink:to="caba_ChildrenSHospitalOfPhiladelphiaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LeaseExpirationMonth" xlink:to="caba_LeaseExpirationMonth_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceDecrease" xlink:to="us-gaap_StockOptionExercisePriceDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TwoThousandTwentyFiveSalesAgreementMember" xlink:to="caba_TwoThousandTwentyFiveSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_StevenNichtbergerMember" xlink:to="caba_StevenNichtbergerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingCashFlowsUsedForFinanceLeases" xlink:to="caba_OperatingCashFlowsUsedForFinanceLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AtTheMarketOfferingSalesAgreementMember" xlink:to="caba_AtTheMarketOfferingSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IncreaseInTheRouAsset" xlink:to="caba_IncreaseInTheRouAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_WeightedAverageNumberOfSharesOutstanding" xlink:to="caba_WeightedAverageNumberOfSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:to="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LeaseExpirationMonthAndYear" xlink:to="caba_LeaseExpirationMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_WuxiAgreementMember" xlink:to="caba_WuxiAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_StevenNichtbergerOneMember" xlink:to="caba_StevenNichtbergerOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" xlink:to="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_NanjingIasoBiotherapeuticsCoLtdMember" xlink:to="caba_NanjingIasoBiotherapeuticsCoLtdMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TwoThousandTwentyFiveInducementPlanMember" xlink:to="caba_TwoThousandTwentyFiveInducementPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" xlink:to="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ExpectedCostIncurredForPurchaseOfPlasmids" xlink:to="caba_ExpectedCostIncurredForPurchaseOfPlasmids_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:to="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_InitialTermsOfAgreementDescription" xlink:to="caba_InitialTermsOfAgreementDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PaymentOfObligationTerm" xlink:to="caba_PaymentOfObligationTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ClinicalTrials" xlink:to="caba_ClinicalTrials_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ContractualExpenses" xlink:to="caba_ContractualExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CapitalizedRDCosts" xlink:to="caba_CapitalizedRDCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_MilestonePayment" xlink:to="caba_MilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_NonVestedCommonStockMember" xlink:to="caba_NonVestedCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingLeaseAssets" xlink:to="caba_OperatingLeaseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PercentageOfEligibleTaxPositionsForRecognition" xlink:to="caba_PercentageOfEligibleTaxPositionsForRecognition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember" xlink:to="caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PersonnelExpenses" xlink:to="caba_PersonnelExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:to="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ResearchServiceAgreementMember" xlink:to="caba_ResearchServiceAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OtherInformationAbstract" xlink:to="caba_OtherInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_UpfrontPayment" xlink:to="caba_UpfrontPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AgreementWithContractManufacturingOrganizationMember" xlink:to="caba_AgreementWithContractManufacturingOrganizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DevelopmentServices" xlink:to="caba_DevelopmentServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_FinanceLesseeUndiscountedLeasePayments" xlink:to="caba_FinanceLesseeUndiscountedLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares" xlink:to="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LesseeUndiscountedLeasePayments" xlink:to="caba_LesseeUndiscountedLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IncomeTaxDisclosureTable" xlink:to="caba_IncomeTaxDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_Caba201AndMuskCaartMember" xlink:to="caba_Caba201AndMuskCaartMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="caba_EmergingGrowthCompanyStatusPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LeaseCommencementMonthAndYear" xlink:to="caba_LeaseCommencementMonthAndYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LonzaAgreementMember" xlink:to="caba_LonzaAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="caba_DeferredTaxAssetsOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IssuanceOfCommonStockFromATMOfferingAmount" xlink:to="caba_IssuanceOfCommonStockFromATMOfferingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_IncomeTaxDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConversionFeatures" xlink:to="us-gaap_CommonStockConversionFeatures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LicenseMaintenanceFee" xlink:to="caba_LicenseMaintenanceFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LaboratoryEquipmentMember" xlink:to="caba_LaboratoryEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="caba_EarningPerShareBasicAndDilutedLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="caba_CommitmentsAndContingenciesDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AdditionalOptionsToBePurchasedByUnderwriters" xlink:to="caba_AdditionalOptionsToBePurchasedByUnderwriters_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AccruedResearchAndDevelopmentServicesCurrent" xlink:to="caba_AccruedResearchAndDevelopmentServicesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" xlink:to="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForCommissions" xlink:to="us-gaap_PaymentsForCommissions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TotalFixedFinanceLeaseCost" xlink:to="caba_TotalFixedFinanceLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_OperatingCashFlowsUsedForOperatingLeases" xlink:to="caba_OperatingCashFlowsUsedForOperatingLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_DeferredTaxAssetsLicenseFeesDeductions" xlink:to="caba_DeferredTaxAssetsLicenseFeesDeductions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TotalFinanceLeaseCost" xlink:to="caba_TotalFinanceLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CollaborativeAgreementPaymentsDue" xlink:to="caba_CollaborativeAgreementPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_NonRule10B51ArrModifiedFlag" xlink:to="caba_NonRule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_SharesRemainingAvailableForIssuance" xlink:to="caba_SharesRemainingAvailableForIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:to="caba_TwoThousandEighteenStockOptionAndGrantPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_MasterTranslationalResearchServicesAgreementMember" xlink:to="caba_MasterTranslationalResearchServicesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_CommitmentsAndContingenciesDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:to="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_PercentageOfPayrollDeductionOnEligibleCompensation" xlink:to="caba_PercentageOfPayrollDeductionOnEligibleCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees" xlink:to="caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_UnvestedStockOptionMember" xlink:to="caba_UnvestedStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LicenseAgreementMember" xlink:to="caba_LicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_June2025FinancingMember" xlink:to="caba_June2025FinancingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_RentExpense" xlink:to="caba_RentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AccruedGeneralAndAdministrativeServicesCurrent" xlink:to="caba_AccruedGeneralAndAdministrativeServicesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AccruedAndOtherCurrentLiabilitiesMember" xlink:to="caba_AccruedAndOtherCurrentLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_SponsoredResearchAgreementsMember" xlink:to="caba_SponsoredResearchAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_LicenseOfIntellectualProperty" xlink:to="caba_LicenseOfIntellectualProperty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:to="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_IncreaseInTheLeaseLiability" xlink:to="caba_IncreaseInTheLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred" xlink:to="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_RegentsOfUniversityOfCaliforniaMember" xlink:to="caba_RegentsOfUniversityOfCaliforniaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="caba_AnupMardaMember" xlink:to="caba_AnupMardaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="89.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_VotingCommonStockMember" xlink:label="caba_VotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares" xlink:label="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue" xlink:label="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockFromATMOffering" xlink:label="caba_IssuanceOfCommonStockFromATMOffering"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockFromATMOfferingAmount" xlink:label="caba_IssuanceOfCommonStockFromATMOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" xlink:label="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_17"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_18"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_19"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_IssuanceOfCommonStockFromATMOffering" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_IssuanceOfCommonStockFromATMOfferingAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_StockIssuedDuringPeriodShareStockOptionsExercised" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_19" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CommonStockAndWarrantsMember" xlink:label="caba_CommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="caba_CommonStockAndWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees" xlink:label="caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_NonCashFinanceLeaseExpense" xlink:label="caba_NonCashFinanceLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_NonCashLeaseExpense" xlink:label="caba_NonCashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="caba_NonCashFinanceLeaseExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="caba_NonCashLeaseExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_StevenNichtbergerMember" xlink:label="caba_StevenNichtbergerMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_StevenNichtbergerOneMember" xlink:label="caba_StevenNichtbergerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AnupMardaMember" xlink:label="caba_AnupMardaMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AnupMardaOneMember" xlink:label="caba_AnupMardaOneMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ArunDasMember" xlink:label="caba_ArunDasMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ArunDasOneMember" xlink:label="caba_ArunDasOneMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_GwendolynBinderMember" xlink:label="caba_GwendolynBinderMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_GwendolynBinderOneMember" xlink:label="caba_GwendolynBinderOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_Rule10B51ArrModifiedFlag" xlink:label="caba_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_NonRule10B51ArrModifiedFlag" xlink:label="caba_NonRule10B51ArrModifiedFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_StevenNichtbergerMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_StevenNichtbergerOneMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_AnupMardaMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_AnupMardaOneMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_ArunDasMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_ArunDasOneMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_GwendolynBinderMember" order="8.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_GwendolynBinderOneMember" order="9.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="caba_Rule10B51ArrModifiedFlag" order="14.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="caba_NonRule10B51ArrModifiedFlag" order="15.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_Disclosure401KSavingsPlan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequentEvent" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" xlink:label="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="caba_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="caba_EmergingGrowthCompanyStatusPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportingUnits" xlink:label="us-gaap_NumberOfReportingUnits"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfReportingUnits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LaboratoryEquipmentMember" xlink:label="caba_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:label="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="caba_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_ShortTermInvestmentsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_InvestmentTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended"/>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateNoteSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedResearchAndDevelopmentServicesCurrent" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ClinicalTrialResearchAndDevelopmentServices" xlink:label="caba_ClinicalTrialResearchAndDevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ManufacturingAndOtherResearchAndDevelopmentServices" xlink:label="caba_ManufacturingAndOtherResearchAndDevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedGeneralAndAdministrativeServicesCurrent" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="caba_AccruedResearchAndDevelopmentServicesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="caba_ClinicalTrialResearchAndDevelopmentServices" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="caba_ManufacturingAndOtherResearchAndDevelopmentServices" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="caba_AccruedGeneralAndAdministrativeServicesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LicenseAgreementMember" xlink:label="caba_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_RegentsOfUniversityOfCaliforniaMember" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_SponsoredResearchAgreementsMember" xlink:label="caba_SponsoredResearchAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PaymentOfObligationTerm" xlink:label="caba_PaymentOfObligationTerm"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_MasterTranslationalResearchServicesAgreementMember" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ObligationToBePaidCommencementDate" xlink:label="caba_ObligationToBePaidCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_SubscriptionAndTechnologyTransferAgreementMember" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LicenseMaintenanceFee" xlink:label="caba_LicenseMaintenanceFee"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OxfordBiomedicaMember" xlink:label="caba_OxfordBiomedicaMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_MilestonePayments" xlink:label="caba_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_NanjingIasoBiotherapeuticsCoLtdMember" xlink:label="caba_NanjingIasoBiotherapeuticsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CollaborativeAgreementPaymentsDue" xlink:label="caba_CollaborativeAgreementPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AutolusHoldingsMember" xlink:label="caba_AutolusHoldingsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_NumberOfFaculty" xlink:label="caba_NumberOfFaculty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_FundingTermEndingDate" xlink:label="caba_FundingTermEndingDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ContractualCostIncurred" xlink:label="caba_ContractualCostIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AdvancePayments" xlink:label="caba_AdvancePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_RemainingResearchAndDevelopmentExpenseToBeIncurred" xlink:label="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_UpfrontPayment" xlink:label="caba_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_MilestonePayment" xlink:label="caba_MilestonePayment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_LicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="caba_RegentsOfUniversityOfCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_ContractualObligation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="caba_AccruedAndOtherCurrentLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_SponsoredResearchAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_PaymentOfObligationTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_MasterTranslationalResearchServicesAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_ObligationToBePaidCommencementDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_SubscriptionAndTechnologyTransferAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_LicenseMaintenanceFee" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_OxfordBiomedicaMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_MilestonePayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_NanjingIasoBiotherapeuticsCoLtdMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_CollaborativeAgreementPaymentsDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_AutolusHoldingsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_NumberOfFaculty" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_FundingTermEndingDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_ContractualCostIncurred" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_AdvancePayments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_OtherExpenses" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_UpfrontPayment" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_MilestonePayment" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingLeaseAgreementMember" xlink:label="caba_OperatingLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CommitmentsAndContingenciesDisclosureTable" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_WuXiAdvancedTherapiesMember" xlink:label="caba_WuXiAdvancedTherapiesMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_DevelopmentAndManufacturingServicesAgreementMember" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_Caba201AndMuskCaartMember" xlink:label="caba_Caba201AndMuskCaartMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LeaseCommencementMonthAndYear" xlink:label="caba_LeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LonzaAgreementMember" xlink:label="caba_LonzaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_Rese-CelAndMuSK-CAARTMember" xlink:label="caba_Rese-CelAndMuSK-CAARTMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LeaseExpirationMonthAndYear" xlink:label="caba_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CellaresAgreementMember" xlink:label="caba_CellaresAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ChildrenSHospitalOfPhiladelphiaMember" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantPurchaseCommitmentDescription" xlink:label="us-gaap_SignificantPurchaseCommitmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ResearchServiceAgreementMember" xlink:label="caba_ResearchServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LeaseExpirationMonth" xlink:label="caba_LeaseExpirationMonth"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AgreementWithContractManufacturingOrganizationMember" xlink:label="caba_AgreementWithContractManufacturingOrganizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AnnualIncreasePercentageOfBaseRent" xlink:label="caba_AnnualIncreasePercentageOfBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_RentExpense" xlink:label="caba_RentExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LeaseAmendmentPeriod" xlink:label="caba_LeaseAmendmentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_InitialTermsOfAgreementDescription" xlink:label="caba_InitialTermsOfAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PaymentOfObligationTerm" xlink:label="caba_PaymentOfObligationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ExpectedCostIncurredForPurchaseOfPlasmids" xlink:label="caba_ExpectedCostIncurredForPurchaseOfPlasmids"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ContractualExpenses" xlink:label="caba_ContractualExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="caba_AccruedAndOtherCurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_OperatingLeaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="caba_CommitmentsAndContingenciesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_WuXiAdvancedTherapiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_DevelopmentAndManufacturingServicesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_Caba201AndMuskCaartMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseCommencementMonthAndYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_LonzaAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_Rese-CelAndMuSK-CAARTMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseExpirationMonthAndYear" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_CellaresAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_ChildrenSHospitalOfPhiladelphiaMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_SignificantPurchaseCommitmentDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_ResearchServiceAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="caba_CommitmentsAndContingenciesDisclosureLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseExpirationMonth" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_AgreementWithContractManufacturingOrganizationMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_AnnualIncreasePercentageOfBaseRent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_RentExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseAmendmentPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_InitialTermsOfAgreementDescription" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_PaymentOfObligationTerm" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ContractualObligation" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_ExpectedCostIncurredForPurchaseOfPlasmids" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_ContractualExpenses" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" xlink:label="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PersonnelExpenses" xlink:label="caba_PersonnelExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ClinicalTrials" xlink:label="caba_ClinicalTrials"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_DevelopmentServices" xlink:label="caba_DevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ManufacturingOfPreclinicalAndClinicalSupplies" xlink:label="caba_ManufacturingOfPreclinicalAndClinicalSupplies"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LicenseOfIntellectualProperty" xlink:label="caba_LicenseOfIntellectualProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="caba_PersonnelExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="caba_ClinicalTrials" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="caba_DevelopmentServices" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="caba_ManufacturingOfPreclinicalAndClinicalSupplies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="caba_LicenseOfIntellectualProperty" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_WuxiAgreementMember" xlink:label="caba_WuxiAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LonzaAgreementMember" xlink:label="caba_LonzaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TerminationFees" xlink:label="caba_TerminationFees"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_WorkOrdersTerm" xlink:label="caba_WorkOrdersTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IncreaseInTheRouAsset" xlink:label="caba_IncreaseInTheRouAsset"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IncreaseInTheLeaseLiability" xlink:label="caba_IncreaseInTheLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_WuxiAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_LonzaAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="caba_TerminationFees" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="caba_WorkOrdersTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCost" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_VariableLeaseCost" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="caba_IncreaseInTheRouAsset" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="caba_IncreaseInTheLeaseLiability" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityAbstract" xlink:label="us-gaap_FinanceLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_FinanceLesseeUndiscountedLeasePayments" xlink:label="caba_FinanceLesseeUndiscountedLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LesseeUndiscountedLeasePayments" xlink:label="caba_LesseeUndiscountedLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="caba_FinanceLesseeUndiscountedLeasePayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="caba_LesseeUndiscountedLeasePayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingLeasesAbtract" xlink:label="caba_OperatingLeasesAbtract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_FixedLeaseCost" xlink:label="caba_FixedLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:label="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingCashFlowsUsedForOperatingLeases" xlink:label="caba_OperatingCashFlowsUsedForOperatingLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_FinanceLeasesAbstract" xlink:label="caba_FinanceLeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OtherInformationAbstract" xlink:label="caba_OtherInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingCashFlowsUsedForFinanceLeases" xlink:label="caba_OperatingCashFlowsUsedForFinanceLeases"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AmortizationExpense" xlink:label="caba_AmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_FinancingCashFlowsUsedForFinanceLeases" xlink:label="caba_FinancingCashFlowsUsedForFinanceLeases"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TotalFixedFinanceLeaseCost" xlink:label="caba_TotalFixedFinanceLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_VariableLeaseCosts" xlink:label="caba_VariableLeaseCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TotalFinanceLeaseCost" xlink:label="caba_TotalFinanceLeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OperatingLeasesAbtract" xlink:to="caba_FixedLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="caba_OperatingCashFlowsUsedForOperatingLeases" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="caba_FinanceLeasesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_FinanceLeasesAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OtherInformationAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OperatingLeasesAbtract" xlink:to="us-gaap_OperatingLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="caba_OperatingCashFlowsUsedForFinanceLeases" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="caba_OperatingLeasesAbtract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_FinanceLeasesAbstract" xlink:to="caba_AmortizationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OtherInformationAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OperatingLeasesAbtract" xlink:to="us-gaap_VariableLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="caba_FinancingCashFlowsUsedForFinanceLeases" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_FinanceLeasesAbstract" xlink:to="caba_TotalFixedFinanceLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OtherInformationAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OperatingLeasesAbtract" xlink:to="us-gaap_ShortTermLeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="caba_OtherInformationAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_FinanceLeasesAbstract" xlink:to="caba_VariableLeaseCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OtherInformationAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_OperatingLeasesAbtract" xlink:to="us-gaap_LeaseCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_FinanceLeasesAbstract" xlink:to="caba_TotalFinanceLeaseCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AtTheMarketOfferingSalesAgreementMember" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_VotingCommonStockMember" xlink:label="caba_VotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember" xlink:label="caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember" xlink:label="caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PreFundedWarrantsMember" xlink:label="caba_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandTwentyFiveSalesAgreementMember" xlink:label="caba_TwoThousandTwentyFiveSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_UnvestedStockOptionMember" xlink:label="caba_UnvestedStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AdditionalOptionsToBePurchasedByUnderwriters" xlink:label="caba_AdditionalOptionsToBePurchasedByUnderwriters"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_VestedStockOptionMember" xlink:label="caba_VestedStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="us-gaap_CommonStockConversionFeatures"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_StockOptionRepricingMember" xlink:label="caba_StockOptionRepricingMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AtTheMarketOfferingSalesAgreementMember" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember_7"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PreFundedWarrantsExercised" xlink:label="caba_PreFundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember_8"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_8.0"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember" xlink:label="caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_MayTwoThousandTwentyThreeFinancingMember" xlink:label="caba_MayTwoThousandTwentyThreeFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="us-gaap_PaymentsForUnderwritingExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_June2025FinancingMember" xlink:label="caba_June2025FinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_December2022FinancingMember" xlink:label="caba_December2022FinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandTwentyFiveInducementPlanMember" xlink:label="caba_TwoThousandTwentyFiveInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceDecrease" xlink:label="us-gaap_StockOptionExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsShares" xlink:label="us-gaap_CommonStockDividendsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_SharesRemainingAvailableForIssuance" xlink:label="caba_SharesRemainingAvailableForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IncreaseInShareReservedPercentage" xlink:label="caba_IncreaseInShareReservedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="us-gaap_StockOptionExercisePriceIncrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PercentageOfPayrollDeductionOnEligibleCompensation" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_AtTheMarketOfferingSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_PreFundedWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandTwentyFiveSalesAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="caba_UnvestedStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandEighteenStockOptionAndGrantPlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_AdditionalOptionsToBePurchasedByUnderwriters" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="caba_VestedStockOptionMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockConversionFeatures" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="caba_StockOptionRepricingMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandEighteenStockOptionAndGrantPlanMember_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_AtTheMarketOfferingSalesAgreementMember_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_PreFundedWarrantsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember_8.0" order="8.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_MayTwoThousandTwentyThreeFinancingMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsForUnderwritingExpense" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_June2025FinancingMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_December2022FinancingMember" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandTwentyFiveInducementPlanMember" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsForCommissions" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_SharesRemainingAvailableForIssuance" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_IncreaseInShareReservedPercentage" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_PercentageOfPayrollDeductionOnEligibleCompensation" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_DE" xlink:label="country_DE"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" xlink:label="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:label="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_DE" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingLeaseAssets" xlink:label="caba_OperatingLeaseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CapitalizedRDCosts" xlink:label="caba_CapitalizedRDCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_DeferredTaxAssetsLicenseFeesDeductions" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="caba_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="caba_OperatingLeaseAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="caba_CapitalizedRDCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="caba_DeferredTaxAssetsLicenseFeesDeductions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="caba_DeferredTaxAssetsOperatingLeaseLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IncomeTaxDisclosureTable" xlink:label="caba_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IncomeTaxDisclosureLineItems" xlink:label="caba_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OrphanDrugCreditsMember" xlink:label="caba_OrphanDrugCreditsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate" xlink:label="caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ResearchAndDevelopmentCredits" xlink:label="caba_ResearchAndDevelopmentCredits"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PercentageOfEligibleTaxPositionsForRecognition" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="caba_IncomeTaxDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureTable" xlink:to="caba_IncomeTaxDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="caba_OrphanDrugCreditsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_ResearchAndDevelopmentCredits" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_PercentageOfEligibleTaxPositionsForRecognition" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_VotingCommonStockMember" xlink:label="caba_VotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_WeightedAverageNumberOfSharesOutstanding" xlink:label="caba_WeightedAverageNumberOfSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="caba_WeightedAverageNumberOfSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EarningsPerShareBasicAndDilutedTable" xlink:label="caba_EarningsPerShareBasicAndDilutedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EarningPerShareBasicAndDilutedLineItems" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_VotingCommonStockMember" xlink:label="caba_VotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="caba_EarningsPerShareBasicAndDilutedTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="caba_EarningPerShareBasicAndDilutedLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_NonVestedCommonStockMember" xlink:label="caba_NonVestedCommonStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="caba_NonVestedCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EarningsPerShareBasicAndDilutedTable" xlink:label="caba_EarningsPerShareBasicAndDilutedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PreFundedWarrantsMember" xlink:label="caba_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EarningPerShareBasicAndDilutedLineItems" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="caba_EarningsPerShareBasicAndDilutedTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="caba_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="caba_EarningPerShareBasicAndDilutedLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_Disclosure401KSavingsPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_UpfrontPayment" xlink:label="caba_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AutolusHoldingsMember" xlink:label="caba_AutolusHoldingsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_MilestonePayments" xlink:label="caba_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="caba_UpfrontPayment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_AutolusHoldingsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="caba_UpfrontPayment" xlink:to="caba_MilestonePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SupplyCommitmentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_VotingCommonStockMember" xlink:label="caba_VotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares" xlink:label="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue" xlink:label="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockFromATMOffering" xlink:label="caba_IssuanceOfCommonStockFromATMOffering"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockFromATMOfferingAmount" xlink:label="caba_IssuanceOfCommonStockFromATMOfferingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_StockIssuedDuringPeriodShareStockOptionsExercised" xlink:label="caba_StockIssuedDuringPeriodShareStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" xlink:label="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_IssuanceOfCommonStockFromATMOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_IssuanceOfCommonStockFromATMOfferingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_StockIssuedDuringPeriodShareStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CommonStockAndWarrantsMember" xlink:label="caba_CommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="caba_CommonStockAndWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_StevenNichtbergerMember" xlink:label="caba_StevenNichtbergerMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_StevenNichtbergerOneMember" xlink:label="caba_StevenNichtbergerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AnupMardaMember" xlink:label="caba_AnupMardaMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AnupMardaOneMember" xlink:label="caba_AnupMardaOneMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ArunDasMember" xlink:label="caba_ArunDasMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ArunDasOneMember" xlink:label="caba_ArunDasOneMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_GwendolynBinderMember" xlink:label="caba_GwendolynBinderMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_GwendolynBinderOneMember" xlink:label="caba_GwendolynBinderOneMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_StevenNichtbergerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_StevenNichtbergerOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_AnupMardaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_AnupMardaOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_ArunDasMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_ArunDasOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_GwendolynBinderMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="caba_GwendolynBinderOneMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LaboratoryEquipmentMember" xlink:label="caba_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:label="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="caba_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="us-gaap_ShortTermInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermInvestmentsAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_ShortTermInvestmentsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CashMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateNoteSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:label="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LicenseAgreementMember" xlink:label="caba_LicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_RegentsOfUniversityOfCaliforniaMember" xlink:label="caba_RegentsOfUniversityOfCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_SponsoredResearchAgreementsMember" xlink:label="caba_SponsoredResearchAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PaymentOfObligationTerm" xlink:label="caba_PaymentOfObligationTerm"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_MasterTranslationalResearchServicesAgreementMember" xlink:label="caba_MasterTranslationalResearchServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ObligationToBePaidCommencementDate" xlink:label="caba_ObligationToBePaidCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_SubscriptionAndTechnologyTransferAgreementMember" xlink:label="caba_SubscriptionAndTechnologyTransferAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LicenseMaintenanceFee" xlink:label="caba_LicenseMaintenanceFee"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OxfordBiomedicaMember" xlink:label="caba_OxfordBiomedicaMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_MilestonePayments" xlink:label="caba_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_NanjingIasoBiotherapeuticsCoLtdMember" xlink:label="caba_NanjingIasoBiotherapeuticsCoLtdMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CollaborativeAgreementPaymentsDue" xlink:label="caba_CollaborativeAgreementPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AutolusHoldingsMember" xlink:label="caba_AutolusHoldingsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_NumberOfFaculty" xlink:label="caba_NumberOfFaculty"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_FundingTermEndingDate" xlink:label="caba_FundingTermEndingDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ContractualCostIncurred" xlink:label="caba_ContractualCostIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AdvancePayments" xlink:label="caba_AdvancePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_RemainingResearchAndDevelopmentExpenseToBeIncurred" xlink:label="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_UpfrontPayment" xlink:label="caba_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_MilestonePayment" xlink:label="caba_MilestonePayment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_LicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="caba_RegentsOfUniversityOfCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_ContractualObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="caba_AccruedAndOtherCurrentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_SponsoredResearchAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_SupplyCommitmentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_PaymentOfObligationTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_MasterTranslationalResearchServicesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_ObligationToBePaidCommencementDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_SubscriptionAndTechnologyTransferAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_LicenseMaintenanceFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_OxfordBiomedicaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_MilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_NanjingIasoBiotherapeuticsCoLtdMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_CollaborativeAgreementPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_AutolusHoldingsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_NumberOfFaculty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_FundingTermEndingDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_ContractualCostIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_AdvancePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_OtherExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_UpfrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" xlink:to="caba_MilestonePayment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="caba_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CommitmentsAndContingenciesDisclosureTable" xlink:label="caba_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="caba_AccruedAndOtherCurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingLeaseAgreementMember" xlink:label="caba_OperatingLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_WuXiAdvancedTherapiesMember" xlink:label="caba_WuXiAdvancedTherapiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_DevelopmentAndManufacturingServicesAgreementMember" xlink:label="caba_DevelopmentAndManufacturingServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_Caba201AndMuskCaartMember" xlink:label="caba_Caba201AndMuskCaartMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LeaseCommencementMonthAndYear" xlink:label="caba_LeaseCommencementMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LonzaAgreementMember" xlink:label="caba_LonzaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_Rese-CelAndMuSK-CAARTMember" xlink:label="caba_Rese-CelAndMuSK-CAARTMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LeaseExpirationMonthAndYear" xlink:label="caba_LeaseExpirationMonthAndYear"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CellaresAgreementMember" xlink:label="caba_CellaresAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ChildrenSHospitalOfPhiladelphiaMember" xlink:label="caba_ChildrenSHospitalOfPhiladelphiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantPurchaseCommitmentDescription" xlink:label="us-gaap_SignificantPurchaseCommitmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ResearchServiceAgreementMember" xlink:label="caba_ResearchServiceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LeaseExpirationMonth" xlink:label="caba_LeaseExpirationMonth"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AgreementWithContractManufacturingOrganizationMember" xlink:label="caba_AgreementWithContractManufacturingOrganizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AnnualIncreasePercentageOfBaseRent" xlink:label="caba_AnnualIncreasePercentageOfBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_RentExpense" xlink:label="caba_RentExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LeaseAmendmentPeriod" xlink:label="caba_LeaseAmendmentPeriod"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_InitialTermsOfAgreementDescription" xlink:label="caba_InitialTermsOfAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PaymentOfObligationTerm" xlink:label="caba_PaymentOfObligationTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ExpectedCostIncurredForPurchaseOfPlasmids" xlink:label="caba_ExpectedCostIncurredForPurchaseOfPlasmids"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ContractualExpenses" xlink:label="caba_ContractualExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_CommitmentsAndContingenciesDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="caba_AccruedAndOtherCurrentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_OperatingLeaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SupplyCommitmentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_WuXiAdvancedTherapiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_DevelopmentAndManufacturingServicesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_Caba201AndMuskCaartMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseCommencementMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_LonzaAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_Rese-CelAndMuSK-CAARTMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseExpirationMonthAndYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_CellaresAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="caba_ChildrenSHospitalOfPhiladelphiaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_SignificantPurchaseCommitmentDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_ResearchServiceAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseExpirationMonth" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_AgreementWithContractManufacturingOrganizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseMinimumRentals" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_AnnualIncreasePercentageOfBaseRent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_RentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_LeaseAmendmentPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_InitialTermsOfAgreementDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_PaymentOfObligationTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ContractualObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_ExpectedCostIncurredForPurchaseOfPlasmids" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="caba_ContractualExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_WuxiAgreementMember" xlink:label="caba_WuxiAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LonzaAgreementMember" xlink:label="caba_LonzaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TerminationFees" xlink:label="caba_TerminationFees"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_WorkOrdersTerm" xlink:label="caba_WorkOrdersTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IncreaseInTheRouAsset" xlink:label="caba_IncreaseInTheRouAsset"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IncreaseInTheLeaseLiability" xlink:label="caba_IncreaseInTheLeaseLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_WuxiAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_LonzaAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="caba_TerminationFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="caba_WorkOrdersTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_VariableLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="caba_IncreaseInTheRouAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="caba_IncreaseInTheLeaseLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AtTheMarketOfferingSalesAgreementMember" xlink:label="caba_AtTheMarketOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_VotingCommonStockMember" xlink:label="caba_VotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_UnvestedStockOptionMember" xlink:label="caba_UnvestedStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember" xlink:label="caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_VestedStockOptionMember" xlink:label="caba_VestedStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember" xlink:label="caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PreFundedWarrantsMember" xlink:label="caba_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_StockOptionRepricingMember" xlink:label="caba_StockOptionRepricingMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandTwentyFiveSalesAgreementMember" xlink:label="caba_TwoThousandTwentyFiveSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandEighteenStockOptionAndGrantPlanMember" xlink:label="caba_TwoThousandEighteenStockOptionAndGrantPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AdditionalOptionsToBePurchasedByUnderwriters" xlink:label="caba_AdditionalOptionsToBePurchasedByUnderwriters"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="us-gaap_CommonStockConversionFeatures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PreFundedWarrantsExercised" xlink:label="caba_PreFundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember" xlink:label="caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_MayTwoThousandTwentyThreeFinancingMember" xlink:label="caba_MayTwoThousandTwentyThreeFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="us-gaap_PaymentsForUnderwritingExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_June2025FinancingMember" xlink:label="caba_June2025FinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_December2022FinancingMember" xlink:label="caba_December2022FinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandTwentyFiveInducementPlanMember" xlink:label="caba_TwoThousandTwentyFiveInducementPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceDecrease" xlink:label="us-gaap_StockOptionExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockDividendsShares" xlink:label="us-gaap_CommonStockDividendsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_SharesRemainingAvailableForIssuance" xlink:label="caba_SharesRemainingAvailableForIssuance"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IncreaseInShareReservedPercentage" xlink:label="caba_IncreaseInShareReservedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="us-gaap_StockOptionExercisePriceIncrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PercentageOfPayrollDeductionOnEligibleCompensation" xlink:label="caba_PercentageOfPayrollDeductionOnEligibleCompensation"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" xlink:label="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" xlink:label="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_AtTheMarketOfferingSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="caba_UnvestedStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="caba_VestedStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="caba_StockOptionRepricingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandTwentyFiveSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandEighteenStockOptionAndGrantPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_AdditionalOptionsToBePurchasedByUnderwriters" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockConversionFeatures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_PreFundedWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_MayTwoThousandTwentyThreeFinancingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsForUnderwritingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_June2025FinancingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_December2022FinancingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandTwentyFiveInducementPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsForCommissions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_SharesRemainingAvailableForIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_IncreaseInShareReservedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_PercentageOfPayrollDeductionOnEligibleCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" xlink:label="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_DE" xlink:label="country_DE"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" xlink:label="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:label="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="country_DE" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IncomeTaxDisclosureLineItems" xlink:label="caba_IncomeTaxDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IncomeTaxDisclosureTable" xlink:label="caba_IncomeTaxDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OrphanDrugCreditsMember" xlink:label="caba_OrphanDrugCreditsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" xlink:label="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate" xlink:label="caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ResearchAndDevelopmentCredits" xlink:label="caba_ResearchAndDevelopmentCredits"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" xlink:label="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PercentageOfEligibleTaxPositionsForRecognition" xlink:label="caba_PercentageOfEligibleTaxPositionsForRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_IncomeTaxDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="caba_OrphanDrugCreditsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_ResearchAndDevelopmentCredits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="caba_PercentageOfEligibleTaxPositionsForRecognition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_VotingCommonStockMember" xlink:label="caba_VotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_WeightedAverageNumberOfSharesOutstanding" xlink:label="caba_WeightedAverageNumberOfSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="caba_WeightedAverageNumberOfSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EarningPerShareBasicAndDilutedLineItems" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EarningsPerShareBasicAndDilutedTable" xlink:label="caba_EarningsPerShareBasicAndDilutedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:label="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_VotingCommonStockMember" xlink:label="caba_VotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="caba_EarningsPerShareBasicAndDilutedTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="caba_VotingCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_NonVestedCommonStockMember" xlink:label="caba_NonVestedCommonStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="caba_NonVestedCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EarningPerShareBasicAndDilutedLineItems" xlink:label="caba_EarningPerShareBasicAndDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EarningsPerShareBasicAndDilutedTable" xlink:label="caba_EarningsPerShareBasicAndDilutedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PreFundedWarrantsMember" xlink:label="caba_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="caba_EarningsPerShareBasicAndDilutedTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="caba_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="caba_EarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_EarningPerShareBasicAndDilutedLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_UpfrontPayment" xlink:label="caba_UpfrontPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplyCommitmentArrangementMember" xlink:label="us-gaap_SupplyCommitmentArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AutolusHoldingsMember" xlink:label="caba_AutolusHoldingsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_MilestonePayments" xlink:label="caba_MilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplyCommitmentAxis" xlink:label="us-gaap_SupplyCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="caba_UpfrontPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentArrangementMember" xlink:to="caba_AutolusHoldingsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="caba_UpfrontPayment" xlink:to="caba_MilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SupplyCommitmentAxis" xlink:to="us-gaap_SupplyCommitmentArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SupplyCommitmentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" xlink:label="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:to="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanysEffectiveIncomeTaxRateDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic" xlink:label="us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" xlink:label="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="caba_FixedLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_FixedLeaseCost" xlink:label="caba_FixedLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_FinanceLesseeUndiscountedLeasePayments" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_FinanceLesseeUndiscountedLeasePayments" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_FinanceLesseeUndiscountedLeasePayments" xlink:label="caba_FinanceLesseeUndiscountedLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_LesseeUndiscountedLeasePayments" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_LesseeUndiscountedLeasePayments" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LesseeUndiscountedLeasePayments" xlink:label="caba_LesseeUndiscountedLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails4">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_LesseeUndiscountedLeasePayments" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_LesseeUndiscountedLeasePayments" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_LesseeUndiscountedLeasePayments" xlink:label="caba_LesseeUndiscountedLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="caba_NonCashFinanceLeaseExpense" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="caba_NonCashLeaseExpense" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionExpense" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="14" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees" xlink:label="caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_NonCashFinanceLeaseExpense" xlink:label="caba_NonCashFinanceLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_NonCashLeaseExpense" xlink:label="caba_NonCashLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="caba_AccruedResearchAndDevelopmentServicesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="caba_AccruedGeneralAndAdministrativeServicesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="caba_ClinicalTrialResearchAndDevelopmentServices" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="caba_ManufacturingAndOtherResearchAndDevelopmentServices" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedResearchAndDevelopmentServicesCurrent" xlink:label="caba_AccruedResearchAndDevelopmentServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AccruedGeneralAndAdministrativeServicesCurrent" xlink:label="caba_AccruedGeneralAndAdministrativeServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ClinicalTrialResearchAndDevelopmentServices" xlink:label="caba_ClinicalTrialResearchAndDevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_ManufacturingAndOtherResearchAndDevelopmentServices" xlink:label="caba_ManufacturingAndOtherResearchAndDevelopmentServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_FinanceLesseeUndiscountedLeasePayments" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_FinanceLesseeUndiscountedLeasePayments" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_FinanceLesseeUndiscountedLeasePayments" xlink:label="caba_FinanceLesseeUndiscountedLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_TotalFixedFinanceLeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_TotalFinanceLeaseCost" xlink:to="caba_TotalFixedFinanceLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_TotalFixedFinanceLeaseCost" xlink:to="caba_AmortizationExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="caba_TotalFinanceLeaseCost" xlink:to="caba_VariableLeaseCosts" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TotalFixedFinanceLeaseCost" xlink:label="caba_TotalFixedFinanceLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_TotalFinanceLeaseCost" xlink:label="caba_TotalFinanceLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_AmortizationExpense" xlink:label="caba_AmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_VariableLeaseCosts" xlink:label="caba_VariableLeaseCosts"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:label="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="caba_DeferredTaxAssetsOperatingLeaseLiabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="caba_DeferredTaxAssetsLicenseFeesDeductions" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="caba_CapitalizedRDCosts" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="7" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="caba_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_DeferredTaxAssetsLicenseFeesDeductions" xlink:label="caba_DeferredTaxAssetsLicenseFeesDeductions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="caba-20251231.xsd#caba_CapitalizedRDCosts" xlink:label="caba_CapitalizedRDCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" name="DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_StockIssuedDuringPeriodShareStockOptionsExercised" name="StockIssuedDuringPeriodShareStockOptionsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_SponsoredResearchAgreementsMember" name="SponsoredResearchAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember" name="TwoThousandEighteenAndTwoThousandNinteenPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember" name="TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_AnupMardaMember" name="AnupMardaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_AccruedGeneralAndAdministrativeServicesCurrent" name="AccruedGeneralAndAdministrativeServicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_WorkOrdersTerm" name="WorkOrdersTerm" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_IncreaseInShareReservedPercentage" name="IncreaseInShareReservedPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_OrphanDrugCreditsMember" name="OrphanDrugCreditsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_DevelopmentAndManufacturingServicesAgreementMember" name="DevelopmentAndManufacturingServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_PercentageOfPayrollDeductionOnEligibleCompensation" name="PercentageOfPayrollDeductionOnEligibleCompensation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_CapitalizedRDCosts" name="CapitalizedRDCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_ExpectedCostIncurredForPurchaseOfPlasmids" name="ExpectedCostIncurredForPurchaseOfPlasmids" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_CommonStockAndWarrantsMember" name="CommonStockAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_OperatingCashFlowsUsedForFinanceLeases" name="OperatingCashFlowsUsedForFinanceLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_RemainingResearchAndDevelopmentExpenseToBeIncurred" name="RemainingResearchAndDevelopmentExpenseToBeIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_ArunDasMember" name="ArunDasMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_TwoThousandEighteenStockOptionAndGrantPlanMember" name="TwoThousandEighteenStockOptionAndGrantPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_UnvestedStockOptionMember" name="UnvestedStockOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_AtTheMarketOfferingSalesAgreementMember" name="AtTheMarketOfferingSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_CellaresAgreementMember" name="CellaresAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_IssuanceOfCommonStockFromATMOfferingAmount" name="IssuanceOfCommonStockFromATMOfferingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable" name="CollaborationsLicensingAgreementsAndOtherAgreementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_NonRule10B51ArrModifiedFlag" name="NonRule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate" name="OperatingLossCarryforwardsFederalCommencementOfExpirationDate" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_CollaborativeAgreementPaymentsDue" name="CollaborativeAgreementPaymentsDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_TwoThousandNineteenEmployeeStockPurchasePlanMember" name="TwoThousandNineteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_AnnualIncreasePercentageOfBaseRent" name="AnnualIncreasePercentageOfBaseRent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_AccruedAndOtherCurrentLiabilitiesMember" name="AccruedAndOtherCurrentLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_NanjingIasoBiotherapeuticsCoLtdMember" name="NanjingIasoBiotherapeuticsCoLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" name="EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" name="EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_GwendolynBinderOneMember" name="GwendolynBinderOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" name="CollaborationsLicensingAgreementsAndOtherAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_FixedLeaseCost" name="FixedLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_WuxiAgreementMember" name="WuxiAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" name="EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_AdditionalOptionsToBePurchasedByUnderwriters" name="AdditionalOptionsToBePurchasedByUnderwriters" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_MasterTranslationalResearchServicesAgreementMember" name="MasterTranslationalResearchServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_FinancingCashFlowsUsedForFinanceLeases" name="FinancingCashFlowsUsedForFinanceLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_AutolusHoldingsMember" name="AutolusHoldingsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_OperatingLeasesAbtract" name="OperatingLeasesAbtract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_LeaseExpirationMonthAndYear" name="LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_EarningsPerShareBasicAndDilutedTable" name="EarningsPerShareBasicAndDilutedTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_IncreaseInTheRouAsset" name="IncreaseInTheRouAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_SharesRemainingAvailableForIssuance" name="SharesRemainingAvailableForIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="caba_TwoThousandTwentyFiveSalesAgreementMember" name="TwoThousandTwentyFiveSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" name="CollaborationsLicensingAgreementsAndOtherAgreementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_LeaseCommencementMonthAndYear" name="LeaseCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_FinanceLeasesAbstract" name="FinanceLeasesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_OperatingLeaseAssets" name="OperatingLeaseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_PreFundedWarrantsExercised" name="PreFundedWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_ResearchAndDevelopmentCredits" name="ResearchAndDevelopmentCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" name="CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_StockOptionRepricingMember" name="StockOptionRepricingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_StevenNichtbergerOneMember" name="StevenNichtbergerOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_IncreaseInTheLeaseLiability" name="IncreaseInTheLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_LonzaAgreementMember" name="LonzaAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_OperatingLeaseAgreementMember" name="OperatingLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees" name="IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_OtherInformationAbstract" name="OtherInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_OperatingCashFlowsUsedForOperatingLeases" name="OperatingCashFlowsUsedForOperatingLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_NumberOfFaculty" name="NumberOfFaculty" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="caba_AmortizationExpense" name="AmortizationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_TerminationFees" name="TerminationFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember" name="TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_WuXiAdvancedTherapiesMember" name="WuXiAdvancedTherapiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_ContractualExpenses" name="ContractualExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_NonCashLeaseExpense" name="NonCashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_PropertyPlantAndEquipmentEstimatedUsefulLives1" name="PropertyPlantAndEquipmentEstimatedUsefulLives1" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_June2025FinancingMember" name="June2025FinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_LesseeUndiscountedLeasePayments" name="LesseeUndiscountedLeasePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_MayTwoThousandTwentyThreeFinancingMember" name="MayTwoThousandTwentyThreeFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_LeaseExpirationMonth" name="LeaseExpirationMonth" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue" name="IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_NonCashFinanceLeaseExpense" name="NonCashFinanceLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_ObligationToBePaidCommencementDate" name="ObligationToBePaidCommencementDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_InitialTermsOfAgreementDescription" name="InitialTermsOfAgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_December2022FinancingMember" name="December2022FinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_PaymentOfObligationTerm" name="PaymentOfObligationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_AgreementWithContractManufacturingOrganizationMember" name="AgreementWithContractManufacturingOrganizationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_LicenseAgreementMember" name="LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_NonVestedCommonStockMember" name="NonVestedCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares" name="IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_VestedStockOptionMember" name="VestedStockOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_TotalFixedFinanceLeaseCost" name="TotalFixedFinanceLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_LicenseOfIntellectualProperty" name="LicenseOfIntellectualProperty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_WeightedAverageNumberOfSharesOutstanding" name="WeightedAverageNumberOfSharesOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_LeaseAmendmentPeriod" name="LeaseAmendmentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_TotalFinanceLeaseCost" name="TotalFinanceLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_VotingCommonStockMember" name="VotingCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate" name="FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_ManufacturingOfPreclinicalAndClinicalSupplies" name="ManufacturingOfPreclinicalAndClinicalSupplies" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_ClinicalTrialResearchAndDevelopmentServices" name="ClinicalTrialResearchAndDevelopmentServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_PercentageOfEligibleTaxPositionsForRecognition" name="PercentageOfEligibleTaxPositionsForRecognition" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_PersonnelExpenses" name="PersonnelExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_LicenseMaintenanceFee" name="LicenseMaintenanceFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate" name="OperatingLossCarryforwardsStateCommencementOfExpirationDate" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_FinanceLesseeUndiscountedLeasePayments" name="FinanceLesseeUndiscountedLeasePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_DeferredTaxAssetsLicenseFeesDeductions" name="DeferredTaxAssetsLicenseFeesDeductions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_MilestonePayment" name="MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_TwoThousandTwentyFiveInducementPlanMember" name="TwoThousandTwentyFiveInducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_ClinicalTrials" name="ClinicalTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_AccruedResearchAndDevelopmentServicesCurrent" name="AccruedResearchAndDevelopmentServicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_EarningPerShareBasicAndDilutedLineItems" name="EarningPerShareBasicAndDilutedLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_StevenNichtbergerMember" name="StevenNichtbergerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_AnupMardaOneMember" name="AnupMardaOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_ArunDasOneMember" name="ArunDasOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_RentExpense" name="RentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_ManufacturingAndOtherResearchAndDevelopmentServices" name="ManufacturingAndOtherResearchAndDevelopmentServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="caba_FundingTermEndingDate" name="FundingTermEndingDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_ResearchServiceAgreementMember" name="ResearchServiceAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_ChildrenSHospitalOfPhiladelphiaMember" name="ChildrenSHospitalOfPhiladelphiaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_GwendolynBinderMember" name="GwendolynBinderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_RegentsOfUniversityOfCaliforniaMember" name="RegentsOfUniversityOfCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_DevelopmentServices" name="DevelopmentServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate" name="OperatingLossCarryforwardsLocalCommencementOfExpirationDate" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_IssuanceOfCommonStockFromATMOffering" name="IssuanceOfCommonStockFromATMOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_OxfordBiomedicaMember" name="OxfordBiomedicaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" name="CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_TwoThousandNineteenStockOptionAndIncentivePlanMember" name="TwoThousandNineteenStockOptionAndIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_Caba201AndMuskCaartMember" name="Caba201AndMuskCaartMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_Rese-CelAndMuSK-CAARTMember" name="Rese-CelAndMuSK-CAARTMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_SubscriptionAndTechnologyTransferAgreementMember" name="SubscriptionAndTechnologyTransferAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="caba_ContractualCostIncurred" name="ContractualCostIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" name="IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_VariableLeaseCosts" name="VariableLeaseCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_AdvancePayments" name="AdvancePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" name="PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="caba_Rule10B51ArrModifiedFlag" name="Rule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 19, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CABA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CABALETTA BIO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001759138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,322,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1685768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2929 Arch Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">759-3100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, Pennsylvania<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Cabaletta Bio, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 82,982<span></span>
</td>
<td class="nump">$ 163,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">50,617<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,272<span></span>
</td>
<td class="nump">2,713<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">138,871<span></span>
</td>
<td class="nump">166,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,922<span></span>
</td>
<td class="nump">2,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">15,700<span></span>
</td>
<td class="nump">7,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,431<span></span>
</td>
<td class="nump">6,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">5,159<span></span>
</td>
<td class="nump">2,293<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">165,083<span></span>
</td>
<td class="nump">185,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,636<span></span>
</td>
<td class="nump">4,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">19,298<span></span>
</td>
<td class="nump">12,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current portion</a></td>
<td class="nump">20,758<span></span>
</td>
<td class="nump">5,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">3,461<span></span>
</td>
<td class="nump">3,986<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">50,153<span></span>
</td>
<td class="nump">27,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">3,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,384<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">53,032<span></span>
</td>
<td class="nump">32,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (see Notes 6 and 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.00001 par value: 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; no shares issued or outstanding at December 31, 2025 and December 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Voting and non-voting common stock, $0.00001 par value: 300,000,000 (293,590,481 voting and 6,409,519 non-voting) shares authorized as of December 31, 2025 and 150,000,000 (143,590,481 voting and 6,409,519 non-voting) shares authorized as of December 31, 2024; 100,479,323 voting shares issuedand outstanding as of December 31, 2025 and 50,743,101voting shares issued and outstanding as of December 31, 2024</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">628,982<span></span>
</td>
<td class="nump">501,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(516,957)<span></span>
</td>
<td class="num">(349,101)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">112,051<span></span>
</td>
<td class="nump">152,335<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 165,083<span></span>
</td>
<td class="nump">$ 185,046<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized shares</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="nump">100,479,323<span></span>
</td>
<td class="nump">50,743,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
<td class="nump">100,479,323<span></span>
</td>
<td class="nump">50,743,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember', window );">Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">293,590,481<span></span>
</td>
<td class="nump">143,590,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">6,409,519<span></span>
</td>
<td class="nump">6,409,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 142,674<span></span>
</td>
<td class="nump">$ 97,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">29,567<span></span>
</td>
<td class="nump">27,938<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">172,241<span></span>
</td>
<td class="nump">125,141<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(172,241)<span></span>
</td>
<td class="num">(125,141)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">6,031<span></span>
</td>
<td class="nump">10,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,004)<span></span>
</td>
<td class="num">(748)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income, net</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(167,856)<span></span>
</td>
<td class="num">(115,864)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments, net of tax</a></td>
<td class="nump">25<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive loss</a></td>
<td class="num">$ (167,831)<span></span>
</td>
<td class="num">$ (115,903)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of voting and non-voting common stock, basic</a></td>
<td class="num">$ (2.1)<span></span>
</td>
<td class="num">$ (2.34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of voting and non-voting common stock, diluted</a></td>
<td class="num">$ (2.1)<span></span>
</td>
<td class="num">$ (2.34)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 236,198<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 469,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (233,237)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,823,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs, value</a></td>
<td class="nump">10,876<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">10,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,483,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock in connection with exercise of stock options, value</a></td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_StockIssuedDuringPeriodShareStockOptionsExercised', window );">Issuance of common stock in connection with exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan, value</a></td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts', window );">Issuance of common stock upon exercise of pre-funded warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,168,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Net unrealized losses on available-for-sale securities, value</a></td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation, value</a></td>
<td class="nump">19,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(115,864)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(115,864)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 152,335<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">501,435<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(349,101)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2024</a></td>
<td class="nump">50,743,101<span></span>
</td>
<td class="nump">50,743,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares', window );">Issuance of common stock, warrants and pre-funded warrants, net of issuance costs, share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue', window );">Issuance of common stock, warrants and pre-funded warrants, net of issuance costs, value</a></td>
<td class="nump">$ 93,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IssuanceOfCommonStockFromATMOffering', window );">Issuance of common stock from ATM offering, net of sales agent commission and fees, share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,545,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IssuanceOfCommonStockFromATMOfferingAmount', window );">Issuance of common stock from ATM offering, net of sales agent commission and fees, Value</a></td>
<td class="nump">12,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock in connection with exercise of stock options, value</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_StockIssuedDuringPeriodShareStockOptionsExercised', window );">Issuance of common stock in connection with exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan, value</a></td>
<td class="nump">291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts', window );">Issuance of common stock upon exercise of pre-funded warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,799,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Net unrealized losses on available-for-sale securities, value</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation, value</a></td>
<td class="nump">20,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(167,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(167,856)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="nump">$ 112,051<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 628,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (516,957)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2025</a></td>
<td class="nump">100,479,323<span></span>
</td>
<td class="nump">100,479,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and pre-funded warrants for the purchase of common stock, net of issuance costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_IssuanceOfCommonStockFromATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock from ATM offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_IssuanceOfCommonStockFromATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_IssuanceOfCommonStockFromATMOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock from ATM Offering Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_IssuanceOfCommonStockFromATMOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock, Warrants and Pre Funded Warrants, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock, Warrants and Pre Funded Warrants, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_StockIssuedDuringPeriodShareStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period share stock options exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_StockIssuedDuringPeriodShareStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=caba_CommonStockAndWarrantsMember', window );">Common Stock and Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="nump">$ 6,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=caba_CommonStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=caba_CommonStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (167,856)<span></span>
</td>
<td class="num">$ (115,864)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">20,939<span></span>
</td>
<td class="nump">19,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,646<span></span>
</td>
<td class="nump">1,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_NonCashFinanceLeaseExpense', window );">Non-cash finance lease expense</a></td>
<td class="nump">11,697<span></span>
</td>
<td class="nump">3,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_NonCashLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">3,671<span></span>
</td>
<td class="nump">2,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accretion of operating lease liabilities</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discount on investments</a></td>
<td class="num">(1,555)<span></span>
</td>
<td class="num">(1,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax', window );">Loss on foreign currency exchange rates</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,559)<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(2,866)<span></span>
</td>
<td class="num">(584)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,550<span></span>
</td>
<td class="nump">1,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">7,432<span></span>
</td>
<td class="nump">3,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(4,227)<span></span>
</td>
<td class="num">(3,291)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest payable under finance lease</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(131,080)<span></span>
</td>
<td class="num">(88,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,229)<span></span>
</td>
<td class="num">(2,211)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(99,037)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of investments</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">49,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(50,266)<span></span>
</td>
<td class="nump">47,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, warrants and pre-funded warrants, net of issuance costs</a></td>
<td class="nump">93,558<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees', window );">Issuance of common stock from ATM offering, net of sales agent commission and fees</a></td>
<td class="nump">12,745<span></span>
</td>
<td class="nump">10,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from the issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock in connection with the exercise of stock options</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance leases</a></td>
<td class="num">(6,261)<span></span>
</td>
<td class="num">(897)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">100,347<span></span>
</td>
<td class="nump">11,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">19<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(80,980)<span></span>
</td>
<td class="num">(29,276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents&#8212;beginning of year</a></td>
<td class="nump">163,962<span></span>
</td>
<td class="nump">193,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents&#8212;end of year</a></td>
<td class="nump">82,982<span></span>
</td>
<td class="nump">163,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,713<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable and accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of use assets obtained in exchange for lease obligations</a></td>
<td class="nump">21,071<span></span>
</td>
<td class="nump">10,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">$ 787<span></span>
</td>
<td class="nump">$ 4,242<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock from ATM offering, net of sales agent commission and fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_NonCashFinanceLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Cash Finance Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_NonCashFinanceLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash lease expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481639/420-10-35-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (167,856)<span></span>
</td>
<td class="num">$ (115,864)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_Rule10B51ArrModifiedFlag', window );">Rule 10b5-1 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_NonRule10B51ArrModifiedFlag', window );">Non-Rule 10b5-1 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_NonRule10B51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Rule 10b51 Arr Modified Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_NonRule10B51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_Rule10B51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rule 10b51 Arr Modified Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_Rule10B51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy, and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cyber Risk Management and Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, under the oversight of the audit committee of our board of directors, have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implemented</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and maintain a cybersecurity risk management program that is designed to identify, assess, and mitigate risks from cybersecurity threats. Our risk management is supported by various tools and technologies, including third-party security solutions, monitoring, and alerting tools, designed to monitor, identify, and address risks from cybersecurity threats.</span></p></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with other third-party providers and consultants to support our cyber risk management efforts, including through periodic security testing and assessments. We have a process to assess certain major </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party vendors and service providers</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including through a review of responses to compliance questionnaires and contractual requirements, as appropriate.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, like other companies in our industry, face a number of risks from cybersecurity threats in connection with our business. Although such risks have not </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">materially affected</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and we do not believe they are reasonably likely to materially affect, us, including our business strategy, results of operations or financial condition, to date, we have, from time to time, experienced threats to and security incidents related to our data and systems. For more information about the risks from cybersecurity threats we face, please see Item 1A- Risk Factors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance Related to Cybersecurity Risks</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors, as a whole and through its committees, has responsibility for the periodic review and oversight of information technology risks, including risks from cybersecurity threats.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee is responsible for oversight of our cyber risk management program</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The day-to-day management of the cyber program is directed by the Director of IT under the direction of the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Currently,</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.</span></span></span></p><div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Director of IT meets with the Chief Financial Officer periodically to discuss and review our cybersecurity risk management processes and to address matters related to potential cybersecurity and information technology risks, with input from the Company&#8217;s third-party technology providers, as appropriate. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#8217;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee periodically reports</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on cybersecurity risk management to the full board of directors.</span></p></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, under the oversight of the audit committee of our board of directors, have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">implemented</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and maintain a cybersecurity risk management program that is designed to identify, assess, and mitigate risks from cybersecurity threats. Our risk management is supported by various tools and technologies, including third-party security solutions, monitoring, and alerting tools, designed to monitor, identify, and address risks from cybersecurity threats.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors, as a whole and through its committees, has responsibility for the periodic review and oversight of information technology risks, including risks from cybersecurity threats.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee is responsible for oversight of our cyber risk management program</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The day-to-day management of the cyber program is directed by the Director of IT under the direction of the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Currently,</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.</span></span></span></p><div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Director of IT meets with the Chief Financial Officer periodically to discuss and review our cybersecurity risk management processes and to address matters related to potential cybersecurity and information technology risks, with input from the Company&#8217;s third-party technology providers, as appropriate. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#8217;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee periodically reports</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on cybersecurity risk management to the full board of directors.</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee is responsible for oversight of our cyber risk management program</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Director of IT meets with the Chief Financial Officer periodically to discuss and review our cybersecurity risk management processes and to address matters related to potential cybersecurity and information technology risks, with input from the Company&#8217;s third-party technology providers, as appropriate. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#8217;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee periodically reports</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on cybersecurity risk management to the full board of directors.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The day-to-day management of the cyber program is directed by the Director of IT under the direction of the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Currently,</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.</span></span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#8217;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cabaletta Bio, Inc. (the Company or Cabaletta) was incorporated in April 2017 in the State of Delaware as Tycho Therapeutics, Inc. and, in August 2018, changed its name to Cabaletta Bio, Inc. The consolidated financial statements include the accounts of Cabaletta and its wholly owned subsidiaries: Cabaletta Bio GmbH and Cabaletta Bio (Germany) GmbH.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is headquartered in Philadelphia, Pennsylvania. Cabaletta is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Principal operations commenced in April 2018.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks and Uncertainties</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company does not expect to generate revenue from sales of engineered T cell therapies for autoimmune diseases or any other revenue unless and until the Company completes preclinical and clinical development and obtains regulatory approval for one or more product candidates. If the Company seeks to obtain regulatory approval for any of its product candidates, the Company expects to incur significant commercialization expenses.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. As a result, the Company is unable to predict the timing or amount of increased expenses or when or if the Company will be able to achieve or maintain profitability. Further, the Company is dependent on third parties for certain research and development activities, including manufacturing services (Note 6 and Note 7). Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. Even if the Company is able to generate revenues from the sale of its product candidates, if approved, it may not become profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then it may be unable to continue its operations at planned levels and be forced to reduce its operations.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Going Concern</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205-40, Going Concern, ("ASC 205-40") the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company has sustained annual operating losses since inception and expects to continue to generate operating losses for the foreseeable future. As of December 31, 2025, the Company has incurred an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">516,957</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and has cash, cash equivalents and investments of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,599</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company&#8217;s ultimate success depends on the outcome of its research and development activities. Management expects to incur additional losses in the future as it continues its research and development and will need to raise additional capital to fully implement its business plan and to fund its operations. The Company intends to raise such additional capital through a combination of equity offerings, debt financings, government funding arrangements, strategic alliances or other sources. However, if such financing is not available at adequate levels and on a timely basis, or such agreements are not available on favorable terms, or at all, as and when needed, the Company will need to reevaluate its operating plan and may be required to delay or discontinue the development of one or more of its product candidates or operational initiatives. Based on the Company&#8217;s current operating plan, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for at least twelve months from the issuance date of this Annual Report on Form 10-K, and the Company will need to obtain additional funding. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company's cash forecast contains estimates and assumptions based on success of ongoing clinical trials, and management cannot predict the amount or timing of all expenditures with certainty. Accordingly, the Company has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. The accompanying financial statements have been</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prepared </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) and under the rules and regulations of the U.S. Securities and Exchange Commission (SEC). All intercompany balances and transactions have been eliminated in consolidation.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to advance payments and accruals related to the Company&#8217;s research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Off-Balance Sheet Risk and Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist of cash and cash equivalents, which are invested in U.S. treasury-based money market funds, and available-for-sale debt securities, which are invested in U.S. treasury securities. A portion of the Company&#8217;s cash is maintained at federally insured financial institutions, and account balances may at times exceed federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk. The Company has no off&#8209;balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and U.S. treasury securities.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments are available-for-sale and carried at estimated fair value. The Company&#8217;s valuations of available-for-sale debt securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than, twelve months from the balance sheet date are classified as current.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors including the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or if more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments as well as amortization of discount or premium is included in interest income.</span></p></div><div><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property, Plant and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying statements of operations. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimated useful lives for property and equipment are as follows:</span></p>
          <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
           <tr style="visibility:collapse;">
            <td style="width:49.17%;box-sizing:content-box;"></td>
            <td style="width:1.66%;box-sizing:content-box;"></td>
            <td style="width:49.17%;box-sizing:content-box;"></td>
           </tr>
           <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated useful life</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Three years</span></span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Three years</span></span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Three years</span></span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_6b79aa44-243a-42b1-94f6-81fb189f1245;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lesser of estimated useful life or remaining lease term</span></span></span></p></td>
           </tr>
          </table></div></div><div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has leases related to its facilities used for offices and laboratory space, which are classified as operating leases as well as leases related to its manufacturing arrangements, which are classified as finance leases.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease and its classification based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. Subsequent to the initial measurement, the Company will continue to account for:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the lease liability at the net present value using the incremental borrowing rate that was in effect as of the lease commencement, lease modification, or transition date, and;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the finance lease and operating lease expense on a straight line basis.</span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases with terms of 12 months or less are considered short-term leases and right-of-use assets and lease obligations are not recognized. Payments associated with short-term leases are expensed on a straight-line basis over the lease term.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to aggregate all lease and non-lease components for each class of underlying assets into a single lease component for real-estate leases and embedded manufacturing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the guidance in ASC 842-10-55-2 to assist in determining lease classification across its leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs include costs incurred for internal and external research and development activities and are expensed as incurred in the accompanying statements of operations. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to entities that conduct certain research and development and clinical trial activities on the Company&#8217;s behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers, which include preclinical studies, contract manufacturing activities and clinical trial activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided and in accordance with agreements established with service providers and includes these costs in accrued and other current liabilities in the accompanying balance sheets and within research and development expense in the accompanying statements of operations. Non-refundable advance payments made for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are received or the related services are rendered. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid expenses in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities and prepaid expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures its stock-based awards granted to employees and non-employees based on the estimated fair values of the awards on the respective grant dates. The Company uses the Black-Scholes option-pricing model (Black-Scholes) to estimate the fair value of its stock-based awards. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company accounts for forfeitures of stock option awards as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base, as well as for net operating loss carryforwards and research and development credits, and are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> interest or penalties related to uncertain income tax benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company calculates basic and diluted net loss per share in conformity with the two-class method required for participating securities because the Company had both voting and non-voting common stock outstanding for a portion of 2024. The rights, including the liquidation and dividend rights, of the holders of the voting and non-voting common stock are identical, except with respect to voting. Each share of non-voting common stock may be converted at any time into one share of voting common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. As of December 31, 2024, no shares of non-voting common stock remain outstanding.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted average number of shares of common stock, including any pre-funded warrants to purchase shares of common stock that may be outstanding. The undistributed loss for each year is allocated to common stockholders based on the contractual participation rights of the voting and non-voting common stock as if the losses for the year had been distributed. As the liquidation and dividend rights are identical, the undistributed losses are allocated on a proportionate basis. Diluted net loss per share attributable to common stockholders is computed under the if-converted method and assumes that all non-voting common stock has been converted to common stock. Since the Company was in a loss position for all periods presented, the effects of the other potentially dilutive securities are antidilutive.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer (CEO). The Company has determined it operates in a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_11331fa4-2d51-42cc-aee7-5b9ce9481ad0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refer to Note 8 &#8211; Segment Reporting for further information related to our segment.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of stockholders&#8217; equity as a reduction of additional paid-in capital or equity generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ASU 2023-09 enhances the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The Company adopted this ASU for the annual period ended December 31, 2025 and the amendments have been applied retrospectively to all prior periods presented in the financial statements. Refer to Note 11 &#8211; Income Taxes for further information.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement (Subtopic 220-40): Reporting Comprehensive Income-Expense Disaggregation Disclosures. ASU 2024-03 requires enhanced disclosures about components of expense captions on the face of the income statement. This standard will be effective for fiscal years beginning after December 15, 2026. Early adoption is permitted. ASU 2024-03 applies on a prospective basis for periods beginning after the effective date. However, retrospective application to any or all prior periods presented is permitted. The Company is currently planning to adopt this guidance when effective and is assessing the impact of the adoption on the Company&#8217;s consolidated financial statements and accompanying footnotes.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no other new accounting pronouncements or changes to accounting pronouncements that, if adopted, would have or may have a material impact on the Company&#8217;s consolidated statements or disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, the Company&#8217;s financial instruments included cash and cash equivalents, available-for-sale debt securities, accounts payable and accrued expenses. The carrying amounts for cash and cash equivalents, accounts payable and accrued expenses reported in the Company&#8217;s consolidated financial statements for these instruments approximate their respective fair values because of the short-term nature of these instruments.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:36.174%;box-sizing:content-box;"></td>
          <td style="width:1.561%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.365%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.561%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.485000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.561%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.365%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.561%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.365%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active Markets<br/>for Identical Assets <br/>(Level 1)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,470</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,470</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,617</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,617</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132,087</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,470</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,617</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:35.42%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.020000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:14.440000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.020000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.020000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active Markets<br/>for Identical Assets<br/>(Level 1)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,634</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,634</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,634</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,634</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level 1 inputs. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For debt securities classified as available-for-sale investments,</span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Company records unrealized gains or losses resulting from changes in fair value between measurement dates as a component of other comprehensive income. The Company did not hold any available-for-sale securities as of December 31, 2024.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.17%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.283000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.283000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.283000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,512</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,512</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,470</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,470</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,982</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,982</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities - due in one year or less</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Included in short-term investments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,592</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,617</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,574</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,599</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Property, Plant and Equipment</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment consists of the following:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,488</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,663</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">277</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">277</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property, plant and equipment</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,074</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,249</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,152</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,506</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property, plant and equipment, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,922</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,743</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,646</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,711</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Accrued and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued and other current liabilities consist of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.272%;box-sizing:content-box;"></td>
          <td style="width:2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.363%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.363%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,716</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,315</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trial research and development services</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,335</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,236</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Manufacturing and other research and development services</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,774</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,255</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative services</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">393</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">342</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,298</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,188</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations, Licensing Agreements and other Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract', window );"><strong>Collaborations Licensing Agreements And Other Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock', window );">Collaborations, Licensing Agreements and other Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Collaborations, Licensing Agreements and Other Agreements</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Amended and Restated License Agreement with the Trustees of the University of Pennsylvania and Children&#8217;s Hospital of Philadelphia</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2018, the Company entered into a license agreement with the University of Pennsylvania (Penn), as amended and restated in July 2019 to include the Children&#8217;s Hospital of Philadelphia (CHOP) as a party, and as amended in May 2020 and October 2021 (the License Agreement) pursuant to which the Company obtained (a) a non-exclusive, non-sublicensable worldwide license to certain of Penn&#8217;s intellectual property to conduct research, product development, clinical trials, cell manufacturing and other activities, and (b) an exclusive, worldwide, royalty-bearing right and license, with a right to sublicense, on a target-by-target basis, under certain of Penn&#8217;s intellectual property to make, use, sell, offer for sale, import, and otherwise commercialize products for the treatment of autoimmune and alloimmune diseases. Unless earlier terminated, the License Agreement expires on the expiration or abandonment or other termination of the last valid claim in Penn&#8217;s intellectual property licensed by the Company. The Company may terminate the License Agreement at any time for convenience upon 60 days' written notice. In the event of an uncured, material breach, Penn may terminate the License Agreement upon 60 days' written notice. Under the terms of the License Agreement, the Company was obligated to pay $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> annually for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> beginning August 2018 for funding to the laboratories of each of Drs. Milone and Payne. This was satisfied through completed sponsored research agreements with a total cost of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,560</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. During the term of the License Agreement until the first commercial sale of the first product, the Company is obligated to pay Penn a non-refundable, non-creditable annual license maintenance fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In May 2020, the Company paid Penn an additional, non-refundable, non-creditable license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> under the amended License Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is required to pay certain milestone payments upon the achievement of specified clinical and commercial milestones. Milestone payments are reduced by a certain percentage for the second product that achieves a milestone, by an additional percentage for the third product that achieves a milestone, and so on, for each subsequent product that achieves a milestone. In the event that the Company is able to successfully develop and launch multiple products under the License Agreement, total milestone payments could be approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Penn is also eligible to receive tiered royalties at percentage rates in the low single-digits, subject to an annual minimum royalty, on annual worldwide net sales of any products that are commercialized by the Company or its sublicensees that contain or incorporate, or are covered by, the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the License Agreement, Penn would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amounts due under the License Agreement as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Master Translational Research Services Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2018 and February 2023, the Company entered into services agreements (the CAART and CARTA Services Agreements) with Penn for research, development and manufacturing services from various laboratories within Penn. The activities are detailed in separately executed Penn organization-specific addenda. In May 2020, the Company amended its Addendum with the Center for Advanced Retinal and Ocular Therapeutics (CAROT) to expand access to vector manufacturing.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expense recognized under executed addenda to the master translational research services agreements with Penn was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,062</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,250</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively. As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> remaining commitments under the CARTA Services Agreement.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exclusive License Agreement with IASO Biotherapeutics</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 7, 2022, the Company entered into an Exclusive License Agreement (the IASO Agreement) with Nanjing IASO Biotherapeutics Co., Ltd. (IASO). Pursuant to the IASO Agreement, the Company received an exclusive, worldwide license under certain IASO intellectual property to use a novel clinical-stage anti-CD19 binder to develop, manufacture, commercialize and otherwise exploit T cell products directed to CD19 for the purpose of diagnosis, prevention or treatment of any autoimmune or alloimmune indications in humans. As partial consideration for the exclusive license, IASO received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. IASO is also eligible to receive up to mid double digit millions in milestone payments based upon the achievement of specified pre-clinical, development and regulatory milestones, and up to an additional low triple digit millions in milestone payments based upon achievement of specified sales milestones, for a total consideration, inclusive of the upfront payment, of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, along with tiered mid-single digit royalties on future net sales for licensed products that may result from the IASO Agreement. Upon the U.S. Food and Drug Association&#8217;s clearance of the rese-cel Investigational New Drug application for the treatment of systemic lupus erythematosus in March 2023, a milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was recognized in the accompanying statements of operations. A milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was paid to IASO in the first quarter of 2024 after the first patient in a rese-cel trial was dosed.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IASO has the right of first negotiation if the Company desires to grant a third party an exclusive license to develop, manufacture, commercialize or otherwise exploit the licensed products in the Greater China region. Pursuant to the IASO Agreement, each of IASO and the Company have agreed, subject to certain exceptions, to refrain from engaging in certain competitive activities with respect to certain programs. The Company also may sublicense through multiple tiers the rights granted to it by IASO under the IASO Agreement at any time, however, it must pay IASO a low double-digit percentage of any revenue obtained from sublicenses or options to third parties, subject to certain customary exclusions. The IASO Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the IASO Agreement, unless earlier terminated. Each of the Company and IASO may terminate the Agreement for a material, uncured breach or insolvency of the other party. The Company may also terminate the Agreement at will upon advance written notice and in the event IASO rejects the Agreement due to bankruptcy-related matters. IASO may also terminate the Agreement if the Company fails to achieve certain specified diligence milestones in a timely manner and/or if the Company commences any patent challenges with respect to the patents and patent applications relating to the licensed sequence, in each case upon advance written notice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licence and Supply Agreement with Oxford Biomedica</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2021, the Company entered into a Licence and Supply agreement (LSA) with Oxford Biomedica (UK) Limited (Oxford), wherein the LSA grants the Company a non-exclusive license to Oxford&#8217;s LentiVector&#174; platform for its application in the Company&#8217;s DSG3-CAART program and put in place a multi-year vector supply agreement. Oxford is eligible to receive regulatory and sales milestones in the low tens of millions and royalties in the low single digits on net sales of products that incorporate the Oxford technology. In May 2023, the Company amended the LSA with Oxford to expand the license to include the Company's rese-cel program for an upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In August 2023, the Company and Oxford entered into a vector supply agreement for rese-cel, and a related second amendment to the LSA, with a total cost under the vector supply agreement of up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which has been fully expensed as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024. In February 2024, the Company and Oxford entered into a third amendment to the LSA to update the patent schedule. In June 2024, the Company and Oxford entered into a fourth amendment to the LSA eliminating royalties on net sales of products that incorporate the Oxford technology if Oxford manufactures the vector. Starting in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2024, the Company and Oxford entered into work orders with a cost of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for certain process characterization and process performance qualification activities as part of commercial readiness activities. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company has recognized project to date expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,673</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> related to these activities. The Company can terminate the LSA or any work order under the LSA at will upon advance written notice and subject to certain cancellation fees.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option and License Agreement with Autolus</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2023, the Company entered into an Option and License Agreement (Autolus Agreement) with Autolus Holdings (UK) Limited (Autolus), wherein the Autolus Agreement granted the Company a non-exclusive license to access Autolus' RQR8 technology in its CD19-CAR T cell therapy program, and subject to additional nominal option exercise fees, up to four additional t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">argets. In January 2025, the Company and Autolus agreed to novate the Autolus Agreement with both Autolus and Autolus Limited jointly assuming the rights, obligations and liabilities of Autolus, under the Autolus Agreement. Under the terms of the Autolus Agreement, the Company was required to pay Autolus an upfront license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that was recognized as expense in the first quarter of 2023 in the accompanying statements of operations, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was paid in 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was paid in January 2024. Autolus is also eligible to receive regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for each licensed target, sales milestones of up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and royalties in the low single digits on net sales of all products that incorporate the RQR8 technology. The Autolus Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the Autolus Agreement, unless earlier terminated. The Company can terminate the Autolus Agreement at will upon advance written notice. Each of the Company and Autolus may terminate the Agreement for a material, uncured breach or insolvency of the other party.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborations licensing agreements and other agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborations licensing agreements and other agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Segment Information</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the CODM in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is the CEO. The Company has determined it operates in a single operating segment and has one reportable segment. The segment consists of the development of clinical and preclinical product candidates for the discovery and development of innovative engineered T cell therapies and related administrative activities. The CODM assesses performance and allocates resources based on the Company&#8217;s consolidated statement of operations, which is reported on the income statement as consolidated net loss and considers forecast-to-actuals variances on a quarterly basis for expenses that are deemed significant. Further, the CODM reviews the segment&#8217;s assets based on the consolidated balance sheet to assess liquidity and funding capacity. The majority of the Company's assets are located in the United States.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s CODM views specific categories within expenses as significant given the direct correlation between cash burn and profitability as a pre-revenue company. Significant segment expenses, as provided to the CODM, are presented below. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional information on the year over year change of segment expenses refer to Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:57.12%;box-sizing:content-box;"></td>
          <td style="width:2.1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:17.34%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2.1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:17.34%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,934</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,239</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trials</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,581</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,286</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Manufacturing of preclinical and clinical supplies</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,240</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,523</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development services</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,350</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,417</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License of intellectual property</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,523</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development costs </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,569</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,215</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administration expenses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,567</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,938</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,031</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,025</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,004</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">748</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">358</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">167,856</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,864</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Manufacturing Agreements</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2021, the Company entered into a Development and Manufacturing Services Agreement (Minaris Agreement) with Minaris Advanced Therapies, LLC, or Minaris (f/k/a WuXi Advanced Therapies, Inc.) to serve as an additional cell processing manufacturing partner for the MuSK-CAART Phase 1 clinical trial, or MusCAARTes</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trial. The Minaris Agreement is scheduled to expire upon completion of Minaris' services related to MuSK-CAART and rese-cel. In August 2023, and as extended in August 2024, the Company entered into an agreement with Minaris to serve as one of the Company's manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and commercial readiness activities for rese-cel. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the August 2023 work orders, Minaris converted the Company&#8217;s non-dedicated suite to a dedicated suite for GMP manufacturing for the Company&#8217;s rese-cel and MuSK-CAART programs, or the Dedicated Suite, for an initial term of 18 months with two 18-month extensions at the Company&#8217;s sole option on six months' notice prior to the end of the term. In August 2024, the Company sent a notice to Minaris to extend the initial term of the Minaris Agreement by 18 months through August 2026.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, the Company agreed to certain monthly minimum runs. In August 2024, the 2023 work order related to GMP manufacturing was amended to reduce the minimum monthly runs through the end of 2024. In lieu of the original $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> termination fee under the terms of the Minaris Agreement, the Company would incur up to a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,080</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> termination </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fee if it terminates both the rese-cel and MuSK-CAART work orders for any reason. The Company may terminate for convenience the Minaris Agreement or any work order with six months' prior written notice. However, the Company may not terminate the Dedicated Suite without terminating</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">both </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the MuSK-CAART and rese-cel GMP run work orders. Minaris may terminate for convenience the Minaris </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement or any work order on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">months' prior written notice, but such notice may not be effective prior to February 202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. In February 2026, the Company notified Minaris that it intended to permit the term to expire in August 2026.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the Company entered into a Development and Manufacturing Services Agreement (the Lonza Agreement) with Lonza Houston Inc. (Lonza) to serve as one of the Company's manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and preparations for commercial readiness. The Lonza Agreement has a term of five years and can be extended for an additional three year term upon notice to Lonza at least </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">months prior to the expiration of the Lonza Agreement. The Company can terminate the Lonza Agreement at will upon nine months advance written notice to Lonza subject to the terms of the Lonza Agreement. Lonza can terminate the Lonza Agreement at will upon 24 months advance written notice to Cabaletta subject to the terms of the Lonza Agreement. Under the initial work order, Lonza will perform cell therapy manufacturing activities for Cabaletta&#8217;s CAR-T cell therapy product, rese-cel, for an initial term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">months with the ability to extend the manufacturing period on a rolling basis subject to the terms of the Lonza Agreement.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Purchase Commitments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the normal course of business, the Company enters into various purchase commitments with third-party contract manufacturers for the manufacture and processing of its product candidates and related raw materials, contracts with contract research organizations for clinical trials and agreements with vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnification</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company enters into certain types of contracts that contingently require the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i) the Company&#8217;s Amended and Restated Bylaws, as amended, (bylaws) under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship, (ii) contracts under which the Company must indemnify directors and certain officers and consultants for liabilities arising out of their relationship, (iii) contracts under which the Company may be required to indemnify partners against certain claims, including claims from third parties asserting, among other things, infringement of their intellectual property rights, and (iv) procurement, consulting, or license agreements under which the Company may be required to indemnify vendors, consultants or licensors for certain claims, including claims that may be brought against them arising from the Company&#8217;s acts or omissions with respect to the supplied products, technology or services. From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In addition, under these contracts, the Company may have to modify the accused infringing intellectual property and/or refund amounts received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may have a material adverse effect on the Company&#8217;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount under these contracts due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Litigation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company may become involved in litigation or legal proceedings. While the outcome of any such proceedings cannot be predicted with certainty, as of December 31, 2025, the Company is not involved in any material litigation or legal proceedings that it would expect to have a material adverse impact on its financial position, results of operations, or cash flows.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases office and laboratory space and has two manufacturing agreements that have been determined to include embedded leases.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating lease commitments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company leases office and laboratory space which include rent escalations and are subject to additional variable charges, including common area maintenance, property taxes and property insurance. Given the variable nature of such costs, they are recognized as expense as incurred. Additionally, some of the Company&#8217;s leases are subject to certain fixed fees which the Company has determined to be non-lease components. The Company has elected the practical expedient to account for lease and non-lease components as a single-lease component and has included fixed payments related to non-lease components in calculating the operating lease liability. The lease term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for our laboratory space was extended in October 2025 through November 2026 resulting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in an increase of the right-of-use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">787</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Finance lease commitments - Embedded leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described further in Note 7, in August 2023, the Company entered into new work orders under the Minaris Agreement for Minaris to serve as one of the Company&#8217;s cell processing manufacturing partners for the global clinical development of rese-cel. Minaris converted the Company&#8217;s non-dedicated suite to a Dedicated Suite for GMP manufacturing for the Company&#8217;s rese-cel and MuSK-CAART programs, for an initial term of 18 months. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The terms of the August 2023 work orders included both fixed costs and contingent variable costs. The lease commenced October 1, 2023. In 2024, the Company remeasured the lease following the resolution of the contingency related to variable costs and an amendment to the 2023 work order, which extended the term of the agreement by an additional 18 months through August 2026. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may terminate the Dedicated Suite lease for convenience with six months&#8217; prior written notice and up to a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,080</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> termination fee if both the rese-cel and MuSK-CAART work orders are terminated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2026, the Company notified Minaris that it intended to permit the term to expire in August 2026.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described further in Note 7, in December 2024, the Company entered into the Lonza Agreement with Lonza to serve as one of the Company's cell processing manufacturing partners. Under the initial work order, Lonza will perform cell therapy manufacturing activities for the CAR-T cell therapy product rese-cel for a term of 12 months with the ability to extend the manufacturing period subject to the terms of the Lonza Agreement. The Lonza Agreement was evaluated under ASC 842 and determined to contain an embedded finance lease commencing in March 2025, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">resulting in the recognition of a right-of-use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,934</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2025, the Company extended the lease term in accordance with the Lonza Agreement resulting in an increase of the right-of-use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,137</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary of leases under ASC 842</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table contains information pertaining to the Company&#8217;s operating and finance leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2025 and 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.224%;box-sizing:content-box;"></td>
          <td style="width:2.001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.387%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2.001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.387%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance leases</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,004</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">748</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,391</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,102</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fixed finance lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,395</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,850</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,508</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">930</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,903</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,780</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating leases</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,211</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,247</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fixed operating lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,211</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,247</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">296</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">750</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,416</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,293</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash paid in the measurement of lease liabilities</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows used for operating leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,227</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,291</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows used for finance leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,713</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">748</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing cash flows for finance leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,261</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">897</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other information</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average remaining lease term - finance leases (in years)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate - finance leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.5</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average remaining lease term - operating leases (in years)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate - operating leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For finance leases embedded in CDMO arrangements, interest expense is recognized using the effective interest method, applying the Company's incremental borrowing rate as required by ASC 842, and amortization expense is recognized on a straight-line basis over the shorter of the life of the asset or the term of the lease.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future lease payments under the non-cancelable leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 are as follows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:
<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance Leases</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating Leases</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,914</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,633</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,280</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total undiscounted lease payments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,194</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,633</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less imputed interest</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,557</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">172</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total lease liability</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,637</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,461</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Company&#8217;s Third Amended and Restated Certificate of Incorporation, as amended, the Company is authorized to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">293,590,481</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of voting common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,409,519</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of non-voting common stock. In May 2024, the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,444,295</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of non-voting common stock were converted to voting common stock and no shares of non-voting common stock are outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">June 2025 Financing</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2025, the Company issued (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,200,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock and accompanying warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,200,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,800,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock and accompanying warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,800,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant. An additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,090,190</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common stock warrants were issued in the financing for shares purchased by the underwriters in the market to cover overallotment demand. The combined offering price of each share of common stock and accompanying common stock warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The combined offering price of each pre-funded warrant and accompanying common stock warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.99999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The pre-funded warrants are exercisable immediately. The common stock and pre-funded warrants were sold in combination with an accompanying common stock warrant to purchase one share of common stock (or a pre-funded warrant in lieu thereof) for each share of common stock or pre-funded warrant sold. Each common stock warrant has an exercise price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The common stock warrants are immediately exercisable from the date of issuance and will expire on September 12, 2026, fifteen months from the date of issuance. Aggregate net proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,558</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after deducting underwriting discounts and commissions and offering expenses. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,800,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants had been exercised and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> remain outstanding. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, no common stock warrants had been exercised and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,090,190</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> remain outstanding. Subsequent to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,775,100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> common stock warrants were exercised for proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,938</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pre-funded warrants and common stock warrants were classified as a component of permanent stockholders&#8217; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants and common stock warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria. In addition, such pre-funded warrants and common stock warrants do not provide any guarantee of value or return.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">At-the-Market Offering</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 31, 2025, the Company converted the Form S-3ASR to a Form S-3 (File No. 333-278126) by post-effective amendments. This Form S-3 was declared effective on March 31, 2025. The Company had a Sales Agreement with TD Securities (USA) LLC (as successor to Cowen and Company, LLC) (TD Cowen) to provide for the offering, issuance and sale of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of common stock from time to time in &#8220;at-the-market&#8221; offerings (2024 ATM Program) pursuant to its S-3, and subject to the limitations thereof. On June 11, 2025, the 2024 ATM Program with TD Cowen was terminated. Prior to termination, the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,609,865</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares pursuant to the 2024 ATM Program for total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,724</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, consisting of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,129</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in 202</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,595</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in 2025.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 7, 2025, the Company filed a Registration Statement (File No. 333-289339) with the Securities and Exchange Commission (SEC), which was declared effective on August 15, 2025 (2025 Shelf Registration Statement), in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, the Company&#8217;s common stock, debt securities or other equity securities in one or more offerings. The Company also simultaneously entered into a Sales Agreement with TD Cowen to provide for the offering, issuance and sale of up to an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the Company's common stock from time to time in &#8220;at-the-market&#8221; offerings (the 2025 ATM Program) under the 2025 Shelf Registration Statement and subject to the limitations thereof (the 2025 Sales Agreement). During the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,160,176</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares pursuant to the 2025 ATM Program for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,151</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subsequent to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,055,260</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional shares, for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,568</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2018 Stock Option and Grant Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2018, the Company adopted the 2018 Stock Option and Grant Plan (the 2018 Plan), which provided for the Company to sell or issue common stock, or other stock-based awards, to employees, members of the board of directors and consultants of the Company. The Company generally granted stock-based awards with service conditions only (service-based awards), although there was one grant with performance conditions. As of December 31, 2020, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unvested options with performance conditions. Stock options granted under the 2018 Plan generally vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d6a034d6-bb46-42f3-a934-8529b7b3bdda;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,959,411</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> options were granted under the 2018 Plan prior to the Company&#8217;s IPO in October 2019. No further grants may be made under the 2018 Plan subsequent to the IPO.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 Stock Option and Incentive Plan</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2019 Stock Option and Incentive Plan (2019 Plan) was approved by the Company&#8217;s board of directors on October 14, 2019, and became effective on October 23, 2019. The 2019 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#8217;s officers, employees, directors and consultants. The number of shares initially reserved for issuance under the 2019 Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,342,288</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which will be increased each January 1 thereafter by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&#8217;s board of directors or compensation committee of the board of directors. On June 1, 2023, at the 2023 Annual Meeting of Stockholders of the Company, the stockholders of the Company approved Amendment No. 1 to the 2019 Plan, increasing the number of shares of common stock reserved for issuance under the 2019 Plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. On January 1, 2026, the total number of shares under the 2019 Plan was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,019,172</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares pursuant to the 2019 Plan Evergreen Provision. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,066,471</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remaining available for issuance under the 2019 Plan.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2025 Inducement Plan</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, the Company adopted the 2025 Inducement Plan (Inducement Plan). The Inducement Plan was adopted by the Compensation Committee of the Company&#8217;s board of directors without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4). In accordance with Rule 5635(c)(4), awards made under the Inducement Plan, including stock options and restricted stock units, may only be granted to newly hired employees as a material inducement to accept employment with the Company. Stock options granted under the Inducement Plan expire no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">later than ten years from the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The number of shares reserved for issuance under the Inducement Plan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">275,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, there were no shares available for issuance under the Inducement Plan.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Repricing</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 19, 2025, the Company&#8217;s Board of Directors approved the repricing of certain outstanding vested and unvested stock options. Pursuant to the repricing, all options granted under the 2018 Plan and 2019 Plan held by current employees, non-employee directors and certain consultants were repriced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.92</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the closing price of the Company&#8217;s common stock on May 19, 2025, to the extent such options had an exercise price in excess of 1.5x the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.92</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> closing price per share. To exercise the repriced options at the reduced exercise price, eligible participants must remain employed with the Company through a retention period of 12 months that begins on May 19, 2025.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the repricing, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,900,096</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vested and unvested stock options outstanding as of May 19, 2025, with original exercise prices ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.88</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.97</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, were repriced. The repricing resulted in incremental stock-based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,813</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> related to vested stock option awards and is being amortized over the retention period, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,208</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> related to unvested stock option awards and is being amortized on a straight-line basis over the remaining vesting period of those awards.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Option Activity</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of stock option activity is presented below:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:33.84%;box-sizing:content-box;"></td>
          <td style="width:1.18%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.6%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.120000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.18%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.64%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.120000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (years)</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of January 1, 2025</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,231,148</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.63</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">989</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,469,050</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.78</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,334</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.01</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">851,492</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.29</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,835,372</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.57</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.1</span></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,371</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options Exercisable at December 31, 2025</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,860,610</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.45</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.8</span></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">899</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average exercise prices and aggregate intrinsic values in this table will not reflect the impact of the May 2025 repricing until the retention period is complete in May 2026.</span></p></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock. The weighted average grant-date fair value of stock options granted during the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.52</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.44</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each award is estimated using Black-Scholes based on the following assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:53.049%;box-sizing:content-box;"></td>
          <td style="width:1.8%;box-sizing:content-box;"></td>
          <td style="width:21.676%;box-sizing:content-box;"></td>
          <td style="width:1.8%;box-sizing:content-box;"></td>
          <td style="width:21.676%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.72</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.46</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.43</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.60</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years&#8212;</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years&#8212;</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.2</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
        </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method, which is the midpoint between the vesting period and the contractual term of the option.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Expected volatility is estimated using the Company's stock price since its IPO in October 2019.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of a stock-based award.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expected dividend</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has recorded stock-based compensation in the accompanying statements of operations as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,470</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,163</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,469</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,302</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,939</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,465</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,159</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of unrecognized compensation cost related to unvested option awards and vested option awards subject to the twelve month retention period, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.1</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2019 Employee Stock Purchase Plan</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2019 Employee Stock Purchase Plan (2019 ESPP) was approved by the Company&#8217;s board of directors on October 14, 2019, and became effective on October 23, 2019. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234,229</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were initially reserved for issuance under the 2019 ESPP, and such number of shares will be increased each January 1 thereafter through January 1, 2029 by the least of (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234,229</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the number of shares of the Company&#8217;s common stock outstanding on the immediately preceding December 31 or (iii) such lesser number of shares determined by the 2019 ESPP&#8217;s administrator. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 1, 2026, the total number of shares available under the 2019 ESPP was increased by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234,229</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares pursuant to the 2019 Plan Evergreen Provision. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136,383</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares remaining available for issuance under the 2019 ESPP.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employee contributions are made through payroll deductions of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of eligible compensation over the offering period. A participant may not accrue rights to purchase more than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding. At the end of each offering period, shares of the Company&#8217;s common stock may be purchased at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lesser of the Company&#8217;s common stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period. Each offering period will be six months in duration and will commence on each December 1 and June 1.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reconciliation of federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:51.379%;box-sizing:content-box;"></td>
          <td style="width:1.679%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.035%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:6.977%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.679%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.036000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:7.216%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Statutory Tax Rate</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,304</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,331</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and Local Income Taxes, Net of Federal Income Tax Effect </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign Tax Effects</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of Cross-Border Tax Laws</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Credits</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,489</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.6</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,769</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in Valuation Allowances (Domestic)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,489</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.9</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,176</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or Nondeductible Items</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">983</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">951</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other Adjustments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">203</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Actual income tax benefit effective tax rate</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within the State Income Tax category, Pennsylvania and Philadelphia accounted for the majority, representing over 50% of the total reconciling impact.</span></p></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consistent with the Company&#8217;s cumulative loss position and absence of taxable income in federal, state, and local jurisdictions, the Company made no income tax payments and received no income tax refunds in the current fiscal year.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal components of the Company&#8217;s deferred tax assets and liabilities consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;">
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:56.257%;box-sizing:content-box;"></td>
          <td style="width:2.159%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:17.712999999999997%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2.159%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:17.712999999999997%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal, state and local net operating loss carryforwards</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,014</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,369</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development costs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,333</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,646</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,050</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,296</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation deductions</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,299</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,919</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License fee deductions</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">221</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,357</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,607</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,805</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,603</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax assets</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">163,044</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,661</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,850</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110,723</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,194</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,938</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,194</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,938</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company increased its valuation allowance by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,127</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the year ended December 31, 2025 in order to maintain a full valuation allowance against its deferred tax assets. Based on the Company&#8217;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December 31, 2025. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal, state and local net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">319,886</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">255,101</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">257,607</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively; $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">319,636</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the federal net operating losses do not expire, and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The state net operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2037</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The local net operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2042</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal and state research and development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,044</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively. The research and development credits begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2038</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s federal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">research </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">credits consist of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,821</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Research and Development credits and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,223</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of Orphan Drug credits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the provisions of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, these net operating losses, credit carryforwards and other tax attributes may be subject to limitation based on previous significant changes in ownership and upon future significant changes in ownership of the Company, as defined by the Code.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company files income tax returns in the U.S. federal jurisdiction and in multiple state and local jurisdictions; however, Pennsylvania and Philadelphia constitute the Company&#8217;s most significant tax jurisdictions due to the concentration of its operational footprint and the resulting apportionment profile. The tax years 2024, 2023 and 2022 remain open to examination by the jurisdictions where the Company is subject to tax.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he Company calculates basic and diluted net loss per share in conformity with the two-class method required for participating securities. In May 2024, the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,444,295</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of non-voting common stock were converted to voting common stock and no shares of non-voting common stock remain outstanding. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the rights of the voting and non-voting common stock are identical, except with respect to voting, the undistributed losses of the Company have been allocated on a proportionate basis to the two classes. Basic net loss per share of common stock is computed by dividing the net loss per share of common stock by the weighted average number of shares of common stock outstanding for the period. The weighted-average shares of common stock outstanding as of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> included outstanding pre-funded warrants to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants were outstanding as of December 31, 2024.</span></p><div><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net loss per share is calculated using the if-converted method as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, which assumes conversion of all non-voting common stock to voting common stock.</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.02%;box-sizing:content-box;"></td>
          <td style="width:3.12%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:27.86%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Voting common stock</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">167,856</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,903,224</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.10</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.4%;box-sizing:content-box;"></td>
          <td style="width:1.92%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.88%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.92%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.88%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31, 2024</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Voting common stock</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-voting common stock</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic net loss per share:</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,728</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,038,726</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485,378</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.34</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.34</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted net loss per share:</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses for basic computation</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,728</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reallocation of undistributed losses as a result of conversion of<br/>&#160;&#160;&#160;&#160;&#160;non-voting to voting common shares</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,864</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,038,726</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485,378</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: conversion of non-voting to voting common shares outstanding</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485,378</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in diluted per share computation</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,524,104</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485,378</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, diluted</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.34</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.34</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:46.491%;box-sizing:content-box;"></td>
          <td style="width:2.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:22.595%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:22.595%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,835,372</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,231,148</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,090,190</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,925,562</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,231,148</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">401(k) Savings Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. 401(k) Savings Plan</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company maintains a defined-contribution savings plan under Section 401(k) of the IRC, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. Effective January 1, 2020, the Plan provided for matching contributions on a portion of participant contributions pursuant to the 401(k) Savings Plan&#8217;s matching formula, up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of eligible compensation. All matching contributions and participant contributions vest immediately. Contributions totaled $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,063</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">894</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, and have been recorded in the statements of operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) and under the rules and regulations of the U.S. Securities and Exchange Commission (SEC). All intercompany balances and transactions have been eliminated in consolidation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to advance payments and accruals related to the Company&#8217;s research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock', window );">Off-Balance Sheet Risk and Concentrations of Credit Risk</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Off-Balance Sheet Risk and Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist of cash and cash equivalents, which are invested in U.S. treasury-based money market funds, and available-for-sale debt securities, which are invested in U.S. treasury securities. A portion of the Company&#8217;s cash is maintained at federally insured financial institutions, and account balances may at times exceed federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk. The Company has no off&#8209;balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and U.S. treasury securities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investments are available-for-sale and carried at estimated fair value. The Company&#8217;s valuations of available-for-sale debt securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than, twelve months from the balance sheet date are classified as current.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors including the severity and duration of the unrealized loss as well as the Company&#8217;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or if more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments as well as amortization of discount or premium is included in interest income.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property, Plant and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying statements of operations. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimated useful lives for property and equipment are as follows:</span></p>
          <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
           <tr style="visibility:collapse;">
            <td style="width:49.17%;box-sizing:content-box;"></td>
            <td style="width:1.66%;box-sizing:content-box;"></td>
            <td style="width:49.17%;box-sizing:content-box;"></td>
           </tr>
           <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated useful life</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Three years</span></span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Three years</span></span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Three years</span></span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_6b79aa44-243a-42b1-94f6-81fb189f1245;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lesser of estimated useful life or remaining lease term</span></span></span></p></td>
           </tr>
          </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1&#8212;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2&#8212;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has leases related to its facilities used for offices and laboratory space, which are classified as operating leases as well as leases related to its manufacturing arrangements, which are classified as finance leases.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease and its classification based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. Subsequent to the initial measurement, the Company will continue to account for:</span></p><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the lease liability at the net present value using the incremental borrowing rate that was in effect as of the lease commencement, lease modification, or transition date, and;</span></div></div><div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the finance lease and operating lease expense on a straight line basis.</span></div></div><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases with terms of 12 months or less are considered short-term leases and right-of-use assets and lease obligations are not recognized. Payments associated with short-term leases are expensed on a straight-line basis over the lease term.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to aggregate all lease and non-lease components for each class of underlying assets into a single lease component for real-estate leases and embedded manufacturing arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the guidance in ASC 842-10-55-2 to assist in determining lease classification across its leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs include costs incurred for internal and external research and development activities and are expensed as incurred in the accompanying statements of operations. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to entities that conduct certain research and development and clinical trial activities on the Company&#8217;s behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers, which include preclinical studies, contract manufacturing activities and clinical trial activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided and in accordance with agreements established with service providers and includes these costs in accrued and other current liabilities in the accompanying balance sheets and within research and development expense in the accompanying statements of operations. Non-refundable advance payments made for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are received or the related services are rendered. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid expenses in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities and prepaid expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures its stock-based awards granted to employees and non-employees based on the estimated fair values of the awards on the respective grant dates. The Company uses the Black-Scholes option-pricing model (Black-Scholes) to estimate the fair value of its stock-based awards. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company accounts for forfeitures of stock option awards as they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base, as well as for net operating loss carryforwards and research and development credits, and are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> interest or penalties related to uncertain income tax benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company calculates basic and diluted net loss per share in conformity with the two-class method required for participating securities because the Company had both voting and non-voting common stock outstanding for a portion of 2024. The rights, including the liquidation and dividend rights, of the holders of the voting and non-voting common stock are identical, except with respect to voting. Each share of non-voting common stock may be converted at any time into one share of voting common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. As of December 31, 2024, no shares of non-voting common stock remain outstanding.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted average number of shares of common stock, including any pre-funded warrants to purchase shares of common stock that may be outstanding. The undistributed loss for each year is allocated to common stockholders based on the contractual participation rights of the voting and non-voting common stock as if the losses for the year had been distributed. As the liquidation and dividend rights are identical, the undistributed losses are allocated on a proportionate basis. Diluted net loss per share attributable to common stockholders is computed under the if-converted method and assumes that all non-voting common stock has been converted to common stock. Since the Company was in a loss position for all periods presented, the effects of the other potentially dilutive securities are antidilutive.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segments</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer (CEO). The Company has determined it operates in a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_11331fa4-2d51-42cc-aee7-5b9ce9481ad0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating segment and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refer to Note 8 &#8211; Segment Reporting for further information related to our segment.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of stockholders&#8217; equity as a reduction of additional paid-in capital or equity generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. ASU 2023-09 enhances the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The Company adopted this ASU for the annual period ended December 31, 2025 and the amendments have been applied retrospectively to all prior periods presented in the financial statements. Refer to Note 11 &#8211; Income Taxes for further information.</span></p><p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement (Subtopic 220-40): Reporting Comprehensive Income-Expense Disaggregation Disclosures. ASU 2024-03 requires enhanced disclosures about components of expense captions on the face of the income statement. This standard will be effective for fiscal years beginning after December 15, 2026. Early adoption is permitted. ASU 2024-03 applies on a prospective basis for periods beginning after the effective date. However, retrospective application to any or all prior periods presented is permitted. The Company is currently planning to adopt this guidance when effective and is assessing the impact of the adoption on the Company&#8217;s consolidated financial statements and accompanying footnotes.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no other new accounting pronouncements or changes to accounting pronouncements that, if adopted, would have or may have a material impact on the Company&#8217;s consolidated statements or disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock', window );">Schedule of Estimated Useful Lives for Property and Equipment</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimated useful lives for property and equipment are as follows:</span></p>
          <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
           <tr style="visibility:collapse;">
            <td style="width:49.17%;box-sizing:content-box;"></td>
            <td style="width:1.66%;box-sizing:content-box;"></td>
            <td style="width:49.17%;box-sizing:content-box;"></td>
           </tr>
           <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Property and equipment</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated useful life</span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Three years</span></span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Three years</span></span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Three years</span></span></p></td>
           </tr>
           <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
            <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_6b79aa44-243a-42b1-94f6-81fb189f1245;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lesser of estimated useful life or remaining lease term</span></span></span></p></td>
           </tr>
          </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated useful lives of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:36.174%;box-sizing:content-box;"></td>
          <td style="width:1.561%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.365%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.561%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.485000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.561%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.365%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.561%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.365%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active Markets<br/>for Identical Assets <br/>(Level 1)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,470</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,470</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term investments:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,617</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,617</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132,087</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,470</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,617</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:35.42%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.020000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:14.440000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.020000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.52%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.020000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active Markets<br/>for Identical Assets<br/>(Level 1)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,634</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,634</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,634</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">162,634</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Debt Securities Classified as Available-for-Sale Investments</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Company records unrealized gains or losses resulting from changes in fair value between measurement dates as a component of other comprehensive income. The Company did not hold any available-for-sale securities as of December 31, 2024.</span>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:49.17%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.283000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.283000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.283000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized Cost</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross Unrealized Gains</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,512</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,512</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,470</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,470</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,982</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82,982</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities - due in one year or less</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Included in short-term investments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,592</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,617</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,574</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,599</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property Plant and Equipment</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment consists of the following:</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,488</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,663</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">277</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">277</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total property, plant and equipment</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,074</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,249</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: accumulated depreciation</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,152</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,506</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property, plant and equipment, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,922</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,743</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued and other current liabilities consist of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.272%;box-sizing:content-box;"></td>
          <td style="width:2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.363%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.363%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,716</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,315</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trial research and development services</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,335</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,236</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Manufacturing and other research and development services</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,774</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,255</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative services</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">393</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">342</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,298</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,188</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Payments for Operating Leases</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future lease payments under the non-cancelable leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 are as follows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:
<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance Leases</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating Leases</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,914</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,633</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,280</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total undiscounted lease payments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,194</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,633</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less imputed interest</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,557</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">172</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total lease liability</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,637</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,461</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Profit and Loss From Segments</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional information on the year over year change of segment expenses refer to Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:57.12%;box-sizing:content-box;"></td>
          <td style="width:2.1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:17.34%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2.1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:17.34%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,934</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,239</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical trials</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,581</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,286</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Manufacturing of preclinical and clinical supplies</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,240</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,523</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development services</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,350</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,417</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License of intellectual property</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,523</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other research and development costs </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,569</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,215</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administration expenses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,567</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,938</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,031</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,025</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,004</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">748</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">358</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">167,856</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,864</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Payments for Operating Leases</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future lease payments under the non-cancelable leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 are as follows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:
<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance Leases</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating Leases</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,914</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,633</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,280</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total undiscounted lease payments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,194</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,633</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less imputed interest</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,557</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">172</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total lease liability</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,637</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,461</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Company's Operating and Finance Leases</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table contains information pertaining to the Company&#8217;s operating and finance leases</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2025 and 2024.</span></p><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:59.224%;box-sizing:content-box;"></td>
          <td style="width:2.001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.387%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2.001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:16.387%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Finance leases</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,004</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">748</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization expense</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,391</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,102</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fixed finance lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,395</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,850</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,508</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">930</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total finance lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,903</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,780</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating leases</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,211</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,247</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fixed operating lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,211</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,247</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">296</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">750</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease cost</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,416</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,293</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash paid in the measurement of lease liabilities</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows used for operating leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,227</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,291</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating cash flows used for finance leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,713</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">748</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing cash flows for finance leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,261</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">897</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other information</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average remaining lease term - finance leases (in years)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate - finance leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.5</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average remaining lease term - operating leases (in years)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average discount rate - operating leases</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of stock option activity is presented below:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:33.84%;box-sizing:content-box;"></td>
          <td style="width:1.18%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.6%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.120000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.18%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.64%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.66%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:13.120000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>Shares</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (years)</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of January 1, 2025</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,231,148</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.63</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">989</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,469,050</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.78</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,334</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.01</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited/Cancelled</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">851,492</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.29</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2025</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,835,372</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.57</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.1</span></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,371</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options Exercisable at December 31, 2025</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,860,610</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.45</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.8</span></span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">899</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average exercise prices and aggregate intrinsic values in this table will not reflect the impact of the May 2025 repricing until the retention period is complete in May 2026.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used to Estimate Fair Value of Stock Options</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of each award is estimated using Black-Scholes based on the following assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:53.049%;box-sizing:content-box;"></td>
          <td style="width:1.8%;box-sizing:content-box;"></td>
          <td style="width:21.676%;box-sizing:content-box;"></td>
          <td style="width:1.8%;box-sizing:content-box;"></td>
          <td style="width:21.676%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.72</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.46</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.43</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.60</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years&#8212;</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1 </span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">years</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years&#8212;</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.2</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has recorded stock-based compensation in the accompanying statements of operations as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,470</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,163</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,469</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,302</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,939</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,465</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reconciliation of federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:51.379%;box-sizing:content-box;"></td>
          <td style="width:1.679%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.035%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:6.977%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.679%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:9.036000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:7.216%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Statutory Tax Rate</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,304</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,331</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and Local Income Taxes, Net of Federal Income Tax Effect </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign Tax Effects</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of Cross-Border Tax Laws</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Credits</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,489</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.6</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,769</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in Valuation Allowances (Domestic)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,489</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.9</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,176</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.2</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or Nondeductible Items</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">983</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">951</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other Adjustments</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">203</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Actual income tax benefit effective tax rate</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within the State Income Tax category, Pennsylvania and Philadelphia accounted for the majority, representing over 50% of the total reconciling impact.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Principal Components of Company's Deferred Tax Assets</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal components of the Company&#8217;s deferred tax assets and liabilities consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:56.257%;box-sizing:content-box;"></td>
          <td style="width:2.159%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:17.712999999999997%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2.159%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:17.712999999999997%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal, state and local net operating loss carryforwards</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,014</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,369</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development costs</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,333</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,646</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credits</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,050</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,296</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation deductions</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,299</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,919</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License fee deductions</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">221</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,357</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,607</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,805</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,603</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax assets</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">163,044</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,661</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,850</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110,723</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,194</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,938</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,194</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,938</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net loss per share is calculated using the if-converted method as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, which assumes conversion of all non-voting common stock to voting common stock.</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:67.02%;box-sizing:content-box;"></td>
          <td style="width:3.12%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:27.86%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31, 2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Voting common stock</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share:</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">167,856</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares outstanding</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,903,224</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.10</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.4%;box-sizing:content-box;"></td>
          <td style="width:1.92%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.88%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.92%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.88%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31, 2024</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Voting common stock</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-voting common stock</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic net loss per share:</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,728</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,038,726</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485,378</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.34</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.34</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted net loss per share:</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses for basic computation</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,728</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reallocation of undistributed losses as a result of conversion of<br/>&#160;&#160;&#160;&#160;&#160;non-voting to voting common shares</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Allocation of undistributed losses</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,864</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,136</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in basic per share computation</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,038,726</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485,378</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: conversion of non-voting to voting common shares outstanding</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485,378</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average number of shares used in diluted per share computation</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,524,104</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">485,378</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, diluted</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.34</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.34</span></p></td>
          <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:46.491%;box-sizing:content-box;"></td>
          <td style="width:2.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:22.595%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:2.16%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:22.595%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options to purchase common stock</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,835,372</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,231,148</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,090,190</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,925,562</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,231,148</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and investments</a></td>
<td class="nump">$ 133,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (516,957)<span></span>
</td>
<td class="num">$ (349,101)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest or penalties related to uncertain income tax benefits | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives for Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=caba_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Lesser of estimated useful life or remaining lease term</a></td>
<td class="text">Lesser of estimated useful life or remaining lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=caba_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=caba_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">$ 50,617<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">132,087<span></span>
</td>
<td class="nump">162,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">50,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">81,470<span></span>
</td>
<td class="nump">162,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">81,470<span></span>
</td>
<td class="nump">162,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">81,470<span></span>
</td>
<td class="nump">162,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">50,617<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | U.S. Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">50,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | U.S. Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Debt Securities Classified as Available-for-Sale Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 133,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">133,599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">81,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">81,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Included in Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">82,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">82,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">1,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Treasury securities - due in one year or less</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">50,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 50,617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 9,074<span></span>
</td>
<td class="nump">$ 8,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(7,152)<span></span>
</td>
<td class="num">(5,506)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,922<span></span>
</td>
<td class="nump">2,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">8,488<span></span>
</td>
<td class="nump">7,663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,646<span></span>
</td>
<td class="nump">$ 1,711<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation expense</a></td>
<td class="nump">$ 9,716<span></span>
</td>
<td class="nump">$ 8,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_ClinicalTrialResearchAndDevelopmentServices', window );">Clinical trial research and development services</a></td>
<td class="nump">5,335<span></span>
</td>
<td class="nump">1,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_ManufacturingAndOtherResearchAndDevelopmentServices', window );">Manufacturing and other research and development services</a></td>
<td class="nump">3,774<span></span>
</td>
<td class="nump">2,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_AccruedGeneralAndAdministrativeServicesCurrent', window );">General and administrative services</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 19,298<span></span>
</td>
<td class="nump">$ 12,188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AccruedGeneralAndAdministrativeServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued general and administrative services current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AccruedGeneralAndAdministrativeServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ClinicalTrialResearchAndDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Research and Development Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ClinicalTrialResearchAndDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ManufacturingAndOtherResearchAndDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Manufacturing and Other Research and Development Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ManufacturingAndOtherResearchAndDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations, Licensing Agreements and other Agreements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Oct. 07, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,674<span></span>
</td>
<td class="nump">$ 97,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_UpfrontPayment', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_LicenseAgreementMember', window );">License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Obligation to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_PaymentOfObligationTerm', window );">Payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_LicenseMaintenanceFee', window );">License maintenance fee</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_MilestonePayments', window );">Total milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborativeAgreementPaymentsDue', window );">Amounts due to agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_SponsoredResearchAgreementsMember', window );">Sponsored Research Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Obligation to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_MasterTranslationalResearchServicesAgreementMember', window );">Master Translational Research Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,062<span></span>
</td>
<td class="nump">$ 3,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_RemainingResearchAndDevelopmentExpenseToBeIncurred', window );">Remaining research and development expense to be incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_OxfordBiomedicaMember', window );">Oxford Biomedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Obligation to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_UpfrontPayment', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_NanjingIasoBiotherapeuticsCoLtdMember', window );">IASO Biotherapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_UpfrontPayment', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember', window );">Autolus Holdings Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_UpfrontPayment', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember', window );">Autolus Holdings Member | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember', window );">Autolus Holdings Member | Maximum | License and Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems', window );"><strong>Collaborations, Licensing Agreements And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborations licensing agreements and other agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CollaborativeAgreementPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative agreement payments due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CollaborativeAgreementPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_LicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License maintenance fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_LicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PaymentOfObligationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of obligation, term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PaymentOfObligationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_RemainingResearchAndDevelopmentExpenseToBeIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining research and development expense to be incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_RemainingResearchAndDevelopmentExpenseToBeIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_SponsoredResearchAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_SponsoredResearchAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_MasterTranslationalResearchServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_MasterTranslationalResearchServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_OxfordBiomedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_OxfordBiomedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_NanjingIasoBiotherapeuticsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_NanjingIasoBiotherapeuticsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_InitialTermsOfAgreementDescription', window );">Terms agreement description</a></td>
<td class="text">Under the August 2023 work orders, Minaris converted the Company&#8217;s non-dedicated suite to a dedicated suite for GMP manufacturing for the Company&#8217;s rese-cel and MuSK-CAART programs, or the Dedicated Suite, for an initial term of 18 months with two 18-month extensions at the Company&#8217;s sole option on six months' notice prior to the end of the term. In August 2024, the Company sent a notice to Minaris to extend the initial term of the Minaris Agreement by 18 months through August 2026.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 142,674<span></span>
</td>
<td class="nump">$ 97,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=caba_Rese-CelAndMuSK-CAARTMember', window );">Rese-Cel and MuSK-CAART [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees', window );">Early termination fee</a></td>
<td class="nump">$ 1,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_DevelopmentAndManufacturingServicesAgreementMember', window );">Wuxi Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_LeaseExpirationMonth', window );">Lease expiration month</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees', window );">Early termination fee</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_LonzaAgreementMember', window );">Lonza Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_LeaseExpirationMonth', window );">Lease expiration month</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_PaymentOfObligationTerm', window );">Payment term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_InitialTermsOfAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial Terms of Agreement, Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_InitialTermsOfAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_LeaseExpirationMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Expiration Month</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_LeaseExpirationMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PaymentOfObligationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of obligation, term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PaymentOfObligationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of early contract termination fees included in liabilities subject to compromise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=caba_Rese-CelAndMuSK-CAARTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=caba_Rese-CelAndMuSK-CAARTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_DevelopmentAndManufacturingServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_DevelopmentAndManufacturingServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_LonzaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_LonzaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">2023</a></td>
<td class="nump">$ 3,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2024</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Profit and Loss from Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_PersonnelExpenses', window );">Personnel</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46,934<span></span>
</td>
<td class="nump">$ 39,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_ClinicalTrials', window );">Clinical trials</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,581<span></span>
</td>
<td class="nump">22,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_DevelopmentServices', window );">Development Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,350<span></span>
</td>
<td class="nump">16,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_ManufacturingOfPreclinicalAndClinicalSupplies', window );">Manufacturing of preclinical and clinical supplies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38,240<span></span>
</td>
<td class="nump">15,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_LicenseOfIntellectualProperty', window );">License of intellectual property</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,569<span></span>
</td>
<td class="nump">2,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administration expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,567<span></span>
</td>
<td class="nump">27,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,031)<span></span>
</td>
<td class="num">(10,025)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,004<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(358)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 167,856<span></span>
</td>
<td class="nump">$ 115,864<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Trials</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_DevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_DevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_LicenseOfIntellectualProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License of Intellectual Property</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_LicenseOfIntellectualProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ManufacturingOfPreclinicalAndClinicalSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Manufacturing of Preclinical and Clinical Supplies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ManufacturingOfPreclinicalAndClinicalSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Personnel Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 24, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,431<span></span>
</td>
<td class="nump">$ 6,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Fixed lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,416<span></span>
</td>
<td class="nump">$ 4,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Additional in fixed undiscounted lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total fixed operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,211<span></span>
</td>
<td class="nump">$ 3,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IncreaseInTheLeaseLiability', window );">Increase in the lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_WuxiAgreementMember', window );">WuXi Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_TerminationFees', window );">Termination fees</a></td>
<td class="nump">$ 1,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_WorkOrdersTerm', window );">Work orders terms</a></td>
<td class="text">The terms of the August 2023 work orders included both fixed costs and contingent variable costs. The lease commenced October 1, 2023. In 2024, the Company remeasured the lease following the resolution of the contingency related to variable costs and an amendment to the 2023 work order, which extended the term of the agreement by an additional 18 months through August 2026. The Company may terminate the Dedicated Suite lease for convenience with six months&#8217; prior written notice and up to a $1,080 termination fee if both the rese-cel and MuSK-CAART work orders are terminated<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IncreaseInTheLeaseLiability', window );">Increase in the lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_LonzaAgreementMember', window );">Lonza Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IncreaseInTheLeaseLiability', window );">Increase in the lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_IncreaseInTheLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in the lease liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_IncreaseInTheLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TerminationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TerminationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_WorkOrdersTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Work Orders Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_WorkOrdersTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_WuxiAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_WuxiAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_LonzaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_LonzaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths', window );">2026</a></td>
<td class="nump">$ 21,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2027</a></td>
<td class="nump">3,280<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_FinanceLesseeUndiscountedLeasePayments', window );">Total undiscounted lease payments</a></td>
<td class="nump">25,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(1,557)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease liability</a></td>
<td class="nump">23,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">2026</a></td>
<td class="nump">3,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_LesseeUndiscountedLeasePayments', window );">Total undiscounted lease payments</a></td>
<td class="nump">3,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease liability</a></td>
<td class="nump">$ 3,461<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_FinanceLesseeUndiscountedLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lessee Undiscounted Lease Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_FinanceLesseeUndiscountedLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_LesseeUndiscountedLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Undiscounted Lease Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_LesseeUndiscountedLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease due in next rolling 12 months following current statement of financial position date. For interim and annual periods when interim period is reported on rolling approach.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Company's operating and finance leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_FinanceLeasesAbstract', window );"><strong>Finance Leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 2,004<span></span>
</td>
<td class="nump">$ 748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_AmortizationExpense', window );">Amortization expense</a></td>
<td class="nump">12,391<span></span>
</td>
<td class="nump">3,102<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_TotalFixedFinanceLeaseCost', window );">Total Fixed Finance Lease Cost</a></td>
<td class="nump">14,395<span></span>
</td>
<td class="nump">3,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_VariableLeaseCosts', window );">Variable lease cost</a></td>
<td class="nump">5,508<span></span>
</td>
<td class="nump">930<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_TotalFinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">19,903<span></span>
</td>
<td class="nump">4,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_OperatingLeasesAbtract', window );"><strong>Operating Leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_FixedLeaseCost', window );">Fixed lease cost</a></td>
<td class="nump">4,211<span></span>
</td>
<td class="nump">3,247<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Total fixed operating lease cost</a></td>
<td class="nump">4,211<span></span>
</td>
<td class="nump">3,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">4,416<span></span>
</td>
<td class="nump">4,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid in the measurement of lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_OperatingCashFlowsUsedForOperatingLeases', window );">Operating cash flows used for operating leases</a></td>
<td class="nump">4,227<span></span>
</td>
<td class="nump">3,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_OperatingCashFlowsUsedForFinanceLeases', window );">Operating cash flows used for finance leases</a></td>
<td class="nump">1,713<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_FinancingCashFlowsUsedForFinanceLeases', window );">Financing cash flows for finance leases</a></td>
<td class="nump">$ 6,261<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_OtherInformationAbstract', window );"><strong>Other inforamation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term - finance leases (in years)</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - finance leases</a></td>
<td class="nump">10.70%<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term - operating leases (in years)</a></td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - operating leases</a></td>
<td class="nump">10.30%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_AmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_AmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid In The Measurement Of Lease Liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_FinanceLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance leases [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_FinanceLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_FinancingCashFlowsUsedForFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Cash Flows Used For Finance Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_FinancingCashFlowsUsedForFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_FixedLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Lease Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_FixedLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_OperatingCashFlowsUsedForFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Cash Flows Used For Finance Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_OperatingCashFlowsUsedForFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_OperatingCashFlowsUsedForOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Cash Flows Used For Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_OperatingCashFlowsUsedForOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_OperatingLeasesAbtract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases [Abtract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_OperatingLeasesAbtract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_OtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_OtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TotalFinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TotalFinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_TotalFixedFinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Fixed Finance Lease Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_TotalFixedFinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_VariableLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Variable Lease Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_VariableLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 07, 2025</div></th>
<th class="th"><div>May 19, 2025</div></th>
<th class="th"><div>Oct. 23, 2019</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 01, 2026</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Jun. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,876,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,479,323<span></span>
</td>
<td class="nump">50,743,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_PreFundedWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Additional common stock warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,090,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,479,323<span></span>
</td>
<td class="nump">50,743,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,090,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, warrants and pre-funded warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,558,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Common Stock Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="nump">$ 1,430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_SharesRemainingAvailableForIssuance', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,066,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.52<span></span>
</td>
<td class="nump">$ 13.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to unvested stock-based awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,939<span></span>
</td>
<td class="nump">$ 19,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=caba_UnvestedStockOptionMember', window );">Unvested Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=caba_VestedStockOptionMember', window );">Vested Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,813,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=caba_StockOptionRepricingMember', window );">Stock Option Repricing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Share-based compensation unvested number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Stock Option Repricing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceDecrease', window );">Stock Option, Exercise Price, Decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Stock Option Repricing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceDecrease', window );">Stock Option, Exercise Price, Decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember', window );">2024 At-The-Market Offering Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,609,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, warrants and pre-funded warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,724,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember', window );">2025 At-The-Market Offering Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,160,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, warrants and pre-funded warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandTwentyFiveSalesAgreementMember', window );">2025 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,055,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, warrants and pre-funded warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,568,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandEighteenStockOptionAndGrantPlanMember', window );">Two Thousand Eighteen Stock Option And Grant Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Share-based compensation unvested number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandEighteenStockOptionAndGrantPlanMember', window );">Two Thousand Eighteen Stock Option And Grant Plan [Member] | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,959,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandEighteenStockOptionAndGrantPlanMember', window );">Two Thousand Eighteen Stock Option And Grant Plan [Member] | Maximum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandEighteenStockOptionAndGrantPlanMember', window );">Two Thousand Eighteen Stock Option And Grant Plan [Member] | Minimum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_AtTheMarketOfferingSalesAgreementMember', window );">At The Market Offering Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuance</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, warrants and pre-funded warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,595,000<span></span>
</td>
<td class="nump">$ 5,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_AtTheMarketOfferingSalesAgreementMember', window );">At The Market Offering Sales Agreement [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember', window );">Two Thousand Nineteen Stock Option And Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,342,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,019,172<span></span>
</td>
<td class="nump">234,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IncreaseInShareReservedPercentage', window );">Increase in share reserved percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember', window );">Two Thousand Nineteen Stock Option And Incentive Plan [Member] | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,469,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember', window );">2018 and 2019 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Stock Option, Exercise Price, Increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 ESPP | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IncreaseInShareReservedPercentage', window );">Increase in share reserved percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_PercentageOfPayrollDeductionOnEligibleCompensation', window );">Payroll deduction percentage of eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock', window );">Employee stock purchase plan maximum annual rights to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock', window );">Percentage of shares to be purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_June2025FinancingMember', window );">June 2025 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Common Stock Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,775,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=caba_TwoThousandTwentyFiveInducementPlanMember', window );">2025 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember', window );">Voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,590,481<span></span>
</td>
<td class="nump">143,590,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember', window );">Voting Common Stock | Two Thousand Nineteen Stock Option And Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,409,519<span></span>
</td>
<td class="nump">6,409,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,444,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_PreFundedWarrantsMember', window );">Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_PreFundedWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_PreFundedWarrantsMember', window );">Pre-funded Warrants | June 2025 Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_PreFundedWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.99999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Decrease in exercise price of Warrents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan maximum annual rights to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_IncreaseInShareReservedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in share reserved percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_IncreaseInShareReservedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PercentageOfPayrollDeductionOnEligibleCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of payroll deduction on eligible compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PercentageOfPayrollDeductionOnEligibleCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares purchased at fair market value of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PreFundedWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PreFundedWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_SharesRemainingAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>shares remaining available for issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_SharesRemainingAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=caba_UnvestedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=caba_UnvestedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=caba_VestedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=caba_VestedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=caba_StockOptionRepricingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=caba_StockOptionRepricingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_TwoThousandTwentyFiveSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_TwoThousandTwentyFiveSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_TwoThousandEighteenStockOptionAndGrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_TwoThousandEighteenStockOptionAndGrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_AtTheMarketOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_AtTheMarketOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_TwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_June2025FinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_June2025FinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_TwoThousandTwentyFiveInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_TwoThousandTwentyFiveInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caba_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caba_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Summary of Stock Option Activity (Details) - Employee Stock Option - 2019 Plan - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,231,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,469,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Forfeited/Cancelled</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(851,492)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,835,372<span></span>
</td>
<td class="nump">11,231,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Options Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,860,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 10.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Cancelled</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8.57<span></span>
</td>
<td class="nump">$ 10.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 9.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (years)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (years), Options Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (years), Options Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,371<span></span>
</td>
<td class="nump">$ 989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average exercise prices and aggregate intrinsic values in this table will not reflect the impact of the May 2025 repricing until the retention period is complete in May 2026.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=caba_TwoThousandNineteenStockOptionAndIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Schedule of Assumptions Used to Estimate Fair Value of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.72%<span></span>
</td>
<td class="nump">3.43%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.46%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">112.00%<span></span>
</td>
<td class="nump">106.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">118.00%<span></span>
</td>
<td class="nump">111.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Summary of Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 3,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,939<span></span>
</td>
<td class="nump">$ 19,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,470<span></span>
</td>
<td class="nump">10,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,469<span></span>
</td>
<td class="nump">$ 9,302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. Statutory Tax Rate Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (35,304)<span></span>
</td>
<td class="num">$ (24,331)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. Statutory Tax Rate Percent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and Local Income Taxes, Net of Federal Income Tax Effect Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and Local Income Taxes, Net of Federal Income Tax Effect Percent</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign Tax Effects Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 24<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign Tax Effects Percent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount', window );">Effect of Cross-Border Tax Laws amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent', window );">Effect of Cross-Border Tax Laws Percent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax Credits amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (9,489)<span></span>
</td>
<td class="num">$ (5,769)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax Credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic', window );">Change in Valuation Allowances (Domestic) amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 43,489<span></span>
</td>
<td class="nump">$ 29,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic', window );">Change in Valuation Allowances (Domestic) percent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(25.90%)<span></span>
</td>
<td class="num">(25.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Nontaxable or Nondeductible Items amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 983<span></span>
</td>
<td class="nump">$ 951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Nontaxable or Nondeductible Items percent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other Adjustments amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 203<span></span>
</td>
<td class="num">$ (29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other Adjustments percent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Actual income tax benefit effective tax rate amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Actual income tax benefit effective tax rate percent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within the State Income Tax category, Pennsylvania and Philadelphia accounted for the majority, representing over 50% of the total reconciling impact.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in domestic income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in domestic income tax contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Principal Components of Company's Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Federal, state and local net operating loss carryforwards</a></td>
<td class="nump">$ 83,014<span></span>
</td>
<td class="nump">$ 44,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_CapitalizedRDCosts', window );">Capitalized research and development costs</a></td>
<td class="nump">31,333<span></span>
</td>
<td class="nump">36,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">25,050<span></span>
</td>
<td class="nump">16,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation deductions</a></td>
<td class="nump">13,299<span></span>
</td>
<td class="nump">9,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_DeferredTaxAssetsLicenseFeesDeductions', window );">License fee deductions</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">7,357<span></span>
</td>
<td class="nump">4,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">2,805<span></span>
</td>
<td class="nump">2,603<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">163,044<span></span>
</td>
<td class="nump">114,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(157,850)<span></span>
</td>
<td class="num">(110,723)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">5,194<span></span>
</td>
<td class="nump">3,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_OperatingLeaseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(5,194)<span></span>
</td>
<td class="num">(3,938)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_CapitalizedRDCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized R&amp;D costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_CapitalizedRDCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_DeferredTaxAssetsLicenseFeesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets license fees deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_DeferredTaxAssetsLicenseFeesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_OperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_OperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 47,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Deferred Tax Assets, Operating Loss Carryforwards, Local</a></td>
<td class="nump">257,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Deferred Tax Assets, Operating Loss Carryforwards, Federal</a></td>
<td class="nump">319,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Federal, state and local net operating loss carryforwards</a></td>
<td class="nump">83,014<span></span>
</td>
<td class="nump">$ 44,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Deferred tax assets, operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">319,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Deferred tax assets, operating loss carryforwards, subject to expiration</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate', window );">Operating loss carryforwards state commencement of expiration date</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate', window );">Federal and state research and development tax credit carryforwards expiration date</a></td>
<td class="text">2038 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">$ 25,050<span></span>
</td>
<td class="nump">$ 16,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_ResearchAndDevelopmentCredits', window );">Research and development credits</a></td>
<td class="nump">$ 13,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_PercentageOfEligibleTaxPositionsForRecognition', window );">Percentage of eligible tax positions for recognition</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized income tax benefits that would affect effective tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">$ 25,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate', window );">Deferred tax assets tax credit carryforwards commencement of expiration date</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Federal, state and local net operating loss carryforwards</a></td>
<td class="nump">$ 255,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate', window );">Deferred tax assets tax credit carryforwards commencement of expiration date</a></td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=caba_OrphanDrugCreditsMember', window );">Orphan Drug Credits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_ResearchAndDevelopmentCredits', window );">Research and development credits</a></td>
<td class="nump">$ 11,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards commencement of expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Federal and State Research and Development Tax Credit Carryforwards Expiration Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards state commencement of expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_PercentageOfEligibleTaxPositionsForRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible tax positions for recognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_PercentageOfEligibleTaxPositionsForRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_ResearchAndDevelopmentCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development credits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_ResearchAndDevelopmentCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=caba_OrphanDrugCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=caba_OrphanDrugCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (167,856)<span></span>
</td>
<td class="num">$ (115,864)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of voting and non-voting common stock, basic</a></td>
<td class="num">$ (2.1)<span></span>
</td>
<td class="num">$ (2.34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of voting and non-voting common stock, diluted</a></td>
<td class="num">$ (2.1)<span></span>
</td>
<td class="num">(2.34)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember', window );">Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (167,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_WeightedAverageNumberOfSharesOutstanding', window );">Weighted average number of shares outstanding</a></td>
<td class="nump">79,903,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of voting and non-voting common stock, basic</a></td>
<td class="num">$ (2.1)<span></span>
</td>
<td class="num">(2.34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of voting and non-voting common stock, diluted</a></td>
<td class="num">$ (2.1)<span></span>
</td>
<td class="num">$ (2.34)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_WeightedAverageNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of shares outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_WeightedAverageNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_EarningPerShareBasicAndDilutedLineItems', window );"><strong>Earning Per Share Basic And Diluted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (167,856)<span></span>
</td>
<td class="num">$ (115,864)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of voting and non-voting common stock, basic</a></td>
<td class="num">$ (2.1)<span></span>
</td>
<td class="num">$ (2.34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of voting and non-voting common stock, diluted</a></td>
<td class="num">$ (2.1)<span></span>
</td>
<td class="num">$ (2.34)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember', window );">Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_EarningPerShareBasicAndDilutedLineItems', window );"><strong>Earning Per Share Basic And Diluted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (167,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic', window );">Allocation of undistributed losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (114,728)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in basic per share computation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,038,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of voting and non-voting common stock, basic</a></td>
<td class="num">$ (2.1)<span></span>
</td>
<td class="num">$ (2.34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Allocation of undistributed losses for basic computation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (114,728)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther', window );">Reallocation of undistributed losses as a result of conversion of non-voting to voting common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,136)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Allocation of undistributed losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (115,864)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in basic per share computation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,038,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Add: Conversion of non-voting to voting common shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485,378<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares used in diluted per share computation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,524,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of voting and non-voting common stock, diluted</a></td>
<td class="num">$ (2.1)<span></span>
</td>
<td class="num">$ (2.34)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic', window );">Allocation of undistributed losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in basic per share computation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of voting and non-voting common stock, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Allocation of undistributed losses for basic computation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther', window );">Reallocation of undistributed losses as a result of conversion of non-voting to voting common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Allocation of undistributed losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in basic per share computation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Add: Conversion of non-voting to voting common shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares used in diluted per share computation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of voting and non-voting common stock, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.34)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_EarningPerShareBasicAndDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earning per share basic and diluted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_EarningPerShareBasicAndDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481679/480-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 65<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-65<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 65<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-65<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to common stock as if earnings had been distributed. Excludes distributed earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=caba_VotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares have been excluded from calculation of diluted net loss per share</a></td>
<td class="nump">66,925,562<span></span>
</td>
<td class="nump">11,231,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares have been excluded from calculation of diluted net loss per share</a></td>
<td class="nump">53,090,190<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares have been excluded from calculation of diluted net loss per share</a></td>
<td class="nump">13,835,372<span></span>
</td>
<td class="nump">11,231,148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_EarningPerShareBasicAndDilutedLineItems', window );"><strong>Earning Per Share Basic And Diluted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">53,090,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=caba_PreFundedWarrantsMember', window );">Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_EarningPerShareBasicAndDilutedLineItems', window );"><strong>Earning Per Share Basic And Diluted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common stock outstanding</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-voting Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_EarningPerShareBasicAndDilutedLineItems', window );"><strong>Earning Per Share Basic And Diluted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
<td class="nump">6,409,519<span></span>
</td>
<td class="nump">6,409,519<span></span>
</td>
<td class="nump">1,444,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_EarningPerShareBasicAndDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earning per share basic and diluted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_EarningPerShareBasicAndDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=caba_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=caba_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401 (k) Savings Plan - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, contribution amount</a></td>
<td class="nump">$ 1,063<span></span>
</td>
<td class="nump">$ 894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SubsequentEvents - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember', window );">Autolus Holdings Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_caba_UpfrontPayment', window );">Upfront Payment</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_caba_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">caba_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>caba_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>154</ContextCount>
  <ElementCount>353</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>58</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>75010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>75020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>75030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>75040 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>75050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>75060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995457 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy, and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995467 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995477 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995497 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995507 - Disclosure - Accrued and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995517 - Disclosure - Collaborations, Licensing Agreements and other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements</Role>
      <ShortName>Collaborations, Licensing Agreements and other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995537 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995547 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995567 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995577 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995587 - Disclosure - 401(k) Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_Disclosure401KSavingsPlan</Role>
      <ShortName>401(k) Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995607 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995617 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995627 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995637 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995647 - Disclosure - Accrued and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995657 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995667 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995677 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995687 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStock</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995697 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995707 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995717 - Disclosure - Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995727 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995737 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives for Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives for Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995747 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995767 - Disclosure - Fair Value Measurements - Schedule of Debt Securities Classified as Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Debt Securities Classified as Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995777 - Disclosure - Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995787 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property, Plant and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995797 - Disclosure - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995807 - Disclosure - Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995817 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995827 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995837 - Disclosure - Segment Information (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995847 - Disclosure - Segment Information - Schedule of Profit and Loss from Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails</Role>
      <ShortName>Segment Information - Schedule of Profit and Loss from Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995857 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995867 - Disclosure - Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995907 - Disclosure - Leases - Schedule of Company's operating and finance leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails</Role>
      <ShortName>Leases - Schedule of Company's operating and finance leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995927 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995937 - Disclosure - Common Stock - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Common Stock - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995947 - Disclosure - Common Stock - Schedule of Assumptions Used to Estimate Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails</Role>
      <ShortName>Common Stock - Schedule of Assumptions Used to Estimate Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995957 - Disclosure - Common Stock - Summary of Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails</Role>
      <ShortName>Common Stock - Summary of Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995967 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995987 - Disclosure - Income Taxes - Summary of Principal Components of Company's Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Summary of Principal Components of Company's Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995997 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic and Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Net Loss Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996047 - Disclosure - 401 (k) Savings Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/Role_Disclosure401KSavingsPlanAdditionalInformationDetails</Role>
      <ShortName>401 (k) Savings Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cabalettabio.com/20251231/taxonomy/role/Role_Disclosure401KSavingsPlan</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="caba-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996057 - Disclosure - SubsequentEvents - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails</Role>
      <ShortName>SubsequentEvents - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="caba-20251231.htm">caba-20251231.htm</File>
    <File>caba-20251231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img117331299_0.jpg</File>
    <File>img117331299_1.gif</File>
    <File>img117331299_2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="534">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="14">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "caba-20251231.htm": {
   "nsprefix": "caba",
   "nsuri": "http://www.cabalettabio.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "caba-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "caba-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 292,
   "keyCustom": 61,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 26,
   "memberCustom": 28,
   "hidden": {
    "total": 8,
    "http://fasb.org/us-gaap/2025": 5,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 154,
   "entityCount": 1,
   "segmentCount": 58,
   "elementCount": 719,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 534,
    "http://xbrl.sec.gov/dei/2025": 39,
    "http://xbrl.sec.gov/cyd/2025": 14,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "75000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "longName": "75010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "75020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "75030 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "75040 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_8afc398a-f701-4181-b888-7da00743bdd1",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8afc398a-f701-4181-b888-7da00743bdd1",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "longName": "75050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_26ba7aad-e65f-4202-9148-f8d56de48c1d",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_26ba7aad-e65f-4202-9148-f8d56de48c1d",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "75060 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_72fa9a9d-1938-4032-8385-aa9b1119676b",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_72fa9a9d-1938-4032-8385-aa9b1119676b",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "995457 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy, and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureBasisOfPresentation",
     "longName": "995467 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995477 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "995487 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment",
     "longName": "995497 - Disclosure - Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities",
     "longName": "995507 - Disclosure - Accrued and Other Current Liabilities",
     "shortName": "Accrued and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements",
     "longName": "995517 - Disclosure - Collaborations, Licensing Agreements and other Agreements",
     "shortName": "Collaborations, Licensing Agreements and other Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "caba:CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "caba:CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformation",
     "longName": "995527 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995537 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeases",
     "longName": "995547 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStock",
     "longName": "995557 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995567 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "longName": "995577 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_Disclosure401KSavingsPlan",
     "longName": "995587 - Disclosure - 401(k) Savings Plan",
     "shortName": "401(k) Savings Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995607 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995617 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "caba:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "caba:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "longName": "995627 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables",
     "longName": "995637 - Disclosure - Property, Plant and Equipment (Tables)",
     "shortName": "Property, Plant and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables",
     "longName": "995647 - Disclosure - Accrued and Other Current Liabilities (Tables)",
     "shortName": "Accrued and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "caba:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "caba:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "longName": "995657 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationTables",
     "longName": "995667 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesTables",
     "longName": "995677 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables",
     "longName": "995687 - Disclosure - Common Stock (Tables)",
     "shortName": "Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995697 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "longName": "995707 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails",
     "longName": "995717 - Disclosure - Basis of Presentation - Additional Information (Details)",
     "shortName": "Basis of Presentation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995727 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails",
     "longName": "995737 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives for Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives for Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_ec1351eb-6c75-4b2b-a584-b9e9880ef824",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "caba:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ec1351eb-6c75-4b2b-a584-b9e9880ef824",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "caba:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "995747 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Financial Assets Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d8e43c4b-0fae-4bc3-81be-0f50e637fc37",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails",
     "longName": "995767 - Disclosure - Fair Value Measurements - Schedule of Debt Securities Classified as Available-for-Sale Investments (Details)",
     "shortName": "Fair Value Measurements - Schedule of Debt Securities Classified as Available-for-Sale Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
     "longName": "995777 - Disclosure - Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details)",
     "shortName": "Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails",
     "longName": "995787 - Disclosure - Property, Plant and Equipment - Additional Information (Details)",
     "shortName": "Property, Plant and Equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails",
     "longName": "995797 - Disclosure - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)",
     "shortName": "Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "caba:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "caba:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
     "longName": "995807 - Disclosure - Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)",
     "shortName": "Collaborations, Licensing Agreements and other Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2a18d8f9-5332-4a23-b605-cb3d2126221d",
      "name": "us-gaap:ContractualObligation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "caba:CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "995817 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "caba:InitialTermsOfAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "caba:InitialTermsOfAgreementDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails",
     "longName": "995827 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Payments for Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
     "longName": "995837 - Disclosure - Segment Information (Additional Information) (Details)",
     "shortName": "Segment Information (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails",
     "longName": "995847 - Disclosure - Segment Information - Schedule of Profit and Loss from Segments (Details)",
     "shortName": "Segment Information - Schedule of Profit and Loss from Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "caba:PersonnelExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "caba:PersonnelExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "995857 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "caba:IncreaseInTheLeaseLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails",
     "longName": "995867 - Disclosure - Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details)",
     "shortName": "Leases - Schedule of Future Minimum Payments for Operating Leases and Finance Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails",
     "longName": "995907 - Disclosure - Leases - Schedule of Company's operating and finance leases (Details)",
     "shortName": "Leases - Schedule of Company's operating and finance leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:FinanceLeaseInterestExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:FinanceLeaseInterestExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
     "longName": "995927 - Disclosure - Common Stock - Additional Information (Details)",
     "shortName": "Common Stock - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "caba:PreFundedWarrantsExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails",
     "longName": "995937 - Disclosure - Common Stock - Summary of Stock Option Activity (Details)",
     "shortName": "Common Stock - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_f9e49f68-10ed-47f9-abad-85f88ab41fed",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dbd59a18-8a5d-4dcd-8c36-896f33080a16",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails",
     "longName": "995947 - Disclosure - Common Stock - Schedule of Assumptions Used to Estimate Fair Value of Stock Options (Details)",
     "shortName": "Common Stock - Schedule of Assumptions Used to Estimate Fair Value of Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails",
     "longName": "995957 - Disclosure - Common Stock - Summary of Stock-Based Compensation (Details)",
     "shortName": "Common Stock - Summary of Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_f804a965-6bd2-440f-a975-8966b026c5f8",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_bbae0f84-acad-4f21-9dc4-943f64e17a13",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails",
     "longName": "995967 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)",
     "shortName": "Income Taxes - Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails",
     "longName": "995987 - Disclosure - Income Taxes - Summary of Principal Components of Company's Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Summary of Principal Components of Company's Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "caba:CapitalizedRDCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "995997 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
     "longName": "996007 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_380f4971-911e-418e-9b42-9f671cdeed55",
      "name": "caba:WeightedAverageNumberOfSharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
     "longName": "996017 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Earnings Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Basic and Diluted Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f0f07fb5-2799-4c77-8564-71079e67edae",
      "name": "us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "longName": "996027 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
     "longName": "996037 - Disclosure - Net Loss Per Share - Additional Information (Details)",
     "shortName": "Net Loss Per Share - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f731d894-5793-46d0-97d4-8c8276db0097",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/Role_Disclosure401KSavingsPlanAdditionalInformationDetails",
     "longName": "996047 - Disclosure - 401 (k) Savings Plan - Additional Information (Details)",
     "shortName": "401 (k) Savings Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09c552e5-3642-480f-b739-e2c13490ca62",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
     "longName": "996057 - Disclosure - SubsequentEvents - Additional Information (Details)",
     "shortName": "SubsequentEvents - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_8afc398a-f701-4181-b888-7da00743bdd1",
      "name": "caba:UpfrontPayment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "caba-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity of Counterparty, Type [Axis]",
        "terseLabel": "Legal Entity of Counterparty, Type",
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r57"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued and Other Current Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r793"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization of discount on investments",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of (discount) premium on investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_AccretionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion Expense",
        "terseLabel": "Accretion of lease liabilities",
        "verboseLabel": "Accretion of operating lease liabilities",
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r1040"
     ]
    },
    "caba_AccruedAndOtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "AccruedAndOtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued and other current liabilities.",
        "label": "Accrued And Other Current Liabilities [Member]",
        "terseLabel": "Accrued and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "caba_AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "caba_AccruedGeneralAndAdministrativeServicesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "AccruedGeneralAndAdministrativeServicesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued general and administrative services current.",
        "label": "Accrued General And Administrative Services Current",
        "terseLabel": "General and administrative services"
       }
      }
     },
     "auth_ref": []
    },
    "caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities And Other Liabilities Current",
        "documentation": "Accrued liabilities and other liabilities current.",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "caba_AccruedResearchAndDevelopmentServicesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "AccruedResearchAndDevelopmentServicesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development services current.",
        "label": "Accrued Research And Development Services Current",
        "terseLabel": "Research and development services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r108",
      "r579"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r58",
      "r114",
      "r575",
      "r605",
      "r606",
      "r1099"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "caba_AdditionalOptionsToBePurchasedByUnderwriters": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "AdditionalOptionsToBePurchasedByUnderwriters",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional options to be purchased by underwriters",
        "label": "Additional Options to be purchased by underwriters",
        "documentation": "Additional Options to be purchased by underwriters"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1100",
      "r1165"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "terseLabel": "Stock-based compensation, value",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "caba_AdvancePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "AdvancePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance payments.",
        "label": "Advance Payments",
        "terseLabel": "Advance payments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r845",
      "r855",
      "r888"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r848",
      "r858",
      "r891"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "caba_AgreementWithContractManufacturingOrganizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "AgreementWithContractManufacturingOrganizationMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement with contract manufacturing organization.",
        "label": "Agreement With Contract Manufacturing Organization [Member]",
        "terseLabel": "Agreement with Contract Manufacturing Organization"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r849",
      "r859",
      "r883",
      "r892",
      "r896",
      "r904"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r359",
      "r368"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "caba_AmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "AmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails": {
       "parentTag": "caba_TotalFixedFinanceLeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization Expense",
        "documentation": "Amortization Expense",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "auth_ref": []
    },
    "caba_AnnualIncreasePercentageOfBaseRent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "AnnualIncreasePercentageOfBaseRent",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual increase percentage of base rent.",
        "label": "Annual Increase Percentage Of Base Rent",
        "terseLabel": "Percentage of annual increase of base rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive shares have been excluded from calculation of diluted net loss per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "caba_AnupMardaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "AnupMardaMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anup Marda [Member]",
        "documentation": "Anup Marda [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_AnupMardaOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "AnupMardaOneMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anup Marda One [Member]",
        "documentation": "Anup Marda One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7",
      "r14",
      "r952",
      "r953",
      "r954"
     ]
    },
    "caba_ArunDasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "ArunDasMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arun Das [Member]",
        "documentation": "Arun Das [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_ArunDasOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "ArunDasOneMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arun Das One [Member]",
        "documentation": "Arun Das One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r84",
      "r110",
      "r141",
      "r142",
      "r143",
      "r182",
      "r194",
      "r209",
      "r212",
      "r252",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r419",
      "r423",
      "r481",
      "r561",
      "r562",
      "r571",
      "r662",
      "r748",
      "r749",
      "r759",
      "r793",
      "r799",
      "r800",
      "r812",
      "r1045",
      "r1046",
      "r1120"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r115",
      "r141",
      "r142",
      "r143",
      "r252",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r419",
      "r423",
      "r481",
      "r793",
      "r1045",
      "r1046",
      "r1120"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r458",
      "r781"
     ]
    },
    "caba_AtTheMarketOfferingSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "AtTheMarketOfferingSalesAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market offering sales agreement.",
        "label": "At The Market Offering Sales Agreement [Member]",
        "terseLabel": "At-The-Market Offering Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r818",
      "r841"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r818",
      "r841"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r818",
      "r841"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "caba_AutolusHoldingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "AutolusHoldingsMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Autolus Holdings [Member]",
        "label": "Autolus Holdings [Member]",
        "terseLabel": "Autolus Holdings Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "terseLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r261",
      "r570"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Available-for-sale securities",
        "verboseLabel": "Fair value",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r261",
      "r457",
      "r476",
      "r477",
      "r478",
      "r479",
      "r558",
      "r723",
      "r781",
      "r784",
      "r791",
      "r1019",
      "r1104",
      "r1105",
      "r1106"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r425",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r480",
      "r778",
      "r779",
      "r931",
      "r1132"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "terseLabel": "Balance Sheet Location",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r425",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r480",
      "r778",
      "r779",
      "r931",
      "r1132"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r940",
      "r999"
     ]
    },
    "caba_Caba201AndMuskCaartMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "Caba201AndMuskCaartMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CABA-201 and MuSK-CAART [Member]",
        "documentation": "CABA-201 and MuSK-CAART [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases included in accounts payable and accrued expenses",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "caba_CapitalizedRDCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "CapitalizedRDCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized R&amp;D costs",
        "label": "Capitalized R&amp;D costs",
        "terseLabel": "Capitalized research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalent",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r106",
      "r725"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r1102",
      "r1103"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Included in Cash and Cash Equivalents",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash and cash equivalents and investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation",
        "periodEndLabel": "Cash and cash equivalents\u2014end of year",
        "periodStartLabel": "Cash and cash equivalents\u2014beginning of year",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r63",
      "r138"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "totalLabel": "Net decrease in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r63"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [Member]",
        "terseLabel": "Cash",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "caba_CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "CashPaidInTheMeasurementOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid In The Measurement Of Lease Liabilities [Abstract]",
        "documentation": "Cash Paid In The Measurement Of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid in the measurement of lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "caba_CellaresAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "CellaresAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cellares Agreement",
        "label": "Cellares Agreement [Member]",
        "documentation": "Cellares Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "caba_ChildrenSHospitalOfPhiladelphiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "ChildrenSHospitalOfPhiladelphiaMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Children S Hospital Of Philadelphia [Member]",
        "terseLabel": "Children's Hospital of Philadelphia",
        "documentation": "Children\u2019s Hospital of Philadelphia."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r111",
      "r112",
      "r113",
      "r141",
      "r143",
      "r168",
      "r169",
      "r172",
      "r176",
      "r184",
      "r185",
      "r252",
      "r275",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r290",
      "r291",
      "r293",
      "r294",
      "r296",
      "r299",
      "r301",
      "r302",
      "r304",
      "r305",
      "r307",
      "r481",
      "r614",
      "r615",
      "r616",
      "r617",
      "r622",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r650",
      "r670",
      "r688",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r929",
      "r1002",
      "r1003",
      "r1011"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r184",
      "r293",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r441",
      "r614",
      "r615",
      "r616",
      "r617",
      "r760",
      "r929",
      "r1000",
      "r1002"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r145",
      "r308"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Additional common stock warrants issued",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "caba_ClinicalTrialResearchAndDevelopmentServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "ClinicalTrialResearchAndDevelopmentServices",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trial Research and Development Services",
        "documentation": "Clinical Trial Research and Development Services",
        "terseLabel": "Clinical trial research and development services"
       }
      }
     },
     "auth_ref": []
    },
    "caba_ClinicalTrials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "ClinicalTrials",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Trials",
        "documentation": "Clinical Trials",
        "terseLabel": "Clinical trials"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "caba_CollaborationsLicensingAgreementsAndOtherAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "CollaborationsLicensingAgreementsAndOtherAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborations licensing agreements and other agreements.",
        "label": "Collaborations Licensing Agreements And Other Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborations licensing agreements and other agreement.",
        "label": "Collaborations Licensing Agreements And Other Agreements Disclosure [Text Block]",
        "terseLabel": "Collaborations, Licensing Agreements and other Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "CollaborationsLicensingAgreementsAndOtherAgreementsLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborations licensing agreements and other agreements.",
        "label": "Collaborations Licensing Agreements And Other Agreements [Line Items]",
        "terseLabel": "Collaborations, Licensing Agreements And Other Agreements [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_CollaborationsLicensingAgreementsAndOtherAgreementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "CollaborationsLicensingAgreementsAndOtherAgreementsTable",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborations licensing agreements and other agreements.",
        "label": "Collaborations Licensing Agreements And Other Agreements [Table]",
        "terseLabel": "Collaborations Licensing Agreements And Other Agreements [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_CollaborativeAgreementPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "CollaborativeAgreementPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative agreement payments due.",
        "label": "Collaborative Agreement Payments Due",
        "terseLabel": "Amounts due to agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (see Notes 6 and 7)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r78",
      "r572",
      "r649"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_CommitmentsAndContingenciesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "terseLabel": "Commitments and Contingencies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_CommitmentsAndContingenciesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Table]",
        "terseLabel": "Commitments And Contingencies Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r269",
      "r270",
      "r719",
      "r1038",
      "r1041"
     ]
    },
    "caba_CommonStockAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "CommonStockAndWarrantsMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock and Warrants [Member]",
        "documentation": "Common Stock and Warrants [Member]",
        "terseLabel": "Common Stock and Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_CommonStockConversionFeatures": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockConversionFeatures",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-voting common stock, terms of conversion",
        "verboseLabel": "Terms of Conversion, Common stock",
        "label": "Common Stock, Terms of Conversion",
        "documentation": "Description of common stock conversion feature. Includes, but is not limited to, conversion price; conversion right; timing of right; terms, event or change in circumstance causing contingency to be met or adjustment to conversion price or number of shares; manner of settlement upon conversion; and method of settlement."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r308"
     ]
    },
    "us-gaap_CommonStockDividendsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockDividendsShares",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock dividends, shares",
        "label": "Common Stock Dividends, Shares",
        "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r803",
      "r804",
      "r806",
      "r807",
      "r808",
      "r809",
      "r1007",
      "r1008",
      "r1010",
      "r1100",
      "r1162",
      "r1165"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized shares",
        "verboseLabel": "Common stock, authorized shares",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r650"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued shares",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance, Shares",
        "periodStartLabel": "Beginning balance, Shares",
        "terseLabel": "Common stock, outstanding shares",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r50",
      "r650",
      "r668",
      "r1165",
      "r1166"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Voting and non-voting common stock, $0.00001 par value: 300,000,000 (293,590,481 voting and 6,409,519 non-voting) shares authorized as of December 31, 2025 and 150,000,000 (143,590,481 voting and 6,409,519 non-voting) shares authorized as of December 31, 2024; 100,479,323 voting shares issuedand outstanding as of December 31, 2025 and 50,743,101voting shares issued and outstanding as of December 31, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r291",
      "r298",
      "r574",
      "r793"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_Disclosure401KSavingsPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "401(k) Savings Plan",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053",
      "r1054",
      "r1057"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Net comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r120",
      "r122",
      "r127",
      "r559",
      "r585",
      "r586"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r736"
     ]
    },
    "caba_ContractualCostIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "ContractualCostIncurred",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual cost incurred.",
        "label": "Contractual Cost Incurred",
        "terseLabel": "Cost incurred"
       }
      }
     },
     "auth_ref": []
    },
    "caba_ContractualExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "ContractualExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual expenses.",
        "label": "Contractual Expenses",
        "terseLabel": "Expense related to agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation",
        "terseLabel": "Obligation to be paid",
        "totalLabel": "Contractual Obligation, Total",
        "verboseLabel": "liability related to agreement",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1006",
      "r1129"
     ]
    },
    "us-gaap_CorporateNoteSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateNoteSecuritiesMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S. Treasury securities - original maturity less than three months",
        "label": "Corporate Note Securities [Member]",
        "terseLabel": "Corporate Note Securities",
        "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r147",
      "r148",
      "r284",
      "r303",
      "r519",
      "r539",
      "r569",
      "r726",
      "r727",
      "r728",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r1095",
      "r1096",
      "r1097",
      "r1098"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r826",
      "r915"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r826",
      "r915"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r917"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r917"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r919"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r917"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r910"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r911"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r911"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r909"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r909"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r909"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r823",
      "r912"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r825",
      "r914"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r825",
      "r914"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r826",
      "r915"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r918"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r916"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r824",
      "r913"
     ]
    },
    "country_DE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "DE",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Debt Securities Classified as Available-for-Sale Investments",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)",
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Total",
        "terseLabel": "Net unrealized losses on available-for-sale securities, value",
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1024",
      "r1025"
     ]
    },
    "caba_December2022FinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "December2022FinancingMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2022 Financing [Member]",
        "documentation": "December Two Thousand Twenty Two Financing [Member]",
        "terseLabel": "December 2022 Financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Offering Costs",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Net deferred tax assets",
        "totalLabel": "Deferred Tax Assets, Net, Total",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "caba_DeferredTaxAssetsLicenseFeesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "DeferredTaxAssetsLicenseFeesDeductions",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets license fees deductions.",
        "label": "Deferred Tax Assets License Fees Deductions",
        "terseLabel": "License fee deductions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "caba_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Deferred Tax Assets, Operating Lease Liabilities",
        "documentation": "Deferred Tax Assets, Operating Lease Liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Federal",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Deferred tax assets, operating loss carryforwards, not subject to expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Federal, state and local net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Deferred tax assets, operating loss carryforwards, subject to expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "caba_DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax credit carryforwards commencement of expiration date.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Commencement Of Expiration Date",
        "terseLabel": "Deferred tax assets tax credit carryforwards commencement of expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation deductions",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_Disclosure401KSavingsPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan, contribution amount",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_Disclosure401KSavingsPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "totalLabel": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r27",
      "r129",
      "r729",
      "r730",
      "r732",
      "r734"
     ]
    },
    "caba_DevelopmentAndManufacturingServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "DevelopmentAndManufacturingServicesAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and manufacturing services agreement.",
        "label": "Development And Manufacturing Services Agreement [Member]",
        "terseLabel": "Wuxi Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "caba_DevelopmentServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "DevelopmentServices",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Services",
        "documentation": "Development Services",
        "terseLabel": "Development services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities",
        "terseLabel": "Reallocation of undistributed losses as a result of conversion of non-voting to voting common shares",
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r817",
      "r818",
      "r841"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r817",
      "r818",
      "r841",
      "r884"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "verboseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "caba_EarningPerShareBasicAndDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "EarningPerShareBasicAndDilutedLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earning per share basic and diluted.",
        "label": "Earning Per Share Basic And Diluted [Line Items]",
        "terseLabel": "Earning Per Share Basic And Diluted [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of voting and non-voting common stock, basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r128",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r166",
      "r168",
      "r172",
      "r175",
      "r176",
      "r181",
      "r288",
      "r358",
      "r414",
      "r417",
      "r454",
      "r455",
      "r560",
      "r587",
      "r739"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic net loss per share:"
       }
      }
     },
     "auth_ref": []
    },
    "caba_EarningsPerShareBasicAndDilutedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "EarningsPerShareBasicAndDilutedTable",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings per share basic and diluted.",
        "label": "Earnings Per Share Basic And Diluted [Table]",
        "terseLabel": "Earnings Per Share Basic And Diluted [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of voting and non-voting common stock, diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r128",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r168",
      "r172",
      "r175",
      "r176",
      "r181",
      "r288",
      "r358",
      "r414",
      "r417",
      "r454",
      "r455",
      "r560",
      "r587",
      "r739"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted net loss per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r178"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r177",
      "r179",
      "r180"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Actual income tax benefit effective tax rate percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r771"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. Statutory Tax Rate Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r144",
      "r378",
      "r405",
      "r771"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance Percent",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r771",
      "r1000",
      "r1005",
      "r1087"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Effect of Changes in Tax Laws or Rates Enacted in the Current Period Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r771",
      "r1000",
      "r1005",
      "r1087"
     ]
    },
    "caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanysEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Unrecognized Tax Benefits amount",
        "label": "Effective Income Tax Rate Reconciliation Changes in Unrecognized Tax Benefits Amount",
        "documentation": "Effective Income Tax Rate Reconciliation Changes in Unrecognized Tax Benefits Amount"
       }
      }
     },
     "auth_ref": []
    },
    "caba_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Unrecognized Tax Benefits percent",
        "label": "Effective Income Tax Rate Reconciliation Changes in Unrecognized Tax Benefits Percent",
        "documentation": "Effective Income Tax Rate Reconciliation Changes in Unrecognized Tax Benefits Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanysEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Amount, Total",
        "terseLabel": "Effect of Cross-Border Tax Laws amount",
        "documentation": "Amount of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r387"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent, Total",
        "terseLabel": "Effect of Cross-Border Tax Laws Percent",
        "documentation": "Percentage of reported income tax expense (benefit) from difference to expected income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r387"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Effects Percent",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r382",
      "r771",
      "r1000",
      "r1005",
      "r1087"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r771"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Nontaxable or Nondeductible Items percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r1000",
      "r1005",
      "r1087",
      "r1089"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other Adjustments percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r1000",
      "r1005",
      "r1087",
      "r1088"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanysEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock Compensation amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1087",
      "r1088"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Compensation percent",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1087",
      "r1088"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and Local Income Taxes, Net of Federal Income Tax Effect Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r771",
      "r1000",
      "r1005",
      "r1087"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r771"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Valuation Allowances (Domestic) percent",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Domestic, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in domestic income tax contingency."
       }
      }
     },
     "auth_ref": [
      "r1000",
      "r1005",
      "r1087"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total",
        "terseLabel": "Tax Credits percent",
        "negatedLabel": "Tax Credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r387",
      "r1000",
      "r1005",
      "r1087"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Percent",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r1000",
      "r1005",
      "r1087",
      "r1089"
     ]
    },
    "caba_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging growth company status.",
        "label": "Emerging Growth Company Status Policy [Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense",
        "label": "Employee-related Liabilities, Current",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1084"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to unvested stock-based awards",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost, weighted average period for recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock Options to Purchase Common Stock",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083"
     ]
    },
    "caba_EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan maximum annual rights to purchase common stock.",
        "label": "Employee Stock Purchase Plan Maximum Annual Rights To Purchase Common Stock",
        "terseLabel": "Employee stock purchase plan maximum annual rights to purchase common stock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r99",
      "r101",
      "r102",
      "r124",
      "r125",
      "r126",
      "r149",
      "r150",
      "r151",
      "r153",
      "r160",
      "r162",
      "r164",
      "r183",
      "r253",
      "r254",
      "r265",
      "r287",
      "r309",
      "r358",
      "r403",
      "r404",
      "r411",
      "r412",
      "r413",
      "r415",
      "r416",
      "r417",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r494",
      "r497",
      "r518",
      "r583",
      "r601",
      "r602",
      "r603",
      "r622",
      "r688"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r845",
      "r855",
      "r888"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r842",
      "r852",
      "r885"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "caba_ExpectedCostIncurredForPurchaseOfPlasmids": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "ExpectedCostIncurredForPurchaseOfPlasmids",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected cost incurred for purchase of plasmids.",
        "label": "Expected Cost Incurred For Purchase Of Plasmids",
        "terseLabel": "Total cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets Measured at Fair Value on Recurring Basis",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1102",
      "r1103"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r723",
      "r791",
      "r1111"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value By Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r479",
      "r723",
      "r791",
      "r1110",
      "r1111"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r456",
      "r458",
      "r459",
      "r460",
      "r461",
      "r467",
      "r468",
      "r470",
      "r477",
      "r526",
      "r527",
      "r528",
      "r723",
      "r757",
      "r758",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r781",
      "r784",
      "r791"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r458",
      "r459",
      "r461",
      "r781",
      "r1105",
      "r1108"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r463",
      "r465",
      "r466",
      "r467",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r557",
      "r781",
      "r785"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r311",
      "r316",
      "r317",
      "r458",
      "r468",
      "r477",
      "r526",
      "r723",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r781",
      "r791"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r311",
      "r316",
      "r317",
      "r319",
      "r458",
      "r459",
      "r468",
      "r477",
      "r527",
      "r723",
      "r757",
      "r758",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r781",
      "r791"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r458",
      "r459",
      "r460",
      "r461",
      "r468",
      "r477",
      "r528",
      "r723",
      "r757",
      "r758",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r781",
      "r784",
      "r791"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r458",
      "r459",
      "r461",
      "r781",
      "r1105",
      "r1108"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r456",
      "r458",
      "r459",
      "r460",
      "r461",
      "r467",
      "r468",
      "r470",
      "r477",
      "r526",
      "r527",
      "r528",
      "r723",
      "r757",
      "r758",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r781",
      "r784",
      "r791"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1108"
     ]
    },
    "caba_FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal and State Research and Development Tax Credit Carryforwards Expiration Date",
        "documentation": "Federal and State Research and Development Tax Credit Carryforwards Expiration Date",
        "terseLabel": "Federal and state research and development tax credit carryforwards expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails": {
       "parentTag": "caba_TotalFixedFinanceLeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r507",
      "r792"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities, current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease liabilities, net of current portion",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails2": {
       "parentTag": "caba_FinanceLesseeUndiscountedLeasePayments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total lease liability",
        "terseLabel": "Total lease liability",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r1001",
      "r1006",
      "r1129"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails": {
       "parentTag": "caba_FinanceLesseeUndiscountedLeasePayments",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Next Rolling 12 Months",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease due in next rolling 12 months following current statement of financial position date. For interim and annual periods when interim period is reported on rolling approach."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityPaymentsDueInRollingYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails": {
       "parentTag": "caba_FinanceLesseeUndiscountedLeasePayments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Rolling Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails2": {
       "parentTag": "caba_FinanceLesseeUndiscountedLeasePayments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Principal payments on finance leases",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r511"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "totalLabel": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization, Total",
        "terseLabel": "Finance lease right-of-use assets",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of finance lease",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r507",
      "r792"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - finance leases",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r792"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term - finance leases (in years)",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r792"
     ]
    },
    "caba_FinanceLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "FinanceLeasesAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance leases [Abstract]",
        "documentation": "Finance leases [Abstract]",
        "terseLabel": "Finance Leases:"
       }
      }
     },
     "auth_ref": []
    },
    "caba_FinanceLesseeUndiscountedLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "FinanceLesseeUndiscountedLeasePayments",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lessee Undiscounted Lease Payments",
        "documentation": "Finance Lessee Undiscounted Lease Payments",
        "terseLabel": "Total undiscounted lease payments",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r262",
      "r263",
      "r264",
      "r286",
      "r306",
      "r441",
      "r452",
      "r475",
      "r480",
      "r483",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r566",
      "r584",
      "r755",
      "r781",
      "r782",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r794",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1101",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110"
     ]
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial assets"
       }
      }
     },
     "auth_ref": []
    },
    "caba_FinancingCashFlowsUsedForFinanceLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "FinancingCashFlowsUsedForFinanceLeases",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Cash Flows Used For Finance Leases",
        "documentation": "Financing Cash Flows Used For Finance Leases",
        "terseLabel": "Financing cash flows for finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "caba_FixedLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "FixedLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2": {
       "parentTag": "us-gaap_OperatingLeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Lease Cost",
        "documentation": "Fixed Lease Cost",
        "terseLabel": "Fixed lease cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on foreign currency exchange rates",
        "label": "Foreign Currency Transaction Loss, before Tax",
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r1113",
      "r1114"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r849",
      "r859",
      "r892"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r849",
      "r859",
      "r892"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r849",
      "r859",
      "r892"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r849",
      "r859",
      "r892"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r849",
      "r859",
      "r892"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "caba_FundingTermEndingDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "FundingTermEndingDate",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding term ending date.",
        "label": "Funding Term Ending Date",
        "terseLabel": "Funding term end date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossRelatedToLitigationSettlement",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) from Litigation Settlement",
        "terseLabel": "Loss related to litigation settlement accrued",
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r1042"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "General and administration expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r672"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "caba_GwendolynBinderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "GwendolynBinderMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gwendolyn Binder [Member]",
        "documentation": "Gwendolyn Binder [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_GwendolynBinderOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "GwendolynBinderOneMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gwendolyn Binder One [Member]",
        "documentation": "Gwendolyn Binder One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r818",
      "r841"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r426",
      "r431",
      "r432",
      "r440",
      "r462",
      "r464",
      "r469",
      "r482",
      "r483",
      "r484",
      "r598",
      "r600",
      "r673",
      "r722",
      "r723",
      "r772",
      "r773",
      "r779",
      "r780",
      "r783",
      "r791",
      "r1093",
      "r1094",
      "r1133"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r426",
      "r431",
      "r432",
      "r440",
      "r462",
      "r464",
      "r469",
      "r482",
      "r483",
      "r484",
      "r598",
      "r600",
      "r673",
      "r722",
      "r723",
      "r772",
      "r773",
      "r779",
      "r780",
      "r783",
      "r791",
      "r1093",
      "r1094",
      "r1133"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r378",
      "r379",
      "r392",
      "r401",
      "r771",
      "r1091"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r378",
      "r379",
      "r392",
      "r401",
      "r771",
      "r1091"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_IncomeTaxDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "IncomeTaxDisclosureTable",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r144",
      "r373",
      "r378",
      "r388",
      "r389",
      "r390",
      "r394",
      "r400",
      "r406",
      "r408",
      "r409",
      "r410",
      "r565",
      "r608",
      "r619",
      "r771"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanysEffectiveIncomeTaxRateDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Actual income tax benefit effective tax rate amount",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r97",
      "r141",
      "r163",
      "r164",
      "r182",
      "r197",
      "r212",
      "r377",
      "r378",
      "r407",
      "r589",
      "r731",
      "r733",
      "r735",
      "r771"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r375",
      "r376",
      "r394",
      "r395",
      "r399",
      "r402",
      "r613"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance Amount",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r771",
      "r1087"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanysEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Effect of Changes in Tax Laws or Rates Enacted in the Current Period Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r378",
      "r383",
      "r771"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanysEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign Tax Effects Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r382",
      "r771",
      "r1087"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanysEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Statutory Tax Rate Amount",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r771"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanysEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "terseLabel": "Nontaxable or Nondeductible Items amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r1087",
      "r1089"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanysEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Adjustments amount",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r1087",
      "r1088"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanysEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State and Local Income Taxes, Net of Federal Income Tax Effect Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r771",
      "r1087"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingenciesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxContingenciesDomestic",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanysEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Domestic, Amount",
        "terseLabel": "Change in Valuation Allowances (Domestic) amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in domestic income tax contingency."
       }
      }
     },
     "auth_ref": [
      "r1087"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanysEffectiveIncomeTaxRateDetails2": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total",
        "terseLabel": "Tax Credits amount",
        "negatedLabel": "Tax Credits amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r387",
      "r1087"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsOther",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Amount",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount",
        "negatedLabel": "Other Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r1087",
      "r1089"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other current liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest payable under finance lease",
        "label": "Increase (Decrease) in Interest Payable, Net",
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r932",
      "r998"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets",
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total",
        "negatedTerseLabel": "Other assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "caba_IncreaseInShareReservedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "IncreaseInShareReservedPercentage",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in share reserved percentage.",
        "label": "Increase In Share Reserved Percentage",
        "terseLabel": "Increase in share reserved percentage"
       }
      }
     },
     "auth_ref": []
    },
    "caba_IncreaseInTheLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "IncreaseInTheLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in the lease liability",
        "documentation": "Increase in the lease liability",
        "terseLabel": "Increase in the lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "caba_IncreaseInTheRouAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "IncreaseInTheRouAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in the ROU asset",
        "documentation": "Increase in the ROU asset",
        "terseLabel": "Increase in the ROU asset"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r849",
      "r859",
      "r883",
      "r892",
      "r896",
      "r904"
     ]
    },
    "caba_InitialTermsOfAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "InitialTermsOfAgreementDescription",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Terms agreement description",
        "label": "Initial Terms of Agreement, Description",
        "documentation": "Initial Terms of Agreement, Description"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r908"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r908"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r908"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Operating and Nonoperating",
        "totalLabel": "Interest Expense, Operating and Nonoperating, Total",
        "verboseLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r194",
      "r196",
      "r198",
      "r212",
      "r493",
      "r748",
      "r749",
      "r1164"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r135",
      "r136"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "verboseLabel": "Interest income",
        "negatedLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r195",
      "r212",
      "r748",
      "r955"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r609",
      "r610",
      "r611",
      "r612",
      "r694",
      "r695"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r691",
      "r693",
      "r697",
      "r700",
      "r701",
      "r702",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r804"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "terseLabel": "Investments",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r691",
      "r693",
      "r697",
      "r700",
      "r701",
      "r702",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r804"
     ]
    },
    "caba_IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock and pre-funded warrants for the purchase of common stock, net of issuance costs",
        "label": "Issuance of common stock and pre-funded warrants for the purchase of common stock, net of issuance costs",
        "terseLabel": "Issuance of common stock upon exercise of pre-funded warrants, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "caba_IssuanceOfCommonStockFromATMOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "IssuanceOfCommonStockFromATMOffering",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock from ATM offering",
        "documentation": "Issuance Of Common Stock from ATM offering",
        "terseLabel": "Issuance of common stock from ATM offering, net of sales agent commission and fees, share"
       }
      }
     },
     "auth_ref": []
    },
    "caba_IssuanceOfCommonStockFromATMOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "IssuanceOfCommonStockFromATMOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from ATM offering, net of sales agent commission and fees, Value",
        "label": "Issuance Of Common Stock from ATM Offering Amount",
        "documentation": "Issuance Of Common Stock from ATM Offering Amount"
       }
      }
     },
     "auth_ref": []
    },
    "caba_IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock from ATM offering, net of sales agent commission and fees",
        "label": "Issuance of common stock from ATM offering, net of sales agent commission and fees",
        "documentation": "Issuance of common stock from ATM offering, net of sales agent commission and fees"
       }
      }
     },
     "auth_ref": []
    },
    "caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock, Warrants and Pre Funded Warrants, Shares",
        "documentation": "Issuance of Common Stock, Warrants and Pre Funded Warrants, Shares",
        "terseLabel": "Issuance of common stock, warrants and pre-funded warrants, net of issuance costs, share"
       }
      }
     },
     "auth_ref": []
    },
    "caba_IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, warrants and pre-funded warrants, net of issuance costs, value",
        "label": "Issuance of Common Stock, Warrants and Pre Funded Warrants, Value",
        "documentation": "Issuance of Common Stock, Warrants and Pre Funded Warrants, Value"
       }
      }
     },
     "auth_ref": []
    },
    "caba_June2025FinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "June2025FinancingMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June 2025 Financing [Member]",
        "documentation": "June 2025 Financing [Member]",
        "terseLabel": "June 2025 Financing"
       }
      }
     },
     "auth_ref": []
    },
    "caba_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "caba_LeaseAmendmentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "LeaseAmendmentPeriod",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease amendment period.",
        "label": "Lease Amendment Period",
        "terseLabel": "Lease Amendment Period"
       }
      }
     },
     "auth_ref": []
    },
    "caba_LeaseCommencementMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "LeaseCommencementMonthAndYear",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement month and year.",
        "label": "Lease Commencement Month And Year",
        "terseLabel": "Lease commencement period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "terseLabel": "Fixed lease cost",
        "totalLabel": "Total operating lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r792"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Company's Operating and Finance Leases",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "caba_LeaseExpirationMonth": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "LeaseExpirationMonth",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expiration month",
        "label": "Lease Expiration Month",
        "documentation": "Lease Expiration Month"
       }
      }
     },
     "auth_ref": []
    },
    "caba_LeaseExpirationMonthAndYear": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "LeaseExpirationMonthAndYear",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration month and year.",
        "label": "Lease Expiration Month And Year",
        "terseLabel": "Lease expiration period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r516"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Type of Counterparty [Domain]",
        "terseLabel": "Legal Entity Type of Counterparty",
        "documentation": "Nature of the other party participating in a financial transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r517"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r517"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Operating lease, description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesTables",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Payments for Operating Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails3": {
       "parentTag": "caba_LesseeUndiscountedLeasePayments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Lessee, Operating Lease, Liability, to be Paid, Total",
        "terseLabel": "Total lease liability",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r1001",
      "r1006",
      "r1129"
     ]
    },
    "caba_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after rolling year three.",
        "label": "Lessee Operating Lease Liability Payments Due After Rolling Year Three",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Three",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails4": {
       "parentTag": "caba_LesseeUndiscountedLeasePayments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Rolling Year Two",
        "terseLabel": "2024",
        "verboseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails4": {
       "parentTag": "caba_LesseeUndiscountedLeasePayments",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Next Rolling 12 Months",
        "terseLabel": "2023",
        "verboseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails3": {
       "parentTag": "caba_LesseeUndiscountedLeasePayments",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional in fixed undiscounted lease payments",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r1116"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "caba_LesseeUndiscountedLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "LesseeUndiscountedLeasePayments",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails4": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Undiscounted Lease Payments",
        "label": "Lessee Undiscounted Lease Payments",
        "totalLabel": "Total undiscounted lease payments",
        "terseLabel": "Total undiscounted lease payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r141",
      "r142",
      "r143",
      "r252",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r420",
      "r423",
      "r424",
      "r481",
      "r648",
      "r741",
      "r759",
      "r812",
      "r1045",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r79",
      "r577",
      "r793",
      "r799",
      "r800",
      "r1000",
      "r1004",
      "r1036",
      "r1112"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r105",
      "r141",
      "r142",
      "r143",
      "r252",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r420",
      "r423",
      "r424",
      "r481",
      "r793",
      "r1045",
      "r1120",
      "r1121"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesSubjectToCompromiseEarlyContractTerminationFees",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Termination fees",
        "label": "Liabilities Subject to Compromise, Early Contract Termination Fees",
        "terseLabel": "Early termination fee",
        "documentation": "The amount of early contract termination fees included in liabilities subject to compromise."
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "caba_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAndServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicenseAndServiceMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and Service [Member]",
        "label": "License and Service [Member]",
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1050",
      "r1051"
     ]
    },
    "caba_LicenseMaintenanceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "LicenseMaintenanceFee",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License maintenance fee.",
        "label": "License Maintenance Fee",
        "terseLabel": "License maintenance fee"
       }
      }
     },
     "auth_ref": []
    },
    "caba_LicenseOfIntellectualProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "LicenseOfIntellectualProperty",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License of Intellectual Property",
        "documentation": "License of Intellectual Property",
        "terseLabel": "License of intellectual property"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "caba_LonzaAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "LonzaAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lonza Agreement [Member]",
        "documentation": "Lonza Agreement [Member]",
        "terseLabel": "Lonza Agreement [Member]",
        "verboseLabel": "Lonza Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "caba_ManufacturingAndOtherResearchAndDevelopmentServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "ManufacturingAndOtherResearchAndDevelopmentServices",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing and Other Research and Development Services",
        "documentation": "Manufacturing and Other Research and Development Services",
        "terseLabel": "Manufacturing and other research and development services"
       }
      }
     },
     "auth_ref": []
    },
    "caba_ManufacturingOfPreclinicalAndClinicalSupplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "ManufacturingOfPreclinicalAndClinicalSupplies",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing of Preclinical and Clinical Supplies",
        "documentation": "Manufacturing of Preclinical and Clinical Supplies",
        "terseLabel": "Manufacturing of preclinical and clinical supplies"
       }
      }
     },
     "auth_ref": []
    },
    "caba_MasterTranslationalResearchServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "MasterTranslationalResearchServicesAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master translational research services agreement.",
        "label": "Master Translational Research Services Agreement [Member]",
        "terseLabel": "Master Translational Research Services Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r271",
      "r272",
      "r273",
      "r274",
      "r321",
      "r351",
      "r352",
      "r353",
      "r369",
      "r461",
      "r555",
      "r597",
      "r599",
      "r607",
      "r640",
      "r641",
      "r692",
      "r696",
      "r698",
      "r699",
      "r703",
      "r715",
      "r716",
      "r717",
      "r718",
      "r720",
      "r721",
      "r754",
      "r760",
      "r768",
      "r772",
      "r774",
      "r775",
      "r784",
      "r785",
      "r789",
      "r790",
      "r796",
      "r1047",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127"
     ]
    },
    "caba_MayTwoThousandTwentyThreeFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "MayTwoThousandTwentyThreeFinancingMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "May 2023 Financing",
        "label": "May Two Thousand Twenty Three Financing [Member]",
        "documentation": "May Two Thousand Twenty Three Financing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "caba_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "MilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "label": "Milestone payment",
        "documentation": "Milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "caba_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "MilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Total milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r271",
      "r272",
      "r273",
      "r274",
      "r321",
      "r351",
      "r352",
      "r353",
      "r369",
      "r461",
      "r555",
      "r597",
      "r599",
      "r607",
      "r640",
      "r641",
      "r692",
      "r696",
      "r698",
      "r699",
      "r703",
      "r715",
      "r716",
      "r717",
      "r718",
      "r720",
      "r721",
      "r754",
      "r760",
      "r768",
      "r772",
      "r774",
      "r775",
      "r784",
      "r785",
      "r789",
      "r796",
      "r1047",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1056"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "caba_NanjingIasoBiotherapeuticsCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "NanjingIasoBiotherapeuticsCoLtdMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nanjing IASO Biotherapeutics Co., Ltd. member",
        "label": "Nanjing IASO Biotherapeutics Co., Ltd. [Member]",
        "terseLabel": "IASO Biotherapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash (used in) provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "negatedTotalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r65",
      "r82",
      "r102",
      "r103",
      "r119",
      "r121",
      "r126",
      "r141",
      "r142",
      "r143",
      "r146",
      "r152",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r163",
      "r164",
      "r170",
      "r252",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r288",
      "r292",
      "r295",
      "r300",
      "r358",
      "r414",
      "r417",
      "r455",
      "r481",
      "r582",
      "r669",
      "r686",
      "r687",
      "r731",
      "r733",
      "r735",
      "r810",
      "r1045"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "caba_NonCashFinanceLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "NonCashFinanceLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash finance lease expense",
        "label": "Non Cash Finance Lease Expense",
        "documentation": "Non Cash Finance Lease Expense"
       }
      }
     },
     "auth_ref": []
    },
    "caba_NonCashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "NonCashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash lease expense",
        "label": "Non cash lease expense",
        "terseLabel": "Non-cash lease expense",
        "verboseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r849",
      "r859",
      "r883",
      "r892"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "caba_NonRule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "NonRule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Rule 10b51 Arr Modified Flag",
        "documentation": "Non Rule 10b51 Arr Modified Flag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "caba_NonVestedCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "NonVestedCommonStockMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-vested Founder Stock",
        "documentation": "Non-vested common stock member.",
        "label": "Non Vested Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvotingCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonvotingCommonStockMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-voting Common Stock",
        "label": "Nonvoting Common Stock [Member]",
        "terseLabel": "Non-voting Common Stock [Member]",
        "documentation": "Common stock securities that do not empower a holder to vote on corporate resolutions or the election of directors."
       }
      }
     },
     "auth_ref": []
    },
    "caba_NumberOfFaculty": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "NumberOfFaculty",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of faculty.",
        "label": "Number Of Faculty",
        "terseLabel": "Number of faculty member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r1014"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r743",
      "r753",
      "r1014"
     ]
    },
    "us-gaap_NumberOfReportingUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportingUnits",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reportable segment",
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "caba_ObligationToBePaidCommencementDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "ObligationToBePaidCommencementDate",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligation to be paid, commencement date.",
        "label": "Obligation To Be Paid Commencement Date",
        "terseLabel": "Payment commencement date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffBalanceSheetCreditExposurePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OffBalanceSheetCreditExposurePolicyPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Off-Balance-Sheet Credit Exposure, Policy [Policy Text Block]",
        "terseLabel": "Off-Balance Sheet Risk and Concentrations of Credit Risk",
        "documentation": "Description of accounting policies and methodologies used to estimate the entity's liability for off-balance sheet credit exposures and related charges for those credit exposures."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r567",
      "r568"
     ]
    },
    "caba_OperatingCashFlowsUsedForFinanceLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "OperatingCashFlowsUsedForFinanceLeases",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Cash Flows Used For Finance Leases",
        "documentation": "Operating Cash Flows Used For Finance Leases",
        "terseLabel": "Operating cash flows used for finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "caba_OperatingCashFlowsUsedForOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "OperatingCashFlowsUsedForOperatingLeases",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Cash Flows Used For Operating Leases",
        "documentation": "Operating Cash Flows Used For Operating Leases",
        "terseLabel": "Operating cash flows used for operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r731",
      "r735",
      "r742",
      "r1013",
      "r1015",
      "r1016",
      "r1017",
      "r1018"
     ]
    },
    "caba_OperatingLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "OperatingLeaseAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Agreement.",
        "label": "Operating Lease Agreement [Member]",
        "terseLabel": "Operating Lease Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "caba_OperatingLeaseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "OperatingLeaseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfPrincipalComponentsOfCompanySDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Operating lease assets",
        "label": "Operating lease assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Total fixed operating lease cost",
        "totalLabel": "Total fixed operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r792"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "verboseLabel": "Monthly fee included in minimum lease payment",
        "terseLabel": "Rent expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "totalLabel": "Operating Lease, Liability, Total",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumPaymentsForOperatingLeasesAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r511"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r792"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term - operating leases (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r792"
     ]
    },
    "caba_OperatingLeasesAbtract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "OperatingLeasesAbtract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases [Abtract]",
        "documentation": "Operating Leases [Abtract]",
        "terseLabel": "Operating Leases:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesRentExpenseMinimumRentals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasesRentExpenseMinimumRentals",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Rent Expense, Minimum Rentals",
        "terseLabel": "Initial annual base rent",
        "documentation": "This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ]
    },
    "caba_OperatingLossCarryforwardsFederalCommencementOfExpirationDate": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "OperatingLossCarryforwardsFederalCommencementOfExpirationDate",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards federal commencement of expiration date.",
        "label": "Operating Loss Carryforwards Federal Commencement Of Expiration Date",
        "terseLabel": "Operating loss carryforwards federal commencement of expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "caba_OperatingLossCarryforwardsLocalCommencementOfExpirationDate": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "OperatingLossCarryforwardsLocalCommencementOfExpirationDate",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards local commencement of expiration date.",
        "label": "Operating Loss Carryforwards Local Commencement Of Expiration Date",
        "terseLabel": "Operating loss carryforwards local commencement of expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "caba_OperatingLossCarryforwardsStateCommencementOfExpirationDate": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "OperatingLossCarryforwardsStateCommencementOfExpirationDate",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards state commencement of expiration date.",
        "label": "Operating Loss Carryforwards State Commencement Of Expiration Date",
        "terseLabel": "Operating loss carryforwards state commencement of expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_OrphanDrugCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "OrphanDrugCreditsMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Orphan Drug credits [Member]",
        "documentation": "Orphan Drug credits [Member]",
        "terseLabel": "Orphan Drug Credits [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_OtherCommitmentDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Committed payment obligation",
        "label": "Other Commitment, to be Paid, Year One",
        "documentation": "Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1006",
      "r1129"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total",
        "terseLabel": "Net unrealized gain (loss) on available-for-sale investments, net of tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r583"
     ]
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses",
        "terseLabel": "Expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r799",
      "r800"
     ]
    },
    "caba_OtherInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "OtherInformationAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Information [Abstract]",
        "documentation": "Other Information [Abstract]",
        "terseLabel": "Other inforamation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "caba_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesScheduleOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r793"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Operating Income (Expense), Net",
        "negatedLabel": "Other income, net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense",
        "terseLabel": "Other research and development costs",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1086"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r847",
      "r857",
      "r890"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r860",
      "r893"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r860",
      "r893"
     ]
    },
    "caba_OxfordBiomedicaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "OxfordBiomedicaMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Biomedica.",
        "label": "Oxford Biomedica [Member]",
        "terseLabel": "Oxford Biomedica"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_PaymentOfObligationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "PaymentOfObligationTerm",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of obligation, term.",
        "label": "Payment Of Obligation Term",
        "terseLabel": "Payment term",
        "verboseLabel": "Payment term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForCommissions",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for commissions",
        "label": "Payments for Commissions",
        "documentation": "The amount of cash paid for commissions during the current period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsForUnderwritingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForUnderwritingExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting discounts and commissions and offering expenses",
        "label": "Payments for Underwriting Expense",
        "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance commissions",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of investments",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r130",
      "r221"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "caba_PercentageOfEligibleTaxPositionsForRecognition": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "PercentageOfEligibleTaxPositionsForRecognition",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of eligible tax positions for recognition.",
        "label": "Percentage Of Eligible Tax Positions For Recognition",
        "terseLabel": "Percentage of eligible tax positions for recognition"
       }
      }
     },
     "auth_ref": []
    },
    "caba_PercentageOfPayrollDeductionOnEligibleCompensation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "PercentageOfPayrollDeductionOnEligibleCompensation",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of payroll deduction on eligible compensation.",
        "label": "Percentage Of Payroll Deduction On Eligible Compensation",
        "terseLabel": "Payroll deduction percentage of eligible compensation"
       }
      }
     },
     "auth_ref": []
    },
    "caba_PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares purchased at fair market value of common stock.",
        "label": "Percentage Of Shares Purchased At Fair Market Value Of Common Stock",
        "terseLabel": "Percentage of shares to be purchased"
       }
      }
     },
     "auth_ref": []
    },
    "caba_PersonnelExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "PersonnelExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Personnel Expenses",
        "documentation": "Personnel Expenses",
        "terseLabel": "Personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "caba_PreFundedWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "PreFundedWarrantsExercised",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded warrants exercised.",
        "label": "Pre-Funded Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "caba_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded Warrants [Member]",
        "terseLabel": "Pre-funded Warrants",
        "documentation": "Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r301"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized shares",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r650"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued shares",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r301"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding shares",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r650",
      "r668",
      "r1165",
      "r1166"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.00001 par value: 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; no shares issued or outstanding at December 31, 2025 and December 31, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r291",
      "r297",
      "r573",
      "r793"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock, warrants and pre-funded warrants, net of issuance costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from the issuance of common stock under employee stock purchase plan",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturities of investments",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r1020"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock in connection with the exercise of stock options",
        "verboseLabel": "Common Stock Warrants Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Net proceeds from exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "terseLabel": "Net Sale Products",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r735",
      "r761",
      "r762"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r556",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r724",
      "r730",
      "r733",
      "r735",
      "r761",
      "r762",
      "r795",
      "r796",
      "r797",
      "r798",
      "r801",
      "r930",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r1043",
      "r1044",
      "r1131",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r556",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r724",
      "r730",
      "r733",
      "r735",
      "r761",
      "r762",
      "r795",
      "r796",
      "r797",
      "r798",
      "r801",
      "r930",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r1043",
      "r1044",
      "r1131",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r119",
      "r121",
      "r133",
      "r141",
      "r142",
      "r143",
      "r146",
      "r152",
      "r160",
      "r163",
      "r164",
      "r252",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r288",
      "r358",
      "r414",
      "r417",
      "r418",
      "r421",
      "r422",
      "r455",
      "r481",
      "r561",
      "r563",
      "r581",
      "r621",
      "r669",
      "r686",
      "r687",
      "r776",
      "r777",
      "r811",
      "r954",
      "r1045"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r516"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r91",
      "r92",
      "r96"
     ]
    },
    "caba_PropertyPlantAndEquipmentEstimatedUsefulLives1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives1",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lesser of estimated useful life or remaining lease term",
        "label": "Property Plant And Equipment Estimated Useful Lives 1",
        "documentation": "Property Plant And Equipment Estimated Useful Lives 1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property, plant and equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r107",
      "r580"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r516",
      "r564",
      "r580",
      "r793"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r91",
      "r92",
      "r578"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property Plant and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r516"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lesser of estimated useful life or remaining lease term",
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r271",
      "r272",
      "r273",
      "r274",
      "r310",
      "r321",
      "r351",
      "r352",
      "r353",
      "r357",
      "r369",
      "r461",
      "r529",
      "r538",
      "r555",
      "r597",
      "r599",
      "r607",
      "r640",
      "r641",
      "r692",
      "r696",
      "r698",
      "r699",
      "r703",
      "r715",
      "r716",
      "r717",
      "r718",
      "r720",
      "r721",
      "r754",
      "r760",
      "r768",
      "r772",
      "r774",
      "r775",
      "r784",
      "r785",
      "r789",
      "r790",
      "r796",
      "r804",
      "r1039",
      "r1047",
      "r1105",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r271",
      "r272",
      "r273",
      "r274",
      "r310",
      "r321",
      "r351",
      "r352",
      "r353",
      "r357",
      "r369",
      "r461",
      "r529",
      "r538",
      "r555",
      "r597",
      "r599",
      "r607",
      "r640",
      "r641",
      "r692",
      "r696",
      "r698",
      "r699",
      "r703",
      "r715",
      "r716",
      "r717",
      "r718",
      "r720",
      "r721",
      "r754",
      "r760",
      "r768",
      "r772",
      "r774",
      "r775",
      "r784",
      "r785",
      "r789",
      "r790",
      "r796",
      "r804",
      "r1039",
      "r1047",
      "r1105",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Profit and Loss From Segments",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r842",
      "r852",
      "r885"
     ]
    },
    "caba_RegentsOfUniversityOfCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "RegentsOfUniversityOfCaliforniaMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regents of the university of California.",
        "label": "Regents Of University Of California [Member]",
        "terseLabel": "Penn"
       }
      }
     },
     "auth_ref": []
    },
    "caba_RemainingResearchAndDevelopmentExpenseToBeIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "RemainingResearchAndDevelopmentExpenseToBeIncurred",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining research and development expense to be incurred.",
        "label": "Remaining Research And Development Expense To Be Incurred",
        "terseLabel": "Remaining research and development expense to be incurred"
       }
      }
     },
     "auth_ref": []
    },
    "caba_RentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "RentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent expense.",
        "label": "Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r147",
      "r148",
      "r284",
      "r303",
      "r519",
      "r539",
      "r569",
      "r726",
      "r727",
      "r728",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r1095",
      "r1096",
      "r1097",
      "r1098"
     ]
    },
    "caba_Rese-CelAndMuSK-CAARTMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "Rese-CelAndMuSK-CAARTMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rese-Cel and MuSK-CAART [Member]",
        "documentation": "Rese-Cel and MuSK-CAART [Member]",
        "terseLabel": "Rese-Cel and MuSK-CAART [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal research and development net deferred tax assets",
        "label": "Research and Development Arrangement with Federal Government, Costs Incurred, Net",
        "documentation": "The net amount of research and development costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "caba_ResearchAndDevelopmentCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "ResearchAndDevelopmentCredits",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "label": "Research and Development credits",
        "documentation": "Research and Development credits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r722",
      "r731",
      "r732",
      "r748",
      "r1128"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfProfitAndLossFromSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Abstract]",
        "terseLabel": "Research and development expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "caba_ResearchServiceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "ResearchServiceAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Service Agreement [Member]",
        "terseLabel": "Research Service Agreement",
        "documentation": "Research service agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r832",
      "r843",
      "r853",
      "r886"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r844",
      "r854",
      "r887"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r851",
      "r861",
      "r894"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureBasisOfPresentationAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r72",
      "r576",
      "r604",
      "r606",
      "r618",
      "r651",
      "r793"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r101",
      "r102",
      "r149",
      "r150",
      "r151",
      "r153",
      "r160",
      "r162",
      "r164",
      "r253",
      "r254",
      "r265",
      "r287",
      "r358",
      "r403",
      "r404",
      "r411",
      "r412",
      "r413",
      "r415",
      "r416",
      "r417",
      "r442",
      "r444",
      "r445",
      "r447",
      "r453",
      "r494",
      "r497",
      "r601",
      "r603",
      "r622",
      "r1165"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r792"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of use assets obtained in exchange for lease obligations",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r792"
     ]
    },
    "caba_Rule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "Rule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b51 Arr Modified Flag",
        "documentation": "Rule 10b51 Arr Modified Flag",
        "terseLabel": "Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Shares Excluded from Calculation of Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of Principal Components of Company's Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1090"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Earnings Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r771",
      "r1087"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "caba_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of estimated useful lives of property and equipment.",
        "label": "Schedule Of Estimated Useful Lives Of Property And Equipment Table [Text Block]",
        "terseLabel": "Schedule of Estimated Useful Lives for Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesForPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r516"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r357"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r73"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Assumptions Used to Estimate Fair Value of Stock Options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r70",
      "r71",
      "r72",
      "r111",
      "r112",
      "r113",
      "r184",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r441",
      "r614",
      "r615",
      "r616",
      "r617",
      "r760",
      "r929",
      "r1000",
      "r1002"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r182",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r199",
      "r200",
      "r201",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r217",
      "r219",
      "r743",
      "r746",
      "r747",
      "r748",
      "r750",
      "r752",
      "r753"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r215",
      "r218",
      "r744",
      "r745",
      "r751"
     ]
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Share-based compensation, vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based compensation, number of shares available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares, Options Exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options Exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of shares, Forfeited/Cancelled",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of Shares, Granted",
        "terseLabel": "Number of options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value of stock options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options outstanding aggregate intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending Balance",
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning Balance",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares, Ending Balance",
        "periodStartLabel": "Number of Shares, Beginning Balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "caba_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options outstanding weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Share-based compensation unvested number of shares",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockBasedCompensationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited/Cancelled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r329",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (years), Options Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (years), Options Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "Common Stock",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r1048",
      "r1057"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Common stock price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "caba_SharesRemainingAvailableForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "SharesRemainingAvailableForIssuance",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for issuance",
        "label": "shares remaining available for issuance",
        "documentation": "shares remaining available for issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments",
        "totalLabel": "Short-Term Investments, Total",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r941"
     ]
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermInvestmentsAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Abstract]",
        "terseLabel": "Short-term investments:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r792"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140"
     ]
    },
    "us-gaap_SignificantPurchaseCommitmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantPurchaseCommitmentDescription",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Commitment, Description",
        "terseLabel": "Development and clinical manufacturing services agreement, Description",
        "documentation": "Excluding long-term commitments, description of arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers, which may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing (such as penalties) of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r78"
     ]
    },
    "caba_SponsoredResearchAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "SponsoredResearchAgreementsMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsored Research Agreements.",
        "label": "Sponsored Research Agreements [Member]",
        "terseLabel": "Sponsored Research Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State [Member]",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r111",
      "r112",
      "r113",
      "r141",
      "r143",
      "r168",
      "r169",
      "r172",
      "r176",
      "r184",
      "r185",
      "r252",
      "r275",
      "r277",
      "r278",
      "r279",
      "r282",
      "r283",
      "r290",
      "r291",
      "r293",
      "r294",
      "r296",
      "r299",
      "r301",
      "r302",
      "r304",
      "r305",
      "r307",
      "r481",
      "r614",
      "r615",
      "r616",
      "r617",
      "r622",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r650",
      "r670",
      "r688",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r929",
      "r1002",
      "r1003",
      "r1011"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Accumulated Other Comprehensive Income",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r50",
      "r54",
      "r55",
      "r99",
      "r101",
      "r102",
      "r124",
      "r125",
      "r126",
      "r149",
      "r150",
      "r151",
      "r153",
      "r160",
      "r162",
      "r164",
      "r183",
      "r253",
      "r254",
      "r265",
      "r287",
      "r309",
      "r358",
      "r403",
      "r404",
      "r411",
      "r412",
      "r413",
      "r415",
      "r416",
      "r417",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r494",
      "r497",
      "r518",
      "r583",
      "r601",
      "r602",
      "r603",
      "r622",
      "r688"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r183",
      "r290",
      "r291",
      "r293",
      "r296",
      "r497",
      "r556",
      "r609",
      "r623",
      "r634",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r650",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r671",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r688",
      "r733",
      "r735",
      "r805",
      "r1163"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r183",
      "r220",
      "r290",
      "r291",
      "r293",
      "r296",
      "r497",
      "r556",
      "r609",
      "r623",
      "r634",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r650",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r671",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r688",
      "r733",
      "r735",
      "r805",
      "r1163"
     ]
    },
    "caba_StevenNichtbergerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "StevenNichtbergerMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Steven Nichtberger [Member]",
        "documentation": "Steven Nichtberger [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_StevenNichtbergerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "StevenNichtbergerOneMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Steven Nichtberger One [Member]",
        "documentation": "Steven Nichtberger One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r846",
      "r856",
      "r889"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083"
     ]
    },
    "caba_StockIssuedDuringPeriodShareStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "StockIssuedDuringPeriodShareStockOptionsExercised",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period share stock options exercised.",
        "label": "Stock Issued During Period Share Stock Options Exercised",
        "terseLabel": "Issuance of common stock in connection with exercise of stock options, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan, Shares",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r49",
      "r50",
      "r72"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock, net of issuance costs, shares",
        "terseLabel": "Common stock issuance, shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r49",
      "r50",
      "r72",
      "r614",
      "r688",
      "r710"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Shares, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r49",
      "r50",
      "r72",
      "r335"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan, value",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r49",
      "r50",
      "r72"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Common stock issuance",
        "verboseLabel": "Issuance of common stock, net of issuance costs, value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r49",
      "r50",
      "r72",
      "r622",
      "r688",
      "r710",
      "r811"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock in connection with exercise of stock options, value",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r50",
      "r54",
      "r55",
      "r72"
     ]
    },
    "us-gaap_StockOptionExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionExercisePriceDecrease",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option, Exercise Price, Decrease",
        "documentation": "Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionExercisePriceIncrease",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option, Exercise Price, Increase",
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "caba_StockOptionRepricingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "StockOptionRepricingMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Repricing [Member]",
        "documentation": "Stock Option Repricing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r54",
      "r55",
      "r66",
      "r652",
      "r668",
      "r689",
      "r690",
      "r793",
      "r812",
      "r1000",
      "r1003",
      "r1004",
      "r1036",
      "r1112",
      "r1165"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Equity, Including Portion Attributable to Noncontrolling Interest, Total",
        "periodEndLabel": "Ending Balance",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r40",
      "r99",
      "r100",
      "r101",
      "r102",
      "r125",
      "r149",
      "r150",
      "r151",
      "r153",
      "r160",
      "r162",
      "r253",
      "r254",
      "r265",
      "r287",
      "r309",
      "r358",
      "r403",
      "r404",
      "r411",
      "r412",
      "r413",
      "r415",
      "r416",
      "r417",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r453",
      "r486",
      "r487",
      "r491",
      "r495",
      "r518",
      "r602",
      "r603",
      "r620",
      "r652",
      "r668",
      "r689",
      "r690",
      "r714",
      "r799",
      "r800",
      "r811",
      "r1000",
      "r1003",
      "r1004",
      "r1036",
      "r1112",
      "r1165"
     ]
    },
    "caba_SubscriptionAndTechnologyTransferAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "SubscriptionAndTechnologyTransferAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscription and technology transfer agreement.",
        "label": "Subscription And Technology Transfer Agreement [Member]",
        "terseLabel": "Subscription and Technology Transfer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r521"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r521"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r521"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r521"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r521"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r522"
     ]
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplyCommitmentArrangementMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supply Commitment Arrangement [Domain]",
        "terseLabel": "Supply Commitment Arrangement",
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r78"
     ]
    },
    "us-gaap_SupplyCommitmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplyCommitmentAxis",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supply Commitment [Axis]",
        "terseLabel": "Supply Commitment",
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r78"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "caba_TerminationFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "TerminationFees",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination fees",
        "label": "Termination Fees",
        "documentation": "Termination Fees"
       }
      }
     },
     "auth_ref": []
    },
    "caba_TotalFinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "TotalFinanceLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Finance Lease Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "terseLabel": "Total finance lease cost",
        "totalLabel": "Total finance lease cost"
       }
      }
     },
     "auth_ref": []
    },
    "caba_TotalFixedFinanceLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "TotalFixedFinanceLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails": {
       "parentTag": "caba_TotalFinanceLeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fixed Finance Lease Cost",
        "documentation": "Total Fixed Finance Lease Cost",
        "terseLabel": "Total Fixed Finance Lease Cost",
        "totalLabel": "Total Fixed Finance Lease Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r286",
      "r306",
      "r441",
      "r452",
      "r475",
      "r480",
      "r483",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r566",
      "r584",
      "r781",
      "r782",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r794",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1101",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "caba_TwoThousandEighteenAndTwoThousandNinteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "TwoThousandEighteenAndTwoThousandNinteenPlanMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2018 and 2019 Plan [Member]",
        "label": "Two Thousand Eighteen and Two Thousand Ninteen Plan [Member]",
        "documentation": "Two Thousand Eighteen and Two Thousand Ninteen Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_TwoThousandEighteenStockOptionAndGrantPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "TwoThousandEighteenStockOptionAndGrantPlanMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen stock option and grant plan.",
        "label": "Two Thousand Eighteen Stock Option And Grant Plan [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "caba_TwoThousandNineteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "TwoThousandNineteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen employee stock purchase plan.",
        "label": "Two Thousand Nineteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2019 ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "caba_TwoThousandNineteenStockOptionAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "TwoThousandNineteenStockOptionAndIncentivePlanMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen stock option and incentive plan.",
        "label": "Two Thousand Nineteen Stock Option And Incentive Plan [Member]",
        "terseLabel": "2019 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "caba_TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Five At The Market Offering Sales Agreement [Member]",
        "documentation": "Two Thousand Twenty Five At The Market Offering Sales Agreement [Member]",
        "terseLabel": "2025 At-The-Market Offering Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "caba_TwoThousandTwentyFiveInducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "TwoThousandTwentyFiveInducementPlanMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Inducement Plan",
        "label": "Two Thousand Twenty Five Inducement Plan [Member]",
        "documentation": "Two Thousand Twenty Five Inducement Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_TwoThousandTwentyFiveSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "TwoThousandTwentyFiveSalesAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Five Sales Agreement [Member]",
        "documentation": "Two Thousand Twenty Five Sales Agreement [Member]",
        "terseLabel": "2025 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "caba_TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Four At The Market Offering Sales Agreement [Member]",
        "documentation": "Two Thousand Twenty Four At The Market Offering Sales Agreement [Member]",
        "terseLabel": "2024 At-The-Market Offering Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfDebtSecuritiesClassifiedAsAvailableForSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government securities",
        "verboseLabel": "U.S. Treasury securities - due in one year or less",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r737",
      "r738",
      "r763",
      "r765",
      "r1130"
     ]
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "terseLabel": "Allocation of undistributed losses for basic computation",
        "totalLabel": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic, Total",
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r173",
      "r174",
      "r289"
     ]
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted",
     "crdr": "debit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted",
        "totalLabel": "Allocation of undistributed losses",
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r173",
      "r174",
      "r928"
     ]
    },
    "us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UndistributedEarningsLossAvailableToCommonShareholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Allocation of undistributed losses",
        "label": "Undistributed Earnings (Loss) Available to Common Shareholders, Basic",
        "terseLabel": "Allocation of undistributed losses attributable to common stockholders",
        "totalLabel": "Undistributed Earnings (Loss) Available to Common Shareholders, Basic, Total",
        "documentation": "Amount of undistributed earnings (loss) allocated to common stock as if earnings had been distributed. Excludes distributed earnings."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r174"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Interest or penalties related to uncertain income tax benefits",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r770"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized income tax benefits that would affect effective tax rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r770"
     ]
    },
    "caba_UnvestedStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "UnvestedStockOptionMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Stock Option [Member]",
        "documentation": "Unvested Stock Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "UpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureSubsequenteventsAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCollaborationsLicensingAgreementsAndOtherAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront license fee",
        "documentation": "Upfront payment",
        "label": "Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r186",
      "r187",
      "r188",
      "r189",
      "r561",
      "r563",
      "r740"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails2": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease costs",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r792"
     ]
    },
    "caba_VariableLeaseCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "VariableLeaseCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails": {
       "parentTag": "caba_TotalFinanceLeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesScheduleOfCompanysOperatingAndFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease Costs",
        "documentation": "Variable Lease Costs",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "auth_ref": []
    },
    "caba_VestedStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "VestedStockOptionMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested Stock Option [Member]",
        "documentation": "Vested Stock Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "caba_VotingCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "VotingCommonStockMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Voting Common Stock",
        "documentation": "Voting common stock.",
        "label": "Voting Common Stock [Member]",
        "terseLabel": "Voting Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantExercisePriceDecrease",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant, Exercise Price, Decrease",
        "terseLabel": "Decrease in exercise price of Warrents",
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r803",
      "r806",
      "r807",
      "r808",
      "r809"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Add: Conversion of non-voting to voting common shares outstanding",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment, Total",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted average number of shares used in diluted per share computation",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r176"
     ]
    },
    "caba_WeightedAverageNumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "WeightedAverageNumberOfSharesOutstanding",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareSummaryOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding",
        "documentation": "Weighted average number of shares outstanding",
        "terseLabel": "Weighted average number of shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of shares used in basic per share computation",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted average common stock outstanding",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r176"
     ]
    },
    "caba_WorkOrdersTerm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "WorkOrdersTerm",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work orders terms",
        "label": "Work Orders Term",
        "documentation": "Work Orders Term"
       }
      }
     },
     "auth_ref": []
    },
    "caba_WuXiAdvancedTherapiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "WuXiAdvancedTherapiesMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WuXi Advanced Therapies.",
        "label": "Wu Xi Advanced Therapies [Member]",
        "terseLabel": "WuXi Advanced Therapies"
       }
      }
     },
     "auth_ref": []
    },
    "caba_WuxiAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cabalettabio.com/20251231",
     "localname": "WuxiAgreementMember",
     "presentation": [
      "http://www.cabalettabio.com/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WuXi Agreement [Member]",
        "documentation": "WuXi Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481155/840-10-25-5"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Subparagraph": "(Note 3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481418/840-10-55-40"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "65",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-65"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "66",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-66"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481679/480-10-45-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481639/420-10-35-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "SubTopic": "310",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001759138-26-000011-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001759138-26-000011-xbrl.zip
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M"@WL-DT(9TE DB@U1H>I"/A\F!V@'QR5EY=9@X.M#PN-' %D#4I+9FX-ULC
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M;X9[I+OAZ+-=UD97CYCC)?;^*NJX3QK-XZ/;=IRQ(HFE3;DAOI^ 3L:D(;
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M7W%%I :MV"9,2A:F(4N&RSZ#+JZU02W23[4&L02/2P-0)</0)T(% ?%3V+!
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M]*5H:Q &/)0JY4G"@A#WAYLXQ5,;&KLL;@RMHSPF2L!K%<K,*(+++&QJ'(1
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MISPD;5!.?3;:P-^,KOY#1U%X/#.I &JRB<@]<VW4%*MRP->@QYMZ- <WO>[
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M.%5$"$H),SPD(@U#HIB,PYAR*6BXN:9NU1&H>^=E-5N3*N N<HJ@ZB[:;M;
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MB'3?*](=CE#70ITXJ[+Z]S,K5%-6-4#?%ZC/F\.\]S 6[V4[EA'WML8#C([
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M23I5<L^[\47K?,2 )UP#C7)PX;&$!^$,;RW)0HFLI[ V*T,=N7+DRLUS)4B
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M%\P($R-,/,XY0M-I?*WFB+18.RT03Q):5YCHY-O([E_)[BYZ9 [,N3MD<4%
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M]?,K#R:C$2&"J)=+R;?6]'4!52JXL>(^WV96UK<G' &WY.K4Q:*-D-1<%1%
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MKUBT@U'@#'DKA%$WM?3T3-SQT1OJJZJ^K8QB*MNMZY5#^BU&KA=->!;  K4
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MW1YF/XV<SK6^&8*>B(=@_@8K@4(AS<'*:\R:'S!:KE."T-&:Y0MR#;9:44G
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MBG9,,YXQ)? >*M_(Q7E=^FO,4!/UM0I($RSEGG<F,\G810W_H\?87>QFZD
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M=5C[2D0HHUC!O)T$%3/AMD:C\)KB*_XN8"ZO33KJ_%[,T\:]3,\OKG[F)T&
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M+M[P_7]PUTV'G"B-X($\)_U8'ZLW&#JRF_$+XY_==A&I&+/SE9-?W94RE_\
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M]@A6/%XJ1F$>C6C99 B0,":P]QN9%7KBRKKMXR<L.X%\0ZTE+DY F<6NFPF
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M_6BA?I\["C52!S$#/;J\(N.M.T3+_D, N*R'\38\XU,[E,"'/R"M$K25KM&
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MJGF8Q8T[ ..9SQ9U*VB .G<+Z<LV#ZYUI4(7A$6)V>>176P*;EP.Q Z0P-F
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MGZTR&Q2C.7<K"?,(=I.5=))6\J@J%A;G8@,H1+G"I>LL*@_07 96DJ%HY3S
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M[CQ*%M%F _U"STGW&4_UL/,:E8L[LF#/8UH 33ZU!_$2/CI4A$%:.0$GA48
M(02LMT&EI'4WM+]D;(!XE([>L3W7HFZA!6.=?#$T!U.#$A23NNR,T9?NKW<<
MI II6^;:3!."5H3:?>&?B&\MWJ0670E)N96@:PA\1..BVV:\.J3MCV8O4^IA
M5K'G!''<3,ES["%<VJ48BH')!$>B1K"/;(USL@\K%Y/,I:BP>4*:&&O>!B6\
MJI\3F4M20+*^?08 [L8W2)4"O 8B8GK5KKEQM,AEZ=<)59F1F=2ANAF1&?R
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M#'?OP=%%?=O EP)L%]S-)OM-#KT0*@=.*$88*H^:I[OT8L[H\2H5\]*>,GX
M_#ZLU$'/AI3C7/,X"JV+<FQ:YXCR\$D^=NQ=Q'^.OQM?(_KZ=:<K/S?\)O=7
MULOE"<>"YAKHG(9?IE8UGFM.".GERCI_-<@<<K,C_4\7"!H'2ZA82M9/)TL+
M'&VXCAY$M^AY3R?#!\99Z[4A8SWA0S-W*V=)Z]RK-+4L]&'1<*6-4J%F"Q7O
ML.I@I!Q,%\OKK4](A<?QV;VW>)OJ=7$:BX:X[1J@IX8I<'G+5?)RFSI;F,<:
MO<6!::/K<K)/U^!B'F,^K]W;6*!T/= NV'7>M?V^:V@:Z#-R,.EN;/2$2DY
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MI[W[N+1>W<C'++S\<A ;_N#"\Z][!5PP4! P)G4L;SJ,S0_E%,R+NW/_KLM
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M$4B9598 O65?*>4ZLBU*UG.*M(:5+J C9(O\(O$IPV*/.R\^":\ Y-MB\SY
M_[PHC> /,Z .E*6A?.]F<.0DI[3%@M_3ED@$*V));K]2U2:TFG,> 3):5_:$
M05>Y"^\M;[L!2)Z-@[!HV>)0;H7$/Y4$6W-@94S0F<_)6V/@X:MPV+QV <KD
MN-V&]WJS^A*9&2&Z28&,3D)K#J<B:"4V7C(H800=<G;R78JJ5U? /"'/B!*.
MH'&E2!<&"HR" \RW>2[<<GQ,JKY3D]M9$,E*2REL>ZXL@W8:T;9@$1W&H(T
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M18H7+GT% 5/+#PT$3A%5#S<+DOL;!3.% ,!+%Z*S%>&#LMUP=$R7$=C,.4]
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M:3$/3>D70VGZ\=JDL.5J[_^AL:@6 C.W!?D/6L1'%UFYMB6:)\WMH6@:91/
M71C;HV-[;O@$H*=;,EKCUSSXE;0OT)!]6>>)".8LW9UON]@;;V\D/%N3P]=D
MIR*T5.N+C@P*H>L8L:_I+C&<O>5/<ZJ(]DX.I.]/E<R3S:N+CK6IV\K#V*A#
M?27,8]AG[B$3<H7T4_OM*(&=1CZX+:(30+^YM4?_!'*<0(X?"^3X]01RG$".
M$\AQ8MK["&];CGIQIR18>_/37*NVG/2.LA 1CR">B+9,B4O0CI[U(.D=]<(U
MW:H.6ZB&2YID/KO*X=EGR$BOTP\CB^4NBJ;NOG'Z3/55)?DFJ4&%4*#5(I=]
MG7F;S17E7DB]@O<Z5A#I6@W+"M)BR#@YM.,>DA*(*6].X]3-?O>;R$5&IA]E
M+"(O<<IRW-8M<T+.[6+1H/TQ4?G*N@M6;5N/$H>UL_:"8;&2!:._MQ2FEAF[
MNO/ 6BWY,GC<HA-#3TM;[B@L9(2:X#,?H2:[XEA0:1\UN?HT<!^,![HO*6B[
M3&+;!_?N/<: GIX^>RE<=!)-\-6Y,F6+]539*4Y3O, )-R"N\ C/. .+*S"1
M_$8JO#HPA=;@(X!9&+"%XFWFFJ=],1C6_7O"@*^$F9>@,*<KG3Q#XW'11A(J
M"Q].OS\[,0E4;'[&\6QH.5#DHY:*(C[%8!_S9.E+ 6)8'CNEEN.KCLP\O=$+
M.D0@+V1O57>TO2_[* 7)_&K!'8(.W:)"%G:M'Q3(3-0K*BIEE^,HGY:E%>1M
M. UTB*K:?\<QL?L+^^ TE,-"L#X<:"%)!Z%L1Q6.@O]>ID92_1TG[N<F)Z7+
M6RE7LRHK=UU*PT6#VJ0_K[S:I4CW<? 'Z\F'@ML2T@(X)/H;?Q?)[CKP>'X.
MA\I8P;R'++I68E@..(Q7JL*MI7Q&9Y!/P'/&8@<R%[1U*@>*UBD47@90]X8!
MR]M2T@GM?'^(AU^8YL):6EZL_ZU]C!S/L\3!@M^\@^DG=^45R=)(JNZ(Q@,I
MO#(>6ZJC\H\UK2A\D>\02K+FU4EV0?*XN>\:N,YNN>222"N_4PQ3V];+(I+8
M\G6$(%>6CI271-]+OL?UFZ:77G*Z\9@1SE(%Y7;#99!-32:E-]*8^;"EWEI*
MT5$K5@'5C:32-.A"9?BYEQJ[Z)M5*:6= ?0],/J0%2I9=P$)G+IYRSX,O1-7
MGIM<@MOJ$EQ_,#L)";+ 9<C=HIP8JAXQ]8E4'D,-P+HBA[^N:6<*4E4XR'US
M!E;DR&>CZMW.,(ZX',&"&L'B^W8NFF584HG<;\U&P^8,QGUL7%/?IK]7MBE6
MBG<'5ZN%5^&,7)DV.$ QM$FS)II"GMFVS^&:!!=I#"*M#L*JSEM'Z0DEG<BJ
M:]G)D><4Q9=^(<U&2:+6]B?.AB!HW"3=X/;B1JY\)X0IK%[&>BPYVQHA ,,+
M(N_$T8[#TK+IY3:EW5U]KP$MD'7A6 )=T)"&]@"W[-RH:%L^.7KF&4C(:E=Y
M6:#5J]W1B>%_P2P@2]$FHHLA&N(>JE(8B+.@'5M =]N5J(.:GK?8!R8)!22V
MN,D%K+C,H=O000%3.OR3X]G/*A1TZ W. 5L*K#A7*+33-?W6U)- U_%Z?!TC
MP3^^_8/*T4HEOFF+'2UV1_Q?WF^%-8>![#TDPVUMR;*:[/]MM?^1B-DO&E[S
ME1([[+9*P!,J;$HQEWQAU'2-7AR+5@^5.2<U6B9ZYO90BBW$#5.<BK^!%(_,
M'-(7CO"%],(J2M9U&1F#P)8F!]<1F_F12VJ29GA4M*''SLZ_Y&RYK$LZ0:#7
M!0<N<($X(F")"D;8E30TQ@FPLIWY<\,;IP++*AE.VYE"L,M/)=<SMLI<8X"L
MB^?N]M"[#$>X"8[Q26*&KII5S'6M\\^F3(J26@+]#+;N!_7V?5@*]/Z#WW7W
M7DDZ?U&7JT^%^3AUW2ZO?;?+;WFO?\!S3&V=[Y%G<)9W0B'=AC=YH\DX$ZCV
MH,,:(9'D[N?"I]MT\YC"[S13*.>=_Z;1)D:?4"+SF;7>)TUOZJ85S>J([["3
MGK8V2@ Y]+Q* ,5^-T<N6%2!W@Q85>Z!7^DWT,WI.=8"6=C^C55/U#(Y "C1
M8PE2TYDNZ14U;<N8S$"7CC1X*LQ&\A_"<JR.;.$4.+/]0<B,F50!IDVCB8&<
M>L+:$/R&N8L)V5'A=E3I8(S@H#"D-N],_1U=B8JT2<!D3*5?.VY ^_R@<U&"
MS4PP6/$Q-*D/9HSDJM72/9SCUH2#-7PM[ D!FQ:_PADH8[WT5TZ).KC.5' 4
MB(Z^0."<(3CCB#@X;1L^4-((MPS$80EZQV1,75@=X\3/P%OYDQJZEUPZ!8"Q
MEE8ZM_[V.W&M!CN.JU2H/9;,PBT/[*FLC&58D^%0,1;AGD2&5Z'W-9=LZHT3
M("G<.%<Y><7(-$@F)ZKI\A8NE %^R;PW*7>)B<:/CGX^UB[/%PFDJABSB-0B
M0Q9%/I  WB.]MYZIF#%0 9BK/#PZ3'HH8%R#6?5\SDZ[1)^]W.G3<^R#HI9_
M>-98V;.H 0>Y(GO1ZC/?P,"ZI!?:[L2\\=31+&7=J FTXVY@SF8RG/0+[CG;
M/JADH[4,,]RW";VH&.B2 :@M:F;T.='HJZ&CQ\4Y,WST61E@US<56T2>;Z&D
MQ:UQ.3SDK;57$RQP@@5^+%C@XPD6.,$")UC@! O\"&_;TY(=H*K1<*M:%EOH
MI2VU,S5;<-5ZWQ&%X&$2XW"<ZFI_S,U#D31XB: @A[Y053'\_GNF<GEUAANQ
M\F((/D5Z\HK=&HWIL[U[O2^ EZ8@HTT*!#>7['YH]"9M+;4R0&$HH-!3#AHI
M5N:L>N?P#%5-ERY EHW.6#2OO\=A3^<(:?Q6:7'&8GVXS@<OJ([6_G49Z2+8
MH$&CK2@*(OAE!Y/_0?YHZ/T4$861M,.H?XJ1I5&FB\@URQ ]5"USPT55*@5Y
M2KP^X;,9\W@]/B9>-];',0OOF?H/G! .OZ72.M?(0Z]L"1+M1-(\!1[ ^J&%
M!;%OO0<_4%.*&H8JJ6J/J9B:),_%SC8T53%(2Y:4&E<)I"E#<4.EJ;07C$<F
M,J&\4".[OC:ENZDZ$"RX.*$L0(19,?F1HG ;#;X\VK6!1*CP<1S/OE54K+YE
MBY/XXS[/E-Z4K4:H(ID5\"N@:+^YM?& .]OH_ILCSNL<Y0) P!BV!\ZW>\</
M'SY^]/7#^#\^TQ+_.W% 1AUM>']/<. <\>W;;W@BV?_;<TKBT]"=O[CWX*OX
MOZ_IQK?IY'IT_.C!PT>/[CWX\M'7C^_=>_SXT5^>7'%_.CS7;[A+G89:ALE2
MCQ=S=LTTL<OS]8,'7P:?QWF6Z:5NRZ&=A>-MD5<Y_4W/-09(6.*YI"O&%1D]
MN$^U,MGMF=;FGV]M,D!G[MIL4>+83X9-:W-:FY_>;KID8U#^L;*,XK:GA3DM
MS$^^,-.RP!,8S6D93LOP$R_#*B\09(G^LQ+W5K758E0OD"GUQA;GI!KR!OD!
M9"^-4MNA.J1F*2TZ2^:YR80#@PNCW .PQ]3K:*1CB@-U->G/D1Z6"*MP8$RH
M9Z 3B,$#RU[YR9C) [J!K@\XWF6N]S4B.)9CP'WI&SE-MQ^0W$%:P7S[BR'9
M@6JW_I<"6GUM2!%C<B(T)CZ!% V5^+G=E](>) C&%*>1IBNZP(@+8A@^WHT]
MEK.<&^&7[ND^A4MQNHE-DY>.._>2G->]H9*'RR#UHMV@\<BZ)RMC\-:@3$#U
M,H1SHTJ_[MX2UDDM6KYKP[%4)/G497V%Q$A6'< 5_Z3%<'U<Y09%<;PJ!/B[
M+M[Q-XMF)HHN&,Y^,G'1=T&8)@B!T./+M<!;2#MBJ'!95(J!;KG/B3,_A]+,
M[TN2*L;8"'%"@U<D D^?_&15;T,K>;*V(A3!KTD3(=&61?=M=)^%Y<B(""-
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MLZ_N_86V14'WK-='AI"!.(O0>05]*J73\]<.Z8"Z[Y2V6F^QR 77()U9:<O
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MD+UM&F>Y(B,9H ] ^!^TS_I2; _BE/IP:RUQQKX5M.\QJI/!GP5_;0V_/F/
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M,3O/BE&0ZH1<G% +OZE%8XVN!&';BC$3#:?,%DPWP?'#.BO*/4Z,N(JLQ>#
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M"B?3(7:7:>5/*__CP@&S<V%3;"48*JIMW_DNK0!\HE&A0)J5XBCBA")?:R(
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M5ZZM*F4>N2--?656BTP3><@:)XO]I"G8U R#:_/B%WHW;?0C.6O.UZSHV?E
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MEY,<E9:BY Y>DC */NF!)+,$XE?05'AFDW[H.I2]A#HG=M-!,]?2NYO134I
M03:^O][]ZA:#A&W^PW !^R'YNU-L&@++MJBEF/UK*&OKW 2=?<U;2-A_6J8!
M:CWU#3/\GA R^D0M_97WHFKNSC7:"MV*(^V)7 CYO1U8&JDAUS'(VMH<>E0Q
MF_Y__3]?/'OZ^<NXIZ'M_+^J%*96@X79Q#(85U5$+B-9@Z]?/?P7]0 K+'1
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M;1/UUJK5(J)!DQ3?>ORE6+K1^YB U!OE0+\1]'QC=L B<X^X:XHOL@03*L_
M5]P&P&=!3^OG]AT_-]H\WS(!SENM@BBR]SMM2_[]<WD;#,'C[S_[81HO#5.6
MSAF\TKZ2%L9$QQIJ<MA9O/CH#CWZKC?V 5CZIJSW*N\WI:5:^,U=OC-!B%1H
MPX9>).C.AO-#V&!5-C+NPFBXM>9*.E*8KFJ1N]D>M=_TS\@8Z;4/3>1H),;)
MMNL/GJF&,1&@%!/OQ88FR>SY,-B[KAMVX"<W#B^V[+&B'4XU:XHW@P3++XOU
M:2Z6S)%3M\9EYJ]([[(2O./$,L"3W%*6\W+V-U%"+8[&*1>C]=24?"8.^TH"
M2W!L[VK?>!WY:$<:.9>SG_ED-?'B63-LYY!P6)D+)/-A'R^'(&WO?MVUT)\$
M,WSGE-@)KL)HASG9[H?MB27]6## W PYZD=B]:Q]W46C\ZQ</(IP@BR[87TY
M^^>I[2YJ?(M>+GK?:5UP$50[[6#S-O0I36YT 5A'MM!M&7V!T3UP;'SB$N0<
M^O;K^F 4"?V);WMKO'+H16-".;Y+NG(P]]($+NYV65NO]WC''YHPY)05[?)F
M"+4,P,T W-\-P/TR W S #<#<.^8%OJ3S=;]HUJ@WWLY>_WJ[>RGV0+$69XQ
M5&F56@V5NCB^D0")HO[K9K;JA#!7.)QQMKY^^XY__-WK5]^_DY1(N02BRDG_
M=R\_EQ->4C+B,);[3>S(7,[>*5G3U,^9K*9CXL5EPE]CRBJ>AE5U8SI3>F8R
M)4F:R(/3WU^_"E,PE3U,V!O ZGKEG;[HI^R!FDL)RP,R9]XNM6.?/)OX7Y1+
MEQPCN)X.\T;.)U3)DTO"DZR:%?O]1G7%7YB3S0I-*YW>S*<7KJUS.J_;EB4=
M]\PBUGNY'[J63;/1C$Y<)43+_J8V*LE\UM6*A3Y&E%:<*8WGB L_8".'V$B_
M=UL)IBM<IV7OC>)A5YH2$,^$]_(K_B)M+'W%*33\,J*@I3?F?I7\:;D )Z80
M=T5W3M^04TX-9%6=^[42]@\>G6:&F1>(9F&M7*XZF;A,PI?4.5X8)WQYVMB,
MO2DSFS_4+?"[51HR[-M?JX6GV#!)I#&SN5!5TZ)TO .Q!I.$KD-C*&8AWS>Q
M*8N3.#$:=KRPHYZ,"0LAEA':[7[';")0A1<.5A<(QGN+O"F6%JJP=Z+Z_J8E
MPVYY4_RZ962@9=;U=\*_^ UXST[\A'/8W[Q[\S7_X3LR$PP$XS[QJ]?MEL+C
MO9/L]W??O'G]ET)$!Q:,0IA,21BO6J7TMH;V8O;B.0]=+O?V:_E#%0W$T3I=
M,)<;W5B_]^UK(5\.[+:%7[I2E.+)%#)'29 OF,'Z*#A].SGBP@_9SWL43M.P
MHD3'Z:"?"=>:@YX0LST">SD7O9PO;3M>I,T,[%047XJ(6^#!771#)2>A&DA$
M5!GH3RVW(55YH9H,BFQ)+O+#):X1IZ4>,/& XYH"IF@'!G/'K/N+=MTP6R*K
M1P%]O;0T$9]=L"]3)J/H9[7B=QRMW' 6\<I,/)N#+^(T;;<5;O!F@5(+IUIT
M92IQ^$1Z2*BU#WX .W),VJ9Q-1W=EO=@\3XM3NT[E@X??UMU"6_H?^!"[(0Q
M(;MF8_QDX@<KT?PX9V*T'V_T<^?MV]0'V8F:R/H-.W[DPW19LFP.YS:N:D6&
M(2XF#,*7BWA.U%6PUZTP3W[?QWS^-TR?C7.4]OK8M>S'F@;B0#(+H903NRU?
M>(YWPWR+@>X(^FN5?_\[U3_ITYS<(SCF'T7U[7YK1C=;'+ 8T)1)#U-@^Q1!
M1QR'A=CO0M./0Z=;[@<6C9;/QQ !2:=/9= E_AFMSEP->L1.Z=<.%9!(-'KB
MM?>>ASRJ'8*I[R8FYF9;>N*1W3(=)T5AS7J_.13J!/RJ7*RL62%D_D?$B5/+
MPXL:3-$I=K)$=('L;7T(XD-8#6=,U2>N4.0(@:YO=$AU+AH>#P6RP) KV&(:
M#J[L$J?&R^%679"UD1A;F 7)(QA $XO)IRA4J0AQ5<DOJ,X -X%%*JYC,H^N
M!:V>:!9$Q8Q3^PO48P]'TWB^4J3^$UURJ14XKY[@[P=?L4.2>'WDU<81326G
M/ 79M"9L9['QG4%5)6Z>]!S71BEH%YW:.G7H]F9EZ'[8!@VZW@A!X29^V_8B
MESRW'=,<[P\[W %LX<S:W+DM?$DN"XD0*2V*_;Z3(]QKM!O/9,09&DTQOT*G
M+,.R.H[B@A^GXGZ9]!E/>G],])(>'LBB>0$,N*!G3@]S].BK.]J,X&1B=*P?
M*V)7-M!39F:OZ.A!--6&TIL(R$5R'J9)R[STI:=0-SEI98'7Q F+DW28$\Y8
MV2[E$S;J8=^1J_0;CZ/OI7[\!@N+++%XD([=PYRZ?P (MR_(UVYT!WN[<<.V
MA&;5-R(0I=A"_7<:^?KPH"9X-\QKB[P+S8';(JJ:J[8&!2^M X2/$P5X37E'
MPEA'FTO09#]:D&$3[%UW92%I.U**G]SZ1T>078GSWWX-6[)!]G0/<CK:V=-R
MO&5-TY%8*,U7NFZ*,?0Q$M@J<78R';YITR%_AA!<@DD:A*.#2I(]SH*X$\SK
MGZA?^"HR-N;8;^)4?]7N$,+2, ;1-S!%$ZW6#&R-RP1)UKL]I$+DJ%Y>E0S2
M'I]6RX$S&34T16#F>BZA(@($:[DX%*G. " Q(<4T\?UCC),D$*5(4<!^8+2<
M[= #;BNZ?6;3["%V=#QU(;4JT%ME8:;%H3Z<5Z/B4@$^8QIO.\5L"MB;@&W;
ME/"LS:%-X$%7J6(@"@/KODC.6NZWXD\;"(SHOZXJ?@XLW:73\W4\R]=P93C)
M<UT>1(Q2)B69-]X4%)7,%Q-AEYN$K+&[%VER(6,-20@WKM)=SMY0%()#_O@1
M1\(:[$+MV5?K\4XKA3I?E=U!O,M8(D)&%_32A$GZ$)DTOS'U/LQ7GW+07(<=
MA'VF?=6+@F-5'VXQ*7A-D!9ENFJX9(*;TMX 1:5].P $2NN?L]H]@Z*"@,:;
MMI_8X3U<5%H?CI-K+"=T)=)K="51B_-T\0_J/,Q[<+0'<]/*L6VUQQ@UVW>X
MBMHV;!]V.MXB9=0XG*%E%S>M3.6!Z%-IKSD=K!U%AWQP-^M6LZ]:%;]Q@IBC
M9E-2NG+>T[ D.!!W0U !",?%A[-D9W+*H5,(4E9I\.TUIE2$,Y'["4\ W4Q:
MT/38JZ%^L&LMHPTSVO#CF=J+)QEMF-&&&6UXQVC#3P-:&(+,A4! *O8]T!31
M^7 OR+&-1-_/%2ZD&U4K8P(2X-J8ZG+ZFDEH-?8>$G*1B831*)/=MUOFSMAC
MU(*+T\S_/)7!8;UUWR)\VLT9NSC(<HB'8SZ8R=_%N:*;.5^:ZN_+K3M^'HO9
M&^@5H:]7U>WC&#"2MX]*%A2[ XE#?A7-UGZCHO/[E@R)?CV6NK>V$,YF'7:A
MP>8(-T$_CFXHF-"-7,IGCH\J*');GRNS3/X2RJK#7H/Q,RSJ(]RFA_X-'P1<
M<!..EI_8?GZMMH)/>7+YY.E_8<CT__5IOU9H(7=%Z:.S]1R\O^^:-2HPKN'L
MO/Y.K\_9L0UGVCU$@K[?T9')J)T0 ," '1J/F@#!J!FELFG7CF;!A@)SCA(R
M(9-@EDA#G2I*2)79YB/&I\&;;P0BA\(7@HV6K.$0BW!%]K?BKNM?]XJDV?N0
M6518&>DA);H@!N8-A#\],"!445GD*F)OJ9KA"#4W>?\</S_4@R%-*\?QY]@>
MM7FO\!Q&%"PTC8GHBKU&WYDQO\B3E^W.T9&.3D33NY=]0:I4P "=_N:8B@#[
M@%-Y>X9/Q7N;E-.,5YEL]GW37N/+FAP,WZQ$S;FZLEKQ6/CU>/U@H5=\(<-2
M2R,?K^&:7M.\U<R3+WW2;/H'.LY%0*A8-K4;W9];%^DXW/.+YJT!.',4O\-1
MM40MH,9R!,W$Z9OSD1_H(XQK(F98X%P);D.;]7K-F'*ILC-HCS/:AG9#FBPJ
M)IYY:.[!O,;_YT(R;\@E]ZSZEV&HRK/CGV+ 4!NR5PQ);+,BL1<_1E-MU#QF
M?]CN:)GV'B18;37_1T<U#A@]NN7;//S&&=V<C5OZ,UU78>P\4/\<247^S.1,
M/)1?&8E9'S^:%(%$M=L (%*X\<B]S:&O4-CC.WJ8Q9'TYO@]09N1\4]^]K15
MQ'0O?5.'B<#ZU+(:=E126@7(*/UT37[03GJ63;OX,%M#6AF)_)Y7;^V6H"F)
M(1N,%2@3,Y/-X605SO@XSA3CSN)S4A(5+ZAYQM(5)\'.HC*<J( QTMFNN:JZ
MM@FM,*7M(%P+7!B3 &O1YZ,JZ@V(5U*H+*V'$N*A3CM1;MF]+E6HU&JCA&Q<
MF@UY63OYCA:.$ *U<D:R;2?]T;%$Z%Q 9=>\Y,$\<0Z-'M3!6^WGWGNRG-&(
M/48\E(.C:HSOI[G-%,4ZY6D<9V7YXB:X>MOADK9YC14Y)@WA9"RDRFBRM$P:
M*8-[ D5#:DZ2XP"OC0"R]8G_Z!(Z6\P])4]I55)& GSXR;)W^X"W#&DF"<68
MF-20#D)&LNNR^6?##!+O]I+=*+4">A!T)C=S,-CM(/NV#^:QV*VT&BTA-6*A
MAX+Q\%KCWH;.L@B_4*35+Y4[&3\N.TX&4-2);(:E+ 22:%5G_&6-0G##O,Q3
M-?"C6G.T;&5E_UL7[@BN*L.B^(Y^.!_&?&?<#\DW0CQ)JPS[%J=X>MY1DM2.
MIR7C<$!W"UJ]/)M:.,.TAW@Z@&FUOX1?@)!D?&"/TNU4Z[M3\0M'L1'=71RH
M>DQ/>#OT]>3EC'(7^FN&T_AWD>P56P&K!7?>IVA\_9H,CN97FUOJ@V)Q^I!(
M0BJ_EQ:L8PN=T?OA;)A$ &-6(F3VR?U$KH.FNK:K1D>!(C?].YY.=/D<B  Z
MZOHB<F:.XAK:KWM@2*I^$U454_L=33YG44I) PI32@PP_FYO9"B\FO0Q<&3V
M)@E1GK+N^(BR@^_;-Z]F?UZU77@K44MIOVA#T@RUHXZ94)<G;^!S='_Q6;$U
M2YDKI>+)'ZJ!3T$9U)1'B10<:'(Q[3ON0<DX:5%W3O3VY''WF7P'[Z_:PC_8
M"24.]YU(8H_6"8-J-/"X-=H@1AI(0@WKF7U#ONX<G8^QK\)K+HW02[J+A%@@
MT/$\@%&"..)""^U6R)!R/!*GE@&SYET)=_\$VU+^DZHZ:)!Z^^V[;W_ZC:_Q
M"DQZ9+/Z=.3^NBX:Z6>7G_]A0_WIS8-RDH//_^X?WY)W=.#")?E)[]XMBMGZ
MS=^+V1MAS?CQ?W@U2KI24&'CW -\ VYAT$P\_NN+8P)>1J13]8NZY6X:W6[B
M/0:P?-U]PG9SB^[0N)*D9ZY@ 7'PGJJ':58#$3"=+G-6#6^Y:!*-3("!E067
MS478JG"' )VV(%323](4[9&6TA77&)OM>(?3G5$<(#X\6<IIX:H=AV-1N,:/
MQ>[E5CT^&NU&&XZT.5U/</YJEQ)X2CUJ8*@I3:?,/*:0&X;9U>!22 ENW)V6
MRI!]V_JZ65DOK(IV_%P]W\&"18^J1)G,S]88ENWS:4SX)[/9<BCJ.3!6@W33
MH)^J<_(W?:^.BTZ_>SO/@>C'++.@44<6B,0.MMAMT9B[(.!?R?"+6\\[@28Q
M1WD>CA%T4^ ,2J@%Q#;)U-P-(MW.0Y4/$F*NE-U8+TP787+MT6H+T&MOJ;#$
MU J7#]?Z,G O _<^(G#O:0;N9>!>!NYEX-Y'>-L_Q4&!)L*VHI-QV_3 MCQ$
MR8$T$4"GNX#T)&-0'R)7PK=G'^5$KEW<N<213K]!(WCJ[L2/H-($%&YH8Z&(
M9922:AZ:?56/A\;E:(LYSH5:PO(T"K.B<,K*=O:)=\Y54.:H"?N[HTN<[RE1
MFJ91;,.Q4=6_5Q(&R2]Q[#*NO_O"/"X7O8N0-S)\@_!$;=738R!6'XJ.GF=G
M*L&$5E+I*XO1@P9\',6DR22RSQ?>BY*@)>6\(]*>P,T3,0CJ.])6_^0>\X/2
MI(OXQW;G]I4@)0%]. 0@ IQ:FN@U:P-3)-M&L 41!YG&^YS VA01SB,.\+69
M/BZL%D>)MJL6FZ;!3V6I5(M K=UNMRUVDG;Q_N$ZR9]ZB!93RJU10W))4N66
M1?/"1_C25LL9"ZC%!$3U5(;!C?(+Q3B0"PF%;H2WX0(Z"#:$W!-A9*GLZKRR
M_(9>^\R/V#%]MUP(C@"A7 0:]ID29K0HMQ*Z:I'+.HI/Z#X=7^$84F?_Z%41
MM=Y:^:)8!L"DY)@"JKI!N6*43XAS"<#W!@24=0.P4:>LFB<,FW;OR)*58\3;
M:(=2'@,Z8.)'\EYQA;@XXLIRQ0? (SA?</'8?B>(XJ 1(\2$_BD#1QP:*X^)
MY![!QIS)XLXYRKPRO.J%4@IS'TO-M7B&V>V!1X13XGKV(AJZM[#'LBENR-UR
M*)7E?2=6$8PGL>JC:69E%)WNI0F(#G!FX0;/T122.-9QKX">*:&=9*EL-.=X
MRN1N>AE-Z@-0RLE[;(P-_YL7F@E4IJDIH-\"Q)_"2ZV"?39TKM;[P4^-^7*6
MS,D. B55U(1SAOS#]TUP/S:X:[1@LO8U!8G!A7J;L[,P9@/S2>:'IM25G;)?
MXS(2/RT87-L'PC2%7G#X0<L!)!B(4BKV#+0]/-PX\/+RCAUMJ2/TB_?"&?3?
MCR87X4KC! VBYP\ 0+2TUF-6"V-L*T>152&]62B=88W")O846XFQM+N*@3.[
M"LBA9+I$_D^GFGE<T56T]R3Z'!X%P(UUKUGDBLO_-^?1^]X)H?-2.>#Y183
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M2SH:1<CRJP&A#S*ML[ZMJ]L3>M]HVMYR=]E;%5J@C>D=%/6*V1M6Z;44Y^N
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M.\ZEP&U90#A]-=2<DV+TQX3 Z3&T7(2=D;A@JA#Z2=DM^1AGE'%PCIH6B8Y
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M?EO.-M5Z0T-?=XXWP:$)='Q=(/(RKQ?/5K?H*W/=UC#)([RQM%)(9\P$]XB
M,6PW!E\>$S;-OC;!BY5(B<6WG+Y1 K*L5A[@422P+G-9@"P>F*=*^B[V0AF*
MGNY6^M<#%O*JTL@@U5V8%%2 B53-@,)F8&1,NNMEN"Y:;\E3&)FV*.61>1RU
M0.2&VMQ0^Y$;:C_/#;6YH38WU&:=JWN0-*U.%SLBV.9L/NP]%Y1Q[_Z!S1-6
M*#R--.<N7T9SCR#CPK^\=R/J7_*Y!W<YL_Z1Z!G[TP]0G("E>RUTI=$9/S<#
MIO;T0G K-#?%O4QIER73:TJQ"=Y=TE>Z*J_:CNYY,(;"Y5&[J%((JLQ8OX]
MARW*K%YD(XQ@WK?0],B=4/])Y+Y?6YO@-Z$5Y#_L!7]:A+YI;V@(88Q]*1+-
M 6,FGBY6PIIJ-_UF\(VXUAL9>)Z$30HWX;X;Z=67_8_F3DA^Z>+_/FH<UQ!U
M,@X,46Y,EG7-/&_6IS09QUG7:VZ >\1^Q:MZOV&^LVLGM'\B#_[KKL9IU:H
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M_9G$M-^L]9'<TA+ST1C]!.@%.Y$DBULLRK!=MMV14Q5P'Y/;YV5V%H*S('4
MGE\LI&3-H5&(WPC#75YOR&[H,&F1K"@17W$9SD"XAL#%R_S>T*W?N!4W&[T2
MT(T&/*\6HFOQMZK';?X_LEO\^+/">A>^_^;5*QS%/?C(%UPAD<-.MCQZU'>2
M/)]]\>)IP2%5VW".8T5O6478Y0#3WHJOO_OAW;>O__GV6]S\TOHKL "33["*
M:-5@;^%=:HVVGT8;273WY%HVT X#Q[!I.R<HM)3@JPL5)?R$'X[SX?@5V6-
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MNZ90+4O?\5[9B8\(\!H7T]_%=HT($+164R?.L1LZ(A=VRS,TS%';KR+5CAN
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MBF1P9KG'SVGJ4"(V$E=N[U=!X($=D3\TLU?#FL8T^SSB'5^1#[3\X&OY\]_
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MOG7P0.QBX$;_1+OQ?0-RA.WC_+KN7AD.GO3I,Q"L]5$\W3B6/4!7)887X;W
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MV5=OGG&.@!*HX'PJ=[^>=XXY^^O4HF+[H)^3JXVK[J_A6D!?"^CK(X*^OEE
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MG;0:3H&[F]RS".I:NL /1=][ ([3<KQE$]L,$P7:EL=MP6";T18C(6[A@/#
M@1R-)5=<!^5SM!G/DPZ%*=I@29V_2XO@[8#PP@$<1^C9V<+VU'EE]E9 $G,X
M! ]IW;M("(;8D3%OSN?"'<#IB$[F$LMXKI%>CS#(57ZBJ%'E8A"_'$VU%H/\
M3.=FKJ<XF4DHZ!3BJ;H)S356 (7A40UQOIWVU%J&K_(PU)!B B+E+.Z]@:Z:
M:!XCZ]7$>B\#S<+X\3%[!)D"MB75V;RG"=46$M5&G+TPYF,'3R(#'NO'1VYZ
M:-)+&E/0S,ER]%^_M]9K 4TMH*F/")KZ8@%-+:"I!32U@*8^PML.((NX^9S;
ME(EQ53E658QYVF\H((0!SU&<AYC8WD?QP7F (M;0HB"S-/Y%S:]0:XBZ$;G!
M(@[>E^3KNV85N3T?&+BFE9%L#F327YN7.6="!KU:Z* $OI0E__J [<0_2NA$
MQ'I7]%)#1^R6.SI,AC'SRZQ3E3]&RA&-R$WI!P'P"O^?\4K*- ]JE *IU3&L
MM@-&3NZW8XE$YMA#"0'*OFE[C"%ZUXZ^1/V5ABFZ")0JL9(JXCK:8;?Z&1M*
M)7"6M#'OHS>PCUYA0RL%6H%8_*_0)@G$Q '0B+L.I6L%"3H<"7WG-Y@T@YX;
MAI+5$+U5](03_4,&!X+L!0$)B5:3",,*P4_^B3-!!CL:_MJ%KS &%6_CVK(I
M4)!%AOQGD\Z=>RK.2>(O"NXK/G!Z#C\:(5+I<7,_=* NAYG[*\^$,JI@&CNT
MC<):T0HMC=M_DPN?/WSW+*,F<2A8Q[@,+C41\30_+;Q@/X$*PY%5K(]#F3:\
M(@7D(@D#4:YB.^WU8&8 Q](4+,:(*6%$ T9_B/D;2P7LT,29A4E53X93%@!A
MG;7 TG#KIT&G!@]A'\#A"4X(FH#+35X> G1D[YE';()XK+T=*P7:+C76MJ7L
M)Y+60*MRCEBB",=I7@HS=_43)#/X(+R,&'HTN5NE*@+6R#\S>1AJ;^0&9U,&
M#[0VDD/%'&Q(S@/[1]<)#DR PVA0S'Q%CRCP7;!PVZ$S+)CF&Q%<>9J4)!,:
M _HR@BYDC]LK[?U+/9$-]B;(MKF;U+ V8==FDP;>@U2;R3\*UTMHK3#ENGE=
MA<L+B"6[B4\3LIT(6(W54LHD>>HHB6BNTOFO=-NSO9U%E&/2"A$DB&M*TDI&
M2$TV.S+=F]249 >!@X!TE.LQU-(/!JL#/2 =L,0@G)_BA>I'J,SA]&>M4E3Y
M4&_V,:1#T.3TXNC\LFE=JG[GBW3D0W>RE;]S0M OH<2;+P/B@<'5/PJ@3B#T
M31GIH:-TK.@O%$KDEA3HMKP$B04(3Z%839#D T>#BP0K3[,Z=!^>?G;Q].^-
M-M$=UR;ZU+2\4+BWI1H*%#2 XP]^QU<!OLS54!/S2$R=%:M=@W\"J!W_N$./
MAE7A=-9#2(T_?$T9I:.ZU[/*>P! A>=7<4_J+/XD1,+#6W8A>A;RJ$Q2-G!'
MB:U])P )!8? //:H6DB>B]^+IZ9]R[ZAI2F=$?\<%9)IALDDC.W +$VGNE5I
M!9_9W*:?)4-WO5:V:1E%X).;-2SO*KA(#TJ/+F**=]!.3 A(CSD2M$]P1+EW
ME$_$Y11(6PT73XX4Y%8 U(R/GR8:H^'?N9MR.;@P\%(1[<%/%OAX;E7O!'JI
MA-59Q& %N"GBC3,V7&$]"G)']:G%,_F=>"8((9BQ."?AXT4$ #+&\J%@6UI3
M5S[ZXV4L !?? VN;%+^Q^E\!VF%H[] ")=!U^.LG[)1;7)3/N^]?TK'/BT$L
M\8IP&9WVMT"F[J8IF1!4UG+*<LC9R132DG*'WJ;3SG@W/4+E"-DF33),RH<D
M@--L@Y8Q$%BO-0*_A'[,QJUTMXTXZ!MB#UWD?Q%(+G+ 6/<T\<"FF+A%HX"S
M,O/<P])"ARQ)+*K199_HA'G?C8B#Q=?INGMU&')2'5]=Z.;GW]II#WR#ID^D
M.6J!9^*S\/\ O1731%^O_GOPF]#[^,2IA)2P_,FDTQE'Q1[21+><N"IP[%"+
M';+;UGW;5)7V#85M="$(R*@)15M&2E>135!!8NR5!9K&D@BX1SKAS[IWW1*0
M[J(49$'9.HOCIJF@K"?R?DI7>A>"CXGDZFQ4@ KW9K_%/>ISAN=>K=7E-+.M
MX;;P#6]=>:=9(",5E(=%14$6GU+E+ P;S@Y_:$@&_-\1,RROL!FG;I+S )+C
MXBHVZFQ!$AT+&[CNK* 2Y+'Y+UA:@69D5M@*?6\S&P#[4R51/=EBFY/^*Q%F
M4-4(E(9AOPG3JW1!2WY"K9 5GYU\5'5. >#:FHB-]O.]W4\+&G%!(WY$-.)?
M%S3B@D9<T(@+&O$CO&WMW01BW1R1.YV[Y"1G[/TD+@<X#%;/C+MDM$36Z%^P
M,XW2IZ1-3IUGVW,H)%3GR?+U9!3C/?NFA0.K.BN-^RH6F8KUI(K&F<Y)PAT
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M"+55J&QTAU5S; ('EA:W@XIMT$3FG%]"1S>AK[3LB65/?'K?Z$Y+DX,#P"%
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M/R(1FO5#C&?E!QC)C&?<8F=%O8%1K<W92YM(T@F@L(!\0;$::G2X4-Z>":+
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M,O5;?25ZFEXHY6#06H#[:OQ:JH*@-6>ER8ES6/+?T4MOMMGM0.I;3L<93%X
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M;S#7(3VM #;9(;W(Q3X,VR?0IM"))!VX,Z5X4+1W @WQUF$]0!@' 3S7WT/
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M>-L?)0;U0_9'.WMJY,*/'=AK]A5NR8>FKLQ\&C0.=2R3$D14SG&0X</*XZJ
M@C=GG2 *N!^UP8_G_R\^]Z>0N)KCQ1/N.'VW8[*N-,,D.0!X+\]?O"3FL%JQ
M&I#]%1%SX>/9EY6[4,DW-*("7&2O'LAXKA02X@K]*+O?0%_64_H6-C,R23U_
M]NKJ#69GH%+P^!LEBO2[F0H]$6%5@5.#J6XI $!*N:6HGJ*3IMWEM:#<RIJ:
M>259C/<#73"_0EWT/'EO]T?GIQ=*'R6C>(6!]!VFWD\0\.Q79^%6I85/U//
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M%>,-'"JRYE!F0J"T4,]S G$Q*@NJ7#&6)]N@)61W:(K%&1VCE7>)@@^4H,J
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MX^.P$S%4%+@:3JW@F>F,-WF]SC\MM-B"'@;4:E&*-&!7;QN(/![.#&EJZ-O
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M^%I\+S@5+UQUTYX;Q/BU-VH3IH\IO9X-EM'F[$NE9/.W^K>K)[[-+V"JUF:
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M_='!=IP..K/MH0=LC</D^:.1"F&><8%2NH9CKQT5>,SM#_&A80LL'T[X"TH
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M>PS.J.RV5;EU9] :W#5^3[%L,NJ$[B9YIUN4[/X\:='' N&8)X/M.)MU1&2
M?LT[EQB>X;&$PK=W*MX<2:.? LIFD2T<XL.;6.&>2T?.Y\S&Y<=8=8R>T"9'
M S^R3N&7]%S3G!D#L4S"31)F6FXK07!$P*N@E!PU;U9?/'U\S^_,U8,OO_WJ
MKP_OW_\;JL]RDS.U2--")_R9B]<_O^@RYF;N]"@3$TZV-A G\], *@$9[!F,
MM-_@N)P:6Z$BT",;A]HQ6O3<"C8@6]?H"=ZA#X!(E29F&!G8TE7>;/.=59;@
M2&:4<"24_.HH%YN3CS*?#V8Y&20(7>UWFH->9@(6\X9%U4V3?#3\@K *I"%!
M,XJ7;3/L^7=D,QKV#LA:&6]. 1]XGMU078+B'N57*FB3YT/_2Z<$4[FZ"=MR
MZIY$V<LAD2TUO+E!(#.!;MM"E\"X%<P\7U/3$--(G$?*7!7U(DZ)ED7-3RO*
MGBZNZ9-8^NGT/"5Y^4#7"\EM;]4WPH2MU9JC=0@U(;<NVQ JQ-T$(?DM>53P
MEE@ #6 0*@$86KU@%?&,@,WPF>7/U/92CY=W3_,G7I8X;,=&D@G+987,BAT%
MK9=@7K'VJ/^&?">R1T6;WU"X%0C_I^M#IX%=7;LR#!P>'UH?#%GF'%_V^>J)
MKJ1M7E;47!&HU[.W%EZ/LRS7CK8+018(K2"=FC%2T]&+0C:J6FOVS%R_A>EF
M&K=>X%I<S$[(JA?8PSL7H[DQ1V-AY@),5@7'3JV69[6CQ2R,D[O@I%.AU5;!
MQNK=K4WC+,JHUT9::L*'\!C';G*JIV?<RZ/M<23JX"-L>JL%77"'W>CG1^4O
M&?Y.X'F.PL?]=/[/93OIM)K3;[>X='R%SM99'327!3$.=?\R)(+:@EI6RU0F
MK?,;*2=1G:B7AL#:NUCX._DY#3\#-7!EB4R:2JJIV /^V4ZZ6EIW]1ZR:'*@
MS-;"0VJ15"_R=)NZT\$T.P&4RI#CU;B]08#("I")KIEI@$O5THY[0G ,CRN]
MT9=M2"6Y2W)60N,!',Y:L+3''2ZD+6>1V>0.4#C&*BZ,TD[P$6R5"#4=_8T9
M2:9_.6XFD:2@7U(R0+;=TG^9)=?&FFC2!1)EF)+C_/+(7;L@(J)I\NK T4[9
M%F?4$G,(M*U_;9+5 ZW)BB >G010%,D.LIIHA%7CX97;<%_SG-<AATZGP=*N
M!"2<D1Y_A#H<77<F5K$K):B_]0:#$!7@IAIST.Q[%X&YI1'C<SU93BY.*^\T
MMT+M4LO7S=#'U9%V]&NJ'-VU" Z9FIDODW[6_XL<G!)*6.JN$_2E[N<6\.%\
M=>1T-*(F_ICB!K-,VR(A>+5K"OA/)("DGV"$*8S=-;PX6"%"PG0EI[,18E 0
M@Z8WRD?)MY%*^<W[^KW WOC(\=%02VUV+0&W-A+B\RT<)RS([$9HZ/2XL%$S
M!;\4VMH><1]V?;X[;,'F+-B<#XC-^7;!YBS8G 6;\Y&Q.7]: IS7W*&Z$4G.
MDPT=R H'^35V/?K\C6/L S=)DS90S,3/07DT+:4Z0NP1E%U0:@/$I1*8.<6J
MK$41 >C>O>&JZ+!':Z*1^I(&Q'%;.K5D!0DY%5A&(T-_JD]7!43/5X]C!GC&
MG5&A067$XVZYF*+@WMO,YI$#),8_<%#+M26,7,!2%B_/5:YC'4"HDH38)TI_
M/_OE288.86F2555T XS@EK50M@3-48L22BS?I\Q UI5KW;^C\YNVXT5Y51IQ
MU1$_$K?!,S7SC':EUDGQ/;VM!:NP#.(6!9!&U%,0X"?8#W:#&2K#/BNJ0H@X
MJ<>A-HGM!&S ('S1A(U39(+8;&7[%WD,I0AUU)L/G=0F=QI*^9E6 SB(1SHE
MFPUIN-VQ/LR)W"%E@;(CF8'/UJ%>!.X6)KX/JA26@([>8H-@(\H.>DPAXRS)
M8Y1=E)@C*>J.SKF%"G59Z1]]I4OJ&JJY6K$KW,Z?"3UJ:JJ*X1=NM\W#>:T;
MA/LT1ZE0=/[E6Z=,&IH"94 !0>1$T;BP^56P[6C;FD!B_:^+,K^LFP[)V"X*
MWI#T,L.)#RDK@) V[9N]NC_+OEKVU2<Y00QQQ1P_8D*349'C#]X(.B-HN8.-
M6'$]FQ@!V8K>;<\GZYDNVV'9#I_?,</GR"3B"56UI/+':W[M:K>ETZ09>D S
MF/B-49G44K)8_F6IW\78@6*#*3P0.0= '6PA7!(&,PQ(R^)?%O\G6?Q8J,)F
M"BX1OV1O3UUNZM4FM48@9R'OFA;@_6L_^NDB,UDT\^<V(B!G4V&SS(F4#JTZ
M!TJF91\M^^A.'"*:^57F7;K&+  %K6.NZ_GG8F@%1(D&GJUBQR2;'& HRJBT
MLY3 >,!M@A0S",E61,AC_Y(0"1$2A.DW$T!7Q'* /:\D*1;ZP[(!EPWX"3;@
MM%*7UM5L(NQ=-JIIUR'VL4"F1:UA=0UX+E$.3?0E<+ >K3@M8BU'4.,\295_
M9&?X:"EEV3'/82BY9@R(RU?=+J<&)V^,*&=_20['ABSG=@ GL*H8!V#U7'V1
MRH,)7KH06F\TK!UFOA1;\^C"0^W'A2#+VNI A>I9&17-,W%%4_D;:>G0D2!4
ME2=<H(BS/@KE9@..XF.Z>DEK)>G:R6S:J]D3LC!TPP45%\-&<",0<*K:#ETG
M[:)<.@E^HGB-S ,G[<JAS"+<\UA\VJ3YQOGW$\48V:6AOT^_HYZFT2GA("S0
M3<>0"\U?\A3BB'9S8SGME?T9Q!,/O46-=_9WQ7L272YH9(6_PCDAJ@7(:$RN
M+]VIG (/2T) ")Q.)\+?KJ?GH0$'=KJMI:V^;1*Y;8M:]?\76[ST& O<M!O"
MH+K^QDF391#F9K*%F&E77F=^!//[+]SYY7FFJ7SBM*>#.[@:\KUM"QC&P5 &
MWPO-': ((91LR6*#@)_FUW[LD$ZBF<KL#A)(@K>ZU *4=!:O#QA1:C=%8A5%
MB;H8Z*F7MO6CDBW,X%GGL$#'XS?J12'.=!>;S*^H#3Q 6$Z2OZXN0"4/"Y*-
M&[VTK^)(#] )"Z<J,(GIHIXPYKM(]BR]*[>457P!PL70&DDL/3JYJ8%9F4E9
M9'NX7(FBFK#(8$#0&,)T[A@\ Q,)1 WD!@$!=VWM#BWG,]F]%:&?7EQ1E^67
M<P%U@A&?C)$&NO$3DTK9^=&K]X<]_4B#QN"FU=50%_YXPHV55$)Z56PW,K>>
M8A,3Y(O17M*N1$<H6H 2#828*=8\,9,EA=,VI(1?.NG\HR'[F7O[W9A:X)!H
MBIP0#[LLK\6^ 5A.@+(*UI,NSU-J5-,0NS []*I%+Z72../H_R#TSIF0K*>G
MURAOZ"]:?\9:60L,?H'!?[BE]NW]!0:_P. 7&/P"@_\X"R RGEN_D+R2GAU"
M[QPBLFXMC(E2KYTZ.4F#KC 6@27]+2[VV/UK300WZ6L'HUML14XQP=K_S=D#
M!BR/H>B)+FDCS'=X#^^Q@Y;)CU5U.$XK8J7JK,3+N/(#@( X5@%ZG\7V 3R)
M9%"R]+%,X4A[ CY?/^C/'EHF#(-*ST,$(LX2V1BRA!/I5*UWO(4D@*H9[H:2
M?RW3$:F?'S&(PC]TPV KO[RSZ&:;HLH>6I,WS.%3*Q<4I1='\46';I6HXT47
MNVQSR_K$L@J7Z.400D2FIH(A(.28-QK5@6F=8A/):/]GVJ@0QF(F $2,D#,G
MA22?&L?DHLH9QHE2YJR@ Z?<60J!AODPN!%$DU,Q,SK/7H4;31[&FPVC1.QG
MX[*A6W9^I*A+7QL=#(,+$HWTZ7=4A5XR.A-^H%GA[IB7L4TZO"NULCC:E7^T
M?K<< "S??1NFG^Z#4?TL@M&?G/KH*>=CM$@@UJUB'Z)I]V2ID7"[78(GD-*-
MZ*ED3=L+1C-K12\7YJB[:_>BU.]SGN<G-,]07K;Y-#Z;=2F8906-&:P-(YVX
M"NP7$--T0+#:9""W3M;JYJ"LP3+3^>Q'](2>9F91^X/S @?EX?W[F1_ (_)%
M:*28OX9^45V@6?#3C;!ILH13W4B3(#8,UP-D4+1,1BZ*$8537J)=#G+:6*0)
MM"CI(,X]0A" WU!\I2@R8L::)ZH2=X1\FM$-$/MP/6U^MYMYUO@%OE_@X=[E
M!>6HP8,E_;%,BPBEYF='YF#>/H$G'#S^*T;+$,=K"<YD8-$HV89\,[--=D9R
M5G'\O$B5?+YO;O*VZ,8E8:$J[?/?.*BD(K:PYPV=:\^VE#/.2V+V]JZ8);KF
MZW>GATA%/+D%)Q8B\6F5!H@!J5QK$(E"*O56J%<RX3]U9D>U:MVBD[$+WNJ&
M&-P/W*NK+[<2@D-1&.:G&5I=^3-B<2.E\EB(OP..PY_4C#_;FL &NYT$ ([M
M->H)#S)VT@[="5]RZ[?VN)['D8K?E>5FL'+O&ND,;*Y-RQK]A:$1)3\*=NUD
MM^B%B >!]S^.#'EN_:OQ-11PL7-Y'<F0T[*/#7I19K6\;[;0GS,X-H(\N)]O
M%T455U_0C=! 'H<WP"OP41_RUJ1D7:F(14[9]'8@F!_UDSN4A;M[,2RD;XV&
MJD.@CQH@I730<.^-L<;AF[+=##MJX]\8 YC3EKX1G8T(>Q_ CM!*8&!'F4MA
M9DU8)7(.:6@@O=4MS-B2L(-KU8X=^SK-,8T^/9(<@"6<3 )G#)(XDP,O(#0,
M7DL$@D4A<GPG5:I#M=V-BJNFK7C.=8A+,=AA8E37M4A5[J2T'BB13U(>AETC
MCYFL45V2&Q@&.K%U44I_3A WM,+0*!&_Z[K"Z]'^D[-_O+KLH@NK&N XH[!L
M/F\8-^ST,N/&B#S:OB:.S)G!D#B9!4LULC! 6+L& &V=9*IX8>;&:.F&KGO;
M*=7-[X$&O)+Q>I_O&;94@)<*\ >L #]8*L!+!7BI "\5X(\&D81#$UC(6*0D
M- 4<SU(^>?7#EV<DI_$Z^,P!7P:_S^WV5^7ET*VN2?^D+4FVQW_PY^'5/T]]
MC_Z^^OD'9<Z*>.G93Y=%V5!M%HF8;97O=AP>[P[\:S\L7SQ[]C/7EPY8F!V#
M<KM#U[N=_YZ/Y5U+J%Y@^0(/]JEW5^0<^XDGJ@@$>)OTC9_.X7"D@0)Z2X1P
M)[Q;?Q%M>=*KV5J@%5Z*$$5)B^6L)H2*@S_P!Z817^==V:4!(]S\+H0GG>C,
ML\/XMG24NIC.Y*2Q X]DP62L0F43-\%T)-1?R8NNUFV3%YI:M#%)B!WLIY4Z
MC6Y#>3^CQL=R*"H"Z$QTI2FU;=,F<T4ABBG=%,[0#\^YU!)EG8RHK$3)+:*I
M$PG;/]@G3ZO!:0O$K;8-;Y=3I0W0RTO0-DE&="-A/YM24*QVZQP+T;NY;'E(
M[=DF*#1V2(,43( $>F_JYL:_<(9\,@;SBK4HPTV-:)]][6,73_GT58*4-F.
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M[R"[TD!N!H]#ZZOL&(B%&O'<T]DL8TX@SN.QIR;MP\H].EZ<<DH43(C12(X
MX:2 )W6+U(B&N1'5N572FC2%K^D6?QI,7E3AI:_<ON>_?,E_^6;*Q"/#0+HD
M[Y0^Z,Y7CQOR%CLN@5PWS%P?YXYFEM5(:?UDTD9X679<814&'5!=-)3 AN(C
M56Q7FB3V_]1[<%V*%H?P,?%'*0]-2>^:\RG^=DBH#'7%E%"'T/F(6T%_-@?C
M$>17:V2%Z5#W$5Q^X\=MW7'OI7QQM!(YQS%)?3!FNX]K!6-&KS6= 5E7*@.#
M+CL_ Y7(.MU<.60RR][$DK\KTY31M:Q(..=AI)WL'?.<2_?,"0OK%T7>^678
M>L.6[-<8*$40H.S?F).N7%YPTP-=Q:72V4VB "PS93EM!$>=B>,:>PQ;K WF
M6'GCI_ZJ:80&"SQW0XMC>-JY")1V?=#M-J? 3&M*"U]3K:VE>><..PO/0FJ]
M[,8QSRA7GZ\ZQR+/$(C=NK/^"F14"*\B6E99Q:3,:BJYJ""'Q@7TY!<X5X9Z
MYWHM^DM!F9^!^,QBT3A<5@_;M'$-T./YG2DF, +0HR=ZOOH^?@?H R4-Y MP
M]EW(6K5XFQ ;JL*W?TPG)7G>M\J$&'J8;C6"PG,D8T.]'9/AB>KN0=G]Q(N/
MX##E#CZ4O^65RRM!?^^&#0Y.(G+KB5R6CN>DH+][\?_-HF3BY9!;"GB!PKN'
M!_^:UZ%G:2 X"T&0P3$PO0/@-00Y6#?%X2PP=NT._M6N_"#E9$R]\[?@;Q?\
M[9\1?_MPP=\N^-L%?_N1\;=_CJS1&-*:)=Y/X9B4^?&3!]_&@UD)%Y&^V'%[
MD@:IX@L<IJ?\JY^>9JN??@E^8JBN=L.:5&^YVSDIO&9'8+S)=:>@66#+Y+G\
MZFHV)0"734L)KN+0;8=Z$US6V3O0*MUWZL @P^%],GIWHI&!F_/SJX#-S:NN
M,>[H"8\L@'09/WL<?"BLE*%='"!-T-<DG8L(T;AY&3XSLF9X?T/<([2]$@G2
M QX+^<Z)67D*R/).>5EQ*BHPL-(T" 23ICIYYQC6TNC\9_ +?\M#,\Y%#"'O
M%P"),N"JH= @D5PD(;92=AX9Z! ="[(U)'OX24Q_F[)4SRE)V^YI"X,"LM?J
M(6M&QU^/;DJ4*MQ-/OMT&:7!##F3@J#SN2[91/TQ2>M@ML=-L<1B[E<X,: =
M7S$ 3ZKVLCYKV0N$>D0@?ILH8[2FW\(28GAR9A,A(<]Q.ATBN[:;35SDG:AK
MLQ%#:WLM6M$T!G%Y94*3+6+/\DBGUA1BGL*9X?7O'=:1;7\^@0PFNU6T^<VQ
MN_FE4?:Z- SD._F,A:4(?3KOD\ATG"H=I*-,.=O;/")R1/./F7,BE3*R2S;Q
MW;.)(ZCZ?FB[P86$0G&*\Z\+N=TI'K8/>\U:WGC9-.V8R6+# G_K%Y++4QLN
M6@S^D,SFDDZ\PUZD7<MI6X_RCM>&=85Y.3?>B73M3&(-I 1O.U3\EUK<$<WV
M0KT3M6-"%30N8[%YWN8K#4(T:]ZGH.!7K]DSS7EV2SKTS+Q,D5"]C?P=G(3^
M'90N"_Y)H1CE4TR+</3L]M2R%UYIP:R;M9@(#]@VH/S6T^FO\/+GB]?9Q-<Y
M32([DYVER\R2J87H9[[O+T[MZJ+FJ\#A"VQ7%(').E4!%O]/-X ,M^QPDM1^
MSIQ3E3)IE[H:_'#RUQ&)\6?CWT4T;%W* P<O?Y!X2)SI<&]>Y]J(]X.KG7VN
M"/ 6"E^<&+NF\(XX\9,@D,0&B*<(<0R1H\N?4G=]*Q\FSP\/S77I #\? W+G
M)UOFF'UZC*OB'VPA)$W\NX#G&O/WANQ_S/S3-8.Z3]ZZU831+.,7.V2@7&Q)
MA*!!?.;>4FN9ZZCSZP.2&8PGL!B%UA2R<UE#8HV34&(<D]''Y\R9&L<O'MSS
M*Z#UHT9CTXBLZ@[E:EITQ;XI:P9Y,,/9@2N3L/HBOP2_]8R^%OU3D1ZF*W[Q
M\!Z%X"7\ZV%/_C?YM&E#<+X2AAVB28T:5'Y7T4Y\%(2,MY.F/0[8E9_5Y2TT
M./S3Y!L.=Y%7$(4@T5#"PH]%K+</ 'UWC7[5PBIMS@TMS>')U2H0F@@*F9T@
MI&.03OFWXUY-$-R&OPL1-8MM<(-BM:5S19 0YJ_F(!SI@H;I<A0&^?G)5F/=
MW"P0Y8EN42D,>B(DZLW?ADM%?HE4/B)M?40:+Z>GLR.MT[;QET:]JK\"<UU;
M=-\Q9H+%4.6QH$2&;;$M6^FWQIKI7-]]QU3>=BQV_KK^0U($@S"9)I6P1_VX
M<G(IFKI#1'W0NC*3I\[/Q-C+5NIB1@8C,/%)6/_15A)''O04!E :IF'3\TE,
M3P7(ZU(9.R:IC3FJV4<]\8"G.$!MV#CJ(I*OL)!63W/4CRB&A&<KRHH=CUE)
MA44;82>NT.21DY[PO$U(E5-JWO>?MV.9C9DPB(+D"@W<N/@57&3YW$Q0=,O\
M!9CBPW,>65BP=FL70GJ+5_F(J88+R3.0 Y"-<G&*F;+!+\8DO&I<[2+XI,)&
M\(R-W-P)Q:KC1/F?+[73DDNYS9 ]*;MVV N((B0[V33]^NK%Z^?\SU=/'S,%
M-K;S)9$)U.S+B6!#TI!(R]I\IKL:^J*YJ>U95IC[,F4>E4#D8A*#&L'&3'K7
MKTK->Y<)%_=5V3K)2&(1D^(BN<7>2;PJ]^;1_16];U53N68/WNX>3F#PU1%4
MN/:ZI(,6+[)V\"!Y8Z(8,A+29+%4F*F#:J;J>]Z42+3RC?QA9UZ2KR[\^G2+
MFGCVJ]BMK\66CBD!E$TO#(K:_/ %ULRH F$C#UGM+N$;A6;_E'E@"8!3(/A(
MS%)\V0E!JTN7C50/0J_)FK34KG-_JHE4*L0DTZ@N;I#U4-#YCJ*:,.E6M-XH
MJ#R]QL-RYD?;@,425:'\H!DAHMA=;9W?HY^MK5Y@0 L,Z /"@+Y<8$ +#&B!
M 2TPH \PVT3'U><B=2:4340CG3J?_A];H"2 UCAHZK#DFKL2(2--%*_!_&$^
MG"PD=Y87U)H+<+B"<"2A0GDS1U%HWKT1/F\D2(5!A5Q.42@+[6$6*)!%UJC
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MIT'&II_KT^!WT'C%C*T0.?M+EGM,&)'H4?-]TZJUEM1,[.LQ+<U!(11."L=
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MTVN@QCOSAZI9^XL\\L'J%?DUN,#3T"]C:V:KGYO"53A1?OCI^:.G6=H_QMF
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MR0S#(A)SZ/<)KM9R#5SXW77V3[D)&+ &D8ZUG_H>1N<Q&YT+FK%(5DI[WEL
MR3,$9*6W&E&G-6];PGVR#\!O;VVO@ECYHF!8"/@%<$]EH0_ ?[>@UK)R3<\Y
MH4A4_B.SSL:#+0Y+H,CR7[HJUZ2IY0>K(*POT2$2::C2$Y" +(',F0LJ64V3
M9;()[6M9.$UH/@CF>6UYIB*SG!D;D&0!)D'@FQ0.)7.1R4$AI6-T\>$]V3E3
MAK'9 P PUL"-(&0:+#<U<X88<(@WW0R*2K]D/OW!*:>>XTD,^=]/.KF/H[;M
M2P-T_CTR$I^#J5S.C1']J]^$>U[WCE;8)@A9N)QHH;?&D6!<=T"YLZ:?;B02
M35-B/DV/*AF=JZ_+MJGURI, (ULY@&IY+U #J'<G%(E5D0DE6MH]FC;78!-Q
M&U<H?#UQKKZ?^'[VM=9-0<8/*5ZZ!KJ](MJ>H8W=IO66KY:-W;M6B;/6KK^A
MO'#"?*D&->I CKU;MK_40U%)*T\"@%?I9H;_$R0=K7SXR4^5/_@BJJQS?5^)
MP9<QGF$+.U\])<0:&:U9>YBHC)MA'7FNB3=@NEKH.&V\,69;91]_I("8:!U2
M\]#:L<2)\GX"NCL6/($>A+]&+^UP>7V(#2:]*+X+([DY&A<K\SE;&:(I@LA&
MDRX^WF7&Q$1V34)D)2TVH2N3EH!*S(>5R+CF].N\<:'O(L!W*:MLRG8S[)@K
M#]%?>#K0-ID]<>QA:)G&!,W&G_[>A]BTZ#VMA)\Z]NN3(ZF1EO=\\EU^B?O2
MRH4G=-FTO#FSQ)?8>8>C:P2&&EY5NJET%Z3M $1#,+&!Q+GIQO8);GH60DT0
M._&3!4_5&W!OZRO5#8"#-Q B6;QUBA$B:6]B,!)V4-4@:M95L!5PA BV"F//
MF+RUVQ#YOCE6R 9H+PD9XTNX7#G)VZ222O%7:'SJFHH<PZIR>C__N'Z9GFVB
M7R,4 [KVN" FE%M48N-0.G;?AGC:"9%W%W25*VIRVJ*1+Y-8F^5"\[$WG<#E
M>[2Y#8GTC:QD*EO6G<R%&,0H1'O*(H8)T1,TF$A"KL,KYP%I@\?./]?B;8MX
M5-'F-\R)*Y$?.^F&$77:0BI=6+$3K(9*C;! W^2_3T=\J2(N5<2[6D7\=JDB
M+E7$I8KXD:N(?UKVBD<J5RXN@#<+_D,C9UO=O-I'A\U-;2@!H#X"KY>Z)O?1
M8S/^<)=OB<^_74/^3ZFQ,FF&"]XJP$O05!*',<:D@2\_TW)($J9RLZNI#>E5
M;JZ\JZ-@J*YO*$&@S\C1K7>=)%6VD2Y*ZU2&[D<AA;"B*LV64Z7L$7Z26HU@
MS<P#C[,$-J>1Q_P -8DEE+FAND,94-;F4$R;?[@";QNF@YI^%43F^JMRXV^T
M'GJ93^C#X4 Q4SOB#@:701BFU8XRO'Q-RP[@UVUTPK.P""FIDW/B@P:AS]\X
MU<N2A](DO@^QC.RAWL(HJ@4Q4\1F#1KED-\75@)ZG*'6#CX?8KV!TUOY]V+W
ME^O6=&-\2RK>,;5!L5F:^8AQR";\@B9TH,Y=TJ+8!8:)W,:;:WG&-"@)*] $
MM)S?>BIMBM"--+J5PY'<-Q=.;Y?PX>)1?8W0R58)A</IV<S&3L9DG$4T"2!]
M#DX;SSQT*+2$B;0/K9G$)L 8V4*Q,D<L0Q"^(.>]Q+D[OV:4T%C?>EP!G@,^
M'*W<4L8"LQ.V'>LJ]B4]31&HF@>I"0M^G-XG1HO@9$*XB*"8$)?5-:\\?Y Z
MB96IF$Z'&HBR0* MM]Q$.L-4N# V9=NA'8OKI50F[YFZ2',6.V]!T60M&8U;
MIRJBTFWHM(X%$LUCW#9M04MA/_3:NT]Q-STHWN6*P]9M*:4R644NQUDJ\@23
M?$62\A$#^X?D+!3/\_NS%KS,DD3-3%Z&\VR6]VF6.<7T[O#7W52O">OR#]=L
M^C@9V#_*]_N,H#JW&HV7..)>"CNHG]TG)/#]PE0S7TDU\_>CGMXEG/J,QO$]
M<2@82%(3DDILJ25CIG\+";8HR(=MG9:5_2F4J<0[RN'8TJTWHF=KT8SP)WJW
MY9*1UHV30O$"W[F[L=J_V$<P)P@M&N_! 1$:]VA!:TW]TJ9.3J??;WO?EH=[
MC\G]' 97PHO.I8<YQU@XN1'VX8!UOW$%8W7IP^'IR<=4/.9L).(.>"K_]K:S
M*R21GD@294(+J 8BX\WN@U;J"6(4C(\[T$6DFSR++FDT"LG.QTJ(XG>Q9!3*
MPD\''R Y/_Q/A3EY==&Z/) I/GUZ8=W"<&$!K-#ULQ':"E_[=?4#@+Z5GB!A
M,;X,UBW>Q'_ZR8N7;,X"Q5/V_B_UZS]GGLG_\NW/%*),_^GQIXAL\N']!W\/
MSTU7#,_=-Y>LF*)^5WPM^3C]P'!K^A<](2&>SB@&$R:AB+%@"I>.   .W6')
MHFQJ RA@P70>JG20[,PEW^>\')?H?7C =-U<3EKG7=DE')1*%Z93,;H%GUL@
MWSIR!P'TF:GL"(Z'LPYS^04'2IU=5?<R(>D*';5"<HZQ8TX.9GVJ.Q=Y0NUB
M\+=& @CW'RV>BAD^HO:YA5XAD1*O$Y>:&E9]%9N8"A!Z,([E6[^D_+<Z$3;J
MG9 /!308M^#56TZ,Y-JD.1K=^( ^,D3XIO$8GH72=9LKCFAHF.Q#ZK*58(\"
MQJZ+))17_BQ'2B-Y(5K(++RD\)V ^_?34?NH_3*_9'?$0*_Y J&; %.D!%98
MQH+W8P9 J:W/NBIX>!3_A:_=6]>>R*S5&OWUUW^.X]21?B@R0$25Z5]T/!8V
MT1!%I2I27(K1:UK3#:E.WLO&%D;V2#+]]+%A3U?]?__OOW_YS5??/;R_V@FK
MZ!>49O_RNP=_._\Z_(XSBF)"[M&.^^HOK*H-?-PELQ5J$Z:@@_Q/+5Q'/^]^
MSXV'F]83<H>AR:-5A)24JXDFD<8D8"1D&79D9VB--)M27ILXX)KB4HX\8F#H
M-.FT)YQM!^2$A>YTSKWQ1UQ1(I-)IJ H=4:$1<?F7#'.BB3@2#'DON:'G]4+
M) #/HCD0D&$WJ5,GOC&O+5EUW3LO.S:TFJ11J8-HF,))&C44\.;^FQ;KU)D]
M+3A,52A7S*19L&0]4HO0B )Z?-:3^\$LD5T>,6P:G>_I-228IX>M2@WMT>9;
MY;-/$1J-]=AA4RWB;,&:3,_@>%S&]'5"F3  )N.7&ZEHQ$S+SA%@L.QV-J$Y
MD^N8;%(_W%:*?'VPL!DC"O'XR+7H'4*'-JPCX=(H65,+[)L'(/#()0.,)BJR
MU4V"L6O"84DI8ZXS /4\F^?,)&7>[4N4 !J6R:;LKHHED[@KVW*=F&EI@(T4
M&\>0IHOB(IED,4=Y,4F,U[(<,3;TF&&QQR-P81ZT6#9:I=SS=O*H4S,C1LY;
MFNA<4JZ1#8/U)[[8CH.&6<.C'?_>"M0%,08\-GG0QQ75_+B:]NKQX\YZO<\2
M7E/XP*_U\2\T"_G7"Q(0*H8=+D'?>O+ZXMYJ1S(S:Y=LN9FJ15P\;!['I[24
MU!)3'\PVZ3AZ.]%V0UX'NX*7^")FA$/:U-1_PB3$P;RWJAT;GK7[G&+1!6^T
MX(T^TE)[</_^ CA: $<+X.B.TA9\WFX0)QV8LCY'Q?UL[2TW^<><:))D VC^
M\PT<<F[F03*J=9?^UK8F+PF^@B 5HK7"7CP3AL<^4I.U,5_W<<.U\P$X?!%3
MNZ_<-51#4$9/&_4DZ&W1>10<#G4FH$F1!F@Q0/'C+Q$>#0)R!=5A19[_=5X)
M.)OBO< GEP9^C)OPCHI_-!>YI,A'E'_:=++AM(<_Q;++G"Z ;$#(0P9W[AEG
MABY"9NA\E8@9/?V5/30;3Z;H(%3)X:1NH-Y1=AK7\_?/0,">%!&_5VKU\#SF
M-UQXQNF)%Z:XA5 BM'Z@//B Z>^_I+#6OUCXJO91=9&_RPSF--0WTZ?=6N:-
M)U$TBQL&-4&='(AIFYGY51XK/$P>%;J9V%(7!V+UX--JACJY)=K&\K8E 8F&
MX^(H>!ARR:U#QQCSD-7:ZJP+R PNIS>N.>=T^M:<,XC?#-"X@(<KH!G :@,D
M3</IOTB;ST"R,2%B" NDT&*B&N[H:DF*?NA/K%!)0PJ6BQ/;DH$NQ@F>*.3$
M&3**HA&(=PVCC#0(M] 8CJPE+=;U62!UBTT\/F:GL$&RVSO"GP$"XXW5)N2%
M@JB1MTZ%[$V)[OSXIZN1\B1]TTK[O%F;DBKAOFSN;8\-@ZJT-?0E&%)TUZ6I
M=LE=)3<<*?=PM83M)3T#+5N;8CJ8D0PUC6.!)RU&T1O,HT7P/G_CQ_B_(47U
MSS01%@)=LVEG;BIO>*$6YXE<'^,DR1#JRLY.I?D:;^5Q=D3U!IJ86"4*JIYQ
M:?&.2#-Y5X"0UMNRW:$EE*HPLT:FBRTWM/6:<$NYT=8'U:MMU=SX)[H#V)@_
M:4;GB23@'K7NM[+/PC+V&Y3F<EISO\2M9(Y18B ,506JB?/5C\T-)?,SOZ)*
MENPB7D>3T)-$(DP<9?:0+*?VKDO(S)2U^C6<( D@QEC&'/5I!\]@E&E9Y5UR
M!L:7(K2?XXV2H-X"LCLT>?>'F6*VEE"_^+7CHN8%<(WWI)#Z\&NJB\ ]\I_T
MOQ-WZ%Y&XG4KEDDFX*\>H46)XY;\* @OXQ:AP6U^ I!&"BI5+"-S-&<6(,_!
M;JGH&MLM<2S\TXH>B-/R'EEDE%#%D1L_#+[K)_56[F"LH7>2O./S$6>[ZNGY
MKWC3V6M;+&9MUA'KRM]89C0+1!]F/+Y\X$_JJQ)Y2AP"M;O!')/&".7.J88#
MP@N].$%S_7[QES.S+\O<UDJO_!P>R>WQZ>L8/RPFF.XS[+CHY!V,%H+<;':U
ML=\'<\RC42LJTU]_EF1$?#B2'XI]^9)[_/4X+XD!.+H(GP[DXSDRXHT_QFB1
M4&:1F ]X >B)&]95>A3P]*'8R!E_"*/EI+;GJF KH@<O94'>B'SZK;R5O!*I
M1[P);P>)GD[M?7U4=NQ*Q04GE0J)M[RA2>8U4[Q+K%B'5"Z*&UHQ]",2ZB97
M_H.5NA^SXV&]*EL'R8M\+])\8SA3J)N;)P@L>"9XI"7/+S/J0C&V<][:+?4+
M<]H]"XX1V\M?GKU:/5P]417G8+GQ>S7<[$92\4[]O,UA3>!A94##O$1MK>CA
M*6R?+K>-X6!>[L3+UHB:80O!SJ;7%U-"VXFZ^?F9U[1%.HC1BXU!G1,E?Y9C
MZL0$1'<T\DA%_Y"6=X#H*.5(^D+H?& K+<LY')I$P-.T:L?W.3Y!5RBY0NBG
M@:]L,.S)TR5%WB:@,V(T &0&QZ*!KHL+AWZLFKUZ 30&&P#X$[HFC(^D6Q2T
MP:GZI!>?9=RDMUQNA;0(@ OQ+:S.U?_I)@4@S(QB5IQ07U.8F\S'N!ZL[XQ)
M9Z?(/(SB5(!(\H/1DS@V#1HKH1_'ZL=H_0BP0=IA%'01@?T\<KO\WXWR.]FQ
MTH8:9_,8B%Y#=<VOG[*3&GN"'Y*E"]QAE[8I\0J7A)4_&W[FHQR1^_GX%QTD
MBXD\JUH]^%O0$/1^T%<XA2A"P:G$-\2#SCV=WXH:,>ZH1R#B)) .\J;+OVOH
MQ4'O?\B2:7(6&H@$$<AF3(,QU%'<+J15D'X)JNM^OUU*<9&F+QQ7)JPUW303
MM79Z<5F -]+L)OKIDM":+!!.>574&GE(:IO7.<C31^^2TL3#O)ME;]>(7T"B
M=TU&HU]% 9]QJXC.#SZM;/(W+G1+P1N%W#"P6U6#CHU0KA]#&9^3["GS2HR[
MP^;.5_!A@KQ"XA?[/C1"8<TDJ]@N;_9M8BKV?/4KK#]?(Z(9I\"%49/1"&P%
MA\-O1DJQ!2UR06 ]B @L[Q4\_(LH,E<%F.;\&-:TE9=S?WKNCR!U_2C/N-I6
M W)UVSC'UTZQ( ?!5PJAHCAR G\$S0S.;X1FCTFDM?$/EK/&;A) QC\2>H$A
M:II&!@VB_\+CQR^\BR*RY]0LA^4QU_H@T2RS!/I1O!((CP$$Z<-*'4 .!]DT
MC LTSZ2P.4(>='+KD OV088/9'%PA5@>K65SQ(#I"1MHBX(C/4I@;<VM"<GI
M39"[:JI"P8]ZGD%KG-KVCF,;T<5W%"W( #V#,^43C\9\>G@;1'*,B?7,CO!U
ME;.4Y\_7E/#E8*U(>V0 @>>1$F'S$2;*QMXX(OU3F/GQ]\+9+P<X6I(!RN_/
MZ)XTC/)T@<YF/FV8$"V^3A>FKL>7O&3"LGSQTB_+>'#_3UX/U/<HY8O,YIQ)
MS9@D<TLY-7E)1W=O?1"7T?_PV:8'%Y3*@E+YD"B5!PM*94&I+"B5!:7R 68[
M>"/_1SV_,>0C. JA<>F$<^"/?FG'@+])#I:01E/Z\; B/A -H33-<$CKXR:%
M&UR"F*A7R'<=27>T2:MG+VB&3UI+$":R^O'9BXL+3NLJTWO?EK'$PWDGQ*=P
M9$(O!GLH5"C><45"6B#XU8E^07MC*.PVU?7YM"^\GP.BSY$+N!JUG@7N#_BY
MC8\EE5(W,B2.^4@TY\8LB4PT*%7^R#+*F3*3$(_=/<C;"PN+25,D&79F?(AH
M^B6F--OK%^UA%&RVP1'YL 3K-31]CF(S#9>$P*(H1K7(6)W(D(P)?"$VAY.E
M;4&\='1V;>$C]M"96S!_CZ9/E8RX&^':HYK!:T.#+30KM"H%("+1]$2;D2B+
M1(?/!SU$_1+J1ERMB?"3&$R.BC&!>83;23C8F:?.L=N'K98?1&^5Z%((+X]-
M AAIM ZK4ZDLWH(6 2)FE$JR(6[:1RU &]F#20L-)\C?N*J\:IKB1&_+',V5
MMD;?E)T3TQ";F\A:)O12BJ4BXP7;+:\6>K[ .TY6C$R:VD<J<TXL[:@2_J^\
M(TF-GEA3>]9= B(RUZ^:X>7;R=6EQ&V,H0V% SUZFN)0]!I=#.]QE9]H!U3
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MHQ0+>X@K (](FN@QYK& /J/&G$T!-;@$*^1$MW.F;#@!(.JHD@JV-FUU_5#
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MO [HP66)94EFE;<_, "E/@Z#P"ZUBYJW%XOH:>4\Y!8Y4$="P,+.%B!&6DE
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MTU?;-2W-93GL-+BU<:_*M]%3BZ2"X7#B?'N^>N+\QRD&?_! =7W<;VXSP##
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M\KI8&.8I0"NR&%<64* ".M"]3>6DE],?O%T)&<=VV'%8J\UWA[V5&C0\#ZY
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M7MHXEI5&I,1]"LK13YFNG.[R.".=(H)_?/@=F:TH5N 5@(T?TTM^W!D?#8_
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MTWX'IV#+8?"!JG[;+TQ**HK*"\D$G4M7YBK/4TE2.36?[1(;I[>J>5>9<],
M'(V19YC%@DL%4I_J0N;'P:/#UJ?)M:'[C9S3)BS'E9_6,K6[O/ =XS:>#XKA
MS_M28;N36.U%\=Y@,MF#4Q'T$?B_!]%@;U\?'!X<[$ZBJ;Y'%?89N? C,N&O
MV1G\["DH,$TK#9Z \N*R%H-$L.+.'9CLR FL,4HKJORBXB52)YS,)KNPJW/
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MK([1>8TT&#%Q>PBEB05\U%E6KM)SE25J<\RB4M^""*<YOFRNO^ZD+\JT-0.
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M7-/UQ[9]8(W=+J2K:"9N!F0[+7(!=D=P;UG26E\@'9(%'U[S/3RKWO-+MW*
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M;?.25 *F2L#<7P*FKQ(P50*F2L \'%LI]+Q_]'R35JGP6[R?I#'8O+O!TT,
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MO,8+,B3'4]+A;:RLT\=%_H[X$706W#/E<0-0G1DH[DA>U>X>*CR&==X#IB<
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MYS#@5G+AKN06:+4(059D8"EW*BSKZJGUTJDUWT5XO2-*ZDW=B;V+]S7;4XK
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M/&D0^V&TS^C78"-RFR'(X>4.O,%0O4RKN2ZUT&F*D3N'G2 /JPH)%2(X3(C
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M\R]7<:2'+J,F25Q*B<UT2OS8]N!/9B9V%/A&$K[A.@;XY0^6_/7-QRO/3&A
M@Y@8@>436[=,XEN^0R@-0L,P M=SX9Z<3F&$+(K?X_R0ZXV+LI2-PW_)Z/4;
M38@P4!-W8,-RC)K0K&(;ANH[INZ'L4,8LRUB4ZJ3T*4>B0++,0S3@X$D+QWJ
M[T6^Q6B'P':R4W<C27H47//W<#;,^NW[<M9V?=-BONF2P(QA[:W$(U1W F+:
M8>18S#(IM5["+Q$-J>3MGSBW_%;$O!YE&^:V0NI1RABPM.[!BT./! &+2&SZ
M8>(%-#:I\^+!-MS]O/$.@4FF<JS:"3(X@/O]<#@UG(!:3D0\YC-B^RZPCPG\
M8,81LVS=,%A,=RF\OY73?+X5>X=>XCLN"P@S08#;9F@1/PI,$L'WOA];AF/8
M.Y;=3QOL$/A#'#?#G?4GR-W->4-==#N7Z):6)2*8.LL"#QV"W2!OP$C%(S=U
MCRH2W8206,V)K36"XI:;K?MO*;?>_V#7"]G=[9+\UU&2)CKF;W35%IA<-3FF
M5[*3WU!M%6$,?^P;ESBIO)BSZFI>K.W0]N9%K+E_8[13X_Q'D^W[B^RI^)]@
M>U1Q*O,WN</FJ\S[_)QCM>D#O?%>J3?N]V(N2M BS*5603L5M#M,T,Y503L5
MM%-!N\$$[5XJ=01>PEKTJS1-AXJ)OE[\\4W[_/GS,P'E[KL9&?K5-<9[>$':
M4*DE.GGJ8P!=T@LZ6JW5%I[1CT4YXR4CVM^::9UB6&-O*% ?, ;\=(>%?VBA
M56R.IO9\@KW BUO1[F%M,QI>4((-]I%'>*/]J&8!_F/)Y(G4XIQ4[DM'<R_E
MO/.5'R+:=%+N]:YMRI<N/WV4M4^Y+-EK3@$W==.MB\1_8XR'A+&B95Y$W_$L
M V1+V77&,'4M!KVO<1 @$MO:RF 9HKC'/N,; K\[,!>>%Y$=,JO4QY$WQTK"
MSH]YM.0GV:@<<R%X5W44"Y]@":*Z.8=L="':X:P$6$9M=(67E4YG67'/1'%/
MW<:G$(<^;&SC\TBC'EZ$]*0!\S,8^"$4LL7]+0M!V?.6#UVI=BP\,YG/9^]_
M_%$<O@#$&Z-W.&/S.0W38AP5TQ^;W4A:/?-C^Y%,0+QF*&+;T.5P/%)JR_6W
M'"]=Y]F^>$!SE8ABOO5G3\OP(]?=SEAWD-5_ ?FM^>2_.@72F"Z,#;ZD^.4)
M++<TY2DH(+!'HC?#35HU=:]I]:2M [(?MPZ^@]>6=K5'?S.-Z@8J %E+?!H^
M)2M$T5ZG.1BOUL(?1W4U+2_,FR\I(Z9EJ7SO'"ZF6-X/8\4M_SNM8OHO[6]9
M$6(#?\8+^'_C!Z.,\&90/)PFVD=^*,>\TWBD(5U7+8UJVJ^;Y4D?2+D'I&M<
MH:"^P@+E80-=8]Q!MQ\[YZ$?V&$X9&'T[3$\*$D)VP5T?,AZM>9+('#I)/G-
M()#_4?+C7^;U>;&'1(!U[\$>QL4L1GAX%^H^-TZQA\UF7HD>8=RK7]SF0(9)
M.O!]9X[K?I3WVI=ZR+@\'V4+EY^:*<G?^8+\UN\5\@<332$[' "78+^WD^QG
MJZ3+9NEBOF[I,H25&@"NL*ZZ39.&+>*L<2/,_NCT;JQZDNM;9SHC>>"+,(ZU
MSTW]GG*KG9LTLY0T._9*#4":V5>-X^JJK<<=ME2SQ]K7QMO6[=#!9 .62U;>
MX#E"2F2=E\BRE<@Z]DKM@&G/QT7Z9:G%P8:^!K#&G\J\FFO_ATYG'[1_P(_7
M(^WK),UHS++9)*7PUP7\_\>++S]I%XLXY=CKYSTE_^I!C#4: ;$-TR2V$]K$
MMT.=>):GNUX8A7&R4@ZA!Y'CF,PAEFO#/;Z>D-"S,"LW,BP[T"/JFG5*;<S2
M]W(2V#/I<SR0U;+-C4FRP]E?*A/N^)EPSX19IYL,YZED.)4,IY+A!I,,]T+[
M;DU*W,UN+;G'QO>\C+@]6&>[&Z#V^7^&/;[C%J<8SA6[FZ1A.J_6U7-<5=%D
MV$X$!Z.N8@(CS"=H>Z6+/BJ#=AU@2*K-8KN,)BQ>'/YTAV%7F&!)%_H5D@(/
M04-CK.ZF+*K A$> 5OP@JR;59.4$&)Z(8>CDO]ZK;LA=ZAKOUNV:'F-679*!
M@@<5/^<G)VS2OA(FX?AQ  !L\'("-D*QF'?!I:'K8_U/]?5 @XS.*O:^$F=3
ML#4J^8T8 (R@P;689"2.<GE?/Z&Y#*Z+&X3$7QF8?]H$  2877N7L<U-WN,W
M_>7'>;DZ(PE'?5CEM9QP"_02:/R]P.3XQ9J&'JL#ZP%ACNL[.$D?(\2Y87@>
M',WDHP0;KYAUG7LE(-V(COQ=0N(MM\WS5?&/\_C9]%NE'EPW!-+5B/*I)L.V
M=L 6-'L>SS4&6.U<F,TU+KL&0M*MD<73P#98X>OI_: <X>KB&8+D^8+C!8S?
M(2G_<M^&=4?_4FU2HEOT_Z7HY;PJ9FG^8'.R)%E/1?[T& ]<XE&/]SR#%GTI
MDC6?OL!M&_O/'7?TT]O9TZ/(KK6[8M>F3!]%-:QR$O+LY"BY4[7Z"WF)#?:D
M5YA**NY>*H8TPU*/JVK"V/R!!*G]B\6>@?*3&)9VR8>UZ905'I2%#[:2C4HV
MOFK9Z"C9N'O9V#:\N9+'=#V80WI@$=EZ;E V?FD&*$NMI_#^B3R9[->B$L?5
M8K++/Q@M*^W3 VDN2J(JB?KJ):JK).I>)2I0FL\DS-C5C*?/@>E[56'NWM50
MA6PWLU >)ZA]^M<":Y*4=%7254G7)[_"4])UO]*55I.K)"MNARI*/\( M5]P
M@$IT*M&I1.?37^$KT;E[T=FTNXTZ(JO?\?9H4O1W'!O6O#R:PJ%DHY*-KUHV
M!H_)1OB$64K;YH0],^=WX#EWYN-986VZX@XRZLZGENPBXR>RM:1KV\BUM8Q5
M33K1#2]D+->*:3KGS0]91!?8YW["[IL3>]L6VZ/^";X2(*\MNDPKK9H4MSD6
M5^)%CPVKJI^6"[6"-8SS8@?)J"\IQ!G8\KZUWC7YQJ(?8)T^W2MVY;G)KFZL
M'D; K169NOPV?/>$A%7.!-B;3)3)BH.A^#MYELB=EDZG+$YA$;-[#68?,=ZA
M#:^K@()TCAW>L(#G">]:FM)#;\51;>[:*>I?!]#1R,5S%GC#W.]7U6(*#[@?
M=D*[.^XL_:48L:HP;Q%OKDX94+65AZNM]!]@-E5;J6HK56WEB1TT,%3E__O/
MG_X_[=L7[9?/OU_\_O'SQ:_:Y;>+;Y]^^_3[M\M!%['MLX+QT0*0Q[;F[@HU
M5[;F\"JA0AI]ORZ+11X3R1T)_[?*"*IF2M5,J9HI53,U!)*JFJD7Q #J#7X(
MO:OJI4YZ^4Y"C TJ#J:?713LG NECB(*59'4Z2ZB$HA*()YS==11!**JC%)B
M5(G1UR9&S[DDZMAB5)5#*9&J1.JK$ZGG7 =U=)&J:J#.:HV5O%3R\IR+GXXB
M+U7AT^DNHA*(2B!N4?%T=(X\9CZERA=7^>(OY;>7;>N=9Z^KW'65NSY(6:MR
MUQ^M;;,>.!3HB0E8Q\T+?V%RUB#GM-?3>I96?&"5=]\*<>)J]PA5]#KAES\5
MM.1'IM8GCDLG5D@S-I]3[:>T& $71,,] K6C%)[QLC?K3^8THCA,(IV2D/DQ
ML6W3(6&H,^+;EJZ;H1^9H;.CDSF_"!GP#1[T4P8K\T9C541G6!Y:+MCAVJ4,
M<K=*XF"%,W+I@^Z!5[>?_Y>)Y@-<ES"QC_'$VRF,[1Z%<:]=@,QSTT2>VX;=
MK;W%AWP4CWCW:-;9B+^3*W9X0^]U5<\;7O3S-*)>GD965-5(J]8$')D(./);
MT)^>-/YT1J-)?<+S_+;@QSM7=9D[O"PMXDVG/8\:H5</7'1+>(MU-&B+W6 9
M?AVF11<5Y:T4-!R5J7]XM D#O\[X\&X,).5G64LU/WIB#P<@386*-J%IF=V/
M<%8TR[0I7%#BI?*D[&HDS[>N'U$CK9HN<ADU.G]P"5MJ5(M,+!=V#EA:,OQJ
MEVL EP$EL+(?5YB? /[W\>58NV8 _V"Z]\C*;(9$ZISB/!.GS6<O/%%^KXIH
MY4QCCJ%?LQ3_UC+CGROM0I2M2=\O+.N"X0ZCVM\*7&+X+H*'OEZQ_NU!,;Y6
M8K0]:&!H,UKRX_2JQ33E741@_W?%P6TJ&MQT*']=R/<@Y<?:1:7%:14MJDJT
M#D%?O6;@@CU)@(UZKYO &ZI%DG"# ;#EHBSQ92CT@4!)64R710V_8TZ%2H/!
M5XL0_H3QPEOB8A'.-78'%@A<'!:+WMRDWL!?&AY[<*:_T9Q>\U$#8[(;FBUH
M5X*R&TY>H;+R.&W'.&UN;-XY _V*/62N 4D+PH,81ZD]YT"[A!%D5:'% ._*
M-.Q25O1L>7R9XX*W#@(1F"UB>!S*]ABY5_S,B37%O2QEN: N3@3H! S5]H]9
MX/S1U)[?/[?#R]E*J9]HE0K%)E'GJQ9!%5O/@\C'$BW,@&%E#?(2Y(#-U&Z0
ML?8%,-#2]2F/_;$[Q#JXHVJ,5"/]Y0V]=BPA10%5")#%47 UU@ 5\[VFS81S
MHH,>DK2<X@:MW1<<=>#;I!^C%ED=?\:7&]B\?$L)"_GMW_.T2?:HWFEOOWZ\
M^/+3.RX3\+5-"RF878CME5J_"7^;Q&ZU+*W?B! /7EK&'*(WX^*(*&$Q(B*M
M0MD)(@C6-*.WK>G>=A;32MZ1#'\HFY955;TVE^W]>,6GNVA"\VL^AFE:54C\
M^I%\4L-%6*]K,_XO5PWQ(D*^:SE]$\^@JHR!59MU%XL)*J:HNK]*3A5:XY9Q
M]<49 )0QPG+!6_@J9-8B1&T!-]&JR#FO(< H^:N%&KZ=,.PWMV23+$F.I&1<
M"36V#')>?<FH>48,ZAK%0UF"-(;_2TH8B-"2S8ZI^FWTX')$0=A<KX3IP+M@
M3BR_!B'$?Y2S0G-'SDK:.2EZ97,J(%%99%H!6[XS@Y([06&5."ZJCRCNK,,M
M6]GYDEKP*IX@P8F.T@1?^=37:2$0%:=8IX_-%N4,EQ >(N4F7K4J.AE@+6[%
MYBA:5P3S<^;+V0L^HA6*Y)3B.B\ DZ'M)UZ\3P0Q\+WYI;L=.2IK]H\P5XN(
MQ8M29+I01+S"E5"FU?=JXT:H%VT]N'YPDXRZ6WAY"+C3A1Z.A0)"=N)#&6N7
MN*"=BYOIL#L@$E)BA Q&-5![<]2\*0R%W:0Q;Q;80[T:G:+Z%&H&#0G ^O*9
M&Z<E0((D)<?)[0 D+*\?OLX;H"T0">#[L&%BFH ^!#+"2%,D,*(1P,OA?0>5
MC- >N&5@"M%J^16X(]#C(ATQ/9-@_>#_%\VO+ 5[05"Y(QZ ID@EH%Q'>(8-
MUNSXAU17/)7E\"JS'$R5Y:"R'%26PV"R'([8[7GO7IZ/: )'H+YY^%7[3;CG
M]HA@A]TGGCL>:Y((NZCV6$;%=+K(X0?1TSPK;KF=TSHT4VZ -#Y&].PB>)61
MG\;(VF@02LNS9/U7%>6R%Z7WL_2<B,?C+]ATG4G7!9V_U]X:[V1DCX-N 1=Y
M9_0N%N4OE_,1"%P^>+WM"D_'EOII?E-D-](.YZZ<E,>JH@G\#UB;'"97B_"?
MP@+#EZ(C'["*]L]%?"W1HO#VUG.2X'+#*L0%$Y8NS>!O;O2C#Y_>=Y%C;?H]
MQ35/O[-<^,)O)P5VH\>Y21L6WC-"F-P9G(3$&T;'V6(D,2Y>6[<[K$=6-4-;
M_P!$P'D7UZ\N5 $#3:.):*<O%K:+E-<T<=Q9S\8U'1J?UW?1L,>&NTT717/L
MVMO<YUOC)[1ZW&E)S9JL^Z.W$!S6V1YX^?MT#@^+M@XJ#Z$QXPZHV@>!8]WV
M7:/[KU\KLG,PH5;BX6,7CDOG3MP%72/P9[D 1?81[#JN.KYQ/?WI;L;RBE6J
M6O!HC66W7-^?>>A[UG6G"?Q]Q/VUY0%U0Q=]@Y=KVW'[\TZ96E+C>V^E+/-F
M +EVLCO,+?-FF!1SZ+%GM 0 S-WI[ 8@]XQ'":*B$IT!TYS;7O%((N4Z041<
M(#P2B.,++:I%Z9R+4HI6"@\)]X)K;1J-E,!+MS5#0YNA"<(G5.2-\] 0.M4;
M[[O<ZR!2OTMS2)Y)M!R_I-<EDQ87W V@/:TF=9R>BH 5O*2E2%%>TSS]-[>A
MFK2E/OF=[<C?D&!>S#FA!"':F<-:%#P,4YN]62J2CE)6-8FEJQ3?N)@5*V_2
MB%7"(/[!&5L:<'C&H_)K\C?W&7,[^+9!B[ V-)_+@HVKH&-U4Y%9STUN$5"3
ML3(>'A5LV3MGK1<90M:)@4-+$?820?5Z=60T)VZBL_=LSKT"\&L\UB[1(X#1
MIPQ#IFTL#+? XS.)BFO@9GGN&R9'\]G4#H\;FF:T3;?I'A@'ETS!KN_.CXVD
M&*BG4']?[T;IIN'17R$V6A;$#,&0U6%$%"Q\!%551*E,]:[XG/A>K^]K4XDS
M9&S^>T.W^E$B/ED6USR2W$\61M#7V/J]!,*:TG@V6GK#GU)37<' E[ILCX $
M_V]QBS'3BSA&-I"U"P(+(D]@+)A+A6$ % 4,!\__PP:&6'F':1/2S_F@&FA2
M!]9E8XQ0GV B$4(/$+@ENTG9+<\#TBJ*R(IKFA9&M6EA0A+7"JRL1&YT618A
M/_U1^\[N.[!(ICQSO(4G3:(ZK 4\:I(V&6,!E]PW53T([;IY1Z)!#$]C!^1%
M19Y&FK>4:*?.[U^(; N9QXEY(#(W@ZW-N5[!F(UF03)T2+(1^ K=_QT'F.8(
M!U*VG#35O*V3IPZ?JB+/0<N)? ],$V5" ?=?U62/8_*I>$NKMT5:1';?+M-C
M&/=;2Q!Y_2K-)5TKGK,E:,AS> 1(J@#T")3#U6?5!G!66:0IO )<'2Y@AC)P
M4ZR_?M1@K+LYQ[0+;HS(]W!@6ROP$;KY9_1><BGC@9@8GY5BNIMX3"QF*>L7
M'L^/YX])JPJVU_@Q6+"OUBE/<QT?,=JMXB4J7J+B):="514O&<)*G$:\! LY
M\(AR+*36_I>6)5TJCW^]YO'SS(-C6\=G%"=YOEVFK.%C6,//H_JA(BE+%<CZ
M,WSY<--_+G(FNPU@P:_TTS>F%AH*//2 YJ$0G;P'A?10,I(L>/."6RE)^^$9
M869@/00/$, S'&ND!_K("/3^X^K[V[ROE9]D%ARFBJ9)RJNW>;QC.@,B">\Q
M&)RP<MRJVMPH ^>&8958E"IC3PB:Q@1[+= 9BJ&S#!NL\POT2KF[I6GKZ=]$
M NHUD'EY?!WJR,X]VJR2TFFU(?U/5E_608E.-8IPZK DP9Y:>%6=$=B-3M39
M@J)6J"X&XA9VQ1T/<HEY/*T>/7>RP//GDZ),YSS]6+M>I#RP]J@AK # \ #
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MQ]0-_]A=5E^^)6++\R/? :RGAP&Q+=LAH>W"YO \R]=]3[<]MJ,M\6LAQ/]
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ME>)2 =T3,9Y%2R5E/+]*#&*.311-<;$(,S9X%'+2QP3N@O#G#4B,P(LLFWH
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M,P:5'?@68;IE>KJC>WJT!]7&#;!S+DI6&U3I$J5+%*N^*EWBZ+'C.Y9%3.J
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M1.Q$-X+$#H)0MW:6HOFQ:Q6W#JV+6CS^4I27(!PO6;0HTWG*JHOXGPLA)4'
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M$L"4*!4R+GC*3+*7RM1'0A(:^H+48W!5_8GJ,;BJ5Q60ZC^\\U95V4C8Q$6
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M3?WT29^OZ,%MO#SKP>UPP>T&Z%$YS?+($,T$)31C">$<\,?0E!>ZB*,DVLO
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M #T"OP5:=%K$S17K7@PU W[@DK\:N/[%<LH7%2J0^;RN/L-W;0X8K C^N:H
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M-X77UI7I?$P'U(-[2-<("C\S2PS EU?MP#9[9=&>\5D#VGFL^,4V9C\PE=>
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M@U5=>9^R]<9._%<ZJNFX>X<B&C W&/'5%V0-^)VHJC_<C^V:K<%,D)T(ID&
M[-77N#"P[G6OZSI;Q]ZNP41[8.L_ET"JA4W\L12 U^ AMF]TL;!5[;2M4L:?
M=F6E:KF*-N.'RQ7QD>1(Q"_8QX(WWTR9=>5*BS;*? GHZQ3"C02Y;OM:\#X)
M6>-A5MO<II+P)73S^OSNS8Q?C"A;CNBV!MP<=&HPV]UJT*;MOK&ZH:O*MXGW
MT_(/+#! @EOWJ5ST%?K#G'Y[#7NW[VPL/L-@]2TW7*%R0DK*JEFX(.99\-O-
MO&VCN;L8+/CW4EVX)8G=S.)JRV>(%[/OK-8YV:T(E;,54JQBJ$XRL+W#HFM.
MU;0]#U;JM<%-+@>)X9;8<RU1Z9,2M=9*_5_!)CG]W-[,W<*!VL!.6'%;2[V>
M.6U919LR#D)\52ZO\.X[GZ25[%OD.OL,:)\!?=(9T%'H4Z!]"K1/@7XRMKHI
MG?F6V9KW2O*,?_A&3FO(D\SP."1"4DJH2BDIHE"1,!,Q3:7@)B[V$7;Z4&--
MXN+ZPQ2S6F<*ZZ7GCQ>%.MZ,U7NG^3GZ3@)+89?VU='8'PD>KS^\VMAYO[&Z
MV]C6Y<6Z2!=$LZ:Z:QZXUB8%>V65;8>KEY4SDM%R;B,W$B[HM*B]0NM.@RGN
M7LTTUGS:SFW@@_2)-3:OITM3 >'E?9>8+U7]1YLIXURXP24P^.6"05C:CO&U
M!MSP5X,E=IDL:.'CPUW,K,ODXEW6SUC4W,ZX1;.C]2X"]+Y<C*@/),*5S7(*
M_I[1?=3(+OHL^!V#>K5>@'GL:K-KV[]KTN8@.8>G35Q"D]F>K^%;??*1(^U-
M9&YWYJKJ(XUKC7LM?<&U=.DD^%SH$-K0$OK=&Z[-5@;2(-4("W$'S0->#RMH
MD=0S;"8QG2 AEW7=]K'K AT8+@$_LSMQM%MBPU:#'*1YRX [.$]>@B"Y;W5;
M-FC6,W ><2%=X[ K_N^N[UU[L]T]Z=:IO&)0&Z.TI^-]$8C;IPF2K>V'8!FF
M-+UK[^AL_6K7_ '8:E9= 06$GFE3;LR@VNO)C@QIRD0:DE!E.!"UB$E1J()(
M0&Y9Q)'.X@>=[$@N^(N/\E*KY720I*I^M]S_*[8-P"[R;A>'T/L)HP2W;BE_
MBZ=8KR<Y487]>EO]?&YE\1NB9 _:I]/J2_-BP(CM!#\WQ<\VM[C);&W]"WQ
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MDAJN,U.(B.9[J:E\P\L:^WWI@;5]B^#K-Y0V.U:G^%;\FIP%2++ TBSXYVK
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MM]9I.Q30HR>%/JG4O=E(LS@4,#D PH\!7;Y'VY76>$SJVKN/VO;Q)/4:P&L
MSZZ>I%X#> UP\NSJ2>HU@-< I\RNXR7I?6,^=T^8\C&?[\5\;K6A+S>JSUX<
MH+AX[>Y5D=?NITQ2KP$\NQX1NWJ2>@W@-< ILZLGJ=< 7@.<,KN.EZ0/S>MY
M:#AGV%##WFKG\SY5T&?8QL*N9KB\\#%:?3QZ3.B?\.%U<&7+!@(<^7[_Q)][
M;8W'B/L3>5:-E,3K''Y[VO[E6'CW&0'C"<8$"QK'<1@SPD6A"&62DR*!ETF<
M1C(M(F:2<+,[5YKS6!:I)E&4)X2&+"=<"4$25<0J4T)KGFQVY\)X]OE,X3^O
M5U'M'4T3UR8'__[Q%1A>L(MPI60X/Y@D:P.$<7@P4=6"M-_XX;]9-*%Y>.,0
M82_+NV3Y632CAQ\//QY^3A1^\D1Q_O^S]^[-C=Q(ONC_]U-4]-FY8T<0<N%9
M0'MW(GK:]JQW[;&/NWWVGK\F\&S5#$5J6*2Z-9_^)E!5?$NM!]4J4O!.](ID
M%0J52.0O7\@4 2.N&4:, 09I"GCBG3.*4DF=<]OP4Y6Z#-I4R'AB$+/6(:4"
M08%)7PF%>6DR_!SC7L[PD^'GR$B<X>>HX<=+IXP6!)%2Q!:A%<"/U@%5E@42
M*&52DVWX\40PS+U"%3,<((L[)(/ER $J8:$DMU1_8?AIR_#_R\^F<==*@LFW
M&7HR]&3H.666S=!SU-!C*37"):S!#* '"Z1X[$Z--6& )\(PM0T]5AHJK+:(
M*E4B)K1"$L/=VG(F*Z\YTRQ#SY'MX^</ .8D[V<*Z+U;M>:H)U>^F5_D5.^<
MY'$Z&0DYR>-T2)HE0&;7(V+73-(L ;($>,GLFDF:)4"6 "^974^7I#G5^\13
MO7\_>W=6O)^E[IG7:_UMC\5W?\I(\87\U0^L,3R 13C68.KC*7[:(:M #+$J
M<(2UK!#3E46ZE 0QIUC%A;>LJG9"5MB2BF*!/ T6L=*52(?X45%#X1>"RW([
M9)7<XN_][.+'E5/\0'EYO!P)7 TT0O7@(M5YSV<@RT"6F3H#V=V #"MJM:TJ
M5 4O +X PXR'OS"1FDLNK0\[6>?,.B:I)\AQ#4 F<4":>88P\\3R0$UIY=,!
MV?&D6600RR"606Q BW"L3)U!['804P!&56D-LIZ!-58IC"1G8%D)J@QE CLN
M=XY.>2FIHPHQ4FFX!X!/8^Q1J(@(@GLJO<W66 :R#&09R :W",?*U!G(;@<R
MQTLBB":H\EPBQE6%M%4.8$)S&F)-"2]V@ R796!2(PFD0PS' A9,</A+,!\(
MCK=E:RR#6$?P1R;&'S)<2@85+B6G$2Y]/YWK\5#D_5#WT\DJ,>2,1+GFI@LS
M]H-78X[^W-XAB'_:&DVPS#NE'5*!6<1,"68V9Q(L=25HA24G5F]K-$YZ1BTS
MJ S:PSV6(HF-AX^\!).^"I96VQK-F]3]\^FJF&!*1J4\#@-]BP]?D':3T2VC
MVV"6(:/;Z:,;QEIC72$N;858R052&HQV82EUTCFLS4[)2"D(T]0&I"L)]KK%
M!AF%)3*!*UD93S#?20-Z:G0;=(VN#&X9W#*X#6P9,KB=/+B5Q+/  =(P]@!N
M@8+I)JU%W(C2!2R]+7><T826KK)4(<4Y1TR5%&E&8RD7RHQFC'FU4Y;EJ<'M
MB$*K&=PRN&5P>_9ER.!V\N!642>4XQB5*A[&,+Q$TIAHE+G22$U*Z]D.N)7"
M8C#14.680JP2<+D6$A$KI 033AD9GAC<CC7<^G*!;3/@"I\T4&#MA=8CCE3
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M0)8 +YE=,TFS!,@2X"6SZ^F2-/=HOZGIP(GT:/\9?KPN+M*I@2+ "N;N[ /
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MM;!F%^@\6'&_"@_UH.-0MW#.X,^H<V0DSJASU*ACE:6V- 1A'@!!F +4*;E
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M\V*1-EAWO]Y)?%K/E^KL[62-+_RJ3$BBSWI&5USLEH[M,O4LE,IP[*&[A4D
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MK[NYN\=VSUF.\MV[OU#4)E9W)G6K<2^2BPA&C*_?VLXHYH[UN<'-%CG.>B*
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M.'5]I_5,-6I=PE<^<>=B#C:)7]^WNOC[PGWH(X^-G\_'G:!9<N/JU.URH#:
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MJ*ARMF+O*1-B?L?,-_.BGMCIA3\6D9RUB"R,LA;Q+%K$5Y_/&7D2/:6BEKE
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MIF/W-&RLSHJ6MGNEUGJ_ <*B/_E 30?$0:ET:**\/_?%V^D%S.2Z&"?J%-,
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M5)\HGC<4J69(DF&IWEY[#=9J"UT[$)=>(JKY7UB0E'=@EF>,Q:^.<[2\<E.
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M-F^3580VR2HY %LLS6.<5'#?^<GL^NN!;W 1ZIB "7963STHYZ7 ]X#5%<;
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MWA+$=6XZDF<.V!SK=4DXS9GR6.SNG/D 0&NLM-G/DY9K_[N>SAX:*R #(\R
MDVX'XRZA*QM(WP*ELXN"S!W9UY]_?Y\32._!EES:R698_3:MTJ)N+-1/;4+X
MU)Y7+O>>#7'G/68;@<'\&URX.*3W<4C-MB?R\R3O]\K% NM.:7'RVHW8MZ%9
M+JF HQKOK7%.[%EVWBX[+5^5BQV.UO123 @?-+=M2ZOSIN;3N%G2<2%0;+ 4
MJHM'70IEXSK.+ES'UE/*W08O'GRV;G?FOCJ3?RY@%9J-U%=^6V[JA9<"+=8F
M;9N-./ 3:+\Y8.&%L]=6=>SX?N6 +B;7_N3M[&336<SO'T;Y5> ?N4;CLQUG
M+=#>_3JM,TT)?,@\OF3-U;W6I6UIM[4K>@3O,6J,;?@$7NG2#[\HR=C04TNR
MYZ7O/O8:'8W!N1]%Q %QS\%P#$PA3*S2.H#M%[8:?B65+&%4HQ0=1=Q%P&M!
M",K>I\ ^$.^WL'<M3/JV;1_01MW_6-+SIVG]TV*^J.,JLOK@HG/&Z8#J;L=1
M+^JU<N=0E^LKVB:MH>V@^S]VLK#U>47: $7;[Q&T2/?9"O04(QH+A'-9)0_
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M*'+$>:1YD#P98KG>BJ90135UAB&BG$ \A(0<5@0IDT3T3 D18N?GQ["!9F+
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M E!F8$C!I[ZYUR7KW!/W^I>1S])=I1B+1UT,ENZ0N!@L?318*#86!X*1BY&
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MPT$YF1DX)O5,YIBV![SA\7#I7YO=R^D;$&@0O@!Z$E5GLF8T3PS=,0X+&!?
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MNK9P<H+[=$24A,5X(=516S5!@YXC2<(9BZ@A:JTB22]10>R7* 5#BF*/RN*
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M_RIK\D=X#,"<\?2.3\KS5Z_A(3^^#G,Q^=.__?CZNKI)__3_ 5!+ P04
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M+_YS#&F1_&LBV+S^#=<#99?+C7A_REFBRR="IW?\7B3&NFLYVBGIU'6P"L%
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M0]'XFPB-)^BGY)( X%-XS'JO% *U6<ZOKZ#YA+V'B%QVW:M.5?EG,R%,'W%
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MQ2+,4]_H5"1)T2: $UAH'1+F)HAW ([UO M?W!@5I.5J]I$C%.818C!0R^)
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M90,/:C'PG'$##U(8>#*3H=15E/4599WE &?F1>2)CWM!SU0W3.9#]%A>+^$
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M*\4J;)DI_HJYU8M,QK40+>9=)<DM3LK$=V&<./[_\;;GH=O[&<)<)#E%V'%
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M0F\D*[*YL0F3CH].IZ<57U1E (H$H7(=W$OX*2^A]MB;)$2/Y#WI>$3LN"_
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MI-NMW]]!OF@C(YM%:H692\0?HJ'#9;EL?_\#L2ZOX0K?VQ+?V1^Q8;XK^;?
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M(XBW<JC<%K1, 7DV4M-6  ^&1YJNW;BDQU#4Z,7$.>I[,TN4Q#Q-O>OE>_D
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MOHXQ1K=A0C[^B?[\@_&WBT8^?36+!9K&I3I,[A?V_H\9]-+0IPJC>,1=]<;
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M'S(7+&O(BHH1<8*D]O]H0U> R-$P?I9.C<D-8UE]>TP;ID9BT;*E=/:? Q?
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M$6\!T2:0:(-&ZLHHR:*90V6WM+G^*&P75&R"YX3R',D\NQ+/L6&>"^8_YOS
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M]U1$<S&6$PL=.+P' @:>FZ_Q,X?W<IBTBN<$RP)F(!F,8%8?*U):="0X*?)
M3(^;-P5-.YZ6BEOJ:/[X9S> $'A3 !;C4X0?XW'*:#I#&S\,#YPL'7C*B8C8
M: @^16-1&1:S5V=/,A2M-RY=&O4-\<8+"L"LDSQ4C[CM3R<X-<!NWL?1"NQE
M"8CB&Y"6O0&)I&KQ-IV\+Z?HS/DG=#>9GE?,Q4<PQ$CR%!HK,32=8-$>"[XX
M!"*4.06-42(D:T,@8CRY[S0J5H"2ZY]BF[=*]($\Y/=N.F3FB:B15'@H=3Q.
M5HK),A/8.S9%TM-%/4F&@D(>7_#R?D+Q5@C([:WLP4U]@K8< ]&]8Q(@:_:
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M1&"P9]+PR8LLSMT5B<O8'7HC7WJK:$DX/(O-I*TSQ\T3ZF,'JN<W6L# [$U
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M!4KQ,[2.0%_WWCNB[CEUBLY.G'PPGW##GV X)XZ(HD7&X!2#(*%F)W@UP3B
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M<%6I^0=_ZX;9&I]#64P?P#5:7PX$6B&M1QM6+,)R3B,"C%'[>JNK8 5)A4<
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M?6 ^ AH]VNSQ3%#M*1S]RL?^@':LF,7*@TIOR-44M7D>[Z/$IRJ!F+Z-4X0
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MY0<H/@=).8HUB@NIB!6<%FUX(75N9,C*U+='*5,TU+&",.;U!R,D&5[<H/:
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MEEAN(\]?^\@KYTJJ+3@_"2R!N38C2>F[%>?D69;@C98D0A !WF8D$IK ^28
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M93TKMH9PFVLQ'LMEK!BXZ#2'%WT(SN=!'3)<;04K2!*>S(_9\[_0*GV*X+C
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MZLH;'?3"\_!:2]A_;O"Y?ZH=L*KLS(/]W&&PGV<9+*!-+N,G+)PT#54H.<=
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MOJP[<AM)]Z_,Z7?;;;L7>\[<A]16K1E)J2-EN6:>ZE!)I$2;269S42G]ZR_
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MF7%I%G6K4+B-!XGUY<)KV[\U-Y*-N"57/ST_)5YXQ=-#:30 Y*^"Q'/)Y+
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MC\-]<V<JA=RABJTD0]0+X3)V6+O)8L+-.VN\M.2*"O;LO-]RT9:VT"QF0DT
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MCU@[0]6/U39@W83O-Y;F);QWCATWP ;W0%66.7OAI/N:2Q0YO=]3F7YX6OQ
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M%T5@OKS6C4JRF@)A<,EKHX).YVO)NE?D-HY3I=4H.H B0GRU6M0+PLUJQ3-
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ML2=:DW#K]>$B_J(-&]3L[LUUYZLTRLMR>6%N5#V@;]DO[&-7IJ\QTIY(%9(
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MLJB<,Y9FD6LVJR1<N):FF0\ BN+PM32U?  (-!>RK1GDVJ2J_:^P:H-B1(X
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M(IV5SXV)@TI$0JLQW/PS5DY8L2/R(-@J<,N2T9N0_*FFYN:.E+XY:;H^;Q_
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M_JIYHUZ$[6\VJ9^VPH(YMD,R3*B(:^O8_K:5@&7D"_38#H0THXBJ^MC^S)>
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MX8D>+F-"AG(,_I*T)^QVA.>H;)P/%!-6";:>[Q6L<X-<0C]!+,76VK%J2@(
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MI@&"5L!KEJ(R0/#V<\I9CA-?V,JX[2Q/PE$6N1/FUTQU#U"C%.GL,TMQ,:/
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M =_ +DF44KX9,.E[4<X.#,'*0\9M]Z/;A'<%:0E2%<4Q?,"O50X4/&U BL*
MPE#GMC,'M0"ZU-R-;15?88KR'.2B\:[(KEO=0,O2%G?>M"PHBNSY:#:2%7F'
M1P3T:SCGU[(WO:<%,%PBR,:VH#NNT8VO\$,0QFC4HHO''Q7HLS5C5FF6/38X
M5N,R"DG@T0MPHJR+K_CB-)M[@[*8I!GJ+C2A,*36=<$O[S_UJ+4^CI:/AZH,
M\;)>T"3;%Z<J+3O#R#H,Z(8E)K*9K#42IUJ-@ ?'Y30Y=4QY]3AUIO0/=[!U
M=KK;T0E\TBBI11+^J'EPQQ7I]A]G\)YA%OU'+P=IM96++!H]2=@]D!4WR2IK
M21Z3=!CRS+M?P-CSQ_RZ8UH(,] 1^=S=HDWWQH_O_'G>Y6&NW?KK\C"7M:PZ
M7?U^7?TVRJ-A%,,Q^F82A:%(EJ.]MUQU)VT!ED&(2R%G/:5(5^@G7\XJ,MW9
M::=?<V</](6]I5F ;0\\K94%^+-?!)/6&7YVI)IQ%V WC+)TZOE>#@]# Z%,
ME*GA)FK ?6".K2XFL;-+685=3.+I.W>_V[E+WKE@^@8P-RT"^5H[6'P508D6
M_ZW(<NFS]KTQJ(@)[-D<;!'/[H0GM4/E#9" *[PQXPM21F(;B[YGW"Q(3$/>
M CJVTU$/?<[Z<:E^,;VQ[4[<UR@<#CKAL,2D)#\&/=;/O/\N87S;E.)BR0<9
MM40?(6RM* VE\S 3PMO8VT1Y@/$INB!0'9K"$R<8H"2O88J2!+.3]G9ZWG^5
MB?#VMGO>M9@5$J*[37[ <Q'(OW=6JA=T8(7G[?W#;N^O8.__4_CMV_CD>B_N
M1 R;>F-G=W.+-K04 !SD2 *YM?\+%'L_FWNPM\77 #8U8_8)\AIE>:'C\4Z7
M]0NE>7 C$)BJ 'ND632]K"%H@:+#"!I+B*A'S^%U7LAV!X=@FD(?05!F>4\B
M]V0BL]/BAI;*M@EG&)S7Z@"1OA,>F*LVYZI+]+;0G]OOZ-2?]HG HTX$+D\$
M8J"O=9(/I$"&0>I?TK1*+O$)@30$F;>BE8UAZ@TW3FTBOJA*1:.( [9^4@GQ
MUG,&*KD!B-D"2>C'RNQB]/ZDA.N\,A=D>+GO,"^X1&!00M%:>, 9M"F(8KK_
M5S\#^1[EG):S7MGAEV>_MF<-;=H1<'62O#W_=W\Z.SU#!EM*UM_QSMY>>1MG
M$Q\4X"R'#T ;WMW9X</'FC$$69&V3<G\ASNL)A_O;F^N\FPXZ/3CYQT.Q]WA
ML-S#P6NGW]N7#C%,1I3N;])X(R1]^*.,,BO1I(;B <$^%:(@E,LJDSOZRTWO
M>!U!JY-N!R^7<@=V2O*E;1NX#L?W*672>P<3W*--2SG%>9$&7S2N6%^QTE#S
M<;=KGYY$L]UMVQ5L6S!FTLP?MRZ;AC9HSFU3_A+3:+1Y HQ#^>B7<?"B3^P
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MAG1NY<Y'TYF2+&4:)26[8O%J!Y.NJ#EY;QOF#574DPI<RX*?+EH=-/Q)BAG
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MB4Q%U^NXR2^!/3SU=/='9:8""00DX)P%U/O94G=?8V&*;9;$17JIZ=M(IF3
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MPFF>7"H2V  7@'V7A'X&=OJ,2!*(WR0-1%AFHD80#*T=Q5%0Z 8Q2S&%?8D
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MXD5N"O'B01>1$RV:DGN$ +5">":O9K.C+VWAEE^_,A?R_++V>QLV^;D!@M^
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MU*0&CNDU8?LV48)6%((DIWZ)*6^DABFL$&J9@>A)M_R]*F,3\LEX*[@FHLF
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M=#2!AI=Q@YA!!!]-R;HBR]+,N.:?\PIX'M+]NT7.+41V)2%U#4V9'U]V3-9
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M-(Y05-&Z )"U^<^:Z$^:[4JVX[80S7%N8!V42+1X+I'H/#\(8$6DB[7E4K8
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M"AP*>X<#TG!$Q\"]N(%NI77K%6S3Q6IZ+6/_XS?H0=,VZ(DI]./K=[*Z=;7
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M=CW<5F9]N+WY/)7;@$25GCM:4-9":.?L:V/4Z,I:"&<V9[K>;'ZZG"UV!$4
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M&U]NW:M5[=!PT-KAMY%#;Z9[-NG)_H8;$46)$HZP^IP*' KW*E_QO=>QM Y
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M\TY$[7#5\Y4LTN[<HL47C!+AZ* ?K54.^V>#XS?'A[W!\>D)^_#Q[/QC[V3
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MCP98;,3'P#2,!4P@1B0)PWI95B!K/0-BC0PY\1NE4]9N!?]FB=(H VP*7#-
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MJ7&<YV";ODY_]>1@VWW7_C]02P,$%     @ @SQW7(A\4%8A"@  (4    \
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M-Y8'51UG\=D)8#E6'',RE44E4LX%5:\'=6\E#X[(2:YIJ&E.P#IT2<VP5@(
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M?>?I;.@3E,#?H:U432*:Y0R68PI5A(M>KX?:GJJNU' U'F%X"R2Y3AJI[OX
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MKYQ3<*QNF'T[Z"<#O>\ET.?H VY[6W>:\"0E67AAQP@L3+ITUS]N99MT9<?
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M!L?EDW31A59[K.:X_7W&9I'YBW=./T5,50<LW;CJ&J1K5.JR!'O8D'6?7KK
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M17=XF;&QWS$%/S<_!PN]_@D^7FWTVS1;KNP0842ZV+>\!)];_5U:_)\G>IF
MW=U'*?SYZ.&;WT?NG?I:?6_AK[=*W_ZZ<4^I^N&I>>Y%Y,[MBA'O%'\<[D5,
MKD_V^:"Z/PVV;\L3^+=^4230+RAY!AJ( B1-K3YB+'0&J'L$D$2]1(Y/)OT2
M*F,?EG!62,S"6?+Z,V^M,$8:A"?&T:SXA>*::?VXTE(S2O.=X@]!CK]3E$8M
MHB5'P1WB<V 9IZD=DXW?0P,C ;;H'R"N3'Q9^ID-;T4(5[@W2F0,0LJ[-'2=
MJ(4*[K[< *;X#RZU6;L*1;F57_=)/X_LN7^D.S9<Z]>G>Z0B H>(>&4]+ZZ2
M]J_!U AHDB$HW[U*ZB&K0IY@?\VT,I^LCY6*&7@-YCS-&$LZ.01Y<@EI^I\H
MDZI"*75C22NZN:W@COJWXZNBGWI^?-\W]R"VV ,Z!S#;UV!C%U&AD#<X)7:2
M,9 UI,40Y0[1K'!G04U.TK6N-9BV#4(]> )L.BND.-@5EP<=)3.>8+.[_0(M
M&Y_6S>C:U5R?&<.-U50\"OA=/IXP/E71M#3Q%5GYS!^?N4/JY?9TE7E3IC+G
MP* DH077IQN53E>D.4*^,L_9O:@/KG"9Z81(N")XX!2)'UK"1]T],/L*=W$@
M7F!REGE]$3[S"SI0>&RX#%#O +0*&DX8AU@EBM[>-4#)FBWG!4%5*M\G+#M*
M \W%Q[$K/$2/=4H":JN3K;"EW44N!-/3C+EKX]CBB-P"UPSX6'UA;-HA/>5'
M6Z/^O_:%<W%&OMH/NX>?]- _K<$8[)PUF+R+C+<Z;&7Z4L@_OR*H%_[JGC23
M5*W!8OHWX]0E-3AS84M/8&4O.8UF-MQZDZ=:]A*[R+AUCA_<^ 9LXR8=$8W[
MYLW$D^"ST0O,E; "UC')?4FQ-7X;=!1P;T=DH/0HB9)(7BA9QF5_,ZU:O>KF
M0K5#D.?> !M;^)*-/V[&/0URW9A2!Z9[>WF[^PGGM\6%%W$8-E:Q_C='Q;5V
M34$A-RU:0I9&[ >@DI7?%NS5F<CJT4E +.L '2CD)1(+R3._#9EPX6I0^("3
M+I!]=,06F8S2=T)S8D@;<0= ^@L0[VR&T<"&=^C^FK![D5@[7= \\K!K+N'Y
MA;%)A9:\SMG9(+1&%:@I4S1A(@_5BU#%]Q?2%0E1_:D.Y!Y'GPP=E!S-!'<:
M1%O?;84#D;Y@8AE[$NSI9]@/SIZ9TT\:_;OQ:HU\ET,H4325:U:/#MOK:3Z%
MZ&!OC-%'S*_!9*&OUU=,H5J$!#%>@3V)$\XX9-(EUHT:66JSW+(O(,)2KX<E
M5INJ7K&KWNKWDU#]^)W))=0[TI<@/J:7SD)(5>3%2C$HA-,U<1!T#/S(160C
M*<,H;9PUW^?NK?YD>J2,I-1D=994@3W+D.JV-C417;URPQF-JR%+NLW.M:T.
MJ<S"*U@K<N6-VT-]_K$29%W3;X6FGXV2A5;J7&6,*%)@#VD<D*I<*T/. V(S
MG#Y8+B,;EGU70B@2(.=(-_6*SX)-#/VT2F&*+_C^&I^H-SF-4IL"?M2_:&Q+
MJO6NN-!;@68*GGL^<TM8AV:S:)?AWR4EPD)1'6#=@4Q&:+>>ORED\.D">YX@
M4O1-4M4J+_L!&,YL\$&W]$"LA1N8RXMY%W8!YUJ#;G:YSR6K3Z]>?J$R,>MW
M[ZA>PQ!E[F9(_C8P7;:2D"PG+0$#CO6\MNR*-4A3@"*%BP(X%\-J8)"T; 7_
M%; *Y/84AQS R<D,-Z\IB[8K!J%I"<5:/2ZZS \>B-5E%-S3R3Y=?'JX0%EO
M,&I"6B!Y(=T#TCF5\^,QB03@+']E'A ^Z))9V446JX^WV(V\7:K Q/D /B>%
M\])M8&85Z-+G_6KPS_1@RN=6'UYBTF[UH\%#9A[>]QA>.R@ULU:TXK:"ZA]2
M_UDK-M.?OD01LV='R_Y[+1#TO"D\RIF2-4>2$LT9.@^P>^B:H"R90[=(2IQT
M.=5(,(25D.6R<2+:@= 3<B!XP+8MW'. ,N.BRT;;%TAW/*2.9MC_+8+?U"Q$
MZ3'_XS*2GHFDA::(TQ$VS=\7GYQ#*$K-<<H/>@)S_T7 (=,&].IH$X^^/F <
MRS_7/ RA(JO1>+C0K+ V.A"1&Z93,<N\<.0SFCF H!"[B>F$+6LP64*ETH7>
MY&2:*0BQ&YON.*'(T@%"HT\F?H-T>'(3& .L6^03&6QM-LX;"!$\G")>1ZF'
M!&*3)_"[IYMK[ -+BV4:$HV]%MQ$*;(,G(TJ'?4B#B+5\".K=)D Y]&%)PA9
M!.JE!\!^&2=0B/-N53CM5N9U.&SV5I]Y#TD;.\XU:XN3'GKU.?9NJ%KLC9[C
MPU:E/[8(KL\42=E_9NO]72*.:HYC+F.:5YI]O!W'?B<L_QSR*H]HZY]>V+OA
MB/!-R).K;UB'_-K?(?_5A,[O\,\L2[ATI#9U7\,?%I<.Z=VXM^]>F\.5WI.<
M+T_<4Z5#^M(6KO78"I^8U6I;Y56.36&PE5L)M5&!)57;Y[Q'EOK59G7]=%^5
MO-Y0,/K#IM1ZH@%S7BX@E=Q. LTKZ++>YR"6*B\#*3R"(!.(Y$L+Q3=P2+ :
MD><"AXX6'AVYC+.HPA(Z]"N[O!'=)/BW(1OQ(9M<1T9#U,>GT<>]BLL2P^N^
MF/;$D';HKF2+J%F)Y+$4468C-3FF^!%>!>>5/#FIFO"FB,?#*$57:^UMSQ(X
MOC=QVY+KFZUK$A..AN@R!7#&,]CR^*WX#VNP!G/!%MI&X#')D(JZ,Q3@_1+[
M2P:GFW#'G?1QGDX_L05]':$;@1OD:T_!]3'K1D='?UIOC')PR@]P-RK=EO;.
MLKF$0E]JP=%.C=L5TXC]4CAJB/Q^:^4\07P5?,"IA#1_B7R&ES%W$122  -8
M]Q:9=SM?Y?5QS9)I!P$W<EKK#L"@2Q382.<1-V&+@P=MOCP=F)SR&K2L"?(C
M!;V]+1\;X72CZ8SK<A-1EL!5=&4<\JFT?[670;C+EG6YJ%WT*/AZ+^#HR<_2
MC:"EK22RG;UQ#[(^C<I;- J,=DC[N]D[+=>*8FEM6?N]==AHME/$&F3]N'BL
M^/='8*K7.A.YGG"1")H14YV" (*H4O+891U(YJ8+;)%93M[B@SA[P#K+90>V
MC*]=V5U[!"F'A0?JQU-"S863V?$5T?J"W[JZ=JLZY?O'#*HO)6L7C-?+JI1P
MEZ! _X/])=0[M%?T$HP1QWP4.W@FBG?ASH-7."BCZ!5[([L6FG!X/[0#;'D6
M==8L]QJ&EQ3HJ$K0F*%ONM[FY4I)\:>W-1$:>Y[H#%C2#,47,,W2TFPON[:I
MAN#!L6I'3\CZ6>/[ZM5ER:BD',FID[5GPB5"EM0%=*^%=H(2_D00U_TVI !$
M\O M0G[[?3"%X2('GN7_$Z\ZYF(,5OLZ/"Q#.[BGV4@L?&FCM3L:'0::7K^-
MM?=NL_N6B5<@=/RY!KN(DJVY!L;%$/2 ?(8B1F@Z8 H?T_'?'X\><*5-%=-T
M([P&UF$2: WBDU*CPQ^<'EGZJ'OZ%7W0FU897A[MD#K18)GZ7"BX!Z7SU>6[
M Q>[D. >G0:^]89FL+H+)?1!C#7XT!LI Q?I:5-=N@A%_-ZF# CY+-3R+OK%
M'H>2=Y2\(9^$S1_.ERI%W#^*DW/)!'RX*X+_Y+P:@'<LIA^P)SK]=^4E*3?H
M;-Z#-XHQU.GG&3;=H537*AZEG2W_6#D6/!F39?DQ=4E9],+L_L4\3O![M4K^
M2[^@10R#_.T$LTU :/&7H-KJ\%+I)X+0MU\>EP1^CQ>:G 4M@!5.>A85I32'
MVD33B4;JM>K&<F--^.9W*.I'?1I&G=PXD8TC\8[)!9MF5UW*KE7$-+*.D[7S
M7L1:!%28GR,(_GO_V0A,%.KR6I'K6K<)"_D^ @N Y"W\!3)YY@SV;2.#(9Q;
M'6X/B"<TI%;F0+&2AIHHOQNL\[^':\N&:BECB\L&3,]C-U*BS'_S9(5[ A<
M3,GJ$]RYV [7 ODR$8D @GI6X?-SP$(_#P3YPGY_(:J3G4K7INJU;J&9@3>%
MC;-S$:0Q2LN$2Y!"<D^?SV =I<5 M=;![L&G<ZML'KGWH[Q4^9ILJK&2>B0:
MPT)UT+5P/L)LT2#H*$Q@$.2IBZGLC<N+F86^6 ;7Z&%X&(\ F[5C6;9]E1I)
MV;&AH]).+_KK&7L-M/VUDVJSOSP(!6V)-R0WQI/.SD743CR<:!I ,G_5KZ8
MBU*51\(8#B('=63$10^Z#C#O0);AW&QZ+FH+3HY#$I#2Z;!OP-U">-DXSK?
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M.:U0^Y=\ON1-97MF65+>WQ, \=Y\+R>I@$Z *J 1^%5B#$F:X$0O;5<_;2I
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MZ!U0AR[;/.S5F[K7U-&&[WT7\7Z$ 4?64>XWE\C]]P]HP9OXCHZ)5UO@CZ-
M_.T30#+=$7@\U$A0NI^9]F>P]^&K;Y*>82P"K$;6#A- /@XD3X*%#4&LP_]=
M'^<,Q:;"K\*![Z-QT+O-?(.>Q:W<J9$(C4CI?GA"OG12=RA9E6-)F,8B2V:
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M?5)>\O))FW'C)M6G=ZTD60;PW^.,L)[52KOVA@@U*LJ G-Z"/QP T;UKQX@
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M8.U;@?*<N[\\W\57)E?J)LLZU KEE)^_[D8;5ZPR-LW=CT'L/,],N2L&./"
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M5"9SCI8\(LM92:?5>:[GS;,DS7C^7MN/CP"5\002_EQXB?\=)AA380S[HRD
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M'DO=D9FIFF-FVJ&5XU2;8]+JHCN;(GNE K/_2KO'%<U, X+H*N?^=RTD4'%
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MW*R9L5HY\?F(;D;L*G8)UB%1+/KI_"/ NB,Z']O3(KZ2-[K@%Y+U:*!\[Q%
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MQW1NBGL.HK#!&MS]4FB?DYF\CYMDXH"MH%5^\?_NEG[I%*;U.\2MBY&>3EM
M -,M.>\[\0&;L= ==F5)ON[\:M#K )'[V Y[67QPX49&83E*?PQ'%C=H8HU
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ME2_-FR-6LIK.*%HT$OGTU<[U!V<\#PJS12O4*EEJ5B .+"?6EUY!^X\ GT=
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M#>/.&[?#%$S3KX(60V2AO%:I?71U2R?@(@L8M,];$F[[Z9FC+ Z643A;CKQ
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M2^%_B".QG+MX?N4<V%].OR;G*JENTJ[2)2N/*B8!G"X(^=#)]S^!_'-OJEK
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M(R@9BRNIR3QN!Q(-Y1W"9W $#?7JO[/OQOU?X&^*K:TUS4+^X^&>I-,NM:-
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MVKZ^;OH]+[_H[H6JIJEJLX?<7)('!P S+C@M_=R><9^M;E?._P %/$XUFS2
M,[[ Z[F;<&EBWR,N<[AG>K*[??W%F4/EI/H93G=R?O$<XXP ".">,C/.#ST[
MGY]JSMV_I_\  /8:M]R:]&NOGWW]6.HHHI"///B->R6/A759(V*LUE.(V !V
M,5VJS#:V5!))X.!R1P"/E_28-L%K&,*1'YSD?.7+[G'S ,&\QOFR'&,(H!!
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M:J*U5K;WH_DO-_F_4^G@[\K].M_Q./\ '%]_9_A?5[D9!AM)RAY(5MI",1D
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M'N?[4MQ<:M^T)KD3R,T'A_PYH&GVMMN?8Q:U2_)8*2$S<S&X.$)*BW8J0HK
M\-:;D*2O#HC%)%^[\N,.NP!MI=C]U6&49B>:_7<HA' Y3AXQ24J\5B)/6[=7
MEE9VU5ERK16T6MVSZ#+:?LL'13T<H1F];_&DWK=]7;>UK622LDTKP]$3EU$F
M6##="R^8H^8@X;9AB<!^BY(PJ XZQ]#@9'5H(E5@Q)2(MP Q5UVH<#>SQ\J
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MV;\TWIJN[TLDCY3^,5P^F:YX'U=&6-GN;K3/,C.URID@N4$BEEWPQ[&+$ R
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M+HIBP%&0Q*\_,/GC2[7*VL6%&RWCWG#;?,=CO;=A1(A;=(7(.X@G[VXU[?\
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M @; R,22S,JJ2!M;?RQ8AB<'PMI05%C3DR842;50G*A.B* 6*@E,'80Y >9
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M22OK?4*D%.#C:Z::MT=[+?T6C_6Q^[5U#A7&22)-BG@G8"2 &')RV& WLJL
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M\PP G5$*;,A3]2>/I$99B%VCSY'."$9LRR;F.2K*V002Q&T\,RR*ZIY;\--
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M0J*HVDG] 6ZGZG^=?#'['^G7$-SJ^J7"$2ZEI$<LW.%$UU?+=S*%*AD4.[N
M<9S]U"51?NDJ<DXXR><CI7SE1I5IMR2OU;MJ[-[VU74^EHZ)7T]WK;R.*^(=
ML+OPCK4!0R>9:S+L"[B> <8R"1D D+R<#T!'S!X<<-9V[%@KK"3N.3D1R,23
MG()W*@.>_8<U]8^+$$OA[5E[_9+AQUX")O8\*_.T$*-IRQ R#@U\D^'^;*)3
MP?+E )/W0)W+*!\H'&3_   8P0BEE'I99*U*N[_#9[M6T?XWM9KO]WEYE&]*
MBU_-OVV6^GG^/G;\T?VA[)U^/?C"=FS/?Q:)*54HR[7T72RVQ(S\V&W$G?\
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MLI">;'87HGU/8N6("36ZQJ=[1("4C5=[JOV-.!\G4D;@,C!.2, +M/! )(+
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M_LZQSGKG[-'G/O7Y/7-V_CCXKSBQ)NM+T)6TZUN(@HMKB[D\I;XJ6ZM UO\
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M9+E7C*RI I"DG]XF1'@%RLJ;D8J2TJ@+%'^Y)*LOL?@:^LHF!G*HLC!E,F$
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M<UGP_P"'_%FF76B^)=.CU+3KLQDP2NZB%HRA62 H1Y4Z.&99T9)%5FBW^6S
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MFHMKEUBM5>W3=JW<Z">&PU.%K;5].M=3@8,GEWMK!<!04.>9D?AB74E,<[2
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M%MV&&0 <'/S+G(8G/O:XQ\O(YYSGJ3GG)SSGO6'H&G)I]DB*FP[5 !4*R@*
M5P,  =,   A@ !6VJ[5"YSCO^/'KTZ5X>^O?^OZW]6>J.K(UJV%QI\D80,04
MPI!88W!6!'.1M)'(.>G>M>D(##! /U&?QY[T7Y=>UGIZ@?":I+I6IZGILP""
MROI%M][$;X)Y/,B$8;)9(W<Q;MSYE8)(SR;,=?;70E'S'IM&/EZ'/((/?![$
M_P 6 , [?Q6\/2Z<\&N6"B:99)$N(%C==]O)*%D<E,;DM@PF",/E5&.5XSP%
MA>+,H='X"H048GAE#(KE?W:3(25>/<[#",WWME?54JL<50C4C%J:2BTY)O3E
M3=OEO>ZNEHK<WSN,HJC7F_AIU+2C)Z*$KQ3_ / F[:6UN[O51[Z"5XRI1CM4
MD'!/!R"W9=JMA6VG<I*@/P6PR]\/>'-<*3:KX?T;4)%C$0FNK*WEN%3.["RB
M-9%!.1E77C[N %QCP7A<_P 7+ ;1CC)Z@*-V/0'<3C&<\UH^<%XP<@8)SUR.
M?S_6LUSP=H2E!VOI)K33MK>[\M']U4\0X15Y.VB3U2O:+V5T[6ZI:J^ZN%CX
M)\%Z80]AX3T*VE5G9)4L8F=&D<-(0THD."02%! 5B67:22=Z6<*0!L1,IA8P
ML2(H0  11H$2/:1LC1%0%22#DJ<7SBN3EN 3UQZGJ3CJ2>>.3GJ:A>YW+M9R
M@&UM\DL:*H7J2S;N#\H!8$R;F).,&FH5*CO*HWKK=N3=[+J[ZZNW5IOO>WB(
M2M[UY*RBNB5U?LK=U;5=G8NRSY+,S$Y  ."2.IPJC<>?O$+MP% ( 4D\MK.J
M16%E=75PWEV\5M/-<3$@>1;P*7D<$\%W4;%4D8S\ISC-#4_&'AC3XF:YUK2"
M\8=6B&I12390,TA9%E&Z5-JQ\$ O\F,%!'\Z>*]=U?XG72:%H4-[:Z DT2W=
MU,64ZI%.?*F00Q-CR C!3'(70[3*JR,!(9J3I8>%E*[3;LFKZV2L[[:WO?2V
MB;=FHT:N(G!N$E%6;<M.VJO:^FKM=6U79YOPK@O?'WC67QGJ,4B2:CJ,8A26
M+$D-K:1QV\$+;D0!0L#R2HRE"2<8DB#']4_#5@+'2XXE7#!R5X(()(Y*D$ @
M'YN"00W((R/G;X3> DT@6)V+MCD).80H9E4XP N%'&%505!4#+$L6^JXT"(J
MX'RYZ#N<_CWQGJ>_6O!KU/:3<K;N][WO?7[M=&VY=]SVX1Y(I=DELE;1*VFG
M3IH/I&.!^/\ ]?\ I_6EHKFE:SN6>-?&'1SJ&BI-#%NGL5>Z@8*2WFV\<KQJ
M"%<D-N= K IE@<9X/@>G7JSB&52$C;D1EN$QG=&6(!<B4L0SE?ER!N)0#[*U
MJR6^LVB*J6!+#>N5(56)!^4]LXY&.6Z U\<^(-)?PMK<MHV5L+[8\4Q!6&WE
MD20.A!78&#;6^\N(P02RC(]G*JO/'V$Y6<E>#D[I-:J-GJFW9)]]+JZ/-S&E
M>"JQ5W!^];>TFE?3^57>UVE9:O7IX9E.,<80H -H8J6R00K*0#G:I;.TG(VH
M&SKQ7&QE+LKKG.UD1LC*8!R0& "[DRK#< .N*XBQN=N"PD"@LDB$\ACN5F!Y
M'.YB/XE#?.@<&,=!'<*X#   C(48&/<+DX7., @$#CT->C4IRBTI*TD]GI_+
M[VC>^^^SNGL>9"JXQ3C-\G\R=]5RWB^W9NVEK/3:&_\  W@35@W]I>#M O/,
M?S"WV*( N3D[?LXB&078_+_&Q/5LUL6&C^'-$WR:/X=TC3'?Y#-:64"R<L,!
M9_+>0<!3D2O,2"F3N"FHLP!P 0#G./3/!XQD@<'L1V!YJ1K@,"1@^X&1@_-S
M@G(VG&#QL8CH[;H=2OR\DJM1IO2#F^6S:;25VKWWNE?OU.GZVYKXI**34O>>
MK:33U=M+-VUUWVL]6:Y:1MSN68!0"QWX*DA06)/W0%VE6*D( 5VG:F//*%W$
M%B,EB68L26(W'+$DC)'RYZ<*.@JK>:A;6D1FN[FVMT'S;[JX6W7 Y)S)+$'
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ME::?;ACB*Q@BMH\N"KEA%&%'FDL)2QPP=FR6(!I33L<G^$J <KGG<<%B2Y)
MV?Q$9!&" C"H9M@R2Y!R.C9R0&X!QDG.,#G.2<!7*XFH:UI5DDC7VLZ?I[H
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M*2J(BD@X W$J6XR,%<8!Q7TC@9SCG&,^W7'^?Z"N9\-:4-+L5B"A<%!@( 2
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MMRIZXY 5CN4<C;@E(8,&QU!(.& 8$ @C!7!R"=PR,@=":\\T^\25%D4NLL3
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MC &-J!!@J77C*Y;)#-G9ER3$8';<< #:N.,A0.0,C& 2V,#<W6J\EQM7Y@<
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M'Y2>^&.Q7C-MN[U?](]5W;W=K62>OSO^@4444@&-U3Z_U%><_$K1X]6\/7D
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MLZEFG[$JG["PF"*M*8&!X@<RESIW6V7XFL;<:^N%,R074)^V)AV1KU%.D%$
M!R W@"2=@)U=A=#(D-F@HEB)-5."!E$ ?]EYME R%RN35E?PT0W%#I6;^6Q4
M\:S:.O#J:M/!W7@OF7*"]),(,]L?J!">Q*W$W? ALB:YKYZ*%/L S CKJIYN
M,XFK5R55P>^AQM5:*" 0IGAN@&@K^V@FD8UH@#/.&%.SLYYZNUYQ')&P;5AT
MND)(=G@IA<;P892?\(W51;Q8IAVR>"^XQN[^WD<#Z<*- +<I=$C-^>*T>J,:
M0B(FG@*B5<9]+R2(DB>%CI%5R7W!T0WP)S"Z,KSGC#[Q]-O L;XV"#83[[S[
MJ!07GQ<-GQ6H(W=B:^>;A^0>5F1+N4N.ENONNIVOJ$DR%-';W0L'S[PY2 _3
MY( -CJ$Q? 1U-SAUA=RH7@,%= RJ<WO&2+IE+"!NQY,WT':N,E&CZ@M)G#OU
M%RPQ6"_>3\#62% 0A24FVVO??M_#Z06!.-!MV@*7+H5@T@G&^*:91(PH+GJ&
M7#HKQ$H>A& !ES)*F'=.)'.-:WOGVY'[X&6HAN-\S:J(".@%G,C<^NE83P[#
M OR0Y9/F<S:B+I5C;]_=G\Q-T8)]!&HXC-P%R+0+(IP"PIK9747/I,="'8+F
M3!(A'W=1L_!')_WF74].M\D]$BJK?#9CY]E<3??H@LNK:L=JG*_A7+R<@>(5
M=Y&1EXS^]59/.2HJMH@$-[S?SLGA0MNNHMV*HE74NSP4!-YHJQZ"79K9P!C.
M;R120!_?E6$WYEC6%K&KLTLMA9Z/-$_@(V_/]YBTY+#CG^5#7 4%^F4OR.'U
MMK5?0?5238>0,J>Q'S)"%SS/9EA7HI[),>;5$/E(J-K0N26\? 'Q+@FQ :,)
M-)]'-,&?3'-#920>0V\SY\XAC@<*S2*BH4)S(?+SI&-&'%>K^J':!3]R)')6
MS0;GOA:_'B@^/YKKEOD^+J5I?Y0@3NZSJ<\EL"_#&+$F:\=QU+M&D6V0RHT&
M0PJ((U!BSCB7[DG]N14$,Y01)]28<P:M*4XT^2I1$N,T]"%=JWZPW(W-+]_6
MQN6XP)P!9XKA21(5P*QDK'-\O?@]5*EE8^)#W)>I<W@"#C*GMX:;"ZG1]CJH
MBM2D@UKC=9#+TSPP42O;;Y_33F.CH\H'?VR]'VQ]&W(G/<Y,N3^[=G#2!EU9
MGX;^ON=_^_O@:-'!,I*H6C8RZ7X02A"!#;"2AU%44 '<2EN3#]Y<!X=9BI/
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MS7]ITCOX@L :RU[UIO**L18O#?5AF:)^R,\+3F\Q[[01(!BF U]$]3?N7]D
M=/7#(D7M_%<JN/Y?4C$_LQ%S( !I!2TD/-C1&*<[U=[(F)R:="P*E'0&/&L2
MB*!61<5I-XC!G<^(1GA=K3FB2Z\LD04R7NRB@&[6 F-"K@F0.]Q3I[H@^ HW
MVF)Q\G<X5/[$@0064ORO$JV-;(8PP-CPB'FYIHW$X-J+Z7".>FZ\89L@$_;&
M9U(UKO&M"Y@5H9/:<J/HG4S[4/'=K\:1;POL;FKM<>$:12Z+B'T\2DSXV\*F
M^U\9!,0EH*"*^(S7IVX?"-QNO(H(^@W#:GB/]&%A;]238<[K]X,KG[)Z##_
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M^<+O]\.IX']C=!H *V,$GC>O1_S6L"B@&_\?&Y;=_[5%<Q]R D\!Q:#BY/O
MHZN--$QLJ  5,=9C,^SZ/+]J%- U-']6E@P9Z.3?N=$FAAZ1I%^P*')"-074
M;*NX":2$C$A\07CUIQSH_2DX&-!K_J:&?W42>&6 .,8,U 05;77J,.NO1WQ
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M_(Z+7%EV'S*",TVS#<!3ET='"V6=U,8Z*K<KD._B]],NR](IS^>IPYZ:W:*
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M#B(S=-S(-%@,_GWD8H?ZQ_(22S^R83WRFYPA:F7.4'MVFK*X#N0$G6 +/<4
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M,RV%7<UHH\K-3:/%NVU228JBN#TRB$+!4AR3#QP<D(^2'//&QP'Y""\"].,
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M#S/^EN=HCSP=I1;U9:R";)98SC<G'5-^N8\DX+R/YU2GL!F^U_^C5.+&8=@
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ME;0.&YR8V+^M\$G@SBPZ'XW^0NH +R,&R6'7R:AU+O.VKK;=0M;_:+R*S$@
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M[NVZN%T(_1_,FOXRFQQ4WR4F6,ARF4>4W ?=F8:OHO.)0O7K0@3-%Q1  BR
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M4VYKMC/86JXTOQV]W;.+(#W:^XA:;Z$ )N#0+<VNZ:!"^%TQTAIX>Z)W_Y.
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M+$*LISS7"JW9)8$+H\O3B^F2:1QHM/7B(X^G&B([\#>N9)O7FW[]@SP1GFG
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MSH#8<X"1N7I\F_31"VA5K+.-"S]:'XR)3-2!CE  !B8@#I(LWLHS3KJ.3<,
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MAZ6U8V+EL,*_0.##:D2DFD4DW.E5C<O6M%RUW(;1_ZYL *E 9*< NJ\1D!3
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M(TB,[NYFHSM&2'<)H[MS'WS/'^\Y=_>YO[K;.3NOK+P,O\!W81P1U"L  (%
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MW-A##RJ_E(M ;7EQFDNL[U<A 67CR&LXT*'Y6AO(X"<< >^%BQ*_FY@V+ S
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M.FB[S)#>+:YBDB1U8AZR^:/NK[XTT^I\Y_)*B@<1O/;::K:3]I$]1#[B\_*
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M'PBAV\"/A;Q#3@5I$SP*XHZS(&+E.9%'A$+2#X/XPR0J7T@_0*+T@? \)O/
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M,-?O&]"2'#XO'  3\EC@+,_2&[+/2K4T+<>!!8S/2L<22D&/!<R2!39O2A&
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M_[_[6[__Z[\!K+\#7*KS,+>;"X=']FQXJ[=ZR[>*6[B,>Z2FF66U:1K'9<&
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M+&]92UR>5Y:UU*4ZW;M,^!*TK"*-+UDG:M_WRO>^]-5O?O%;7_[^M[\ 'FN
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M@8A! Z ?Z:A7.KSDCT&M'U/26K^IU64E,2H_^<B':X&'#6H41=N421%  "!
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M-\,YSG*>,YWK;.<[XSG/>MXSG_OLYS][3\V"'C2A"VWH0R,ZT8I>-*,;#69
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MH9VJJ9ZZJ10:F9,)?3]I-LU3$(B0#CG1!<!1$*3Y$T^:&.AP$^D@#Q<RJP
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MYCN^Z&NZZ1N7I2N^ZON^[NLG+5N2</N"KE>[NMN[^@N\^.N[MON_^<N_O"O
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M/&&L<S3=. (8!U'=^BH6U5V=8H'>?'0/K&$ZXN(LLU"MWTT2^1 1]JT;O0H
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M2NX4T[CUA[,EV[!%V[55VT5VY$1N9$@^V$A&Y+-L6^$"(<-RM;I%KNST_Y-
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MU*5"=:I*O6I4D4K5K6+5JEEEJE<O2,.3$#$E5M%'2ICX$@"P"P B*6M'$ $
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M$**EB:9IJJ9KRJ9M>H2G&9RY^9O"*7FNV2-S*J=QBJ=[JJ=]2J=Y&FQ+Z:>
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M!T2<C(FL2&1,.>12E6Z417;,Q5N2NDT:/=0K/1(;0\^20ISPK"9DB@9,PJ)
M,+FK"#Q;*Y\\B6\$JI^PNZ<@1F-$QI5P.QOCN))0+]#R!Y3 L[H2/2$CO9=)
M/+!4O)S$2?_32TN=1$N3T+R4@,BL<$N!D,ICO,BJ!*VG_"FU9$N^#,NS],N]
M+ O5Z[X>+$S%<<?R@SXJTRX[>PUY/!$;; U[/#G5$"K7X+^@.J=B^RG:^+[+
M4+O9>!-A9 W]^\75\,>M\K\[HTB+U W/_+A_),P$-$SJT#[9O$T?=!R>W*KV
MZ@U7++ZU"@YWP"KW(\T<[(>+XPU^ "W%C W0"DD,T3_1,*^@8L3L^"QZH,W<
MU$ZY.4#NG$T^0LQ%#,7B4#2E7+ZULD[+H$%LQ(VD5)D+Y,$^V<5\R,[A>$W@
M5!F/<PYW^#>5VT&HR@WF,T^5:4;<D*JZ&C_+,"UTL(T%+(W^5,3_)@/0!,/-
M[WP<FS2L/B3"W4PZ'?$KMJL1"7V,I9R1=WC.BS!%=: 1XL)+/?RI>2B2X230
M\@M#(WP1MV,1K/O#4SN1X>'1#052(442.H01[:*''BE2C9A1][M"O1Q2* W2
M- S$<YS)=91)+-T4\00M=NL4MJJ'6Z%1V3%094S/3&'/Q]@>390]Y/+%M4H'
M2@&Y%0Q0/)&_I0*F"%4Y-X7/*WU%*RW'<:+%/ZW2+%5'0.W -N485V2YV+03
MC<.Q?*B'2MS(.G&'Y=3 >]#(#J6*$(I)1T')%,DI9 %*1Z5)4^U30S6?=#S5
M0QW4:$I)SO@V5-G%[-K,T<H7.8U52B4-_W@0TPJ$OX9,U#AMU$&YQLZ+U&=\
MR3*E4XZ4SS]9U#FIOC6M%%@U5HY#UHR<TPI-55<M5/;)4']:2\ 4UXS:T1RR
M2I#80[)05W+(.Z) UX8 O9!X5/V*U$GM)Z!P5Y+(49@P5W(M2X"5"+(4RW'M
M2[,,S(/]UZJ32Y5@6)F02WKM+'N%5X.0UX0UV(#]RXLM6(X=(SC93O"TT/MX
MT/; S\Z@U<6RU:D"D ?%S]\\V=C\#.9[6>FP5BW$5F7]P. ,69 56=*PS9X-
MV@N-$)-E#YJ%S9W=##0E0PH%JOA0!^E+6LD -:72O3R2SLH0KZTJ(]Y(MY]2
M3:'EV:&5#^\46_^S]1N2[0P[!2KX0R2]$D#SH,ZI EO5,,6+-,X ]8YTX+W7
M+%JDY=/XB]G*S-GV<U:9-5S,E!WU!#_DLL_-2-M#XTS/6-ODF@V3Q=JP]5GZ
M %<YE-+,\M<NX=<60<W;TI%+5:IYN C1?#(:^41\?='1HI&EM4L<=5$7 =V#
M$-W<O=$H!24T[%W/#5[@30@E;9'BU0@ZG-TRK-W7U0AV'5[AC=[#HM)N]5-O
M1=5V@E6#R=8ZX3RXY1X^FZK>S)6#3,B%)%_.#-:ZVM,[?4ABU55FO0S.,[=6
M/$9$J =6K-/W9=/UC5;!O=Y6!6!"%29!%>#JY58#SE*'U!]H_<SW'='_E2G5
M=J"S\:)'RM#%MK)@TC!%,!4-KU0KY2.-IIR*<>S47<4,PZ&*P8.49+5$I[5>
M&$;@&&:X5<5>&PY@%-+>2J%@+925$_TI?. 3TAT/Q\T3UQVM>0A%=_ VVUK6
M;9V,%LXW.-V5V9T'/S'%GQO6I 447]VN.Z% MB)/3:U::>G(=IA=?\B'5;D'
MORJZDDS?04'$+@:Q+_XL,=;6%Y9A/6955>%<A,W8/V8)?RTBBI6)(V9;FG ;
M$!:*QWR,?I#4@8 '.[3=B;#8C(#@@'&'C]B["N8)?84(W5V(0>Y80%[+@=78
M4L98@MU85DYEMW#8FH!EC'!+3.X'3:8(3O:K_Q5]NR=5951>95=N96 FV,',
M7&,>6QF4W GQ6\GXX='"!],88F<I8LU T+6"YM*@W/-;C98EW/QL7]=X6?US
MYJF"YM"87;"=X], 8^0BSV^6'636W'@&VG@^YK-%#F;NCJ-MA]_49D\\XWY"
M+]-8![M%NL:$C2=TOZ*+&^D,WZG YM<@L$V]YWJN:/DU)XK.:+159N;H!].:
MA\N\0XC6C:%4NR3FY_]%0<.=#)MM,GQTC<D$2?)+:=- 8Z&RU!Z6C99.0CR6
ML]>@VA),QF2^50?E:*6],5NFW)?NZ;V29XW>7"#,-.DM-=S-$MV=D12&PN7-
M$:/L+'D8B*N6@>=M$?]_UBL%65JNO%W>U5';U=&UAM[G^=VIANNY[L/C%8F[
M)EZ](NN;.^N AMVIJFNZ'FQ1HMX$GN$;'F (TF'MX=Y/25PG&^E<D6;]$NI=
MF=;A$]8[:>"_;=\QSN,Y@>P.FQ6;'JVDSNG-3ND]3NP#)K@"1FP<7NW8YN/6
M9NW#EFW%INW;YN,:GFW;ANW<3FSD&C_<KFW?/N[@1F[CABT_5MA??NY ANX7
MTRM]D&Y?CF[L-F4?S>[K=F[N)N5AMF[P%F]A)N]@/N_P_NXC(R-[=FKW;F_X
MMNCWEN_XG@UZ?FKZSF_\WN_YYN_ZWJFR[6\!_V_<,$4UE@U5' \"U^\!9_#_
M!>>.YA9L"<>L0YZ*>Y 1)E:9"=]P6))KPOYP#@]Q$!]Q$2_Q&#%LX%YN%=_M
MWRYN%E?N%T]N&5]QV'YM%T_Q&*?Q&]]QW<9Q'^?Q%N]Q>.GM&<]Q(__Q#/)H
M,8P,&$?R('_R)@?R*$^4YNYN*Q]O]>ZHTMXO?2CO+$]O[P[SJ-AN,<?R,O?R
M,T=O\P;S*T?S-E?S+U]S\2YF!Z]S_[;S!K]S/<]SQKEO/G_P/\=S0!]T02]T
M_@AP0M_S1 ]T13=T1G_TSXAP$I]T$Z]T2L<2#[=T3;_T3>]T3O]TUB(C*2]R
M)Y]R*"?U4==Q(5_U4Q\V&V=U4X]U5(?U66_U(T_U_UNG=?0A<E6W]5*O=5GO
M]6#/=5_']5_7I2HW\S=G<V5O=C=W=CA/<[$\Y3BO=FF7<VM?=FR_]FR'=F9_
M=G '2SIO='*'=$=?='0_=P;W\W0O]W8W=W=7]WA?/427=WB_]W?/=WO7][N2
M=$__=U /^$[/=($O>( _>(-/>(2W$A0W=H?7=6(?]F./>&"O>&&W^'IY]6*'
M^(GO^(??>)"7^(\7>=?B=8J_>)0_>97W>(X?>8QG^9"7#$S;N'Y ARM AW2P
M>9S7^9R_^9[?>9_G>:$/>J('>J/_>:0?^J-7^J0O^J9?>J=G>JF/>JJ'>JM_
M>JR?^JO7^JRO^J[?>J_G>O^Q#WNR!WNS_WJT'_NS5_NT+_NV7WNW9WNYCWNZ
MM_IZX(=9X(=ZF'NX[_NW_WN^!_RZ%WR_#WS#'_S#+WS$7WS%;WS"?_S$AWS&
MEWS'CWS+G_S+KWS,WWS-[WS*__S,?WR9XX=^P ?>BL'3G^!V0/W55WW6?WW7
MC_W4G_W6IWW8MWW9KWW=O_W=SWW>_WW?#W[<'_[>)W[@-W[A+W[E/_[E3W[F
M?W[GCW[DG_[FIW[HMW[IKW[MO_[MSW[N_W[O#W_L'__N)W_P-W_Q+W_U/__U
M3W_V?W_WCW_<1P32/\;V1W_\OW_]A__\Y__]EW^ :.>NW3N!! T6')CPH$*$
M#AO_0F0H<2'%AQ,M5HR8\:)&C!X[@N0H<B/)CR--E@R9\J1*E"Y;PF0I<R7-
MES-MUHR9\Z9.G#Y[ N4I="=1A/3Z\9NE+VA1IC^'/FT*U2G5J5:E8HVJM6I6
MKENO?NT*UBO9L6;%H@VKMFQ:MFO/>JSG#P#=NOSFTI5'3]Z\4GOGZ>7KEV_@
MOG\+#P;\-S'BPXL="X9LF/!CRI$M3U9\67/FQI@95^8,>K-GT9)'=PY=>K7J
MUJ1=IWXM.S9MU+9/X_Z<V[3NWKQ_LYY]VW?PVKN+#P<..SGRX\N="X=NG/AS
MZM&M3U=^77OVYMB95^<.?KMW\=+'=P]??KWZ]N3=IW\O_S\^??3VS^/_GM^\
M_O[\_[,WWWW^!5C??@4.""!\"2)XX((."@BA@00^2&&$%DZHX(4:9M@@A@Q6
MR"&(&WHHHH0C=AABB2NJV"*)+J;XHHPQTHBBC2?B^&&.)NK8(X\_LCCCC3X&
M6>..10X))(Q)(GGDDDX*":611#Y)99163JGDE5IFV2263%;))9A;>BFFE&-V
M&6:9WN&#5UUOPAFGG'/26:>==^*9IYY[\MFGGW\"&JB@@Q):J*&'(IJHHH9F
MTZBCVC@:*:21-CHII99*2FFEFF:#Z:.<>KJIIJ%V"JJIHYYZ::J9HMJJJJZR
M^JJLL=+Z*:RVSHIKK:+FRNNNI?_>ZJNNPPI;++"]'OLKJ<NN2FRRSC(;[+/&
M1HMLM<HV2VVVTW)[+;3;>JNMM.%V"ZZYXYYK;;K8HMNNNNZR^VZOB]);K[WW
MXINOOOORVZ^__P(<L, #$URPP0<CG+#""S/<L,,/0QRQQ!-37+'%%V.<L<8;
M<]RQQQ^#'++((Y-<<L66HHQKRKRN?&S++ZL<,\LRNTPSS#/C7'/.-^O<,\\_
MVQSTSD+[3#300R-==-)'*]TTTT\;'?724CM--=138UUUUE=KW3777UL=]M9B
M>TTVV&.C77;:,)O<MMMOPQVWW'/37;?==^.=M]Y[\]VWWW\#'KC@@Q->N.&'
M(YXXP.3_,K[NM_ ^+F^\DT=.N;B25Y[YY9:7"_GFFG>.^>>CA\YYXYZ7#OKI
MHJ=.^NJF.^YZ[*W3_KKJL]LN.^JYUXY[NHH#'[SPPQ-?O/''(Y^\\LLSW[SS
MST,?O?334U^]\&>KG3WVVYO=_=K>:P\^]]^3'W[YXYN?/OKKB]_^^>ZK#S_[
M[],??_WSVY\_S];SW[___P,P@ (<( $+:, #(C"!"ER@G/3A!7+( (+CB" %
M)5A!"DX0@AJ4008OV,$-?A"#%[3@!DGHP1%R$(4A-"$(5>C"$J80ABN,X0EE
M^,(:XK"%-MQA#D7(0QWVD(4^#"(-@6C$(1Y1B$HL(A*;N,09_T+QADEDXA.E
MZ$0J8C&*/[RB%HG8Q2E^D8M6K.(6R>C%,681C6$T(QC5Z,8RIA&.:XSC&>7X
MQCKBL8UVW&,>Q<A'/?:1C7X,)!T!:<A!'E*0BBPD(ANYR#E"\HZ)9.0C)3E(
M=(3C&^$ 1R;'P4E-?M*3F=QD)S])RF^($I2E'&4H3=E*5JY2E:AT92Q/F4I;
MTG*6L-2E+&_YRE[FTI>U_"4N=RE,7A83F,8,)C.7Z4QE0C.9TB0F-8=I3616
M$YO7/"8WFQG-;';SF=/<IC?'J<USAO.;Y!0G.,O93G:N4YWH=&<\S9E.>])S
MGO#4ISSO^<Y^YM.?]?PG/O<I4'X6%/^@!@TH0Q?J4(5"-*$2)2A%!VI1A%84
MHQ<]*$<;&M&,=O2A$]VH1T>JT9.&]*,D%2E(2]I2EJY4I2AU:4Q-FE*;TG2F
M,-6I3&_ZTI[FU*<U_2E.=RI4GA85J$8-*E.7ZE2E0C6I4B4J58=J5:2V5!WW
MR <^ZO$F?;0"K&+5AUC#&E:RFG6L955K6L^Z5K>VE:QOE6M<T;I6NZ85KVR]
MZUSU"E>^UK6O@@TL80%KV+P.]K![16QA&:O8OSHVLHN=+&0I2]?'7E:RE=UL
M9BWKU\YR]K.B3:QF06O:T3;6LZ15+6'S85;7PK85L9VM/F!;6]G6-A_YT <^
MN-H*?/QV%G3_<1-QZU+<X1HWN<A=+@".VUSE/I>YSITN=*DKW>IB][K:C2YW
MK=O=['YWN]X=+WC)*][RHO>\Z@TO>\W;WO2^=[WNG2]\Z2O?^N+WOOJ-+W_M
MV]_\_G>__ATP@ DLX (C^, *YBX]N)J/K?86'[S5;6YW:]O9OO:VK@7KAF5;
M6M1B%L0?7FUH27Q:$XN8M2%&,8M36V(7GQC&*7[QBF7<XAKC>,0VWG&.5:SC
M'M/XQT+V,9&#7.08 QG)0S8RDY5\Y!D[N<E0EFMO[R'7&R\YREJ>,I:?W&4I
M?WG+8>8RC[-,YB2?V<QC7G.9O=QF,+]9S'%.LYO1S&8[S_G.:LXS_Y_Q#%C=
M0IC.</;SG@E=YT(C^M"*'G2B&;UH.1O:T9*&=*,I_6A!6WK2F-ZTGB_=:4U_
M.M-(?K"#OXK;M^X6U7Y-=5M975979UC5LF[UJFL]ZU?;FM:WCK6N>XWK77,X
MU[_V-:^';>QB(SO8P#XUL97=;&8?V]G1AG:RJ2WM:L/ZVMJV-K>SW6UA8QO<
MV_8VN<7];0Z_-MT8WK"&V]W;W4;XM[]U,#Z$&^![&QC?"=;W@O/M[WW_N]\
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MJNS)MFS*LBS,TNS+VNS,WJS+XNS.ZJPW:FFYABNYCO^KN0IMT1+MT8;KM0*
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MWYZ=^W?OX<F#-S_^O'CUY=&W7Y^>_7OW\>G#MS__OGS]]?'WWY^?O__\"Y!
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M[YG5)59EW3JJY4Q^B:U8(\9,Z#06&JJ,1L3JBNJPL)8]B$W$Q!),%X=Q0@\
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M>]QQCZC*K1[HE,X\G(XQ?A1X/>_ A\CZP0^OE><=0D?SS65>]I7'I>7SA*=
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MLTD@I*5P#]):[X%+KRA+0I)*&!=PIR,BAP@ /F>)B)@B1P=PQE0@.Y):[9$
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MVZ/>$V?I8V;^0( 5H5W@0[4?=+7I([0C>4%R"@#G([4& 6"-@;4:%&GBXW\
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M>M(KTN+_Q'B"MWG"Q(M"Q1CX'A2$$&A7#RF4#O/@8F@'*6B***&4Q7,V(/V
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MY4JN[53N[5#^[=V^[>*.[><>'"\]Y#Y>Y#1-Y$'>[O'^[O(.[]':_]-\M1U
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MCV:((+X/E&8#+4[HCNCCRP!>B*!BV'6()";CD$!DT-6([/59U$5)C*Z(F :
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M',4K&<H!-\ZAQ!+/-##D&JK]/$Z@%' 7YV_.(G#B@%$JA+'H^F$6C [\! $
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M69_GV9\ .I-RY&M7\Y>9R9F7J9D(>J +ZJ )NIE;D4K\QTK_=Y0!V&="PI3
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MJ8L-LVNS&G2S-3M$,$O$-US$,T-$1C1$16S$2(3$1RQ$2R1$3(2SB)$S"KS
M"53 QLFSM? V=D,W4RQ%5+2V4U3%5"1%5GQ%5XS%;IO%<&LW6:S%5;S%=8-%
M6MQ%7;3%7@1&7&S%8,S%8B3&8>3%9/Q%8US&8U1&7WQ&9D3&:'1&:ZQ&;$0T
M 0R+>"M D1HXR'L\R<.W<=RWR#M'<43'R2M'<&3'@\- #N2I2FHPH#+_"Z&2
M'WQPN!ALP7U\01G\1WX$2'\,2(GK!VC0!VC@AX-,R(542(1T2(9\R(:<2(FL
MR(B\2(C,2(K$2(K<P8&\.)!+K"Y$#'R .>CP0P"8.X+X07J0CD!T"S7L";Q
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M)$_T-,_9P(=.\(3VW 7WC,_WE,_XA,_VO$]/L$_ZU$_\Y,_ZI,_YQ,\ W4\
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MD-%0AT8((A"-*#(F8@R*-+,B?"#"%"]"U:EJ:*H;EBJ'-,3A#G4(I18\ (A
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M$1]SCCN@ZD8W-===F CK&Z+Z5@:%)#(1BEK8&/\5N6B4/"0E@0=L8 $CN)1
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M8 O*X O.8 S2X W:8 Z>Q;U1G[[QFZ,E&J,)880HW! BVO'01L' BW.%U[F
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M/1!5_TI0^]1<TFG(TAWC"8G(?D5=BKB0B51=(?9B+O+B8S+F#941$4W) 2"
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M>AOV>DLFX,XP&R6 #*>=Y^+FXZZ8.0]N&8&NVV5N<+*=$-%U7X_I,_]W9[*
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MNFP,RRP;65>'Y?%A@/XS'0F]5UJ*\B[A0"0+Q ))!"Q&L(3_#,=?(OU82,H
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MLS>!\S=Y<SCM,0*Y<""H[DCXH><>*,+ 8R,W0@118NE*DB(0# <G CM/HJ'
M U.FS%4,*,9<@B*/9,(6I05%3 A-0G]XQ!]Z;"$T4,@>*.A6<GYF$$=FH3DO
MHCNA$SX?(CSE ?^$X&%_NC ,R= +$_1 #10Y%;1!%[0,$11"'10,']1"*Q1#
MQY!!,U1"+U1#(W1#/Y1""X(H55,T3]0T410U6^<-<S$TY/ .]<B.8I3P@O$Y
M5&W2$D,K6> /-U$0%9$P2M$M@ W4U((/3_$L*FWU@G35EO0M+BT09X$%=(TN
M/(_V0D,5;8W7FA0SCA2R'@-'9XW3=A$7@;%,B=%&SU08US1-==%%W]1,W31.
MR51.T51-VY1.\Y0XC%&[D%$:_U0;\0Y0BU)0 ]49E?)0"Y50$Y51IU%1D?)1
ME;(U8?-VR!&=9O-W&,X[;H0XA=-3.Q54@S-4BY-4/U543[541]4[]]'_Z]3!
M4N2D'V"%4H P/(:,4C(2/'+L"=HS2 HR(GC5'^JA5T@2 !B(7=Y!!*F$'TRJ
M6)9N3((U4YXN1P1R5*05 *BU42+R26",5FC5.W?%Q9#DP8"27'TR*,^U7(52
M7='57-.57=?57>.U7><57NGU[$H441VU40<54IV1*1U3+YY2*J,R*@N/,2?+
M\5K&L ;K&X8&UQ9VU&+F$ W+2T>1+1)VKA[V$,<!'"31*FM&*R&68B569$?M
MU'AF]E!Q,0&V,/NR,2&395_V,6?695<69F^69EM69V6V9@_69V/69J4&^WJK
M,G]K-5.S-%<T:=G01%/4:97V:)L6:E64:9<6_VFCUHPFU37Q+S;-"U/Y3WB(
MQU13%57'UFQ5%6W+-FW)EFW/5FT%Y3@Y-$0[5&Y!U&Y'E&Y%=$+WUD/SUF_G
M%G#OEF_K%F\#MW %MV\-=W#U-G$1EW 7]V\=EW$Y%%^QUG*I]FHQU_M:=$[Y
M D9G%'3QB$;SL$[9]$Y/MW3Q=#;(<C&^$DE--W515T\[EW;M-'9O=W9M-W=A
M=W=5MW9Y%TYU-WAYET]AQT\-55^3EU_S=7DCU7GW%7F;%WH757FCUWH%#ARY
MME)W)^$P=>'2"Q\X]6W;=FW=EGS'UWS3MWS7%WW9-[]$KE[C]UWG5U[EMW[I
MUU[O5W_SEW_MMW_QU_]_ QB !WA_!;B WZ5RI[=?JY=ZI;=?X"IHF49@"79@
M\\I@@?9G<;9G,=AK2&]B$4GTAK1D,SAG>79G(_B$27B#-3B%.9B%31B&43B&
M5;B%7UB&;YALAI:;CE=SK59JJ_9RGQ:(>SB(IU:(,_>(?QB)C9B)"V[@7M/@
MN%<V?Z<V^T]LW5=]VU>+SY>+L[B+L1B,M]B+GR1N)]>,(_=PTQAR%;=QU;B-
MUUART1B.W?AQW]B.ZQB/SYB-\UB.[UB/XWB/_YB.!9F'*I>(#SF)?5B1\PR"
M>U=VA]=WA?=W(QEX)_F1+1EW(?F2)9F3*[F3*1F4-]F31SF4,QF3'7G<)#/_
M.XY1E8VV@:]W@1U8EF&9>6GY>1DXEFU9@6OYE;$7O"AU'*78O,Z1G385P<8X
MC+]8C),9F9?9F949FINY .&7@/_W@*_9FK/9@+6YFK?9F[L9G+'YF\4YG+F9
MG,]9FQ,8EWDYEWNYG;_I7VV8AF?8A4L8A^MYA>UYGN]9GO&YAO79G^FYGP<:
MH DZGP_ZGQ%:H N:LG0XF_J&5P$'D9MXB8<XD8O8HBE:B3=ZD2<ZHS^ZHN5/
M:Z%XO+H61KZVBL/VF)F9I9]9FE^ZI:,YIF':I<&XC/N8CP,9IPG9CW?:IW4:
MJ %9J ?YIX=ZCH^ZIX.:J)4:J7/:J)/ZJ9V:J WY_Z(].J0Y&J/=L)$UV90_
M691+&97#FJO%^I3'VJS+&JV]NJM)^:O;>JW!^JS5FJSE>I6*]XP@VI7?F9WW
M^I9GV9WY>I?[6I?76;#_NK#U>MXF]>"V-_^&.5/!5WQENJ8G6[(KFZ8M>Z8S
MF[)A&GU\Z:0SM1Q#NZ3O[Y?1X[ !F[ #6[53F[7]&K%7V[51.[9/F[9A>[!G
MV[8-&[9[YQ[( [=;^[:#6[>!>[A_V[B%^[6).[GY-9X96J'YV;D36KH7^KGW
MV;H#&KJK&[NOVZ"G.[N]F[NCF[K!>[O+&VH<FMWP^MRL&JO9NZ.K&KXU^KWE
M.ZO;.[Y!VK[':*1=TU*[=___4EJ]KGBS-1NS!]S "QS!+UO!"3SC.KLR_V7A
MO"*T8P0V%QN*2WN^\3O#KWK#\UO#Z[O#0QS$1]R]2?R^.=S$Z;O$5]QU>-LH
M6%S%3]S#41S&/[S&:5S&1?S&9YS'LXMSZ3JMV?JMW7JNA;S(X3K(D1S(E]S(
MX[K)DYS(G5S)GYS)I[PU[-ITU/LRBQNY9;O+:UNYO9S+QWRYOSRW$5NQQ3&*
M&UOAT-&8%_S X3S!&9S.X[S.Y]S.Y<3!BWG_\&'"RVNT+]R)3?O,Q;S,R=S0
M$QW,CQO1%]W,P]S1&[W0(_W0*UW1??M??/O1&=W2*?W2(7W20QW41YW3/YVY
M(3C_O+6[N\>;U;^[U5.=O%?=U6<=UE_=O,6;UF]=U7&]UG-=UGL],O6&,K'#
M:'=<QW,\Q6T<V8T]V7$\QI]=V?4[>TEZS4W:=VC3-@4<S[==SKO]SKT]S[G]
MVVT:KHKY'B+<S]&):RT\O#"\V7O\W8\=VIT]VNN=WN\=WIE=WY>=W^<]W_L=
M=5P<W^7=WO_=WPE^X.-=X??]X!<>OG^<RB/>RJ,<RH?<XH^<XJL\XR5^XR?^
MXJ6\XT/^XRL>XT<>%K%<=+0\&3M=U$O=TU^^Y3==YB6=U&<>G*9]L8.9S;W7
MS6OD'M8A&X)>&X(^&X9>Z(G>Z(L>Z9?^Z)M>Z9T^Z:.>_^F?GNJE'NJGWNJK
M'NNW_NJ[7NN]/NO#GNN_GNS%'NS'WNS+'NW7_NS;7NW=/NWCGNW?GN[E'N[G
MWN[K'N_W_N[[7N_]/N\#G^__GO %'_ 'W_ +'_$7__ ;7_$=/_$CG_$?G_(E
M'_(GW_(K'_,W__([7_,]/_-#G_,_G_1%'_1'W_1+'_57__1;7_5=/_5CG_5?
MG_9E'_9GW_9K'_=W__9[7_=]/_>#G_>?_AM07==CG=>/W]9_7?E]/?F9'_J?
M7_IWG?J1O_J7?_JM7_NQGVITB1X4OQPD<X/6&^ 3GN$+'N$-'OT=ON'/W_QI
M9]JWML(O];^S?:7#'=S%'?_'??__^U___Q\@  #P)W!@08("$1I,>+ APX<+
M(RJ<6'!>/GSY[EW$A_%>*XP@]6',)[(5R7PF]:%<:;*E/I<P2;Z<F9+F2YFM
M:.+4J<]FS9Q =P;M"?0F49X^A1I->G0HTZ=%?R*-JE2J4ZI-EV*%.K7K5:]:
MP5H-^[4LV;-CTU9=FU5M6[9<S;J-BQ;NUKMB[>9]RY?N7+QR]0;N"[@NX;U^
M!1M.?'@PX\>%_R(N*C)C4\62'4?&S+GQXLV>,W^>3%ISZ=&F4Z->+;IU9\BG
M78=^#1JV:MFV6;/-=S'C+'[]^/T>#ERX\=_!B2,_;CPY<^?$H3=GOEQY<>O2
MJS^G?GW_.W;NV;M'!T_^NWGOZ,>?5Y]^^GKW[;6SGP^?OOSZ^._K%Y^?__[P
M )87GW\$!OC>?P+:5V""_1DXH(,*0M@@@P@>N*"%$E;X((47;H@AAQEV&"&(
M)'YHHH<HCGBBBBE.N**++>['CT88Z991;P4!X%-/.[;%8U0_VN3CD#T6"221
M1QHII)*4,3D3DDLF*6645#8YI955/NED3E!BZ:665X*9)9=;!ODEF6&B.::9
M8I[)IIIN=MGFG'#2^>:=<M:I)THW#<52GR>E-%)E^'STT48@X7//+!!1U*A#
M$D'J:*2/5DKII9-F*NFFEFK:*:>8@NIIJ)^62NJIHZ8JZJJF_ZK:*JNHPNIJ
MK*_62NNML^8JZZZVZMHKK[@"ZVNPOQ9+[+'#)@NI11TAVENA(0TZZ$HJM<02
MGS$!J2>>9>;);9K?KNGMN-V6"RZYYYHKKKIQLFLGNNNF*V^\]+8[K[WUONON
MMO#BZZ^^]P*<+[_[AOLOP0$C/+#!6E9V#X\%]ROPP0 Q0,Z_#"M,L<063ZQQ
MQAQ7[#'&'T<L<L(ADPSRR2,OC++)[/+6T2S].)=<S.[17)W-U^$\L\S"Z=PS
MSS #[7/0-0MM=-%(WWRTTDGGO+333>\<]<]3$\WTU5!C+;765'-M==9@;QUV
MUV-_+?;99*-M=MILK^WVT' _K7;<5=/MM=UE_^,]M]QMZ]TWWV\#[G?@=0MN
M>.&(WWVXXHGGO;CCC>\=^=^3$\[XY9!C/O>,O:E[(T8YZC;;Z+GA5MOIL=&6
M.NFHWZ:ZZZRO7OKKHL\>.^RVYWXZMKQ;ZWN@)$G[[*'W<'01(J8PBJRPS!NK
MK//-+P_]]-)7_[SUT5^O??;<4[^]]]UC#_[XXI?_O?GAGW\^LY\;[Q%(%U46
M?$K47NM[G_B;+GOKM?.O/^[^H]W_^K>_ @+0@ 0\H (3R, !.E" $+Q= R.H
M.P0^4((7K""7.G(9#%(P@!X,H08G*$(0CC"#)DRA!3^XPA*V\(0L7*!L7.8;
M$<&(13B\H0XUE$,>[O_0ACX,(A"'&*(BEBA&1#QB#Y/X(B$:L8E,1.(3I:C$
M'TYQB5>T8A6=N,4H8K&+6>0B%,/H12V.$8QH/*,:F<.Y&KGF<_D('<OFJ+*4
M7<R.&RM9'>EX1S[F<65[#&0?!?E'/'8,8[TSRI^L5:W@\890ADI4HA9%/O6E
M[Y*5Q"3Z,LG)37K2DIT$Y2<U*<I2DO*4H43E*%/)RNHQRPLM>$ L9RG+6M+R
MEK;,)2YWJ<M>\O*7O@PF,(<IS&(2\YC&3"8REZG,9C+SF<Z,)C2G*<UJ4O.:
MULPF-K>IS6YR\YO>#"<XQRG.<I+SG.9,)SK7J<YVLO.=[HPG/.<93D$<TI#_
M>ARD/@OIQWM>B8:+&IQ @88/!QCTH A-J$(7RM"%KD-RFJ-<1"V7N8I"U*(2
MQ2A%+\K1C'9THQX-*4A'.M#*E72B)]5H2C^Z4I&VE*2/8VE,73I3F)JTIB_-
M*4YW>M.>HI2G*&TC2>8%1SG&D(0P=*$,CXK"%ZIPJ4I%ZE.EZM2J0A4RB?S=
M[QHI/T)=A'C&PP?RE&?*5I9UE6@]JUI5N5:SLO6M;HUK6N$Z5[FVM:YX%26S
MND#+!/32K[@$;"X%V]>_&C:PAQUL8@N+V,8JUK&,?:QD(TO96A+6LHO%+&0U
M.UG.5C:6EP5M9D6[6=)VUK2??4!H53M:UI;6M:>%_VUJ5TO;UM;VM;>-;6YG
M:]O>XM:WN@4N;W]+W. 6=[C&32YRE^O9YJ+6N;*%[FZE*USJ'M>ZRL4N<Y_+
MW>AV=[K?K6YXKSO>[)9WN]Y-+WC5*U[VDO<!]F2J?*/:U*M.U2T %6.,"MJ
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M^=5IU0K:T%*;^M0/I:E/^2'AIWW#P0T6L4Q7/>N?-HT%#A:QK6_6:E7O6J5
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MW==BRL-YX<-!C,M)_,-*K-BWW-B0S=B2G=C]U,32)\\O"2UC=JP!W=G^[-D
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M-3$4'4,1W6=]_M 4!>A^5E%_#E&"EC46_;\CW-_\E='_9J+1^I7?B(9HAMA
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M;-=EB?\/XMYU";T/>ZXK)K<2?J;LGB]HR1;HR?YYH3]1H/?Y@U;"A,:T?"3
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M,^98(XX]ZN@CCS\*Z>$#+11Y9 M#WHB D4T>B<"-2$KI))536FG_9)  ((#
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M<XZBR**6'SU"1*GT<4)YD,GGO'D'J_IAPWL(2^@XH@>GE)ZB/K>VZJZ5U3K
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MI=A(J72I+U:*R>EFDURFAVC*EAY)BP1GI>CI;O!?KB#GI03D/B()-N[&+K9
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MP1Y[:[&A/MOLKM<N.VVVWW;[:+CGEIMLM.O&^^ZV]58[[K[IWOMOO@D?/.0
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M$):OAERL9+@T",<8HC-,+J1:^/K&3 +&M , [+ ."=K!;EFX?'T#78#U5[4
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M'__[OW__]>]_^ON_)9H^9A/  #S ^4M ]4/ !51 ^6M "'Q "<P_!IQ _C-
M!]RB<].QBUHWEDNY#URYD ,YBR-!D0/!$6RY%$3!$E3!%F3!$Q3!I5(XL%I!
M&8S!$,Q!&]3!%[Q!$_Q!%\3!'1S"'N1!(2Q"(CQ")01"&&1"'W3!E],L*MLR
M+ZM",+O")K/"+,3"*?RR+?S"+M3",.3"*Z-",LPR+QQ#,"S#-&1#,73#,W0'
MN0, NC/#-43#-\3#.&Q#/;Q#.U1#0(1#/__DPS\4Q$#LPT,L1$0T1$9<1$=4
M1,^ZO!U[1$*LQ#R$1$O<PTO,Q$'<1$_41%#LQ%!,1$XDQ4\4150TQ5%T0]I+
MB-N+/EA\/EF,15J<15MTH>&SLUK<Q5OL15[\15\,1F <1F'$O42KJ$7+P NL
M0 I41@!T1@R,P&:4QF6$1F:L1FI\QFR$-85K/PO4QF^,QG"\1G"<QG&T1G3<
M1G(41W-L1VR<0&73,75,QW.<1WNL1WQTQW)\1WUD1W[\QWT,2'_LHPT<,W6[
MO28,0B<TPH5,PH9$0HA<0H6<R(2LR">T2(8<.1J42(QT2(J\2)#,R(Z,R(?D
MR)#TR)$T29$\29+__,B5?$F4)*PHC#G80SV;;+V;K$F<W$F=[$G9X\F?],F<
M#$JB'$JC!,JC!+TYI+NB1$JG%,JG;$JHG$JIK,JDM,JHO$JMS$JNI,JM=#I)
MS+ROQ$JO[$JR/,NQ3$NS5,NR;$NT7$NX=$NV++M6)+-B)$:\O$N]S$N^G+.!
MJ,&^#,R]'$S!+$S"/$S#3$P:FCY^Z,=U?$QZ=,S(!,B!K$S(O$?)Q$S*O,Q\
M#";VV\S)%$C.S,S.%,W0M,S3'$W0U$S39$T#),#6+$W4=$W5C$W2O,W5E,W:
MG$W=3$W?A*:"K#VO>D65C$F8;,F4+$GE=$GC;$[D9,GB?$Z$V\CCC$[K_US.
MY&1.Z73.Z]3.[LQ.\(1.[!1/[QS/ZC1/[M2JF53%5&Q$3#Q%]HQ/]RS%^83/
M^EQ%2K3/_,3/]^1/^MS/]LRRI;S/ .W/ OU/ Y5/ %70!"50!D50"-7/!EU0
M!ZU0"KW02-0Q'IM0#HU0_Y10#SU0$!W1#RU1$371!R71$UW1%$51"Q6MNCP(
MXE1,&D5,&ZU1'-VS7+Q1'LU1'^U1(/U1(0U20#M&?TA&VOS-WDQ2)EU2)\5-
MV\Q-*.7-*=U-[.M&):W2+)52+HU2+Z72+@73+[72+1U3<(K'BFI2+573,"53
M-C73-Q53.773)VW3+0W.#D1(\@S/\RQ//^73]/_\TST=U#X%U.W$'^H4U$(E
MU$ UU.]DU$-]U$6=U$:%5$FM5$J-5/0TJ?6,R[>42T^=2U$-55(%55/]5%0=
MU5-5U525H@%=U5)M55B=55FM55:]U5C%55K555L-U;#<U5P-5F =UEXE5EX]
M5F$M5F5%5F/5N1BU/2(=4FF-5FJ=5@0:/L"L5FVUUFWM5F[]5F_=2\9<TSJ%
MTW*=TS)%USBE4W)M5SM=UU?[3'-UUWE]UW-E5WNE5W6]UW3%UWK-)-C<5WWU
M5X'-5X/]UX)%6()=V'[U33PE"(RRU$V]5$U55$R]V(IUU(G=6(M%PD3-6(GM
M6(H=68[56)$MV9 U697_35F6S522/=E]ZU0,#=$69=$7I=F;5=&:W=F<==&9
MU=F>M=F?]5DM>]4.!=JA%=JC)5J<35J>==J@?=JE5=JFG5JIA=!?M=JHW5JH
M[5JM]=JJ#5ND_5JR%5NF'5NSI=KK>M:"F-%P!5>X?5NYC;X=C5N[G5N\O5N]
MS5N^_2 C15)^A5?!#5S"'=B&'5S#1=R#35CQPU+%5=C#+=Q@,@CAY$#*'8A5
M:*4.!(#(35QN*DB"."=\@-A\0*=^4#?*S8=TZ-S%9=C'72,T93;)A=S7?2;4
MW5S<A5A]< ?6!:;*!8" !%S/30=^*"6('8C:5<;?I=W995PP>MB#?-F5=5F4
M_Z5>F)U>C)7>ELU>^DE4[ 59Z_U>[0W?[05?[KW>\AW?\Q7?ZFU4F5W69&56
M^&U6^IU?^Y5?_(U?_:U?JGO5^]W?_^7?Q4LW K[= K;<BIH'IS-@ ,[?QAM=
M@[0HMT-==9@M>8A@ U8W? A@#G;@#O[5#FY@$2X\#$;@ RYAK\J'$(8Z$P:
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MS,\ 44"NO_#B V]\_?<GCW_Q^MN?O__[_Z]_ !R@  OHNN<! !H&#"#_&LC
M_P<2T($1A. ")VC!"F(0?\RSG3OH@0^;]2-\&;N'\#Z8FP:Y[DE=,9_M(M8/
MV-'O=Q_KRBQ8A[*Q=&YU)DQ//2180/0%3WI=H6#KJ'=!'R*1B$H\XA(SV,0D
M,C&*J\.;/Z#H1"E:,8M/W"(6N=B7[.F,?"S$W<0ND@_A,<HAU)+=^]8#D=YE
MKX4N<UT;'5*[#R(,(M_+#?%LYH]W1$H?+U0=LM*3C][]9BS^.-\<DP=$TRD'
M8]RSG:C& @_640\?MBOD1AI4.DXJY)"_2V1(%BE'A&FQBZJ\(BM3V<HFUJQE
M# %<7>ABRUKBLB59P<A-$&B1J.ERE[ND!TJ"M4M_T/]#'0))!SW:R)%TN$0]
M"$FF0-IQ0V'RDB78S,I.EKG+64U$#_!0H47P$9-MFF<@\G#F-_6@3G8FY!ZW
MG&<NZ[D4) $ F/;<)SW[R<]_^C.@ !VH-K-"E6U:9!4GV:5*9)05< I$G.1D
MB#E7PE"!8I2@&LTH1S?JT;4PZCCCZI.XS/6GDI*T7"E%UTC!M5+[[+),ZN-(
MI42$4(;4(S.<8D@_(+6.6V6EIIV9:$(4Z!>09$5^4\H*;K)RGFWV=#'PD!9'
MZ &;7<J&J B9U6&0RA&C8N:;@,064#G"K<_LLJ4H=2E;U^I6E;85KF]EZ5_P
MV2"3JE6N>J7K2_/*U[C^=:[_)YW-30L;S_GL4A_W$0]'W(K5S@AS%>H8;%;
M"IZ=<J>O WJL?KR*D"JEJ1W"% Y@!QO8O9HVM7Y5+5Y;JUG I-&UI5TM;64K
MV-J^5D"&->R.6//0YYC0(NJPC"_9HQ]XVN8UG!W,,>^QUYA&2)BT8NUTG'I5
M;T$(JZ+1KFO4L<MGQ>JA]&&L15X+7>5BE[JSM2UJ<;O>W,)FIF)AE^0RQ[C+
MU;=R^<6<?A66,K 5RH,@#-OT^"$/@3B)EHQ-SSVZ5K.(O<-@=&J(/Y!6QXUP
M+7O]@(<ZAR21"P-@*VT3K<GZT36_'3A@2,)8/9:6#XQ5N+_WM:_C:(Q?Q-G8
MOE#;_R^/<2SC&O_XQC,.<HZ);&3^(KG'0TZRCYG\-;IASH_O&,@\!"DT*)L$
MQ"(6&HG38V)X"4[)0';RF,4LY#(WV<Q%)O.9V[QF,6\.(3GT#>O<4><[G\[.
M><9SZ_3<9SZ_SL^!!C3H!%UH0O?%T(E&-)WW[.@_/WK0D3[TI!==Z49#.M.2
M+B+&%.V;=;Q#'H)\68WJK#T#>PX>.#-=&:LRJSJG,2%K++2V=++GG"DD5Y2>
M#L8V[9WU['IT+\.'I]T!XA [^I&-/M5&3K3K?F L'Y0&951$N6M2=L64F!9V
MQ"RMZ6"#V]N^#O>VR5UL1I_[TNG^MKC-C>YWJQO>["YWN_\3C4"CKGO<]:8W
MO_/M[G@#?-[^WO? ^RUO?1L\X @O.,,!33XPGG#2&@/2N6/X;]^4(A_41N6@
MD?IP?=R#5O]F]D5$OF^7U:/A %=VL5&I<E[7YHTO7_C!+TYSA=L\YP2O^<YQ
MWG.!\SSA0*>BT&\.=)\77>=)_[G1FZ[TF3\=DP\GWRR@40_K[5P?$&;WW3 -
M;4N:FV'=AC3+@ZL]?_042$W?H,$UIFNF4UK4*F2[I%E>.N@9VN,-Z6&^'[P>
M36):<)<\>:?A+7>=X=GN2(<ZW!N_],<S'O)!C[R>8RE,6G8T\Q_%I:J(Q*Q[
MR(1($9;)>*!)$^_^RB3%I2]-_*'_'I@PQQUQ>;U+3+02U.<&]"SILD4T[_O-
M'P6?W00^\7]O_.(C__@<=155U"-[GS"?+;0O:%B2;WWE7S_[V.?H7;3RWN_?
MEKVG';]ZPP]?*;FH\]MQ3E.! X_-CB4?P 7.<&_$&U%^BA\@7\4[KF6:Z'C&
MB*B&=<C?;4128W7+=WS&\G"$8DF'HT##/=0#/-B(2PD@9%V*^8%?>XE?^7'@
M^9&?7TW,785@![J7!J+@!VY@"8*@?A3'"RZ'/Q1@?\3'<[A*@;C#BZ5?LEP6
ML^R*/^ #>#6&Y\'@KEA6"_X:0R"(UG6%<Z%+LOC#/*R@![+@%)Z@"J9@%:[)
MG"@$%GJA_Q9^(16*X14.2F)T4*TEB7M@"!3Z( YE!@#RQPTFH$6<QC7Q2FUP
MCPLN1WZXRON520[.5QO2!ZI<5VX,8 9J2 T:!APNU8Q ""#>X7@,HK<@H0E:
M8B5BHA6"AWPM1\RPV9NE62@NF9H=F0Q,71C1B(R-D-3,T$*T&-M4TD7@@TDP
MX7K(7MI@C\N0C.#D R@.A#MDW,9M!-*DS"VJ1,8\7[_\URB*(IHQXS,ZHT3L
MF"]&HYN58C-:XR=>(S1F(REJXS=ZH];L3=FXW>&,(XT!H\:!T2[F#35V(S:Z
M8SQN8S7*(SC"XSR^(S>Z39PYRBJYTC]Z$4#Z8T 2Y$!VSRG"S_]#!$_*G CP
M,&%ZJ!TC,5CK?%U(#%X6>4_JT!WI3!SP6)SI*-OHX%I41.0KE<[A38\(F8Q)
MLJ1 MF1!OJ1!QF3_W-M,NN1-PB1.RJ1.VJ02;:1)?B0,C=WL9 ?$@9'OF!TJ
M7H0G@:11(F1.JDY(2AU[&!#UO!%4[B16]F16<N56QB31:25/BF58DF57<MI8
MS _(>-KL**53 L!9AL3_!&54-A+KM&);^H-([1&P[<Y<LHZJX27XG-)&U(]4
M^N7J!&5&PE&O_>6Q(20 2"1AEJ57CJ593B;_6)YZ8)[V<>;Q[=8QR1]/[%(R
MPIY!"<5%3<0N_81J6E16C-Y/O,,,[=;_.64%;7*$;?9>9^HF/>&3/FW?;@+G
M;PIG</(3:D*?:YZF:;I$;$K3-I6F50QG=!*G=%+G=)Y$2(WA)6IB)F9A=G(G
M!W[F-PT7F8QF'(;GY;VA4\556NV&=;4*4P5(6J'7=V @ H8@)(;G4\'G=X)A
M?WKG=@)H=PZ&75VA?Q;H?PJH=B8H?[8G1XBA?.*'?&Z&5H72/*BA7BS7>S 3
M<FU3._C*><84^&6H:% 5 %C5@Y!85E@#@QYHBRIH&+HHBVIG;,EHC08HC+YH
M"89H? G3744HB'+77K!G=,$G:8SH8S13>#:5@Q*I?=)'B29)/C!)8IR7D:;7
M?P3I8D H'XI$_U@Q%4RIYV1 :4-(Z694J60<Z8+>J('F*(*^!B<VRF;:HS[B
M8SV&(^(LXYQ6Q!SY2YC1F)\"S3*.3<9D6*<135$^)L*<&,483<80(Z/J:3[2
M8YU2ZMM,(YU&JIW>8Z96ZIUBJJ=.*J>*ZD)%#)&)3Y25JM @:F!>1*&.!:A*
M:JQJZJ=N*JS.:JC:ZCSRXYQ1WN3YZN+]ZM$)J],Y7J\"Z['"95<8:Y^EC%Y\
M&ZL>Y>L(SK(JIJ"QG:'13\4-):7975"^'& FI!&U6[8&*[%*'K*:Z[*F:[E&
M';H^74V>Z["VJ[P6*[O6J[O>*[W&Z[JBZ[6R*[GN65#>950D7ETZ7O\]7-/?
M6)K6(0S6[>N\UIW!TAL?_9SK-4R^\JN^JBO$<BS&=NS#>FS(2A[1;:S(EBS(
MHNS)JFS032N@H6%5&-Q(+I+&@L[ (H*YQ9I"))O$#AP]C!K(:)NU"F;;;6N[
MZ9U"O%#+#6W$<ERXX1WI'&U4\!V@^9U#-*2?5>M4AD3>N5"__62C*1[-XFO*
MVBO9CNW*MH/E[=)F5F?;>M1X^-/TO01Y')3)F$0@KL-,8!M#/&>2V$2.G$4^
MP(A$R&U*% =N.@1MBH7;,BXN"9]U-F[D0N[D4F?TW83E0A]PJ 3@BH3@EL3,
MU&9K5I_DDB[EFF[I.D7W^4->J&GKXJB-NB[_FWYG&1:H)#:I^A4AJX27([(6
M(YKI'EH*6MH@</P'(6HI\>+5F(Y$F5(I\!ZB\,KNFKII],;N]'+)"%9OC$JO
M]F9OFW*O337*]RGB4R'O[DK%?,"#\?8%!4H@/[2($)8&>0W198B=19!6]UH)
M):X&.2%3?O2([UKO]U+OZVZO][8I%T8% >-O <.N C?B^?9'_<[(9-4' UJ$
M X*+0S7*M:3&\Y3O$.IO8;@#/*S"/>@#<5#P>TCP102@\R+6!P=O7,J&V(G%
M)"J@;_U*9^#>>AR(!DMF>H:%@= N?"!B:M!P>15O"#OP #-Q 'LOG&Z$)^;J
MJ-9J%8^BH.:CH[(B_XM532Q6A>Y-1%).4W_MT##*#*!RS<#&V,-H<=/DZ3&Z
MS*+FAA7C*AW+JI%=*A73ZA[7,1_?L1[W<2#_\9V>8W\5<MH<LAH/3!N+#1I/
M\2/;\:T.<B1W*B4#\N7LJF5J,F5>9B=O\DTJ)D%^[>S(+ 4?445VA3Q@42B+
MSBCC7GKT9=&BCE3*K#Q 4=2BG>^X\F%6)B=_LB?[<C ?4%$),S#W\C$;<S(/
MI"M?$2]SVTHFZT(D$V*&)#XY1 CY#CK4!@J]SL#.V>S@\B#)I%0*QH)%A?^(
ML5NRL#(7\R^[<SO#<^B Y3LC,SVS\S&S\O&D#"#A#AYMQ!G%3CK+C^M <?\N
MZT[?-,1@KC/HZ* AWHXQA40(:>32JB0L>V3$2.'OB"OND/,L2ZSJ8(\DU8X7
M+X0Z:.T0'21:<B1&+R9%-V73QO,]R[0]%T]F)M7IXC1;L"8][?1+^#!#F-Y+
M[##?FL1/)P0\Q$1Q$37U>859*"=+K'#"U%[H!M-M3K55HVY.RT1O:G56>W57
M@[52&.=,C+530R=%E#5%1#5"]"U#A/5;?W5<=R9V"K 3-W 3UW5>M]:.?N"9
M5G!68'!)P4-6#-*;$C9M?.EHG!=:[6=U%"F:7NEAY*)%],-L#':7$K&38L9:
MOV5];.D"@_82VS4#NQ2!&O!=CW9HX_5II\EBE];_9S^O151&<(6%3Y55>3*&
M9R4)/HP58+P#9B4$_/(%A?H#L>A%#AX3]Z;I<"<4A>@VD(JV7J.V=)/V M-H
M=4<W:ZMV=O(UF5 H^X$&<:^(;X]I5)S'9 -I0A0B'6[&<\>3VOV%.]BA<*&&
M5FU8?-_#E#J&A)X';2=)1NL!CFP3!TO&F%J#VKG#/<#(962I87!V5$B67QS+
M,36B;(.I@R*&?S<$@ LX-A'XA[)W:F?W=&NW7$'Q1<@I)/NQ)+-XD+WQ/1(J
MP!1T@^5+U3:$,@7,@R&,% L$S,6XO  J.XX%,9%-=<5QOF!QT3#RO;SXBE>R
MDU]RT5RJ(+=XE#\YE5_Y_R1#N8IC.:K:K9>GAZFF*EIC#)'?BY$K*IBUXY9;
M,I=K>9>[>97'N:YRSL>BK=CB><;JN9V7[9V;:\N>[=<JFC^;4;$)=)ZE,S<?
M&NHA##QL6M8*AK]^#L#^F;=ZCN(1^LYL&D2O!S_;F<9D]*YM-+:.G9_S^=GV
M>:JC^JKG>:'!JZF;K*JW>JRS^I[3^JP7G:2W.J4/FK>F\]FYC":)>J)&\;CE
M(K$#@+3=.M-*YJZE+X6QVV C.\_*NJV;+:[#^K5;>[:?&\E6^ZEC^[<O.[A;
M.Z /7<;(3[#5+[&3$+E9;$(FDZ7SWD);&D*'JT$'6T%W4J_+\J"K\T/4!N!)
M6O](ZXRBSSO,GALNMR4_/SIC$MY8^/MC'IO <RNUUSJY8_RX:[RV4YK:WK1<
M@SQ3P"TN%>Y+/+M((!..;^A9K+%*G/@.ECQ!G,5,E'&2$'DYE)7S7;495_5Z
M*&YNAGS03\3C"GW1P_71>S7FDK7FGB;34T3--\3-YWQ6D"9:BP328[W1:WTN
MJ2[KCCAVKS:)B_T&#C$(VBZ"C"19C#>HO:QYUP<_^ @\2#BUZ<2RB,0#NC!C
MC*]GP_!EJ*]?U&(GR<-B)*E( 'A?S/>&^X6 >]Z'9[8,ASW8BWCD;[>;8._7
M5WZ)4S[FC_@%JM?>MTK?)YHUM*%2:;@_R'UII /_MB'_"2'(.]#]NN04B_[]
M7DS4VL-&V\.\$F]^[T_^[U.W8"%PG?A^\'-^\;-7V?N'_%[$LY &*1&AK57(
MQ3"'^1PO N;O#5=&.@0^&R;$6:T&>JO'"R&&'$Y([.>&424^  R^:5SVKI %
MB#O$@3A))'8%/QP( 'LI[XX&^J^'^@.$/P #"<K3LVY=.SWM$@HD2/!@PH42
M$2IDJ+#B1(P2+T:T2)$CR(\;1WK4:+)CQI0A29Y4*=(E2Y0P5Y9\V;)F3)LR
M;\YL5XJ@PZ  ^,DH)X.<4:5'DQYUBG2ITJ91ISZM*C4JTZQ0GVKMRI7JUJM>
MPWX="]:J6+5F90@5RA9N6;D#_]T"2!NWG+ZZ=(?RY0L/*UM^?0'L!5!*AM_"
M=@,;7>RW<5I\A T+M#P47^2VA,D^52SP;%+#>#5W+HWV=.BU<N^R3KVZ=>S3
M]1;7>TW:=&[4NE7CWOV[MVO>L&\+!TY\N._@LI,;7UZ<^7'ER*4[=_S9>CG*
MV;=+IOS],M_,G1\_AGZ^>?3GZ=%75T]]O?OV\>G#MS\=?W;][\TB<LA/G8L"
M3&C =@H\4, $"5300 817!#"!B-\4,(**;S0P0PGU-!"#C'<$,0.0_Q0Q!))
M/-%##<MSR,040S0,Q83>^>ZSH>YIT9T5:2SO0QT!*!%&!RGS<,@-:PPQQQJ5
M7&S#R?\J(ZP?PO 1\C,76QS1RABOW%+++K/\$LLPN01S3#&UI(<@:,CTTLPU
MW6P3SC+E9'/.-^N,D\X\[=033P;1J4>?Q_K!1YX^(]2C'GSZB9(N?_3)IY0W
MY;F'GR@=&G0>0^_<E$].]_Q4TTY%!=734$D=U50"[VDTU5)=1?754V5M%=9:
M,X0G'[WXTD>?2&FELKQ^9E5GGES+XX>?>^BALQ1]+"T,TW1B73 =0(/BA]!1
MY4&6H'ZPI4<C5(DUUB%_H*E'6EM-K390NK"51]UIY8V7WEGG_72>Q81ZJ*BO
M_-WJWX !'EC@@@D^V."$$5Y88<\>(JAAAJ-Z&&*)G8+'&HK_-2:(GXB/ FIC
M /K10ZF- ]Z8X78R#IECHR:C6)Y_31YX9IDU]MCBG''>6>>>>?Z*MH%L^]GG
MHHD^VNBDD5Y:Z::9?MKIJ#U&N6&J&;:Z*Y59;KF<EQ^..2NLI1X;ZK+)/MOL
MM-%>6^V"5QV('YKDQFENG^SN"6^>]-Z);YW\S@GPNO/N.W"Z#;][[[\%3[QP
MQ$O:>'#%#U\'<L)%<F??K0&@9W*.VLF<97\<UV-CP"N?J73$4Z]I8\GU #WD
M?AAG=&LUU_'Z(8->2CWRQGM?W/+.@Q_==\:!=_UWX9$W7OGBA\<[: #T:?YX
MYY=_GGGBJ]^>^NZU]S[Y[\4/G_SL_\O''OWKU;>>?>['-Q_^]-L'/_[UW3_?
M?OKEO[_^^=_?7W_Y>]_;"O,_ >+/?PCD'P -F,#^+?" #PR@ W>B,7XP4($3
MA" %(XA!"39P@R'4X A!2,(,EA"%)U3A!RL"LO+PI5_[F<]]9,@>&\KGAO7)
M#W]JB,/=J(,>O I*/_)1#Y+Q$(DETY$.K8.H0%V*4$G,(0VEZ$,F5O&*,]RA
M%F5 &X$,K8=9G.(6QQA&*G(1BV<L8QK):$4UNK&-8H2C&:?C1$%%$8UY7*,>
MY\A&.O[1CX'DHQP)^<9"XL4_<!N0.Q[$2 4Y$D*0E) D%]E(2S[RDI',Y"0W
M64E,?E*3H/_DI"@]&4I3CO*4I43E*E792H90\I6=C"4I9YG*6K+REJY<!RQQ
MI:O%\,I7N-QE(]^!CR<.9!;ZP <\A G+8=+RF;:,9C-E.4U=.M.1O0R*H_+Q
MCEQ^DUW7PL<\JHG-<IX3FN9,)SJEJ<YVLI.:ZY3G.^<93WI&$DT#L9T[[=G/
M:\+SG_4,Z#W]^4UK&I2? RWH01F:4(0"]*$"C2A!%5K1B2[4H0V%J$8ERE&*
M7M2B'L7H1C-:4I*>M*,F32E*/ZK1M_G#'R(-J4I;2M.1KA2G-67I376:TWX:
M9B+8'(QB@CG3G1K5ITCMZ5)YVE2E.A6D496I5&WZ5*M2]:A8Q6G_OF '-[9]
MM6U@%6M8R3K6I6".8OTHZUK-RE:WMO5LT:,'7-]:5[K>U:YYQ>M>]=I7OO[5
MKX$%[& %^S1$T$4?+%2L!QG;0<=R$+(B3.%B'RO9%38VLB:D;&8GBUG+;O:S
MGM6L:#M;V=&:%B5>E!YI+XO:UG+VM:%U+6A/"UO:EM:VK+UM;&LKV]S.5K?!
M!>YP?UM<N=VC7,3U[7)[VUS<,O>YSL4;[A[3*W50Q!V*(@P \@%=WD87O-\5
M[V[)*USC2K>\RD6O:%V8.8'$\)" '*0AZ1O'^LIWC_G=#674T1M&N64>@M1O
M? 7<Q_G:%\'X-?!15 M& A]8P0\>\'T+_RSA!5_8PAFF,(0KO.$))[C#(.;P
MB#\<80]C^,0:[L]_ZO4K%]_KQ2V&\8QE7&-[V3C&-]9QCGE,XQW[N,<X!O*0
M.Y5/ -B.R#\6\I*5W.0@.SG)3Y9RE*G,Y"E;N<I0QO*6M?S2F&;YREH6<YC)
M#&8NY6-)3^++C;A<YC:;^<UQ'C.<YRSG,'/UA5PC[)X+RV<_!ZQ=%(,&/-*Q
M%'@@=V/Y^/.B^]SH/4</C(Z6-*,I/6E+5QK3E]9TICF]:4^3C8!Q6Z]ZPYO>
M\Y;:O-XUM:I3/>I3C[?5J"8UK&>]:E>SVK71FYZL7VUK7N.ZU[&F=;!K+6Q?
M#QO8R;[ULG_-;/]D.UMO!!3=LYM=;6I?^]C99B":-:>Q*5E;V\46-[')K6QP
M&QO=XS9W"[>[F!B&V,0B+C&\Z4UB%.?'23M2<S[F;6\5QQO@]>YWB1N<8H/+
M^]X!]_?!%3[PA O\X0M'^+\A3G&)-SSB#K>XQAF.Q$02Y:I3%7E5M<K4D)-\
MY%E->5)+#M65F[SE)U<YRFD^<YNS_.4NKSG.=P[SG,L\I4;>Y\U]WG.=$_WH
M/$<ZT(N^])@__>=0-SK3D]YTI5_=ZEFO^M:I+G,O1QWL4Y>ZT\-.=K&7'>NH
ME <]^'%,NO3C4=[4>M?'GG:ZHWWN=<\[WKFN][[S_>XJQ?/&WMUIPW__&O$]
M0S/L&#\0?"0>\H>7O,#D.GG+1Q[SE]=\YCF_><]W'O0Z.VQA$ION<D/;].L.
M]^G/K6[4N[[UK,=VZE\O^]4#6[6[MCWM8Z]ZWL\>]L#???!O7WO?$__WQ>^]
M\1%=P.$___C0-_[TEU]]X4<?^]2_OO:5OWWKLZ2]#WOOQ2O><?*?G^,3)\X[
M[N$LVKVW'_4 6_HQOO&,W]_^^=]*P>E??O7_O_[,K__0#_\$L  !T/\"$ $)
M4/\6<  ?\ #K[^, I,XJT,TLD,XN4 ,SD /MK ,QT -#$ 1'< /I1.A(\ -+
M$ 5%4 5;, 5?D 5A< 5GT 5C, 2_3@9KD 9S_Y ';7 '?5 '@[ '?Y (A5 $
M!\^"/D\)0X\)E] )FU"P(.T)IQ *J= *JQ +KU +L]#30BW[OB_YPA#YQE#Z
MP) ,O]#[TK#[UE ,RU"\=(W[VA -V? ,X[ .S= -Z3 /Y= .]_ .L4W:\' .
M^5 0^W 0_U /#]$/%U$1&]$0']$CPN\AQL\!(S !+Y$!#; !%9 3,1$"-]$3
MYXC_.C$3*Q$42Y$4/U$35]$463$5+1$50_$45;$5:W$_)C#PS$X7[<[O<I$7
M :\7@Q$8A_'LBG$7]\X8?S$9D?$8_VX9)^D$B;$9?9$9E7$:A?$9J=$9KU$:
MK=$;JQ$<M_$;Q3$<<__QZ[(1&[D1';NQ'--Q'+41'MVQ'=F1'.LQ'NGQ'M=1
M'U$*"2FF\+AP"P,2( =2("VO\@@2(0LR(1=2(1N2(1]R"4?/41(1$M60$"T2
M$2^2(@N1(S&2$2MR(SV2)G)/(TLR(T_R(SLR)%?2)%-2)$&R)1T1A)I/=%R2
M)5%2)E]2)6,2)G&R)VV2)W>R#B5Q*.#+%67Q*&-1*6GQ%6<1%ID2*6TQ.D;1
M*:LR*:%R*9]2*ZU2*K.2*YOR*K<R++\R*B,,%XMP"(T0+8$P+=N2+=]R+>-2
M+>>R+:/1+>7R+ND2+O42+_<R+__2+P.S+ST$!P63+P\3, <3,0TS,1=3,1O_
M$S*YK!\?YA\=TC(A$C,O4S-Q1@HSTS,W$S0_4S1#DS1'TRF\\"=S\B:!TB>%
MDC5?4S6#4B=G<S6]"PY=,S9;DS9ELS93TS=Q\S=W4S=[<X"" CB/4SAA,SB)
M,SES4SF1DSFCLR2)$H;&TCJ[$BNS4RRQ<SO!DCO)\N)&L2S'TRNOTSO/DSRU
M$SS5TSS3LSO=<SW?$XW.$A_ET1[M,Q_543_?$3_[LS[_<Q_Y$T#W<QX#M$ ;
M*1H-]#X'5$ 5-#\;E$ 7U$']<T(9]$ A%$,O]$#/,4(?5$,EM$,I-$0M%$0S
MM$0_U$-/5$53E$5G:3(#K1_F81[HH11DE$9MM$9G_S1';U1'<=1'>Q1(>51(
M=Y1(?W1(C;1(@S1)CU1)D=1)FQ1*F51*EY1*GW1*K;1*HS1+KU1+L=1+NQ1,
MN51,MY1,OW1,S;1,PS1-SU1-T=1-VQ1.V51.UY1.WW1.[;1.XS1/[U1/\=1/
M^Q10^510]Y10_W10#;50 S51#U51$=51&Q52&552%Y52'W52+;52(S53+U53
M,=53.Q54.554-Y54/W543;540S553U554=556Q5665565Y567W56;;568S57
M;U57<=57>Q58>558=Y58?W58C;58@S59CU59D=59FQ5:F55:EY5:GW5:K;5:
MHS5;KU5;L=5;PY2 :.>8_/_A1DNA7,^U1LTU7=%U'M2U7=G57>,57N=U7>OU
M7>U57O&57N^57_.U7_?57P,68 =67POV7PU68!&68 ^681.V81?682,68B=6
M82OV82U68C&68B^68S.V8S?68T,69$=68TOV8TU69%&69$^695.V95?696,6
M9F=696OV96U69G&69F^69W.V9W?69X,6:(=69XOV9XU6:)&6:(^6:9.V:9?6
M::,6:J=6::OV::U6:K&6:J^6:[.V:[?6:\,6;,=6:\OV:\U6;-&6;,^6;=.V
M;=?6;>,6;N=6;>OV;>U6;O&6;N^6;_.V;_?6;P,7< =7;POW;PU7<!&7< ^7
M<1/_MW$7=E7"H]LFEW(KUW(O%W,S5W,WEW,[UW,_%W1#5W1'EW1+UW1/ER"R
M0757EW5;UW5?%W9C5W9GEW9KUW9O%W=S5W=WEW=[UW=_%WB#5WB'EWB+UWB/
M%WF35WF7EWF;UWF?%WJC5WIW%W6KUWJO%WNS5WNWEWN[UWN_%WS#5WS'EWS+
MUWS/%WW35WW7EWW;UWW?%W[C5W[GEW[KUW[O%W_S5W_WEW_[UW__%X #6( '
MF( +.!NT87416'45^( 3V($7^($;&((G6((KF($O.((QF((UV((SV(,W^(,[
M&(1'6(1+F(-/.(11F(15V(13V(57^(5;&(9G6(9KF(5O_SB&<9B&==B&<]B'
M=_B'>QB(AUB(BYB'CSB(D9B(E=B(D]B)E_B)FQB*IUB*JYB)&;B LUB+MYB+
MN]B+OQB,PUB,QYB,R]B,SQB-TUB-UYB-V]B-WQB.XUB.YYB.ZSASIQ>/\UB/
M]YB/^]B/_QB0 UF0!YF0"]F0#]F0[5B1%YF1&]F1'QF2(UF2)YF2*]F2+QF3
M,UF3-YF3.]F3/]F,(YAU&7B47Y>411F5*;B47?>453F5*WB56[>58?F59]F6
M31F763F797F78]F7:[F7@5F7AYF7B?F771F9:3F9;]F8A;F8G_F8E5F:F1F:
MG3F:J?F:@WF9M7F:N1F;K1F<M_^YF<6YFLDYF\>YF]'YF\TYG-.YG-WYG-]Y
MG>&YG>?9GKU9FT%9G_>9G_O9G_\9H -:H >:H O:H \:H1-:H1>:H;,7D1\:
MHB-:HB>:HBO:HB\:HS-:HS6ZH3O:HS\:I$-:I$>:I$O:I$\:I5-:I5>:I4DZ
MBJ_XI6.:BF%ZIF7:BFV:IF^ZIG=:IWLZIW\:IX.:IX%ZJ(7:IXV:J(^ZJ)=:
MJ9LZJ9\:J9^XI:>:JJO:JJ\:J[-:J[>:J[O:J[\:K,-Z?C>:K,O:K,\:K=-:
MK=>:K=N:K,4:KN-:KN>:KNO:KN\:K_-:K_>:K_NZV^H9G]4YL.5YL./9L %;
ML!.;L!7_^[#9V;'I^;'OF;$1>[$KN[$A&[,EV[(I^[(UN[,+F[-#.[)!>[0G
MN[0W^[0_V[0SF[19>[4].X']6K9GF[9KV[9O&[=S6[=W6Z!-LS1_V[>#NR"G
M@K@;H[C)XKC!(KF7V[B;&[F=6[FAF[F?F[JCN[JGV[JS&[NW6[J[^[J]6[O!
MF[N_F[S#N[S'V[S3&[W76[S;^[S=6[WAF[W?F[[CN[[GV[[S&[_W6[[[^[[]
M6[\!?+S3(1W6@1S( 1S"X1O (<&?(!P2_!O"P<$=O,$?7,(M/,(G',,OG,(O
MO,(_W,-#O,-'W,))',1-7,1+7,5/?,53G,5?W,5C',5GO,5I_QS&;5S&:US'
M;WS'<YS'?]S'@QS'A[S'B1S(C5S(BUS)CWS)DYS)G]S)HQS)I[S)J1S*K5S*
MJUS+KWS+LYS+O]S++WP<S*$*RH$<PAS+T[S+U1S,V1S-UQS.VSS.WUS.ZYS.
M[]S-\WS.]=S.^1S/]QS0^SS0_US0"YW0#]W/*9P<RKP<S"'1!_W1#3W2$1W2
M*UW2+9W2+UW3,YW3)]W3,?W3-SW4.QW42UW433W$]8 >5MV%1 8PXA/6V[,\
MOU/6V9/6;QT]9SW7;7W7Y9/7X;/6?5W88QW7@;W8==W8&RX=P&$<(IS9G;W9
M'SS:GUW:H=W:JQW;J5W;IYW;KWW;O?^]V[,]W+]=W,'=W,L=W<E=W<>=W<]]
MW=V]W=,]WM]=WN'=WNL=W^E=W^>=W^]]W_V]W_,]X/]=X '>X L>X0E>X0>>
MX0]^X1V^X1,^XA]>XB'>XBL>XRE>XR>>XR]^XSV^XS,^Y#]>Y$'>Y$L>Y4E>
MY4>>Y4]^Y5V^Y5,^YE]>YF'>YFL>YVE>YV>>YV]^YWV^YW,^Z']>Z('>Z(L>
MZ8E>Z8>>Z8]^Z9V^Z9,^ZI\>W],A'^ZAB/@E4PJ<Z]>AZ[_>Z\,>[,=>[,N>
M[,_>[-,>[==>[=N>[=_>[>,>[N=>[NN>[N_>[O,>[_=>[_N>[__>[P,?\ =?
M\ N?\.=>'<;_/O'#OC7X^[\?/\ AW_$CG_(GW_(%'/,E/_,K?_,O7_,_G_-!
MW_-#G_1'W_0['_5%/_5+?_5/OQS4(4#*H1P@G,$5O/:?H/87',2=7<)S'\-O
M']5'7?B#G_A/W?A)_?B'/_F+'_F;7_F=G_F?7_JCG_C) 1T:O1R@?_FW7_N[
M?_JY__N]G_K!?_S%G_S/W_S3/_S7/\YEWQS>G_W1/_[5O_SGW_[K'__E/__I
M7__[G___'R">A ,73B!!@P4')CRH$*'#AA 92EQ(\>%$B^'TX,.7;Q6 CP#Z
MY>.G3R1)DR5'ICRI$J7+EC!9REQ)\^5,FS5CYKRI$Z?/GD!Y"MU)__3G4*-%
M@R8]JA2ITZ90F4I=2O7I5*M5HV:]JA6KUZ#Y3(Z$QF]L67YD1^([BT^?6GUK
M[\'5=R]?VWX@_>7=^U%O7[X _ 8&++@PX<-_$P]6;)@QXL60&T=^++DRY<N.
M,T_6;)DSYLV@.X?^++HTZ=.>4X]6;9HUZM6P6\=^+;LV[=NN<\_6;9LW[MW
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MY_;//_[W__ZDZ[__\G=_ $A__P=_!,A_!BB "5B _H> #3B "OB "^B  <B
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M-_B07C[J./[P7>O0#VG3#^]P7[@;$K:D!R\K-]AZ6\-Z-5UZ6UD"8),, .Z
M7.[PP5OC#Z-<7_4@&7GQ#NLUR?VP6VZ:-[*%N_X I=;ENV],K1'WP?_^$,=/
MYL:!P5S"S,;;U;I^T0^TM<I8<\++-<>.8TN3C,O3=;J/3,'*51@!ALP@D<IS
M ,N_U*MRXP_T<%R)+#:^9<NQ/ =Z0+5YL0X.YLM<X\WF+#GC5;EQPZWXI<M>
MTP^\_%\2C#:H?'+6K#;^7%W:S%_<_!'>#,ZW),Y70\[T5<I8XP_PS ;RD!C/
M=<X?@5NF'!C S ;MT,=<,]#T5:4@80VPA<]N4ZS%%<A8@Z0 ?38FW;R[Z[S+
M>],Z;=,\';W)^],X#;TYW=-#[=,//<0]W,/8&\3<B]1,#1:223YM5D23:K'I
M4Q=TUK[PN]7JV]5:[=7O"]9<_=5]9K()A++_H.?+)\Q2[? 7_+!-&=T:].!.
MB>07A^S.@7'7"-P.@EP<3[ .?M$9,8M,<8T9^:M,[?H8])!,^+ ;Y7Q.0^L7
M]##+HR$'[G#)HV&U<]#8DLU/$!T8,5M,!_P9"9Q.A L;B\U, AP8:RT'8F89
M];!+D?T1<XU,=8T9A_Q5EZP7]3M5L[VZP83' * /#:76<K#!FM$/R#2NB/&K
M<_#;CWU,MYT:SGU,G$W;_O39_A#:N130M,T&>&T8_7!-"TP8Q;I+W@T ]&"N
ME7'>X*3=CU':Y$T9[OW0LJ''YC3=JY';T&2MLR$/G*;?G5'=NW3=ZIW=A<'=
M<Y#>Y1S>>S'>W33:_YXA!XX,$OB@3*>]V"0]&#\K!VIL&@!^3[L- /+@#EFM
M&,J]#K&AX+[DWR .P#4,XS:<PS)>XR0\PS,>PS%^XSN.PSJ^:3OLU$*N1CYS
MM[C7U$B>U$\]%7X+B>(IN&=]VHP[Y51>Y59^Y5B>Y6/BN/+I?I0]S#>F)< 5
MRCXR#SD+6_3PT?A]75KBN_H #[,E#U<*S8J1#]B<#DKT$?<0R7(PTEHBT[M5
M-?D Y[0E#Q^MW- E)NGP6T'K-O20RNL TT#S7E\.&8-^2^F@25R##_[;YZL-
MNM+<(S)=79L, ,.5T6Y3#__6#J7N(]7UT??0#K3E#J50-8><6U^^R+0E)O__
MENO")<P @ \7W>?TH.G!3G!9<N8UAMF4W%QB+EX<;>FE,-B6K"5_G.<@D0YR
MX.O#]>G!WL&PM0[%;NW+-<F ?EVE7EN5KDF#'K-RL [,3KJ\A>T?H>R5#A+0
M, ^+S@;'JB71I;K>1@__-@>E$.^Q'%ST#@#*/@?&;N>^50K KLR_KB7"_EOM
M,.X]<N'0!?  D.^+#EOS$.^X3&/>C@_@_NX8OZWE+NK>E>[,M>X@T>[A'N\N
M35N-#HJ]7NM=TNFYU>:U2ZWPL+*HOBST .[M,+K>UE[1KDG0,*3L;.S6[LKL
M[.U0FEL<[_&X%?):,O)$+=1>+[U@#]0[;=1C7]3_9O_U8M_U81_4]T>]2C[D
MC[G4<+_D<W^P)\HH*0JXYGC5Y"O6?D_680WX8QWXA#_XAO_WOB&_>9?A2%6S
MO938WI9/OEP/X=2S8]8.^1T913M-O\W:YO3;*ZM+F.T/KKQ.4AM-PDVF$5X8
MAUQ/[E 8E#].C0T9&C].(_X1\BU-(XX/Q009[?3A(=%,L\_A D79>D$/\U2S
M[02FO\3XQH32DLM-LZ\7L2U-S*^T>?%4D)&T3$5G^;M-#,Y/IZT7O$]."US?
MM-36?8&DLO\7L1U-8*JSV6],D'%/P _AP33]%OY.S!WLT[30 ,&/S1PY3^00
M?,(&'P  _A@"4(?P8$$V_P\=4D1(SV*_@A,32M3'T"$]@P@'NFO(4*!$D_U$
M G#WL:-)BP P=JPY\^83AR)9UDO9T.- G?QZ IAGDN7.H3EEEBQXU)]2.4$!
M$(6:,-_+?D_E++2*CVI)H#WQ>=3X$I_7EB\98CVH42J =6P7'KTW]N ZJTEW
MWJL)0-]0A"'=TB-<T'##?#/+BDP,U>A#OVR9ZL5\6;-ESG S=UX*6J?HK)XW
MFR8=6?5GU*U#NQX-N_1KVK%KS[:=&_?NU:=O]T[-^K=PW<!E&Q_NNSAQWLR1
M+U?>//ISZ<&G.\=^7;MU[L>S=T\.'KKXZMZWFR=/7?UW].W#NQ\OAYZ^?OGX
MT?^WC_]^_?WY^>L'\#\!_2.P/P,#+!#! P=<,$$&%83P00D=I+!!"R.L$,,+
M)]PP0PXU!/%#$3TDL4,3\<GGGGS 4BG$$ETT$4891XR1QAE?M#%'''>LD<<;
M>P3R1R%U#)+((7TT,DDD*[2O27Z@X<<^**74!Q]^\*GRRA7U41%+%;_,QZ&C
M'K**S#$#([-,-,U,TZTTSW23S3;A5#/.->^T,\\Z]Z2SSS;Y_-//.0,E=%!#
MWRP4T4/E5+111A_%$]!%(Q7444H3A53/2C.5U%)-,;UTTD]%[93334/UM%14
M305UU%1/=9554F%5-=954?6G'A3OP><>/=B08Z)@YP#_5MB#BB5H6&2#/7;8
MJL@TEEAGE9U6CG?(A&;8>2R:I]EHBPW*GV6#'=.?>[Q-]B S_4&7V3E<$HF?
M=H>%MR%XYL67V':XDM;8Q6"B]J!5TOQV6GC,=!?<HS@J6 Y_CLJVX8<?*L79
M?]U)5UI^@NIG6< LRGA<.>0AD^%^YX FS7[N#3AD9PD.V3"',!:9X(#[&;,?
MC!.N]F2>&YY#JIY%]EG9FOHI^J!2+!HL:6)KFHIH8$/J29YQ4WZ(96^M$GGC
MC6@>>FB982KZ7W8#MNILEP_"FB%YHFW;GW?P33/BHE&R*.&T'$I*ZF$7[CGN
MN9WV6UB^\KXYYYU;_KF>HRH&_SK8DM>FG%FO1=*9<+%? EM8LW]..VRVR7R;
MH+0><N?GC,T\]^1Z&:IG[7N$COS@AY#FV2UQPW:I)X%X#\KJ8!VG6/1D)U<]
M><:7S[?PRIG7/'+HG5>^>>.KC_YYZZ7?7OOLL:=^^NO%Y_Y[\KT/OWOPQU?_
M_/7+3]_\]N>7O_[X[V??_OSQAW]___L'(/K^)\  OH^ !S1@ MVW0/KQ#X$,
MU%\!(>A ['FB2$NZ8 :/I$$E<1"#&P1A!T/X01&6$!\G3%')2+A"#[9PA"XL
M(0M?.,,8PE"&-:3A#75H0QXJ*!_\^:&3IC0+)V')/EBR$A*Y5"4N;0E,]9J+
MFZ*8-O\T3=&*5<2B%+-(12UVD8M?O*(7PPC&+8[1C&5$HQC32$8UMI&-;SRC
M&^, -$#+OPC'-<[1CG7$HQSS2$<]]I&/?[RC'P,)R#T.TI"%1*0@$TE(16HQ
M5UU*D1[.\YXYR$4E\#$(O$9B$'4T,B4[N=9+Y,$;H*3$'[PA64JZHII4.F25
M8W%'/>K!J_U \2'0T(M%Y%6:?04E-4[QR+9>LIE0-H1=G"GFPVY"CZ/$3B=6
MP25&^'(4[[@%-SA#4V5<8TG!F(9CD1$F8VQ#-:C58SV;T8-%CHE).:A#3 R9
M16^LLAINVN0S"QO+4?01FG#ZHS%L(>=+<F4>9CXD+S>9!<3XZ137"/^4+2_1
MQV[ZR9'=?*PAYRI).ACI2\] M#SOH <^Z)$/^BQ&*H.934!-:<[/I-.34QF/
M9U0JIGH0%"]42>@M%SI,T#AT(!H]BAZ&$U!U#*65#*$':CK)4]E(92G$8PCN
M+",/?&J&JK=#B$LW"M/R4#*F7NWJ5\4:5K*>,SWL :M9V8G6L:HUK6PM*US=
MVE:YUG62=+UK7/,Z5[V>=:]V]6M@U_I7P@KVK84=K&'QJMB^)M:QM[%@#GN(
M0\KN4+*7K>QD+9O9%^XJA0_1;&@QNUG2BI:SIRWM:$V;6M2NUK4RBE)LA:@/
M*AV1B4KL4A,]2Z<_]=:WOP5N<(4[7.(6U[C_QT5N<I6[7.8VU[G/A6YTI3M=
MZE;7NM?%;G:UNUWN=I>YN4(1-%8DR0GF[W6#PQ^+&E*L?R679Y<#0#X*-R;(
MK>UUJ6O8ZU8QK?8.%QXN*Z7;1+:5XFTO3>-ZW=N6!U^M%0V^YJ36Y) UIK-D
MK&T 0$SV;+8V>;R.3!4FVNO:@:Z!/:1T/!M3._P&#]Z>JX'.TBC(%-BL&"OW
M'91+<.34ZTQE610 _T4PF? [+Q;WUL7/,U/&*#RO'#-/O?OUEH_KBV(RO<-O
M:3K9A=T;93)-.6#P):[P"E;D/QUY7 1>;@231>8V'5EY27;7DHO69'P]>5@7
MSK#SL%4M^-KMS&2"_[#UL+RL,?TW>?"]\:')1(]DH5FY:IXQI,LKP1=36M*5
M?B"F(TW!26?ZTI_FM*8[O>D!DMK2H09UJ4>]:E&W.M6G5K6K43WK6+_:T[2&
M=:YO76M<[]K2D6VM:H4=;&*SUMBO+;9I3[@K%2+[V,-^=K*A[6QJ3]O:TL9V
MM L41-EV^XBQ->*5F)C;>XP[1?19Y"%?FFYVK]O=6VTWO-^M;GG7F][WCC>^
MYYUO?N_;W_;N-\#_K6^!%YS@^#87)'VUV.,<-:+GU(=4BIJ0=*-T(FR6*FJ2
MN4NEZG(SO?SD1P 31G]4"274#,WE,BX18'[F="6_R3ST61MWS#PW& ^-2?]'
M_ 2M.J0>;'DG ,KS,8?D@S3H&-M+Z@(7A\^F=P#HBFFNRI!]*F<=<;O=SMUS
M\J@.ELV#9'1LCLH/T7!M*4&))U5D_I"J2T<=6(_JSB.C\X*@HR8_3\S:5?*;
MEE.D)\J<JLTM4U"&B 4CZS;Z4/Z^SJ6$:8O\X,<]X %%XEP=3?W0.D+H'4V_
MOOWR<A\+W9]@]Y?@7>U'X0??>7J0H)='F X9)5;P%O+(4!XZB% H1@[6DX[1
M9II=IPW7WZ+Y17+^L0P_+&/YNGS 'K^QR7<^\Q$+?>HCW_K/O[[TE=_\ZF/?
M^]J//O>S+_[ODQ_\W3__^*>O_NVOGZS UG:ULRW___A?N_[S[VR*5D0F^O??
M_O['OP"\OP$$0 +\/\ER$BF)K2EYDBQ!(BWQ$B?2/Q4)NE=IE5K!0%K1P O<
MP%GAP _TP!"T0!&4E1$TP1)$P5NQE17,0! \015L01*$P0Y\01:DP12T01?$
MP1BL01[<P1N<01T,PD,!KQ3IE5_A-='!)H;PLNUQIS1)AW2Q&4W[E[!;GG]1
ML'E1+\18G@MSL:]@G7Q9FGAIEV+"L+7AFNNI,888,F+Q&H< LJ$A,+XAG+&)
MG7$Y'0 X%S,$@"P\F3$9GS4$ /(RGP 3B6[IER4$@"8TP_I:%@9#(!]C0@9*
M)8;PLP$:PX=8!_0))8?8_Z>NZ3+H*;&+0I?9P[!O><,?LQ^B*S"7X:9[8(-.
M%+"A2<6^"9O'T,-Q,<5 \QE(3)[[6AW$D;1=5!U)Y+%V"2< 2+T$DL1%C+"@
ML+5-8\5)+)A7C$6W$+.0J47-P458_!MHX9XIE): JJFP<8OLT2J&V$1WB9M[
M<9JX042BB9O6 99S[#53\[5\Q,=]9+5H[,=[_,<DU#5^E#6!U,> '$B$/,B"
M3$B&7$A_=$B"A,B)!,B(5$B)K$B*-$B,W$CH@;\"!,D#%,"0'$F19*UE^ZRH
M,L"29,F5=$F2?$F3A,F9W"!NL\DGB1(B C?:$K<D&C=SBT 5L:6!"[B#*\JC
M)/_*I#0XI%Q*I31*IV3*IVS*J93*JHS*JX3*K*3*HWRD%8DD]_.(I0HY\W"'
MRW$(LH,+38*)YP.JAX"-FL.JW'C"J*J-N6P(EGN)=&B.H&.IFYB,X8N-FH@)
MUVA+V&&)WV.(U2A,>[J,Q8P,TFL(?B"9HV@'V@@Z>( -N_2'LR@):UJ-R7R(
ML&0HD%@]I4#,J\!+VM.+UV,(LLI$?V*X:50'])"XG3@<U;P,SU2*K>@)MCC-
MIF"JUV!-H4.-GI-,J]@9WYRG>Y*QIX@;WS,[VQ ^<6&)C>D)=\RKY[0-MYC-
MVNB+U+P(WAC.K##+N6D_B@O.V!C/XM0ET&1#S/A-YO3_B<,+"LRD.:GXIXG0
MS,^ (O-LC:7J"?F2B%X2$]X T(8P4-TLB/($2_-ST :%T/,,OPB=4 E%OP>U
M4/:KT V]4 KMT PM/P_5T _ET!$UT1 %T?1#T1)=41*%+)IL21B-R1B5R1JE
M$<_R,1G541N=T1[=41H%4A^U-F];0)Z$!IY4(MR2P-WRKB9UTB>%TBB5TBFE
MTBJUTBO%TBS5TBW%TB(4+WP@+XOTL2\DG': JC1IL&(Q1'\H*LJQ!C)I'7<9
MT^;9,<*I4ZE1K[P %S(A1)Y)1H88G(2!TSJ#0GQQM/A"ESFE'$4MQ@_++]]*
MAWR1Q"B4QS3)ARP;5,I)1\:4_X,Y11N#(AI%+1;]$AVQ% KX\;$[5#5#M(D%
M^A=>!)8\+1Q#M!MW(1,H.QE&#1;XPE61,56U <7>:M-&-:C(R<-+S9V'4-5H
M$=7 631TR42&B,)?!#27J5:B29,12YH\?,]1O=5211AAX59"%!E2G1]>99Y?
M91XP(Y-A;1E=;9=CM3 H=)HW31,K<Y8Z51Y))-=I.=1+!,.'P-6?L;.&R=-I
M&5?F,5>-;$B&?<B,A-B.M,B)=5B.;-B(O5B)K=B+Y%B*Q=B'U=B/M5B0S=B2
M)=F3'=F4[=B-/8B/Y-$?%=(@A=F9I2&4]#&9?=F<Q=F=C=F>I5F>!9*;3$!P
MVTG;BO] +S&W<AO*K=1*JVQ:K&3:J'5:J87:J;7:JL7:I]5:JMW:J^W:K*6C
MA//*A6O1J& W?[ :VKB+V[D'O92#=J"JN1A,EE!0RUA.S;A;NST*=#").12)
M1'N"=:B'I[,FS\!%?^#;RU"I?FC;A#!3*B()PBA<VIC<[0R*[HR-:<1-RU!$
MG^O.=<"'H>S+CSA-?Y#,=9@(=]"[GD@JXIO/K'BY?M#+CO*EH2!0MIL'MYT#
MP37+/@R.D8.=N8HXT *KC1L-ISJ-FIA=B6!%?D!=I:A<@[A=JLM=TAW<FA@E
MU=#<\&PHCO+.H%H*W .MB:/=WER-NB6*X2V]YUT'>NC='S/_#?%5"?)EB;55
MB;=Q7'K(*3>Q73?1A^K=BWKHW=B3"+]%JHE3AWFP3HLP3_687L&HWH$07%O*
M7KW87IOH*>_-#:L0JF>:BWKXW!^Z/*J(3MY(Q0,N"'68G;0QI](8S<!,3Q?.
M2Z\P8 Q#8 5.FP;&4!95T1[>81<]41\6T;(E8B%.T1\.8B0N8B4V8AYFXB<>
MXB8&XB6.8B@^8O=S6:#569_=XI_EX@[R+/7RXC'NXC+6XC/^XC2FMJ%EP#9V
M0 =<TB8"DPK\02',01F\XQX$PCRN8SSVP2'48SO^8SX&Y#X.9#_>XT%6Y$1F
M9$%N9$1VY$B&Y$D^Y$HV9$,N0E[Q_Q6(U=P4/$;"&4Y+\8N .=-:;9E11%3*
MB=;&4&4R865VO!1^ +E3Q=1!048/% N1\3& 31=:91Y?QI=9=B7S^5-!D:^P
MH>-((5=6S.5I4:\T[%2(&9I;\8<V+!SU=49+BQN.B"!H)@@?0];ER4-Y"1AL
M#M==9IP/] <5$QVX1![F0>=\Z:>F699#A<9B66%+%)U\UL.PV198X<)VL>>>
M\)G^@A-_V-1OH69K'I9HI91X+#5U9N>&<>>XA.<]DV>FF1<PHQ-H2-6,Z2=6
M=AZ'UA21GA9#' QQ)I.4GI<\9.F3(6D^@6B355F/#=F;INF5%5F=QFF4Y>F<
MMFF@9MFAWO_IH/9IHZYIHN[II"YJI1;JIHZ?+%9C,YYJ-";C,[;99J/JJZ[J
MKN;JK][JL :BL1:BG"PB)'UCI#U:.1;AKW5KKH5KKXUKL)7KNJ;KNWYKN\YK
MO)[KO?;KN>[*79&D]OLCR+L'>DC<[GB'!9:B?VJ-OZ,+T"!<=W"-R:[LH*#L
MG*LB?X"'D@@H[)0); Y0U7B'F;*(?-!=IH#LNE"-U>8-UUZ-H./FZW"'SJT)
M?!A6T-#?*_(G;SJ*=:1A*>),-G#MUKC>*[H'[C I_TPKM7PX]DC%N96#_86(
MVX BT,,(^TV)Y'88I2,EPJ4B[A8.V3X.V,:,R8X,%KDIO_/NQV[_[^";&"U:
M"]E0;X/2BQ-6I;25 T6LS-@X;BQ*;MFH;2\RO._[;RT2;]\@[]\P[\M ;\S@
M333I;^KVC >/CK(D\(FK/8O [J>X;MWX\-T8\"\J<"E.XBI&\2M6<2=.<19?
M\2DV<2I^\1.?<1EW\1N'<2O&<1K?<1O/\19_4;'V:B$':ZON8ASE/R)7<B-G
M\B%O\B*?:B*MK08TVMO2+=W2/][BTBWG\B[W\B\'\S 7\S$G\S(W<Y'0E7SX
MTC!UZJ-N<Z9>ZI]V\V(9$U-&:CF'\Z>.\SOG<_FI<SP']#Z'ZCU_<^;Y<T$G
M]$'7\T6?\T1W=$;/\T:']$ O=$2?=$N7__1,C_1-IW1%U_1.?_1/QW1.[W.I
MAO)37W(G5W48RNK;6?541_4GA_59E_5D$UHBM1+;JG)R2UIT^VN][NM@!_9A
MYVMB__5B1_9C5W9A3W9F7_8S$EO!YO$?K_$8MW8=[U#'$PF,ZO%K!_)I!W<?
M!W=M)T5Q-W=OKW9L'W>IP"AT[W9U/W=X=W=J?_=OCW=[G_=PS_=[3W=\E_=_
M]_> [_>!KW>"I_>#OSY3I_57KW6&=_@,"N,D;_A8?_B%I_B+MW@?ZK8V+E*?
M3*(X!A,*7&1)MN1"-GE"1OF1I^1+/GF5+_F4?^27=WF6AWF2I_F9;_F8OWF=
MSWF;[_F5!^1,/O]"3R?U2C=ZH@]T2YE64+_THP_UHD=Z _,32GUZIA=UIV]Z
M_@$4JL_ZJA]UJX=ZK\?ZJX_ZL0_[KD=[LA?[LF?[M7?[M#][M8=[L*?[K\\7
MA9_XC,_[O:]X$6EUE<1XO@_\OB?\P9])FP0BG,P'G=3UGNS))5KK)VIV8W?V
MRJ?\RY_\S']VS;=\SL?\S0?]SA>H61K;P2[XTT=X?D?](,8B M9W@#?XUQ?X
MTV]]U4_]?<=]V&^/VL_]V;]]W?]]WY?]V+?]X5_]XD?^WB=^Y3]^Y@_^Y0=^
MXW_^YH_^W<#[PM=[[!=\BT=RT,I^P__^\-_^\8_RH9WR(ZUR)3W:+#__\_9W
M__>'__B7__FG__JW?S-)\S6/^_VO>[/O?_X!"'S6 !"$1D_.'#D*Y[!9J!!A
M0X0/&3I<&#&AQ8H0-5*4F-'C1I =,88D.7+B190<4WXTR;*D2I$O3[:,Z7(E
M3IDY;^KLR?.GS: U%0HD", @S*%)E])D.O/I3J%.HRIM:A6J3ZE7J4[-6A4K
M4*5%"Q[<ZK5K6+1:P:[E:C;MV[9GXWYUR[;NW+MJ\<+52W<OX+^"_1*V:SCO
MX;Z)Y2I&[+@Q9,:2^4X.7/AQY<&+*7.VO-DSYLZ:0X..+/JRZ=*94:_^/#KU
M:ZV>^.GKEX^V;=RW:^_.S5LW\-_"?1/O;3QX_W'DQX<O3\Y<.?3GTIU3;VX]
M>G7LUZ=OS\Y=._COXKV3[VX^/'E\ZO/=,PJ@//KSX^7#GQ__OOW\]??3[X^?
M_W_^Z2<@@ ,&>*"!"1:XH'_YY'8;A/Q$B(^$_."CSVT77GA//AOJLR%[M1GE
MSX@E$D3BB28"@.***K+XHHLQICACBS3":*.,->IXXXXY\OBCCT'B.&2/1 )I
MI)!%*GGDDDDR^:2342(Y99-40FFEE%5J>>6667+YI9=A8CEFEV2":::89:IY
MYIIIPNC//1SBPYX><CPAT1-L)'3GGGK:B:>??-H9**![%OIGGX8FBNB@BC;*
M:)Z.1@HIH8L*.NFEE?\^FJFDFF)Z**>4=CJJJ*6&>BJHJ5JJZJ:L?KHJK*W&
M^JJLM=)ZJZ>YDHKJK+J:ZJJOO-H:++"[%OMKK\8FB^RPRC;++*[.1@LML<L*
M.^VUU3Z;K;3:8GLLM]1V.ZZXY89[+KCI6JONMNQ^NRZ\[<;[KKSUTGNOM_F2
MB^Z\^IKKKK_\VALPP/L6_&^_!B>,\, *-\PPO@Y'##'!"PL\\<45/YRQQ!IC
M?##'%.\ZFX($FHP@@RB?7++*+;/\<LHPKQQSRG/*Z9[+-,^\<\X\R]PST#\+
MK7/01 _ML]%)(WU<A+=!4^'33G]HX=1S@@@BAQR2R*)[7*O8M7M?BTTCV&'_
MZUAVV%Z3/?;9;*O=]MIQPSWWVW6;3??==INM=]IY^[WWWWT#/KC@A:-]N-N!
M(RXWWXOC3;CCC2<.^>2&5QZYXI=KSGCFG%/NN>6@8_[YXZ&7/KKIDHN^^>FL
MOUB/S?C<HP=KI[E6NVJVDQ:;[K#ASGONP0,__._%WW[\[L8GC[SOS+>V//3-
M1_^\]-53?WWOV NOO/79>[^]\]\3'S[XTXO/O?;CFU]^]^RGC_[YY*O?_OSO
MRP^_^_&O7[_^].//?_X"", !DDQI15O: 1-X- 4:<($.;" $NZ,>F[DG@@Q$
MX ,Q:,$,7K"#'/S@!D.HP1%*Z$$/XD?49C$A#%&-_T(:TL<]/@3##LV00_UP
M$P[1I,,V[9!-/LPA#X/XPQX"<8A"+"(2B:C$(R[1B$Y,(A.C^,0F0G&*4JQB
MF/Q1#SG1:6,@^Z+%P.C%,))QC&;\6!G1>$:/L;%C;A09'$,F1S&JL8YMC",=
M[SC'-.HQCV_<XQK_Z$<\\E&0A21D(!%I1T,F$I"+5&0?#^G(2#9RD)-DY",O
M"4E,4C*3EORD)$%9R5"2<I2F]*3%"DA"$*Y2A!YT)2M?V<I9'LAF'<)9+',)
MRUW24I>]Y*4L@^E+86ZP0DU#(0NAP<(7OE!.,[3EV^XFS6E2LYK6O"8VLZG-
M;7*SF][\)CC#*<YQDK.<YO\\)SK3J<YULK.=[GPG/.,ISW!J<4[0Z%"=^F>_
M_?VOG_?[)S\!ZC^![G.@ 3VH01-:T(7JLZ$"]"="&?I0@CIT@!!5:$4O*E&+
M4G2B$<UH1SGZ48]BE*0;U2A(1RK2DJ[TI"%%J4E3RE*8MK0JJB3F+W.*TYT.
MLZ? ]&EO)LB>"NH4J#S]*5*+FM2C*K6I3&V9@XYY3 IE:)DR=&8,L28B*G+U
MBEVU(EBQ^%6Q>K6L81TK6LU*UK.J-:UL?>M:X^I6N;:U17#BXNPVJ5=-\E64
MJ#QE)P/+R<'NU:^"+6PI_ZK8P_8UL8PU+&$;"]C(0A:QD[7L8BGK6,U>5K*9
MQ>S_8S<+6LY^UK.A[6QE34O:TY8VM:X5K6I'*]M3W=2HMEWJ;9V:VZ?N]C>V
MQ <N<2M<W0Z7M\7M[7&32]R3'3-J*(1:U:I&0ZRRI[I;ZUSK5J?=[')7==W%
MKG?#"][QDDZ\Y25OZM"+NO6Z3KWM/2]\TQM?]F[7O/*]+WV_.]_WXI>_^;7O
M?]U;7P'KMW#U9(_L:/?2!:N4I@YF\$PA[-(&2UBF$XXPA3.,X0U?N,,6_G!,
M0UQ3$3]8PQXF<851;&(0C[C%)>8PBU]\8A>GF,8K5C&,<3QC&2^DMLHU[G*!
M+&3D!OF!0FV/47Y,Y"$KN<E%=C*3G\RSJ)8P0BE<855=_WC5JTZWNC><*YCK
M"M<PCUG,="TSFL^L9C*OV<QL?K.;XYQF.*=9BWAUQQSRD.<]ZUG/<]CSG_T,
MZ$$+NM!_)C2?#]UG1"\ZT(EV=*,3;>A(+WK2C+ZTI3.MZ$=+>M.4YG2E/8UI
M46L:TJ,V=:D[C6I2LWK5KE8UK$/]:EG'&M2V_C2N3UWK7*>:UKZ^M:Y_S>M6
M[SK8P.[UL8DM;&,/>];)=G:SBXWL:"][VLR^MK6SK>QG=UH/>= #MZN];6J'
MN]SD/C>VQYUN:*];VNK6-KOA[>YXO[O>]+[WO/,M;GSO6]_F;G>_ _YO>0L<
MW00?N+W];?"$%QS@".>WI+\]!_]P'WSA$+>XPAV.\8977.,>[SC(&?[PC(?\
MX@#WL92CK/(ELQS*+<]0=8%KE)6[O.8I?SG-;V[SE1NSY\J46I9E>+5G6G>>
M1C\ZTI.N]*4SO>E.?SK4HR[UJ5,]Z@>^YV^?^2$:7JBJ4NTYE7$N]IV/7>=F
MSSG:RYYVLK/][/G(!S3FU/:UGUWM=I_[W>N.][WKO>]IUT?<Y^3WO-.]\(0_
M/-\-GWC$#W[Q"SHR417?^,E+OO*,M_Q2J?SU#%6HZRW4>E9KN%4YMWG.I*=S
MZ5./^M6?OO6F?[WJ71][&/5#'\DH!3)*(8QDY%X8N-<][W7_^]WW?OC!]WWO
MCV_\XB?_G_G =S[QA=_\9T #1;#'TET[%',8<EG+6N:\T\#^W-^$W?&4OSSZ
MS8_Y\ZL__>Q_/VZLQI[UT]_]]6\__N%O__WG__[&V3J'\)_^]9\ ^I\!%B "
M$J ".M5O!=< /N !+F $0J#:-1?40)?W64B784W1 9A_?>" [5<(]M<(!I@(
M%I@)DB *@N *EB +>J +QF +SB ,TB"!U2 .WB!X^8,P>$(P^" 0_J 0!B$1
M#J$1%B$2'J$2)B$3+N$10H,*YB#A'-@]R,[V.9.&M!#5 )W/51EPE!\%2F "
MAB$93J 9CN$9[MS;52$^B*$;EB$:QN$;IB$<SN'^P=!ZU*$>_](A'\KA'OIA
M']KAWD%>DOVA(!HB(@9B(I*?"5F9A*A0YUF5]W'?T&6-@\P>)K+>]<F>)F8B
M)W[B)H:B)XIB)XY5,@!A)R!A*A[A*A)A*P[A*Z*B*LXB*]*B*Q9A*91BC]B9
M]F4-Z E=='F=A5Q@^&E>(RHB,@*B,AYB,C+C,K*?_%'(,S;C(CJC-58C-E*C
M-G(' .;#-'[C-6YC.()C-I*C&3;@S)FC.HXC.Y8C;HD?%_[<YS73!A9=U=TC
M/N:C/NXC/_:C/_YC/_J#$S8A00ZD018D0A[D$$*AU%U=+V[@UKV0,&Z>%ZZC
M.UZD.&*D168D1_[,V\4=&'9D.XJD1O^.Y$:>I$DV$.#E(4FV)$J6)$RZ9$K&
MY- 0(D',I$S2)$Z^)'AH'CP.HS#2HX=HU9>!XB@>I2Z2HE$F)5(NI5,J)50V
M)5@]0RS^8%5ZPE5FI2W"XE;*8BU^Y2W^8#(\98G ">Q4(3W@0SWD0UJN)>RX
MI5KFPUG*976MI25RB%V*GB_N98CP90SYI5[VI6#^Y6 &)F$>IF$F)F N9F$R
M)F(ZIF(VIF0^YF1&)F5>IF5F)F1N9F5R)F9ZIF9VIFA^YFB&)FF>IFFF)FBN
M9FFR)FJZIFJVIFR^YFS&)FW>IFWF)FSN9FT"YEG&)6[R9G#V)G$.IW'J9G$B
MYW$*IW(V)W/_/F=R0N=R1B=U3J=U.F=U8N=U2J=V=B=W?F=V@N=?RHY:RHYW
MAB=Z;F=ZGJ=ZMB=[OJ=XPN=ZQB=]SJ=]NF=]XN=]RJ=^]B=__N==WE(Z[B2!
MZJ2!YB1T6& Q(E,&6@WH59?6V. )2F$4ZN"$6FB%7JB&9BB'IJ"'OB"&?J@,
M4JB(2FB'@NB&EBB)CLTS*&1"OJB+QBB,$N%8CBB&^@,]S ,]E,(\Z"B/^FB/
M[FB0_JB0 JF1%BF2$JF2#BF3'NF2.FF3)FF4/JF40JF55BF64JF63BF77NF6
M>FF79FF8?JF8@JF9EBF:DJF:CBF;GNF:NFF;IFF<OJF<PJF=UBF>_]*IGLXI
MG][IGOIIG^9IH/ZIH *JH18JHA*JH@XJHQ[JHCIJHR9JI#ZJI$*JI58JIE*J
MIDXJIU[JIGIJIV9JJ'ZJJ(*JJ98JJI*JJHXJJY[JJKIJJZ9JK+ZJK,*JK=8J
MKM*JKLXJK][JKOIJK^9JL/XJFJ[">B#931XH3RYK@;:D,3IB/D!B4$;74#ZH
M#4DEMC*EMI+EMD9EMV8KMX:KM\I9,G E6)IK6*8KNJZK5ZIKN[*K6(KKB@AI
M*="KO?)HO>+KO<Y#OO+KOO8KP/ZKP.HKP?IKP0;LP0ZLP2XLPC*LPC8LQ#ZL
MQ"8LQ3ILQ4;LQ4ZLQ6XLQG*LQG8LR'ZLR/]F+,EZ;,F&[,F.K,FN+,JRK,JV
M+,R^K,RF+,VZ;,W&[,W.K,WN+,[RK,[V+-#^K-#F+-'Z;-$&[=$.K=$N+=(R
MK=(V+=0^K=0F+=4Z;=5&[=5.K=5N+=9RK=9V+=A^K=AF+=EZ;=F&[=F.K=FN
M+=JRK=JV+=R^K=RF+=VZ;=W&[=W.K=UN+#U J ,B*+,J:[.>Y$_*HSPR4_<1
M780").,VKN,^+N1&KN1.KCRU:!)64]RE Q+Z S^L0CLXH3NL C_X T$:Q>5F
M$Q+6J-7!#MP]Y- YJ.=Y'D6&9. "[N#>KN#FKNWJU$>J!^[N+O#6KO#^[O .
MWDH*7O 2K_+J;O'_)B_S-IE-OL?S3J_S5F\!^N374=46?AY6<5D,%>6XAB^X
MBN^WEJ^\FB_YGJ_ZIN^/4*4JKDA8JH,\^ .):.X0DL@-?>5[P&]6TF\^K(A5
MVB)!!#!8CJ7X9E_6A9Z<:&'L$F,7,B+U-J\$+Z_U4O#PRM\]5' $6S ';[ '
M:W#/=.,$?_ (@W )GW 'WP<Z$H0)IS *D_"/*>AS24V#0F2 7E>*HNB)VF@.
M\_ .FZB*AJ@.!W$/ _$0'[$/$_$/KV@2(W$+6JX2$@1!I@/\#B%!O , X ,2
M E<N @ 3MH<60^$](.0 (Z3J,G&!4:$54A<S,7 RL1"T)@?MNC =P[ =_[?P
M'1/>&OIN'M<Q'O_Q"P/R3N(A\@:R(?OQ(?>Q(HMD]"*R(R]R(D/5,1:CM&YO
M%C93XEHB^(XO)Z-O)Z_O)[-O*(^R)Y?RCI3KN_+O++9#%6.E)Y!(,(QN.[RB
M._B#/G1"*Q,P%L^"5:[(.\"K)Y0Q,!OP4?*B+1%FM5ZR58'?#,_P)#^R($,R
M-$<R-8<0!D<S-E>S-&]S-N??0VIS-W,S.(_S-._<,?\M.8MS.:OS<A3N&P>=
M4"IN/D03Y=:S/=\S/N>S/N^S.T%Q$4JQ$L+#*AB%'A#A *L#  <AB:A#, #T
M/P, 0_L@%0/ 00HS0:HNU#ED G,=URWS3T+(.O^'LTBG\TB'M'WT;ANR<TFK
M-$FWM$G#TO&^W4K/M$NS]$O;M 8U,D[3]$W_,?:*G_;&;B9[[^B)LBD;-2@?
M-2DG-5,CM5,OM3^X+RLVB3[0 P$#(8FD(CT  #T 83T 0#WXH"HO)%<3X3P
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M4_F25_F47SF7/WF76[F7ASF8C_F6BWF9D[F6 W:!+\TW4[B;-SB<*_A.G_.
M_\;YA-OY3KHS%R)N:T,3/_\YH >ZH \ZH3]N<0?A<1.A'ESQ$5HT%/ZO-2#Z
M=&,U -@O$B[ZC2.A10\D1C^=1E]AA^3!@/?WJ(^WJ;OWJ=>W@),ZJZ<Z?[OZ
M?[<ZJL^ZJI<ZK;_ZK<<ZK*_ZKMMZK<OZKZ?ZFKM,3..YL<LYLM^Y(.MTLK]Y
MLV/D3T]5) 9=]Q*EB9/XB6<[MF_[M7=[B7_[CDBU*^:RC_^@/H U$68U$.8X
MCR,ZB_O@_UYW5M*#/^0#NI:Q5L;K <>)ZU(B#&4YP#=YP&.YP!<\P1_\EY^Y
MPJ?YP"<\PQN\PS>\F3\\PD^\Q*/YQ2]\QE-\Q$.\Q?]3RK"7S&8?N[*7O+.;
MO.Z.]K.O/,HC8VIC( /;L&OC,&_K-G?;/,[7O,X+-V[?_,X/M\_SO&_GO- #
M-]#W\*'+J-+/Z-(O_783?>5X-ZCC0WCC>K#G.J]CO:];/=?KNM8#>]=G_=6/
M?=AOO=>3_=F7/=BG/=N+O=KW^MJ[??*$?($0,H*?/-Z3?-ZS?$HR>\O__=Y?
MGH53,I:Y<;525X=KN[<K/KAS>^,OON,SOKBF>+D'N8I;?N5?ON9G/N?G.XVZ
M]18])#+#D*AKO,=C_.F;?L6C_NJK?L>W/L=_/.QO/.VG?NRS_NOGONSK/N[O
MON_W/O"[_L33?7^,/-_K/?+_'[_R3Z/* W[R._\!ZCDRP7,F/R0]%SKV9[_V
M;S_W=_\U)3W3AW_3BS\3=KK3?3H;BWK<F[W<MS_[O__ZQS_<S__7TS_:N[_\
MU[_^WS_\V__;[S] R)$S1^! -@()(CPXL."<A0D-(FSX<*)$A18C,KRH,2-$
MAQ@_<@SID>)&DB!+=JPH,N7(E2=9HI09DR9,FR]QFLRI4F=/GC]=^@P*M&51
M/?KZY>.'5"G3I4F?-M4'#1^^?$VA.M6:E2M6KU'!;OTJ-FS7LF/-DE6;EBU:
MMV?AKGTK-V[;NG/MTM6;ER]>OW<![_TK.'#?PH,-$U:<F#%BQX<A+WXL.7+C
MRI,M_U/6G)DSUJI6[P$0#:#S9=.;,:<^71KU:M6M8;.6_7JV:]NQ:><&G ^J
M4M_\?N,#S@^?/J7%B]_+EUQ?\GSWD([V)YVZZ.G6JP.XKCW[=N_=P6,7SWW\
M]_+AR:<WKQ[]>O?MX9^7SW[^^_KQZ>>WKQ__?O_] ;Q/0/X&_*_   E,T$ %
M$5S0P08A/%!"!B=TSY]./ DFPPTQU-!#3SK<4,,0/R210Q%/_'!$%%=4$406
M7W0Q1&@HK/%![/RY1SG0EM,'NN0(>H*A)]@(<L@BY1 R2"253)+)(XU<,DHG
MIR2RRB>E3!)*+;-LTDHNJ03S2R^Q#)/,*]$4L\PQMSQ3S?\TW8RSS3F[I--,
M.]FL4\\[]\R3SS_]#'3-0>'$D] W$96SST,5!9110PM=-%)')Q6TTD<E3112
M33-MU%).*07U4T\Q#9742U$5M=11-SU5U51=C;7563NEU51;6:U5UUMWS977
M7WT-=M5A8<65V%>1E;778Y4%EEECBUTV6F>G%;;:08]JK+GG\L'MMMJ\#1?<
M<743MUQROSU7W739-;===-V-%]YYUY6W7GK9Y1&?T0!X]]Y__0W87H'Q'=C@
M@A$&^&"%S?I-*6B&@_CAYHBCV"KGG%-.N>FVX[?C[#SF%^21QPM9Y/1,%OGC
MDDE&N>657699YIAIAMGFDVO&^>;_DW=66>>?>0;:YZ")'MKHE)%^6>BD9^Z9
MZ9R+?MIII:.F^FBKI5X:ZZV;UKKKJK^^.NRLP08@&1A=3!OMM=5NF^VWW58Q
M&;+%AKIN[^H!#1^->]PQCZ)FNDDHP&O:::C#"1><J, -3[QQQ@>'?/'"(Z=\
M<L41ESQSRS?'W/'*/=?\\\L?YWSTSDL/W73165_===5A3UUVT&<GG?;;;<\=
M==QWU_WTWUN/G7?@7Z^]]^.)%][WX(U/OGGFAX=^^>*CIWYZY9&7/GOKM\?>
M^>J]U_[[ZY\W/=O!?*SJ*H(9;I_]]Q>&/V'YW8_?_OGOKQ___?7OG_[_U_*9
MY_"+?P L_V#^#.@_!"[P@ U48 %YXYO>\$-BLPB.<2HF'.3XJ#D^ZANW^A$A
M&XGP1B.L$ E1>$(5FI"%)71A"EL(PQ>N<(8QI*$,<7A#'=J0A^_YA@-D\( @
MLD"(10SB-R+4#V'$"$4F:E$38>1$)I8HBE64D14W1*,=UO [_JC'CK@%G1WY
M* _42A:TSBBM-)JQ6=9:HQO;^"PUQO%:=7RC'-F(1CK>T8Y[]*,> 3G'0.91
MD(4DY"'A.,A$&G*1B,1C(R'Y2$GV49&3Y.,E_\A(2V;2D934I"<[B<E*@C*2
MI-SD*-5TOKLLAUL,?. K$QA+5\K2@;2$Y2QQ6<M<WE*7O008C_]",QI;#G.7
MQ/2E,7F93&0N$S;#<1@%,0@-#&YP@V,$X\9PEDUM;I.;W?3F-\$93G&.DYSE
M-.<YT9E.=:Z3G>UTYSOA&4]YSI.>\CS $(7H !8<8#0'8 $0C<A/<_8#&LDH
MA3!(@8R#)G2A"D6H0QGZT(9.5*(5C>A%(9I1BF*4HL^ !LSJ*4XO6@4:K+3F
M<LH(OO*%CWOCZ]Y*8:I2F9)OIB^MJ4MQ*CZ=MG2G+/5I3&D:5)L*-:<\->I/
M;]I3H Z5J45%*E&5FM2C+M6I5(TJ5*<JU:<V]:I<S2I6MUI5K5KUJUX-J^A4
MJ9:IJ$^9Q73K,=_:5KC.5:YU929=[VK_U[@23(#!% U>]QI8P Y6KX3-ZV$)
M$T%G+O8XPRG.<3IHS<@^)SI;S&$/+\O%S+;'B ^8P0.(&,0@?C:T122M/A&P
MH-&"MK.D;2UK1>M9V#[@/]\P[6Q72\1_>J,_LBUM;E_[6]\:L3JW%:YK8XM<
MXQ)7A<M-+FCQ<US</L"RU<7L#H$;1,UBY[E$M.Y[8HN !!&1M)O]KGFOF][W
MY.B:?8NL*>$KRD_*-Y2<+"5][VO?4\Y7O_'M+W[W6U]4_I?  S8P?P\L8 0O
M6,$-SF^"'\S@"#LXP!.V<(4Q[%\(9QC &I8PAPO\X6NEM2O;ND=Q#"O8PJX8
ML2EV,8M5W&(8_[]8QC76%[]J'&,=TWC',_9QCO'U3(E1,&(6L]@',\8MCGG-
M;G1S,M>:#.6IC4W*3%[9=/$9VRQW]K<.Z)J6L1QFX>(S:@C8<FS'/%L64(W+
MG3US$=,<6I6Y6<QTCK,0[Z8S.[OY $XS<YV#^&0J#SK*A)YRSL#LW;L!]&EI
M/O2C108.UJX9 '#F<I]'4UHDE@W2G+;RIST=ZCR+FFXC?<[>N(6QOW6U):60
M#C_ 2M:SEE6LL1[KK6V=$7EL!QH6@0<!95V1>@"@U[G>WJY'4^Q9+SO8N$9>
M:/KQDG?@^*ORX)>R:VW69AL[V]UFM4R&C6V)_%J8S':VMVG][72OV__<W%9W
MN[5][G=O.][N9C>]T0WOWY%8*B=6'Y!_W&. #US@!>?QP0..<((/MJ\$3/C#
M%PYQ@TM<X7M5[,6)G \+.G::1F8.QCRHG!">E^3J1>]V>VCI1.]YY:+U<G[N
MW/(V@QF\,[<YFN',69GC?.<Y%P^@;ZYR+D<(Z#)XN7V"3F:3EQSE"W(T>DJK
MZ)H+E^FBN:<0,5UIGN?\.E>70=:7'O:FGQR'7FRO&/LF8B[I@SSRV+"'*0SW
M"\L=Q)7D!W;@,2:V6\?M!0[F=/+^=E7=G3MYK[O:0QSW)-%#.GV'$MNO(X]3
M$A[PB9][AS%O^</G\>\ "'R6^K&==]"=])G_%[SF2X]ZTR/^]*UG_>L5KWK9
MNS[VE>2W25%,<=U'G/<3[WW%@;][WP\_^,0)(XZ)+_SB)__WRG?^;1A;Y(E!
MEIH>Q)B20YI][6__G4DONM!EH,TWC__[V@RS#!  #G[Y$Z!;Y^;WR3_FDX&?
M_O%W\SGK/UOU;U/2/0\T]P%PG=YLF]*LF]ROG@"*TD2CB$Y&M$0FM%XN "5P
M MO)U$I*7ZPOI>S-'8#MWN3- ^U-W^;M Y&* _D%WV9"9/)M=DQP-% 0!.LM
M!@''8V1P!$/P!440!E>P>E00)/3 8VZ0!'%P"(6P"(/P"&M0!VTP"7.P"8D0
M"7<0"L4GK=;**IZ/__FP</FT\ JWL/F\, NY$#,:;C2Z$ R_L S1, QY#^.>
MJ;$@B_JLCX,RIK+$CNRJ[@[KT#J""T!*"[D<8#VRB[8NB[S4K#W^#+C6S#V&
MRP'Q<#ND:^Q^+A"SBS_>3+G^#Q+S,!-?R!*I2Q,#A+5^3KIT2SV*"!--T0X]
M\838RZ3<"TA6STGR 3OHX?)F#_9HD?9NT1:99%^L Q]>,5 8SSKNH?8ZA1>U
MPQ=KD1B5L9$083OH01=3#Q<W+Q>7L<*"43N&,4_VY3KJ01JC$1I_<1K%\1NK
MD1RI\1S',1S-,1V3$1TOY7Q,+/?.4 W-L![3<![QT1[I\1Z+Z<:$21_SD?\?
M!7(?"3*6A"QBBDR#C@SD^ :;.FW4(%+0"FTB'U(B*Y)KL(PB#]'2@F;E2$UI
M/+)NTBS\B&;F(K+*^&4 *=+*[*S]X$R\AF8C(?  #0W43K(F/Q(GC88F5S(G
MFZP4^87^Q.O*%,TB;=(H??(B=1(IC<;43HQO5"T*188%><,ZH*$=>((>^.$Z
M_ $:WD%WW*$J_<$?\*$=6F(>ME([NO(=HO!PT))C^N$>U.%T2B$ZI@,X2F$)
M#\(=*JLKL?(DZ"'TK/(K/6<>]&$L_PH:W"YVVN$>1LX?^"$O(T(\V))YTJ$>
M^&'D2(,?Z&$N(4<S 4 =&L<P$9,T%+-X&O,Q(_/_(BA3K+22*^\A'6S',#73
M&O(!'I!'';2R-O-A'K"G+D7#&NBA(_2 '@Y3.J !'DBG8]+!"57*.,D0'_0
M=/2@.(1).DDP+!\S']SA)4HA+;5#'Y3S ]7A.S6S'_3A*\G',$=#'X:3=BXS
M,\F0,SV3<D!3-$VB8R1B'K2H7[K1")GP"0,40-NR0/7R0)4P09U3"A540 VT
M06_J*-+GWP"R0@<R( O20C/T0C440^MB#/]J0T740SNT1#G4,"YN@BKH@J@O
M@^0P#OE&,T^Q$5%Q1L4._!#DZ<9#1]-K)#/+SFIT-+9N1K%,G^A,$1-M(Y5N
M.MX,B?;#&X1. =<CYHPH_[7PPQM<DOS0;T!XE$GA3Q"Y:[KF TO]3XA@TCP
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MD_/NS5VGWNLV4/*NLV_,]55ZV7&W<E0+N7C?AG;\<<#TQ', Y1T'@O3.'(&
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M@1;(@1/8@17H@2$(@EA!&'^3&(5Q&-U6.-AE.)/Q5@\"@S$H@S/_Z""=U1F
M-1^>81\Q:""0]1FDE1E 2(.:X5K%\5O,<1D&)P.@!0 C-QV7T5C)P1G@L!S8
M086[X8,%YQT)\AG7(QSHT1GAD5H UQI@>!D[N!GYH8,&%QIB:!_ 889#*(=S
M2(=UR!D1,B$':$$9 FLLPV1HT2Y2 F<V]C&#R",",XB4LB%_R"X7@S!IX8@\
M1B( ,R\0LV4VAB.,F!8@4V69LB? PE\58PU^XFH'88@.<XH/DXA,0F0:LV5<
M@BT<<XGU4"*I*"/W\C#;<A8_IR;2\F!;THHI\XJ;$HN6>!FT"&D+(RR6THD
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M<$C+"1':R0^F1U+:27939*.4%$[R8$7HZ8SW0$=LT XZ$CKW]Z,@U)S%E*+
MA'F90P_P=$Z.PP\QRD+\4#FXQP:?TDS R1 9=A99%*"Z1*  8*"14Z6R1*&O
M)TN3-U!3^CEM^G_U-X#^QW]XNG]ZZJ>]>:>!NJ>"^J=Y"JB#BJB%VJ>'JJ@"
MN*B&"JF/*JDH58 CP1@(F)5<J:E>R:F9VJE=Z:FA"JJC>H%%M7SL\JF;*JJJ
M2JJIZJH3:()6A57>ME5G::M@57W0I5G295N\:ES1I:N]&JR_NJO#ZER;)1["
M>A;@DQQ[583%6EP !UEZI7"/-5PV"*S/55EH_TBLRNHGUW$ LD6&I]$XF<F&
M='6$[W99G+5;LV492D@?SBIO9?6LGZ-;Z#IQ[PH<\7I8]=JM_WJLT)JM RNP
M!>NM!@NPBH6'U75=AJ-=/GDC-<9*^R*/#<,O #"/K7*QW-@A$@LQ'DMCCN-,
M.)*/>&4-V[@IG<A#',.BE3&R4:(.H5-9^]B'!YJQA&*S$W.@'"LCX$FL+ (M
M]9A7P.)$&W*Q&5LBS3BPJP*FEY$/F^*S 0NT>B*T>D6TE]:,?T(K++ITT)(.
M9R5<Q1(JY76L3$<B-?:R'P.>RQ62L#@YX;*QFQ)H 0L PJ*RE((C<7LQ5^J)
MT'*J<N4/N^(HDZ:WT/]2N'IRN)7BD)!C:!-CG71;&?C0*I<AM'@EMDD+N:\2
M*DT;)R:2M1?3C-S(,?<I5KU"DSSYDS,9DZ<+L:S;DZ^;NJX;NZM+NS;9NK6+
MNJIKN["KN[DKN[H;E"Y!:V/1JJOZJL6+O*RJO,>[O,;KO,D[$56))]#[O,U+
MO==KO=E+;=8V&%>5#]I&EH1#J[LI<Y,1=;1IF[6)ONM[FZ"CA,[CA;BQ<>-*
M<F_HF9&#;\AA'OSZ#5'85Y*I;QBGA .\<(WD;^Q+6GSI6/13.1ZWF$>H/@3T
M'P#\.=K!&IL) .:*A>$Z._\K<<UJ.>OQ .)C.=QZ%AI\<!S\/.>1OBW,ONK_
MV[XNS'(OIX<Q9T&.:D]<^B1_%$[TL$\]_,..X\,+H</ZF,.10[._5,0 D,0;
M!&>A([G=%SFED$$7*BC\1*=-[$'TT#Q5AZA #*1"C$]@#$)/;#G^D)P01:'3
M)<5CIQ!!JD^)]#A(UB2UM,6AXT139,:XF<;[M,:@,RA+W*,I)4J#LD]-.\1_
M](>[@WCX],>5$WP>M,1:7%![+#H10D\CVCC]T!!+3,4K%$D15'4'8<7UM:5(
M#$^GBLG[%%^<(R=ST'</-<FM-,L$5<OZ5#F[IU%<;#J)7$10%"/N<+Z9\\EQ
M[#ETS*-W_#AYW)T%U<P4E<N$RJC3'*DXS*?6+,W5_WS-VYS-D\K-B4K-WMS-
MV S.VCS.W]RHZ!S.?U2I+*&'+H6]S"O/U3O/\4S/]VS/^:R]2Y&!1X7/^ZS/
M]0S0 ^VJ8MF]*7B"CF&6V.6"=NC0#PW1 H*MH/$_K!/!F)6N!"R$EX&#];O
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M#NOSR6+!-%9L'#/#+&.W?FNXCFNYGFNZ3J5V_E>'-NB\9NB'UNN^YFN_#FS
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M@G"#'[0*!"^5FQ%V,(0I%*$*4>C"%L*07=.9H<?T89V1G8QDWGG@#B%H'_@
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MA%^15/H<VCI !&;AAM$YQ,>ISN:X_YQ*U"$ 5")"U!R==43-797MN$Q-Y,Z
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MXFRL)>X2-.U2-/UR-"TLPJXD-$E3-?N2-5/3(C_,G5;3-6>S-&E3-LD-)@'
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M+LP=(**(/NC!MI?H@6#OR"=!])$7>ZIE'?A0"$$3!X]>\<-Q5TM'/49UD7Y
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M>W=MV5\]M'J>R)DCYPF;].?;LU>/7CU\]_/;RU]__[U^^_'W^^^OOOP '%!
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M6V^_!3=<<<<EMUQSST4W77779;===]^%-][G:,-MWME0\F?>>F>K1Z5[D@.
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MN4-8C$NH0\64R@?G3*BS!#]T3+W@C+;$<*8%M#\@_\5L_$6([,QD2@5S#$S
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M$9>/>P).HQTMZ4=)>E*/HG2E*FVI25GZ4I>F-*8TG:E-87I3F>)TIQ[5!S0
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M2(1'6(1+J(1-F(1/B(11R(10.(52Z(16Z%GG97U8ERW QG5>%UG0LA'S%8
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M6O2A.8S3'^PT(@+2G]WTG=[4'J$% *.E(+:<L2"K&P1-'X4$@&[<(:G=,."
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MB<CSX <D@0<,I))<Q9XJ.518P<"20BFK[0=Z*#(68=4LH4:1E.!>M?\32 6
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M*6LF_Q].#Q>G$BN;,BNA<BNE4BN_DBO!,NW8[AZ2J/38*(N,41JIA>[.<O1
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M0J7BY(<P).*H2 R 4ID04R5V%1!C;..'>)@D1<PQC4<\ #M Q+^08<$X) X
MQY I8F0=GB3)2TZ(476(*2*#V,I"_K&)L:SB+7LYPF".LIBU'&8RC__9*EC)
MQQ2I^<LV#[.9;'YS--U\S#C769IXIO,RYRQG.^_9SW#.<Y\%?6<]!]K0?"[T
MH!$-Z$3_F="/9C2D#[WH2BOZTI&V=*8Q36E..[K3FPXUJ$<=S=@"^-0"3K5A
MNOD=@@[TU0"%M4!C3>M9V]K5M<;UK66MZU[S^M>Y!O:N@TWL81O;U\5&=G]T
MY!V$_F@@ >:OM*--;51/V]K55G6V,\IMM^1#2QX=H%E&.E(&PP6N;4TW6]>-
M;G;+U=WJ;K>\WSWO>-/[WO;.-[SW76]^X]O?^NZWP/\]\#=M*Q_=6JUK%WY9
MAG^VX1!_N,1+F]K73ORT"H\XQ3-^\8H[?./_%@?YQS$><I*/W.,:-WG*4=YQ
MCHM\Y2Y7><M+SO*7FUK;V,[Y-F^;E?+ZO+T_1V_0V2MTH!N]Z$@GNM+7RW3U
M.OV]3W>OU(?>=*A;?>I'7WK4J;[UK%<=ZTG_.M>O/G:LQU<XJUE??0>"\[9?
MV^W9?KO<XTYWG3MIHP8>8  )"%*QA-0K"GRBX =/^,(;_O"(3[SB%\_XQCO^
M\9"/O.0GO_@HJEG3I&ZTYB?]Z<YO7M*@Q[SG.?]YT9?>TZ<7]>A#CWK2NY[U
MJD]]YE]O>MJW'O:SQ_WJ:Z][V>_^]KP//O#O?/.YV[WNUV%U1Y7-?&$W/]G.
MCS[TIW]LZ5>?^L^__[[VL\]]ZW<?^]X//_@!VIUFT\9'[(/V\=</=_8;O_WP
M?[_\MVTEO',TW!PMMT@-6-*" _S__A> !#>  4>  &B  EB "GB "YB #/B
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MK=C*K=_JK=HJKN ZKN%J</505SM)#U2%#R[SG#5Q#WA5#S^!#Q(J,O/ 4O(
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M,B</:@(-,^,/;*(.*$D//\$/%PM:[X 3^F"Q$*N^_$NQ]UNQ&3O &%O _DO
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MG-?YI%5T3B_U3@?UH-_T4"?U4?=YHR?ZHR_ZI5?ZID_ZIQ=ZH!_ZJ/_YJF=
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M-S_WQ[_][Z\?_>P/?_OC#__YJY_^Y9=__?-_?_N?'__[UW__\5_Z_1\!!B
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MQ9;;;+\U=:$)(320PHKN\0@ !N%]L,%T_^F=U]YXZ\7W7GGU[9???_,%>-^
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M#L !:VP:+R<<C(S'QH=Y]F]+<(S^JN?(NBP$_=,W1S! C_,_!91 !Q1 #[1
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M<M[ZM+/X@1Y8EAY8HC*RV6:=XQV0=C0+QW]?]C)(AC?"V25606C)N63.YB1
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MDA:J XUL_;2C98 N-EGEB%.2"6")K]5#8#V]12EFC;"YP\*2O<%3X6I94O@
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MZVRI<# *T9C"=*;PW*=-)XI3F=8TIS1MZ3EOJE.?2C2H/^7I3HDZU)X6%:E
M56I2C^K4ID)UJD*5:E6->E6F8G6I4=WJ4[/:5:V*-:QDI2I7S?K5LX(5K595
MJUO3ZLP8^E&/@:2K(/U2K=/DXVA\!5I?C>;7P )VL$4KK-*@AMB_&K9IB17L
M8I^FV,-&EK&3A:QC)7M9RF;6LH3%;&<U^UG./K:QH27M:"MK6L^>=K.I!>UJ
M2XM:;$GM-%1+S?:P9M?<SG6W=>7M77VKV]X*][?##2YQLY89RLBM_S*4"0UH
M/F.41?+-D?GPT^  )YNK89<WVKVN=P6W7>%T%[S?#5QXSUO>\9HWO=EM+W?=
M*U[XHI>\]%UO?=6+7_FR][W\C6]_YVO? .?WO_OUKX$!/. #%QC!^KUO@P7\
MX 0SF, .IC"$+2SA!6NXP@KF\(0[?&$09]C#&PXQ@$^7#UN>T%#\\\>N8(05
M>C0)?JNA$Z.B"9MW/(A_]T#4;>L!*![_JH"PF=T+ 82\V"@0@+.AQY#X-YOP
MC:D4@3L2LEKW&B<WJL4.,I XK_;.,F'K:G 2$/&XIZCRS<:$N,JF-H6YX_6N
MPT#]"*B6VJNE]+%&QI;J*&RVJ;IW6 -**O]$X9$+S>9#KQC1C%ZTHU/X:$5#
M>M*2KK0++]W"3!L:TYO6=*(Y_6E/-QK2<BTN<$]MZAKF\!X[/*.KTPCK,<H:
MC;-^=:UC3>M<VUK7N-ZUKWL-[%L+F]?#_G6Q@TWL9!M;V<CN"5'8*"TW\@_5
MQS6NM:E][517&]O<UG:VMSTV0HK[;I;!#"+MYIGGEJ:1?:/N/5T)[U;*.Y;Q
MIO>\7XGO>N?[WOKN-[__;>^ [UO@_B8XP =>'_SH1]0 *A)M)/BCJ[ (28-R
MS2SHH6/_J ,>2G$-/P!U&UB%/$R[B6 !:U.H$)Z<-85"%O3^7*7=U#DK]!"0
M/&#<FRZS[]U0$M[_ U2$FSE7"4:$NH<P6= .-^&&SP'*YHKP!Z!UU(/G\D"1
M'E;C#T2'5#O]0-#5E=RHF<?&Q1;Z)J.JB15]U(.@_H''/&#\&QN/VM(,IS2H
MYW[W2.?=[G6G>Z?_'FK X[WO>_=[X \_>,'KG?",!U2IP0WY;TL^;M;:JVM5
MB_G+:UZTF>?\YEOK^="#?O2Q96WI86OZU*-^]:]M?>=)KWK7?_[TLA<][5]_
M^]G''O>[USWK96O;VCKR:I'O=O&];?S)(W_YQV^^\IVO&$,NUVYX4_?>K.6W
MU(2W=-SOOO>_#_[PBW_\Y"^_^<^/_O2K'_PH5K'@SPP :R0Z<)G"\N+R_YEG
M,D>*QUN.G@F9/!L5!'^ -D#N(R#\<SOP1SC^@$(==16%<D^&4SVCPCR)8V6&
MTCC^0#\%PF. =W*%4R@ * \MTH$L9EZ 0F5846:,DH*/$R2&EWB(MWB*QW<T
M"(,S*(,UF(,WJ(,QZ(,X^(,]"(1#*(1%R(,W^'C/IX3)AVJKUFK-!H7')H7,
M-H7+9H512(59>(55B(5;J(5="(9<*(9?.(9>:(9A2(9%M$9'T49%\48/R'Q+
M&(=,.(=U"'UV*(=WJ(=>,V[)A4CGIDA^LVZH\4@'5W (=XB):(B+:'"-B(B,
M^(B.J(B2"(F3&(F7:(F9*&^S5$MC959GEBUK1?],..</&:=4P&0;_E!U$B4<
M<X93K;A/$0( 0M=6 C)F#UB+_N$/*Y*+UR1V - .\"2+!*4.<M(:^%%6OO2+
MZ^,.H+@:_'!T3?4.1&<;^0!G:#5UU9%0SA1RHEA4]8!SF@%G?I85Q91.+04/
M)S55O3,G9'4/[!@<]*!.;]6+GNB-<%6/R4B/7I6/;,6/_VB/^QB0^ B0^DB0
M ]F/]YB0 FF0"WF0#5F0_HB0$:F0%,F0$@F1$UE,24B'>]B1>917U])[MC>2
ML/=[OE=[)IF2N4>2)]F2*UF2+*F2O.>2,XF2- F3-2F3.QF3/:F3/IF308F3
M0ZE9LX4/PG<:Q)>'2_G_D4V)AT[ID4\IE5$I2'[(7.367-#E7-$EB-1E&M9%
M8F%I8B4V8F,IEF6)EA&FEABVEB+6EA\&EV3YEG+)EG7IEG89EV<YEWJ)EW1Y
MEW^9EV8IF&G9EWP)F'X9F(1YF(:9F _6?CM8>)'9>) YF4%XA/_Q=5@AF3:X
MF8>7/U?Q#I3)F95)A)=)FD;8F9:9FJ6YFJAYFJ8YFK$IFK.IFJ_9FK I@QPY
ME4RYFV'CA&6(AF<(G,.9AL)9G,&)G,1IG,N9G,>IG,W)G,\IG<Y)G=$Y"\_&
MAM'FAM/6F]U)E;SYG5 )GN,IGATI;I&!E>:6-XJD;J,A7>Y6B?%)B?.)B?)9
M_Y_TJ8GX:9_Y>9_]R9__N9\!JI_ H7#YL!^R69L(RIJVR: *^A]6 1LZUZ"T
MJ7?"04]B=AM=YJ"XF: 4ZIH;>ILA.J$=2J(+"J(C:J(>RJ$I6J(?JJ+LHYOA
MZ9WD>1<A:7DO290X>I,[JJ,]:I,^RI,_*:1"R:,_:J1!2J1 "I0Y>J1+6J1(
MRJ10^J1.JJ0G:91(R3\RJJ4TNJ7E.:->VJ5?6C;2UUQE:GWLMDC:MWYKRJ9M
MZJ9O"J=Q*J=S2J=U:J>&\Y@B>J)[^J(HZJ(*1'\MNJ*3]H&- P\LBJA_FJB#
MRJAZVJ=\*JB.&JE^VJB4*JF+>JF*FD(S$*-<ZJE@BO\6OUF=T$FJTVF=IUJJ
MHVJJJ8JJJ^JJJ@JKK1JKK$JKKWI&:X@4VED55P.JO2JF80JLG_JKPJJE?2A]
MG[&>[=EN[%:( ^J? OJLS@J@T@JMTQJMUVJMV5JMVTJMW<I)G)AB&IF1XXJ1
MY5J1XFJN%WFNY'J/>@8 )_*0Z1JOZRJOU)0=J^B0^6J1\ZJN_<JO_ZJOZ$JO
M ^NO <NN!;NO!ENO"<NP HNP#@NP#7NP$0NQ"DNP%&M.G>JKP0JJ-BJE59JD
M33JD44JE(ANR'VNR)#NR4[JR(*NR)UNR*"NS,4NS+9NR+ NS/WFESU(UM\6Q
MP[JQQ"JT04NT0,M\5KE<TZ?_E=#5;DU+76 YF'L9M84YM8M9M8U)M8J)M5:K
MM8CIM8SYM5<;MET+MF4KMF9+MF>KMFG+ME+;MEGKMG$+MU2;IYAJJ7<+J7;+
MF;NH/YE:J88V#_@ @+A%3YKZMX^*N).:MX;KMXV+MXFKMY#+N(^KN))[N(VF
ML4;[LU$IJK+JN;4ZJ[8*NI\KNJ4;NJ=+NJ@[NJMKNJGKNLV)G;G*+-+&JYH[
MM+9;M)M[N[J;NWMQGG13;IF12,_5GF@Z72.%K=R:O-ZJK<RKO,V[O-$+O=/[
MO-7KO-=;&P5ZH);KN(M[N9%;N>$+ON,[N=[;O=Q+N>3[O>6+ON:;ONPKOO"K
MON>K_T*9R[NXBX<>B[,OR[_[Z[\N^[\W"\ #+, %/+,V>\ YJ\#]2\ )S, &
M7+,+',"3M;.,T;-*V;L9C+_WR\&[Z\&]2Z9W0WWHIC?&6WE?>:<IK,(KS,(M
M[,(O#,,Q+,/:50^HL[XW3+_S^[XXO,,Y++\_S,/N*\3M2\3Q&\1%K,-#;,0^
M?,3ARZD=K,$RVKFLJ[JM2\6O:\597,5;C,5<?,5?K,5=+,9@7$6XVH:["D<;
M_,%J',5K#,5L/)7&ZH?("AJ!B'WN.5T=A[W4N\?6*[U^S,=_W,>#+,B%',B'
M#,BS04OA.K$6^["-++$+6[&1?+&.C+&2#,F3K,F9S,F8[/_)E4S)C_S)H@S*
MFSS*EUS*G9S*IVS)K1S*J$S*L0S+L^S(]NO&MYQ\^HO $?S #CS!O/S+NRS,
M$MS P%S,P]S+Q@S!R!S,Q+S,SNS+Q5S!BW'!LH/+</S&V7S-VMS&<82TRI65
MQ,N5=YP:*+RUYSRV<LNUZHS.:,O.Z3RWZUR8", "#I D]<P""-#.:_O.[AS/
M^YQ@WD#/D)+/X,"UB# #.7 %"LW0"^W0#:W0D-0%$'T%7J!>\]#07;#0'PC0
M_<S/_PS/\BS2^URW0,S$)]W#*:W$28S$)JW2+=W$++W$+SW3*^W2-AW3-PW3
M=_?$V^S33CG%84S&8RS41>W%1DW_U$>MU$G-U$/MU$C]U#X1NV?\AEF!S3]]
MU=V<U5O-S8/QNTE[&<)+PDL[B%V9&CQ'R(B<UGY<@PC ':-Y'?:\*VXM'G#M
M&HV7'K3R':R2'55R+'3]'5Z 2\HS"ZPQV&*B=%AWV"U"9(F\UH]=G]I+TS)-
MV3I=TSL]V99=V3G-V2B-TYZ-V9^=V9T]VJ!]V;EBRUK=U=6FR\^<S,Q\S-"L
MS-'LVLW\VK(-V[4=V[?-V[;MV[O]V[HMW"TSS851-5F*U:N=W,NMVLQ]U2%<
M?=6W-]?7M'\SP]?MPHGG (A3>(;S#8?'W7TW.)<9.:[" HGC*XHCUW^WW8K#
M#_. "/ -_]_P, ,#,@/R'=_Q#1N+#2!7(#A>,"3_<5O83>#FAV+0H%?D[!E]
M,[S#ZX?)U=P1SM7.K=P27N$3;N$4;ESYD _/EN$?CN$A?N$CKN&\%=1+'=5-
M#=4KCN(LKN(M#N,O+N,I3N,N3D5FK*M5#>(DON,E+N(^#GER7$ATW. FS*QZ
M;,B.G>2031NS#-BRD<G'@0 7^^2\$>5WS<EYC53) 5;&(=<3V][HP0_U34XS
M@-:UP4N'/0.(P(O\_1^-S>1*KM:/"*X]6];6(L[H!M:%5!E;04A #N@]+N@_
M/N@\3NB'[I'1E9V%'NB(WNB&#ND^K<NX3>F]#=R7/MRSK>FY3?_;G;[IE1[<
MGL[IGV[IF3[JI_XSQ3T8U7P5D<[HK^[HL.[J7LWG>UXW2ZL9U7V\YAS2'0W2
M_CS2O2[L[DQR(/8-ZSTFWN!=BP+LK.'7_M'>[X4 3:+LY,7L'^V6Q>[K . K
M#C!?7QXH G8 H'( ]X7L5%)B8S[8,X!=M''8%;WNUK4?_]$%@@T@'#WLV+[M
M^Y[O;QOL:U(5^$!=TI5N!3_"WUP6?R[KC\[P"^_PL0[QLP[I',YJ1QGQ#7_Q
M#R_Q&'^')QX1^I #.   7) #7##R(7_R)D_R(D_R*H_R+7_R+%_R,3_R#^$/
M>: '<P  .*_S/+_S.?_S/0_T/D_T0V__]',@+C-NXTL?XS7>]$RO]$\O]5%/
M]4[?$5.=X]RY\1K/\5W/]1O[U>"LGG6<YXSTGF<MYVD?Y\XJ*>BA*=(!<JL4
MX'V2'&]/''%/GVTO;V'2'U6B[,3A#6,R]^<-'-^M]^"A*=Z>'6-^2V:>&^\^
M"X<-/5B#2[BD#_;>'W"^Y)L_YP!:H,?=E26LE<E*QU?)7)&!^AFO^EN_^E[?
M^E__^E^JZ+(;^ZQO^ZY_^[#?&*U], 74 !30  #@ , / +\?_,,?_,8O_,2O
M_,A?_,3O_+\O _3R#FP  '+P!')P_4]@_=BO_=C?_=F__>'__=R__>7?_=-(
MZJ&^_I@NZJ#N__[M;^KP/_^E_O[V+__WS_ZH#GQ3P[/E#!  ! +@IZ]?OH('
M$R(TR%!APX41(4Y\6-'A18D6,V*DR%%CQXTA08[\6-+C29$F4Z(DR5)ERY4Q
M8<Y\6=/E39DV<^*DR5-GSYU!9_)#6)0H/VCZ$"9%B$^?4ZCZ[N5S.A5?OJG^
M!F[EVM7K5[!AQ8XE6];L6;1IU:YE*U;&@[=O63Q0"_?!W+A@Y=I]VS;LWKAW
MR]K%"U?O7;YT_:X-O'?Q7\*1 0O^.K?PWLN&O1[(_/;;6@> '; XD);?C!EP
M9VC]FOKM%0#S^,X"D,.U%P!>7#_ ]]CW;^#!A0__[:_>56A4L5*5RO_\:M2F
M2H\:I?[3ND_L0J]KSP[4^_;OW<&/%U^>^_GPZ,FK-Y_>_?KW[>'/EU^?_?WX
M^.E'S)</&CY\]LMO0 $+M(_  PW4+T$&%W00P0<5A'!""<E["BM\^)F%GWXT
MY-##@RAH   '1"31Q!)'3/%$%5%TL448 <!APPXW]$>..=@  $<Y=LS1QQYQ
MU)%''X><(\@?B122(!I!=+))*#^,LD8IJZ3RRB>MS!++*;?TLDLPM0R32S'+
M)//,+\U,$\TQUW2S33C5C)--.>ND\\XW[<P3SSGW]+-/0/4,E$]!"R7TT#\-
M313101=UM%%(%8V444DKI?32+Y^ZZA[M -S_=*L*&Z10U% C)/544U,=5=52
M5W6U587RB74Z6C.,+KJJF+OGJ>9V[6<@U@ (=EA@BQ6(V&.-%5999)=-]EEG
MHVUV6F:KA9;::ZV55EMLM\WV6V_#[;;;S%(;UUB[4L,KW+?4M>M<<)N=R]W
M6!"76V7;1>PM>.^-5]ER'^AW8  "<Y<%!/3%"P%D$WZ 7@3FW5<S:1^>6 8$
M_M78WWM/:W>&7[-U%[9^4'M8$'S2G<4?W>S*AV."-XX99GQEKIEFFW/&>>>9
MM?+G'JN6JXI7J_B!RFCI;$6*UJ7X@Q755Z%^FE6IJZ;ZZJBQGCIKKK?VVNJN
MP?XZH^>PTEILM,]6_SOLM<=F^VVWXTX;;H;X"5H??_CQ!V\-^?;GY14;>!$
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M#S_YQS\/[\^#^^@O/_O/G_[UPU_\ZI]__-LO?_/3/__V?__]_=]_ -0_]Q-
M_!M _B/ _T/  #Q !JP_!]R_!S3 ""Q "DS !H1 #)3 #*S !9Q "_3 #MS
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MJ(ZNM"7_*->814G*D8K!+.8O^2B#2W[PC)M,9!)9D$I;.K,<GS)FCUA 3'V
MPUJ3%&&D[!C-,-KQ2XUDIB+-R4@H47.*UVSFKMP90F#>R)V9(F,XPE%";MGQ
MC7P$92G=J4D8V;"2HVPG/H6IQF,.:8NSS",FT<G$3<*HF*MTYA(AZB*)=O%%
M7TQF/5W9T#8J])F0I",U/7DC4-;)G?C4YC?C:=.:XM2=+>M@Q^8C,X)4<((:
M#"I1,2C4HQ9UJ$9-*E*7ZE2E0K6I464J59=ZLN=  V7\R"I6Y<,/EM6G*S.3
M&<SZ95:="8T@:06:6@^R5J6UU2!OA5I<"S+7N[HUKW+5JUWY_UK7O[(UL' 5
M+%T)B]>]$J0O@UTL !"S5]E4IJ\"T<U@$(!7R&9&LIJ=[%\8>]C-?HTL<T4,
MVN*Z%M#V+'+ "8L#/@M8S_K5L+&%+6)16UC:VM:ULJWM:V_K6]WBMK? _>UL
MH\85KR0'L\A1;G)O0YSE.M<XS:6L=)EKW>A"E[K97>UUM3M=[F+WN\\5;W7#
MVUWP>O>\XU5O>=-KWO>Z-[[HG>]ZX4O?]MYWN_65[W[S2]X(3O6I4AUP50-L
MX'S(IU_UL11^\K'" T'XP1)NT($>!"0.A0C#)S)1B4:480Z+2 Y7K!=_I,G'
M1O$#EU4B1YBJY")OY(=*L/K1K6S%I/]:RDB<HZI2M_A!QC3U&$+6@C%_JD3D
M/@G)&Q R,;.TU ]OR'A7# X3L'C4J)G*P$EI"@>.JRQ)=R6YQ4G><:"ZG"86
M3^O&AH(5F7NT)B;?R,E0KA*O@)2M)LV+36EJTI+WG&4Q'TG),=+QGZ"$8WCU
MZ #(8I2@F]BC<O#'RR]2U#BLY68SB3//*7(T'RLEZ4V".=".VO)]P#%3*?5Y
M7' N-)T5W0\XUSE.8\9TF-,<J49]^D5'GF6/G,RB=X%+S4@V<HQ=_.<BUWK8
MNE;VBYE=Q6(E&S]8_L9]*KUG7T]97MJV%#3X=0^+[6L^_R*P@ M,[@.;.]WE
M7C>ZV7WN=ZO_N]WRAO=Y2&:RDFT59;-(6<N^ZE6PPJQF9+49R4HWNM0=/.$&
M7SCJ%-YPAB/\:789'0!"0+V_ @(C Z8$CKR'>=HW5KN4L>G7,*6;.,2MIMBI
M=3PP+VE<4D!WEN",Y"4.C_C#:T[SF\\\YR7?N<UUWO.=;25F7<!O?XM.]*.'
M/.D:7SI[E=YTIMO7Z$Z/.M*ASM^J/SWK5)_ZU;GN7ZUWW>I?W[K8I5YVK),=
M[&,/N]K-[A@ TWO>\8X[W47&09DAV)=(/*$,!=3W__R=A2]L(05HJ,AW#%$.
M.BPB$17_0\<W/HB*_] 1;VK.<)XY\SEJIS$M[5$9/'*1HJR1+R6=1E=Z_HW_
M()1QZF$%14)Q2I&<_J:UCZ1$'&53F1&U_# Y[?DG#O.=K%QQBRIUT4*9L_8O
MDN@L!$K\+!%3G2)E)Q9;W_E><A[W&'W^[K&Y?;V#7Y%GMB.-"DK[>7YP^'RL
MH>GU6<YO?G[[0GID1UO/+&=.$J:Z'VE.IZC^_[>(E+R>_''>2G'?JB2?_3F1
M32F@)/F3&BG?1R42[&74%J74 2+4.6%4_G%3[MF']"V31.4> (;> $(4Y\%2
M*T$@^J5@[[F).<5?#*I> =(@]3'?#;;13LE,3YF5OPS$W &ANP6AW EA$1+A
M$=:=$28A$@XAO6G556U5OT%#OP$<P'506?G47&7%_Q9R81=ZX1>"81CBQ#=4
MW$H$A0.P@ -\@QBR81NZH4!4G&&HX1O281W:X1WB8<\<E^N@'=NEW1_Z82"N
MW2"Z'2 28A\>HM<5HB N8B*>G2(B8B-*8B12(B1:XB-B8MM58B8:XB1>HB9^
M(F; 71.2HA*68E0E&'W(BX-1V(2A4(2U8H-8V(],2(>12(A]F(=MF"[:8H9M
MFYE@&8]IFI_5BHI8BZ DB;6 @YX9FZ($VYEMBI LXZ]9&:(-":M58YE@GK%M
M4JG\HHWYF3/B"IP=2;-HF:R 8X]\BJN0HQ/!B3(2B^>50Z7X&).XFI-LHY^1
M@S<ZVS<ZR9U543IF%#:JX_\YIHDSPJ,Q!@J#1=F>K6.8!".D-9\TB@N0#6.P
MZ",]TA@ZRDLP7B-#<B/HY9E'+A-!?J0UTM0[^AFO76.$'*.R[%FI)&1%AB2]
MA)% 1HFM%>2., FJH22*H8NQ\8HR9EM1DEA1WDN_@)NWC=LI+N%3.F54FN)4
M,B%50J552F55E@R^0>'*:!7+N,Q8S8S W0S/X9Q9^MQ9_MQ:JF5;IN5;HF5<
MLB5<SJ5<NJ5=TN5=UN5>ZF5?YN5?XF5@\J7"K4[K_,]A.E #)1!B+F9B$A!C
M/M !*69D*M!D6N9C.J9D8F9C<B9E0N9E:F9H5N9F>F9FCJ9H?B9I@N9ILF9J
MHJ;_:;IF:\+F;';F:L;F;=)F:=:F:O*F9(XB5@*G5EZE!=V=!UG>"1U(X"DG
MX0U>@A@>%.%0Y#V>Y"T>Y$T>XUVG=59>#>)@_X6?#?+>=W:G/9%G\)FG>(8G
M=Z8G>'JG>K8G>Y8G>K[G>)ZG>\:G?=8G)CF: .8G?5Y1^0V4?^*G?-XG?/;G
M>@JH@1+H@<[G>N[3]"5HA"+HA#9HA1:HA%HH@UXHA6YHAB[HAPYHB-I@!*J@
MAXHH#NH@/O!@!P%5< [GBV8EC+IHC-+HC-JH<)(B%')5OG556/W;P $IP:%5
M<0U7D1+ID?+6;N46DBYID@:7D@H7DT:IDQ(7E1JIE4HI_Y1JZ9-R:94VZ9=.
M*9ANJ9>&:9F.Z96*:9>BJ9FJ:9:V*9;":9J2Z9FZJ7%U!1\RXB:"(B?F:2CV
M*9\ZXIX*:B?J*:'Z:: :*J!ZHJ(6ZI\.JJ,FZJ,B*J12ZJ1:ZJ*^78WBZ(W*
MJ'.DXH+5"RN^HBO"XJC&HH.4B8;UXB[>HJKB(JN.F*89I:P>9:W2ZJWZXZSF
MJJWN*J[JZJ_R*K#Z:K 2Z[!&8S$*JY,T))[U:K,FZ[,6J[-&*[0:*[<8J[1>
M*[5BZ[9J:[=.Z[=F*[CFJI&]F:%QJ[C.0K?A2\:$6[\T):=J:J?*:[S2*[S:
MZZ;B*U3:&\K@&U?MVU=2X;_5C/_ C57,X,Q@"J9?)BQ@(FS#*JS#,NS#2FS$
M4NS"6BS$7NS$9FS%8FS':NS#!5T^#-VA8FJDFFREEBS*-NJEKFS*LBS)MFS,
MPNS,,BK-2JK+XJS,UNS.WJS.]JS-GBQ(_&:^UBO1KEMQYET-\AUSQA#3)B?A
M&1XF(1YV5B=U)E[53N?C;6>'<JV&>BV(*NB)<NC7BJV)ANW98FC7@FW:DNW9
M BB?L2TI:='8KBW=EJW:WFW;QFW9 J39[BW:VBW@^FW@_FWA$N[A#JZ'7J#N
M)0K>"FY\INB*NNL/WNN\5F[16J[1:F[F<B[F%M43@NX4=E58OHQ88N%9Y6'J
MJN[JLF[_Z[KNZ\)N[,KN[-)N[2K$5MSIR_)LT.8LT*JL[^KNS^[N[PYO\/*N
MSQXO\/9N\2ZO\#IO\C(O\A+O\U+7T';NY6+OQGSJ*I)J]YYJJ<ZB?M3BJZYJ
M^9+O^:*(MX;K^IXK^ZIO^\+O^\HONM(O^]+1^N+3-,ZO^]9O_/;O_O[BLAX;
M !/P_QHP_R*P_R9P =-J.80DG3%PKB;EM[$K4P[$YGIN]EXO!FMP!G/P!\/H
MOG;E5P(LZ5XAS11L<VSL"GLLQW[L"[MP#+,P#,^P#+=P#>/P#>LP#>^P#=-P
M82)7;MJF$/>F;.[F:QZQ$>OF$@]Q$N.F$Q,Q$C-Q$3_Q%$MQ_Q-;L1)C\193
M<11K<1=#<1AG<15S\16#\1A[,1F?<1EKL?5Z\ ;#<78@[7B>$!?D  X @!WC
ML1[G\1WW\1[[,1\+<B 3,A<DTCSD 0#D@1[,@2+K02(O<B,O,B0SLB-3LB0_
MLB-C,B3/@]XBKN,:;N*"\B=[LBB7\BB;<MVF<MZJ,BJ[\BG#<BO',BN':#89
M'RG+<B[3\N/.,B_KLB_O<BBK[8,VTC/QYR\;;N2"C$_A0XN"\!M#<P=+\S-/
M<QQ7,WKHJ%;MZ!3Z:%@!:<&B[IK2:9RRZ9R^J9R*\SF7<SJ;<SNS\SO7*3R3
M\SBC<SS;\SRK,SVO\SW7,SZ[,S_OL_\_RW,_$W1 ?RGN!G'RIL-CA9<[\(-P
MW8-CZ$%!]-="%ZD(X4,I(.I$P]5N6/1 3"_T4N\AKH);)=<)\4P^M$8ZX(/4
MJ!4_N(-(RW1(T[3QUG3SSK1-ZS1.W[3T[K1/3Z(;7_-0Y^OV1O!1'[ "*S52
M+W!2,_52.W54-_540S55/_552W55:S566W56<_56>W58=[6OJJM25K"X7; U
M4_-:JW5;1S-;OW4<BW"_ZAN_A:6_C:7I$MS!\G!?^_!?Y[!?!S9@]_!@&W9A
M([9@)S9A*W9C W;(CFSQND/:O,-TS</#R<-=U,/21#1XT4/)J70EOD/6R(-M
M?';/X,-(\_3_3WM=UL!#<.@#T;0#6[0#SGR./[A#3RLO4//V;OMV]/ZV:O<V
M<!.W< =W3A.&4,,U4<OH'",S+@<S= /S= MS+U?W<Z\R=4OW=4=W=G.W=GOW
M=HMW>)/W*V.W>7<W>H.W>G]W>X\W>[_WURISQ/B4#PI$7.,W<^?W<O.W6^NW
M4X'NR8AN%)*N%7XSZMIN@BOX@C-X@SOX@T-XA$LX'2(T']JL/!3$0P]$/A@'
M2AO$/<B#'H"$'G3R0:0#713$TDF%.C0B/!0$-!!$:+=&0:C#<>MV<9O7:1]$
M9X.&AAL$/QC&91]$/M"#B&.$'L"#AP,5<@^W<>/XC3MYE#.YC;/V_Y-7N91#
M^4PHMW_W=Q,:M5B#]5B'^9A_=9F#N9F+.9J3^9FS>9JW^9J[>9S#^9RK>9V_
M^5%/\%*BM4!T^7_W^9]S>:#OMZ"/#%<&^%>5,%YC8<"E,%\S]J,?MF-'.J0O
M]J1;>J5CNJ1G.J5K>J=S.EJQ3D*C<?^4PLZX SP(33\T)H9##30DD#\4#8O;
MSF8/#8>39CT(C:LCD&WSN1?30]&\PV0+C?G@^D#H.ANKL1DK^Q=[CX;KC+_X
M3#]H#Z\'C9 #@$8CSY *Q+$3SP?EC+0G.[.+>[B3>QJ;NQ@C^[F/^KJG.[JO
M\;LO>[F[>[RK>[NS^Y8/>KY?D'.7MW7']_]Y^WN_ _S IW? P[? %SS!K[?!
M,[S"NS?"+[S#_WO"4WS$5_S#'WS&-WQTSW?%,+,S$SJ@Z[O(^WG(FSPT9S-6
M:;/ >K->]V ^:'M!Z_/,YW/-_[-  S3-W[S,V_Q &_3/Z[S/!WW.]SS1[SS0
M%SW.*SW/'_W0+SW2-SW3[.'P^J#/S#9-^,P[M$8S$X2K:P;7\_E;P/I Q/1^
M':S.E#UN[ Q[E31!K$-(%$1,@\;9 T#:K_;=-[E]K</2^(,,K'UDC+U K +6
MJ\U8N'C7)\="$X1&8_F53[F5XSV51S[DYWV66[[C7S[>XWO)C_S'?+F<VSGH
MW_GHBW[ITSGIG[[_Z8=^ZK/^ZKL^ZK^^ZL/^[,M^A)0U!6M,N]HW )!\[Y\\
MYP._[W<^$,ZU@-=UHH.5HJ/PHN_UI7NZ\W\Z]$O_ID__\U/_]5M_]D<_]LLP
M9.ML,P\[2(#]ZBQ&"%VPK!\' ,#,.Z _2+3#MV.$.M!]S_C#VR.&L/<,<GRT
M0' =2J/520"$/G\ "-)[(.,!BX,+$2IT!V @1(7W(!*LV,\=PH8,%RK4V'%A
M.XO^^FFL-S!B17_T/')L*2,?P90I^[W[N/%FPG;Z*LJT6&\AOI'W<+KD6/3C
M2Y#K^LT<B:]AS(I 6PJ5291?RG='$R[D-[*>#($$\2F508^F.J0@<[*0_]>/
M'SV;7=MR-4O7:%V]>?DFM?MWK]_ ;/L2%EQX;6*\AQD;=JSX;F3 B!<_K@QY
M<F/,@S=3ELSY<NC/GC-;'JU9=.G.J$^;5IT:=.O5KF._E@V;=&W=N3EVX:>O
M7[[?P8<+!VZ<^/'BRY4W3_X<>73FT*=+=VZ=^O7JV[5WS_[=.+][^?#E$\AO
MUGE_Y]/[R\I>/7SWZ]VW?U\_/O[Y\N^CS^]_/_WZLX\^  ?\CT#^"DQ0P 41
M?#!  QV,D$$)%;RP00PMS)###3VL$$0(#Z10Q E'/-'$%#4,D<0645RQ1!A=
M5+%#%E^L,48<9Y3QQ@]S]'%''7NTD48@A_R12/\>BTQ2R"61?#)((YV,DDDI
ME;RR22RMS)+++3?4)Y_Q\ %ON_+&H\@B[LCT#KLVU723S3?EC)/.->V$\\XY
M\ZP3SS[U])///P4-E- ]#07TT$$3+1311N?D1[A((>4'&C IM10??3+=5!\Q
M.R4OS'Q2LHC44DT]%=5455V5U59=?1766&6=E=9:;;T5UUQUW9777GW]%=A@
MA1V6V&*-/1;95/VII[PK:.--LWY([0>DARSJ9[152MV-M0=XLHB>4E@E*C1H
M2)UG-H1&S2?=U+X:Z:5W2.6',G/!E4I9:$'ZMB 6I%W5G]#$?17=OO!=%9H'
M2M5WMH-597=;D!9F@1[_4O$1K52@]"!5+;P&MHC;9[L-N=W;3+8-99)Q&YGA
ME45^N>246SY999IGEIGEG&%V.>::<=[99IU[OMGGHHD^6FB>'_"-444=;1KJ
M1:5^&CI-P\0'/7[@FD7KK+?NFNNOQ?::[+#+!AOML<U>.^VSU6Z;[;?E=ION
MN.N&&^^Y[=X[[[OU[IOOOP7WF_# "P<<\<$-7SSQPQ5OG/'')7><\L@KAQSS
MR2W?///+->^<\\]%]YSTT$L''?7135\]]=-5AUQ3,Q7%A_8PIZ4:=Z=UCSIW
MWG>?^O?>@?>=^.&-%Q[YX)4O/ODX\R%.TNCYP5JX3*O7]--,[\'^3.!&^MZG
M__![&M\I\<LG'WSTS4___/;9?W_]^-6?WWWYZZ<??OSMS__^_OG_?W\!U-\
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MJ(;8J9?D_XL@-,^)PJ>8I,@?YF*7I*@?VLV8Y"& 2J*6[,N#3HV8?+"5U@T
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M-I#+)3<C)0FB)@,CMQBB(DN%'UI"\CBCOP!@'I)/!I(2-?*.]#R"[T#2MAY
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M/OB]3_[QN]>^Z+<2EKJGWXU2O+__M7CZ1)SA^GO8_B'&/_WOS__\]W___A>
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M,]#ED;L%60Z+3'D(G1@7'3>7U6B[*S?(L=%Q\](%', Y/< &K-,]S=,^'=1
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M?'3I_437/1\] .4!],O'3Q]Z]>S7IW_?'O^^>_KS[<O''U]__?S\]]__KS\
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MPTC4!-_MA,P" ,WVQ,\&K<^R#=$R!.! D43(PV85H4]@BD- 2E@T[4-(VE%
M;4=JA=WH@Z2I@WNZC=0RIP9%D3S@&9C]!!06A#_00X!*4?V\3:558*G5#5<!
M1G-B1#^0K=F6T$]@+4R^1=OHPSQ,Q#HPZ8"^!#_$#2( !4GN#1?JA-\"0-BV
M1>1"BA;:S3R$9SMPRY)IJ(AVJ(E^KN>&+NF"KNF.[NG"K.J6:.JR+NJ^[NJ2
MJ.P"(K.QJ^W2Z^U2%R+"Z+SV;KW^;NX"+^X.+^Q9(H\&+_+_$J_P^FYP@2*'
MB&)\D:*2%M-+LJ,\/N/UCN,Z;N\[9B\Z<F\\8J]!\:(U<6.5'$ TE2GX)A-'
MJ2]+]8Z33-3 ?6_W@AR"U6]-D2;]PB/%+9CW6J_X:B_^[N__KF\ $_ ! [ L
MVFGE[5!W01[/L116&8H#$P2S+$H% \ %GTH&;S"CI,I, E4_X,^@R.!&"(NG
M,0VKF'!!M-W_0JJM0!!*K6W[_.KZ=E;'(&&*].R]R+ TT3#<2@JK"@2[&/!#
M((MA%2.RL/!#T,L0P_"ATB]H72L5:VL59RL6;^L5:[$5=W$6;S$8>S$7$TJW
M)B_S*J\9GTQ;*M?RMG$:OS$:Q_$9_\_Q)+VK!<NQ&^,Q'--Q@]RK>AFF>R5F
M]"[F]*(7RJ[L(;,L(JNLR;XFXF1<R5[L@3G@\1"<G.A-PGX8^UFIRIXF;I)O
M;IYIFS!R(I<R*9_R(B,R;W[/B";NVO2LB:X#4]$M=C*%*W_55=RR1H 54NCR
M0/ R4?"50Y2$ ]1#\VD$+$^%6QF$0K*%KSB$ 2DSVS1S7*3#W<*-/PC0,MM$
M6WPG1LS"GL5$30 S5MP#=;H-/FS@'=Y-F)V1-Z,$.%/$?^)R46PS #1S6>C!
M+'_SGD5600RN3ZC#W&8$/T#*/(]53]@S-6^%0H/%/1QS3:1S[)XH18ON1%NT
MZUYTZ<)N1O]W].QB]$=OM$:W;DB3-+"5L1ZG-!^K=':\:!ZO-$R_M$SO\4RS
M=&;L:*'6=$S3-$_;-(7@JY$::;TQYC"9B+[1*5(GM5+CR93.2#(:"<3!IBA/
MXSZM2"9OG(+9&(M,]35J7/F!24!AG)K^&\(MM5F?-5J[' ./,5M[Y8H0YQ>#
M)9\^<%N+<1BS%JL^Q%W7=5SW-5__]5X'MET/ME\+=F$3-F#;-4KOM$\SMN^.
M*QOWM&/K-&5+=F4W=ES:L09CMF5W-F=_-F$2:?'I*WSAF]D0D]J@LB*OMBFG
M,FL_\L->#T;ICE8[Q,;>ML9J[-[<T_CU=C]AF&\/H,B*27[-WR?_>ZPBYT[V
MK=]KNW9K-S=T/S<"NFQO>G1%B[1U Z$%@W2& E!E=(\\M/-5N.!!U#)'E_1Y
M7W=84(H^\,-SE,+[G$7: D!^8C=ZCW1Z<[=^V[=ZYS=_[[=) [A_!_A_%SB!
M'_B VUH,(,)E3[9GS^ON-KB$/_B$@W:%._AS&6].4SB'6WB'JZCSKI<O#;+7
M-"8Q&77X"G"*(["*%_  *S"+QSB,IR,H.V/[)ICW#03![3A5R\XXA6;_EDDV
M2F-78[7#E6,TNCA#Z>^,P^*)O>F+&[&,2WF31[F5KWB58SF52_E:&W9B[]9.
MSNR7)^O:F-UC-4 [O"U&3#%B>[E@BPL^_WR= [A#*:2*/^#P8>?YF+MYF_>Y
MGO/YG_OYG@LZH ]Z;,D @W_XA2_Z7ZZQAS\ZAD<ZHT/ZI/^,9BLZIE-ZII^;
M'Q<F>P4R\I6V\IFB8ZJV=)LZJCMWJD>W])48F+X3"VBIJL\ZJ]/ZJ=OZJM]Z
MK>]ZF=?#RQIX@N,W&J6P1B"H=8<H ^W7<@K[L0-[[(J:]9@WL]]WLR/XM/?W
MM0MXMCM[M0=[MV^[M7^[N%,[N0-BHFLZNDMZN"YII;?[IKM[NL-[I..TN<F[
MO;\[OH>2:(NB+R&IO14U*J:UP \\P1>\P1\\PB>\PB\\PXL+/=XIH4>\:9D5
M  B6H0=%.M!=V?_)W<47^K6J0P1O?,=+_,@'NLF7/,I[/,FK_,FS?,JW"Z+?
M>[SG.[I!]LS?O+KCO,SG/,]7QJ7K/,WOO-#WL7KAJ_$!T[Z68K^F-JXW/:_G
M.M0[O:Y/?=0_O=17/=5?O=9;O6U2-RN7N[:/.[:+?=B#/;>;?;BCO;>K/;BO
M_=BS/=F?_=O/?=G3O=S7/=[?O8DN^- #O=_K+BOU?<\'/>'_O> #IH;7>^$/
MON$O_LR$>"_-&XD+DVF?XE,F\)9?N9)O/N9K?N=KN>>W^.=SONB7_I2'_NF#
MONJ3?NJS?I:[?N:O_NC/ONEK8Y>O/.ZW?.Z_O.[W/N__OLL'_^X+O^__$S_P
M#S_R%S_,GSOC-__A>Y>C.[_C3W_C5[_T?^O/7[_V/[_UOT:GAV(^'&:_PY>H
M$_7R,3W79WWZ8SW[;[WZOW_[K[_[QS_\S[_]0\\JVWW:Z[_;Y_W^^S] 4&C@
MP(% !PT,%AR(<*#"@PD-,B08$>+"B@\;4LQH<2/&B1P_>G0H<>1%DAI#G@19
MLJ-*D2A9IC0YLR5-F35QWM09DR=,GRM_O@0Z5&A1ET=M]B2*-*=2HTF#,MT9
M%>K2JD^;4LUJ=2O6J5R_>G4J=>Q5LEK#G@5;MJM:L6C9IH48 Y&^?OGXV<6K
M-^_=OGO]\A4<F#!@PW\1#SZL.''AQHL=,Y8<_YDR9,N/,4^^K#ESY<Z;/7,6
M'9HT:-.?48\^K3IU:7WX\MW+QYIVZ=:K;=?&O?MV;]V^<P?G_9NX<.##C1='
MOOQX<^7.DT=G_IRZ=.C3K5?'OKTY;-GX (0'<)V\]O+9T7,WOS[]>?7MV;^7
M[YY^_,S\\.;'SP^:/KS]\<+GM0$%_$Z?[V++QQ_Q&&S0P0<AC%#""2FLT,(+
M,<Q0PPTY[-###T$,4<0122S1Q!-13%'%%5ELT<478:30GWI@XX("A6X4*$>$
M<.Q11Q]Y_%'(((G<T4@@CQPRR2*1;%)))YE\4LHHJ5S22BBOG#++*K'L4DLO
MN?Q2S##)W-),,,\<,__-,M%L4TTWV7Q3SCCI7--...^<,\\Z\>Q33S_Y_%/0
M0 G=TU! #QTTT4(1;5111QE]5%(9ZH+/TOGLR_32^C;5%--.0?T44WV@P0<V
M43E%U=-465W5U5!;A?55566ME=9;8\5UUEQYW74R4[UCT-9>A_6UV&-U19;8
M9)E=UEF^\O%+OVGYP6<_ 0,<T,![M(W-+O$6#"]< ,8M%]QSQ4677'7-3=?=
M==]M%]YYY:V7W7OCQ9=>?>W-U]]]_^T7X($%+IC?@P-&F&"%#4[8X84?;ACB
MB26NF.&+(\:88HTMSMCCC3_N&.2112Z9XY-#1GE??^Z1S<:VS(H9YIGEHCG_
MKIOARGDMG=_:V>>>@79+:)EK+AKGGX>VF>>DC5Z:Z*.#?MIII9&6NFJJH\::
M::BWGKKIJ[_..NRNP>;::K'-UOILLM'V.NV)Z#*V6;F?59;NN^W.>^["7DL0
M[[T!KSOPOP4OG/##]38\<<0'7]QQ7+W+!SSQ%&_<\LHQ9SSSQS>_W#YJH=DO
M]/]>J]:_:B4_,'4$95MP7 9?5Q?V!V-_=W8':Y_W]@9S[YWVWW$'GG?A=R]>
M]N-M1UYWY7T/WOGAGS<^^>F7I[YYZ+&7OOKMK]>^>^:)!S]Z\;,GW_OPK4>?
M>_6_3W]\]\N'__SWUZ>__?KCQW_^_._OGWWA9U2C_T4-$%($E%2D$&C !!:0
M@0=4X ,;N$ '1A""$[2@!#%8P0Q2D(,7U. '.[A!#X80A",TH0A16,(4^HA2
MFG,AYU[H.1C.4(;3.9"I\E'#SNTPACRDH0]UV$,A_G"(023B$0$#K-@(RXA-
M!.(3BPA%)$K1B='*C[3X@Y]9Z = IK.6@ K4K0)YJQ\J,UG*T$@R,ZXQC6=4
M8QO9^$8YNI&.<:PC'/$X1SON,8]WU&,?^?A'0?J1D($T&<M<YC9%EFV1;6/D
M(QT92;9-<FV55-LEQV;)3&+R;9UL)"4Y^4E->A*2H-SD*4DIR5&*,I2E7*4K
M6ZG*6)HRE;1D9=/B-L4H[O]2E[UT(B^7TS?9 ).*Q23F,7UIS&0B\Y?+=&8S
M3Q.YR85'F="LYC69B<UG:G,Q^P'=Z;H(1@*I;HR1RUV,T)E.=:Z3G>UTYSOA
M&4]YSI.>];0G.P.8#VBL;G7C_"(X3T>M:6TSFP4EZ$&M:="$(I2;#=5<#DME
M18<R5*$37>A%+9K1BFZ4HC D%0XQRM&0=G2D)=4H24]J4I'638GW8&)*8;I2
MF:)TIM:,UNB\F5-K92M;Y3Q0M[A51D .=9"&-"I1"XG4HQ95J4UEZE.3"M6E
M1I6J4[6J4ZN*U:M*%9&22Y!/N?7/?P8HIZ!#C$1K&E.:KE6E;%5K6^'Z5NC
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M3EF>TG@V-BA?H5^C 0@: $MYM"A!#&$NQ"D]/]PNROTQ!\-*]-"?'>[1F@/
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M-T9+(,-(=U]*VQSSV7&_#Y(\K/3;36S2M(:5<^+!-;&?D3?*TJA:>@&9<@L
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MSQ_3""B3$;_  ]\%O-CR^+6[<W9AV;21S^NIW)=I%<-!6).WF=<IQ3-&#H+
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M>-,[UTO@0>C&P\HM+>$L*C@M#((\9:JRN'))3.(X36W*Z28GD,M487/*I"U
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M-.Z,_8S[3@$MA;RW--0+_[=[O 3X3+(P K\.[NR!KQ4OD=9O0=+9UO.+?]&
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MM 6:%/.MH=667:Q6%&-^X'(T Z<R@6CTF ^K54Y6_;B/S%1XKY_0IO8O/1K
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M.Z ?U13L8M.G7ET3 R<N$\8)/$(V&NFEC7\/</[UF/1_7O"O1@ O8E,)X"N
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M5Q%DVC3JT07C2E%*B2%;@,-?JL?DU-!OY1):P@&A;&33O (1U:!368],L/%
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MFLQ *5KLSXH]_=55IH=+*LO.7W4/_LIV?DCDPW1ZON6:2JW#%V0X^S'I[+_
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MOIJGV'XXF.JU=8U.W"+PS<YSA@%YG.U03S(*)V_J]P8LN%Q_0?F^4VHTCNN
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MI *A+SGN0]1G1*W&0IBO_*)6,S),/O,MB6LJP$LVDF[7U+!_H%4 DN$K8Z"
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M83_L <3P9F-8T5SM1'+ -"_9F@(I]5?365C\V86$C2X_RL-14<K31TI_K/Q
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M+R'A>@[L, /^:#__#-=L:%'H?4ZRR,TAKJ8Z6Z:QS8T'!J;J(XW8D#:LF.>
MT_PFK[U&@32)VN&I<\M5E"T>P;W/4*5)SX;^C1]7S"WV9P8[LVUK2M'XULV>
M4@9, DBT'?1?/@!$N@ZB-.-]74<T8S]7B3DY#%=Y74?&\JQLAR!+ZI J>8--
M1G#7V.?IFAJ<0UX *I_^ND(\D>A:IGPF3^],[I ,R\S?Q<Q.DT,0,3-/1AAU
MX-AFD)8>=M6[E$*K-QM*+H,-^NSK&AOJA-'/W>I>CY*K,DS]L1)0-8P-\+G,
M$8UG"!U*;Q1,"F-R-[?IS5<@DF$8QS6<RGS2>Z.JOG%0K1)IZM2ZF5:(1>6.
MT>9QF:NR?MI[W,6F"2&^1U4UQUL^SPQM7A2 =@C[>>ZS79WK>13W-W9 9/T5
M!E.%3FHA1]2:919P#8'$@KE^-.ZG?CU;P_&[Z^X^/_ ._3)TJ/#QM:1H%!=6
MK#< +25X!"E$$I".$=DE M C;+,FG7@(:R6$O43N 7..-*#&>UG"O=9?;[=E
M %!:^ <:+)V6HZE=7]&R VT*AW^JKP4WB-/)+W9&YTX 5FVXRI?=A>B3C"P"
M^[Z9RXD6\S[W!G)U!AP/W^0^#4QW2T('UAA7GI19"SHT\-C2J$WKV^GK;$_G
M>FZGFDGZ1*)V[]TG7QY>/O/>R"H9.6:3E>33/QH\I/2PQIO0]>5U8&HF^470
MECC=CBNYP!D'1@+IJMA(>'EO>[=E2X?CK:#U%UR'4K2D \NNI<']QH>^'VRE
MB KQUN6C3H O_9NLV7M"*TEG/R&0$1Q\)=2I5*=#'\<7@*P'O+S)_3!ZXD?L
M,]H.,@E&O\4] EBP$OD2J$4:8 2CVW-U69&_8^G'^&W\/GX'7\BE7M@94K!5
MY')L597Y(HW$(RR"J8Z1HQABM?-&5BD<!H][N/3NZZD.0\1(T8\ +XC9Z[L/
M\FIMX!><VAJN>#I?EI=_9(U'4]X21G)G3GN3/Y30K*OX^_Z:]MZ!G20T7AY1
M7\5+<J\ (2SO9IH1WB*R50"2@*JB8=9]R\O'Z]]7)U[;GIP/9-NU%A:[W CP
M*;BFN1Y9LJI905E.FG$@D9-OO1\,_6OB>^=0:'_MVYH %!O+B014)E%BRLEZ
MPSJDEA!(!U;*ORO>!W76<LRLCK4>O8H*>RH==&M8PC/@XL(Y((N_,K%":6^_
MLG->WF#J-D4 *M^KVEW8YE"YW'7VBEPQQ%T?"M=DYMG9C> 6R@T?73BZP^M+
ML74%F6PYLA+:H[&Z6O$3ED(&(B[RB;X"D&:% -3!#'$2@ Y,A+:05VU@GC2N
M.O2  /0SCCBK$/,=?\!=2JT[H: T^(D5P3P8M3C7DN%UF>CEA:Q;-3S5E1U\
M]\XR*L9?I8HS\[JTL;IJ<S'Q(W,77ZR;]\(OQ-=@J$I<+I3"/_..LN:E:]'(
M:F^86HX<W@1'+2X2C]?4]/D7)^[#*+%FHN]0_*/NA< L,EHFCO?Y?RI94@Y1
M<: L#T]LBN<)O<XG_%\3NEHP;C=X>S[W2@S/,:=F)F,Z5?;)E_.>5'7CM=-$
MW%L&OKA.*P'^[#GB[KFES:W!;.T57TMDOT>HI0#4\A+VU_SJ(^P&#N9AS@\^
MA/UW35*;5?J&G"PW >C&T0"^% .V<1=NT83M4]C. C*'7=GU \*]+,G?@Q6
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MG Z' 77B:O#4H;ZF(&\F4<T+EQ3:^/!)_BG/H1'_(B$,^&DXL&JA;_$W?2E
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MHV26WES\) M7AHVWD>]ABDX7JE3Q[YZZY,@9J=@NFM.4=HHX,\#?"Q.ZBNO
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M]_I!,S?EB?(%F!N19N*]+LE?Q!I.#NE?$CF,F?8,RICKD#_*]RI"7#D ;L_
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M3@%1;;086=%%5[F5<>?@;W\-[G'4/HV$?Z*>!^O?M?JS&YC*X):4;N7PCZ0
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MHR<Z'B@>^S/ !0,DAG<3^,$DW_E@6K4.NH]*^&BR=:>AHO..A]^VBW=E7AO
M>=XHT7MR!$32U&/ &H9@](OPN=YGBY!JX3RYXS[!F7"MY[?<YG^-[1-8IC(Q
ML36.A,.5^V$U&&]R7:D 2^CMCT<1YMQAR&=,N\COT7:#X!@3Q4N%?G7@V.GZ
M6GKPRP:#36W@<>LG9Z/+S''A,:GA#/_J0J',6\7SF[_*:G@@W^@PJ]5E90+Q
MW?EJ'&Z.!Q+^-'W>^DK_6C4>:8>'1PC,JRQC_D/,!#K+O<](@67CULVPIC2.
MT9VAT_85-0E4E><GDB,U<]5K#H]>FM;0&U6V9MF8[Z&JGM1ZZ%TV;H642@WA
M6*$>M[J $]:%P6WNX,&=YO2H).O/0^L:\&M9FE4<1ZL!6F[#)U+EEQ>O,R86
MR4ZS<4TSMSWWO(+\;"<58X 3V Z;6^TP ;XB$QE&YM>G4J3J\Y<BQ/3/@5-$
M#@++BY6W%Z2^IM@4)%-MY&^1NA[+H-X=-_W3(6;Q('6$3?KV':>3KG/385RC
MNE=W=*.1@PF )P#)T]T"E. 6'DB:;<FXP@-YTS>?&FF4 Y5.K\[%"4<_*QCS
M<SS\]<A3I<%FU\PP2W/WL'?WHG5]%>V-\R/4,$W^.P"[BV6$>CQ5DQPV ^>!
M9-!7<*5F$F\S(+N DV&R'G;_>)AXRI/=%3-;I))7U61I+PP&:Y2N9#F,5B _
MO_#H5I);I2\!\C$NDVR)OTS*8#4.9E<-;%(3I89O#FIM""%DKE?0?_>OO]72
MG*F-N?99W.?1-?5EA60$XDJ%4?85JUE#/:?MN>41EF?$)*P*W)$411((F"3K
M=_A-7& $917X!>LQ3<"^5:O"HY6+[J<'?V&:32XA%%H<7,H+)*./D9\K^G='
MV T3V8( HYS;4]A!/$47Z[S+,&TE2J1^)4HR(E__11_,A??'&=W%SWMRF9-M
MFZ'AB84Q5<96NZ3=L\J 2*:"5*%<N@ZJV+"4X%]7^;G-F7R69".5"5^KP"AL
M_\MI@$R5NN_GO"NOAD1A#VCHX..PTF6#--T0_W*O+W2+EJ[\?2Z3K8Y2^H?'
MER84GR=6 /#K#56L/>D&$Z5>P:"^<AXH YLP62- TV;TV]4.<)70WHRA2LG6
M1,50X9>$0+[I.#BR^X>]NI'J!Y-,"LLM_DI$Z,+LBN<5?7WMNE43%0I)$.BA
MJL0J_&*?H/2( W-M!GFI4*ED2K>"/4.35/2]ATCU_!^\O6=04VNX-AQUHR(B
M33J*2E,AH-(4D-@ ,4($I)>H2 D1(M*BA&1++P(;V(""D$T3D1)I06JDBX@(
MH4@H(4'I)4$(2U+XPCYS9KYYYWPSYSUSYONQUI\U:R7SK+M<]WKN^[K>D\%K
M04+ULC^H.OEG9*I74ZK&(-<7(>\)*\E%#M=+W'A]BK)2@YY15^L8>K6A1FZ8
M!#G=X9S$VLZ?J?OOS_:$H/YXK-5O:/KG>]_/KBMCF!9>9)=H#'(KF-1;Q:LU
MSN '/5? GI4(-+/-@)#KP%.F.]TKW.@ 31!LY,BTN?NMR:KL:I&(D,/$/S'M
MHW*/1B6\GR7ET1MK7!4MJH?*4-8'+7@UQ)!S\YEBR8LVK%)NL9$P6YES<JA%
M$UCOM1U>OC=<@Q?QYBE^ZTM=W.8UE_5HC06RU8;\?,%*HHY.BW*U&X.WG8YI
M6S1G'-2L$%='-'6S]G%3=?K'A*95$Z:77OJJ 2GTY&J@F/ZFUL\]>P5[NIYH
MFWR]IM'E50U<D')Q8&.R#+SJ)VT]4A M6)O]<ND+:?H?ZONU#JWQ)_#HX\<&
M6S2\<<*</=-/@YKAMM4-C-D"^F68 U.S#*Q1KKO':W])P9B.DUX:*D3@SU2>
M+*;/W?H(IBXQ8] _*9NUP'5H>_)BEE!HE[GFUZ"^E+\!P</'X;Q#H4P<JXE<
MQ)!,2O=E5$\S&Z,7YUJS3(OT2DO1^4CS#*0LQH.N1R1W%2$01OY3%.]@.;^<
MHNOH2A>J:OE3]V(W"E>%7Q[G\)<_% F7X+CSC87B3.<]UXUI(QR$7RW#& WH
MAMK'M2@!;[JL-'/*$LR'G5#[T<&K.BULF[>UHYNQX$<GV'XYR+).>!&UFLH1
M*V8] "Z7.* SZ<)?:YDS'11,"LQ7Y 7XT09A[]4 03MH%.-R9";R;>IX9 96
M==3(I.AFU#X$[\'3\FTJ"B50*.I$:16N+:\Y/S[N[-SU5ROJC].5[7^(=I4J
MW.F4*_/OEGMG&O_NW=$]UQ+\UG&CF^.\XT769RZ2[5SA<WYU85.D"%7"1QQE
M!\03,E=L)TE@K@)0Q@':AA,AODF-@,P]T@"\FA&:5V-,5I3G3_87^=BW*#!:
M7CY,<XN7_^ZW/QOW#BD7EM:#DOQ",2WVT$_= 35,G:ME'MN*Y, \IE>NM9LS
M?>=B:K-A0HL-A1<F$ WP6#^=I9>!OF9WZOZ4K= H"Y*N:ZBO2Q"''8:)7ZB.
M5@Q7%(%,1SP[.&QO!_2SKR[EJD0C(P+>(H[_P2AOB0IYJMXS9[D.$#J>%<?^
M^&OB4_^</D?)ZNN30?#'E/4D%XKS[ Z(0+8^V5.*M\AHX$XVP]H501P(L,;V
MP02DF0_8.P!Q3#/ZD4K-2CI<W*?J)FM$%*IC_A;([MA.O3:RK153$^LFL_Y7
M-\IWKZ-W _A%6L^;A2I^:06IREP>G5X;,YLF1!N+H:\DC)+3-V&20.+*R-1:
MY]3Y(?<8-JI#WU_]Y@-'RD&-P%[3C&!R#518VT)?>O^W?LVMC_BQ]FG2\C#-
MAB82X28PV'2RV/)^FEU+)#2,+B(Z>:6L<@I(Z-!?=UG<;II_^'*\:)),^:XQ
MV/IFW''\W)^A46*)M7XK.R X^5#ZI;+4&KM>SC9B(/#0Z?RW7_ZWU<QV0)>>
MG<ZO[[_">X^;YM>5ZWR0)89;GL&X[H#>]=.$L>11>C='%,^S4*1K<5^C$DB;
MCIR3!,JS*4,MD]\*ML:7GD4=M;K]Y_\G71_?3!!\S]'B2>[/$8EJTE;,81[H
MD$.T5#5\(/[261.>_P4+>)CUH]3(U[?$QWJ"XMI:B'B9-7)FQ9,T\A?E.J)H
M*;>;&4$GQC "6D/<-$=65E&3%>Z#-:ZJWRY RY"9=EOV4L$B(3\MCN0\NE_5
MT- \I"DV0ODZ$N"+PF%'G@7-T>!Q1N85:)++$ =*=[6<<QC53<AH'-(5(MIH
MK*<[#(@IW8V>HDS)T(E55;7Q\H;R%^]55X<+.9R,NLQ)4W=H2!9STV^W#G[A
M-OP._!1#$U;8-O_0;?LU,_/E3%AD6+H:>Z'<:>IUZ.];SF;O[#-R5YC\966G
MS?YW&1Y%RB&>(O\N3X%^5).%8@Z#W2'W5TMS0QWQEZZB\)+$5=^'VS^@?_@&
ME""JQIV<KI8NO,Q:/ U^0!JX,]D>4K2$KTSG4$<7,I<]F',K#">./--UJBBD
MU(158B18XJ)8^W'[<E(.JX1S1B/EHZ8OK@I<1J@5/C6['9IM3\[RE3I3\WVC
M6;QM!_3SUW*YY87N^S-KG?IQX>P[YMA-S21![*^"Y);E&34MI$;7>FUTJ5;0
MF%7:@NH.*)J*@$\L<R?]4KE'\N/59_K1_[>FISX+H>RCKW1'^9+;CDN1HK5$
M?40_4?I6:KZB.)#[IVZ,#%RQ,FKTA=DF.2K'XXS<%HA6Y1-Z Q9O$5F)) ]F
M,3V'U+ZRU]E"CR4V W82U4':['635P]^:1)0-G5M?7>*'.E_/&M4R,!U,4XN
M+)[U==1&:@>4O:6O+YTI,3G9KSL\.30X,>GJ\OG7A,N$Y8H&N5^G;-!"9U#;
M7*-*VRCIRVIGG-KLKR^CWTT=C(Q(81<)2.L+(R_@WQ,L%PM'MJHCE;.V"E_C
M;!GL"%R-CTU_@ %B^O3=S"%&+:+1'7E5W?YMX=]>D07ZJX4_Y387/DM"@BP?
MEPL?M8)+85G_;89)_A&JUDJ-SXII[WLB[YR=K-_F5+LL6.'XU0M=ANE*.C!:
M9G>P0C6)]5F4$'!8U)Q;Z@6JSM#V/YX3Y+YMX1N >HH2F"QD3#JY7I?L*Q^N
M*;G<W-<T7]5N)'&C3^%;G[Q&"E3^PLT7%2_NAN..(1=0?T+X:T23'))NPZH-
M&^$/P==X7W(70EKS%G]9)NE/ZI2PA.5V0&&M39,*(T1*1"N6>B_<]\$ZK*!'
M&W[_]#13G/OEIX^M"OAT#S=CO*I(;6[5O YI7OL;'FLDSRVZ]28DPP8.S[,$
MON@:^/8JWA)4L3XD6/_@;:>NE]32X*U#MP)+NHJI=ZU,PDH F?_E><__T8PH
M!X_[KSA0"10<H-G-R>EN)[#UM0[N@!:_ ,WP!,D7/+5U3LHX;#HY;UN7#Q_2
M=T!_AW/X4;:AE!]/8703'&*8X[ #:E7!_3Q! D%6W_%O30-2X)0@%STL*?\<
M@4E@$/KX(=7NP?^-C?SG(<FSWN25[YZW%&1W0-I:[+0=T&3!3R"-=X^TZK4#
M>JPX7,R1YU_2K]\!!8_M@)I9I-);/.L=T/_!FAK3@5\WZ-H!3=3Q\N]<OIW)
M,WF)8B?N@$HDK\6?)AS>_!^QS;YO@M%RA+JP"J,8)7JBP3'W=JSJ(*'F<JAY
M/2)U_.Z@KB%"8U/8^$>K\H7:VI6RJO$)TRJM[,/)\N))'U='O\)K[%?N,]19
M#HQE@QU0%T3>R=O&1^S+MDBTAGN8<]=Q%>^#YM+7&9MY^@$?4R]<-RX)85V6
M^NRH!.7>&OUB\7%XK6AM<#SW +\L:#V[ [J7@PMUP>PEU_Q^B:GV=M,%4O)^
MFT&>@FOZ99R_I[UX 46<NC?G-UV$I@KC6D_N@!Y0!=%S;5.& TUGZ+00VF4<
MC"F9%%&";EMS9G1NKF8^R<RPV^[*+AN'][]=&)@T.5HU9HZI=(WMD,X-JTF[
MJC8'Z>P'M/3C5C7]RG@"&-$!G=ZCP5"8*,9V&!64O?0V[J1G9ENN1.- ><W8
MW_=BNQ-J7]:M?^G]&R(&X'E">]@A0+2Y7#L]^ODTH/S5U^@\8^ECGUQ)?^^Q
M_C@=B-BBU::B 5QP_X'^\/'J)S&H>ER[_&D[)!WA1.E9F2>@/O)ZE^0[W$Y]
M:U+)6VQ19>J5N^?-RQV+^EI<NDA)[P@FZDE)/6[B!T>)3]?R3<2UQ7K/RULY
MQMIP#( $WB%A-A+(>V@!964 I8]4OL[0J**D2)F'J9@ZQFLG]<[1Y#-IWA]=
M^"&=),6Y 3R?61A9ZG8S8"8G^EE1;M0S47&;)+&O57HA!GUE<+>;%6.&+\^Y
MIZ7U'1\(A(_2#T4LJ:S;[X"T2 P#7+*BV.C,@:[^!/C1&2+2$!<+%\/<I[,-
M]>]4.7Y'4C99!<646T??7Z",P5!_E-<G],A?\M0P_]4L83K$,2M''#\^X*LR
MI)NS.R_OJ]JVIR%T$G:W,;ZK;5"2=\;/KSA>ICODL;HFR89O\']!]L"ZM"AS
M5YF>Q0_]C,XP()9I=-/"=;,&"DR\_>S"E$"E5L3/*3.""ZX-ZG-PSPRC>7#5
MYD6;/2)$/\TJ(4R<GP7A>5PD1HDAC&\C1.&$6V0=C)Y0,,8,M4B.[&%FB6T]
M7-C;SN"ZZ_2?G:M3 Q4/O>2GS!VIFE]@848,IU;=OB\#SN/.)LI;TA*?*J__
M(5I@KD&^]=/Z8GZBXX^4[V=/93P J181ON* LR'=!, *4KF5/&[9S%9+,#YS
MD"<!./>F>;3IQZ]4=,>MY7_'S"<F1Y3KLL+7P22/854RY*E":H?EUYZG2G%J
M9U2&2?TEG$+L=Y+"'+> A( E0*0BU_L*EGAJ]56,5/-F;/\T0:3PF4CDC"A1
MH"G-^UE8SN;RS7?E):Y37UL+L\Q0K]X2*B#W"6,C<$H,ZR40P&B8%2QDE)!0
M1S%7<\476*B]:.]N7,4-LBFF%Z'[AJT6_:CB;_VQ3?"3S]9%MJ7"SK]03*_@
ME.2_[:>3OZ, %1&.1,CUAF\<"-L&@V%L&-1VO3LQ8GP$+>14ZQBXY'KQ0N]]
MID2'E$3$,>[(/U<^,+ Y(1)C3M]C,;>8DY-N\X,(^("M775U#;D<',@60H:J
MR\M[:RR7K9S<'=0:I*B$4RB4*95_![5NYD7K.M 3)<5L[^[QK+OUF4J^6*2F
M%K+N*ITW!Y?&*LU3#_"D.-> (OI^JT+TOM;M'5#\FI*76.WW@<#QA.\Z@ -W
MJ?S6[.E ]LU1+?#PE_,G-!=%?J]/N4+#G@:%&E.-UV=#2XBG;_SR4WE:^#TB
MRG5U_.[C@GVUN+LXAHMB,H01R=G/2/XX>6JK=X1W 1WK\XQSWIS=P=!Z[E4]
M]#,^Z-IQL7= !>Y(MGW SXG6@D46[:'0R>3?-F6SF]"ZQ< [=@EAU&G2],1B
MD]#T"HJNEHA1FE84=LXFB +C'13%*!U#S'D)GY830RLUI7^$Y;URU]>W>IJT
M9TS&R^@,84,$")ON4Z=U_\F19&Q=LVY0>XY1H5$/+(#>FO+Z&",I7@4.F;;*
M!Y#(TV,,V%?S"9C:;TM^U:N!V0^1@""6^-BC/!-/(SQW.Y[F'&^N1$6I)1G9
M'IN-HCDC)*/;1BC/@&RW\"N=*VL;KL977GD$\CZ<_:<&1?K)Q=ZP3_]1,.:Z
M30(47]HS=_4#?799>X1*621F</*_K9WX_>7Y@&/>OZV==@,5:@W,VK6,PBY-
M6(+F)OC8G'47O?<:^>5?8E:04BU*]HQMYO(:VQAC![0',X3P!]"6VS-7PV<0
M\>S.AI3='M.<W1[3-?%%.=?:KN%@*$(UTUWCD3IP<DAK+<B9/6ECW9#+MAJJ
M6$6MK?D]1%2@M%"JH0FEI7$NF1FA<3]2'1\^</P1[*F<=@OE0<4M;7\_;6:O
M2=$:W?YUUGZ3_\__0.SNEA\J8-U-H!\O]6#ACG*"1WXP(_LUL*Y#;L(#O(%\
M0/6KI3%:+19Y7*WJ\1>YT4ZQ.82 V7HS0XUF6LGLGU%L1T4Z2;_,BDGFN!8
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MP?)E7>3E:[TA%/ *JJ)<=2C0L*3@YB98E4Y95/K0J^#:OR+(OH,YRGUII!1
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MV5(_ S:][&R3-5"97+.0!8E^0*PW?)Y$[;"JD(']S<M%_F+O<OD>@HVQ6=>
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MX#1X]J'3^64=_Y/4I,XI6N(Z[9Y7+VKS/.%;:CN@1K->IAJG%3?1SYN&E,(
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MQ2C%(TW^3.V.]=_&B@SIJ""JE$^'06$JQ?M94-<_+"+[0VAC^UZ*8]L^HZV
M]L,^ZS??X?[4BLTU&.47%^PNO%B3%82",9DA'$6V:(P4";S 40Q810$E+MV@
M)UV&#LKUYYS:CGP"%\3+M!7ZY+_9@)+F+0Y.U@?;N1%X!V;]:[DW^*'I<,L>
MK6AC"8#-BA[1"/>A2M2F3:\==($J]BN&<Q2?S#@TUJ2!8G7[I2]W)DX\?'\!
M,!@>];-<FW5NPTJ/-*'H^'\;?5!O@83.!EXR?U';C-::1X(FK^TV^AS]\_&H
M=-V=CB-'].<4[+?6&#":7P(#2E/\MT7I8"!IE[T/HWNLS?240>)PU&M$R9+$
MB6E7I-.KIF'"09#NY'+?\]>"X2-<$@1 ?6D8K+EKMXX+WP%%H%QA5OGQOVU8
MX\ ROCIYN97I17\A;8ZDRXL<L<@#U#7^(,R@CAK,&\MER/3LQRWW7?NMV_CA
M3K1!<&:HZ@^'L5'7I(<5@\[$S"G<:7X!CN>_21+ND4B<P1M\**M?D&/\ 1;E
M)G)&[94?!17AI[FRF3#N9?.S#U6*)O(+N?+RCGN"CS27HQ>D=(,YW&+#IJ3U
MFRO*J=I&J8;2(2$JKR9?9GAZ*E>+FRNGFNNN4:NZ6Z%4BA(K$K!A/!M6TYLZ
MS_1X(<=AL2.)QN+D&UG]"9L'Q[ _B&YRY$UHPI,O\5MG#CL/?1*^7XKUS>DY
MW:F9XKP-[E_LY0F"&?*\H\7+SZ>Y<.LJMGX\[\)$+Q/F@E :]S^>7N[<ZCM=
M"E[^(WH,HX9XX[.T[UU"Z$J ]1W!X!"NWKL,*2DGV\2,5V\HK1[%B)&,$2DI
MNX$RNY$,N\=%NZPW-_=V"S2)=1^U>GLH)?\M:(]='$C\)FBON1IH3X]R+FA?
M27EJ%;2R7>W+>)AK_UP"3ZB..;><9=:6/-9HUMQ!J?F%L64VB9G7=N7<&VU1
M9%C\S1;\=:)Y2+Y3[@5K<$70.+EP(O*)>R#/%[G8/QXP$\$;4*Q5[.0CKV^3
MV<W[=T"=^@:*$0Z7O,W".6=+:=3#O7L?%BI9DW7F:[-?SJ@(\XJ>GO%ZZF;V
MV[(RK?'1<O%Q!Y6142S!?NL1=@/7*M2RJZ5FQKQ.UUH1+G-$D;$*WDO3N /]
M&D\3.7 Z<+AA9:7P@Z%?(.S0M4#VWRI7ZYA_/]RO=(9[Q;Z=RK"$A]_A'. F
M\T31#Z /(^!,XRCI#KSTASO54+KB\>O[ZWZX^OYVFC,9\!AHTOM:E)YF\B+&
M_U?=A&Z9;>JOT;5+/M LWPTG+1.N"[+A1K)R4F6W7'6/TOL;-ZXX3H[%VMK>
M<7P5>VB/\I_JP TNL<40LJ+(AF$<@2(!\@2 N\-4H"B&5W5T*H9CSI7^ _C<
M=#>ZRBTJ_OZF+N20AVG!.[>>>HII,*^"-%T,/TZB7<5^4A37O6R\M9RK <3L
MQ9QE/#4W:HP:PGB@0E!E4^,&>#W9#?S!<73"W9H/B0%2><B'C3,(JVZFKHU^
MU6_2TO;$2&1(9@\6M7&(1R=-Y^#VX&BYD(?XJ%R1EBJV='R3R1M<6P?SLQ'6
M]A/3+/%!A$VH^M#'SMGG^8G2[1+N)W)$1;\<F>'DX5HANXO>;L(;YD=PC$"H
M!XLJA*!\8I*24F9^@6&11G+N([I"Z@/A)D324ZD<VI-I#\_1^Y>L,N&K?K%@
M:N\V9V\3,7X35[P$**;@&(Z[7OB.Y.$)!!2Y<?&=BL<V.QA_(Q1R7;]@A0:$
MB;4SSI\86&^_ RS%:)32V>L4=.[]]+,'>=>6N'*GBT_OTC#'<,1/VJ?J_6PI
MKPO%2H6)_,K,)PWDQ[OU]_/A1#B\CC?'XR-E"KY'GR-F/ZW%T2!0O*R!RE+'
MISQY0)HV-UQ>F'J9M8Y>ZJR<FL?*/!^.[M;+NHM5&\E_?#NC(3KSS>VCVDJ$
MS6H327^7=^.O+%W6F\OSS=WFUL$[(($/'[)PXP:?ST"/5@.ZT\C01QNB1 )]
MB2C$ZZ=H5HC(_$X((7PZQ/W&_R=K@/@:%& S8NCGGJ?=9B:WE31I5@L8NS1T
M/V^R*H7#?S*3SP=2Y;QC;2#^DG_^3.2'6AL W[MN9JN/-AO0:C3%F4 85\*>
MM1FN47#MXC?C2J:<,*JC9?1/O]3>DSV!J.+%"P+3RS4?AFMJE1_N;P:M*/OQ
MDI< &V[,#LC'%<JZP?W'2)]I:>A<;M\VJC=J?!2(RG-L (\0ILL]D8ZZ>QZJ
MH&EA,//F*G(M]^P9CVCU[)6S\K*KX)6*N70<$1]%DC(^AD$RW-*8!V@A"8')
MLFBH8]3#FF&=A/3,GI?Y1A1LD<^XEDZ.4_^S;ESAXAVG13UM3_52[]</*D2@
M0::2^4._&VZ-;)JK8TF,[KP!$\PE-A^JMUXE>:'&KD.'P!PK>@),&F,6+[O_
M%:.T=6LD*SG>JYF"B1K]$?>FAA'\>M 7L58[&_VS/'(08>!9&2#R?6J<6-:C
MIO:P8@=$6)RS83_"#K?(<%.,]P,Q=,UB< [UA>[!"AW%:*QT[A5/IMJ+U7+J
MLIM'0\,MBFJL"*L[MN*Z:26"V#5X)KK@+>*;"T[J&6Y%F#EG.KJ).SH/EVTY
M#83"1X/"S-R&-V%'T&L=4XH?2,.;R+%:X5O; 06+P3?);FX3%O[&HDI-B>D4
M?]?B%2NV+<:*6V&LZHHQ =+"%.Z,%S;@(C$GW_2<8ZR%;TAE]EEHW0RWTP)W
M+)<8$THG]H653IW.") LD]*SP^F,7$B?R@:3OBP56Y@:C-61?F-(VAMJM&[.
M40*+,Q!DH7B50>H6D01:V'=)58.!?4(=N8J,[F2MVFPV^V6Y1N"\ZFB-,,PE
M=W5]T<%WVAD*K,YFF<0IJWRN8X$9ST3B@JE"'&'%+@LS\V'L&?V81YI&04'_
M?#=Y,[] 5Z_1MQ^1"RH3[Q,D#N;>+RH:\BMY&_:"6G9."'\*\I$$*'4O2P2.
M9L%7@I@!)M[@?\S2ID-B="_*>C1DV:+5@%=/$6<3,[YU##H!IV^7^7EDS'5\
MZU0(GE(8TL054#ZH(1M_:VDM;0]U52<$QSOY#3K]=@U>V@&!..M\W\C_MTE&
MF*V(N=% )F![Z/UQ_L5MR8(R/\8>UQEK[4JF2O^'9&K_KF3J*F7UG'#+FX;'
MOY12'2BD^%M<O@&$3W+X#XG\Q8I@]+=>/K75]PU["!WD-?(@_G:G6A+'7R")
M\%8C6S )M]Q_N)66C89FI'Y=7W,D=OB1U;&GARQV%5,]APJ\-=='.21AK-<'
M7A]D?ZTB162FOZT_HN'Q*QSM(M,OI]BG3F]&&S$E1]0J 0AV+^X_]U5KMS.H
M*'SW\0#2]IKI<O(:WGRP9D7H%EG'XOA788CY0 W[LCKT/1&F2>FV)*\4U%15
MU\&FP__=/X)$ZUA12-DP?HWP$;X".<JQX19L)H!'<F6KDFDQX5X9EP=R0ARA
M%J@N:>+RE?75C68QG6.7E*W'5S PG(1 -V1PTD4RG<V##W]!WEJONTGH7-L6
M.!H9)? RRO:/:O'=!B[SW>Y-A@ &RMZ%?M=('OBQ.@L2?Z4(=-,4.EYZW.PL
MA6,(X)ZZTTG2$U.G?H*URI<UDW)H_^R T!/H@CL#-.]V^8  O4_*U<K9P>9U
M/\+4F4AZ]Y^\@QACIE8'/YD[;=;%8$[2G ^T#!&*3[[)65>J(>N,N_9JYI7Y
M9%I()F6^&5_]T-R<*W/*I5()B.2^YP<DE#1O%"ZWN19OK.Q8,REY@*7V9Y.J
ME[8S &T="?BR[9<EHZCI:[DRFWUWE/"70//PFF:60'B;H3K4;Y0UP&W@:6#'
M6C2BUSJ6C=09<U<:LE "G N#*,\/@SK106A<[68V,6FRR80>5Y[S3Z9#/;$N
M>D16K79@6:<7F?UA%:M45J0^3^3PP\92[[L<8PMXQZZ>RF@CNV&"L%#*.UC)
MEG=!VUQKYI:UG$!8H,H!DF7]-ZSHPM;[E=SV-OLC$B[,M_&V6H>GU%)/%L[;
M[#E,8B2WEDQV^>FLB3OUP+-W0 P+%*"V6LUV0"]2NW,ODPF!:V/L5J="&&'J
M0]8 [P12[T5:<;B._/,JTUJU7ISD(C%)WH+\VL'98G_I6\J$XP[H0;"4E(%M
M5$9FT1AE@>*9C?"]7XQ@Z3&='!T<QMHR6!G!P>^5'SL[4<:[%:18C'R3PZ=3
MNN+C08^3[?D^!5G:4*W9^.%,2NCMG1OE"?K%GRX_<H^0"T&*[ K1%"^O_*<0
MC02CG,:8T%[V7L.XE]8\4XO4R-7KR9#EF+U=R%^Q<DWM</EJE:K6_6V3LXAK
M#>9=?AI,/03QG)3;$GFROJLY(]H3?B*2"H1\9&F_[/^2^@5C6^)"N6TZ6CN@
M943\(GXVK>K16[,L\Z=+\[5>OS)#GX:\G7)=E-[2=H/#7?J?AH8$*%GLTI"I
M]_L'&%5 >W5^&?9J)$$-J[7%S747\/NPDDB( O8<1Q\P^^=I0@GF"C,XD=8:
MH(!%L7P3?PX>@SNF7YKTS4<([G)_BX/+WIQT^+/X<^E6&N_@?88T3QP6CQ?=
M 7E;/.C%OF*,FL(%T->>NG]!S8C(7%DKGW+LC4A(E&Y[W%,\>5*=G2S3]E'?
MT/_6BA:DO61WQ*&WBA,,C^-J \[M3KO3"C3J >#)U_^85JC!"\\[8>#_,:U
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MN-<HM4_;<NHQQVRWA!<PX58V^;--,,+?L,J<QTHT5C,S@,9*I$]>(+="A#?
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M/SON$:1L\.O-FG41"#/G;0Q5'E7<)+'C4CESW';"06J3!.H[!F @!-\YUEF
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MT),&DOFN'=_!$0>/=O(Q<B46PYZ#;A712#$XL!0S^#+=.VI#!@9NF53J79]
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M^SW$*2>UK.U^^QBU#O7N@/V# IQ3>46>1.JK(+Z'1U[B*R0R=[#I=%^%%D$
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MYS"*,WBRR%XA;Z\K+:>3D+_2'H1A'_WZV3QGIJJX>^9.X;DN+TQ'D4;"ND\
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M,#2V B,KSZ%:46&<7#QWUWLXP7L1>@V"+<B*I,H3G_WM(O]VD7_'_RD7R4-
M5/F\0GQ?RR>!3*G R>9A?!U-8X&>O38)QLO45A/S)]4'+L_[D!%D["1C8!&%
M8_21(9J3_=3;CA,0R> )W&YF'%',;GCC?ET"G <6+/#%D_S\\L,/C36CETEJ
M7?Y#AER=CQZI*P>=4#_N(=&8,B1_HE48>]IK[M+ZU=I;=F\-N'3?NOD6Q3\9
M56!PS\32T5?:>A(Y'*TJS8M8$!R07+"9W^ZV ^9GP0%=@3+WHR&+BF "YMX#
MV1!X)Y:+%&^LJME&#X0_U9JGBV<MF<&RV]4UA<)]#],2\3U-1L2V]R4UEF<#
M4L5+D(\L8)-J#CK]F\;-(5+%4JO0M4T9YSO$*=STKT3[&Y*"@A)9/K':ZG+E
M1TO-'\R+B-1#Z=.: 5SBA=KM:\,08K =LO,PP@Q1\;V'/<4.6;G7BCQK;T_/
MMPG7CFO-%'8.VLY M$I[PE:C,HTFT-KH%S9LB=0,?:X.[[@E[+Q+:SKJ)?*L
M>A!QZ9L!R_C&'G2WV%0N.3Q,O-+T!31[,1![(#*&]->]R/?[U'@7G07R(68T
MXRTX0RA0L+FVS>>CG2\3T/JQP<WDJ:N;)YA+)SU6$!;EIZZF[B%Z3ONNGX2E
MA;?1U*_FRQ*E?FXB##Y;)B![1_>4H#W:S_$=-FK7%M5NMQ0\:+7-!# !A]6^
M=X(X#NE8%\+3,SK?YM&N$M>NV+>5UO&V-4O:N;F8>TEZ7ZA7]76?#@==:..]
M6GY4'-/DOX'.]X7_.A:H7=POXYEQ5']$L=1TN;QZTFAH7;2Y*:/B>IO2%X-+
M7;^PC7BA%GP(P&@T\%6F&BD\=M>T]0[)Y]5NW&E['?O:&M7<':S)1$<GP]I&
M2]@[9>5*X:&K6<^* #UL GT]^Q:I)54TU%[ZO=R'XDR ?,-.+":C>7[9>%P7
M#Z?) '%JG\NG)_</@,]QQJ]4EQ:FS\2U5DQ6QQQZ'IZR^I1@E\$O\3XPPDUS
M=*L^.Y+Q9G6+RCCN1:QAG!D(U12E9"/<*DTH464(%ZA<_0.62+^*5ZZMM+GK
M_--K1TK(O&TDGG<QV;-!@DUIY/C!"Y-72$6=>MUIQV)$IW$"B..4+;1I<3.P
M/IB?-K 0-V]%2P%'@<EFZGXLSC<JAI2!B7H#^YS!5Q#CPW@D76&%9__"?\#^
M?2ME;#1=.C@_ F;!\?/@VW185J34LYV?_[UB-PSX-^/3]/1V!IB8/[['!+CY
MPF^3."89@S5KL\3HE9@\>MQ:LY;?+,M,O*SII^KB[E&5R8C4!?L@5&\U_5=4
MY\!XG&/E($.I#/GT0F^B;W&++>-%?M5Q+FWVQ<8T1,2,P5C"PTRU^W?Q#=],
MY@PB#!>JX]]8\HG6OB"?:F9[=:GGK9%E356NO@\#ICLQ[<T RJ:,@4HG#QX5
MV8__B@K63XQT*!M99P(2E5'!WS5*H];0GV>[+]75U5369&YL^+JYR=S]HXS$
M/&0&-W/HCS(2I]AS=V-L]9SBDX6T7;Q/' ?&H@_*24I+,U@\-M:I/E/@87J+
M/[VB2[WPA&+[TMNG4.C/C=%%SO4-F0)V#Y^#--H&M3BK$BXCN_WW3XEEK-R5
M6-YHJ:+1]V^JELTV##<WQ4VI"WWH>=E/TMS;]#BGRH_RH6=F^*=I5C !KGNI
MOV8QOIAH\VQUKOVPBL013@K'-Z>2$'B7.,8YF-K9UDY!GC%U=>RI3)=Q652I
ML*&:><R5IYJ)!5&&1N-S!,*0Z.<.CAP36]-BTU!;KT*]EE+^U\5&,%_S?!$5
M/;\./<6EZ.(ON1$?[-@=3^2>U)9,DC)+*2_4+[F@^CIA75RO?5^>HDDZ$EKD
M"W$<H\F7V3;%HO'3$-,OZ"@)WX0!\R&0\_ NF\W1O?6-]:50)@"G!:F&$+4W
MHPBM++#B;C[BJFSG1KN1CZ/I$-OD-,>Q%H-ILUHD]=.%*@F;)D,;.P+O(W]A
M@W!,_>XC>0$IQ](*EIK?'6P%O< +?!9*;M8-;[ZR?+99!?UP?A(.?)4%GA"4
M15M^ GDI94./OD)Q]/[B&ZNNK,:U,##A0YC"_*()IDE3D%_551'AZA8/FB]M
M[7&!0A6?BT80"D)D?XV= 8YX<?U<\9%7ZN2;J4C=G>J[1LBSCP,7]24&@*E:
M/#>E'&^[\? /YF26JA"@ZNHX^/17V[QAAFBWY!B1"6C3-R=Q)4DXV;3?/B6;
M4T6N<[YLVMK?F)WEZBLYV#YL*-);V*.3",$M(E2!1!M,%&82P=DL0.,=+JN9
M\!5HW=.\0CII OY]YC+I4<CD;73];=+3W&_\MC.3K]^S(;C O8NOX@Y$$\C]
M4LHC#^IK#(ZMI^UNVCYLSYK(T?&NA\7,W*FQOI'4A^DY$T.MWH:T8=<%2*:(
M&,QYACC--'DQ ,'KVV#6.'36;<8-$[9^P1/#-M'5D$'6/%\^M X,/?Q>^/(O
M5<$.^%B;W9*M:DV/)NE*=@EMM&>Y=9FK0@IF9_'>@\P5DRC;%8PGJ57M()P-
MOY5FAGZTS7>N3\R9:'WTI*%W:5EM>,B+97$CZ/3#_8&7P%.*D*A9[L:?B)TZ
M,S4,%9)E#'XQ@ZN7>KB4ON"QHIH3\2(]2,R(US:CZ_,D'"KEIO*9,=.H\7[9
M\>P7!?#)AY:%=[-\G^H.*UP0[ #M>OM;QCL=0>;C.AGM3;F-5_*IXE+[_2PZ
M4OD?<Q+S'-$,>5?+AIV!,$$@O^ASA8A035E2CH]2PI3=K1NG#GQ"U[V*8;58
M]G/8M8RW6D68G7A;WP]I=)ARZV+2HK^-VRG70@U-=)1)H?!Z]L('_O,U#5$9
MVKG36T3E2P=Q'/>VZS^B U>Y\3?0J)''ISQ_&_9'0:-2I-[*B/![YOHXP;L0
M%&D4+6W@!1.P5N=KQ@3<B7NU2^O$[N!9O);,0AP;(H*>"CJ!6#E#$L2\.:!B
MV,$+;\+IX?>8 %6714T6LW9YV#':W_HPXN\P,ID %P1%'+GF-V?\#'$XD(N
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MP^*6'S4TLI2G('NV=-W (9KAW[#_%N>L2"Q0/\3R $DA-%8&UQ>S<M68H(V
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M&_ +*IFV=K6-:3RUYV/I/9:"<1[:F FH<[K/^?[,#0^I3C;&X> A1#6BC0G
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MO+(^W#2Q$^%NH)DT[,*MEIZ8)N7:RL&M1&>G]Z5 =< ZQ3Y*:_N,()$W='>
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MK!G\(=#J/US*FF(#M";HRSJ#K0I_0?V 7+OV81S/OL9NIB\?&)9'@ HI[2/
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M/49)CCU*$<S0DR=(C$4E!G;?IA:Q^3&#!?V7&2G^&]*#)K:$"2<S(Y!?MX\
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MEOBA8*^'  RTI)F F^D%38QND'Q#\BWNTI:6&5+59#F1RHFB, RT)<5U%P
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M2P$](,4O@$3 L6I]'C_5YQ$&YR==^9I?G;CA&I[$-VM%]JC#)<>;:6:I)]2
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M/2=UO,ZZ0TSYG<[%=@QB:C]V"$:_'SMXQY']GFSB(1<77,L[R(T/KN/$ '0
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MDZ[& X>$:YB,<\*]"M.=5"S93B*>G5I6&'? V;JF47\'%R_^U46,3\R_F&,
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MKRS)N=-A:9FC?$V50CS0L]/QS8M8]=4M?/F_.^;[']0OGOS.C3S\0O38.O4
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MU7G$.;[3YN/BN;."&\AU%2&HR:2'K<)[C?_4+YB$B6X0G;,"S!W!0I40%+J
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M^^]_1>VI&/9(+!#<6ELCS%=QT3P\__?F2X'(2$-5+B)JD5R3-Q(N"S3Z>B$
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MC5*?XJMSD:RD;'_,MP) V8N\KO8:-JNQ.,=OEFQFE:51UZ^HLF;JJ+H'<B$
M,CP=T#$.&PQ-:7<2 08D7,-<AR//.H^B,$N=1*?L,,W'#Y1MK!T&Z\O'[BSQ
M<;SYE:[8N>HS<6U2EV]]]Q<@3.4A0Y:GIY2TR5VM8,Y1P*-MV-$=GPGZ.(RX
M6O:R7SLYH#VG,5%Y,^_>\KD$Y2K'^R<J;#5.C"X,#V,?WKY'LLV>QY(>C?SX
M'O LT.1*F&<3\@MB^1&R5O,3F@_!195R *?HJ3(L@-GI2A/?51V+:8FG^<JT
MXPU>6Q_[XG\BY-YX$TL*/,C?1":*,CRR/(8PAV":-H-^5MH*CA*%O]!@H)AF
M]@EYD'&4(I$ Y6,8N))AA^'WOJ"#G&QW>A])8FMJL,]TOQ>^]Q;B%LM_56)O
MH+Y:$*ZF@?WP13&QU"D[_4KNHXBQ9<+UX.WLK)R@XN&"=TZ.=C_MQKZ%A(>'
MZMABLX*S:'4C0IH0U1I]&.R \>]O:E5I'2*U>/DR21IRJYAMCWT,(< ZX!U@
M-J7\''5:Q\6S?\R< L.:%3,N#"BGO3K54FX@NAAY\0)N-OM:8H\!+J'?3(6_
M6[\3+,JF( 1 #MS!0YR&#.I(D[]@5.()^U;\1M4(',2)4!%4(J7^A3JVFL:Y
M^MW6W'3.Z#H.2YTY:?+&\_N9VR(EA3[,>O^= ON&+;9 [&$=;90M=T8"/##;
MB E:-HO3AN[&>)"_$H1^%K86':B=]3!?"'"2R@?UK4P],G-0GTQ0BY0:4G*4
M=M -APZ-#LR$W-_G0Y[0MQQ4]_FRR6W+6K<FX *DOVT5!.FNS+8_>]1O$?#H
MM[E"QI=0L9?Y)66#'UITOT8IP-WR;0]4W.K\_?G:L^HC3UX^WB?UY).PCFT(
M+-@OW4$JNT# KJX1/[#ZIND#[F--(R;S/!9?E^_H4QY:J)WNJ7SV?I;PK=_I
MAHN+H0=$4CS=Z],*\N7.9EYLEDLK3+O$P?V9;/^HZ,)GX0.\+0)B'& SI#L2
MD"]=,:.#O;6"4IHH^+5D"9ZSZ;)KC:(T"2O<D+ILQ8M8-^I:<I4!Z>F&X\L"
M<9L7FM9+(MPUCX]'GS]1NNE"O\@:A'(2?"3BM@B\S4+>:$7++V*I"8T7RT(O
MP+-;<.2G9N?3T'8=BN^?+> <N:\1338F;'\*+_NY71PW.DPU@-YGM9(PSDUT
M*0:"VI4RU8B'[?>!V.:+ J5OVOM-?"O@EW87^%8W')2O$[OBG"U65CAO'[V"
MQV3<7$_ONCUX+G_Z?%UXI'.<C9S<>4JE=%4>@E!5N@TV@-3A,8-*2K!EO[.-
M-4WU4:O?5XG7<R87A^>D<R8I1PL5T]MT;J9WG+MH9&AK=?50A6WI&<@G*-6:
MAWB>O@5C9C0&4,#'?81$9%(;?=11;:D@TL\[326E+I5 FI^$U;#:TDM[OP=K
M@2I</Y>(52BDGZV9N</8304I*Y/3T6M$EA5AJO[/IH(6L <B0Z.T#-9R"QA"
MU%_XD7.)%A/@%$; P:SRT-,%1U.0RP2N%O*[RM$D$Z^@=TL:/Y-S[J[+W/\F
MUY7C4S/$('P;E<A#_BNH2?P=^;=54E)&KU96/*B<PS<V?8SK[Q^>U,RAS"U2
M#.*XX&>?J?:H]>.,^#V+)T9MKDIQ=J[A601R]GC0:##T$;@,!4@*EM/_0EA3
MMSM@R4AA/16$%6T[_F:!*W7M$\XH&>%+L3BQH!!Q/VMW.VGSL]J*ZRT<1O-"
M$NJXET-DZ3'G^U<Q=*F7L(\I>-A8*HN31-T#;2$:AUC""%Y,?Z0\PJG::SDH
MV<HGX3P0/J5[[=(7I:K2 !<U37'9D14I<:?O\47.#O8+ZSO/%W,&16+S.E/V
M0+F$NOB5'"1;OH]NMTA\@"R/5'5YH 'MUJ4B1B103EXJOI1Z>HE'HWQZ[0B@
M8(MYU'J?)ECP?M0G7S+*_6,U-D6"QPO":^X5K@-.N)YN(B/UVV31HJS\48V)
M7WTX(WOF7EF9R7?3+TWG<,5O8<-CD3)-##_F.SU=5E]8'1'=R9,P*4,+A#T<
M$<0=&_GF0E:22Q(TZ&/(E"19\'@UV\GG!V%?9UL?,,1]S+]U7^^H01BL!1V3
M?PE8H8%;D$<1''=A#.MI7V^2R0=;GBW'4T="-Y4\K-+50J)-?FQ\]MN,L"5;
M$KFX%!)XI8+LB.J1#\:NXZ2:320WEUA'"J@0"B&)I>@#%:S4<9VV.(HX!<#O
MUPT'YDG<&5*;X*(8)0=QJ0#9@(?UP)N/J3>'ZE8XO\,;]2M?D?/-0@EDL5JY
MV46THL00-[QK>9NJV4*HC6_E.8@0IZKM"X0=6?""!;S[PF<001%[-)6;%]*>
M4]+:@N&&66=1=N\?[W,PDK(5;';*+*Z[2-?U%7"#Y6Y>7C3+-]\8#5-9)_7X
M/3'@MSGQOSLI[&^SNU\W\5O>F7^#M -3KR%WU)!/"5O^S<I[H"$/:AS!:XGF
M^K=]O6!BV6\9*?*HTTW7$F5+_OH_H&SH/UQN-$,2:3[(.,]\B^ !MZ4^8W$.
M((*F=C:5M.W--7:GK0:J*M0CY(W"E2"&(VK:$RK0'QA92LYJJ^.*T.T/.%R_
MNACD.CXK0M)VL*)J#_1J#T2DLXY@:![DB.&R:8G11'.S:94V1W.-R=^P(XNX
MN)Q(U5\U]EXBQ6M/SR>V#IA064^F)S2_];_Q%1EK31L#**P]4+NMGO! X^$*
M;*8_Q=QBM^%MXX.1<SVU3Y$8J]F*S(+$PIYCUZV:WLY1AHP5\-?>OK 92WR&
MN@BD)NV!C$C<"*]6Z0Y[BZ& ;OY,11Z!F1Z>*(JBTF7Y_!X>:V%Y@8*7=^6^
M5YJTJ7SUNO=AL-BJ\H;:A<U%TVK6P\TU0FW7BB8-M76'UI&:$LD#=%G]*$ZU
M&E!IO$JV1ZO,4<&I2H$?-T4]U6#B\'N36_T][0Z>-<-!28Y7W#V#(O:;6\W;
M4K'E!3XTHO<P:7AMI92MO;\!8G27"$+'Z!XHUI'6NL3B_04F^_X*"^I$,\M+
M/)V#2K>@SQJ%F/4%OR;EUNM\4I?I3N$K6I"D97"-CH+7'NBHV$CL!@]@ -L#
MI:L0);;N [UT93B%_HET2D>LS-.JJ\P[6$^"=ELC9!TNT96%NQ,6]'6W]S'#
MPM_-RXVBI&;OHZ4[-'.K0JOYR?DRWR*@U/0'!EC=R(5UK]](4B4O4ML-'V6>
M^KYQ$8CT?/0%''3;I.'6NZ&F4=-;F>,N5L4EV3N\E)&^/5 'M# R/)IR0T-5
M(/'+A8_ X)^4,,#;[IG0D+]EF2RYS/UVF4V^2GRMZ8MQD0*')L0A&>)@VUU5
MG>[;_OZ%S!!6.YMK6Y*B);!ZS]4&,\P!>UH*M^GOSNFI[:<(&Y=WB[O?*FQQ
M^6BO"@9X<+[FAS1M-9?YI-AY<HGFA1.K0I.U*[4MS0-,H_61/&Q! 2W(9 5H
M:=26 R&0?O8'8D*L?F"87%;5PX&Z 8;-N/[-"%%(_^K;IH$@)P6KFBRN"6VK
M ?3=J-7.W7ZX7Z5R02)ETFXV^33R%I)JK@+(3XQT.CGW3*FL&%4M?$#<'@Z2
M.POXTJY4J*4>7Y X4841+0F'[0.2+/J6-YHXKM'J'GU5;!0.+;5;(!HE*QF@
MXXJQ=;1QD?L$7KV>^(_-I[Y8?YKS4Z,]\N:O-C'D]^<;-2RRR1090/+(WWYO
M\K'#*EM*AMFT\6#7<PH8X\VD2B36MLV^AB;F*0I:=@26D3^$JO!2BE[(N01H
M\4^("&N$)J&D'O9R&UXQ='OZ^L.&W"P\/JK%%0G_]3:17LL\_%_!_?\+@_O[
M=MCJ]:#Y/R(D,EMZP./=H+51'7O:=2,JJG7R3JXR+P/B&ZQC'B'8-G_]@8Z8
M%[JI:28\LN>]60G/I2OGDT)HCM Z$M41E@JE?@![HGD0POTJB#4>!B]U,=E6
MMFCB6+X.K4Y#ZSNZL>!W">L[=5E/J-I\;*:F.<)]["*^5RQ2<5@U)#+>39;(
MU8C9 ZFT05]"V!_^@\HG&.#92ZPG&[4ML4DGW'G $2H,GW4&7QICG5@[O#*,
M,=/^?M18?6&JAMKZ>=]80)7CO&>/2I< \PJRA9.UGRV<$7K *[J!CZ"C.H_8
M8@)UNZ6V1UP:R@6_9[?&, _W.:\7;N[3WC_JU1\UZD@X])&X[]B,#9'^<]$L
MBWMS-(RPN >2W!XK-95]B[T<]=\MA$P"H"S3A09N-%\&5*<,T\+G/$F'&7KJ
M:#Y]?I0D,-]UP0%:V=0M)Z?@)<X7?2VKWU![*J-=I$CT1+8*4Q>^U.D@U(8^
M"*_O8LG@!)U/4R%Q&(* 3[V1W]W^0&Z-^=N$P&/=XI:^/F<2=3_UR!F/S-U5
M #@ #$W2"6BA:7>1^!MOS&[V2@"U=VBV;_)=3<3*EX36)SI*QU1!!OFO8%):
M$<]<;%QJ,5%2-M=M>#6+\2Q4OT:AZ)>>'=M\M$7W?'Z?05COI]28W:XNBV<H
M[DA>3^=[4+9FZ-@%Q^<L2JT?SRT9'R]?<N@I.?Y+S5Q$@>D\ ^I:WK)Z7O&7
M==:\=;!Y4U8%ZQUA*AFZ#TF^'=G]$'%M2+&YEX)*(0[F7\J;374;=#[>K]?W
M%CC7K9^:/PD7@M ,,N)\AR?E;JR<><_"#LO$-6H7 OIM.8=C&+INXKEOX-#K
M_8W:!0O49_HNA;^P%[QPOJ_UZX*QMC\^H9;?5.(F%*3PI_D0_;Z;2"KI$2=+
MCC#U[H_40;!^@GF5 ^DD#&!!?IU +6R-O).[0AQKU=3T!^)V!:UGON9D/_-K
MU _R#3EQ;OJ&UL-UZ913K_= $ EL2)<QP4-B-)?2VP%?E8R^T]>H[E\,7+E3
MYM7H2S$R/]R*/PM6;[5?W(W%EH5S<I-&L4(UZ0DG/Z-:9FIZ=&HL=-+-U?IU
M:LT5ZM)[%)\YFTBE?0EE7Q[!TJ\2W*72O<]O03692$?1'RF_=U1:" -K]P,M
MG2!/&"<IJ0GB%ZBDQXTG"R=\6(JTX&K7-[]$=-/C\NE6@S)V2I3QCGM1 HIN
M.%P>!5.+3?$I+W.IC[.W5GTS +A1"5U[(&$=G[<,;<"5[ OIU+LX,O];;4+(
M)-;9]K9H:2/^8R:E=B"P1[96K^#]HJ8@+ACU .T?&G1 ]CNX1&54E76DEEK[
M22/,(PGIA?_<K  ?31=% U<#\>5C$G&[!X#C2FON,:,^XJKX)ZT[Z4YZV6_T
M%BK/_]@TMM4>C9QAQA+NJ>QG=1*XE3;PQ@_4UQ(GI6LQ'X',:=HA/W719442
M-=73ZFN2OQM93.3>O0^8_4?5KTS[>EC&^JWR3?:N.@Q?,(.4KPRPCO9H?<,;
MC(:PS>Q+\-*.,K35^0C5X[':4QWP%/0HW*<E1Z#FK>.O28$?=;T\"P\K7+V/
M+*OE.IK9$(^"GM9^F<^ YH&IUKVCHF18)VRTBU+:WDEM3BYB0 #(U$0XY7S"
M=)Y6ZW"/8_,':ER>'KX*0#KCZU/D,-]4K?H4@TX]6-D\>E[+[]U6_; %K]"M
M"18*,@]C".A/'ZQOE?A93L'*&&^B$K!LD#ZR<40LBOD>*JJXQ3I[]?O:./S\
M2(>0#\9.^&ZB!K%&R"&XMGF85;DKW,KHJPWQC0PC]30P;O<9"#P9#R-]DN":
M ,:F2UO0AW^V_YX 4!348S59*_7QJX,,FV('M9A WM;TNG[\B;3V5,F:M[4\
M&]SH&0[6D5ZJ"TN:-1*L=[FI3A6.G$+%J<.$QWO.^6&0?-X_OI"1G*-70"LX
M^S]9*(+7,\4]XB:2^)Y([.Z!*N_6P=@*VSH'OYV^3  #=]$'F>\BU7ZR>L&U
M?PC8,TCEX;PIPE'HQ*^L[5._80Q(I&N_CF2)\=$#'>^ W%O]%7/RPNE'BU](
MQLA'+!+R88#R2!>ZVA/)B71GBF_[=F("5#K HBW\N4Z!35?0@1('[6^>0%V:
MW -9P?@651U[ZMTZXXOOQ#XHE-:\/_I:\IM4XRI3$,U(G=NV&H1AD@WW0+9#
MRO.$P4VSL4HCR^:&YST!X1'A.MF:(2%\6 >3567I=*_[KMEIHZGGRRP-[@:C
M[D6V2.Q+71&EVS!D@=!0=YB."JP2_4PGL%*<#@/T$1+U#D.5RH#VF9'B^EIJ
MJTG="FY$J?:Q&<\2UU8?$\_BB^S,/[F.T->)E ?R*G[V:$:QA!8@:0;EWM#(
M4T$185.*TVV1@BEDD2M!CN^D/C;!JY3J',5NSA$7E C9O:.'MQKZD*[0>((
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M,DEZ4M=1G(AS5A;*9!C"Q3?D.#["KQOQTZV?<=:7(DIW?->UJBY;1VO6S-)
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MT5-"=/XZYIHP$?+GL).IR U4*/@;JMN((0#^X_FA8X>[YF\VT:$Q+,%3K).
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ML*W"VZ;. M!3!$_R6#$[ AO#E<(&"D#/PX5$UQ1;0-B8$(#^U<E"B_S8L%T
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M=KO\K_OU7 Z)U M=35=$W9&@H-JTRK4A(63:^=K10L;R'S3^OY5$> D-L]!
MH<# #8DH=L0AX$XI)A!+V4731G)U"NABO+SP:=1N:_&BGPI8KK-G#0P;D$NC
M-1K'5L&[YR95L\D7A\/,@X+?J.(2]' [@"IR^B$H5[J.+^*>'_&18K'4"GYL
MV!#8R+%"--Q"WKG=1Z%G6+5D*5^N<<.;6- TK(=#M:PZ*(G/6'",;DMZGQU"
MK&R8>)*56)9]*)7,![/6E_U98!HDR4P;F&DC[8]0 =*=6-@D$WB)62E-8E\
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M4W=MGF T3]T66HOMEW+_#NJ)_$/^U_Z$W&\_<N-G3;=O"KG>(RD!Z$,>UT(
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MTY<3Q("/;:*>"T![#+D_0Y@IV)N\#(<%.$.HF0PQ]P4P)3U; )+PJ=;5= G
MO.CN*XH):E+[?<C*Z=6U6KP1QSZM >I/X=NC$DL?Y=C?\W"Q'G9<S_OT2OKH
MMZ\9Z6KN=,;P5/\Z]WP,1UP ZM/@E6*9,8"Y -3SF8@7@&(F!* 6'0'HQRQD
M193?B^/.S7.Y?H12W)YO076:%?<8H<NND=^;Z]C/WB"1IY&-S:MU#Y5^[K1<
MO_)@<DKFM :J3O4":GA]W!:!717_L^9^_%OW*!/"PKUU?.P,B1D(%H!>"H'
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M*M[W7-I]4;3B9 GZVM4JS_8X5LR,1!1?#..YQGC 'ROQ>C#,/\3\UO1!-H=
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M+[J;\X<I'FRBHZTFW3U<2WQJR=E76$=^9$/ XF;M ] >DU_)(#4^,99=;;_
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M,=)N4^H1E1T<*7YFS54(W[+-P4[$?O#$>)(R/_DP5H1I5<OHM8T5?N.YU:!
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MAZG3D !7$SX:V(^J^L?&V+!<:E<'D1,@'X=ZH&&H>7NK;',M/ARH LH;Q_,
MY^WLMS.KFH%BZ!LQ,,_HF&JK *)3'),DQ=*"9$$=B!L=":E02P(!NEE2(L5
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M[-T;66)2N4>G;AUE)!09:0F]\C3.-K?RZNPOVN13-H$0,_@L-L)9=L1^"EC
M38UKOD4),OD*9WAU"N>21(_1W!0#8R9V@"&NN3IY7WI*F2B:65ML1ERD3]OK
MH37KXL]9-WUQ7+I%8\ZBTGWR7-P= =FC3!KZ\Z5K=@(BX=DQ3;?/4EZ]B7(I
M/:0MFN/26VQH;9AQ54E09BA.._6^<S9-<L#UUMQ EEW"S%"N^(&$(JWF>\_'
M]2[JY@^;%3F7'H61[-.=?V=Y&R@F[S)=AB:^2*#-7Z4BXRG!XF2+B*IYW%'H
MN#^VO1D#_A:D*(/_WK=6]V#<SJFR"^ %YTUA44H6HGX '(=E%^H7+=J1U"@P
MXE>JWY/%EVLD4)S$Y-6A5"_BIF1.6=/VI%" "* B]^FX:2N)S\,GL@0@2[^J
M&L2LI<4=8)ZN&73#7:.A(I<5U)%F?0HR7A,RIBT 5V/+ X#BM$P(W>Y4K6;)
M>LG\A96!Y</V-'+V8P\'(4 _UTDV@L.HS)9DY?_@-Y7VFF+73#':[@_&70$%
M+K4-WU]3@".NR6'2\FFJL=8F \ODO@5Y#-?L,G]\SJQ5</X4]C28^YA<=+0D
M6;SHM8V6><QL;66&,GG%T?B2RIM(.[V;H'A/1-.*WOGGL6YH&07#</$E?XM0
MJ>^$LU.T3SY>[PSEKJ<FN$S56#T/4[@S)(3FL&)V=BH=$$A6T+-5:@9"(4[0
M<G)Y#_,X>'ER#,T!ZK?<K\H\1O4+J5=V]KYWXXM-A;2QE,)$8:EKZE"AGSI4
M6(3N*7"=.#U,.#AN;=XPX!NKO;0TM8&A.X(R;,0!X.TTPXY+JAV28"AL1 <U
MZ"S2JXCVSQD, 6W"BHGJ:>A]>6/RXLH8JZ)G<&D=*65&[*/TU3\UHKNP4DL@
MOI$F"ALAT.0.T$2W1D(]PZ/F>IJJ_(R/I!GVYUVA?G'UXZZ[7#)_7J[UF5JM
M1IR4<W>!BQ"LJ,V8@'FIU;J+>:E)KLM@D6&I%<%1,M%EL%!<)5'R1IIWAFYW
MC:&7ATF\5[Q[%79LWY7T4X;I]ONN7 @]L:^@F3O*^#_4XE><_:N+CGX6'OTL
M//I[C+]OX='_'EAW["?<:]9D_6"0)_7I^Y$2H=$IDT'F;H_RW*]*D=(&JOZ2
M0T=%A:-=G]A1:/67^JRZ'&5*DC*/6:\1^WU$5->28%^WA)2#=H HAI[_@2ER
M<CLL>YTS-:@V6YEII7G)@&?A;+45MB+GW;)]\4PJ/20XUS_BUX&I<-<&#6L6
MEUG_4MF:N[[%)[P83GM(0?\@\9L?O0K& "%F *C%JIY"CO3<8"/"8%U%'V;H
MF[ 1H1:=5;V-%T% +P3B,3!=('W&WI[!\:#**PV4-/L;QR;G2U'M=N=IYA5T
M%%?0:4)E] ?DK"4MG^X(\QDNE$4/\^2$4C)# P7JN[GGU#/,2L-!;%?)#-'C
M=?F@WX@NW1_/'#.PXWH]:PPX=>7.PG+(%/H]R)"%PXHSSZYZU.MDL>HNQSDR
MS>R0 00T%P?\!S0V(O=+<.;$AD[W4O:># RKX58NX(0^W3L+>$2AE!O[0T'&
M$U E)\DBRNR\@J1DXDK][40W#LM%R3_RNP7)Q7J*IJ7AA7J^RA)%$T/R9+[)
M:37EQ.EG1@):+8>/ONEO^^22>?+PN+9)1>Q-<;^C9C%3G,XJ0<\3TM@(:3TI
M%@?1"?EYC'Z;50A4B('+U <MHBH#:\!KG7S_Y.Y!YH4I*5<.%,.Y9 T%&C!%
M"L$';:O^MX7CN.<%MA^U])1VD6L4K'L6 WRJ!Q87/2:9%F U&[%GU5]Q?K&:
MM /E%,<[@[I+;>NA^X5!,J"U'LV1WA.3!?6E]BPVJE)]MBMT0AU;A)XN(HUJ
M5C2.@15FO?49^I;1C >+BK5\^+6[.E-Q^[]?B)%S\?\0<CA?B9"OUK+K2YJN
M:=OOLRI+0S8K^,<MS6KO^YZ;) #G/ZBA/MXKK3]2<%>>4'TZ.[SLN=[2#==N
M4XNZ;S=H?'<6U@QRV(AD(2GZLC5L);NQHZGFL<4P]3O/RE33#\Z;3=Z@8X_U
MJF&F"A0RL',?AZRC@WFOXEJ!@VM<7)J%<Q7:28H\\Z/TR&P=7S6C(I<M]ZB>
M *ZP&1Q5&PV>32HNF16"??@M2Z[%7"4I_]:M (HZAD)LEEASWS&T,B?U(!9C
M$=*2>6F8J:F8DJMYBH1N>S&C,E$A5L*3EYSC8M&].YWDJQGW1NKP_H'\-N5C
M]D84L]5#&D(80XQ7YAF?(K-^*+@=NU%'<PI:-SS64_C^0I+QGTHR&6H*5J^M
MQB82SWX\ST94?W$C!"*3CU@L<VX_NV1@AWCG57X3/042&&K.=J)IIJ^B[0;E
M#;PIAL22V5KY9.,SA4".DQ(;<8BI8%\Z=_^^C'I;^#-XYCN&36J?2JG&8O3"
M'1M#UE0G,4QN*;H;56&PL9A&I""?-JJ2K%P"$PI??/Z5N+]^=\',<.#%FS<_
MNP;:A13/0VIIIGT$YW/KGPG!7!1,1*G'U[BK_<ORNFYNZ[\-!ZEUM7W<V56H
M$GT)^E3\_MLA1>MP_)-BD^$-,]WFISSI:>5ZC6>22M5/W6\X)+N;QB_I(KMS
MW<E6PJS-+%_O< /!TR3#^73&6+[>_0HT?\2*^^3R;O\NBFRD_/+>( UJ<B33
ME\*R7\2-B/)1[X<4@;C6U'QZ<-A0,<#*R)I)2A[-V/CLTR4\KKVZ,%3.2FW^
M.+?BGD1?>8?KPR\XP& M2NCWJ,0CL:-6'U/P+6=2O"6#=E+-BTM:7'</%6<[
M&]B+/X7..*ED1@:-XL+Q> 6&K68S](MSI?-ZAM3EP46-,ZZ0:/P-ZE(N:U?0
M:? "-7]2*<2M$1ETC+HW7$/$_TK'0A]PQ]_Q6G@'0QL:T^OW,5KLX4:3UU&\
M8.;JM=ZU.G>+-KM3#8-JNJ7!X1/NZ!N-;XSD6;"_==#50=P47I*-:+W'1C37
M?D(#6SI/I//B6^46H4\1+-[F1O>,!3NSQ?3#7P",K9/P B9KP(>X>#,BB?2$
MAHD=&?(T]#\GFFUZO-G@1KZIP&*VA3Q^OZU6?_$^;4'OKX$L*S-/[HQ<?4'A
MFXR%Y(?WCDIH-SJ:*,?ZOWDO'W#L?,)7@LOUA/37^FD0ML TP2=C;\U*_L.@
M'1NR9$P$DE--QA7#UU"60<;O W5:K'PSDW-G ^V2[R:EWH?_-Q3IG#M3*QJ=
M.RIY\N3(K,JY^+M]5X=2@[/KT:^0%=4+'?G,$ZMJ!I3(2A)WT*]IBXKTX:0K
M 95Q'+,K 7_(6YV:&+.RZ2IT,?\ 5!("%F7RHX8<>]U.AG^:\[.:)@0I@$:3
M0.CH;[4Z(?*XU\'5"UXN6QD#*W9S6^.#B46C;;X%$^^!^8;6^_S&EL[\?A;5
M*[.COLEC'OQ&.OA6,0D]0Y-MGIR0,Y:0,S[F/C<66+6.,0_>@GGQ]C_+TY6Z
M8B]UW1Y'G<TY__^!'.+//.+//.+?<OPM\XCHGF0FGSUT<)TJ13]$HN(F?Q,]
MP,HC.J<10?VU!N]?^X)<,:@6_,/1O @6D5R ID#%Y,2!I764T&PFJI^GRQ0\
MG#MG)T"+HXO&4Z1P_& U.;0Z<P^N_=B;#QX"OVC?C+&]V9<O6K9DXCZBS1WE
ME9Y!CW*7JG;*&W[][*M@]>&I68<:Q0-E2@(FRTG\L2K7=6O,6BT*IK3#SN:P
MMBJBO"I/=)M<#R6^&&6V@D0V8C<.OLE60;#F#'T \1J-N4Y6$=B(_2AZ-1W#
ME.0PNLG*TNAF1;-2Z#W@58!\>8;$PT:0#Z\2":5 .4"6AMH@T@H!M2"[*+M@
MZ[B G)9AN !-NFR$6]P8H]5D#E<)M'.XVE(3JPAG"&0@9$)8AFP4(KH_57B9
MS\8I]D601M\W6[GK0_5*>?X]-M3&1-K.=A-_/"6#%'8FY#>:P-/UL0=.HXW(
MZG["P=:+HS?MQK7+[)UE%ATS=CXLN5YO7!YQX'V;[KM#.3&'<1'MM!:3YV_)
MQU]D)-K8I'T?!+I232+.I7=BMPRJ^?LJ8HA9Y5S9 Y)7TL$0E5;#>DHZU5+L
MJ*S#TD?:S2^VDM!@H8H[X6'H[:Q+A4:CVKFHM4DVXDDX<3(.6/,C;CX$7)"0
M5P+0JHFFZA"W5$G,MR@"?-^4_VT7@*::/AOQ*XF9_@K&M"(4^1!-EK436/%J
M82.>%W]@(]">I*[$X$'BYJLM$IBT) IM;QQ\^PK%I*#Z>:&3V\D,=3:B=X*-
M^/X+JP#8?+]=0<\!-(FR$3/+P"H"&D QOTDQ/\)W__]ZZ0)XX>1:B6NPMNCL
MXH+TLEG!'< YLPUS^#IOV8A(#_+R]!2*>7 G&_'Q%.L"BG("#YXBL426H=^1
MHQ%L1'HNDL8]S#R\##W=8"/.<RUJPG]H0ORP#''WP"O]">:*XM*H3<FX?_Z!
MPU_\5KZA?3&0&]<__9Q/8QTX*OS]X''\T\9N6:8\B7EBN&KB&N!.%5]@(QBZ
M_@]Z"!&+L73K##GHB-CW$-DTF>DT!3:"?F5NF6ZM"BP>=M@[8OV-C> #FJZR
M$9//C0/Z_4_1F?V8^FX]HXK91DE6&M&E5&HA4).515DE-)R:K'K-RBZTIO1-
M&&0B^THQ2E]L\9^#WI3D0D+ ?_UV,:0'X6\O(E&-;)6NORFO8.7";,5:\UM
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MK32%ES!)4A%OGIN-<K8T+&:IINB?^R!Q_:/PH.LF&X$\YZ:)[CS:%C2,@KX
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MYLA.H3;Y";+;E+>/834GE4S#,:.MDEDUL-\%E[IJ@FO _"**=4Z<WP'&V06
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MZ.+R;3DWGOG7U8/)2^J,.:Z@-6.%*Y&UVN%#KP.U[ &3H@U9SW75/)/MM&A
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MP2-2HSW% ++XR$9T/XV W'V)$-H:3;;!763Y^^;:,\86;R*9Z;Y_QE4BW4^
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M/@R;;T>'R5/-F/&^P/"/+'[FC9KZ-YKD /5!I)PRT>R;PY>B0NM9X%'_BT?
M2A['##=2-'V2?X17",?#,77^#MR_V#=8'Q@R-$IBM;$KPZB;J\I82%Q/@8[A
M[2O!RSL7S?L_NTQQJIT5/M6@XG"?:E+)7TEZEE5K-*0$?P'\("?+U"B:Z/*#
M)-6&2FCJ21%ZG5924\6=LZ8WQ/Y\ML*IIP4ZN-I(=WNG! _=,YGV#ZOI49W4
MJ,ZS<EHB_RE.5^:4K ?'AI2Q;[$42U:$CZ1KG@W1EB%/%[T4X.7>-)B67MQH
MH#-XY"M7.:I=-5OB81 Y*^PWPF5W4JJNM'@D.J)W=YI[DFU6T%(QMP]8W6,
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MANS4T,3;T2A'8#(WWTSXSLRVJ-Z>T(,JO1)4JII#JBEY6(5G/O_K>/I1[K.
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MSR["HY#=+2U>3L#%CD:(:E2?F>:%2TSB.NI9L>3,$ST^]6NVI%H)--2\3L)
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MJ4IB)=UV^2@5%#P J[5M70LGT1%H:F9<*3L-%\;?GMU0B7^E(^,R[ N!?#D
M\:9PUPPRE.5!RY](=^_?<4W=RP2=YGK/\>_S.>@("/0() FZ=)#(@9L)G3Z
M(TL!KC0P/7Q$N<X3P:_N2X6^^INN8]+,3WTS[4%:0\MW]:#*@1+KP0JA2MF_
M+457B^;V08%+'A"H$ZY[=^,RZOH&P61A8XF%D,&+,G-8YQ9PH. CC%M 1VD
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M82YA*^57$/2SK+[@D^:A?D\A$AZ7SAW/ C!D2='GOY]]&-F^-+)3@QZ&KR/
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ML.)R@MH;M0'AF?_R>ESZ^DBEBL_9OEFW0ZY5T8[):8MW=2[Z)OZ8N7;DE<W
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M9H7UX;XK07V.XSV<Y3ZH;6@9BB5]QY?B?X>R>,WH$,9M $*,Y29+M&$/,K2
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M+?B7&H"R0"<.\(2.+9$CHY8UC$9)4!YX?$0F3T!23[6? /(4(IT'=W]"6';
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M=]0D+O=O,-']G=#^@)HY1QFCG_UC?*&AYKNM;&^>G,602B&(^!T]OS%=-D@
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M/Y_ ,,"V?&G_U#ZM$G]X@M#TV<""5!PV9@6C3&:/A244WU3=DGWT_8HII(<
MA!-H!FQ0-IUNR5&9P2UKK&!MYID^I]]-,ET/?T>_+7*!FS:=P*D4V-EDO]D^
M+O40K]K?+_@JP,ID8G/=3[3A FFYFB_I3P,TOGO]A]3G+S5Z9UKJ;MIZ;S[4
MONE\Q6!N;:38+F<V:>OCBML]?";A*8>L^OHM%U.4IG5;_&*;I(%1^H5%UG'
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MXG$?6I/BX(G;-=M-@9SI.XX>Q6R( AP.$MZ!YZP]6XPYI#1^>0N\C*?K,G2
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M3OQ%B.4;E1L5H_,UT/&G"%S4U7</08/=SJ' ;"9(O_:;&U0_5_HJ/FS2X2Z
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M2@"S(M3*\G.+1TN7,+$-EJ.)>>8&DI_^=Q/[_X\U4!W"N 7":E,N?X@ <O4
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M42*8&B35]],>,XV!*%<<8GHK'H1JP;_/$+;]<4#'#HJRGP+N284"LFOI$JB
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M300A_0!-E=6^9LR?[Q7Q%R_9T($)*#@*((>@ ?=(8Z^'1B2!5\3?S4\&1JA
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M$C]NQT"LU[_0KV]4N0B5OB8HP%?-</EY=^<._'Q,DRDGG+L+SZ-CZF@5P"O
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MF>V*WDD"_#XYYNH]5MP[?H.>,5FO\M5/_+*;RNY\&]/-%+(E6XK%S*>'3Y;
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MOAJ:N-G(NH9M-MX"W=,<O0/O$>A0T$AIQQU 6#U%Z])WVTX=9NB4_)!S&RF
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M9CI(Z;[2A2OW9AO:ZVROG(N]!1*I]"Q]93V_NO#0/#>OGI#T'>M*@(A!?$0
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M"Z";9>0./[3N8:A/GYV\/M =<:H\P@+L"WT#$]%%E(ZWYAY6K2K^'GSV665
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M[2"4=^.$%"&ZM[LI-5"(QY!=(U8F*12'&]V'\'\H1X:"&%":8CT#28/&<96
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M<R,[FG./QS)MN<TI.R \M*46>PS8 9D%84.Q_)XJR#I3Q.7+HZB^%C$QKRQ
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M5]4QK'6AM8O<>")1MVSMYZI\HHZ)?.(E_X2QW7ZSS?B0\NR)J:B)_$?N:QZ
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M<:UP&80C.#P/JNI%C3UJ0 7OE;JU+\!BW$UZIMSMK)=&6:5XT8>,X^_UU*
MLM\WXS-[!,XC(OH;(]'*$4 &8]]-P)R^V 81TX6J)5%W0'M0U@Z,9U_TOYB
M\R,+[-V%$9ZPR+KZB^"\]Z>N=/OK7FS%R4<7."5Y;_GL!IH&!^Z PL-8!@!F
M<C I:!:%F8R,M-0PSD[RN8SZU_K[SZ)V@]/QM7QN%WU=3^KKC=&_%63M3H*3
M?Z8V&U;61E.*\UV-FKC.P#8CQ>U#"IH=M1F&U;1.]T<VK;XG@RRJ^U=R7EYS
M.EEU>:Q*\VM8A8 K+7QOKGM.7(E,+;)Z_-A:BU$%.Y![&@Y%=U JE%JQ(Y16
M,RHT7'LO"5MPO9:W2R-]9DZ3JX?L["77\@=]C2>_!:BI2LAK2JNF(T-*X&]F
M4B9^C, <'6 &+'GT+[TKG%*T.A!$A;R.<6-Z'QC4=:%%$A$QD$,H[497,:O!
ME3."H4$IB)@0':/RR[<UA-RW&WM-2DO_?JLE<L=)AX-% 6_6]>"KO_4DV>#?
MIWX'JWV^ ?INH@%VL4@X*[7-):/+VQ2+RA82#2OA\+O%C2T(A 0^')^75_L6
M63R,EG]8]*.$I+2I!N_;)L_.+DWQ:OD5)X4D^,=F04Y$'0G ];2-IQ(WK1B=
M),I!V-AD0+DK=T\$S>'TDLVKMF@%QO6>1]TG6ZI>R/BPX,V8"NNE>EJW< <U
MQ)\9!&AY9YMX,ML1"/IJX\C#0?,?>0+S6MN&:4Z%<T,7<K>L/YJ-)X\I?7 Q
MG"&%9^,K1CJV=T 1US[]'1_+X'ALPI );#7NQ ZH,C.6!4;WD70!2VI0<3'Y
MH)%L @UY4&8KMC7+C5<^HO,,]Z-NUD1!K;&.[(GTY3,ZU0)F(0@G9-!_!BW-
MA629H1$>:IC+O4VAG" _A\3J7>Y3,HT7GB>=A>]#N;M^N%ZWK?9R^12]PEVR
M5S -C"]>UF39O_HPV]'_?8_X!;46B3#\.(&4&?D<V2&SZHR!N5\3^>L;I^'B
M[WS[MD772O.%+U]";3^\D[@AGP@ZKL$-QP@$0WRID CXD3IP,/\$@/B>*4+G
MT(@JJE5(X?EMW^]*2O*FSR?7 E8"AQA&O 5G BJ\IH<@*&%Z0IF_QUVEK:,>
M,2@Q88HL9_K0*R^::0=BXC#,PWVEM:DI_64WMJ2Q-LEO@SN]: RF=&RSCP2N
MVI0-(6<1Z+O*#!DN/X458A\L3A\C5\8WFCT=#;9DD.)G@-EF.]\&&"62)-A/
M4Y8(_T3_&J0FB:H8SM7\=Q#6*=:T-))[?O_,KFOE#J@ @I=JVP$=X?["[-,-
M8J0VFPK]IK>^?W"C)S>]'2,"5%IX.5%+]RK:_Y2Z/_ L;+GO1F*[4YY!H;NA
M8O1/>\RA'=#1X  :-EI/BV'=#)592$(XJC RJPM1D8[]!4I:TA$Y.MT7FF3O
MP&Q'(V (@7-^HW^&]9$NSQ-&&Z25/Y64$'DJ?COZ_37LE1&U50Q=BQ6G%ZW,
M?, ]K,PZ/(+^G7D5.Q7? CZ)1 L'7QF@AAGU(*G"CQG[V@:+]R_9^8Z)YA@%
M4;&"36!"5EF#TK9F$<8[;VZM=#H&D=(SD^3Y8_[]^P=(9X[-T.YSL02]"\!&
M#N^4D=336]#N;HH/'RFQVHZ/J%/+;Y$@QP=[Y?\41828_R43O_&D5L0J[1%3
M*U73NH94[FXW\[,-^O5;'SX=.X$YB&G0ACR!\\V;NVF[+,W25ZWBKKY^X0BT
MF:6V29<V'1NYII1JP?!H+?=);*_./3.\3(V^)3UQ[K:7"L9]=SJBT/*^A.4-
M_B\']A8>VYV.$-SS/6]7_/F/326;F*ST+F6DLN72@%*6$Z9!%BT8;$!'5]*P
MPY4W" ",86U:]8W\E=X9OO$3$&[MO2ESQ\<T5N?^MV]AC2,9(Y_#3/K7 YZK
MHSQMC(KG>_7_&TF.7$LOFJ^)B"ERE];#.?OFN]>8;4SPWAKZ;>(15+ @>:4=
M$>0<X'$YE[!IE7K)='^S:':[>'F=YY>?-W9 !C5<-9Y2*<4(KY-!W#&,.,R0
M&-W5T3HH*\%@C31&)^07T4X>&;F.GA(8=( V2Z.+BL=T@CN]"^\&'G5W$<?#
M(?_6-',T5R5'*VK(]V+1%]IFZL7-;=.QGWE]>G=WO("T WHN'"F-SG)FD@^S
MM=.XRJ@Z7;1SK0V@3>L-.?*3>BS@@?X7@#3;5.,[4!4IYM9'(;1+*NESO@[1
MH&R1@Y-J[%,44)TUH\FZ8@W?_99[1M/N1$4;ZP?[\*3;JD^M[6E5OG<[('=4
M/D;T>N-GD?&1^8_7N^8EG@RS/& W;0,7N?"AM'8[ZW2'LP7=N*F"'^>RHW/^
MWR)Z_G=,S_^G,3V[_X[I]((IZU;A5WIG:AG^#=!H^%&T*"I_!V3\C<[9?,.5
M 9K@=$=B4):#PQ_*V-Q0(#82N<[JB%6EL>[VX9Y]_>B"3UQH[*+2+H_>FI]Y
M:'G+NT!!^\5[)2E4EZC7>[BO?!^T\\J%]7-/"ON;:*Z]S?>+9>VJE/O"[33.
MDL%W?,^>NZ=E,F*.,(NO@E"GR/3[:MO7R2,\,2L\V[P#XKH53\./ WTM.R"1
MX >EP%3;Q+DAMMN4FBAEUP1) E5@11H*UB];N/Q%GKA-*B^">F,*)XP+0TW3
MJZ?3&F.[O.P[)?+L[RG6F)>^P=F='S<LM4L6]</W?OIXK[.X]'F7KJSY^^D!
M!6NUGVM+0K9-PUWYPOLCFAY^4LUK/_\[[_"=$SUOJV'N\SH.O KE+J%%, VU
M<#HT7B98"7@\==T=&;_/EN'?U+T?A;62Q(A6?0,?*, !R+L#2&['/I2F5<3H
MLO6++1'U"G4O#_VSR6,A=]-/M\U6X@2%OY*DU:<?C#[T&?AR[=S:B%AMW4DF
M(?*'UVR4O1:U\P2!+*+2T*11%)47OATA>:S(^_%90]^0+\F!NM$#\VM5T[^V
MJJR&@'O9Y%PD ":R18E,!\Y+])'@XXRA[[9Z"GK54^2HC]C7&PU3&,EA5/0/
M-ZM,2=+@&4TKYLB!=X.;< 0QWJ=3_4N/)U1%]!A&2Z/CH_.'3SG''^R+8:(G
M/KG]=/SI^1_>^'QKKU<,,N7.MFNW2QA0>WXJ.$:X^9K2(+F2H>&E[L9Y\?:_
MC2TZON 63N-<_Y?$V;!I=T]&9<4?7DO_ZR[XW[=A_O=MF/^_;L/X+!H$I[%\
M@ZU3)PN6XAE3-*&,]JJ!DCJ!D,]S4N=:GA$84K$N!/JS,'\0WQ6SQU\03.+"
M@1LP*W]9NVL'FNXL*]2ZA<RN:>V ]N_E9,UR\LCNR"@];0()03XT5Q,#B%%I
M*IG.56@!>D9+9VSL= &8H";B+E0$E/97BF,=4B[>.G.![?#_&",(Y:3H\2V0
MJPK:5B.P!]:;O/ADP0P^99J0X;B_7BSUI.HU#:3$PL*O4M%NY\_#\.O1W03E
M#).2DHZ#U3<P=60AE/=M.B;21^XPX&)&Z&'K4#/DS'ZKGU3LU*TUNV+4JT+]
MVO<<G"1?HDGPHS<<DR?TRT1=4]KB28S0(VRQ"$.@@Z7O[A>]]IT).1Q\^@5C
MMOU97$>+HU;BY<E79XV40I>I'U6TF[=?[V?>G</D! [R_^3 _WI;)4]W]$+2
M*6P2?=>]X?]J$^&&>$ ULJVH3H/>1&U;VLR>^(#34W#_A^IK-=<_;:TG2@^F
MYX<7.+1]TLBOI!6']U-/B:H&RX3^+!#%J UL0WF+Z@JDJS5C1\-H(37VQ]=Q
MD9+H$X!+3FA+W9MU(=7K^@YAQR]DPM]JX$2%BN,.J>Q+D=@JMVF?@*ZPXD;<
M?\=_K-W: 7VOX.>2(9/QY$H^.3Y>R2U"H[69G[ZR;P+K*8XJWSZB7M;VZ>[A
M[]@!'5)-D+F\$@>^TT7#2(ZI.^O]UE@4"$IVZ9T\SZY"=^V !)R!4<805:T1
MQ1Z(;"/IT8<B\>>SY$W=LL87[LL=A6>!WHV@(V6S0KYW;T..+<(II(R"/_/:
M(7')^78-3OGS*7XC:*RSAW2+AXN3,S_,SFZT^;/*?["&$_^U2+\LDK[PZN6%
MST2,VN+V@HNCU9WK&^@89-N:ZJ[![2^)?^1E)$-4+ERN4JXM7JY#&];-DUGA
M$VH>%TQDW(EO?,%GIHSH ]6>K:O-VA%I[H<Z/#]X"/XY.!?-5N)M[G0PFD@G
M-PKSH;NUS>:D-UN$/(6E@"^#6OLGZ5IA*W6=EV6^K1T7LV=$_QFW,=Y7K/7:
M]]R?\X?N>+979,FZ*<SBLBET2,KVN>RO.O%SL]Q#QR>'4X1'C&CB#!&D.OD(
M6R;?C#@=4)K4(CU1*TF[]"&GAKZX;(%*5SG8CAWN'F%-Q9*7IEE:P;; MSY]
MR6(J6< !!EA<(WRM8>37,.8<1<+:GZ?1'##F7ZOK8R72U!>#VO\<HB:DSF
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M@L#T]^2QZ?(TRO@O$,EK&BJ"J&Z%>BN2!8(-/:]$&WLNW!Z9M3]:+<A15IF
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ML^?GW1"!;<3@]!+$4__)8K^[4J/!,#2K++ 8.CEQ\6F%"@BT7J\R9TV$,C\
MIMNG64:-C)4.0Z20J4^ 79N1>'660(3]M)6#A&V68UQ0W2NE+T;W7I8Q"TXE
M6@Z>R%0/UF_PR11:S%LUU:F*=$7I]/T0 =3F:&"1*/Q!A#<SN#^8#RH>X4:H
MXZ78V[$WE:N 4$KXVE<<FG*K]"5&#*@=_::FR)?_I8;>VP [(_':>_-.Q2-V
M/MX(&&)F 1W3(B\\+KX2MV=H+R0*RT\Y*PTU:E,6);9UXBA-&C\$D5T%3A\>
M:77JS0QKN/R]56\7'OEXA3+R/&<<]>C7_E43]0:"(V$S(HKPE0 H;S0;;U]
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M%*C3PIM+[&EJURS!>U5%"8,P_="$%ER7-FN%^],AS/<QE5[VJ2O;-H"U<>U
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MAX;03[1S<["&3V6%7IB3@QH(K&/=.\M!OZ[KV_8#%;S)Y,?8O/D JS'RV$U
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M8_.6<$"*CVD+[*[.)LA6F3[8CMKJ"HED$N7]^P"Y64P,ME$!.W6""((LYW-
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M&?62V$U;8W"=$<G?LC5E=>75,1^_5M14ILN'4\=0Z=2T@_'49,W[?F[W!&;
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MP.U?^B(+)+$V8G1IHT9E:@[*]9:Y7:/T\3I41^MG5&VKX_VNW#NM[JJ.,'X
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M?"MF%*"^D9&^+BO-'D^8D9%@H+]]50>6 HN6L/<H QQ(96@/*^-H<=K$%X?
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MJRVO[/\1YFA2G#V 7#??.'X"+TIZC*%2U(B1[&A,LR7S().[\&?]KJE/)#@
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MI[(*+#5</L%,KDNIH?S+DGR"2?>JJ5R91X#_T;2)*'?WH^^BY!.\+CM5+[
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M#4').2V%>+\'VHEQO"H:QV=2;.Q<C1+#H&1ZM-/_K?.RJTS8)P[$R.Y[G-V
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MS>-M"8'9:,B9)W95F,H087;3M-M%7<?0)+-UEN#2('F6*3I-EP$3@5V)6>A
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M!A,WDQ;;-0.+F#PCI# =9N\VD%E[>'?WF,KXR] +/8DRL^&XJ0)X:4",8MP
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MSL80>/,259*)BR*!QU<ZL2 <4[V[+<38LI$!?\:6N8+9TW#(VO+T1)&.S(.
M737!]^;1^1G#:&=?BHK1R,RIJ$I&S/XFPZB#W3E?<-AWC\A?EX+E2R9P.Q@'
M_^1%((Q\GRG'@63F4'^7$ $N*J]^Q?7Z-V6Q8IIXS!C&[$$X7Y/HY[L;4N+%
M%#L-I*387F&UG: 7U(5FDN#67(-84F@-4?CJH0U45O$?>QR0*!=XS2?'#<L4
M!&$#!%M]^;'7_<YS8Z%-N $"HR7"\][A:,JDW6P8:L!3,7S$SCWBAN#!,I/P
M!)/O1K;&1B?F#8X?>FI][4CTL2-Q!USC#MR*Y?[XRC7Z6-;55YT'/;?+>SX^
M<>1QP?L3CR&B6WVSI_V*@8O4B:@AIF&QE]:NE/+.'=Y2(SD>.791.9^B10)"
MU(7XW$Y,.KF;KU0N[=[UD0,!G6!<4ON9CS[/A4,2'L:LP,[.LOFK: M+*;VM
MF-%ZX\:)7?%(M7:X=(MHZLMYVX7@]Z@37T*>\2XK/_I!.YNEVU ?TU+LI7GX
M*N\H!Y*N%:FM[8B$+?1(M\:K7T^MVG+8@A,(5%A?#%M"L!6V=0*^#Z#64'LY
M$.6%NL%U&9A->?509>&"KJ5%8_@]Y74!O1G^,:6/!]T4J^NJ P^E2QPL>F7R
M$Y\EQ8'HQ3^#"?CUO@!$0Z%,)2KQ=3&* VFO@X87Y:QVEW&_'$'"(Q[D.YUX
M:9B>Z/UKWO:KO8V2MOUW]QL7C=?6&69<>K1NVL'^I"<VT+0S]&O*O7<TCXY0
M")6>/)6FI^TX$"H-2I'P08^D=!/3:TJ\E@XV*0PKWZH,TRZ6P#]L%TI4]5E7
M$YJ3>B;HWIJV$JRV4+/NHVMXPEP]<SR59"9?.8SC\HLCNV]BTL&+7B-!V+"A
MV]B\_/S +S! QV:DNN]2SH]T"L7=)"-"G2<[P?BZ(<^[QSL)[1R($#"5!2]3
MPVM'+3)-&0:@+)T^7F?J-84O9%Y*=+]XHSC[=;.#Q_.E]Q]M91T[?75DS2)$
MWH;5PK_S3Z\L^3$,0@>UB@@<B$3H443=<@IA5S"4U]Z"J/ED[<6IDR6I9'/U
MENRB4H5OR=8-8;_L/YKT8ZN4\O7?,$=-N19E-4L_)!^8@LT0?@)N5X&66[B;
M<R7ME1@1M"F";RQUDRV%6B^6\#_SIJKO'K+I2L+8W3C_ZI[.>RME['VA@[@*
MKNKOV%N./@A63*W(.#GBZ:G%4/.AIBZ*H]+M"Q*V;+'AK$&FZ:V[=HN.,3TG
M>.WQ1VK]W*#-?D@4O%U/GFKY7!TC!L)<AAM.47QVT56,C0B52HRT,S:#:C?/
MQ\U\V1HP*3F4^/#ZF_LRDM/W/RWF'&_*1T?\-"*>Q:2E,)/7^SB02P5*OUZS
M^3(8[A-L FEG21XMAHAM[XT(2/J_V'O/H":[<.\W/HJ*B(A2E*K2E*K2% )Y
M%&DB1FJ  %'IQ!@5@= 2!2F"@(" @A#IG0B$7B)=1*2#A!(2E%X22HBD<.+>
M>\[,GK-GSJ<S9\Y[W@_)AS63=>=>ZRJ__WVOM2XI<488W22[)M(Q>H_HU71]
MSN31)SZ>*)J0B$-X,SN73[@I<#Z^I,<#X5$ =D%(+TY[9HPR/ZY=J\E<O)C]
M&6A#(?"CQ-O3^F-8+N5+Z+-40N0CA5'-OB"'IHAVLZ%5E=3GX]JI_B<2#,6H
MQ7S(%".3;$C*+:.'VBOI-,B;IO.S3HI._ETS2E12&-[$]#1<2G'\.4' R^*D
MMJ!J5LFT/='H9NC=/Q& _MN<)P0XB:$2&:T9M&;5"JJT>846'S@?4/J;2X8(
M57&"X#+9S&A<_Q2UI4"HP2_,19X/ZBUU 3]2'?1>UA14"03YBPB0_>/1LJP;
MC+SR/@KFM;X6#1S'NG$]9(\0HSEMYM1B[3=U/Q1A1"&7(>Z]J'" !MA^OI#[
MI%W",_KS?,JW^<$<A5*L6LH&Y\C"M#11(88PFT_XC O-3R'9L+.!"H7]@DJU
M;3H>T2R?XV^N30KOA@6#RI?6>9<4B!UZWU_X.)MKLT2TZ:?CD"KZYQ@UY*N$
MI9,L;5ITQ]4G=R>VOWJT[3RZ>5=_T:43(SYBO?4?\E0=_%]+\(BID8394NG/
MD"AW,U?&;ZEXG_-MW13I?X*-ALXS.Y_MQ7:_^I%\<I'40GBS=O_I9AVLDB/!
M\F 8TP)[=@3"L:>!O+1C8T*G'&O#6%8Y\"U[I9/_+(LT^/[:=0A^41D1O2<>
M8%T9\:^=!XM1@FS/E*-)A^V4<(4.&#;&M3E)1=_Z84V2@'=J@U9%P93"=&:O
MY7!!35/U.[]$WH2*A(]B>CG+J;\Y#Y_+#)F#=$$],NS3GKB%+0YO$5<%68_K
MRZ"2;K(S]P%>L;;$C<[ D00OV G]2]]3Z%<9,=:/Y%)?-7E(7.+_,*[V0P4O
M??*&9/V8&C!6S2H"\7!=\N8^8.]@V6ESIS.W54_T;RRR__G_8Q';OT?OT[C!
M^X@B]WX4,&25H9T-QB6%+]("C'$8C8-EAWDP;1CJQF"&R?/&^$AG8>K3 3PA
M/L6V-K!XQ4& I=0GVBXE2HWLT!-O(SK79DVA=,Q!%#=Z^FP)^)_@NS2/&,SK
MYM/0QH'USLYZTNDU:(GMPPOU4:?^E3U8:=U[QOV8@[SRL2:PLB6FJADC*TVU
MB6=HE;22A/U9GES:?.*I?XQA,<<5!F2U,?WSG/[ FN9B3\R)E@N.3A@DH_S;
M+IEG_I,F0I0<&?MXIVB-)9@?#*Q+;Y/^A_!Y ZBG^J$P^ *>^O@SYSKCA#PY
M@.(!D7Q1(!97_*SSP2G\LC7"QS8[)?'=^H*EZ)N/PT5'KO=U8FXSS"D[$OD1
M I%U,<)6QSX_BU7&ZGQ,RHEH[^*W:G7Y1=+4T0BPD= ,LLXN_'$MD)9S,[1(
M;<[@%DT$6WY+_P?'B7BKTM'>%*LE46%T\;>-ZH43A^5B=&U-FGY%F!XR"*S#
MQ8.J:KOC)R 40V[*[R?RD9&Q'('@6T-2R_-ZI[O$],;>[>5G/,#!I23 0@P#
MB-.>]AN6>% YRM\!/P#TGUTS@U(CH^(^^/J2U_PMJ^/7CHRU\'"^@6K\NYD7
MD9P3P>=IN]'!>B$%RPY=6 K;N=^<2@KUA2.4(#'MQ'<Z"AT"41 =T5?5L3?[
M(:<F3+.\=-@SQ55VRYOYF2Y#7&T(NIQB]KK(V?K)2/&/XL<,C)NMS?UATX(S
M-ZT&\=6AWDM:,P5T'K63SSZJPLRDTQ]2GS^Q?./H8S)W^=UGFW?9OWF[R@)'
M/G-8#W^C($^2\RX:7=F%:!JB/WF2J$:8R7CKP>V,N\P.;!4L4LU74JMK;ZN=
MV!_3<AY<ZJD-\:MP=/0DXCE2U,/-G\R+O)Y]I6L/+0;.5^7T^!["<65;;$+H
M)D*-\:Q_C9OY##96N=_AX$X<Q]=WI,XXR@',U*HIT@NP&IO,7\]LR"\O[5=T
MOH:"G;W6HO1E1J7@6_%M[;L_AMY(N#;>5NG,>T[T(GPC*NV8<22JF(_V 0-,
MIC+7SJQH\'U AI,T]3=VTH,329KPV <<P\; 6,N+^P!K5"0GO+J%:X^;L%%L
M\CC+6(V/BV_%K9A98<(?@>7^;_N 9#QD.95UW8/.]:JL7;H]=Y8+*%Q T&D
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M:9Y_B(3[-.DXM4^G3AA<H>:G(P*.+J=-8S]P6BY3RH>8;)[KSSH)2FJ0['V
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MQ2@A"SU P+<D #./C5CR0\C=;9,$G1%&S=>UE/[.S*O'7.K QYWXJQ8#_]$
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M6LN=*?P0@Q%5C>:;P@^+[0S]X5</*^:&]]R[JW2X4@>\ N,<[6=:>,/.MO#
MI8^P7(I,"QF]LW<:;#_D.4]_'W+VQO#O1*U#VI9DOII-F9'3,W3O4;<:W!!X
M5).V4&Z?$A!;J<D*WP>T"C4]\">3)F]*"W2JEQ7$MYQAD-IWGSQFC\3GQ:IW
MB0P+*2 S#E!'BH1>($W*505-3'/YV8&V _[.:1*^#W.T$:>KF+LLY!\>M!&F
MU5U?#]-6S$[&DL>2@^@8H6"_<1GJ&U.)=%47JGLTHAHG-F/<WW=H60-\?.:\
MI=1XQ^8+ZQ?&*QD8"1 5@HV'4>M!<)P@RL7L/PJ)'/UI3!TV^\]"(F7R0?L
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MX]'4;M"I=830S)39.5./ :#:0A;V%C6C=+E$LM399J9*]HJWSK#95?M)KWV
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M,XE>_I>K;J,Y<H39PKWX"$W0)('^ MN6 #5V.5Q+;M:UA!O>"D6>7D(?H?[
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MT;A%ZOG:'1Y.;ZWU3!2+3JI$^[$:C^5+N)?W6&V,4R%G_^8T<I @K?"3C,?
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MP38'M"G3+[K$R]-ZSM2F3[?ZL/,I5&-.]%\;F88SBC7C(;7/-M=97$'499:
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MVLA)94FNE3>,44[74@\A8L;*!34>U1::N?GUS#MED4:KYQO<7RQLH/= 1[2
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MN](YGZ$&;:C7&PGXR,\1T!25VXDNF7QT2K$T_]S#V#-!-VF08DE &OH-!EA
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M8ISV]_A)C^!.L3T0+K=A4_U?>M5/S]GH%98TXN<>B QI XLSM(=UE IG"2)
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M= X7_FNG\^.BJ.-U?2-JQ[=?X5'KS946W\/IFY^!8::%,:#$B*/IM.(/'T&
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MW_BGRD3.34=*)TR-;9#I3*Z15^'^6@O]^O[M77%*-F&"$WAL\/T7HCUL>0Z
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M?-Q\P9$R,BLG_$;W@42('*I#+_\LM.L]%L93.U@A$A#,.@BH*9[/<P*BH')
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M,:#UHTTO^1H=;/C5W.'CD65*B_%2WI=9UJ_9=>'^BU3%F[TU%C6Z;AL/*>[
M*E0;:X/CXTI[0@]@)($]O/GV5CUR3)C?$R->G-AQ+[/6^623M/V:ZGN;*[4#
MZC8(DXWE-L>.W(E'CYY9I5L;>S_Q-M7\0VY6:VTI;MPK\E-S)]EPNUDT.<'>
M[5FNS-/TTIHJ@2A!GNR!-G8O)#-[H20]5C)0RGR@KH@S'F1;/LU!&4"?%1CR
M,V9-OP"WSZJ]0"H-QN209B'%QP7\5.>&/_DFU%3NG##>9[:S;2J@P#($P@Q3
M@UE6$NA;9MPCJ#L=B>Y-731R<!E3=E5).%5P9O10.7,O:_WI"Q;BYDQ&9ZQY
MNC*0^Z_Y  ?KF*JID)$<(CG)@Z7OJJL*7/X7O)&4I"R\8$PVWR[9@K[BRMSD
M\?=:IYTF2 5H>1^8=H3KDS?ZN5\']*%^5+)@OOTAY;YL@IZB6>:UC27H0 Y;
M1' ,S#Y. .G;,@F0DN5R2HS<">T@F9+VK2$V_UC@DF^^^4GUO6]Y6(Y*QXI:
M//FV-\"_VC_NF8/QO1LW;4E;PUGFSQK7@\"X#=525N_.X26%J3A2,]TO9WYF
M2P\- 1KUWQ;RF*HJ"JUS<,M!CW+4:T$NDBJH'%/B'DYO"8I-41^P,8G]X?3[
M=J95W%@::WG)NK:F'[SXJ+:^OBIMF;4X:9)"FUV<A>R<0W-*3H)-!B39RR0%
M/'JDF #?U.*A\@([:+D0(\;MJM9:E)N8 / [A>1[K_ 3&$LOYCW.XSZ>^@SD
MVU25?HC!P])= CW.F1%^"[GK!'A3<@=,M&,V.Y8A%FO8<_CI1"Z?.4-R02JN
M%4LRO5?2Z8"V1I_9J?M^KY/\L+W%4*?^)4I:J;Q,3J*O</'K7P<U"_LR]><W
MX]B,:P>)&L9(Y)'$OTX6,N>N"&B66FH6*42=SKC<K9B@IW+R9)+__3S^XY#U
MN"UIM& $ZRDG!2.&/N6I$.'PAZV!_(:JHPNT8:6 2(H+TU&S(_&I;$7Y-V<8
MRZ;JK"99]?1E,YK9G] : K+3+\N3O)%:;P'9!']<G4!';(6XC,*V0<4!"QH&
MD4_UV">8?HGO+B*+9^V$<KR.XQ93#6?'C?(D9%;Q>-470/Z8K X-WPQ^C3U8
M'GA0UZ,%O!?(: P@[M)O+Z]DJD<'9_P,$/6V>50FB8,]CS"Q?V@"L=L5GJ/B
M#V/!N,H;LSW.N!8K$"J'"HVMM6?0VTB/JTVCV.)X+T-9XF,EH=?X,G+$BXG*
M^/?&K>][59QGUN-?[EM[PUI/FF=825<><YH*W/K*"Z6AG!K,43:HF)G<@(V1
M^BMWB%$9S;Y=K\W QI3O>S?M$!")U"S4N#*XBA09,9;)N5':_[C,4F+*<L!;
MPD"EET:TL;PUV>],_H7]2B:0<E@/_^F[51RP9<P^^-)BN24?39'0YT-DFMS^
M\2#>;U*L[#G^W=NE0 N5MH+.+SSLNFN;6U98]R;KQH6 &LLE^#UN*0&& ]0.
MS&^#&!TW^WVA+T0ZF(3V[#/W2_L5*OLUH>&;!CUVQM_[RS\-/5ZS.EQ8\V'*
M0E[(OBXV2_3G ;8BR>F3NWRG?!LR1EZ$:\2^2C149M]ERA(CT8[X&_5^G5^N
MN>?<N^IT;[I:'2>G5E8H:1E#TE,S')#0'#F[_+%H4=W[T42MV%B<)-N,>2MZ
M#+<+\($P/:+1UP)EPV.^>/H_HWCIK%]PBY<Y?V;XX/G\;C^_\[&#OP?/%"U.
MAI..N=_*H4.:P$?0!X!/-.2K4>U$2ZP$2G^:M;D)TS%A-?79]*_*@IUPMZ)6
M.B+5LWI_?].<RW^]AV09 -=/\G%RT-01/46F()LF3$3"H_T_$8-AP.- A&_]
M049V(9UP%'6G87/OU9" -A>E/[6JZ0T!#Q&.+;I91?$YU_W#'YL'!@K(?ODL
MMTL?H@4-P#9>0.O :7AR)<NW3YUN_["<^:B8=AURN\$9I=-8K\0,>?=<+D9H
M,0)Y0<?6UTXFRL(NV3_*^V?]3T*5/,FH&;?'DW 0O6L,%V$H\_K:%T"L*>7
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M>E2L\B7[#LUJG_=,5;JE%Z6=K/>V:-E_WU;_2NL2@ =\K%RM$1Z(@H5UE_8
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MOUU5!*;%!/;T5!C.1335G(--RAHHOYW)Y %]2W:)JZH-2\GCM+L74$P(F<R
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M>O=?2,UH1;BO[HY2T4"P(C,<$.63%:<'>*,+UJK6#^VI(IIX&D$4NZG89@:
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MY.)42&< L)N[)>WNK!6P!D5Z+?(+_A?WM@CZ'DH_QD/.F\0OBTX"(Q@ OM5
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M.],QT3,)>M64@.*[6F>D,'9Y5!U2/CH!$- -MG1H_./=H9!A74SW2^I=[*Z
M+P/PF2Y >3OIP4-5);N]1Y,Z8M24"RGFMA5FQT1J;6ON:Z3Y;?D9H..\^959
MI7.Z\N-QT^>K8SETLA&LT KD4C(9M*5#2<VG\'4\LQEO?^'IXZ/\ NYS*#N?
MP-1#SA(22E65REIP[MWR4PH2Q<YR-[&UZE.<GNI1PSS;-3T/Z;J&QR2O;#;0
MO,"D*B*\ FH7V(JH9(L V0$C9XG<L5E:1!3K(@Y,<>JPY4A9^JY1EM'MYQ;
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MR5XIKGR6\1\A DO_*PO,J"\>H0S VN$:IGN]P^^"': H4 F$&M^ H'<=+F
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MZ9^6.%5'B!F?+P1W&9H/+GZMPKV[_Y\J8"D*F!KRFWVW,FY,@V<!.Y0QRMO
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ME\:+Q,'IID7W:S)3)]U-OPL[G1__,?4\ZXCT)T&5@GYW;ZG5_'B#&M(:M2_
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MT*_3YRP+<XF*M&&ZM-S>5K[ASZYV^LO^XVPV+YFW0F$A9?(34TEKP*EN,<-
MJH8DVD-UPAF!C >7B27*.GV9&<Y=-=!+PSCTMI%,^^YUMYFOZ[>)'.2) +V)
M[(L5JW1=[I]1+5?9$JRDN&;=6ZJ]H-=H ZP:3WEN;M%'V%O^)7KQ85-JOFQ[
MVONH(6-YZ#%6E!53!Y_N'0O3PX>>>M9[B5GG[%(VD5WYPV;CZE#E\HHO0QKG
M_D!Z@?./K[HK_QD//=H;G'R@-[)[F>+RX2F[E%V3L7XTXKZ#X-71"S6!NU@+
M;?Z_-;&-GP]O8=(Y42Y!VIN@B0[9OHGF-_/1BYEY^@B$^ N +*.MXYXEC\O4
M$*-,N1KR0A6!EB%4R_GR('_%&O!-K,2JTR2W"-HZG>:?>;,([V=1WS^/#EPR
M:L>195LF;/&R(A[U"Z-C4T64G%;S+6P,P:6,-Q2^B&W-[,=2@97C_G5%*+#?
M_>+#;&+J _<C-K8:S: #%+@;2CP4^A19<[62HOH&19=5.*9+$?QI&>(&8^>9
M#\-@#(6&U!L<9U\95!RDLJC;J-,BI@[AP""Q%"7I>A26Z>"ZL;<Q@$]<9^^E
MN]*F%EAHNO2P7_Z']9ZZW''-UWC^SSXB^3<#F;+?E#G3BBC ,HVP%,IU1ER6
M66%B]S]K2A@VBS#%_]PKCC)S$A[/-?72/M#",L7;[AQ[6O^$^:0^(#FZOA_S
M*3E0?N V1 'ICRSQ8/3,)Z][E*U54MT7*1S?4O=,\Y/Q^&L5F>]><00Y-.5N
M#WNON,I"#<F\TCGS):%H1,N?7\BJ>G1X<RBV=NC!_<$;!N4>=JA]QQKN_+YK
M)]9D>7\NSG8+:8%P"#24C J !U<IX[Q@]L<!-<30(:X'E2T=D*U50UA5SK?$
M]I?\49()"8 9" =^KHU)]Y:OKXEIY0/&J@XU1-_.TQR^,G!<95_MJ.?VK=M5
MX\3Y/&OQJGIC7+1)>POJAX#FR)2P"HS 5/XLTPM]'6/2],JO.'W(<-VK?; L
M> ,S]_-85&?\O/S"&L_B8Z_.;# 2&PY^3+CTN_A"MOO9[5TU<=^59ZYZI0T3
M!8:JKCOEJ2"!@+1<[C ],MV>;-60LY=ABN>/49]F<Q%424<U$#ZSW^*@& .<
M0UT-CHUX'=>*"[WL4O0ZY&)]]IE LPHUI*48+%-##O8*EJE6,S03]@D#WS3U
MAMA(;R=9S8=V(M_3NY7?1L$4$+H:,GH*."^$S6E]!=5OA6I("N(]4U+&V 'T
MV'VMR([#)JDA7P(\%#NPM_/FO%TW 'Q3 4SERY*A&U3,$J4U/$(-R2"*0*'<
MV$\->72L1 WYU1BI"$_[UX,Q5ADZML,7M^;IP20I4J@:8A7VM4)5>E)UJZ1-
M5V%!\%!#7G%=LJ?4D+^EW$\.,C\A8UV=5.UL8%Q?,YJ1I1PUQ*3@?WD+H_WO
M/ 7&/TDXI88\1DDUBGTY;[4:,E.7=K&!*5P$6'VRZ2^(X>Y49G54WN)WDP#X
M390:TE'ZO[R&4@W\O6> IWB&L/%LPD^:*79L Q3D@H&JZ455WAS-I4%U>J%V
ME/*O!@W[5^^H$"'_[>?_[:S\-:]_9U[;WM'*S"P"+4^L$I46B3[?^N:\@?&]
M@X='C\-?S^QZO*JVIG0S9A /#<H#<LS(N4,-I-XKY+&(H8=Y%P(J+ST?&HN)
M^=#@>*Y.>4(-69$C*%'JPY.@X"$P33/%M/?X4-EEL$N0MM4+NS3<Q+U@<O7$
M[##^P8AD^OT"\6%14\ZQ_@OU["D[.;[*R,\F4KQ#_F:F:D.M5\[3S76^C^AU
M;<*NQU[3H:\7'>/FAC9OOK>)%U1A9'RU\_HZG33HW8CNS;]0#]F%Y-C^LOZ%
M[^F4-L\YCY:T&Z3=((V4]Y[-/"?Y5)>OG5DOR&E>^Z37\0#'IXC6\&9I1W7I
M%GKQ$ P^],D[I@0(/SOAB^CAV;Z'Z@#!9LN.SLSKWLJN5VS&!0.*DXL&G&S2
M37/2T+)%7W)==T#?0ON6>!'T ER7F#JC12Y1L:D$)M?$-[TH+%H/Y;_U0<GX
M8@@E1X;9=Z2FKE=DW?BE\%G.BUIJJBF>(+Q5E(NTL9_=FNF)M!%UW/,*MK2T
MC)YZ#2P%W0Y)C./G@.4@T4;?LP<S;'H5M^_L4/?F!?V@H, /KP]8G0WBG?TP
M?/2)^])"GV,]?H/^W$(':93!B:/[_Q,%\?]6*.\=A1J!L<_-5TL1J8J 4N "
M>+(Y:#W'.4" 08BR-*MQ(-=<,OP@JA+MG_@^L@L]=&1!Y(_)>-,]8"??UR!,
MLWU)K<O%I5IJ1/ E+!>&4):K(6'8)-A:VPM_.QY[>)RG2_7VK"I(;T7J4+?>
MZVJY=J+W(L?9/:1@$A&]7^$N:##3/YE^(*_39/JV/=%AV_F^5PAQI\*H5\,*
M>@DN&/EZT %+1;MN_+JYT,$TG@] \W219R88YK6,/#])26M#@[Y14>4$PZ*/
M]M"QE:D7I94-7\5#,<RK);_1 +WQ8:>^Q[U ]NU7$5-#]?,:SXTZ$9^U>XCL
M8H?[$O^US9@M,R0-1/&XN%:FY.ZX&L)%KF#H$[,$MFU G2887.JQQXH&J9K7
MNSW/4D,B)#(FOTL- 8\V>JR'<E5K.4 MP-\$$A\K?E)U,5+5$.^CI"L<F49J
M?<=09L+XOS,OVNIH7-:C0 VYJ#@-ULJ02<S5JL$295H "Z"2]56K=;]%*AM:
MN<N21#"^MN3C;P :# Y4:219'$Z@0Y,ND=LL>FE[[GI<I<BD+*KH&;Z$ZAXN
MW'U1V26M7K1W-_#M_*L+\G\S0V@<4PO_]:2I%''=.4"#./]PU)3CO$6 L1+C
M_NFH:52!T!\8I';E_.-1TS?UW#EYU]>CIF^ISVY$IIX:'W^D.Y(NJU+F. ?*
M+0E8:6ASGM$0<$D-"28FG]+H_)]9]BZF1Z64N*B<R[C'8)I77=^H!@8?&@?>
MA#>Q(]] V[F.28I]J"HA[#TK7%_Q"?F^6V$(DVVE*4M4JSZ \N>+-CEJR,IN
MOE$.4#6.J^/:4,KP69W#RUB5]D0O/Q!^,7M97FQIN'_\1R$97#,L/,3YF-A^
MW)LOWDZ H4>[UP@OJR'K^^]DY&7!A2_$)3;XDOXP9:RBNQ)VGLE-:X/56';R
M5BI.LQ*YC7NC/H)> E*:>7IP!0_-6V5/#/5@2(_E/6Z/!0J)66W1S $C)UY"
MA( ]E^21%)FRB^/WC"[YQ*85A<,^4&YJM,(T%/1H&=XGR<Q7DOEP$_"JFQ2;
M$(6L09X!4&!L6W9(5?7C2>BY/G$ES<JV;J*^C@.[T+=3;$M6=&^=XFJQ#J<K
MIBH6&E3+A^17-5ZM+3"SE;F"=P8;MX\R5T]J H26)HRB50==5TNC2X)E#6F)
M"P[<J0KSG&6)SNBR,YZ.<96-]H8,S1>Z$M9F' TO!&\#T+I\?I:6WV"!X@59
M)^1U?< 7"@@= ^"G3KB'7XG_$VH&_G]KA&9Y$*G??)DRC;1J$C!2H,^5H6M>
ME@6 R&:2 2ONMR%\0Z?)PX22T@F35?1J6D.-9"K[$I5X\A0[2GE@>T$O-677
M%ZH8%L@I9#GOJU":5@J=/!(C4Q!MYAOZ(X=6[G]''12'!K#G<X2!NP_WS*7L
M8@<,>9WNC[(:^+FF=V[(]956U32E:BR!S6*OB[#9DKIMJ%-J)B>1!KA,<9'T
M@?,Y;'%XT%H0,R)V %81=DE2\TN'S@X%3.@"+I_4D-OS<H,^6SM3J E(]Z5B
M\'B2'8W*L@-6@A<Q7FTI_*1&S_*C12%C,KL2G1BTA*Q0,$([&3]*L4D$0#!M
MB)]NIR?*ZF\KT *7J^V,K?VDE\'GE"4"Z)IPG'\'K928>+2NIO<28[ LZ,,'
M93J\EEI=/^N<XQ6VX;#@V)7;<]@XV I%H)0I *XSUH!KNL4,*ZD:DC0WK8,*
M"F&47 XN4=:=DXEQ_JJ.7AKF2&]KKFFOSVR;^=9^:^K7G(<N*CNWPDYWZ?VG
M;:+!%TI7->0&C-3)X:TG.7().*F=JT<K5",KVZXYT#"&_5E)YS0 UR4@1"_X
M4^*H;W3]>C_UVFD$5MP2G_H>PE5!Z<=^V[$TW$VJ-;S5*35Q-*!!O&_Q(^4[
MY0-F:-X251?O>X*9Y.9SF=.ERV'^F,+A[=*EJ3F:B#C:O=[[7 A6 )@)?_@0
M[M0^WM?H'AM6ZQX:51E^>=SIH!,B?J[B]SFSE9[4N@4Z=\<KGN/DY5-9SCD3
M-7.:?_GK.9C27_\+5,#]9?_!1OF4J%JY1+Y<$[;+I%$\L8>$XBDUTS!"U18P
MS:_?]4<N1M7?ZVJNV,^9WQ?P.\%#F6\]QWU#273=(G2J>DQ([M*R@Z_"TZ&B
M'&(TF],1M%*2F:6$(PREIOSNZRIK$-K&U%9MQJ.]I;@;SH'%C R!KNYDF87_
M,)=Z]X/;SI,!+Y=.Y96A%IX$A%]SK2T^.S"Y:$X)#:X,6V [%:44?=AQ1-B=
M_TM.'*7W8@-E5JSR^#)V AE.&N)5+R0!P6DIB_4WG/-63^:MBA)S.2U(,V&=
M[X] RVG^*#;8H:@8'E/DM34'EJ0P+$-JAKA/L$>18K0X^XKU]6CD\K<W\\'Z
M5AF+@#ACCUGW/AME7XN D6'@%KC"P/0P.#]"7"D#P'H!^0C -6[F8N;\?>L%
M30?88\)1:'SD%YMI#)8ZY(FI_,304(5(PV2X]%!&N4.^ *F',MD+)G&[;]E8
M2KO  )DO\ZVP>=A:JONK<R ?:P9Z'5>]E")O-'I\?;\396 G5@VI=7;C-QWC
MG.F)TGTR&<VA8Z;?TZRLT'DUX4:X:$=S9#H.XZR[&:[,53T'ZC]?5T,PT"5-
M15P48S7XF6_FH,78J'!.B#%BS_1?N/$:G'Y^8R9F.DIW:;AQ^F!K3*A]^QAE
MA!@T,]BJVO",06-(ZF\3 BNW$,W5D&PU!"9\]L8WSVKL]D*0L%8-L00Q[Y7+
M_U]=C/)_E5E)EJA6T-20I=M9SO:%^$'94= XMEC(V,:)' INSC-5_%+-G;SF
M$1>9<HQ-M&H#M)V=:BIE_HDI42NW3U'SUH6W;Z5)S"HY_M_GC1'VWU,)^2S,
MENA3YS^*&"2O9S. PK!$M4*[D(#K%P.AW==S=_11-&#DX=.0)8#=HA(/]!.L
MI-AV7YSOFC"9T\F  -,A='/0=TW5='IU_['R81-IUBWL)@Y5:2*'2])N.)^K
M(%F<<#\_&"$2W3GEXZ4R6P XF<U(CJ5B#5:V6@U)N (2H9VVMYS@27-I:5 #
MQ=ZHHB$P-! I8H((F&X5K0$#ATL^+EK3YCL?"F &:LAY?&P[R2*O[4=_(6E]
M1]9(3SX>?9KE'&"9I(;8PT;N\23PAQ:C#$J4?+_BJJ2JB"C):G'**$3J..^N
MG)!5\)')I!VU=&;:&4:_[]C'86'0"LD6<0J9++MO5RSAW&GTBK&Y68IVY )Q
M!.R(,F"14A%WC9GU10W)4OR8@E+&JR%8DO9FS3IN>'K"W3#_[9]=[O&7_><9
MX9,<07J3NUI925J.KQWI3HY@5C/K2.WE^-#V)RB3B[5EH%4[U_YY0P_!HV@P
M7*.C.&^3JYI+AL>YN=5\L] VDAF5$XD5/[!?#DN:YBZ3D< \^2X%G..JKSCS
M3@VI<?8HO-10S:#&5#6Z")BZ@=Z7C3($/*WPFD&N1G&"5Q%RZY;!L[0F\GS*
M?%5^/II.NBMPL?#KH:HATXL,$R43%FQF(6.!NW)UZ_OF>*L(GI+H(M@MU3I\
MP_%><@0&,X][DOM6@T;9RAG40O9\VHW&0'U_FT8";%.@?_@B+%[A[9 C<)>T
M!9GV;SK!J(@"LWO+7HA41JHQ,46Q!"14<?C=;=CUA,W2S@3&9H*CU*:(#S75
MQ /OOU47Y=K3:^AG/M9G;S_W-#76VLV[;V?)LU[[AZ8GZQI9]F\VS<@]V#NQ
MU 9A@V=:$D^'<%F2WFF^!<1*+5K]LS0.QC?SG*/HX8'3A]F3KR:"4P7KSF</
M>XIHVH[':W('3_;,/]PU-GN88Y?<91;LP6"PILDV8X(*Z\;4)I.IO \]RB>D
M_S" 6ER-_/Q \EG@F.JZ!C_:BESC:@IF^4C24A0695LK^&J('@IN,N07N/-*
MP!N#)Q\\7#+SBR>-3GZ8R'Z;4C88A#(9NQM#+! :.7(#YX<*>>]A(NNO41J$
MR\^BS-=+D$FVD;QO2#WW4/0<-*!C[G+$S**M!G^-S?[L(]5M?7A^/O0?:[%H
M>(4IKN(#?O0G6J_S$1OK*)X.B%)@RH7KD![,SVK(LA>?RKRRAM-:!^LG.7G'
M2B9"#$[XGO^S7>6_MB&[<0J#DZH50WPA3#<<N50-N:"[#D"#:0A5/\L9)ZW=
M;\RN<UU336,TLK!VMO&+U'?^7QTP#2'?64MI:]*>:G1Y#%Z;[#PN^;ZZ0O/K
M.JGN]9.HB+_A)K9F*C)/<@H*[M!56*6!AYD7NP=JVY!233A@4>&W\PSMO"A?
M+*$DW@D)_$:4*4X-N9>FJN&TY6ZFI:NL.Z<C4S8AP3-JR*5&\+*BY2M:8F<"
M4U_LW^]'X.%X*@ABW$.T3/X-."KKD;8.#3$T'G@]=W7?HT0!M&W/SRD1%)O,
M/;:ZUYV78S?D=AV75N6'NC1RLM(#AE'FRUBVUHW[!2O1PHKIE?B ]F&X'$KJ
MY.EK7I9V2P+J/_]-,Q/XJX?E1OE24X%#?H@])[%Q"5]85G1X*B+8$P/0%!X5
MRLR9P9:@-76--(94>Y[\H3=PPGP]R]E+$+A,_C.X3H)\KF&4G2W 4L(Z\.KW
M1<MN*K2+NX.+&;6EGN7A"PO^"46Q9.&UMQ77)E;YA/M/-95-7GLSYVN43;J+
MC@*LBY.+4$X'C?PQY$.._6(-SB(Y]T^7O:ID6$Z4E$\MVN91"L(6'>[RARR.
M2-20Q#FRXX%WD=8.G8=Z[+S-.SA'679$BZ.TVUW>+"K9X=6VG52E([SFAJF7
MJ>GA<S0J+<$J%E]PVVY_D;MAV7^IEBE_V7^.D6)5O+PGT'_ A**A@HE_Q 0\
MR9S@EJWU-TS(E>#U.R^^U?I'3/C@'1JCW?0/F/"YS1Q:I\$$*3R^,5 13C@$
M7AU-B\O=([5M!6Z9F_0U6HP"RR?A1?B;K8OEA^I]$5[K<7I=!NP9>$@IBAY_
M7\;-3:N<R'+,/O2L,.B,T,1E7I9%1.$<%]=Q7JHA=;HBHJ15]@(\YWC=&:<K
M\]"PWKI)J [) B4[/H1/?.ZZD9ZP^=X8US&3(T>V9C,'+HD; _A6.5T!4+WW
M7*ZW]O!7 M :M.7=>0U< ]V+JD9:R>E.CTK 4 U9TC4UJUHM]/)@1P$ZDXN(
MK[U<)_V-FO+#?9W>WB*/+W#\+U(*)A=#^A#TB(JB<%^?YMB227^B2&_H/<_?
M6[N_J._'LP%=ZZL+TE#*?.9%[!U>S4*J;:.N%&CF9L;OO)99%*P!0H-6%.!X
M71&#+O8H.>M=">JW+1CY9@9MZG7/K"X8"G)?T5HQOBL\FHNX;4=>&90Z[5DG
M.?)"Z&T?51XZOT[^C1K2C+1+NXV 2QID-#;!4./5'4:+E]: )P4?6/Z@VW.5
M;9HG:T.@?V?GE4G'KD>@1T<]:V!8R+Y&SADG+9,:9&6YKN^UPZX(E[F:L13!
M\F?(S[;(*F2UHT:["#I% ^C'BKT@!5U&N !:%D[0;1,)L.*<)H?63JAV9+(U
MDM +!@<\?8(B!!:_'W?,JC/!WG .*!OD-IMG\+V-6X-V2AP3J14-UFZ'NPOD
M:DBW0@WAOXWI$>HJEBF8CCB5Q[S8/0;6#*0"6FI(&+"D66HZTIT2R5L/NA*]
MCO?D^53?].F=JK0GVAST&K+RZ[%OL-X=](ZV39#-4EF9A1Y]0J>S[+6M_*FW
MB1:^O=B(IO/4O5STH4KY7_?,_!VKNMK.^%&2]JNS2RF^OI.T0_+Y1N/V0F6Z
M'-$V;,VQZ]8&8X_*B?-U#X*5^62THZ\_)FLPRFK0Q;57[/BC\O'B%)=E-MMM
M@)U=)HZ17U*L4Z81=,N$)'LV=0@G6)6-:>J^H=)%^??'N>Z11K%+MI:@"X.\
MSI,XL7S>4M,AZ"GOT,YK"3D.=TL\BI%^J'<:H9U^6-)!462JWL/J<1UJR""T
M;3?0@JT ?E;\R%)XQ%:!^GR;V^S1UF'#V4OG696?^^:W7;ID;VL"IFH[[%5T
MKP:3W\C-9#0!%CPXQ]0*NS;?G3CZP-/6\3W+X)-+=!HP@X3!=XMAX#9=A6%Z
M.\^,R=\#;I&L@(/NKDLF@WSCR_$<$3TW1[I,D/!@V2"?\S//Y354<INP1XK,
M0RU36*04-@O$Z(.]!*;!9'9$AH"Y6K&O5G'F\>V7=4,#G+6E%;8@;NA+//'<
M?RP5X#+/04%+9)L:PI6W<WUKJR88%I)E(C4DI/ZD%-HF3-F!AH%'+F'F]XEM
M@%4*JZ?].WG>4LNDJ7EKRU,LFEGX<AI,%Z\K0F0-6Z0N^'JO;#'?KFIQ-51L
M!,])W%H<2-^!7B-8'?R2EDQD:+K<JC4[T@')-68O7GQ8H(GUZ/KW1*^V7(N&
MWLB'#H.GI(Y)MO8P/2'T_ T,XF330^?>$RGSL21 XOQZ\O2)'K1M\S4UQ#]J
M+W- KA%EYS2B[(=W*GV%Y=]$V=Y"; .#T8"/:'03,/6&W/Y'>]<>U-2U[G>O
M6A\4HB)0>9A:JZ@8."VO"D*.#P3DQ"B*O ZD52D$A!R/(%$2=D4%!#%5*SE*
M(14$1, (!.()D CA44L5(22!( D)5200V5$(&[*S<T/KN3-W;L_,_>/.Z9D[
M_/'-9&;/_O;ZK;W7^GV_+^M;BV)=J5)8JVLB9>]B0ASO^?/JYNJ\O+S[K-MQ
M$>GS90I[YT59?'%.W\^)S9&-KUM_]TS1@OVK#&-E^!Z,G<S$<J1"\U-*?'L>
M9IZ\^5V-=N/^F=(VWS5:\RK/5>1H')1?B6N6_D+[]7_&U7=%#H4IPH;B;:T;
MR]6HO7BZT.X NM<()$W^.I(&EK;+&NIND_D;M$; -)32&@]!HVWC]*T)W;!?
M59*[MX,SY@/D\,/>"1$!4F1KW'&10;T<33R5TXVAOM4TI,KMKW0=H:>VKK-&
M196>X3T<QBJR+3L+V5E*GM_C?8PK\^ 6)WAX\(JN5I%M"ZL:(O)OW!OCUKP+
M9MY&D,*&A.[50U6]@\_]/@GV6OOMX2;6J8##?Z%+0V;BFZ;P3\MRT*N")!:\
M@2!I- DCE6+BO$7!DM<U%63F6<;$U$@ ]/JJN>1V2HI-=CV8Y;M97)_GNO,9
MI_]% 4&\ 4ZK\BL?LXVYJW6BDMI.YQ^@'E).@$^CZTKB40?Q- D#G]_7Q\&E
M[>IC<Q(I>R0GDCA/2/[BJ:Z*$_4XIQ 1Y6C&#+&/H^_?Q.'7-&;:50;=C>$^
MS-E^+'FMFV3T<.S:RG(UCSW.[RRAV<"CVF,ZJK8-NXK_ 2P-ACPO?R1*,5\[
M[?2A275+C$" >,.>YM[Z0LO(VKXIAU3"M;!$%U6-)+E+'QE%(O;65P9\+YXJ
M]-!)Y\B&?/PPA[78=ZL1. 8'Z;X6@4H_^,VX'K_?"%PH>/I0; K">-\I( :9
M%8?*^F7=0H6&$'M04H^I@1MD^E9?2^CI55USFJI4W,</1XEW;P=6\Y7[OHOE
M27D]IO!HMCPI:\[M($E(FN@R DO>,Y2#,2YU9-"BZ:2!.^P->J,X4MNR^\@A
M:':'0J-GP-^.*2@/)#1L8[C6829[TA2P+);2<$9@^?M<JV]11W2PGJNW,P)[
M674NB/52W5%X3)=HIL(I$%<N8^-;@2I*NRB<\Q"FTU\8 8H<;"M7E0\DY]F:
M>,;CZC$?(X XGB5]W:2A1-9"HYEXY18>B1-T[UHZL0X5#,_:ORG=K&Y^,41Y
M2X+&?S)\49RS]7+&O\&H_/UM=$?D"'89O$@HR\JEI:K8%E2GUEO$ 7P]C: :
M.O4G2)'%Z>8J(LGY>)FMI"XEIFR S@UNKA-I?$6GL#*7^YKJ]8H=6M-\D"G@
M2!$;.^7,1;Y(V3UPK,4(0'4I-]Z JA'DCS429#LTI\#WVRBT6Z"LF\74M^V^
MB=6=V<E.1D!S"36]^*,)IZTCREBF#R(SS_?Q(7+2CY=C7"Z2NHNG8S6=;91L
M^5(X<!A<C03 5U51GJV^RZ KM^9^*8)IRDV(B:_UIWQP<#?%?H:767HWNCNQ
MS"3(;R:>J1R_U?SB"J.D7Q'/E.1?!WT4]:.(M6K\0'T?@M%CQVSG)<.-)HJV
ML\/KJZON?3K>5^R*:C754?F46YY@O9N@M;I1=C'E2Q7)OLJKR79O^7UR*,DB
M&7?6QY,D,@*K4 ^T!S2U/FYR98N*DL=:3?,?,>SK^@G]L:%OE%L+Z<[I<AT<
MB7S3H(MMC7#G%RB)9B8*;KD]]ED""6+$\6)U0]/?GBVJU@T%OFB\WI[@Z:'K
M2<=#%MD'@\+3NKE$&.^S(P\7&RY&_"K5_(^T[U=6)/!T\YM?>,FY58JH^+/\
MFDIU:K!<'7&_LB*ZR^?U[8IXF[HGJ71ZJILT-/50T,F3VZ[]\/I4'#L,=H%<
M59T:S$BVKSVR%CI2.L+ZD%BFMNT::W =X]&K,Z^6=C#2[HV;/*>5Q7E9%]C7
M183YT:O4IZVY$?S;I7$-U[HKU;+$&WUV<<P]S,<;'H_/G-(M,@(9.]4FR55-
M4C$T"254J4E_G==,;_X8*F\-+.%!65=VD#9=KWPDJY^YHNH[$1H-,3+8Q77-
MSTY,5;H]0TZJ-D\ZT_S+$GS7]&ZC>=^C=D[5S2\GSPA!_F!@>L"3J@M\>[A;
M6P1.F&E<0P30\\^H_LH4W4W#C:H  68BI23-9S)[ @D]+O4@K7&IFB*N- )?
MA9%7OO+"9!2-M/50ST]G<"Y["1I-*JD+_7"T,,D41C[B:P2.ISS]371C,68;
MFH7@370S7TS5X.5QJ3A.Y_&/8JHC$4DW2LD-!W?^6DRU4A;6+]L]7TSU:>1@
MN_W!8O.MFZLM_E+\;R!#%NQ?:VP&&,_HC]2=,3Q(/+$)9BN?[!-UV#K?<J-@
MD  HJ8R'N>(6]9%:QVN3!3]_'J$^:]%8]GB;9X.NP1<'&8'LZN3/IR=71<'Q
M.)M0B?.TIWY%SOL%^\<X"$/5J2LW#0!2NDA09Z/KS#:1I</\CI]0)0%]UFSZ
MQ8#4DLE@]''/-M.E]7P]> 597TM<!7M.K+-_AN?2B)5G;*7"20LC0 X; Z$'
M[DZS'MBG$?/[0R$L0YE@F*&HL^DD<L8%%M5X96'3&9?K1L 2FS7G7MHI')]T
MT?]'-[K)"*Q Q7?B)(*8'D[NJVUXY6+QCB6C"6>')K,1HFF>)O0:BO[\W)NN
M,#'R8KD5CSA)NF<$7!ZB/J_8]7@R&W:<T7CKM]#+#\.YPZ!&\-[@+%Z;XHOM
M2E6QLAZ_- )?1!J!-L5!_9+,NF&#K#M[@K;]2Y-?^44E!0YP?\C^ NK4#54+
M!K$JWD]#;F(1X0R6B#[%-GAJS/5;X[5R! N?KR#?^D!V31VA$&J.-S1"XVVU
M@2FWGU0XA+:FUKX[J^?US6(2E2UDWZ:JS%=L3Q[:T#9W_-!V]G/VP"AJ5C%,
M/RKIW&,H][531UM(R_HX@S9::6LEV5VQJ" J*+3O6+,D1; \X:P0%@IM*9EN
M63W1:MRB8+BP$LX)F&X<PN\3;21X[FQ$8^Z6W9%TOWAV<]=G0PE#<2@J<-5K
M8!=]<'HWGN-394E;"S</L^WEW?,S+IS4>3@*WVEMNY=967;1-.?Z A+1G[3\
MBV6=]PADBI6N3JDWB[P[;;[U=6_X1'VBAVI</HZ\&)\$+X+0(=9@FM*S7\/I
MOF**NO/S,-D:Q/]NG,#J(Q&ZT:0SSX #/4.O0HLV:1/OEXX\\13>NG&_P*&T
M@ZED6;_"'M,?*;D;5S<6\<3PM'SCO4+I\^.O\'7S'X [ZJ\;\0/=L2N,P'!S
MD7.]WH'9H?@ZW5Z"]JB\00UF-<U)ZURNI$PPEG49"JT4_8BEJA^9?V?8[ D/
MM52'@FT8,_(M04$Y^3/P*+UH-))G6 8Y(M9$G8WV]-53%=3S'7)W.#+M_5+W
MR]%8K4+(LE3;-K^H.M*0NKQJD #]*%4Y9_ 2V[BNX;NMY-R$RFH)BSIC>]B:
M^&4J?=]!>KKA@Z$M[%I%F2"_7$VW4O%7&^X8@5@2%LXB0LQSOKXT*RT[9YI2
M;]+TU-A6TAK$7$5<J0:_J/E[WZ2@;BK*+JJYCYW>7C80'6\#?M5P?4+GP?0\
M=2)C^7%B_#W7NLC*WWU]XK_2K-Z N6"2HE_4$KVN;P>A"A6QEE"2AUPG6.0&
MB,G@8+%P)K'!%/Z9YJM8..@1,_T3;71U;=K#.XWHCSV4]):C3*_"F8&I0:>N
MA[Y.\[522SB&;VA6NBY\EDZQ"OU,[2]DVA9=IRN[S;@7FC8X9A-UEX^L6RM-
M(65;PI3VL_MG-=O*Q.[5&QX5.=8\$+D'.)_8(*EW2AA:M_AGYN'@"T4]8 I3
M/H7_<C/[1;>J$[%)&_&\E'Q1E(ZAV4&AK8V#U9Y1-7U-.U6,E20D6*QQ9FL2
M-5.$V-9ORO*&?9::E-GR]*&S1[6^ET;R-ASAT=V=.7>KJBB)[N!/+GG8!H:&
MJ-\5T5V&1,)#(Z35KSQO);%*X]>MKN'508QSTY%13J'TM/W,<,@EHPKQ'C8<
M"^:(?PJM2? JNY1:.9OO%>S^UN\.^>1 UZVQ5!@DG2PN<6P\B)"4Y2HP6F$/
M#M]FU6),FMA0?FR$=)EO+T9"R\#64++C.5_L#W*\]J]P5HM^?1^RL7( /DX:
MXZ_0VL]]>ZFD/Y*V1TS#'O,H8]80[D:VW$D(]4H=(6K,3=W;I^VH2:$7I_\$
MFD\IEL:YDGDW<JCCJFK.V<DKYI+2.^2>@00OQPL<PI<(5ID7)+1M'"<F6@LJ
M:/M[=_C9G]WX^G8I^>JFTN^'4.#@@9=R63H((I]6Q;50)O$^_,FW?Q_'6OMZ
M(U_!XY7WN=HL56I>^L?1+::0\WX!)L==;]@= !FDEY*J7T\_;-JBG+F9C%TV
MQNT=Z+_=T_1IV9CM'FM>>D%,PK$E^84QE*77>_P"[P7&W6 >7Q,ZCIG7B8O3
M#>7I7O2"*#B7; 0^T QOITW"?T/^V'/_M>]'BC/@H [4;H%#==4;PNOUSG5W
MPEK >4*H&';QWB.9:/)7,N!]B:$3;][I1$N][JCA6_Z3>S0O"*]3,'#(),QC
MK=S(T1+;UKP%N1HCH#ITUY AW NE:^S:4N7V E,@;KD+XB*?V'YRY "5I4]2
M*S2,?;A9Y\DY(W#N9>S6FBNY<GJ^PM,(6"",5OP !EW6HCVFHDMNCF!D282@
M884PH=E#]<8$/'0N#GY2]3CM#IE9A+T5:=?L1'I&6UHVRZO25 U2[WDS[,-(
M\&F]T(MQSNVT.!$)+ /WF5XA^C[-T5"T [-4R#KONT)$,Q^&W7&[P^D>'?2@
M SR!>#IPU61*5&RD9#+%)RVJ[TZ.7= R=GWA?E0M#1!-55OWAKGE.1)JZZ=S
MG$+6-.CGONO]KKQ15-L#1G/G#TGYO3?66+#?V4BW0 Z(K&;J@N"9.P$H%MI?
M #EUZ&XEA+\JV@;O+AF+MNVU#L"E",N$*DJ6Y$ $%=\6$2>>SD[!??6RMTN(
M?B[6).>Y[N%JY3=*'WW#'HM9<XN8<K+B\\8R:?FXHH?UPR]3T6*RH0)='46*
M)YDI16 <?G$$F9=_;XYU<0DKL^ED3$()V3;%,!'!%!92PHIF#O35FPU,1[I\
M$*? U NRO?A_7_?-NC0'Q\/BY"%K2A?&&O9NEP-:B]M*%P<XM"U]A3;ZNHZH
M(7T <W?W(9XJ!U>-SD-6R-!EYE;)!N*/D!)%E!/39D3.H+\NUZXQX6%JRXY@
M_-S'4JL10:;"@K^%;"W'P@7#V"4TOV<GIC>G%! L.].MGC5%W8E0ZW3<_"-S
MU0T%*C/S73^:[S/#[4)[[5[=CKQ;36'C>D-R7AX_\Y<H!X%EG#1!%3A;C9U-
M_V6=K835P8 _QD_4C#2&OTY?'8^ZPU9LYX+R_C&H7YW*6D6S</Y>+)\\*$EA
M86#I05:';6;I7;)E5TF[-5.[03CG=SE?=J2,%]+V(#Y_3OH2\XLW#7$XJ.(7
M;RO@\>\;2G_U=AJT:/I+8FSONO_R=KYE+KV@7 T%_>JMS;9Y*M5KWEO3(77^
MW+;/ Y,%Y=.G0HY@JIN3D=,(L>.>DQS=D-Z%Y92W!I%6JTFK?1<A8="5\^\6
M-'%#(,=LYB-=:%!EY_?";=%>W >LEKG,@KOQ;P?#X^:>WJR6DVU_9N:[E"A(
M?G3R)_+EP7&WTMP,[BM>(1M'L#;416U>8"YMN8J]"G9J/TN4&8':)H(2=^H0
MI,A.[N;V/Q]C*@;F)'DI,17A="ZAN4GT&GUR"BO;EO0Z<9-B\9L.Y,6:]Z8H
MB(>CYJ01\"?H]YK$S"1\TP@\\:';&0&,B2(R,HQ CXD#?@J!3)*CL#G]KSW[
M)QOU;2,V34<-P?B] J4&#QT@S;D8@=D<_G(C\)9;@JX3F6;9)4:@V @8@;]5
M#K.,@/=9Y$5Q+G]R\NC/66\ZC<![I)_3\T"A#!S^7C!%,MUF1;,T J,4?\2G
M'%UA9@3\YN_]-+0%CYZ>GNWRLZ$KY,)KV"XLL@2\.G^>^F\U#@OI6/!F%X.-
M$4#:28M-31J4CN+61,V :18!X#80LD+]7TE_XPE3O]$2TG><@ZE#AHGMZY$:
M(_ H=!9;0OJ?_GO^:3?Y*5)G'BR 70"[ '8![ +8!; +8!? +H!= +L ]O\C
M6.EVE0+>NE3S8H2$B5^W5@+&L58-D'FL 5_1*:6+.;STT;KUC(E0B>P"?@#%
M08X73)JZV9&FN^J?:KA1'4[GM[].[IKDD+G<_.O(JO\.\Y]H-.JFNBHU^K%X
MFK22>CZDKWXH+:J/75](B910[M?[D,+$T]X5E!1<:$@?.^9= N#E_)JU6PF5
MC16E#Q_F!QY/W<X)=K@VL/'-BLW%YRY:Z6S.X8=9@@9V6U3TZ![("$ST:(\1
MF^M%7XEC"CK3U[*42=]('D2%RW8<D7\$WT)7/:.X;\J?L\G:R^DK%[_&!;_1
MR3LB<;ZH:G J08E'5F;-9XLS^_A_0(Z_RQ;OXHMH>"4#HWB7+4YR=F^V:S_E
M6_>/;+'P^$:H@_MKMCA0DQ)6577B_O3I8OGC:Z-+FIA=H3-.K LIX]CEZ&+:
M?):TX1*4IF3\FB6-BSA2ZIGI9O:/+.E]G%L@+52U^.*[+*GB<PF-6$'^)4M:
MFI9"7Y)?F'9RZ?1CB(0N=]);T>QXYP\_A-XOU:9%UYEZ:QQ'&ME;N32W.E&3
MXK#>+:NG'(HN*(-3E0TU9;(MC7W)L[2=P]6DT%KQ).M 5DAXLF$EF502X9MW
MAYH:T-N$5QJ<",\X#F:$FAX.P=*_IE[DEH<-$.&.UHJ2JYT(M3EF.#Q!-/%]
M9F]'1^^'B8FX+W/D\LVJO)416:EO4,'PS7T\_5:40A2B'Z)?@K$L>'UY.\,F
MHA\^K[NL?5T 9?Z@CCA11UW4^@V9[ZUM?WF54JGV0#^JZ6L*)-]C9^S84$$B
MGSYMD_ZA./DFWU%6=?;90RDGP6[HXY%=?,-S TMP%#.0JXNK>6;ZI,*0K9"*
MRMZMV$&RI!&^)*L8EV9L"Q59U8A[5?Q5N#N$RPQ^!G(Y_??QG"F796"KIW)-
M08A$4(ML+VNI)$4^F;YHM6]+LMX(L'_H"''$R0OS<U',4Z7?FI"5O_=J_P7[
M]S.KGU%OV QR5>6S$U682X(EJ"7B)ZV:ZD].(% Z08LFK$H3+0W@\IJ:N;W5
M]2XKX^8N3MB>L.%=-#SW^/1/#351I.@_?Q*$^^GIBS5+9 /]<$*[ /)G]WNV
M%:WK<XNR4S*RD?<JH@W7)^0XB-DFP$;#68%ZG^GZYXH!G=Q;VI2@#/15+%X]
MQ@1E_+5]NC#Y\\?'=+C ;=-FQ.^:(HW 8@=#(87F<S>2:CFRM(-M#M\GUH(Q
M"=&XZX_D[M!T?M<XV47 V>%:0@UZ9)M?KLMS=\'A?)^HAAPG0D6#\99TOEE@
M<E=OSI]K)@0N/]0')VCP!8+14^V@\A%V^C0X>\Y$':="<V NNLQ;[Q=.S3K0
M #EV8#+XGT!WP./HCY*F2,<K-"N5W9#.HY<$QE%C]T),QM20Z\3<=7E$!+V@
MG<<=//%%0]\F_>*9OX[E^UDY?ZH1I] CWCJ[;Y+7C@V<.6,_BGS.TCTT L6Y
M^NV@,DKK:N)&<RRD F4C:([+Q LC<#&UK1M-=CL8?$VT7Z&/G:W;?R85L9E=
M^K^^<5<0P1O4L%X*BZ+F_UG9:00L' WW\:^*T:<D.)3V)Q.![O;_+6]K#KQ[
MY(-1)M@"?@,*+QF!!,;<9D$=$[526.)GG_7\EC._-9]P1%QT #VQ_84"(OW\
M6ZWZ+5]^RW%N&B/0 !98+$!<@+@ <0'B L0%B L0%R N0%R N #Q_QRB^RLC
M@#$"PQF@C;N+!H0C6%A?>ZKG8_U2G0WB9 3,J04JDHYY4Z?0$$V7 WZ&"89<
M'=YEOWYIOQ'@&@$.7YRF8TRP'^PTW#FX_U-BBJB; S[).72-4 X[HUDEH/!K
MO'K""+Q=9 3@E^P24-EF!&KQAC4DF:<16#&9"2*OXHHK\WT$KHY'*!K\WUT>
M8\.H0>AR4/\^[-3F!5[B4 8&A4Q>_DV=H"Z2RFTK\IT_0.*./C'O*<M3EW6A
M*575O9IZZ,C DN>U$6#\*Z[@"WY0XO[.B;D;-PJ?8\,0/.P-,92>.@&R57"1
M9>%K"U(,Y_6IJ)41R-CA.JS0L"?8#48@QM2G1J!U>^F80$8:$,@B&/V^ Z-T
MAF9&$/L&%>/_=G#_XQ/7UO](/*VH/#$5O[GX;QF_>V'2@OVK#6,<^$]02P$"
M% ,4    " "#/'=<4?4(VF+:! "!S3, $0              @ $     8V%B
M82TR,#(U,3(S,2YH=&U02P$"% ,4    " "#/'=<,#/XI@-T 0#7%18 $0
M            @ &1V@0 8V%B82TR,#(U,3(S,2YX<V102P$"% ,4    " "#
M/'=<R[O9Y"R,  #E1P4 $               @ '#3@8 8V%B82UE>#$P7S,X
M+FAT;5!+ 0(4 Q0    ( (,\=UR]HQ_?ICL  %6] 0 /              "
M 1W;!@!C86)A+65X,3!?."YH=&U02P$"% ,4    " "#/'=<DE,\D#L$  "8
M&@  #P              @ 'P%@< 8V%B82UE>#(Q7S$N:'1M4$L! A0#%
M  @ @SQW7/4P;+Q6!0  SR\   \              ( !6!L' &-A8F$M97@R
M,U\Q+FAT;5!+ 0(4 Q0    ( (,\=US>9Y:(,0H  +H_   /
M  "  =L@!P!C86)A+65X,S%?,2YH=&U02P$"% ,4    " "#/'=<B'Q05B$*
M   A0   #P              @ $Y*P< 8V%B82UE>#,Q7S(N:'1M4$L! A0#
M%     @ @SQW7/?&N\!1!@  ^2<   \              ( !AS4' &-A8F$M
M97@S,E\Q+FAT;5!+ 0(4 Q0    ( (,\=URH!46.1@8  /(G   /
M      "  04\!P!C86)A+65X,S)?,BYH=&U02P$"% ,4    " "#/'=<O_<A
MP$,=  "WV@  #@              @ %X0@< 8V%B82UE>#1?,BYH=&U02P$"
M% ,4    " "#/'=<?EG$A*@^ @!,;0( $@              @ 'G7P< :6UG
M,3$W,S,Q,CDY7S N:G!G4$L! A0#%     @ @SQW7(NS]?PY^ 0 9_@$ !(
M             ( !OYX) &EM9S$Q-S,S,3(Y.5\Q+F=I9E!+ 0(4 Q0    (
M (,\=US:,P'H38L' !,/"@ 2              "  2B7#@!I;6<Q,3<S,S$R
>.3E?,BYJ<&=02P4&      X #@!C P  I2(6

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>caba-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:caba="http://www.cabalettabio.com/20251231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="caba-20251231.xsd" xlink:type="simple"/>
    <context id="C_80a04733-0f39-46fd-b536-fb1363c8d09a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_81d87e23-aacc-4a1f-bb17-8d1d063bc827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8260baff-a8b4-45a6-baff-5209fef975bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_848456ab-d285-4d96-bbb7-61690adf497f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_861b1b33-e760-4f7d-921f-9f81e9699673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_8624a3cf-a78d-4c1b-b918-bf5987be2150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_86c00fdd-0440-4c28-9ac0-005ffb97dc98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_88a0af93-4579-4bef-b89d-e83437cf1886">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_8a513f9d-25e1-4123-992e-02e1600e5c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="C_8aef1329-81e5-4652-81c2-c852b8d7cbfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8afc398a-f701-4181-b888-7da00743bdd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8b9c77dd-2189-4362-bddb-fa1398cd7baf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8d6d69e2-dda1-4ea0-94e8-32274096c469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-21</startDate>
            <endDate>2019-10-23</endDate>
        </period>
    </context>
    <context id="C_8fdeb9c1-e391-4554-b8f2-1372cdb91313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_90e4ec5b-1296-4608-ba2a-60bd4683d74f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9110b0c0-85f9-4944-8142-2673163f54ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9448925f-7edb-4e94-9f16-2bf8d36d4bb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_95690f42-b502-4305-81ac-58e03c9072fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_95be2256-2ce7-4d09-8e55-757a475e082c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandTwentyFourAtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9b692d20-2d25-4b0c-9112-df05af5b8f14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-21</startDate>
            <endDate>2019-10-23</endDate>
        </period>
    </context>
    <context id="C_a2620028-ec6f-4274-a235-71be3c62c04d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_a37aa587-2f96-418b-936d-2a9c780d2b31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_a412af93-e740-4e39-b6e6-1cea95e44cc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:SponsoredResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a5873561-482d-4211-8d1a-100b3d8724c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a5bfe75d-e5fd-47a2-9113-a7d3d374a0e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-01</instant>
        </period>
    </context>
    <context id="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a76bf89e-0076-44be-bb89-64f8a0be9373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-23</instant>
        </period>
    </context>
    <context id="C_a7cf1e88-d94b-419a-946f-6fef5bc3a6d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a8062a63-67f4-417e-aa58-0c10ea3f25d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_aa89a8f6-fbbc-4204-881f-c09f6fd89717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_abd6b14f-1396-44f4-b7be-b17c6ae488c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:June2025FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_ac256694-f886-4361-a4f9-4104adc42ab6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:WuxiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_ad2a1234-93ce-48dc-96ba-3cf1de4b7bff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_b10e6031-e107-4203-ad40-05b14067806e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b2015ae2-7987-46fd-9f1a-14a53e158ee2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b4761317-427b-4343-a89f-5a138a161168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b7652f53-0a7b-4044-a278-9b0b094b3818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:MasterTranslationalResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b7f6bbbb-6c89-48bc-8dc4-f9feb90a3989">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:NanjingIasoBiotherapeuticsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_b8a71800-f4b2-48f9-bccb-e404ed69141b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_b91d5295-ad40-4ba7-93e0-4f6e19c9bd4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_bbae0f84-acad-4f21-9dc4-943f64e17a13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_bbf56b13-a2f8-466a-a449-916231816cd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bf882905-b0ee-4b75-99c2-4fea38e7170e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c1c27316-e3fc-40d0-af16-e93b32732100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_c5e572df-716d-4de5-9c9d-63027d072da4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_c776a8c2-6701-42d5-9906-29329e10a253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:NanjingIasoBiotherapeuticsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-07</instant>
        </period>
    </context>
    <context id="C_c8b36cac-3990-46a9-8114-ac5487ea54a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ca4270cc-f26d-45c8-b902-287451c596e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_ccb31ebd-a7c1-4540-8895-81d30d0fcefb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_cd82e612-a082-48f2-92a1-6e1196a216e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:LonzaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_ce57e4a4-13e3-4eba-acdf-d75280f60ad4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ce88c5ac-13e2-456a-a311-22121b1635b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">caba:StockOptionRepricingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-19</startDate>
            <endDate>2025-05-19</endDate>
        </period>
    </context>
    <context id="C_cfcf9106-b91e-443d-b454-eae693a2da98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_d5ccabe0-42f9-4792-b82a-3e639809d25d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_d8e43c4b-0fae-4bc3-81be-0f50e637fc37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_daa2ae1c-8456-4d82-aeee-31d8df8ec889">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_dd8bc73d-ffbf-455c-a0b5-28fd1d7b9c00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">caba:StockOptionRepricingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-19</startDate>
            <endDate>2025-05-19</endDate>
        </period>
    </context>
    <context id="C_e26415e9-74b5-445d-8fc5-da0f16985c3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_e4c08503-897b-4429-95f6-4ae813ed7f89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_e53823f2-5fac-496e-8cc6-671906c1651f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e6e85024-5586-4627-9417-cf890b8d4e9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e7b46819-cb47-4a65-abeb-52c116bdf1ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e89f40c1-a23f-40a4-8bee-23bda33abf3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:AutolusHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ec1351eb-6c75-4b2b-a584-b9e9880ef824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">caba:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ed842e09-7bf5-4486-9ae9-cadd5f4e3ba9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:WuxiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-24</startDate>
            <endDate>2024-02-24</endDate>
        </period>
    </context>
    <context id="C_f0f07fb5-2799-4c77-8564-71079e67edae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f31f321e-4cd2-4185-92e3-2690e8409af5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f4a1bbdb-8974-49d9-84ce-4c03b4cc5207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f6fec174-bee9-4e5c-b065-1b69e2425c7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f731d894-5793-46d0-97d4-8c8276db0097">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f7fa1328-feb2-4be1-8511-2b7650cd1cce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-23</instant>
        </period>
    </context>
    <context id="C_f804a965-6bd2-440f-a975-8966b026c5f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_f9e49f68-10ed-47f9-abad-85f88ab41fed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_fe0a6b1e-4837-4292-aa3f-e02510edce97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ff686e3b-b5f7-498f-866d-a3514dd25fe3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:MasterTranslationalResearchServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_fff8e9a1-e956-45e4-b598-b1977fa3c367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:NanjingIasoBiotherapeuticsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_024369a9-8747-4977-86bc-392c39212422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="C_079cb61a-3d40-45c2-80a6-92ffcd32eec0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_086e189e-9e52-4c9c-bd06-f74bb4383472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_08dd7fa2-382e-4330-ac22-084c92a87490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_09c552e5-3642-480f-b739-e2c13490ca62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_0aa15530-7fe2-4778-84a1-34356a306f70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">caba:OrphanDrugCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_0bea9175-88d0-41db-856a-9e2da9edda2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:June2025FinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_0c2ad5d4-742d-4a38-be11-a6e3ac78b64f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:NanjingIasoBiotherapeuticsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_0cc46475-ebfa-4cb1-8610-3a9fac50cfa5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_0dc245ae-95a8-4120-80e6-fdc0fc50dc5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1246f5d0-6b41-48ca-8d69-6d21472a4329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="C_1308d5b8-718f-4b53-9940-2c08e1043f52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-01</instant>
        </period>
    </context>
    <context id="C_141635e9-25cf-411e-813a-935f24e93c8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1535e593-36e6-42c7-88b6-f44cc18d20a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_16102a2e-2a9b-4c06-88d6-cd190d09c7a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenAndTwoThousandNinteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-19</startDate>
            <endDate>2025-05-19</endDate>
        </period>
    </context>
    <context id="C_188e5d31-bb66-43a0-923f-07b3e3e5e7ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_206c187b-7d49-476f-aa68-2c6889189b8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_22909102-0e37-4650-b154-28e36d4712cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_230d7c39-9555-4903-a435-0134ba444e94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_257b7837-c492-46b4-8e4c-f8c32fc79674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:AutolusHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_26ba7aad-e65f-4202-9148-f8d56de48c1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">caba:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_26cba5b6-ff41-4da4-a18a-c184d569c17f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_27282b93-17b5-4ddf-b071-79f5ec3755de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_27b86f31-4de3-446f-a21a-b648b1caf82f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_27ee9d75-5f66-482b-86f1-88d8cb0a5d9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_281e3d4d-125e-4a9b-80b5-a01331ef864c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:AtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-07</startDate>
            <endDate>2025-08-07</endDate>
        </period>
    </context>
    <context id="C_28aa1ca1-487f-4ec6-a7ce-bf5b8437c05e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandEighteenStockOptionAndGrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_2a18d8f9-5332-4a23-b605-cb3d2126221d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_344e5b09-4b43-4e4c-aece-b1dccaea79db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenStockOptionAndIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_344f4aad-150b-49f4-ab92-dffefb18753f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">caba:UnvestedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_34daf3e1-57d3-4a11-a83e-a499f1e0f442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:June2025FinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_36c99cf7-ca6d-4bef-8c7d-d86f756b67a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_380f4971-911e-418e-9b42-9f671cdeed55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_383948ef-273f-45f3-8285-76bb7b9800da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_39d08eb8-8fae-43b4-8fb0-2080c3f9bfa0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:AutolusHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3a126bb1-aa0b-4ca4-9d54-2b0f17069a24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">caba:Rese-CelAndMuSK-CAARTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3a1c09a0-02a7-4e33-a36d-e454e4730213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3a5e1afc-a743-4a56-b440-dbd774e83bda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3b4d07dc-82b8-43f1-b613-4a8e7b71d9a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3d0986e1-7018-41a1-8dff-d52329443bdd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3ffe9587-1afc-4c50-9fc3-01d795f0f236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandTwentyFiveSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_44bcec1f-529b-4c9d-949c-c36ef0fc03f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_47fea706-96f6-4208-96a0-a6f66f6cd4b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4cd483e2-d5ac-481f-a4e4-14e2c5f3b0c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4df289a5-f84c-498b-9dea-19951da65c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4e7202fb-fc1c-4811-8134-37c7e8ba4ea8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:DevelopmentAndManufacturingServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_522cbfa4-2c21-424d-9038-128e92ccffdf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_52dc384d-c584-4bd9-9b46-8ad7c00c3f6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_53241714-a77e-447f-a6cb-6e14c8221a31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandTwentyFiveAtTheMarketOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_53f6eed2-717f-409c-9e2e-aeb5ff23e199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:June2025FinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">caba:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_5622934b-004c-469d-b5bd-42fbf445d82b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandTwentyFiveInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_56867ab7-d91f-49f7-8e38-359323e03001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_57a2c95e-1173-4087-adbb-3d92d6dbeea3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_5923d687-6b09-4b10-ab7a-35a81dfd434d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_598dae7f-b88a-453f-bb9e-2b82884748a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:OxfordBiomedicaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="C_5c1cb0e3-26dc-41c6-a7e9-aa32d0639495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5f4640a1-b6f6-4783-b105-897dd65c4d00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="C_62c46a84-f119-4e55-9084-2d63a76277e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_63066961-ec40-4822-b55c-b127b3bbe2fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">caba:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_66b45ca8-e68d-4849-8c5f-5bbff16e963f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">caba:VestedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_68400128-05f8-412b-8bce-a9b588eb4efa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_6d087c0e-36a2-45cb-b85c-7485d4eed9e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">caba:StockOptionRepricingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-19</instant>
        </period>
    </context>
    <context id="C_6ebe76ca-6547-40a0-a4fb-a46ca3d1dafe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_6f0d1f48-cee2-4ab8-ae48-a9a04ad2fe08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:AutolusHoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_70a0fab7-be2b-4ccd-99f2-f48e769150b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7100f48a-8add-4128-a465-4164ef21fd92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_72fa9a9d-1938-4032-8385-aa9b1119676b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_77952c23-092c-4512-8995-d28a63420b8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_77e60dc1-c4d2-45f5-a2f2-00307e31ec35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_792e0634-91e5-4b0d-aabc-c71a1e755f4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7b8638c5-f1ef-4620-8819-259d96ac947a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">caba:LonzaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_7e3f7626-666d-4e8c-8445-9541d4f207e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7e7085e6-b579-40fa-abdc-6e0040e9e363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
        </entity>
        <period>
            <instant>2026-03-19</instant>
        </period>
    </context>
    <context id="C_7e883d39-427a-4782-a11e-f726f65e38ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001759138</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <unit id="U_Segment">
        <measure>caba:Segment</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_e2d8e1c8-abad-4975-8fb0-29afbef25850">0001759138</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_debbdddf-3755-4212-a1ba-5a5e8c0c061f">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_167f4452-39b1-4651-9793-471cc2862419">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      id="F_437f05d5-bc3e-4917-9472-758eed38a299"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      id="F_8ac70644-54ad-4b79-9c48-216491e81014"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_cfcf9106-b91e-443d-b454-eae693a2da98"
      id="F_6b79aa44-243a-42b1-94f6-81fb189f1245">http://www.cabalettabio.com/20251231#PropertyPlantAndEquipmentEstimatedUsefulLives1</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="0"
      id="F_11331fa4-2d51-42cc-aee7-5b9ce9481ad0"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_c5e572df-716d-4de5-9c9d-63027d072da4"
      id="F_d6a034d6-bb46-42f3-a934-8529b7b3bdda">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_ee1217d9-029c-47b8-ad17-a22489920a62">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_8b36a69f-cd01-4509-9af3-66da1d2ac22a">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_faa8d701-882d-4c84-981a-3d3b5aede45e">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_c06fc779-6843-4f10-b814-30983b86b531">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_ceaba6b7-e873-4ab3-a671-656dd15ff93a">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_1070a541-7c5f-4b4d-ad82-ba78c89d0e2f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_ccbc2d84-a59f-4a96-9e0c-02255ea8d7f6">001-39103</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_f2c29154-45cf-441b-b85a-c3e51685dda9">CABALETTA BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_93830fa7-2a86-42e0-bc0d-4bad71afceb1">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_d9aba0dc-3382-4887-97fb-6fc614c74530">82-1685768</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_cc6978f0-1c0d-4ba4-92b4-a63d6f22b0cc">2929 Arch Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_2eb6b669-a29d-4455-8347-5446bad82558">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_92936e26-f21a-4516-93ea-02e60f26d442">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_c690595f-e88a-4c36-9cba-c897180ae5b7">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_43d996c9-a729-44c7-8996-a7258e64c94a">19104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_7f1d258f-b848-425a-b812-ed7c112aab5c">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_5a78b995-6ce2-4954-9f7c-b667c1f47a49">759-3100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_2ec5f6e6-4c71-411f-be00-0610bb45b884">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_84fa459e-2c99-49ba-919a-7060400793ee">CABA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_9fce271b-3f35-4a76-8e8d-e305a5393e7e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_bdc4e508-8036-4586-bbd8-18860df1ed82">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_4a1dfbc0-fc61-4fd8-84f4-123de75db998">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_3a86f853-d637-4083-ac4b-32523d34b11c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_fb5b3368-95a3-425d-896b-d88d7ffae299">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_c2f8791c-aa11-4e93-a833-c4b63619ba13">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_70556f90-29f9-425a-b99c-a515fe3966d9">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_ce1c237a-8b70-4c3b-a969-f5f378a76516">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_b4d1a710-8863-47c9-bd38-a32c36b9854a">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_41f0aefd-94eb-46d9-9966-54896a7bc2ca">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_a96331f0-2d36-4f68-ab53-99da13853bf8">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_27ee9d75-5f66-482b-86f1-88d8cb0a5d9e"
      decimals="-6"
      id="F_986ee9d4-98e1-4318-a1a2-f4d20ad367ca"
      unitRef="U_USD">137000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_7e7085e6-b579-40fa-abdc-6e0040e9e363"
      decimals="0"
      id="F_a2b4cecb-5d4b-44bd-bd64-4e775f2df757"
      unitRef="U_shares">111322671</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_c5ee7f1f-8e7b-4286-becb-3d819f285855">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C. Cybersecurity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cyber Risk Management and Strategy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We, under the oversight of the audit committee of our board of directors, have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;implemented&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and maintain a cybersecurity risk management program that is designed to identify, assess, and mitigate risks from cybersecurity threats. Our risk management is supported by various tools and technologies, including third-party security solutions, monitoring, and alerting tools, designed to monitor, identify, and address risks from cybersecurity threats.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;engage &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;with other third-party providers and consultants to support our cyber risk management efforts, including through periodic security testing and assessments. We have a process to assess certain major &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;third-party vendors and service providers&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, including through a review of responses to compliance questionnaires and contractual requirements, as appropriate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We, like other companies in our industry, face a number of risks from cybersecurity threats in connection with our business. Although such risks have not &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;materially affected&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and we do not believe they are reasonably likely to materially affect, us, including our business strategy, results of operations or financial condition, to date, we have, from time to time, experienced threats to and security incidents related to our data and systems. For more information about the risks from cybersecurity threats we face, please see Item 1A- Risk Factors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Governance Related to Cybersecurity Risks&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors, as a whole and through its committees, has responsibility for the periodic review and oversight of information technology risks, including risks from cybersecurity threats.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee is responsible for oversight of our cyber risk management program&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The day-to-day management of the cyber program is directed by the Director of IT under the direction of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Financial Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Currently,&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Director of IT meets with the Chief Financial Officer periodically to discuss and review our cybersecurity risk management processes and to address matters related to potential cybersecurity and information technology risks, with input from the Company&#x2019;s third-party technology providers, as appropriate. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#x2019;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee periodically reports&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; on cybersecurity risk management to the full board of directors.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_27f71d03-effc-4301-8e60-d9bc79d19c11">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We, under the oversight of the audit committee of our board of directors, have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;implemented&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and maintain a cybersecurity risk management program that is designed to identify, assess, and mitigate risks from cybersecurity threats. Our risk management is supported by various tools and technologies, including third-party security solutions, monitoring, and alerting tools, designed to monitor, identify, and address risks from cybersecurity threats.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_acf1f37a-1362-4aec-a191-d50a96c7cf89">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_42da5cd5-225c-4480-af7c-56e787742cbe">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_99f19f0f-a213-4db8-89ba-20b500d6beb7">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_96e4a2cc-418a-408f-819e-34ba4163eeec">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_376ad518-1d1f-4d9c-956a-37edf4050db9">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors, as a whole and through its committees, has responsibility for the periodic review and oversight of information technology risks, including risks from cybersecurity threats.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee is responsible for oversight of our cyber risk management program&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The day-to-day management of the cyber program is directed by the Director of IT under the direction of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Financial Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Currently,&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Director of IT meets with the Chief Financial Officer periodically to discuss and review our cybersecurity risk management processes and to address matters related to potential cybersecurity and information technology risks, with input from the Company&#x2019;s third-party technology providers, as appropriate. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#x2019;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee periodically reports&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; on cybersecurity risk management to the full board of directors.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_573268d9-3b42-4c63-bfdc-42bcfba00bc4">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee is responsible for oversight of our cyber risk management program&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_71f0520f-e15a-4a43-bbe0-7f030333517d">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The day-to-day management of the cyber program is directed by the Director of IT under the direction of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Financial Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Currently,&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_8ff9b025-d7b8-4092-bebd-a711f64f9638">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_cb66aa25-0ce5-460c-babf-8d27c62afc33">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the Director of IT reports to the Chief Financial Officer and provides periodic updates to the Chief Financial Officer on cyber matters.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_a43d36be-293f-41e7-995c-df67ca36a20a">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Director of IT meets with the Chief Financial Officer periodically to discuss and review our cybersecurity risk management processes and to address matters related to potential cybersecurity and information technology risks, with input from the Company&#x2019;s third-party technology providers, as appropriate. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#x2019;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee periodically reports&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; on cybersecurity risk management to the full board of directors.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_91b218f2-2719-46e0-b67e-1500ff70d099">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Chief Financial Officer provides periodic reports on cybersecurity and information technology matters to the audit committee, which is responsible for reviewing and overseeing the Company&#x2019;s risk management process, including risks from cybersecurity threats, as set forth in the audit committee charter.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_19936983-bcaa-461e-881e-1ae321668e70">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_72fa9a9d-1938-4032-8385-aa9b1119676b"
      id="F_dc0b6ea2-f6aa-4e0a-8d47-f6e2f4c981fb">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_72fa9a9d-1938-4032-8385-aa9b1119676b"
      id="F_85208bd5-ee43-4aa0-b6a7-c9351127403f">false</ecd:NonRule10b51ArrAdoptedFlag>
    <caba:Rule10B51ArrModifiedFlag
      contextRef="C_72fa9a9d-1938-4032-8385-aa9b1119676b"
      id="F_6823e826-92d8-43f7-a059-24bc53e32aa3">false</caba:Rule10B51ArrModifiedFlag>
    <caba:NonRule10B51ArrModifiedFlag
      contextRef="C_72fa9a9d-1938-4032-8385-aa9b1119676b"
      id="F_3ba7aaee-b607-40b7-99ec-d28bf79ad2a5">false</caba:NonRule10B51ArrModifiedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_72fa9a9d-1938-4032-8385-aa9b1119676b"
      id="F_a159a35c-7e8e-486e-b29d-2dce34011eda">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_72fa9a9d-1938-4032-8385-aa9b1119676b"
      id="F_b7f856e9-e2d5-42b3-8c92-c7f888d31514">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_09d6e2f9-4122-45b4-84b0-737067bcbdff">42</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_1cdbfc0a-be8d-4425-bb0e-843002b8c2b5">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of Cabaletta Bio, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, stockholders&#x2019; equity and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_e9cf2c99-8b3e-45ca-b3a6-bdfbe311f1c6">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_d378c85d-b0b9-4345-b46e-47738087047e">Philadelphia, Pennsylvania</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_2f8e7a26-b267-409d-97b3-edf77837ebaf"
      unitRef="U_USD">82982000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_f78f9ab8-4fa8-4885-92bd-2d427f6d1a2a"
      unitRef="U_USD">163962000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_550fc29e-c230-4061-8748-0b716bf56fca"
      unitRef="U_USD">50617000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_52134146-b85f-4290-b1c4-cb7d261c2eeb"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_1e11ae7c-3eb5-4e66-be83-099791b511c5"
      unitRef="U_USD">5272000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_38c6a7d6-3034-4d72-8138-e58e0690b407"
      unitRef="U_USD">2713000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_5d5cbf41-5029-43b2-8c6f-6c65b3b6d97c"
      unitRef="U_USD">138871000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_9ab0b0c9-2a29-47de-91d4-965c3ee2eac0"
      unitRef="U_USD">166675000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_82bf70ec-d138-48c7-ad92-efc2c8ea6c31"
      unitRef="U_USD">1922000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_2bd0a6ac-43dd-4d52-94e6-cb813ff518c6"
      unitRef="U_USD">2743000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_4285c0cd-5a2a-40d8-9f69-43180807d3c2"
      unitRef="U_USD">15700000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_0961d633-6b7e-4cc3-bc97-38b148fe90fa"
      unitRef="U_USD">7020000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_51a0252c-a123-43a0-9c1c-5f3664f8398b"
      unitRef="U_USD">3431000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_b61f6c8f-fc38-494d-92dc-b612d148a31f"
      unitRef="U_USD">6315000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_9d67312a-27e5-4625-b4e9-2820bb875885"
      unitRef="U_USD">5159000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_ccbcd729-845a-4be8-9865-48e5585ce5d3"
      unitRef="U_USD">2293000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_197c34a7-4eca-462e-807b-e1460e45def6"
      unitRef="U_USD">165083000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_85d708a2-aaac-4175-aaf6-46e1b5e83cd4"
      unitRef="U_USD">185046000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_48374643-47b0-47f1-9d5b-2ffc4a15240e"
      unitRef="U_USD">6636000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_43cb3a28-4350-471c-a031-d262d23cf5d1"
      unitRef="U_USD">4923000</us-gaap:AccountsPayableCurrent>
    <caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_1589bd51-2dc0-4dc8-a773-19af6fbd0989"
      unitRef="U_USD">19298000</caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_efe2b1d6-f007-494b-9ceb-c379c8d5ed5a"
      unitRef="U_USD">12188000</caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_a50da081-ebc9-4669-8cf7-290eea15a3e4"
      unitRef="U_USD">20758000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_a40acd1c-5019-4eba-b960-468265253413"
      unitRef="U_USD">5989000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_e4f4a0ae-6b3c-42f6-95bd-45082b1234af"
      unitRef="U_USD">3461000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_af6aeb8c-d808-46d5-bee6-5482df4e961d"
      unitRef="U_USD">3986000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_620b834f-d5fd-4aae-965f-c98172765192"
      unitRef="U_USD">50153000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_f2830f73-dcdb-4ca6-b34e-89c60302637b"
      unitRef="U_USD">27086000</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_eda64ecf-80af-4413-9f39-b078fd394a00"
      unitRef="U_USD">2879000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_f043c7f0-e9ce-4830-98a8-e307040b8fa6"
      unitRef="U_USD">3241000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_d9c785a8-877c-474b-8eca-13900c2c666e"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_3d1ad65b-78ca-4c44-b90e-6af57a049031"
      unitRef="U_USD">2384000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_9ab0a480-a758-4970-8459-bf0e89265dd4"
      unitRef="U_USD">53032000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_aeaca352-ff0d-465d-8ba4-2ab1de0777ee"
      unitRef="U_USD">32711000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="INF"
      id="F_659b8981-a914-4e18-8a9b-3ca74cbe6fec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="INF"
      id="F_1a3c13e9-27a5-4682-bea6-cd89dbf2c242"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="INF"
      id="F_c79ce3f6-48d0-449a-bbbe-459be37977af"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="INF"
      id="F_2a97f776-6224-4023-984b-382901794ff8"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="INF"
      id="F_9087ad02-416a-414f-acf5-7104a6295117"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="INF"
      id="F_e277851d-1ee1-46c6-8eb5-b2966b461e41"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="INF"
      id="F_35828212-92c4-4978-af4a-4057068df3b5"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="INF"
      id="F_266a5a8e-419e-4f55-b99c-ff3d6a8872e9"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_ad2b6a7a-c4ba-42d6-8983-e032705070c5"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_50d58533-2a54-451c-8b8d-2b3cc8f1fd0f"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_522cbfa4-2c21-424d-9038-128e92ccffdf"
      decimals="INF"
      id="F_64ea3c2c-dd5e-48e6-9f31-4f22a596cf76"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_848456ab-d285-4d96-bbb7-61690adf497f"
      decimals="INF"
      id="F_94c9c5e6-0433-467e-aa10-d7be8e953acb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_3b4d07dc-82b8-43f1-b613-4a8e7b71d9a0"
      decimals="INF"
      id="F_5b4e11cc-8efc-43af-8fef-1065976ed0dd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_27b86f31-4de3-446f-a21a-b648b1caf82f"
      decimals="INF"
      id="F_615dcdf9-4aaa-4245-bd18-5c98461423c1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="INF"
      id="F_ced2a442-26b0-4982-9d41-5ffce9432967"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_522cbfa4-2c21-424d-9038-128e92ccffdf"
      decimals="INF"
      id="F_500995a2-87ed-46f4-9975-5d877395f340"
      unitRef="U_shares">293590481</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_3b4d07dc-82b8-43f1-b613-4a8e7b71d9a0"
      decimals="INF"
      id="F_61bd4854-7869-4142-9f02-da93dcdba3df"
      unitRef="U_shares">6409519</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="INF"
      id="F_e1d63e2d-3629-4f91-bd0a-c31bd499788d"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_848456ab-d285-4d96-bbb7-61690adf497f"
      decimals="INF"
      id="F_a58e32e5-d252-49e7-9f3f-3f25181b7760"
      unitRef="U_shares">143590481</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_27b86f31-4de3-446f-a21a-b648b1caf82f"
      decimals="INF"
      id="F_1c2aa31d-0e5d-492c-a29f-a64b007c52d6"
      unitRef="U_shares">6409519</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="INF"
      id="F_00ac8bac-1b50-4a87-ac3e-1e566b4b243b"
      unitRef="U_shares">100479323</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="INF"
      id="F_ec3ba541-72d9-49ab-a1bd-2a151380e67c"
      unitRef="U_shares">100479323</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="INF"
      id="F_e0ae1fcd-3cc9-4cc6-80e4-49be6a94bead"
      unitRef="U_shares">50743101</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="INF"
      id="F_d08f9ea2-eefb-4a26-8aad-245239369d98"
      unitRef="U_shares">50743101</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_e45fcaff-2091-45bb-b039-0f51170b411f"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_62194617-fabf-4ca4-8bdf-b3dca4712176"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_7ec5ba68-247d-421b-b46a-f4681c3e1e5c"
      unitRef="U_USD">628982000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_c138a7e3-0d9e-4173-aefb-f3d54511f95e"
      unitRef="U_USD">501435000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_f64c8c86-a1a2-48c5-8c45-c49e355f6c2b"
      unitRef="U_USD">25000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_7a290193-f740-43c9-bccd-69bbb130b892"
      unitRef="U_USD">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_35e27410-2aeb-4d83-85ae-edfee3a14ad8"
      unitRef="U_USD">-516957000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_b352ce51-6092-4f3a-8ab2-bcb0afd1530a"
      unitRef="U_USD">-349101000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_e73c1259-07c8-4975-ac3e-c44515c71723"
      unitRef="U_USD">112051000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_58333bd3-a532-472c-9a67-30bc8cd174ed"
      unitRef="U_USD">152335000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_42318b62-0a8b-4081-967b-8c072d393b0f"
      unitRef="U_USD">165083000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_55741dc2-fb8b-4c60-bee8-b4a49cd43266"
      unitRef="U_USD">185046000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_d306c02c-a2ec-43fb-a03c-2ce7c7e508dd"
      unitRef="U_USD">142674000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_c47121bf-3f91-483e-a799-6dfbcba3edf9"
      unitRef="U_USD">97203000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_0a1c0805-e016-407f-a7e8-f4aeac0ff19c"
      unitRef="U_USD">29567000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_b0b9879e-da9c-498b-8acb-79df405fe6f6"
      unitRef="U_USD">27938000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_5dd706a2-3cc0-4a0e-9c2a-c348b69b5b01"
      unitRef="U_USD">172241000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_d7494f70-8be1-4e63-9ea6-9affefd35dc4"
      unitRef="U_USD">125141000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_9c25ed65-52c2-47bc-a73f-f07639df4e9c"
      unitRef="U_USD">-172241000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_0d540766-4953-4373-87a6-9c6030d32904"
      unitRef="U_USD">-125141000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_adb0c1c9-d57f-4ebe-902b-c3833333a7b6"
      unitRef="U_USD">6031000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_4a8f5e84-1fe8-4122-ab62-ba84d37eccdf"
      unitRef="U_USD">10025000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_b18fc903-fd66-461c-90e3-8455876e47f8"
      unitRef="U_USD">2004000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_a8e8ef8b-5666-4228-a6da-66dd15d527be"
      unitRef="U_USD">748000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_862504c7-588b-450c-9523-4a100a7f3966"
      unitRef="U_USD">358000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_f9137afc-7998-4758-8e5c-6f4cea0d0124"
      unitRef="U_USD">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_f198c91e-99d8-4b62-9e5d-0885e185ab04"
      unitRef="U_USD">-167856000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_e54d6890-3967-4994-8166-09b2e1e4c546"
      unitRef="U_USD">-115864000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_65a1880e-2a4b-4ccc-ac2c-4f019f499b03"
      unitRef="U_USD">25000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_5c0b81ae-bbfd-49db-8ea8-49f087d990ab"
      unitRef="U_USD">-39000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_a38e80d5-7f4a-46ac-8e17-3b19852ad5a6"
      unitRef="U_USD">-167831000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_77e32d69-adbb-4592-ba75-7ace4d07fb57"
      unitRef="U_USD">-115903000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="2"
      id="F_09840fd9-827d-4efb-a13a-6087b96febfd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.1</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="2"
      id="F_64de83a0-5c06-43a0-89ab-3a160cb5fce3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.1</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="2"
      id="F_fc74a907-2158-4a1a-a0bb-af2423e5494c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="2"
      id="F_a619d248-352a-42d1-b59d-b1ba87019c2d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_a5873561-482d-4211-8d1a-100b3d8724c2"
      decimals="0"
      id="F_34cbfa23-83e0-46be-907e-8ef5f6daab64"
      unitRef="U_shares">47823232</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_a5873561-482d-4211-8d1a-100b3d8724c2"
      decimals="-3"
      id="F_bd503319-18c5-406a-b19c-2e705392714d"
      unitRef="U_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9448925f-7edb-4e94-9f16-2bf8d36d4bb9"
      decimals="-3"
      id="F_c7663efa-cf45-44b2-9106-adae51e43e09"
      unitRef="U_USD">469396000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_56867ab7-d91f-49f7-8e38-359323e03001"
      decimals="-3"
      id="F_637ee382-318d-4f72-ba17-38faef91ac88"
      unitRef="U_USD">39000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="C_36c99cf7-ca6d-4bef-8c7d-d86f756b67a3"
      decimals="-3"
      id="F_eb6c62e6-1256-4604-a0cd-5e7f953c7e23"
      unitRef="U_USD">-233237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8afc398a-f701-4181-b888-7da00743bdd1"
      decimals="-3"
      id="F_e3a6d019-8ac8-4426-8610-bff42059893f"
      unitRef="U_USD">236198000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_792e0634-91e5-4b0d-aabc-c71a1e755f4a"
      decimals="-3"
      id="F_f4851507-cd69-4ded-95d6-296a6ce49d98"
      unitRef="U_USD">252000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a8062a63-67f4-417e-aa58-0c10ea3f25d7"
      decimals="0"
      id="F_65ffabdb-3384-49b7-bc4e-afbad27db7e5"
      unitRef="U_shares">1483070</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a8062a63-67f4-417e-aa58-0c10ea3f25d7"
      decimals="-3"
      id="F_2810d5fc-5600-4a5a-a070-33d3bb32f808"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_3d0986e1-7018-41a1-8dff-d52329443bdd"
      decimals="-3"
      id="F_073fb50c-ad14-476d-9226-829010fe5df9"
      unitRef="U_USD">10875000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_2b7d65eb-aa4a-496c-b4c2-b87c51d3e3a3"
      unitRef="U_USD">10876000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <caba:StockIssuedDuringPeriodShareStockOptionsExercised
      contextRef="C_a8062a63-67f4-417e-aa58-0c10ea3f25d7"
      decimals="0"
      id="F_d2d4b8ed-535e-4cf5-af48-c6615f390bbf"
      unitRef="U_shares">210695</caba:StockIssuedDuringPeriodShareStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3d0986e1-7018-41a1-8dff-d52329443bdd"
      decimals="-3"
      id="F_7c0929d0-b984-43c7-8a19-6df5b591f0af"
      unitRef="U_USD">1430000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_383169b9-4e7e-482d-bad2-17e4248e6625"
      unitRef="U_USD">1430000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_a8062a63-67f4-417e-aa58-0c10ea3f25d7"
      decimals="0"
      id="F_acd46bd8-9f26-455a-b4b7-6bd057c6c8a3"
      unitRef="U_shares">58056</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_3d0986e1-7018-41a1-8dff-d52329443bdd"
      decimals="-3"
      id="F_a3aae3a5-e2ff-4cbd-a735-6a3048f3562c"
      unitRef="U_USD">269000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_66e4b514-766c-4fa7-8dcf-517655d514bf"
      unitRef="U_USD">269000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <caba:IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts
      contextRef="C_a8062a63-67f4-417e-aa58-0c10ea3f25d7"
      decimals="0"
      id="F_a0dd0ead-01e6-4292-a20f-6ea278ca6cc4"
      unitRef="U_shares">1168048</caba:IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_3d0986e1-7018-41a1-8dff-d52329443bdd"
      decimals="-3"
      id="F_c73041a3-51d1-4171-b4bb-ee4588ed302f"
      unitRef="U_USD">19465000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_b55b946a-6212-43a6-ad1a-48d55fa2bd53"
      unitRef="U_USD">19465000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_4df289a5-f84c-498b-9dea-19951da65c82"
      decimals="-3"
      id="F_de639036-6ad4-429b-81ab-2ef41b46f080"
      unitRef="U_USD">-39000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_53856b55-2a9f-46f2-9195-3051d5b75191"
      unitRef="U_USD">-39000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_5c1cb0e3-26dc-41c6-a7e9-aa32d0639495"
      decimals="-3"
      id="F_5bca21f3-1fce-499f-b02e-c80b95699bfe"
      unitRef="U_USD">-115864000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_5b04f371-5d55-41a2-a5af-efaaff456548"
      unitRef="U_USD">-115864000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_188e5d31-bb66-43a0-923f-07b3e3e5e7ce"
      decimals="0"
      id="F_c8a9f62e-f48d-44d8-963b-07423e17d84d"
      unitRef="U_shares">50743101</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_188e5d31-bb66-43a0-923f-07b3e3e5e7ce"
      decimals="-3"
      id="F_37653100-8c11-40e1-bc4c-cf9fa8f4e953"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f6fec174-bee9-4e5c-b065-1b69e2425c7e"
      decimals="-3"
      id="F_34f34023-7966-429e-b131-755684f12052"
      unitRef="U_USD">501435000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_77e60dc1-c4d2-45f5-a2f2-00307e31ec35"
      decimals="-3"
      id="F_83d80b34-3d1a-442c-8ca4-27825d698eeb"
      unitRef="U_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ce57e4a4-13e3-4eba-acdf-d75280f60ad4"
      decimals="-3"
      id="F_d96b067e-4e74-4c5b-a3b6-d1d86444a460"
      unitRef="U_USD">-349101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_3a7de615-f93a-414d-80a0-2608e8a53351"
      unitRef="U_USD">152335000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_26ba7aad-e65f-4202-9148-f8d56de48c1d"
      decimals="-3"
      id="F_891f5225-9d18-4a7b-94a0-b9c8de58adb4"
      unitRef="U_USD">6442000</us-gaap:PaymentsOfStockIssuanceCosts>
    <caba:IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares
      contextRef="C_ca4270cc-f26d-45c8-b902-287451c596e5"
      decimals="INF"
      id="F_8e567cc8-8a97-485a-ad19-b2819a0f7a7e"
      unitRef="U_shares">39200000</caba:IssuanceOfCommonStockWarrantsAndPreFundedWarrantsShares>
    <caba:IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue
      contextRef="C_f31f321e-4cd2-4185-92e3-2690e8409af5"
      decimals="-3"
      id="F_850450de-4f7d-48bc-b9e1-0d15f1afca8d"
      unitRef="U_USD">93558000</caba:IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue>
    <caba:IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_8fbd6931-150a-4610-a684-5e4b47715039"
      unitRef="U_USD">93558000</caba:IssuanceOfCommonStockWarrantsAndPreFundedWarrantsValue>
    <caba:IssuanceOfCommonStockFromATMOffering
      contextRef="C_ca4270cc-f26d-45c8-b902-287451c596e5"
      decimals="INF"
      id="F_c88fb4f5-0112-4c79-b7e0-3a1a3b522026"
      unitRef="U_shares">5545041</caba:IssuanceOfCommonStockFromATMOffering>
    <caba:IssuanceOfCommonStockFromATMOfferingAmount
      contextRef="C_f31f321e-4cd2-4185-92e3-2690e8409af5"
      decimals="-3"
      id="F_744a14b2-30ed-4e1c-909f-5e3017c15755"
      unitRef="U_USD">12745000</caba:IssuanceOfCommonStockFromATMOfferingAmount>
    <caba:IssuanceOfCommonStockFromATMOfferingAmount
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_8d26905e-4141-441e-bdf5-466478d2a5b4"
      unitRef="U_USD">12745000</caba:IssuanceOfCommonStockFromATMOfferingAmount>
    <caba:IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts
      contextRef="C_ca4270cc-f26d-45c8-b902-287451c596e5"
      decimals="0"
      id="F_9e97bc2d-093b-4633-9aa7-4da1dc2fcffb"
      unitRef="U_shares">4799971</caba:IssuanceOfCommonStockAndPreFundedWarrantsForThePurchaseOfCommonStockNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_ca4270cc-f26d-45c8-b902-287451c596e5"
      decimals="0"
      id="F_86f3a8fc-1286-48ba-b9a8-9ca65fc2d666"
      unitRef="U_shares">177876</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_f31f321e-4cd2-4185-92e3-2690e8409af5"
      decimals="-3"
      id="F_35a0f6fd-44af-43d6-a2f6-e8ac88cbde58"
      unitRef="U_USD">291000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_3c920189-98f6-40a8-b9d1-2d0574e3d668"
      unitRef="U_USD">291000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <caba:StockIssuedDuringPeriodShareStockOptionsExercised
      contextRef="C_ca4270cc-f26d-45c8-b902-287451c596e5"
      decimals="0"
      id="F_2997a1f8-8a4a-44f4-84df-180abfc270e5"
      unitRef="U_shares">13334</caba:StockIssuedDuringPeriodShareStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_f31f321e-4cd2-4185-92e3-2690e8409af5"
      decimals="-3"
      id="F_eef8d855-baae-41fe-849a-aadb1b8b58bc"
      unitRef="U_USD">14000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_31256f51-dad7-41e3-bf5f-5c7774d1ed17"
      unitRef="U_USD">14000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f31f321e-4cd2-4185-92e3-2690e8409af5"
      decimals="-3"
      id="F_0c98afbf-2d9d-45cb-aa6b-2a30b5cb31d3"
      unitRef="U_USD">20939000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_ddc50e56-a75e-4ad0-92ec-17366dafcf8b"
      unitRef="U_USD">20939000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_e6e85024-5586-4627-9417-cf890b8d4e9a"
      decimals="-3"
      id="F_d7557ae0-5bab-430b-a29d-b2fdc93265ab"
      unitRef="U_USD">25000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_f5fdb854-961e-47d0-a891-1f599e664041"
      unitRef="U_USD">25000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_383948ef-273f-45f3-8285-76bb7b9800da"
      decimals="-3"
      id="F_069e17a2-25a7-4760-a62f-ecfcc6b54998"
      unitRef="U_USD">-167856000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_65fa3bfd-57c1-4a3e-80a8-8b25c9964b3b"
      unitRef="U_USD">-167856000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_6ebe76ca-6547-40a0-a4fb-a46ca3d1dafe"
      decimals="0"
      id="F_19cf5b63-b004-412b-be3a-4e46741ebe45"
      unitRef="U_shares">100479323</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_6ebe76ca-6547-40a0-a4fb-a46ca3d1dafe"
      decimals="-3"
      id="F_38d8d03a-337f-41bd-84a3-319f4cf4f70b"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_08dd7fa2-382e-4330-ac22-084c92a87490"
      decimals="-3"
      id="F_cfb3b90e-0bce-4e81-90a2-b3964e60c281"
      unitRef="U_USD">628982000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_b10e6031-e107-4203-ad40-05b14067806e"
      decimals="-3"
      id="F_7763c5c4-4abf-466f-a7a2-7831b81a2d65"
      unitRef="U_USD">25000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquity
      contextRef="C_d5ccabe0-42f9-4792-b82a-3e639809d25d"
      decimals="-3"
      id="F_ed5dd864-0fa1-4922-bdaf-ed9e94240f73"
      unitRef="U_USD">-516957000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_a93bb60f-2d4b-4b65-aff9-bc8cd373f098"
      unitRef="U_USD">112051000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_4bdfc344-76a5-46a7-88bb-49d4fa796d10"
      unitRef="U_USD">-167856000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_7f7b73b1-2152-45f1-ae04-ab7a6a7d4c0e"
      unitRef="U_USD">-115864000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_f4e0fb01-ee62-4b79-bd74-c1eae0f1ff38"
      unitRef="U_USD">20939000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_01ff2726-cf27-4663-9b5c-75398d6d88a1"
      unitRef="U_USD">19465000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_bc7bb283-8084-4a8b-aff5-716990a7622e"
      unitRef="U_USD">1646000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_43575656-ff4b-4327-b250-3370730a0ab8"
      unitRef="U_USD">1711000</us-gaap:Depreciation>
    <caba:NonCashFinanceLeaseExpense
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_39e6ebb2-dd81-40ff-9249-e1f35f1d7349"
      unitRef="U_USD">11697000</caba:NonCashFinanceLeaseExpense>
    <caba:NonCashFinanceLeaseExpense
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_ff38928b-38ac-4b70-9ff6-67b3c0cb7c10"
      unitRef="U_USD">3102000</caba:NonCashFinanceLeaseExpense>
    <caba:NonCashLeaseExpense
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_89fbf1c3-d57a-4012-baca-b2e991864a04"
      unitRef="U_USD">3671000</caba:NonCashLeaseExpense>
    <caba:NonCashLeaseExpense
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_ba8002bd-8f6c-4a69-9701-1473beb0e3ef"
      unitRef="U_USD">2838000</caba:NonCashLeaseExpense>
    <us-gaap:AccretionExpense
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_64ce1ca5-0cf9-4cb1-9160-0bfd71cdf463"
      unitRef="U_USD">532000</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_fdc68fce-083f-4bc1-93f9-15bc29a58f31"
      unitRef="U_USD">405000</us-gaap:AccretionExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_32bc8974-0da0-4acd-a5a2-204a805ef14c"
      unitRef="U_USD">1555000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_fdb3152b-5e0d-4133-8e69-451172c4505c"
      unitRef="U_USD">1528000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_da3e7700-a6cb-4f89-8430-c2b44aae0fc3"
      unitRef="U_USD">225000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_ab28945f-eb98-403c-82d7-d13f3baf494e"
      unitRef="U_USD">38000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_b82cf237-a0dc-4bc9-aca2-6034fcdc8c47"
      unitRef="U_USD">2559000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_bd74671f-e8b4-4683-aac9-f45a9e921318"
      unitRef="U_USD">-528000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_8c1ef0ea-7353-49e7-bd83-e1fa58de954a"
      unitRef="U_USD">2866000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_7be861bc-2575-417c-8a91-deef00d2f18f"
      unitRef="U_USD">584000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_c79d5a0d-483b-4785-9cb1-6ceeb11d3013"
      unitRef="U_USD">1550000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_caf59ccd-44eb-4db5-9060-aa5d65235fb5"
      unitRef="U_USD">1011000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_2ef9b133-feeb-4db4-b880-b9df39d861f5"
      unitRef="U_USD">7432000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_5e0dfacc-b28e-402b-859a-811add5d7ea0"
      unitRef="U_USD">3947000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_95199238-9e53-4ac0-babd-f7fa980e70ce"
      unitRef="U_USD">-4227000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_41ff91ee-04bf-47fe-b1f8-31a730fab637"
      unitRef="U_USD">-3291000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_409cd2f1-b392-4fa4-818d-a9c8d485e6ca"
      unitRef="U_USD">291000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_f2221969-1776-496c-880b-4d132e93606e"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_a9f376f1-cbce-44ad-acfd-67bca31d6360"
      unitRef="U_USD">-131080000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_e1aa07c9-0327-479b-9ebb-144510e24ff3"
      unitRef="U_USD">-88222000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_aa77acc6-d6cd-4977-8f99-5400b88b7efd"
      unitRef="U_USD">1229000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_ba6a03df-7e7a-4498-bd76-ad3962f0c252"
      unitRef="U_USD">2211000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_dc52c2a6-b251-448c-85b9-7b4d2ace5cba"
      unitRef="U_USD">99037000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_fccb7108-ed6f-4b79-8205-b204218ac74d"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_56743e5f-e7b9-43ab-8f17-09482f421400"
      unitRef="U_USD">50000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_acdb552a-b67a-46cf-b197-c90b24039f53"
      unitRef="U_USD">49500000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_8d9f1122-21f2-4631-b786-09b53a2bc63c"
      unitRef="U_USD">-50266000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_222a45c6-95c2-4109-9ae6-3af9aa840795"
      unitRef="U_USD">47289000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_afad77e2-842e-46f4-809d-02bc73145baf"
      unitRef="U_USD">93558000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_6acbacd4-9d5c-4250-ba74-b233eda0f8e1"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <caba:IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_cbb160b5-e8f5-4b2e-ab29-e94ddddc7fed"
      unitRef="U_USD">12745000</caba:IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees>
    <caba:IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_3025f14d-03cd-4c84-b774-0bc4f45ee581"
      unitRef="U_USD">10875000</caba:IssuanceOfCommonStockFromATMOfferingNetOfSalesAgentCommissionAndFees>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_fc12a56d-7795-4998-8661-9bd8dc30e419"
      unitRef="U_USD">291000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_6d83b216-987d-4cb9-a089-a060140cb6c1"
      unitRef="U_USD">269000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_ea256a18-3374-491d-94f5-2fa86945cfbd"
      unitRef="U_USD">14000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_09e8bcdc-9ff2-49bb-b9dc-d63dd4baa61e"
      unitRef="U_USD">1430000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_3f4c9889-e041-4f86-98d0-e0bbb21ea299"
      unitRef="U_USD">6261000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_615ed76b-cd75-4f2e-a146-972ffce585c7"
      unitRef="U_USD">897000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_ff548daf-f56b-47cb-a876-492eac217fc5"
      unitRef="U_USD">100347000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_83d6fbff-79e3-4f43-b277-e75445160865"
      unitRef="U_USD">11677000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_c5ba3046-f5e5-48f8-9a9e-b482f6340b03"
      unitRef="U_USD">19000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_06120ef5-6ab6-457f-a3a6-e3da7313b9a2"
      unitRef="U_USD">-20000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_4c491197-2e8c-432d-ad5e-7fb4afa5d40f"
      unitRef="U_USD">-80980000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_1bc0f8d4-29c9-4188-a2a4-b775e00c4c2d"
      unitRef="U_USD">-29276000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_e17728b3-33b4-48ad-8e7a-3b2b6eb8a3c7"
      unitRef="U_USD">163962000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_8afc398a-f701-4181-b888-7da00743bdd1"
      decimals="-3"
      id="F_3994007a-4722-4787-ac36-8140b473cbc6"
      unitRef="U_USD">193238000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_8f211700-c213-4122-a50a-abd950ccbc43"
      unitRef="U_USD">82982000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_837a15ac-ec2f-443e-b4f2-5ff6318cd6b7"
      unitRef="U_USD">163962000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_09911eae-1d78-4d43-9f62-f9c55da276e9"
      unitRef="U_USD">1713000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_d2ac43c9-678f-45c0-a59c-435084fbc04f"
      unitRef="U_USD">748000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_e72e542c-81ba-42ca-8556-1662f62b3398"
      unitRef="U_USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_6e8301a2-a257-42f9-aad7-df31e86a6b22"
      unitRef="U_USD">404000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_1d3a498a-0757-4b18-adec-0b0095440a74"
      unitRef="U_USD">21071000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_3df95b7e-ace3-4325-8415-d687cacd47e2"
      unitRef="U_USD">10963000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_59838a3c-2f12-435b-b9ec-b7846599ee35"
      unitRef="U_USD">787000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_7943d1d4-980f-4889-8a71-99fa8777bdce"
      unitRef="U_USD">4242000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_cefc8b67-affc-4a11-ad05-23f2b53c7b14">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cabaletta Bio, Inc. (the Company or Cabaletta) was incorporated in April 2017 in the State of Delaware as Tycho Therapeutics, Inc. and, in August 2018, changed its name to Cabaletta Bio, Inc. The consolidated financial statements include the accounts of Cabaletta and its wholly owned subsidiaries: Cabaletta Bio GmbH and Cabaletta Bio (Germany) GmbH.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is headquartered in Philadelphia, Pennsylvania. Cabaletta is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Principal operations commenced in April 2018.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company does not expect to generate revenue from sales of engineered T cell therapies for autoimmune diseases or any other revenue unless and until the Company completes preclinical and clinical development and obtains regulatory approval for one or more product candidates. If the Company seeks to obtain regulatory approval for any of its product candidates, the Company expects to incur significant commercialization expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. As a result, the Company is unable to predict the timing or amount of increased expenses or when or if the Company will be able to achieve or maintain profitability. Further, the Company is dependent on third parties for certain research and development activities, including manufacturing services (Note 6 and Note 7). Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. Even if the Company is able to generate revenues from the sale of its product candidates, if approved, it may not become profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then it may be unable to continue its operations at planned levels and be forced to reduce its operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 205-40, Going Concern, ("ASC 205-40") the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. The Company has sustained annual operating losses since inception and expects to continue to generate operating losses for the foreseeable future. As of December 31, 2025, the Company has incurred an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;516,957&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and has cash, cash equivalents and investments of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,599&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company&#x2019;s ultimate success depends on the outcome of its research and development activities. Management expects to incur additional losses in the future as it continues its research and development and will need to raise additional capital to fully implement its business plan and to fund its operations. The Company intends to raise such additional capital through a combination of equity offerings, debt financings, government funding arrangements, strategic alliances or other sources. However, if such financing is not available at adequate levels and on a timely basis, or such agreements are not available on favorable terms, or at all, as and when needed, the Company will need to reevaluate its operating plan and may be required to delay or discontinue the development of one or more of its product candidates or operational initiatives. Based on the Company&#x2019;s current operating plan, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern for at least twelve months from the issuance date of this Annual Report on Form 10-K, and the Company will need to obtain additional funding. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company's cash forecast contains estimates and assumptions based on success of ongoing clinical trials, and management cannot predict the amount or timing of all expenditures with certainty. Accordingly, the Company has concluded that substantial doubt exists about the Company&#x2019;s ability to continue as a going concern. The accompanying financial statements have been&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;prepared &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_5090b568-8470-453a-a307-bdfb9b447a2b"
      unitRef="U_USD">-516957000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_0ba23519-4180-4f99-a0f8-fbfe4665b58e"
      unitRef="U_USD">133599000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_1cb34cf1-fb2f-476b-87e5-03f3ffeafc3f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) and under the rules and regulations of the U.S. Securities and Exchange Commission (SEC). All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to advance payments and accruals related to the Company&#x2019;s research and development expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Off-Balance Sheet Risk and Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist of cash and cash equivalents, which are invested in U.S. treasury-based money market funds, and available-for-sale debt securities, which are invested in U.S. treasury securities. A portion of the Company&#x2019;s cash is maintained at federally insured financial institutions, and account balances may at times exceed federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk. The Company has no off&#x2011;balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and U.S. treasury securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments are available-for-sale and carried at estimated fair value. The Company&#x2019;s valuations of available-for-sale debt securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than, twelve months from the balance sheet date are classified as current.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors including the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or if more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments as well as amortization of discount or premium is included in interest income.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying statements of operations. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Estimated useful lives for property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;
          &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
           &lt;tr style="visibility:collapse;"&gt;
            &lt;td style="width:49.17%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:49.17%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_6b79aa44-243a-42b1-94f6-81fb189f1245;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lesser of estimated useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
          &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&#x2014;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has leases related to its facilities used for offices and laboratory space, which are classified as operating leases as well as leases related to its manufacturing arrangements, which are classified as finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease and its classification based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. Subsequent to the initial measurement, the Company will continue to account for:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the lease liability at the net present value using the incremental borrowing rate that was in effect as of the lease commencement, lease modification, or transition date, and;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the finance lease and operating lease expense on a straight line basis.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases with terms of 12 months or less are considered short-term leases and right-of-use assets and lease obligations are not recognized. Payments associated with short-term leases are expensed on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to aggregate all lease and non-lease components for each class of underlying assets into a single lease component for real-estate leases and embedded manufacturing arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASC 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the guidance in ASC 842-10-55-2 to assist in determining lease classification across its leases.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs include costs incurred for internal and external research and development activities and are expensed as incurred in the accompanying statements of operations. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to entities that conduct certain research and development and clinical trial activities on the Company&#x2019;s behalf.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers, which include preclinical studies, contract manufacturing activities and clinical trial activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided and in accordance with agreements established with service providers and includes these costs in accrued and other current liabilities in the accompanying balance sheets and within research and development expense in the accompanying statements of operations. Non-refundable advance payments made for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are received or the related services are rendered. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid expenses in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities and prepaid expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures its stock-based awards granted to employees and non-employees based on the estimated fair values of the awards on the respective grant dates. The Company uses the Black-Scholes option-pricing model (Black-Scholes) to estimate the fair value of its stock-based awards. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company accounts for forfeitures of stock option awards as they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base, as well as for net operating loss carryforwards and research and development credits, and are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; interest or penalties related to uncertain income tax benefits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company calculates basic and diluted net loss per share in conformity with the two-class method required for participating securities because the Company had both voting and non-voting common stock outstanding for a portion of 2024. The rights, including the liquidation and dividend rights, of the holders of the voting and non-voting common stock are identical, except with respect to voting. Each share of non-voting common stock may be converted at any time into one share of voting common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. As of December 31, 2024, no shares of non-voting common stock remain outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted average number of shares of common stock, including any pre-funded warrants to purchase shares of common stock that may be outstanding. The undistributed loss for each year is allocated to common stockholders based on the contractual participation rights of the voting and non-voting common stock as if the losses for the year had been distributed. As the liquidation and dividend rights are identical, the undistributed losses are allocated on a proportionate basis. Diluted net loss per share attributable to common stockholders is computed under the if-converted method and assumes that all non-voting common stock has been converted to common stock. Since the Company was in a loss position for all periods presented, the effects of the other potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its Chief Executive Officer (CEO). The Company has determined it operates in a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_11331fa4-2d51-42cc-aee7-5b9ce9481ad0;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment and has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Refer to Note 8 &#x2013; Segment Reporting for further information related to our segment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of stockholders&#x2019; equity as a reduction of additional paid-in capital or equity generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. ASU 2023-09 enhances the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The Company adopted this ASU for the annual period ended December 31, 2025 and the amendments have been applied retrospectively to all prior periods presented in the financial statements. Refer to Note 11 &#x2013; Income Taxes for further information.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement (Subtopic 220-40): Reporting Comprehensive Income-Expense Disaggregation Disclosures. ASU 2024-03 requires enhanced disclosures about components of expense captions on the face of the income statement. This standard will be effective for fiscal years beginning after December 15, 2026. Early adoption is permitted. ASU 2024-03 applies on a prospective basis for periods beginning after the effective date. However, retrospective application to any or all prior periods presented is permitted. The Company is currently planning to adopt this guidance when effective and is assessing the impact of the adoption on the Company&#x2019;s consolidated financial statements and accompanying footnotes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There have been no other new accounting pronouncements or changes to accounting pronouncements that, if adopted, would have or may have a material impact on the Company&#x2019;s consolidated statements or disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_03df1f58-c4e8-42e1-a64c-cf8c87ce852f">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) and under the rules and regulations of the U.S. Securities and Exchange Commission (SEC). All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_9d48347b-3dbb-4638-98b1-b4a32f8e35e3">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to advance payments and accruals related to the Company&#x2019;s research and development expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_df623267-f9a9-4103-bc2a-b58ce00ee88c">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Off-Balance Sheet Risk and Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist of cash and cash equivalents, which are invested in U.S. treasury-based money market funds, and available-for-sale debt securities, which are invested in U.S. treasury securities. A portion of the Company&#x2019;s cash is maintained at federally insured financial institutions, and account balances may at times exceed federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk. The Company has no off&#x2011;balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and U.S. treasury securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:OffBalanceSheetCreditExposurePolicyPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_a64c1888-61ff-4048-be0f-0519b978d93e">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investments are available-for-sale and carried at estimated fair value. The Company&#x2019;s valuations of available-for-sale debt securities are generally derived from independent pricing services based upon quoted prices in active markets for similar securities, with prices adjusted for yield and number of days to maturity, or based on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than, twelve months from the balance sheet date are classified as current.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unrealized gains and losses are excluded from earnings and are reported as a component of comprehensive income. The Company periodically evaluates whether declines in fair values of its available-for-sale securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors including the severity and duration of the unrealized loss as well as the Company&#x2019;s ability and intent to hold the available-for-sale security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or if more likely than not it will be required to sell any available-for-sale securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other-than-temporary, if any, on available-for-sale securities are included in interest and other income, net. The cost of investments sold is based on the specific-identification method. Interest income on investments as well as amortization of discount or premium is included in interest income.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_0a36fa20-bc44-4d54-910d-06b245cbaf29">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment are recorded at cost less accumulated depreciation. Cost includes the acquisition costs and all costs necessary to bring the asset to the location and working condition necessary for its intended use. Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the accompanying statements of operations. Expenditures for normal, recurring or periodic repairs and maintenance related to property and equipment are charged to expense as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if it will result in future economic benefits.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Estimated useful lives for property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;
          &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
           &lt;tr style="visibility:collapse;"&gt;
            &lt;td style="width:49.17%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:49.17%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_6b79aa44-243a-42b1-94f6-81fb189f1245;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lesser of estimated useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
          &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <caba:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_c0458b50-0d62-4392-99d9-c4cfc921e62e">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Estimated useful lives for property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;
          &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
           &lt;tr style="visibility:collapse;"&gt;
            &lt;td style="width:49.17%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
            &lt;td style="width:49.17%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Three years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
           &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
            &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_6b79aa44-243a-42b1-94f6-81fb189f1245;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lesser of estimated useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;/tr&gt;
          &lt;/table&gt;</caba:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_ec1351eb-6c75-4b2b-a584-b9e9880ef824"
      id="F_f3171ae7-6dcf-466a-a644-40c8ef88b0e8">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_b91d5295-ad40-4ba7-93e0-4f6e19c9bd4e"
      id="F_f3ad56f2-b0c0-4d7b-85da-43404400f759">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_62c46a84-f119-4e55-9084-2d63a76277e0"
      id="F_476bd066-38dd-4e11-8daa-f028cd52693f">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_e9c97b39-2d0a-486c-8260-0e38e8387433">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&#x2014;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_f8776c33-73d7-4a8d-bbef-2c63ca5c6706">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has leases related to its facilities used for offices and laboratory space, which are classified as operating leases as well as leases related to its manufacturing arrangements, which are classified as finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease and its classification based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. Subsequent to the initial measurement, the Company will continue to account for:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the lease liability at the net present value using the incremental borrowing rate that was in effect as of the lease commencement, lease modification, or transition date, and;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:5.5235502658900995%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the finance lease and operating lease expense on a straight line basis.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases with terms of 12 months or less are considered short-term leases and right-of-use assets and lease obligations are not recognized. Payments associated with short-term leases are expensed on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. Rather, entities would account for each lease component and related non-lease component together as a single lease component. The Company has elected to aggregate all lease and non-lease components for each class of underlying assets into a single lease component for real-estate leases and embedded manufacturing arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASC 842 allows for the use of judgment in determining whether the assumed lease term is for a major part of the remaining economic life of the underlying asset and whether the present value of lease payments represents substantially all of the fair value of the underlying asset. The Company applies the guidance in ASC 842-10-55-2 to assist in determining lease classification across its leases.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_e0220077-85f2-49e8-918e-b6fa25a8c56a">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs include costs incurred for internal and external research and development activities and are expensed as incurred in the accompanying statements of operations. Research and development costs consist of salaries and benefits, including associated stock-based compensation, and laboratory supplies and facility costs, as well as fees paid to entities that conduct certain research and development and clinical trial activities on the Company&#x2019;s behalf.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records accrued liabilities for estimated costs of research and development activities conducted by service providers, which include preclinical studies, contract manufacturing activities and clinical trial activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided and in accordance with agreements established with service providers and includes these costs in accrued and other current liabilities in the accompanying balance sheets and within research and development expense in the accompanying statements of operations. Non-refundable advance payments made for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as expense as the goods are received or the related services are rendered. The Company makes significant judgments and estimates in determining the accrued liabilities and prepaid expenses in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities and prepaid expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_0cbf6195-81ef-4e6f-88bd-e9e136af2cff">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures its stock-based awards granted to employees and non-employees based on the estimated fair values of the awards on the respective grant dates. The Company uses the Black-Scholes option-pricing model (Black-Scholes) to estimate the fair value of its stock-based awards. The Company recognizes compensation expense for time-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The Company accounts for forfeitures of stock option awards as they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_e69e799f-4ee0-4499-802d-004b37e4da85">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax base, as well as for net operating loss carryforwards and research and development credits, and are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; interest or penalties related to uncertain income tax benefits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="0"
      id="F_03565315-7203-48ad-95d1-350f274496e1"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_d97cf6a0-da61-4ec8-98b6-b19e1c096e03">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company calculates basic and diluted net loss per share in conformity with the two-class method required for participating securities because the Company had both voting and non-voting common stock outstanding for a portion of 2024. The rights, including the liquidation and dividend rights, of the holders of the voting and non-voting common stock are identical, except with respect to voting. Each share of non-voting common stock may be converted at any time into one share of voting common stock at the option of its holder by providing written notice to the Company, subject to the limitations provided for in the amended and restated certificate of incorporation. As of December 31, 2024, no shares of non-voting common stock remain outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted average number of shares of common stock, including any pre-funded warrants to purchase shares of common stock that may be outstanding. The undistributed loss for each year is allocated to common stockholders based on the contractual participation rights of the voting and non-voting common stock as if the losses for the year had been distributed. As the liquidation and dividend rights are identical, the undistributed losses are allocated on a proportionate basis. Diluted net loss per share attributable to common stockholders is computed under the if-converted method and assumes that all non-voting common stock has been converted to common stock. Since the Company was in a loss position for all periods presented, the effects of the other potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_a375f181-9513-4033-987e-b6cc862efd2f">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its Chief Executive Officer (CEO). The Company has determined it operates in a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_11331fa4-2d51-42cc-aee7-5b9ce9481ad0;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating segment and has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Refer to Note 8 &#x2013; Segment Reporting for further information related to our segment.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="0"
      id="F_9cdebfd8-e46b-4f24-a6ff-6982ab163d81"
      unitRef="U_Segment">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_83b38a72-2c8e-4b21-9aec-68d1f89c7d5e">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;After consummation of the equity financing, these costs are recorded as a reduction to the carrying value of stockholders&#x2019; equity as a reduction of additional paid-in capital or equity generated as a result of such offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_377b946d-223e-4b8f-b468-59c9b016b30b">&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. ASU 2023-09 enhances the transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The Company adopted this ASU for the annual period ended December 31, 2025 and the amendments have been applied retrospectively to all prior periods presented in the financial statements. Refer to Note 11 &#x2013; Income Taxes for further information.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement (Subtopic 220-40): Reporting Comprehensive Income-Expense Disaggregation Disclosures. ASU 2024-03 requires enhanced disclosures about components of expense captions on the face of the income statement. This standard will be effective for fiscal years beginning after December 15, 2026. Early adoption is permitted. ASU 2024-03 applies on a prospective basis for periods beginning after the effective date. However, retrospective application to any or all prior periods presented is permitted. The Company is currently planning to adopt this guidance when effective and is assessing the impact of the adoption on the Company&#x2019;s consolidated financial statements and accompanying footnotes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There have been no other new accounting pronouncements or changes to accounting pronouncements that, if adopted, would have or may have a material impact on the Company&#x2019;s consolidated statements or disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_8ae0a55e-7427-4b18-8049-5fae6f9b1473">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and 2024, the Company&#x2019;s financial instruments included cash and cash equivalents, available-for-sale debt securities, accounts payable and accrued expenses. The carrying amounts for cash and cash equivalents, accounts payable and accrued expenses reported in the Company&#x2019;s consolidated financial statements for these instruments approximate their respective fair values because of the short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:36.174%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.561%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.365%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.561%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.485000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.561%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.365%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.561%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.365%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical Assets &lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;132,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:35.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.020000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:14.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.020000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.020000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level 1 inputs. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For debt securities classified as available-for-sale investments,&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the Company records unrealized gains or losses resulting from changes in fair value between measurement dates as a component of other comprehensive income. The Company did not hold any available-for-sale securities as of December 31, 2024.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.17%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.283000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.283000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.283000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities - due in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Included in short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,599&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_d567607c-9362-4232-87f0-66697bd735b1">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:36.174%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.561%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.365%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.561%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.485000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.561%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.365%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.561%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.365%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical Assets &lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;132,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:36pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:35.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.020000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:14.440000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.020000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.020000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_57a2c95e-1173-4087-adbb-3d92d6dbeea3"
      decimals="-3"
      id="F_b4222028-ab9d-48ca-9328-3251c5918f30"
      unitRef="U_USD">81470000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_70a0fab7-be2b-4ccd-99f2-f48e769150b3"
      decimals="-3"
      id="F_73daa6f1-5a41-449d-a387-eddb93383ddd"
      unitRef="U_USD">81470000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e26415e9-74b5-445d-8fc5-da0f16985c3a"
      decimals="-3"
      id="F_e8d9ba62-206f-477d-aaaf-7c4f2f3348a2"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_c8b36cac-3990-46a9-8114-ac5487ea54a4"
      decimals="-3"
      id="F_c33b6daf-7c14-4716-95e5-01a24fc56b49"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ShortTermInvestments
      contextRef="C_c1c27316-e3fc-40d0-af16-e93b32732100"
      decimals="-3"
      id="F_f2b2c9f5-1a87-4a7c-a082-4d94756ec477"
      unitRef="U_USD">50617000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_4cd483e2-d5ac-481f-a4e4-14e2c5f3b0c8"
      decimals="-3"
      id="F_193cac77-7fe6-4d82-bee6-128a5858cefd"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_7e883d39-427a-4782-a11e-f726f65e38ec"
      decimals="-3"
      id="F_93e270cb-ce47-4791-8546-e639b3461d58"
      unitRef="U_USD">50617000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_7100f48a-8add-4128-a465-4164ef21fd92"
      decimals="-3"
      id="F_d50262a2-7e58-4597-ac9d-dea53fd92de6"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d8e43c4b-0fae-4bc3-81be-0f50e637fc37"
      decimals="-3"
      id="F_fc4ed9ad-9f4c-4b02-a548-ce96371852ca"
      unitRef="U_USD">132087000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8624a3cf-a78d-4c1b-b918-bf5987be2150"
      decimals="-3"
      id="F_f11aa1a7-58c7-4056-9a97-6c33d8dd1ab0"
      unitRef="U_USD">81470000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_230d7c39-9555-4903-a435-0134ba444e94"
      decimals="-3"
      id="F_02e4f556-11e7-4f32-a8cc-5b60df18ec06"
      unitRef="U_USD">50617000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_206c187b-7d49-476f-aa68-2c6889189b8f"
      decimals="-3"
      id="F_73d69d51-09fc-4b50-8bbf-a7d0b8a20ce4"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_8aef1329-81e5-4652-81c2-c852b8d7cbfa"
      decimals="-3"
      id="F_3870089b-e610-4452-a68e-82296e3a4b0c"
      unitRef="U_USD">162634000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_47fea706-96f6-4208-96a0-a6f66f6cd4b4"
      decimals="-3"
      id="F_bb6cbd9b-e377-4945-951f-77e37b99a45e"
      unitRef="U_USD">162634000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b4761317-427b-4343-a89f-5a138a161168"
      decimals="-3"
      id="F_d10dcf35-30b2-4fb6-829f-d92233d44053"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_8260baff-a8b4-45a6-baff-5209fef975bd"
      decimals="-3"
      id="F_154b9651-fd7a-4a97-a8c9-5870a0030027"
      unitRef="U_USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_52dc384d-c584-4bd9-9b46-8ad7c00c3f6d"
      decimals="-3"
      id="F_e7a0d805-30a4-4250-93b8-2a7b745f835c"
      unitRef="U_USD">162634000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a7cf1e88-d94b-419a-946f-6fef5bc3a6d5"
      decimals="-3"
      id="F_71678396-c6c4-4f68-9d36-b9c88e2ccc92"
      unitRef="U_USD">162634000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8fdeb9c1-e391-4554-b8f2-1372cdb91313"
      decimals="-3"
      id="F_04fbbcab-1fac-4651-9264-3e1b97d44f18"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_bf882905-b0ee-4b75-99c2-4fea38e7170e"
      decimals="-3"
      id="F_b4d29b7f-8405-46ca-b5fc-3acbd9256f5c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_0fb78e6d-f2d0-413e-a89d-dabc163151fb">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the Company records unrealized gains or losses resulting from changes in fair value between measurement dates as a component of other comprehensive income. The Company did not hold any available-for-sale securities as of December 31, 2024.&lt;/span&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:49.17%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.283000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.283000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.283000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;82,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities - due in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Included in short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,599&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_44bcec1f-529b-4c9d-949c-c36ef0fc03f1"
      decimals="-3"
      id="F_2af4e0cd-4a47-4cb5-9ca8-733c2b37d8f6"
      unitRef="U_USD">1512000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_44bcec1f-529b-4c9d-949c-c36ef0fc03f1"
      decimals="-3"
      id="F_32c5dcbe-fc46-46ba-9722-4806983f5699"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_44bcec1f-529b-4c9d-949c-c36ef0fc03f1"
      decimals="-3"
      id="F_a750e98e-277e-44a6-8e60-813e27ce7aa5"
      unitRef="U_USD">1512000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e4c08503-897b-4429-95f6-4ae813ed7f89"
      decimals="-3"
      id="F_eb425be2-7b8e-4585-a52b-9feb34549674"
      unitRef="U_USD">81470000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e4c08503-897b-4429-95f6-4ae813ed7f89"
      decimals="-3"
      id="F_43e6d4d4-f0f3-4d79-8570-7595d4597fa5"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e4c08503-897b-4429-95f6-4ae813ed7f89"
      decimals="-3"
      id="F_12d8c408-f984-40c1-8081-6aec59b2ea44"
      unitRef="U_USD">81470000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_95690f42-b502-4305-81ac-58e03c9072fa"
      decimals="-3"
      id="F_16c8695f-8ac0-482f-a655-221cacaa6b47"
      unitRef="U_USD">82982000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_95690f42-b502-4305-81ac-58e03c9072fa"
      decimals="-3"
      id="F_3fc5ce7b-35f4-4f21-92cd-e3ba86002e1b"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_95690f42-b502-4305-81ac-58e03c9072fa"
      decimals="-3"
      id="F_95b6453d-a4fd-4337-9646-e808f3ed1326"
      unitRef="U_USD">82982000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_77952c23-092c-4512-8995-d28a63420b8a"
      decimals="-3"
      id="F_acaac770-40dd-4510-b866-4f02298a9d36"
      unitRef="U_USD">50592000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_77952c23-092c-4512-8995-d28a63420b8a"
      decimals="-3"
      id="F_8419a0b9-c8a9-41ef-8120-b78fc3114fa9"
      unitRef="U_USD">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_77952c23-092c-4512-8995-d28a63420b8a"
      decimals="-3"
      id="F_8b00e883-2e9d-4a05-8934-556fadb671ba"
      unitRef="U_USD">50617000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_575e3285-55c6-43aa-87ed-8d1f64f6650d"
      unitRef="U_USD">133574000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_976204a2-bcfa-429c-935b-456d43545c0a"
      unitRef="U_USD">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_664d9914-b834-4f01-afa4-441ee457c534"
      unitRef="U_USD">133599000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_8abf6481-87af-442b-8de5-59f0f0f9c4a3">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. Property, Plant and Equipment&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,646&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,711&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_f84f2a08-2c1c-4252-bce6-1fc4ea85040e">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_079cb61a-3d40-45c2-80a6-92ffcd32eec0"
      decimals="-3"
      id="F_f6865cd1-157e-47ec-b207-43c176e6d431"
      unitRef="U_USD">8488000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7e3f7626-666d-4e8c-8445-9541d4f207e3"
      decimals="-3"
      id="F_e2943582-2b0c-43c4-bd92-e00043e4792f"
      unitRef="U_USD">7663000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b91d5295-ad40-4ba7-93e0-4f6e19c9bd4e"
      decimals="-3"
      id="F_996825bb-4c88-4594-b55e-1a74f2473d17"
      unitRef="U_USD">277000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_086e189e-9e52-4c9c-bd06-f74bb4383472"
      decimals="-3"
      id="F_3600135a-17c0-4ecd-9ec6-850abf0ccb0a"
      unitRef="U_USD">277000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_62c46a84-f119-4e55-9084-2d63a76277e0"
      decimals="-3"
      id="F_f3b7a53e-02f6-4843-b9df-ae95763d2151"
      unitRef="U_USD">196000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5923d687-6b09-4b10-ab7a-35a81dfd434d"
      decimals="-3"
      id="F_ebc18a1c-5344-4d12-b8ee-aea5f7bb5b76"
      unitRef="U_USD">196000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_cfcf9106-b91e-443d-b454-eae693a2da98"
      decimals="-3"
      id="F_47850371-bb20-4577-a166-4202ce8fb1f7"
      unitRef="U_USD">113000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_86c00fdd-0440-4c28-9ac0-005ffb97dc98"
      decimals="-3"
      id="F_2acbc5c4-4e83-4776-8f43-1987bd3973e2"
      unitRef="U_USD">113000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_2fa4bd0a-a645-40e1-a091-743d87dc10ab"
      unitRef="U_USD">9074000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_7c4f00e2-aa83-4688-8ed1-dc27d14f580a"
      unitRef="U_USD">8249000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_ea36faa4-e8d3-4d56-a8de-d5fb3c4080f5"
      unitRef="U_USD">7152000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_519fc079-0dc8-4c80-8152-a2d73460ec27"
      unitRef="U_USD">5506000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_bcdbdcdd-b3a7-46c4-a88d-1cb2058ddb83"
      unitRef="U_USD">1922000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_1dd54461-2a8f-4e86-8893-82de6d340424"
      unitRef="U_USD">2743000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_97afa9d4-f23c-4edf-a0f2-bad9653ad49c"
      unitRef="U_USD">1646000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_2c7ff21e-8108-4d19-aaef-63fd313baae5"
      unitRef="U_USD">1711000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_4b12ccac-47bf-4985-b52f-55f2c3f4614d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Accrued and Other Current Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued and other current liabilities consist of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:59.272%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.363%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.363%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical trial research and development services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Manufacturing and other research and development services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <caba:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_e5c06651-2055-4a67-80c6-63bf59343514">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued and other current liabilities consist of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:59.272%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.363%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.363%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical trial research and development services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Manufacturing and other research and development services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</caba:AccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_6e5827dc-0bf1-4d4c-a67f-035558b655b9"
      unitRef="U_USD">9716000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_c9c3c0b2-15f8-449c-a056-8bfdcf068fb7"
      unitRef="U_USD">8315000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <caba:ClinicalTrialResearchAndDevelopmentServices
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_f9263f0f-f124-4c42-be66-f589aa82d77b"
      unitRef="U_USD">5335000</caba:ClinicalTrialResearchAndDevelopmentServices>
    <caba:ClinicalTrialResearchAndDevelopmentServices
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_fd2c00a9-07de-46b7-b116-e4c1dffaa10a"
      unitRef="U_USD">1236000</caba:ClinicalTrialResearchAndDevelopmentServices>
    <caba:ManufacturingAndOtherResearchAndDevelopmentServices
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_e665d1c7-430e-4c7c-b743-f44a7d19e7a0"
      unitRef="U_USD">3774000</caba:ManufacturingAndOtherResearchAndDevelopmentServices>
    <caba:ManufacturingAndOtherResearchAndDevelopmentServices
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_b9cb739e-b94b-4966-8b68-73a0eddc89f1"
      unitRef="U_USD">2255000</caba:ManufacturingAndOtherResearchAndDevelopmentServices>
    <caba:AccruedGeneralAndAdministrativeServicesCurrent
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_0a537980-75ca-44ab-ad39-ca7863c3641c"
      unitRef="U_USD">393000</caba:AccruedGeneralAndAdministrativeServicesCurrent>
    <caba:AccruedGeneralAndAdministrativeServicesCurrent
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_11f58680-6862-4943-b35e-55696f400d1e"
      unitRef="U_USD">342000</caba:AccruedGeneralAndAdministrativeServicesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_a2ce2952-0467-4e9b-b5f4-d06698a26fda"
      unitRef="U_USD">80000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_ace0bcb6-9981-4777-88d2-7ee426ba9c96"
      unitRef="U_USD">40000</us-gaap:OtherLiabilitiesCurrent>
    <caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_6a9f1d11-7775-49d4-b42c-caa5ce697c61"
      unitRef="U_USD">19298000</caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_ce1329e6-81cb-4569-bb84-e1618782ad81"
      unitRef="U_USD">12188000</caba:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <caba:CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_f84c25a1-0d29-4a7a-8237-72ec5b04485e">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. Collaborations, Licensing Agreements and Other Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Amended and Restated License Agreement with the Trustees of the University of Pennsylvania and Children&#x2019;s Hospital of Philadelphia&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2018, the Company entered into a license agreement with the University of Pennsylvania (Penn), as amended and restated in July 2019 to include the Children&#x2019;s Hospital of Philadelphia (CHOP) as a party, and as amended in May 2020 and October 2021 (the License Agreement) pursuant to which the Company obtained (a) a non-exclusive, non-sublicensable worldwide license to certain of Penn&#x2019;s intellectual property to conduct research, product development, clinical trials, cell manufacturing and other activities, and (b) an exclusive, worldwide, royalty-bearing right and license, with a right to sublicense, on a target-by-target basis, under certain of Penn&#x2019;s intellectual property to make, use, sell, offer for sale, import, and otherwise commercialize products for the treatment of autoimmune and alloimmune diseases. Unless earlier terminated, the License Agreement expires on the expiration or abandonment or other termination of the last valid claim in Penn&#x2019;s intellectual property licensed by the Company. The Company may terminate the License Agreement at any time for convenience upon 60 days' written notice. In the event of an uncured, material breach, Penn may terminate the License Agreement upon 60 days' written notice. Under the terms of the License Agreement, the Company was obligated to pay $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; annually for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; beginning August 2018 for funding to the laboratories of each of Drs. Milone and Payne. This was satisfied through completed sponsored research agreements with a total cost of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,560&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. During the term of the License Agreement until the first commercial sale of the first product, the Company is obligated to pay Penn a non-refundable, non-creditable annual license maintenance fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In May 2020, the Company paid Penn an additional, non-refundable, non-creditable license fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; under the amended License Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is required to pay certain milestone payments upon the achievement of specified clinical and commercial milestones. Milestone payments are reduced by a certain percentage for the second product that achieves a milestone, by an additional percentage for the third product that achieves a milestone, and so on, for each subsequent product that achieves a milestone. In the event that the Company is able to successfully develop and launch multiple products under the License Agreement, total milestone payments could be approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Penn is also eligible to receive tiered royalties at percentage rates in the low single-digits, subject to an annual minimum royalty, on annual worldwide net sales of any products that are commercialized by the Company or its sublicensees that contain or incorporate, or are covered by, the intellectual property licensed by the Company. To the extent the Company sublicenses its license rights under the License Agreement, Penn would be eligible to receive tiered sublicense income at percentage rates in the mid-single to low double-digits. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; amounts due under the License Agreement as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Master Translational Research Services Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2018 and February 2023, the Company entered into services agreements (the CAART and CARTA Services Agreements) with Penn for research, development and manufacturing services from various laboratories within Penn. The activities are detailed in separately executed Penn organization-specific addenda. In May 2020, the Company amended its Addendum with the Center for Advanced Retinal and Ocular Therapeutics (CAROT) to expand access to vector manufacturing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expense recognized under executed addenda to the master translational research services agreements with Penn was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,062&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, respectively. As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; remaining commitments under the CARTA Services Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Exclusive License Agreement with IASO Biotherapeutics&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 7, 2022, the Company entered into an Exclusive License Agreement (the IASO Agreement) with Nanjing IASO Biotherapeutics Co., Ltd. (IASO). Pursuant to the IASO Agreement, the Company received an exclusive, worldwide license under certain IASO intellectual property to use a novel clinical-stage anti-CD19 binder to develop, manufacture, commercialize and otherwise exploit T cell products directed to CD19 for the purpose of diagnosis, prevention or treatment of any autoimmune or alloimmune indications in humans. As partial consideration for the exclusive license, IASO received an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. IASO is also eligible to receive up to mid double digit millions in milestone payments based upon the achievement of specified pre-clinical, development and regulatory milestones, and up to an additional low triple digit millions in milestone payments based upon achievement of specified sales milestones, for a total consideration, inclusive of the upfront payment, of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;162,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, along with tiered mid-single digit royalties on future net sales for licensed products that may result from the IASO Agreement. Upon the U.S. Food and Drug Association&#x2019;s clearance of the rese-cel Investigational New Drug application for the treatment of systemic lupus erythematosus in March 2023, a milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was recognized in the accompanying statements of operations. A milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was paid to IASO in the first quarter of 2024 after the first patient in a rese-cel trial was dosed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;IASO has the right of first negotiation if the Company desires to grant a third party an exclusive license to develop, manufacture, commercialize or otherwise exploit the licensed products in the Greater China region. Pursuant to the IASO Agreement, each of IASO and the Company have agreed, subject to certain exceptions, to refrain from engaging in certain competitive activities with respect to certain programs. The Company also may sublicense through multiple tiers the rights granted to it by IASO under the IASO Agreement at any time, however, it must pay IASO a low double-digit percentage of any revenue obtained from sublicenses or options to third parties, subject to certain customary exclusions. The IASO Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the IASO Agreement, unless earlier terminated. Each of the Company and IASO may terminate the Agreement for a material, uncured breach or insolvency of the other party. The Company may also terminate the Agreement at will upon advance written notice and in the event IASO rejects the Agreement due to bankruptcy-related matters. IASO may also terminate the Agreement if the Company fails to achieve certain specified diligence milestones in a timely manner and/or if the Company commences any patent challenges with respect to the patents and patent applications relating to the licensed sequence, in each case upon advance written notice.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Licence and Supply Agreement with Oxford Biomedica&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2021, the Company entered into a Licence and Supply agreement (LSA) with Oxford Biomedica (UK) Limited (Oxford), wherein the LSA grants the Company a non-exclusive license to Oxford&#x2019;s LentiVector&#xae; platform for its application in the Company&#x2019;s DSG3-CAART program and put in place a multi-year vector supply agreement. Oxford is eligible to receive regulatory and sales milestones in the low tens of millions and royalties in the low single digits on net sales of products that incorporate the Oxford technology. In May 2023, the Company amended the LSA with Oxford to expand the license to include the Company's rese-cel program for an upfront fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In August 2023, the Company and Oxford entered into a vector supply agreement for rese-cel, and a related second amendment to the LSA, with a total cost under the vector supply agreement of up to approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which has been fully expensed as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024. In February 2024, the Company and Oxford entered into a third amendment to the LSA to update the patent schedule. In June 2024, the Company and Oxford entered into a fourth amendment to the LSA eliminating royalties on net sales of products that incorporate the Oxford technology if Oxford manufactures the vector. Starting in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 2024, the Company and Oxford entered into work orders with a cost of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for certain process characterization and process performance qualification activities as part of commercial readiness activities. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company has recognized project to date expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,673&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; related to these activities. The Company can terminate the LSA or any work order under the LSA at will upon advance written notice and subject to certain cancellation fees.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Option and License Agreement with Autolus&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2023, the Company entered into an Option and License Agreement (Autolus Agreement) with Autolus Holdings (UK) Limited (Autolus), wherein the Autolus Agreement granted the Company a non-exclusive license to access Autolus' RQR8 technology in its CD19-CAR T cell therapy program, and subject to additional nominal option exercise fees, up to four additional t&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;argets. In January 2025, the Company and Autolus agreed to novate the Autolus Agreement with both Autolus and Autolus Limited jointly assuming the rights, obligations and liabilities of Autolus, under the Autolus Agreement. Under the terms of the Autolus Agreement, the Company was required to pay Autolus an upfront license fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; that was recognized as expense in the first quarter of 2023 in the accompanying statements of operations, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was paid in 2023 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was paid in January 2024. Autolus is also eligible to receive regulatory milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for each licensed target, sales milestones of up to a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and royalties in the low single digits on net sales of all products that incorporate the RQR8 technology. The Autolus Agreement will continue on a country-by-country, licensed product-by-licensed product basis until the expiration of the royalty term as identified in the Autolus Agreement, unless earlier terminated. The Company can terminate the Autolus Agreement at will upon advance written notice. Each of the Company and Autolus may terminate the Agreement for a material, uncured breach or insolvency of the other party.&lt;/span&gt;&lt;/p&gt;</caba:CollaborationsLicensingAgreementsAndOtherAgreementsDisclosureTextBlock>
    <us-gaap:ContractualObligation
      contextRef="C_2a18d8f9-5332-4a23-b605-cb3d2126221d"
      decimals="-3"
      id="F_9deff189-2904-49d6-894c-aa7725d281e6"
      unitRef="U_USD">2000000</us-gaap:ContractualObligation>
    <caba:PaymentOfObligationTerm
      contextRef="C_26cba5b6-ff41-4da4-a18a-c184d569c17f"
      id="F_530bd16c-e4ac-4c05-9e15-681494f1fcb0">P3Y</caba:PaymentOfObligationTerm>
    <us-gaap:ContractualObligation
      contextRef="C_a412af93-e740-4e39-b6e6-1cea95e44cc4"
      decimals="-3"
      id="F_635a760d-2c74-4762-8eba-c1269677808a"
      unitRef="U_USD">12560000</us-gaap:ContractualObligation>
    <caba:LicenseMaintenanceFee
      contextRef="C_26cba5b6-ff41-4da4-a18a-c184d569c17f"
      decimals="-3"
      id="F_6e39b83a-9dc5-4ffc-b412-53d8f7dcda33"
      unitRef="U_USD">10000</caba:LicenseMaintenanceFee>
    <caba:LicenseMaintenanceFee
      contextRef="C_1246f5d0-6b41-48ca-8d69-6d21472a4329"
      decimals="-3"
      id="F_f20b5ab3-4459-4a78-b987-982dc6835b59"
      unitRef="U_USD">33000</caba:LicenseMaintenanceFee>
    <caba:MilestonePayments
      contextRef="C_26cba5b6-ff41-4da4-a18a-c184d569c17f"
      decimals="-3"
      id="F_5c961d10-ab74-4113-a7b3-2c7945c09b3e"
      unitRef="U_USD">21000000</caba:MilestonePayments>
    <caba:CollaborativeAgreementPaymentsDue
      contextRef="C_2a18d8f9-5332-4a23-b605-cb3d2126221d"
      decimals="-3"
      id="F_12174316-244e-4188-a7b1-25c92d7719d1"
      unitRef="U_USD">0</caba:CollaborativeAgreementPaymentsDue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ff686e3b-b5f7-498f-866d-a3514dd25fe3"
      decimals="-3"
      id="F_bc8c38f6-9fa7-44a9-96c2-2418d5ad83cd"
      unitRef="U_USD">5062000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_b7652f53-0a7b-4044-a278-9b0b094b3818"
      decimals="-3"
      id="F_18863ca1-3705-4690-923e-37775d269194"
      unitRef="U_USD">3250000</us-gaap:ResearchAndDevelopmentExpense>
    <caba:RemainingResearchAndDevelopmentExpenseToBeIncurred
      contextRef="C_ff686e3b-b5f7-498f-866d-a3514dd25fe3"
      decimals="-3"
      id="F_0831f95b-1733-47e0-8199-86f93f4dd180"
      unitRef="U_USD">0</caba:RemainingResearchAndDevelopmentExpenseToBeIncurred>
    <caba:UpfrontPayment
      contextRef="C_c776a8c2-6701-42d5-9906-29329e10a253"
      decimals="-3"
      id="F_e61bede0-b95d-46e2-9c57-ebd235043e6c"
      unitRef="U_USD">2500000</caba:UpfrontPayment>
    <caba:UpfrontPayment
      contextRef="C_0c2ad5d4-742d-4a38-be11-a6e3ac78b64f"
      decimals="-3"
      id="F_3baa4ff1-b71c-4381-8346-3203600fb2a9"
      unitRef="U_USD">162000000</caba:UpfrontPayment>
    <caba:MilestonePayment
      contextRef="C_fff8e9a1-e956-45e4-b598-b1977fa3c367"
      decimals="-3"
      id="F_cc76cc45-4b4a-47f1-9b72-3f12cda59ae1"
      unitRef="U_USD">1000000</caba:MilestonePayment>
    <caba:MilestonePayment
      contextRef="C_b7f6bbbb-6c89-48bc-8dc4-f9feb90a3989"
      decimals="-3"
      id="F_376df2b7-9801-42bd-8e74-cd52a9595c29"
      unitRef="U_USD">1500000</caba:MilestonePayment>
    <caba:UpfrontPayment
      contextRef="C_8a513f9d-25e1-4123-992e-02e1600e5c57"
      decimals="-3"
      id="F_c353442a-4933-469f-ad3e-55a7e4d6a070"
      unitRef="U_USD">500000</caba:UpfrontPayment>
    <us-gaap:ContractualObligation
      contextRef="C_598dae7f-b88a-453f-bb9e-2b82884748a9"
      decimals="-3"
      id="F_ecec3570-0431-4157-acbd-93b3d0821b5b"
      unitRef="U_USD">5000000</us-gaap:ContractualObligation>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_daa2ae1c-8456-4d82-aeee-31d8df8ec889"
      decimals="-3"
      id="F_410bfa13-d8cd-4ea2-a1dd-4fc4cd3be164"
      unitRef="U_USD">23000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherExpenses
      contextRef="C_daa2ae1c-8456-4d82-aeee-31d8df8ec889"
      decimals="-3"
      id="F_18ad6865-98bf-4c29-a53f-09664f3d6883"
      unitRef="U_USD">8673000</us-gaap:OtherExpenses>
    <caba:UpfrontPayment
      contextRef="C_257b7837-c492-46b4-8e4c-f8c32fc79674"
      decimals="-3"
      id="F_f6d2f075-f916-4387-beca-58f03df0ac2e"
      unitRef="U_USD">1200000</caba:UpfrontPayment>
    <caba:UpfrontPayment
      contextRef="C_8afc398a-f701-4181-b888-7da00743bdd1"
      decimals="-3"
      id="F_554237f9-ee21-43fa-9c05-c2ece619e90b"
      unitRef="U_USD">1100000</caba:UpfrontPayment>
    <caba:UpfrontPayment
      contextRef="C_e89f40c1-a23f-40a4-8bee-23bda33abf3d"
      decimals="-3"
      id="F_9b6950be-4598-4f0d-9bdb-101190abc33f"
      unitRef="U_USD">100000</caba:UpfrontPayment>
    <caba:MilestonePayment
      contextRef="C_39d08eb8-8fae-43b4-8fb0-2080c3f9bfa0"
      decimals="-3"
      id="F_301476d6-0902-46dd-b745-5dd999966404"
      unitRef="U_USD">12000000</caba:MilestonePayment>
    <caba:MilestonePayment
      contextRef="C_6f0d1f48-cee2-4ab8-ae48-a9a04ad2fe08"
      decimals="-3"
      id="F_0c4bc1d2-572f-47d8-8de9-dbcd53200c61"
      unitRef="U_USD">15000000</caba:MilestonePayment>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_28bfd0c5-92d5-4018-b852-98b0fe4f0b36">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Manufacturing Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2021, the Company entered into a Development and Manufacturing Services Agreement (Minaris Agreement) with Minaris Advanced Therapies, LLC, or Minaris (f/k/a WuXi Advanced Therapies, Inc.) to serve as an additional cell processing manufacturing partner for the MuSK-CAART Phase 1 clinical trial, or MusCAARTes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; trial. The Minaris Agreement is scheduled to expire upon completion of Minaris' services related to MuSK-CAART and rese-cel. In August 2023, and as extended in August 2024, the Company entered into an agreement with Minaris to serve as one of the Company's manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and commercial readiness activities for rese-cel. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the August 2023 work orders, Minaris converted the Company&#x2019;s non-dedicated suite to a dedicated suite for GMP manufacturing for the Company&#x2019;s rese-cel and MuSK-CAART programs, or the Dedicated Suite, for an initial term of 18 months with two 18-month extensions at the Company&#x2019;s sole option on six months' notice prior to the end of the term. In August 2024, the Company sent a notice to Minaris to extend the initial term of the Minaris Agreement by 18 months through August 2026.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In addition, the Company agreed to certain monthly minimum runs. In August 2024, the 2023 work order related to GMP manufacturing was amended to reduce the minimum monthly runs through the end of 2024. In lieu of the original $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; termination fee under the terms of the Minaris Agreement, the Company would incur up to a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,080&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; termination &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;fee if it terminates both the rese-cel and MuSK-CAART work orders for any reason. The Company may terminate for convenience the Minaris Agreement or any work order with six months' prior written notice. However, the Company may not terminate the Dedicated Suite without terminating&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;both &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the MuSK-CAART and rese-cel GMP run work orders. Minaris may terminate for convenience the Minaris &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Agreement or any work order on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;18 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;months' prior written notice, but such notice may not be effective prior to February 202&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. In February 2026, the Company notified Minaris that it intended to permit the term to expire in August 2026.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2024, the Company entered into a Development and Manufacturing Services Agreement (the Lonza Agreement) with Lonza Houston Inc. (Lonza) to serve as one of the Company's manufacturing partners for the global clinical development of rese-cel in multiple indications, including potential late-stage clinical trials and preparations for commercial readiness. The Lonza Agreement has a term of five years and can be extended for an additional three year term upon notice to Lonza at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;18 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;months prior to the expiration of the Lonza Agreement. The Company can terminate the Lonza Agreement at will upon nine months advance written notice to Lonza subject to the terms of the Lonza Agreement. Lonza can terminate the Lonza Agreement at will upon 24 months advance written notice to Cabaletta subject to the terms of the Lonza Agreement. Under the initial work order, Lonza will perform cell therapy manufacturing activities for Cabaletta&#x2019;s CAR-T cell therapy product, rese-cel, for an initial term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;months with the ability to extend the manufacturing period on a rolling basis subject to the terms of the Lonza Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Other Purchase Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the normal course of business, the Company enters into various purchase commitments with third-party contract manufacturers for the manufacture and processing of its product candidates and related raw materials, contracts with contract research organizations for clinical trials and agreements with vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Indemnification&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company enters into certain types of contracts that contingently require the Company to indemnify various parties against claims from third parties. These contracts primarily relate to (i) the Company&#x2019;s Amended and Restated Bylaws, as amended, (bylaws) under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities arising out of their relationship, (ii) contracts under which the Company must indemnify directors and certain officers and consultants for liabilities arising out of their relationship, (iii) contracts under which the Company may be required to indemnify partners against certain claims, including claims from third parties asserting, among other things, infringement of their intellectual property rights, and (iv) procurement, consulting, or license agreements under which the Company may be required to indemnify vendors, consultants or licensors for certain claims, including claims that may be brought against them arising from the Company&#x2019;s acts or omissions with respect to the supplied products, technology or services. From time to time, the Company may receive indemnification claims under these contracts in the normal course of business. In addition, under these contracts, the Company may have to modify the accused infringing intellectual property and/or refund amounts received.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may have a material adverse effect on the Company&#x2019;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount under these contracts due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Litigation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, the Company may become involved in litigation or legal proceedings. While the outcome of any such proceedings cannot be predicted with certainty, as of December 31, 2025, the Company is not involved in any material litigation or legal proceedings that it would expect to have a material adverse impact on its financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <caba:InitialTermsOfAgreementDescription
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_5b8699db-1202-40fe-b1e4-7eacab256d24">Under the August 2023 work orders, Minaris converted the Company&#x2019;s non-dedicated suite to a dedicated suite for GMP manufacturing for the Company&#x2019;s rese-cel and MuSK-CAART programs, or the Dedicated Suite, for an initial term of 18 months with two 18-month extensions at the Company&#x2019;s sole option on six months' notice prior to the end of the term. In August 2024, the Company sent a notice to Minaris to extend the initial term of the Minaris Agreement by 18 months through August 2026.</caba:InitialTermsOfAgreementDescription>
    <us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees
      contextRef="C_4e7202fb-fc1c-4811-8134-37c7e8ba4ea8"
      decimals="-3"
      id="F_2262e021-d71a-49d3-a1df-9f8f4c979223"
      unitRef="U_USD">1500000</us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees>
    <us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees
      contextRef="C_3a126bb1-aa0b-4ca4-9d54-2b0f17069a24"
      decimals="-3"
      id="F_82aedeb9-3f06-4511-adfc-511b6233634b"
      unitRef="U_USD">1080000</us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees>
    <caba:LeaseExpirationMonth
      contextRef="C_3a5e1afc-a743-4a56-b440-dbd774e83bda"
      id="F_86dea01e-6700-4920-b7fa-97aedeb42783">P18M</caba:LeaseExpirationMonth>
    <caba:LeaseExpirationMonth
      contextRef="C_7b8638c5-f1ef-4620-8819-259d96ac947a"
      id="F_09119637-ddbe-406b-aadb-b342f45cd979">P18M</caba:LeaseExpirationMonth>
    <caba:PaymentOfObligationTerm
      contextRef="C_7b8638c5-f1ef-4620-8819-259d96ac947a"
      id="F_0a2b98cd-3dac-4342-946a-0527e371ace0">P12M</caba:PaymentOfObligationTerm>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_44168fb3-fe3d-491a-9736-057ab96f960a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the CODM in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is the CEO. The Company has determined it operates in a single operating segment and has one reportable segment. The segment consists of the development of clinical and preclinical product candidates for the discovery and development of innovative engineered T cell therapies and related administrative activities. The CODM assesses performance and allocates resources based on the Company&#x2019;s consolidated statement of operations, which is reported on the income statement as consolidated net loss and considers forecast-to-actuals variances on a quarterly basis for expenses that are deemed significant. Further, the CODM reviews the segment&#x2019;s assets based on the consolidated balance sheet to assess liquidity and funding capacity. The majority of the Company's assets are located in the United States.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s CODM views specific categories within expenses as significant given the direct correlation between cash burn and profitability as a pre-revenue company. Significant segment expenses, as provided to the CODM, are presented below. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For additional information on the year over year change of segment expenses refer to Item 7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:57.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical trials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Manufacturing of preclinical and clinical supplies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Development services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License of intellectual property&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other research and development costs &lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administration expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;167,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_60655a41-2814-4071-b009-37f32178f1b2">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For additional information on the year over year change of segment expenses refer to Item 7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations.&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:57.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Clinical trials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Manufacturing of preclinical and clinical supplies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Development services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,417&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License of intellectual property&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other research and development costs &lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administration expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;167,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.&lt;/span&gt;&lt;/p&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <caba:PersonnelExpenses
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_99783da7-5586-4880-ad89-55ec4a642833"
      unitRef="U_USD">46934000</caba:PersonnelExpenses>
    <caba:PersonnelExpenses
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_36d884e3-38a9-4394-af7d-0399ff2edb0c"
      unitRef="U_USD">39239000</caba:PersonnelExpenses>
    <caba:ClinicalTrials
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_c1379d3a-ac41-48da-b060-78942b1d616a"
      unitRef="U_USD">39581000</caba:ClinicalTrials>
    <caba:ClinicalTrials
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_31d50464-d5fd-4016-962c-53a8d5404c5e"
      unitRef="U_USD">22286000</caba:ClinicalTrials>
    <caba:ManufacturingOfPreclinicalAndClinicalSupplies
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_af200196-9993-44fb-becd-defad0322e59"
      unitRef="U_USD">38240000</caba:ManufacturingOfPreclinicalAndClinicalSupplies>
    <caba:ManufacturingOfPreclinicalAndClinicalSupplies
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_5b7357ae-dd61-439f-a06a-7c951f6d33e8"
      unitRef="U_USD">15523000</caba:ManufacturingOfPreclinicalAndClinicalSupplies>
    <caba:DevelopmentServices
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_548280e2-624e-43b5-84df-52759aabaf96"
      unitRef="U_USD">15350000</caba:DevelopmentServices>
    <caba:DevelopmentServices
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_300add9f-e067-4594-94c4-97da800a4e81"
      unitRef="U_USD">16417000</caba:DevelopmentServices>
    <caba:LicenseOfIntellectualProperty
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_0700414e-ba41-4329-b244-b59809f934fc"
      unitRef="U_USD">0</caba:LicenseOfIntellectualProperty>
    <caba:LicenseOfIntellectualProperty
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_2ef6ea52-e0c6-4538-9b7a-400006921686"
      unitRef="U_USD">1523000</caba:LicenseOfIntellectualProperty>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_d92528eb-7b2c-4ba7-8060-2a7ca155f441"
      unitRef="U_USD">2569000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_ea99062d-d4be-49eb-bbc9-f6883b27d25f"
      unitRef="U_USD">2215000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_9e22eb4e-ed4d-485d-968b-35d0b672f7d4"
      unitRef="U_USD">29567000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_c8868e6c-2db9-44d7-ba4b-beed8d4b399e"
      unitRef="U_USD">27938000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_73c4df2d-0913-4542-8af3-fed2994e517a"
      unitRef="U_USD">6031000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_eb4549b7-e1ea-4fed-baa6-2be63918af04"
      unitRef="U_USD">10025000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_baca9cdc-aaf7-4147-ba0f-9881d75a6637"
      unitRef="U_USD">2004000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_a27f2ae7-5a6e-4c12-86a2-60335724d98d"
      unitRef="U_USD">748000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_a7bb3598-7665-48ff-8ded-bc7c18b90f6f"
      unitRef="U_USD">358000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_9b6eed00-521d-46d1-830b-54e27676cd29"
      unitRef="U_USD">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_2527d65c-b994-4258-8290-baaf8f86e594"
      unitRef="U_USD">-167856000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_a19d82db-3832-4fa0-8eee-07cdfddaba00"
      unitRef="U_USD">-115864000</us-gaap:NetIncomeLoss>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_1bb3060e-498b-47c7-b5f8-6e71fa0467c8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company leases office and laboratory space and has two manufacturing agreements that have been determined to include embedded leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Operating lease commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company leases office and laboratory space which include rent escalations and are subject to additional variable charges, including common area maintenance, property taxes and property insurance. Given the variable nature of such costs, they are recognized as expense as incurred. Additionally, some of the Company&#x2019;s leases are subject to certain fixed fees which the Company has determined to be non-lease components. The Company has elected the practical expedient to account for lease and non-lease components as a single-lease component and has included fixed payments related to non-lease components in calculating the operating lease liability. The lease term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for our laboratory space was extended in October 2025 through November 2026 resulting &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in an increase of the right-of-use asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;787&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Finance lease commitments - Embedded leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As described further in Note 7, in August 2023, the Company entered into new work orders under the Minaris Agreement for Minaris to serve as one of the Company&#x2019;s cell processing manufacturing partners for the global clinical development of rese-cel. Minaris converted the Company&#x2019;s non-dedicated suite to a Dedicated Suite for GMP manufacturing for the Company&#x2019;s rese-cel and MuSK-CAART programs, for an initial term of 18 months. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The terms of the August 2023 work orders included both fixed costs and contingent variable costs. The lease commenced October 1, 2023. In 2024, the Company remeasured the lease following the resolution of the contingency related to variable costs and an amendment to the 2023 work order, which extended the term of the agreement by an additional 18 months through August 2026. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company may terminate the Dedicated Suite lease for convenience with six months&#x2019; prior written notice and up to a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,080&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; termination fee if both the rese-cel and MuSK-CAART work orders are terminated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2026, the Company notified Minaris that it intended to permit the term to expire in August 2026.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As described further in Note 7, in December 2024, the Company entered into the Lonza Agreement with Lonza to serve as one of the Company's cell processing manufacturing partners. Under the initial work order, Lonza will perform cell therapy manufacturing activities for the CAR-T cell therapy product rese-cel for a term of 12 months with the ability to extend the manufacturing period subject to the terms of the Lonza Agreement. The Lonza Agreement was evaluated under ASC 842 and determined to contain an embedded finance lease commencing in March 2025, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;resulting in the recognition of a right-of-use asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,934&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As of December 31, 2025, the Company extended the lease term in accordance with the Lonza Agreement resulting in an increase of the right-of-use asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,137&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Summary of leases under ASC 842&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table contains information pertaining to the Company&#x2019;s operating and finance leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended December 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:59.224%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.387%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.387%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total fixed finance lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fixed lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total fixed operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cash paid in the measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating cash flows used for operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating cash flows used for finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financing cash flows for finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Other information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average remaining lease term - finance leases (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average discount rate - finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average remaining lease term - operating leases (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average discount rate - operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For finance leases embedded in CDMO arrangements, interest expense is recognized using the effective interest method, applying the Company's incremental borrowing rate as required by ASC 842, and amortization expense is recognized on a straight-line basis over the shorter of the life of the asset or the term of the lease.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future lease payments under the non-cancelable leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 are as follows&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;:
&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <caba:IncreaseInTheLeaseLiability
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_e8abadef-6987-4911-9b80-a1471dad5d29"
      unitRef="U_USD">787000</caba:IncreaseInTheLeaseLiability>
    <caba:WorkOrdersTerm
      contextRef="C_ed842e09-7bf5-4486-9ae9-cadd5f4e3ba9"
      id="F_a6d8cca1-0618-4cb7-b561-7ed19d135eaf">The terms of the August 2023 work orders included both fixed costs and contingent variable costs. The lease commenced October 1, 2023. In 2024, the Company remeasured the lease following the resolution of the contingency related to variable costs and an amendment to the 2023 work order, which extended the term of the agreement by an additional 18 months through August 2026. The Company may terminate the Dedicated Suite lease for convenience with six months&#x2019; prior written notice and up to a $1,080 termination fee if both the rese-cel and MuSK-CAART work orders are terminated</caba:WorkOrdersTerm>
    <caba:TerminationFees
      contextRef="C_ed842e09-7bf5-4486-9ae9-cadd5f4e3ba9"
      decimals="-3"
      id="F_79e7e981-21bb-4dad-adb7-49eaa72118ae"
      unitRef="U_USD">1080000</caba:TerminationFees>
    <caba:IncreaseInTheLeaseLiability
      contextRef="C_ac256694-f886-4361-a4f9-4104adc42ab6"
      decimals="-3"
      id="F_0fd4bfa1-ffa3-4c43-9760-453b3d21a6aa"
      unitRef="U_USD">14934000</caba:IncreaseInTheLeaseLiability>
    <caba:IncreaseInTheLeaseLiability
      contextRef="C_cd82e612-a082-48f2-92a1-6e1196a216e6"
      decimals="-3"
      id="F_394bc474-39f8-42c2-9466-cb0edf5d4d6f"
      unitRef="U_USD">6137000</caba:IncreaseInTheLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_6f32e4aa-8051-49ab-8a36-1f22d03c8a9c">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table contains information pertaining to the Company&#x2019;s operating and finance leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended December 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:59.224%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.387%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:16.387%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total fixed finance lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,508&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total finance lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fixed lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total fixed operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cash paid in the measurement of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating cash flows used for operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating cash flows used for finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Financing cash flows for finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;897&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Other information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average remaining lease term - finance leases (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average discount rate - finance leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average remaining lease term - operating leases (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average discount rate - operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_854a8055-7028-4f7b-93d2-597e6a40853f"
      unitRef="U_USD">2004000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_f5de6c51-2309-4ea2-8259-16173b53d01a"
      unitRef="U_USD">748000</us-gaap:FinanceLeaseInterestExpense>
    <caba:AmortizationExpense
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_1c2de715-32a5-48c9-bfe4-9fc197f4aea6"
      unitRef="U_USD">12391000</caba:AmortizationExpense>
    <caba:AmortizationExpense
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_a9166b4e-2668-420b-a4c5-ba33df370d4b"
      unitRef="U_USD">3102000</caba:AmortizationExpense>
    <caba:TotalFixedFinanceLeaseCost
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_b333ce1d-54ae-47dc-8ed4-fe6ec650823a"
      unitRef="U_USD">14395000</caba:TotalFixedFinanceLeaseCost>
    <caba:TotalFixedFinanceLeaseCost
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_e8dc6cfb-faac-4fae-add2-61f225021954"
      unitRef="U_USD">3850000</caba:TotalFixedFinanceLeaseCost>
    <caba:VariableLeaseCosts
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_d7068e2c-9496-430a-ad56-7b0c32d04c8b"
      unitRef="U_USD">5508000</caba:VariableLeaseCosts>
    <caba:VariableLeaseCosts
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_53ff1429-22cf-4245-95b4-110532f929e0"
      unitRef="U_USD">930000</caba:VariableLeaseCosts>
    <caba:TotalFinanceLeaseCost
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_373fc392-8c05-4de2-90b7-42c683241907"
      unitRef="U_USD">19903000</caba:TotalFinanceLeaseCost>
    <caba:TotalFinanceLeaseCost
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_6a7e7833-cbed-4dd7-aa9a-01fce356f75d"
      unitRef="U_USD">4780000</caba:TotalFinanceLeaseCost>
    <caba:FixedLeaseCost
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_7b432d8f-76b4-494e-8668-3c244cdec9bc"
      unitRef="U_USD">4211000</caba:FixedLeaseCost>
    <caba:FixedLeaseCost
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_2293155c-2489-4c11-a604-482af1f1090d"
      unitRef="U_USD">3247000</caba:FixedLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_bb8dde73-5188-49cd-84fb-ad8a61823cf9"
      unitRef="U_USD">4211000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_467ca1b4-9dcf-4e28-b388-4cb1618b0f19"
      unitRef="U_USD">3247000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_f99e93fe-10f0-43da-a889-4a70b03382bd"
      unitRef="U_USD">171000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_6ca2f902-b9e0-4d95-9db7-01f7f89858ef"
      unitRef="U_USD">296000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_d0fd8f7a-670a-4a1d-963c-70da60a69e44"
      unitRef="U_USD">34000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_b060c207-1d2b-4166-8769-5480204a6e7b"
      unitRef="U_USD">750000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_59fc16aa-8b45-4572-ab83-b689bd62430c"
      unitRef="U_USD">4416000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_963e514b-f7bd-4f4f-8703-5007f25cecb1"
      unitRef="U_USD">4293000</us-gaap:LeaseCost>
    <caba:OperatingCashFlowsUsedForOperatingLeases
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_d9326f8f-8791-40ed-8a25-d84b9bb4faa6"
      unitRef="U_USD">4227000</caba:OperatingCashFlowsUsedForOperatingLeases>
    <caba:OperatingCashFlowsUsedForOperatingLeases
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_a39f2b90-ead1-4cbb-814b-c47adac0d34a"
      unitRef="U_USD">3291000</caba:OperatingCashFlowsUsedForOperatingLeases>
    <caba:OperatingCashFlowsUsedForFinanceLeases
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_0c9342b7-09bf-4d99-a0c1-7adfc1a06a25"
      unitRef="U_USD">1713000</caba:OperatingCashFlowsUsedForFinanceLeases>
    <caba:OperatingCashFlowsUsedForFinanceLeases
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_6c13918a-db93-44db-8051-2031b7dccd2b"
      unitRef="U_USD">748000</caba:OperatingCashFlowsUsedForFinanceLeases>
    <caba:FinancingCashFlowsUsedForFinanceLeases
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_08ae1b11-c7d6-4f9f-b3fc-555ece156486"
      unitRef="U_USD">6261000</caba:FinancingCashFlowsUsedForFinanceLeases>
    <caba:FinancingCashFlowsUsedForFinanceLeases
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_397fbb12-0b00-4b2e-9089-2c187d0cd9df"
      unitRef="U_USD">897000</caba:FinancingCashFlowsUsedForFinanceLeases>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      id="F_38f2601f-46c4-458a-b51e-2c7a3fdf30f7">P1Y1M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      id="F_21bf3441-3d5c-49d6-a0c7-f971c284b23e">P1Y8M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="3"
      id="F_ef7f8064-fdc7-4b4b-872d-b094e0c4885f"
      unitRef="U_pure">0.107</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="3"
      id="F_7d353294-0eb2-4eb9-9c4e-358c9065e48d"
      unitRef="U_pure">0.115</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      id="F_6de51dca-456f-49e6-b75a-d3549281a010">P0Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      id="F_3fed4c2e-e587-42f3-9061-7641c599004d">P1Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="3"
      id="F_707a6853-ba95-4379-847c-b6a49621484c"
      unitRef="U_pure">0.103</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="3"
      id="F_d52503c4-f580-43e1-b071-24da1856dccb"
      unitRef="U_pure">0.11</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_8d57d0fe-c8cd-46cb-90ad-9b93f64fba20">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future lease payments under the non-cancelable leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 are as follows&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;:
&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Finance Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,637&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_93747e79-b533-4ea7-9b74-c1ad3e9d150d"
      unitRef="U_USD">21914000</us-gaap:FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_8be4089e-a2ba-4ddc-bcaf-cfb1eb3e70e1"
      unitRef="U_USD">3633000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_561bb511-e92a-4ab8-9d76-ae7afc229f95"
      unitRef="U_USD">3280000</us-gaap:FinanceLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_faf3a651-5e1b-4de2-ba40-ece4abadf4f8"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <caba:FinanceLesseeUndiscountedLeasePayments
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_98bf4a03-a695-4140-ad26-8e8023d369fd"
      unitRef="U_USD">25194000</caba:FinanceLesseeUndiscountedLeasePayments>
    <caba:LesseeUndiscountedLeasePayments
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_091ab1bc-4b99-47a1-a99c-bc734d35a271"
      unitRef="U_USD">3633000</caba:LesseeUndiscountedLeasePayments>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_2eb3dd14-3d0a-40f5-bcc7-8aa5f342a625"
      unitRef="U_USD">1557000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_22173212-5039-4e3a-9e6f-9a0723c1d776"
      unitRef="U_USD">172000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_eed694f6-b8b6-4aea-8830-1216752fc6c6"
      unitRef="U_USD">23637000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_ebdaf7f0-684a-4db2-ac70-9153d2431787"
      unitRef="U_USD">3461000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_24faf7e8-5b2f-4e3c-a3fc-477f704e437a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the Company&#x2019;s Third Amended and Restated Certificate of Incorporation, as amended, the Company is authorized to issue &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;293,590,481&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of voting common stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,409,519&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of non-voting common stock. In May 2024, the remaining &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,444,295&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of non-voting common stock were converted to voting common stock and no shares of non-voting common stock are outstanding as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;June 2025 Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2025, the Company issued (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,200,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock and accompanying warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,200,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,800,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock and accompanying warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,800,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per pre-funded warrant. An additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,090,190&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common stock warrants were issued in the financing for shares purchased by the underwriters in the market to cover overallotment demand. The combined offering price of each share of common stock and accompanying common stock warrant was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The combined offering price of each pre-funded warrant and accompanying common stock warrant was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.99999&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The pre-funded warrants are exercisable immediately. The common stock and pre-funded warrants were sold in combination with an accompanying common stock warrant to purchase one share of common stock (or a pre-funded warrant in lieu thereof) for each share of common stock or pre-funded warrant sold. Each common stock warrant has an exercise price per share of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The common stock warrants are immediately exercisable from the date of issuance and will expire on September 12, 2026, fifteen months from the date of issuance. Aggregate net proceeds were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,558&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; after deducting underwriting discounts and commissions and offering expenses. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,800,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pre-funded warrants had been exercised and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; remain outstanding. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, no common stock warrants had been exercised and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,090,190&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; remain outstanding. Subsequent to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,775,100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; common stock warrants were exercised for proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,938&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The pre-funded warrants and common stock warrants were classified as a component of permanent stockholders&#x2019; equity within additional paid-in capital and were recorded at the issuance date using a relative fair value allocation method. The pre-funded warrants and common stock warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#x2019;s common stock and (vi) meet the equity classification criteria. In addition, such pre-funded warrants and common stock warrants do not provide any guarantee of value or return.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;At-the-Market Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 31, 2025, the Company converted the Form S-3ASR to a Form S-3 (File No. 333-278126) by post-effective amendments. This Form S-3 was declared effective on March 31, 2025. The Company had a Sales Agreement with TD Securities (USA) LLC (as successor to Cowen and Company, LLC) (TD Cowen) to provide for the offering, issuance and sale of up to an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of common stock from time to time in &#x201c;at-the-market&#x201d; offerings (2024 ATM Program) pursuant to its S-3, and subject to the limitations thereof. On June 11, 2025, the 2024 ATM Program with TD Cowen was terminated. Prior to termination, the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,609,865&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares pursuant to the 2024 ATM Program for total net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,724&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, consisting of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,129&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in 202&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,595&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On August 7, 2025, the Company filed a Registration Statement (File No. 333-289339) with the Securities and Exchange Commission (SEC), which was declared effective on August 15, 2025 (2025 Shelf Registration Statement), in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, the Company&#x2019;s common stock, debt securities or other equity securities in one or more offerings. The Company also simultaneously entered into a Sales Agreement with TD Cowen to provide for the offering, issuance and sale of up to an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the Company's common stock from time to time in &#x201c;at-the-market&#x201d; offerings (the 2025 ATM Program) under the 2025 Shelf Registration Statement and subject to the limitations thereof (the 2025 Sales Agreement). During the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,160,176&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares pursuant to the 2025 ATM Program for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,151&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Subsequent to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,055,260&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; additional shares, for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,568&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2018 Stock Option and Grant Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2018, the Company adopted the 2018 Stock Option and Grant Plan (the 2018 Plan), which provided for the Company to sell or issue common stock, or other stock-based awards, to employees, members of the board of directors and consultants of the Company. The Company generally granted stock-based awards with service conditions only (service-based awards), although there was one grant with performance conditions. As of December 31, 2020, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; unvested options with performance conditions. Stock options granted under the 2018 Plan generally vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d6a034d6-bb46-42f3-a934-8529b7b3bdda;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,959,411&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; options were granted under the 2018 Plan prior to the Company&#x2019;s IPO in October 2019. No further grants may be made under the 2018 Plan subsequent to the IPO.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2019 Stock Option and Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2019 Stock Option and Incentive Plan (2019 Plan) was approved by the Company&#x2019;s board of directors on October 14, 2019, and became effective on October 23, 2019. The 2019 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company&#x2019;s officers, employees, directors and consultants. The number of shares initially reserved for issuance under the 2019 Plan was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,342,288&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which will be increased each January 1 thereafter by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the number of shares of the Company&#x2019;s common stock outstanding on the immediately preceding December 31 or such lesser number of shares determined by the Company&#x2019;s board of directors or compensation committee of the board of directors. On June 1, 2023, at the 2023 Annual Meeting of Stockholders of the Company, the stockholders of the Company approved Amendment No. 1 to the 2019 Plan, increasing the number of shares of common stock reserved for issuance under the 2019 Plan by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares. On January 1, 2026, the total number of shares under the 2019 Plan was increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,019,172&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares pursuant to the 2019 Plan Evergreen Provision. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,066,471&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares remaining available for issuance under the 2019 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2025 Inducement Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2025, the Company adopted the 2025 Inducement Plan (Inducement Plan). The Inducement Plan was adopted by the Compensation Committee of the Company&#x2019;s board of directors without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4). In accordance with Rule 5635(c)(4), awards made under the Inducement Plan, including stock options and restricted stock units, may only be granted to newly hired employees as a material inducement to accept employment with the Company. Stock options granted under the Inducement Plan expire no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;later than ten years from the date of grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The number of shares reserved for issuance under the Inducement Plan was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;275,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, there were no shares available for issuance under the Inducement Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Option Repricing&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 19, 2025, the Company&#x2019;s Board of Directors approved the repricing of certain outstanding vested and unvested stock options. Pursuant to the repricing, all options granted under the 2018 Plan and 2019 Plan held by current employees, non-employee directors and certain consultants were repriced to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.92&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the closing price of the Company&#x2019;s common stock on May 19, 2025, to the extent such options had an exercise price in excess of 1.5x the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.92&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; closing price per share. To exercise the repriced options at the reduced exercise price, eligible participants must remain employed with the Company through a retention period of 12 months that begins on May 19, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As a result of the repricing, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,900,096&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; vested and unvested stock options outstanding as of May 19, 2025, with original exercise prices ranging from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.88&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.97&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, were repriced. The repricing resulted in incremental stock-based compensation expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,021&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,813&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; related to vested stock option awards and is being amortized over the retention period, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,208&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; related to unvested stock option awards and is being amortized on a straight-line basis over the remaining vesting period of those awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Option Activity&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of stock option activity is presented below:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:33.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.120000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.120000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price &lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value &lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,231,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,469,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;851,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,835,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options Exercisable at December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,860,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average exercise prices and aggregate intrinsic values in this table will not reflect the impact of the May 2025 repricing until the retention period is complete in May 2026.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company&#x2019;s common stock. The weighted average grant-date fair value of stock options granted during the years ended December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.52&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.44&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of each award is estimated using Black-Scholes based on the following assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:53.049%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:21.676%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:21.676%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.46&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.43&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&#x2014;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&#x2014;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards. These assumptions include:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method, which is the midpoint between the vesting period and the contractual term of the option.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Expected volatility is estimated using the Company's stock price since its IPO in October 2019.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of a stock-based award.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Expected dividend&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has recorded stock-based compensation in the accompanying statements of operations as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,159&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of unrecognized compensation cost related to unvested option awards and vested option awards subject to the twelve month retention period, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2019 Employee Stock Purchase Plan (2019 ESPP) was approved by the Company&#x2019;s board of directors on October 14, 2019, and became effective on October 23, 2019. A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234,229&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were initially reserved for issuance under the 2019 ESPP, and such number of shares will be increased each January 1 thereafter through January 1, 2029 by the least of (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234,229&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the number of shares of the Company&#x2019;s common stock outstanding on the immediately preceding December 31 or (iii) such lesser number of shares determined by the 2019 ESPP&#x2019;s administrator. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 1, 2026, the total number of shares available under the 2019 ESPP was increased by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234,229&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares pursuant to the 2019 Plan Evergreen Provision. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;136,383&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares remaining available for issuance under the 2019 ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Employee contributions are made through payroll deductions of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of eligible compensation over the offering period. A participant may not accrue rights to purchase more than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; worth of the Company&#x2019;s common stock for each calendar year in which such right is outstanding. At the end of each offering period, shares of the Company&#x2019;s common stock may be purchased at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the lesser of the Company&#x2019;s common stock on (i) the first trading day of the relevant offering period and (ii) the last trading day of the relevant offering period. Each offering period will be six months in duration and will commence on each December 1 and June 1.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_522cbfa4-2c21-424d-9038-128e92ccffdf"
      decimals="0"
      id="F_87b2f489-cf05-4982-a31d-27af14821d52"
      unitRef="U_shares">293590481</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_3b4d07dc-82b8-43f1-b613-4a8e7b71d9a0"
      decimals="0"
      id="F_cc68b551-fda4-4ed1-b286-33c7c51a5d05"
      unitRef="U_shares">6409519</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_5f4640a1-b6f6-4783-b105-897dd65c4d00"
      decimals="0"
      id="F_798bc61a-7822-45ff-873b-e1974e552a50"
      unitRef="U_shares">1444295</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_abd6b14f-1396-44f4-b7be-b17c6ae488c3"
      decimals="0"
      id="F_669c497e-a0cc-4c29-8658-22010f0edc0a"
      unitRef="U_shares">39200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_34daf3e1-57d3-4a11-a83e-a499f1e0f442"
      decimals="0"
      id="F_8ea07131-b184-43eb-8ec6-c48ba30a605a"
      unitRef="U_shares">39200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <caba:PreFundedWarrantsExercised
      contextRef="C_e7b46819-cb47-4a65-abeb-52c116bdf1ac"
      decimals="0"
      id="F_7964875a-8a75-47ce-a49c-943634807a7f"
      unitRef="U_shares">10800000</caba:PreFundedWarrantsExercised>
    <caba:PreFundedWarrantsExercised
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="0"
      id="F_4d55cdeb-e7b7-4166-8021-2d6eadc9824d"
      unitRef="U_shares">10800000</caba:PreFundedWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="5"
      id="F_59a369e5-d7d7-4bc1-9efc-f3e5a510fd62"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.00001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="0"
      id="F_0b213839-c9a6-4091-94f7-33dce0104cca"
      unitRef="U_shares">3090190</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0bea9175-88d0-41db-856a-9e2da9edda2e"
      decimals="2"
      id="F_cb8bc065-3e74-419e-b815-dab3b1dd1454"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_53f6eed2-717f-409c-9e2e-aeb5ff23e199"
      decimals="5"
      id="F_8ce028a0-8491-4916-8691-0a544d99e891"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.99999</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="C_34daf3e1-57d3-4a11-a83e-a499f1e0f442"
      decimals="2"
      id="F_ece243c0-ec13-40fb-86ec-485843de019f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.5</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_34daf3e1-57d3-4a11-a83e-a499f1e0f442"
      decimals="0"
      id="F_700f1eda-349f-4405-8ef6-ae0d5321b7d2"
      unitRef="U_USD">93558</us-gaap:ProceedsFromWarrantExercises>
    <caba:PreFundedWarrantsExercised
      contextRef="C_34daf3e1-57d3-4a11-a83e-a499f1e0f442"
      decimals="0"
      id="F_c13b0b73-7357-4092-bff0-a9de6e61a37f"
      unitRef="U_shares">4800000</caba:PreFundedWarrantsExercised>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_53f6eed2-717f-409c-9e2e-aeb5ff23e199"
      decimals="0"
      id="F_43821615-ebf6-45d7-b52e-306d5e4a8419"
      unitRef="U_shares">6000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="0"
      id="F_1480babe-658a-4886-9fd1-e2e78bc42128"
      unitRef="U_shares">53090190</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_abd6b14f-1396-44f4-b7be-b17c6ae488c3"
      decimals="0"
      id="F_d9aebb9e-7811-4d58-a5a2-2b1ef0fd301a"
      unitRef="U_USD">2775100</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_abd6b14f-1396-44f4-b7be-b17c6ae488c3"
      decimals="0"
      id="F_b67efd7b-1f5a-4d07-a30c-2e29491dbe6b"
      unitRef="U_USD">6938</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a37aa587-2f96-418b-936d-2a9c780d2b31"
      decimals="-5"
      id="F_36030fdd-73c8-474e-a1b1-eec2768c9631"
      unitRef="U_USD">200000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_95be2256-2ce7-4d09-8e55-757a475e082c"
      decimals="0"
      id="F_b8c99599-b1de-42b1-a2e7-75256dc37194"
      unitRef="U_shares">2609865</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_95be2256-2ce7-4d09-8e55-757a475e082c"
      decimals="-3"
      id="F_377fd149-106a-4271-86dc-b6e318b6b305"
      unitRef="U_USD">7724000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_f4a1bbdb-8974-49d9-84ce-4c03b4cc5207"
      decimals="-3"
      id="F_79219b52-2c4a-4c9f-b8f2-f52be50d449b"
      unitRef="U_USD">5129000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_1535e593-36e6-42c7-88b6-f44cc18d20a0"
      decimals="-3"
      id="F_30e9a2ec-217e-4f13-918f-796ccefc21b7"
      unitRef="U_USD">2595000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_281e3d4d-125e-4a9b-80b5-a01331ef864c"
      decimals="-5"
      id="F_a5c01a0f-8bc5-440f-8f99-2eb7034142f1"
      unitRef="U_USD">150000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_53241714-a77e-447f-a6cb-6e14c8221a31"
      decimals="0"
      id="F_cbddf141-5375-47ce-910f-feed5ae5d297"
      unitRef="U_shares">4160176</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_53241714-a77e-447f-a6cb-6e14c8221a31"
      decimals="-3"
      id="F_bd37d6ea-0557-4a93-8d3b-98e7a3a52d15"
      unitRef="U_USD">10151000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_3ffe9587-1afc-4c50-9fc3-01d795f0f236"
      decimals="0"
      id="F_f55d032f-afad-490c-868d-0110d5b53260"
      unitRef="U_shares">8055260</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_3ffe9587-1afc-4c50-9fc3-01d795f0f236"
      decimals="-3"
      id="F_074acb03-504f-4b58-aff4-689b957b082f"
      unitRef="U_USD">22568000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_861b1b33-e760-4f7d-921f-9f81e9699673"
      decimals="0"
      id="F_f33b4ce7-3264-4fab-b961-d8c2b763358c"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_aa89a8f6-fbbc-4204-881f-c09f6fd89717"
      id="F_a82376ac-9919-40eb-9ce2-78409f33e2d0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_28aa1ca1-487f-4ec6-a7ce-bf5b8437c05e"
      decimals="0"
      id="F_b71f145b-0274-4ab1-8b02-376a6c673584"
      unitRef="U_shares">1959411</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f7fa1328-feb2-4be1-8511-2b7650cd1cce"
      decimals="0"
      id="F_98e990f4-be0d-4c4c-9d37-01a788dd89d9"
      unitRef="U_shares">2342288</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <caba:IncreaseInShareReservedPercentage
      contextRef="C_9b692d20-2d25-4b0c-9112-df05af5b8f14"
      decimals="2"
      id="F_bec31805-08b6-4d11-9011-8e2570400b33"
      unitRef="U_pure">0.04</caba:IncreaseInShareReservedPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a5bfe75d-e5fd-47a2-9113-a7d3d374a0e7"
      decimals="0"
      id="F_a5177e6b-9b76-43ac-828b-322a5cadd590"
      unitRef="U_shares">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1308d5b8-718f-4b53-9940-2c08e1043f52"
      decimals="0"
      id="F_e1d55460-0d18-48f0-86b4-4717fc7120f9"
      unitRef="U_shares">4019172</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <caba:SharesRemainingAvailableForIssuance
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="0"
      id="F_b08c8298-c3f2-4f2a-8e5b-b9d771825114"
      unitRef="U_shares">1066471</caba:SharesRemainingAvailableForIssuance>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_5622934b-004c-469d-b5bd-42fbf445d82b"
      decimals="0"
      id="F_42ba35c4-d2e8-417e-a9cc-68c3fdaa23cd"
      unitRef="U_USD">275000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="C_16102a2e-2a9b-4c06-88d6-cd190d09c7a0"
      decimals="2"
      id="F_8b893ede-1910-493e-8b33-89078a56d37d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.92</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="C_16102a2e-2a9b-4c06-88d6-cd190d09c7a0"
      decimals="2"
      id="F_313dfe9a-eb2f-4cb4-b8c7-8cf65a2090e3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.92</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_6d087c0e-36a2-45cb-b85c-7485d4eed9e0"
      decimals="0"
      id="F_6600a1e8-26fe-45f7-82d9-6bc961549827"
      unitRef="U_shares">9900096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:StockOptionExercisePriceDecrease
      contextRef="C_dd8bc73d-ffbf-455c-a0b5-28fd1d7b9c00"
      decimals="2"
      id="F_f39bc7a2-cf50-48a4-b43b-a0e245b0b60d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.88</us-gaap:StockOptionExercisePriceDecrease>
    <us-gaap:StockOptionExercisePriceDecrease
      contextRef="C_ce88c5ac-13e2-456a-a311-22121b1635b4"
      decimals="2"
      id="F_309fddac-3328-4a8c-bab0-bcdfd333d548"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.97</us-gaap:StockOptionExercisePriceDecrease>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f804a965-6bd2-440f-a975-8966b026c5f8"
      decimals="0"
      id="F_87c25c75-dce8-4a7f-945a-5db139d4976f"
      unitRef="U_USD">3021</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_66b45ca8-e68d-4849-8c5f-5bbff16e963f"
      decimals="-3"
      id="F_93fd81a2-5072-4cc8-952e-87d1bb857a1b"
      unitRef="U_USD">1813000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_344f4aad-150b-49f4-ab92-dffefb18753f"
      decimals="0"
      id="F_263772e6-710a-47fa-8bd2-22f6114536be"
      unitRef="U_USD">1208</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_0894dc2d-c269-4979-b1d2-937f2a62243b">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of stock option activity is presented below:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:33.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.120000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:13.120000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price &lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value &lt;/span&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,231,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,469,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;851,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,835,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options Exercisable at December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,860,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted average exercise prices and aggregate intrinsic values in this table will not reflect the impact of the May 2025 repricing until the retention period is complete in May 2026.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_f9e49f68-10ed-47f9-abad-85f88ab41fed"
      decimals="0"
      id="F_28f881cc-8d17-4d81-8cde-0f06e00a029e"
      unitRef="U_shares">11231148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_f9e49f68-10ed-47f9-abad-85f88ab41fed"
      decimals="2"
      id="F_e9e68f48-16ac-48e9-a196-ca01bc017555"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_344e5b09-4b43-4e4c-aece-b1dccaea79db"
      id="F_3762cc34-96fa-4d3d-93a3-a12b8ee69c03">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_f9e49f68-10ed-47f9-abad-85f88ab41fed"
      decimals="0"
      id="F_84809593-766c-4e4f-921c-01b456a76dd6"
      unitRef="U_USD">989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16"
      decimals="0"
      id="F_adb428e1-3e80-4340-9d39-b41e6b3261e7"
      unitRef="U_shares">3469050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16"
      decimals="2"
      id="F_dd88b983-a9d1-402b-abf4-72008a80eafd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16"
      decimals="0"
      id="F_742dea64-0c0f-4787-a5af-9b3107630115"
      unitRef="U_shares">13334</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16"
      decimals="2"
      id="F_3e127737-dbcb-4e43-8404-99aeae424e1d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16"
      decimals="0"
      id="F_ddbbaca2-d4f5-499b-a90f-cbf5c904658c"
      unitRef="U_USD">9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16"
      decimals="0"
      id="F_428c27b9-d651-457f-9999-c7f4adb49bec"
      unitRef="U_shares">851492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16"
      decimals="2"
      id="F_2fc57670-68c2-40ed-aa05-239005c777b4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_27282b93-17b5-4ddf-b071-79f5ec3755de"
      decimals="0"
      id="F_125142a9-05d7-4292-b1bc-84d64f91a484"
      unitRef="U_shares">13835372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_27282b93-17b5-4ddf-b071-79f5ec3755de"
      decimals="2"
      id="F_e53e7da2-e18c-4919-92a9-0a8e1378d3ec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16"
      id="F_76c435a1-72b8-4a26-ab91-8647c569896c">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_27282b93-17b5-4ddf-b071-79f5ec3755de"
      decimals="0"
      id="F_24b538e9-4d41-4e26-9cb5-05ac1e543de0"
      unitRef="U_USD">2371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_27282b93-17b5-4ddf-b071-79f5ec3755de"
      decimals="0"
      id="F_df429972-fbfa-4028-9af2-ba0226d1bcb2"
      unitRef="U_shares">7860610</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_27282b93-17b5-4ddf-b071-79f5ec3755de"
      decimals="2"
      id="F_9761809e-1865-40ba-8285-293bc8977423"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_dbd59a18-8a5d-4dcd-8c36-896f33080a16"
      id="F_8d9bcdc3-3b1a-4602-aa78-c568e5f12bdf">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_27282b93-17b5-4ddf-b071-79f5ec3755de"
      decimals="0"
      id="F_f7ca623a-0882-47ef-85cf-be529169c529"
      unitRef="U_USD">899</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="2"
      id="F_397e69a9-a6c2-45c5-bab0-b1afdc4afce8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="2"
      id="F_cbc8e038-9b68-4135-a338-ec7211752a48"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_305beabf-0ef4-487a-a051-bfd332fcf710">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of each award is estimated using Black-Scholes based on the following assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:53.049%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:21.676%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:21.676%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="3" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.46&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.43&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&#x2014;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&#x2014;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="4"
      id="F_6de4eb7e-87b8-4167-b589-d6f9f1c2fe77"
      unitRef="U_pure">0.0372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="4"
      id="F_0823b432-8e3c-4cf4-8d18-d35a29935b93"
      unitRef="U_pure">0.0446</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="4"
      id="F_8b716806-15a2-4d73-92cb-91cc546147da"
      unitRef="U_pure">0.0343</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="4"
      id="F_4c8d6d69-9683-4d59-a1a4-ad9df9f8f1e8"
      unitRef="U_pure">0.046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0dc245ae-95a8-4120-80e6-fdc0fc50dc5b"
      id="F_a771ca15-1b0a-403f-832e-5930e72af6af">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_68400128-05f8-412b-8bce-a9b588eb4efa"
      id="F_96829827-e0c1-4bc7-acd7-c080514f672d">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_90e4ec5b-1296-4608-ba2a-60bd4683d74f"
      id="F_7e611fb2-2c44-4fe3-8329-f6a2258faee5">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9110b0c0-85f9-4944-8142-2673163f54ec"
      id="F_6348024d-3b03-4da6-aba2-97ee3867a0b1">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="2"
      id="F_a234c06b-4ca4-4fb9-987f-82eda4210f62"
      unitRef="U_pure">1.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="2"
      id="F_69857f92-feec-4ec6-b2cf-58a250d4a3e9"
      unitRef="U_pure">1.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="2"
      id="F_bd02d351-97a0-4a47-bdb2-227a411dbf38"
      unitRef="U_pure">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="2"
      id="F_418a6345-d04d-4de5-ae3c-cd0f09fc1fa3"
      unitRef="U_pure">1.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="2"
      id="F_2b5e1c50-1223-4b70-a499-94bc6fa5a542"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="2"
      id="F_8991adaa-c078-4407-a30f-b8f8cbeb070f"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_a0c7bb0b-34f9-43a4-8dcd-e211fdeaa76c">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has recorded stock-based compensation in the accompanying statements of operations as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bbae0f84-acad-4f21-9dc4-943f64e17a13"
      decimals="0"
      id="F_0fe8cc25-b293-453b-aab0-ff6f7cebd34a"
      unitRef="U_USD">11470</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8b9c77dd-2189-4362-bddb-fa1398cd7baf"
      decimals="0"
      id="F_15bf36e8-f384-4679-8c72-ab829ec34d59"
      unitRef="U_USD">10163</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_81d87e23-aacc-4a1f-bb17-8d1d063bc827"
      decimals="0"
      id="F_e3976aef-fbb0-4fca-8610-723067272186"
      unitRef="U_USD">9469</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_141635e9-25cf-411e-813a-935f24e93c8e"
      decimals="0"
      id="F_cccf6ab5-bbf3-4de1-835b-055c278a90ec"
      unitRef="U_USD">9302</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3a1c09a0-02a7-4e33-a36d-e454e4730213"
      decimals="0"
      id="F_94b151de-fa48-4b29-8b3e-c7aa6706d51c"
      unitRef="U_USD">20939</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_80a04733-0f39-46fd-b536-fb1363c8d09a"
      decimals="0"
      id="F_5199d807-616f-4eb3-b850-cd5947ff3d29"
      unitRef="U_USD">19465</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="0"
      id="F_39e32d22-755e-4e06-97df-98ee990ca5c4"
      unitRef="U_USD">35159</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_4d956b69-3881-4468-adbc-5c2762cf8c8d">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a76bf89e-0076-44be-bb89-64f8a0be9373"
      decimals="0"
      id="F_355b6116-dcc3-4fe9-b048-8c6cff15b3c1"
      unitRef="U_shares">234229</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ccb31ebd-a7c1-4540-8895-81d30d0fcefb"
      decimals="0"
      id="F_b43dc70c-ea66-4570-b99f-08f85bafacc6"
      unitRef="U_shares">234229</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <caba:IncreaseInShareReservedPercentage
      contextRef="C_8d6d69e2-dda1-4ea0-94e8-32274096c469"
      decimals="2"
      id="F_a15d49ba-30f2-4a41-8268-6d1e8c06551d"
      unitRef="U_pure">0.01</caba:IncreaseInShareReservedPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_024369a9-8747-4977-86bc-392c39212422"
      decimals="0"
      id="F_e56f0c2e-2f68-4543-99be-0a66e9f79021"
      unitRef="U_shares">234229</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_22909102-0e37-4650-b154-28e36d4712cc"
      decimals="0"
      id="F_03951777-a386-49dc-b405-e6402c945a1e"
      unitRef="U_shares">136383</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <caba:PercentageOfPayrollDeductionOnEligibleCompensation
      contextRef="C_63066961-ec40-4822-b55c-b127b3bbe2fc"
      decimals="2"
      id="F_6b426a4c-d67b-47d8-a4a0-5a1c30652f83"
      unitRef="U_pure">0.15</caba:PercentageOfPayrollDeductionOnEligibleCompensation>
    <caba:EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock
      contextRef="C_63066961-ec40-4822-b55c-b127b3bbe2fc"
      decimals="0"
      id="F_44bf8795-5db4-469e-a6ff-702ff73f4cb0"
      unitRef="U_USD">25</caba:EmployeeStockPurchasePlanMaximumAnnualRightsToPurchaseCommonStock>
    <caba:PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock
      contextRef="C_63066961-ec40-4822-b55c-b127b3bbe2fc"
      decimals="2"
      id="F_28084e2f-f1ed-47b5-8309-1d4228911278"
      unitRef="U_pure">0.85</caba:PercentageOfSharesPurchasedAtFairMarketValueOfCommonStock>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_c7e29131-212f-477c-b7b1-dfc7ccce31c2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The reconciliation of federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:51.379%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.679%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.035%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:6.977%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.679%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.036000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:7.216%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Statutory Tax Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State and Local Income Taxes, Net of Federal Income Tax Effect &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign Tax Effects&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effect of Cross-Border Tax Laws&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax Credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in Valuation Allowances (Domestic)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nontaxable or Nondeductible Items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other Adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Actual income tax benefit effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Within the State Income Tax category, Pennsylvania and Philadelphia accounted for the majority, representing over 50% of the total reconciling impact.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Consistent with the Company&#x2019;s cumulative loss position and absence of taxable income in federal, state, and local jurisdictions, the Company made no income tax payments and received no income tax refunds in the current fiscal year.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:56.257%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.159%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.712999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.159%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.712999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal, state and local net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License fee deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;163,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;110,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company increased its valuation allowance by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,127&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the year ended December 31, 2025 in order to maintain a full valuation allowance against its deferred tax assets. Based on the Company&#x2019;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December 31, 2025. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had federal, state and local net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;319,886&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;255,101&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;257,607&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;319,636&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the federal net operating losses do not expire, and the remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The state net operating losses begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The local net operating losses begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2042&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had federal and state research and development tax credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,044&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively. The research and development credits begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s federal&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;research &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;credits consist of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,821&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of Research and Development credits and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,223&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of Orphan Drug credits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the provisions of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, these net operating losses, credit carryforwards and other tax attributes may be subject to limitation based on previous significant changes in ownership and upon future significant changes in ownership of the Company, as defined by the Code.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company files income tax returns in the U.S. federal jurisdiction and in multiple state and local jurisdictions; however, Pennsylvania and Philadelphia constitute the Company&#x2019;s most significant tax jurisdictions due to the concentration of its operational footprint and the resulting apportionment profile. The tax years 2024, 2023 and 2022 remain open to examination by the jurisdictions where the Company is subject to tax.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; unrecognized income tax benefits that would affect the Company&#x2019;s effective tax rate if recognized.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_e4ea1660-34d3-4023-bb68-0e0351098dd6">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The reconciliation of federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:51.379%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.679%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.035%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:6.977%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.679%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:9.036000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:7.216%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Statutory Tax Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State and Local Income Taxes, Net of Federal Income Tax Effect &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign Tax Effects&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effect of Cross-Border Tax Laws&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax Credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in Valuation Allowances (Domestic)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,176&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nontaxable or Nondeductible Items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other Adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Actual income tax benefit effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Within the State Income Tax category, Pennsylvania and Philadelphia accounted for the majority, representing over 50% of the total reconciling impact.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_3ed2dbc6-ca7c-49cc-915f-1c32d67ab8e1"
      unitRef="U_USD">-35304000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="3"
      id="F_e972b140-9343-421b-8c56-77e4d17595d8"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_1e5ce6e8-190b-4e3e-932c-6386c80bbac3"
      unitRef="U_USD">-24331000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="3"
      id="F_1602532f-b5da-4027-ad11-da5d6ad2baa9"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_ff4b9c29-de45-4861-b7a3-e7d6162129c9"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="3"
      id="F_4bcd57e1-e3fd-44e0-b5d3-f0238dc5238e"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_b7161c44-d327-4a04-b67c-59b4ab1359a9"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="3"
      id="F_baeb6475-4eeb-4dc6-8b63-3cb09f80023e"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_6a778a45-1ff8-49a0-b0c7-b57da6ae2760"
      unitRef="U_USD">24000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="3"
      id="F_ee07fbe4-a5d7-402e-9d5e-df87ca273d25"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_1eb6c5e0-15be-4272-8efd-3bb6d297de01"
      unitRef="U_USD">-4000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="3"
      id="F_2bee05e2-6a3b-4d76-8472-71df3fba103e"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_735fa2ae-70a7-4bca-b67a-b1946356f745"
      unitRef="U_USD">94000</us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="3"
      id="F_f361c478-428e-4368-83b1-3608d806c9fb"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_35379415-995b-4710-aa5b-04f4d5ead147"
      unitRef="U_USD">6000</us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="3"
      id="F_ef224295-2408-475d-964e-a937ef863660"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_cdc5fb1c-a879-4c27-9514-cb2fbc2bfe0b"
      unitRef="U_USD">9489000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="3"
      id="F_9f03756f-c91f-4b52-83d6-73b76c79fb35"
      unitRef="U_pure">-0.056</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_67864d40-6293-4647-b911-8c064299c7df"
      unitRef="U_USD">5769000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="3"
      id="F_86ee114b-1a0a-4f48-9a69-e97ad023b94f"
      unitRef="U_pure">-0.05</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesDomestic
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_1f15ba88-677f-4cc8-9ec4-2a5329ad3344"
      unitRef="U_USD">43489000</us-gaap:IncomeTaxReconciliationTaxContingenciesDomestic>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="3"
      id="F_a146cb86-ded9-4a44-8acc-4542bc14746d"
      unitRef="U_pure">-0.259</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesDomestic
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_bd8b1729-02e5-4a53-ba81-a2973cc03f3f"
      unitRef="U_USD">29176000</us-gaap:IncomeTaxReconciliationTaxContingenciesDomestic>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="3"
      id="F_f937f475-f566-4493-aede-9961179a50d5"
      unitRef="U_pure">-0.252</us-gaap:EffectiveIncomeTaxRateReconciliationTaxContingenciesDomestic>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_59eb30a5-4811-42a4-bd4d-d627d277bbc5"
      unitRef="U_USD">983000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="3"
      id="F_3b84e29e-f7cc-4a0e-be33-cd159466fff8"
      unitRef="U_pure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_b0b89267-23fd-4ff4-ba46-c03e8f25f298"
      unitRef="U_USD">951000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="3"
      id="F_ae92f9dd-4cb5-43cb-8e09-3cf3359984c4"
      unitRef="U_pure">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_b7ea2e88-3838-4c00-ae0d-535ac1352b47"
      unitRef="U_USD">203000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="3"
      id="F_cc6f4b63-b9cd-4a00-b9f4-19cb8085d5da"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_1a51b821-7b28-47dd-b029-d4d75de95750"
      unitRef="U_USD">-29000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="3"
      id="F_20f7ac60-4a97-4013-aaae-628c7ae0a35c"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_ce9cccbe-4ea7-40c9-b81f-1cfd5d4382ec"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="3"
      id="F_c0e17926-5820-4311-87cb-59d1450d2e06"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_1b2804d7-1d30-494e-8956-252f430c1dc0"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="3"
      id="F_8df79e82-fc0e-45fd-8f63-cbf7448a9816"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_94237748-569c-4c17-bb95-641bdee37c60">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:56.257%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.159%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.712999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.159%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:17.712999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal, state and local net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License fee deductions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;163,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,661&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;110,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_3600340b-45af-4da4-9a85-ea11c0024494"
      unitRef="U_USD">83014000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_5ef6af83-0cd7-46bf-998d-44861b5c1c5b"
      unitRef="U_USD">44369000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <caba:CapitalizedRDCosts
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_0eb3cc28-0c59-4b8a-bc46-bd7e1b2d985d"
      unitRef="U_USD">31333000</caba:CapitalizedRDCosts>
    <caba:CapitalizedRDCosts
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_7be5d29a-d460-4b18-b025-c91f4db0c518"
      unitRef="U_USD">36646000</caba:CapitalizedRDCosts>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_cc185ee3-4f39-4d9e-b5a3-4765b977cc0f"
      unitRef="U_USD">25050000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_83795f5c-15f8-46ce-b2b4-1dcf4b62c03d"
      unitRef="U_USD">16296000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_92301624-ddf4-44cc-bb2a-fb098a491d65"
      unitRef="U_USD">13299000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_f45cdc71-cf79-4739-9875-08f6b1869edc"
      unitRef="U_USD">9919000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <caba:DeferredTaxAssetsLicenseFeesDeductions
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_209a0d10-bee1-442d-bc05-378b119fc282"
      unitRef="U_USD">186000</caba:DeferredTaxAssetsLicenseFeesDeductions>
    <caba:DeferredTaxAssetsLicenseFeesDeductions
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_9832d3ae-4d38-4900-9b4e-92a672d2246d"
      unitRef="U_USD">221000</caba:DeferredTaxAssetsLicenseFeesDeductions>
    <caba:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_5d0e3026-ef9b-4135-b392-24812b13f188"
      unitRef="U_USD">7357000</caba:DeferredTaxAssetsOperatingLeaseLiabilities>
    <caba:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_89277a1a-4e56-4a14-8268-c86e522e8e34"
      unitRef="U_USD">4607000</caba:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_51ecac8a-07cf-4a56-9e30-df24d2fa6d55"
      unitRef="U_USD">2805000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_848bf0a8-e3d9-40a9-b894-0ed573df3e7e"
      unitRef="U_USD">2603000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_efb4c9fa-fb92-43e3-9e3d-9381ef12befc"
      unitRef="U_USD">163044000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_d997f921-7beb-4b1f-9eab-677e1f8b3013"
      unitRef="U_USD">114661000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_9a0acd04-86a0-4ba2-a4b8-7393a7431ccc"
      unitRef="U_USD">157850000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_ab1df6fa-53d5-448c-871e-bede4e9926bb"
      unitRef="U_USD">110723000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_1d29a4ad-1eb2-4cd3-a738-ff13f9f70bdf"
      unitRef="U_USD">5194000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_9f298182-7c75-429c-a66f-98504346526b"
      unitRef="U_USD">3938000</us-gaap:DeferredTaxAssetsNet>
    <caba:OperatingLeaseAssets
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_dcec5997-d438-4bd8-ae63-522e34000dfa"
      unitRef="U_USD">-5194000</caba:OperatingLeaseAssets>
    <caba:OperatingLeaseAssets
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_e2e7e4b9-10dd-4d24-a51d-4b11632f1040"
      unitRef="U_USD">-3938000</caba:OperatingLeaseAssets>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_efc067d8-8755-49eb-93b2-3edb4a5151d6"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_a74feb08-4ef2-4bb8-b4a1-03e7cbf7ec23"
      decimals="-3"
      id="F_a4c024de-d943-45b1-8eb1-4d2d65361368"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_9e3d88a5-ee94-4ece-926d-da05cbd20ac8"
      unitRef="U_USD">47127000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_db573bb5-9802-4e78-9949-fc9e97c355bc"
      unitRef="U_USD">319886000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_b2015ae2-7987-46fd-9f1a-14a53e158ee2"
      decimals="-3"
      id="F_a1bbb5dc-20b2-465b-8e13-9705e055be7a"
      unitRef="U_USD">255101000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_e2465898-cd50-48db-9257-e27d8e4c3159"
      unitRef="U_USD">257607000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_835550a9-6649-48fe-8c75-870dc32719dc"
      unitRef="U_USD">319636000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_2de8b241-f70e-4a6c-bd55-b4b0077f0a6f"
      unitRef="U_USD">250000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <caba:OperatingLossCarryforwardsStateCommencementOfExpirationDate
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_b1470ce0-a832-4040-8d52-6bec43177e59">2037</caba:OperatingLossCarryforwardsStateCommencementOfExpirationDate>
    <caba:DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate
      contextRef="C_ad2a1234-93ce-48dc-96ba-3cf1de4b7bff"
      id="F_2d06a8c9-9b75-4914-a3eb-a4888a7c5ff7">2037</caba:DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate>
    <caba:DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate
      contextRef="C_a2620028-ec6f-4274-a235-71be3c62c04d"
      id="F_8c8a6bb7-1a6c-466e-ad76-efd3fa88c3c6">2042</caba:DeferredTaxAssetsTaxCreditCarryforwardsCommencementOfExpirationDate>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_88a0af93-4579-4bef-b89d-e83437cf1886"
      decimals="-3"
      id="F_06389d5a-d3f3-4bb2-be15-8a2b49b3f2ad"
      unitRef="U_USD">25044000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_b2015ae2-7987-46fd-9f1a-14a53e158ee2"
      decimals="-3"
      id="F_93ea6c2e-ace2-4c6e-ab5f-1fe9c17719a0"
      unitRef="U_USD">6000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <caba:FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_8a4e288b-dc1e-4cd3-bf51-1ff9bf877e9b">P2038Y</caba:FederalAndStateResearchAndDevelopmentTaxCreditCarryforwardsExpirationDate>
    <caba:ResearchAndDevelopmentCredits
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_09d4139d-10d6-49f5-a5c9-e8d299d52fd3"
      unitRef="U_USD">13821000</caba:ResearchAndDevelopmentCredits>
    <caba:ResearchAndDevelopmentCredits
      contextRef="C_0aa15530-7fe2-4778-84a1-34356a306f70"
      decimals="-3"
      id="F_142dc645-6f00-4374-9708-63fb6f28289b"
      unitRef="U_USD">11223000</caba:ResearchAndDevelopmentCredits>
    <caba:PercentageOfEligibleTaxPositionsForRecognition
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="2"
      id="F_021fdf16-cfe9-46a3-b328-713a6469b1a3"
      unitRef="U_pure">0.50</caba:PercentageOfEligibleTaxPositionsForRecognition>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_eb2e097d-4a48-4180-9c7d-7f86b4b64b4f"
      decimals="-3"
      id="F_15603d93-ba3f-431b-a253-10a8d3dbf681"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_8fd290ef-d623-4d71-9667-9bfc2a15777f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;T&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;he Company calculates basic and diluted net loss per share in conformity with the two-class method required for participating securities. In May 2024, the remaining &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,444,295&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of non-voting common stock were converted to voting common stock and no shares of non-voting common stock remain outstanding. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since the rights of the voting and non-voting common stock are identical, except with respect to voting, the undistributed losses of the Company have been allocated on a proportionate basis to the two classes. Basic net loss per share of common stock is computed by dividing the net loss per share of common stock by the weighted average number of shares of common stock outstanding for the period. The weighted-average shares of common stock outstanding as of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; included outstanding pre-funded warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pre-funded warrants were outstanding as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Diluted net loss per share is calculated using the if-converted method as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, which assumes conversion of all non-voting common stock to voting common stock.&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:3.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:27.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Voting common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;167,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,903,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Voting common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Non-voting common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in basic per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,038,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Diluted net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses for basic computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reallocation of undistributed losses as a result of conversion of&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;non-voting to voting common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in basic per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,038,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Add: conversion of non-voting to voting common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in diluted per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,524,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:46.491%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:22.595%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:22.595%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,835,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,231,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,090,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,925,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,231,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_5f4640a1-b6f6-4783-b105-897dd65c4d00"
      decimals="0"
      id="F_4b411676-cf1c-4c23-86f9-23dd0204f318"
      unitRef="U_shares">1444295</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_f731d894-5793-46d0-97d4-8c8276db0097"
      decimals="0"
      id="F_23efd6d8-b176-470e-8820-4cc09291646b"
      unitRef="U_shares">6000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_e53823f2-5fac-496e-8cc6-671906c1651f"
      decimals="0"
      id="F_214f96df-2900-4f19-9cc0-5c908eb68695"
      unitRef="U_shares">0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_c64d00a3-1b7c-4486-92c1-206407d70400">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Diluted net loss per share is calculated using the if-converted method as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, which assumes conversion of all non-voting common stock to voting common stock.&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:67.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:3.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:27.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Voting common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic and diluted net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;167,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,903,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Voting common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Non-voting common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in basic per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,038,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Diluted net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses for basic computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114,728&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reallocation of undistributed losses as a result of conversion of&lt;br/&gt;&#160;&#160;&#160;&#160;&#160;non-voting to voting common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Allocation of undistributed losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in basic per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,038,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Add: conversion of non-voting to voting common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average number of shares used in diluted per share computation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,524,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;485,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_380f4971-911e-418e-9b42-9f671cdeed55"
      decimals="-3"
      id="F_d3fac89e-935a-41e3-9a54-ea45e3c28d6e"
      unitRef="U_USD">-167856000</us-gaap:NetIncomeLoss>
    <caba:WeightedAverageNumberOfSharesOutstanding
      contextRef="C_380f4971-911e-418e-9b42-9f671cdeed55"
      decimals="0"
      id="F_cbef18e3-7fda-403d-a709-972bb750cb7c"
      unitRef="U_shares">79903224</caba:WeightedAverageNumberOfSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_380f4971-911e-418e-9b42-9f671cdeed55"
      decimals="2"
      id="F_3ef2c1b4-1f4e-43df-a2b9-f1179b916fdb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.1</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_380f4971-911e-418e-9b42-9f671cdeed55"
      decimals="2"
      id="F_fe3bc1ba-2d74-4974-b4b9-abd62091788e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.1</us-gaap:EarningsPerShareBasic>
    <us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic
      contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae"
      decimals="-3"
      id="F_ddfdb086-ae95-4527-9dc9-2d63d404d0a9"
      unitRef="U_USD">-114728000</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
    <us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic
      contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178"
      decimals="-3"
      id="F_3a519f07-e0d2-4c28-b1c6-5f98fd4be1ac"
      unitRef="U_USD">-1136000</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae"
      decimals="0"
      id="F_27d739f7-b98a-47e0-893d-51b21b335e33"
      unitRef="U_shares">49038726</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178"
      decimals="0"
      id="F_bfde7ffa-224c-4688-858e-42d328119c6c"
      unitRef="U_shares">485378</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae"
      decimals="2"
      id="F_b634d0ed-88f4-4572-9c2b-d47be903d282"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178"
      decimals="2"
      id="F_5ff5c644-043f-4a12-b6d8-aa542dbd44bd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae"
      decimals="-3"
      id="F_a5bb5e10-c1c0-4ff0-814f-8750f79f2f11"
      unitRef="U_USD">-114728000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178"
      decimals="-3"
      id="F_d9f38c04-2835-4caf-bb64-3e8e3b64d5e9"
      unitRef="U_USD">-1136000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae"
      decimals="-3"
      id="F_083b2507-17d6-46e3-bf3a-71b008b1dbbf"
      unitRef="U_USD">-1136000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178"
      decimals="-3"
      id="F_04d4349a-4d68-4203-9922-5d3b9046a81b"
      unitRef="U_USD">0</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae"
      decimals="-3"
      id="F_012d23db-c2f5-4a52-a5ea-9f43e0541e19"
      unitRef="U_USD">-115864000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178"
      decimals="-3"
      id="F_20691cf8-6555-4c7c-9fa5-ca5eb450d414"
      unitRef="U_USD">-1136000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae"
      decimals="0"
      id="F_d9a8acde-a698-4292-9b43-a8e57340d3e3"
      unitRef="U_shares">49038726</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178"
      decimals="0"
      id="F_baa2ce55-4e5f-423b-b528-23ea3598a218"
      unitRef="U_shares">485378</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae"
      decimals="0"
      id="F_6b654116-9318-41a4-9b2b-383d54ddfb05"
      unitRef="U_shares">485378</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178"
      decimals="-3"
      id="F_0c148d89-1ddf-4edc-9b1f-5f62a698ba01"
      unitRef="U_shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae"
      decimals="0"
      id="F_2501529e-1d2d-4d58-b86c-1c6ade5f0c93"
      unitRef="U_shares">49524104</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178"
      decimals="0"
      id="F_45bf5e1a-c5b3-436b-a13c-90cd29e80a16"
      unitRef="U_shares">485378</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_f0f07fb5-2799-4c77-8564-71079e67edae"
      decimals="2"
      id="F_a0c7f37a-a0d2-4d71-8074-f64ddef9ea55"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0fa6f5c7-fcec-4700-a402-f8f61ee52178"
      decimals="2"
      id="F_448a20db-26db-4bc9-8a3d-49732d6e5d36"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_c2526544-0177-4e44-827c-80f23c7f3955">&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive:&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:46.491%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:22.595%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:2.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:22.595%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,835,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,231,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,090,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,925,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,231,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0cc46475-ebfa-4cb1-8610-3a9fac50cfa5"
      decimals="0"
      id="F_9ec0917f-bcc3-4f51-83e1-3cfa458f7309"
      unitRef="U_shares">13835372</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bbf56b13-a2f8-466a-a449-916231816cd2"
      decimals="0"
      id="F_ce1e38f4-4ece-4386-8c0f-7fc9925b046c"
      unitRef="U_shares">11231148</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b8a71800-f4b2-48f9-bccb-e404ed69141b"
      decimals="0"
      id="F_26dea99f-122a-4f65-89a1-d8890cfd6ff4"
      unitRef="U_shares">53090190</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_fe0a6b1e-4837-4292-aa3f-e02510edce97"
      decimals="0"
      id="F_14b62989-b587-485e-9df5-308c97b557b4"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="0"
      id="F_ca3571ad-efb1-47b0-a0c9-2dc34ab3ffed"
      unitRef="U_shares">66925562</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="0"
      id="F_f9585cbe-3082-4268-9a06-f5435d080da9"
      unitRef="U_shares">11231148</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      id="F_78d14481-46ef-4790-ad6e-1a5a2da4f43a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13. 401(k) Savings Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:24.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company maintains a defined-contribution savings plan under Section 401(k) of the IRC, or the 401(k) Plan. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. Effective January 1, 2020, the Plan provided for matching contributions on a portion of participant contributions pursuant to the 401(k) Savings Plan&#x2019;s matching formula, up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of eligible compensation. All matching contributions and participant contributions vest immediately. Contributions totaled $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,063&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;894&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, and have been recorded in the statements of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="2"
      id="F_5260a620-3a59-44c7-a004-dc7be6f10178"
      unitRef="U_pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_09c552e5-3642-480f-b739-e2c13490ca62"
      decimals="-3"
      id="F_c1fa6d3c-e6ed-49f4-85f9-0b7b744ed492"
      unitRef="U_USD">1063000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_a53762f9-68cd-45a5-a798-37f4b1f7ea4a"
      decimals="-3"
      id="F_85dab938-0473-4514-9928-8366e7289cdf"
      unitRef="U_USD">894000</us-gaap:DefinedContributionPlanCostRecognized>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_d92528eb-7b2c-4ba7-8060-2a7ca155f441"
          xlink:label="F_d92528eb-7b2c-4ba7-8060-2a7ca155f441"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ea99062d-d4be-49eb-bbc9-f6883b27d25f"
          xlink:label="F_ea99062d-d4be-49eb-bbc9-f6883b27d25f"
          xlink:type="locator"/>
        <link:footnote id="FNT_a817dc11-a357-48c9-937a-02cf05c1a9c1" xlink:label="FNT_a817dc11-a357-48c9-937a-02cf05c1a9c1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d92528eb-7b2c-4ba7-8060-2a7ca155f441"
          xlink:to="FNT_a817dc11-a357-48c9-937a-02cf05c1a9c1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ea99062d-d4be-49eb-bbc9-f6883b27d25f"
          xlink:to="FNT_a817dc11-a357-48c9-937a-02cf05c1a9c1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_dd88b983-a9d1-402b-abf4-72008a80eafd"
          xlink:label="F_dd88b983-a9d1-402b-abf4-72008a80eafd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_24b538e9-4d41-4e26-9cb5-05ac1e543de0"
          xlink:label="F_24b538e9-4d41-4e26-9cb5-05ac1e543de0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_84809593-766c-4e4f-921c-01b456a76dd6"
          xlink:label="F_84809593-766c-4e4f-921c-01b456a76dd6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ddbbaca2-d4f5-499b-a90f-cbf5c904658c"
          xlink:label="F_ddbbaca2-d4f5-499b-a90f-cbf5c904658c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_2fc57670-68c2-40ed-aa05-239005c777b4"
          xlink:label="F_2fc57670-68c2-40ed-aa05-239005c777b4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e53e7da2-e18c-4919-92a9-0a8e1378d3ec"
          xlink:label="F_e53e7da2-e18c-4919-92a9-0a8e1378d3ec"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e9e68f48-16ac-48e9-a196-ca01bc017555"
          xlink:label="F_e9e68f48-16ac-48e9-a196-ca01bc017555"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f7ca623a-0882-47ef-85cf-be529169c529"
          xlink:label="F_f7ca623a-0882-47ef-85cf-be529169c529"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9761809e-1865-40ba-8285-293bc8977423"
          xlink:label="F_9761809e-1865-40ba-8285-293bc8977423"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3e127737-dbcb-4e43-8404-99aeae424e1d"
          xlink:label="F_3e127737-dbcb-4e43-8404-99aeae424e1d"
          xlink:type="locator"/>
        <link:footnote id="FNT_81b3b034-bf57-4e0a-a22f-af0f469cef56" xlink:label="FNT_81b3b034-bf57-4e0a-a22f-af0f469cef56" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted average exercise prices and aggregate intrinsic values in this table will not reflect the impact of the May 2025 repricing until the retention period is complete in May 2026.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_dd88b983-a9d1-402b-abf4-72008a80eafd"
          xlink:to="FNT_81b3b034-bf57-4e0a-a22f-af0f469cef56"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_24b538e9-4d41-4e26-9cb5-05ac1e543de0"
          xlink:to="FNT_81b3b034-bf57-4e0a-a22f-af0f469cef56"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_84809593-766c-4e4f-921c-01b456a76dd6"
          xlink:to="FNT_81b3b034-bf57-4e0a-a22f-af0f469cef56"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ddbbaca2-d4f5-499b-a90f-cbf5c904658c"
          xlink:to="FNT_81b3b034-bf57-4e0a-a22f-af0f469cef56"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_2fc57670-68c2-40ed-aa05-239005c777b4"
          xlink:to="FNT_81b3b034-bf57-4e0a-a22f-af0f469cef56"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e53e7da2-e18c-4919-92a9-0a8e1378d3ec"
          xlink:to="FNT_81b3b034-bf57-4e0a-a22f-af0f469cef56"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e9e68f48-16ac-48e9-a196-ca01bc017555"
          xlink:to="FNT_81b3b034-bf57-4e0a-a22f-af0f469cef56"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f7ca623a-0882-47ef-85cf-be529169c529"
          xlink:to="FNT_81b3b034-bf57-4e0a-a22f-af0f469cef56"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9761809e-1865-40ba-8285-293bc8977423"
          xlink:to="FNT_81b3b034-bf57-4e0a-a22f-af0f469cef56"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3e127737-dbcb-4e43-8404-99aeae424e1d"
          xlink:to="FNT_81b3b034-bf57-4e0a-a22f-af0f469cef56"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_baeb6475-4eeb-4dc6-8b63-3cb09f80023e"
          xlink:label="F_baeb6475-4eeb-4dc6-8b63-3cb09f80023e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_4bcd57e1-e3fd-44e0-b5d3-f0238dc5238e"
          xlink:label="F_4bcd57e1-e3fd-44e0-b5d3-f0238dc5238e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ff4b9c29-de45-4861-b7a3-e7d6162129c9"
          xlink:label="F_ff4b9c29-de45-4861-b7a3-e7d6162129c9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b7161c44-d327-4a04-b67c-59b4ab1359a9"
          xlink:label="F_b7161c44-d327-4a04-b67c-59b4ab1359a9"
          xlink:type="locator"/>
        <link:footnote id="FNT_7b1988d3-18b3-4e45-95d7-cf5f32b934e9" xlink:label="FNT_7b1988d3-18b3-4e45-95d7-cf5f32b934e9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within the State Income Tax category, Pennsylvania and Philadelphia accounted for the majority, representing over 50% of the total reconciling impact.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_baeb6475-4eeb-4dc6-8b63-3cb09f80023e"
          xlink:to="FNT_7b1988d3-18b3-4e45-95d7-cf5f32b934e9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_4bcd57e1-e3fd-44e0-b5d3-f0238dc5238e"
          xlink:to="FNT_7b1988d3-18b3-4e45-95d7-cf5f32b934e9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ff4b9c29-de45-4861-b7a3-e7d6162129c9"
          xlink:to="FNT_7b1988d3-18b3-4e45-95d7-cf5f32b934e9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b7161c44-d327-4a04-b67c-59b4ab1359a9"
          xlink:to="FNT_7b1988d3-18b3-4e45-95d7-cf5f32b934e9"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
